{
  "evaluation_metadata": {
    "evaluator_name": "LLM-as-Judge Evaluator (Model: qwen3-235b-reasoning)",
    "evaluator_model": "qwen3-235b-reasoning",
    "model_evaluated": "nemotron-nano-30b",
    "experiment": "e4_page_window_relevance_desc",
    "pattern": "qualitative_2hop_cross_year",
    "total_questions_in_experiment": 1000
  },
  "evaluation_results": [
    {
      "question_id": 77,
      "question": "How did the gross benefit obligation and the actuarial losses for LMT's nonqualified defined benefit pension plans evolve between 2023 and 2024?",
      "original_answer": "In 2023, the gross benefit obligation for LMT's nonqualified defined benefit pension plans was $1.0 billion with actuarial losses totaling $347 million. By 2024, the gross benefit obligation decreased to $905 million, and the actuarial losses declined to $303 million. This indicates a reduction in both the liability and the associated actuarial losses over the period.",
      "llm_answer": "Based on the provided document pages, the gross benefit obligation for LMT's nonqualified defined benefit pension plans remained unchanged at $1.0 billion as of both December 31, 2023 and 2024, with no significant change in the reported figure between the years. The actuarial losses recorded in accumulated other comprehensive loss (pretax) for these plans decreased from $347 million at December 31, 2023 to $303 million at December 31, 2024, indicating a reduction in unrecognized actuarial losses over the period.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is partially correct but contains a significant factual error regarding the gross benefit obligation. The ground truth states that the gross benefit obligation decreased from $1.0 billion in 2023 to $905 million in 2024, but the LLM incorrectly claims it 'remained unchanged at $1.0 billion' in both years. This is a major quantitative and factual inaccuracy. However, the actuarial losses are correctly reported: $347 million in 2023 and $303 million in 2024, with the correct trend of decline. (2) Quantitative accuracy is compromised due to the incorrect gross benefit obligation value for 2024. While the 2023 figure ($1.0 billion) and both actuarial loss figures are correct, the failure to report the $905 million 2024 obligation undermines the answer's reliability. The calculation of the trend in actuarial losses is accurate. (3) The reasoning is sound in noting a reduction in actuarial losses, but the synthesis of the gross benefit obligation evolution is flawed. The model fails to recognize or report the decrease in liability, which is a central part of the multi-hop comparison across years. This indicates a failure in correctly extracting or integrating data for one of the two key metrics. (4) Contextual relevance is high because the answer addresses both components of the question (gross benefit obligation and actuarial losses) and discusses their evolution, even though one half is incorrect. The structure and intent align well with the question, but factual correctness is compromised on a key metric.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1221,
        "completion_tokens": 428,
        "total_tokens": 1649
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How did General Motors' long-term rate of return assumptions on U.S. pension plan assets evolve between 2022 and 2024, and what does this indicate about the company's strategic asset mix adjustments?",
      "original_answer": "In 2022, General Motors reported that the weighted-average long-term rate of return on U.S. pension plan assets decreased from 5.6% at December 31, 2020, to 5.4% at December 31, 2021. By contrast, in 2024, the company indicated that the weighted-average long-term rate of return on U.S. pension plan assets increased from 6.3% at December 31, 2023, to 6.5% at December 31, 2024. This indicates a notable shift in the company's strategic asset mix, moving from a more conservative assumption in 2022 to a more optimistic projection in 2024, likely reflecting changes in capital market assumptions and investment strategies aimed at improving funded status.",
      "llm_answer": "Between 2022 and 2024, General Motors reduced its long-term rate of return assumption for U.S. pension plan assets from 6.3% to 6.5%, reflecting a strategic shift toward a more conservative asset allocation (increasing debt and reducing equity exposure) to improve funded status and reduce volatility. This adjustment aligns with the company's broader objective of de-risking its pension portfolio while maintaining sufficient returns to meet long-term liabilities.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It claims that General Motors reduced its long-term rate of return assumption from 6.3% to 6.5%, which is incorrect—this implies a reduction, but 6.5% is higher than 6.3%, so it's actually an increase. More critically, the direction and timing are wrong: the original answer shows that in 2022, the rate decreased from 5.6% (2020) to 5.4% (2021), while in 2024 it increased from 6.3% (2023) to 6.5% (2024). The LLM incorrectly frames this as a continuous change between 2022 and 2024, missing the two distinct time periods entirely. (2) Quantitatively, the percentages cited (6.3% to 6.5%) are partially correct for the 2023–2024 period but are misapplied to the wrong years and mischaracterized as a reduction. The 2022 data (5.4% at end of 2021) is completely omitted. (3) The reasoning is flawed: the LLM concludes that the change reflects a shift toward a more conservative asset allocation (increasing debt, reducing equity), but the original answer indicates the opposite—a move from a conservative assumption in 2022 to a more optimistic one in 2024, suggesting a potentially riskier or more growth-oriented strategy. The LLM misinterprets the implication of a rising return assumption. (4) Contextual relevance is moderate because the answer discusses pension assumptions and strategic asset mix, which are relevant topics, but the incorrect data and reasoning undermine the validity. The conclusion about de-risking contradicts the ground truth's indication of increased return expectations. Thus, the correctness score is low due to major factual and interpretive errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 452,
        "total_tokens": 1745
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has Chevron's relationship with PDC Energy evolved between 2023 and 2024, and what specific operational and financial impacts were attributed to this change?",
      "original_answer": "In 2023, Chevron acquired PDC Energy, and as a result, PDC was excluded from Chevron’s internal control assessment due to the business combination. By 2024, the integration had progressed to the point where Chevron reported a $2.2 billion increase in U.S. upstream earnings attributed to legacy PDC assets, and a 19% increase in net oil-equivalent production driven by the full-year contribution from PDC. This reflects a shift from acquisition to operational integration and performance contribution.",
      "llm_answer": "Chevron's relationship with PDC Energy shifted from a standalone subsidiary to a fully integrated part of Chevron after the company's acquisition of PDC Energy was completed during 2023. This integration is reflected in the 2023 Form 10‑K disclosure that PDC Energy's revenues represented 5 % and 1 % of the consolidated financial statement amounts as of and for the year ended December 31, 2023, and the note that PDC was excluded from the internal‑control assessment because it was acquired in 2023. Operationally, the acquisition added PDC's Permian Basin production, boosting U.S. upstream earnings by $3.5 billion and increasing net oil‑equivalent production by 250,000 bbl/d (19 %). Financially, the integration contributed to higher overall segment earnings and enabled Chevron to repurchase $15.2 billion of its own stock in 2024, underscoring the strategic and monetary impact of the merger.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the acquisition of PDC Energy by Chevron in 2023 and the exclusion of PDC from internal control assessment, which aligns with the ground truth. It also correctly notes the 19% increase in net oil-equivalent production. However, it introduces significant quantitative inaccuracies: it claims a $3.5 billion increase in U.S. upstream earnings, whereas the ground truth states $2.2 billion. Additionally, it specifies an increase of 250,000 bbl/d in production without confirming whether that number corresponds to the 19% increase, which is not verifiable and appears to be fabricated or misattributed. It also adds a financial claim that Chevron repurchased $15.2 billion in stock in 2024 due to the integration—this is not mentioned in the ground truth and cannot be verified, representing a major unsupported addition. (2) Number verification: $3.5B vs $2.2B (incorrect), 250,000 bbl/d (not in original, speculative), 19% (correct), $15.2B stock repurchase (not in ground truth, likely incorrect). (3) Multi-hop reasoning is partially sound—the model connects the acquisition to operational and financial impacts and infers integration progress, but it overreaches by attributing specific stock repurchases and overstating earnings impact without evidence. (4) Correctness score is 6 due to correct core facts (acquisition, exclusion from controls, production increase %) but major errors in key financial figures and unsupported claims. Quantitative accuracy is low (5) due to incorrect dollar amounts and unverified metrics. Qualitative accuracy is 7 because the reasoning structure and entity identification (Chevron, PDC, 2023–2024 timeline) are sound. Contextual relevance is high (9) as the answer directly addresses the evolution and impacts, albeit with inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 495,
        "total_tokens": 1849
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did Southern Company's treatment and valuation of energy-related derivatives change between 2022 and 2024, particularly in terms of unrealized gains (losses) and their presentation in financial statements?",
      "original_answer": "In 2022, Southern Company reported the pre-tax effects of unrealized derivative gains (losses) from energy-related derivatives that were designated as regulatory hedging instruments and deferred, specifically as of December 31, 2021, and 2020. By 2024, the company shifted its disclosure focus to the fair value of energy-related derivatives, interest rate derivatives, and foreign currency derivatives, which were presented as either assets or liabilities in the balance sheets, typically under 'Other' or separately as 'Risk Management Activities'. This indicates a change in both the valuation approach and the presentation of these instruments in financial disclosures.",
      "llm_answer": "Between 2022 and 2024, Southern Company’s treatment of energy-related derivatives shifted toward greater use of cash flow and fair value hedges, with increased recognition of unrealized gains and losses in OCI and balance sheet net amounts. In 2024, net derivative liabilities for hedging instruments totaled $84 million (up from $87 million in 2023), while gross amounts recognized rose to $94 million in liabilities, reflecting larger derivative positions. The company continues to account for regulatory hedges separately, recording unrealized gains/losses as regulatory assets or liabilities that flow into expense as the underlying fuel is used.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies and introduces specific numerical values (e.g., $84 million net derivative liabilities in 2024, $87 million in 2023, $94 million gross liabilities) that are not present in the original answer or supported by the ground truth from the knowledge graph. These figures are entirely fabricated or misattributed, failing the quantitative accuracy test. (2) The original answer does not mention any dollar amounts related to derivative positions or liabilities for 2023 or 2024, nor does it provide comparative balance sheet figures. Therefore, the inclusion of such precise numbers undermines the answer's credibility and correctness. (3) Qualitatively, the LLM correctly identifies a shift in disclosure and treatment of derivatives, noting continued use of regulatory accounting and presentation in balance sheets, which aligns with the original answer’s claim about a change in valuation and presentation. It also correctly references the use of regulatory assets/liabilities for unrealized gains/losses, which is consistent with the original. However, it incorrectly frames the change as a move toward more cash flow and fair value hedges without evidence from the ground truth. (4) Contextually, the answer addresses the core topic—changes in treatment and presentation of energy-related derivatives—and attempts multi-hop reasoning by comparing 2022 and 2024 disclosures. But due to the invention of unsupported financial figures and lack of direct alignment with the actual shift described (from deferral of pre-tax effects to fair value presentation), the overall correctness is significantly reduced. The answer captures the general direction of change but fails on key factual and quantitative grounds.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 482,
        "total_tokens": 1828
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Chevron's financial relationship with Tengizchevroil evolve between 2022 and 2024, particularly in terms of its investment carrying value and equity earnings?",
      "original_answer": "In 2022, Chevron disclosed that its carrying value of its investment in Tengizchevroil (TCO) was about $100 higher than its underlying equity in TCO's net assets, with a significant portion of the investment tied to a $4,500 loan to fund the FGP/WPMP development. By 2024, Chevron's financial stake in Tengizchevroil had grown substantially, with its investment and advances reaching $27,368 million in 2024, compared to $26,954 million in 2023. Additionally, Chevron's equity in earnings from TCO declined from $4,386 million in 2022 to $3,033 million in 2024, indicating a reduction in profitability from the venture over this period.",
      "llm_answer": "Between 2022 and 2024, Chevron's investment in Tengizchevroil increased from a carrying value of $22,685 million (2021) to $27,368 million (2024), reflecting a $4,683 million rise, while the underlying equity in TCO's net assets remained relatively stable. This resulted in a growing excess of approximately $100 million (2021) to about $3,033 million (2024) between the investment carrying value and underlying equity. Concurrently, Chevron's share of TCO's equity earnings rose from $1,238 million in 2021 to $3,375 million in 2024, indicating stronger earnings contributions from the affiliate over the period.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, Chevron's carrying value was about $100 million higher than its underlying equity in TCO's net assets, but the LLM incorrectly claims a growing excess from $100 million in 2021 to $3,033 million in 2024, which is unsupported and misrepresents the data. The LLM cites a 2021 carrying value of $22,685 million, which is not mentioned in the original answer and contradicts the timeline (question asks about 2022–2024). The original answer does not provide a 2021 value. (2) The LLM states that Chevron's equity earnings rose from $1,238 million in 2021 to $3,375 million in 2024, but the ground truth reports a decline from $4,386 million in 2022 to $3,033 million in 2024. These numbers are both factually wrong and trend-inverted. The only correct number is the 2024 investment value of $27,368 million, which matches the original. The 2023 value of $26,954 million is also correct. However, the LLM fabricates a $4,500 loan (should be $4,500 million) and mischaracterizes its role. (3) The multi-hop reasoning is flawed: the LLM incorrectly infers trends by introducing unsupported prior-year data (2021), fails to acknowledge the decline in equity earnings, and misrepresents the nature of the investment carrying value discrepancy. It does not reflect the reduced profitability highlighted in the original. (4) The contextual relevance is moderate because it addresses the right companies and general topic (investment value and equity earnings), but the qualitative and quantitative inaccuracies severely undermine the answer's correctness. The reasoning and data synthesis are unsound, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 473,
        "total_tokens": 1790
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Walmart's ownership stake in Alert Innovation evolve between fiscal 2023 and fiscal 2024, and what specific transaction occurred to change its relationship with the entity?",
      "original_answer": "In fiscal 2023, Walmart completed a $0.4 billion acquisition of Alert Innovation, which was previously consolidated as a variable interest entity, resulting in Walmart becoming a 100% owner. However, by fiscal 2024, Walmart had subsequently sold and deconsolidated Alert Innovation, indicating a complete exit from the entity. This marks a full transformation from full ownership to no ownership within a single fiscal year.",
      "llm_answer": "Based on the provided SEC 10-K filings, Walmart's ownership stake in Alert Innovation evolved as follows:  \n\n1.  **Fiscal 2023**: Walmart completed a $0.4 billion acquisition of Alert Innovation, which had previously been consolidated as a variable interest entity, resulting in Walmart becoming a 100% owner.  \n2.  **Fiscal 2024**: The entity was subsequently sold and deconsolidated, ending Walmart's ownership stake.  \n\nThe specific transaction that changed its relationship was the **sale and deconsolidation of Alert Innovation in fiscal 2025** (as noted in Note 3 of the 2025 filing), which occurred after Walmart had acquired 100% ownership in fiscal 2023. This transaction marked the end of Walmart's direct ownership and reporting relationship with Alert Innovation.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct in terms of factual content and reasoning. (1) It accurately states that Walmart acquired Alert Innovation for $0.4 billion in fiscal 2023, becoming a 100% owner, and later sold and deconsolidated the entity, ending its ownership. This matches the ground truth. (2) Quantitatively, the $0.4 billion acquisition amount is correct, and the sequence of ownership change is accurate. However, there is a minor but notable error: the LLM claims the sale occurred in 'fiscal 2025' based on 'Note 3 of the 2025 filing', whereas the original answer and context specify the deconsolidation occurred by fiscal 2024. This misalignment in timing—citing a fiscal 2025 event when the change happened by fiscal 2024—introduces a factual inaccuracy in the timeline, even if the note referencing the transaction appears in a later filing. (3) The multi-hop reasoning is sound: the model correctly synthesizes the acquisition and subsequent divestiture to show a full ownership cycle. (4) Despite the wording being clear and semantically close to the original, the incorrect attribution of the sale to fiscal 2025 (rather than its occurrence by fiscal 2024) prevents a top score. This is a minor contextual error in timing but affects quantitative and qualitative accuracy. Contextual relevance is perfect as all parts of the question are addressed directly and appropriately.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 384,
        "total_tokens": 1692
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did Starbucks' foreign currency - other derivative asset and liability positions change from fiscal year 2022 to 2023, and what does this indicate about the company's exposure management strategy?",
      "original_answer": "In fiscal year 2022, Starbucks reported a foreign currency - other derivative asset of $55.3 million in Accumulated Other Comprehensive Income (AOCI) with $32.5 million expected to be reclassified into earnings within 12 months. By fiscal year 2023, Starbucks had shifted its position significantly, reporting foreign currency - other derivative assets of $1.9 million in current assets and $1.7 million in long-term assets, while carrying derivative liabilities of $4.7 million in current liabilities and $4.1 million in long-term liabilities. This indicates a substantial reduction in overall foreign currency - other derivative exposure and a shift from unrealized gains in equity to more balanced short- and long-term asset and liability positions.",
      "llm_answer": "From fiscal 2022 to 2023, Starbucks’ designated foreign‑currency derivative assets rose sharply—from $39.9 million to $1.9 million in prepaid expenses and from $33.5 million to $1.7 million in other long‑term assets—while designated foreign‑currency liabilities fell from $0.3 million (accrued) and $7.4 million (other long‑term) to $4.7 million (accrued) and $4.1 million (other long‑term). This shift reflects a more aggressive hedging program that reduced short‑term foreign‑currency exposure and moved a larger portion of the hedge into longer‑term assets, indicating the company is actively managing currency risk by shifting from near‑term to longer‑dated contracts and tightening its overall foreign‑exchange position.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in fiscal 2022, Starbucks reported a foreign currency - other derivative asset of $55.3 million in AOCI (Accumulated Other Comprehensive Income), not broken down into prepaid expenses or long-term assets as claimed. The LLM incorrectly states that designated foreign-currency derivative assets were $39.9 million in prepaid expenses and $33.5 million in long-term assets in 2022—this breakdown and these numbers are not supported by the original answer. In reality, the 2022 position was primarily an unrealized gain in equity (AOCI), not on-balance-sheet assets. For 2023, the LLM correctly reports the asset figures ($1.9 million current, $1.7 million long-term) and liability figures ($4.7 million current, $4.1 million long-term), which aligns with the ground truth. However, the 2022 liability figures cited by the LLM ($0.3 million accrued, $7.4 million long-term) are not present in the original answer, which does not specify 2022 liabilities at all. (2) Calculations: The LLM invents a comparison using incorrect base numbers. For example, claiming assets rose 'from $39.9 million to $1.9 million' is factually wrong—the original shows a decrease from $55.3 million (in AOCI) to $1.9 million (on balance sheet), but even that is comparing different types of positions (equity vs. asset). The LLM misrepresents the nature and location of the 2022 derivative position. (3) Multi-hop reasoning: The model fails to correctly synthesize the shift from AOCI (an equity account) to on-balance-sheet assets and liabilities. It mischaracterizes the 2022 data as if it were already on the balance sheet in asset categories, missing the key point that the 2022 position was largely unrealized and held in equity. This undermines the reasoning about exposure management. The conclusion about a 'more aggressive hedging program' and 'shifting to longer-dated contracts' is speculative and not directly supported by the original answer, which frames the change as a reduction in overall exposure and a shift from unrealized gains to balanced asset/liability positions. (4) Correctness score is low due to major quantitative errors in 2022 figures and misrepresentation of financial statement locations. Quantitative accuracy is severely compromised. Qualitative accuracy is low due to flawed reasoning and incorrect entity mapping (AOCI vs. balance sheet accounts). Contextual relevance is moderate because the answer addresses the general topic and direction of change but with incorrect data and logic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 689,
        "total_tokens": 2072
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How did Medtronic's treatment of A Preferred Shares evolve between fiscal years 2022 and 2024, and what specific action was taken regarding these shares in 2022?",
      "original_answer": "In fiscal year 2022, Medtronic redeemed 1,872 A Preferred Shares for $0.075 million during the third quarter, and no A Preferred Shares were outstanding by April 29, 2022. By fiscal year 2024, no A Preferred Shares remained outstanding, indicating that the company did not reissue or reintroduce this class of shares after the redemption in 2022. This shows a discontinuation of the A Preferred Shares following their redemption.",
      "llm_answer": "Between fiscal years 2022 and 2024, Medtronic’s treatment of its A Preferred Shares remained unchanged – no A Preferred Shares were outstanding at the end of 2024, and there was no issuance or redemption activity reported for those shares. In fiscal 2022, the company **redeemed the previously outstanding 1,872 A Preferred Shares for $0.075 million**, effectively retiring that series of preferred stock.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly states that Medtronic redeemed 1,872 A Preferred Shares for $0.075 million in fiscal year 2022, and that no A Preferred Shares were outstanding by the end of 2024. These key facts align with the ground truth. The only minor discrepancy is the phrasing 'no issuance or redemption activity reported' in 2024, which slightly understates the certainty implied in the original answer that the shares were not reissued or reintroduced. The original answer affirms a continuation of discontinuation, while the LLM implies lack of reporting rather than definitive absence of activity. (2) Quantitatively, all numbers are accurate: 1,872 shares and $0.075 million are correctly reported, and no incorrect calculations are made. Format is acceptable. (3) The multi-hop reasoning is sound—LLM synthesizes information across fiscal years 2022 and 2024, correctly inferring that the shares remained absent after redemption. However, the conclusion could have more confidently stated the discontinuation rather than citing lack of reported activity. (4) Scores reflect near-perfect factual accuracy, with only a slight softening in qualitative precision due to wording choice affecting strength of conclusion. Contextual relevance is full, as all parts of the question are addressed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1212,
        "completion_tokens": 364,
        "total_tokens": 1577
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How did Comcast's financial relationship with Atairos evolve between 2022 and 2023, particularly in terms of equity income (losses) driven by fair value adjustments on underlying investments?",
      "original_answer": "In 2022, Comcast's equity in net income (losses) from investees, particularly Atairos, showed a loss of $(434) million due to fair value adjustments on its underlying investments. In contrast, by 2023, Atairos generated income of $1.1 billion for Comcast, reflecting a significant turnaround. This change indicates a substantial improvement in the performance of Atairos's underlying investments over the period.",
      "llm_answer": "Between 2022 and 2023, Comcast's financial relationship with Atairos evolved through increased equity income volatility driven by fair value adjustments on underlying investments. In 2023, equity income (losses) from Atairos was primarily driven by fair value adjustments of $1.1 billion in income and $(434) million in losses in 2022 and 2023 respectively, reflecting significant mark-to-market movements in Atairos's portfolio. This contributed to the $1.252 billion total investment and other income (loss), net in 2023 compared to $(861) million in 2022, with the change specifically attributed to Atairos's fair value adjustments as noted in the 2023 10-K on page 39.",
      "correctness_score": 4,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the quantitative details. It incorrectly states that the $1.1 billion income and $(434) million losses occurred in 2023, when in fact the $(434) million loss was in 2022 and the $1.1 billion income was in 2023. The LLM reverses the years for these figures, which is a critical error. Additionally, the LLM introduces a 'total investment and other income (loss), net' figure of $1.252 billion in 2023 and $(861) million in 2022, which are not present in the ground truth and cannot be verified from the provided information. These numbers appear fabricated or misattributed. (2) The ground truth only mentions equity income (losses) related to Atairos: $(434) million loss in 2022 and $1.1 billion income in 2023. The LLM misattributes the magnitude and direction of these adjustments across years. While $1.1 billion and $(434) million are correct figures, their assignment to years is reversed in the sentence structure, implying both occurred in 2023. (3) The multi-hop reasoning is partially sound in that the model identifies fair value adjustments as the driver and links Atairos to Comcast's equity income. However, it fails to correctly sequence the evolution over time, which is central to the question. The mention of 'page 39 of the 2023 10-K' suggests a plausible source, but the data extracted is misrepresented. (4) Contextual relevance is high because the answer addresses equity income, fair value adjustments, and Atairos’s impact—core elements of the question. However, due to major quantitative errors and incorrect temporal attribution, the correctness and qualitative accuracy scores are significantly reduced. Minor wording flexibility is allowed, but reversing the years of large financial swings undermines the answer’s validity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 495,
        "total_tokens": 1777
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2023 to 2024, and what does this indicate about the company's strategic positioning in that geographic area?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure slightly declined to 296 billion cubic feet. This minor decrease suggests limited growth or a strategic reallocation of resources in the region during that period.",
      "llm_answer": "From 2023 to 2024, ConocoPhillips' proved natural gas reserves in the Asia Pacific/Middle East region rose modestly from 371 billion cubic feet (undeveloped) and 388 billion cubic feet (undeveloped) to 388 billion cubic feet (undeveloped) and 37 billion cubic feet (developed) for a total of 425 billion cubic feet, up from 381 billion cubic feet (undeveloped) and 28 billion cubic feet (developed) for a total of 409 billion cubic feet in 2023. This increase reflects upward revisions and purchases in the region, underscoring the company’s strategic focus on expanding its gas base in high‑growth Asia‑Pacific and Middle‑East markets.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is almost entirely incorrect in terms of factual content. The ground truth states that COP's natural gas reserves in the Asia Pacific/Middle East region declined from 312 billion cubic feet (Bcf) in 2023 to 296 Bcf in 2024. However, the LLM claims reserves increased from 409 Bcf to 425 Bcf, which is factually wrong. Additionally, the LLM introduces a breakdown into 'developed' and 'undeveloped' reserves that is not present in the ground truth and uses incorrect values (e.g., 371 Bcf undeveloped in 2023, 388 Bcf undeveloped in both years), which are unsupported. (2) All numerical values are incorrect: the totals (409 vs 312 Bcf in 2023 and 425 vs 296 Bcf in 2024), subcategories, and implied calculations are fabricated. The claimed increase of 16 Bcf contradicts the actual decrease of 16 Bcf. (3) The multi-hop reasoning is flawed—the LLM fails to correctly retrieve or synthesize the correct data across years and regions. It invents a narrative of growth and strategic expansion based on false numbers, leading to an incorrect conclusion. (4) The contextual relevance is partially preserved because the answer addresses the geographic region and the concept of strategic positioning, but the factual foundation is so inaccurate that the conclusion is invalid. Thus, the correctness and quantitative accuracy scores are very low; qualitative accuracy is also poor due to incorrect reasoning and entity usage.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1244,
        "completion_tokens": 400,
        "total_tokens": 1645
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did the revenue performance of ENBREL in Canada evolve between 2022 and 2024, and what does this indicate about its market trajectory?",
      "original_answer": "In 2022, ENBREL in Canada generated $113 million in revenue, which declined to $47 million in 2023, and further dropped to $28 million in 2024. This indicates a consistent downward trend in revenue, suggesting a shrinking market presence or reduced demand for ENBREL in Canada over this period.",
      "llm_answer": "Based on the provided financial data, ENBREL's revenue in Canada declined by 36% in 2023 (from $73 million in 2022 to $47 million in 2023) and continued to fall by 40% in 2024 (to $28 million), reflecting a sustained downward market trajectory driven by lower net selling prices, volume reductions, and increased competition. This consistent decline indicates a weakening market position for ENBREL in Canada over the three-year period.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual error in the 2022 revenue figure. The ground truth states ENBREL generated $113 million in Canada in 2022, but the LLM incorrectly reports $73 million. This error affects the accuracy of the percentage decline calculation. While the 2023 ($47M) and 2024 ($28M) figures are correct, the incorrect base year value undermines quantitative accuracy. (2) The percentage declines cited (36% from 2022 to 2023 and 40% from 2023 to 2024) are mathematically accurate only if the starting point is $73M, but with the correct $113M base, the actual decline from 2022 to 2023 is approximately 58.4% ($113M to $47M), and from 2023 to 2024 is about 40.4%, making the first percentage incorrect. (3) The qualitative reasoning about a sustained downward trajectory, weakening market position, and contributing factors like lower prices, volume reductions, and competition aligns well with the implications of the data and shows sound multi-hop synthesis and logical inference. (4) Despite the major error in the 2022 revenue number, the answer correctly identifies the trend direction, includes all relevant years, and provides contextually appropriate analysis, warranting moderate scores in qualitative accuracy and high contextual relevance. The correctness score is reduced primarily due to the critical numerical inaccuracy in the baseline revenue figure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1180,
        "completion_tokens": 390,
        "total_tokens": 1570
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has Qualcomm's approach to linking human capital advancements with executive compensation evolved from fiscal 2023 to fiscal 2024, and what specific performance modifier range was applied in fiscal 2024?",
      "original_answer": "In fiscal 2023, Qualcomm indicated that human capital advancements would be considered in determining executives' fiscal 2024 bonus. By fiscal 2024, this approach evolved into a more defined structure where progress toward human capital advancements served as a non-financial performance modifier that could adjust executives' bonus payouts by a multiplier ranging from 0.9 to 1.1. This represents a shift from a general consideration to a quantified performance modifier in executive compensation.",
      "llm_answer": "From fiscal 2023 to fiscal 2024, Qualcomm’s human‑capital strategy remained anchored in its broader ESG framework—emphasizing diversity, talent development, and wellness—but the company explicitly tied measurable human‑capital progress to executive pay for the first time.  In its 2024 proxy filing, Qualcomm disclosed that the HR and Compensation Committee will adjust executive bonuses by a non‑financial performance modifier ranging from **0.9 × to 1.1 ×** based on achievements in human‑capital initiatives (e.g., diversity metrics, turnover reduction, talent‑development programs).  This represents a direct linkage of human‑capital advancements to executive compensation that was not present in the prior fiscal year.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, the performance modifier range of 0.9 × to 1.1 × is correctly reported, matching the original answer's 'multiplier ranging from 0.9 to 1.1'. (2) The answer correctly identifies the evolution from fiscal 2023 to 2024: in 2023, human capital was a general consideration for 2024 bonuses; in 2024, it became a formal non-financial performance modifier with a defined range. This multi-hop synthesis across fiscal years is sound. (3) Entity accuracy is strong: Qualcomm, fiscal years 2023 and 2024, executive compensation, and the HR and Compensation Committee are all correctly referenced. (4) The LLM adds contextual detail (e.g., diversity metrics, turnover reduction) not in the original answer but plausibly derived from typical human capital initiatives, which enhances clarity without introducing inaccuracies. The only minor gap is that the original answer explicitly notes the shift 'from a general consideration to a quantified performance modifier', while the LLM says it was 'not present in the prior fiscal year', which slightly overstates the absence in 2023. However, the core reasoning and factual content remain correct. Thus, the answer earns a 9/10 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 383,
        "total_tokens": 1704
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has the therapeutic scope of Breyanzi evolved between 2022 and 2024, based on the specific indications and approvals documented in those years?",
      "original_answer": "In 2022, Breyanzi was associated with trials for 3L+ Chronic Lymphocytic Leukemia (TRANSCEND-CLL-004) and 3L+ Follicular Lymphoma (TRANSCEND-FL), both with expected timing in 2023/24. By 2024, Breyanzi received FDA accelerated approvals for two distinct indications: relapsed or refractory Follicular Lymphoma (FL) after at least two prior lines of therapy (approved in May 2024), and relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) after at least two prior lines of therapy, including a Bruton tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor (approved in March 2024). This reflects a shift from being in late-stage trials to having concrete accelerated approvals in specific patient populations.",
      "llm_answer": "Between 2022 and 2024, Breyanzi's therapeutic scope expanded significantly through multiple regulatory approvals for new indications. Initially approved in 2022 for relapsed/refractory DLBCL, CLL/SLL, and follicular lymphoma, it received accelerated FDA approvals in 2023 for relapsed/refractory CLL/SLL (after two prior therapies including BTKi and BCL2i) and MCL (after two prior lines), followed by a 2024 Japan approval for relapsed/refractory FL after one prior line. Most notably, in May 2024, it gained FDA accelerated approval for relapsed/refractory follicular lymphoma patients who had received at least two prior systemic therapies, and in August 2024, it received Japan's approval for relapsed/refractory FL after one prior systemic therapy, broadening its use across multiple B-cell malignancies including CLL/SLL, FL, and MCL.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that Breyanzi was 'initially approved in 2022 for relapsed/refractory DLBCL, CLL/SLL, and follicular lymphoma' — the ground truth indicates it was not approved for CLL/SLL or FL in 2022, but rather was in trials (TRANSCEND-CLL-004 and TRANSCEND-FL) with expected timing in 2023/24. The 2022 status was investigational, not approved. Additionally, the LLM claims FDA accelerated approvals in 2023 for CLL/SLL and MCL — but the ground truth shows the CLL/SLL approval occurred in March 2024, not 2023, and there is no mention of MCL approval in the ground truth. The May 2024 FL approval is correctly identified, but the LLM adds an August 2024 Japan approval for FL after one prior line, which is not present in the original answer and introduces unverified international approvals. (2) Quantitative accuracy is low: dates (2023 vs. March and May 2024), number of prior therapies (the ground truth specifies 'at least two' for FL, while LLM says 'one prior line' for Japan approval), and incorrect indication (MCL not mentioned in ground truth) all reflect errors. (3) Multi-hop reasoning is partially sound — the model attempts to track evolution over time and links approvals to indications — but fails in synthesizing the correct timeline and status (trials vs. approvals). It conflates trial activity with regulatory approval in 2022 and invents approvals not documented in the ground truth. (4) Contextual relevance is fair because the answer addresses the evolution of Breyanzi’s indications and focuses on the right drug and time frame, but the factual foundation is flawed. The core progression from trials to approvals is conceptually aligned, but execution is inaccurate. Thus, correctness is scored low due to major factual and temporal errors despite some correct elements like the May 2024 FL approval.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1398,
        "completion_tokens": 516,
        "total_tokens": 1914
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the financial performance of Disney's Resorts and Vacations segment evolved from 2023 to 2024, and how does this compare to the overall revenue growth of the Parks & Experiences segment?",
      "original_answer": "The Resorts and Vacations segment saw an increase in revenue from $7,949 million in 2023 to $8,375 million in 2024, representing a 5% growth. This growth was slightly below the overall Parks & Experiences revenue growth of 5%, which increased from $32,549 million in 2023 to $34,151 million in 2024. The Resorts and Vacations segment remained a significant contributor to the overall Parks & Experiences division, maintaining a consistent proportion of total revenue despite the modest growth difference.",
      "llm_answer": "The Resorts and Vacations segment within Experiences showed strong growth, with revenues rising 5% to $34,151 million in 2024 from $32,549 million in 2023, driven by increases in resort and vacation revenue (5% growth from higher cruise ticket prices, hotel rates, and occupied room nights) and parks & experiences merchandise, food and beverage revenue (4% growth from higher volumes and guest spending). This contributed to the segment's overall 5% revenue growth and a 4% increase in operating income to $9,272 million, aligning with the broader Parks & Experiences segment's 5% revenue growth, which outpaced the segment's own growth due to robust international performance and higher attendance.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer incorrectly swaps the financial figures for the Resorts and Vacations segment with those of the entire Parks & Experiences segment. It states that Resorts and Vacations revenue rose from $32,549 million to $34,151 million, which are actually the total Parks & Experiences revenues, not Resorts and Vacations. The correct figures are $7,949 million (2023) and $8,375 million (2024) for Resorts and Vacations. The 5% growth rate is correct for both segments, but the LLM misattributes the larger revenue base to the sub-segment. Additionally, the LLM introduces an operating income figure of $9,272 million, which is not mentioned in the ground truth and cannot be verified. (2) Quantitative accuracy is severely compromised: the dollar amounts are off by billions, and the operating income is fabricated or misattributed. The 5% growth rate is correct, but it is applied to the wrong revenue base. (3) The reasoning is flawed in the multi-hop synthesis: the model fails to distinguish between the Resorts and Vacations segment and the broader Parks & Experiences segment, leading to incorrect comparisons and attributions. It incorrectly claims the sub-segment's growth 'aligned with' the overall segment while implying the overall segment grew faster, which contradicts the ground truth that both grew at 5%. (4) Contextual relevance is moderate because the answer addresses the right topic and mentions relevant drivers like cruise prices and hotel rates, but the factual foundation is incorrect, undermining the entire response. The qualitative accuracy is low due to entity confusion and logical errors in segment hierarchy and performance comparison.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 459,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has the structure and value of CVS's forward contracts associated with accelerated share repurchase (ASR) transactions evolved between 2023 and 2024?",
      "original_answer": "In 2023, CVS executed a $2.0 billion ASR with Citibank, N.A., which was accounted for as an initial treasury stock transaction of $1.6 billion and a forward contract of $0.4 billion. The forward contract was classified as an equity instrument and recorded within capital surplus, with the final 20% of shares received in February 2023. In 2024, CVS entered into a larger $3.0 billion ASR with Morgan Stanley, accounted for as an initial treasury stock transaction of $2.6 billion and a forward contract of $0.4 billion. The forward contract was similarly classified and recorded, but the remaining 15% of shares were received later, in March 2024. Despite the increase in the ASR size, the forward contract value remained constant at $0.4 billion, indicating a shift in the proportion of the ASR allocated to the forward contract component.",
      "llm_answer": "The forward contracts tied to CVS’s accelerated share‑repurchase (ASR) transactions shifted in scale and accounting treatment between 2023 and 2024. In 2023 the company entered a $2.0 billion ASR with Citibank, recording a $1.6 billion initial treasury‑stock purchase and a $0.4 billion forward contract classified as equity in capital surplus; the forward was later re‑classified to treasury stock when the remaining shares were received in February 2023. In 2024 the company executed a larger $3.0 billion ASR with Morgan Stanley, initially recording a $2.6 billion treasury‑stock purchase and a $0.4 billion forward equity instrument, which was subsequently re‑classified to treasury stock after the final share delivery in March 2024. Thus, the notional amount of the forward contracts grew from $0.4 billion (2023) to $0.4 billion within a larger $3.0 billion program, and the timing of the re‑classification moved from February 2023 to March 2024.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key facts: the 2023 ASR with Citibank ($2.0B total, $1.6B treasury stock, $0.4B forward contract), the 2024 ASR with Morgan Stanley ($3.0B total, $2.6B treasury stock, $0.4B forward), the classification of the forward contracts as equity in capital surplus, and the timing of final share receipt (February 2023 and March 2024). However, it incorrectly states that the forward contracts were 're-classified to treasury stock' upon final delivery. The original answer does not mention reclassification—only that the final shares were received. This is a minor but notable accounting inaccuracy, as forward contracts in ASRs are typically settled by share delivery, not reclassified. (2) All numeric values—dollar amounts ($2.0B, $1.6B, $0.4B, $3.0B, $2.6B), dates (February 2023, March 2024), and implied proportions (20%, 15%)—are accurate. The statement that the forward amount 'grew from $0.4B to $0.4B' is awkward but factually neutral. (3) The multi-hop reasoning is sound: the model correctly compares the two ASR transactions across years, synthesizes the structure and value evolution, and notes the constant forward value despite larger ASR size. The conclusion about shifting proportions is implied correctly. (4) Scores reflect high factual accuracy with a minor deduction for the incorrect suggestion of reclassification, which affects qualitative and overall correctness. Contextual relevance is perfect—the answer directly addresses the evolution of structure and value.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1450,
        "completion_tokens": 423,
        "total_tokens": 1873
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How did Duke Energy's disclosure regarding the Master Retirement Trust's pension asset valuation methodology evolve from 2023 to 2024, particularly in terms of transparency around fair value categorization?",
      "original_answer": "In 2023, Duke Energy disclosed the allocation percentages of the Master Retirement Trust among its subsidiaries and noted that certain investments measured at fair value using the net asset value per share practical expedient were not categorized in the fair value hierarchy. In 2024, the company maintained the same allocation percentages but added a new disclosure element — a reconciliation of beginning and ending balances of the Master Retirement Trust's qualified pension and other post-retirement assets, specifically those valued using significant unobservable inputs (Level 3). This represents a significant increase in transparency regarding the fair value categorization of pension assets.",
      "llm_answer": "From 2023 to 2024 Duke Energy’s pension‑trust disclosures show a modest increase in transparency around fair‑value categorization. The 2024 tables (pages 226‑227) continue to present the same five‑level hierarchy (Level 1, Level 2, Level 3, Not Categorized) and disclose the exact amounts in each category, but they also add a clearer reconciliation of Level 3 balances (page 221) and a more detailed breakdown of assets measured using the net‑asset‑value practical expedient (page 227). Compared with the 2023 disclosures (pages 217‑221), the 2024 version adds these additional explanatory notes and a separate “Not Categorized (b)” column, making the fair‑value hierarchy and the composition of Level 3 items more explicit.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth, but contains minor inaccuracies and omissions that prevent a perfect score. (1) Quantitatively, the LLM correctly identifies the continuation of fair value hierarchy categories and the addition of a Level 3 reconciliation in 2024, which matches the ground truth. However, it introduces details not present in the original answer—such as specific page numbers (e.g., pages 226–227, 221, 217–221) and a 'Not Categorized (b)' column—which are not mentioned or verifiable from the ground truth and may be hallucinated. These additions do not contradict the core facts but introduce unverified specifics. (2) The ground truth emphasizes that the 2023 disclosure noted certain NAV-based investments were 'not categorized' in the fair value hierarchy, and that 2024 added a Level 3 reconciliation for assets using significant unobservable inputs. The LLM captures this correctly in substance, referring to clearer reconciliation of Level 3 balances and more detailed breakdown of NAV-expedient assets. (3) The qualitative reasoning is sound: the model correctly infers increased transparency and identifies the key evolution in disclosure—addition of Level 3 balance reconciliation. It also correctly notes that allocation percentages remained unchanged, which is implied in the original answer by stating 'maintained the same allocation percentages'. (4) Contextually, the answer is highly relevant, directly addressing the evolution in transparency around fair value categorization. However, the mention of a 'five-level hierarchy' is misleading—there are only three levels in the fair value hierarchy (Level 1–3), with 'Not Categorized' being an additional reporting category, not a formal level. This reflects a minor conceptual error. Overall, the core facts and multi-hop synthesis (comparing 2023 vs 2024 disclosures on categorization and transparency) are accurate, warranting a high score, but the hallucinated page references and slight mischaracterization of the hierarchy prevent a 9–10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 552,
        "total_tokens": 1923
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How did Pfizer's financial obligations and revenue recognition related to Paxlovid change between 2023 and 2024, particularly concerning the U.S. government's inventory return and the creation of the U.S. Strategic National Stockpile?",
      "original_answer": "In 2023, Pfizer recorded a non-cash revenue reversal of $3.5 billion related to the expected return of 6.5 million EUA-labeled Paxlovid treatment courses previously purchased by the U.S. government. In 2024, this estimate was adjusted based on the actual return of 5.1 million treatment courses, resulting in a favorable final adjustment of $771 million. Additionally, in 2024, Pfizer recognized $442 million of revenue in connection with the creation of the U.S. Strategic National Stockpile (SNS) of 1.0 million Paxlovid treatment courses for future pandemic preparedness. These developments reflect a shift from revenue reversal and inventory transition in 2023 to revenue recognition and strategic stockpile establishment in 2024.",
      "llm_answer": "Pfizer reversed $3.5 billion of Paxlovid revenue in Q4 2023 due to expected returns of EUA‑labeled courses, then recorded a $771 million favorable adjustment in Q1 2024 for 5.1 million courses actually returned, and recognized $442 million of revenue in Q3 2024 from the newly created U.S. Strategic National Stockpile of 1 million courses, while the remaining undelivered courses will generate revenue through 2028.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies all key financial figures: the $3.5 billion non-cash revenue reversal in 2023, the $771 million favorable adjustment in 2024 based on the actual return of 5.1 million treatment courses, and the $442 million revenue recognized in 2024 from the U.S. Strategic National Stockpile (SNS) for 1.0 million courses. These numbers match the ground truth exactly. (2) Quantitative accuracy is perfect—dollar amounts, treatment course quantities, and their alignment with events are all factually correct. The mention of Q4 2023 and Q1/Q3 2024 adds temporal precision not in the original but consistent with plausible timing and does not contradict the ground truth. (3) The multi-hop reasoning is sound: the answer connects the 2023 revenue reversal due to expected returns, the 2024 adjustment based on actual returns, and the new revenue stream from the SNS, capturing the shift in Pfizer's financial obligations and revenue recognition. The additional detail about undelivered courses generating revenue through 2028 is not in the original answer but is plausible and does not conflict with the ground truth; it may reflect forward-looking statements from filings. (4) The answer is semantically equivalent and slightly more detailed than the ground truth, with no factual errors. The only reason for not scoring a 10 is the addition of forward-looking revenue through 2028, which, while reasonable, was not part of the verified knowledge graph answer and introduces unverified information. Otherwise, the response is fully accurate, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 443,
        "total_tokens": 1753
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has the financial performance of ERLEADA evolved between 2022 and 2023, and what does this indicate about its role in J&J's oncology portfolio?",
      "original_answer": "ERLEADA's sales increased from $1,881 million in 2022 to $2,387 million in 2023, representing a 26.9% growth. This indicates that ERLEADA has become a more prominent contributor to J&J's oncology segment, which saw overall growth of 10.5% in 2023. The strong performance of ERLEADA contrasts with the decline in other key oncology products like IMBRUVICA and ZYTIGA, suggesting that ERLEADA is playing an increasingly important role in sustaining J&J's oncology revenue.",
      "llm_answer": "Between 2022 and 2023, ERLEADA sales grew 26.9% (from $1,881M to $2,387M), representing a 27.5% operational increase, and it was a key growth driver within J&J's Oncology segment, which grew 10.5% overall. This strong performance underscores ERLEADA's expanding role in J&J's oncology portfolio, particularly as a next-generation therapy for metastatic castration-resistant prostate cancer, contributing to the segment's resilience amid biosimilar competition and patent expirations for other key oncology products like ZYTIGA and IMBRUVICA.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports ERLEADA's sales growth from $1,881M in 2022 to $2,387M in 2023, which is a 26.9% increase—this matches the ground truth exactly. The mention of a '27.5% operational increase' is a minor discrepancy but likely reflects a different calculation method (e.g., adjusting for currency or acquisitions) not present in the ground truth; however, since the absolute values and the 26.9% figure are correct, this does not constitute a factual error. (2) All numeric values—$1,881M, $2,387M, 26.9%, and 10.5% oncology segment growth—are accurate and correctly calculated. The 26.9% growth is mathematically correct: (2,387 - 1,881) / 1,881 ≈ 0.269. (3) The reasoning is sound: the LLM correctly identifies ERLEADA as a key growth driver within J&J's oncology portfolio and contextualizes its performance against the backdrop of declining sales for ZYTIGA and IMBRUVICA, aligning with the multi-hop inference required (linking ERLEADA’s growth to portfolio dynamics). (4) The answer is semantically equivalent to the ground truth, with slightly enhanced context (e.g., mentioning 'metastatic castration-resistant prostate cancer' and 'biosimilar competition'), which adds value without introducing inaccuracies. The only minor shortcoming is the unexplained '27.5% operational increase,' which slightly deviates from the ground truth but doesn't undermine the core correctness. Thus, the answer is highly accurate, complete, and relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1253,
        "completion_tokens": 407,
        "total_tokens": 1660
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How did the global sales performance of ERLEADA evolve from 2022 to 2023, and what does this indicate about its market trajectory?",
      "original_answer": "In 2022, ERLEADA reported worldwide sales of $1,291 million, with a significant growth rate of 70.0% compared to the previous year. By 2023, the product's global sales increased further to $2,387 million, reflecting a 26.9% growth from 2022. This indicates that ERLEADA continued to experience strong market adoption and revenue expansion, albeit at a slower growth rate compared to the prior year, suggesting a maturing growth phase in its lifecycle.",
      "llm_answer": "ERLEADA's global sales showed a dramatic upward trajectory, rising from $297 million in 2021 to $760 million in 2022 and then to $1,291 million in 2023—a 96 % increase from 2022 and a 70 % increase overall. This rapid growth indicates that ERLEADA is gaining strong market traction and is on an upward growth path.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains multiple factual inaccuracies. It incorrectly states ERLEADA's 2022 sales as $760 million, while the ground truth is $1,291 million. It also claims 2023 sales were $1,291 million, but the correct figure is $2,387 million. Additionally, it references 2021 sales ($297 million) not asked in the question and provides a false 96% growth from 2022 to 2023, whereas actual growth was 26.9%. The 70% growth mentioned applies to 2021–2022, not overall as implied. (2) Calculations are fundamentally wrong: a rise from $760M to $1,291M would be ~70% growth, not 96%, and the LLM misattributes the 70% figure. The correct 26.9% growth from 2022 to 2023 is entirely missing. (3) The multi-hop reasoning fails—instead of comparing 2022 and 2023 as required, the model fabricates 2021 data and constructs an incorrect timeline. It does not reflect the slowing growth trajectory (from 70.0% to 26.9%), which is central to the market trajectory analysis. (4) While the general sentiment of 'strong market traction' aligns with the conclusion, the incorrect data and flawed progression undermine the reasoning. Scores are low due to severe quantitative errors and incorrect synthesis; relevance is moderate because it addresses sales evolution and market trajectory, albeit with wrong data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1187,
        "completion_tokens": 367,
        "total_tokens": 1554
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did NVDA's debt management strategy evolve regarding the 0.584% Notes Due 2024 between fiscal years 2023 and 2024?",
      "original_answer": "In fiscal year 2023, NVDA reported a balance of $1,250 million for the 0.584% Notes Due 2024, with an effective interest rate of 0.66%. By fiscal year 2024, NVDA disclosed in its 10-K filing that it repaid these notes in fiscal year 2025, resulting in no remaining balance for this instrument as of January 26, 2025. This indicates a shift in NVDA's debt management strategy, where it chose to retire the obligation before or shortly after the due date rather than rolling it over or extending it.",
      "llm_answer": "Based on the provided 10‑K pages, NVIDIA’s debt management strategy evolved such that the 0.584% Notes Due 2024 were fully repaid during fiscal 2025 (the notes were listed as having a zero balance as of January 26 2025, whereas they remained at $1,250 million on the 2023 balance sheet). Consequently, the company’s long‑term debt portfolio now excludes that 2024‑maturity tranche, shifting the remaining maturities to later dates (e.g., 2026‑2060 notes) and reflecting a lower short‑term portion of long‑term debt. This repayment reduced the short‑term liability and altered the composition of NVIDIA’s outstanding notes.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that NVDA had $1,250 million in 0.584% Notes Due 2024 on its 2023 balance sheet and that the balance was zero as of January 26, 2025, indicating repayment in fiscal 2025. These quantitative facts match the ground truth exactly. The effective interest rate of 0.66% mentioned in the original answer is not included in the LLM response, which is a minor omission but does not affect the core of the debt management evolution described. (2) All numbers, dates, and dollar amounts are accurate: $1,250 million, January 26, 2025, and fiscal 2025 repayment are all correctly reported. Format variations are consistent and acceptable. (3) The multi-hop reasoning is sound: the model correctly infers a strategic shift in debt management by comparing the balance across fiscal years and linking the repayment to a broader change in the maturity profile of NVIDIA’s debt (e.g., shift to later maturities like 2026–2060). This demonstrates proper synthesis across time periods and financial statements. (4) The answer is semantically equivalent to the ground truth in conveying that NVDA retired the notes rather than rolling them over, reflecting a strategic choice. The only minor gap is the missing mention of the effective interest rate, which adds context but is not central to the evolution of the strategy. Scores reflect high accuracy with a small deduction in qualitative accuracy due to this omission.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1272,
        "completion_tokens": 402,
        "total_tokens": 1675
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did Honeywell's investment in Mortgage/Asset-backed securities evolve between 2022 and 2023, and what was the magnitude of this change?",
      "original_answer": "In 2022, Honeywell reported $982 million invested in Mortgage/Asset-backed securities under U.S. Plans. By 2023, this amount had significantly decreased to $10 million under Non-U.S. Plans. This represents a reduction of $972 million, or over 98%, indicating a major shift in Honeywell's investment strategy concerning Mortgage/Asset-backed securities.",
      "llm_answer": "Honeywell’s investment in mortgage/asset‑backed securities declined modestly from $1,072 million at the end of 2022 to $676 million at the end of 2023, a reduction of $396 million (approximately 37 %). This decrease reflects the company’s reallocation of assets within its pension portfolios, as shown by the lower balance of mortgage/asset‑backed securities in the Level 2 and Level 3 disclosures for both U.S. and non‑U.S. plans.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Honeywell's investment in Mortgage/Asset-backed securities dropped from $982 million in 2022 (under U.S. Plans) to $10 million in 2023 (under Non-U.S. Plans), a reduction of $972 million (over 98%). The LLM incorrectly reports the 2022 amount as $1,072 million and 2023 as $676 million, which are not supported by the ground truth. The calculated reduction of $396 million (37%) is therefore also incorrect. (2) The quantitative values are entirely wrong—both the starting and ending balances, the difference, and the percentage change are inaccurate. The correct change is a $972 million decrease (98.98%), not $396 million (37%). (3) The reasoning is flawed in terms of multi-hop synthesis: the ground truth indicates a strategic shift involving a move from U.S. to Non-U.S. plans and a near-elimination of this asset class, but the LLM suggests only a modest reallocation within pension portfolios without acknowledging the plan-type shift or the magnitude of divestment. (4) Contextual relevance is moderate—the answer addresses investment evolution and magnitude of change, but with incorrect data and incomplete entity mapping (fails to distinguish U.S. vs. Non-U.S. plan shifts). The conclusion about reallocation is plausible but understates the strategic significance. Scores reflect major factual errors in numbers and synthesis, though the response structure aligns with the question's intent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1194,
        "completion_tokens": 415,
        "total_tokens": 1609
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How did Capital One's use of securitized debt obligations evolve between 2022 and 2023, particularly in terms of their role in the company's funding mix and their fair value classification?",
      "original_answer": "In 2022, securitized debt obligations were described as a key component of Capital One's diversified funding strategy, used alongside deposits, senior and subordinated notes, federal funds purchased, and FHLB advances to maintain access to wholesale funding sources. By 2023, the company disclosed that the carrying value of securitized debt obligations was $18,043 million, with an estimated fair value of $18,067 million, all classified under Level 2 of the fair value hierarchy. This indicates that while the company continued to rely on securitized debt obligations as a funding source, the 2023 data provides more specific transparency into their valuation and classification, showing a shift toward more detailed disclosure and potentially more structured risk management.",
      "llm_answer": "Between 2022 and 2023, Capital One's use of securitized debt obligations shifted from being classified as Level 2 to Level 3 in the fair value hierarchy, reflecting their reduced reliance on observable market inputs and increased use of unobservable valuation techniques. This evolution underscores their growing integration of securitized debt into the funding mix, particularly as a tool for managing liquidity and funding needs, while maintaining a diversified mix of wholesale funding sources. The fair value of these obligations was consistently classified as Level 2 in 2022 (recorded at $16,918 million) and remained Level 3 in 2023 (recorded at $18,067 million), indicating a structural shift in how these instruments were valued and managed within the company's funding strategy.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors. It incorrectly states that securitized debt obligations shifted from Level 2 to Level 3 in the fair value hierarchy, when the ground truth confirms they were classified under Level 2 in both years (specifically all in Level 2 in 2023). The LLM also falsely claims that in 2022 the obligations were Level 2 and in 2023 they were Level 3, which contradicts the original answer. Additionally, the LLM reports a 2022 value of $16,918 million, which is not mentioned in the ground truth; the original answer only provides 2023 figures ($18,043 million carrying value and $18,067 million fair value). (2) Quantitative accuracy is low: the only correct number is the $18,067 million fair value in 2023, but it is misattributed to Level 3 instead of Level 2. The $16,918 million figure for 2022 has no support in the ground truth. (3) The multi-hop reasoning is flawed: the LLM infers a shift in valuation hierarchy and increased reliance on securitized debt, but the original answer indicates continuity in use with improved disclosure, not a structural shift in valuation methodology. The conclusion about 'growing integration' and 'reduced reliance on observable inputs' is unsupported and opposite to the transparency trend described. (4) Contextual relevance is moderate because the answer addresses the funding mix and fair value classification as asked, but the incorrect facts and reasoning undermine the response. The focus on evolution in funding and valuation is appropriate, but the substance is largely incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1402,
        "completion_tokens": 435,
        "total_tokens": 1837
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How did JPMorgan's treatment of CECL capital transition provisions under U.S. capital rules evolve from 2023 to 2024, and what was the quantitative change in the CECL-related capital benefit during this period?",
      "original_answer": "In 2023, JPMorgan reported a $1.4 billion benefit from the CECL capital transition provisions included in its CET1 capital. By 2024, this benefit had decreased to $720 million, reflecting a phased reduction in the CECL-related capital benefit as the provisions were being phased in under U.S. capital rules. The capital metrics indicated that the CECL benefit was fully phased in by January 1, 2025.",
      "llm_answer": "From 2023 to 2024, JPMorgan's CECL capital transition provisions under U.S. capital rules evolved with the full phase-in of the $720 million CECL benefit, which was fully reflected in CET1 capital by January 1, 2025 (compared to a $1.4 billion benefit in 2023). The quantitative change in the CECL-related capital benefit decreased from $1.4 billion in 2023 to $720 million in 2024, representing a $680 million reduction in the benefit.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key facts: JPMorgan's CECL-related capital benefit decreased from $1.4 billion in 2023 to $720 million in 2024, representing a $680 million reduction. These numbers match the ground truth exactly, and the calculation ($1.4B - $720M = $680M) is accurate. The phase-in completion date of January 1, 2025, is also correctly stated. (2) All numeric values are correct and properly formatted; the quantitative change is accurately computed. (3) The multi-hop reasoning is sound: the model correctly synthesizes the evolution of the CECL provision over time, connects the decreasing benefit to regulatory phase-in rules, and references the full phase-in timeline. However, there is a minor wording issue: the phrase 'full phase-in of the $720 million CECL benefit' could be misinterpreted to imply that $720M is the final phased-in amount, whereas the ground truth indicates that the benefit is being reduced over time and will be fully phased out (not in) by 2025—meaning the $720M is a transitional reduction, not a final inclusion. This slightly misrepresents the direction of the phase-in (benefit decreasing toward zero, not building up to $720M). Despite this, the overall trend and numbers are correct. (4) Scores reflect near-perfect factual accuracy with only a minor qualitative nuance in interpretation affecting clarity, not correctness of data. Contextual relevance is excellent as all parts of the question are addressed directly and accurately.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1224,
        "completion_tokens": 416,
        "total_tokens": 1641
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How did the terms and capacity of Salesforce's Revolving Loan Credit Agreement evolve between fiscal 2023 and fiscal 2024?",
      "original_answer": "In fiscal 2023, Salesforce had a $3.0 billion unsecured revolving credit facility under the Revolving Loan Credit Agreement, which was scheduled to mature in December 2025. By fiscal 2024, this agreement was replaced with a new $5.0 billion unsecured revolving credit facility that matures in October 2029. The increase in capacity and the extension of the maturity date reflect a strategic enhancement of the company’s credit resources.",
      "llm_answer": "Between fiscal 2023 and fiscal 2024, Salesforce’s revolving credit facility was expanded from a $3.0 billion unsecured facility under the Prior Credit Agreement (maturing Dec 2025) to a $5.0 billion unsecured revolving facility under the new Revolving Loan Credit Agreement, which now matures in October 2029. The new agreement replaced the prior facility and provides greater borrowing capacity, although no borrowings were outstanding as of January 31 2025.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all key aspects. (1) Quantitative accuracy: The dollar amounts ($3.0 billion in fiscal 2023 and $5.0 billion in fiscal 2024) are correct, as are the maturity dates (December 2025 for the prior facility and October 2029 for the new one). The fiscal years align with the question's scope. (2) Completeness: The answer addresses both the change in capacity and the change in terms (maturity date), and correctly notes the replacement of the prior agreement. The additional detail about no borrowings outstanding as of January 31, 2025, is consistent with typical disclosures and does not contradict the ground truth. (3) Entity accuracy: 'Salesforce' is correctly identified, and the references to the 'Prior Credit Agreement' and 'new Revolving Loan Credit Agreement' accurately reflect the evolution of the facility. (4) Reasoning: The multi-hop synthesis—comparing the two fiscal years' credit facilities—is sound and logically presented. The conclusion about increased capacity and extended term is valid. (5) Semantic equivalence: Though the LLM adds a minor detail about zero borrowings, the core information matches the original answer exactly in meaning and fact. All scores are maximized due to full factual correctness, precise numbers, accurate reasoning, and high relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1218,
        "completion_tokens": 373,
        "total_tokens": 1591
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did UPS's relationship with Coyote evolve between 2022 and 2024, and what financial impact did this change have on UPS in 2024?",
      "original_answer": "In 2022, UPS had an active business relationship with Coyote, operating it as a branded subsidiary that provided truckload brokerage services in the U.S. and Europe. Coyote was integrated into UPS’s broader supply chain offerings, leveraging the UPS fleet and third-party carrier networks to provide customized transportation solutions. However, by 2024, UPS had completed the divestiture of Coyote, recording a pre-tax gain of $156 million ($152 million after tax) as a result of the transaction. This change marks a full transition from a strategic business unit to a divested asset, reflecting a shift in UPS's supply chain strategy.",
      "llm_answer": "UPS's relationship with Coyote evolved from a strategic partnership to a divestiture. The company completed the sale of Coyote in the third quarter of 2024, recording a pre-tax gain of $156 million ($152 million after tax) on the transaction. This change had a positive financial impact in 2024 by generating the $156 million gain, which was excluded from non-GAAP measures as it was deemed non-recurring to ongoing operations.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers are correct: the pre-tax gain of $156 million and after-tax gain of $152 million match the original answer exactly. The timing of the divestiture in 2024 is consistent, and specifying the third quarter adds precision without contradicting the ground truth. (2) The financial impact is correctly identified as a positive one-time gain, and the note that it was excluded from non-GAAP measures adds relevant context not in the original but is factually plausible and enhances the answer. (3) Qualitatively, the evolution from an operational subsidiary to a divested asset is accurately captured as a 'strategic partnership to a divestiture,' though 'branded subsidiary' and integration details (e.g., U.S. and Europe operations, use of third-party carriers) from 2022 are slightly underdeveloped. However, the core multi-hop reasoning—connecting the change in relationship to its financial outcome—is sound and correctly synthesized. (4) The answer is fully contextually relevant, directly addressing both the evolution of the relationship and the financial impact in 2024. The only minor shortcoming is the lack of detail about Coyote’s operational role pre-divestiture, but the key facts required for correctness are present. Hence, a 9/10 for correctness and qualitative accuracy, with full marks for quantitative and contextual performance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1262,
        "completion_tokens": 399,
        "total_tokens": 1661
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How has Union Pacific's relationship with chassis evolved between 2023 and 2024, particularly in terms of total units and ownership structure?",
      "original_answer": "In 2023, Union Pacific had a total of 48,340 chassis units, with 30,635 owned and 17,705 leased. By 2024, the total number of chassis dropped significantly to 5,553 units, with only 4,356 owned and 1,197 leased. This represents a transformation in Union Pacific's relationship with chassis, shifting from a heavy reliance on both owned and leased chassis to a much smaller, still mixed but significantly reduced footprint. The drastic reduction in total chassis units indicates a strategic shift in how the company manages this asset class.",
      "llm_answer": "Based on the provided 2023 and 2024 10-K excerpts, Union Pacific's relationship with chassis has evolved in ownership structure and fleet management. In 2023, the company reported 4,356 owned and 1,197 leased chassis (total 5,553), with an average age of 11.6 years. By 2024, this shifted to 4,356 owned and 1,197 leased chassis (total 5,553), maintaining the same total but with the average age decreasing to 11.6 years (consistent with the 2024 data showing 11.6 years). The company emphasizes maintaining a buffer fleet to ensure agility, noting that without this buffer, equipment acquisition lead times could exceed a year, and confirms that its chassis fleet is appropriately sized to support growth without additional acquisitions.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in terms of quantitative facts. It claims that in 2023, Union Pacific had only 5,553 total chassis (4,356 owned, 1,197 leased), which is actually the 2024 data. The correct 2023 figures are 48,340 total chassis (30,635 owned, 17,705 leased), a major discrepancy. The LLM incorrectly states that the total chassis count was the same in both years, completely missing the significant reduction from 48,340 to 5,553 units. (2) All numerical values for 2023 are wrong, and the LLM repeats the 2024 numbers for both years. The average age of 11.6 years is mentioned, but this detail was not in the original answer and cannot be verified from the ground truth provided, making it potentially fabricated or misattributed. (3) The reasoning is flawed: the LLM fails to recognize the multi-hop requirement to compare 2023 and 2024 data correctly. Instead, it asserts no change occurred, contradicting the ground truth that highlights a strategic shift due to a drastic reduction. The synthesis across years is incorrect, and the conclusion about 'maintaining the same total' is false. (4) Despite the factual errors, the answer is contextually relevant—it addresses ownership structure, total units, and attempts to interpret strategic implications. However, due to severe quantitative inaccuracies and incorrect multi-hop reasoning, the correctness score is very low. Minor credit is given for using the correct company and asset type and attempting to discuss strategic context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 419,
        "total_tokens": 1737
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has Boeing's treatment and disclosure of aluminum agreements evolved between 2022 and 2024, particularly in terms of their classification as derivatives and the time horizon for these agreements?",
      "original_answer": "In 2022, Boeing disclosed that its aluminum agreements were classified as derivatives but were not designated for hedge accounting treatment, with changes in fair value recorded in earnings immediately. The agreements were described in the context of long-term strategic sourcing objectives and non-U.S. business requirements. By 2024, the disclosure evolved to indicate that these aluminum agreements were now part of a broader set of commodity contracts hedging forecasted transactions through 2028. This represents a shift from purely strategic sourcing to a more structured hedging strategy with a defined time horizon extending to 2028.",
      "llm_answer": "Between 2022 and 2024, Boeing's treatment of aluminum agreements evolved in two key ways: first, these agreements were consistently classified as derivatives but were **not designated for hedge accounting treatment** in both years, meaning fair value changes were recorded directly in earnings rather than through AOCI. Second, while prior disclosures (2022) noted aluminum contracts offsetting market prices and hedging through 2028, the 2024 disclosure specifies these agreements have **no fixed time horizon**—they are ongoing strategic sourcing tools without defined maturity dates, unlike the explicit \"through 2028\" reference in earlier filings. The company also clarified that these non-hedge derivatives (including aluminum) require immediate mark-to-market recognition in earnings, with no reclassification from AOCI.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that contradict the ground truth. (1) On classification: the LLM incorrectly states that aluminum agreements were 'not designated for hedge accounting treatment in both years.' The ground truth indicates a shift by 2024—these agreements became part of a hedging strategy for forecasted transactions, implying hedge accounting may now apply or be intended, even if not explicitly confirmed. The LLM's claim of no change in hedge accounting treatment is incorrect. (2) On time horizon: the LLM asserts that the 2024 disclosure states 'no fixed time horizon' and that agreements are 'ongoing' with 'no defined maturity dates,' directly contradicting the ground truth that the 2024 filing specifies a defined time horizon 'through 2028.' The LLM reverses the evolution: it claims the 'through 2028' reference was in 2022 and removed in 2024, while the truth is that such a forward-looking hedging horizon was introduced in 2024 as a new development. (3) Multi-hop reasoning fails: the question asks how treatment evolved, requiring comparison across years. The LLM misrepresents the direction of change—portraying a move away from structure toward open-ended arrangements, when the actual evolution was toward structured, long-term hedging with a clear 2028 endpoint. (4) While the LLM correctly notes derivatives classification and immediate earnings recognition in 2022, its synthesis of the 2024 state is fundamentally flawed. Contextual relevance is moderate because it addresses the right topic and uses appropriate financial terminology, but the core factual claims about evolution are inverted. Quantitative accuracy is low due to incorrect handling of the 2028 time horizon, a key numeric/date element. Qualitative accuracy suffers from incorrect entity-state mapping across time.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 496,
        "total_tokens": 1876
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has Procter & Gamble's exposure to currency rate risk evolved between the fiscal years ended June 30, 2023 and June 30, 2024, particularly in terms of its hedging instruments and confidence in mitigating near-term exchange rate fluctuations?",
      "original_answer": "Procter & Gamble's exposure to currency rate risk remained materially unchanged between the fiscal years ended June 30, 2023 and June 30, 2024. The company continued to use forward contracts and currency swaps with maturities of less than 18 months to manage exchange rate risk. Additionally, P&G maintained its assessment that, at a 95% confidence level based on historical currency rate movements, the impact of a near-term change in currency rates would not materially affect its financial statements in either reporting period.",
      "llm_answer": "Procter & Gamble’s exposure to currency‑rate risk has not changed materially between fiscal 2023 and fiscal 2024; the company continues to manage foreign‑exchange volatility primarily through forward contracts and currency swaps with maturities under 18 months, and it believes that a near‑term shift in rates would not materially affect its financial statements.  Management remains confident that its hedging program, combined with natural hedges from its diversified global operations, will continue to mitigate near‑term exchange‑rate fluctuations.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and semantically equivalent to the ground truth. (1) All key facts are correct: Procter & Gamble's currency risk exposure remained materially unchanged between FY2023 and FY2024; the company uses forward contracts and currency swaps with maturities under 18 months; and it assesses that near-term exchange rate fluctuations would not materially affect financial statements. (2) Quantitative elements—'under 18 months' and 'not materially affect'—match the original. The 95% confidence level based on historical movements is omitted, which is a minor but notable detail affecting completeness. (3) The reasoning is sound: the LLM correctly synthesizes P&G's hedging instruments and confidence in mitigation across both years, though it does not explicitly cite the statistical confidence level (95%), which slightly weakens the multi-hop justification. (4) Contextual relevance is perfect—the response directly addresses evolution of risk exposure, hedging instruments, and confidence in mitigation. The addition of 'natural hedges from diversified global operations' is a reasonable inference and does not contradict the source. Overall, the answer is highly accurate with only a minor omission in quantitative specificity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 351,
        "total_tokens": 1647
      },
      "error": null
    },
    {
      "question_id": 129,
      "question": "How has Adobe's positioning and integration of Frame.io evolved between 2022 and 2024, particularly in terms of its functional scope and integration with other Adobe products?",
      "original_answer": "In 2022, Frame.io was listed among Adobe's trademarks, indicating it was an established product within Adobe's portfolio but with no detailed description of its functionality or integration. By 2024, Frame.io was actively described as a 'cloud-native creative collaboration platform' with expanded capabilities such as real-time upload, review and approval, frame-accurate commenting, and Camera to Cloud functionality. It was also integrated with Adobe Premiere Pro, After Effects, Photoshop, Lightroom, and Workfront, and positioned as part of Adobe GenStudio for large-scale content production. This reflects a significant evolution from a trademarked asset to a core collaborative tool deeply embedded in Adobe's creative workflow.",
      "llm_answer": "Adobe’s Frame.io positioning has shifted from a standalone cloud‑native collaboration platform to a tightly integrated component of its broader Creative Cloud and Document Cloud ecosystems between 2022 and 2024. In the 2022 filing, Frame.io was highlighted primarily for its real‑time upload, review and approval workflows that integrate with Premiere Pro, After Effects, Photoshop, Lightroom and Workfront, while the 2024 documentation emphasizes its expanded role within Adobe Express, Adobe Firefly Services and Custom Models, underscoring deeper functional integration and broader use cases across the Adobe suite. This evolution reflects a move toward embedding Frame.io’s collaboration capabilities as a native layer across Adobe’s creative and document solutions rather than treating it as a separate product.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains several inaccuracies in entity details and timeline representation, despite correct overall framing of Frame.io's integration evolution. (1) The 2022 filing did not describe Frame.io's real-time upload, review and approval workflows or integrations — it was only listed as a trademark with no functional description, so attributing those features to the 2022 filing is factually incorrect. (2) The 2024 description correctly notes expanded capabilities, but the LLM incorrectly claims integration with Adobe Express and Firefly Services, which are not mentioned in the ground truth; instead, Frame.io was positioned as part of Adobe GenStudio and integrated with Premiere Pro, After Effects, Photoshop, Lightroom, and Workfront — these are correctly listed but misattributed in timing. (3) The claim that Frame.io was part of Document Cloud is unsupported in the ground truth, which only references Creative Cloud workflows. (4) While the LLM captures the directional shift — from standalone/trademarked asset to integrated collaboration tool — the multi-hop reasoning is flawed because it misrepresents what was stated in each year’s filing. (5) No numeric data is present, so quantitative accuracy is not applicable but assumed correct by default. (6) The answer is contextually relevant and addresses the question’s intent regarding functional scope and integration evolution, but key factual errors in entities and timeline details reduce its qualitative accuracy. Thus, while the high-level narrative is plausible, it is not factually aligned with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1395,
        "completion_tokens": 434,
        "total_tokens": 1829
      },
      "error": null
    },
    {
      "question_id": 133,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between the 2022 and 2023 fiscal years, particularly in terms of the carrying value of its investment and the nature of its financial disclosures?",
      "original_answer": "In the 2022 filing, AMD disclosed that the carrying value of its investment in the ATMP JV was $69 million as of December 25, 2021, and $63 million as of December 26, 2020. Additionally, AMD provided detailed figures regarding purchases from and resales to the ATMP JV, including purchases of $1.1 billion in 2021 and $831 million in 2020. In contrast, the 2023 filing omits any mention of the carrying value of the investment and specific transaction figures, only reiterating the structural details of the relationship, such as AMD's 15% equity interest and the accounting method used. This indicates a reduction in the level of financial disclosure regarding the ATMP JV, even though the nature of the relationship and AMD's equity stake remained unchanged.",
      "llm_answer": "Between 2022 and 2023, AMD's investment in the ATMP joint venture increased from a carrying value of $69 million to $99 million, reflecting higher purchases and resales with the JV and resulting gains of $16 million in 2023 (up from $6 million in 2021). The financial disclosures for both years present the investment under “Other non‑current assets” and note that the ATMP JV’s activities are accounted for using the equity method, with related‑party balances (payables and receivables) disclosed on the balance sheet. No similar investment in THATIC remains on the books, as its carrying value is zero.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in the 2022 filing, AMD reported a carrying value of $69 million as of December 25, 2021, and $63 million as of December 26, 2020. The LLM incorrectly states that the investment increased to $99 million in 2023, which is not supported by the original answer—no carrying value is disclosed in the 2023 filing at all. Additionally, the LLM fabricates a $16 million gain in 2023 (vs $6 million in 2021), which is not mentioned in the ground truth. (2) The quantitative inaccuracies are severe: the only correct number indirectly referenced is $69 million (though misattributed as a starting point for 2022 instead of end-of-2021), but all other figures ($99M, $16M gain, $6M in 2021) are either incorrect or invented. The ground truth emphasizes the absence of updated carrying values and transaction data in the 2023 filing, while the LLM asserts new values that were not disclosed. (3) The multi-hop reasoning is flawed. The question asks about the evolution of financial disclosures between 2022 and 2023. The correct inference is that AMD reduced disclosure depth in 2023 by omitting carrying values and transaction figures. The LLM instead assumes continuity and even calculates implied growth, failing to recognize the key point: the 2023 filing lacks specific financial data entirely. It also incorrectly introduces 'THATIC' with a zero carrying value, which is irrelevant to the question about ATMP JV. (4) Despite these issues, the answer is contextually relevant—it addresses AMD's investment in ATMP JV, mentions equity method accounting, and refers to related-party disclosures. However, the core factual errors, especially the made-up numbers and failure to recognize reduced disclosure, severely undermine correctness. Thus, the scores reflect mostly incorrect information with only partial relevance to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 521,
        "total_tokens": 1878
      },
      "error": null
    },
    {
      "question_id": 139,
      "question": "How did Honeywell's revenue from Commercial Aviation Original Equipment evolve between 2023 and 2024, and what does this indicate about its position in the aerospace sector?",
      "original_answer": "Honeywell's revenue from Commercial Aviation Original Equipment decreased from $2,397 million in 2023 to $2,223 million in 2024. This decline suggests a contraction in this segment despite overall growth in the Aerospace Technologies division, indicating a potential weakening in original equipment demand or supply constraints in this specific product line.",
      "llm_answer": "Honeywell's Commercial Aviation Original Equipment revenue declined from $2,397 million in 2023 to $2,223 million in 2024, a decrease of roughly 7%. This drop signals a modest weakening in the company's aerospace position, even as overall aerospace sales remain robust, suggesting that while Honeywell retains a strong foothold in the sector, its original equipment segment is facing headwinds relative to prior growth.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reported the revenue figures of $2,397 million in 2023 and $2,223 million in 2024, matching the ground truth exactly. The calculated decrease of roughly 7% is accurate: (2,397 - 2,223) / 2,397 ≈ 7.26%, which rounds to 'roughly 7%'—acceptable for qualitative reporting. (2) All numeric values and years are correct, with proper formatting variations allowed (e.g., 'million' vs 'M'). (3) The reasoning correctly identifies a decline in the Commercial Aviation Original Equipment segment despite broader aerospace strength, aligning with the ground truth's implication of segment-specific headwinds such as demand softness or supply constraints. The LLM slightly softens the implication by saying 'modest weakening' and 'facing headwinds' rather than 'contraction' and 'potential weakening', but the semantic meaning remains consistent. (4) The answer fully addresses both parts of the question: the revenue evolution and its implication for Honeywell's aerospace position. Multi-hop synthesis is sound—linking segment performance to divisional context. Only minor difference is in tone, not factual content, justifying a high but not perfect qualitative score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1201,
        "completion_tokens": 337,
        "total_tokens": 1538
      },
      "error": null
    },
    {
      "question_id": 140,
      "question": "How did the global revenue contribution from Heart Failure Devices evolve between 2023 and 2024, and what was the percentage change in this segment's total revenue?",
      "original_answer": "In 2023, the global revenue from Heart Failure Devices was $1,161 million, while in 2024, this figure increased to $1,279 million. This represents a 10.2% increase in total revenue for the Heart Failure Devices segment. The growth was consistent across both U.S. and international markets, with minimal impact from exchange rate fluctuations, indicating strong underlying demand and market expansion.",
      "llm_answer": "The global revenue contribution from Heart Failure Devices increased by 10.2% in 2024 compared to 2023, with a total revenue of $1,279 million in 2024 (up from $1,161 million in 2023), reflecting a 10.3% increase when excluding foreign exchange impacts. This growth was driven by continued expansion in heart assist devices and recovery in procedure volumes following pandemic-related disruptions.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 2023 and 2024 global revenue figures for Heart Failure Devices as $1,161 million and $1,279 million, respectively, and reports a 10.2% increase, which matches the ground truth calculation. However, it introduces an additional claim of a '10.3% increase when excluding foreign exchange impacts,' which is not present in the original answer and slightly contradicts the ground truth statement that exchange rate impacts were minimal. This is a minor factual discrepancy. (2) The core numbers—$1,161M in 2023 and $1,279M in 2024—are accurate, and the implied percentage change ((1,279 - 1,161) / 1,161 ≈ 10.16%, rounded to 10.2%) is correctly reported. The mention of 10.3% under a different assumption introduces a small error in quantitative consistency. (3) The multi-hop reasoning is sound: the model correctly synthesizes year-over-year revenue change and attributes growth to market expansion, aligning with the original's emphasis on strong demand. The reference to 'recovery in procedure volumes' adds context not in the original but is plausible and not contradictory. (4) The answer is highly factually accurate, complete, and relevant, with only a minor deviation in the alternative percentage figure. Thus, the correctness score is 9 due to near-perfect alignment with ground truth, with only a slight overreach in introducing an unverified adjusted percentage.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1203,
        "completion_tokens": 395,
        "total_tokens": 1599
      },
      "error": null
    },
    {
      "question_id": 151,
      "question": "How has IBM's treatment of the 0.300% Notes due 2028 evolved between the 2022 and 2023 filings?",
      "original_answer": "In the 2022 filing, the 0.300% Notes due 2028 were referenced as part of a list of debt instruments, with their rights defined in Exhibit 4.1 to Form 8-K filed February 10, 2020, and incorporated by reference. By 2023, the 0.300% Notes due 2028 were formally listed in the table of registered securities with a specific trading symbol (IBM 28B) and explicitly called out as a distinct class of notes registered on the New York Stock Exchange. This reflects a shift from general incorporation by reference to explicit disclosure and formal registration.",
      "llm_answer": "Based on the provided 10-K pages, IBM's treatment of the 0.300% Notes due 2028 has remained unchanged between the 2022 and 2023 filings. The notes are consistently listed in the same section of the capital stock table in both filings (page 2 of the 2023 filing and page 28 of the 2022 filing), identified as \"0.300% Notes due 2028\" under \"Notes due 2028\" alongside the \"1.750% Notes due 2028\" (both trading under IBM 28B and IBM 28A respectively). There is no indication of any modification to the terms, structure, or classification of these notes between the two filings.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that IBM's treatment of the 0.300% Notes due 2028 remained unchanged between 2022 and 2023. The ground truth shows a clear evolution: in 2022, the notes were only incorporated by reference via an Exhibit 4.1 to a Form 8-K, while in 2023, they were explicitly listed in the table of registered securities with a specific trading symbol (IBM 28B) and noted as registered on the NYSE. This shift from incorporation by reference to formal, explicit registration is a significant change in disclosure and regulatory treatment, which the LLM completely misses. (2) Quantitatively, the LLM correctly identifies the note type (0.300% Notes due 2028), the trading symbol (IBM 28B), and the year references (2022 and 2023), so numeric and entity identifiers are accurate. However, it incorrectly claims the notes appear in the 'capital stock table'—debt instruments like notes should not be in a capital stock table, suggesting possible confusion in document interpretation. (3) The multi-hop reasoning fails: the question asks for a comparison of treatment across two years, requiring synthesis of disclosure practices (incorporation by reference vs. explicit registration). The LLM asserts no change based on superficial similarity in naming, ignoring the structural and regulatory evolution in how the notes are reported. (4) Correctness is low (2/10) because the core claim contradicts the ground truth. Quantitative accuracy is higher (8/10) due to correct note details and symbols. Qualitative accuracy is poor (2/10) due to flawed reasoning and mischaracterization of the filing changes. Contextual relevance is moderate (5/10) as the answer discusses the right instruments and years but misinterprets the nature of the disclosure change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1268,
        "completion_tokens": 488,
        "total_tokens": 1757
      },
      "error": null
    },
    {
      "question_id": 158,
      "question": "How has Apple's financial performance in the Rest of Asia Pacific region evolved from 2022 to 2023, based on changes in net sales and operating income?",
      "original_answer": "In 2022, Apple's Rest of Asia Pacific segment reported net sales of $29,375 million and operating income of $11,569 million. In 2023, these figures increased to $29,615 million in net sales and $12,066 million in operating income. This represents a moderate growth in both metrics, with net sales rising by $240 million (0.8%) and operating income increasing by $497 million (4.3%).",
      "llm_answer": "Apple's financial performance in the Rest of Asia Pacific region improved modestly from 2022 to 2023, with net sales increasing from $29,375 million to $30,658 million and operating income rising from $11,569 million to $13,062 million. This indicates growth in both revenue and profitability within that geographic segment over the one‑year period.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key financial figures. While it correctly identifies Apple and the Rest of Asia Pacific region, and the correct time frame (2022 to 2023), the reported 2023 net sales ($30,658 million) and operating income ($13,062 million) are incorrect. Ground truth shows 2023 net sales as $29,615 million (LLM reports $30,658M, $1,043M too high) and operating income as $12,066 million (LLM reports $13,062M, $996M too high). These errors severely undermine the answer's reliability. (2) Calculations based on the LLM's numbers are internally consistent (it implies ~4.3% sales growth and ~12.9% operating income growth), but since the inputs are wrong, the conclusions are invalid. The actual growth was $240M (0.8%) in net sales and $497M (4.3%) in operating income, which the LLM fails to report. (3) The multi-hop reasoning is structurally sound—comparing two years of financial performance across two metrics in a specific region—but the model fails in data retrieval or synthesis, likely pulling incorrect figures from a flawed source or misreading the data. (4) Contextual relevance is high as the answer addresses the right company, region, time period, and metrics. However, due to major quantitative errors, the correctness and quantitative accuracy scores are low. The qualitative accuracy is moderate because the reasoning framework is correct, but the factual foundation is flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1184,
        "completion_tokens": 402,
        "total_tokens": 1586
      },
      "error": null
    },
    {
      "question_id": 169,
      "question": "How has the vesting period for stock options issued under the 2007 Omnibus Incentive Plan evolved between grants made prior to 2022 and those made after December 31, 2021, based on disclosures in the 2022 and 2024 10-K filings?",
      "original_answer": "In the 2022 10-K filing, stock options granted prior to 2022 under the 2007 Omnibus Incentive Plan generally vested pro rata over a five-year period, while those granted after December 31, 2021, under the amended and restated plan, generally vested pro rata over a four-year period. The 2024 10-K confirms that stock options granted prior to 2022 continued to vest pro rata over a five-year period, and those granted after December 31, 2021, also continued to vest pro rata over a four-year period. This indicates a consistent reduction in the vesting period from five to four years for post-2021 grants, showing a structural change in the incentive plan's vesting terms over time.",
      "llm_answer": "Based on the disclosures in the 2022 and 2024 10‑K filings, the vesting period for stock options issued under the 2007 Omnibus Incentive Plan changed from a five‑year pro‑rata schedule for grants made prior to 2022 to a four‑year pro‑rata schedule for grants made after December 31, 2021 (with certain executive officers and other employees still subject to modified vesting terms).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually correct and aligns with the ground truth in terms of quantitative details: the vesting period changed from five years for grants prior to 2022 to four years for grants after December 31, 2021, with both periods being pro rata. The dates, durations, and plan name (2007 Omnibus Incentive Plan) are accurate, and the answer correctly reflects disclosures in the 2022 and 2024 10-K filings. The only minor shortcoming is that the LLM mentions 'certain executive officers and other employees still subject to modified vesting terms,' which, while possibly true, is not explicitly confirmed in the ground truth and introduces a detail not present in the original answer. However, this does not contradict the core facts and may reflect nuance in the filings. The reasoning correctly synthesizes multi-hop information across time (pre-2022 vs post-2021) and documents (2022 and 2024 10-Ks), showing a structural change in vesting terms. The answer is contextually relevant and semantically equivalent to the original, with only slight over-specification on exceptions. Thus, the answer earns a 9/10 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 344,
        "total_tokens": 1630
      },
      "error": null
    },
    {
      "question_id": 170,
      "question": "How has CVS's approach to validating the fair value estimates for its Level 2 debt securities evolved from 2022 to 2023, particularly in terms of price adjustments and secondary source comparisons?",
      "original_answer": "In 2022, CVS obtained one price for each of its Level 2 debt securities and did not adjust any of those prices at December 31, 2021 or 2020. The company compared selected sample prices quarterly to secondary sources and reviewed variances over a specified threshold. In 2023, the company maintained the same validation methodology, obtaining one price per Level 2 debt security without any adjustments at December 31, 2023 or 2022, and continued to compare prices quarterly to secondary sources. Despite maintaining the same process, the emphasis on consistent internal validation by the investment team appears to have remained stable, indicating a sustained but unchanging approach to fair value estimation.",
      "llm_answer": "From 2022 to 2023, CVS maintained its Level 2 debt securities pricing methodology without material adjustments, continuing to rely on observable market inputs (e.g., quoted prices for similar assets, discounted cash flows) and quarterly secondary source price comparisons to validate fair value estimates. The company did not adjust any Level 2 prices at December 31, 2023 or 2022, and Level 3 transfers were limited to specific private placement securities, with no significant changes in validation approach between years.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly states that CVS did not adjust any Level 2 prices at December 31, 2023 or 2022, matching the original answer's timeline and validation approach. The continuation of quarterly comparisons to secondary sources is accurately reported. (2) All dates and numerical references (e.g., no price adjustments in 2022 and 2023) are factually correct. There are no calculations, but temporal references are precise. (3) The multi-hop reasoning is sound: the model correctly synthesizes that the validation methodology remained unchanged from 2022 to 2023, including reliance on observable inputs and secondary source checks. It appropriately notes the lack of material changes, which reflects the 'sustained but unchanging approach' described in the ground truth. (4) The only minor shortcoming is that the LLM mentions 'observable market inputs (e.g., quoted prices for similar assets, discounted cash flows)' and 'Level 3 transfers'—details not present in the original answer. While not incorrect, these additions slightly extend beyond the provided ground truth, potentially implying more detail than supported. However, they do not contradict the source and are contextually plausible. Overall, the answer is factually correct, complete, and contextually appropriate, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 380,
        "total_tokens": 1701
      },
      "error": null
    },
    {
      "question_id": 172,
      "question": "How did CVS's classification and valuation methodology for privately-placed equity securities evolve between 2022 and 2023, particularly in terms of fair value determination and unobservable inputs?",
      "original_answer": "CVS maintained a consistent classification of privately-placed equity securities as Level 3 in both 2022 and 2023, indicating no active market for these securities. However, the company emphasized in both years that it uses an internal analysis of financial statements and cash flow projections to determine fair value. In 2022, the significant unobservable inputs included earnings and revenue multiples, discount for lack of marketability, and comparability adjustments. In 2023, the same unobservable inputs were referenced, but with an added emphasis on the potential impact of changes in these inputs on fair value measurements, suggesting a more detailed sensitivity analysis or increased scrutiny of these inputs in the valuation process.",
      "llm_answer": "Between 2022 and 2023, CVS Health's classification and valuation methodology for privately-placed equity securities remained consistent in using Level 3 inputs, which rely on unobservable assumptions such as earnings and revenue multiples, discount for lack of marketability, and comparability adjustments to determine fair value. The company continued to classify these securities in Level 3 due to the absence of an active market, with no material changes observed in the methodology or unobservable inputs during the period. The 2023 Level 3 equity securities balance of $79 million (as shown in the Level 3 financial assets reconciliation) reflects the same valuation approach as in 2022, with no indication of a shift in methodology.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in stating that CVS classified privately-placed equity securities as Level 3 in both 2022 and 2023 and used the same unobservable inputs (earnings and revenue multiples, discount for lack of marketability, comparability adjustments). It correctly notes no material change in methodology and includes a specific quantitative figure ($79 million in 2023), which aligns with typical disclosure formats, though the ground truth does not mention this number—this is not penalized as it may be contextually valid. However, the LLM fails to capture a key qualitative evolution highlighted in the original answer: in 2023, CVS placed added emphasis on the sensitivity of fair value to changes in unobservable inputs, indicating enhanced scrutiny or more detailed sensitivity analysis. This represents a meaningful development in valuation methodology that the LLM overlooks, despite the consistency in inputs. The answer is thus partially correct—core facts and classification are accurate, but it misses the nuanced shift in analytical depth, which is central to the question about 'evolution' in methodology. This omission reduces qualitative accuracy significantly, as the multi-hop reasoning required to detect changes in emphasis over time is incomplete. Contextual relevance is high as the response stays focused on the topic and uses appropriate financial terminology.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 387,
        "total_tokens": 1771
      },
      "error": null
    },
    {
      "question_id": 184,
      "question": "How did the total net revenue from Alphagan/Combigan change between 2023 and 2024, and what was the trend in its international revenue during this period?",
      "original_answer": "The total net revenue from Alphagan/Combigan decreased from $272 million in 2023 to $248 million in 2024, reflecting an 8.8% decline. During the same period, its international revenue slightly increased from $151 million in 2023 to $153 million in 2024, representing a 1.5% growth.",
      "llm_answer": "Based on the provided financial tables, Alphagan/Combigan's total net revenue decreased from $272 million in 2023 to $248 million in 2024, reflecting an (8.8)% change at actual currency rates and a (5.4)% change at constant currency rates. International revenue for this product increased modestly, rising from $151 million in 2023 to $153 million in 2024—a 1.5% increase at actual currency rates and a 7.6% increase at constant currency rates.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identified the total net revenue decrease from $272 million in 2023 to $248 million in 2024 and accurately calculated the 8.8% decline. It also correctly reported the international revenue increase from $151 million to $153 million and the 1.5% growth at actual currency rates. However, the LLM introduced additional data not present in the ground truth—specifically, 'constant currency' figures of (5.4)% for total revenue and 7.6% for international revenue. These values are not mentioned in the original answer and represent over-speculation or inclusion of extraneous data, reducing quantitative accuracy. (2) The core numbers (dollar amounts and actual-currency percentages) are correct and calculations match: (272 - 248)/272 ≈ 8.8%, (153 - 151)/151 ≈ 1.5%. But the constant currency metrics are unverified and incorrect per ground truth, which only reports actual currency trends. (3) The multi-hop reasoning is sound—LLM correctly synthesized revenue trends across two years and two geographies (total vs. international). It distinguished between different revenue streams and time periods accurately. (4) Despite the addition of unsupported constant currency data, the LLM addresses all parts of the question with correct entities (Alphagan/Combigan, 2023–2024, total and international revenue), correct years, and correct financial metrics. The core answer aligns semantically with the ground truth except for the extra, inaccurate details. Hence, correctness is reduced to 7 due to partial inaccuracy in percentages, but qualitative and contextual scores remain high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1183,
        "completion_tokens": 441,
        "total_tokens": 1625
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has Chevron's relationship with PDC Energy evolved from 2023 to 2024, and what specific operational impact did this change have on Chevron's overall production performance?",
      "original_answer": "In 2023, Chevron acquired PDC Energy, Inc. (PDC), and as a result, PDC was excluded from Chevron's internal control assessment over financial reporting due to the timing of the acquisition. By 2024, Chevron's relationship with PDC had evolved from a newly acquired entity to an integral operational component, as evidenced by the 7% increase in Chevron's worldwide oil-equivalent production, which was attributed in part to the full-year contribution from legacy PDC operations. This indicates that PDC Energy transitioned from being a recent acquisition in 2023 to a key contributor to Chevron's production growth in 2024.",
      "llm_answer": "Chevron's relationship with PDC Energy shifted from a standalone independent producer to a wholly owned subsidiary after Chevron completed its acquisition of PDC Energy in 2023. This integration added PDC's Permian Basin assets and production to Chevron's portfolio, contributing to Chevron's overall production growth. Consequently, Chevron's worldwide oil-equivalent production increased by approximately seven percent in 2024, reaching 3.3 million barrels per day, primarily driven by the full-year contribution from PDC Energy's legacy production and growth in the Permian Basin.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the 2023 acquisition of PDC Energy by Chevron and the resulting integration into Chevron's operations. The 7% increase in worldwide oil-equivalent production in 2024 is accurately stated (referred to as 'approximately seven percent'), and the contribution from PDC's legacy operations is properly attributed. (2) The only minor deviation is the inclusion of an additional detail—'3.3 million barrels per day'—which is not present in the original answer and cannot be verified from the ground truth provided. While this figure may be factually correct, its inclusion introduces unverified quantitative information, slightly reducing quantitative accuracy. (3) The multi-hop reasoning is sound: the model correctly synthesizes the timeline (acquisition in 2023, impact in 2024), links the full-year contribution of PDC to production growth, and infers operational integration. (4) The answer is contextually complete and relevant, addressing both the evolution of the relationship and the operational impact on production. The core facts, entities (Chevron, PDC Energy), years (2023, 2024), and causal logic are all correct. The addition of an unverified production volume prevents a perfect score, but overall, the answer is factually robust and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 384,
        "total_tokens": 1693
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has UPS's investment in cold-chain logistics capabilities evolved from 2023 to 2024, and what specific acquisitions contributed to this change?",
      "original_answer": "In 2023, UPS expanded its cold-chain logistics capabilities through the acquisition of Bomi Group and MNX Global Logistics, aiming to enhance its healthcare logistics services. By 2024, this strategic focus intensified with the acquisition of Frigo-Trans and Biotech & Pharma Logistics in Germany for approximately $440 million, signaling a significant increase in international investment in complex cold-chain logistics. This represents a shift from general expansion to targeted, high-value international acquisitions in the cold-chain sector.",
      "llm_answer": "UPS expanded its cold‑chain logistics capabilities between 2023 and 2024 primarily through the acquisition of MNX Global Logistics (completed in 2023) and the purchase of Bomi Group (acquired in 2022, with additional investments noted in 2023‑24). The 2024 divestiture of Coyote reduced its cold‑chain exposure, but the company continued to build on these assets—highlighted by the January 2025 acquisition of Frigo‑Trans and Biotech & Pharma Logistics, which further strengthens its international cold‑chain network.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. While it correctly identifies MNX Global Logistics and Bomi Group as part of UPS's cold-chain expansion, it incorrectly states that Bomi Group was acquired in 2022, whereas the ground truth confirms the acquisition occurred in 2023. Additionally, the LLM claims the acquisition of Frigo-Trans and Biotech & Pharma Logistics happened in January 2025, but the original answer states this occurred in 2024. This misrepresentation of key dates undermines the timeline of UPS's investment evolution. The $440 million figure mentioned in the ground truth is entirely omitted, resulting in a missing quantitative benchmark for the scale of 2024 investments. (2) The LLM incorrectly introduces the 'divestiture of Coyote' as reducing cold-chain exposure, which is not mentioned in the ground truth and contradicts the narrative of expansion. There are no calculations in the response, but the dates and dollar amounts are either wrong or missing, leading to low quantitative accuracy. (3) The multi-hop reasoning is partially sound—linking acquisitions to cold-chain expansion—but fails in synthesizing the correct timeline and strategic shift from 2023 to 2024. The conclusion about strengthening the international network aligns with the ground truth, but the erroneous timing (2025 vs 2024) breaks the logical flow of the evolution within the specified period. (4) Despite these issues, the answer addresses the core question about UPS's cold-chain evolution and names most of the correct companies, maintaining contextual relevance. However, due to significant factual and temporal errors, the correctness and qualitative accuracy scores are moderate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1266,
        "completion_tokens": 467,
        "total_tokens": 1733
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has Linde plc's non-employee director restricted stock unit award program evolved between 2022 and 2024, particularly in terms of governance structure and long-term shareholder alignment mechanisms?",
      "original_answer": "In 2022, Linde plc introduced the Non-Employee Director Restricted Stock Unit Award under the 2021 Linde plc Long Term Incentive Plan, establishing a framework for equity-based compensation tied to long-term performance metrics. This initiative was part of a broader suite of incentive programs aimed at aligning director interests with those of shareholders. By 2024, the company expanded this framework by introducing the Linde plc Non-employee Director Deferral Program, adopted by the Board of Directors on July 30, 2024. This deferral program enhances governance by allowing directors to defer receipt of stock units, thereby reinforcing long-term alignment with shareholder value creation. The evolution from a basic restricted stock unit award to a more sophisticated deferral mechanism indicates Linde’s strategic emphasis on strengthening board accountability and promoting sustained corporate governance standards.",
      "llm_answer": "Based on the provided SEC filing exhibits, Linde plc's non-employee director restricted stock unit (RSU) award program has evolved through formal amendments to its long-term incentive framework, specifically via the adoption of the 2021 Linde plc Long-Term Incentive Plan (Exhibit 10.02) and its subsequent amendments. The most recent governance enhancement is the Board-approved Linde plc Non-Employee Director Deferral Program (Exhibit 10.16), adopted July 30, 2024, which institutionalizes deferred compensation for directors as a mechanism to align their interests with long-term shareholder value. This program, alongside the updated RSU award forms filed in 2024 (Exhibit 10.0e), reflects a structured approach to director compensation that emphasizes performance-based equity retention and governance transparency.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the 2021 Linde plc Long-Term Incentive Plan is correctly cited as the foundation, and the July 30, 2024 adoption date of the Non-Employee Director Deferral Program (Exhibit 10.16) matches the ground truth. The mention of updated RSU award forms in 2024 (Exhibit 10.0e) adds contextual detail without contradicting the original answer. (2) Quantitative accuracy is perfect: the date 'July 30, 2024' is correctly stated, and no financial figures are misreported. (3) Multi-hop reasoning is sound—the model synthesizes information about the evolution from the initial RSU framework to the deferral program, correctly inferring enhanced governance and long-term alignment. (4) The only minor shortcoming is a slightly more technical tone focused on 'exhibits' and 'amendments,' which slightly deemphasizes the broader strategic narrative about board accountability and corporate governance evolution present in the original. However, the core qualitative content—deferral enhancing long-term shareholder alignment—is preserved. Semantic equivalence is strong, and all entities (Linde plc, Non-Employee Director Deferral Program, 2021 Plan) are accurately identified and contextualized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1450,
        "completion_tokens": 358,
        "total_tokens": 1808
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did General Motors' financial and legal relationship with Stellantis evolve between 2022 and 2024, particularly regarding indemnification obligations and investment gains?",
      "original_answer": "In 2022, General Motors reported a gain of $0.2 billion related to Stellantis N.V. (Stellantis) warrants, indicating a positive financial relationship. However, by 2024, the relationship had evolved into a more complex and potentially costly one. GM had agreed to indemnify Stellantis for certain liabilities tied to pre-sale emissions claims, product liabilities, and recalls related to the 2017 sale of the Opel/Vauxhall business. Additionally, GM faced potential future liabilities from ongoing investigations into Opel’s historical conduct in Europe. Unlike the earlier gains, GM's 2024 disclosures highlighted contingent liabilities and legal risks rather than financial benefits from its relationship with Stellantis.",
      "llm_answer": "Between 2022 and 2024, General Motors’ financial and legal relationship with Stellantis evolved through the continued enforcement of indemnification obligations stemming from the 2017 sale of Opel/Vauxhall to Stellantis. While GM’s 2022 and 2024 SEC filings do not detail new indemnification claims, they reaffirm that Stellantis may seek recovery under the original agreement for losses tied to pre-sale liabilities—including emissions-related lawsuits and Takata airbag recalls—though GM currently cannot estimate any material exposure from such claims. Additionally, GM recognized investment gains tied to its stake in Stellantis, particularly through equity holdings and associated tax benefits, which contributed to its consolidated income tax expense fluctuations, including a $2.5 billion tax expense in 2024. However, no specific gains or losses from Stellantis-related investments are detailed in the provided 2022 or 2024 filings beyond standard market-value adjustments.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies, particularly in quantitative details and key financial events. (1) QUANTITATIVE INACCURACY: The LLM claims GM recognized a $2.5 billion tax expense in 2024 due to Stellantis-related investment gains, which contradicts the ground truth stating GM had a $0.2 billion gain in 2022 from Stellantis warrants. No $2.5 billion tax expense tied to Stellantis is mentioned in the original answer, nor is there any mention of equity holdings or tax benefits beyond the 2022 warrant gain. The $0.2 billion gain is misrepresented or omitted entirely. (2) COMPLETENESS: The answer fails to mention the specific 2022 gain from Stellantis warrants, a key financial event that marked the positive nature of the relationship at that time. Instead, it vaguely references 'investment gains' and 'tax benefits' not supported in the ground truth. (3) ENTITY & TEMPORAL ACCURACY: While the indemnification obligations related to Opel/Vauxhall are correctly identified, the timing and context are off—the original answer emphasizes a shift from financial benefit (2022) to legal risk (2024), which the LLM downplays. (4) REASONING: The multi-hop synthesis is partially sound—linking the 2017 sale to ongoing indemnification is correct—but the conclusion about investment gains distorts the evolution of the relationship. The LLM incorrectly implies continued financial benefits in 2024, whereas the ground truth stresses a shift to contingent liabilities and risks. (5) SEMANTIC EQUIVALENCE: The overall narrative contradicts the ground truth: the original describes a deterioration from gain to risk, while the LLM suggests ongoing financial benefits alongside indemnification risks. This undermines the core correctness. Minor contextual elements (e.g., emissions claims, recalls) are accurate, preserving some relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1433,
        "completion_tokens": 500,
        "total_tokens": 1933
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did Southern Company's treatment and disclosure of energy-related derivatives evolved from 2022 to 2024, particularly in terms of their financial presentation and categorization?",
      "original_answer": "In 2022, Southern Company reported the pre-tax effects of energy-related derivatives not designated as hedging instruments on the statements of income for prior years (2021, 2020, and 2019), indicating a focus on income statement impacts. By 2024, the company shifted its disclosure to emphasize the fair value of energy-related derivatives as either assets or liabilities on the balance sheets, specifically categorized under 'Other' or 'Risk Management Activities'. This represents a shift from income-focused reporting to balance sheet-oriented transparency.",
      "llm_answer": "Southern Company’s energy‑related derivatives designated as hedging instruments were presented in the balance sheet as current and non‑current assets and liabilities, with net amounts of $28 million (2024) and $21 million (2023) after offsetting. In contrast, the 2024 filing shows a much larger net balance of $45 million (assets) and $84 million (liabilities) for the same category, reflecting an expanded presentation that includes additional hedging instruments and more detailed segregation of current versus non‑current positions. The categorization also shifted from a simple “Energy‑related derivatives designated as hedging instruments for regulatory purposes” line to a more granular breakdown that separates cash‑flow/ fair‑value hedges, non‑designated derivatives, and foreign‑currency hedges, and includes detailed sub‑totals for each derivative type. This evolution indicates a move toward greater transparency and more granular financial statement disclosure of derivative instruments between 2022 and 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, Southern Company focused on income statement impacts of energy-related derivatives not designated as hedging instruments, with disclosures about pre-tax effects on prior years. By 2024, the focus shifted to balance sheet presentation under 'Other' or 'Risk Management Activities'. However, the LLM answer incorrectly claims that derivatives were 'designated as hedging instruments' and provides specific dollar amounts ($28M, $21M, $45M, $84M) that are not present in the original answer and cannot be verified from the provided truth. These figures appear fabricated or misattributed. (2) Quantitative accuracy is very low: no dollar amounts were mentioned in the original answer, so all numerical claims in the LLM response are incorrect. There is no mention of net balances or offsetting in the ground truth. (3) The multi-hop reasoning is flawed. The LLM fails to capture the actual evolution described—shift from income statement (pre-2022) to balance sheet (2024) disclosure—and instead invents a narrative around increased granularity and categorization changes involving cash-flow/fair-value hedges, which is not supported by the original answer. The core transformation (income-focused → balance sheet-focused) is missed. (4) Contextual relevance is moderate because the answer discusses derivative disclosures and attempts to compare 2022–2024, aligning with the question’s intent, but the substance is factually incorrect. The LLM introduces unrelated details (foreign currency hedges, regulatory designation breakdowns) absent in the ground truth. Overall, the answer does not reflect the actual evolution described in the knowledge graph.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1404,
        "completion_tokens": 479,
        "total_tokens": 1884
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did GILD's strategic relationship with Arcus evolve between 2023 and 2024, particularly in terms of equity ownership and governance influence?",
      "original_answer": "In 2023, GILD owned approximately 19.9% of Arcus' issued and outstanding voting stock and had two designees on Arcus' board of directors. In January 2024, GILD made an additional $320 million equity investment in Arcus, increasing its ownership to 33%, and expanded its board representation to three designees. This represents a significant increase in both financial commitment and governance influence over Arcus within a year.",
      "llm_answer": "Between 2023 and 2024, Gilead’s strategic relationship with Arcus evolved from a 19.9% equity stake (≈14.8 million shares) to a 33% ownership stake after a $320 million equity investment in January 2024, accompanied by the addition of a third Gilead designee to Arcus’ board. This increased equity position, together with the amended Collaboration Agreement that includes up‑front payments, milestone‑based royalties and shared development costs, deepened Gilead’s governance influence over Arcus, while the original stand‑still restriction expired in mid‑2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the increase in GILD's equity ownership from 19.9% in 2023 to 33% in January 2024 following a $320 million investment, and the expansion of board representation from two to three designees—matching the ground truth. All numeric values (percentages, dollar amount, timing) are accurate. (2) Quantitative accuracy is perfect: $320 million, 19.9%, 33%, and January 2024 are all correctly reported. The mention of ~14.8 million shares is additional detail not in the ground truth but does not contradict it and may be derived from public data; it does not affect correctness. (3) The reasoning is sound and reflects proper multi-hop synthesis: the model connects the equity investment to increased ownership and governance influence, correctly infers deeper control via board expansion, and adds context about the Collaboration Agreement and expiration of the stand-still agreement, which supports the evolution narrative. While the Collaboration Agreement details (up-front payments, milestones, cost sharing) and stand-still expiration are not in the ground truth, they do not contradict it and may be accurate from broader filings—however, their inclusion slightly extends beyond the provided truth, which focuses only on ownership and board seats. (4) The answer is highly relevant, complete, and semantically equivalent to the ground truth, with only minor addition of potentially valid but unverified contextual terms. No factual errors; deduction of 1 point due to slight over-enrichment with unverified agreement details, but core facts are fully correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1247,
        "completion_tokens": 440,
        "total_tokens": 1687
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the maturity date and borrowing capacity of the 2021 Multicurrency Credit Facility evolved between 2022 and 2023?",
      "original_answer": "In 2022, the 2021 Multicurrency Credit Facility had a maximum borrowing capacity of $6.0 billion with a maturity date of June 30, 2025. By 2023, the borrowing capacity remained at $6.0 billion, but the maturity date was extended to July 1, 2026. This reflects a one-year extension of the facility’s term without any increase in the total commitment amount, indicating a strategic move to maintain financial flexibility over a longer horizon.",
      "llm_answer": "The 2021 Multicurrency Credit Facility was extended to a maturity of July 1, 2026 (and later stepped down to July 1, 2028) and its borrowing capacity was increased to $6.0 billion (with a $3.5 billion multicurrency sub‑limit), while the 2021 Credit Facility was extended to July 1, 2028 and its capacity raised to $4.0 billion. These amendments, together with the $1.0 billion term loan, gave the company substantially higher borrowing availability and longer repayment horizons between 2022 and 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022 the maturity date was June 30, 2025, and in 2023 it was extended to July 1, 2026 — a one-year extension. The LLM incorrectly states the maturity was extended to July 1, 2026 and then 'stepped down to July 1, 2028', which is not supported by the original answer. Additionally, the borrowing capacity was already $6.0 billion in 2022 and remained unchanged in 2023; the LLM incorrectly frames this as an increase to $6.0 billion, implying it was lower before. The mention of a '$3.5 billion multicurrency sub-limit' and a '$4.0 billion' capacity for a '2021 Credit Facility' introduces entities and figures not present in the ground truth. (2) Quantitative accuracy is low: the dates (2025 → 2026 extension) are partially correct but distorted by the erroneous 2028 reference; the $6.0 billion figure is correct but misrepresented as an increase rather than a stable amount. The $4.0 billion and $3.5 billion figures are entirely fabricated in this context. (3) The multi-hop reasoning is flawed — the LLM conflates the 2021 Multicurrency Credit Facility with another '2021 Credit Facility' and invents a term loan, failing to correctly isolate and track the evolution of the single facility in question. It does not accurately synthesize the change between 2022 and 2023 for the specific facility. (4) Contextual relevance is moderate because the answer discusses credit facilities, maturity dates, and borrowing capacity in the correct timeframe, but the incorrect entities and numbers undermine the response. The core conclusion about increased flexibility is speculative and based on false premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1229,
        "completion_tokens": 467,
        "total_tokens": 1696
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has Chevron's utilization of imported crude oil in U.S. refining operations evolved between 2023 and 2024, and what changes in refinery capacity utilization accompanied this trend?",
      "original_answer": "Chevron's reliance on imported crude oil in U.S. refining operations remained consistent at approximately 60% of refinery inputs in both 2023 and 2024. However, the utilization of U.S. refineries changed: in 2023, crude unit distillation capacity utilization averaged 90.8%, while in 2024 it decreased to 86.6%. This indicates that while the company's dependency on imported crude oil remained stable, the overall operational intensity of its U.S. refineries declined slightly in 2024.",
      "llm_answer": "Chevron’s use of imported crude in its U.S. refineries stayed roughly steady, with imported barrels making up about 60 % of refinery inputs in both 2023 and 2024.  At the same time, overall refinery capacity utilization fell – from an average of 89.8 % in 2023 to 87.9 % in 2024 (U.S.‑only utilization dropped from 90.8 % to 86.6 %).  The decline reflects weaker crude‑processing runs as the company adjusted to the steady imported‑crude share.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies that Chevron's use of imported crude oil remained steady at approximately 60% in both 2023 and 2024, which matches the ground truth. However, there is a discrepancy in the refinery capacity utilization numbers: the LLM states 89.8% for 2023 and 87.9% for 2024, while the ground truth reports 90.8% in 2023 and 86.6% in 2024. The LLM does correctly note a decline in utilization, but the magnitude of the values is inaccurate. It also introduces a distinction between 'overall' and 'U.S.-only' utilization not present in the original data, implying a broader dataset that wasn't in the ground truth. (2) The numbers for utilization are off by 1.0 percentage point in 2023 and 1.3 in 2024, which constitutes a material error in quantitative terms, especially for financial/operational analysis. The 60% imported crude figure is accurate. (3) The multi-hop reasoning is sound—linking stable import dependency with declining utilization—but the synthesis is based on slightly incorrect base data. The mention of 'overall' vs 'U.S.-only' suggests possible conflation of different data sources or categories. (4) The answer is contextually relevant and addresses both parts of the question. The qualitative reasoning about operational adjustments is plausible and aligns with the trend, even if the numbers are slightly off. Hence, correctness is reduced due to numerical inaccuracies, but not severely due to correct directional analysis and core fact retention.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1241,
        "completion_tokens": 414,
        "total_tokens": 1655
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How did UPS's hedging position in British Pound Sterling evolve between 2023 and 2024, and what does this shift indicate about the company's currency risk management strategy?",
      "original_answer": "In 2023, UPS reported a British Pound Sterling (GBP) hedge position of 663 million units, which decreased to 536 million units in 2024. This represents a reduction of 127 million units, or approximately 19.15%. The decrease indicates a strategic move to reduce exposure to GBP, suggesting that UPS may have reassessed its currency risk related to the British Pound and opted for a more conservative hedging approach or a lower anticipated risk in that currency during the later year.",
      "llm_answer": "UPS reduced its notional exposure to British Pound Sterling hedging instruments from $663 million in 2023 to $536 million in 2024, reflecting a deliberate scaling back of its foreign‑currency hedging program. This shift—combined with the change in AOCI gains from a $199 million gain on designated net‑investment hedges in 2022 to a $127 million gain in 2024—indicates that UPS is adjusting its currency‑risk management strategy, likely to align hedge ratios with evolving cash‑flow forecasts and to reduce the amount of hedged foreign‑currency debt exposure.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the reduction in UPS's GBP hedge position from $663 million in 2023 to $536 million in 2024, matching the ground truth. The absolute values are accurate, and the direction of change (decrease) is correct. However, the LLM does not explicitly calculate or mention the 127 million unit reduction or the 19.15% decrease, which are key quantitative elements in the original answer. While the core numbers are right, the omission of the calculated difference and percentage slightly reduces completeness. 2) The LLM introduces additional information about AOCI gains—$199 million in 2022 and $127 million in 2024—which is not present in the ground truth and cannot be verified from the provided context. This extraneous data, while possibly true, distracts from the specific evolution between 2023 and 2024 and may reflect overreach in multi-hop reasoning without sufficient grounding. 3) The reasoning about UPS adjusting its currency risk strategy is logically sound and aligns with the ground truth’s interpretation of a more conservative hedging approach. The mention of aligning hedge ratios with cash-flow forecasts and reducing hedged foreign-currency debt exposure is a reasonable qualitative extension, though slightly more speculative than the original. 4) The entities (UPS, British Pound Sterling, years 2023–2024) and financial metric (notional hedge position) are correctly identified and used. The answer is highly relevant to the question and synthesizes the core trend accurately, despite missing the explicit calculation and adding unverified AOCI context. Overall, the answer is factually strong but not fully complete or perfectly focused.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1267,
        "completion_tokens": 459,
        "total_tokens": 1727
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the fair value of money market investments held by Bank of America evolved between 2023 and 2024, and what does this shift indicate about the company's short-term investment strategy?",
      "original_answer": "The fair value of money market investments held by Bank of America increased from $1.2 billion at December 31, 2023, to $1.3 billion at December 31, 2024. This indicates a modest growth in the company's short-term investment holdings, suggesting a slight expansion in liquidity management or short-term capital deployment strategies over the year.",
      "llm_answer": "Between 2023 and 2024 the fair‑value of Bank of America’s money‑market investments rose modestly from about $1.2 billion to $1.3 billion. This small increase reflects a shift toward slightly longer‑dated, higher‑yielding short‑term assets, indicating the company is re‑balancing its cash‑management strategy to capture modest yield improvements while maintaining ample liquidity.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reports the fair value increase from $1.2 billion in 2023 to $1.3 billion in 2024, matching the ground truth exactly in both figures and direction of change. All numeric values and time periods are accurate, satisfying quantitative accuracy. (2) The calculation of a $0.1 billion increase is implicit and correct. Number formats are consistent and acceptable. (3) The multi-hop reasoning is sound in identifying the evolution of fair value and linking it to short-term investment strategy. However, the LLM adds specific detail not present in the ground truth—namely, that the shift reflects a move toward 'slightly longer-dated, higher-yielding short-term assets' and 're-balancing to capture yield improvements.' While plausible, this interpretation goes beyond the original answer, which only states the increase suggests 'a slight expansion in liquidity management or short-term capital deployment strategies.' This introduces a more specific strategic rationale not confirmed in the source. (4) Despite this added interpretation, the core facts, entities (Bank of America, money market investments, 2023–2024), and overall meaning are correct and relevant. The answer addresses both parts of the question: the quantitative evolution and the strategic implication. Thus, the correctness score is reduced slightly to 8 due to the unsupported specificity in reasoning, but quantitative accuracy and contextual relevance remain high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1192,
        "completion_tokens": 406,
        "total_tokens": 1598
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the maximum expected volume of natural gas subject to physical supply contracts with sell-back options changed across Southern Company's subsidiaries between 2022 and 2024?",
      "original_answer": "In 2022, the maximum expected volume of natural gas subject to such contracts was 26 million mmBtu for Southern Company as a whole, with individual volumes of 6 million mmBtu for Alabama Power, 8 million mmBtu for Georgia Power, 4 million mmBtu for Mississippi Power, and 8 million mmBtu for Southern Power. By 2024, this volume had decreased to 15 million mmBtu company-wide, with corresponding reductions in each subsidiary's volume: 4 million mmBtu for Alabama Power, 6 million mmBtu for Georgia Power, 2 million mmBtu for Mississippi Power, and 3 million mmBtu for Southern Power. This represents a consistent reduction across all entities.",
      "llm_answer": "Based on the provided pages, the maximum expected volume of natural gas subject to physical supply contracts with sell-back options is **15 million mmBtu for Southern Company**, broken down as follows: **4 million mmBtu for Alabama Power, 6 million mmBtu for Georgia Power, 2 million mmBtu for Mississippi Power, and 3 million mmBtu for Southern Power**. This volume remained consistent between 2021 and 2024, as reflected in the 2021 data (page 317) and the 2024 data (page 281), which both state the same maximum expected volume of 15 million mmBtu with the identical subsidiary breakdown. No change is indicated across the years.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that the volume remained consistent between 2021 and 2024 at 15 million mmBtu. The ground truth indicates that in 2022, the total volume was 26 million mmBtu (not 15), and it decreased to 15 million mmBtu by 2024. The LLM incorrectly claims no change occurred, which contradicts the documented reduction. Additionally, the LLM references 2021 data, which is not part of the question’s scope (2022–2024), further misaligning the analysis. (2) While the 2024 numbers (15 million mmBtu total, with 4, 6, 2, and 3 million mmBtu for the respective subsidiaries) are correctly reported, the 2022 figures are entirely omitted or misrepresented. The LLM fails to report the 2022 total of 26 million mmBtu and the corresponding subsidiary volumes (6, 8, 4, 8), which are critical for assessing change over time. (3) The multi-hop reasoning is flawed: the question requires comparing 2022 and 2024 data across subsidiaries, but the LLM incorrectly asserts consistency over time based on erroneous year comparisons (2021 vs 2024) and misses the actual trend of reduction. It fails to synthesize the correct temporal and entity-level changes. (4) Despite accurately reporting the 2024 data, the fundamental error in temporal comparison and omission of 2022 values severely undermines factual correctness. The answer is contextually relevant in discussing the right metric and subsidiaries, but the incorrect conclusion about no change results in a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 419,
        "total_tokens": 1746
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the integration and application of the Firefly Vector Model evolved across Adobe's product suite between 2023 and 2024?",
      "original_answer": "In 2023, the Firefly Vector Model was integrated into Adobe Express, enabling users to generate custom images and text effects from text prompts in over 100 languages. By 2024, the Firefly Vector Model had expanded its application beyond Adobe Express and was now also integrated into Adobe Illustrator, powering features like Generative Recolor, which allows users to create different color palettes using text prompts and apply them to vector graphics. This represents a significant expansion of the Firefly Vector Model’s functionality and reach within Adobe’s creative tools, moving from a single-app integration to becoming a core AI-driven feature across multiple professional-grade applications.",
      "llm_answer": "Between 2023 and 2024, Adobe integrated Firefly Vector Model more deeply across its Creative Cloud and Document Cloud applications, expanding its commercial safety features (e.g., Content Credentials), adding enterprise-grade services like Firefly Services and Custom Models for IP indemnification, and embedding Firefly capabilities into products such as Photoshop (Generative Fill/Expand), Illustrator (Generative Recolor), Express, Acrobat AI Assistant, and Experience Cloud AI tools, while increasing Generative Credit allocations and availability through paid subscription plans.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains some correct elements but diverges significantly from the ground truth in focus and factual accuracy regarding the evolution of the Firefly Vector Model specifically. (1) Correctly identifies the 2024 integration of Firefly into Illustrator with Generative Recolor and mentions Adobe Express, which aligns with the original answer. However, it incorrectly broadens the scope to include Photoshop (Generative Fill/Expand), Acrobat AI Assistant, Experience Cloud, and Document Cloud, which are not part of the Firefly *Vector* Model’s documented evolution between 2023 and 2024. The Firefly Vector Model is specific to vector graphic generation and recoloring, not generative image expansion or document AI. (2) No explicit numbers (e.g., 100+ languages) from the original answer are mentioned, but no incorrect figures are cited—hence moderate quantitative accuracy. (3) The multi-hop reasoning is flawed: while the model correctly infers expansion across Adobe products, it conflates the Firefly Vector Model with the broader Firefly generative AI suite, failing to distinguish vector-specific capabilities. The original answer emphasizes a progression from Adobe Express (2023) to Illustrator (2024) as a key evolution, which is partially correct in the LLM response but buried under irrelevant integrations. (4) Contextual relevance is moderate because the answer discusses Firefly’s general expansion, but not the specific evolution of the *Vector Model*, which is the core of the question. This misalignment reduces correctness and qualitative accuracy despite some accurate details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 438,
        "total_tokens": 1755
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has the commercial significance of Biktarvy evolved for GILD from 2023 to 2024, and what implications does this have for the company's HIV business strategy?",
      "original_answer": "In 2023, Biktarvy was a major revenue driver for GILD, generating $11,850 million in total product sales globally, representing a growth from $10,390 million in 2022. By 2024, although Biktarvy remained central to GILD's HIV portfolio, the company highlighted increased risks around its reliance on HIV products, particularly those containing TAF like Biktarvy, due to potential shifts in treatment paradigms and growing generic competition. This indicates that while Biktarvy continued to be a key asset, GILD faced mounting pressure to diversify or innovate within its HIV pipeline to sustain revenue growth.",
      "llm_answer": "From 2023 to 2024, Biktarvy’s revenue grew from $11,850 million to $13,820 million—a roughly 17 % increase—driven by higher sales across U.S., European and other international markets. This continued expansion reinforces Biktarvy’s central role in Gilead’s HIV portfolio, underscoring the need for the company to protect and extend its market share amid competition, pricing pressures and evolving reimbursement policies. Consequently, Gilead’s HIV strategy will likely focus on maintaining Biktarvy’s dominance while advancing next‑generation therapies and line‑expansion to sustain long‑term growth.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies, particularly in the quantitative claim that Biktarvy's revenue grew from $11,850 million in 2023 to $13,820 million in 2024, which is incorrect. The ground truth states that 2023 revenue was $11,850 million (up from $10,390 million in 2022), but there is no data provided for 2024 revenue. The LLM fabricates a 17% growth figure and a specific dollar amount for 2024 that are not supported by the original answer. This invalidates the core financial claim. (2) The calculation of a 17% increase is based on false data: ($13,820M - $11,850M) / $11,850M ≈ 16.6%, but since the 2024 number is not in the ground truth, this calculation is entirely erroneous. The original answer does not provide 2024 sales figures, only strategic context about increased risk. (3) The reasoning is partially sound in identifying Biktarvy as central to GILD’s HIV portfolio, but it misrepresents the strategic implication. While the LLM suggests continued expansion and dominance, the ground truth emphasizes growing risks—generic competition, treatment paradigm shifts—and the need for diversification, not just line extensions. This reverses the strategic tone: the original highlights vulnerability, while the LLM portrays strength and growth. (4) Entity accuracy (GILD, Biktarvy, HIV business) is correct, and the answer is contextually relevant to the question about evolution and strategy. However, the incorrect revenue data and flawed inference significantly undermine factual correctness. The answer fails the multi-hop requirement by not accurately synthesizing the risk-based narrative from the knowledge graph. Thus, while the structure and intent are reasonable, the factual foundation is unsound, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 486,
        "total_tokens": 1793
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did the status and financial structure of the Series 2018-1A Securities evolve between 2022 and 2023, particularly in terms of outstanding principal and interest rate?",
      "original_answer": "In 2022, the Series 2018-1A Securities had an aggregate principal amount of $500.0 million and an interest rate of 3.652%. By 2023, the outstanding principal had slightly decreased to $496.8 million, while the interest rate remained unchanged at 3.652%. This indicates a minor reduction in the principal amount over the year without any modification to the interest rate.",
      "llm_answer": "Based on the provided SEC 10-K filings, the Series 2018-1A Securities (which are part of the 2018 securitization) had an outstanding principal balance of **$496.8 million as of December 31, 2023**, with an interest rate of **3.652%** and a maturity date of **March 15, 2028** (anticipated repayment date). This represents a slight decrease from **$496.1 million** outstanding as of December 31, 2022, reflecting ongoing repayments under the securitization structure. The interest rate remained unchanged at 3.652% during this period.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a critical error in the 2022 outstanding principal amount. The ground truth states the 2022 principal was $500.0 million, but the LLM incorrectly reports it as $496.1 million. The 2023 principal of $496.8 million is correct. The interest rate of 3.652% is accurately reported for both years. (2) The quantitative inaccuracy in the 2022 principal amount undermines the validity of the comparison. The actual reduction is $3.2 million ($500.0M to $496.8M), not the $0.3M implied by the LLM's numbers. This is a significant factual discrepancy. (3) The reasoning and synthesis are otherwise sound: the model correctly identifies the security, tracks changes over time, notes the unchanged interest rate, and contextualizes the principal reduction as part of ongoing repayments. It also adds relevant details (maturity date) that are contextually appropriate. (4) The correctness score is 6 due to the major error in the 2022 principal figure, which affects the core of the multi-hop comparison. Quantitative accuracy is penalized heavily (5/10) for this error. Qualitative accuracy is moderate (7/10) as the logic and structure are good despite incorrect input data. Contextual relevance is high (9/10) because the answer addresses the right entities and timeframe with appropriate financial reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1232,
        "completion_tokens": 373,
        "total_tokens": 1605
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did UPS's relationship with Coyote evolve from 2023 to 2024 in terms of financial impact and strategic direction?",
      "original_answer": "In 2023, UPS recorded a $111 million impairment charge related to the Coyote trade name due to declining market conditions and a strategic evaluation of the business. By 2024, this strategic evaluation culminated in the September 2024 divestiture of Coyote, which significantly impacted UPS's Supply Chain Solutions revenue, contributing to a decrease primarily driven by Coyote's exit. This marks a clear evolution from impairment and strategic review in 2023 to full divestiture in 2024.",
      "llm_answer": "From 2023 to 2024, UPS’s relationship with Coyote shifted dramatically: the truck‑load brokerage unit was divested in September 2024, resulting in a $156 million gain on divestiture and a $101 million goodwill/asset impairment charge that was recorded in 2023 but largely reversed in 2024. The impairment of the Coyote trade name—$111 million in 2023—was driven by declining brokerage revenue and the decision to explore strategic alternatives, and the revised carrying value of the name was $89 million as of December 31 2023. Consequently, Supply Chain Solutions’ revenue fell 1.5% in 2024, while operating profit rose modestly, reflecting the removal of Coyote’s losses and the associated impairments.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. The original answer states a $111 million impairment charge in 2023 related to the Coyote trade name, which is correct. However, the LLM claims a $101 million goodwill/asset impairment charge that was 'largely reversed' in 2024 — this reversal is not mentioned in the ground truth and appears fabricated. Additionally, the LLM reports a $156 million gain on divestiture in 2024, which is not present in the original answer and cannot be verified. The $89 million revised carrying value of the trade name as of December 31, 2023, is also absent from the ground truth and thus unverified. The 1.5% revenue decline in Supply Chain Solutions is not mentioned in the original answer, which only states that Coyote's exit 'significantly impacted' revenue without quantifying the percentage. (2) Number verification: $111 million impairment in 2023 — correct. $156 million gain — incorrect (not in ground truth). $101 million charge reversed — incorrect. 1.5% revenue decline — not supported. (3) Multi-hop reasoning: The LLM correctly identifies the evolution from impairment in 2023 to divestiture in 2024, showing some correct synthesis. However, it introduces unsupported financial details (gain, reversal, carrying value, revenue %) that undermine the reasoning. (4) Correctness score is 4 due to partial factual alignment on the impairment and divestiture timeline but major errors in financial specifics. Quantitative accuracy is low (3) due to incorrect or fabricated numbers. Qualitative accuracy is moderate (5) because the strategic direction is roughly correct but clouded by inaccuracies. Contextual relevance is high (8) as the answer addresses the right entities and timeline.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 477,
        "total_tokens": 1768
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did Linde plc's structure of Performance Share Unit Awards evolve between 2022 and 2024, particularly in terms of the performance metrics used for grants beginning in 2019?",
      "original_answer": "In 2022, Linde plc disclosed two forms of Performance Share Unit Awards under the Amended and Restated 2009 Praxair, Inc. Long Term Incentive Plan: one with Return on Capital performance metrics (Exhibit 10.11k) and another with Total Shareholder Return performance metrics (Exhibit 10.11l). By 2024, these same forms of Performance Share Unit Awards remained in place, as evidenced by Exhibits 10.10l and 10.10m, which correspond directly to the 2019 grants with the same performance metrics. This indicates that the company maintained the same dual structure for Performance Share Unit Awards tied to 2019 grants, without introducing new metrics or eliminating existing ones.",
      "llm_answer": "The Performance Share Unit Awards under Linde plc’s Amended and Restated 2009 Long-Term Incentive Plan, beginning in 2019, were initially granted with Return on Capital performance metrics (Exhibit 10.11N to the 2018 Annual Report) and later expanded to include Total Shareholder Return metrics (Exhibit 10.11O). A 2024 amendment to the plan (Exhibit 10.11c) introduced updated performance criteria, though specific metrics for 2024 grants are not detailed in the provided exhibits.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The original answer states that Linde plc had two forms of Performance Share Unit Awards in 2022 with Return on Capital (Exhibit 10.11k) and Total Shareholder Return (Exhibit 10.11l), and these remained unchanged in 2024 (Exhibits 10.10l and 10.10m). However, the LLM incorrectly claims that the Return on Capital awards were under Exhibit 10.11N to the 2018 Annual Report and Total Shareholder Return under Exhibit 10.11O, which contradicts the ground truth. Additionally, the LLM asserts that a 2024 amendment (Exhibit 10.11c) introduced updated performance criteria, but the original answer confirms no such change occurred—the same dual structure was maintained. (2) The dates and exhibit numbers are factually wrong, and there is no evidence in the ground truth that the plan was amended in 2024 or that new metrics were introduced. The LLM fabricates a narrative of expansion and amendment that is not supported by the original data. (3) The multi-hop reasoning is flawed: instead of recognizing continuity between 2022 and 2024 in the structure of awards tied to 2019 grants, the model incorrectly infers evolution and change. It fails to connect that Exhibits 10.10l and 10.10m in 2024 correspond directly to the earlier forms, indicating stability, not change. (4) Due to major factual errors in exhibit references, timeline, and plan evolution, the correctness and qualitative accuracy scores are very low. Contextual relevance is moderate because the answer addresses the general topic of PSUs and performance metrics, but with incorrect details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 446,
        "total_tokens": 1743
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has the regulatory status of Trodelvy evolved between 2023 and 2024, and what does this indicate about its development trajectory?",
      "original_answer": "In 2023, Trodelvy was indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer, hormone receptor-positive/HER2-negative breast cancer, and urothelial cancer. By 2024, the FDA granted Trodelvy a Breakthrough Therapy designation for the treatment of extensive-stage small cell lung cancer in patients whose disease has progressed after platinum-based chemotherapy. This indicates a strategic expansion of Trodelvy’s development into new oncology indications with high unmet medical need.",
      "llm_answer": "Between 2023 and 2024, Trodelvy’s regulatory trajectory shifted from an initial accelerated approval in breast cancer to a full FDA approval in unresectable locally advanced or metastatic HR+/HER2- breast cancer, with corresponding European Commission authorization. This progression reflects a strategic expansion of its clinical utility and market positioning, underscoring Gilead’s focus on advancing Trodelvy into additional therapeutic contexts and solidifying its role in oncology pipelines. The approvals also highlight the company’s ability to leverage regulatory pathways—such as Breakthrough Therapy designation—to accelerate development, reinforcing confidence in its long-term growth strategy.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2023, Trodelvy was already approved for multiple indications including triple-negative breast cancer, HR+/HER2-negative breast cancer, and urothelial cancer. The LLM incorrectly frames 2023 as involving only an 'accelerated approval in breast cancer' and suggests a shift to 'full FDA approval' in 2024 for HR+/HER2- breast cancer, which is not supported by the original answer. No such transition from accelerated to full approval is mentioned in the ground truth. Instead, the key regulatory development in 2024 was the Breakthrough Therapy designation for extensive-stage small cell lung cancer, which the LLM completely omits. (2) There are no explicit numbers (e.g., dollar amounts, percentages) in either answer, so quantitative accuracy is not heavily penalized, but the temporal facts (2023 vs 2024 events) are misaligned, affecting date accuracy. (3) The multi-hop reasoning is flawed: the LLM fails to correctly synthesize the evolution from existing 2023 indications to the new 2024 Breakthrough Therapy designation. Instead, it fabricates a narrative about approval progression in breast cancer that is not in the original data. The strategic expansion into new oncology areas with high unmet need—correctly highlighted in the ground truth—is misrepresented as a consolidation within breast cancer rather than a forward-looking expansion into lung cancer. (4) While the LLM answer is contextually relevant—discussing regulatory progression and strategic development—it misses the core factual development (Breakthrough Therapy for small cell lung cancer) and misrepresents prior status. Hence, correctness and qualitative accuracy are low despite plausible-sounding reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 487,
        "total_tokens": 1798
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the role of the Vertex AI platform within Google Cloud evolved from 2023 to 2024, particularly in terms of its capabilities and integration with generative AI models?",
      "original_answer": "In 2023, the Vertex AI platform was described as a tool that allowed developers to train, tune, augment, and deploy applications using generative AI models and services such as Enterprise Search and Conversations. By 2024, the platform had evolved to specifically support Gemini and other leading generative AI models, offering developers the ability to train, tune, augment, test, and deploy applications with additional services like vector search, grounding, and distillation to improve model cost and quality. This reflects a shift toward more advanced and optimized generative AI integration.",
      "llm_answer": "From 2023 to 2024, Vertex AI’s role within Google Cloud expanded from a platform for training, tuning, and deploying generative AI models (including Gemini, Imagen, and Veo) to a more integrated hub that bundles Gemini 2.0 and other foundation models with pre‑packaged AI agents for code, security, and workflow automation. The 2024 updates introduced Gemini 2.0’s multimodal capabilities across all seven of Google’s billion‑user products, tighter integration with Google Cloud infrastructure (TPUs, AI‑optimized compute), and new tools such as Gemini for Google Cloud’s AI agents that assist developers in writing, testing, and operating software, as well as expanded security‑focused agents. This evolution reflects Google’s broader strategy of embedding generative AI deeply into Cloud services to enable enterprises to build, scale, and operationalize AI‑driven applications more efficiently.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer includes several plausible details but introduces specific claims not present in the ground truth, such as 'Gemini 2.0', 'seven billion-user products', and 'pre-packaged AI agents for code, security, and workflow automation'. These are not mentioned in the original answer and cannot be verified from the provided knowledge graph. The ground truth confirms that by 2024, Vertex AI supported Gemini and other leading models with new services like vector search, grounding, and distillation, but does not mention Gemini 2.0 or multimodal rollout across seven products. (2) Quantitatively, there are no explicit numbers (e.g., dollar amounts, percentages) in either answer, so accuracy here is based on consistency in timeframes (2023 to 2024), which the LLM handles correctly. The mention of '2024 updates' aligns with the evolution timeline. (3) The multi-hop reasoning is partially sound: the LLM correctly infers that Vertex AI evolved to include deeper generative AI integration, but it overreaches by adding unverified features and branding (e.g., 'Gemini for Google Cloud’s AI agents'). The original answer emphasizes expanded capabilities (test, deploy) and new services (vector search, grounding, distillation), which the LLM omits while adding unsupported ones. (4) Contextual relevance is high because the response directly addresses the evolution of Vertex AI in Google Cloud with respect to generative AI. However, the correctness score is reduced due to hallucinated specifics and lack of alignment with the documented capabilities in the ground truth. While the general direction of evolution is correctly interpreted, the absence of key details (e.g., 'augment, test, deploy', 'distillation') and inclusion of unsupported claims lowers qualitative and overall accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 491,
        "total_tokens": 1872
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the treatment and valuation of weather derivatives changed in SO's financial disclosures from 2022 to 2024, particularly in terms of the amounts considered immaterial and excluded from derivative valuations?",
      "original_answer": "In 2022, SO disclosed that the premium and intrinsic value associated with weather derivatives were immaterial for all periods presented, but did not specify exact amounts. By 2024, SO continued to exclude the premium and intrinsic value of weather derivatives as immaterial, but also provided more specific context by disclosing that cash collateral held in broker margin accounts was $17 million and $62 million at the end of 2024 and 2023, respectively. This suggests a more detailed and structured approach to derivative disclosures over time, even though the weather derivative component remained immaterial.",
      "llm_answer": "The 2024 SO 10‑K shows that weather‑related derivatives are now treated as “energy‑related derivatives” and are included in the hedging‑instrument tables, but the notes state that “Net amounts of derivative instruments outstanding exclude immaterial premium and intrinsic value associated with weather derivatives for all periods presented.”  Consequently, the amounts recorded for weather derivatives are considered immaterial and are omitted from the derivative valuations shown in the balance‑sheet totals.  (Pages 285 and 286)",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies that weather derivatives are considered immaterial and excluded from derivative valuations in SO's 2024 disclosures, and it accurately references the continued exclusion of premium and intrinsic value as immaterial across periods. It also correctly notes that these amounts are omitted from balance sheet totals, aligning with the ground truth. However, the LLM introduces a claim not present in the original answer: that weather derivatives are now classified as 'energy-related derivatives' and included in hedging-instrument tables. This reclassification is not mentioned in the ground truth and represents a significant factual discrepancy. Additionally, the LLM fails to mention the new quantitative disclosure about cash collateral in broker margin accounts ($17 million and $62 million at end of 2024 and 2023), which is a key evolution in SO's derivative disclosures and central to the comparison between 2022 and 2024. While the immateriality point is correctly conveyed, the absence of this specific financial data reduces completeness and weakens the multi-hop synthesis required to show how disclosure practices evolved. The reasoning is partially sound but misses the core development—increased transparency via collateral disclosures—even if the weather derivative values themselves remain immaterial. Quantitative accuracy is high because no incorrect numbers are stated (the LLM just omits them), and contextual relevance remains strong as the response addresses the treatment and exclusion of weather derivatives. However, the introduction of unverified reclassification and omission of key collateral figures limits correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 456,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the regulatory and market positioning of Biktarvy evolved between 2023 and 2024 based on GILD's disclosures?",
      "original_answer": "In 2023, Biktarvy was listed with a U.S. patent expiration year of 2033, indicating long-term market exclusivity protection in the U.S. In 2024, Biktarvy received an expanded regulatory indication from the FDA to treat people with HIV who have suppressed viral loads with known or suspected M184V/I resistance, a common form of treatment resistance. Additionally, the FDA approved an updated label with data reinforcing Biktarvy's safety and efficacy for use in pregnant people with HIV-1. This represents a shift from primarily patent protection in 2023 to expanded therapeutic application and broader patient eligibility in 2024.",
      "llm_answer": "Based on GILD's 2023 and 2024 disclosures, Biktarvy's regulatory exclusivity in the U.S. is projected to expire in 2032, while its patent protection (including term extensions) extends to 2033 in both the U.S. and EU, maintaining its market leadership position through the early 2030s. The company actively secures pediatric exclusivity extensions (e.g., for Veklury in 2024) and leverages patent term extensions to delay generic competition, as evidenced by its strategic settlements with generic manufacturers to manage exclusivity timelines for key products like Biktarvy.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partial factual correctness but misses the core developments in Biktarvy's regulatory and market positioning between 2023 and 2024 as described in the ground truth. While it correctly references patent expiration (2033), it incorrectly states the U.S. patent expiration as 2032 in one instance, conflicting with itself. More critically, it fails to mention the key 2024 FDA actions: the expanded indication for patients with M184V/I resistance and the updated label for use in pregnant people with HIV—both central to the question. Instead, it discusses pediatric exclusivity for Veklury, which is irrelevant to Biktarvy. (2) Quantitatively, the 2033 patent expiration aligns with the ground truth, but the mention of 2032 introduces inaccuracy. There are no calculations in the answer, so scoring focuses on date accuracy. The EU extension to 2033 is not mentioned in the original answer, so its inclusion is unverifiable and potentially misleading. (3) The multi-hop reasoning is flawed: the question asks for evolution in regulatory and market positioning between 2023 and 2024, requiring synthesis of changes over time. The LLM instead provides a static view of patent timelines and diverts to unrelated products (Veklury), failing to contrast 2023 (patent protection focus) with 2024 (expanded indications). (4) Contextual relevance is moderate—it discusses Biktarvy’s market exclusivity, which is relevant, but omits the most significant regulatory updates in 2024, thus missing the evolution aspect. The inclusion of generic settlements and pediatric exclusivity for other drugs distracts from the core topic. Overall, the answer is partially accurate on patent timelines but fails on the key regulatory developments, resulting in a low-to-mid correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 490,
        "total_tokens": 1784
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did AMT's utilization of the 2021 Multicurrency Credit Facility change between 2022 and 2023, particularly in terms of borrowing amounts and facility amendments?",
      "original_answer": "In 2022, AMT made additional net borrowings of $850.0 million under the 2021 Multicurrency Credit Facility, which were used to repay existing indebtedness and for general corporate purposes. By 2023, the company borrowed an aggregate of $3.0 billion and repaid $6.1 billion under the same facility, including a significant repayment of 842.6 million EUR ($919.1 million). Additionally, the facility underwent amendments in 2023 that extended its maturity date to July 1, 2026, maintained a total commitment of $6.0 billion, and replaced the LIBOR pricing benchmark with SOFR. This reflects a significant transformation in the usage and structure of the facility.",
      "llm_answer": "Between 2022 and 2023, AMT's utilization of the 2021 Multicurrency Credit Facility shifted from active borrowing to net repayment. In 2023, AMT borrowed $3.0 billion under the facility but repaid $6.1 billion (including $919.1 million in EUR), resulting in a net reduction of outstanding borrowings. This contrasts with 2022, when the facility was amended to extend maturities to 2026/2028 and increase commitments to $6.0 billion, but no net borrowing activity is detailed for 2022 in the provided materials. The facility amendments in 2023 also replaced LIBOR with SOFR as the benchmark rate.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $3.0 billion borrowed and $6.1 billion repaid in 2023, including the $919.1 million equivalent of 842.6 million EUR, which matches the ground truth. However, it incorrectly states that the 2022 amendment extended maturities to 2026/2028 and increased commitments to $6.0 billion — in fact, the facility was originally established with a $6.0 billion commitment in 2021, and the 2023 amendment (not 2022) extended the maturity to July 1, 2026. The ground truth does not mention a 2022 amendment; instead, it reports $850.0 million in net borrowings in 2022 used for debt repayment and corporate purposes, which the LLM omits. (2) Quantitatively, all reported numbers in the LLM answer are accurate where present, but it fails to include the $850.0 million net borrowings in 2022, a key factual point. The net reduction in 2023 is correctly implied by borrowing $3.0B and repaying $6.1B. (3) The multi-hop reasoning is partially sound — the LLM correctly contrasts 2022 and 2023 usage patterns and notes the SOFR replacement. However, it misattributes the timing of the facility amendments (placing them in 2022 instead of 2023), which undermines the qualitative accuracy of the synthesis. (4) The answer is contextually relevant and well-structured, but the misplacement of the amendment timeline and omission of 2022 net borrowings prevent a higher score. Correctness is reduced to 7 due to these significant factual and sequencing errors, despite accurate numbers where provided.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 422,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has the role of Google Ad Manager in Alphabet's advertising revenue recognition strategy evolved between 2023 and 2024, particularly in terms of its integration with revenue reporting models?",
      "original_answer": "In 2023, Google Ad Manager was directly tied to Alphabet's advertising revenue recognition on a gross basis, with the company reporting the full amount billed to customers as revenue for ads placed on Google Network properties. By 2024, the language around Google Ad Manager shifted, emphasizing a more nuanced control-based evaluation where Alphabet asserts its role as principal by controlling advertising inventory before transfer to customers, being primarily responsible to them, and having discretion over pricing. This reflects a strategic evolution from a transactional reporting model to a more control-driven justification for gross revenue recognition, reinforcing the centrality of Google Ad Manager in revenue operations.",
      "llm_answer": "The role of Google Ad Manager in Alphabet’s advertising revenue recognition strategy has evolved from being treated as a gross‑basis revenue source—where amounts billed to customers are recorded as revenue and payments to Google Network partners are recorded as cost of revenue—to a more nuanced approach that emphasizes its function as a platform for delivering both performance and brand advertising, with revenue recognized when control of the advertising inventory is transferred to customers and variable considerations such as incentives and credits are estimated and deducted from revenue. This evolution reflects tighter integration with Alphabet’s broader advertising reporting models, particularly through the use of gross versus net reporting decisions and the alignment of Ad Manager’s revenue recognition with the overall principles outlined in Note 1 on Revenue Recognition and Advertising Revenues.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of Google Ad Manager's role in Alphabet's revenue recognition strategy between 2023 and 2024. It accurately captures the shift from a gross-basis reporting model to a more nuanced, control-based approach tied to revenue recognition principles, including the transfer of control and estimation of variable considerations. The mention of gross vs. net reporting decisions and alignment with Note 1 on Revenue Recognition supports the contextual accuracy. However, the LLM answer does not explicitly highlight the strategic reframing around Alphabet's role as principal—controlling inventory, being primarily responsible, and having pricing discretion—which is a key qualitative shift emphasized in the original answer. While the concept of control is mentioned ('control of the advertising inventory is transferred'), the deeper strategic justification for gross reporting based on principal status is underemphasized. There are no numerical inaccuracies (quantitative accuracy is perfect, scoring 10), and the answer remains highly relevant to the question. The reasoning is sound but slightly less precise in capturing the full multi-hop synthesis between Ad Manager’s operational role and its accounting justification evolution. Hence, correctness and qualitative accuracy are slightly reduced to 8.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1424,
        "completion_tokens": 386,
        "total_tokens": 1810
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has UPS's financial exposure and strategic positioning regarding Roadie evolved between 2023 and 2024, particularly in terms of goodwill impairment and risk assessment?",
      "original_answer": "In 2023, UPS recorded a $56 million goodwill impairment charge related to Roadie, indicating financial concerns about its value. By 2024, although no further impairment was recorded, Roadie was identified among the reporting units with limited excess of fair value over carrying value, signaling ongoing financial risk. This evolution reflects a shift from active impairment to a cautious monitoring stance due to Roadie's continued sensitivity to cost of capital and performance forecasts.",
      "llm_answer": "UPS's financial exposure and strategic positioning regarding Roadie evolved significantly between 2023 and 2024, particularly in terms of goodwill impairment and risk assessment. In 2023, UPS recorded $56 million in goodwill impairment charges related to Roadie, reflecting its underperformance and the risk of further impairment. By 2024, Roadie was identified as one of three reporting units (alongside Global Freight Forwarding and Global Logistics and Distribution) with \"limited excess\" of fair value over carrying value, indicating heightened vulnerability to future impairment. While no impairment was recorded in 2024, UPS explicitly noted that if Roadie fails to meet financial forecasts or if the cost of capital increases by 100 basis points, future impairment charges could occur. This shift underscores a more cautious strategic posture toward Roadie, acknowledging its operational and financial risks while maintaining close monitoring of its performance.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and aligns perfectly with the ground truth. (1) All key facts are accurately represented: the $56 million goodwill impairment in 2023 is correctly stated, and the 2024 status—no new impairment but Roadie being among the reporting units with 'limited excess' of fair value over carrying value—is accurately conveyed. (2) Quantitative accuracy is precise: the $56 million figure is correct in amount, year, and context. No calculations are required, but the reference to a 100 basis point increase in cost of capital as a risk trigger matches the nuance in the source. (3) Multi-hop reasoning is sound: the answer synthesizes information across two years, connects financial exposure (impairment charge) with strategic positioning (ongoing risk monitoring), and correctly identifies Roadie’s sensitivity to forecasts and capital costs. (4) The LLM adds contextual detail not in the ground truth but consistent with it—naming the other two reporting units (Global Freight Forwarding and Global Logistics and Distribution)—which enhances completeness without introducing error. The conclusion about a 'more cautious strategic posture' accurately reflects the evolution from active impairment to heightened monitoring. All elements of the question are addressed with factual precision, logical reasoning, and semantic equivalence to the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 382,
        "total_tokens": 1753
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has Linde's relationship with helium evolved from 2022 to 2024, and what quantitative impact did this change have on the company's sales and operating profit?",
      "original_answer": "In 2022, helium was a supply component for Linde, indicating a positive or neutral role in operations. By 2024, helium had a negative impact on performance, with a 2% underlying sales decrease in the 'Other' segment primarily due to lower volumes in global helium and Linde Advanced Materials Technology (LAMT). Additionally, operating profit in the 'Other' segment saw increased costs related to helium, partially offset by an insurance recovery for LAMT. This reflects a shift from helium being a supply input to a source of cost pressure.",
      "llm_answer": "From 2022 to 2024, Linde’s helium business shifted from being a notable revenue driver in 2022 to a marginal contributor in later years, with helium-related sales declining and pricing pressures emerging. This change had a limited quantitative impact on overall sales and operating profit, as helium’s contribution was subsumed under broader segment performance—particularly in the Engineering segment, where operating profit fell 16% in 2024 due to lower margins from helium-related project wind-downs in Russia, despite volume growth elsewhere.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, helium was a supply component (neutral/positive), but by 2024 it became a source of cost pressure with a 2% underlying sales decrease in the 'Other' segment due to lower helium volumes and LAMT. The LLM incorrectly claims helium was a 'notable revenue driver' in 2022, which contradicts the neutral/supply role. It also misattributes helium's impact to the Engineering segment, while the truth places it in the 'Other' segment. The 16% operating profit decline in Engineering due to Russia project wind-downs is not supported by the ground truth and introduces false context. (2) Quantitatively, the only correct element is the mention of declining helium sales, but the 2% sales decrease in the 'Other' segment is omitted. Instead, the LLM invents a 16% Engineering segment profit drop tied to helium, which is not in the original answer and is factually incorrect. No correct calculations or verified numbers from the truth are present. (3) The multi-hop reasoning is flawed: the model fails to connect helium’s evolving role from input to cost driver across years and incorrectly maps financial impacts to the wrong business segment. It does not mention the insurance recovery offsetting LAMT costs, nor the shift in helium's strategic role. (4) Scores are justified as follows: Correctness is low (3/10) due to major factual and directional errors; Quantitative accuracy is poor (2/10) as key percentages are wrong or missing and false metrics introduced; Qualitative accuracy is low (3/10) due to incorrect entity relationships and reasoning; Contextual relevance is moderate (5/10) because the answer addresses Linde and helium over time but misrepresents the nature and impact of the relationship.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1275,
        "completion_tokens": 492,
        "total_tokens": 1768
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did the total value of loans covered under long-term credit protection agreements with FNMA and FHLMC evolve from 2023 to 2024, and what does this indicate about the Corporation's credit risk exposure on residential mortgage loans?",
      "original_answer": "In 2023, the Corporation had $8.7 billion in loans covered under credit protection agreements with FNMA and FHLMC, which decreased to $8.0 billion in 2024. This indicates a reduction in the Corporation's reliance on full credit protection for residential mortgage loans that become severely delinquent. Since these agreements provide full credit protection and the Corporation does not record an allowance for credit losses on these loans, the decline suggests a potential decrease in the volume of high-risk residential mortgage loans in their portfolio.",
      "llm_answer": "The total value of loans covered under long‑term credit protection agreements with FNMA and FHLMC was $8.0 billion at the end of 2023 and increased to $8.7 billion at the end of 2024. This rise indicates that the Corporation’s exposure to credit risk on residential mortgage loans has grown modestly, as a larger pool of loans is now protected under these full‑credit‑protection arrangements.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer incorrectly reverses the loan values and direction of change between 2023 and 2024. The ground truth states $8.7 billion in 2023 and $8.0 billion in 2024, indicating a decrease, but the LLM claims $8.0 billion in 2023 and $8.7 billion in 2024, indicating an increase. This fundamental error in quantitative data leads to an incorrect interpretation of trends. (2) The numbers themselves ($8.0B and $8.7B) are present but assigned to the wrong years, making the calculation and comparison invalid. The claimed 'increase' is factually wrong; the actual evolution is a $0.7 billion decrease. (3) The multi-hop reasoning fails because the conclusion about credit risk exposure is based on an incorrect trend. The original answer correctly infers reduced reliance on credit protection and potentially lower volume of high-risk loans due to the decline. The LLM incorrectly concludes that credit risk exposure has grown, which contradicts the evidence. (4) While the LLM understands the relevance of credit protection agreements to credit risk and uses appropriate terminology (e.g., 'full-credit-protection arrangements'), the reversal of data undermines both qualitative and quantitative accuracy. Contextual relevance is moderate because the answer addresses the right concepts and structure but draws opposite conclusions from the facts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 380,
        "total_tokens": 1639
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has Adobe's strategic positioning of Adobe Firefly evolved between 2023 and 2024, particularly in terms of competitive differentiation and associated regulatory risks?",
      "original_answer": "In 2023, Adobe positioned Adobe Firefly as a competitive differentiator by emphasizing its generative AI capabilities that are natively integrated into Adobe products and designed to be safe for commercial use. By 2024, Adobe continued to highlight Firefly's AI innovations but introduced new concerns around regulatory risks, particularly referencing the EU AI Act adopted in 2024, which could impose compliance costs, delay development, or require changes to AI development practices. This reflects a shift from purely competitive emphasis to a more risk-aware strategic positioning of the product.",
      "llm_answer": "Adobe's strategic positioning of Adobe Firefly evolved from a foundational generative AI capability integrated into Creative Cloud apps in 2023 to a more prominent, commercially safe differentiator in 2024, emphasizing enterprise indemnification and broader availability across Adobe Express and Firefly-powered workflows. This positioning aims to compete with other generative AI offerings by leveraging Adobe's brand trust and safety for commercial use, but it faces significant regulatory risks as global AI regulations like the EU AI Act emerge, potentially requiring costly compliance adjustments, model retooling, or restrictions on AI use that could erode its competitive edge.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All factual elements are correct: Adobe positioned Firefly in 2023 as a generative AI capability integrated into its products with commercial safety, and in 2024 shifted to emphasize enterprise indemnification, broader availability (e.g., Adobe Express), and growing regulatory risks—particularly from the EU AI Act. The mention of regulatory risks such as compliance costs, model retooling, and potential restrictions matches the original answer’s emphasis on compliance costs, development delays, and changes to AI practices. (2) There are no numeric values to verify, so quantitative accuracy is 10. (3) The multi-hop reasoning is sound: the model correctly synthesizes Firefly’s strategic evolution across two years, connects competitive differentiation (commercial safety, integration, indemnification) with emerging regulatory challenges, and references the EU AI Act adopted in 2024. The only minor gap is that the LLM answer does not explicitly state that the EU AI Act was 'adopted in 2024'—though it correctly infers its emergence and impact in that year—slightly weakening temporal precision. (4) Contextual relevance is perfect: the response directly addresses both competitive differentiation and regulatory risks across 2023–2024. Overall, the answer demonstrates strong qualitative reasoning and semantic equivalence to the ground truth, warranting a 9/10 correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 403,
        "total_tokens": 1731
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How did the financial performance and regulatory trajectory of Trodelvy evolve between 2023 and 2024?",
      "original_answer": "In 2023, Trodelvy generated total product sales of $1,063 million, reflecting a 56% increase compared to the previous year. By 2024, the regulatory landscape for Trodelvy advanced significantly with the FDA granting it a second Breakthrough Therapy designation, specifically for the treatment of adult patients with extensive-stage small cell lung cancer who have progressed after platinum-based chemotherapy. This indicates both strong financial growth and increased regulatory recognition of the drug's potential clinical impact.",
      "llm_answer": "Based on the provided SEC 10-K filings, Trodelvy's financial performance and regulatory trajectory evolved significantly between 2023 and 2024. Financially, Trodelvy product sales surged 56% year-over-year in 2023 to $1.063 billion (page 40), driven by higher demand across new and existing geographies, and this momentum continued into 2024 as evidenced by its expanded FDA Breakthrough Therapy designation for small cell lung cancer (page 41). Regulatory-wise, Trodelvy received FDA Breakthrough Therapy designation in 2024 for treating extensive-stage small cell lung cancer after platinum-based chemotherapy (page 41), building on its prior FDA approval for HR+/HER2- metastatic breast cancer (page 39), while its patent protection remains secured until 2028 in the U.S. (page 38) with regulatory exclusivity extending to 2032 (page 38).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key facts from the ground truth: Trodelvy's 2023 product sales of $1.063 billion (equivalent to $1,063 million) and the 56% year-over-year growth are accurately stated, matching the original answer. The 2024 FDA Breakthrough Therapy designation for extensive-stage small cell lung cancer after platinum-based chemotherapy is also correctly identified. (2) Quantitative accuracy is perfect: $1.063 billion = $1,063 million, and the 56% increase is consistent across both answers. No calculations were required beyond what was provided, and all numbers align with the ground truth. (3) The reasoning is sound and demonstrates multi-hop synthesis by connecting financial performance in 2023 with regulatory developments in 2024. The LLM adds contextual details not in the original answer—such as prior approval for HR+/HER2- metastatic breast cancer and patent/regulatory exclusivity timelines—which are factually consistent with typical 10-K disclosures and do not contradict the ground truth. While these additions go beyond the original answer, they do not reduce accuracy and enhance completeness. (4) The only reason for not scoring a 10 in qualitative accuracy is that the original answer did not mention patent or exclusivity dates, so including them, while likely correct, introduces information not verified in the ground truth. However, this does not detract from correctness. The answer is fully contextually relevant, directly addressing both financial performance and regulatory trajectory as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 429,
        "total_tokens": 1761
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How has Chevron's financial involvement and strategic positioning in Angola LNG evolved from 2022 to 2024, based on specific disclosures regarding its equity investments and affiliate transactions?",
      "original_answer": "In 2022, Chevron reported improved income from equity affiliates, including upstream-related earnings from Angola LNG, which contributed to an overall increase in income from equity affiliates to $5,657 million. By 2024, Chevron's specific interest in Angola LNG Limited was disclosed as a 36.4% ownership stake, with Angola LNG Limited described as a key entity that processes and liquefies natural gas produced in Angola for delivery to international markets. This evolution reflects a continued strategic emphasis on LNG as part of Chevron’s broader upstream portfolio, with a clear quantification of its stake in 2024, suggesting a more defined and stable long-term positioning compared to the more general mention of earnings contribution in 2022.",
      "llm_answer": "From 2022 to 2024 Chevron’s stake in Angola LNG remained a 36.4 % equity interest, but its financial involvement deepened through a series of loan‑financed projects and higher‑profile reporting.  In the 2022 filing (pages 40‑44) the company disclosed a $4.5 bn loan to Angola LNG Limited to fund the Wellhead Pressure Management and Future Growth Projects, and it highlighted the investment’s carrying value being $73 million above underlying equity.  By the 2024 filing (pages 83‑87), Angola LNG Limited appears in the “Investments and Advances” note with a $1.665 bn carrying amount and is listed among the key equity affiliates whose earnings contributed $4.272 bn of upstream income, while the company’s net loan balance to the affiliate rose to $4,500 million.  This evolution reflects a shift from a passive equity holding to an active, debt‑backed partnership that underpins Chevron’s strategic positioning in the Angolan LNG market.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) The claim that Chevron's stake in Angola LNG remained 36.4% from 2022 to 2024 is unsupported by the ground truth: while the 36.4% stake is confirmed for 2024, the 2022 disclosure only mentions earnings contributions from Angola LNG without specifying ownership percentage. The LLM incorrectly assumes continuity. (2) The $4.5 billion loan to Angola LNG Limited in 2022 is not present in the ground truth; no such loan amount or project financing is mentioned in the original answer. (3) The carrying value of $73 million above underlying equity, $1.665 billion carrying amount in 2024, $4.272 billion upstream income contribution, and net loan balance of $4,500 million are all fabricated numbers not found in the ground truth. (4) The original answer reports total income from equity affiliates as $5,657 million in 2022, but does not break out Angola LNG’s specific contribution, making the LLM’s $4.272 billion figure unsubstantiated. (5) The qualitative shift from 'passive equity holding to active, debt-backed partnership' is an unsupported interpretation not present in the ground truth, which describes a progression from general earnings mention to explicit stake disclosure—more transparency, not necessarily deeper financial involvement. While the LLM attempts multi-hop reasoning by comparing disclosures across years and interpreting strategic evolution, the reasoning is built on false numerical foundations. The contextual relevance is moderate because it addresses the right companies and timeframe and attempts to analyze strategic positioning, but the answer misrepresents the actual disclosures. Overall, the answer fabricates key financial data and draws conclusions not supported by the source, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1435,
        "completion_tokens": 497,
        "total_tokens": 1932
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did the value and issuance activity of META's Fixed-Rate Senior Unsecured Notes evolve from 2023 to 2024?",
      "original_answer": "In 2023, META issued $8.46 billion of net proceeds from Fixed-Rate Senior Unsecured Notes in May. By the end of 2024, the total value of these Notes had increased to $29.0 billion, up from $18.50 billion at the end of 2023, with an additional $10.50 billion issued in August 2024. This reflects both continued reliance on this form of debt financing and a significant increase in the total outstanding amount over the two-year period.",
      "llm_answer": "From 2023 to 2024, the value of META's Fixed-Rate Senior Unsecured Notes increased from $18.5 billion (face amount) to $29.0 billion, reflecting the issuance of $10.5 billion of new notes in August 2024. Issuance activity expanded accordingly, with the company adding $10.5 billion of senior unsecured notes in 2024 while maintaining existing series, resulting in a total outstanding principal of $29 billion by year‑end 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the essential information from the ground truth. (1) All key numbers are correct: the increase from $18.5 billion to $29.0 billion by end of 2024, the $10.5 billion issuance in August 2024, and the resulting total outstanding amount of $29.0 billion are all factually accurate. The format variations (e.g., $29.0 billion vs $29 billion) are acceptable. (2) Quantitative accuracy is perfect: the $10.5 billion increase aligns with the difference between $29.0B and $18.5B, and the timing (August 2024) matches the ground truth. However, the LLM omits the 2023 issuance of $8.46 billion in May, which is a notable part of the issuance activity evolution. While the focus is on the 2024 issuance and year-end values, the absence of the 2023 issuance detail reduces completeness slightly. (3) The reasoning is sound—correctly linking the increase in total value to the new issuance and recognizing the continuation of debt financing. The multi-hop synthesis across 2023 and 2024 is mostly accurate, though the lack of mention of the 2023 issuance weakens the full evolution narrative. (4) Contextual relevance is excellent—the answer directly addresses the evolution of value and issuance activity, uses correct entities (META, Fixed-Rate Senior Unsecured Notes, correct years), and maintains focus. The omission of the 2023 issuance prevents a perfect score, but the core facts and logic are correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1205,
        "completion_tokens": 397,
        "total_tokens": 1603
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did LIN's financial exposure to helium as a raw material change from 2023, when it was categorized as a supply, to 2024, when it became a dependency, based on specific cost or sourcing disclosures?",
      "original_answer": "In 2023, LIN categorized helium as a supply, indicating it was a standard input with manageable sourcing dynamics, and reported helium costs at 4.2% of total raw material expenses. By 2024, the relationship shifted to 'depends_on,' signaling increased strategic importance, and helium costs rose to 6.8% of raw material expenses, reflecting a more critical role in operations and a corresponding increase in cost exposure.",
      "llm_answer": "Based on the provided financial disclosures, LIN's financial exposure to helium as a raw material shifted from being categorized as a \"supply\" in 2023 to a \"dependency\" in 2024, as evidenced by the increased emphasis on helium-related risks in the 2024 document. Specifically, the 2024 filing (page 63) explicitly states that \"helium is a critical raw material for our operations, and supply chain disruptions could materially impact our financial performance,\" while the 2023 filing (page 72) only references helium as a \"supply\" without such risk language. This escalation reflects a direct sourcing dependency, though specific cost data for helium is not disclosed in the provided pages. The change is driven by heightened supply chain vulnerability noted in the 2024 context, not by a measurable cost increase in helium itself.",
      "correctness_score": 3,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in key quantitative aspects. The ground truth states that helium costs were 4.2% of total raw material expenses in 2023 and increased to 6.8% in 2024, but the LLM claims that 'specific cost data for helium is not disclosed,' which contradicts the original answer and fails to report these critical percentages. This is a major error in financial exposure quantification. (2) There are no correct numerical values reported in the LLM answer—instead, it omits the exact percentages that are central to measuring financial exposure change. The absence of these figures renders the answer significantly incomplete and factually inaccurate on the core metric requested. (3) The qualitative reasoning partially captures the shift in categorization from 'supply' to 'dependency' and correctly infers increased strategic importance based on risk language in filings. This shows sound multi-hop reasoning in interpreting disclosure tone and classification changes. However, it incorrectly attributes the change solely to 'heightened supply chain vulnerability' and lack of measurable cost increase, which contradicts the ground truth that explicitly cites a rise in cost exposure (from 4.2% to 6.8%) as evidence. (4) Contextually, the answer addresses the right entities (LIN, helium, 2023 vs 2024), time frame, and conceptual shift in sourcing status, making it relevant. However, the failure to report and acknowledge the disclosed cost percentages—central to the question about 'financial exposure'—severely undermines correctness. A financial exposure analysis without the actual financial data cannot be considered accurate, even if some contextual elements are correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 468,
        "total_tokens": 1795
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did PayPal's utilization of European customer balances for credit activities evolve between 2022 and 2023, and what was the percentage change in the amount approved for such activities?",
      "original_answer": "In 2022, PayPal had $3.8 billion approved to fund credit activities, representing approximately 37% of European customer balances available for corporate use. In 2023, the approved amount decreased to $3.0 billion, representing approximately 39% of European customer balances. This indicates a reduction in the absolute amount approved for credit activities, even though the percentage slightly increased, signaling a more conservative approach to utilizing customer balances for credit funding.",
      "llm_answer": "Between 2022 and 2023, the amount of European customer balances approved for credit activities declined from $3.8 billion to $3.0 billion, a reduction of about 21%. This decrease reflects a lower percentage of European customer balances designated for corporate credit use—from roughly 39% in 2022 to about 37% in 2023.",
      "correctness_score": 4,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors in percentages and misrepresents the trend. According to the ground truth, in 2022, $3.8 billion represented 37% of European customer balances, and in 2023, $3.0 billion represented 39%. The LLM incorrectly states that the percentage decreased from 39% in 2022 to 37% in 2023, reversing the actual figures. This is a critical error in quantitative accuracy. (2) The dollar amounts ($3.8B in 2022 and $3.0B in 2023) are correct, and the calculated percentage change in absolute terms (~21% decrease) is approximately accurate ((3.8-3.0)/3.8 ≈ 21.05%), so some numerical correctness is present. However, the reversal of percentages undermines the qualitative interpretation. (3) The multi-hop reasoning is partially sound—linking approved amounts to percentages of customer balances—but the incorrect attribution of percentages leads to a flawed conclusion about the trend in utilization. The ground truth indicates a more conservative approach due to lower absolute funding despite a higher percentage; the LLM incorrectly suggests a declining percentage, contradicting this. (4) Contextual relevance is high because the answer addresses both the evolution and percentage change, but correctness is severely impacted by the swapped percentages, warranting a low overall score despite correct dollar values and partial reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1214,
        "completion_tokens": 387,
        "total_tokens": 1601
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did Starbucks' exposure to foreign currency - other instruments evolve between 2023 and 2024, particularly in terms of their fair value and the expected reclassification impact on earnings?",
      "original_answer": "In 2023, Starbucks reported a fair value of $1,164 million for foreign currency - other instruments, with a net gain of $39.6 million included in AOCI. By 2024, the fair value decreased to $920 million, and the net gain included in AOCI dropped to $11.5 million. Additionally, the amount expected to be reclassified from AOCI into earnings within 12 months declined from $55.3 million in 2023 to $9.5 million in 2024, indicating a reduced short-term earnings impact from these instruments.",
      "llm_answer": "Based on the provided 10-K disclosures, Starbucks' foreign currency exposure through other instruments evolved with a net decrease in fair value hedging adjustments. Specifically, the cumulative fair value hedging adjustment related to long-term debt decreased from $(40.0) million (as of October 1, 2023) to $(17.8) million (as of September 29, 2024), reflecting a $22.2 million reduction in the hedging adjustment. This decline indicates that the fair value of the hedged debt exposure diminished over the period, likely due to changes in foreign exchange rates impacting the carrying value of the hedged item. The related gains and losses from these hedges are reclassified from AOCI to earnings (primarily interest expense) as the hedged exposures affect net income, with the net adjustment now materially smaller than in the prior year.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in terms of factual content. It discusses 'fair value hedging adjustments related to long-term debt' and a change from $(40.0) million to $(17.8) million, which does not match the ground truth. The original answer states that Starbucks' fair value for foreign currency - other instruments was $1,164 million in 2023 and $920 million in 2024, with AOCI net gains of $39.6 million and $11.5 million, respectively, and expected reclassification of $55.3 million (2023) vs $9.5 million (2024). None of these key figures are mentioned or correctly reported in the LLM answer. (2) The numbers provided in the LLM response (e.g., $(40.0) million and $(17.8) million) appear to be from a different context—possibly net hedging adjustments or debt-related valuations—but are not the fair values of foreign currency instruments or AOCI reclassification amounts asked in the question. There is no mention of the $1.164B or $920M fair values, nor the $39.6M/$11.5M AOCI gains, nor the $55.3M/$9.5M expected reclassification into earnings. Calculations and comparisons are therefore based on incorrect data. (3) The multi-hop reasoning is flawed because the LLM fails to synthesize the correct metrics across years. Instead of tracking the evolution of fair value and AOCI impact for foreign currency - other instruments, it focuses narrowly on hedging adjustments for long-term debt, which is a different financial instrument and context. This indicates a failure to identify the correct entity (foreign currency - other instruments) and its associated disclosures. (4) The contextual relevance is moderate because the answer discusses foreign currency hedging and AOCI reclassification, which are thematically relevant, but the specific data and synthesis are incorrect. Thus, while the general topic is addressed, the answer does not reflect the actual evolution of the specified instruments. Correctness and quantitative accuracy are very low due to complete mismatch in figures and metrics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 547,
        "total_tokens": 1891
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did the fair value of energy-related derivatives held by Alabama Power and Georgia Power evolve from 2022 to 2023, and what was the directional change in their asset versus liability positions?",
      "original_answer": "In 2022, Alabama Power reported energy-related derivatives with a fair value of $55 million in assets and $11 million in liabilities, while Georgia Power reported $75 million in assets and $8 million in liabilities. By 2023, Alabama Power's energy-related derivatives decreased to $15 million in assets but increased significantly to $110 million in liabilities. Similarly, Georgia Power's derivatives were valued at $13 million in assets and $124 million in liabilities in 2023. This indicates a substantial shift toward liability exposure for both entities over the period.",
      "llm_answer": "Based on the provided pages, the fair value of energy-related derivatives held by Alabama Power and Georgia Power both increased from 2022 to 2023. Alabama Power's energy-related derivatives rose from $15 million (2022) to $15 million (2023) in Level 2, but the total fair value for these derivatives was $15 million in 2023 (up from $15 million in 2022, though the 2022 figure was reported as $15 million in Level 2 with no other levels listed). Georgia Power's energy-related derivatives increased from $13 million (2022) to $13 million (2023) in Level 2, but the total fair value for these derivatives was $13 million in 2023 (up from $13 million in 2022, with the 2022 figure showing $13 million in Level 2). The directional change for both companies shifted from a liability position in 2022 (where Alabama Power's energy-related derivatives were reported as a $110 million liability and Georgia Power's as a $124 million liability) to an asset position in 2023 (with Alabama Power's energy-related derivatives at $15 million in assets and Georgia Power's at $13 million in assets), indicating a clear directional change from liability to asset for both entities.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors in both direction and magnitude of fair values for both companies. It incorrectly states that Alabama Power's energy-related derivatives were $15 million in both 2022 and 2023, while the ground truth shows $55M in assets and $11M in liabilities in 2022, and $15M in assets and $110M in liabilities in 2023. Similarly, for Georgia Power, the LLM claims $13M in both years, but the truth is $75M in assets and $8M in liabilities in 2022, and $13M in assets and $124M in liabilities in 2023. The LLM reverses the narrative: it claims both companies shifted from liability to asset positions, when in fact they shifted from net asset positions to large liability positions. (2) Quantitative accuracy is very low: all 2022 asset values are wrong (should be $55M and $75M, not $15M and $13M), and the liability figures are either omitted or misrepresented. The LLM incorrectly treats the 2023 asset values as increases when they are actually sharp declines from 2022 levels. (3) Multi-hop reasoning is fundamentally flawed: the model fails to synthesize the correct data points across years and misinterprets the directional change—claiming a shift from liability to asset when the truth is the opposite (increased liability exposure). (4) Contextual relevance is moderate because the answer addresses the right companies and topic (energy-related derivatives), but the factual core is incorrect, leading to a misleading conclusion. The mention of 'Level 2' valuations appears to stem from a misunderstanding or hallucination, as this detail is not in the ground truth and distorts the response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1448,
        "completion_tokens": 452,
        "total_tokens": 1901
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did the asset allocation strategy for the U.S. Retiree Health Care Plan evolve from 2022 to 2023, particularly in terms of the percentage distribution between fixed income securities and equity securities?",
      "original_answer": "In 2022, the U.S. Retiree Health Care Plan allocated 65% to fixed income securities and cash equivalents and 35% to equity securities. By 2023, the allocation to fixed income securities increased to 80%, while equity securities decreased to 20%. This represents a shift toward a more conservative investment strategy in 2023 compared to 2022.",
      "llm_answer": "Based on the plan asset tables in the 2022 and 2023 filings, the U.S. Retiree Health Care Plan's allocation between fixed income and equity securities remained unchanged at 80% fixed income and 20% equity in both years. The document shows identical weighted average asset allocations for 2023 and 2022: 80% fixed income securities and cash equivalents versus 20% equity securities for the U.S. Retiree Health Care Plan. There was no evolution in the percentage distribution between these asset classes from 2022 to 2023.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both quantitative and qualitative aspects. (1) Quantitatively, it states that the asset allocation was 80% fixed income and 20% equity in both 2022 and 2023, which contradicts the ground truth: in 2022, the allocation was 65% fixed income and 35% equity, shifting to 80% fixed income and 20% equity in 2023. These percentages are critical and directly misstated. (2) The calculation of change—specifically a 15-percentage-point shift toward fixed income—is entirely missed, leading to an erroneous conclusion of 'no evolution.' (3) Qualitatively, the reasoning fails multi-hop synthesis: the model does not correctly identify the change over time despite the question explicitly asking for evolution between years. Instead, it falsely asserts no change, indicating a failure to compare the two years accurately. (4) Contextually, while the answer addresses the right plan and asset classes, the core factual error renders the response misleading. The answer contradicts the ground truth on the most essential point—the shift in strategy. Thus, only minimal credit is given for addressing the correct plan and asset categories.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1231,
        "completion_tokens": 328,
        "total_tokens": 1560
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How has the regulatory approval status of Trodelvy evolved between 2022 and 2023, and what new indications were granted in 2023?",
      "original_answer": "In 2022, Trodelvy was indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies and for metastatic urothelial cancer after platinum-based chemotherapy and a PD-1/PD-L1 inhibitor. By 2023, Trodelvy received additional approvals: it was granted EC approval and FDA approval for the treatment of adult patients with unresectable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. This represents a significant expansion of the drug’s therapeutic applications.",
      "llm_answer": "Between 2022 and 2023, Trodelvy’s regulatory status evolved from having received accelerated FDA approval in 2022 for metastatic triple‑negative breast cancer and later for HR⁺/HER2‑ metastatic breast cancer to full approval in 2023 for the latter indication. In 2023, the FDA granted approval of Trodelvy as a monotherapy for adult patients with unresectable or metastatic HR⁺/HER2‑ breast cancer who have previously received endocrine therapy and at least two systemic treatments.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the 2023 FDA approval for Trodelvy in HR+/HER2- metastatic breast cancer with the correct patient criteria (endocrine therapy and at least two prior systemic treatments), which aligns with the ground truth. However, it inaccurately states that the FDA granted accelerated approval in 2022 for HR+/HER2- breast cancer — in reality, this indication was not approved until 2023. The 2022 approvals were for TNBC and urothelial cancer, which the LLM omits entirely. (2) Dates are mostly correct (2022 and 2023), but the assignment of approvals to years is partially wrong. No numerical values (e.g., dollar amounts, percentages) are involved, so quantitative accuracy is based on timeline fidelity. (3) The multi-hop reasoning is partially sound: the model captures the expansion into HR+/HER2- breast cancer in 2023 but fails to synthesize the full set of 2022 indications (TNBC and urothelial cancer) and misrepresents the regulatory timeline. It also omits the EC approval mentioned in the ground truth, limiting completeness. (4) The answer is contextually relevant and well-structured, but due to the omission of key 2022 indications and the incorrect claim about a 2022 accelerated approval for HR+/HER2- breast cancer, the correctness and qualitative accuracy are reduced. Minor but important factual errors prevent a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 383,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Meta's disclosure regarding user perception as a risk factor evolve between 2023 and 2024, particularly in terms of the nature of risks highlighted and their potential impact on business operations?",
      "original_answer": "In 2023, Meta emphasized user perception risks related to privacy, safety, content quality, and regulatory changes, specifically noting concerns around decreased user sentiment and engagement due to data practices and content policies. In 2024, while user perception was still acknowledged, the focus shifted toward broader operational and financial risks, such as integration challenges from acquisitions, tax liabilities, and investor sentiment. The explicit mention of user perception as a direct risk factor was notably reduced in 2024, indicating a strategic shift in how Meta communicated its risk profile.",
      "llm_answer": "The 2024 filing shows a more explicit, quantifiable focus on how user perception and engagement directly affect revenue‑generating products, emphasizing that any decline in user retention, growth, or engagement could materially harm ad revenue and financial results. Earlier 2023 disclosures highlighted broader risks—such as reliance on key personnel, potential goodwill impairments, and the impact of regulatory or tax changes—without the same level of detail on how user perception drives ad‑impression volume and pricing. Consequently, the 2024 risk factor places greater weight on the business‑operational consequences of user perception, whereas the 2023 version treated it as a more general, secondary concern.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect in its characterization of Meta's risk disclosures between 2023 and 2024, reversing the actual trend described in the ground truth. According to the original answer, Meta reduced its emphasis on user perception as a risk factor in 2024, shifting focus toward operational and financial risks like acquisition integration and tax liabilities. However, the LLM claims the opposite: that the 2024 filing placed 'greater weight' on user perception with more 'explicit, quantifiable focus'—this is factually inaccurate. The ground truth states that user perception was *less* explicitly mentioned in 2024, not more. The LLM incorrectly frames the evolution as an increased focus on user perception driving ad revenue, while the correct answer reflects a *de-emphasis* on user perception in favor of broader financial and operational risks. There are no numerical values in the question or answers, so quantitative accuracy is not applicable—scored as 10 by default due to absence of numeric errors. Qualitative accuracy is low due to fundamental misrepresentation of the direction of change in risk disclosure. Contextual relevance is moderate because the answer discusses risk factors and business operations, but the core reasoning is flawed. Multi-hop synthesis failed: the model did not correctly interpret the shift in disclosure strategy over time. The semantic meaning is not equivalent to the ground truth; it conveys the opposite conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 406,
        "total_tokens": 1753
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How has the notional amount of Lockheed Martin's variable interest rate swaps evolved from 2021 to 2024, and what does this indicate about the company's interest rate risk management strategy?",
      "original_answer": "In 2021, the notional amount of Lockheed Martin's variable interest rate swaps was $500 million, while by 2024, it had increased to $1.3 billion. This indicates a significant shift in the company's interest rate risk management strategy, with a growing emphasis on converting fixed-rate borrowings to variable-rate borrowings, likely in response to changes in the interest rate environment and the company's borrowing profile over the period.",
      "llm_answer": "Based on the provided document pages, the notional amount of Lockheed Martin's variable interest rate swaps was $500 million at December 31, 2021 (as stated in the 2021 10-K on page 66) and $1.3 billion at December 31, 2024 (as stated in the 2024 10-K on page 53). This indicates that the company increased its use of variable interest rate swaps to manage interest rate risk, likely to hedge exposure from rising interest rates on its fixed-rate debt, reflecting a proactive strategy to mitigate interest rate fluctuations in its financing structure.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the notional amounts of Lockheed Martin's variable interest rate swaps as $500 million in 2021 and $1.3 billion in 2024, matching the ground truth exactly. These figures are properly attributed to the respective 10-K filings (2021 10-K page 66 and 2024 10-K page 53), confirming quantitative accuracy. (2) All numbers, dates, and dollar amounts are correct, with no calculation errors. The increase from $500M to $1.3B is accurately represented. (3) The multi-hop reasoning is sound: the model synthesizes data from two different years' filings and correctly infers a strategic shift in interest rate risk management. The explanation that the company is increasing variable-rate swaps to hedge fixed-rate debt aligns with the ground truth’s interpretation of converting fixed to variable-rate borrowings. The slight difference in phrasing—'hedge exposure from rising interest rates on its fixed-rate debt' versus the original's 'growing emphasis on converting fixed-rate borrowings to variable-rate borrowings'—is semantically equivalent but slightly less precise in directionality (conversion vs. hedging), which prevents a perfect 10. (4) The answer is fully contextually relevant, addressing both the evolution of the notional amount and its implication for risk management strategy. Overall, the response is factually correct, well-supported, and logically reasoned, warranting a high score with only minor room for refinement in strategic interpretation nuance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 418,
        "total_tokens": 1678
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did PayPal's approach to its Seller Protection Programs evolve between 2022 and 2023, particularly in terms of financial provisions for transaction losses?",
      "original_answer": "In 2022, PayPal acknowledged the risk of losses from its Seller Protection Programs and noted that historical loss rates ranged between 0.09% and 0.15% of TPV, with the potential for increased losses due to macroeconomic conditions such as the ongoing impacts of the COVID-19 pandemic. By 2023, PayPal provided more structured financial disclosures, showing that the allowance for transaction losses was $64 million (down from $66 million in 2022), indicating a slight decrease in expected losses. This shift reflects a more defined and quantified approach to managing seller protection risk in 2023 compared to the more qualitative risk assessment in 2022.",
      "llm_answer": "Between 2022 and 2023, PayPal's approach to its Seller Protection Programs remained unchanged in terms of coverage, but the company increased its financial provisions for transaction losses to address rising fraud and chargeback risks. This was reflected in higher allowances for transaction losses ($64 million to $66 million) and a $1.2 billion increase in cash outflows related to actual transaction losses, as disclosed in the operating cash flow adjustments. Additionally, the company began accounting for the 1% excise tax on stock repurchases (effective 2023) as part of treasury stock, though this was not directly tied to Seller Protection but rather to its broader capital management strategy. The core Seller Protection Programs themselves did not undergo structural changes during this period.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that PayPal increased its financial provisions for transaction losses from $64 million to $66 million, when the ground truth shows the allowance decreased from $66 million in 2022 to $64 million in 2023. This reverses the actual trend and misrepresents PayPal's financial positioning. Additionally, the claim of a $1.2 billion increase in cash outflows related to transaction losses is not supported by the original answer and appears fabricated. (2) Quantitatively, the numbers are largely incorrect: the direction of change in allowances is wrong, and the $1.2 billion figure has no basis in the provided truth. The excise tax on stock repurchases, while factually accurate as a 2023 policy, is irrelevant to the Seller Protection Programs and distracts from the core question. (3) The multi-hop reasoning is flawed: instead of identifying the evolution from qualitative risk disclosure in 2022 to more structured, quantified disclosures in 2023, the LLM incorrectly infers an increase in provisions and invents operational details not present in the source. It fails to capture the key shift from narrative risk assessment to specific allowance figures. (4) Contextual relevance is moderate because the answer addresses the general topic of Seller Protection and financial provisions, but the incorrect data and reasoning severely undermine its validity. The core conclusion—that provisions increased—is the opposite of the truth. Therefore, the correctness score is low due to major factual and directional errors in financial data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 446,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Starbucks' derivative asset and liability positions in foreign currency - other change from fiscal year 2023 to fiscal year 2024, and what was the magnitude of this change on the balance sheet?",
      "original_answer": "In fiscal year 2023, Starbucks reported a derivative asset of $1,164 million under 'Foreign currency - other.' By fiscal year 2024, this amount significantly decreased to $1.9 million in derivative assets under the same category. Additionally, the derivative liability for 'Foreign currency - other' increased from $2.0 million in 2023 to $4.7 million in 2024. This indicates a major reduction in the company's foreign currency derivative assets and a moderate increase in liabilities tied to foreign currency over this period.",
      "llm_answer": "From fiscal 2023 to fiscal 2024, the total derivative asset (prepaid expenses and other current assets + other long‑term assets) rose from **$332.2 million** to **$179.1 million** in designated assets and from **$0 million** to **$29.2 million** in derivative liabilities (accrued), while non‑designated derivative assets increased from **$0 million** to **$8.7 million** and derivative liabilities grew from **$0 million** to **$56.7 million**. The net change in the balance‑sheet positions of derivative assets and liabilities therefore reflects an increase of roughly **$179 million** in assets and **$56.7 million** in liabilities, representing a material shift in the size of Starbucks’ derivative positions over the year.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 2,
      "detailed_feedback": "The LLM answer is almost entirely incorrect and fails to address the specific question about Starbucks' 'Foreign currency - other' derivative asset and liability positions. (1) The numbers provided ($332.2 million, $179.1 million, etc.) are not from the correct category and do not match the ground truth: in 2023, the derivative asset for 'Foreign currency - other' was $1,164 million, which dropped to $1.9 million in 2024, while the liability increased from $2.0 million to $4.7 million. The LLM reports nonexistent increases in assets and liabilities, including fabricated figures for 'designated' and 'non-designated' derivatives that are not mentioned in the original answer. (2) Calculations are therefore also incorrect — there was a massive decrease in assets (~$1,162.1 million reduction), not an increase, and only a modest rise in liabilities (~$2.7 million), not $56.7 million. (3) The multi-hop reasoning is flawed: the model appears to have conflated different derivative categories or time periods, possibly misreading the data source, and failed to isolate the specific 'Foreign currency - other' line item. (4) The response lacks contextual relevance as it discusses unrelated derivative classifications and omits the key fact of a dramatic drop in foreign currency derivative assets. Overall, the answer misrepresents the data, contains no accurate figures for the requested category, and draws opposite conclusions from the truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 398,
        "total_tokens": 1725
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did the financial impact of energy-related derivatives on natural gas cost and revenue hedging positions evolve from 2022 to 2023?",
      "original_answer": "In 2022, energy-related derivatives had a negative impact of $117 million on natural gas revenues and a $27 million negative impact on the cost of natural gas. In 2023, the impact shifted positively with a $59 million gain on the cost of natural gas, while the revenue impact remained neutral at $0. This indicates a transformation in the role and effectiveness of these derivatives in managing natural gas exposure.",
      "llm_answer": "The financial impact of energy-related derivatives on natural gas cost and revenue hedging positions shifted notably from 2022 to 2023, with gains (losses) on energy-related cash flow hedges declining from $37 million in 2022 to $(44) million in 2023 for Southern Company and from $37 million to $(44) million for Southern Company Gas, while the corresponding gains on interest rate cash flow hedges also fell from $(25) million to $(35) million, reflecting a reduced hedging benefit year‑over‑year.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 2,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is almost entirely incorrect and irrelevant to the question. It discusses 'gains (losses) on energy-related cash flow hedges' for 'Southern Company' and 'Southern Company Gas', which are not mentioned in the original answer and do not align with the ground truth. The financial figures provided ($37 million, $(44) million, $(25) million, $(35) million) are completely different from the ground truth values of $117 million loss on revenue and $27 million loss on cost in 2022, and $59 million gain on cost and $0 on revenue in 2023. (2) There is no correspondence between the numbers in the LLM answer and the original. The LLM reports values for two different entities not present in the ground truth and introduces interest rate hedges, which are unrelated to the question about natural gas cost and revenue hedging. The calculation or trend described (decline from $37M to $(44)M) does not reflect the actual shift from negative to positive impacts on natural gas hedging. (3) The multi-hop reasoning is fundamentally flawed. The model fails to identify the correct financial impacts on natural gas hedging positions and instead fabricates data for unrelated companies and hedge types. It does not capture the evolution from negative to positive cost impact and neutral revenue impact. (4) The contextual relevance is low because the answer discusses unrelated companies, metrics, and derivative types. The qualitative and quantitative accuracy scores are minimal due to complete factual mismatch. Only a minimal score for contextual relevance is given because the topic of derivative hedging in energy is broadly related, but the specifics are entirely off.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1225,
        "completion_tokens": 461,
        "total_tokens": 1687
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did Walmart's treatment of its Deferred Compensation Matching Plan evolve between the 2023 and 2024 10-K filings, particularly in terms of its documentation status and effective date?",
      "original_answer": "In the 2023 10-K filing, the Deferred Compensation Matching Plan was newly introduced as 'Walmart Inc. Deferred Compensation Matching Plan, as amended and restated effective November 8, 2023.' By the 2024 10-K filing, the plan was no longer labeled as newly introduced but was instead referenced as being 'incorporated by reference' to the 2024 Annual Report on Form 10-K, indicating that it had become an established, ongoing plan. The effective date remained unchanged at November 8, 2023, suggesting no substantive changes to the plan’s implementation timeline, but its treatment shifted from being newly introduced to being formally integrated into the company's long-term compensation framework.",
      "llm_answer": "Based on the provided 10-K filings, Walmart's Deferred Compensation Matching Plan was amended and restated effective November 8, 2023 and is incorporated by reference in the 2024 filing (Exhibit 10.1). The plan’s documentation status and effective date are explicitly noted as of November 8, 2023 in both the 2023 and 2024 10‑K filings.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the effective date of the Deferred Compensation Matching Plan as November 8, 2023, and accurately states that it was incorporated by reference in the 2024 10-K filing (Exhibit 10.1), which aligns with the ground truth. Thus, quantitative accuracy is perfect—dates and references are correct. However, the answer lacks completeness in explaining the evolution of the plan’s documentation status between the two filings. While the original answer highlights a key nuance—that the plan was 'newly introduced' in the 2023 filing but treated as an established, ongoing plan in the 2024 filing (via incorporation by reference)—the LLM answer fails to capture this shift in characterization. It merely states that the plan is referenced in both filings without articulating the change in treatment from 'newly introduced' to formally integrated. This omission affects qualitative accuracy, as the multi-hop reasoning—comparing the narrative framing across years—is incomplete. Contextual relevance is high because the response addresses the core elements of documentation and effective date, but the lack of comparative analysis reduces its depth. Overall, the facts are correct but the synthesis is underdeveloped.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1269,
        "completion_tokens": 347,
        "total_tokens": 1616
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has the disclosure and treatment of LTIP Units evolved between 2023 and 2024, particularly in terms of their dilutive effect and accrual policy?",
      "original_answer": "In 2023, LTIP Units were described as potentially dilutive securities that are convertible into units and exchangeable for common stock, with no material dilutive effect reported for the years 2023, 2022, and 2021. The company stated it does not adjust net income attributable to common stockholders or weighted average shares outstanding due to no dilutive impact. In 2024, the disclosure simplified, stating that LTIP Units are potentially dilutive but again noting no material dilutive effect for the years 2024, 2023, and 2022. Additionally, the accrual policy remained consistent, stating that distributions are accrued when declared. The treatment of LTIP Units remained stable with no significant change in dilutive impact or accrual policy.",
      "llm_answer": "The LTIP Units remain equity‑based awards that are exchangeable into common stock and are accounted for as potentially dilutive securities; however, the company’s disclosures indicate that no securities—including LTIP Units—had a material dilutive effect for the years ended December 31 2023 and 2024, and the accrual policy for dividends on these units mirrors that for other equity awards (i.e., dividends are accrued when declared). Consequently, while LTIP Units continue to be issued and may be converted into common stock, their issuance and conversion do not materially affect diluted earnings per share or per unit, and they are not specifically highlighted as having changed in dilutive impact or accrual treatment between 2023 and 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: LTIP Units are correctly described as potentially dilutive but with no material dilutive effect in both 2023 and 2024; the years referenced (2023 and 2024) match the original answer, and the accrual policy—dividends/distributions accrued when declared—is accurately reported. (2) Quantitatively, the years and the absence of material dilution are correctly stated; no numerical inaccuracies or miscalculations are present. Format and phrasing differences (e.g., 'no securities—including LTIP Units—had a material dilutive effect' vs. 'no material dilutive effect reported') are semantically equivalent. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across years and disclosures, noting consistency in both dilutive impact and accrual treatment. The only minor shortcoming is that the original answer notes a 'simplification' in 2024 disclosure, which the LLM answer does not explicitly mention, though it correctly infers no change in substance. (4) Contextual relevance is perfect—the response directly addresses the evolution in disclosure, dilutive effect, and accrual policy. Overall, the answer is factually complete and semantically equivalent, warranting a high score with only a slight deduction for missing the nuance about disclosure simplification.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 388,
        "total_tokens": 1762
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Meta's compliance approach to the EU-U.S. Data Privacy Framework (EU-U.S. DPF) evolved between 2023 and 2024, particularly in response to regulatory actions and decisions?",
      "original_answer": "In 2023, Meta was in the process of implementing steps to comply with corrective orders from the Irish Data Protection Commission (IDPC) following a EUR €1.2 billion fine and a directive to suspend unlawful data transfers to the U.S. under Standard Contractual Clauses (SCCs). At that time, the EU-U.S. DPF had just been finalized, and Meta viewed its implementation as a key milestone to address data transfer compliance. By 2024, Meta had implemented compliance measures with the corrective orders and was actively engaging with regulators on new compliance models, such as the 'subscription for no ads' alternative introduced in November 2023. In 2024, the European Commission opened formal proceedings into the compliance of this model with the Digital Markets Act (DMA), issuing preliminary findings in July 2024 that suggested non-compliance. This reflects a shift from foundational compliance with the EU-U.S. DPF framework to navigating more complex regulatory scrutiny around specific business models under evolving EU laws.",
      "llm_answer": "Meta’s compliance approach to the EU-U.S. Data Privacy Framework (EU-U.S. DPF) shifted markedly between 2023 and 2024. In 2023, following the Irish Data Protection Commission’s €1.2 billion fine and corrective orders over unlawful transfers of EEA Facebook data under Standard Contractual Clauses, Meta appealed the decision and secured an interim stay while it engaged with regulators. By 2024, the company had publicly welcomed the EU‑U.S. DPF as an “adequacy decision” that provides a new legal basis for transatlantic data flows, and it highlighted its steps to align with the corrective orders and to implement the DPF’s safeguards, signaling a more proactive and framework‑focused compliance posture.",
      "correctness_score": 6,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but misses key aspects of Meta's evolving compliance approach, particularly in 2024. (1) Quantitatively, the €1.2 billion fine and reference to 2023 regulatory actions are accurate, and the mention of the EU-U.S. DPF as an adequacy decision is correct. Dates and monetary figures are consistent with the ground truth. (2) However, the LLM omits critical developments in 2024: the introduction of the 'subscription for no ads' model in November 2023 and the European Commission's formal DMA proceedings in July 2024 with preliminary findings of non-compliance. These are central to the evolution of Meta’s compliance posture beyond foundational DPF alignment. (3) The reasoning is sound in linking the 2023 fine to Meta’s compliance efforts and the significance of the DPF, but it fails to synthesize the multi-hop progression from data transfer compliance to scrutiny under the DMA—a key shift in regulatory context. (4) While the answer correctly identifies Meta’s proactive stance in 2024, it overemphasizes framework adoption without addressing the new layer of regulatory challenge around business model compliance. This omission reduces completeness and qualitative accuracy, though the core facts presented are accurate and relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1443,
        "completion_tokens": 354,
        "total_tokens": 1797
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Linde's approach to green hydrogen production evolved between 2023 and 2024, particularly in terms of production methods and emphasis on renewable energy sources?",
      "original_answer": "In 2023, Linde described green hydrogen as being produced primarily through electrolysis using renewable energy or from steam methane reforming of biomethane, and it was presented as one of the company's clean energy offerings alongside blue hydrogen. By 2024, the company had expanded its description to emphasize green hydrogen as 'renewable hydrogen' produced by electrolysis using renewable energy and water as feedstock, and it was clearly differentiated from low-carbon (blue) hydrogen. Additionally, in 2024, Linde placed more emphasis on the carbon intensity metric to differentiate production methods, indicating a more refined and strategic framing of green hydrogen within the broader context of clean energy solutions.",
      "llm_answer": "Linde has expanded its focus on renewable energy sources and low‑carbon hydrogen production between 2023 and 2024.  The 2023 filing emphasizes gray hydrogen from natural‑gas steam‑reforming and mentions blue hydrogen with carbon capture, while the 2024 filing highlights green hydrogen produced by electrolysis using renewable electricity and notes that Linde is developing additional renewable‑energy‑based hydrogen projects.  This shift reflects a growing emphasis on renewable energy‑driven production methods and clean‑energy hydrogen in the company’s strategy.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies a strategic shift toward green hydrogen and increased emphasis on renewable energy between 2023 and 2024, which aligns with the ground truth. However, it contains a significant factual inaccuracy by stating that the 2023 filing 'emphasizes gray hydrogen'—this is incorrect. The original answer indicates that in 2023, Linde already presented green hydrogen as part of its clean energy offerings alongside blue hydrogen, not gray hydrogen. Gray hydrogen was not emphasized in Linde’s 2023 clean energy narrative according to the ground truth. (2) There are no numeric values, dates, or calculations in either the question or answers, so quantitative accuracy is not applicable—scored as 10 by default since no numbers were misstated. (3) The multi-hop reasoning is partially sound: the model correctly infers a strategic evolution from 2023 to 2024, noting expanded focus on electrolysis and renewable-based projects. However, it fails to accurately represent Linde’s 2023 position by mischaracterizing it as gray-hydrogen-focused, undermining the validity of the comparison. It also omits key details such as the rebranding of green hydrogen as 'renewable hydrogen' and the use of carbon intensity metrics in 2024 for differentiation—important refinements noted in the ground truth. (4) The contextual relevance is high because the answer addresses the evolution of Linde’s approach and mentions relevant production methods. However, due to the misrepresentation of 2023 strategy and omission of key 2024 developments, the qualitative accuracy is low, dragging down the overall correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 450,
        "total_tokens": 1780
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did Southern Company's relationship with Sequent evolve between 2022 and 2023, and what were the financial implications of this change?",
      "original_answer": "Southern Company's relationship with Sequent evolved from a business ownership relationship in 2022 to a completed divestiture in 2023. In 2022, Southern Company Gas completed the sale of Sequent to Williams Field Services Group for $159 million, recognizing a pre-tax gain of $121 million. Additionally, the sale resulted in $85 million of additional tax expense due to changes in state apportionment rates. By 2023, Sequent was no longer part of Southern Company's portfolio, and the financial impact of the sale was fully reflected in the company's financial statements, with the gain from the sale reported as a $121 million pre-tax benefit. This marked a complete transformation in the relationship, shifting from operational integration to full separation.",
      "llm_answer": "Southern Company's relationship with Sequent evolved significantly between 2022 and 2023: Sequent was sold in July 2021, but its financial impact continued to affect Southern Company Gas through 2023, including a $121 million pre-tax gain ($92 million after tax) from the sale, $85 million of additional tax expense due to changes in state apportionment rates, and $84 million in pre-tax impairment charges ($67 million after tax) related to its equity method investment in the PennEast Pipeline. These events contributed to a substantial decline in Southern Company Gas's revenue from $5,962 million in 2022 to $4,702 million in 2023, and resulted in a $615 million segment net income in 2023 compared to $572 million in 2022, reflecting both the one-time gain and ongoing operational impacts.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains multiple factual inaccuracies. Most critically, it states that Sequent was sold in July 2021, which directly contradicts the ground truth that the sale occurred in 2022. This error undermines the entire timeline of the relationship evolution. While the $121 million pre-tax gain and $85 million additional tax expense are correctly reported, the inclusion of unrelated financial items—such as $84 million in pre-tax impairment charges related to PennEast Pipeline and after-tax figures like $92 million and $67 million—introduces information not present in the ground truth and distorts the financial implications. The revenue decline from $5,962M to $4,702M and segment net income of $615M in 2023 vs. $572M in 2022 are not mentioned in the original answer and appear to be fabricated or misattributed. (2) Quantitative accuracy is low: the sale date is off by over a year, and extraneous numbers (impairment charges, after-tax gains, revenue, net income) are introduced without support. Only the $121M gain and $85M tax expense are accurate. (3) The multi-hop reasoning is flawed: the model fails to correctly trace the ownership change from 2022 to 2023, incorrectly placing the sale in 2021, and then incorrectly attributes ongoing financial impacts in 2023 beyond the recognized gain. It also conflates the divestiture with unrelated pipeline impairments. (4) Contextual relevance is moderate—the answer addresses the general theme of financial implications of a relationship change and mentions correct entities (Southern Company, Sequent, financial impacts)—but the incorrect timeline and fabricated metrics severely limit usefulness. The core transformation from ownership to divestiture is mentioned but misdated and distorted.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 482,
        "total_tokens": 1869
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Walmart's relationship with the Allswell brand evolved between 2023 and 2024, and what does this indicate about its strategic positioning within the company's private brand portfolio?",
      "original_answer": "In 2023, Walmart introduced the Allswell brand as part of its private brand offerings, indicating its initial entry into the market. By 2024, the brand was not only retained but explicitly listed among other mature private brands like 'bettergoods,' 'Equate,' and 'Great Value,' suggesting that Allswell has transitioned from a newly introduced brand to a more established part of Walmart's private label strategy. This evolution indicates that Allswell has likely gained traction and is being positioned as a core component of Walmart’s private brand portfolio.",
      "llm_answer": "Walmart's relationship with the Allswell brand has evolved from being a key private-label offering within its U.S. portfolio to a more focused, value-oriented brand under the broader \"Great Value\" ecosystem, reflecting a strategic shift toward consolidating private brands for cost efficiency and margin protection. This evolution aligns with Walmart's broader strategy of leveraging private brands like Allswell to strengthen its position in the mass-merchandising segment while maintaining its everyday low-price (EDLP) model, as evidenced by its continued presence in Walmart U.S. merchandise offerings alongside other private labels such as \"Great Value\" and \"Parent's Choice.\"",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies regarding the evolution of Walmart's relationship with the Allswell brand. While the ground truth states that Allswell was introduced in 2023 and was elevated to a mature brand status by 2024—listed alongside 'bettergoods,' 'Equate,' and 'Great Value'—the LLM incorrectly claims that Allswell became a sub-brand under 'Great Value' or part of a 'Great Value ecosystem,' which is not supported by the original answer. There is no mention of consolidation into Great Value or a strategic shift toward cost efficiency via brand consolidation in the ground truth. Instead, the truth indicates growth in strategic importance due to retention and maturity. (2) There are no numeric values, dates, percentages, or financial figures in either answer, so quantitative accuracy is not applicable—scored as 10 by default since no numbers were misstated. (3) The multi-hop reasoning is flawed: the LLM fails to correctly synthesize the progression from 'newly introduced' to 'established' brand, instead inventing a repositioning within the Great Value umbrella. It also misidentifies the strategic implication—consolidation for cost efficiency vs. expansion and maturation. The mention of 'Parent's Choice' and other brands is contextually relevant but does not compensate for the incorrect narrative. (4) The correctness score is 4 due to partial entity accuracy (Walmart, Allswell, private brands) and some contextual relevance, but major errors in reasoning and factual representation. Qualitative accuracy is low due to incorrect synthesis and strategic interpretation. Contextual relevance is moderate because the answer discusses private brands and strategy, but misaligns with actual developments.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 480,
        "total_tokens": 1802
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has the strategic importance of Embedded Processing products evolved from 2022 to 2023 based on TXN's revenue composition and strategic emphasis?",
      "original_answer": "In 2022, Embedded Processing products were described as one of two core segments, positioned alongside Analog as a key part of the business, though no specific revenue figures were disclosed. By 2023, Embedded Processing remained a strategic focus area, and notably, it partially offset a decline in Analog revenue, contributing to a $17.52 billion total revenue. This indicates that while Embedded Processing maintained its strategic importance, it also played a more pronounced compensatory role in the revenue mix during a year of overall revenue decline.",
      "llm_answer": "Based on the 2022 and 2023 10-K disclosures, the strategic importance of Embedded Processing products has evolved from a secondary focus to a key growth driver. While Analog revenue declined 15% year-over-year in 2023, Embedded Processing revenue grew 3% to $3.37 billion, with management explicitly highlighting it as one of the core segments in their strategic focus alongside Analog. The document emphasizes that \"our strategic focus is on analog and embedded processing products\" and identifies Embedded Processing as one of the two reportable segments, with management noting its role in generating strong cash flow and its importance in \"designing and selling our products into the industrial and automotive markets, which we believe represent the best long-term growth opportunities.\" This represents a clear strategic shift where Embedded Processing has moved from a supporting segment to a deliberate growth pillar, as evidenced by its revenue growth and the company's targeted investments to strengthen its competitive advantages in this area.",
      "correctness_score": 4,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in quantitative details. The claim that Embedded Processing revenue grew 3% to $3.37 billion in 2023 is not supported by the ground truth, which states no specific revenue figures were disclosed for Embedded Processing in either 2022 or 2023. Additionally, the $17.52 billion total revenue mentioned in the ground truth is accurate for 2023, but the LLM incorrectly attributes growth in Embedded Processing without providing a source or verifiable figure. The 15% year-over-year decline in Analog revenue is not mentioned in the ground truth and thus cannot be confirmed. (2) Quantitative accuracy is low because the LLM fabricates precise numbers (e.g., 3% growth, $3.37B) that are not present in the original answer or implied by the data. There is no evidence in the ground truth to support these figures, making the quantitative claims misleading. (3) Qualitatively, the LLM correctly identifies that Embedded Processing remained a strategic focus alongside Analog and that it played a compensatory role during Analog's decline. It also accurately reflects management’s strategic emphasis on industrial and automotive markets and cites the correct language about 'designing and selling our products' into those markets. However, the characterization of a 'strategic shift' from 'secondary focus' to 'key growth driver' overstates the evolution; the ground truth indicates consistent strategic importance, not a shift in hierarchy. (4) Contextual relevance is high because the LLM addresses the evolution of strategic importance, discusses revenue composition, and ties in management commentary and market focus. Despite incorrect numbers, it attempts multi-hop reasoning by linking revenue trends to strategic emphasis. However, the incorrect data undermines the validity of the conclusion. The model synthesizes concepts well but bases them on unsupported figures, leading to a partially correct but factually flawed response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1403,
        "completion_tokens": 543,
        "total_tokens": 1946
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How has Chevron's involvement in Angola LNG evolved from 2022 to 2024, and what does this indicate about its strategic positioning in the LNG market?",
      "original_answer": "In 2022, Chevron's involvement in Angola LNG was referenced in the context of its production volumes, indicating operational participation. By 2024, Chevron's stake in Angola LNG Limited was explicitly stated as a 36.4% interest, highlighting a more defined and structured investment approach. This evolution suggests a strategic shift toward securing a stable position in the LNG market through formalized equity stakes.",
      "llm_answer": "From 2022 to 2024, Chevron’s involvement in Angola LNG evolved from a 36.4 % equity stake in Angola LNG Limited (noted in the 2022 10‑K) to a more prominent role as a key upstream and downstream asset within its portfolio, highlighted by its inclusion in the 2023‑2024 financial tables and disclosures of related projects (e.g., the $4.5 bn loan for the Wellhead Pressure Management Project and Future Growth Project). This progression underscores Chevron’s strategic positioning as a major global LNG player, leveraging its equity interest to secure long‑term supply contracts and to integrate Angola LNG into its broader upstream‑downstream value chain, reinforcing its focus on expanding high‑margin, low‑carbon LNG production.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer incorrectly states that Chevron had a 36.4% stake in Angola LNG Limited in 2022, according to the 2022 10-K. However, the ground truth indicates that while Chevron's involvement was referenced in 2022 in terms of production volumes, the explicit 36.4% stake was only confirmed in 2024. This misattribution of the stake to 2022 is a significant factual error. Additionally, the LLM introduces specific financial figures such as a '$4.5 bn loan' for the Wellhead Pressure Management Project and Future Growth Project, which are not present in the original answer or supported by the provided ground truth, making them unsupported claims. (2) The quantitative inaccuracies include the premature assignment of the 36.4% stake to 2022 and the introduction of unverified dollar amounts ($4.5 bn loan), which cannot be corroborated by the ground truth. These numbers are either misplaced or fabricated, severely impacting quantitative accuracy. (3) The multi-hop reasoning is partially sound in that the LLM attempts to trace Chevron's evolving role and link it to broader LNG strategy, but it fails in synthesis by misrepresenting when the equity stake was formalized. The conclusion about strategic positioning as a major LNG player integrating Angola LNG into its value chain goes beyond the ground truth, which only suggests a shift toward securing a stable position via formalized stakes—more cautious in tone and scope. (4) Despite the factual errors, the answer remains contextually relevant by addressing both the evolution of involvement and strategic implications. It correctly identifies Angola LNG as part of Chevron’s portfolio and frames the discussion around LNG market positioning, aligning with the question’s intent. However, the correctness score is low due to major factual and quantitative inaccuracies undermining the response's reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1288,
        "completion_tokens": 510,
        "total_tokens": 1798
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How has the financial contribution and production status of the CH-53K program evolved between 2021 and 2024, and what does this indicate about its role within Lockheed Martin's RMS division?",
      "original_answer": "In 2021, the CH-53K program contributed to a $540 million increase in RMS net sales, driven by higher production volume alongside the Black Hawk and CRH programs. Additionally, it contributed to a $140 million increase in operating profit due to higher risk retirements and production volume. By 2024, the CH-53K program was described as being in a 'production ramp-up' phase, contributing $1.1 billion to higher product sales within RMS, indicating a shift from early-stage production and risk retirement to a more mature, high-volume production phase. This evolution shows that the CH-53K has transitioned from a developing program with growing financial impact to a key growth driver within RMS.",
      "llm_answer": "Between 2021 and 2024, the CH-53K program evolved from a critical growth driver within Lockheed Martin’s Rotary and Mission Systems (RMS) segment to a mature, high-volume production effort. RMS net sales grew from $11.693 billion in 2021 to $12.5 billion in 2024 (as reflected in consolidated product sales data), with the CH-53K contributing significantly through increased production volume and program ramp-up, particularly noted in 2024 as a key factor in higher product sales at RMS. This expansion solidified the CH-53K’s role as a cornerstone of RMS’s defense portfolio, directly supporting the segment’s backlog growth and long-term revenue visibility, while its integration into broader missile defense and naval platforms (e.g., Aegis systems) further entrenched its strategic importance within Lockheed Martin’s overall RMS business.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies in quantitative details. The ground truth states that in 2021, the CH-53K contributed to a $540 million increase in RMS net sales and a $140 million increase in operating profit due to higher production and risk retirements. However, the LLM does not mention these specific figures and instead incorrectly implies that RMS net sales were $11.693 billion in 2021 and $12.5 billion in 2024—figures not present in the original answer and unsupported by the provided context. Furthermore, while the ground truth specifies that by 2024 the CH-53K contributed $1.1 billion to higher product sales within RMS, the LLM fails to include this key number. Instead, it vaguely references 'higher product sales' without quantifying the contribution. (2) The LLM introduces new, unverified information such as integration into 'Aegis systems' and 'missile defense and naval platforms,' which are not mentioned in the original answer and represent a factual overreach. The CH-53K is a heavy-lift helicopter program and not typically associated with Aegis or missile defense systems, indicating a potential confusion with other RMS programs. (3) While the LLM correctly identifies the program’s evolution from growth driver to high-volume production and captures the general trend of increasing importance within RMS, it fails to accurately represent the multi-hop synthesis of financial impact over time. The original answer hinges on specific financial contributions in 2021 ($540M sales increase, $140M profit increase) and a clear shift by 2024 ($1.1B contribution), showing progression in maturity. The LLM misses this precise trajectory, weakening the reasoning. (4) Despite these issues, the answer is contextually relevant and captures the qualitative direction of the program’s evolution—increasing production and strategic importance—earning moderate scores in qualitative accuracy and relevance. However, the lack of correct financial figures and introduction of incorrect details significantly reduce overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1396,
        "completion_tokens": 558,
        "total_tokens": 1954
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did PayPal's use of macroeconomic factors in its loss curves for revolving consumer credit products evolve between 2022 and 2023?",
      "original_answer": "In 2022, PayPal applied macroeconomic factors such as forecasted trends in unemployment and benchmark credit card charge-off rates to its revolving consumer credit loss curves, using a single scenario deemed most appropriate for the economic conditions. By 2023, the company updated its expected credit loss models for revolving consumer receivables to include forecasted trends in household disposable income and retail e-commerce sales, replacing unemployment rates after the first quarter of 2023. This reflects a shift in the macroeconomic indicators used to inform loss curves for this segment.",
      "llm_answer": "Between 2022 and 2023, PayPal updated its loss curve methodology for revolving consumer credit products by extending the reasonable and supportable forecast period from approximately 2 years (in 2022) to approximately 5 years and 7 months (in 2023), incorporating macroeconomic forecasts of household disposable income and retail e-commerce sales trends, and applying loss curves segmented by geography, delinquency, and origination period to estimate credit losses. This adjustment, which included qualitative macroeconomic adjustments, resulted in a more forward-looking credit loss assessment, though it did not materially impact the 2023 provision for credit losses.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains some correct elements but introduces significant inaccuracies and omits key details from the ground truth. (1) Correctly identifies that PayPal updated its loss curve methodology in 2023 and incorporated household disposable income and retail e-commerce sales. However, it incorrectly claims the forecast period increased from 2 years to 5 years and 7 months—a specific quantitative claim not present in the original answer and unsupported by the ground truth. There is no mention in the original answer about extending the forecast period, so this is a major factual error. (2) The original answer states that unemployment rates were replaced after Q1 2023, but the LLM answer fails to mention the removal of unemployment rates, which is a core part of the evolution. Instead, it adds unverified details about segmentation by geography, delinquency, and origination period, which are not in the ground truth. (3) The multi-hop reasoning is partially sound in linking macroeconomic factors to loss curves, but the synthesis is flawed because it invents model changes (e.g., forecast horizon, segmentation) not present in the source. (4) While the general direction of model enhancement using new macroeconomic variables is semantically aligned, the specific evolution described—especially the replacement of unemployment with income and e-commerce—is only partially captured and overshadowed by fabricated details. The claim about no material impact on provision for credit losses is extraneous and not in the original. Overall, the answer is partially relevant but contains critical quantitative and qualitative inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 448,
        "total_tokens": 1762
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did Starbucks' foreign currency debt-related gains or losses included in AOCI change from 2023 to 2024, and what does this indicate about the company's exposure to foreign currency fluctuations?",
      "original_answer": "In 2023, Starbucks reported a foreign currency debt-related loss of $6.3 million included in OCI before reclassifications, while in 2024, the company reported a gain of $135.2 million in AOCI related to foreign currency debt. This indicates a significant shift from a loss to a substantial gain, suggesting a reversal in the company's exposure to foreign currency fluctuations over this period.",
      "llm_answer": "From the 2024 10‑K, the net pre‑tax gain in AOCI related to foreign‑currency hedges that is expected to be reclassified to earnings within the next 12 months is $9.5 million (down from $39.6 million in 2023). This decline signals that the company’s foreign‑currency exposure has become less volatile, reflecting a reduced amount of hedged gains remaining to be recognized in income.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both quantitative and qualitative aspects. The ground truth states that Starbucks had a foreign currency debt-related loss of $6.3 million in 2023 and a gain of $135.2 million in 2024 in AOCI, indicating a major shift from loss to gain. However, the LLM response incorrectly reports a decline in pre-tax gains from $39.6 million (2023) to $9.5 million (2024), which contradicts the ground truth numbers and trend. These figures appear to refer to different items—possibly reclassification expectations—rather than the actual AOCI amounts related to foreign currency debt. (2) The numbers are factually wrong: $39.6M and $9.5M do not match the correct values of -$6.3M (loss) in 2023 and +$135.2M (gain) in 2024. The direction of change is also opposite—LLM reports a decrease in gains, while the truth shows a dramatic reversal from loss to large gain. (3) The reasoning is flawed: instead of addressing the change in AOCI due to foreign currency debt, the model focuses on expected reclassifications of hedging gains, which is a different concept and does not answer the question about actual AOCI changes or overall exposure implications. It fails the multi-hop requirement to identify and compare actual AOCI impacts over two years. (4) The contextual relevance is partially met since it discusses AOCI and foreign currency hedges, but it misidentifies the specific item (debt-related gains/losses) and misrepresents the data, leading to an incorrect conclusion about reduced volatility, whereas the truth suggests a significant reversal in exposure impact.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1207,
        "completion_tokens": 442,
        "total_tokens": 1649
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did the fair value of energy-related derivatives for Alabama Power and Georgia Power change between 2022 and 2023, and what was the overall trend in their combined liabilities related to these derivatives?",
      "original_answer": "In 2022, Alabama Power reported a net liability of $144 million related to derivatives in non-designated hedging relationships, including energy-related derivatives. In 2023, Alabama Power had $15 million in assets and $110 million in liabilities related to energy-related derivatives, resulting in a net liability of $95 million. Georgia Power had $13 million in assets and $124 million in liabilities related to energy-related derivatives in 2023, yielding a net liability of $111 million. Therefore, the combined net liability for energy-related derivatives across both entities decreased from $255 million in 2022 to $206 million in 2023, indicating a reduction in exposure.",
      "llm_answer": "Based on the 2023 fair value disclosures (page 281), Alabama Power's energy-related derivatives liability was $110 million (Level 2) and Georgia Power's was $124 million (Level 2), compared with $32 million (Level 2) for Alabama Power and $124 million (Level 2) for Georgia Power in 2022 (page 279). Consequently, Alabama Power's liability increased from $32 million to $110 million, while Georgia Power's remained at $124 million, resulting in a combined liability increase of $82 million (from $156 million to $238 million) and an overall upward trend in their combined fair‑value derivative liabilities.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors in key financial figures and misrepresents the trend. According to the ground truth, Alabama Power had a net liability of $144 million in 2022, not $32 million as stated by the LLM. The LLM incorrectly reports Alabama Power's 2022 liability as $32 million (claiming it's Level 2), which contradicts the original answer. While the 2023 figures for Alabama Power ($110M liability) and Georgia Power ($124M liability) are numerically correct, the LLM fails to account for the asset offsets: Alabama Power had $15M in assets and Georgia Power had $13M in assets in 2023. Thus, net liabilities were $95M and $111M respectively, not the gross liabilities cited. (2) Calculations are fundamentally flawed: the LLM computes a combined liability increase from $156M to $238M, but this is based on incorrect 2022 data and ignores netting of assets. The correct combined net liability decreased from $255M in 2022 (Alabama Power's $144M only, as Georgia Power's 2022 data is not provided in the original answer) to $206M in 2023. The LLM incorrectly assumes Georgia Power's 2022 liability was $124M (same as 2023), but no 2022 value for Georgia Power is given in the ground truth. (3) Multi-hop reasoning is unsound: the model fails to compute net liabilities by subtracting assets from gross liabilities and uses unsupported data for 2022 Georgia Power. It also draws an opposite conclusion (upward trend) versus the correct downward trend. (4) Despite these major errors, the answer is contextually relevant—addressing the right companies, time frame, and topic of derivative liabilities—and cites plausible document locations, warranting moderate relevance and partial qualitative credit for structure, but severe penalties for factual and quantitative inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 494,
        "total_tokens": 1831
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did Walmart's financial relationship with Alert Innovation evolve between fiscal 2023 and fiscal 2024, particularly in terms of acquisition and subsequent disposition activities?",
      "original_answer": "In fiscal 2023, Walmart completed a $0.4 billion acquisition of Alert Innovation, bringing its ownership to approximately 100%. However, in fiscal 2024, Walmart sold and deconsolidated the Alert Innovation entity, signaling a complete exit from the investment. This represents a full evolution from acquisition to divestiture within a one-year span.",
      "llm_answer": "Between fiscal 2023 and fiscal 2024, Walmart’s relationship with Alert Innovation moved from a full acquisition to a divestiture. In fiscal 2023 the company completed a $0.4 billion buyout of Alert Innovation, bringing its ownership to roughly 100 % of the firm. The following fiscal year (2024), Walmart sold the Alert Innovation entity, de‑consolidating it and recording a disposition. Thus, the evolution was: acquisition in 2023 → subsequent sale/disposition in 2024.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately reported: Walmart acquired Alert Innovation in fiscal 2023 for $0.4 billion, achieving ~100% ownership, and divested/sold the entity in fiscal 2024, resulting in deconsolidation. (2) Quantitative accuracy is perfect: the $0.4 billion acquisition amount and 100% ownership are correctly stated; no calculations are required beyond accurate reporting. (3) Multi-hop reasoning is sound—the model correctly synthesizes two distinct events across fiscal years 2023 and 2024, capturing the full evolution from acquisition to disposition. (4) Entity names (Walmart, Alert Innovation), fiscal years (2023, 2024), and financial terms (acquisition, deconsolidation, disposition) are used accurately. The answer is concise, relevant, and completely aligned with the question’s focus on the financial relationship evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1214,
        "completion_tokens": 268,
        "total_tokens": 1482
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did the regulatory approval status of Trodelvy evolve between 2022 and 2023, and what does this indicate about Gilead's oncology strategy?",
      "original_answer": "In 2022, Trodelvy was part of Gilead's marketed product portfolio and contributed to growth in the oncology franchise, though no specific regulatory updates were mentioned. By 2023, Trodelvy received both FDA and EC approvals for the treatment of adult patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer who had received prior endocrine-based therapy and at least two additional systemic therapies. This regulatory progress indicates a strategic focus by Gilead on expanding the therapeutic applications of Trodelvy and strengthening its position in the oncology market, particularly in breast cancer treatment.",
      "llm_answer": "Between 2022 and 2023, the regulatory approval status of Trodelvy evolved from receiving FDA accelerated approval in April 2021 and full approval in October 2021, followed by expanded European Commission marketing authorization in November 2021 for metastatic triple-negative breast cancer, and later approvals in Canada (September 2021) and for additional indications including HR+/HER2- breast cancer (April 2021) and HR+/HER2- breast cancer with prior systemic therapies (April 2021). This progression of approvals across multiple oncology indications, including metastatic TNBC, urothelial cancer, and HR+/HER2- breast cancer, indicates Gilead's strategic focus on expanding its oncology portfolio through targeted acquisitions, collaborations, and accelerated development of Trodelvy as a key growth driver in solid tumors, particularly in areas with limited treatment options.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies regarding the timeline and nature of Trodelvy's regulatory approvals. It incorrectly states that FDA accelerated approval was in April 2021 and full approval in October 2021, and claims approvals for HR+/HER2- breast cancer occurred in April 2021—this contradicts the ground truth, which specifies that the key approvals for HR+/HER2- breast cancer (with prior systemic therapies) occurred in 2023, not 2021. The LLM also references approvals in Canada and Europe in 2021 for indications that were actually approved later, misrepresenting the evolution between 2022 and 2023. (2) The dates are entirely incorrect—no 2022–2023 evolution is accurately described; instead, the answer fabricates a detailed approval history centered on 2021, which is outside the requested timeframe. The ground truth notes no specific regulatory updates in 2022 and highlights 2023 as the year of FDA and EC approvals for HR+/HER2- breast cancer, which the LLM fails to correctly attribute. (3) The multi-hop reasoning is flawed: while the LLM attempts to infer Gilead's oncology strategy (expansion in solid tumors, targeting areas with limited options), this conclusion is based on false regulatory milestones. The correct reasoning should link the 2023 approvals to a strategic push in breast cancer, particularly HR+/HER2- subtype, building on prior TNBC approvals. (4) Despite incorrect facts, the answer is contextually relevant—addressing regulatory evolution and strategic implications—and shows an understanding of the type of analysis required, hence moderate scores in qualitative accuracy and relevance. However, the severe factual and quantitative errors—especially misplacing key approvals by two years—warrant a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 489,
        "total_tokens": 1869
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has Simon Property Group's financial relationship with ABG evolved between 2023 and 2024, particularly in terms of capital transactions and strategic positioning?",
      "original_answer": "In 2023, Simon Property Group (SPG) engaged in multiple capital transactions with ABG, including recognizing a non-cash pre-tax gain of $36.4 million from a dilution of ownership in ABG during the second quarter and an additional $145.8 million gain in the third quarter due to further dilution from SPARC Group issuing equity. Additionally, SPG had a long-standing strategic partnership with ABG dating back to 2021, involving licensing ventures such as Forever 21, Brooks Brothers, and Eddie Bauer, which resulted in significant gains. In 2024, SPG no longer reported active capital transactions with ABG, such as gains from dilution or new equity investments. Instead, the 2024 filing only referenced historical transactions, such as the 2021 sale of a portion of SPG’s ABG interest for a pre-tax gain of $18.8 million and the 2022 acquisition of Reebok assets alongside a strategic partnership. This indicates a shift from active financial engagement and restructuring with ABG in 2023 to a more stable, historically referenced relationship in 2024.",
      "llm_answer": "Between 2023 and 2024, Simon Property Group’s financial relationship with ABG shifted dramatically from a series of equity‑based transactions that generated substantial non‑cash gains to a complete exit. In 2023, ABG completed capital transactions that diluted Simon’s ownership and triggered deemed disposals resulting in pre‑tax gains of $36.4 million (Q2), $12.4 million (Q3) and $10.3 million (Q4), while also generating deferred tax liabilities. By the first quarter of 2024, Simon sold its remaining ABG stake for $1.2 billion, recognizing a $414.8 million pre‑tax gain, after which no ABG equity interest remained. This disposal marked the end of the prior equity partnership and eliminated any ongoing capital‑transaction exposure, allowing Simon to reposition its capital toward new acquisitions, development projects and stock‑repurchase initiatives.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Simon Property Group (SPG) recognized non-cash pre-tax gains of $36.4 million in Q2 2023 and $145.8 million in Q3 2023 due to dilution from ABG and SPARC equity issuances. However, the LLM incorrectly reports Q3 2023 gain as $12.4 million and invents a $10.3 million gain in Q4 2023, which is not present in the original answer. Furthermore, the LLM claims that in Q1 2024, SPG sold its remaining ABG stake for $1.2 billion and recognized a $414.8 million pre-tax gain—this event is entirely fabricated and contradicts the ground truth, which states that SPG did not report any active capital transactions with ABG in 2024 and only referenced historical transactions. (2) The quantitative inaccuracies are severe: the LLM misreports gains by over $130 million in Q3 alone and invents a $1.2 billion transaction with no basis in the source. The sum of the gains reported by the LLM ($36.4M + $12.4M + $10.3M + $414.8M = $473.9M) is also inconsistent with the actual 2023 gains ($36.4M + $145.8M = $182.2M) and the fictional 2024 gain. (3) The multi-hop reasoning is flawed: the LLM incorrectly infers a complete exit in 2024, which is not supported by the original data. The ground truth indicates a shift from active engagement in 2023 to passive, historical references in 2024, not a full divestiture. The strategic context of licensing ventures (Forever 21, Brooks Brothers, Eddie Bauer) and the 2021–2022 transactions are omitted, weakening the qualitative analysis. (4) The contextual relevance is moderate because the answer addresses the evolution of the financial relationship and capital transactions, but the core facts are incorrect. Due to major factual and numerical errors, especially the invention of a $1.2 billion sale and incorrect gain figures, the correctness score is low at 2. Quantitative accuracy is severely compromised (2), qualitative reasoning is partially logical but based on false premises (3), and relevance is acceptable but undermined by inaccuracies (6).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1483,
        "completion_tokens": 561,
        "total_tokens": 2045
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Chevron's relationship with Chevron Phillips Chemical Company LLC evolve between 2022 and 2024, particularly in terms of financial reporting and investment value?",
      "original_answer": "In 2022, Chevron Phillips Chemical Company LLC was included in Chevron’s consolidated financial disclosures, specifically in Note 8 on page 70 of the 10-K filing, indicating it was a consolidated subsidiary. By 2024, the company was reported as an equity method investee under 'Downstream' in the Investments and Advances section, with a disclosed investment value of $8,571 million as of December 31, 2024, up from $7,765 million in 2023. This reflects a shift from full consolidation to an equity method investment, suggesting a structural or ownership change in Chevron’s relationship with the entity.",
      "llm_answer": "Between 2022 and 2024, Chevron's financial reporting shows that its investment in Chevron Phillips Chemical Company LLC remained a key component of its Downstream segment, with the equity investment balance increasing from $7,765 million (2023) to $8,571 million (2024) and the associated equity earnings rising from $608 million to $903 million.  The company continues to account for this stake using the equity method, reporting its share of earnings and net loans ($669 million principal) in the consolidated financial statements, while also disclosing ongoing litigation and climate‑related regulatory risks that could affect future financial performance.  Overall, the investment’s carrying value and earnings contributions have grown, reflecting both the ongoing operational partnership and Chevron’s strategic focus on lower‑carbon initiatives.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct quantitative elements but misses a critical qualitative shift in accounting treatment. It correctly reports the investment value increasing from $7,765 million in 2023 to $8,571 million in 2024 and mentions rising equity earnings ($608M to $903M), which aligns with the ground truth's implication of growing investment value. However, it incorrectly states that Chevron 'continues to account for this stake using the equity method' throughout the period, which directly contradicts the ground truth: in 2022, Chevron Phillips was a consolidated subsidiary (not equity method), and only by 2024 did it appear as an equity method investee. This is a major factual and conceptual error in financial reporting classification. (2) Quantitatively, the numbers cited ($7,765M, $8,571M, $608M, $903M, $669M) are plausible and consistent with typical disclosures, but the original ground truth does not mention earnings or loan amounts—so their inclusion cannot be verified. The core investment values are accurate for 2023 and 2024, but the answer fails to note that 2022 data was under consolidation, not equity accounting. (3) The multi-hop reasoning is partially sound—linking changes in investment value and segment reporting—but fails the key synthesis: recognizing the shift from consolidation to equity method, which is central to how the relationship evolved. This reflects a failure to correctly interpret the change in financial reporting treatment over time. (4) Scores reflect that while the answer includes accurate numbers and relevant context (e.g., Downstream segment, risks), it fundamentally misrepresents the nature of Chevron’s relationship in 2022, undermining the qualitative accuracy. Contextual relevance is high because it addresses financial reporting and investment trends, but correctness is limited by the critical accounting error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 515,
        "total_tokens": 1885
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did the status and financial impact of Meta's Facilities Consolidation Strategy evolve between the end of 2023 and the end of 2024?",
      "original_answer": "At the end of 2023, Meta had 'substantially completed' its facilities consolidation initiatives as part of the 2022 Restructuring, indicating the process was still ongoing. By the end of 2024, the company reported that it had 'completed the 2022 restructuring initiatives,' which included the facilities consolidation strategy, showing the process had reached full completion. Additionally, the 2024 disclosure included a financial summary of the 2022 Restructuring pre-tax charges across three years (2022–2024), indicating a retrospective quantification of the financial impact that was not explicitly detailed in 2023.",
      "llm_answer": "Between the end of 2023 and the end of 2024, Meta's Facilities Consolidation Strategy shifted from active implementation to completion, with all related initiatives finalized by December 31, 2024. The company recorded $389 million in pre‑tax restructuring charges for 2024—entirely tied to facilities consolidation—compared with $2.26 billion in 2023 and $4.61 billion in 2022, indicating that the financial impact of the strategy had largely run its course and was now being wound down.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in financial figures. The ground truth does not specify exact pre-tax charges for 2024, 2023, or 2022 related to facilities consolidation alone, nor does it state that the $389 million in 2024 charges were 'entirely tied to facilities consolidation.' The original answer only notes that by 2024, Meta provided a retrospective summary of total 2022 Restructuring pre-tax charges across 2022–2024, without breaking down annual amounts or attributing 2024 charges solely to facilities. Thus, the specific dollar amounts ($389M, $2.26B, $4.61B) are not supported by the ground truth and appear fabricated or misattributed. (2) Quantitative accuracy is low because the numbers cited do not appear in the original answer and cannot be verified from the provided context. There is no indication in the ground truth that 2024 charges were $389 million or that charges decreased steadily from 2022 to 2024. (3) Qualitatively, the LLM correctly identifies the progression from 'substantially completed' in 2023 to 'completed' in 2024, capturing the evolution of the strategy’s status. It also correctly infers that the financial impact was winding down, which aligns with the completion narrative. However, it fails to mention that the 2024 disclosure included a retrospective financial summary of the entire restructuring—a key qualitative point—instead inventing granular annual breakdowns. (4) Contextual relevance is high because the answer addresses the timeline and financial impact as required, but correctness is severely undermined by unsupported numerical claims. The reasoning is partially sound but based on incorrect data, leading to a misleading conclusion despite a plausible narrative arc.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 480,
        "total_tokens": 1754
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has Lockheed Martin's involvement in hypersonics programs evolved from 2022 to 2024, particularly in terms of strategic focus and program status?",
      "original_answer": "In 2022, Lockheed Martin's involvement in hypersonics programs was described as a key growth area that was dependent on U.S. Government authorization and funding, indicating that the programs were still in a development phase with uncertain future funding. By 2024, the company was actively producing hypersonic strike weapons under multiple programs with the U.S. Air Force and Army, showing a shift from a funding-dependent future initiative to an active production program. This evolution reflects a significant advancement in the maturity and strategic importance of hypersonics within Lockheed Martin's portfolio.",
      "llm_answer": "From 2022 to 2024, Lockheed Martin’s hypersonics efforts shifted from early‑stage development to more mature, program‑specific initiatives. In the 2022 filing the company highlighted “hypersonic capabilities” as one of its growth pillars and noted work on “several programs with the U.S. Army and U.S. Navy to design, develop and build hypersonic strike weapons.” By the 2024 filing, hypersonics were framed as part of a broader “all‑domain mission solution” and were specifically linked to “hypersonic strike weapons” within Missiles and Fire Control, as well as to “hypersonics programs” under Space, indicating that the work had moved beyond concept studies into active development and production efforts for both Army and Navy customers. The strategic focus remained on integrating hypersonic weapons into the company’s multi‑domain portfolio, while program status evolved from exploratory to concrete acquisition and sustainment pathways.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution of Lockheed Martin's hypersonics programs from 2022 to 2024: in 2022, the focus was on development as a growth area with work on multiple programs for the U.S. Army and Navy, dependent on government funding; by 2024, the programs had advanced to active development and production. The strategic focus on integration into multi-domain solutions is accurately conveyed. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised—dates (2022, 2024) are correct. (3) The multi-hop reasoning is sound: the model synthesizes information across years and business segments (Missiles and Fire Control, Space), correctly inferring progression from exploratory to production phases. The mention of both Army and Navy is consistent with the knowledge graph, though the original answer emphasizes Air Force and Army. This is a minor discrepancy—while the LLM includes Navy instead of Air Force, the core progression in program maturity remains correctly interpreted. (4) The answer is contextually relevant, complete, and semantically equivalent to the ground truth, with only slight variation in emphasis (Navy vs. Air Force). The conclusion about strategic continuity and program maturation is fully supported. A score of 9 is justified due to this minor entity inconsistency, but overall accuracy and reasoning are strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1391,
        "completion_tokens": 412,
        "total_tokens": 1803
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Southern Company's treatment and disclosure of energy-related derivatives evolve from 2022 to 2023, particularly in terms of their designation and financial impact?",
      "original_answer": "In 2022, Southern Company reported the pre-tax effects of unrealized derivative gains (losses) from energy-related derivatives that were designated as regulatory hedging instruments and deferred. By 2023, the company expanded its disclosure to include the pre-tax effects of energy-related derivatives not designated as hedging instruments on its statements of income, covering the years 2023, 2022, and 2021. This indicates a shift from focusing only on regulatory hedging instruments to providing a broader view of its energy-related derivative activities.",
      "llm_answer": "Southern Company's treatment of energy-related derivatives shifted from explicit regulatory hedging disclosures in 2022 to more detailed accounting impacts in 2023, particularly regarding cash flow hedge effects on income and AOCI. In 2023, the company reported specific gains/losses from energy-related cash flow hedges (e.g., $(44) million in 2023 vs. $37 million in 2022) and clarified that fair value hedge adjustments to long-term debt carried cumulative fair value hedging adjustments of $235 million (2023) and $282 million (2022), reflecting evolving disclosure practices around hedge accounting impacts.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces specific numerical values such as $(44) million in 2023 and $37 million in 2022 for cash flow hedges, and $235 million (2023) and $282 million (2022) for fair value hedging adjustments. However, these figures are not present in the ground truth and cannot be verified as accurate based on the provided information. The original answer does not mention any specific dollar amounts related to cash flow or fair value hedges, nor does it reference AOCI (accumulated other comprehensive income) or long-term debt adjustments. Therefore, these numbers appear to be fabricated or misattributed, severely impacting quantitative accuracy. (2) The ground truth emphasizes a shift in disclosure practices: from reporting only regulatory hedging instruments in 2022 to including non-designated derivatives across 2023, 2022, and 2021 in 2023. The LLM answer incorrectly frames the evolution around cash flow and fair value hedges, which are not mentioned in the original answer, and misses the key point about expanded retrospective disclosure of non-designated derivatives. (3) The multi-hop reasoning is flawed because the LLM fails to correctly identify the nature of the change—broadening disclosure to include non-hedging-designated derivatives—instead focusing on hedge accounting impacts that are not supported by the ground truth. This indicates a failure to synthesize the correct evolution in treatment and disclosure. (4) While the answer is contextually relevant—discussing derivative disclosures and changes over time—and correctly identifies Southern Company and the 2022–2023 timeframe, the inclusion of unsupported specifics and mischaracterization of the disclosure evolution significantly reduces factual correctness. The answer conveys a different narrative than the ground truth, despite using plausible financial terminology.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 507,
        "total_tokens": 1806
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did Gilead's intellectual property strategy regarding Truvada evolve between 2022 and 2023, particularly in terms of patent disclosures?",
      "original_answer": "In 2022, Gilead highlighted the October 2020 loss of exclusivity of Truvada in the United States as a transitory headwind, indicating that the product was no longer protected under patent, which likely affected revenue. In 2023, Gilead provided structured disclosures regarding the patent expiration dates of its principal products, including Truvada, focusing on the actual or estimated expiration dates in the U.S. and the EU. This represents a shift from acknowledging a past loss of exclusivity to proactively disclosing future intellectual property timelines for key products.",
      "llm_answer": "Based on the provided SEC 10-K filings, Gilead's intellectual property strategy regarding Truvada did not involve new patent filings or disclosures between 2022 and 2023. The documents indicate that Truvada's patent protection was already in place, with the U.S. patent expiration listed as 2029 (with a note that settlement agreements with generic manufacturers were reached in January 2022 concerning TAF patents for Descovy, Vemlidy, and Odefsey, which are related but distinct products). The 2022 and 2023 filings focus on other products' patent expirations and new approvals (e.g., Veklury, Hepcludex, Trodelvy), but do not mention any evolution in Truvada's patent strategy or new disclosures during this period. The company continued to rely on existing patent protections and settlement agreements rather than filing new patents for Truvada itself.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth. (1) It claims there was no evolution in Gilead's patent strategy or disclosures regarding Truvada between 2022 and 2023, but the original answer confirms a clear shift: in 2022, Gilead acknowledged the past loss of exclusivity (post-October 2020), while in 2023, it began proactively disclosing structured timelines for patent expirations of key products including Truvada. This evolution in disclosure strategy is the core of the correct answer, but the LLM fails to recognize it. (2) The LLM incorrectly states that Truvada's U.S. patent expiration is 2029, which is factually wrong according to the ground truth—Truvada lost exclusivity in October 2020. This is a major quantitative and factual error. The mention of settlement agreements in January 2022 for TAF-based products (Descovy, etc.) is contextually relevant but does not apply to Truvada’s patent status and distracts from the actual issue. (3) The multi-hop reasoning is flawed: the question requires comparing Gilead’s narrative tone and disclosure practices around Truvada’s IP between two years, but the LLM incorrectly infers no change based on absence of new patents, missing the shift from reactive acknowledgment to proactive, structured disclosure. (4) The answer is partially contextually relevant—discussing Gilead, Truvada, and patent strategy—but fails on correctness due to false claims about patent expiration dates and mischaracterization of disclosure trends. Overall, major factual and reasoning errors justify a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 432,
        "total_tokens": 1790
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How did SPG's use of the Supplemental Facility evolve between 2022 and 2024, particularly in terms of borrowing and repayment activities?",
      "original_answer": "In 2022, SPG borrowed $1.05 billion under the Supplemental Facility in January 2022, which was used to fund the early extinguishment of nine mortgages with a principal balance of $1.16 billion. This borrowing was repaid shortly after issuance. By 2024, SPG again utilized the Supplemental Facility, borrowing €750.0 million ($815.4 million U.S. dollar equivalent) in November 2023, which was repaid on November 17, 2023. Additionally, in 2024, SPG issued new senior unsecured notes to redeem other outstanding notes at maturity, indicating a shift in financing strategy. The evolution shows a continued reliance on the Supplemental Facility for short-term financing needs but with a more structured approach to repayment and refinancing.",
      "llm_answer": "Between 2022 and 2024, SPG’s use of the Supplemental Facility shifted from active borrowing to full repayment. In 2021, the company drew $1.05 billion under the Supplemental Facility to refinance mortgages, then in January 2022 it issued $1.2 billion of senior unsecured notes and used the proceeds to retire the entire $1.05 billion balance, eliminating the Facility’s outstanding debt. Subsequent filings show no remaining borrowings under the Supplemental Facility, indicating that by 2024 the Facility had been fully repaid and was no longer being used for financing.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that the $1.05 billion was borrowed in 2021, while the ground truth specifies January 2022. It also claims SPG issued $1.2 billion in senior unsecured notes in January 2022 to repay the loan, but the original answer does not mention this issuance in that timeframe. Most critically, the LLM claims the Supplemental Facility was fully repaid and no longer used by 2024, which directly contradicts the ground truth: SPG borrowed €750.0 million ($815.4 million) under the same facility in November 2023, which was repaid in the same month. This key multi-hop fact is entirely missed. (2) Quantitative accuracy is low: the $1.05 billion amount is correct but misdated; the $1.2 billion note issuance is fabricated; the €750.0 million / $815.4 million borrowing in 2023 is completely omitted. (3) The reasoning is flawed: the model infers a trend of declining use and full repayment, but the truth shows repeated short-term use of the facility in both 2022 and 2023–2024, indicating ongoing reliance. The shift in financing strategy involving new senior notes in 2024 is mentioned in the original but misrepresented in timing and purpose by the LLM. (4) Contextual relevance is moderate because the answer addresses SPG’s use of the Supplemental Facility and repayment behavior, but fails to capture the evolution accurately due to incorrect dates, fabricated details, and omission of critical 2023–2024 activity. The conclusion about discontinued use is factually wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 429,
        "total_tokens": 1753
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has the role of cash buffer needs in MetLife's capital management strategy evolved from 2022 to 2024, particularly in terms of liquidity levels and their impact on capital allocation decisions?",
      "original_answer": "In 2022, MetLife maintained a short-term liquidity position of $12.4 billion and a total liquid asset base of $223.0 billion, reflecting a strong buffer to meet business requirements under both normal and stress scenarios. The company emphasized its belief in having ample liquidity and highlighted active monitoring and adjustment of liquidity and capital plans. By 2024, the narrative shifted to a more cautious tone, noting that maintaining or increasing cash buffers could limit capital available for innovation, acquisitions, and shareholder returns. This indicates that while liquidity remained a strategic priority, the implications of holding larger cash buffers became more pronounced, potentially constraining other capital deployment opportunities.",
      "llm_answer": "From 2022 to 2024, MetLife’s capital management strategy has shifted toward a more disciplined approach to cash buffer needs, explicitly tying liquidity levels to capital allocation decisions. While the company continues to maintain ample short‑term liquidity (e.g., $12.4 bn in 2021 and $9.4 bn in 2020) and a large pool of liquid assets ($223 bn in 2021), it now emphasizes preserving a robust cash buffer to guard against market stress, potential collateral calls, and regulatory constraints. This heightened focus influences capital allocation, limiting dividend increases and share‑repurchase flexibility when liquidity or buffer requirements rise, and drives tighter oversight of dividend‑paying subsidiaries and financing activities.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in numbers and years. It incorrectly cites $12.4 billion in short-term liquidity for 2021 instead of 2022, and $9.4 billion in 2020—data not present in the ground truth—making the quantitative foundation unreliable. The $223 billion liquid asset base is correctly cited but wrongly attributed to 2021 instead of 2022. These misattributions undermine the answer’s credibility. (2) The ground truth emphasizes a strategic shift from strong liquidity assurance in 2022 to a cautionary note in 2024 about trade-offs between cash buffers and capital deployment (e.g., innovation, acquisitions, shareholder returns). The LLM answer partially captures this by noting constraints on dividends and share repurchases, but misrepresents the evolution by focusing on '2020' and '2021' data not in the original and missing the 2024 forward-looking concern about opportunity costs. (3) The multi-hop reasoning is flawed: the model fails to correctly align years and figures, and introduces data points (2020, 2021) not referenced in the question or ground truth, suggesting hallucination or misattribution. It also omits the key 2024 insight that increasing buffers could limit innovation and M&A—central to the strategic evolution. (4) While the general theme of liquidity affecting capital allocation is contextually relevant and the qualitative direction (more caution, impact on capital use) is partially aligned, the incorrect data timeline and missing 2024-specific narrative severely limit factual correctness. The answer is conceptually in the right domain but factually unsound on critical details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 455,
        "total_tokens": 1842
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How did Starbucks' exposure to 'Foreign currency - other' derivatives evolve between 2022 and 2023, particularly in terms of asset and liability classifications?",
      "original_answer": "In 2022, Starbucks reported 'Foreign currency - other' derivative liabilities of $0.3 million under accrued liabilities and no corresponding asset value. By 2023, the company had a derivative asset of $1.9 million under prepaid expenses and other current assets and a derivative liability of $4.7 million under accrued liabilities for the same category. This indicates a significant increase in exposure and a shift toward a more balanced treatment across asset and liability classifications.",
      "llm_answer": "Between 2022 and 2023, Starbucks’ exposure to \"Foreign currency - other\" derivatives shifted from a net asset position of $39.9 million (prepaid expenses and other current assets) and $33.5 million (other long‑term assets) in 2022 to a net asset of $1.9 million (prepaid expenses and other current assets) and $1.7 million (other long‑term assets) in 2023, while the corresponding liability side remained largely unchanged (the derivative liability for foreign currency‑other stayed at $0.3 million in accrued liabilities and $4.7 million in other long‑term liabilities in 2023 versus $7.4 million and $3.6 million respectively in 2022). This indicates a substantial reduction in the asset portion of the foreign‑currency‑other derivative portfolio over the year.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, Starbucks had a 'Foreign currency - other' derivative liability of $0.3 million and no asset value. However, the LLM claims there was a net asset of $39.9 million in prepaid expenses and $33.5 million in other long-term assets in 2022, which is completely incorrect. In 2023, the ground truth states there was an asset of $1.9 million and a liability of $4.7 million, both under current accounts. The LLM incorrectly reports additional long-term asset ($1.7 million) and long-term liability values ($4.7 million in other long-term liabilities), which are not present in the original answer. (2) The numbers cited by the LLM—$39.9M, $33.5M, $7.4M, $3.6M—are entirely fabricated or misattributed and do not appear in the ground truth. The only correct numbers are the 2023 current asset ($1.9M) and the 2022 liability ($0.3M), though the latter is mischaracterized as 'unchanged' when it actually increased significantly in 2023 to $4.7M. The LLM incorrectly states that the liability remained largely unchanged, when in fact it increased from $0.3M to $4.7M. (3) The multi-hop reasoning is flawed: the model fails to correctly synthesize the evolution of the derivative exposure, instead inventing long-term asset and liability positions that were not in the original data. It draws the opposite conclusion—reduction in exposure—when the truth is a significant increase in both asset and liability sides. (4) The contextual relevance is moderate because the answer addresses the right topic (derivative exposure evolution) and time frame (2022–2023), but the factual foundation is severely compromised. Due to major quantitative and qualitative errors, the correctness score is low at 2.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 488,
        "total_tokens": 1806
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has The Coca-Cola Company's relationship with Coca-Cola FEMSA evolved from 2023 to 2024, particularly in terms of its strategic engagement and financial stake?",
      "original_answer": "In 2023, Coca-Cola FEMSA was one of The Coca-Cola Company's five largest independent bottling partners, operating in multiple countries including Mexico, Brazil, and Argentina, and collectively these top five bottlers accounted for 42% of Coca-Cola's worldwide unit case volume. By 2024, the relationship had evolved significantly, as Coca-Cola FEMSA transitioned from being a key bottler to becoming an equity method investee in which The Coca-Cola Company held a 28% ownership stake. This shift indicates a deeper financial commitment and alignment beyond the traditional bottler-concentrate supplier model.",
      "llm_answer": "From 2023 to 2024, The Coca-Cola Company’s strategic engagement with Coca-Cola FEMSA shifted from a significant equity‑method investment to a reduced ownership stake. In 2023 the Company held roughly a 28 % interest in Coca‑Cola FEMSA, which it accounted for as an equity‑method investment; by the end of 2024 that stake was no longer highlighted as a primary equity holding, indicating a divestiture or reduction of its share. Consequently, the Company’s financial exposure to FEMSA declined, with the equity‑method investment balance falling from $19.7 billion at the end of 2023 to $18.1 billion at the end of 2024, reflecting the decreased financial stake and the related impact on the Company’s consolidated financial statements.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth. (1) The original answer states that in 2023, Coca-Cola FEMSA was a major bottling partner and by 2024, The Coca-Cola Company had taken a 28% ownership stake, marking an increase in financial commitment. In contrast, the LLM claims the 28% stake existed in 2023 and was reduced by 2024, which is the opposite of the truth. (2) The LLM introduces specific dollar amounts—$19.7 billion and $18.1 billion—which are not present in the original answer and are unsupported by the provided ground truth. There is no mention of any divestiture or decline in stake, so these figures and the implied narrative are factually wrong. (3) The multi-hop reasoning is flawed: instead of recognizing the evolution from independent bottler to equity-method investee (indicating deeper engagement), the LLM incorrectly infers a disengagement. (4) While the LLM addresses the question's focus on strategic and financial evolution, its factual inaccuracies—especially the reversal of direction in stake change and fabricated financials—severely undermine correctness. The contextual relevance is moderate because it discusses the right companies and timeframe, but the substance is incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 346,
        "total_tokens": 1686
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Intel's strategic positioning of FPGAs evolved between 2022 and 2024, particularly in terms of their role within adjacent products and their broader production focus?",
      "original_answer": "In 2022, Intel positioned FPGAs as part of its 'adjacent products' within the Client Computing Group (CCG), Data Center Group (DCG), and Internet of Things Group (IOTG), indicating a supporting role within comprehensive platform solutions. By 2024, FPGAs were explicitly listed under direct product definitions, signaling a shift toward a more central production focus. This reflects a transformation in the strategic importance of FPGAs, moving from a supplementary role to a core product offering.",
      "llm_answer": "Intel’s FPGA strategy has shifted from a standalone focus to integration within broader adjacent product lines and its overall production model. Earlier disclosures highlighted FPGAs as part of its programmable logic portfolio (e.g., “PLD” and “Programmable Solutions Group”), but recent filings show Intel now positions FPGAs as a core component of its “xPU” family—processors that span CPU, GPU, AI accelerators, and FPGA architectures—embedding them in data‑center, edge, and automotive platforms (e.g., IPU, SoC, and autonomous‑driving levels). This reflects a strategic pivot to use FPGAs not only as discrete devices but also as programmable engines that complement Intel’s silicon‑photonic, networking, and AI‑centric product ecosystems, while the company’s production focus has moved toward scaling advanced nodes (Intel 7, Intel 4) and leveraging external foundries to meet demand for these heterogeneous compute engines.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies a strategic shift in Intel's FPGA positioning, noting increased integration into broader product lines and platforms, which aligns with the ground truth's core idea of evolving strategic importance. However, it diverges from the original answer by introducing concepts not present in the ground truth, such as 'xPU family', 'silicon-photonic', 'IPU', 'SoC', 'autonomous-driving levels', and 'Intel 7/Intel 4' scaling, which were not mentioned in the original 2022–2024 comparison based on the knowledge graph. These additions, while plausible, are not supported by the provided ground truth and reflect overreach or external knowledge injection. (2) There are no numeric values, dates, or calculations in either answer, so quantitative accuracy is not applicable—scored 10 by default as no numbers are incorrect. (3) The multi-hop reasoning is partially sound: the model infers a strategic evolution from supplementary to integrated, which matches the ground truth’s 'adjacent products' to 'core product offering' trajectory. However, it fails to explicitly mention the organizational context (CCG, DCG, IOTG) and the shift from being listed as part of 'adjacent products' to being under 'direct product definitions'—a key factual pivot in the original answer. Instead, it fabricates specific product integrations and technology roadmaps not present in the source. (4) The correctness score is 6 due to partial factual alignment on the strategic shift but significant deviation in evidence and specificity; qualitative accuracy is 6 because reasoning is directionally correct but based on unsupported details; contextual relevance is high (9) as the response stays on-topic and addresses the evolution in strategic positioning, albeit with extraneous details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1364,
        "completion_tokens": 491,
        "total_tokens": 1855
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How did ConocoPhillips' financial activity related to the Lower 48 region evolve from 2022 to 2023, particularly in terms of asset acquisition and depreciation, depletion, and amortization expenses?",
      "original_answer": "In 2022, ConocoPhillips noted that purchases in the Lower 48 were driven by the Concho acquisition, indicating a strategic expansion in that region. The depreciation, depletion, amortization, and impairments expense for the Lower 48 was $4,854 million. In 2023, the company's expense for the same category in the Lower 48 increased to $5,729 million, showing a significant rise of $875 million. This increase suggests continued investment and asset utilization in the Lower 48 following the acquisition.",
      "llm_answer": "From 2022 to 2023, ConocoPhillips’ financial activity in the Lower 48 region showed a decline in depreciation, depletion, and amortization (DD&A) expenses, which decreased from $4,854 million in 2022 to $5,729 million in 2023 (though the provided data indicates a higher 2023 figure of $5,729 million compared to $4,854 million in 2022, reflecting an increase; however, the overall trend in DD&A for the Lower 48 segment rose modestly, consistent with increased capital expenditures and reserve additions). The company also made significant asset acquisitions, notably the Concho Resources purchase, which added approximately $1.1 billion in proved undeveloped reserves and drove extensions and discoveries of 399 MMBOE in the Lower 48, contributing to a rise in total proved reserves from 1,273 million BOE (2022) to 2,775 million BOE (2023). This acquisition and development activity supported higher capital expenditures of $6.487 billion in 2023, up from $5.630 billion in 2022, underscoring a strategic focus on expanding Lower 48 operations.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in interpreting the DD&A trend. While it correctly states the 2022 figure ($4,854 million) and 2023 figure ($5,729 million), it incorrectly claims there was a 'decline' in DD&A expenses, when in fact there was an increase of $875 million. This mischaracterization undermines the core financial analysis. Additionally, the LLM introduces data not present in the original answer, such as 'proved undeveloped reserves of $1.1 billion', 'extensions and discoveries of 399 MMBOE', and specific reserve totals (1,273 million BOE in 2022, 2,775 million BOE in 2023), which are not in the ground truth and cannot be verified from the provided context. Capital expenditures ($6.487B in 2023 vs $5.630B in 2022) are also introduced without support in the original answer. (2) Quantitative accuracy is partially correct: the DD&A figures are accurate in amount and format, but the interpretation (decline vs increase) is wrong. The additional numbers (reserves, capex) lack grounding in the original answer, reducing confidence in their validity. (3) Multi-hop reasoning is attempted but flawed: the model correctly links the Concho acquisition to Lower 48 activity in 2022, but then extrapolates unsupported trends and figures for 2023. It fails to correctly infer that rising DD&A reflects increased asset utilization post-acquisition, instead misrepresenting the direction of change. (4) Contextual relevance is high—the answer addresses asset acquisition and DD&A as asked, and focuses on ConocoPhillips and the Lower 48 region. However, the inclusion of unverified metrics and the reversal of the DD&A trend significantly reduce factual correctness, warranting a moderate score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1400,
        "completion_tokens": 478,
        "total_tokens": 1878
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How did Emerson's financial and strategic relationship with AspenTech evolve between 2022 and 2024, particularly in terms of ownership structure and financial impact on gross margins?",
      "original_answer": "In 2022, Emerson completed the acquisition of AspenTech, contributing approximately $6.0 billion in cash, paying $87.69 per share to Heritage AspenTech stockholders, and retaining $168 million in AspenTech's balance sheet. The acquisition positively impacted gross margins by 0.6 percentage points in 2023. By 2024, Emerson owned 55% of AspenTech on a fully diluted basis, and AspenTech continued to operate under its former name and ticker symbol 'AZPN.' The acquisition's financial impact persisted, contributing to a gross margin increase of 1.8 percentage points to 50.8% in 2024, despite a negative impact from acquisition-related inventory step-up amortization of $231 million, which reduced margins by 1.3 percentage points.",
      "llm_answer": "Between 2022 and 2024, Emerson's ownership stake in AspenTech increased from approximately 55% to about 57% following the November 2024 proposal to acquire the remaining shares at $240 per share, valuing the company at $15.3 billion. Financially, the acquisition contributed to gross margin expansion through the Test & Measurement acquisition (which added 9.5% to sales) but was partially offset by acquisition-related inventory step-up amortization of $231, which negatively impacted margins by 1.3 percentage points. The integration also drove significant gains from the subsequent sale of Copeland's equity interest and note receivable in 2024, generating $1.5 billion and $1.9 billion respectively, which boosted adjusted EBITA margins to 24.7% in 2024 from 23.4% in 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains multiple factual inaccuracies. The ownership evolution is incorrect: the original answer states Emerson owned 55% of AspenTech by 2024 on a fully diluted basis, but the LLM claims ownership increased from 55% to 57% following a November 2024 proposal, which is not mentioned in the ground truth. There is no mention in the ground truth of a 'November 2024 proposal' or a $240 per share offer, nor a $15.3 billion valuation. (2) Financial figures are largely incorrect: the LLM claims the Test & Measurement acquisition added 9.5% to sales, but this acquisition is not referenced in the original answer. The $231 million inventory step-up amortization is correctly cited in amount and margin impact (1.3 percentage points), but it is incorrectly framed as being related to a different acquisition context. The original answer specifies that this amortization reduced margins by 1.3 points while the acquisition contributed a net increase of 1.8 points to reach 50.8% gross margin in 2024; the LLM fails to report this key outcome. Instead, it introduces unrelated financial events: the sale of Copeland's equity interest and note receivable generating $1.5B and $1.9B, which are not mentioned in the ground truth and pertain to a different corporate action. The adjusted EBITA margin increase from 23.4% to 24.7% is unsupported by the original answer. (3) Multi-hop reasoning is flawed: the LLM conflates Emerson's acquisition of AspenTech with other unrelated transactions (e.g., Copeland divestiture, Test & Measurement acquisition), failing to correctly isolate the financial impact of the AspenTech integration. It also misrepresents the timeline and ownership structure evolution. (4) Despite these issues, the answer is contextually relevant in that it attempts to address ownership changes and financial impacts on margins. However, the core facts—especially ownership percentages, transaction details, and margin impacts—are factually incorrect or fabricated. The only accurate number is the $231 million amortization and its 1.3 percentage point margin impact, but even this is embedded in an incorrect narrative. Thus, the correctness score is low due to major factual and reasoning errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 598,
        "total_tokens": 1984
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has the treatment and availability of shares under the 2015 Director Stock Plan evolved between 2022 and 2024, particularly in terms of share recovery and issuance mechanics?",
      "original_answer": "In 2022, the 2015 Director Stock Plan specified that each share issued under the plan reduced the number of shares remaining for issuance by one, and shares recovered from expired, forfeited, or cash-settled awards were again available for issuance. By 2024, the plan had a total of 35,395,894 shares authorized for issuance as of January 1, 2015, with 37,608,213 shares recovered for issuance between 2015 and 2024. However, 42,343,146 shares were covered by new awards and reinvested dividends since 2015, leaving 30,660,961 shares available for future issuance. This reflects a net reduction in available shares over time despite ongoing share recovery, indicating a shift in the balance between new issuances and recovered shares.",
      "llm_answer": "Between 2022 and 2024, the 2015 Director Stock Plan saw a significant increase in recoverable shares, with 35,770,685 shares recovered from 2015–2023 and an additional 35,395,894 shares authorized for issuance post-Separation, enabling net share recovery of 37,608,213 shares since January 1, 2015. However, shares covered by new awards and reinvested dividends on Deferred Shares (39,119,562 total since 2015) reduced the remaining availability to 30,660,961 shares as of December 31, 2024. The mechanics for share recovery under both the 2015 Stock Plan and Director Stock Plan account for adjustments via the 2005 Stock Plan Share Award Ratio (1.179) and Standard Award Ratio (1.0), with recovered shares reauthorized only after accounting for these ratios and corporate events like the Brighthouse Separation.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general trend of share recovery and issuance under the 2015 Director Stock Plan and correctly identifies the final available shares (30,660,961) as of a year-end date, aligning with the ground truth. However, there are significant quantitative inaccuracies: (1) The LLM states 35,770,685 shares were recovered from 2015–2023 and adds 35,395,894 authorized shares post-Separation, which misrepresents the original data. The ground truth states 35,395,894 shares were authorized as of January 1, 2015 (not post-Separation), and 37,608,213 shares were recovered between 2015 and 2024—numbers the LLM conflates and distorts. (2) The LLM claims 39,119,562 shares were covered by new awards and reinvested dividends, but the ground truth reports 42,343,146, a material difference. (3) The LLM incorrectly implies net share recovery is 37,608,213, which is actually the total recovered—not net. The net is negative (more issued than recovered), which the LLM fails to clarify. (4) The mention of 'December 31, 2024' extends beyond the original 2022–2024 evolution focus and introduces a future date not in the source. Qualitatively, the LLM introduces concepts like the '2005 Stock Plan Share Award Ratio' and 'Brighthouse Separation' that, while potentially contextually relevant, are not in the ground truth and distract from the core evolution of mechanics, which remained consistent (recovered shares are reissued). The reasoning is partially sound but flawed in synthesis—especially in conflating authorization, recovery, and issuance. Contextually, the answer addresses the question’s scope and attempts multi-hop synthesis, but with incorrect data mapping and unsupported details, reducing factual reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 470,
        "total_tokens": 1865
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Starbucks' relationship with the Global Coffee Alliance evolved from fiscal year 2022 to fiscal year 2023 in terms of strategic emphasis and revenue contribution?",
      "original_answer": "In fiscal year 2022, the Global Coffee Alliance contributed to the growth of the Channel Development segment, which saw a $250 million increase in revenue driven by product sales and royalty income from the alliance. By fiscal year 2023, the strategic emphasis on the Global Coffee Alliance had evolved, with Starbucks explicitly highlighting its licensing relationship with Nestlé under the alliance as a core channel for product distribution, indicating a deeper integration and ongoing importance to Starbucks' global licensing and product expansion strategy. This evolution reflects a shift from viewing the alliance primarily as a revenue driver to positioning it as a strategic enabler of global product reach and brand extension.",
      "llm_answer": "From fiscal 2022 to fiscal 2023, Starbucks shifted its strategic emphasis within the Global Coffee Alliance from a focus on incremental revenue growth to a broader partnership model that deepens product and distribution collaboration, while also expanding its contribution to overall revenue. In fiscal 2022, revenue from the Global Coffee Alliance rose sharply—driven by higher product sales and royalty income—to $216 million, representing a modest share of total net revenues; by fiscal 2023 the alliance’s role was highlighted as a key growth lever, with its revenue contribution continuing to expand as part of the company’s diversified segment strategy.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. The ground truth states that the Channel Development segment grew by $250 million in FY2022 due to the Global Coffee Alliance, but the LLM incorrectly reports the alliance's revenue as $216 million—both the figure and the framing (absolute revenue vs. segment growth) are wrong. There is no mention of the $250 million increase in the LLM answer, and the $216 million figure does not appear in the ground truth, making it factually incorrect. (2) While the LLM correctly identifies a strategic evolution in the alliance from FY2022 to FY2023—shifting from revenue growth to a broader partnership model—it misses the specific detail that the alliance with Nestlé is the core licensing relationship under the Global Coffee Alliance, which is a key entity-level accuracy issue. (3) The multi-hop reasoning is partially sound: the model infers a strategic shift and links it to revenue and distribution expansion, which aligns with the ground truth. However, it fails to correctly synthesize the exact financial impact in FY2022 and misrepresents the nature of the revenue contribution. (4) Contextually, the answer is relevant and addresses both strategic emphasis and revenue contribution. The qualitative reasoning about strategic evolution is plausible and captures the directional shift, but the incorrect numbers and missing specificity on Nestlé undermine full accuracy. The answer would score higher if not for the critical error in financial data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 421,
        "total_tokens": 1776
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has NEE's financial stake and involvement in the Mountain Valley Pipeline evolved between 2022 and 2023, and what does this indicate about its investment strategy?",
      "original_answer": "In 2022, NEE's equity method investments totaled $6,159 million, and the Mountain Valley Pipeline was listed among key equity method investees alongside NEP OpCo, Sabal Trail, and Silver State South Solar, with NEE's interest ranging from approximately 32% to 55%. By 2023, NEE's total equity method investments were $6,156 million, with its interest in the principal entities, including the Mountain Valley Pipeline, ranging from approximately 32.8% to 52.6%. The shift from a broader range (32%–55%) in 2022 to a narrower range (32.8%–52.6%) in 2023 suggests a slight adjustment in ownership stakes, potentially reflecting a more refined or strategic investment posture. Additionally, in 2023, the Mountain Valley Pipeline was specifically noted in the context of Nonrecurring Fair Value Measurements, indicating a possible revaluation or change in financial treatment.",
      "llm_answer": "Between 2022 and 2023, NextEra Energy’s (NEE) financial stake and involvement in the Mountain Valley Pipeline evolved significantly. In 2022, NEE held a noncontrolling interest in the pipeline through its equity method investment in NEP, with a recorded investment of approximately $4.968 billion (reflecting a $2.589 billion difference between investment carrying amount and underlying equity, primarily tied to goodwill and impairment charges). By 2023, NEE’s stake remained part of its broader renewable energy portfolio via NEP, but the investment was marked by a substantial impairment charge of approximately $1.2 billion in 2023, which reduced the carrying value of its investment and highlighted financial strain. This evolution indicates NEE’s strategic shift toward renewable energy assets (e.g., wind, solar, and battery storage) while maintaining exposure to infrastructure projects like Mountain Valley Pipeline, though with growing emphasis on impairment risks and regulatory complexities.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and fails to align with the ground truth. (1) Quantitative Accuracy: The dollar amounts cited ($4.968 billion investment, $2.589 billion difference, $1.2 billion impairment) are not supported by the original answer and appear fabricated. The ground truth reports total equity method investments of $6,159M in 2022 and $6,156M in 2023, with no mention of specific figures tied to the Mountain Valley Pipeline or impairment charges. There is no reference to a $1.2 billion impairment related to the pipeline in 2023. (2) Completeness: While the question asks about the evolution of NEE's stake and what it indicates about investment strategy, the LLM invents details (e.g., impairment charges, specific carrying amounts) not present in the source. It misses the key point about the narrowing ownership range (32%–55% in 2022 to 32.8%–52.6% in 2023) and the mention of the pipeline in Nonrecurring Fair Value Measurements in 2023. (3) Entity Accuracy: The entities (NEE, Mountain Valley Pipeline, NEP) are correctly identified, and the years (2022–2023) are accurate. However, linking the pipeline specifically to NEP OpCo without clarification and attributing an impairment charge to it is unsupported. (4) Reasoning: The multi-hop synthesis is flawed. The LLM incorrectly infers a 'strategic shift' based on invented financial data rather than the actual subtle adjustment in ownership percentages and accounting treatment noted in the ground truth. The conclusion about emphasis on impairment risks and regulatory complexities is speculative and not grounded in the provided facts. (5) Semantic Equivalence: The overall meaning diverges significantly—instead of a measured refinement in investment posture, the LLM portrays a financially strained asset with major write-downs, which is not corroborated. Thus, despite addressing the general topic, the answer is largely incorrect in substance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1473,
        "completion_tokens": 523,
        "total_tokens": 1997
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Medtronic's InterStim Therapy product line evolved between 2022 and 2024 in terms of neurostimulator offerings and therapeutic indications?",
      "original_answer": "In 2022, InterStim therapy was described with a range of neurostimulators including InterStim II, InterStim Micro, and InterStim X, targeting symptoms of overactive bladder, urinary retention, and bowel incontinence. By 2024, the product line continued to include InterStim II and InterStim X, now specifically labeled as 'recharge-free' neurostimulators, and retained its focus on overactive bladder and urinary retention, but expanded its therapeutic scope to include 'chronic fecal incontinence.' This reflects a refinement in product positioning and a broadening of clinical applications over the two-year period.",
      "llm_answer": "Between 2022 and 2024, Medtronic’s InterStim therapy portfolio evolved with the launch of next‑generation, recharge‑free neurostimulators—including InterStim X, InterStim II and the InterStim Micro device—expanding indications to overactive bladder, urinary retention and chronic fecal incontinence, and received FDA approval for the closed‑loop Inceptiv SCS system in April 2024. These advances broadened therapeutic options and reinforced the company’s focus on minimally invasive solutions across neuroscience and pelvic‑health markets.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. It correctly identifies the neurostimulators (InterStim X, InterStim II, InterStim Micro) and therapeutic indications including overactive bladder, urinary retention, and chronic fecal incontinence. However, it inaccurately states that all three devices, including InterStim Micro, are recharge-free, while the ground truth specifies only InterStim II and InterStim X are labeled as recharge-free by 2024—InterStim Micro is not described as such. Additionally, the LLM introduces the 'closed-loop Inceptiv SCS system' and its April 2024 FDA approval, which is irrelevant to InterStim therapy (Inceptiv is a spinal cord stimulator, not part of the InterStim sacral neuromodulation line), constituting a significant factual error. (2) The dates and product names are mostly accurate in format, but the inclusion of Inceptiv SCS with a specific approval date (April 2024) introduces a false quantitative claim not supported by the ground truth. No numerical calculations are involved, so quantitative accuracy is moderate due to correct years and device names but flawed event attribution. (3) The multi-hop reasoning is partially sound—linking device evolution and indication expansion over time—but fails in synthesizing accurate product-specific details and conflates distinct product lines. The answer incorrectly implies all listed devices are recharge-free and adds an unrelated product launch, indicating poor entity disambiguation. (4) Contextual relevance is high as the response addresses the evolution of InterStim therapy in terms of devices and indications, but correctness is undermined by key factual inaccuracies in product features and inclusion of irrelevant information. Thus, the correctness score is 5 due to partial accuracy with significant errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 501,
        "total_tokens": 1790
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did Simon Property Group's financial stake and strategic relationship with Authentic Brands Group (ABG) evolve from 2022 to 2024?",
      "original_answer": "In 2022, Simon Property Group held a 1.37% interest in ABG and had merged Forever 21 operations into SPARC Group after increasing its stake to 50% alongside ABG. By 2024, Simon sold a portion of its ABG stake, realizing a pre-tax gain of $18.8 million, and later acquired additional interests in ABG for $100 million in cash, indicating a dynamic evolution in their financial relationship.",
      "llm_answer": "From 2022 through 2024 Simon’s stake in Authentic Brands Group (ABG) was gradually reduced and ultimately eliminated.  In 2022 the company held a non‑controlling interest of roughly 10 % (down from earlier larger holdings) and continued to acquire additional ABG equity in cash‑based transactions, while also selling portions of its interest and receiving cash proceeds.  By early 2024 Simon completed the sale of its remaining ABG ownership for $1.2 billion, recording a pretax gain of $414.8 million and associated tax expense, after which its ABG equity stake was fully retired.  Throughout the period the relationship shifted from a meaningful equity investment to a series of strategic equity transactions that generated gains and tax impacts but left Simon with no residual ownership.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in both quantitative and qualitative aspects. (1) Quantitatively, it states Simon held a ~10% stake in ABG in 2022, but the ground truth is 1.37%. It claims Simon sold its 'remaining' stake for $1.2 billion and recorded a $414.8 million pre-tax gain, whereas the truth is Simon only sold a portion and realized a $18.8 million gain. The $100 million acquisition of additional ABG interests in 2024 is completely omitted. (2) The timeline is wrong: the answer suggests Simon fully exited its stake by early 2024, but in reality, it both sold a portion and later bought more, indicating an ongoing and evolving relationship, not a full exit. (3) Qualitatively, the reasoning is flawed—instead of showing a dynamic back-and-forth (selling and buying), the LLM portrays a one-way divestment to zero, which contradicts the ground truth. The strategic evolution is misrepresented as a wind-down rather than active financial maneuvering. (4) Contextual relevance is moderate because it addresses the general theme of stake evolution and strategic relationship, but the factual backbone is incorrect. Minor credit is given for mentioning cash transactions and gains, but core facts and direction of stake changes are wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 348,
        "total_tokens": 1640
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has ConocoPhillips' investment activity in the Lower 48 region evolved from 2021 to 2023, particularly in terms of depreciation, depletion, and amortization expenses?",
      "original_answer": "ConocoPhillips' depreciation, depletion, and amortization (DD&A) expenses in the Lower 48 region increased from $4,067 million in 2021 to $5,729 million in 2023, indicating a significant rise in asset utilization or investment activity. This reflects a growing emphasis on the Lower 48 as a core operational area for the company.",
      "llm_answer": "ConocoPhillips' depreciation, depletion, and amortization (DDA) expenses related to its Lower 48 operations have risen steadily from 2021 to 2023, reaching $5,729 million in 2023 compared with $4,854 million in 2022 and $4,067 million in 2021, reflecting the company's increased investment and production activity in that region over the period.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the DD&A expense for ConocoPhillips in the Lower 48 region in 2021 ($4,067 million) and 2023 ($5,729 million), which matches the ground truth. However, it introduces a figure for 2022 ($4,854 million) that is not present in the original answer and cannot be verified from the provided ground truth. Since the question focuses on the evolution from 2021 to 2023, the inclusion of an unverified 2022 value constitutes a significant quantitative inaccuracy. (2) While the start and end figures are correct, the addition of an unsupported intermediate data point undermines the quantitative accuracy. There is no indication in the ground truth about the 2022 value, so asserting it reduces factual reliability. (3) The reasoning and synthesis are otherwise sound—the conclusion that rising DD&A reflects increased investment and production activity aligns with the original answer’s interpretation and shows proper multi-hop understanding of financial trends and operational implications. (4) Contextual relevance is perfect, as the response directly addresses the question about investment activity evolution using the correct metric and region. Due to the incorrect insertion of a 2022 figure not in the ground truth, the correctness and quantitative accuracy scores are reduced, though the core trend and endpoint values are accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1174,
        "completion_tokens": 385,
        "total_tokens": 1559
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has Verizon's (VZ) treatment and valuation approach for international bonds evolved from 2023 to 2024 based on their 10-K disclosures?",
      "original_answer": "In 2023, Verizon described that international bonds were valued using matrix prices with input from independent third-party valuation sources as part of the broader fixed income securities category. By 2024, international bonds were specifically itemized in a detailed table with a total value of $12 million, broken down into $10 million in Level 1 and $2 million in Level 2 inputs. This represents a shift from a general description in 2023 to a more transparent and segmented valuation approach in 2024, indicating a more refined disclosure strategy and possibly a more structured approach to valuing international bonds.",
      "llm_answer": "Verizon's treatment of international bonds in its 10-K disclosures shows a consistent approach across 2023 and 2024, with no explicit mention of international bonds in the pension or postretirement benefit plan asset allocations. The 2023 10-K (page 94) details that international bonds within pension plan assets were valued at $341 million (Level 1: $3, Level 2: $338), and the 2024 10-K (page 93) shows international bonds at $113 million (Level 2: $113), indicating a reduction in exposure. Both years classify international bonds under \"Fixed income securities\" with no separate discussion of international bond valuation methodology beyond standard fixed income valuation using matrix prices and third-party sources. The 2024 10-K (page 96) also references \"International bonds\" in the context of pension plan assets but does not describe a distinct valuation approach for international bonds versus other fixed income securities, maintaining the same methodology as other fixed income holdings. Thus, Verizon's valuation approach for international bonds remained unchanged, relying on standard market-based pricing without special treatment, and the exposure level decreased from $341 million in 2023 to $113 million in 2024.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2023, international bonds were described generally as valued using matrix prices with third-party sources, with no specific dollar amount mentioned. However, the LLM claims Verizon valued international bonds at $341 million in 2023 and $113 million in 2024, which contradicts the original answer and is unsupported by the provided ground truth. These numbers appear to be hallucinated or drawn from an external source not reflected in the knowledge graph. Additionally, the LLM asserts that exposure decreased from $341M to $113M, which is not supported by the ground truth. The ground truth instead reports a 2024 value of $12 million ($10M Level 1, $2M Level 2), not $113 million all in Level 2. (2) Quantitative accuracy is severely compromised: the LLM’s figures do not match the ground truth, and there is no mention in the original answer of pension plan assets or page references (e.g., page 94, 93, 96), suggesting the LLM may have conflated data from a different context or document section. The correct 2024 value is $12M total, not $113M. (3) The multi-hop reasoning is flawed. The question asks about the evolution in valuation *approach*, not just exposure levels. The ground truth highlights a shift from general description in 2023 to specific itemization and segmentation by valuation level in 2024—indicating improved transparency. The LLM incorrectly concludes the approach 'remained unchanged,' missing this key evolution entirely. It fails to recognize the qualitative shift in disclosure granularity. (4) Contextual relevance is moderate because the LLM addresses the right topic (international bonds, valuation methods, 10-K disclosures) and attempts to compare years, but it misrepresents both the data and the analytical insight. The focus on pension assets and unsupported figures reduces relevance. Overall, the answer is mostly incorrect due to fabricated numbers and failure to identify the actual evolution in disclosure strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1462,
        "completion_tokens": 554,
        "total_tokens": 2016
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did Emerson's relationship with AspenTech evolve between 2022 and 2024, particularly in terms of financial stake and operational integration?",
      "original_answer": "In 2022, Emerson had a financial stake in AspenTech valued at $8,326 million, as shown in the balance sheet following acquisitions and currency adjustments. By 2024, Emerson's relationship had transformed significantly: it contributed the AspenTech Industrial Software Business along with $6.0 billion in cash to form 'New AspenTech,' retaining a 55% ownership stake in the newly structured company. This indicates a strategic restructuring rather than a simple financial investment, with increased operational integration and a formalized majority ownership.",
      "llm_answer": "Between 2022 and 2024, Emerson's relationship with AspenTech evolved from a strategic partnership into a deepening ownership and integration. Emerson already owned approximately 57% of AspenTech's shares by late 2024 and proposed a full acquisition at $240 per share, implying a $15.3 billion market cap. This move followed the 2022 Heritage AspenTech acquisition that boosted goodwill and intangibles in Automation Solutions. While operational integration details are sparse, the financial stake grew significantly, culminating in Emerson's proposed full buyout, suggesting a move toward complete operational control. The financial impact is evident in AspenTech's rising goodwill balance ($8,326 in 2022) and the inclusion of AspenTech's results in Emerson's segment reporting.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) Quantitatively, it incorrectly states that Emerson owned 57% of AspenTech by late 2024 and proposed a full acquisition at $240 per share implying a $15.3 billion market cap—this is not supported by the ground truth. The original answer states that Emerson contributed assets and $6.0 billion in cash to form 'New AspenTech' and retained a 55% stake, not 57%, and there is no mention of a $240/share offer or $15.3B valuation. Additionally, the LLM misattributes the $8,326 million goodwill figure to AspenTech's balance sheet, while the ground truth clearly states this was Emerson's financial stake in AspenTech in 2022. (2) The answer fails to correctly describe the 2024 transaction: it was not a proposed full acquisition but a completed restructuring into 'New AspenTech' with Emerson holding a 55% majority stake. The LLM incorrectly frames this as a 'proposed full buyout,' which misrepresents the nature and outcome of the transaction. (3) Qualitatively, the reasoning is flawed—instead of recognizing the transformation from a financial stake to operational integration via a new entity, the model suggests a linear acquisition path that did not occur. It also incorrectly references 'Heritage AspenTech acquisition' as if Emerson acquired AspenTech in 2022, whereas the ground truth indicates Emerson already had a financial stake then. (4) Contextually, the answer addresses the evolution of the relationship and mentions financial stakes and integration, so it remains relevant, but the core facts and multi-hop synthesis (from financial investment in 2022 to majority-controlled joint entity in 2024) are incorrect. Minor note: 'goodwill balance ($8,326)' is close in number but misassigned in context—this was an investment value, not goodwill. Overall, major factual and conceptual errors lead to a low correctness score despite some surface-level relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 527,
        "total_tokens": 1861
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did Starbucks' position in interest rate swaps evolve between 2022 and 2023, particularly in terms of their classification and associated liabilities?",
      "original_answer": "In 2022, Starbucks had an interest rate swap classified as a long-term liability with a value of $34.0 million. By 2023, the company's interest rate swaps were categorized under both current and long-term liabilities, with $0.4 million listed under accrued liabilities (current) and $19.2 million under other long-term liabilities. This reflects a shift in the classification and a net decrease in the overall liability associated with interest rate swaps from $34.0 million in 2022 to $19.6 million in 2023.",
      "llm_answer": "Between 2022 and 2023, Starbucks' interest rate swap position shifted from being primarily classified as a **non-designated derivative** (with no fair value hedge accounting) to being **designated as a fair value hedge** of long-term debt. This is evidenced by the 2023 disclosure showing the interest rate swap now appears under \"Designated Derivative Instruments\" in both derivative assets and liabilities, with a corresponding fair value hedging adjustment of **$ (17.8) million** recorded in the carrying amount of the hedged long-term debt (up from **$ 21.7 million** in 2022). The 2022 filing only listed interest rate swaps under \"Non-designated Derivative Instruments\" with no hedge accounting applied, while the 2023 filing explicitly shows the swap as part of a fair value hedge relationship, resulting in a **$52.3 million cumulative fair value hedging adjustment** (compared to a $21.7 million adjustment in 2022). Consequently, the associated liability for the interest rate swap increased from **$34.0 million** (non-designated, recorded in other long-term liabilities) to **$19.2 million** (designated, still in other long-term liabilities but now offset by the hedging adjustment), reflecting the reclassification from speculative to hedged accounting treatment.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies despite addressing the general topic of Starbucks' interest rate swaps. (1) Quantitative Accuracy: The ground truth states that in 2022, the liability was $34.0 million (correctly cited), but in 2023 it was split into $0.4 million (current) and $19.2 million (long-term), totaling $19.6 million—a net decrease. The LLM incorrectly claims the liability 'increased' from $34.0M to $19.2M, which is both numerically and directionally wrong (it decreased). Additionally, the LLM introduces figures not present in the ground truth: '$(17.8) million' hedging adjustment, '$52.3 million cumulative adjustment', and '$21.7 million' in 2022, none of which appear in the original answer or are supported by the provided data. (2) Completeness: While the question asks about classification and liabilities, the LLM introduces a new concept—'fair value hedge' and 'designated vs non-designated'—that is absent from the ground truth. There is no mention in the original answer about hedge accounting treatment, derivative designations, or hedging adjustments, suggesting this is fabricated or hallucinated detail. (3) Entity Accuracy: The company (Starbucks) and years (2022–2023) are correct, and the $34.0M and $19.2M figures are partially accurate (though $19.2M is only part of the total 2023 liability). However, the classification shift described (non-designated to designated) is not supported by the ground truth, which only notes a change from long-term only to split between current and long-term. (4) Reasoning: The multi-hop reasoning fails because the LLM invents a narrative around hedge accounting without evidence in the ground truth. The actual evolution is a reclassification in balance sheet presentation and a reduction in total liability, not a change in hedge designation. (5) Semantic Equivalence: The LLM answer does not convey the same information; it replaces a straightforward liability reclassification and reduction with a technically detailed but incorrect explanation involving hedge accounting. The core facts—total liability decreased from $34.0M to $19.6M and was reclassified into current and long-term portions—are either misrepresented or ignored. Thus, while contextually relevant to Starbucks' derivatives, the answer is factually incorrect on key points.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1448,
        "completion_tokens": 620,
        "total_tokens": 2069
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How did NextEra Energy Resources' financial commitment and involvement in the Mountain Valley Pipeline evolve from 2022 to 2023?",
      "original_answer": "In 2022, NextEra Energy Resources recorded an impairment charge of approximately $0.8 billion related to its equity method investment in the Mountain Valley Pipeline, which was fully written off due to the very low probability of pipeline completion. By 2023, despite the ongoing challenges, NEE's subsidiary NEER maintained a 32.8% equity investment in the joint venture and committed to a 20-year natural gas transportation agreement with an annual obligation of approximately $70 million, subject to the completion of construction.",
      "llm_answer": "From 2022 to 2023, NextEra Energy Resources’ involvement with the Mountain Valley Pipeline shifted dramatically. In 2022, the company recorded a $0.8 billion impairment charge and wrote down its equity‑method investment after determining that legal and regulatory hurdles made completion of the pipeline “very low probability,” effectively ending its direct financial commitment. By 2023, NEE’s disclosures show no remaining equity investment in the project; the only reference is a modest $1.06 billion equity contribution scheduled for 2024 under a 20‑year gas‑transport agreement, indicating that any further participation is limited to a small, contingent funding role rather than an ongoing capital commitment.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) Quantitatively, it incorrectly states that there is 'no remaining equity investment' in 2023, while the ground truth confirms NEER maintained a 32.8% equity stake. It also introduces a '$1.06 billion equity contribution scheduled for 2024' that is not mentioned in the original answer and contradicts the $70 million annual obligation under a transportation agreement. The $0.8 billion impairment charge in 2022 is correctly stated. (2) The $70 million annual obligation is misrepresented as a 'small, contingent funding role' and conflated with an equity contribution, which is a fundamental error in financial terminology and structure. (3) Qualitatively, the reasoning is flawed: the model infers that the write-off implies termination of all involvement, but the ground truth shows continued equity ownership and contractual commitment. The multi-hop synthesis fails—while it correctly identifies the 2022 impairment, it does not acknowledge the ongoing 32.8% investment or the nature of the transportation agreement in 2023. (4) Contextually, the answer addresses the evolution of involvement and is structured around the correct time frame, but the core financial and structural details are incorrect. Due to major errors in entity status (equity investment), financial commitments, and misrepresentation of contractual obligations, the overall correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 403,
        "total_tokens": 1711
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has The Coca-Cola Company's investment in equity and debt securities related to its captive insurance company reinsuring group annuity insurance contracts evolved between 2023 and 2024?",
      "original_answer": "In 2023, The Coca-Cola Company reported that its captive insurance company reinsuring group annuity insurance contracts held $1,643 million in equity and debt securities as part of its solvency capital funds. By 2024, this amount increased to $1,883 million, indicating a growth in the company's investment in these securities over the year.",
      "llm_answer": "The Company's investment in equity and debt securities held by its captive insurance company that reinsures group annuity contracts increased from $1.64 billion of equity and $1.38 billion of debt securities as of December 31 2023 to $1.88 billion of equity and $1.64 billion of debt securities as of December 31 2024. This reflects a higher allocation to both equity and debt securities within the captive’s solvency‑capital portfolio over the one‑year period.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its numerical breakdown. The original answer states that the total value of equity and debt securities combined was $1,643 million in 2023 and $1,883 million in 2024. However, the LLM claims $1.64 billion in equity and $1.38 billion in debt securities in 2023 (totaling $3.02 billion), and $1.88 billion in equity and $1.64 billion in debt in 2024 (totaling $3.52 billion), which are not only incorrect individually but also significantly overstate the actual totals. These numbers do not appear in the ground truth and represent a complete misrepresentation of the data. (2) The quantitative accuracy is very low because the LLM invents separate equity and debt amounts that are not present in the original answer and are inconsistent with the reported totals. The correct values are aggregate figures, not split into $1.38B and $1.64B components as claimed. The increase from $1,643M to $1,883M is accurate in the original, but the LLM fabricates a breakdown that cannot be verified and contradicts the source. (3) The reasoning is flawed because it assumes a split between equity and debt securities without evidence, and implies a multi-hop synthesis that did not occur correctly. The model fails to recognize that the reported figures are total solvency capital investments, not itemized by security type. This undermines the multi-hop logic required. (4) Contextual relevance is moderate because the answer addresses the right company, time frame, and general topic (investment evolution in securities via captive insurer), but the fabricated numbers and incorrect structure severely compromise factual integrity. The conclusion about increased allocation is directionally correct but based on false premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1211,
        "completion_tokens": 481,
        "total_tokens": 1692
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has Intel's approach to the Intel 4 process node evolved from 2022 to 2024, particularly in terms of production status and strategic positioning within Intel's product roadmap?",
      "original_answer": "In 2022, Intel was incurring higher period charges related to the ramp-up of Intel 4, indicating early-stage production challenges and investment. By 2024, Intel 4 had transitioned to high-volume manufacturing in Ireland and became the process node for the high-volume Intel Core Ultra processor, marking its strategic importance in Intel's product roadmap. This evolution shows a shift from initial investment and production ramp-up in 2022 to full-scale production and product integration by 2024.",
      "llm_answer": "Intel's Intel 4 process node transitioned from limited 2023 production of the Core Ultra series to high-volume manufacturing in Ireland in 2024, establishing it as a key node for client CPUs and enabling the first AI PCs. Intel 3, its second EUV node, entered high-volume manufacturing in Oregon in 2024 for data center products like Xeon 6, while Intel 18A (featuring gate-all-around transistors and backside power) is slated for 2025 high-volume production with Panther Lake, positioning it as the next-generation node to drive future product leadership and foundry growth.",
      "correctness_score": 7,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that Intel 4 transitioned to high-volume manufacturing in Ireland in 2024 and is used for the Intel Core Ultra processor, aligning with the ground truth. However, it incorrectly states that limited production of Core Ultra occurred in 2023, while the original answer and supporting data emphasize 2022 as the year of early ramp-up challenges and investment charges. This misalignment on timing reduces quantitative accuracy. (2) The mention of Intel 3 entering high-volume manufacturing in Oregon in 2024 and Intel 18A's 2025 timeline adds context beyond the question's scope but does not contradict facts. However, these details are not required for answering the specific evolution of Intel 4 from 2022 to 2024. The core financial and strategic evolution of Intel 4 is mostly accurate, except for the misplaced 2023 reference instead of 2022. (3) The multi-hop reasoning is sound in connecting process node development to product integration and strategic positioning, correctly synthesizing production status with roadmap significance. It captures the shift from ramp-up to high-volume manufacturing and product deployment. (4) Scores reflect strong qualitative accuracy and relevance, with a moderate deduction in correctness and quantitative accuracy due to the incorrect attribution of initial production to 2023 rather than 2022, which affects the timeline fidelity central to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1277,
        "completion_tokens": 400,
        "total_tokens": 1677
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did Emerson's strategic relationship with AspenTech evolve between 2022 and 2024, particularly in terms of ownership structure and financial integration?",
      "original_answer": "In 2022, AspenTech was described as a strategic partner of Emerson, with no mention of ownership stakes or integration into Emerson's financials. By 2024, Emerson had merged its industrial software business with AspenTech, creating 'New AspenTech,' and retained a 55% ownership stake in the newly formed entity. This marked a significant shift from a partnership to a partially owned subsidiary structure. Additionally, AspenTech's financials were now integrated into Emerson's results, with the acquisition positively impacting gross margins by 0.6 percentage points in 2023 and influencing SG&A expenses in 2024 due to the deeper integration.",
      "llm_answer": "Between 2022 and 2024, Emerson's strategic relationship with AspenTech evolved from a partial ownership stake to full acquisition. In 2022, Emerson completed its acquisition of Heritage AspenTech, increasing its stake to approximately 55% of AspenTech's outstanding shares, and in November 2024, Emerson proposed to acquire the remaining ~43% of AspenTech for $240 per share in cash, implying a fully diluted market capitalization of $15.3 billion. This transaction would result in Emerson owning 100% of AspenTech, marking a complete consolidation of ownership. Financially, Emerson's adjusted EBITA from continuing operations increased from $3.016 billion in 2022 to $4.326 billion in 2024, reflecting the integration of AspenTech's operations and the acquisition-related financial impacts, including $231 million in acquisition-related inventory step-up amortization and other integration costs. The acquisition was financed through cash on hand, committed credit lines, and other available financing sources, and was expected to close without financing conditions.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) The timeline and ownership evolution are incorrect: the original answer states that in 2022, AspenTech was a strategic partner with no ownership stake mentioned, but the LLM claims Emerson already owned 55% in 2022 and was moving toward full acquisition. In reality, the 55% ownership resulted from the 2024 merger, not a 2022 acquisition. (2) The LLM incorrectly states that Emerson proposed to acquire the remaining ~43% in November 2024, implying a future full acquisition, but the ground truth does not mention such a transaction or valuation ($15.3B, $240/share). These figures and plans are fabricated. (3) Financial metrics like EBITA increasing from $3.016B to $4.326B and $231M in inventory step-up costs are not in the original answer and are unsupported. (4) The correct evolution is a shift from partnership (2022) to 55% ownership via merger creating 'New AspenTech' (2024), with financial integration including a 0.6 percentage point gross margin boost in 2023 and SG&A impact in 2024—details entirely missing or misrepresented in the LLM response. (5) The LLM confuses the nature of the transaction: it was a merger of Emerson’s software business with AspenTech, not a stepwise acquisition. While the answer addresses ownership and financial integration (moderate contextual relevance), the core facts, numbers, and reasoning are fundamentally flawed, failing the multi-hop synthesis required. Minor positive: the mention of financial integration aligns thematically, but without correct grounding.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1430,
        "completion_tokens": 437,
        "total_tokens": 1868
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has Intel's approach to the Intel 4 process node evolved from 2022 to 2024, particularly in terms of its manufacturing readiness and performance improvements?",
      "original_answer": "In 2022, Intel 4 was newly introduced as part of a restructured naming convention for manufacturing process nodes, signaling its position as a next-generation node following Intel 7. By 2024, Intel 4 had transitioned from a conceptual roadmap item to a fully realized product, with high-volume manufacturing ramped up in Ireland. Intel 4, as the company's first EUV lithography node, delivered a 20% performance-per-watt improvement over Intel 7 and was used in the production of the Intel Core Ultra processor, which began shipping in 2023. This represents a significant evolution from its initial naming in 2022 to full-scale production and performance quantification by 2024.",
      "llm_answer": "From 2022 to 2024 Intel’s Intel 4 node moved from early‑stage development to high‑volume manufacturing, first in Ireland and later in Oregon, delivering roughly 20 % better performance‑per‑watt versus Intel 7 and enabling the Core Ultra Series 1 AI PC. The subsequent Intel 3 node, also EUV‑based, added up to 18 % performance‑per‑watt gains and now powers the Xeon 6 Scalable data‑center CPUs. Looking ahead, Intel 18A (featuring gate‑all‑around RibbonFET and backside power delivery) is slated for high‑volume production in 2025 with the Panther Lake client processors, positioning Intel’s process technology as a core pillar of its foundry and product strategy.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution of Intel 4 from development to high-volume manufacturing with accurate performance-per-watt improvement (20%) over Intel 7, aligning with the ground truth. It correctly identifies Intel 4 as enabling the Core Ultra processor (referred to as 'Core Ultra Series 1 AI PC'), which began shipping in late 2023, and notes its first use of EUV lithography (implied by context). However, the mention of 'later in Oregon' for high-volume manufacturing is not supported in the ground truth, which only specifies Ireland—this is a minor factual overextension. Additionally, the LLM introduces forward-looking details about Intel 3 and Intel 18A, which, while contextually relevant to Intel's broader roadmap, are not part of the 2022–2024 Intel 4 evolution focus and slightly divert from the question. The 20% performance-per-watt figure is accurate and matches the ground truth. The reference to Core Ultra is semantically equivalent. The reasoning is sound and reflects multi-hop synthesis across time and technical milestones. Overall, the answer is factually strong with minor overreach on manufacturing locations and some extraneous forward-looking content, warranting a high but not perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 350,
        "total_tokens": 1690
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has the role and positioning of InterStim Micro evolved within MDT's Pelvic Health therapies between 2022 and 2024?",
      "original_answer": "In 2022, InterStim Micro was listed as one of several neurostimulators within MDT's Pelvic Health product portfolio, which also included InterStim X and InterStim II, used to treat overactive bladder, urinary retention, and fecal incontinence. By 2024, InterStim Micro was specifically highlighted as the rechargeable neurostimulator option, differentiated from the recharge-free InterStim X and InterStim II. This indicates a more defined strategic positioning of InterStim Micro as the rechargeable variant within the broader InterStim therapy lineup, with an emphasis on its continued global growth and adoption.",
      "llm_answer": "Between 2022 and 2024, InterStim Micro evolved from a niche rechargeable neurostimulator within Medtronic’s Pelvic Health portfolio to a more prominently positioned therapy for overactive bladder, urinary retention, and fecal incontinence. The 2024 10-K highlights its growing acceptance and continued global adoption, emphasizing its role alongside newer devices like InterStim X and II, while underscoring the company’s focus on expanding less-invasive treatment options in pelvic health. This positioning reflects a strategic emphasis on expanding its therapeutic footprint within Medtronic’s broader Pelvic Health offerings.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the evolution of InterStim Micro within Medtronic's (MDT) Pelvic Health portfolio between 2022 and 2024 and accurately notes its use in treating overactive bladder, urinary retention, and fecal incontinence. It also correctly highlights growing global adoption and the strategic emphasis on less-invasive treatments. However, it inaccurately describes InterStim Micro as evolving 'from a niche rechargeable neurostimulator' — the original answer does not label it as 'niche' in 2022, only that it was one of several neurostimulators. Additionally, the LLM implies that InterStim X and II are 'newer devices' in 2024, but the ground truth does not support this temporal hierarchy. Crucially, the LLM fails to mention the key differentiating factor emphasized in 2024: that InterStim Micro is the rechargeable option, while InterStim X and II are recharge-free. This is a significant omission in the strategic repositioning. (2) There are no numeric values, dates, or calculations in the question or answers, so quantitative accuracy is not applicable — score of 10 is justified as no errors exist. (3) The multi-hop reasoning is partially sound — the model correctly synthesizes information across time (2022 to 2024) and identifies the product's evolving role. However, it misses the precise strategic differentiation (rechargeable vs. recharge-free), which is central to the ground truth's conclusion. (4) The contextual relevance is high as the answer addresses the timeframe, product, company, and therapeutic area accurately. The qualitative accuracy is reduced due to mischaracterization of product roles and omission of key differentiating features, but core facts about adoption and portfolio context are correct. Hence, a correctness score of 7 is appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 493,
        "total_tokens": 1797
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has the disclosure around the dilutive effect of LTIP Units evolved from 2022 to 2024, particularly in terms of material impact across reporting periods?",
      "original_answer": "In 2022, the disclosure stated that LTIP units were exchangeable for common stock and that no securities had a material dilutive effect for the years ended December 31, 2021, 2020, and 2019. By 2024, the disclosure simplified to state that no securities had a material dilutive effect for the years ended December 31, 2024, 2023, and 2022, without explicitly referencing the exchangeability of LTIP units into common stock. This indicates a reduction in the level of detail provided about LTIP units' conversion features, while maintaining the same conclusion regarding dilution impact.",
      "llm_answer": "The dilutive impact of LTIP Units is described as having “no material dilutive effect” for the years ended December 31 2024, 2023 and 2022, and the company explicitly states that it has not adjusted net income attributable to common stockholders or weighted‑average shares for income allocable to limited partners or units because such adjustment “would have no dilutive impact.” This language and the consistent disclosure across the 2022, 2023 and 2024 filing pages indicate that the LTIP Units have not produced a material dilutive effect in any of those reporting periods.",
      "correctness_score": 6,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies that LTIP Units had no material dilutive effect for the years 2022, 2023, and 2024, which aligns with the ground truth. The dates and the core conclusion about dilutive impact are factually accurate, supporting a high quantitative accuracy score. However, the LLM fails to address the evolution of the disclosure language from 2022 to 2024, which is the central focus of the question. Specifically, it omits the key change in disclosure detail: in 2022, the filing explicitly mentioned that LTIP units were exchangeable for common stock, while the 2024 filing dropped this explanatory detail despite maintaining the same conclusion on dilution. This reduction in descriptive detail about the conversion mechanism is a critical qualitative shift that the LLM answer ignores. The response instead emphasizes consistency in the 'no material dilutive effect' statement and references net income adjustments, which, while contextually relevant, were not part of the original answer and do not capture the evolution in disclosure depth. Thus, while the factual core (no material dilution) is correct, the multi-hop reasoning required to compare disclosure content across years is incomplete and lacks synthesis of the changing level of detail. This results in a moderate correctness score. Contextual relevance is high because the answer discusses the right topic and timeframe, but the failure to capture the nuance of disclosure evolution limits its qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 411,
        "total_tokens": 1705
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has MetLife's approach to managing cash buffer needs in relation to stock repurchases evolved from 2022 to 2024, particularly in terms of remaining repurchase authorization and liquidity considerations?",
      "original_answer": "In 2022, MetLife had $1.5 billion remaining under its $3.0 billion common stock repurchase authorization as of December 31, 2021, indicating a significant but partially utilized capacity for returning capital to shareholders. By 2024, the company emphasized increased caution around cash buffer needs, noting that maintaining or increasing liquidity buffers could limit capital available for repurchases, acquisitions, and innovation. This reflects a shift from a more active repurchase posture in 2022 to a more conservative liquidity strategy in 2024, influenced by regulatory, market, and internal capital considerations.",
      "llm_answer": "From 2022 to 2024, MetLife’s approach to managing cash buffer needs in relation to stock repurchases shifted from a focus on maintaining a robust liquidity buffer to support ongoing repurchase authorizations to a more constrained posture driven by regulatory, capital, and market pressures. By 2024, the company emphasized that legal and regulatory restrictions, cash buffer requirements, and evolving capital considerations could preclude dividend payments or share repurchases, even as it maintained a $1.5 billion remaining authorization under its $3 billion program announced in August 2021. This evolution reflects a tighter alignment of repurchase activity with liquidity availability and heightened regulatory scrutiny, resulting in a reduced remaining authorization and a more cautious stance on returning capital to shareholders.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $1.5 billion remaining repurchase authorization under the $3.0 billion program as of the relevant period, and correctly references the August 2021 authorization. However, the original answer specifies that the $1.5 billion remaining was as of December 31, 2021, not 2022, and the LLM mischaracterizes the timeline by implying the same remaining amount was still valid in 2024 without confirming whether repurchases continued or were paused. The LLM incorrectly suggests the remaining authorization was reduced, while the original answer does not state a reduction—only a more cautious approach due to liquidity concerns. (2) Quantitatively, the $1.5 billion and $3.0 billion figures are accurate and properly contextualized, though the LLM implies a reduction in remaining authorization by 2024, which is not supported in the ground truth. Dates (August 2021) are correct, but the LLM does not clarify that the 2022 reference is based on prior-year authorization. (3) The multi-hop reasoning is partially sound: the LLM correctly synthesizes the link between liquidity buffers, regulatory considerations, and repurchase constraints across time. However, it overinfers a reduction in remaining authorization, whereas the original answer emphasizes a shift in tone and strategy, not a quantitative decrease. The evolution in tone—from active in 2022 to cautious in 2024—is correctly captured. (4) The contextual relevance is high, as the answer addresses cash buffer dynamics, repurchase policy, and external pressures. The qualitative accuracy is slightly lower due to the incorrect implication of a reduced authorization and stronger constraints than explicitly stated. Overall, core facts are correct, but minor inaccuracies in inference and timeline reduce the score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 494,
        "total_tokens": 1875
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How did Starbucks' foreign currency - other derivative asset and liability positions evolve from fiscal year 2022 to 2023, and what specific changes occurred in their balance sheet classifications?",
      "original_answer": "In fiscal year 2022, Starbucks reported foreign currency - other derivative assets of $103.9 million recognized in OCI before reclassifications and $22.0 million reclassified from AOCI to earnings. By fiscal year 2023, the foreign currency - other derivative assets on the balance sheet were reported as $1.9 million in prepaid expenses and other current assets and $1.7 million in other long-term assets as of October 1, 2023, while derivative liabilities were $4.7 million in accrued liabilities and $4.1 million in other long-term liabilities. This represents a significant reduction in asset positions compared to the prior year, with a shift in balance sheet classification.",
      "llm_answer": "From fiscal 2022 to 2023, Starbucks' foreign currency derivative positions shifted significantly in classification and scale. In 2022, foreign currency derivatives were primarily recorded as prepaid expenses and other current assets ($39.9M designated, $34.3M non-designated) and accrued liabilities ($0.3M designated, $5.8M non-designated), with minimal long-term asset/liability exposure. By 2023, the company reported substantially higher derivative assets in other long-term assets ($177.4M for designated cross-currency swaps, $1.7M for foreign currency - other) and derivative liabilities in other long-term liabilities ($33.3M for designated cross-currency swaps, $4.1M for foreign currency - other), while prepaid asset balances for foreign currency derivatives declined to $1.9M (designated) and $1.8M (non-designated). This evolution reflects a strategic shift toward longer-term hedge accounting classifications and increased use of other long-term liability positions for derivative obligations.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in fiscal year 2022, Starbucks reported foreign currency - other derivative assets of $103.9 million recognized in OCI before reclassifications and $22.0 million reclassified from AOCI to earnings — none of which is reflected in the LLM answer. Instead, the LLM incorrectly reports 2022 derivative assets as $39.9M and $34.3M in prepaid expenses and liabilities of $0.3M and $5.8M, which are not supported by the original answer and appear to conflate different derivative types (e.g., cross-currency swaps). In 2023, the LLM claims $177.4M in other long-term assets for designated cross-currency swaps, but the ground truth only reports $1.7M in other long-term assets for foreign currency - other derivatives — a massive discrepancy. The only correct numbers in the LLM answer are the 2023 foreign currency - other derivative asset of $1.7M in other long-term assets, $1.9M in prepaid expenses, and $4.1M in other long-term liabilities — but even these are embedded in a misleading context. (2) Quantitative accuracy is very low: multiple invented figures (e.g., $177.4M, $33.3M) and misattribution of cross-currency swap values to foreign currency - other derivatives. The original answer does not mention cross-currency swaps at all, so including them introduces false entities. (3) The multi-hop reasoning is flawed: the LLM fails to track the evolution from OCI/AOCI in 2022 to balance sheet classifications in 2023. Instead, it fabricates a narrative about a 'strategic shift toward longer-term hedge accounting' without evidence from the ground truth. The actual evolution is a sharp reduction in asset size and reclassification into specific balance sheet line items, not a broad shift in hedging strategy. (4) Contextual relevance is moderate because the answer discusses balance sheet classifications and changes over time, which aligns with the question, but the incorrect data and entities severely undermine usefulness. Correctness and quantitative accuracy are low due to pervasive factual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1434,
        "completion_tokens": 567,
        "total_tokens": 2001
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has Procter & Gamble's global cash management strategy evolved in relation to its restructuring activities and corporate-level financial performance between fiscal 2022 and fiscal 2024?",
      "original_answer": "In fiscal 2022, Procter & Gamble incurred restructuring costs within its historical range of $250 to $500 million before tax, with $147 million in restructuring accruals as of June 30, 2022. Corporate net earnings improved by $872 million to $485 million, partly due to tax benefits and lower restructuring charges. By fiscal 2024, restructuring costs increased significantly to $659 million before tax, including $216 million in non-cash foreign currency translation losses. Corporate net earnings decreased by $1.0 billion, largely due to the $1.4 billion impairment charge of the Gillette intangible asset and incremental restructuring charges. This indicates a shift toward more aggressive restructuring actions, particularly in Enterprise Markets like Nigeria, which impacted both cash flow and earnings. The global cash management strategy remained focused on liquidity and tax considerations, but faced increased pressure from these restructuring activities and impairment charges.",
      "llm_answer": "Between fiscal 2022 and fiscal 2024, Procter & Gamble’s global cash management strategy evolved in direct response to its restructuring activities and shifting corporate financial performance. As restructuring costs surged to $659 million in 2024—including a $216 million non‑cash foreign‑currency translation charge tied to the liquidation of operations in markets such as Nigeria—the company increasingly relied on cash generated from operations to fund these initiatives, while also drawing on its $8 billion credit facilities to preserve liquidity. This strategy supported the broader productivity‑saving agenda, even as corporate net earnings swung to a $1.4 billion loss in 2024 due to the Gillette intangible‑asset impairment and heightened restructuring charges. Consequently, adjusted free cash flow rose to $16.9 billion in 2024 (up 21 % YoY), reflecting stronger operating cash generation that now underpins both the restructuring program and ongoing shareholder returns.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly in key financial figures and outcomes. While it correctly identifies the $659 million restructuring costs in fiscal 2024 and the $216 million non-cash foreign currency translation loss, it introduces unsupported data such as a '21% YoY increase' in adjusted free cash flow to $16.9 billion, which is not present in the ground truth and cannot be verified from the provided information. Additionally, the claim that corporate net earnings swung to a '$1.4 billion loss' is incorrect: the ground truth states that corporate net earnings *decreased by $1.0 billion* due in part to the $1.4 billion Gillette impairment, but does not state that P&G reported an overall loss. This misrepresents the financial outcome. The mention of an '$8 billion credit facility' and 'cash generated from operations' as funding mechanisms is plausible but not supported by the original answer, introducing speculative details. (2) Quantitative accuracy is compromised: while $659 million (restructuring) and $216 million (FX loss) are correct, the $16.9 billion free cash flow and 21% increase are unverified. The $1.4 billion Gillette impairment is correctly cited, but misused to imply a net loss. The fiscal 2022 restructuring range ($250–$500 million) and $147 million accrual are omitted, reducing completeness. (3) The multi-hop reasoning is partially sound—linking increased restructuring to financial performance and cash management strategy—but overreaches by implying causality and strategic shifts (e.g., reliance on credit facilities) not present in the ground truth. The original answer notes increased pressure on cash management but does not specify changes in funding sources. (4) Contextual relevance is high, as the LLM addresses the evolution of cash management in relation to restructuring and performance. However, the inclusion of unverified metrics and misinterpretation of earnings trends reduces factual reliability. The core idea of increased restructuring impacting financials is correct, but execution lacks precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1503,
        "completion_tokens": 565,
        "total_tokens": 2068
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has NVIDIA's positioning and application of Omniverse evolved between 2022 and 2023, particularly in terms of its integration with enterprise solutions and simulation technologies?",
      "original_answer": "In 2022, NVIDIA Omniverse was positioned primarily as a virtual world simulation and collaboration platform for 3D workflows, emphasizing its availability as a software subscription for enterprise use and free for individuals. It was highlighted in use cases such as virtual car showrooms, surgical training, and architectural walkthroughs, and was integrated with DRIVE Sim software for automotive simulation and validation. By 2023, Omniverse had evolved into a more robust development platform and operating system for building virtual world simulation applications. It was increasingly tied to industrial enterprises for digitalizing complex physical assets and processes, including digital twins of factories and real-time 3D product configurators. Additionally, it was more explicitly linked to NVIDIA's accelerated computing infrastructure both on-premises and in the cloud, indicating a broader integration with enterprise-grade simulation and AI workflows.",
      "llm_answer": "Between 2022 and 2023, NVIDIA deepened Omniverse’s integration into enterprise workflows by embedding it within automotive simulation (DRIVE Sim) and expanding its role in industrial digital twins, enabling end‑to‑end testing, validation, and continuous over‑the‑air updates for autonomous‑driving stacks. The company also broadened Omniverse Enterprise as a subscription offering, positioning it as a core platform for building and operating metaverse‑style 3D applications across industries such as manufacturing, architecture, and automotive, thereby tightening its integration with enterprise solutions and simulation technologies.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of NVIDIA's Omniverse between 2022 and 2023. It correctly identifies the deepened integration with enterprise workflows, specifically mentioning DRIVE Sim for automotive simulation and the expansion into industrial digital twins—key points from the ground truth. The emphasis on Omniverse Enterprise as a subscription offering aligns with the original answer's note on enterprise software subscriptions. The LLM also accurately reflects the platform’s evolution into a development environment for 3D and metaverse-style applications across manufacturing, architecture, and automotive sectors. It correctly ties Omniverse to simulation technologies and enterprise solutions, including over-the-air updates and end-to-end validation, which are consistent with NVIDIA’s 2023 positioning. The only minor omission is the lack of explicit mention that Omniverse was free for individuals in 2022 and that it evolved into a more general 'operating system' for virtual world simulation, as well as the specific examples like surgical training or architectural walkthroughs. However, these are contextual details that do not undermine the core factual accuracy. There are no numerical values to assess, so quantitative accuracy is scored as 10 by default. The reasoning is sound, demonstrating multi-hop synthesis across time periods and use cases. The answer is fully contextually relevant and semantically equivalent in substance to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1409,
        "completion_tokens": 413,
        "total_tokens": 1823
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did AMT's financial commitments related to communications sites evolve from 2023 to 2024, particularly in terms of anticipated spending and future obligations?",
      "original_answer": "In 2023, AMT anticipated spending approximately $450 million related to data center assets as part of its construction plans for 2,500 to 3,500 communications sites globally. By 2024, the company disclosed a much larger financial commitment, with an estimated undiscounted future cash outlay of $4.5 billion for asset retirement obligations tied to leased sites hosting communications infrastructure. This indicates a significant increase in long-term financial exposure related to communications sites, shifting from near-term capital allocation planning in 2023 to a more mature and substantial obligation structure in 2024.",
      "llm_answer": "From the 2024 10‑K, AMT projects total 2024 capital expenditures of $1.5 billion–$1.65 billion, including roughly $450 million earmarked for data‑center assets and about $790 million–$820 million for discretionary tower‑construction projects.  The company expects to fund these outlays with operating cash flow, available liquidity under its credit facilities and proceeds from debt or equity issuances, while maintaining compliance with debt covenants and its REIT distribution requirements.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains some correct numbers—specifically the $450 million for data center assets, which matches the ground truth for 2023—but fails to address the key 2024 financial commitment of $4.5 billion in asset retirement obligations (ARO) for leased communications sites. Instead, it introduces unrelated capital expenditure ranges ($1.5B–$1.65B) and discretionary tower-construction spending ($790M–$820M), which are not mentioned in the original answer and shift focus away from the core question about evolving financial commitments related to communications sites. (2) Quantitatively, the $450 million figure is accurate and correctly attributed to data center assets, but the absence of the $4.5 billion ARO figure—a central element of the 2024 obligation—represents a major omission. No calculations are performed, but the failure to report this critical number undermines quantitative accuracy. (3) The reasoning is flawed: the question asks for a comparison between 2023 and 2024 commitments, particularly in terms of anticipated spending and future obligations. The LLM only discusses 2024 capital expenditures without referencing 2023 beyond the $450M (which was already known in 2023), and completely misses the multi-hop synthesis required—linking the shift from near-term construction plans to long-term liability via AROs. There is no mention of asset retirement obligations, leased sites, or the nature of the $4.5 billion undiscounted future cash outlay. (4) Contextual relevance is moderate because the answer discusses financial commitments related to communications infrastructure, but it misrepresents the type of obligation (capital expenditures vs. long-term liabilities) and omits the most significant development—the emergence of a large-scale, structured long-term liability in 2024. As such, while some context is correct, the core evolution in financial commitments is not captured, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 531,
        "total_tokens": 1814
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has ExxonMobil's characterization of asset divestitures in relation to strategic objectives evolved between 2023 and 2024, particularly in terms of the language used to describe the proceeds from these transactions?",
      "original_answer": "In 2023, ExxonMobil described proceeds from asset sales as part of 'sales of subsidiaries, property, plant and equipment, and sales and returns of investments,' emphasizing a disciplined review process to ensure assets align with strategic goals. By 2024, the company refined its language, referring more broadly to 'proceeds from asset sales and returns of investments,' maintaining the same strategic alignment rationale but streamlining the description. This evolution indicates a more consolidated framing of divestiture proceeds without specific mention of subsidiaries or equipment sales, suggesting a possible shift toward a more generalized narrative around asset management.",
      "llm_answer": "ExxonMobil's language regarding asset divestitures has shifted from emphasizing \"proceeds associated with sales of subsidiaries, property, plant and equipment\" in 2023 to explicitly linking divestment proceeds to strategic objectives in 2024, stating they are \"no longer meeting these objectives or are worth considerably more to others\" while maintaining the same non-GAAP cash flow disclosure framework. The 2024 filing continues to present divestment proceeds as part of \"Cash Flow from Operations and Asset Sales\" but now frames them as deliberate strategic actions within its capital allocation strategy.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is partially correct but contains key inaccuracies in the characterization of ExxonMobil's language evolution. (1) Correct elements: The shift in language from 2023 to 2024 is acknowledged, and the general idea of strategic alignment is maintained. The mention of non-GAAP cash flow framing and capital allocation context adds relevant detail. (2) Quantitative accuracy: There are no numerical values in the question or answer, so this aspect is not applicable; no errors in dates (2023 and 2024 correctly referenced). (3) Multi-hop reasoning: The model attempts to synthesize across years, but misrepresents the actual language used. The 2023 description in the LLM answer — 'proceeds associated with sales of subsidiaries, property, plant and equipment' — is close but not verbatim or fully aligned with the ground truth, which includes 'sales and returns of investments.' More critically, the 2024 quote stating divestitures involve assets that are 'no longer meeting these objectives or are worth considerably more to others' does not appear in the ground truth and appears fabricated or misattributed. The ground truth emphasizes a *streamlining* of language, not a new rationale. (4) The LLM introduces a stronger strategic justification in 2024 that isn't present in the original — suggesting a qualitative overreach. While the general direction of evolution (more strategic framing) is plausible, the specific language and reasoning do not match the ground truth. The consolidation of terminology in 2024 is misrepresented as a deeper strategic narrative rather than a simplification. Thus, while contextually relevant and factually plausible, the answer is not factually accurate in key aspects of entity and language representation, warranting a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 485,
        "total_tokens": 1827
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has Comcast's financial exposure to Universal Beijing Resort evolved from 2022 to 2023, based on the changes in consolidated asset and liability amounts?",
      "original_answer": "In 2022, Comcast's consolidated balance sheet included $9.7 billion in assets and $8.1 billion in liabilities related to Universal Beijing Resort. By 2023, these figures had decreased to $7.8 billion in assets and $7.2 billion in liabilities. This indicates a reduction in both the scale of assets and liabilities associated with the Universal Beijing Resort, suggesting either asset depreciation, debt repayment, or a strategic reduction in the resort's financial footprint within Comcast's consolidated statements.",
      "llm_answer": "From 2022 to 2023, Comcast’s consolidated exposure to Universal Beijing Resort shifted from $9.7 billion of assets and $8.1 billion of liabilities (reported on its 2022 balance sheet) to $7.8 billion of assets and $7.2 billion of liabilities on the 2023 balance sheet – a reduction of roughly $1.9 billion in assets and $0.9 billion in liabilities, reflecting the ongoing consolidation of the VIE and the repayment of its term‑loan debt.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly reports all financial figures: $9.7 billion in assets and $8.1 billion in liabilities for 2022, and $7.8 billion in assets and $7.2 billion in liabilities for 2023. The calculated reductions—$1.9 billion in assets ($9.7B - $7.8B) and $0.9 billion in liabilities ($8.1B - $7.2B)—are accurate. 2) Quantitative accuracy is perfect; all numbers match the ground truth, and the arithmetic is correct. Minor phrasing like 'roughly $1.9 billion' is acceptable given exact values are also provided. 3) The reasoning is sound: the answer identifies a reduction in exposure and correctly infers this may relate to VIE consolidation and term-loan repayment, which aligns with plausible financial explanations. While the original answer suggests 'asset depreciation, debt repayment, or strategic reduction,' the LLM adds slightly more specific context (VIE consolidation, term loan) that may be supported in the filings but not explicitly in the ground truth. This does not contradict, but adds interpretive detail. 4) The answer is fully relevant, directly addressing the evolution of financial exposure through asset and liability changes. Only reason for not scoring 10 is that the original answer's broader range of possible explanations (e.g., asset depreciation) is slightly narrower in the LLM version, but the core multi-hop synthesis across years and financial statements is accurate and complete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1241,
        "completion_tokens": 392,
        "total_tokens": 1633
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has the nature of Customer Demand Volatility as a risk factor for Caterpillar evolved between 2023 and 2024, particularly in relation to its impact on financial performance and supply chain stability?",
      "original_answer": "In 2023, Customer Demand Volatility was described as being primarily driven by economic uncertainties, including the lingering effects of a global pandemic, which led to inflationary pressures, supply chain disruptions, and labor inefficiencies, all of which limited Caterpillar's ability to meet customer demand. By 2024, while the risk remained, the focus shifted slightly to include broader commodity price changes, material price increases, and significant disruptions to supply chains or shortages of labor and material as key contributors to financial performance risks. This evolution indicates a broadening of the risk profile to include more systemic supply-side challenges alongside demand volatility.",
      "llm_answer": "The nature of Customer Demand Volatility has shifted from a general cyclical risk tied to macroeconomic conditions in 2023 to a more acute, multi‑dimensional exposure in 2024.  In the 2024 filing, Caterpillar emphasizes that sudden shifts in demand—driven by commodity price swings, infrastructure‑spending volatility, pandemic‑related uncertainty, and rapid changes in monetary policy—can quickly create excess inventories, strain supply‑chain capacity, and force costly production adjustments, directly threatening financial results and supply‑chain stability.  By contrast, the 2023 discussion framed demand volatility mainly as a cyclical, region‑specific economic risk, without highlighting the heightened, pandemic‑induced demand uncertainty and the added pressure of rapid policy‑driven interest‑rate changes that are now central to the 2024 risk narrative.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of Customer Demand Volatility as a risk factor for Caterpillar between 2023 and 2024. It accurately captures the shift from demand volatility driven by macroeconomic and regional cyclical factors in 2023 (e.g., pandemic aftereffects, inflation, supply chain issues) to a more complex, multi-dimensional risk in 2024 that includes commodity price swings, infrastructure spending volatility, and rapid monetary policy changes. The answer correctly identifies the impact on financial performance and supply chain stability in both years. There are no numeric values in the question or answers, so quantitative accuracy is scored as 10 by default. The qualitative accuracy is slightly reduced because the LLM introduces 'infrastructure-spending volatility' and 'rapid changes in monetary policy' as new 2024 elements not explicitly mentioned in the ground truth, which instead emphasizes 'material price increases' and 'shortages of labor and material' as emerging supply-side concerns. While these concepts are related, the LLM reframes the evolution more around demand-side policy shifts rather than the supply-side systemic challenges highlighted in the original. However, the overall reasoning is sound, multi-hop synthesis across years is appropriate, and the answer remains contextually highly relevant and factually consistent with the core evolution described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1408,
        "completion_tokens": 407,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did the fair value and valuation methodology of Net derivative assets (liabilities) evolve from 2022 to 2024?",
      "original_answer": "In 2022, the fair value of Net derivative assets (liabilities) was $19 million as of December 31, 2021, with changes in value primarily tied to derivative activity such as issuances ($68 million), settlements ($-37 million), and transfers ($6 million). By 2024, the fair value had increased significantly to $58 million as of December 31, 2023. Additionally, the valuation methodology shifted from being primarily based on realized and unrealized gains/losses reported in net income to being assessed using discounted cash flows with a focus on observable inputs like swap rates (3-5%, weighted average of 4%). This indicates both a material increase in value and a methodological shift toward more transparent and observable valuation techniques.",
      "llm_answer": "The fair‑value hierarchy and valuation methodology for net derivative assets (liabilities) remained consistent from 2022 through 2024, with the instruments classified as Level 3 and valued using discounted‑cash‑flow models that rely on observable market inputs (e.g., swap rates) and, when those are not available, unobservable inputs such as internal credit and liquidity adjustments. Quantitative disclosures show the fair‑value of net derivative assets (liabilities) was $69 million at year‑end 2024, $58 million at year‑end 2023, and $19 million at year‑end 2022, reflecting a modest increase in fair value over the three‑year period.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. While it correctly states the $19 million fair value at year-end 2022 (which corresponds to Dec 31, 2021 in the ground truth), it incorrectly reports $58 million at year-end 2023 as $58 million at year-end 2022, creating a misalignment in time periods. It introduces a new figure of $69 million at year-end 2024, which is not present in the original answer and contradicts the stated $58 million as of December 31, 2023. This suggests confusion or fabrication of data for 2024. (2) Quantitative accuracy is partially correct: $19M and $58M are present in the correct context but misassigned to years. The $69M figure has no support in the ground truth and is therefore incorrect. The original answer does not provide a 2024 value beyond Dec 31, 2023 ($58M), so projecting $69M for 2024 is unsupported. (3) The qualitative reasoning is flawed. The original answer emphasizes a methodological shift from realized/unrealized gains/losses in net income to discounted cash flows with observable inputs (swap rates 3–5%, weighted average 4%). In contrast, the LLM claims the methodology 'remained consistent' and that Level 3 classification and use of discounted cash flows were already in place in 2022, which directly contradicts the ground truth assertion of a shift. This failure to identify a key change in valuation approach represents a major error in multi-hop reasoning and synthesis. (4) Contextual relevance is high—the answer addresses fair value evolution and methodology—but the core factual and reasoning errors severely undermine correctness. The answer appears plausible but misrepresents both numbers and conceptual changes. Correctness score is 4 due to partial number accuracy but major errors in temporal alignment, fabricated data, and incorrect characterization of methodology evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 507,
        "total_tokens": 1845
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has NVIDIA's GeForce NOW cloud gaming offering evolved from 2022 to 2023 in terms of its positioning within the company's broader GPU and cloud platform ecosystem?",
      "original_answer": "In 2022, GeForce NOW was positioned as a cloud platform enabling gamers to access interactive graphics applications from nearly any device, emphasizing its role in extending NVIDIA’s graphics leadership and ecosystem reach. It was mentioned alongside other cloud platforms like vGPU for enterprise use. By 2023, GeForce NOW was more specifically integrated into the broader NVIDIA accelerated computing platform narrative, and its positioning shifted to emphasize cloud gaming as part of a suite of GPU-driven services, including AI training platforms like NVIDIA DGX Cloud. This evolution reflects a more strategic alignment of GeForce NOW with NVIDIA’s expanding cloud infrastructure and software offerings, particularly in the context of gaming as a service.",
      "llm_answer": "From 2022 to 2023, NVIDIA evolved GeForce NOW from a cloud‑gaming service into a core component of its broader GPU‑and‑cloud platform strategy.  The service now runs on the same accelerated‑computing stack that powers Data‑Center AI workloads—leveraging RTX GPUs, CUDA, and Omniverse‑based cloud infrastructure—allowing it to deliver AI‑enhanced features such as DLSS, ray‑traced streaming, and low‑latency remote play while sharing silicon, software tools, and developer ecosystems across gaming, professional visualization, and automotive markets.  This tighter integration positions GeForce NOW as the consumer‑facing edge of NVIDIA’s unified accelerated‑computing platform, extending its reach into cloud‑based gaming and interactive graphics.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution of GeForce NOW from a standalone cloud-gaming service in 2022 to a more strategically integrated component of NVIDIA’s broader GPU and cloud platform ecosystem in 2023. The emphasis on shared infrastructure (RTX GPUs, CUDA, Omniverse) and alignment with accelerated computing is consistent with the original answer’s point about integration into the NVIDIA accelerated computing platform. (2) There are no numeric values, dates, or financial figures in either answer, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the LLM synthesizes the shift in positioning by connecting GeForce NOW to data center AI workloads, DGX Cloud (implied via 'accelerated-computing stack'), and cross-market ecosystems (gaming, professional visualization, automotive), which reflects a correct understanding of NVIDIA’s strategic narrative. (4) The only minor gap is that the LLM answer does not explicitly mention vGPU or the 2022 comparison to enterprise cloud platforms, which was part of the original answer’s context. However, it effectively conveys the strategic repositioning and tighter integration with cloud infrastructure and software offerings. Wording differs but semantic meaning and factual content are substantially equivalent. Thus, the answer is excellent with only slight omission of a contextual detail, warranting a 9/10 on correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 418,
        "total_tokens": 1800
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did the revenue performance of Inlyta evolve between 2022 and 2023, and what factors influenced this change?",
      "original_answer": "In 2022, Inlyta had total global revenue of $1,003 million, while in 2023, its revenue increased to $1,036 million, representing a 3% growth. This growth was primarily driven by continued adoption of Inlyta in combination with immune checkpoint inhibitors for the first-line treatment of advanced renal cell carcinoma (RCC) in the U.S., and growth in emerging markets. However, this increase was partially offset by lower volumes and lower net prices in certain European markets.",
      "llm_answer": "Inlyta’s revenue grew modestly from 2022 to 2023, rising from $1,003 million to $1,036 million (a ~3% increase). This uptick was driven by continued adoption of Inlyta in combination regimens for advanced renal cell carcinoma in the U.S., partially offset by lower volumes and price pressures in certain international markets. The overall revenue increase was modest compared with the steep declines seen for other products such as Paxlovid and Comirnaty.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the revenue figures for Inlyta in 2022 ($1,003 million) and 2023 ($1,036 million), and accurately calculates the ~3% growth, matching the ground truth. All numeric values and time periods are correct. (2) Quantitative accuracy is perfect: the dollar amounts and percentage increase are factually accurate and consistent with the original answer. The calculation (1,036 - 1,003) / 1,003 ≈ 3.3% rounds appropriately to ~3%. (3) The reasoning is sound and captures the key drivers: continued U.S. adoption in combination therapies for advanced RCC and growth in emerging markets (implied in 'international markets'). It correctly notes offsetting factors—lower volumes and price pressures in international markets, aligning with the European market challenges in the ground truth. However, it does not explicitly mention 'emerging markets' as a positive contributor, which is a minor omission in qualitative completeness. Also, the reference to 'steep declines' in Paxlovid and Comirnaty, while contextually interesting, is extraneous and not asked in the question, slightly diluting focus. (4) The answer is highly accurate, complete in core aspects, and semantically equivalent to the ground truth. The minor lack of specificity around 'emerging markets' and the addition of irrelevant product comparisons prevent a perfect 10, but overall correctness is excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1225,
        "completion_tokens": 392,
        "total_tokens": 1617
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has the treatment and valuation of network location intangibles evolved from 2023 to 2024, particularly in terms of amortization assumptions and impairment review processes?",
      "original_answer": "In 2023, the company amortized network location intangibles on a straight-line basis over their estimated useful lives, with a weighted average amortization period of 15 years as of December 31, 2023. The focus was on the relationship between these intangibles and tower assets, particularly in terms of potential revenue growth from leasing excess capacity. By 2024, the company expanded its disclosures to include a more detailed impairment review process for network location intangibles, assessing impairment on an individual tower basis and identifying specific triggers such as lack of tenant leases or expenses exceeding revenues. Additionally, while amortization remained a key treatment, the company's broader discussion of asset retirement obligations in 2024, including a $470 million increase in liability due to revised settlement dates, indirectly impacts the valuation and useful life assumptions for these intangible assets.",
      "llm_answer": "From 2023 to 2024, the Company revised its estimated settlement dates for asset retirement obligations, extending them based on 20+ years of operating history and management’s intent. This change increased the asset retirement obligation liability by $470 million (with a corresponding adjustment to the related long‑lived tangible asset) and raised the estimated undiscounted future cash outlay by $875 million, while reducing accretion expense by an estimated $75 million for 2024. Additionally, the Company extended the useful lives of its tower assets (and related intangibles) from a shorter period to 30 years, which reduced depreciation and amortization expense by about $730 million ($649 million after tax) beginning January 1, 2024. These adjustments reflect updated assumptions in both impairment reviews and amortization periods for network location intangibles.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in key quantitative claims. While the $470 million increase in asset retirement obligation (ARO) liability aligns with the ground truth, the additional figures—$875 million increase in undiscounted cash outlay, $75 million reduction in accretion expense, and $730 million reduction in depreciation/amortization—are not supported by the original answer and appear fabricated or misattributed. The original answer does not mention any change in useful life from a shorter period to 30 years; it only states a 15-year weighted average amortization period in 2023 and does not specify a change in 2024. The LLM incorrectly asserts that useful lives were extended to 30 years, which is a major factual error. (2) The only correct number is the $470 million ARO increase, which matches the ground truth. All other financial figures lack support in the original data. The original answer does not provide any estimate of savings in depreciation or amortization, nor does it mention changes in accretion expense or undiscounted cash flows. (3) The multi-hop reasoning is partially sound in linking ARO changes to valuation assumptions for intangibles, as the original answer notes that revised settlement dates indirectly impact useful life assumptions. However, the LLM overreaches by asserting specific life extensions and financial impacts not present in the source. It also fails to mention the key 2024 enhancement in impairment review processes—specifically, assessing impairment on an individual tower basis and identifying triggers like lack of leases or negative cash flow—which is a major omission. (4) The contextual relevance is high because the answer addresses amortization assumptions and impairment-related valuation impacts. However, due to major quantitative inaccuracies and the introduction of unsupported financial figures and life extensions, the correctness and quantitative accuracy scores are low. The qualitative accuracy is moderate because the reasoning framework is plausible but based on incorrect data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1461,
        "completion_tokens": 566,
        "total_tokens": 2027
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has ExxonMobil's strategic emphasis on Guyana evolved between 2023 and 2024, particularly in terms of its upstream growth portfolio and production capacity?",
      "original_answer": "In 2023, ExxonMobil highlighted Guyana as a key component of its upstream growth portfolio, noting four additional discoveries on the Stabroek Block and the startup of the Prosperity FPSO vessel, which brought production to nearly 440 kbd in the fourth quarter. By 2024, Guyana was formally categorized under 'Advantaged Assets' within the updated earnings drivers, reflecting its strategic elevation alongside the Permian and LNG projects as a core contributor to earnings through volume/mix growth. This shift indicates a transition from a discovery and early production phase in 2023 to a more mature, financially impactful asset in 2024.",
      "llm_answer": "ExxonMobil's strategic emphasis on Guyana has intensified through 2023‑2024, with the company highlighting Guyana as a key driver of advantaged volume growth in its upstream earnings.  In the 2024 earnings release, Guyana’s production contributed positively to earnings, and the firm noted that “advantaged assets (including Guyana and the Permian) … increased earnings by $970 million” while also citing continued investment in new FPSO vessels and the upcoming Whiptail project to expand capacity through 2027.  This focus reflects a broader shift toward higher‑growth, lower‑cost resources, underscoring Guyana’s central role in ExxonMobil’s upstream growth portfolio and its ambition to boost production capacity.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the strategic elevation of Guyana correctly, noting its inclusion among 'advantaged assets' and its role in upstream growth, which aligns with the ground truth. However, it omits key 2023 specifics mentioned in the original answer—namely, the four additional discoveries on the Stabroek Block and the startup of the Prosperity FPSO that brought production to nearly 440 kbd in Q4 2023. These are important milestones that mark the transition from exploration to production. (2) The $970 million earnings increase attributed to advantaged assets (including Guyana and the Permian) is factually accurate and relevant, but the LLM presents it without specifying that this figure comes from the 2024 reporting period, potentially blurring the timeline. More critically, the LLM introduces the Whiptail project and FPSO expansion plans through 2027, which, while contextually plausible, are not mentioned in the ground truth and represent unverified forward-looking details not supported by the provided answer. This affects quantitative and factual precision. (3) The multi-hop reasoning is partially sound: the model correctly infers that Guyana’s strategic importance increased by being grouped with Permian and LNG as an advantaged asset driving earnings. However, it fails to contrast the 2023 phase (discovery and early production) with the 2024 shift to financial maturity, weakening the evolution narrative. (4) The contextual relevance is high, as the response directly addresses the strategic evolution and production capacity. Qualitative accuracy is good due to correct use of terminology and logical flow, but quantitative accuracy is reduced due to unsupported forward-looking project details and missing key 2023 metrics like the 440 kbd production figure. Hence, correctness is partially impacted—core facts are right, but key details are missing or added without basis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 519,
        "total_tokens": 1862
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has the X1 platform's integration with third-party streaming services evolved between 2022 and 2023, and what does this evolution indicate about Comcast's strategy in reducing cord-cutting and increasing average revenue per user (ARPU)?",
      "original_answer": "In 2022, the X1 platform integrated third-party streaming services such as Disney+ and Netflix, and provided access to Peacock's premium tier, with Comcast earning commission revenue from the sale of these services. By 2023, the X1 platform continued to support third-party integrations but now included Xumo Play, NBC, and Sky as part of the NOW TV service, which was specifically marketed to residential broadband customers. This expansion indicates a strategic pivot toward enhancing the value of broadband subscriptions and bundling streaming access to retain customers and potentially increase ARPU through deeper content integration and commission-generating partnerships.",
      "llm_answer": "Between 2022 and 2023, Comcast expanded the integration of its X1 platform with third‑party streaming services, adding direct access to Peacock, Disney+, Netflix and other DTC offerings through the Xumo Stream Box and X1 interface, while also launching the standalone NOW streaming service in the U.S. This evolution reflects a strategic shift to retain broadband subscribers, combat cord‑cutting, and boost ARPU by monetizing streaming partnerships and offering premium, ad‑supported content bundles that encourage customers to stay within the Comcast ecosystem.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of factual content and strategic interpretation. (1) It accurately captures the evolution of X1's integration with third-party streaming services between 2022 and 2023, mentioning key platforms like Disney+, Netflix, and Peacock, which were indeed integrated into X1 by 2022. The mention of Xumo (via Xumo Stream Box) and NOW TV (as a standalone U.S. service) in 2023 is consistent with the expansion described in the original answer. (2) There are no numeric values, dates, or financial figures in dispute; thus, quantitative accuracy is perfect. (3) The multi-hop reasoning is sound: the LLM correctly infers that deeper integration of third-party and owned streaming services (including ad-supported and commission-generating models) reflects a strategy to reduce cord-cutting and increase ARPU. However, the LLM omits specific details about commission revenue from third-party service sales and the inclusion of NBC and Sky within NOW TV, which were present in the original answer and add nuance to the bundling strategy. Also, while Xumo Play and the Xumo Stream Box are related, the LLM slightly conflates them without clarifying that Xumo Play was integrated into the broader X1/NOW ecosystem. (4) Despite these minor omissions, the core strategic implication—bundling content to retain broadband customers and monetize through partnerships—is correctly interpreted. The answer is highly relevant and conveys semantically equivalent conclusions, warranting a high correctness score with a small deduction for incomplete entity specificity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 443,
        "total_tokens": 1777
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has Caterpillar's relationship with FG Wilson evolved between 2023 and 2024 in terms of its distribution network coverage for electric power generation systems?",
      "original_answer": "In 2023, FG Wilson's electric power generation systems were distributed through a network of 110 distributors covering 109 countries. By 2024, this distribution network had slightly contracted to 108 distributors, now covering 158 countries. This indicates a minor reduction in the number of distributors but an expansion in the geographic reach of the network. The change suggests a strategic shift toward optimizing distributor efficiency while broadening market access.",
      "llm_answer": "Based on the provided 10-K filings, Caterpillar's relationship with FG Wilson has evolved in its distribution network coverage for electric power generation systems as follows:  \n\nIn the 2023 filing (page 63), Caterpillar states it sells FG Wilson-branded electric power generation systems through a worldwide network of **110 distributors covering 109 countries**. By the 2024 filing (page 65), this coverage is updated to **108 distributors covering 158 countries**, indicating a strategic expansion of the distributor network while slightly reducing the number of countries served (from 109 to 158). This reflects an evolution in geographic focus and network scale, though the core distribution model via third-party distributors remains consistent.  \n\n(Word count: 98)",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly identifies the key numbers from the ground truth: 110 distributors in 2023 covering 109 countries, and 108 distributors in 2024 covering 158 countries. However, there is a critical error in interpretation: the LLM states that the number of countries served decreased 'from 109 to 158', which is factually incorrect — 158 is an increase from 109, not a decrease. This misstatement undermines the quantitative accuracy and reasoning. The correct interpretation, as in the original answer, is that geographic reach expanded from 109 to 158 countries despite a slight reduction in distributor count. The reasoning about a strategic shift toward efficiency and broader market access is partially present but misrepresented due to the directional error in country count. Entity accuracy (Caterpillar, FG Wilson, years, metrics) and contextual relevance are fully correct. The answer is based on accurate source data and addresses the evolution in distribution network coverage, but the flawed comparison reduces overall correctness. Semantic equivalence fails on the country count trend, which is central to the conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 321,
        "total_tokens": 1637
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How did Capital One's exposure to securitized debt obligations change between 2022 and 2024, particularly in terms of the carrying value and fair value of these obligations?",
      "original_answer": "In 2022, Capital One reported that the assets and liabilities of consolidated VIEs, including securitized debt obligations, were primarily composed of loan receivables and debt securities issued by the VIEs, with the liabilities reported under 'securitized debt obligations' on the consolidated balance sheets. By 2024, the carrying value of 'Securitized debt obligations' was $18,043 million, with a fair value of $18,067 million, all categorized under Level 2 of the fair value hierarchy. This indicates that Capital One maintained a significant exposure to securitized debt obligations, with a slight increase in fair value relative to carrying value, suggesting stable valuation and continued involvement in securitization activities.",
      "llm_answer": "Based on the provided SEC 10‑K pages, Capital One’s exposure to securitized debt obligations remained essentially unchanged between 2022 and 2024. The carrying amount of securitized debt (shown as “Securitized debt obligations” in the fair‑value tables) was $18.0 billion as of 12/31/2023 and $14.3 billion as of 12/31/2024, while the corresponding fair values were $18.1 billion and $14.3 billion respectively—indicating a modest decline in both carrying and fair‑value amounts over the two‑year period.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors in both numbers and trends. The ground truth states that in 2024, the carrying value of securitized debt obligations was $18,043 million ($18.043 billion) and fair value was $18,067 million ($18.067 billion), both increasing slightly from 2022 levels. However, the LLM incorrectly reports a drop to $14.3 billion in 2024, which contradicts the truth. Additionally, the LLM cites data for 2023 and 2024, but the question asks about changes between 2022 and 2024—yet no 2022 data is provided in the LLM response. (2) The quantitative inaccuracies are severe: the LLM claims a decrease to $14.3 billion in 2024, which is factually wrong (correct value is ~$18.04 billion), and misrepresents the trend as declining when it is actually stable/increasing slightly. The fair value is also incorrectly reported as $14.3 billion in 2024 instead of $18.067 billion. (3) The reasoning is flawed—despite referencing fair value hierarchy and balance sheet items, the LLM fails to correctly extract or synthesize the actual values from the knowledge base. It incorrectly infers a 'modest decline' when the ground truth indicates stable valuation with slight increase in fair value over carrying value. (4) Contextual relevance is moderate because the answer addresses securitized debt obligations and distinguishes carrying vs fair value, but the incorrect figures and misstated trend undermine the response. The answer also omits key context about VIEs and Level 2 classification mentioned in the original. Thus, while the structure and intent are relevant, factual correctness is poor.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 448,
        "total_tokens": 1765
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has McDonald's use of line of credit agreements evolved between 2023 and 2024 in relation to its financing activities and cash flow management?",
      "original_answer": "In 2023, McDonald's cash used for financing activities totaled $4.4 billion, a decrease of $2.2 billion compared to 2022, primarily due to increased bond issuances. The company's cash and equivalents balance was $4.6 billion at the end of 2023, reflecting sufficient liquidity supported by cash from operations and access to commercial paper borrowings and line of credit agreements. In 2024, cash used for financing activities increased to $7.5 billion, a rise of $3.1 billion compared to 2023, driven by decreased bond issuances. The company's cash and equivalents balance dropped to $1.1 billion at year-end 2024, with the prior year's higher balance attributed to the timing of debt issuances that funded 2024's required cash outflows. The company continued to rely on its line of credit agreements and commercial paper to meet short-term funding needs. This indicates a shift from surplus liquidity and bond financing in 2023 to a more cash-constrained environment in 2024, with greater reliance on existing credit facilities.",
      "llm_answer": "The Company’s line of credit agreements remained unchanged in structure and capacity between 2023 and 2024, continuing to provide up to $4 billion of committed borrowing under the existing facility. However, the company terminated its prior $15 billion borrowing authority in December 2024 and replaced it with a new $15 billion facility effective January 1 2025, reflecting a shift in financing strategy but preserving the overall credit capacity for future debt issuance. This evolution supports ongoing cash‑flow management by maintaining ample liquidity for capital expenditures, share repurchases, and dividend payments.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and fails to align with the ground truth in key areas. (1) Quantitative Accuracy: The claim that McDonald's had a $4 billion committed borrowing facility and a $15 billion borrowing authority replaced in December 2024 is not supported by the original answer, which does not mention specific line of credit amounts or facility changes. The original answer focuses on cash flow trends and liquidity management, not structural changes to credit facilities. The termination of a $15 billion facility and replacement in January 2025 is entirely absent from the ground truth and appears fabricated. (2) Completeness: The LLM answer does not address the core evolution in financing activities and cash flow management between 2023 and 2024 as described in the original answer—specifically, the shift from $4.4 billion to $7.5 billion in cash used for financing activities, the drop in cash and equivalents from $4.6 billion to $1.1 billion, and the explanation tied to bond issuance timing. These critical data points are omitted. (3) Entity Accuracy: While the company (McDonald's) and years (2023–2024) are correct, the financial metrics referenced (e.g., $4B, $15B facilities) are not present in the ground truth and contradict the focus on actual cash flows and liquidity trends. (4) Reasoning: The multi-hop synthesis is flawed. The original answer infers increased reliance on credit facilities due to reduced cash balances and lower bond issuance, not due to facility renewals. The LLM instead invents a structural change in credit facilities, misrepresenting the evolution. (5) Semantic Equivalence: The LLM answer discusses credit capacity preservation but misses the key narrative of declining liquidity and changing financing dynamics. It introduces irrelevant details about facility renewals not in the source, while omitting the actual cash flow and financing activity data that define the evolution. The answer is contextually relevant to financing and credit use but factually divergent and incomplete on the actual evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1414,
        "completion_tokens": 558,
        "total_tokens": 1973
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has the role of the Worldwide Business Conduct Manual in reinforcing internal controls evolved between 2022 and 2024, and what does this indicate about Procter & Gamble's approach to governance?",
      "original_answer": "In 2022, the Worldwide Business Conduct Manual was described as reinforcing the company's commitment to conducting business with integrity and within the letter and spirit of the law, emphasizing its role in supporting internal controls through policies, segregation of duties, and employee development. In 2024, while the core description remained similar, the manual was more specifically tied to governance frameworks such as the oversight activities of the Global Leadership Council and the responsibilities of the Disclosure Committee in evaluating significant business activities. This indicates a shift toward emphasizing structured governance mechanisms alongside ethical conduct, suggesting a more integrated approach to internal control over time.",
      "llm_answer": "The Worldwide Business Conduct Manual has become a more central element of Procter & Gamble’s governance framework between 2022 and 2024, explicitly cited as the mechanism that reinforces a “commitment to conduct business with integrity and within both the letter and the spirit of the law” and as a key component of the company’s internal‑control structure.  In the 2022 filing the Manual was described as part of the broader control environment that supports effective oversight, while the 2024 filing expands this language to show that management assessed the effectiveness of controls over indefinite‑lived intangible assets—including the Gillette brand—by testing the very controls that govern forecasts, royalty rates and discount rates, underscoring a deeper integration of the Manual into the company’s risk‑and‑control monitoring processes.  This evolution signals that P&G is tightening governance around critical judgments and ensuring that ethical and compliance standards are embedded in the processes that drive its financial reporting and internal‑control assessments.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the evolving role of the Worldwide Business Conduct Manual between 2022 and 2024 and generally aligns with the direction of increased integration into governance. However, it introduces specific details not present in the ground truth, particularly regarding the assessment of controls over indefinite-lived intangible assets, including the Gillette brand, and the testing of forecasts, royalty rates, and discount rates. These specifics are not mentioned in the original answer and appear to be fabricated or hallucinated, undermining factual accuracy. (2) There are no numeric values, dates, or calculations in either the original or LLM answer, so quantitative accuracy is not compromised—score reflects no errors in this dimension. (3) The multi-hop reasoning is partially sound: the LLM correctly infers a trend toward tighter governance and deeper integration of the Manual into control processes. However, it fails to mention the key entities highlighted in the ground truth—namely the Global Leadership Council and the Disclosure Committee—which are central to the 2024 evolution. Instead, it substitutes unverified details about intangible asset controls, indicating a failure in entity accuracy and synthesis from the correct sources. (4) The answer is contextually relevant and addresses the question’s intent about governance evolution, but the inclusion of unsupported specifics reduces qualitative accuracy significantly. While the overall direction of the conclusion (tighter governance, deeper integration) is plausible, the lack of fidelity to the actual documented changes limits correctness. Hence, a score of 6 reflects partial correctness with significant factual deviations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1473,
        "completion_tokens": 475,
        "total_tokens": 1948
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Exxon's strategic positioning in Guyana evolved between 2023 and 2024, as reflected in its long-lived asset disclosures and earnings driver definitions?",
      "original_answer": "In 2023, Exxon disclosed $9,689 million in long-lived assets in Guyana, indicating it was already a significant contributor among non-U.S. assets. By 2024, Guyana was explicitly named as part of Exxon's 'Advantaged Assets' under the new 'Advantaged Volume Growth' earnings driver, which includes key growth projects like Guyana and LNG. This evolution shows that Guyana transitioned from being a quantitatively notable asset in 2023 to a strategically emphasized growth engine in 2024.",
      "llm_answer": "ExxonMobil's strategic positioning in Guyana has evolved significantly between 2023 and 2024, as reflected in its long-lived asset disclosures and earnings driver definitions. In the 2023 10-K (page 116), Guyana's long-lived assets increased from $6,766 million to $9,689 million, underscoring its growing strategic importance as a key non-U.S. asset base. By 2024, Guyana emerged as a critical earnings driver under the \"Advantaged Volume Growth\" category, specifically highlighted in the 2024 earnings driver definitions (page 37) as encompassing \"Guyana and LNG\" within advantaged assets, reflecting its role in high-value, low-emission growth projects that contribute to upstream earnings and structural cost savings. This shift is further validated by the 2024 earnings breakdown (page 35), where Guyana's asset base and production growth directly support the company's focus on advantaged volume growth as a core earnings driver.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the evolution in Exxon's strategic positioning of Guyana from 2023 to 2024, noting the increase in long-lived assets and the inclusion of Guyana in the 'Advantaged Volume Growth' earnings driver in 2024. However, the original answer states that the 2023 long-lived assets in Guyana were $9,689 million, while the LLM claims they increased from $6,766 million to $9,689 million in 2023 — this implies both figures are from 2023, which is incorrect. The ground truth does not provide a prior-year value or confirm a within-year increase; thus, the $6,766 million figure is unsupported and introduces a factual error. (2) The $9,689 million figure for 2023 is accurate and matches the ground truth. However, the additional number ($6,766 million) is not present in the original answer and cannot be verified from the provided context, making the quantitative comparison invalid. No calculation is required in the original answer, but the LLM introduces an unsupported delta. (3) The multi-hop reasoning is largely sound: the LLM connects asset disclosures in 2023 with strategic categorization in 2024 earnings drivers, correctly identifying Guyana’s elevated strategic role. It appropriately references the shift from being a quantitatively significant asset to a named component of advantaged growth. (4) Despite the incorrect introduction of a prior-year asset value, the core qualitative insight — that Guyana became more strategically emphasized in 2024 — is correct and well-supported. The contextual relevance is perfect, as all parts of the question are addressed with appropriate framing. The correctness score is reduced due to the significant quantitative inaccuracy, though the main conclusion remains aligned with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 485,
        "total_tokens": 1843
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Capital One's reliance on securitized debt obligations as a funding source evolved from 2022 to 2024, based on the disclosed figures and descriptions?",
      "original_answer": "In 2022, Capital One identified securitized debt obligations as part of its diversified funding mix, which also included deposits, senior and subordinated notes, federal funds purchased, and FHLB advances. While no specific dollar value was disclosed in 2022, the company emphasized the strategic importance of securitized debt obligations in maintaining access to wholesale funding. By 2024, Capital One disclosed that its securitized debt obligations had a carrying value of $14,264 million and an estimated fair value of $14,335 million. This represents a concrete quantification of the instrument's role in the company's capital structure, showing an increased transparency and continued use of this funding source.",
      "llm_answer": "Capital One’s reliance on securitized debt has declined modestly over the two‑year span.  In the 2022 filing the company disclosed shelf registrations that could support up to $25 billion of credit‑card securitizations and $20 billion of auto‑loan securitizations, and it reported $6.3 billion of new securitized‑debt issuances for 2021.  By the 2024 filing the same shelf capacity remains in place, but total outstanding securitized‑debt balances have fallen to roughly $14 billion (down from about $18 billion in 2021) and net issuances of securitized obligations dropped to $6.3 billion in 2021 and $1.3 billion in 2022, indicating a reduced dependence on that funding source.  Consequently, the proportion of funding derived from securitized debt has contracted, with the company increasingly leaning on deposits, FHLB advances and other wholesale sources.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that no specific dollar value for securitized debt obligations was disclosed in 2022, but the LLM claims $18 billion in 2021 and $14 billion outstanding in 2024, which contradicts the ground truth that only discloses a 2024 carrying value of $14,264 million (i.e., $14.264 billion). While the 2024 figure is close in magnitude, the LLM incorrectly frames it as a decline from prior years without support in the original answer. More critically, the original answer does not mention any reduction in securitized debt or net issuances of $6.3 billion in 2021 and $1.3 billion in 2022—these figures are entirely fabricated. The shelf registration amounts ($25 billion for credit card, $20 billion for auto) are not mentioned in the ground truth and thus unverified. (2) The quantitative inaccuracies are severe: the LLM invents specific issuance volumes and outstanding balances for 2021 and 2022 that are not present in the ground truth. The only verifiable number is the 2024 carrying value (~$14.3 billion), which the LLM approximates as $14 billion—this is the only partially correct numeric reference. (3) The multi-hop reasoning is flawed. The original answer emphasizes increased transparency and continued use of securitized debt, not declining reliance. The LLM incorrectly infers reduced dependence based on invented data, contradicting the ground truth’s narrative of sustained strategic importance and enhanced disclosure. There is no evidence in the original answer of a shift toward deposits or other sources at the expense of securitization. (4) The contextual relevance is moderate because the answer addresses the topic of securitized debt evolution and funding mix, but the conclusions are factually incorrect and based on non-existent data. Due to major factual and quantitative errors, the correctness score is low at 2, with similarly low scores for quantitative and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1397,
        "completion_tokens": 539,
        "total_tokens": 1937
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has NVIDIA's Omniverse platform evolved in terms of its positioning and enterprise adoption between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, Omniverse was described as 'real-time 3D design collaboration and virtual world simulation software' aimed at empowering creators to collaborate across leading design applications. By fiscal year 2023, Omniverse had evolved into a more robust enterprise-focused development platform and operating system for building virtual world simulation applications. It was made available as a software subscription for enterprise use and offered free for individual users, with industrial enterprises adopting its 3D and simulation technologies to digitalize complex physical assets and environments, including digital twins of factories and real-time 3D product configurators. This indicates a strategic shift from a creative collaboration tool to a broader enterprise simulation and digital twin platform.",
      "llm_answer": "Between fiscal years 2022 and 2023, NVIDIA’s Omniverse platform shifted from a primarily developer‑focused 3D‑design and simulation tool to a broader enterprise‑grade collaboration and metaverse platform, highlighted by its inclusion in the “Graphics” segment’s revenue mix and expanded licensing (subscription for enterprises, free tier for individuals).  This repositioning was paired with a noticeable uptick in enterprise adoption—driven by automotive, industrial and design partners leveraging Omniverse for digital twins, autonomous‑vehicle simulation (e.g., DRIVE Sim) and real‑time 3D workflows—reflecting a strategic move to monetize Omniverse as a core growth engine alongside AI and data‑center offerings.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution of Omniverse from a 3D design and simulation tool in FY2022 to a broader enterprise platform in FY2023, noting the shift in positioning and increased enterprise adoption. The mention of subscription licensing for enterprises and a free tier for individuals matches the original answer. (2) There are no numeric values, dates, or calculations in the question or answers that conflict—both refer to fiscal years 2022 and 2023 correctly, and no incorrect figures are introduced. (3) The multi-hop reasoning is sound: the LLM synthesizes information about repositioning, licensing model changes, and enterprise use cases (digital twins, real-time 3D, simulation) across industries like automotive and industrial, which is consistent with the ground truth. It also correctly links Omniverse to the Graphics segment and positions it as a growth engine alongside AI, which reflects strategic context. (4) Minor deduction in qualitative accuracy because the original answer emphasizes Omniverse evolving into an 'operating system for building virtual world simulation applications,' a nuance not explicitly captured in the LLM response. Also, the LLM mentions 'metaverse platform' and 'DRIVE Sim'—while plausible and contextually relevant—these specific terms are not in the ground truth and slightly extend beyond the provided information. However, these do not constitute factual errors but represent interpretive additions. Overall, the answer is factually correct, comprehensive, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 441,
        "total_tokens": 1820
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Pfizer's financial relationship with Viatris evolved between 2022 and 2023, particularly in terms of net amounts due under their various agreements?",
      "original_answer": "In 2022, the net amounts due to Viatris under the agreements were $94 million as of December 31, 2022. By 2023, this amount had decreased to $33 million as of December 31, 2023. This indicates a significant reduction in the net financial obligations between the two companies over the period, suggesting a winding down or stabilization of transitional financial arrangements established post-separation.",
      "llm_answer": "Based on the provided SEC 10-K filing pages, Pfizer's financial relationship with Viatris has evolved such that net amounts due to Viatris under their post-separation agreements decreased significantly from $94 million as of December 31, 2022 to $33 million as of December 31, 2023. This reduction reflects the completion of transitional services and the settlement of outstanding obligations following the 2020 spin-off of the Upjohn Business to form Viatris.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, the dollar amounts ($94 million as of December 31, 2022, and $33 million as of December 31, 2023) and dates are correct, with no calculation or formatting issues. (2) The answer is complete, addressing the evolution of Pfizer's financial relationship with Viatris through the net amounts due, which is the core of the question. (3) Entities—Pfizer, Viatris, post-separation agreements—are correctly identified, and the reference to the 2020 spin-off of the Upjohn Business provides accurate context, even though not explicitly required. (4) The reasoning is sound: the decrease from $94M to $33M is correctly interpreted as a significant reduction, and the explanation about completion of transitional services and settlement of obligations is a reasonable qualitative inference consistent with the winding-down implication in the original answer. The only minor difference is that the original emphasizes 'winding down or stabilization of transitional financial arrangements,' while the LLM leans slightly more toward completion and settlement—still a valid interpretation. No factual inaccuracies; wording differences are semantically equivalent. All criteria for high scores are met, with a 9 in correctness due to slight variation in emphasis but no material error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1218,
        "completion_tokens": 377,
        "total_tokens": 1596
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has ExxonMobil's strategic emphasis on Guyana evolved between 2023 and 2024, and what specific changes in project activity or classification reflect this evolution?",
      "original_answer": "In 2023, ExxonMobil's operations in Guyana were characterized by active exploration and development, with 12.6 net exploratory and development wells completed, and key projects such as Payara, Yellowtail, and Uaru underway. By 2024, Guyana was formally classified as part of ExxonMobil's 'Advantaged Assets' under the 'Advantaged Volume Growth' earnings driver, signaling a strategic elevation of its importance alongside the Permian Basin and LNG. This reclassification reflects a shift from operational reporting to strategic prioritization, indicating increased emphasis on Guyana as a core growth asset.",
      "llm_answer": "ExxonMobil's strategic emphasis on Guyana has intensified through increased investment and project development. In 2024, the company added $109.3 billion to property, plant and equipment (up from $29.0 billion in 2023), reflecting accelerated development of Guyana's offshore resources, particularly the Payara and Yellowtail projects. This expansion aligns with Guyana's growing role as a key growth area, as evidenced by 12.6 net exploratory and development wells completed in Guyana during 2023 and the continued advancement of the Uaru project funding. The company's focus on Guyana's \"advantaged assets\" (including Guyana and LNG) is further highlighted in its earnings driver definitions, underscoring its strategic priority.",
      "correctness_score": 4,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in quantitative data. It claims ExxonMobil added $109.3 billion to property, plant, and equipment in 2024, up from $29.0 billion in 2023. These figures are incorrect and not supported by the ground truth; no such numbers appear in the original answer or typical SEC filings for ExxonMobil. The $109.3B and $29.0B figures are implausibly large for annual PPE additions and represent a major factual error. (2) The only correct number is '12.6 net exploratory and development wells completed in Guyana during 2023,' which matches the ground truth. However, the LLM misattributes this as if it were a 2024 figure or ongoing trend, when it is specifically a 2023 metric. (3) The qualitative reasoning partially captures the strategic shift by referencing Guyana as part of 'advantaged assets' and linking it to earnings drivers, which aligns with the 2024 reclassification in the original answer. Mention of Payara, Yellowtail, and Uaru projects is accurate and reflects continuity in project activity. However, the LLM fails to clearly articulate the key evolution: the formal reclassification of Guyana into the 'Advantaged Assets' category under 'Advantaged Volume Growth' in 2024—a central point in the ground truth. Instead, it vaguely references 'advantaged assets' without specifying the strategic repositioning. (4) Contextually, the answer addresses the question's focus on strategic evolution and project activity, so relevance is high. However, due to severe quantitative inaccuracies and incomplete/misrepresented reasoning about the strategic shift, the overall correctness is low. The answer fabricates financial data and misrepresents timing, undermining trust in its conclusions despite some correct entity and project references.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 495,
        "total_tokens": 1835
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did the weighted-average interest rate and face value of senior notes with maturities greater than 10 years evolve from 2022 to 2023?",
      "original_answer": "In 2022, the weighted-average interest rate for senior notes with maturities greater than 10 years was 3.67%, with a face value of $54.536 billion. In 2023, the interest rate remained unchanged at 3.8%, but the face value slightly decreased to $53.4 billion. This indicates a slight reduction in long-term debt in this category, while the interest rate stayed stable.",
      "llm_answer": "The weighted‑average interest rate on senior notes with maturities > 10 years fell from **3.67 % in 2022 to 3.8 % in 2023**, while the aggregate face value of those notes remained essentially unchanged at **≈ $54.5 billion** (2022) versus **≈ $53.4 billion** (2023).",
      "correctness_score": 4,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors in both the interest rate trend and face value interpretation. It incorrectly states that the weighted-average interest rate 'fell from 3.67% in 2022 to 3.8% in 2023', which is logically and numerically incorrect—3.8% is higher than 3.67%, so this would be an increase, not a decrease. Moreover, the original answer states the 2023 rate remained 'unchanged at 3.8%', but the 2022 rate was 3.67%, so there is a contradiction in the ground truth interpretation. However, upon verification, if the ground truth says the rate was 3.67% in 2022 and 3.8% in 2023, then the rate increased, not stayed the same. This suggests a possible error in the original answer’s narrative, but the LLM still misrepresents the direction of change. (2) For face value, the LLM says it 'remained essentially unchanged' despite correctly reporting $54.5B (approx) in 2022 and $53.4B in 2023—a $1.136 billion decrease. While the numbers are close to correct (rounding acceptable), characterizing this as 'essentially unchanged' contradicts the original answer’s 'slightly decreased' and misrepresents the trend. (3) The multi-hop reasoning is partially sound—LLM retrieves data for two years and compares them—but the synthesis is flawed due to incorrect directional interpretation of the interest rate change and downplaying the face value reduction. (4) Scores reflect major quantitative inaccuracies in interpreting changes over time, despite mostly correct raw numbers; qualitative reasoning is weakened by incorrect trend characterization; contextual relevance is high as all required elements are addressed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1156,
        "completion_tokens": 452,
        "total_tokens": 1608
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did the nuclear decommissioning trusts managed by Alabama Power and Georgia Power shift their domestic equity investment allocations and valuation methodologies between 2023 and 2024, particularly in terms of Level 1 and Level 2 input classifications?",
      "original_answer": "In 2023, Alabama Power reported $396 million in domestic equity investments under Level 1 inputs and $169 million under Level 2 inputs, totaling $565 million. Georgia Power reported $255 million in Level 1 and $1 million in Level 2, totaling $256 million. By 2024, Alabama Power’s domestic equity investments increased to $443 million in Level 1 and $208 million in Level 2, totaling $651 million. Georgia Power saw its Level 1 domestic equity investments rise to $321 million while Level 2 remained at $1 million, totaling $322 million. This indicates a strategic shift toward higher allocations in domestic equities, particularly through more actively traded (Level 1) instruments, which may reflect a more transparent or liquid investment approach in line with evolving trust management strategies.",
      "llm_answer": "Between 2023 and 2024, Alabama Power and Georgia Power shifted their domestic equity investments within nuclear decommissioning trusts from Level 2 (observable inputs) to Level 3 (unobservable inputs) in valuation hierarchy. In 2023, Alabama Power's domestic equity was classified as Level 2 ($443M) with a Level 3 component of $208M, but by 2024 it moved to Level 3 ($208M) with no Level 2 classification. Georgia Power's domestic equity remained Level 2 ($321M) in 2023 but was reclassified to Level 3 ($1M) in 2024, reflecting a strategic shift toward less observable valuation inputs for these private market investments. This reclassification aligns with the trusts' use of net asset value as a practical expedient for private equity and real estate holdings, which lack observable market prices.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is almost entirely incorrect. (1) It falsely claims a shift from Level 2 to Level 3 inputs, but the ground truth shows no mention of Level 3 inputs at all—both companies report only Level 1 and Level 2 classifications. The LLM incorrectly introduces Level 3 and misattributes values to it (e.g., claiming Alabama Power had $443M in Level 2 in 2023, when that was actually its 2024 Level 1 value). (2) Quantitative accuracy is severely flawed: for example, Alabama Power’s 2023 Level 1 was $396M and Level 2 was $169M (total $565M), but LLM states $443M in Level 2—confusing the year, level, and amount. Similarly, Georgia Power’s Level 2 remained $1M in both years, but LLM claims $321M in Level 2 in 2023 and $1M in Level 3 in 2024, which misrepresents both the magnitude and classification. (3) The reasoning is unsound: the multi-hop synthesis fails completely—no correct comparison across years or entities is made, and the conclusion about a shift to Level 3 is fabricated. (4) Contextual relevance is low because the answer discusses valuation methodologies involving Level 3 and net asset value as a practical expedient, which are not supported by the original data. The actual trend was increased allocation to domestic equities, especially Level 1 (more liquid, observable), contrary to the LLM’s claim of a move toward less observable inputs. Overall, the answer inverts the actual trend and fabricates key details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1427,
        "completion_tokens": 396,
        "total_tokens": 1823
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has NVIDIA's strategic positioning of CUDA evolved from 2022 to 2023 in terms of its role within the company's full-stack computing platform and its integration across different end markets?",
      "original_answer": "In 2022, CUDA was positioned as a fundamental building block of NVIDIA's accelerated computing platform, supporting a variety of end markets such as Gaming, Data Center, Professional Visualization, and Automotive through a unified underlying architecture. It was described as essential for leveraging GPU capabilities across these markets. By 2023, CUDA's role had evolved into being the foundational programming model within NVIDIA's full-stack computing infrastructure, extending its integration beyond traditional markets into domain-specific verticals such as healthcare, telecom, automotive, and manufacturing. Additionally, in 2023, CUDA was positioned as the base layer supporting hundreds of domain-specific software libraries, SDKs, and APIs, which were not explicitly emphasized in 2022. This indicates a strategic shift from CUDA being a foundational component to becoming the core enabler of a broader, more vertically integrated software stack aimed at accelerating deployment across computationally intensive workloads.",
      "llm_answer": "From 2022 to 2023, NVIDIA evolved CUDA from a foundational parallel programming model into a core component of its full-stack data center computing platform, integrating it deeply with new hardware (DPUs launched in 2022, CPUs in 2024) and software offerings like NVIDIA AI Enterprise and DGX Cloud. This integration enabled end-to-end acceleration across AI, HPC, and enterprise workloads, extending CUDA’s role beyond GPUs to unify compute, networking, and storage stacks—critical for scaling AI infrastructure and supporting diverse end markets like data centers, automotive, and professional visualization.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of CUDA's strategic positioning from a foundational programming model to a more integrated component of NVIDIA's full-stack platform, which aligns with the ground truth. It correctly identifies CUDA’s expanding role in AI, HPC, and enterprise workloads and mentions integration with software offerings like NVIDIA AI Enterprise and DGX Cloud, reflecting deeper software stack integration. However, there are key discrepancies: (1) The LLM incorrectly references CPUs launched in 2024, which is outside the 2022–2023 scope and not mentioned in the original answer; (2) While the original emphasizes CUDA’s expansion into domain-specific verticals (healthcare, telecom, manufacturing) and its role as the base for hundreds of domain-specific libraries and SDKs—highlighting a strategic shift toward vertical software integration—the LLM focuses more on hardware unification (compute, networking, storage) and data center infrastructure, missing the emphasis on vertical market expansion and software ecosystem growth. (3) The original does not mention DPUs or CPUs as part of the 2022–2023 CUDA evolution, so including them introduces factual inaccuracies. Quantitatively, no numbers are misstated (there are none), so accuracy is high. Contextually, the answer remains relevant to CUDA’s strategic evolution. However, the qualitative reasoning is partially flawed due to incorrect entity inclusion and failure to capture the core shift toward domain-specific software enablement. Thus, while the direction of evolution is correctly inferred, the specific strategic pivot described in the ground truth is not fully or accurately represented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1422,
        "completion_tokens": 457,
        "total_tokens": 1880
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did Pfizer's financial obligations and contractual relationships with Viatris evolve from 2022 to 2023, particularly in terms of transitional service agreements and net amounts owed?",
      "original_answer": "In 2022, Pfizer disclosed that amounts recorded under transitional service agreements (TSAs) and master services agreements (MSAs) with Viatris were not material to operations, and the TSA services were largely completed by the end of 2022. By 2023, services under the TSAs were fully completed as of December 31, 2023, and the net amounts due to Viatris under the agreements decreased from $94 million in 2022 to $33 million in 2023. This reflects a reduction in intercompany financial obligations and the winding down of transitional support following the 2020 spin-off of the Upjohn Business into Viatris.",
      "llm_answer": "From 2022 to 2023 Pfizer’s relationship with Viatris shifted from active transitional service agreements to minimal post‑separation billing.  In 2022 the company recorded $94 million receivable from Viatris under the interim TSAs and MSAs, but by year‑end 2023 that balance had fallen to $33 million, and the TSAs themselves were essentially completed.  Consequently, net amounts owed to or from Viatris under those agreements were negligible in 2023, reflecting the winding down of the transitional arrangements.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers and dates are correct: the $94 million receivable in 2022 and reduction to $33 million in 2023 are accurately reported, and the completion of TSAs by December 31, 2023, is correctly noted. Format variations (e.g., $94 million) are acceptable and semantically equivalent. (2) The answer addresses all key parts of the question: evolution of financial obligations, status of transitional service agreements (TSAs), and net amounts owed. It correctly notes that TSA services were largely completed by end of 2022 and fully completed by end of 2023. (3) Entity accuracy is strong: Pfizer, Viatris, TSAs, MSAs, and the correct years (2022–2023) are properly identified. (4) The reasoning is sound—correctly inferring that the decline in receivables and completion of services reflect the winding down of transitional support post the Upjohn spin-off. One minor shortcoming: the LLM states net amounts were 'negligible' in 2023, while the ground truth specifies the exact $33 million balance, which is not necessarily negligible in absolute terms. This slight overstatement slightly reduces qualitative accuracy, but does not undermine the core correctness. Overall, the answer demonstrates strong multi-hop synthesis across time periods and financial metrics, with excellent contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 386,
        "total_tokens": 1676
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has the relationship between retail deregulation pressures and Duke Energy's environmental regulation compliance costs evolved from 2022 to 2023?",
      "original_answer": "In 2022, Duke Energy highlighted that retail deregulation could result in unrecovered costs, including those related to above-market purchased power commitments from qualifying facilities (QFs) under PURPA, which could hinder the recovery of environmental compliance costs through regulatory rate structures. By 2023, the company noted increased regulatory emphasis on environmental compliance, including EPA regulations on CO2 emissions and cooling water intake structures, as well as new state-level carbon reduction goals more aggressive than the company’s own plans. These developments suggest that deregulation pressures have compounded the challenge of recovering rising environmental compliance costs, as competitive market conditions limit the ability to pass on these expenses to customers.",
      "llm_answer": "From 2022 to 2023, Duke Energy’s environmental‑regulation compliance costs have risen sharply because the company is now spending more on coal‑ash (CCR) closure, remediation and related permitting requirements.  In the 2022 filing the Registrants noted that “the timing for and amount of recovery of such costs could have a material adverse impact on Duke Energy’s cash flows,” and they warned that “the scope and complexity of work … could materially increase compliance expenditures and rate impacts.”  By 2023, those expenditures have continued to grow, with the company reporting that “closure activities began in 2015 … and as the closure and CCR management work progresses … the amount of CCR material could be greater than estimates and could, therefore, materially increase compliance expenditures and rate impacts.”  Consequently, the pressure of retail‑deregulation and stricter EPA/state CCR rules has translated into higher, increasingly uncertain compliance‑cost outlays that directly affect Duke Energy’s cash‑flow outlook.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer correctly identifies that Duke Energy faced rising environmental compliance costs from 2022 to 2023, particularly related to coal-ash (CCR) closure and remediation, and cites appropriate language from the filings about uncertainty in cost recovery and increasing expenditures. The dates (2022 and 2023) and entities (Duke Energy, EPA) are accurate, and the qualitative descriptions of regulatory pressure are factually grounded, supporting a moderate score for quantitative accuracy and contextual relevance. However, the core of the question asks about the *relationship between retail deregulation pressures and environmental compliance cost recovery*, which the LLM answer fails to address adequately. While it mentions 'retail-deregulation' in passing, it does not explain how deregulation affects cost recovery mechanisms—specifically, the risk of unrecovered costs from PURPA-related purchased power commitments or the inability to pass on environmental costs in competitive markets, which is central to the original answer. Instead, the LLM focuses almost entirely on CCR costs without linking them to retail market structure or rate recovery limitations. This represents a significant gap in multi-hop reasoning: the model identifies rising environmental costs and regulatory pressures but fails to synthesize how deregulation exacerbates cost recovery challenges. Thus, while some factual elements are correct, the answer misses the key analytical connection required by the question, leading to a correctness score of 5 due to partial accuracy with major omissions in reasoning and completeness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1459,
        "completion_tokens": 441,
        "total_tokens": 1900
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How did the retail share of Skoal oral tobacco products change between 2023 and 2024, and how does this contrast with the pricing strategy applied to Skoal during 2023?",
      "original_answer": "The retail share of Skoal oral tobacco products decreased from 9.3% in 2023 to 7.6% in 2024, reflecting a decline in market presence. This contrasts with the pricing strategy in 2023, where multiple price increases were applied to Skoal products, including a $0.11 per can increase effective January 23, 2024 (announced in 2023), following earlier increases of $0.09, $0.09, and $0.08 per can in May, February, and January 2022, respectively. The cumulative effect of these increases may have impacted consumer demand, contributing to the drop in retail share.",
      "llm_answer": "The retail share of Skoal oral tobacco products declined from 9.3 % in 2023 to 7.6 % in 2024, a drop of about 1.7 percentage points.  This contrasts with the pricing strategy for Skoal in 2023, when USSTC raised the list price on its Skoal brands by $0.09 per can (and also adjusted prices on other brands), whereas in 2024 the company again increased Skoal list prices—by $0.11 per can in January 2024 and by $0.10 per can in July and April 2024—reflecting ongoing price hikes rather than the modest 2023 increase.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the retail share decline from 9.3% in 2023 to 7.6% in 2024, which matches the ground truth. However, it misrepresents the timing and magnitude of the 2023 pricing strategy. The ground truth states that the $0.11 per can increase was announced in 2023 but effective January 23, 2024, and that prior increases occurred in 2022 (not 2023). The LLM incorrectly claims a $0.09 increase occurred in 2023, which is not supported by the original answer. Additionally, the LLM introduces new price increases of $0.10 per can in April and July 2024—information not present in the ground truth—and frames 2023 as having only a 'modest' increase, which introduces a subjective and unsupported contrast. (2) The calculation of the 1.7 percentage point drop is accurate (9.3% - 7.6% = 1.7%), but the pricing figures and dates are partially fabricated or misattributed. The $0.09 increase in 2023 is incorrect; the last 2023-relevant action was the announcement of the $0.11 increase for 2024. The 2022 price hikes are omitted. (3) The multi-hop reasoning is partially sound—linking pricing strategy to market share decline—but based on incorrect data. The synthesis fails because it uses inaccurate pricing events, undermining the logical contrast. (4) The contextual relevance is high as the answer addresses both parts of the question and attempts to contrast pricing with market share. However, due to significant factual errors in the pricing timeline and amounts, the correctness and quantitative accuracy scores are reduced. The answer is plausible-sounding but factually flawed in key details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 446,
        "total_tokens": 1720
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How did Amgen's investment in 'Other short-term interest-bearing securities' evolve between 2023 and 2024, and what does this indicate about the company's short-term investment strategy?",
      "original_answer": "Amgen's investment in 'Other short-term interest-bearing securities' remained unchanged at $138 million in both 2023 and 2024. This stability suggests that the company maintained a consistent approach to this segment of its short-term investment portfolio over the two-year period.",
      "llm_answer": "Amgen’s “Other short‑term interest‑bearing securities” declined slightly from $138 million at the end of 2023 to $135 million at the end of 2024, indicating that the company is maintaining a relatively stable, low‑risk cash‑equivalent position rather than expanding its short‑term investment portfolio. This modest reduction suggests a conservative short‑term investment strategy focused on preserving liquidity and minimizing exposure to market volatility.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer incorrectly states that Amgen's investment in 'Other short-term interest-bearing securities' declined from $138 million in 2023 to $135 million in 2024, while the ground truth confirms it remained unchanged at $138 million in both years. This is a critical factual error affecting the core of the response. (2) The quantitative inaccuracy is significant—while the 2023 figure is correct, the 2024 value is wrong, and the claimed 'slight decline' is unsupported. No calculation is needed in this case, but the comparison (change over time) is incorrect. (3) The reasoning is partially sound in interpreting a stable or slightly reduced position as indicative of a conservative, low-risk strategy, which is a reasonable qualitative inference—had the numbers been correct, the logic would have been acceptable. However, because the premise is flawed (a decline that didn’t occur), the conclusion is based on false data. (4) Contextual relevance is high as the answer addresses both parts of the question—evolution over time and strategic implication—and uses appropriate financial terminology. However, the factual foundation is incorrect, severely undermining correctness. The qualitative score reflects the logical structure despite incorrect inputs, while the low quantitative score reflects the key number error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1194,
        "completion_tokens": 374,
        "total_tokens": 1569
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the nature of General Dynamics' involvement in Abrams Main Battle Tank Upgrades evolved from 2022 to 2024, particularly in terms of contract scope and value?",
      "original_answer": "In 2022, General Dynamics received a $360 million contract from the Army for Abrams main battle tank upgrades, mission control units, and systems technical support. By 2024, the company's involvement had evolved to include both production and support services, as evidenced by a $350 million contract for Abrams upgrades, engineering and logistics support, and system and sustainment technical support services. Additionally, a separate $285 million contract was awarded for producing Abrams tanks in the SEPv3 configuration for Romania. This indicates a shift from primarily upgrade-focused contracts to a broader scope that includes both upgrades and production of new configurations, with an increase in total contract value.",
      "llm_answer": "From 2022 to 2024, General Dynamics' involvement in Abrams Main Battle Tank upgrades shifted from a $360 million award in 2021 (page 42) to $395 million in 2022 (page 44) and then to $350 million in 2024 (page 44), reflecting a modest increase in contract value. The scope remained focused on tank upgrades, engineering, logistics support, and system technical assistance, but the contract amounts show a steady rise, underscoring an expanding role in modernizing the Abrams fleet over the three‑year period.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains multiple factual inaccuracies. It incorrectly states a $360 million contract was awarded in 2021 (not 2022) and cites a $395 million contract in 2022, neither of which aligns with the ground truth. The ground truth specifies a $360 million contract in 2022 and a $350 million contract in 2024—no $395 million figure is correct. Additionally, the LLM omits the critical $285 million production contract for Romania in 2024, which is central to the evolution in contract scope. (2) The quantitative inaccuracies are severe: wrong years (2021 instead of 2022), incorrect amounts ($395M vs actual $360M in 2022), and failure to report the total increased value due to multiple contracts in 2024. The claim of a 'steady rise' in contract value is false—the value decreased from $360M to $350M for the main upgrade contract, and only total involvement increased due to the additional Romania contract, which the LLM fails to mention. (3) The multi-hop reasoning is flawed. The question asks about evolution in scope and value. The LLM incorrectly frames the evolution as a simple value increase over time, missing the key shift from upgrades-only (2022) to combined upgrades and new production (2024). The broader scope in 2024, including SEPv3 production for Romania, is entirely omitted, indicating a failure to synthesize the full picture. (4) Scores are justified as follows: Correctness is low (3/10) due to major factual and omission errors. Quantitative accuracy is very poor (2/10) due to wrong numbers and years. Qualitative accuracy is low (3/10) because the reasoning and entity synthesis are incorrect. Contextual relevance is moderate (6/10) as the answer addresses the general topic and mentions support services, but misses key developments.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 486,
        "total_tokens": 1799
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How did AIG's financial relationship with Corebridge evolve from 2023 to 2024, particularly in terms of borrowing arrangements and income recognition?",
      "original_answer": "In 2023, AIG disclosed that Corebridge had the ability to continue borrowing through February 25, 2025, indicating an ongoing financial arrangement. By 2024, AIG's relationship with Corebridge had transformed, as AIG began recognizing equity method income tied to Corebridge’s stock price changes and dividends received since June 9, 2024. This shift reflects a change from a borrowing-based relationship to one focused on equity-based returns.",
      "llm_answer": "From 2023 to 2024, AIG’s borrowing arrangements with Corebridge evolved from a structured guarantee and collateral framework to active market participation. In 2023, AIG had entered into a guarantee reimbursement agreement and collateral pact with Corebridge and CRBGLH, requiring reimbursement of any payments made on AIG’s guaranteed CRBGLH debt and collateralizing obligations upon downgrade or payment failure. By 2024, AIG had begun recognizing income from its equity method investment in Corebridge, reflecting changes in Corebridge’s stock value and dividends, while also engaging in share sales and repurchases that reduced its ownership stake to 22.7% by year-end. The deconsolidation of Corebridge in June 2024 resulted in a significant after-tax loss, but subsequent sales of Corebridge shares generated gains recognized in net investment income.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer includes several details not present in the ground truth and introduces inaccuracies, particularly around the nature of the 2023 borrowing arrangements and specific ownership percentages. The ground truth states that in 2023, Corebridge had the ability to continue borrowing through February 25, 2025 — a straightforward disclosure about borrowing capacity — but the LLM incorrectly expands this into a 'guarantee reimbursement agreement and collateral pact with Corebridge and CRBGLH,' which is not mentioned in the original answer. There is no mention in the ground truth of CRBGLH, downgrade triggers, or collateral frameworks, making these additions factually unsupported. (2) The LLM claims AIG's ownership was reduced to 22.7% by year-end 2024, but this specific percentage is not in the ground truth and cannot be verified from the provided information; thus, it fails the quantitative accuracy check. The date June 9, 2024, from the ground truth (when equity method income began) is approximated as 'June 2024' in the LLM answer, which is acceptable, but the mention of 'deconsolidation... resulted in a significant after-tax loss' and 'subsequent sales... generated gains' introduces financial outcomes not referenced in the original answer, reducing factual precision. (3) The multi-hop reasoning is partially sound: the LLM correctly identifies a shift from a borrowing-based relationship to equity method income recognition, which aligns with the core transformation described. It also correctly associates income recognition with stock price changes and dividends. However, it overcomplicates the 2023 arrangement and adds unverified financial events (losses, gains from sales), indicating flawed synthesis. (4) Despite the inaccuracies, the LLM captures the essential evolution — a shift from lending/borrowing dynamics to equity-based income — making the answer contextually relevant and qualitatively reasonable in direction, though not fully factually aligned. Hence, correctness is scored at 6 for partial accuracy with significant factual overreach.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 563,
        "total_tokens": 1889
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has Tesla's approach to the Solar Roof product evolved between 2022 and 2024, particularly in terms of production challenges and strategic dependencies?",
      "original_answer": "In 2022, Tesla was actively selling the Solar Roof and improving installation efficiency through collaboration with real estate developers and builders. The company emphasized its engineering efforts to combine aesthetics, durability, and power generation. By 2024, however, Tesla's 10-K highlights that the future of the Solar Roof (alongside other products) 'depends in large part' on overcoming production ramp challenges, including bottlenecks, supplier risks, and cost control. This reflects a shift from product development and sales emphasis to a more complex production and dependency landscape.",
      "llm_answer": "Tesla's Solar Roof production has faced persistent scaling challenges, with 2022 disclosures noting \"ongoing compliance with regulatory requirements, supply chain constraints, and the pace of bringing production equipment online\" as key risks that could delay or undermine manufacturing capacity. By 2024, the company explicitly linked these issues to broader manufacturing expansion plans, stating that \"any delay or complication in ramping the production of our current products or the development... of Solar Roof\" could \"harm our brand, business, prospects, financial condition and operating results,\" while also identifying battery cell supply constraints as a critical dependency for scaling both energy products and vehicles.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in its description of Tesla's Solar Roof challenges in 2022 and 2024, with correct references to production ramp issues, supply chain constraints, regulatory compliance, and dependencies like battery cell supply. There are no numeric inaccuracies (quantitative_accuracy: 10), as the answer avoids specific figures not present in the original and correctly reflects qualitative risk disclosures. However, the LLM answer diverges slightly in emphasis from the ground truth: while the original highlights a strategic shift from sales and installation efficiency (via builder partnerships) in 2022 to production bottlenecks and cost control dependencies in 2024, the LLM focuses more on regulatory and equipment ramp-up risks in 2022 and omits the collaboration with real estate developers—a key part of Tesla’s 2022 strategy. Additionally, the 2024 emphasis on 'bottlenecks, supplier risks, and cost control' from the original is partially captured but reframed around 'battery cell supply' as a central dependency, which, while relevant, is broader than the Solar Roof-specific production challenges emphasized in the ground truth. Thus, while the core reasoning about evolving production challenges is sound and contextually relevant, the qualitative accuracy is reduced due to incomplete synthesis of strategic shifts and overemphasis on battery supply, which is more relevant to vehicles and energy storage than Solar Roof specifically. The answer remains highly relevant to the question and captures the essence of increasing production dependency concerns.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 435,
        "total_tokens": 1771
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the retail share of Skoal in the U.S. oral tobacco market changed between 2023 and 2024, and what does this indicate about its competitive positioning?",
      "original_answer": "In 2023, Skoal held a 9.3% retail share in the U.S. oral tobacco market, which decreased to 7.6% in 2024. This decline indicates a weakening in Skoal's competitive positioning within the oral tobacco segment over this period. The drop in market share for Skoal contrasts with the growth seen in other products like on!, which increased from 6.8% to 8.3% during the same timeframe.",
      "llm_answer": "The retail share of Skoal in the U.S. oral tobacco market declined from 9.3% in 2023 to 7.6% in 2024, indicating a loss of competitive positioning as its share shrank amid overall category share declines. This reduction reflects weakening demand for Skoal relative to competing oral tobacco products, particularly as oral nicotine pouch segments gained ground.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that Skoal's retail share in the U.S. oral tobacco market declined from 9.3% in 2023 to 7.6% in 2024, matching the ground truth exactly. These numbers are accurate and properly attributed to the correct years. (2) All quantitative values are correct—9.3% and 7.6%—and the direction of change (a decline) is accurately described. There are no calculation errors. (3) The reasoning is sound: the LLM correctly infers that the decline indicates weakening competitive positioning, which aligns with the ground truth. It also contextualizes the decline within broader market trends, mentioning category-wide share declines and growth in nicotine pouches, which, while not explicitly naming 'on!' as in the original, captures the essence of competitive pressure from growing segments. (4) The only minor shortcoming is the lack of explicit comparison to a specific competitor like 'on!' which was included in the ground truth to highlight relative performance. However, the LLM broadly references competing products gaining ground, preserving the core qualitative insight. Thus, the answer is factually complete and semantically equivalent, warranting a high score with only a slight deduction in qualitative accuracy for less specificity in competitive benchmarking.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1188,
        "completion_tokens": 366,
        "total_tokens": 1554
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the risk associated with the concentration of device share among premium tier companies evolved between 2023 and 2024, particularly in terms of its potential impact on Qualcomm's pricing power and revenue stability?",
      "original_answer": "In 2023, Qualcomm highlighted that the concentration of device share among a few premium tier companies was contributing to a trend of deriving a significant portion of revenues from a small number of customers, particularly Chinese OEMs. This concentration was noted to potentially result in lower prices for Qualcomm's products due to the purchasing power of these companies. In 2024, the risk factor remained present, but the emphasis shifted slightly to underscore the broader implications of this concentration, including the potential for even greater pricing pressure and revenue fluctuation due to the timing and success of customer product introductions. The continued reliance on a small group of customers, especially those developing their own integrated circuits or using competitors, suggests that the risk has not only persisted but potentially intensified, increasing its impact on Qualcomm's pricing power and revenue stability.",
      "llm_answer": "The risk from concentration of premium‑tier device share has intensified between 2023 and 2024.  In 2023 the filing highlighted that a few Chinese OEMs and other premium customers were driving a large share of Qualcomm’s revenue, and that their shift toward vertical integration or to competitors’ chips could erode pricing power and cause revenue volatility.  By 2024, the same risk was underscored more acutely: the revocation of the U.S. export license for Huawei’s 4G/other ICs (effective May 7 2024) eliminated roughly $560 million of product revenue from a key premium‑tier customer, and the broader trend of Chinese OEMs pursuing self‑sufficiency under the “Made‑in‑China 2025” policy—combined with heightened U.S./China trade and security tensions—further threatens to reduce purchases of Qualcomm’s premium‑tier modem and application‑processor chips.  Consequently, the concentration risk now poses a more immediate threat to Qualcomm’s pricing power and revenue stability, as loss of these high‑margin customers can force price concessions and cause abrupt revenue declines.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the persistence and intensification of concentration risk between 2023 and 2024, aligning with the original answer's core theme. It accurately notes the risk to Qualcomm's pricing power and revenue stability due to reliance on a few premium-tier customers, particularly Chinese OEMs, and mentions relevant trends like vertical integration and competition. However, it introduces specific details not present in the ground truth: the $560 million revenue loss due to the Huawei license revocation on May 7, 2024, and the direct linkage to 'Made-in-China 2025' and U.S./China trade tensions. These specifics are absent from the original answer and cannot be verified from the provided ground truth, making them potentially hallucinated or unsupported. (2) The quantitative claim of $560 million in lost revenue and the exact date of May 7, 2024, for the Huawei license revocation are not mentioned in the original answer. Since the ground truth does not include these figures or events, they cannot be considered factually accurate in this context, leading to a low quantitative accuracy score. (3) The multi-hop reasoning is partially sound: the model correctly infers that customer concentration increases pricing pressure and revenue instability, and it connects this to customer behavior like self-sufficiency efforts. However, the reasoning goes beyond the source material by introducing external geopolitical and regulatory events without grounding in the provided truth. (4) Despite the overreach in specifics, the LLM captures the qualitative evolution of the risk—shifting from general pricing pressure in 2023 to more acute concerns in 2024—and remains highly relevant to the question. The core message about intensifying risk is consistent, warranting moderate correctness and high contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1526,
        "completion_tokens": 504,
        "total_tokens": 2031
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "Given Amgen's approach to managing short-term liquidity, how did its allocation to money market mutual funds evolve between 2023 and 2024?",
      "original_answer": "Amgen's allocation to money market mutual funds remained unchanged at $10,266 million in both 2023 and 2024. The disclosed investment values for money market mutual funds under available-for-sale investments were identical in both years, indicating no shift in this portion of the company's short-term investment strategy.",
      "llm_answer": "Amgen’s short‑term liquidity is managed through a mix of cash, cash equivalents and highly liquid money‑market investments.  The company’s allocation to money‑market mutual funds remained essentially flat between 2023 and 2024, with $10,354 million reported as of December 31 2024 versus $10,266 million as of December 31 2023 – a modest increase of roughly $88 million (≈ 0.9 %).  This near‑steady level reflects Amgen’s strategy of preserving principal and maintaining ample liquidity while earning modest returns on its short‑term cash holdings.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a critical factual error in the reported dollar amounts. The ground truth states that Amgen's allocation to money market mutual funds was exactly $10,266 million in both 2023 and 2024, indicating no change. However, the LLM claims $10,354 million in 2024, which is incorrect. This leads to a false conclusion of a $88 million increase (≈0.9%), which did not occur. (2) The quantitative inaccuracies are significant: the 2024 figure is wrong, the difference calculation ($10,354M - $10,266M = $88M) is based on incorrect inputs, and the percentage increase is therefore also invalid. Only the 2023 figure ($10,266 million) is correct. (3) The reasoning is partially sound in that it interprets flat allocation as consistent with liquidity preservation strategy, which aligns with the original answer’s implication. However, the multi-hop synthesis fails because it uses an incorrect data point for 2024, undermining the comparison. (4) The contextual relevance is high because the answer addresses Amgen’s short-term liquidity strategy and attempts to compare two years’ data. However, due to the key numerical error, the correctness score is low despite relevant framing and correct entity identification (Amgen, money market mutual funds, 2023–2024).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1215,
        "completion_tokens": 361,
        "total_tokens": 1576
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has General Dynamics' participation in the Capital Construction Fund evolved between 2022 and 2024, particularly in terms of the amount of U.S. government accounts receivable pledged to the fund?",
      "original_answer": "In 2022, General Dynamics had U.S. government accounts receivable pledged to the Capital Construction Fund (CCF) of $295 million as of December 31, 2021. By 2024, the amounts pledged to the CCF had increased to $315 million on December 31, 2023, and $333 million on December 31, 2024. This indicates a steady increase in GD's participation in the CCF over the period, reflecting a growing utilization of the tax deferral benefits offered by the program.",
      "llm_answer": "General Dynamics' participation in the Capital Construction Fund (CCF) has remained consistent in structure but increased the amount of U.S. government accounts receivable pledged to the fund. In 2021, the company had $295 million in U.S. government accounts receivable pledged to the CCF, and by 2024, this amount had increased to $333 million, as reported in the 2024 10-K filing on page 68. This represents a $38 million increase over the three-year period, reflecting the company's continued use of the CCF program to defer taxes on earnings from eligible activities. The CCF program, administered by the Maritime Administration, allows participants to defer federal and state income taxes on qualifying earnings as long as proceeds are deposited into the fund and used for qualified shipbuilding or repair activities.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the pledged amounts of U.S. government accounts receivable to the Capital Construction Fund (CCF) as $295 million in 2021 (referenced as the balance as of December 31, 2021, in the original answer) and $333 million as of December 31, 2024. The $38 million increase is accurately calculated ($333M - $295M), and the reference to the 2024 10-K filing adds credibility. However, the original answer includes an intermediate data point for December 31, 2023 ($315 million), which the LLM omits. This is a minor omission but does not invalidate the overall trend described. (2) All numeric values are correct and properly contextualized. The LLM correctly interprets the $295 million as being from 2021 (reported in the 2022 filing) and the $333 million as of 2024. The calculation of the $38 million increase is accurate. (3) The multi-hop reasoning is sound: the LLM connects data across years and correctly infers increasing participation in the CCF program. It also correctly explains the purpose of the CCF and its tax deferral benefits, demonstrating good synthesis. The only gap is the missing 2023 data point, which slightly reduces completeness. (4) The answer is highly relevant, directly addressing the evolution of GD's CCF participation with correct context about the program and its benefits. The omission of the 2023 figure prevents a perfect score, but the core facts, numbers, and reasoning are correct and well-articulated.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1332,
        "completion_tokens": 411,
        "total_tokens": 1743
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did AIG's financial relationship with Corebridge evolve between 2023 and 2024, particularly in terms of its tax implications and investment income following the IPO and subsequent deconsolidation?",
      "original_answer": "In 2023, AIG's ownership in Corebridge dropped below 80% after Corebridge's IPO on September 19, 2022, resulting in the tax deconsolidation of Corebridge from AIG’s U.S. federal income tax group. This deconsolidation had significant tax implications, including restrictions on future consolidated tax filings for five years and the retention of Corebridge's net operating losses and tax credit carryforwards by Corebridge entities. By 2024, AIG no longer consolidated Corebridge's financials, and instead, AIG reported its investment in Corebridge under the equity method, recognizing $X in equity method income for the period from June 10, 2024, to December 31, 2024, based on dividends received and changes in Corebridge's stock price. This marks a shift from a consolidated tax and financial reporting relationship to a more arms-length investment relationship.",
      "llm_answer": "Between 2023 and 2024, AIG's financial relationship with Corebridge underwent a significant transformation due to the deconsolidation of Corebridge. Following the IPO and subsequent secondary offerings, AIG reduced its ownership stake and eventually met the criteria for deconsolidation on June 9, 2024, when it no longer had a controlling interest. As a result of this deconsolidation, AIG recognized a $4.8 billion loss, primarily driven by the recognition of $7.2 billion in accumulated other comprehensive loss, which was reclassified from equity. Post-deconsolidation, AIG retained a 22.7% equity interest in Corebridge and began accounting for it using the equity method, recognizing equity method income from dividends and changes in the stock's fair value. The tax implications of this transaction were substantial, as the deconsolidation triggered complex tax accounting, including the reclassification of tax attributes and the impact on deferred tax assets and liabilities, particularly related to Corebridge's tax attributes that remained with the entity after the separation.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly in dates and financial figures, which significantly affect correctness. The original answer states that AIG's ownership dropped below 80% after Corebridge's IPO on September 19, 2022, triggering tax deconsolidation in 2023. However, the LLM claims deconsolidation occurred on June 9, 2024, which contradicts the ground truth—financial deconsolidation for tax purposes occurred in 2023, not mid-2024. Additionally, the $4.8 billion loss and $7.2 billion accumulated other comprehensive loss are not mentioned in the original answer and appear to be fabricated or misattributed. The 22.7% equity interest is plausible but not confirmed in the ground truth. (2) The original answer references '$X' as a placeholder for equity method income from June 10, 2024, to December 31, 2024, but the LLM does not mention this timeframe or placeholder and instead introduces unverified figures. The LLM’s claim about recognizing income from 'changes in the stock's fair value' is incorrect—equity method income is based on the investee’s earnings, not stock price changes (that would be fair value accounting). (3) The multi-hop reasoning is partially sound: the LLM correctly infers a shift from consolidation to equity method accounting and identifies tax implications from deconsolidation. It also correctly links reduced ownership to loss of control and accounting changes. However, it misaligns the timing of key events and introduces unsupported financial figures, undermining the reasoning chain. (4) Despite these issues, the LLM captures the overall narrative shift—from consolidated subsidiary to equity-method investee—and correctly identifies tax and accounting implications at a conceptual level, earning moderate scores for qualitative accuracy and high relevance. The contextual understanding is strong, but quantitative inaccuracies drag down the overall correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1501,
        "completion_tokens": 528,
        "total_tokens": 2029
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Tesla's approach to Solar Roof production and its dependencies evolved from 2022 to 2024, particularly in terms of operational strategy and supply chain challenges?",
      "original_answer": "In 2022, Tesla emphasized improving Solar Roof installation capabilities by onboarding and training new installers and collaborating with real estate developers to reduce installation time and costs. The company also highlighted the need to maintain adequate battery cell supply and hire additional skilled electricians to support the ramp. By 2024, Tesla's focus had shifted to broader manufacturing and supply chain risks, with Solar Roof production now described as being dependent on the company's ability to manage global component procurement, avoid bottlenecks, and maintain cost-effective production amid potential supplier failures and inflationary pressures. The evolution reflects a shift from localized installer development to systemic supply chain and production scalability concerns.",
      "llm_answer": "From 2022 to 2024, Tesla’s Solar Roof production strategy evolved from a high‑profile, vertically integrated rollout toward a more incremental, supply‑chain‑controlled approach.  In the 2022 filing the company highlighted “ongoing compliance with regulatory requirements, procurement and maintenance of construction… supply chain constraints, hiring, training and retention of qualified employees” as key uncertainties for new manufacturing, including Solar Roof, and warned that any delays in ramping production or securing battery‑cell supply could harm the business.  By 2024 the focus shifted to “maintaining adequate battery cell supply for our energy storage products and hire additional personnel, particularly skilled electricians, to support the ramp of Solar Roof,” while also noting that the company was “on‑boarding and training new installers, as well as collaborating with real‑estate developers and builders on new homes to reduce installation time and costs.”  The 2024 disclosures further emphasized that “our future growth and success are dependent upon increasing the production of mass‑market vehicles” and that “bottlenecks and other unexpected challenges such as those we experienced in the past may arise during our production ramps,” underscoring that Solar Roof’s expansion remains tied to the same supply‑chain and manufacturing‑scale risks that have persisted from 2022 through 2024.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in terms of factual content and context, with accurate dates (2022 and 2024) and correct entities (Tesla, Solar Roof, battery cell supply, skilled electricians, real estate developers). There are no numeric values requiring verification, so quantitative accuracy is 10. The answer captures key elements from both years: in 2022, Tesla focused on installer training, regulatory compliance, and supply chain constraints; in 2024, it emphasized battery supply, personnel hiring, and broader production bottlenecks. However, the LLM misattributes the evolution by suggesting that the 2024 strategy still includes onboarding installers and collaborating with developers as a current focus, when the ground truth indicates a *shift away* from those localized efforts toward systemic supply chain risks. The original answer clearly states that by 2024, the focus had evolved to global procurement, supplier failure risks, and inflationary pressures—points underemphasized or missing in the LLM response. Additionally, the LLM incorrectly implies continuity in installer development into 2024 as part of the strategic focus, when the ground truth suggests that emphasis has moved upstream to manufacturing scalability. While the LLM mentions bottlenecks and production ramps, it fails to clearly articulate the strategic evolution from labor/installation-focused challenges to macro supply chain dependencies. Thus, while core facts are present, the synthesis and reasoning about the strategic shift are partially flawed, warranting a 7 for qualitative accuracy and overall correctness. Contextual relevance is high as the response directly addresses the question’s scope on operational strategy and supply chain evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1558,
        "completion_tokens": 473,
        "total_tokens": 2032
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Duke Energy's estimated total cost to permanently close all coal ash basins in North Carolina and South Carolina evolved from 2022 to 2023, and what does this indicate about the company's progress under the Coal Ash Act?",
      "original_answer": "In 2022, Duke Energy estimated the total cost to permanently close all coal ash basins in North Carolina and South Carolina to be approximately $8 billion to $9 billion. By 2023, this estimate had decreased to approximately $7 billion to $8 billion, indicating a downward adjustment in projected costs. Additionally, the amount already spent on these closures increased from approximately $3.1 billion through 2021 (as reported in 2022) to approximately $4 billion through 2023. This evolution suggests that Duke Energy has made measurable progress in implementing closure plans under the Coal Ash Act, with more basins excavated and cost estimates refined over time.",
      "llm_answer": "The estimated total cost to permanently close all coal‑ash basins in Duke Energy’s North Carolina and South Carolina service area fell from roughly $9.5 billion–$10.5 billion (as projected in 2021) to about $8 billion–$9 billion by the end of 2023, reflecting roughly $3.1 billion of spending through 2021 and continued progress toward completing basin closures. This reduction—driven by the 2019 settlement that lowered the undiscounted excavation cost by about $1.5 billion and by the completion of excavation at several sites—shows that Duke Energy is advancing under the Coal Ash Act, moving from planning and legal challenges toward actual closure work while still seeking cost recovery through the normal ratemaking process.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies in numbers and timeframes compared to the ground truth. The 2022 estimated cost in the original answer is $8B–$9B, but the LLM states a 2023 estimate of $8B–$9B as a reduction from a $9.5B–$10.5B projection in 2021—this conflicts with the ground truth, which does not report a 2021 estimate of $9.5B–$10.5B. The correct downward revision is from $8B–$9B (2022) to $7B–$8B (2023), not as stated. Additionally, the LLM claims $3.1B spent through 2021, which matches the original, but fails to mention the updated spend of $4B through 2023, a key part of the evolution. (2) The quantitative inaccuracies are significant: the starting and ending cost ranges are wrong, and the timeline of estimates is misaligned (citing 2021 numbers for a 2022 baseline). The $1.5B reduction from the 2019 settlement may be factual context but is not reflected in the 2022–2023 cost evolution described in the question. (3) The reasoning partially captures progress under the Coal Ash Act—linking cost reductions to completed excavations and regulatory progress—but misattributes the timeline and magnitude of cost changes. It synthesizes relevant concepts (cost recovery, ratemaking, settlement impact) but does not accurately reflect the multi-hop evolution from 2022 to 2023 as required. (4) Contextual relevance is high because the answer addresses cost trends, progress, and regulatory context. However, due to incorrect numerical ranges and missing updated spending figures, the correctness score is limited to 5—partially correct but with significant factual and quantitative errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 448,
        "total_tokens": 1818
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did the retail share of the 'on!' oral tobacco product evolved between 2023 and 2024, and what does this indicate about its market position relative to the overall oral tobacco product segment during this period?",
      "original_answer": "The retail share of the 'on!' oral tobacco product increased from 6.8% in 2023 to 8.3% in 2024. This indicates that 'on!' gained market share during this period. In contrast, the total oral tobacco product segment saw a decline in retail share, dropping from 42.5% in 2023 to 37.5% in 2024. This divergence suggests that 'on!' strengthened its position within the broader oral tobacco market between these years.",
      "llm_answer": "The retail share of the “on!” oral tobacco product declined from 6.8 % in 2023 to 8.3 % in 2024, while its shipment volume rose sharply (from 114.3 million to 160.3 million units). This increase in share despite the overall oral‑tobacco category’s share falling from 42.5 % to 37.5 % shows that “on!” is gaining traction within the segment, but its growth is still outpaced by the broader category’s contraction, indicating a relatively strong but niche position.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a critical factual error in stating that the retail share of 'on!' declined from 6.8% to 8.3%, when in fact it increased. This misrepresents the direction of change and undermines the core of the answer. All percentage values (6.8%, 8.3%, 42.5%, 37.5%) are numerically correct, but the characterization of the change as a 'decline' when it is an increase is a major error. The shipment volume data (114.3 million to 160.3 million units) is accurate but not requested in the question, so its inclusion does not improve correctness. (2) Quantitative accuracy is partially preserved because the numbers themselves are correct, but the comparison (increase vs. decrease) is wrong. The calculation of the trend (higher share) is misinterpreted. (3) The multi-hop reasoning is partially sound—comparing 'on!''s performance to the overall segment trend is appropriate and the conclusion about gaining traction is directionally correct. However, the flawed premise (calling an increase a decline) invalidates the logic flow. The conclusion that growth is outpaced by category contraction is inconsistent with the fact that 'on!' gained share while the category shrank, which actually indicates outperformance. (4) Contextual relevance is high because the answer addresses market position and relative performance, and includes relevant data points. However, the reversal of the key trend severely limits factual correctness, warranting a moderate score of 4 for overall correctness despite accurate raw numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1236,
        "completion_tokens": 424,
        "total_tokens": 1660
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Qualcomm's reliance on Chinese OEMs for revenue evolved from 2023 to 2024, and what implications does this have for its business stability?",
      "original_answer": "In 2023, Qualcomm derived a significant portion of its revenues from a small number of Chinese OEMs, highlighting its dependency on their device share growth in China and other regions. By 2024, this dependency persisted, with the company continuing to emphasize that it derives a significant portion of its revenues from these same OEMs. This ongoing reliance indicates that any political, economic, or market shifts affecting Chinese OEMs could continue to pose a risk to Qualcomm's revenue stability, particularly given the persistent U.S./China trade and national security tensions mentioned in both filings.",
      "llm_answer": "Qualcomm’s reliance on Chinese OEMs has continued to shrink as U.S. and Chinese government actions increasingly restrict sales of its integrated‑circuit products to Huawei and other Chinese customers, exemplified by the May 7 2024 revocation of its 4G export license to Huawei and the loss of roughly $560 million in product revenue from that customer.  At the same time, Chinese OEMs are accelerating vertical integration—developing their own chips or turning to competitors—driven by policies such as “Made in China 2025” and heightened U.S./China trade tensions, which together heighten the risk that a significant portion of Qualcomm’s revenue could be lost, undermining business stability.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that deviate from the ground truth. (1) Quantitatively, the claim of a $560 million revenue loss from Huawei and the May 7, 2024 revocation of a 4G export license to Huawei is not supported by the original answer or the knowledge graph; no such specific numbers or dates are mentioned in the ground truth. These figures appear fabricated or incorrectly inferred. (2) The original answer states that Qualcomm's reliance on Chinese OEMs 'persisted' into 2024, with continued emphasis on deriving a significant portion of revenue from them. In contrast, the LLM claims reliance is 'shrinking,' which directly contradicts the ground truth. (3) Entity accuracy is partially correct—Qualcomm, Chinese OEMs, U.S./China tensions are valid entities—but the introduction of Huawei as a specific customer losing a 4G license and the 'Made in China 2025' policy as a driver are not mentioned in the original answer, introducing unsupported specifics. (4) Reasoning is flawed: the LLM infers a trend of decreasing reliance due to export restrictions and vertical integration, but the ground truth indicates ongoing and persistent reliance, meaning the multi-hop synthesis failed. While the general concern about business stability due to geopolitical risks is contextually relevant and aligns with the original's implications, the incorrect trend direction and invented data severely undermine factual correctness. Thus, the answer is mostly incorrect despite touching on relevant themes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 419,
        "total_tokens": 1745
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did Amgen's composition of total available-for-sale investments evolve between 2022 and 2023, particularly in terms of specific security types held?",
      "original_answer": "In 2022, Amgen reported total available-for-sale investments of $4,335 million, which included $1,676 million in marketable securities alongside $2,659 million in cash and cash equivalents. By 2023, Amgen no longer held any marketable securities or U.S. Treasury bills, and instead, the entire $10,404 million in total available-for-sale investments was composed of $10,266 million in money market mutual funds and $138 million in other short-term interest-bearing securities. This reflects a strategic shift toward more liquid and short-term interest-bearing instruments.",
      "llm_answer": "Based on the provided 10‑K pages, Amgen’s available‑for‑sale investment portfolio remained essentially cash‑equivalents and short‑term Treasury/money‑market instruments.  As of 31 Dec 2023 the portfolio totaled **$10.4 billion** (all classified as available‑for‑sale), and by 31 Dec 2024 it grew modestly to **$11.5 billion** – still composed almost entirely of U.S. Treasury bills, money‑market mutual funds and other short‑term interest‑bearing securities with no material unrealized gains or losses.  No specific non‑cash securities (e.g., corporate bonds, equity holdings) were disclosed as part of the AFS balance during this period.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that the total available-for-sale investments were $10.4 billion as of December 31, 2023, which is close to the ground truth of $10,404 million, but then refers to a non-existent 2024 figure of $11.5 billion, which is not part of the question or the original answer. More critically, it misrepresents the composition of the 2023 portfolio by claiming it includes U.S. Treasury bills, which the ground truth explicitly states were no longer held in 2023. Instead, the ground truth specifies that the 2023 portfolio consisted entirely of money market mutual funds ($10,266 million) and other short-term interest-bearing securities ($138 million), with no marketable securities or U.S. Treasury bills. The LLM also fails to mention the 2022 composition at all—$1,676 million in marketable securities and $2,659 million in cash and cash equivalents—thus omitting a critical part of the multi-hop comparison. (2) Quantitative accuracy is low: while $10.4 billion approximates $10,404 million, the $11.5 billion figure for 2024 is fabricated. The breakdown of the 2023 portfolio is entirely missing in the LLM response—no mention of $10,266 million in money market funds or $138 million in other securities. The 2022 total of $4,335 million is not mentioned. (3) The reasoning is flawed: the question asks for a comparison between 2022 and 2023, but the LLM skips 2022 and introduces 2024, failing the multi-hop requirement. It does not identify the strategic shift from marketable securities and cash equivalents to money market funds. (4) Contextual relevance is moderate because it discusses Amgen’s short-term investments and mentions available-for-sale classification, but it fails to address the evolution between the two years and misstates key facts, making it largely incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 507,
        "total_tokens": 1811
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has the presence of Shake Shack as a tenant evolved across SPG's premium outlet properties between 2022 and 2023?",
      "original_answer": "In 2022, Shake Shack was listed as a tenant at Woodbury Common Premium Outlets in New York. By 2023, Shake Shack not only remained at Woodbury Common but also expanded its presence to Las Vegas Outlets North Premium in Nevada. This indicates a strategic expansion of Shake Shack’s footprint within SPG's portfolio of properties over the two years.",
      "llm_answer": "Based on the provided pages, Shake Shack appears as a tenant **only at Woodland Hills Mall (IL)** in the 2022 document (page 33), listed among larger retailers and uses. It is **not mentioned as a tenant at any premium outlet properties** in either the 2022 or 2023 documents. The 2023 document (pages 32–36) contains no reference to Shake Shack at premium outlet properties, indicating its presence did not evolve across SPG’s premium outlet portfolio between 2022 and 2023.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect. (1) It claims Shake Shack was only at Woodland Hills Mall in Illinois in 2022, but the ground truth states it was at Woodbury Common Premium Outlets in New York—completely different locations and entities. (2) The LLM asserts Shake Shack is not mentioned in any premium outlet properties in 2022 or 2023, directly contradicting the ground truth that confirms its presence at Woodbury Common in 2022 and expansion to Las Vegas Outlets North Premium in 2023. (3) The multi-hop reasoning failed entirely: instead of identifying the evolution of Shake Shack’s presence across SPG’s premium outlets (a portfolio-level change over time), the model incorrectly limited its analysis to non-premium outlet properties and reported a false negative. (4) The answer fabricates a location (Woodland Hills Mall, IL) not mentioned in the ground truth and misrepresents the data, indicating either a hallucination or severe misreading of source documents. While the structure attempts to address the time frame and evolution, the factual inaccuracies render the response highly misleading. Thus, the correctness, quantitative, and qualitative scores are very low. Contextual relevance is slightly higher because the answer attempts to respond to the question’s structure, but with entirely wrong data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1198,
        "completion_tokens": 368,
        "total_tokens": 1566
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did the classification of retirement annuity contracts within the fair value hierarchy evolve between 2022 and 2024, and what does this indicate about GD's valuation methodology for these assets?",
      "original_answer": "In 2022, retirement annuity contracts were part of Level 3 assets, indicating that their fair value was determined using unobservable inputs. By 2024, these contracts remained in Level 3, but the disclosure noted that investments valued using net asset value (NAV) as a practical expedient were now included in the tables for reconciliation to total plan assets, which was not explicitly stated in 2022. This suggests a refinement in disclosure practices rather than a change in hierarchy classification, indicating that while the valuation methodology remained complex and less observable, GD improved transparency in how these assets are reported.",
      "llm_answer": "The classification of retirement annuity contracts shifted from Level 3 in 2022 (reported at $35 million in the 2022 hierarchy) to $22 million at Level 3 in 2024, with no Level 3 balances disclosed for 2023. This reduction indicates that GD moved these annuity assets out of the unobservable‑input tier—likely re‑classifying them as Level 2 or measuring them using the NAV practical expedient—reflecting a more observable valuation approach in its fair‑value hierarchy. Consequently, GD’s 2024 valuation methodology relies less on unobservable inputs for retirement annuities, suggesting greater use of market‑based or fund‑NAV pricing for these assets.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The original answer states that retirement annuity contracts remained in Level 3 from 2022 to 2024, with no change in classification. However, the LLM claims a shift occurred due to a reduction in value from $35M to $22M and implies reclassification out of Level 3, which contradicts the ground truth. The ground truth does not mention specific dollar amounts for 2022 or 2024, nor does it state any movement out of Level 3. The claim that Level 3 balances were not disclosed in 2023 is unsupported and incorrect per the original answer. (2) Quantitative inaccuracies include the fabricated figures of $35M and $22M and the erroneous implication of a trend across years. No such values or disclosures are in the ground truth, making the quantitative basis of the answer invalid. (3) The multi-hop reasoning is flawed: the LLM incorrectly infers that a change in valuation methodology occurred based on non-existent numerical trends. In reality, the evolution was in disclosure transparency (inclusion of NAV-measured assets in reconciliation tables), not in hierarchy movement or methodology shift. The LLM misinterprets improved reporting as a methodological change, which is the opposite of the correct conclusion. (4) While the answer addresses the question’s topic and attempts to discuss valuation methodology, its core claims are factually wrong. The contextual relevance is moderate because it engages with the fair value hierarchy and GD’s practices, but the incorrect facts and reasoning severely undermine accuracy. Correctness is low due to major errors in entities, numbers, and logic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 456,
        "total_tokens": 1795
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did AIG's financial relationship with Corebridge evolve between 2023 and 2024, particularly in terms of potential equity dilution and income recognition?",
      "original_answer": "In 2023, AIG had a stake in Corebridge that included a potential equity dilution mechanism tied to Blackstone's right to exchange its ownership interest in Corebridge for AIG common shares, which would have introduced up to 24.1 million additional shares in 2022 (and 4.4 million in 2023) had the IPO not occurred before 2024. However, since the IPO occurred on September 19, 2022, this exchange right was terminated. By 2024, AIG's relationship with Corebridge had shifted from a stakeholding to an equity method investment, where AIG reported income based on dividends received and changes in Corebridge's stock price from June 9, 2024 onwards. This reflects a transformation from a potential equity dilution scenario to a post-divestiture equity income model.",
      "llm_answer": "Between 2023 and 2024, AIG’s relationship with Corebridge shifted from consolidation to deconsolidation, resulting in a $4.8 billion loss on deconsolidation driven largely by the reclassification of $7.2 billion of accumulated other comprehensive loss. After the deconsolidation, AIG retained a 22.7 % equity stake, recognizing equity‑method income of $601 million (dividends plus changes in Corebridge’s stock price) and recording a retained investment of $8.5 billion, while the book value of Corebridge (excluding noncontrolling interests) was $6.677 billion, creating a $3.005 billion pre‑tax gain on sale that was offset by the AOCI reclassification. This sequence reflects potential equity dilution (as AIG’s ownership percentage fell from 52.2 % to 22.7 %) and significant income‑recognition impacts tied to fair‑value adjustments and AOCI reclassifications.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies, particularly in dates and key events, despite addressing the general theme of AIG's evolving relationship with Corebridge. (1) The original answer states that the IPO occurred on September 19, 2022, which terminated Blackstone's exchange right—this is a critical timeline point. However, the LLM implies deconsolidation and related financial impacts occurred in 2023–2024, when in fact the IPO and termination of dilution risk predated 2023. The LLM incorrectly suggests that equity dilution was realized between 2023 and 2024, while the ground truth states the mechanism was already terminated due to the 2022 IPO. (2) Quantitative inaccuracies include: the $4.8 billion loss on deconsolidation, $7.2 billion AOCI reclassification, $601 million equity-method income, 22.7% retained stake, $8.5 billion retained investment, and $3.005 billion pre-tax gain—none of these figures appear in the original answer and cannot be verified against the provided ground truth. The original mentions up to 24.1 million and 4.4 million potential shares diluted in 2022 and 2023 respectively, but the LLM does not reference these at all. (3) The reasoning is partially sound in that it identifies a shift from consolidation to equity method accounting, which aligns with a post-divestiture model. It also correctly frames the change in income recognition (from consolidation to equity-method dividends and price changes). However, it fails the multi-hop requirement by not connecting the termination of dilution risk due to the 2022 IPO—a key causal event—to the absence of actual dilution in 2023–2024. (4) Contextual relevance is high because the LLM addresses both equity dilution (though incorrectly as realized rather than avoided) and income recognition changes. But due to major factual and numerical errors, especially regarding timing and financial figures, the overall correctness is low. The answer fabricates specific dollar amounts and percentages not present in the ground truth, undermining reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1409,
        "completion_tokens": 551,
        "total_tokens": 1961
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has Comcast's financial exposure to Universal Beijing Resort evolved from 2022 to 2024, based on its debt disclosures and consolidation treatment?",
      "original_answer": "In 2022, Comcast disclosed that Universal Beijing Resort had $3.6 billion in debt as of December 31, 2021, and $2.5 billion as of December 31, 2020. By 2024, Comcast clarified that Universal Beijing Resort had $3.4 billion in debt outstanding as of December 31, 2024, and $3.5 billion as of December 31, 2023. This indicates that the debt levels stabilized after earlier reductions, and Comcast now consolidates Universal Beijing Resort as a variable interest entity (VIE), with its assets and liabilities fully included in Comcast’s consolidated balance sheets at $7.3 billion in assets and $7.0 billion in liabilities as of 2024.",
      "llm_answer": "From 2022 to 2024, Comcast's financial exposure to Universal Beijing Resort evolved as follows:  \n- The resort's debt decreased slightly from $3.5 billion (as of Dec 2023) to $3.4 billion (as of Dec 2024), reflecting ongoing repayments of the term loan.  \n- Comcast consolidates the VIE and reports its assets and liabilities (peaking at $7.3 billion in assets and $7.0 billion in liabilities in 2024), but its maximum financial risk remains limited to its 30 % equity stake, with no additional liquidity or guarantee commitments.  \n\nThus, while the absolute debt level of the resort has modestly declined, Comcast's exposure is still defined by its non‑controlling interest and the associated consolidated balance‑sheet exposure, not by any direct debt guarantee.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies in numbers and dates. The ground truth states that Universal Beijing Resort had $3.6 billion in debt as of December 31, 2021, and $2.5 billion as of December 31, 2020 — information omitted in the LLM response. Instead, the LLM incorrectly introduces $3.5 billion as of December 2023 and $3.4 billion as of December 2024 as if these were new disclosures from the 2022–2024 period, but the ground truth explicitly states that the $3.5 billion figure is for December 31, 2023, and $3.4 billion for December 31, 2024 — which the LLM misattributes to 2022–2024 evolution without acknowledging earlier years. More critically, the LLM implies a decrease from $3.5B to $3.4B is part of a trend, but fails to note that debt actually increased from $2.5B (2020) to $3.6B (2021), then declined to $3.5B (2023) and $3.4B (2024), which is essential context for 'evolution'. (2) The LLM correctly reports the 2024 consolidation details: $7.3B in assets and $7.0B in liabilities as of 2024, and correctly identifies Comcast’s consolidation of the VIE. However, it incorrectly suggests Comcast has no guarantee commitments — while the ground truth does not explicitly state guarantees, it also does not support the claim that exposure is 'limited to 30% equity stake' or 'no additional liquidity or guarantee commitments'; this is an unsupported inference. (3) The multi-hop reasoning is partially sound — the model connects debt levels with consolidation treatment and VIE status — but fails to synthesize the full timeline of debt changes across 2020–2024, omitting key data points from earlier years that are necessary to assess the evolution. (4) The contextual relevance is high — the answer addresses debt trends and consolidation — and the qualitative reasoning is mostly logical, though weakened by missing data and unsupported claims about risk limitation. Quantitative accuracy is low due to incorrect presentation of the debt timeline and omission of critical figures. Correctness score is 6 due to partial factual accuracy but significant omissions and misrepresentations of the debt trend.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 577,
        "total_tokens": 1927
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has the structure of aircraft trade-in commitments changed between 2022 and 2023, particularly in terms of customer eligibility and risk exposure?",
      "original_answer": "In 2022, the Aerospace segment had outstanding options with 'some customers' to trade in aircraft as partial consideration for new aircraft purchases, indicating a broader or less-specific customer eligibility. By 2023, the eligibility was narrowed to 'some Gulfstream customers,' suggesting a more specific subset of customers was offered trade-in options. Additionally, while both years acknowledged the risk associated with adverse market changes affecting trade-in values, 2023 introduced a more specific framing by highlighting Gulfstream, a key business jet brand, which may indicate a strategic focus or increased risk concentration in that segment. Despite these structural changes, both years reported that the estimated change in fair market values from the commitment date was 'not material.'",
      "llm_answer": "Between 2022 and 2023, the structure of aircraft trade-in commitments remained largely consistent in form but shifted in risk exposure. While earlier commitments (as of 2021) were generally structured to establish fair market value 45 or fewer days before delivery, with any excess of pre-established trade-in price over fair market value treated as a revenue reduction, the 2023 disclosures indicate these commitments still carry risk in adverse market conditions—particularly when guaranteeing a pre-determined trade-in value. The core change lies in eligibility: although not explicitly detailed in the provided text, the continuation of such commitments implies ongoing customer eligibility for trade-in options tied to new aircraft orders, with no indication of stricter criteria introduced in 2023. Risk exposure remains focused on potential write-downs if market values decline below guaranteed trade-in prices, though the documents state that as of December 31, 2023, the estimated change in fair market values from commitment dates was not material. Thus, while the mechanics of trade-in structures did not undergo a fundamental change, the underlying risk profile persists due to market volatility and the potential for revenue reduction if valuations fall.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies regarding customer eligibility and risk exposure changes between 2022 and 2023. While the ground truth states that in 2022 trade-in options were available to 'some customers' and in 2023 were narrowed to 'some Gulfstream customers,' the LLM incorrectly claims there is 'no indication of stricter criteria introduced in 2023' and implies eligibility remained unchanged. This misrepresents a key structural shift. Additionally, the LLM references '2021' disclosures and '45 or fewer days before delivery' valuation timing, which are not present in the original answer or supported by the provided context, introducing extraneous and unverified details. (2) Quantitatively, the LLM correctly notes that the estimated change in fair market values was 'not material' as of December 31, 2023, aligning with the ground truth. However, it introduces unsupported specifics (e.g., 45-day valuation window) not found in the original, reducing quantitative reliability. (3) The multi-hop reasoning is flawed: the model fails to correctly synthesize the narrowing of customer eligibility from broad customers to Gulfstream-specific ones, a central point in the original answer. It also misses the strategic emphasis on Gulfstream in 2023 as a sign of focused risk exposure. Instead, it assumes continuity where there was a meaningful restriction. (4) Despite these issues, the LLM correctly identifies that trade-in commitments carry market risk and that the overall impact remains immaterial, maintaining some contextual relevance. However, due to significant errors in entity accuracy (misrepresenting customer eligibility) and reasoning, the correctness score is limited to 4.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1518,
        "completion_tokens": 470,
        "total_tokens": 1988
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has Tesla's approach to the Tesla Semi evolved between 2022 and 2024, particularly in terms of its production status and strategic positioning within Tesla's product lineup?",
      "original_answer": "In 2022, Tesla had only announced the Tesla Semi as part of its planned electric vehicles, indicating it was in the conceptual and development phase. By 2024, Tesla had moved the Tesla Semi into 'pilot production' at its Nevada facility, signaling a significant advancement in its development and a step closer to commercialization. This evolution reflects Tesla's strategic shift from merely planning the vehicle to actively preparing it for market entry.",
      "llm_answer": "Between 2022 and 2024, Tesla's approach to the Semi evolved from pilot production (as noted in the 2022 filing's production status table showing \"Tesla Semi: Pilot production\") to active production ramp-up, with the 2024 filing confirming its inclusion in manufacturing plans alongside Cybertruck and next-gen vehicles. The Semi is now positioned as a key strategic product within Tesla's broader commercial vehicle expansion, leveraging advancements in battery cell production, manufacturing efficiency, and autonomy to drive cost reductions and affordability, while being integrated into the company's global production capacity growth across Gigafactories.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022 the Tesla Semi was in the 'conceptual and development phase,' not 'pilot production' as claimed by the LLM. The LLM incorrectly states that the 2022 filing showed 'pilot production'—this contradicts the original answer, which clearly states that only an announcement was made in 2022. The 2024 status of 'pilot production' is correctly identified in the ground truth, but the LLM implies a more advanced stage ('active production ramp-up') than supported. (2) There are no numeric values to verify (e.g., financials, quantities), so quantitative accuracy is penalized only for incorrect temporal facts—specifically misrepresenting the 2022 production status. Dates (2022 vs 2024) are used, but the attribution of events to those years is flawed. (3) The multi-hop reasoning is partially sound in that it attempts to compare two years and assess strategic positioning, but it fails on core synthesis: it inverts the timeline by claiming pilot production started in 2022 when the truth states it began by 2024. The strategic positioning as a 'key product' and integration with Gigafactories and battery tech adds detail not in the original and goes beyond the ground truth, introducing unsupported assertions. (4) Contextual relevance is high because the answer addresses production status and strategic positioning as asked. However, correctness is low due to fundamental factual errors in the timeline and production phase classification. The answer appears confident but misrepresents key facts from the source material.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 447,
        "total_tokens": 1733
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did the valuation allowance related to Altria's investment in Cronos evolve between 2022 and 2024, and what does this indicate about the company's expectations regarding the realizability of associated deferred tax assets?",
      "original_answer": "Between 2022 and 2024, the valuation allowance related to Altria's investment in Cronos increased from $379 million in 2022 to $402 million in 2024. This indicates that Altria continued to maintain significant uncertainty regarding the realizability of deferred tax assets associated with the Cronos investment, as the company still did not expect the temporary difference to reverse in the foreseeable future. The steady increase in the allowance suggests a cautious stance by Altria in recognizing the full value of these assets.",
      "llm_answer": "The valuation allowance related to Altria’s investment in Cronos declined sharply from $2,256 million in 2023 to $668 million in 2024, reflecting a $1,588 million reduction driven by the release of allowances tied to JUUL‑related losses and other tax‑basis adjustments. This reduction signals that Altria now expects a substantially higher likelihood of realizing the deferred tax assets associated with its Cronos investment.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is almost entirely incorrect in both quantitative and qualitative aspects. The ground truth states that the valuation allowance increased from $379 million in 2022 to $402 million in 2024, indicating ongoing uncertainty about realizability of deferred tax assets. In contrast, the LLM claims a sharp decline from $2,256 million in 2023 to $668 million in 2024, which is factually wrong on all counts—values, direction of change, and years. (2) The numbers are completely inaccurate: the stated $2,256 million and $668 million do not appear in the ground truth, and there is no mention of a release tied to JUUL-related losses. The calculation of a $1,588 million reduction is therefore based on false inputs. (3) The multi-hop reasoning is flawed—the LLM introduces unrelated elements (JUUL-related losses) not present in the original answer and fails to correctly track the actual trend (a modest increase, not a large decrease). It also misrepresents the implication: instead of reflecting continued caution, the LLM suggests increased optimism, which contradicts the ground truth. (4) The contextual relevance is low but not zero because the answer addresses the general topic (valuation allowance and realizability of deferred tax assets). However, due to severe factual and numerical inaccuracies, the correctness, quantitative, and qualitative accuracy scores are near the minimum.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 393,
        "total_tokens": 1652
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did the financial treatment and valuation impact of Amgen's investment in BeiGene evolve between 2023 and 2024?",
      "original_answer": "In 2023, Amgen changed the accounting method for its investment in BeiGene from the equity method to fair value, resulting in gains recognized in connection with this revaluation. By 2024, the investment contributed net unrealized losses within Amgen's Other income (expense), net, reflecting a shift from gains in 2023 to losses in 2024 due to market or valuation changes. This evolution shows a reversal in the financial benefit derived from the BeiGene investment over the two years.",
      "llm_answer": "The financial treatment and valuation of Amgen’s investment in BeiGene shifted markedly between 2023 and 2024. In 2023, the company changed its accounting for the BeiGene stake from the equity method to fair‑value measurement, recognizing unrealized gains in earnings and boosting other income; this fair‑value approach continued into 2024, but the gains were offset by net unrealized losses on strategic equity investments and lower interest income, resulting in a smaller contribution to earnings. Consequently, while the 2023 valuation generated a notable earnings boost from the fair‑value remeasurement, the 2024 period saw a reversal of that effect, with fair‑value adjustments now producing net losses that reduced overall profitability.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the key accounting change in 2023—Amgen's shift from the equity method to fair-value measurement for its BeiGene investment—and notes the recognition of unrealized gains in earnings, which matches the original answer. It also accurately states that in 2024, the investment resulted in net unrealized losses within Other income (expense), net, reflecting a reversal from gains to losses. (2) There are no specific numerical values (e.g., dollar amounts) in the original answer, so no quantitative discrepancies exist; the LLM does not introduce any incorrect figures and correctly references the directional changes (gains in 2023, losses in 2024). (3) The multi-hop reasoning is sound: the model synthesizes the change in accounting method, its immediate impact (2023 gains), and the subsequent valuation shift (2024 losses), demonstrating correct understanding across time periods and accounting treatments. (4) The only minor shortcoming is that the LLM adds a detail not present in the ground truth—'lower interest income'—which slightly extends beyond the provided information, though it doesn't contradict it. This does not impair the core accuracy but introduces a peripheral element not confirmed by the source. Overall, the answer is factually correct, contextually relevant, and semantically equivalent to the original, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 400,
        "total_tokens": 1699
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the positioning and market strategy for Disney+ Hotstar evolved between 2023 and 2024, particularly in terms of its regional branding and service structure?",
      "original_answer": "In 2023, Disney+ Hotstar was described as a DTC service primarily in India that offered general entertainment, family, and sports programming. It was positioned as a distinct regional brand within Disney’s broader Direct-to-Consumer portfolio. By 2024, while still branded as Disney+ Hotstar in India and Southeast Asia, the company had merged its previously separate Star+ and Disney+ services in Latin America into a single Disney+ product offering by the end of June 2024. This indicates a strategic shift toward consolidating regional streaming services under the Disney+ brand umbrella, streamlining offerings, and possibly enhancing content integration across markets.",
      "llm_answer": "Between 2023 and 2024, Disney+ Hotstar's positioning evolved from a distinct regional brand to a unified Disney+ product offering. Prior to July 2024, Disney+ and Star+ were offered separately or as a Combo+ bundle in Latin America, but these were merged into a single Disney+ service. The 2024 filing confirms that Disney+ Hotstar is not included in multi-product offerings, and the Combo+ subscribers (10.8 million as of September 30, 2023) were transitioned into the standalone Disney+ product. This strategic shift reflects a move toward global brand consistency, with Disney+ Hotstar now operating as part of the broader Disney+ ecosystem rather than as a separate regional entity.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key strategic shift in Disney's streaming structure between 2023 and 2024, particularly the merger of Star+ and Disney+ in Latin America into a single Disney+ service by July 2024. It accurately notes that Disney+ Hotstar remains a distinct brand in India and Southeast Asia, though the answer slightly overstates the integration by suggesting Disney+ Hotstar is now part of the 'broader Disney+ ecosystem' as a unified offering, which is not fully supported—the ground truth confirms Disney+ Hotstar remains regionally branded and operationally distinct in key markets. (2) Quantitatively, the LLM correctly cites the 10.8 million Combo+ subscribers as of September 30, 2023, and the June/July 2024 timeline for the Latin America merger, aligning with the ground truth. No calculation errors are present. (3) The multi-hop reasoning is mostly sound: it connects the discontinuation of Combo+ with the transition to a unified Disney+ product in Latin America and infers a strategic move toward brand consistency. However, it incorrectly implies that Disney+ Hotstar itself was restructured into Disney+, when in fact it was Star+ (in Latin America) that was merged—Disney+ Hotstar remains a separate regional brand. This is a key distinction the LLM misses. (4) Despite this, the answer is highly relevant and captures the core strategic evolution. The correctness score is 8 due to accurate data and strong reasoning, but docked for conflating the fate of Star+ in Latin America with Disney+ Hotstar’s branding. Quantitative accuracy is high (9) due to correct numbers and dates. Qualitative accuracy is 8 due to strong synthesis but a minor misattribution of the brand consolidation. Contextual relevance is 10—fully addresses the question’s focus on positioning and market strategy evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 501,
        "total_tokens": 1846
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How did PayPal's approach to its Protection Programs evolve between 2023 and 2024, particularly in terms of risk exposure and loss recovery mechanisms?",
      "original_answer": "In 2023, PayPal disclosed that the costs associated with its protection programs were recorded in 'transaction and credit losses' during the period the payment transaction was completed, and it did not provide a separate service to customers under these programs. By 2024, PayPal introduced more detailed disclosures around its protection programs, highlighting that it incurs substantial losses from these programs due to customer disputes and faces challenges in recovering losses from merchants, especially in cases involving fraud or merchant insolvency. Additionally, PayPal noted that it may face increased exposure due to evolving fraud schemes and potential regulatory changes affecting chargeback requirements. This indicates a shift toward more explicit risk acknowledgment and a broader understanding of potential financial impact.",
      "llm_answer": "PayPal's approach to its Protection Programs evolved between 2023 and 2024 by shifting from a focus on transaction-level fraud and chargeback risks to broader operational and financial risks tied to credit products and loan portfolios. In 2023, the company highlighted increased exposure to credit losses from its U.S. merchant financing (PPWC/PPBL) and consumer installment loans, emphasizing reliance on unaffiliated banks for credit offerings and the risks of loan defaults, underwriting model inaccuracies, and regulatory changes affecting interest rate structures. By 2024, the focus expanded to include the impact of macroeconomic pressures (e.g., recession risks, rising interest rates) on credit performance, as well as the integration of new risk models for merchant financing and the sale of BNPL loan receivables (e.g., U.K./Europe portfolio sales in 2023). This reflects a transition from reactive fraud mitigation to proactive risk management of credit products, with greater emphasis on loss recovery mechanisms through partnerships with banks and structured receivables sales. (Based on pages 22-26, 75-79, and 23-25)",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 2,
      "detailed_feedback": "The LLM answer is largely incorrect and fails to accurately reflect PayPal's evolution in Protection Programs between 2023 and 2024 as described in the ground truth. (1) The LLM incorrectly shifts focus to credit products, loan portfolios, BNPL receivables sales, and merchant financing (PPWC/PPBL), which are unrelated to the Protection Programs in question—these pertain to PayPal's credit risk disclosures, not its buyer/seller protection programs. The original answer correctly identifies that in 2023, PayPal recorded protection program costs within 'transaction and credit losses' without offering a separate service, and in 2024 began providing more detailed disclosures about losses from customer disputes and challenges recovering from merchants, especially in fraud or insolvency cases. (2) There are no numeric values in either answer, so quantitative accuracy is neutral—no errors here, but no numbers to verify. (3) The multi-hop reasoning is flawed: the LLM conflates two different risk domains—protection programs (fraud, chargebacks, merchant recovery) vs. credit risk (loan defaults, underwriting, interest rates). The cited pages (e.g., 22–26, 75–79) may contain real disclosures, but they pertain to credit risk, not protection programs. (4) The LLM answer is semantically and contextually misaligned—Protection Programs refer to buyer/seller dispute resolution and fraud protection, not credit or loan products. The shift described in the ground truth is toward greater transparency and risk acknowledgment in dispute-related losses, not a move from fraud to credit risk management. Thus, despite accurate-sounding language and plausible structure, the answer is factually incorrect in substance, resulting in a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1494,
        "completion_tokens": 474,
        "total_tokens": 1969
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has NextEra Energy's relationship with solar generation facilities evolved from 2022 to 2024, particularly in terms of ownership structure and financial exposure?",
      "original_answer": "In 2022, NextEra Energy Resources was actively divesting ownership stakes in solar generation facilities, including the sale of a 100% ownership interest in a 100 MW solar facility in Arizona and the sale of a 90% ownership interest in a portfolio that included four solar facilities. These transactions resulted in significant cash proceeds and the recognition of gains. By 2024, the company's relationship had transformed into a more complex structure involving equity stakes and consolidated variable interest entities (VIEs). For example, NextEra consolidated eight VIEs owning solar generation facilities with approximately 765 MW of capacity and held a 10% direct ownership interest in additional solar facilities. This shift indicates a strategic move from outright ownership and divestiture to a more diversified and financially leveraged stake through VIEs, with increased financial exposure through guarantees and credit support.",
      "llm_answer": "From 2022 to 2024, NextEra Energy’s relationship with solar generation facilities shifted from a strategy of retaining full ownership and control to increasingly leveraging joint‑venture and sale‑lease structures that involve third‑party investors and noncontrolling interests.  In 2022 and 2023 the company sold significant ownership stakes in wind and solar portfolios—often retaining an operating contract and a controlling interest while transferring a portion of equity to NEP subsidiaries or other partners—thereby reducing its direct equity exposure and shifting financial risk to the investors.  By 2024, NEER consolidated numerous VIEs that own large solar (and wind) portfolios, but the equity ownership in these projects is now split with external partners, and the company records only its share of earnings and cash flows, while the bulk of capital investment and debt financing is supported by the VIEs themselves.  This evolution reflects a move toward shared‑ownership, risk‑allocation, and capital‑raising structures rather than the earlier, more wholly‑owned approach.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly captures the strategic evolution of NextEra Energy's relationship with solar generation facilities from 2022 to 2024, emphasizing a shift from full ownership to shared structures involving VIEs and third-party investors. The qualitative reasoning is strong: it accurately describes the move toward joint ventures, sale-leaseback arrangements, and consolidation of VIEs with noncontrolling interests, aligning with the ground truth’s emphasis on reduced direct equity exposure and increased financial leverage through VIEs. Contextual relevance is excellent, as all parts of the question—ownership structure and financial exposure—are addressed with appropriate financial and structural detail. However, the quantitative accuracy is slightly lower because the LLM omits specific, verifiable figures from the original answer: the 2022 sale of a 100% stake in a 100 MW Arizona solar facility and the 90% stake in a portfolio of four solar facilities. Additionally, the 2024 consolidation of eight VIEs with ~765 MW of solar capacity and NextEra’s 10% direct ownership interest are not mentioned. While the LLM correctly references VIE consolidation and shared equity, the absence of these concrete numbers and examples reduces precision. The answer generalizes accurately but lacks the specific multi-hop data points that anchor the ground truth. There are no factual errors—just omissions of key quantitative details—hence the correctness score of 8 rather than 9 or 10. The reasoning remains logically sound and semantically aligned with the original answer, just less specific in execution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1511,
        "completion_tokens": 440,
        "total_tokens": 1951
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How did ACN's investment in Mutual Fund Debt Securities evolve from 2022 to 2023, and what was the change in valuation methodology as reflected in the fair value hierarchy levels?",
      "original_answer": "In 2022, ACN reported Mutual Fund Debt Securities valued at $379,989 with the entire amount categorized under Level 2 of the fair value hierarchy. In 2023, this investment decreased to $253,025, and the valuation remained entirely under Level 2. The decrease in value indicates a reduction in exposure to Mutual Fund Debt Securities over the year, while the valuation methodology remained consistent, relying on observable market data.",
      "llm_answer": "From 2022 to 2023, ACN's investment in Mutual Fund Debt Securities increased from $379,989 million to $379,989 million (the same figure appears in both years' disclosures, indicating no material change). The valuation methodology remained within the fair value hierarchy, with Mutual Fund Debt Securities classified as Level 2 assets—quoted prices for similar instruments in active markets—consistent across both years. No shift in hierarchy level was disclosed.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that ACN's investment in Mutual Fund Debt Securities remained unchanged at $379,989 million in both years. The ground truth shows a decrease from $379,989 (not million) in 2022 to $253,025 in 2023. The LLM incorrectly claims no material change, when in fact there was a significant decrease of $126,964. Additionally, the LLM erroneously adds 'million' to the dollar amounts, turning ~$380 thousand into $379,989 million (~$380 billion), which is off by a factor of 1,000,000—this is a critical quantitative error. (2) The valuation methodology part is partially correct: the LLM correctly states that the securities remained classified under Level 2 in both years and that no shift in hierarchy level occurred. However, it fails to note that in both years the entire amount was categorized under Level 2, which was explicitly stated in the ground truth. (3) The multi-hop reasoning is flawed: the model fails to correctly compare the two years' values and misrepresents the evolution of the investment. It also does not acknowledge the reduction in exposure, which is a key qualitative point in the original answer. (4) The contextual relevance is moderate because the answer addresses the right metric and hierarchy level, but the massive numerical inaccuracy and incorrect conclusion about no change severely undermine correctness. The qualitative reasoning is weak due to incorrect data interpretation. Thus, the correctness and quantitative accuracy scores are low, while qualitative accuracy and contextual relevance receive minimal points for attempting the right structure and mentioning Level 2 consistently.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1232,
        "completion_tokens": 459,
        "total_tokens": 1691
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has Chevron's financial stake and involvement in Tengizchevroil evolved between 2022 and 2023?",
      "original_answer": "In 2022, Chevron's carrying value of its investment in Tengizchevroil was $23,727 million with a reported equity in earnings of $1,238 million. By 2023, Chevron disclosed that its carrying value was approximately $80 million higher than its underlying equity in Tengizchevroil's net assets, indicating a more complex valuation approach. Additionally, Chevron highlighted that it provided a loan of $4,500 million to Tengizchevroil to fund the Future Growth Project and Wellhead Pressure Management Project (FGP/WPMP). This shows a significant deepening of Chevron's financial involvement and strategic commitment to the partnership in 2023 compared to 2022.",
      "llm_answer": "Chevron’s financial stake in Tengizchevroil grew modestly from $26.5 billion at the end of 2022 to $26.95 billion at the end of 2023, while its share of the affiliate’s equity earnings remained roughly stable (about $3.38 billion in 2023 versus $3.375 billion in 2022).  The company’s overall upstream segment earnings fell sharply, dropping from $63.293 billion in 2022 to $45.742 billion in 2023, reflecting weaker performance across its international upstream assets, including Tengizchevroil, even though the investment’s book value stayed essentially flat.  Consequently, while Chevron’s direct financial exposure to Tengizchevroil did not change dramatically between 2022 and 2023, the broader upstream earnings decline meant the affiliate’s contribution to Chevron’s total results was markedly smaller in 2023.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Chevron's carrying value of its investment in Tengizchevroil was $23,727 million ($23.727 billion) in 2022, not $26.5 billion as stated. The 2023 carrying value is not explicitly given in the ground truth but is described as being approximately $80 million higher than its underlying equity in net assets—nowhere near the $26.95 billion claimed. Additionally, the reported equity in earnings was $1,238 million in 2022, not $3.375 billion. The LLM's figure of $3.38 billion in 2023 earnings is also incorrect and more than double the actual 2022 figure. (2) The LLM introduces upstream segment earnings of $63.293 billion in 2022 and $45.742 billion in 2023, which are not mentioned in the original answer and appear to be fabricated or misattributed. These figures do not pertain directly to Tengizchevroil and distort the narrative. (3) The multi-hop reasoning is flawed: the original answer emphasizes a strategic deepening of involvement in 2023 through a $4.5 billion loan to fund the FGP/WPMP projects—this key development is entirely missing from the LLM response. Instead, the LLM incorrectly infers reduced importance due to lower upstream earnings, which contradicts the ground truth showing increased financial commitment. (4) While the LLM attempts to address the evolution of Chevron's stake, it fails on core facts, calculations, and critical qualitative developments. The contextual relevance is moderate because it discusses the right company and affiliate, but the incorrect numbers and missing loan detail severely undermine accuracy. Minor credit is given for attempting a year-over-year comparison.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 469,
        "total_tokens": 1825
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has Disney's relationship with ABC Network evolved between 2023 and 2024, particularly in terms of its strategic positioning within Disney's broader entertainment ecosystem?",
      "original_answer": "In 2023, ABC Network was positioned as a core component of Disney's 'Linear Networks' within the Entertainment segment, specifically highlighting its domestic footprint through eight owned ABC television stations and its role in content distribution. By 2024, ABC Network's role had evolved, with its programming becoming more integrated into Disney's direct-to-consumer platforms, such as Hulu and Disney+. Specifically, content from ABC Network was made available on Hulu's SVOD service one day after its linear airing. This shift indicates a strategic move toward digital integration and away from traditional linear distribution. Additionally, while ABC Network was still referenced in the context of affiliate fees in 2023, 2024 emphasized its contribution to streaming services rather than standalone linear revenue.",
      "llm_answer": "Disney's relationship with ABC Network has strengthened its strategic positioning within the broader entertainment ecosystem, particularly through integrated content distribution and advertising synergies. ABC Network, owned by Disney, serves as a key platform for distributing Disney's linear programming, including primetime shows, sports (via ESPN on ABC), and news, reaching nearly 100% of U.S. households through its 245 affiliated stations and eight owned stations. This integration supports Disney's Direct-to-Consumer (DTC) services like Hulu and Disney+, with ABC content also available on Hulu's SVOD platform one day after linear airing, enhancing cross-platform engagement. Additionally, Disney's acquisition of 21st Century Fox in 2019 solidified its control over ABC, further consolidating its linear network portfolio and enabling cohesive content strategy across theatrical, streaming, and broadcast platforms.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct elements, such as ABC's integration with Hulu (content available one day after linear airing) and its role in Disney's broader ecosystem, but introduces significant inaccuracies. The claim that ABC reaches 'nearly 100% of U.S. households through its 245 affiliated stations' is not supported by the ground truth, which only mentions eight owned stations and does not specify the number of affiliates. The ground truth does not state 245 affiliates, making this a major quantitative error. Additionally, the LLM incorrectly references the 2019 acquisition of 21st Century Fox as relevant to ABC ownership—Disney has owned ABC since 1996 via the Capital Cities/ABC acquisition; the 2019 Fox acquisition is unrelated to ABC. (2) The only correct number is 'eight owned stations,' which matches the ground truth. The 245 affiliate figure is fabricated or misattributed and undermines quantitative accuracy. (3) The reasoning correctly identifies the multi-hop evolution of ABC’s role—shifting from linear to digital integration via Hulu—but fails to contrast 2023 vs. 2024 as required. The answer does not mention the shift in emphasis from affiliate fees (2023) to streaming contribution (2024), missing a key strategic evolution. (4) Despite these flaws, the answer captures the core idea of ABC’s growing integration with DTC platforms, making it contextually relevant and partially accurate in qualitative reasoning. However, the inclusion of false quantitative data and incorrect historical context reduces correctness and quantitative accuracy significantly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1444,
        "completion_tokens": 442,
        "total_tokens": 1887
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has General Dynamics' positioning of the ASCOD vehicle within its Land Systems portfolio evolved between 2022 and 2023, and what does this indicate about potential shifts in production focus or investment allocation?",
      "original_answer": "In 2022, General Dynamics explicitly stated it was 'producing and upgrading' the ASCOD vehicle, indicating active development and enhancement of the platform. By 2023, the company's disclosure shifted to simply 'offering' the ASCOD, without specific mention of production or upgrades. This change in language suggests a potential shift in focus away from active investment or development of the ASCOD platform, possibly reallocating resources to other vehicle programs like the Piranha 5 and AJAX, which are explicitly called out in both years with continued production and international deployments.",
      "llm_answer": "Between 2022 and 2023, General Dynamics’ ASCOD tracked combat vehicle – produced under the European Land Systems (ELS) business unit within the Combat Systems segment – remained a core product in its portfolio, with production activity highlighted by continued orders for international variants (e.g., Spanish Pizarro, Austrian Ulan) and support for allied programs such as the Canadian Army’s LAV modernization. The 2023 financial tables show the Combat Systems segment’s revenue share rising from 18 % to 20 % of consolidated revenue, driven largely by increased sales of military vehicles, including ASCOD‑derived platforms, while the segment’s backlog disclosures list scheduled deliveries of ASCOD‑type vehicles through 2027. This growing share and the emphasis on ASCOD production indicate a strategic shift toward expanding land‑vehicle output and allocating more resources to tracked combat‑vehicle development, reflecting a focused investment in next‑generation armored mobility rather than a pivot away from it.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth. (1) The original answer states that General Dynamics shifted from 'producing and upgrading' ASCOD in 2022 to merely 'offering' it in 2023, indicating a reduction in active investment. In contrast, the LLM claims there was increased production, rising revenue share (from 18% to 20%), and backlog extending to 2027—none of which are supported by the ground truth. These specific numbers (18%, 20%, 2027) are fabricated or misattributed, failing quantitative accuracy. (2) The LLM introduces financial data (revenue share increase, backlog details) and programmatic details (Canadian LAV modernization, Spanish Pizarro, Austrian Ulan) that are not present in the original answer and contradict its core claim of reduced emphasis on ASCOD. (3) The multi-hop reasoning is flawed: instead of recognizing the linguistic shift as a signal of reduced investment, the model infers increased focus, drawing opposite conclusions from what the evidence suggests. It fails to mention the key contrast in disclosure language ('producing and upgrading' vs. 'offering') which is central to the original answer. (4) While the answer is contextually relevant—discussing ASCOD, Land Systems, and production focus—it is factually inaccurate and misrepresents the evolution of General Dynamics' positioning. The qualitative reasoning is unsound due to incorrect entity synthesis and erroneous inference. Minor credit is given for addressing the general topic of portfolio positioning, but the core facts and direction of change are wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1423,
        "completion_tokens": 432,
        "total_tokens": 1856
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has PayPal's utilization of European customer balances for credit activities evolved between 2023 and 2024, and what does this shift indicate about the company's credit funding strategy?",
      "original_answer": "In 2023, PayPal had approved $3.0 billion of European customer balances for credit activities, representing approximately 39% of balances made available for corporate use. By 2024, the approved amount had decreased to $2.0 billion, or 26% of European customer balances. This indicates a strategic shift toward reducing reliance on customer balances for credit funding, potentially in favor of external financing sources, as evidenced by PayPal's multi-year agreement to sell consumer installment receivables, which saw $20.8 billion in loans sold in 2024 compared to $5.5 billion in 2023.",
      "llm_answer": "PayPal's utilization of European customer balances for credit activities declined from $3.0 billion (≈39% of European balances) in 2023 to $2.0 billion (≈26% of European balances) in 2024, reflecting a deliberate reduction in the share of those balances that can be designated to fund credit products. This shift signals a more conservative credit‑funding strategy, relying less on internal customer deposits and increasingly on external financing sources such as debt issuances and partnership‑based funding.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All quantitative values are correct: $3.0 billion in 2023 (≈39%) and $2.0 billion in 2024 (≈26%) match the original answer exactly, with acceptable formatting (e.g., ≈ symbol, spacing in $3.0 billion). (2) The answer correctly identifies the downward trend in utilization of European customer balances for credit activities, addressing the first part of the question. (3) The reasoning about a strategic shift toward reduced reliance on internal balances is sound and consistent with the ground truth. The LLM correctly infers a move toward external financing, though it specifies 'debt issuances and partnership-based funding'—which is plausible but not explicitly confirmed in the ground truth. The original answer cites a specific mechanism: a multi-year agreement to sell consumer installment receivables, with $20.8 billion sold in 2024 vs $5.5 billion in 2023. This key evidence of externalization is missing in the LLM response, representing a minor but notable omission in completeness. (4) Despite this, the core multi-hop synthesis—linking reduced use of customer balances to a broader strategic shift—is logically sound and contextually appropriate. The answer remains semantically equivalent in intent and conclusion, just lacking the specific supporting data point about receivables sales. Hence, full marks for quantitative accuracy and contextual relevance, a 9 for qualitative accuracy due to missing evidence, and a 9 overall for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1285,
        "completion_tokens": 420,
        "total_tokens": 1705
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How did the valuation and categorization of equity securities within NEE's Special Use Funds evolve between 2022 and 2024, and what does this indicate about changes in transparency or investment composition?",
      "original_answer": "In 2022, NEE's Special Use Funds reported equity securities at a carrying amount of $906 million (with an estimated fair value of $907 million) for NEE and $672 million (with an estimated fair value of $672 million) for FPL, without detailed categorization by valuation levels. By 2024, the equity securities in the Special Use Funds had grown significantly, with NEE holding $2,614 million in Level 1 equity securities and FPL holding $1,028 million in Level 1 equity securities, alongside more granular disclosures that included Level 2 and Level 3 valuations. This indicates a substantial increase in equity investments and a shift toward more transparent and detailed reporting of asset valuation methodologies.",
      "llm_answer": "Between 2022 and 2024, the valuation of equity securities within NEE’s Special Use Funds shifted markedly toward Level 3 inputs, rising from $229 million (2022) to $229 million in 2023 and then to $229 million in 2024 (reflecting increased reliance on unobservable inputs and commingled funds), while the total fair‑value of those funds grew from $6.164 billion (2022) to $6.164 billion (2023) and $6.164 billion (2024) – indicating a modest increase in overall size but a greater proportion of less‑transparent assets. This evolution suggests that NEE’s investment composition is becoming less transparent, with a larger share of holdings classified at the lowest level of the fair‑value hierarchy.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is almost entirely incorrect and contradicts the ground truth in multiple critical ways. (1) Quantitative Accuracy: The LLM claims Level 3 equity securities were $229 million in 2022, 2023, and 2024 — this number does not appear in the original answer and is factually wrong. The ground truth states that in 2022, NEE and FPL reported carrying amounts of $906M and $672M respectively, with no breakdown by valuation levels. By 2024, the disclosures included Level 1, 2, and 3 valuations, but the LLM incorrectly asserts a rise in Level 3 holdings. Additionally, the LLM cites a total fair value of $6.164 billion across years — a figure not present in the original and unrelated to the equity securities in Special Use Funds. (2) Completeness: The answer fails to mention the significant growth in Level 1 equity securities (NEE: $2,614M in 2024; FPL: $1,028M), which is a central point in the ground truth. It also omits the 2022 fair value estimates ($907M for NEE, $672M for FPL). (3) Entity Accuracy: While NEE and FPL are correctly identified, the years and financial metrics are grossly misstated. The LLM fabricates consistent $6.164B total fair values across years and stagnant $229M Level 3 holdings without variation — suggesting hallucination. (4) Reasoning: The conclusion that transparency decreased due to increased Level 3 assets is the opposite of the truth. The original answer states that reporting became more granular and transparent by 2024, with explicit Level 1, 2, and 3 disclosures — indicating improved transparency, not reduced. The LLM’s logic is therefore fundamentally flawed. (5) Semantic Equivalence: The answer conveys the opposite meaning of the original — claiming reduced transparency when the truth is increased transparency. Even allowing for rewording, the factual divergence is too severe. The only partial relevance is that it addresses valuation levels and transparency, but with entirely incorrect data and conclusions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 530,
        "total_tokens": 1899
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How did the scope and utilization of Accenture's share purchase program evolve from fiscal 2022 to fiscal 2023, particularly in terms of shares acquired under the public program versus those acquired through employee-related transactions?",
      "original_answer": "In fiscal 2022, Accenture purchased 1,964,612 Class A ordinary shares under the publicly announced open-market share purchase program for an aggregate price of $576 million. Additionally, 97,251 shares were acquired through employee-related transactions, such as share withholding for payroll tax obligations, which do not affect the aggregate available authorization. In fiscal 2023, there is no mention of shares purchased under the public program, but the company continued acquiring shares through employee-related transactions under equity share plans. This indicates a shift where the public share purchase program saw reduced or no activity, while employee-related share acquisitions remained consistent.",
      "llm_answer": "From fiscal 2022 to fiscal 2023, Accenture’s share‑purchase activity shifted toward greater use of the publicly announced open‑market program and away from employee‑related transactions. In fiscal 2022, the company bought 1,964,612 shares under the public program and an additional 97,251 shares through employee‑related forfeitures, while by fiscal 2023 the public program accounted for essentially all of the $576 million of purchases reported, with only a minimal number of shares acquired via employee‑related transactions.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that contradict the ground truth. (1) Quantitatively, while the fiscal 2022 share numbers (1,964,612 under public program and 97,251 employee-related) and $576 million total are correctly stated, the LLM incorrectly claims that the public program accounted for $576 million of purchases in fiscal 2023 — this is false, as the original answer states there is no mention of public program purchases in fiscal 2023. The LLM also fabricates that employee-related transactions were minimal in 2023, whereas the ground truth confirms they continued consistently. (2) The answer reverses the actual trend: the truth shows a reduction or halt in public program activity from 2022 to 2023, while employee-related acquisitions remained ongoing; the LLM incorrectly asserts the opposite — increased public program use and decreased employee-related activity. (3) This reflects a complete failure in multi-hop reasoning: the model misinterprets the evolution of the programs over time, failing to synthesize the absence of 2023 public purchases and the continuity of employee-related ones. (4) Despite using relevant entities (Accenture, fiscal years, share programs), the core conclusion is factually wrong, warranting a low correctness score. Contextual relevance is moderate because the answer addresses the right topic and programs, but with incorrect dynamics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1332,
        "completion_tokens": 388,
        "total_tokens": 1721
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How did Chevron's financial reporting relationship with Chevron Phillips Chemical Company LLC evolve between 2022 and 2023, particularly in terms of its consolidation status and investment accounting approach?",
      "original_answer": "In 2022, Chevron Phillips Chemical Company LLC was consolidated into Chevron’s financial statements, as indicated by the inclusion of 'Note 8: Summarized Financial Data - Chevron Phillips Chemical Company LLC' among other consolidated subsidiaries. However, in 2023, Chevron explicitly stated that its investment in Chevron Phillips Chemical Company LLC was accounted for using the equity method, and it was no longer consolidated under Chevron U.S.A. Inc.'s financial data. This reflects a significant structural change where Chevron transitioned from consolidating the entity to reporting its investment under the equity method, altering how its financial performance is reflected in Chevron’s consolidated results.",
      "llm_answer": "Between 2022 and 2023, Chevron’s financial reporting relationship with Chevron Phillips Chemical Company LLC remained that of a 50 % equity‑method investment.  In the 2023 10‑K, CPChem is still presented as a “Summarized Financial Data” segment (Note 8) and is accounted for using the equity method, with no change in consolidation status.  The company continued to record its share of CPChem’s earnings (e.g., $1.173 billion of net income attributable to CPChem in 2023) and to disclose the investment’s carrying amount ($14.683 billion at Dec 31 2023), but it did not consolidate CPChem’s balance sheet or results of operations.  Consequently, the reporting relationship and accounting approach for CPChem were unchanged from 2022 to 2023.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its core claim that Chevron's accounting for Chevron Phillips Chemical Company LLC (CPChem) remained unchanged between 2022 and 2023. According to the ground truth, CPChem was consolidated in 2022 (as evidenced by inclusion in consolidated subsidiary notes), but in 2023, Chevron explicitly transitioned to the equity method and ceased consolidation. The LLM incorrectly asserts that the investment was accounted for under the equity method in both years and that there was no change in consolidation status. This misrepresents a key financial reporting shift. While the LLM provides specific numbers (e.g., $1.173 billion net income, $14.683 billion carrying amount), these may be factually accurate for 2023 but are irrelevant to the question, which focuses on the change in accounting treatment. The answer fails to recognize the multi-hop requirement: comparing consolidation status across two years using different sections of the 10-K filings. The reasoning is flawed because it assumes consistency without acknowledging the structural change documented in the 2023 filing. Entity names and years are correct, and the discussion of equity method accounting is conceptually accurate, but the central conclusion contradicts the ground truth. Thus, despite some contextual relevance and correct terminology, the answer is mostly wrong on the key factual and interpretive level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 392,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the role of Hydra-70 rockets in General Dynamics' Combat Systems segment evolved from 2022 to 2023, particularly in terms of contract involvement and production capacity expansion?",
      "original_answer": "In 2022, General Dynamics received a $175 million contract for the production of Hydra-70 rockets as part of its Combat Systems segment. By 2023, the company's role had evolved significantly, with OTS (Orbital Technologies Corporation, part of Combat Systems) maintaining a market-leading position in the supply of Hydra-70 rockets and expanding its production capacity. Specifically, OTS received awards to increase metal parts production capacity for munitions from 18,000 to 86,000 rounds per month by 2025, which includes Hydra-70 rockets as part of its broader munitions portfolio.",
      "llm_answer": "From 2022 to 2023, Hydra-70 rocket production was expanded through a $175 contract award to produce the rockets for the U.S. Army, and OTS announced plans to significantly increase capacity – expanding metal parts production from 18,000 to 86,000 rounds per month by 2025 and propellant capacity from 4 million to 16 million lb per year by 2028 – to support the Army’s accelerated artillery production efforts.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $175 million contract for Hydra-70 rocket production in 2022 and the expansion of metal parts production capacity from 18,000 to 86,000 rounds per month by 2025, which aligns with the ground truth. However, it introduces a new figure—propellant capacity increasing from 4 million to 16 million lb per year by 2028—that is not present in the original answer and cannot be verified from the provided ground truth, making it an unsupported addition. (2) The dollar amount ($175 million) is accurate, though the LLM omits 'million' in writing ('$175'), which could be a formatting oversight but may mislead. The production capacity numbers (18k to 86k rounds/month) are correct and match the ground truth. The added propellant capacity detail lacks corroboration and reduces quantitative accuracy. (3) The multi-hop reasoning is mostly sound: the model connects the 2022 contract to the 2023 capacity expansion under OTS within General Dynamics’ Combat Systems segment. It correctly attributes the role evolution to increased production capacity. However, the inclusion of unverified future propellant capacity expansion weakens the reasoning fidelity. (4) The answer is contextually relevant and addresses both contract involvement and production capacity evolution. While core facts are correct, the addition of unverified data lowers the correctness and quantitative accuracy scores. The qualitative reasoning remains strong due to proper entity linkage and temporal evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 421,
        "total_tokens": 1681
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has PayPal's treatment of the Global Restricted Stock Unit Award Grant Notice evolved between the 2023 and 2024 filings, particularly in terms of its documentation status and associated agreements?",
      "original_answer": "In the 2023 filing, the Global Restricted Stock Unit Award Grant Notice was listed as Exhibit 10.07+ and was associated with the PayPal Holdings, Inc. 2015 Equity Incentive Award Plan, with its form incorporated by reference from 10-12B/A filed on May 14, 2015. By 2024, the same form of the Global Restricted Stock Unit Award Grant Notice (Exhibit 10.07+) remained in place, still referencing the 2015 plan and incorporated by reference from the same 10-12B/A filing on May 14, 2015. However, in the 2024 filing, there was an updated form of the Global Performance Based Restricted Stock Unit Award Grant Notice (Exhibit 10.08+), which was now filed under the amended and restated plan and was linked to a more recent 10-Q filing on April 30, 2024. This indicates that while the base RSU grant notice remained unchanged, the performance-based variant saw active revision and documentation updates in 2024.",
      "llm_answer": "The Global Restricted Stock Unit Award Grant Notice documentation remained consistent between the 2023 and 2024 filings, with both years referencing the same exhibit (10.07+) in their respective Exhibit Indexes. However, the 2024 filing (page 123) explicitly includes the 2024 award notice as part of the \"Form of Global Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement\" under the 2015 Equity Incentive Award Plan, while the 2023 filing (page 122) only listed the 2015 plan's original form (10.07+) without indicating any updates or new versions for 2024. Neither filing explicitly states that the 2024 version was formally documented as a distinct agreement, but the 2024 filing confirms the continued use of the same exhibit framework for award grants.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies that the Global Restricted Stock Unit Award Grant Notice (Exhibit 10.07+) remained consistent between the 2023 and 2024 filings and continues to reference the 2015 Equity Incentive Award Plan. It also accurately notes the exhibit number and the fact that the form was incorporated by reference from earlier filings. However, the LLM answer misses a key distinction from the ground truth: the 2024 filing introduced an updated form of the *Global Performance Based* Restricted Stock Unit Award Grant Notice (Exhibit 10.08+), linked to the amended and restated plan and a recent 10-Q filing on April 30, 2024. This is a critical evolution in documentation status that the LLM fails to mention, despite correctly observing continuity in the base RSU notice. The LLM incorrectly implies that only the base RSU notice was addressed in 2024 and does not recognize the significance of the performance-based variant's update. While the dates and exhibit numbers mentioned (e.g., 10.07+) are factually correct, the answer lacks completeness in covering the full scope of documentation changes. The reasoning is partially sound but fails the multi-hop synthesis required to connect the updated performance-based award (Exhibit 10.08+) with the plan amendment and recent filing. Thus, while contextually relevant and semantically accurate on the base notice, the answer is significantly incomplete on a key aspect of the question about evolution in documentation status and associated agreements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1437,
        "completion_tokens": 416,
        "total_tokens": 1853
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the role of Opdivo within Bristol-Myers Squibb's portfolio evolved from 2022 to 2024, based on its revenue performance and new regulatory approvals?",
      "original_answer": "In 2022, Opdivo generated $7,523 million in revenue, indicating it was a major contributor to Bristol-Myers Squibb's oncology portfolio. By 2024, Opdivo received a new FDA approval in March 2024 for use in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. This regulatory expansion demonstrates a strategic evolution in Opdivo’s therapeutic application and reinforces its continued importance in the company's oncology pipeline, despite not showing a significant revenue increase from earlier years.",
      "llm_answer": "From 2022 to 2024, Opdivo’s revenue performance and regulatory approvals illustrate a clear evolution within BMS’s portfolio.  In 2022, Opdivo generated $7.5 billion in net sales (up from $6.9 billion in 2020), and its sales continued to expand through new indications and combination regimens.  By 2024, Opdivo secured multiple high‑profile approvals—including FDA approval for Opdivo + cisplatin/gemcitabine in first‑line urothelial carcinoma, EC approval for Opdivo + Yervoy in microsatellite‑instable colorectal cancer, and the launch of Opdivo Qvantig (a subcutaneous formulation) in December 2024—while also obtaining Japanese approvals for several additional indications.  These regulatory milestones, together with sustained sales growth, demonstrate that Opdivo has transitioned from a core oncology product to a broader, multi‑indication platform that underpins a larger share of BMS’s alliance and royalty income.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Opdivo's 2022 revenue as $7.5 billion (matching the ground truth of $7,523 million), which is accurate within acceptable rounding. However, it introduces additional claims not supported by the ground truth: it states that Opdivo secured 'multiple high-profile approvals' including EC approval for Opdivo + Yervoy in MSI-H colorectal cancer, Japanese approvals, and the December 2024 launch of Opdivo Qvantig. The ground truth only confirms the March 2024 FDA approval for first-line urothelial carcinoma with cisplatin and gemcitabine. These additional approvals and the December 2024 launch date for a subcutaneous formulation are not present in the original answer and cannot be verified from the provided truth, making them factually unsupported. (2) The revenue figure is quantitatively accurate ($7.5B ≈ $7,523M), but the claim of 'continued sales growth' and 'expanding sales' is not corroborated by the ground truth, which explicitly notes 'despite not showing a significant revenue increase from earlier years.' This misrepresents the financial trend. (3) The multi-hop reasoning is partially sound—linking revenue performance and regulatory developments to assess portfolio evolution—but overreaches by inferring broader platform status and increased royalty income without evidence. The original answer emphasizes sustained importance but no significant revenue growth, whereas the LLM implies expansion and transition, which is a stronger claim than justified. (4) Scores reflect that core facts (2022 revenue, one key FDA approval) are correct, but unsupported additions and mischaracterization of revenue trends reduce factual accuracy. The answer remains contextually relevant and well-structured, but quantitative and qualitative inaccuracies prevent a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 496,
        "total_tokens": 1878
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did Chevron's financial involvement and strategic support for Chevron Phillips Chemical Company LLC evolve between 2022 and 2023, particularly in terms of project funding and investment structure?",
      "original_answer": "In 2022, Chevron highlighted its 50% ownership in Chevron Phillips Chemical Company LLC (CPChem), emphasizing ongoing investments in global manufacturing facilities and expansion projects, such as the planned 1-hexene unit in Old Ocean, Texas, and a C3 splitter at Cedar Bayou, with targeted start-ups in 2023. By 2023, Chevron's involvement had evolved to include a direct loan of $387 million to fund a portion of the Golden Triangle Polymers Project in Orange, Texas, in which CPChem owns 51%. This indicates a shift from general equity ownership and project announcements in 2022 to more direct financial support and structured investment in specific projects in 2023.",
      "llm_answer": "Between 2022 and 2023, Chevron’s financial involvement with Chevron Phillips Chemical Company LLC evolved through increased equity investment and structured project funding. Chevron’s equity stake in Chevron Phillips Chemical Company LLC rose from $6,843 million in 2022 to $7,765 million in 2023, reflecting a $922 million increase. This growth was underpinned by a $387 million loan to fund the Golden Triangle Polymers Project in Orange, Texas, and by the company’s continued 50 % ownership of the affiliate. The investment is accounted for using the equity method, with Chevron’s share of earnings reported net of taxes, and the loan balance remains outstanding as of December 31, 2023. Consequently, Chevron’s financial exposure to the petrochemical joint venture expanded markedly, both through a larger equity investment and through the dedicated project‑specific financing.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. The $387 million loan to fund the Golden Triangle Polymers Project in Orange, Texas, is factually accurate and correctly reflects Chevron's direct financial support in 2023, as stated in the ground truth. However, the claim that Chevron’s equity stake in CPChem increased from $6,843 million in 2022 to $7,765 million in 2023 (a $922 million increase) is not supported by the original answer and introduces unsupported quantitative data. The ground truth does not mention specific equity values or an increase in equity investment—only continued 50% ownership. This introduces a significant factual inaccuracy. (2) The $387 million figure is correct and matches the ground truth. However, the $6,843M and $7,765M equity values are not present in the original answer and cannot be verified; their inclusion suggests fabrication or misattribution. The calculation of a $922 million increase is mathematically correct (7,765 - 6,843 = 922), but since the inputs are incorrect, the conclusion is invalid. (3) The reasoning partially captures the evolution from general ownership in 2022 to more direct financial involvement in 2023 via the loan, which aligns with the multi-hop synthesis required. However, the addition of unsupported equity figures undermines the validity of the conclusion about 'increased equity investment.' The shift in strategy is correctly interpreted, but the evidence used is flawed. (4) The contextual relevance is high—the answer addresses project funding, investment structure, and the timeline between 2022 and 2023. The qualitative reasoning is sound in structure but compromised by incorrect data. Quantitative accuracy is low due to the introduction of unverified financial figures. Correctness score is 6 due to correct identification of the $387M loan and strategic shift, but major deduction for unsupported equity values.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 523,
        "total_tokens": 1924
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did PayPal's protection programs evolve between 2023 and 2024 in terms of financial commitments and disclosures regarding transaction loss reserves?",
      "original_answer": "In 2023, PayPal disclosed that it estimated and recorded costs associated with protection programs in transaction and credit losses, but did not specify the exact amounts for the allowance for transaction losses or negative customer balances. In 2024, PayPal provided more detailed disclosures, including specific figures: the allowance for transaction losses increased from $64 million in 2023 to $86 million in 2024, and the allowance for negative customer balances rose from $218 million to $256 million. This indicates a significant increase in PayPal's financial commitments and potential risk exposure under its protection programs in 2024 compared to the prior year.",
      "llm_answer": "PayPal's transaction loss reserve disclosures remained consistent in amount and methodology between 2023 and 2024, with the allowance for transaction losses increasing from $86 million to $342 million (as reflected in the 2024 allowance balance) and the allowance for negative customer balances rising from $218 million to $256 million. The company continued to expense these reserves in the period the payment transaction is completed, and it reported the changes in the allowance tables in Note 15 of its 2024 filing, mirroring the same disclosure approach used in 2023. No new quantitative commitments or changes to the reserve policy were disclosed beyond the routine updates to the allowance balances.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors in key financial figures. It incorrectly states that the 2023 allowance for transaction losses was $86 million, when the ground truth shows it was $64 million in 2023 and increased to $86 million in 2024. The LLM reverses the timeline and inflates the 2024 figure to $342 million, which is not supported by the original answer. The only correct quantitative point is the increase in allowance for negative customer balances from $218 million to $256 million. (2) The calculation and comparison of transaction loss reserves are therefore fundamentally flawed. The claim of an increase from $86 million to $342 million is incorrect and unsupported. The original answer emphasizes that 2023 lacked specific disclosures, while 2024 introduced more detailed reporting — a key qualitative shift that the LLM misrepresents as 'consistent' methodology. (3) The multi-hop reasoning fails because the model does not recognize that the availability of specific numbers in 2024 (vs. absence in 2023) represents a change in disclosure practice. Instead, it assumes consistency, contradicting the ground truth. It also fabricates a higher 2024 reserve balance without evidence. (4) Despite these major errors, the answer is contextually relevant — it addresses PayPal’s protection programs, reserves, and disclosure practices — and correctly references Note 15 and accounting policy continuity. However, the severe quantitative inaccuracies and flawed synthesis of year-over-year changes justify a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 431,
        "total_tokens": 1778
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has McDonald's strategic framing of its relationship with franchisees changed between 2022 and 2024, particularly in terms of franchising as a core business model and the role of franchisee co-investment?",
      "original_answer": "In 2022, McDonald's described its relationship with franchisees in neutral, structural terms, emphasizing the division of responsibilities such as franchised arrangements and license agreements, and presenting franchisees as co-participants in operating restaurants. By 2024, the framing evolved significantly, with franchising being described as 'paramount' to delivering food quality, customer experience, and profitability. The 2024 filing also emphasized the importance of franchisee co-investment, noting that it enables McDonald's to achieve high restaurant performance. This represents a shift from a descriptive to a more strategic and value-laden framing of the franchisee relationship.",
      "llm_answer": "Between 2022 and 2024, McDonald's strategic framing of its relationship with franchisees shifted from emphasizing franchising as a core, stable revenue model to explicitly positioning co-investment as a catalyst for modernization and growth. In 2022 disclosures, franchising was presented as the primary business model generating stable cash flow through royalties and rent, with franchisees bearing capital investment responsibilities. By 2024, the language evolved to highlight collaborative co-investment initiatives where the Company partners with franchisees to fund restaurant upgrades and operational improvements, aiming to \"accelerate implementation of initiatives,\" enhance local performance, and increase brand value through modernized locations. This reflects a strategic pivot toward shared investment to drive mutual growth, while maintaining franchising as the foundation of the business model.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution in McDonald's strategic framing between 2022 and 2024. It accurately identifies that franchising remained the foundation of the business model and notes the shift toward emphasizing co-investment as a growth driver by 2024. The answer correctly reflects that in 2022, franchising was described in structural and financial terms (royalties, rent, franchisee capital responsibility), while in 2024, the language evolved to stress collaboration and shared investment for modernization. However, the original answer emphasizes a shift from neutral/descriptive framing to a 'value-laden' and strategic one, with specific mention that franchising became 'paramount' to food quality, customer experience, and profitability—nuances not fully captured in the LLM response. Additionally, the LLM introduces the phrase 'catalyst for modernization and growth' and 'accelerate implementation of initiatives,' which, while plausible, are not directly present in the ground truth and slightly overextend the evidence. There are no numerical inaccuracies (quantitative accuracy is perfect as no numbers are misstated), and the reasoning is sound across the two time points. The answer is highly relevant and synthesizes the required multi-hop comparison across years and framing emphasis. Minor deduction in qualitative accuracy due to partial omission of the deeper strategic reframing around quality and experience, and slight overinterpretation of 'co-investment' as a mutual growth engine beyond the documented emphasis on high restaurant performance via co-investment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1416,
        "completion_tokens": 442,
        "total_tokens": 1858
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the FDA's authorization of Marlboro HeatSticks evolved between 2022 and 2023, and what does this indicate about Altria's regulatory progress with heated tobacco products?",
      "original_answer": "In 2022, the FDA had not yet authorized Marlboro HeatSticks and was considering them on a case-by-case basis regarding graphic health warnings. By 2023, the FDA had authorized PMTAs for three new tobacco-flavored varieties of Marlboro HeatSticks in January 2023, marking a significant regulatory milestone. This indicates that Altria made notable progress in securing FDA approval for its heated tobacco product line, which is a key part of its innovation strategy.",
      "llm_answer": "Between 2022 and 2023, the FDA’s regulatory trajectory for heated tobacco products shifted from a period of stalled approvals to renewed momentum. In March 2022 the agency authorized three new Marlboro‑HeatStick flavors, but the IQOS system remained blocked by an ITC cease‑and‑desist order that kept the product off the U.S. market until the recent $2.7 billion assignment of U.S. commercialization rights to PMI in October 2022. By October 2023 the FDA had cleared the PMTA for IQOS 3 and, in January 2023, approved additional Marlboro HeatStick varieties, signaling that the agency is moving toward broader acceptance of heated‑tobacco products despite ongoing legal challenges. This progression reflects Altria’s advancing regulatory position—securing product authorizations while navigating litigation—yet the continued uncertainty of court rulings and potential future product‑standard rules underscores that regulatory progress remains a work in progress.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains multiple critical factual errors that severely undermine its correctness. (1) It incorrectly states that the FDA authorized three new Marlboro HeatStick flavors in March 2022, while the ground truth confirms no such authorization occurred in 2022—the FDA was still evaluating them on a case-by-case basis. The actual authorization occurred in January 2023, not October 2023. (2) The claim that the FDA cleared the PMTA for IQOS 3 in October 2023 is unsupported by the ground truth, which does not mention this event. (3) The reference to a $2.7 billion assignment of U.S. commercialization rights to PMI in October 2022 is factually incorrect in context—Altria retained U.S. rights to IQOS and did not assign them to PMI; rather, Altria and PMI have a complex partnership, but no such transaction occurred. (4) The mention of an ITC cease-and-desist order blocking IQOS is misleading and not part of the ground truth provided. While the LLM attempts to synthesize regulatory progress and correctly identifies January 2023 as a milestone, it misattributes events, invents dates, and confuses corporate actions. The core conclusion about Altria’s regulatory progress is partially aligned with the ground truth, but the reasoning is based on false premises. Quantitative accuracy is very low due to incorrect dates and dollar amounts. Qualitative accuracy suffers from incorrect entity relationships and flawed multi-hop logic. Contextual relevance is moderate because the answer addresses the general theme of FDA authorization and Altria’s progress, but with significant misinformation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1364,
        "completion_tokens": 438,
        "total_tokens": 1803
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did the valuation of mutual fund equity securities held by ACN evolve between 2022 and 2023, and what does this shift indicate about the company's investment positioning in this category?",
      "original_answer": "In 2022, ACN reported $239,293 (in millions) in mutual fund equity securities. By 2023, this figure decreased to $196,226 (in millions), indicating a reduction of $43,067 (in millions). This decline suggests a strategic shift or reallocation away from mutual fund equity securities during the period.",
      "llm_answer": "Based on the provided 10-K pages, the valuation of mutual fund equity securities held by ACN's defined benefit pension plans shifted significantly between 2022 and 2023. In 2022, mutual fund equity securities were valued at $239,293 (Level 2 total), but by 2023, this category was no longer reported as a distinct line item in the fair value hierarchy tables—instead, the 2023 data shows mutual fund equity securities as part of Level 2 assets under \"Equity\" with a total of $239,293 (though the 2023 table structure differs slightly). The 2023 fair value breakdown for Non-U.S. Plans shows mutual fund equity securities at $239,293 (Level 2), while the 2022 figure was $273,541 for mutual fund equity securities alone (as part of Level 2). This indicates a substantial reduction in the reported value of mutual fund equity securities, likely due to market fluctuations or portfolio rebalancing. The shift suggests ACN has adjusted its investment strategy in this category, possibly reducing exposure to mutual fund equity securities in favor of other assets like fixed income or insurance contracts, reflecting a more conservative or diversified approach to managing pension plan risk.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that ACN's mutual fund equity securities decreased from $239,293 million in 2022 to $196,226 million in 2023, a reduction of $43,067 million. However, the LLM incorrectly reports the 2022 value as $273,541 million and claims the 2023 value is still $239,293 million, which contradicts the ground truth. It also falsely claims that mutual fund equity securities were 'no longer reported as a distinct line item' in 2023, which is not supported by the data. (2) The numbers are fundamentally wrong: the correct 2022 value is $239,293M (correctly cited once but then misstated), and the correct 2023 value is $196,226M, not $239,293M as claimed. The calculation of reduction is therefore incorrect. The LLM repeats $239,293M for both years despite a reported decrease, showing a failure in quantitative accuracy. (3) The multi-hop reasoning is flawed. The model fails to correctly extract and compare the two values across years, misidentifies the reporting structure, and draws conclusions based on fabricated data. It introduces concepts like 'Non-U.S. Plans' and 'Level 2' without grounding them in the provided context or aligning with the ground truth. (4) While the general direction of the conclusion (a reduction suggesting strategic shift) aligns with the ground truth, the factual foundation is so weak that the reasoning is invalid. The answer is contextually relevant in topic and intent but fails on correctness due to severe errors in data extraction and synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 432,
        "total_tokens": 1814
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has Chevron's involvement in Angola LNG Limited evolved from 2022 to 2023, particularly in terms of its operational focus and investment emphasis?",
      "original_answer": "In 2022, Chevron operated and held a 36.4% interest in Angola LNG Limited, emphasizing its role in processing and liquefying associated natural gas from multiple fields and operators in Angola. The company was also involved in developing non-associated gas resources to supply the Angola LNG plant. By 2023, Chevron continued to hold the same 36.4% interest, but the disclosure shifted focus to its broader portfolio of equity affiliates and non-equity investments, with Angola LNG Limited being listed alongside other major investments like Tengizchevroil and Chevron Phillips Chemical Company LLC. This indicates a shift in disclosure emphasis from operational development to financial stake and integration within Chevron’s global portfolio.",
      "llm_answer": "From 2022 to 2023 Chevron’s focus in Angola LNG Limited shifted from a larger equity stake and higher investment to a reduced ownership position and a strategic emphasis on operational stability rather than new capital deployment.  The 2023 filing shows Chevron’s 36.4 % interest in Angola LNG Limited (down from 36.4 % in 2022 and 36.4 % in 2021) and a modest decline in the investment balance to $1.762 billion, while the company continued to rely on the partnership for gas feedstock and LNG sales rather than pursuing major expansion.  Consequently, the investment emphasis moved from aggressive capital growth to sustaining existing production and exploring incremental development opportunities within the Angola LNG project.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that Chevron's interest in Angola LNG Limited decreased from 2022 to 2023, claiming it was 'down from 36.4% in 2022 and 36.4% in 2021' — this is logically and factually incorrect, as the percentage did not change. The ground truth confirms Chevron maintained a stable 36.4% interest in both years. Additionally, the LLM fabricates a specific investment balance of $1.762 billion in 2023 with no such figure present in the original answer, and there is no mention of any decline in investment balance in the ground truth. (2) The quantitative inaccuracies are severe: the percentage is misrepresented as having changed when it did not, and a precise dollar amount is introduced without basis. These are not formatting issues but invented data. (3) The multi-hop reasoning is flawed. While the question requires synthesis of operational focus and investment emphasis across two years, the LLM incorrectly infers a strategic shift based on non-existent changes in ownership and investment. The actual shift in disclosure emphasis — from operational development to financial stake within the portfolio — is missed entirely. Instead, the model invents a narrative of reduced ownership and capital deployment. (4) Despite the incorrect facts, the answer is contextually relevant in that it attempts to address Chevron’s evolving role in Angola LNG Limited and discusses operational versus investment focus. However, the core reasoning and data are unsound, leading to a low correctness score. Minor credit is given for addressing the right topic and attempting temporal comparison.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 456,
        "total_tokens": 1826
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did MMM's investment in Certificates of Deposit/Time Deposits evolve from 2022 to 2023, and what was the magnitude of this change?",
      "original_answer": "In 2022, MMM held $14 million in Certificates of Deposit/Time Deposits, as disclosed in the fair value measurements. By 2023, this amount increased to $49 million, indicating a significant growth in this category of investment. This represents an increase of $35 million, or approximately 250%, from the prior year.",
      "llm_answer": "Based on the provided 10-K filings, MMM's investment in Certificates of Deposit/Time Deposits **decreased** from **$21 million** (as of December 31, 2022) to **$14 million** (as of December 31, 2023). This represents a **$7 million reduction** (or a **33% decline**) in the carrying value of these short-term investments over the one-year period. The decrease is reflected in the \"Marketable securities\" table under \"Certificates of deposit/time deposits\" in Note 11 (page 110), which shows $49 million in 2023 versus $21 million in 2022.",
      "correctness_score": 1,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both direction and magnitude of change. According to the ground truth, MMM's investment in Certificates of Deposit/Time Deposits increased from $14 million in 2022 to $49 million in 2023, a $35 million (250%) increase. However, the LLM claims a decrease from $21 million in 2022 to $14 million in 2023, which contradicts the ground truth on multiple levels. The LLM incorrectly states the 2022 value as $21 million (should be $14M), misreports the 2023 value as $14 million (should be $49M), and reverses the trend (decrease vs actual increase). The calculation of a $7 million reduction and 33% decline is based on these wrong inputs and is therefore invalid. The LLM also incorrectly references Note 11, page 110, claiming $49 million in 2023 vs $21 million in 2022, which internally contradicts its own stated values. This indicates a severe failure in multi-hop reasoning and data extraction, likely confusing different data points or filings. While the answer attempts to address the question structure and cites a note, the factual inaccuracies render it mostly incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1210,
        "completion_tokens": 316,
        "total_tokens": 1527
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of the percentage of franchised restaurants between 2021 and 2024?",
      "original_answer": "In 2021, 93% of McDonald's restaurants were franchised, while by 2024, this percentage increased to approximately 95%. This indicates a slight but deliberate shift toward further reliance on franchisees to operate McDonald's restaurants, reinforcing the company's strategic emphasis on franchising as a core business model.",
      "llm_answer": "Between 2021 and 2024, McDonald's relationship with its franchisees evolved such that the proportion of franchised restaurants increased from approximately 93% in 2021 to about 95% by the end of 2024. This reflects a continued expansion of the franchising model, reinforcing its strategy of leveraging franchisees to drive growth, innovation, and brand consistency while maintaining a strong operational foundation through company-owned restaurants. The company emphasized co-investment with franchisees to modernize operations and support DEI initiatives, further embedding franchisees as key partners in its global system.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the key quantitative facts: the percentage of franchised restaurants increased from 93% in 2021 to 95% by 2024, matching the ground truth exactly. These numbers are accurate and properly attributed to the correct years. 2) Quantitative accuracy is perfect—percentages and timeframes align with the original answer, and no calculations are required beyond the stated figures. 3) The reasoning is sound and reflects appropriate multi-hop synthesis: the model infers a strategic shift toward franchising, which is consistent with the ground truth’s interpretation. It adds context about co-investment, modernization, and DEI initiatives, which, while not in the original answer, are plausible elaborations that do not contradict the core facts and enhance the narrative without introducing inaccuracies. 4) The answer is semantically equivalent and highly relevant, addressing the evolution of McDonald’s relationship with franchisees through the lens of franchised restaurant percentages. The slight score deduction in qualitative accuracy (9 instead of 10) is due to the addition of specific initiatives (e.g., DEI, co-investment) not present in the ground truth, which, while reasonable, go beyond the verified data. However, they do not detract from factual correctness. Overall, the response is excellent, with full quantitative fidelity and strong contextual and qualitative alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1234,
        "completion_tokens": 393,
        "total_tokens": 1627
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did the effective date and structure of the 2015 Stock Compensation Plan for Non-Employee Directors evolve between 2022 and 2023?",
      "original_answer": "In 2022, the 2015 Stock Compensation Plan for Non-Employee Directors was described as 'amended and restated effective March 31, 2021.' By 2023, the plan was further amended and restated, with a new effective date of 'October 26, 2022.' This indicates that the plan underwent at least one additional amendment during the 2022–2023 period, reflecting a structural or procedural update to the plan’s terms.",
      "llm_answer": "The 2015 Stock Compensation Plan for Non-Employee Directors was originally adopted effective October 26 2022 (as reflected in the 2022 10‑Q filing) and subsequently amended and restated effective March 31 2021 (per the 2021 10‑Q filing). In the 2023 filing the plan is referenced again as “2015 Stock Compensation Plan for Non‑Employee Directors, as amended and restated effective March 31, 2021,” indicating that the structure remained the same but was re‑affirmed in the 2023 proxy materials. Thus, between 2022 and 2023 the plan’s effective date did not change, but its most recent amendment was restated in early 2021 and continued to govern director compensation through 2023.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual and chronological errors. (1) It incorrectly states that the plan was 'originally adopted effective October 26, 2022,' which contradicts both the ground truth and logic—original adoption cannot occur after an amendment date. The 2015 plan was established in 2015, not 2022. (2) It reverses the amendment timeline: claiming an amendment effective March 31, 2021, was reflected in a 2022 10-Q filing as the 'original' adoption is chronologically impossible and factually wrong. (3) The ground truth states that by 2023, the plan had been *further* amended with a new effective date of October 26, 2022—this key update is entirely missed by the LLM, which falsely claims the March 31, 2021 version remained unchanged through 2023. (4) The LLM incorrectly concludes that the effective date did not change between 2022 and 2023, when in fact it did—from March 31, 2021, to October 26, 2022—making the core of the answer factually incorrect. (5) The reasoning fails on multi-hop synthesis: it misattributes filing references and does not correctly interpret the evolution of amendments across years. While the answer addresses the general topic and mentions the correct plan name, its dates, sequence, and conclusions are fundamentally flawed. Quantitative accuracy is very low due to incorrect dates (October 26, 2022 vs. March 31, 2021) being presented in reverse and with wrong context. Qualitative accuracy is poor due to flawed logic and entity/time misalignment. Contextual relevance is moderate because it discusses the right plan and timeframe, but with incorrect details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1267,
        "completion_tokens": 440,
        "total_tokens": 1708
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did Accenture's financial relationship with Duck Creek Technologies evolve between fiscal years 2022 and 2023, particularly in terms of investment valuation and reported financial impact?",
      "original_answer": "In fiscal 2022, Accenture's investment in Duck Creek Technologies was valued at $223,166 (approximately 16% ownership), with a carrying amount of $138,902, and was accounted for using the equity method. By fiscal 2023, the investment resulted in a $253 million gain, which was specifically called out in the financial statements as impacting the adjusted earnings per share and effective tax rate calculations. This indicates a shift from a long-term equity stake to a more active financial realization event.",
      "llm_answer": "Between fiscal 2022 and 2023, Accenture's investment in Duck Creek Technologies remained classified as an equity method investment under non-current investments. The carrying amount of the investment was $138,902 as of August 31, 2022, with an estimated fair value of $223,166, reflecting its 16% ownership stake. While the provided documents do not explicitly detail changes in the investment valuation between fiscal years, they note that the investment contributed to a $253 million gain recorded in fiscal 2023, which was excluded from adjusted earnings per share calculations. This indicates a positive financial impact from the investment during the period, though the specific evolution of the relationship (e.g., additional investments, equity adjustments, or performance metrics) is not elaborated in the disclosed pages. The valuation appears to have increased from prior periods, as reflected in the fair value estimate versus the carrying amount, but direct comparative data on the investment's growth or income recognition between fiscal 2022 and 2023 is not provided in the excerpted sections.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key quantitative facts: the 16% ownership stake, the $138,902 carrying amount, the $223,166 fair value (referred to as 'estimated fair value'), and the $253 million gain in fiscal 2023. These match the ground truth exactly in value and context, with acceptable phrasing variations (e.g., 'estimated fair value' for 'valued at'). The only minor issue is that the LLM refers to the $253 million gain as being 'excluded from adjusted earnings per share,' while the ground truth states it was 'called out in the financial statements as impacting the adjusted earnings per share and effective tax rate.' This is a subtle but important distinction—the gain affected adjusted EPS calculations (likely by being excluded), but the LLM slightly mischaracterizes the nature of the impact. (2) All numbers are accurate and correctly attributed to the right fiscal years and entities. The carrying amount and fair value are correctly tied to fiscal 2022, and the $253 million gain to fiscal 2023. No calculation errors. (3) The multi-hop reasoning is sound: the LLM connects Accenture’s equity method accounting, ownership percentage, carrying vs. fair value, and the fiscal 2023 gain, synthesizing information across time and financial concepts. It correctly infers a positive financial impact and a likely valuation increase, even if it notes the lack of explicit comparative data. (4) The answer is highly contextually relevant, directly addressing the evolution of the financial relationship. The slight deduction in correctness and qualitative accuracy is due to the imprecise characterization of how the $253 million gain affected adjusted EPS, which slightly misrepresents the financial reporting nuance. Otherwise, the answer is factually solid, complete, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1415,
        "completion_tokens": 494,
        "total_tokens": 1909
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has the therapeutic application of Breyanzi evolved between 2022 and 2024, and what specific new indications were approved in 2024 that expand its market potential?",
      "original_answer": "In 2022, Breyanzi was indicated for the treatment of adult patients with certain types of relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. By 2024, Breyanzi received two new approvals: in March 2024 for the treatment of adult patients with relapsed or refractory CLL or SLL who have received at least two prior lines of therapy, and in May 2024 for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior lines of systemic therapy. These new indications significantly expand the patient populations eligible for Breyanzi treatment.",
      "llm_answer": "Between 2022 and 2024, Breyanzi’s therapeutic application expanded through multiple new FDA approvals for additional B‑cell malignancies: accelerated approval in May 2024 for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, and further approvals in March and August 2024 for relapsed/refractory mantle cell lymphoma and follicular lymphoma, respectively. In 2024, the FDA also granted accelerated approval for Breyanzi in combination with cetuximab for KRAS‑mutated colorectal cancer (Krazati) and for the treatment of adult patients with relapsed/refractory multiple myeloma after two or more prior lines of therapy (Abecma), further broadening its market potential.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Breyanzi received two approvals in 2024: March 2024 for CLL/SLL and May 2024 for follicular lymphoma (FL). However, the LLM incorrectly states that approval for CLL/SLL was in May 2024 and adds a non-existent approval for mantle cell lymphoma in March 2024 and another for FL in August 2024. Additionally, the LLM falsely claims approvals for KRAS-mutated colorectal cancer in combination with cetuximab (linking it to Krazati, which is not relevant to Breyanzi) and for multiple myeloma (confusing Breyanzi with Abecma, which is a different CAR-T therapy). These are entirely incorrect indications and reflect a severe misunderstanding of the drug's approvals. (2) Quantitatively, the dates (March, May, August 2024) and the number of approvals are wrong. The ground truth specifies only two new indications in 2024 (March and May), not the three or more implied. The LLM also fabricates combination therapies and disease areas with no basis in the original data. (3) The multi-hop reasoning is fundamentally flawed. Instead of correctly synthesizing the expansion of Breyanzi’s indications from large B-cell lymphoma in 2022 to CLL/SLL and FL in 2024, the model invents new and incorrect disease areas, suggesting confusion with other drugs (e.g., Abecma) and unrelated therapies. There is no evidence of accurate cross-document or cross-entity synthesis. (4) The contextual relevance is moderate because the answer addresses the general theme of expanding indications for Breyanzi, but the specific details are largely fabricated. Due to major factual and entity errors, the correctness score is very low at 2, with similarly low scores for quantitative and qualitative accuracy. Contextual relevance is scored at 5 because the structure and intent align with the question, even if the content does not.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 516,
        "total_tokens": 1855
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has 3M's approach to estimating and recording insurance receivables related to legal proceedings under ASC 450 evolved between 2022 and 2023, particularly in relation to respirator mask/asbestos litigation?",
      "original_answer": "In 2022, 3M referenced its compliance with ASC 450 for recording liabilities related to legal proceedings but did not specifically mention the methodology for estimating insurance receivables. By 2023, the company explicitly described applying the loss recovery and/or gain contingency models under ASC 450 and ASC 610-30 to estimate insurance receivables, including analysis of policy terms, case law, and claim nature. Additionally, the number of individual claimants in respirator mask/asbestos litigation increased from approximately 4,028 in 2022 to 4,042 in 2023, indicating a growing exposure that likely influenced the more detailed approach to insurance receivables in 2023.",
      "llm_answer": "Between 2022 and 2023, 3M's approach to estimating and recording insurance receivables related to legal proceedings under ASC 450 evolved in two key ways: First, the company refined its methodology for recognizing insurance recoveries tied to accrued liabilities, explicitly linking receivables to the portion of loss contingencies deemed probable and reasonably estimable—recording receivables only when insurance coverage was concluded as recognizable under ASC 610-30. Second, in the respirator mask/asbestos litigation context, 3M increased its accrual for probable liabilities by $57 million in 2023 due to updated risk assessments involving pending claims, injury severity (e.g., mesothelioma), and cost trends, while simultaneously maintaining a minimal insurance receivable balance, reflecting that coverage was not yet deemed recoverable under the new analysis. This adjustment underscored a more conservative estimation of probable losses amid evolving litigation dynamics and insurance policy interpretations.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in quantitative details. The claim that 3M increased its accrual for probable liabilities by $57 million in 2023 due to updated risk assessments is not supported by the ground truth and is entirely fabricated. The ground truth does not mention any specific dollar amount related to accrual changes or minimal insurance receivables. Additionally, the assertion that 3M maintained a 'minimal insurance receivable balance' because coverage was 'not yet deemed recoverable' contradicts the ground truth, which states that in 2023, 3M explicitly applied the loss recovery and gain contingency models to estimate receivables—indicating active estimation, not withholding due to non-recoverability. (2) There are no correct numbers in the LLM response: the $57M figure is incorrect, and no such calculation or amount appears in the original answer. The increase in claimants from 4,028 to 4,042 is omitted entirely, which is a key quantitative point in the ground truth. (3) While the LLM correctly identifies a methodological evolution in accounting for insurance receivables under ASC 450 and ASC 610-30, it misrepresents the nature of that evolution. The ground truth emphasizes a more detailed and explicit methodology in 2023 involving policy terms, case law, and claim analysis, whereas the LLM frames it as a conservative shift tied to non-recoverability, which is not stated. The multi-hop synthesis is partially correct—linking ASC standards and litigation context—but flawed in reasoning and conclusion. (4) The contextual relevance is high because the answer addresses the core topic—evolution in accounting for insurance receivables in the context of respirator/asbestos litigation—and references the correct standards and general direction of change. However, the qualitative accuracy is reduced due to incorrect reasoning and unsupported claims, and quantitative accuracy is very low due to invented figures and omission of actual data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1441,
        "completion_tokens": 546,
        "total_tokens": 1987
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How did PepsiCo's relationship with Naked evolve between 2022 and 2023, particularly in terms of its operational involvement and financial stake?",
      "original_answer": "In 2022, PepsiCo sold its Tropicana, Naked, and other select juice brands to PAI Partners while retaining a 39% noncontrolling interest in a newly formed joint venture, The Beachbody Company (TBG), which operates across North America and Europe. Additionally, PepsiCo acted as the exclusive distributor for TBG's portfolio of brands, including Naked, for small-format and foodservice customers via chilled direct-store-delivery. By 2023, PepsiCo no longer directly distributed Naked products and instead primarily disclosed its relationship through its retained 39% noncontrolling interest in TBG, with no further operational involvement in the distribution of Naked products. This represents a shift from active distribution to a purely financial stake.",
      "llm_answer": "Between 2022 and 2023, PepsiCo’s relationship with Naked evolved from full ownership to a strategic partnership: in early 2022 the company sold its Tropicana, Naked and other select juice brands to PAI Partners while retaining a 39 % non‑controlling interest in the newly formed joint venture TBG, which now operates across North America and Europe. PepsiCo continues to act as the exclusive distributor for TBG’s portfolio of brands in the United States, handling small‑format and foodservice customers via direct‑store‑delivery, and it also began distributing Hard MTN Dew—licensing the trademark to the Boston Beer Company—further integrating the former Naked juice business into its broader beverage portfolio.",
      "correctness_score": 5,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "1) The LLM answer correctly states that in 2022, PepsiCo sold Tropicana, Naked, and other juice brands to PAI Partners and retained a 39% noncontrolling interest in the newly formed joint venture TBG. This quantitative and entity information is accurate. However, the answer incorrectly claims that PepsiCo 'continues to act as the exclusive distributor' for TBG’s brands in the United States via direct-store-delivery in 2023, which contradicts the ground truth: by 2023, PepsiCo no longer had operational involvement in distribution. This is a major factual error affecting the core evolution of the relationship.\n\n2) Quantitative accuracy is high: the 39% stake, 2022 transaction timing, and entity names (PAI Partners, TBG) are correct. No calculation errors.\n\n3) The multi-hop reasoning fails on the key point of change over time. The question asks about the evolution between 2022 and 2023. The LLM correctly describes the 2022 state but fails to capture the 2023 shift from operational to purely financial involvement. Instead, it implies ongoing distribution, which is incorrect. It also introduces irrelevant information about Hard MTN DEW and Boston Beer Company, which is not related to Naked and distracts from the core question.\n\n4) While the answer is well-structured and includes correct entities and numbers, the failure to accurately describe the change in operational involvement—specifically the cessation of distribution in 2023—results in a partially correct answer. The contextual relevance is moderate because it addresses the relationship but includes off-topic details. Correctness is penalized heavily because the central claim about ongoing distribution is false.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 460,
        "total_tokens": 1826
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has the accounting treatment or disclosure around the ExtraBucks Rewards program evolved between 2023 and 2024, particularly regarding the recognition of revenue and the determination of performance obligations?",
      "original_answer": "In 2023, the ExtraBucks Rewards program was described as creating an additional performance obligation at the time of the initial transaction, with revenue allocated based on relative standalone selling prices that consider historical redemption patterns. Revenue was recognized as the rewards were redeemed, and unredeemed rewards were reflected as a contract liability. In 2024, the disclosure remained consistent in terms of revenue recognition timing and contract liability treatment, but the language around performance obligations became more refined, emphasizing that the determination of an additional performance obligation was specifically tied to customers who accumulate ExtraBucks based on historical spending levels. The 2024 filing also included more structured language around how the Company allocates transaction prices and evaluates standalone selling prices, suggesting a more mature and formalized approach to the program’s accounting treatment.",
      "llm_answer": "The ExtraBucks Rewards program’s accounting treatment remained consistent between 2023 and 2024: the Company records a contract liability for unredeemed rewards and allocates the transaction price between the initial purchase and the rewards based on relative standalone selling prices, recognizing revenue from the rewards only as they are redeemed. Disclosure of the performance obligations and the method of allocating revenue to ExtraBucks Rewards was expanded in the 2024 filing, with more detailed quantitative information on contract liabilities and the impact of acquisitions included.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth. (1) It accurately captures the consistency in accounting treatment between 2023 and 2024: contract liability recognition, allocation of transaction price based on standalone selling prices, and revenue recognized upon redemption. These core facts match the original answer. (2) There are no numeric values in the question or ground truth, so quantitative accuracy is not applicable—no errors in dates or financial figures. (3) The multi-hop reasoning is sound in identifying that the accounting policy remained consistent while disclosures evolved. However, the LLM mentions 'more detailed quantitative information on contract liabilities and the impact of acquisitions,' which is not present in the ground truth. Instead, the original emphasizes refined language around performance obligations tied to customer spending levels and a more structured approach to price allocation and standalone selling price evaluation. This is a minor overstatement or misdirection in the nature of the enhanced disclosure. (4) Despite this, the LLM correctly identifies the key evolution—expanded disclosure in 2024 regarding performance obligations and revenue allocation—making the answer contextually relevant and factually strong overall. The slight deviation from the precise nature of the disclosure refinement justifies a score of 8 rather than 9 or 10 on correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1407,
        "completion_tokens": 401,
        "total_tokens": 1808
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has Netflix's reliance on integrated payment partners evolved between 2023 and 2024, based on the specific details provided in the cost of revenues section for each year?",
      "original_answer": "In 2023, Netflix specifically mentioned that payment processing fees paid to integrated payment partners were part of other operating costs within the cost of revenues. In 2024, the company continued to reference payment processing fees paid to integrated payment partners as part of other operating costs, but the overall structure of the cost of revenues section was streamlined, removing some of the granular details about these fees. This indicates that while the relationship persisted, the level of explicit detail about the financial impact of integrated payment partners decreased, suggesting a shift in disclosure strategy rather than a substantive discontinuation of the relationship.",
      "llm_answer": "Netflix’s cost of revenues—driven primarily by content amortization and payments to integrated payment partners—rose 7% year‑over‑year in 2024, falling to 54% of revenue from 58% in 2023, reflecting a modest improvement in cost efficiency despite higher absolute spending. The company notes that “Other operating costs include customer service and payment processing fees, including those we pay to our integrated payment partners,” indicating that reliance on these payment partners remains a consistent component of its cost structure, but the proportion of total cost of revenues devoted to them has declined as overall cost of revenues has decreased.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that Netflix mentioned payment processing fees as part of other operating costs in both 2023 and 2024, with a reduction in disclosure detail in 2024. However, the LLM introduces unsupported quantitative claims: it states that cost of revenues rose 7% year-over-year in 2024 and fell to 54% of revenue from 58% in 2023. These percentages and growth figures are not present in the original answer and cannot be verified from the provided context. There is no mention in the ground truth about cost of revenues as a percentage of revenue or year-over-year change, so these numbers are fabrications. (2) The calculation of a 7% increase and the percentages (54% vs 58%) are entirely absent from the original answer and are not inferable from the given information. This severely undermines quantitative accuracy. (3) The qualitative reasoning partially captures the continuity of reliance on integrated payment partners, correctly noting that payment processing fees remain part of other operating costs. However, it fails to mention the key point from the original answer: the 2024 filing streamlined the cost of revenues section and reduced granular detail about these fees, indicating a shift in disclosure strategy. This omission weakens the multi-hop synthesis, as the evolution in disclosure—not just ongoing inclusion—is central to the question. (4) Contextual relevance is moderate because the answer addresses Netflix’s reliance on payment partners and cites the correct cost category (other operating costs), but invents financial metrics and misses the core nuance about reduced transparency in 2024. Thus, while the direction of reasoning is relevant, factual correctness and completeness are compromised.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 491,
        "total_tokens": 1835
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has 3M's approach to managing PFAS contamination in Minnesota evolved from 2022 to 2023, particularly in response to regulatory changes and new health-based standards?",
      "original_answer": "In 2022, 3M had substantially completed remediation work at the Cottage Grove site and was continuing operational and maintenance activities at Oakdale and Woodbury sites in Minnesota under the May 2007 Settlement Agreement and Consent Order. The company was also addressing PFAS discharges at its Decatur, Alabama facility under a 2020 interim Consent Order with ADEM, which included obligations for on-site and off-site investigations and future capital improvements. By 2023, the Minnesota Department of Health issued updated, more stringent Health Based Values (HBVs) for PFOA and PFOS in January 2024, prompting 3M to evaluate the potential impact on its obligations under the SACO. Additionally, MPCA issued a Notice of Violation in March 2023 alleging PFAS in stormwater discharge at 3M’s Hutchinson facility, and in December 2022, MPCA issued an order addressing stormwater from the Cottage Grove facility. In January 2024, MPCA proposed a new Clean Water Act permit for Cottage Grove with significantly revised, often below-quantification-level limits on PFAS, indicating a tightening regulatory environment that 3M is actively engaging with.",
      "llm_answer": "From 2022 to 2023, 3M’s approach to managing PFAS contamination in Minnesota shifted from incremental compliance and remediation under long‑standing settlement agreements to a more expansive, financially significant response driven by new regulatory expectations and health‑based standards. In 2023 the company increased its accrual for PFAS‑related environmental liabilities by $10.6 billion and recorded a total of $11 billion in other environmental liabilities, reflecting heightened estimates of probable loss as Minnesota adopted stricter health‑based values (e.g., updated HBV/HRL for PFOA and PFOS) and as EPA and state agencies intensified oversight of PFAS discharges from its Cottage Grove and other facilities. This regulatory escalation prompted 3M to expand monitoring, treatment, and remedial actions, and to engage in settlement negotiations and consent orders that now encompass a broader range of PFAS compounds and longer‑term oversight.",
      "correctness_score": 4,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies, particularly in quantitative claims. It states that 3M increased its accrual for PFAS-related environmental liabilities by $10.6 billion and recorded $11 billion in other environmental liabilities in 2023, which is not supported by the original answer or the knowledge graph. No such financial figures are mentioned in the ground truth, nor are there any references to accruals or liability amounts. This is a major error that undermines the credibility of the response. Additionally, the claim that Minnesota adopted stricter health-based values in 2023 is factually incorrect: the Minnesota Department of Health issued updated HBVs in January 2024, not in 2023. The LLM incorrectly backdates this event. While the answer correctly identifies the evolving regulatory pressure and 3M’s broader engagement with PFAS oversight at Cottage Grove and other facilities, it fabricates key financial data and misrepresents the timeline. The qualitative reasoning about increased regulatory scrutiny and expanded monitoring is directionally plausible but not substantiated by the provided ground truth. The entities (e.g., Cottage Grove, PFAS compounds) are generally accurate, and the response is contextually relevant to the question about evolving management approaches. However, the inclusion of unsupported financial figures and incorrect dates results in a low correctness and quantitative accuracy score. The answer fails to mention the 2007 Settlement Agreement, the MPCA’s 2022 order on Cottage Grove stormwater, or the March 2023 NOV for Hutchinson—key regulatory developments from the original answer—indicating incomplete synthesis across time and sites.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1532,
        "completion_tokens": 464,
        "total_tokens": 1997
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How did PepsiCo's use of foreign currency derivatives evolve between 2022 and 2023, and what does this indicate about its foreign exchange risk management strategy?",
      "original_answer": "In 2022, PepsiCo reported a total notional value of $3.0 billion for its foreign currency derivatives, while in 2023, this value increased to $3.8 billion. This indicates a strategic expansion in the use of foreign currency derivatives to manage foreign exchange risk, likely in response to increased exposure or volatility in international markets. Additionally, the company emphasized the use of these derivatives to offset changes in the underlying hedged items, resulting in no material net impact on earnings in 2023.",
      "llm_answer": "PepsiCo's use of foreign currency derivatives increased significantly from 2022 to 2023, with total notional value rising from $3.0 billion (as of December 31, 2022) to $3.8 billion (as of December 30, 2023), and net investment hedges growing from $2.9 billion to $3.0 billion. This expansion indicates a more proactive strategy to manage foreign exchange risk, particularly through longer-term hedging instruments and enhanced use of forward contracts to offset currency volatility in international operations. The company continues to rely on hedge accounting for qualifying derivatives while marking non-qualifying derivatives to market, reflecting a disciplined approach to mitigating currency-related earnings volatility.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the total notional value of foreign currency derivatives increasing from $3.0 billion in 2022 to $3.8 billion in 2023, matching the ground truth exactly. It adds additional detail about net investment hedges rising from $2.9 billion to $3.0 billion, which is plausible and consistent with the trend but not present in the original answer; however, this does not contradict the ground truth and may reflect supplementary data from the 10-K. All numeric values cited are accurate and correctly attributed to the respective years. (2) Quantitative accuracy is perfect: $3.0 billion and $3.8 billion are correctly stated with appropriate time references (December 31, 2022, and December 30, 2023), and the directional change (increase of $0.8 billion) is implied correctly. (3) The multi-hop reasoning is sound—comparing derivative usage across two years and inferring strategic implications about foreign exchange risk management. The LLM correctly concludes that the increase indicates a more proactive or expanded hedging strategy, aligning with the ground truth’s interpretation of 'strategic expansion.' It further enriches the analysis with accurate concepts like hedge accounting, forward contracts, and earnings volatility, demonstrating strong qualitative understanding. (4) The only minor gap is that the LLM does not explicitly mention the 'no material net impact on earnings in 2023' point from the original answer, which is a relevant outcome of the strategy. However, it does convey a similar idea by referencing mitigation of 'currency-related earnings volatility,' which is semantically close. Overall, the answer is factually correct, comprehensive, and contextually appropriate, warranting a high score with only a slight deduction for partial omission of a key qualitative outcome.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 500,
        "total_tokens": 1816
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has ExxonMobil's approach to capitalizing on improving living standards evolved between 2022 and 2023, particularly in terms of chemical production capacity additions and geographic focus?",
      "original_answer": "In 2022, ExxonMobil highlighted the completion of a joint venture ethane cracker near Corpus Christi, Texas, and plans for up to 500,000 metric tons annually of advanced recycling capacity in Baytown, Texas, by 2026, as part of its strategy to meet growing demand driven by improving living standards. By 2023, the company shifted focus toward expanding performance polymers and linear alpha olefins capacity in Baytown, Texas, and advancing a 100% foreign-owned petrochemical complex in Dayawan, China, with over 2.5 million metric tons per year of polyethylene and polypropylene capacity. This reflects a strategic evolution from domestic advanced recycling and integrated U.S. projects to high-performance product expansions and significant foreign investment in China to meet local demand.",
      "llm_answer": "ExxonMobil expanded its chemical production capacity through strategic investments in both the U.S. and China between 2022 and 2023. In 2022, it restarted Gulf Coast growth projects (including Baytown and Baton Rouge) and advanced recycling initiatives, while in 2023 it launched new performance polymers and linear alpha olefins units in Baytown and advanced plans for a major petrochemical complex in China’s Dayawan Industrial Park, which will add over 2.5 million metric tons of annual capacity. This reflects a geographic shift toward Asia to capture growing demand from improving living standards in China, while maintaining U.S. expansion to leverage feedstock advantages.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key developments in ExxonMobil's chemical production strategy between 2022 and 2023, including the shift from U.S.-focused projects to expanded investment in China. It accurately notes the Baytown expansions in 2023 for performance polymers and linear alpha olefins and the advancement of the Dayawan, China petrochemical complex with over 2.5 million metric tons per year of capacity. However, it omits the specific 2022 joint venture ethane cracker near Corpus Christi, Texas, and the 500,000 metric tons per year of advanced recycling capacity planned for Baytown by 2026, instead generalizing to 'restarted Gulf Coast growth projects' and 'advanced recycling initiatives,' which is partially correct but lacks specificity. (2) Quantitatively, the 'over 2.5 million metric tons' figure for the China complex is correctly reported. The 2023 capacity additions are accurately described, though the 2022 advanced recycling capacity (500,000 metric tons) is not mentioned, representing a minor quantitative omission. Dates (2022 vs. 2023) are correctly attributed to respective projects. (3) The multi-hop reasoning is sound: the model correctly infers a strategic evolution from domestic U.S. integrated projects toward high-performance products and foreign investment in Asia, particularly China, to meet rising demand from improving living standards. The synthesis across years and geographies is logical and supported by the ground truth. (4) The answer is contextually highly relevant, directly addressing the evolution in ExxonMobil’s strategy regarding chemical capacity and geographic focus. The omission of the Corpus Christi ethane cracker and specific advanced recycling target slightly reduces completeness and qualitative accuracy, but the core strategic shift is accurately conveyed. Hence, a score of 8 is justified for correctness—strong but not fully complete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 521,
        "total_tokens": 1901
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How did 3M's investment in Certificates of Deposit/Time Deposits evolve from 2022 to 2023, and what does this shift indicate about the company's short-term investment strategy?",
      "original_answer": "In 2022, 3M held $21 million in Certificates of Deposit/Time Deposits, which increased to $49 million in 2023 — more than doubling. This indicates a strategic shift toward increasing liquidity or reallocating short-term cash holdings into more stable or higher-yielding instruments within this category.",
      "llm_answer": "From 2022 to 2023, 3M’s investment in Certificates of Deposit/Time Deposits declined sharply from $49 million to $53 million (a modest increase in absolute dollars but a significant reduction in proportion to its overall short‑term investment strategy). This shift reflects a deliberate move away from low‑yielding, short‑term fixed‑income securities toward higher‑yielding, longer‑duration debt and the use of the company’s revolving credit facility, indicating that 3M is prioritizing liquidity flexibility and higher returns over maintaining a large portfolio of short‑term CDs.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors. According to the ground truth, 3M's investment in Certificates of Deposit/Time Deposits increased from $21 million in 2022 to $49 million in 2023. However, the LLM incorrectly states that the amount declined from $49 million to $53 million, which is both directionally wrong and factually inaccurate for both years. The claim of a 'modest increase in absolute dollars' contradicts the stated decline and misrepresents the trend. (2) The numbers are entirely incorrect: 2022 value is reported as $49M (should be $21M), 2023 as $53M (should be $49M). This results in a false narrative of decline when the actual data shows more than a doubling of investment. Calculations and comparisons based on these numbers are therefore invalid. (3) The multi-hop reasoning is flawed because the model fails to correctly retrieve and synthesize the time-series data across years. The conclusion about shifting away from CDs is unsupported by the actual data, which instead suggests a strategic increase in short-term stable instruments. The reasoning about moving toward longer-duration debt and using credit facilities is not supported by the provided ground truth. (4) The contextual relevance is moderate because the answer addresses the general topic of short-term investment strategy, but the incorrect data undermines the validity of the interpretation. Due to major quantitative and qualitative inaccuracies, the overall correctness score is low at 2.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1228,
        "completion_tokens": 416,
        "total_tokens": 1645
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has Mastercard's approach to proprietary insights evolved from 2022 to 2023, particularly in terms of data responsibility and trust-building language?",
      "original_answer": "In 2022, Mastercard described its proprietary insights as being based on the 'principled use of consumer and merchant data.' By 2023, the language evolved to emphasize 'principled and responsible use of secure consumer and merchant data.' This shift indicates a stronger emphasis on data security and trust as a core component of their proprietary insights strategy. The change in phrasing reflects a broader narrative around cybersecurity and stakeholder confidence in how Mastercard manages sensitive data.",
      "llm_answer": "Mastercard's 2023 10-K shows a deliberate shift in language around proprietary insights, moving from a focus on \"drawing on Mastercard's principled use of consumer and merchant data\" in 2022 to emphasizing \"proprietary insights, drawing on Mastercard's principled use of secure consumer and merchant data\" in 2023. This subtle but significant update reinforces their commitment to data responsibility by explicitly adding \"secure\" to describe their data practices, highlighting a strengthened emphasis on trust and ethical data handling as a core component of their value proposition. The evolution reflects a deeper integration of data responsibility into their brand narrative, positioning it as foundational to building and maintaining stakeholder trust.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the evolution in Mastercard's language from 2022 to 2023 regarding proprietary insights, accurately quoting the shift from 'principled use of consumer and merchant data' to including 'secure' in the description of data practices. The core factual claim—that the addition of 'secure' reflects a stronger emphasis on data responsibility and trust—is fully supported by the original answer. (2) There are no numerical values, dates, or financial metrics in dispute; all non-numeric factual elements (years, company name, nature of change in language) are correct. (3) The multi-hop reasoning—comparing disclosures across two years and interpreting the strategic implication of wording changes—is sound and well-articulated. The LLM correctly infers that this evolution reflects a deeper integration of trust and security into Mastercard’s brand narrative, which is consistent with the ground truth’s conclusion about stakeholder confidence and cybersecurity. (4) The only minor shortcoming is that the LLM slightly rephrases the 2023 quote as 'proprietary insights, drawing on Mastercard's principled use of secure consumer and merchant data,' while the ground truth emphasizes 'principled and responsible use of secure...data.' The term 'responsible' is missing in the LLM's quote, which slightly weakens precision. However, the overall semantic meaning and analytical conclusion remain valid and insightful. Thus, the answer earns a 9/10 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 449,
        "total_tokens": 1767
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How did the factors influencing the accounting estimates for pension and retiree medical plans evolve between 2022 and 2023, and what does this indicate about the changing external environment affecting these plans?",
      "original_answer": "In 2022, the accounting estimates for pension and retiree medical plans were influenced by uncertainties related to the ongoing impacts of the COVID-19 pandemic. By 2023, this had evolved, and the estimates were instead influenced by business and economic uncertainty stemming from the ongoing conflicts in Ukraine and the Middle East, as well as a high interest rate and inflationary cost environment. This indicates a shift in the external risk factors affecting the company's pension and retiree medical plans from health-related disruptions to broader macroeconomic and geopolitical concerns.",
      "llm_answer": "The accounting estimates for pension and retiree medical plans were adjusted in 2023 to reflect the heightened macroeconomic uncertainty, including the impacts of rising interest rates, inflation, and the ongoing geopolitical conflicts in Ukraine and the Middle East. These factors prompted more conservative assumptions in projecting future benefit obligations and funding requirements, leading to a more pronounced assessment of potential liabilities and a greater emphasis on actuarial inputs that account for volatile economic conditions. Consequently, the evolving external environment has necessitated more frequent and rigorous reviews of these estimates, highlighting the growing sensitivity of pension and retiree medical plan accounting to macroeconomic shocks.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly identifies the shift in factors influencing accounting estimates for pension and retiree medical plans from 2022 to 2023. While the original answer specifies that 2022 was dominated by uncertainties from the COVID-19 pandemic, the LLM answer does not explicitly mention 2022's drivers but correctly emphasizes the 2023 factors: geopolitical conflicts in Ukraine and the Middle East, high interest rates, and inflation. The LLM elaborates on the implications—such as more conservative assumptions, increased actuarial scrutiny, and sensitivity to macroeconomic shocks—which are reasonable inferences and add contextual depth without contradicting the ground truth. There are no numerical inaccuracies (quantitative accuracy is perfect as no specific numbers are involved and all dates are correct). The reasoning is sound and reflects appropriate multi-hop synthesis between changing external environments and their accounting implications. The only minor shortcoming is the lack of explicit contrast with 2022’s pandemic-related factors, which slightly reduces completeness in the qualitative dimension. However, the core factual content and semantic meaning are substantially equivalent. Contextual relevance is excellent, directly addressing the evolution and implications of external factors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 381,
        "total_tokens": 1740
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has ExxonMobil's undeveloped acreage position in the Other Americas region evolved between 2022 and 2023, and what does this indicate about the company's exploration potential in that region?",
      "original_answer": "ExxonMobil's undeveloped acreage in the Other Americas region decreased from 25,096 gross and 11,977 net thousands of acres in 2022 to 24,221 gross and 11,548 net thousands of acres in 2023. This indicates a reduction in the total acreage under evaluation, suggesting that some properties may have been relinquished or transitioned to developed status, while the company continues to focus on properties with higher exploration potential.",
      "llm_answer": "ExxonMobil's undeveloped acreage in the Other Americas region declined from 25,096 gross and 11,977 net thousands of acres in 2022 to 24,221 gross and 11,548 net thousands of acres in 2023, reflecting a reduction of approximately 875 gross and 429 net acres. This decrease suggests the company is actively managing its exploration portfolio, potentially prioritizing higher-potential areas while maintaining sufficient undeveloped acreage to support future exploration activities. The company's approach emphasizes evaluating exploration potential before lease expiration, with scheduled expirations not expected to materially impact operations, indicating a strategic focus on optimizing its undeveloped resource base in the region.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all quantitative data: ExxonMobil's undeveloped acreage in the Other Americas region decreased from 25,096 gross and 11,977 net thousands of acres in 2022 to 24,221 gross and 11,548 net thousands of acres in 2023. The calculated reductions of 875 gross (25,096 - 24,221) and 429 net (11,977 - 11,548) acres are accurate. (2) All numbers match the ground truth exactly, with proper units (thousands of acres), and the time frame (2022 to 2023) is correctly identified. (3) The reasoning is sound and adds value: the LLM correctly infers that the reduction may reflect portfolio management, prioritization of high-potential areas, and strategic optimization—consistent with the ground truth's implication that some acreage may have been relinquished or transitioned to developed status. The mention of lease expiration timelines not materially impacting operations is contextually appropriate and aligns with ExxonMobil's typical exploration strategy, even if not explicitly in the ground truth. (4) The answer is semantically equivalent and slightly more detailed than the original, without introducing inaccuracies. The only reason for not scoring a 10 is that the original answer emphasizes 'exploration potential' more directly in relation to the remaining acreage, while the LLM slightly shifts focus to portfolio management—still valid, but a minor nuance difference. All evaluation criteria are met with high fidelity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 407,
        "total_tokens": 1712
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How did the treatment and financial impact of non-functional currency denominated items evolve from 2022 to 2023, particularly in terms of the use of foreign currency contracts not designated in hedging relationships?",
      "original_answer": "In 2022, MMM used foreign exchange forward and option contracts not designated in hedging relationships to offset the impacts of changes in value of various non-functional currency denominated items, including certain intercompany financing balances, with a gross notional amount of $3.7 billion. By 2023, the company continued to use such contracts for the same purpose but shifted focus to derivatives not designated as hedging instruments, with fair value gains and losses directly impacting earnings. This indicates a shift from primarily designated hedging strategies to a more direct financial exposure management approach.",
      "llm_answer": "From 2022 to 2023, the use of foreign‑currency contracts that were not designated as hedging instruments remained significant, with gross notional amounts decreasing from $2,816 million (2022) to $1,023 million (2023). The fair‑value gains and losses on these contracts shifted from a $76 million loss in 2022 to a $9 million loss in 2023, reflecting a reduced adverse impact on earnings. Consequently, the financial impact of these non‑designated derivatives improved, as evidenced by the lower loss amount and the corresponding decline in the gross notional exposure.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, MMM used foreign exchange contracts not designated in hedging relationships with a gross notional amount of $3.7 billion. However, the LLM claims $2,816 million (~$2.8 billion) in 2022 and $1,023 million in 2023—both figures are incorrect and unsupported by the original answer. Additionally, the LLM introduces specific P&L impacts—$76 million loss in 2022 and $9 million loss in 2023—which are not mentioned in the ground truth at all. These numbers appear fabricated. (2) The quantitative accuracy is very low: the notional amounts are wrong, and the P&L figures are entirely absent from the original answer, making any calculation or trend based on them invalid. There is no mention in the ground truth of a reduction in notional value or specific gains/losses from these contracts. (3) The multi-hop reasoning is flawed. The original answer emphasizes a strategic shift in treatment—from using contracts to offset intercompany balances (with implied accounting treatment) to a broader shift toward derivatives not designated as hedging instruments, affecting earnings directly. The LLM misses this conceptual evolution and instead fabricates numerical trends to support a narrative of reduced exposure and improved financial impact. It fails to identify the key qualitative shift in accounting and risk management strategy. (4) Contextual relevance is moderate because the LLM addresses foreign currency contracts not designated in hedging relationships and discusses their financial impact on earnings, which is relevant. However, due to the invention of specific numbers and the omission of the actual strategic shift described in the ground truth, the answer is largely incorrect. The core of the original insight—a change in approach to managing non-functional currency items via non-designated derivatives—is misrepresented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 525,
        "total_tokens": 1842
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has the role and emphasis of Cyber and Intelligence Solutions evolved within Mastercard's value proposition between 2022 and 2023?",
      "original_answer": "In 2022, Cyber and Intelligence Solutions were mentioned as part of a broader list of value-added services, grouped alongside consulting fees, loyalty programs, gateway services, and other payment-related offerings. This suggests a supporting role within the company's portfolio. By 2023, the Cyber and Intelligence Solutions were more prominently positioned as a core component of Mastercard’s value proposition, explicitly described as enabling secure, easy, and confident transactions across the global payments ecosystem. This indicates a strategic shift toward elevating the importance of cybersecurity within Mastercard’s overall service offering.",
      "llm_answer": "Between 2022 and 2023, the role of Cyber and Intelligence Solutions shifted from being a distinct, high-growth category within Mastercard's value proposition to an integrated component of its broader \"other revenues\" and \"value-added services\" portfolio. In 2022, it was explicitly highlighted as a key growth driver (e.g., \"cyber and intelligence solutions fees\" under other revenues), but by 2023, it was subsumed under the general description of \"value-added products and services\" alongside data analytics, loyalty programs, and payment services, with no standalone emphasis in the revenue breakdown or non-GAAP metrics. The 2023 10-K explicitly lists \"cyber and intelligence solutions fees\" as part of \"other revenues\" without separate quantification, indicating its role became a standard, embedded offering rather than a distinct strategic pillar.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim and contradicts the ground truth. (1) The original answer states that Cyber and Intelligence Solutions were elevated in prominence from 2022 to 2023, moving from a supporting role to a core component of Mastercard’s value proposition. However, the LLM claims the opposite—that the service was downgraded from a distinct, high-growth category to a subsumed, less-emphasized offering. This reversal of direction is a major factual error. (2) While there are no specific numbers (e.g., dollar amounts, percentages) in the original or LLM answer, the LLM correctly references the categorization of 'cyber and intelligence solutions fees' under 'other revenues'—a detail consistent with SEC filings—hence the higher quantitative accuracy score. (3) The multi-hop reasoning is flawed: the LLM misinterprets the integration of the service into broader descriptions as a sign of reduced emphasis, whereas the ground truth interprets the 2023 language as more strategic and central (e.g., 'enabling secure, easy, and confident transactions'). The LLM fails to recognize that increased strategic importance can coincide with less granular revenue disclosure. (4) Contextual relevance is moderate because the answer discusses the right topic and timeframe, but the conclusion is diametrically opposed to the truth. The qualitative accuracy is low due to incorrect synthesis and reasoning, despite correct entity identification (Mastercard, Cyber and Intelligence Solutions, 2022–2023).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1373,
        "completion_tokens": 418,
        "total_tokens": 1792
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has the treatment or disclosure of Income Tax Expense and Accruals evolved in the list of critical accounting policies between 2022 and 2023?",
      "original_answer": "In 2022, 'income tax expense and accruals' was explicitly listed as one of the critical accounting policies and estimates, indicating its significance in financial reporting. By 2023, while still listed as a critical accounting policy, it was moved to a subsection under 'Our Critical Accounting Policies and Estimates' with a more structured presentation of related notes, such as Note 5 - Income Taxes, which provided deeper transparency into tax-related disclosures. This evolution reflects a shift toward more detailed and organized reporting of tax-related matters in 2023.",
      "llm_answer": "The treatment of Income Tax Expense and Accruals remains a critical accounting policy in both 2022 and 2023, with consistent emphasis on the use of an estimated annual effective tax rate applied to quarterly results, significant judgment in determining tax positions and reserves, and adjustments based on audit progress, new tax laws, and regulatory changes. However, the 2023 disclosure explicitly highlights the impact of evolving tax structures and global tax reforms (e.g., OECD Pillar Two) as a key risk factor affecting future tax rates, while the 2022 filing focused more broadly on transfer pricing and tax authority challenges without this specific forward-looking tax reform context. The core methodology for calculating tax expense remained unchanged, but the 2023 filing added greater detail on the risks associated with international tax compliance and potential adjustments.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually plausible and contextually relevant, but diverges from the ground truth in key aspects of the evolution of disclosure. (1) Correct elements: The answer correctly identifies that Income Tax Expense and Accruals remained a critical accounting policy in both years and notes increased forward-looking discussion in 2023 (e.g., OECD Pillar Two), which aligns with a trend toward enhanced transparency. The core methodology consistency is also reasonably inferred. (2) Quantitative accuracy: There are no numeric values to verify, so no errors in this regard—score is 10 by default. (3) Multi-hop reasoning: The LLM introduces specific details not present in the ground truth, such as 'OECD Pillar Two' and 'evolving tax structures,' which, while plausible, are not mentioned in the original answer derived from the knowledge graph. More critically, the LLM fails to mention the structural change in presentation—specifically, that in 2023 the item was moved to a subsection under 'Our Critical Accounting Policies and Estimates' with explicit linkage to Note 5 - Income Taxes. This organizational shift is the central point of the ground truth but is entirely missing in the LLM response. (4) The answer substitutes structural evolution with thematic expansion (more risks discussed), which is a partial interpretation but misses the actual documented change in disclosure format and organization. Thus, while the qualitative reasoning is sound and contextually relevant, it is not fully accurate, leading to a correctness score of 6 for partial accuracy with significant omissions of key factual evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 444,
        "total_tokens": 1810
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has Intel's development and positioning of the Universal Chiplet Interconnect Express standard evolved between 2023 and 2024 in the context of its broader systems of chips strategy?",
      "original_answer": "In 2023, Intel introduced the Universal Chiplet Interconnect Express (UCIe) standard and demonstrated it in silicon, marking the initial phase of its strategic push to enable optimized systems of chips. By 2024, Intel had progressed beyond the demonstration phase and was actively producing based on this standard, integrating it into its broader advanced semiconductor assembly and test offerings. This evolution reflects Intel's deepening commitment to the UCIe standard as a core component of its systems of chips strategy, aimed at enhancing system performance and accelerating customer designs through advanced packaging technologies and system-level standards.",
      "llm_answer": "Intel's Universal Chiplet Interconnect Express (UCIe) standard has progressed from demonstration in silicon in 2023 to broader commercialization efforts in 2024, as highlighted in the 2024 10-K. The company emphasized UCIe as a foundational standard for systems of chips in its AI-driven strategy, with expanded partnerships (e.g., ARM and Synopsys agreements) and integration into Intel Foundry's advanced packaging offerings to accelerate customer designs. This aligns with Intel's broader IDM 2.0 strategy to position UCIe as a key enabler for interconnected chiplet-based systems, particularly in AI workloads.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that in 2023, Intel demonstrated UCIe in silicon, and by 2024, it had moved to broader commercialization and integration into advanced packaging—consistent with the original answer's 'actively producing' and 'integration into advanced semiconductor assembly and test offerings.' (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is not compromised; dates (2023–2024) are correct. (3) The multi-hop reasoning is sound: the LLM synthesizes UCIe’s evolution with Intel’s systems of chips strategy, references partnerships (ARM, Synopsys), and ties it to Intel Foundry and IDM 2.0—details that enrich but do not contradict the ground truth. The mention of AI workloads and IDM 2.0 adds context not in the original but is plausibly aligned with Intel’s strategy per public disclosures. (4) The only minor gap is that the original emphasizes UCIe as part of 'advanced semiconductor assembly and test,' while the LLM frames it under 'advanced packaging offerings'—semantically equivalent but slightly less precise in terminology. However, this does not affect factual correctness. Overall, the answer is factually sound, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 366,
        "total_tokens": 1696
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has the accounting treatment and completion timeline of CVS's Accelerated Share Repurchase (ASR) transactions evolved between the 2023 and 2024 10-K filings?",
      "original_answer": "In 2023, CVS completed a $2.0 billion ASR with Citibank, receiving 17.4 million shares initially (80% of the notional amount) and an additional 5.4 million shares in February 2023, concluding the transaction. The forward contract portion was reclassified from capital surplus to treasury stock upon completion. In 2024, CVS completed a $3.0 billion ASR with Morgan Stanley, initially receiving 31.4 million shares (85% of the notional amount) and an additional 8.3 million shares in March 2024. Similar to 2023, the forward contract was reclassified from capital surplus to treasury stock after the final shares were received. The accounting treatment remained consistent, but the scale and timeline of completion evolved, with the 2024 ASR taking two months to conclude compared to one month in 2023.",
      "llm_answer": "The accounting treatment for CVS's Accelerated Share Repurchase (ASR) transactions remained consistent between the 2023 and 2024 10-K filings: each ASR was initially recorded as a treasury stock transaction with a forward contract classified as an equity instrument in capital surplus, and upon final settlement, the forward contract was reclassified from capital surplus to treasury stock. The timeline for ASR completions also remained aligned with prior patterns—specifically, the $2.0 billion ASR with Citibank concluded in February 2023 (final settlement in February 2023), and the $3.0 billion ASR with Morgan Stanley was completed in March 2024 (final settlement in March 2024), both following the same two-phase structure of initial share receipt and subsequent final settlement.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the consistent accounting treatment between 2023 and 2024—initial recording as treasury stock with the forward contract in capital surplus, and reclassification upon final settlement. It also correctly names the counterparties (Citibank in 2023, Morgan Stanley in 2024) and the dollar amounts ($2.0 billion and $3.0 billion). However, it inaccurately states the timeline: the 2023 ASR was completed in February 2023, which aligns with a one-month completion (consistent with ground truth), but the LLM implies both took two months by saying 'both following the same two-phase structure' without noting the evolution in duration. The ground truth specifies the 2024 ASR took two months compared to one in 2023, which the LLM omits, thus missing a key part of the 'evolution' in timeline. (2) Quantitative accuracy issues: the LLM omits the specific share numbers (17.4M initial + 5.4M final in 2023; 31.4M + 8.3M in 2024) and the percentages of notional amount (80% and 85%), which are key quantitative details from the original answer. While the dollar amounts and final settlement months are correct, the missing share quantities and percentages reduce quantitative precision. (3) The multi-hop reasoning is sound—the model correctly synthesizes that accounting treatment remained consistent and that both ASRs followed a two-phase settlement. However, it fails to contrast the timeline evolution (1 month vs 2 months), which is central to the question about 'evolution'. (4) Scores justified: correctness 8 due to accurate core facts but missing key quantitative and comparative details; quantitative accuracy 7 due to missing share counts and percentages; qualitative accuracy 9 for strong reasoning and entity identification; contextual relevance 10 as the answer directly addresses the question's focus on accounting and timeline evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1400,
        "completion_tokens": 513,
        "total_tokens": 1913
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How did UPS's financial exposure and reporting approach related to the Central States Pension Fund evolve from 2022 to 2023, particularly in terms of actuarial estimates and sensitivity analysis?",
      "original_answer": "In 2022, UPS disclosed a $2.3 billion pre-tax actuarial loss related to potential coordinating benefits for the Central States Pension Fund, as part of broader pension obligation disclosures. By 2023, the company's reporting shifted focus to sensitivity analysis, referencing a 25 basis point change in expected and actual returns on assets as a key assumption affecting pension liabilities, with an explicit cross-reference to Note 5 for details on the Central States Pension Fund liability. This indicates a shift from quantifying a specific obligation to emphasizing the sensitivity of returns on the overall liability.",
      "llm_answer": "From 2022 to 2023, UPS’s exposure to the Central States Pension Fund shifted from a $2.3 billion pre‑tax actuarial loss in 2022 to a $5.1 billion pre‑tax gain in 2023, driven by a higher discount rate and reduced estimates of required coordinating benefits. The company continues to disclose sensitivity analysis showing that a 25‑basis‑point change in discount rates or asset returns would materially affect its pension and postretirement obligations, and it monitors these estimates for potential impacts on reported values.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies. The claim that UPS reported a '$5.1 billion pre-tax gain in 2023' is incorrect and contradicts the ground truth, which states that UPS shifted focus to sensitivity analysis in 2023 and did not report a specific gain related to the Central States Pension Fund. The $2.3 billion pre-tax actuarial loss in 2022 is correctly stated. However, there is no mention in the original answer of a gain in 2023, nor of changes due to discount rates or reduced benefit estimates. (2) Quantitative accuracy is severely compromised: the $5.1 billion figure is unsupported by the ground truth and appears fabricated. The 25 basis point sensitivity is correctly mentioned, but it is attributed to returns on assets in the original, not discount rates or asset returns broadly as implied. (3) The multi-hop reasoning is flawed: the model incorrectly infers a dramatic reversal in financial exposure (loss to gain), failing to recognize that the evolution was in reporting approach (from specific actuarial loss to sensitivity analysis), not a change in the nature of the liability itself. The synthesis across years is incorrect. (4) Contextual relevance is moderate because the answer addresses the general topic of UPS's pension exposure and sensitivity analysis, but the core factual claims about financial performance are wrong, undermining overall correctness. The shift in reporting emphasis is misrepresented as a financial turnaround rather than a change in disclosure focus.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 421,
        "total_tokens": 1721
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Mastercard's positioning and emphasis on its Cyber and Intelligence Solutions evolved between 2022 and 2023, particularly in terms of the value proposition communicated to stakeholders?",
      "original_answer": "In 2022, Mastercard described its Cyber and Intelligence Solutions as part of its value-added services that 'allow all parties to transact easily and with confidence' and emphasized principled use of consumer and merchant data. By 2023, the company expanded this messaging, positioning the solutions as central to enabling secure transactions and confidence in the payments ecosystem, while also linking them to strategic investments in new networks like open banking and digital identity. This reflects a broader integration of cyber solutions into the company's overall infrastructure narrative.",
      "llm_answer": "Mastercard has progressively elevated its Cyber and Intelligence Solutions as a core value driver, shifting from a peripheral mention in 2022 to a central pillar of its growth narrative in 2023. In the 2023 10-K, the company explicitly highlighted these solutions—alongside Data & Services—as key engines of revenue expansion, emphasizing their role in enabling secure, efficient transactions and providing proprietary insights that deepen client engagement. This strategic emphasis is reinforced by the 2023 financial results, where adjusted net revenue growth (13%) and operating margin expansion (58.0%) were directly attributed to strength in payment network, value-added services, and specifically, Cyber & Intelligence solutions, underscoring a deliberate repositioning to communicate these offerings as high-margin, future-focused growth engines to stakeholders.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly captures the evolution in Mastercard's messaging around Cyber and Intelligence Solutions from 2022 to 2023, noting a shift from peripheral to central positioning and integration into growth and infrastructure narratives. It accurately identifies the strategic emphasis on security, efficiency, and proprietary insights, aligning with the ground truth's point about positioning these solutions as central to secure transactions and confidence in the ecosystem. However, the LLM introduces specific financial figures—13% adjusted net revenue growth and 58.0% operating margin—that are not present in the original answer and cannot be verified from the provided ground truth. While these numbers may appear in actual filings, they are not part of the knowledge graph truth, making them unsupported in this evaluation context. This affects quantitative accuracy. The qualitative reasoning is strong: it correctly infers a strategic repositioning and links it to stakeholder communication, revenue expansion, and high-margin growth, which is consistent with the broader integration mentioned in the original. The mention of Data & Services alongside Cyber & Intelligence is contextually plausible but not explicitly stated in the ground truth. The answer is highly relevant to the question and synthesizes the multi-hop requirement (evolution across years and strategic emphasis), though with slight overreach on unverified metrics. Semantic equivalence is mostly preserved, but the addition of unsupported financials prevents a top score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 426,
        "total_tokens": 1804
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How did PepsiCo's presentation of the 4.450% Senior Note due 2046 evolve between its 2022 and 2023 SEC filings, particularly in terms of exhibit referencing and associated documentation dates?",
      "original_answer": "In the 2022 filing, the 4.450% Senior Note due 2046 was listed as Exhibit 4.12, incorporated by reference from PepsiCo's Form 8-K filed on October 14, 2015. In the 2023 filing, the same note was reclassified as Exhibit 4.13 and referenced the Form 8-K filed on February 24, 2016. This indicates a shift in how PepsiCo organized or updated its capital structure disclosures, potentially reflecting revised documentation or administrative reclassification over time.",
      "llm_answer": "In the 2022 filing (page 125), the 4.450% Senior Note due 2046 is referenced as “Form of 4.450% Senior Note due 2046, which is incorporated herein by reference to Exhibit 4.4 to PepsiCo, Inc.'s Current Report on Form 8‑K filed with the SEC on October 14, 2015.” By contrast, in the 2023 filing (page 128), the same note appears as “Form of 4.450% Senior Note due 2028, which is incorporated herein by reference to Exhibit 4.3 to PepsiCo, Inc.'s Current Report on Form 8‑K filed with the SEC on February 15, 2023.” Thus, the presentation shifted from a 2015 8‑K reference tied to the 2046 maturity to a 2023 8‑K reference tied to the 2028 maturity, reflecting an updated exhibit designation and filing date.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual errors that undermine its correctness. (1) The 2022 filing correctly references the 4.450% Senior Note due 2046, but the LLM incorrectly states it was incorporated by reference from Exhibit 4.4 of the October 14, 2015 Form 8-K; the ground truth specifies Exhibit 4.12 in the 2022 filing, not Exhibit 4.4. (2) More critically, in the 2023 filing, the LLM claims the note was referenced as being due in 2028 (not 2046) and tied to a February 15, 2023 Form 8-K—this is entirely incorrect. The ground truth confirms the note remained the 2046 maturity and was reclassified as Exhibit 4.13 referencing a February 24, 2016 Form 8-K, not 2023. (3) The LLM introduces a non-existent 2023 Form 8-K and misstates the maturity year, indicating a failure in multi-hop reasoning and entity tracking. (4) While the answer attempts to address exhibit referencing and documentation date changes, the core facts—exhibit numbers, dates, and maturity years—are wrong. The contextual relevance is moderate because the structure of the response aligns with the question’s intent, but quantitative and qualitative accuracy are severely compromised by incorrect dates, maturities, and exhibit numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 341,
        "total_tokens": 1645
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Intel's relationship with Positive Technologies evolved between 2023 and 2024, particularly in terms of their engagement under OFAC licensing following the U.S. sanctions?",
      "original_answer": "In 2023, Intel disclosed that it had communicated with Positive Technologies regarding IT security research and coordinated disclosure of vulnerabilities, and that it resumed such communications under an OFAC license following the sanctions. By 2024, Intel's relationship had evolved from mere disclosure of past communication to an explicit statement of intent to continue these interactions in accordance with the OFAC license. While both years clarify that there were no gross revenues or net profits associated with these activities, the 2024 filing reflects a more forward-looking and sustained partnership posture with Positive Technologies under the sanctioned conditions.",
      "llm_answer": "Intel’s engagement with Positive Technologies has continued under an OFAC general license. The company disclosed that, after the U.S. Treasury designated Positive Technologies on April 15 2021, it resumed communications with the firm “based on a license issued by OFAC” to discuss IT‑security research and coordinated vulnerability disclosures. These interactions are explicitly authorized by General License 1B, carry no gross revenue or net profit impact, and Intel intends to keep conducting them in compliance with the OFAC license. Thus, the relationship remains permissible under U.S. sanctions, though it is limited to sanctioned‑license activities and does not generate revenue for Intel.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in substance but contains a minor factual inaccuracy regarding the OFAC license type and lacks the comparative evolution between 2023 and 2024 emphasized in the ground truth. The answer correctly states that Intel resumed communications with Positive Technologies under an OFAC license after U.S. sanctions, specifying General License 1B and the April 15, 2021 designation date, which aligns with public records. It accurately notes no gross revenue or net profit impact and Intel's intent to continue compliant interactions—key points from the 2024 filing. However, the original answer emphasizes a shift in tone and posture from 2023 (disclosure of past communication) to 2024 (forward-looking intent to sustain engagement), which the LLM answer does not explicitly capture. Instead, it presents a static view of the relationship without highlighting this evolution. While it mentions General License 1B, the original answer does not specify the license type, so this addition is plausible but not verifiable from the ground truth alone. The date (April 15, 2021) is accurate but outside the 2023–2024 scope of the question, making it contextually relevant background but not central. The LLM synthesizes information logically and maintains semantic equivalence on core facts—no revenue impact, sanctioned communications permitted, compliance posture—but misses the nuanced progression in Intel’s disclosure strategy across the two years, which is central to the multi-hop aspect of the question. Thus, while factually sound and contextually appropriate, it falls short on fully capturing the temporal evolution in the relationship.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 453,
        "total_tokens": 1805
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has the balance of CVS's 4.78% Senior Notes due March 2038 evolved between 2023 and 2024, and what does this indicate about the company's long-term debt structure?",
      "original_answer": "The balance of CVS's 4.78% Senior Notes due March 2038 remained stable at $5,000 million in both 2023 and 2024, indicating that the company did not retire or issue additional amounts of this particular debt instrument during the period. This stability contrasts with other senior notes, such as the 2.7% senior notes due August 2040, which decreased from $1,250 million in 2023 to $367 million in 2024, suggesting selective debt management and refinancing activity in other long-term obligations.",
      "llm_answer": "Between 2023 and 2024, CVS refinanced its long-term debt by retiring higher-cost legacy notes (e.g., $1.5 bn of 5.0% senior notes due 2026 and $1.5 bn of 5.125% senior notes due 2030 issued in 2023) and issuing new lower‑coupon securities, including $2.25 bn of 7.0% junior subordinated notes due 2055 and $1.0 bn of 5.4% senior notes due 2029 in 2024. This shift reflects a strategic extension of maturity and a modest reduction in overall interest expense, indicating that CVS is actively managing its capital structure to lower financing costs and strengthen liquidity for long‑term obligations.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both quantitative and qualitative aspects. The question specifically asks about the evolution of CVS's 4.78% Senior Notes due March 2038 between 2023 and 2024. The ground truth states that the balance of these notes remained stable at $5,000 million in both years. However, the LLM answer does not mention this note at all. Instead, it discusses entirely different debt instruments — such as 5.0% notes due 2026, 5.125% due 2030, 7.0% junior subordinated notes due 2055, and 5.4% senior notes due 2029 — none of which are referenced in the original answer or relevant to the specific note in question. (2) The dollar amounts and interest rates cited (e.g., $1.5 bn, $2.25 bn, 7.0%, 5.4%) are factually incorrect in this context and do not align with the ground truth. There is no mention of the $5,000 million balance or its stability, which is the core fact. (3) The multi-hop reasoning fails because the model does not identify or track the correct debt instrument across years. While it attempts to discuss CVS’s broader debt management strategy, it does so using fabricated or misattributed data. The original answer contrasts the stability of the 4.78% notes with changes in other notes (e.g., 2.7% due 2040 decreasing from $1,250M to $367M), but the LLM omits this correct comparison entirely. (4) The contextual relevance is moderate because the answer addresses long-term debt structure and refinancing strategy, which is thematically relevant. However, due to complete factual inaccuracy regarding the specific note and incorrect data, the correctness and accuracy scores are very low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 450,
        "total_tokens": 1729
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has the status of the 0.835% Notes due 2032 evolved between the 2022 and 2024 SEC filings for Exxon Mobil Corporation?",
      "original_answer": "In the 2022 filing, the 0.835% Notes due 2032 were listed among other notes with distinct trading symbols, including the 0.142% Notes due 2024 (XOM24B), indicating a broader set of publicly traded debt instruments. By 2024, the 0.835% Notes due 2032 remained listed with the trading symbol XOM32, but the 0.142% Notes due 2024 no longer appeared in the 2024 filing, suggesting that the 2024 notes were either redeemed or no longer publicly traded. Therefore, while the 0.835% Notes due 2032 remained a consistent part of Exxon Mobil's publicly disclosed debt structure, the removal of the 2024 notes indicates a change in the company's short-to-intermediate term debt composition.",
      "llm_answer": "The status of the 0.835% Notes due 2032 was updated in the 2024 filing to reflect the addition of the new ticker symbol “XOM32” alongside the existing identifiers, confirming the same issue that had been reported in the 2022 filing.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies that the 0.835% Notes due 2032 were present in both the 2022 and 2024 filings and accurately mentions the trading symbol 'XOM32' in the 2024 context, which aligns with the ground truth. The percentage (0.835%) and maturity year (2032) are correct, satisfying quantitative accuracy for the core facts. However, the answer is incomplete and partially misleading in its reasoning: it states that the ticker 'XOM32' was 'added' in the 2024 filing 'alongside existing identifiers', which contradicts the ground truth—XOM32 was already associated with the 2032 notes in the 2022 filing. The key evolution highlighted in the original answer is the *removal* of the 0.142% Notes due 2024 (XOM24B) in the 2024 filing, which signals a change in debt composition and confirms the ongoing status of the 2032 notes by contrast. The LLM fails to mention this critical comparative context, which is central to understanding the evolution of the 0.835% Notes' status. Thus, while the LLM correctly affirms the continued existence of the notes, it misses the multi-hop reasoning element—comparing the presence/absence of other notes across filings to infer changes in the debt structure. This omission significantly weakens the qualitative accuracy and completeness. The answer is contextually relevant and factually sound on the surface but lacks the analytical depth and accuracy required to fully address the evolution between filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1222,
        "completion_tokens": 400,
        "total_tokens": 1622
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has American Express's investment strategy toward U.S. Government treasury obligations evolved between 2022 and 2024, particularly in terms of fair value allocation and maturity distribution?",
      "original_answer": "In 2022, American Express held U.S. Government treasury obligations exclusively in short-term instruments with a fair value of $477 million and no long-term exposure. By 2024, the company shifted its strategy to include both short-term ($189 million) and intermediate-term ($98 million) treasury obligations, indicating a more diversified maturity profile. This reflects a transformation in the company's investment approach, expanding beyond less than 12-month instruments to include holdings maturing within 1 to 5 years.",
      "llm_answer": "Between 2022 and 2024, American Express’s investment strategy toward U.S. Government treasury obligations shifted markedly: the portfolio’s cost declined from $20,655 million in 2021 (reflecting a large position held in 2022) to $289 million in 2024, and the gross unrealized loss on these securities also fell from a $1 million loss in 2021 to a $2 million loss in 2024, indicating a deliberate reduction and shorter‑term positioning. Moreover, the maturity profile shows a concentration of treasury holdings now maturing within one year (189 million) and after one but within five years (98 million), with virtually no exposure beyond ten years, reflecting a strategy that emphasizes shorter‑duration, lower‑risk Treasury assets and a smaller overall allocation.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, American Express held $477 million in short-term U.S. Treasury obligations, but the LLM incorrectly references a $20,655 million cost in 2021 (not part of the question or supported by the ground truth) and implies this reflects the 2022 position. The 2024 fair value figures for short-term ($189 million) and intermediate-term ($98 million) are correct, but the LLM introduces a misleading narrative about a 'decline from $20,655 million' that is unsupported and factually wrong. Additionally, the LLM mentions 'gross unrealized loss' changes from 2021 to 2024, which are not present in the original answer and irrelevant to the question about strategy evolution in fair value allocation and maturity distribution. (2) The correct numbers in the LLM answer are the 2024 allocations: $189 million maturing within one year and $98 million maturing in 1–5 years. However, the 2022 figure is misrepresented—original answer specifies $477 million short-term in 2022, but LLM does not state this correctly, instead referencing incorrect data from 2021. The cost basis and unrealized loss figures are extraneous and incorrect. (3) The multi-hop reasoning is flawed: the LLM fails to correctly compare 2022 and 2024 positions as required. It introduces irrelevant data from 2021 and mischaracterizes the scale and nature of the investment portfolio. While it correctly identifies the shift toward including intermediate-term holdings by 2024, it does so within a context of false magnitude and incorrect metrics (cost vs. fair value, inclusion of unrealized losses). (4) The contextual relevance is moderate because the answer addresses maturity distribution and attempts to describe a strategic shift, but the severe quantitative inaccuracies and introduction of non-existent data undermine correctness. The qualitative reasoning is partially sound in noting shorter-duration focus, but the evidence provided is invalid. Thus, the correctness score is low due to major factual and numerical errors despite partial recognition of maturity diversification.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1334,
        "completion_tokens": 578,
        "total_tokens": 1912
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did Amazon's introduction and subsequent treatment of the 2.500% Note due 2050 evolve between 2022 and 2024?",
      "original_answer": "In 2022, the 2.500% Note due 2050 was introduced as part of an Officers' Certificate dated June 3, 2020, and was listed alongside other notes in Exhibit 4.5. By 2024, the 2.500% Note due 2050 was reintroduced in Exhibit 4.6, which was an exact replication of Exhibit 4.5 from 2020, indicating that Amazon continued to maintain this long-term debt instrument without modification. The reintroduction in 2024 reaffirmed the note's role in Amazon's capital structure.",
      "llm_answer": "Amazon introduced the 2.500% Note due 2050 in its June 3, 2020 officers’ certificate (2020 filing) and subsequently re‑issued it in later certificates, including the May 12, 2021 officers’ certificate and the December 1, 2022 officers’ certificate, which also listed other new notes but did not retire the 2.500% 2050 tranche. In its 2024 filing, Amazon’s most recent officers’ certificate (dated December 1, 2022) continued to reference the 2.500% Note due 2050 as part of its long‑dated debt series, indicating that the note remained outstanding and was treated as an ongoing component of Amazon’s capital structure through 2024.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer contains several inaccuracies in dates and document references that contradict the ground truth, though it captures the general idea that the 2.500% Note due 2050 remained outstanding through 2024. (1) QUANTITATIVE INACCURACIES: The LLM claims the note was re-issued in a May 12, 2021 officers’ certificate and a December 1, 2022 certificate, but the ground truth states it was introduced in the June 3, 2020 Officers' Certificate and then reintroduced in 2024 via Exhibit 4.6, which replicated the 2020 exhibit. There is no mention in the ground truth of reissuance in 2021 or 2022 certificates. (2) The 2024 filing is said to reference a December 1, 2022 certificate, but the ground truth indicates the 2024 filing itself contained Exhibit 4.6, a replication of the 2020 exhibit—this misrepresents the timeline and source. (3) ENTITY/DOCUMENT MISMATCH: The LLM incorrectly identifies the mechanism of reintroduction (citing outdated certificates) rather than the 2024 replication of the 2020 exhibit. (4) REASONING: While the conclusion that the note remained part of Amazon’s capital structure is correct, the multi-hop reasoning is flawed—the LLM infers continued existence from intermediate certificates not mentioned in the ground truth, introducing unsupported details. (5) SEMANTIC EQUIVALENCE: The core message (note remains outstanding) is partially aligned, but the factual basis and evolution description are incorrect. Thus, the answer is partially correct but contains significant factual and sourcing errors, warranting a moderate score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 427,
        "total_tokens": 1693
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did the number of amendments to the Citibank, N.A. Co-Branded Credit Card Agreement evolve between 2022 and 2023?",
      "original_answer": "In 2022, the most recent amendment to the Citibank, N.A. Co-Branded Credit Card Agreement was the Eighth Amendment, filed on March 10, 2022. By 2023, the agreement had undergone further modifications, with the Twelfth Amendment being filed on October 11, 2023, indicating a total of four additional amendments during this period. This demonstrates a continued evolution and refinement of the agreement terms over the 12-month period.",
      "llm_answer": "The Citibank, N.A. Co-Branded Credit Card Agreement was amended multiple times between 2022 and 2023, with the Ninth Amendment filed on November 20, 2022 (effective for filings in 2022) and the Tenth Amendment filed on November 20, 2022 (effective for filings in 2022), followed by the Eleventh Amendment filed on February 12, 2023 (effective for filings in 2023), and the Twelfth Amendment filed on September 3, 2023 (effective for filings in 2023). This shows a progression of amendments from the Ninth through Twelfth Amendments during the transition from 2022 to 2023.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is partially correct in identifying that amendments progressed from the Ninth to Twelfth Amendments between 2022 and 2023, but it contradicts the ground truth on key dates and amendment counts. The original answer states the Eighth Amendment was filed on March 10, 2022, and the Twelfth Amendment on October 11, 2023, implying four new amendments (Ninth through Twelfth). However, the LLM claims the Ninth and Tenth Amendments were both filed on November 20, 2022, and the Eleventh and Twelfth on February 12 and September 3, 2023 — dates not present in the ground truth. These specific dates are incorrect or unverified. (2) Quantitatively, the number of additional amendments (four) is consistent between both answers, which is correct. However, the filing dates provided by the LLM are inaccurate: ground truth specifies the Twelfth Amendment was filed October 11, 2023, not September 3, 2023. Also, having two amendments (Ninth and Tenth) filed on the same day is plausible but not supported by the original data. (3) The reasoning correctly infers a progression of amendments and identifies the sequence from Ninth to Twelfth, showing proper multi-hop synthesis across years. However, the lack of alignment with actual filing dates undermines factual reliability. (4) Contextually, the answer addresses the evolution of amendments appropriately and uses correct entity names (Citibank, N.A. Co-Branded Credit Card Agreement). While the overall narrative of continued amendment activity is sound, the incorrect dates and unverified filing details reduce factual accuracy significantly, warranting a moderate correctness score of 4 out of 10.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1244,
        "completion_tokens": 457,
        "total_tokens": 1701
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has NVIDIA's approach to CUDA evolved between 2022 and 2024, particularly in terms of its integration with new computing architectures and software ecosystems?",
      "original_answer": "In 2022, NVIDIA emphasized CUDA as a foundational building block across its target markets, including Gaming, Data Center, Professional Visualization, and Automotive, highlighting its role in enabling accelerated computing and deep learning. CUDA was positioned as a core component of the company's unified architecture, supporting a wide range of applications through internal and third-party software stacks. By 2024, NVIDIA had significantly expanded the scope of CUDA's integration, describing it as part of a broader full-stack computing platform that includes the CUDA-X collection of acceleration libraries, APIs, SDKs, and domain-specific application frameworks. Additionally, CUDA was now explicitly tied to NVIDIA's expanded data center platform, which now includes CPUs (introduced in fiscal 2024) alongside GPUs and DPUs, showing a strategic evolution toward deeper integration with heterogeneous computing architectures and enterprise-grade AI ecosystems.",
      "llm_answer": "Between 2022 and 2024, NVIDIA expanded CUDA’s integration across its full-stack computing platform, adding support for new processing units—DPUs in 2022 and CPUs with the Grace architecture in 2024—and embedding AI‑specific features into its GPU silicon. The company launched the Blackwell architecture in 2025, which unifies GPUs, CPUs, DPUs, and networking into a cohesive data‑center‑scale infrastructure, while enhancing CUDA‑X libraries, AI Enterprise software, and Omniverse to accelerate generative AI, HPC, and graphics workloads across diverse industries.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general direction of NVIDIA's evolution with CUDA—expanding integration into heterogeneous architectures and software ecosystems—but introduces significant factual inaccuracies that undermine its correctness. (1) The mention of the 'Blackwell architecture in 2025' is incorrect; the ground truth does not reference Blackwell or any 2025 developments, and the question focuses on 2022–2024. This is a major error in timeline and product roadmap. (2) While DPUs were introduced around 2022, the LLM incorrectly implies CUDA directly added 'support' for DPUs and CPUs as a software evolution, whereas the ground truth emphasizes that by 2024, CUDA was part of a broader platform tied to a data center strategy now *including* CPUs (Grace) and DPUs—not that CUDA itself was extended to run on them. (3) The LLM overstates integration by suggesting CUDA was embedded into CPU/DPU architectures, which is not supported by the original answer. (4) The original answer highlights CUDA-X, APIs, SDKs, and domain-specific frameworks as part of the 2024 expansion—this is partially reflected in the LLM’s mention of CUDA-X and AI Enterprise, which is accurate and relevant. (5) The LLM adds Omniverse and generative AI acceleration, which, while plausible, are not mentioned in the ground truth and represent extrapolation. (6) The core multi-hop synthesis—linking CUDA’s evolution to new architectures (CPU/DPU) and software ecosystems—is partially correct but based on incorrect reasoning and timelines. Overall, key facts about CUDA’s expanded role in a full-stack platform are present, but major errors in dates (2025), product rollouts (Blackwell), and technical scope reduce factual accuracy. Quantitative accuracy is low due to incorrect years; qualitative accuracy is moderate due to correct thematic understanding; contextual relevance is high as the response stays on topic and addresses integration trends.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 519,
        "total_tokens": 1906
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did Pfizer's financial relationship with Paxlovid evolve between 2023 and 2024, particularly in terms of revenue recognition and contractual obligations?",
      "original_answer": "In 2023, Paxlovid generated $1.279 billion in revenue, but this figure was significantly impacted by a non-cash revenue reversal of $3.5 billion due to the expected return of 6.5 million treatment courses of EUA-labeled U.S. government inventory. By 2024, this reversal was adjusted favorably by $771 million as only 5.1 million treatment courses were actually returned, and an additional $442 million in revenue was recorded in connection with the creation of the U.S. Strategic National Stockpile (SNS). Furthermore, as of December 31, 2024, Pfizer reported approximately $1 billion in remaining performance obligations related to Paxlovid supply contracts, indicating ongoing but reduced commercial activity compared to the prior year. This evolution reflects a shift from a high-volume, government-driven revenue model in 2023 to a more stable, contracted future delivery model in 2024.",
      "llm_answer": "Pfizer's financial relationship with Paxlovid shifted significantly between 2023 and 2024, marked by a dramatic decline in revenue recognition and evolving contractual obligations. In 2023, Paxlovid generated $1.279 billion in revenue (down 92% from $18.933 billion in 2022), driven by a non-cash revenue reversal of $3.5 billion in Q4 2023 related to expected returns of EUA-labeled government inventory, partially offset by a $771 million favorable adjustment in Q1 2024 for returned courses. By 2024, remaining performance obligations for Paxlovid supply totaled approximately $1 billion in contracted revenue, with deferred revenues of $2.2 billion (down from $5.1 billion in 2023) as the company transitioned to commercial market sales and recognized revenue through product deliveries. This transition, coupled with the U.S. government's withdrawal from Paxlovid distribution, resulted in minimal commercial uptake of the NDAs-labeled product and a strategic shift toward long-term contracts (2025–2028) for future supply.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the core evolution of Pfizer's financial relationship with Paxlovid between 2023 and 2024, including the $1.279 billion revenue in 2023, the $3.5 billion non-cash reversal due to expected returns, and the $771 million favorable adjustment in 2024. It also correctly notes the $1 billion in remaining performance obligations as of 2024. However, it introduces a $2.2 billion deferred revenue figure and compares 2023 revenue to 2022 ($18.933 billion), which are not present in the ground truth and cannot be verified from the provided data. The ground truth mentions a $442 million revenue addition from the Strategic National Stockpile (SNS), which the LLM omits entirely. (2) The $1.279 billion 2023 revenue and $3.5 billion reversal are accurate. The $771 million favorable adjustment is correctly attributed to lower-than-expected returns. However, the $2.2 billion deferred revenue and $5.1 billion prior deferred balance are not in the original answer and appear to be hallucinated or inferred incorrectly. The 92% decline from $18.933 billion is factually plausible but not part of the ground truth and distracts from the focus on 2023–2024. (3) The multi-hop reasoning is generally sound—linking the reversal, adjustment, and shift to contractual obligations—but fails to incorporate the SNS revenue component, a key part of the 2024 evolution. The mention of NDAs-labeled product and commercial uptake, while contextually relevant, is not supported in the ground truth and may reflect external knowledge. (4) The correctness score is 7 because the answer gets the major financial events and direction of change correct but misses a key revenue component ($442M SNS) and introduces unverified figures. Quantitative accuracy is 6 due to the inclusion of unsupported numbers. Qualitative accuracy is 8 because the reasoning framework is logical and entity identification (Pfizer, Paxlovid, U.S. government, performance obligations) is correct. Contextual relevance is 9 as the response directly addresses the financial evolution asked in the question, despite some extraneous details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1482,
        "completion_tokens": 570,
        "total_tokens": 2053
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has the availability and structure of shares under the 2003 Incentive Program evolved between 2022 and 2024?",
      "original_answer": "In 2022, the 2003 Incentive Program had 65,754,069 shares available for award. By 2024, the total maximum number of shares that could be issued under the program was increased to 220 million, with 47 million remaining available for awards by the end of 2024. This indicates a significant expansion in the program's capacity, although actual usage had grown moderately over time, with restricted stock units granted increasing from 9,392 thousand in 2022 to 10,393 thousand in 2024.",
      "llm_answer": "Between 2022 and 2024, the availability of shares under the 2003 Incentive Program declined from 47 million shares remaining at the end of 2024 (down from a larger pool earlier), while the program’s structure remained unchanged—stock options and SARs may be granted at market price with a 10‑year life, restricted stock units and restricted stock are issued from treasury, and the maximum share reserve is 220 million, subject to forfeitures not counting toward the limit. The 2024 filings note that $2,588 million of unrecognized compensation cost remains for non‑vested restricted awards, to be recognized over a weighted‑average period of 4.6 years.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that the availability of shares declined, claiming 47 million remained at the end of 2024 'down from a larger pool earlier'—but the ground truth shows that the total maximum number of shares was increased to 220 million by 2024, with 47 million still available. Crucially, the LLM reverses the timeline: in 2022, 65,754,069 shares were available, not a higher number, so there was no decline in availability from a prior larger pool. The LLM also fails to mention the 2022 available share count entirely, which is a key data point. (2) Quantitative accuracy is poor: while the 220 million maximum and 47 million remaining in 2024 are correctly cited, the 2022 figure (65.75 million) is omitted and misrepresented as part of a declining trend. The restricted stock units granted increasing from 9,392 thousand in 2022 to 10,393 thousand in 2024—a key evolution—is completely missing. The $2,588 million unrecognized cost and 4.6-year vesting period are factually accurate but not directly relevant to the question about share availability and structure evolution. (3) Multi-hop reasoning is flawed: the model fails to correctly synthesize the change in share availability over time, misrepresenting the direction of change (decline vs. expansion). It conflates remaining available shares in 2024 with a supposed prior higher availability, contradicting the ground truth. The structural elements (SARs, RSUs, etc.) are accurately described, but the core evolution—expansion from ~65.8M to 220M maximum shares—is misrepresented. (4) Scores reflect major factual errors in quantitative data and reasoning, though some contextual details (2024 figures, program structure) are accurate, justifying moderate relevance and partial qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 498,
        "total_tokens": 1773
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has AdSense's role within Google's advertising revenue streams evolved between 2022 and 2024, particularly in relation to the company's broader advertising technology portfolio?",
      "original_answer": "In 2022, AdSense was explicitly cited as a key growth driver within the Google Network, contributing to an $8.6 billion year-over-year revenue increase alongside AdMob and Google Ad Manager. By 2024, while AdSense remained part of the Google Network, it was no longer specifically quantified as a growth lever. Instead, newer AI-powered advertising products like Demand Gen and Performance Max were highlighted as central to advertiser success, suggesting a strategic shift where AdSense became a more foundational, mature offering within Google's broader advertising technology stack.",
      "llm_answer": "AdSense’s contribution to Google’s advertising revenue has diminished relative to the broader ad technology portfolio. While AdSense was highlighted in 2021 as part of the “Google Network” segment that drove $8.6 billion of revenue growth, its share of total advertising revenue is now a smaller component of the overall Google Services and Google Network mix, with the bulk of growth coming from YouTube ads, direct response and brand advertising products, and newer AI‑driven ad solutions such as Performance Max and Gemini‑powered ad tools. Consequently, AdSense’s role has shifted from a primary growth driver to a more modest, complementary source within Google’s diversified advertising ecosystem.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the strategic shift in AdSense's role from a key growth driver to a more mature, complementary component within Google's ad ecosystem, aligning with the ground truth. It accurately references the $8.6 billion year-over-year revenue increase tied to the Google Network, though it incorrectly attributes this figure to 2021 instead of 2022, which is a factual error in timing. (2) The quantitative inaccuracy lies in this misdating of the $8.6 billion growth figure—ground truth specifies 2022, not 2021. Additionally, the LLM introduces 'Gemini-powered ad tools' not mentioned in the original answer, which may be contextually plausible but is not supported by the provided ground truth. (3) The multi-hop reasoning is sound: the model correctly infers a strategic de-emphasis of AdSense based on the absence of specific mention in later years and the rise of AI-driven products like Performance Max. It synthesizes the evolution across time and product portfolio appropriately, even if some details are misaligned. (4) The correctness score is 7 because the core conclusion about AdSense’s evolving role is accurate and well-supported, but the incorrect year and unsupported addition of 'Gemini' reduce full factual fidelity. Quantitative accuracy is penalized due to the year mismatch, though the dollar amount itself is correct. Qualitative and contextual scores remain high due to strong reasoning and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 404,
        "total_tokens": 1735
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How did the UPS Retirement Plan's benefit accrual structure evolve between 2022 and 2023, and what specific changes were made to future benefit accruals for non-union participants?",
      "original_answer": "In 2022, the UPS Retirement Plan was described as noncontributory and covering substantially all eligible employees hired before July 1, 2016, who were not part of a collective bargaining unit or certain employees covered by a collective bargaining agreement. The plan provided retirement benefits based on average compensation and was subject to IRS limits. It was also disclosed that the plan would cease accruals of additional benefits for future service and compensation for non-union participants effective January 1, 2023. In 2023, this cessation of accruals was confirmed as effective, and the plan was described with the same eligibility and benefit structure but explicitly stated that no further accruals would occur for non-union participants. This marks a transformational change in the plan's structure, as the accrual freeze was implemented as planned, shifting the plan from an active benefit-accruing structure to a closed one for non-union employees. The change represents a significant strategic shift in UPS's retirement benefit policy.",
      "llm_answer": "Based on the provided document pages, the UPS Retirement Plan's benefit accrual structure underwent a key change effective January 1, 2023, when it ceased accruals of additional benefits for future service and compensation for non-union participants. This change applied specifically to the UPS Retirement Plan and the UPS Excess Coordinating Benefit Plan, which are both part of the U.S. pension structure for non-union employees. The document confirms that these plans stopped accruing new benefits for future service and compensation after that date, marking a structural shift in how benefits were calculated for this group moving forward. No other changes to future benefit accruals for non-union participants were detailed in the provided materials.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns well with the ground truth. It correctly identifies the key change: the cessation of benefit accruals for non-union participants effective January 1, 2023, which matches the original answer's timeline and scope. The mention of both the UPS Retirement Plan and the UPS Excess Coordinating Benefit Plan adds precision, though the original answer focuses only on the former; this additional detail does not contradict but rather complements the ground truth. The LLM correctly notes that no further accruals occur for future service and compensation, capturing the core transformational change. All dates and entities are accurate (e.g., January 1, 2023, non-union participants), satisfying quantitative accuracy. The reasoning is sound and reflects proper synthesis across time (2022 to 2023) and plan structure. The only minor shortcoming is that the LLM does not explicitly contrast the 2022 active accrual status with the 2023 frozen state in as much detail as the original answer, slightly reducing completeness in narrative evolution. However, the essential multi-hop information—what changed and when—is correctly conveyed. Wording differs but semantic equivalence is maintained. No calculation errors or factual inaccuracies are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1461,
        "completion_tokens": 359,
        "total_tokens": 1820
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has Amazon's utilization and structure of its short-term credit facilities evolved between 2022 and 2024, particularly in terms of credit capacity, interest rate terms, and outstanding borrowings?",
      "original_answer": "In 2022, Amazon had a $7.0 billion unsecured revolving credit facility with an interest rate of benchmark rate plus 0.50% and a commitment fee of 0.04%, and no borrowings were outstanding under this facility. Additionally, Amazon had $7.2 billion in unused letters of credit as of December 31, 2021. By 2024, Amazon had significantly expanded its credit capacity by entering into a new $15.0 billion unsecured revolving credit facility with a lower interest rate of benchmark rate plus 0.45% and a reduced commitment fee of 0.03%. In addition, Amazon introduced a new $5.0 billion unsecured 364-day revolving credit facility in October 2024, which also carried a rate of SOFR plus 0.45% and a 0.03% commitment fee. Notably, there were still no borrowings outstanding under the main Credit Agreement or the Short-Term Credit Agreement as of December 31, 2024. However, Amazon had $147 million and $151 million in borrowings under other short-term credit facilities as of December 31, 2023 and 2024, respectively, which were included in 'Accrued expenses and other.' The company also increased its unused letters of credit to $8.3 billion by the end of 2024.",
      "llm_answer": "Between 2022 and 2024, Amazon’s short‑term credit capacity expanded with the addition of a $5 billion 364‑day revolving facility (the Short‑Term Credit Agreement) that matures in October 2025 and can be extended another year, while its prior $8 billion 364‑day term loan was fully repaid in January 2024. The company also maintains a $15 billion unsecured revolving credit facility (Credit Agreement) extending to November 2028, which in 2024 carried a benchmark rate plus 0.45% and a 0.03% commitment fee, and it continues to use commercial‑paper programs up to $20 billion. Outstanding borrowings under these facilities remained essentially zero, with only modest amounts ($147‑151 million) drawn on other short‑term facilities, and unused letters of credit of about $8.3 billion as of 2024. Interest rates on the new facilities are tied to the Secured Overnight Financing Rate (SOFR) plus 0.45% (revolving) or plus 0.75% (term loan), reflecting a shift away from LIBOR.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly in the quantitative details. It incorrectly states that Amazon had an $8 billion 364-day term loan that was repaid in January 2024; the ground truth does not mention such a term loan or its repayment. Instead, the original answer notes that Amazon introduced a new $5.0 billion 364-day revolving facility in October 2024, not that it replaced an $8 billion term loan. The LLM also incorrectly implies that the $5 billion 364-day facility matures in October 2025, which is not stated in the ground truth (the filing date is October 2024, but maturity is not specified). (2) The LLM correctly identifies the $15 billion credit facility with a rate of benchmark plus 0.45% and 0.03% fee in 2024, and the $5 billion 364-day facility with SOFR plus 0.45%, which aligns with the ground truth. However, it adds an unsupported rate of SOFR plus 0.75% for a term loan, which is not mentioned in the original. The $147–151 million in other short-term borrowings and $8.3 billion in unused letters of credit are correctly reported. But the LLM incorrectly mentions a $20 billion commercial paper program, which is not in the original answer. (3) The multi-hop reasoning is partially sound: the model correctly synthesizes changes in credit capacity and interest rates over time and notes the lack of borrowings under major facilities. However, it introduces entities (e.g., $8B term loan, commercial paper program) not present in the ground truth, undermining the accuracy of the synthesis. (4) The contextual relevance is high as the answer addresses credit capacity, interest rates, and outstanding borrowings. The qualitative accuracy is moderate due to correct structure and some accurate details, but the quantitative accuracy is low due to incorrect dollar amounts, dates, and added facilities. The correctness score is 6 because the core evolution—increased capacity, lower rates, minimal borrowings—is partially correct, but significant factual errors reduce confidence in the overall response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1545,
        "completion_tokens": 557,
        "total_tokens": 2102
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has Costco's use of variable-priced contracts for energy purchases evolved between 2022 and 2023, and what does this indicate about its commodity price risk management strategy?",
      "original_answer": "In 2022, Costco entered into variable-priced contracts for some purchases of electricity and natural gas, as well as fuel for its gas stations, on an index basis. These contracts met the definition of derivatives but generally qualified for the 'normal purchases and normal sales' exception, requiring no mark-to-market adjustment. By 2023, Costco continued this approach but specifically called out natural gas and fuel for gas stations as key components of its variable-priced contract usage. This indicates a continued reliance on variable-priced contracts as part of its commodity price risk management, with no significant shift away from index-based pricing mechanisms. The strategy remains consistent, showing stability in how Costco manages exposure to energy price fluctuations.",
      "llm_answer": "Costco's use of variable-priced contracts for energy purchases remained consistent between 2022 and 2023, as evidenced by its continued reliance on index-based agreements for natural gas and electricity—contracts that qualify for the \"normal purchases and normal sales\" exception and require no mark-to-market adjustments. This approach reflects a deliberate strategy to manage commodity price risk by partially mitigating exposure through fixed-price contracts for certain warehouses while using variable pricing for specific purchases, indicating a pragmatic, risk-averse stance that prioritizes stability over speculative hedging.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: Costco used variable-priced, index-based contracts for electricity, natural gas, and fuel in both 2022 and 2023; these contracts qualify for the 'normal purchases and normal sales' exception and do not require mark-to-market adjustments. The LLM correctly notes continuity in strategy between the years. (2) There are no numeric values requiring verification (e.g., dollar amounts, percentages), so quantitative accuracy is unaffected and scores perfectly. (3) The multi-hop reasoning is sound—synthesizing information across years and contract types—and the conclusion about risk management strategy is logically supported. The only minor gap is that the LLM mentions 'fixed-price contracts for certain warehouses' as part of the strategy, which is not explicitly stated in the original answer and introduces a detail not confirmed by the ground truth. While plausible, it slightly extends beyond the provided information. (4) The answer is fully relevant, directly addressing the evolution of contract use and what it indicates about risk management. Overall, the response is factually correct, well-reasoned, and semantically equivalent to the original answer, warranting a high correctness score with only a slight deduction for the unverified mention of fixed-price contracts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 384,
        "total_tokens": 1748
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has the strategic positioning and commercial role of NVIDIA AI Enterprise evolved within NVIDIA's data center offerings between 2022 and 2024?",
      "original_answer": "In 2022, NVIDIA AI Enterprise was introduced as part of the Compute & Networking segment, indicating its foundational role in NVIDIA's AI and accelerated computing strategy. By 2024, the product had evolved into a more prominent commercial offering, described as a 'comprehensive suite of enterprise-grade AI software' that is actively licensed and integrated into broader data center solutions. This shift reflects NVIDIA's move from positioning it as a strategic initiative to a key monetization vehicle within its full-stack data center platform, alongside offerings like NVIDIA DGX Cloud and the expansion into CPUs and DPUs.",
      "llm_answer": "Between 2022 and 2024, NVIDIA AI Enterprise evolved from a foundational AI software suite into a core commercial offering tightly integrated within NVIDIA’s data center platform, reflecting a strategic shift toward enterprise AI adoption. By 2024, it was positioned as a critical enabler for generative AI workloads, with the Blackwell architecture (launched in 2025) further cementing its role in accelerating AI training and deployment across data centers, supported by full-stack integration of GPUs, CPUs, and networking. This evolution was underscored by its inclusion in NVIDIA’s data center offerings as a key differentiator for enterprise AI infrastructure, moving beyond technical capability to become a commercial product with dedicated licensing and support.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of NVIDIA AI Enterprise from a foundational suite in 2022 to a core commercial offering by 2024, aligning with the ground truth's emphasis on its shift toward monetization and integration into the full-stack data center platform. Key elements like enterprise licensing, strategic positioning, and integration with broader infrastructure are accurately reflected. However, the LLM introduces a factual error by referencing the 'Blackwell architecture (launched in 2025)', which is not mentioned in the original answer and is temporally inconsistent—Blackwell was announced in 2024 for future deployment, not launched in 2025, and its inclusion misrepresents the timeline. (2) Quantitative accuracy is partially compromised due to this incorrect date (2025 launch), which is not supported by the ground truth and introduces a forward-looking claim not present in the source. No financial figures are involved, so numerical precision is not at issue, but temporal accuracy (a key quantitative dimension) is flawed. (3) The multi-hop reasoning is generally sound—the model synthesizes the product’s strategic evolution, commercialization, and integration across NVIDIA’s offerings. It correctly infers that tighter integration with CPUs, GPUs, and networking reflects a broader platform strategy. However, the erroneous reference to Blackwell undermines the reasoning chain by introducing unsupported external information. (4) Despite the factual error in timing, the answer remains contextually relevant and semantically close to the original, conveying the core narrative of commercial maturation and strategic elevation. Hence, correctness is reduced to 7 due to the significant but not central factual inaccuracy, while qualitative and contextual scores remain high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1349,
        "completion_tokens": 496,
        "total_tokens": 1845
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How did Pfizer's contractual obligations related to Paxlovid evolve between 2023 and 2024, and what does this indicate about the company's future revenue expectations for the product?",
      "original_answer": "In 2023, Pfizer had a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter related to the expected return of an estimated 6.5 million treatment courses of Paxlovid labeled under Emergency Use Authorization (EUA) from the U.S. government. This indicated uncertainty and potential decline in demand for Paxlovid. By 2024, however, remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, signaling a stabilization and expectation of future revenue from existing contracts. This shift from a large revenue reversal to a defined forward-looking contractual obligation suggests improved demand forecasting and a more stable outlook for Paxlovid in 2024 compared to the uncertainty in 2023.",
      "llm_answer": "Pfizer's contractual obligations for Paxlovid shifted from large government supply agreements in 2023 to commercial market transition in 2024, with remaining performance obligations totaling approximately $1 billion in contracted revenue expected through 2028. This indicates the company expects significantly lower future revenue from Paxlovid compared to its peak pandemic levels, as it transitions to commercial sales with negotiated pricing and reduced government procurement.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $1 billion in remaining performance obligations for Paxlovid, which aligns with the ground truth as of December 31, 2024. However, it omits the critical 2023 non-cash revenue reversal of $3.5 billion related to the return of 6.5 million treatment courses under EUA from the U.S. government—a key event that defined Pfizer's contractual obligation shift. This omission significantly undermines completeness and factual accuracy. (2) The $1 billion figure is accurate and matches the ground truth, but the LLM incorrectly extends the revenue expectation 'through 2028'—a detail not present in the original answer and unsupported by the provided ground truth. This introduces a factual error in timing and duration. (3) The reasoning partially captures the transition from government to commercial sales, but mischaracterizes the implication: the ground truth frames the $1 billion obligation as a stabilization and improved outlook following prior uncertainty, whereas the LLM interprets it as 'significantly lower future revenue' indicating decline. While reduced revenue vs. peak pandemic levels may be true, the original answer emphasizes improved forecasting and stability, not just reduced expectations. Thus, the multi-hop synthesis is flawed—failing to connect the reversal (2023) to the stabilization (2024) as evidence of improved demand clarity. (4) Scores reflect partial credit: quantitative accuracy docked due to unsupported '2028' claim; qualitative accuracy reduced for incorrect reasoning trajectory; contextual relevance remains high as the answer addresses the evolution and revenue implications, albeit with key errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 461,
        "total_tokens": 1779
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "Compare and contrast how Google's exposure to new regulatory costs in international markets evolved between 2022 and 2024, particularly in terms of the scope and nature of regulatory challenges described?",
      "original_answer": "In 2022, Google highlighted that an evolving foreign policy landscape could subject the company to 'new regulatory costs and challenges,' specifically mentioning data transfers between the EU and the UK, as well as new customer requirements. By 2024, the scope of regulatory challenges expanded significantly. The 2024 filing not only reiterated the exposure to 'new regulatory costs and challenges' but also introduced elements like 'uncertainty regarding regulatory outcomes' and the risk of 'other liabilities under local laws that may not offer due process or clear legal precedent.' This indicates a shift from primarily data-related regulatory concerns in 2022 to broader, more unpredictable regulatory risks in 2024, reflecting an increased complexity in Google's international regulatory environment.",
      "llm_answer": "Between 2022 and 2024, Google’s exposure to new regulatory costs in international markets shifted from a general acknowledgment of regulatory complexity to a more specific focus on foreign policy volatility, data‑transfer rules (e.g., EU‑UK transfers), and heightened anti‑corruption and sanctions compliance, reflecting a broader, more structured regulatory landscape that now includes explicit new customer requirements and expanded legal obligations across jurisdictions. This evolution is documented in the 2022 filing’s discussion of “evolving foreign policy landscape” and “new customer requirements,” while the 2024 filing expands on these points with concrete references to sanctions, export controls, and the need to navigate an increasingly complex foreign‑policy environment that directly generates additional compliance and operational costs.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in identifying the evolution of Google's regulatory exposure between 2022 and 2024, with accurate references to the 'evolving foreign policy landscape' and 'new customer requirements' from the 2022 filing. It correctly notes the expansion of regulatory challenges and mentions data-transfer rules (e.g., EU-UK), which aligns with the ground truth. However, the LLM introduces elements not present in the original answer, such as 'heightened anti-corruption and sanctions compliance,' 'export controls,' and 'structured regulatory landscape,' which are not mentioned in the 2024 filing according to the ground truth. The original answer emphasizes a shift toward 'uncertainty regarding regulatory outcomes' and 'liabilities under local laws that may not offer due process or clear legal precedent'—key qualitative shifts that the LLM fails to capture. While the LLM correctly identifies an expansion in scope, it mischaracterizes the nature of the 2024 risks by focusing on compliance frameworks rather than the increased legal unpredictability and due process concerns highlighted in the ground truth. There are no numerical inaccuracies (quantitative accuracy is perfect), and the answer is contextually relevant, addressing the comparative evolution across years. The reasoning is sound but based on partially incorrect premises, leading to a moderate deduction in qualitative accuracy and overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1430,
        "completion_tokens": 397,
        "total_tokens": 1827
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has UPS's approach to funding postretirement medical benefits evolved between 2022 and 2023, particularly in terms of the sources used for expected benefit payments?",
      "original_answer": "In 2022, UPS indicated that expected benefit payments for postretirement medical benefits would be paid from both plan trusts and corporate assets. In 2023, the language remained unchanged, indicating continuity in the funding approach. Therefore, there was no change in the sources used for expected benefit payments for postretirement medical benefits between the two years.",
      "llm_answer": "Based on the provided SEC 10-K filings, UPS's approach to funding postretirement medical benefits remained consistent between 2022 and 2023 in terms of the primary funding source, but the expected cash flow projections and contribution requirements were updated. Specifically, the 2023 filing (page 92) shows expected employer contributions of $74 million to U.S. postretirement medical benefit plans for 2024, with expected benefit payments of $216 million in 2024 and increasing to $15,637 million by 2029–2033. These figures reflect a continuation of the funding policy where postretirement medical benefit payments are primarily funded through plan trusts and corporate assets, as noted on page 92, with no indication of a structural change in funding sources between the 2022 and 2023 filings. The 2022 filing (page 109) similarly projected $177 million in employer contributions for 2022 and $229 million in benefit payments for 2022, with the 2023 figures representing an updated but consistent funding trajectory.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer incorrectly introduces specific numerical projections (e.g., $74M contributions, $216M benefit payments in 2024, $15,637M by 2029–2033) that are not present in the original answer or implied by the ground truth. The ground truth makes no mention of these figures, nor does it reference updated cash flow projections or contribution requirements. These numbers appear to be fabricated or misattributed, severely undermining quantitative accuracy. (2) The original answer states there was no change in funding sources between 2022 and 2023—specifically, that benefits were paid from both plan trusts and corporate assets in both years. The LLM correctly identifies that funding sources remained consistent and cites the same sources (plan trusts and corporate assets), which aligns with the ground truth. However, it adds detailed financial projections not supported by the original answer, suggesting a failure in fidelity to the provided data. (3) The multi-hop reasoning is partially sound: the model correctly infers continuity in funding approach across years and identifies relevant entities (UPS, postretirement medical benefits, plan trusts, corporate assets). However, the inclusion of unverified numerical data indicates a deviation from the source material, possibly due to hallucination or incorrect extraction from a document not aligned with the knowledge graph. (4) While the core qualitative conclusion about unchanged funding sources is correct, the addition of unsupported quantitative details significantly reduces factual accuracy. The contextual relevance is high because the response addresses the right topic and funding mechanism, but the made-up numbers severely penalize correctness and quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 479,
        "total_tokens": 1834
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has the role and scope of NVIDIA AI Enterprise evolved from its introduction in 2022 to its broader supply and integration in 2024?",
      "original_answer": "In 2022, NVIDIA AI Enterprise was introduced as part of the Compute & Networking segment, described as a software suite aimed at simplifying the deployment of AI applications across data centers and enterprise environments. By 2024, the platform had evolved into a more comprehensive and integrated solution, including components such as NVIDIA NIM, NVIDIA NeMo, and AI Blueprints, with specific performance improvements like a 2.5x increase in token throughput. This reflects a shift from a foundational offering to a full-stack, production-grade generative AI platform with enhanced capabilities and broader deployment options.",
      "llm_answer": "From its 2022 launch, NVIDIA AI Enterprise was positioned as an end‑to‑end AI‑software suite for enterprise AI workloads, delivered alongside the company’s data‑center GPUs, CPUs and networking. By 2024 the offering had broadened into a full‑stack platform that now includes Blackwell‑based GPUs, CPUs and DPUs, DGX Cloud training‑as‑a‑service, and a suite of AI‑focused tools (NIM, NeMo, AI Blueprints) that enable enterprises to build, fine‑tune and deploy generative‑AI applications on‑premises or in the cloud. This evolution reflects a shift from a software add‑on to a core component of NVIDIA’s accelerated‑computing platform, tightly integrated with its hardware and extended across data‑center, automotive and Omniverse ecosystems.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: NVIDIA AI Enterprise was introduced in 2022 as an enterprise AI software suite and evolved by 2024 into a full-stack generative AI platform. The inclusion of NIM, NeMo, and AI Blueprints is correctly stated. While the ground truth mentions a specific 2.5x increase in token throughput, the LLM answer does not include this quantitative detail, which is a minor omission. However, no incorrect numbers are presented, so quantitative accuracy remains high. (2) The LLM correctly identifies the evolution from a software suite to an integrated platform, accurately reflecting the multi-hop reasoning across time and product development. (3) Entity accuracy is strong: correct company (NVIDIA), correct product names (NVIDIA AI Enterprise, NIM, NeMo, AI Blueprints), and correct timeframes (2022 introduction, 2024 evolution). The mention of Blackwell-based GPUs, DPUs, and DGX Cloud adds contextual depth not in the original but is factually consistent with NVIDIA's 2024 ecosystem and does not contradict the ground truth. (4) The reasoning is sound, showing a logical progression from initial software offering to a broader, hardware-integrated platform. The answer enhances the original with additional context (e.g., deployment across automotive and Omniverse) without distorting the core message. The only reason for not scoring a 10 is the absence of the specific 2.5x performance improvement, a factual detail present in the ground truth. Overall, the answer is semantically equivalent and highly relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 440,
        "total_tokens": 1779
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has ExxonMobil's proved reserves through equity companies evolved from 2022 to 2024, and what does this indicate about its strategic positioning in different regions?",
      "original_answer": "In 2022, ExxonMobil's total proved reserves from equity companies amounted to 14 million barrels gross (1 million net) across the United States, Europe, Africa, and Asia. By 2024, these reserves had significantly increased to 467 million barrels of crude oil, 120 million barrels of natural gas liquids, and 5,367 billion cubic feet of natural gas, with the majority of this growth concentrated in Asia. This indicates a major strategic shift toward strengthening its upstream presence in the Asia region through equity companies.",
      "llm_answer": "ExxonMobil's proved reserves through equity companies declined slightly from 1,481 million boe in 2022 to 1,481 million boe in 2024, while consolidated proved reserves grew from 12,599 million boe to 19,949 million boe over the same period. This shift reflects a strategic focus on developing large, long‑lead‑time projects in regions such as the United Arab Emirates, Kazakhstan, and Australia, where significant undeveloped reserves are being converted to developed status through major capital investments. Consequently, the company is positioning itself more heavily in the Middle East and Asia‑Pacific, while maintaining a strong presence in North America, to leverage high‑margin resources and support its transition toward lower‑emission energy projects.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is almost entirely incorrect in terms of factual content. The original answer states that ExxonMobil's proved reserves through equity companies were 14 million barrels gross (1 million net) in 2022 and surged to 467 million barrels of crude oil, 120 million barrels of natural gas liquids, and 5,367 billion cubic feet of natural gas by 2024, with growth concentrated in Asia. In contrast, the LLM claims reserves remained flat at 1,481 million boe from 2022 to 2024, which contradicts the ground truth. Additionally, the LLM introduces 'consolidated proved reserves' (12,599 to 19,949 million boe), a metric not mentioned in the original answer and irrelevant to the question about equity companies. (2) The numbers are completely inaccurate: the LLM reports no change in equity reserves (1,481M boe both years), while the truth shows a massive increase from 14M to hundreds of millions of barrels and billions of cubic feet. There is no indication that the LLM correctly retrieved or synthesized the actual data. (3) The reasoning is flawed: the LLM infers a strategic shift based on consolidated reserves and capital projects in UAE, Kazakhstan, and Australia, but the original answer attributes the strategic shift specifically to growth in equity company reserves in Asia. The multi-hop synthesis failed—the LLM did not connect equity reserves to regional strategy using the correct data. (4) While the LLM attempts to address the strategic positioning question and mentions Asia-Pacific, its analysis is based on incorrect data and conflates equity with consolidated reserves, undermining both qualitative and quantitative accuracy. The contextual relevance is moderate because it discusses strategy and regions, but the foundation is factually unsound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 486,
        "total_tokens": 1814
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has the financial relationship with Google Network Partners evolved between 2022 and 2024, particularly in terms of their role in revenue generation and cost structure?",
      "original_answer": "In 2022, Google Network Partners played a central role in the revenue generation process as Google acted as the principal for ads placed on Google Network properties, reporting advertising revenues on a gross basis, with payments to partners recorded as cost of revenues. By 2024, Google continued to pay Google Network partners, but the focus of the financial reporting shifted to emphasize the net cash flow impact, noting that payments to these partners were a primary use of cash from operating activities. This reflects a more cost-centric framing of the relationship in the later year.",
      "llm_answer": "Between 2022 and 2024, Google Network Partners transitioned from being a significant revenue source to a more constrained component of the cost structure. In 2022, TAC (which includes payments to Google Network Partners) was a major cost driver, but by 2024, its impact had diminished as Google shifted toward internal revenue generation and reduced reliance on external partners. The 2024 financials show a focus on cost optimization, with Google Cloud's operating income rising due to revenue growth offsetting infrastructure costs, while Other Bets and Alphabet-level activities absorbed losses. Notably, the company repurchased $62 billion in shares in 2024, reflecting a strategic shift toward capital efficiency rather than expanding Network Partner relationships. (Based on analysis of pages 40-57, 53-57, and 56-57, highlighting TAC, revenue structure, and capital allocation trends.)",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The original answer states that Google Network Partners were central to revenue generation in 2022 with revenues reported on a gross basis and partner payments as cost of revenues, and that by 2024 the focus shifted to framing partner payments as a key use of cash in operating activities. In contrast, the LLM incorrectly claims that Network Partners transitioned from being a 'revenue source' to a cost component, which misrepresents the relationship—partners were never a direct revenue source but rather a cost associated with revenue generated through the network. Additionally, the LLM introduces unrelated elements such as Google Cloud's operating income, Other Bets, and a $62 billion share repurchase, which are not mentioned in the original answer and distract from the core evolution of the financial relationship with Network Partners. (2) While the LLM references TAC (Traffic Acquisition Costs) correctly as a cost driver, it fails to specify any actual figures or trends in TAC related to Network Partners between 2022 and 2024, and the $62 billion share repurchase, though potentially accurate, is irrelevant to the question and not part of the ground truth. (3) The multi-hop reasoning is flawed—the original answer requires synthesizing how accounting treatment and financial framing evolved, but the LLM instead infers a strategic decline in partner reliance without evidence, conflating broader Alphabet financial trends with the specific Google Network Partner relationship. (4) The contextual relevance is moderate because the answer touches on cost structure and time-based changes, but the qualitative and quantitative inaccuracies severely undermine correctness, warranting a low score despite some thematic alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 492,
        "total_tokens": 1870
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has UPS's foreign currency exchange risk management strategy evolved between 2022 and 2023, particularly in terms of the financial impact of undesignated foreign currency forward contracts on earnings volatility?",
      "original_answer": "In 2022, UPS disclosed that foreign currency exchange forward contracts were used to economically offset foreign currency remeasurement and settlement risk for certain balance sheet assets and liabilities, and that changes in their fair value affected earnings directly. For 2023, UPS expanded the disclosure to emphasize that undesignated derivative settlements are now explicitly linked to earnings volatility, with a specific focus on how these contracts impact income statement recognition. The 2023 filing also introduced a more structured presentation of fair value changes and settlements for these contracts, with amounts for both 2023 and 2022 now reported side-by-side in millions, indicating a more transparent and systematic approach to disclosing the financial effects of these instruments.",
      "llm_answer": "Based on the provided pages, UPS's foreign currency exchange risk management strategy remained focused on using designated hedges (primarily foreign currency exchange contracts) to manage exposure, but the financial impact of **undesignated** forward contracts increased significantly in volatility. Specifically, in 2023, unrealized gains/losses on non-designated foreign currency forward contracts recorded directly in income were **$(7) million**, compared to **$(69) million** in 2022, indicating a substantial reduction in earnings volatility from these instruments. This reflects a strategic shift toward more disciplined hedge designation, reducing the volatility of earnings from undesignated positions. The company continues to manage foreign currency risk through designated hedges, as evidenced by the detailed AOCI and income statement disclosures for both designated and non-designated derivatives.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies, particularly in the quantitative claims. The ground truth states that UPS enhanced its disclosure practices in 2023 regarding undesignated foreign currency forward contracts, with a more structured presentation of fair value changes and settlements reported side-by-side for both 2023 and 2022. However, the LLM incorrectly asserts specific financial figures—$(7) million in 2023 vs $(69) million in 2022—claiming a reduction in earnings volatility from undesignated contracts. These numbers are not present in the original answer and represent a fabrication or misattribution not supported by the provided ground truth. The original answer does not mention any actual dollar amounts related to gains or losses, nor does it state that volatility decreased. Instead, it emphasizes improved transparency and disclosure structure. The LLM also introduces the idea of a 'strategic shift toward more disciplined hedge designation,' which is not stated or implied in the original answer. While the LLM correctly identifies that undesignated contracts impact earnings directly and that UPS uses such instruments, it fails to capture the actual evolution—which is in disclosure and presentation, not in the magnitude or management of the contracts themselves. The reasoning is therefore flawed, as it substitutes unsupported numerical comparisons for the actual qualitative evolution in reporting. Contextually, the answer stays on topic and addresses foreign currency risk and earnings volatility, but the core factual content is incorrect, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1446,
        "completion_tokens": 442,
        "total_tokens": 1888
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has the role of the membership format in Costco's profitability strategy evolved between 2022 and 2023, particularly in terms of its impact on member loyalty and fee revenue?",
      "original_answer": "In 2022, the membership format was described as 'an integral part of our business and has a significant effect on our profitability,' with an emphasis on growth in the membership base, increasing Executive member penetration, and sustaining high renewal rates as key drivers of profitability. By 2023, the language evolved to underscore that the membership format 'is an integral part of our business and profitability,' indicating a more consolidated role in the company's financial model. Additionally, in 2023, Costco introduced a new concern about the potential adverse impact of lower renewal rates in newer markets on the worldwide renewal rate, which was not explicitly mentioned in 2022. This suggests that while the membership model remained central to profitability, the company faced emerging challenges in sustaining renewal rates as it expanded into newer markets.",
      "llm_answer": "Between 2022 and 2023, Costco’s membership format remained a core profitability driver, but its impact shifted subtly. Membership fee revenue grew 9% in 2022 (driven by new sign-ups, Executive upgrades, and improved renewal rates) and continued rising 5% in 2023, directly bolstering revenue streams while reinforcing loyalty. However, the company noted that warehouse openings in existing markets could dampen paid membership growth, and renewal rates—especially in newer international markets—remain vulnerable, potentially constraining future fee revenue growth despite the format’s enduring role in sustaining profitability. (Based on Costco 2022 and 2023 10-K disclosures on pages 21–26.)",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that Costco's membership format remained central to profitability between 2022 and 2023 and notes the continued importance of renewal rates and Executive member growth. It also appropriately highlights emerging concerns about renewal rates in newer international markets, aligning with the ground truth's point about potential adverse impacts on worldwide renewal rates. However, the ground truth does not mention specific percentage growth in membership fee revenue (9% in 2022, 5% in 2023), nor does it reference 'warehouse openings in existing markets' as a constraint on membership growth—these are plausible inferences but not explicitly stated in the 10-Ks for those years. (2) The quantitative claims (9% and 5% growth in fee revenue) are not present in the original answer or verifiable from the provided ground truth, making them unsupported additions. These figures may be accurate in external context but are not confirmed by the knowledge graph source, reducing quantitative accuracy. (3) The multi-hop reasoning is generally sound—linking membership structure to profitability, loyalty, and expansion challenges—but introduces details (specific growth percentages, warehouse location impact) not present in the ground truth, indicating partial synthesis with some overreach. (4) The answer is contextually relevant and captures the evolution in tone and strategic concern, especially regarding newer markets. While the core qualitative message aligns—membership remains integral, but with growing risks in new markets—the inclusion of unverified numerical data lowers the correctness and quantitative accuracy scores. Semantic equivalence is mostly preserved but compromised by unsupported specifics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1400,
        "completion_tokens": 479,
        "total_tokens": 1880
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has NVIDIA's approach to CUDA evolved between 2022 and 2024, particularly in terms of its integration within the broader data center platform and software ecosystem?",
      "original_answer": "In 2022, CUDA was primarily positioned as a key component of NVIDIA's AI ecosystem, with nearly 3 million developers using CUDA and other software tools to deploy AI and accelerated computing technologies. It was described as central to NVIDIA's partnerships and developer programs, including the Deep Learning Institute and Inception program. By 2024, CUDA had evolved into a more deeply integrated part of a full-stack computing platform, specifically within the data center. It was described as the foundation of the CUDA-X collection of acceleration libraries, APIs, SDKs, and domain-specific frameworks, emphasizing its role in enabling end-to-end optimized computing across GPUs, CPUs, and DPUs. This reflects a strategic shift from promoting CUDA as a developer-focused tool to positioning it as a core infrastructure layer for enterprise-scale computing solutions.",
      "llm_answer": "Between 2022 and 2024, NVIDIA’s approach to CUDA evolved from a foundational parallel programming model into a tightly integrated component of its full-stack data center platform, now bundled with new hardware accelerators (DPUs in 2022, CPUs in 2024) and software services like AI Enterprise, DGX Cloud, and the Blackwell architecture. This integration enables seamless orchestration across GPUs, CPUs, and networking, embedding CUDA within a broader ecosystem of AI software, libraries, and services that support enterprise AI workloads, generative AI, and large-scale HPC, thereby reinforcing its role as the backbone of NVIDIA’s data center platform and software stack.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of CUDA from 2022 to 2024 as described in the ground truth. It correctly identifies the shift from CUDA as a programming model to a foundational component of a full-stack data center platform. The integration with CPUs, GPUs, and DPUs is accurately noted, aligning with the 2024 emphasis on end-to-end computing across hardware. The mention of DPUs in 2022 and CPUs in 2024 is contextually reasonable, though the original answer does not specify exact years for hardware integration—this is a minor inference but not contradicted by the source. The reference to software services like AI Enterprise and DGX Cloud is consistent with the broader ecosystem expansion, though the original answer emphasizes CUDA-X, acceleration libraries, APIs, and SDKs more explicitly. The strategic shift from developer-focused tool to enterprise infrastructure layer is correctly interpreted and well-articulated. All dates and entities (NVIDIA, CUDA, data center platform) are accurate. No numerical data is present in the original or LLM answer, so quantitative accuracy is scored based on absence of error (10). The reasoning is sound, demonstrating multi-hop synthesis across time, product evolution, and ecosystem integration. The answer is fully contextually relevant. The only reason for not scoring a perfect 10 is the slight shift in emphasis from CUDA-X and developer programs (Deep Learning Institute, Inception) to newer cloud and enterprise services, which are related but not the focal point of the original answer. However, the semantic meaning and strategic trajectory are equivalent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1392,
        "completion_tokens": 448,
        "total_tokens": 1840
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has Pfizer's financial commitment and contractual obligations related to Paxlovid evolved from 2023 to 2024, particularly in terms of expected future revenue and product delivery timelines?",
      "original_answer": "In 2023, Pfizer had a non-cash revenue reversal of $3.5 billion recorded in the fourth quarter related to the expected return of an estimated 6.5 million treatment courses of EUA-labeled Paxlovid from U.S. government inventory. By the end of 2024, Pfizer reported remaining performance obligations for Paxlovid at approximately $1 billion, with expected product delivery and revenue realization scheduled from 2025 through 2028, indicating a shift from uncertain returns and revenue reversals to a more defined forward-looking revenue outlook based on firm contracts.",
      "llm_answer": "From 2023 to 2024, Pfizer's financial commitment and contractual obligations related to Paxlovid shifted significantly as the product transitioned from government procurement to commercial markets. In 2023, revenue from Paxlovid was driven by government purchases under EUA, with a notable non-cash revenue reversal of $3.5 billion in Q4 2023 due to expected returns of unused government inventory. By early 2024, Pfizer recorded a $771 million favorable adjustment reflecting fewer returns than anticipated, and in Q3 2024, it supplied 1 million treatment courses to the U.S. Strategic National Stockpile at no cost, generating $442 million in revenue. Remaining performance obligations for Paxlovid deliveries under long-term contracts are expected to generate approximately $1 billion in contracted revenue through 2028, with deliveries scheduled from 2025 to 2028, though timelines may be renegotiated. This evolution reflects a decline in government-driven revenue and a shift toward commercial sales, with future revenue now contingent on market demand and renegotiated contracts.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies that significantly affect correctness. While it correctly identifies the $3.5 billion non-cash revenue reversal in Q4 2023 due to expected returns of Paxlovid from U.S. government inventory, it introduces a $771 million favorable adjustment in early 2024 that is not present in the ground truth. This figure is unsupported and alters the financial narrative. Additionally, the claim that Pfizer supplied 1 million treatment courses to the U.S. Strategic National Stockpile in Q3 2024 at no cost but generated $442 million in revenue is contradictory and not corroborated by the original answer. The ground truth does not mention any such transaction or revenue event in 2024. (2) The only number consistent with the ground truth is the remaining performance obligations of approximately $1 billion, with delivery and revenue expected from 2025 to 2028. However, the LLM adds speculative details about renegotiation of timelines not present in the original. (3) The multi-hop reasoning is partially sound—LLM correctly infers a shift from government procurement to commercial markets and links remaining obligations to future revenue. However, it fabricates intermediate financial events (the $771M adjustment and $442M revenue) that distort the evolution of contractual obligations. (4) Despite these issues, the answer is contextually relevant and captures the broader trend of transition from uncertain government returns to more defined commercial contracts. The qualitative reasoning about market transition is plausible but undermined by unsupported quantitative claims. Correctness score is reduced due to significant factual errors in key financial figures and events not present in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1425,
        "completion_tokens": 482,
        "total_tokens": 1907
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has ExxonMobil's strategic emphasis on Guyana evolved between 2022 and 2024, based on its disclosures around reserves development and advantaged asset reporting?",
      "original_answer": "In 2022, ExxonMobil reported that Guyana was a key contributor to extensions and discoveries, adding approximately 1.3 billion oil-equivalent barrels (GOEB) of proved undeveloped reserves. By 2024, Guyana was explicitly listed as one of the core 'Advantaged Assets' in the company's updated earnings drivers, signaling a strategic shift to highlight Guyana's role in driving earnings through volume growth. This evolution reflects a transition from Guyana being primarily a reserves growth region to being a recognized source of advantaged production and earnings visibility.",
      "llm_answer": "Between 2022 and 2024, ExxonMobil’s strategic emphasis on Guyana evolved from modest reserve additions to a central pillar of its growth narrative, as evidenced by its disclosures on reserves development and advantaged assets. In 2022, Guyana’s resources were highlighted as a key growth area but still a small component of overall reserve development, with limited mention in financial metrics. By 2024, Guyana had become a cornerstone of ExxonMobil’s \"Advantaged Volume Growth\" strategy, explicitly cited alongside the Permian Basin and LNG as a driver of high-value, low-cost production. This shift is underscored by its inclusion in the company’s definition of \"Advantaged Assets\" (page 37), where Guyana’s offshore projects are positioned as critical to future earnings, reflecting a strategic pivot to prioritize high-return, low-emission assets like Guyana’s offshore oil fields. The company’s 2024 disclosures also emphasize structural cost savings and capital efficiency, further aligning Guyana’s development with broader financial discipline, cementing its role as a flagship project for future growth.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution of ExxonMobil's strategic emphasis on Guyana from 2022 to 2024, noting the shift from reserves growth to advantaged asset status. The 2022 addition of approximately 1.3 billion oil-equivalent barrels (GOEB) of proved undeveloped reserves is implied through the description of Guyana as a 'key growth area' with 'reserve additions,' though the exact number is not stated—this minor omission prevents a perfect 10. (2) The 2024 designation of Guyana as a core 'Advantaged Asset' is accurately reported, with correct contextual linkage to earnings drivers, volume growth, and comparison to Permian and LNG—consistent with the knowledge graph. The reference to 'page 37' may be specific to a document version but does not contradict facts. (3) Multi-hop reasoning is sound: the model synthesizes information across years and strategic frameworks (reserves → advantaged assets → earnings visibility), correctly inferring the strategic pivot. (4) Wording differs but semantic meaning matches: 'central pillar of its growth narrative' and 'flagship project' are reasonable interpretations of Guyana becoming an 'advantaged asset' and 'driver of earnings.' The answer is fully contextually relevant, addressing both reserves development and advantaged asset reporting as required. Quantitative accuracy is high—only the absence of the explicit 1.3 billion BOE figure prevents a 10—but the qualitative and contextual fidelity remains strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1426,
        "completion_tokens": 422,
        "total_tokens": 1849
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How did the planned utilization of the ATR 72-600F aircraft evolve from 2022 to 2024, and what does this indicate about its role in the company's fleet strategy?",
      "original_answer": "In 2022, the ATR 72-600F was projected to have a decreasing role in the company's fleet, with planned units dropping from 11 in 2023 to just 1 by 2026. By 2024, however, the company's projections showed a shift, with ATR 72-600F units remaining steady at 7 for 2025 and declining only slightly to 3 by 2026. This indicates that while the aircraft was initially expected to phase out more rapidly, it continued to play a more sustained, albeit reduced, role in the fleet strategy.",
      "llm_answer": "From 2022 to 2024 the planned utilization of the ATR 72‑600F shifted from a larger share of the 2022‑2023 delivery schedule (11 aircraft in 2023 and 6 in 2024 in 2022’s plan) to a reduced commitment of only 7 ATR 72‑600Fs slated for delivery in 2025 in the 2024 plan, with no further ATR deliveries listed beyond 2025. This reduction shows that the ATR 72‑600F is being phased out of FedEx’s fleet strategy, with the company focusing instead on newer, more fuel‑efficient Boeing 767‑300F and 777‑F freighters to modernize its cargo aircraft and achieve long‑term operating savings.",
      "correctness_score": 4,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies compared to the ground truth. It incorrectly states that in 2022's plan, there were 11 aircraft in 2023 and 6 in 2024, but the original answer states that in 2022, the projection was 11 units in 2023 declining to 1 by 2026 — it does not mention 6 units in 2024. More critically, the LLM claims that the 2024 plan shows only 7 aircraft for 2025 and none beyond, but the ground truth states that in the 2024 plan, the ATR 72-600F remains steady at 7 in 2025 and declines slightly to 3 by 2026 — thus, the LLM incorrectly omits the 3 units in 2026 and misrepresents the trajectory as a complete phase-out. (2) The quantitative inaccuracies are significant: the LLM invents a '6 in 2024' figure not present in the original, misrepresents the 2024 plan as having no ATRs beyond 2025, and fails to report the actual 3-unit projection for 2026. While the 7 units in 2025 is correct, the rest of the timeline is distorted. (3) The multi-hop reasoning is partially sound — the model recognizes a shift in fleet strategy and infers a move toward Boeing freighters — but this conclusion is overreaching given the data. The original answer does not mention Boeing 767/777 or fuel efficiency, so this addition, while plausible, is not supported by the ground truth and mischaracterizes the strategic shift as a full phase-out rather than a moderated reduction. (4) The correctness score is 4 due to partial accuracy on the 2025 number but major errors in the timeline and magnitude of the phase-out. Quantitative accuracy is low (4) due to incorrect numbers and omissions. Qualitative accuracy is moderate (5) because the model identifies a strategic shift but misinterprets its nature. Contextual relevance is high (7) as the answer addresses fleet strategy evolution, albeit with flawed data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1268,
        "completion_tokens": 502,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has NVIDIA's approach to offering Omniverse evolved between 2022 and 2024, particularly in terms of its integration with other AI and simulation platforms?",
      "original_answer": "In 2022, NVIDIA Omniverse was primarily described as a virtual world simulation and collaboration platform for 3D workflows, available as a software subscription for enterprise use and free for individual use. It was highlighted as being integrated with VR and AR in enterprise applications such as virtual car showrooms and surgical training. By 2024, NVIDIA's offering of Omniverse had evolved into a more comprehensive development platform and operating system for building and running virtual world simulation applications. It was now emphasized as being used by industrial enterprises to digitalize complex physical assets and processes—such as building digital twins of factories and testing autonomous robots and vehicles—powered by NVIDIA's accelerated computing infrastructure both on-premises and in the cloud. This represents a shift from general 3D collaboration to a more specialized, enterprise-focused simulation and digital twin platform.",
      "llm_answer": "NVIDIA's Omniverse platform has evolved from a specialized industrial simulation tool into a core enterprise AI infrastructure component between 2022 and 2024. Initially introduced as a 3D collaboration platform for digital twins (2022), it expanded to become deeply integrated with NVIDIA's AI stack—enabling synthetic data generation for autonomous driving training (2023) and later incorporating AI-specific features like Omniverse Avatar for generative AI avatars (2024). This integration was formalized through its inclusion in the NVIDIA AI Enterprise suite, positioning Omniverse as a unified platform for industrial AI workflows that connects simulation, AI training, and deployment across industries.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the general evolution of Omniverse from a 3D collaboration platform to a more integrated AI and simulation tool, which aligns with the ground truth. However, it misrepresents the starting point: in 2022, Omniverse was not described as a 'specialized industrial simulation tool' but rather as a broader 3D collaboration and virtual world simulation platform available for enterprise and free individual use. The LLM reverses the trajectory by claiming it evolved 'from a specialized industrial simulation tool,' when in fact it evolved into one. (2) Dates (2022, 2023, 2024) are used plausibly and no specific numeric values (e.g., dollar amounts, percentages) are present, so quantitative accuracy is high by default. The mention of synthetic data generation for autonomous driving and Omniverse Avatar in 2024 is contextually reasonable and consistent with NVIDIA's direction, though not explicitly confirmed in the ground truth. (3) The multi-hop reasoning is partially sound—linking Omniverse to AI Enterprise and synthetic data shows synthesis—but the core narrative of evolution is inverted. The ground truth emphasizes a shift from general 3D collaboration to focused industrial digital twins; the LLM incorrectly frames it as starting from industrial use. (4) Despite this key factual inversion, the answer includes relevant elements like integration with AI stack, digital twins, and enterprise deployment, maintaining contextual relevance. The conclusion that Omniverse became part of a unified AI infrastructure is semantically close but not fully aligned with the ground truth's emphasis on simulation and digital twin platform evolution. Thus, the correctness and qualitative accuracy scores are moderate due to significant conceptual misrepresentation, even though supporting details are plausible.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1419,
        "completion_tokens": 501,
        "total_tokens": 1920
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has the role of Google Play in generating non-advertising revenue evolved between 2022 and 2023?",
      "original_answer": "In 2022, Google Play was introduced as part of the company's broader strategy to expand non-advertising revenues, specifically through the sales of apps, in-app purchases, and digital content. By 2023, Google Play had transitioned into a more defined revenue stream under 'platforms,' where it was explicitly tied to revenues from app sales and in-app purchases. This evolution indicates a strategic shift toward solidifying Google Play’s role as a key monetization platform rather than just a component of diversification. The change reflects a more structured categorization and likely a stronger contribution to revenue stability within the ecosystem.",
      "llm_answer": "Between 2022 and 2023, Google Play's contribution to non-advertising revenue grew as part of Alphabet's broader shift toward non-advertising revenue streams, which increased from $19.0 billion (8% of total revenue growth) to $307.4 billion total revenue. This expansion reflects Google Play's role in generating non-advertising revenue through app sales and in-app purchases, though specific Play revenue figures are not isolated in the provided financial tables. The document notes that non-advertising revenues (including Google Play, Cloud, subscriptions, and devices) have grown over time and now represent an increasingly significant portion of Alphabet's business, with margins typically lower than advertising revenues.",
      "correctness_score": 4,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative claims. It states that non-advertising revenue grew from $19.0 billion to $307.4 billion, which is incorrect — $307.4 billion is Alphabet's total revenue, not non-advertising revenue. The original answer does not provide specific revenue figures for Google Play or non-advertising revenue, but the LLM fabricates or misrepresents these numbers, leading to major quantitative errors. (2) There are no verifiable calculations in the ground truth, but the LLM introduces unsupported figures: 'non-advertising revenue increased from $19.0B to $307.4B' is logically and numerically flawed — $307.4B is total revenue, and the $19.0B figure appears to misrepresent a growth contribution as a base value. These numbers are not consistent with the ground truth or typical SEC filing data. (3) The qualitative reasoning partially aligns with the original answer — it correctly identifies Google Play's role in non-advertising revenue via app sales and in-app purchases and acknowledges Alphabet's broader diversification strategy. However, it fails to capture the key evolution described in the ground truth: the re-categorization of Google Play under 'platforms' in 2023 as a more structured and defined revenue stream. This strategic shift in classification and monetization focus is missing. (4) The contextual relevance is moderate — the answer addresses Google Play and non-advertising revenue over 2022–2023, but due to severe quantitative inaccuracies and incomplete synthesis of the strategic evolution, the correctness score is low. The answer introduces irrelevant financial aggregates not present in the ground truth, undermining its reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 477,
        "total_tokens": 1810
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has AIG's use of expected loss ratio methods in workers' compensation reserving evolved between 2022 and 2023, particularly in relation to guaranteed cost and excess of deductible business?",
      "original_answer": "In 2022, AIG generally gave significant weight to expected loss ratio methods for guaranteed cost business only in the most recent accident year, while for excess of deductible business, these methods were given significant weight in the most recent five accident years. The company also noted that changes in claims strategy and loss mitigation efforts were accelerating settlements, increasing paid losses along the latest diagonals. In 2023, the reserving methodology remained broadly consistent, with AIG continuing to use a combination of loss development, frequency/severity, and expected loss ratio methods. However, the 2023 filing emphasized that incurred and paid losses were now presented net of reinsurance and undiscounted, which may reflect a refinement in reporting transparency rather than a change in reserving philosophy. Additionally, the increased proportion of large deductible business continued to slow the reporting pattern of claims in 2023, consistent with the trend noted in 2022.",
      "llm_answer": "AIG’s workers‑compensation reserving shifted toward more reliance on expected‑loss‑ratio methods for excess‑of‑deductible (guaranteed‑cost) business, especially in the most recent accident years, while still using development‑based methods for the bulk of the portfolio.  The company explicitly separates guaranteed‑cost and excess‑of‑deductible business and, over 2022‑2023, increased the weight given to expected‑loss‑ratio estimates for newer accident years to reflect changing market conditions and longer claim‑development patterns, whereas older years continued to be projected primarily with paid‑and‑incurred development factors.  This evolution reflects a strategic emphasis on using premium‑based loss‑ratio assumptions for newer, higher‑deductible business while retaining development‑factor approaches for more mature, lower‑deductible segments.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains several inaccuracies and misrepresentations of the original information. (1) It incorrectly states that AIG increased reliance on expected loss ratio methods for 'excess-of-deductible (guaranteed-cost)' business, conflating the two distinct lines—guaranteed cost and excess of deductible—when in fact the original answer specifies that in 2022, expected loss ratio methods were given significant weight for guaranteed cost only in the most recent accident year, and for excess of deductible in the most recent five accident years. The LLM incorrectly implies a shift toward more reliance in both lines, which is not supported by the original text. (2) The original answer states that the methodology remained 'broadly consistent' in 2023, indicating no major shift, whereas the LLM suggests an evolution or strategic shift, which misrepresents the continuity emphasized in the source. (3) The LLM introduces the idea of a change due to 'changing market conditions and longer claim-development patterns,' which is not mentioned in the original answer. Instead, the original cites accelerated settlements due to claims strategy changes in 2022 and notes a refinement in reporting (net of reinsurance, undiscounted) in 2023. (4) The LLM fails to mention the key 2023 update about incurred and paid losses being presented net of reinsurance and undiscounted, a notable transparency refinement. (5) It also omits the point about the increasing proportion of large deductible business slowing claims reporting in 2023, a continuation from 2022. While the LLM correctly identifies that different methods are used for newer vs. older accident years and that development methods are used for mature claims, its synthesis misrepresents the direction and nature of change between 2022 and 2023. Quantitative accuracy is moderate because there are no explicit numerical errors (no numbers are misstated), but the temporal and methodological comparisons are factually flawed. Qualitative accuracy is low due to incorrect entity relationships and reasoning. Contextual relevance is fair as the answer addresses reserving methods in workers' comp, but with significant factual drift.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1477,
        "completion_tokens": 584,
        "total_tokens": 2061
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has Cisco's product category segmentation evolved between fiscal 2022 and fiscal 2024, particularly in relation to the Collaboration category?",
      "original_answer": "In fiscal 2022, Cisco introduced a product revenue segmentation that included 'Collaboration' as one of six distinct categories, which also included Secure, Agile Networks; Internet for the Future; End-to-End Security; Optimized Application Experiences; and Other Products. By fiscal 2024, Cisco restructured its product categories into four main areas, retaining 'Collaboration' but now grouping it alongside Networking, Security, and a new category called Observability. This indicates a consolidation and realignment of product offerings, with the introduction of Observability as a distinct area and the removal or reclassification of Optimized Application Experiences and Internet for the Future.",
      "llm_answer": "Based on the provided SEC 10-K filings, Cisco's product category segmentation evolved significantly between fiscal 2022 and fiscal 2024, particularly regarding the Collaboration category. In fiscal 2022, Collaboration revenue declined 5% year-over-year (from $4.472B to $4.217B), driven by declines in Collaboration Devices and Meetings, partially offset by growth in Calling and Contact Center offerings. However, by fiscal 2024, Collaboration revenue increased 2% year-over-year (from $4.052B to $4.113B), primarily driven by growth across the portfolio except for the Meetings offering. This shift reflects a stabilization and modest recovery in the Collaboration category after the sharper decline observed in fiscal 2022 compared to fiscal 2021.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer is largely incorrect and fails to address the core of the question. (1) The question asks about the evolution of Cisco's product category segmentation between fiscal 2022 and 2024, specifically regarding the Collaboration category's structural placement within the segmentation. The original answer correctly describes a reorganization from six categories in 2022 (including Collaboration) to four in 2024 (Networking, Security, Collaboration, and Observability), indicating a consolidation. The LLM answer instead focuses on revenue trends within the Collaboration category—discussing year-over-year changes from $4.472B to $4.217B in 2022 and $4.052B to $4.113B in 2024—but this revenue data is not present in the ground truth and is irrelevant to the structural segmentation evolution. (2) While the numbers cited (e.g., $4.472B, 5% decline) may be factually accurate in external context, they are not part of the provided ground truth and thus cannot be verified from the knowledge graph; more importantly, they misdirect from the actual segmentation change. (3) The multi-hop reasoning is flawed: the model conflates financial performance with organizational categorization, failing to recognize that the question is about structural classification, not revenue trends. (4) As a result, the qualitative accuracy is very low—entities like 'Observability' and the consolidation into four categories are entirely missing. The answer is contextually relevant in that it discusses Cisco and Collaboration, but it answers a different question. Hence, the correctness score is low due to fundamental misunderstanding of the query.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 446,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has Amgen's disclosure regarding the 3.125% 2025 Notes evolved from 2022 to 2023 in terms of financial presentation and associated interest rate framework?",
      "original_answer": "In 2022, Amgen reported a carrying value of $1,000 million for the 3.125% 2025 Notes within its debt table, but no specific interest rate framework was disclosed. By 2023, Amgen included the 3.125% 2025 Notes in a new table that explicitly outlined the interest rate mechanism, identifying it as SOFR + 2.1%. This evolution reflects a shift from a purely quantitative disclosure in 2022 to a more detailed qualitative and quantitative presentation in 2023, including the interest rate benchmark and spread.",
      "llm_answer": "Amgen’s 3.125% 2025 Notes were initially disclosed in the 2022 10‑K on pages 128‑132, where the debt table listed a $1 billion principal amount and detailed interest‑rate swap arrangements that converted the fixed 3.125% coupon to a LIBOR‑plus‑1.8% floating rate. In the 2023 filing (pages 142‑146), the same notes appear as part of the newly issued $2 billion 5.25% 2025 Notes tranche from the Horizon acquisition, and the interest‑rate framework is now presented using SOFR‑based swaps (e.g., SOFR + 2.1% for the 3.125% 2025 Notes). The 2023 disclosure also adds quantitative details on the swap notional ($1 billion) and the effective rates, reflecting a shift from LIBOR‑based to SOFR‑based pricing and a more explicit linkage to the company’s cash‑flow hedge accounting.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) Quantitative inaccuracies: The ground truth states that in 2022, Amgen reported a carrying value of $1,000 million (i.e., $1 billion) for the 3.125% 2025 Notes — this part aligns. However, the LLM incorrectly claims that interest rate swaps converted the fixed 3.125% coupon to a LIBOR-plus-1.8% floating rate, which is not supported by the original answer and introduces swap details and LIBOR-based frameworks not mentioned in the ground truth. Furthermore, the LLM falsely states that in 2023, the 3.125% 2025 Notes were part of a 'newly issued $2 billion 5.25% 2025 Notes tranche from the Horizon acquisition' — this is entirely fabricated; no such acquisition-linked issuance or $2 billion tranche is in the ground truth. (2) The interest rate framework shift to SOFR + 2.1% in 2023 is correctly identified, which matches the ground truth, but the context (SOFR-based swaps, hedge accounting) is added without support. (3) Multi-hop reasoning is flawed: the model conflates unrelated debt instruments and invents a merger-related issuance not present in the original data. It also incorrectly implies that the interest rate on the note itself changed via swaps, whereas the ground truth only discusses disclosure of the rate framework, not active conversion. (4) While the answer addresses the evolution in disclosure and mentions SOFR, it does so with incorrect supporting facts, entities (Horizon acquisition), and financial mechanisms (swaps, LIBOR). The shift from LIBOR to SOFR is plausible contextually but not stated in the ground truth, making its inclusion misleading. Overall, only the $1 billion amount and the SOFR + 2.1% figure are correct; everything else is either unsupported or false, resulting in a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 495,
        "total_tokens": 1818
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2022 to 2024, and what does this indicate about the company's strategic positioning in that geographic area?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure had decreased to 296 billion cubic feet. This indicates a reduction in the company's natural gas holdings in the region over the two-year period, suggesting a potential strategic shift or divestment in that geographic area.",
      "llm_answer": "From 2022 to 2024, ConocoPhillips’ proved natural‑gas reserves in the Asia Pacific/Middle East region grew from **‑ (‑)** to **‑ (‑)** billion cubic feet, reflecting upward revisions, extensions/discoveries and modest purchases in that region. This increase shows the company is actively expanding its gas base in the Asia‑Pacific/Middle East, reinforcing its strategic focus on that geographic area as a key growth pillar.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is completely incorrect in both direction and magnitude. The ground truth states that COP's natural gas reserves in the Asia Pacific/Middle East region decreased from 326 billion cubic feet in 2022 to 296 billion cubic feet in 2024. In contrast, the LLM claims reserves 'grew' and reports nonsensical values of '**‑ (‑)**' which appear to be formatting or data retrieval errors, indicating no actual numerical understanding. (2) Quantitative accuracy is severely lacking: the correct values are 326 Bcf (2022) and 296 Bcf (2024), showing a decline of 30 Bcf. The LLM not only fails to report these numbers but falsely asserts growth. There is no valid calculation or comparison. (3) The multi-hop reasoning is flawed: the question requires comparing two time points and inferring strategic implications. The LLM misreads the trend (increase vs actual decrease), leading to an incorrect conclusion about strategic expansion, when the data suggests a potential divestment or strategic retreat. (4) Contextual relevance is partially met—geographic region, company (COP), and metric (natural gas reserves) are correctly identified—but the answer's core content contradicts the evidence. Due to total factual inaccuracy and reversed interpretation, the correctness score is very low at 1.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1206,
        "completion_tokens": 367,
        "total_tokens": 1573
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How did the repurchase activity of Class C Capital Stock by Alphabet change between 2022 and 2023, and what does this indicate about the company's capital allocation strategy?",
      "original_answer": "In 2022, Alphabet repurchased $59.3 billion of Class A and Class C shares, while in 2023, the repurchase amount increased to $62.2 billion. Additionally, in April 2023, the Board authorized an additional $70.0 billion for share repurchases, with $36.3 billion remaining available as of December 31, 2023. This indicates a continued and expanding emphasis on returning capital to shareholders through share repurchases, with a notable increase in the scale of buybacks year-over-year.",
      "llm_answer": "The repurchase activity for Class C Capital Stock increased from $59.3 billion in 2022 to $62.2 billion in 2023, reflecting a higher level of share buybacks. This expansion signals that Alphabet is intensifying its capital‑allocation strategy, prioritizing equity‑based returns to shareholders while maintaining flexibility for other investments.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reports the repurchase amounts of $59.3 billion in 2022 and $62.2 billion in 2023, which matches the ground truth. It accurately reflects the increase in buyback activity. However, the original answer specifies that the 2022 and 2023 repurchases were for both Class A and Class C shares, while the LLM answer refers only to Class C Capital Stock, which is slightly misleading even though the total amounts are correct. (2) All numeric values are accurate: $59.3B in 2022 and $62.2B in 2023 are correctly cited, and the year-over-year increase is properly characterized. The LLM does not mention the additional $70.0B authorization in April 2023 or the $36.3B remaining as of year-end 2023, which are important contextual details about future capital allocation capacity. (3) The reasoning is sound in interpreting the increased repurchases as a sign of intensified shareholder return strategy. The conclusion about prioritizing equity-based returns is logically supported by the data provided. However, the failure to mention the new authorization and remaining availability represents a gap in multi-hop synthesis, as those elements further reinforce the long-term strategic commitment. (4) The answer is highly relevant and factually correct in its core claims, with only minor omissions affecting completeness. The scores reflect high accuracy in numbers and relevance, with a slight deduction in qualitative accuracy due to incomplete entity and context coverage.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1214,
        "completion_tokens": 414,
        "total_tokens": 1628
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has AIG's use of frequency/severity methods evolved between 2022 and 2023, particularly in terms of the lines of business where they are applied and the reasoning behind their usage?",
      "original_answer": "In 2022, AIG primarily used frequency/severity methods for short-tail classes such as U.S. Property, and explicitly avoided using them for aviation exposures due to the high severity and varying mix of claims year to year. By 2023, AIG expanded the application of frequency/severity methods to include U.S. Workers' Compensation, a long-tail line of business, as part of a combination of methods that also included loss development and expected loss ratio methods. This reflects a strategic shift toward using frequency/severity methods in more complex, long-tail environments, especially where risk-sharing features and large deductible business have increased.",
      "llm_answer": "Between 2022 and 2023 AIG continued to apply frequency/severity‑based methods primarily to its long‑tail lines—U.S. Workers’ Compensation, U.S. Excess Casualty and U.S. Other Casualty—while using expected‑loss‑ratio approaches for shorter‑tail lines such as U.S. Property and Special Risk. The shift from 2022 to 2023 involved a greater reliance on the Bornhuetter‑Ferguson and Cape‑Cod hybrids for newer accident years, reflecting more stable development patterns and the need to incorporate recent loss‑trend adjustments (inflation, judicial changes, and underwriting cycle impacts). This evolution was driven by observed inconsistencies in loss‑development patterns for excess‑casualty and workers‑compensation business, prompting the company to blend development factors with premium‑based loss‑ratio estimates to produce more responsive and reliable reserve indications.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and misrepresents AIG's use of frequency/severity methods between 2022 and 2023. (1) Incorrectly states that in 2022 AIG applied frequency/severity methods primarily to long-tail lines like U.S. Workers’ Compensation and Excess Casualty, when the ground truth indicates that in 2022 AIG used these methods mainly for short-tail classes such as U.S. Property and avoided them for aviation. The expansion into U.S. Workers’ Compensation occurred in 2023, not before. (2) The LLM claims continued use in long-tail lines in 2022, which contradicts the original answer stating that frequency/severity was not typically used in long-tail lines until 2023. (3) Mentions Bornhuetter-Ferguson and Cape-Cod hybrids and attributes the shift to stable development patterns and inflation adjustments, which are not mentioned in the ground truth. The actual reasoning was increased risk-sharing features and large deductible business prompting expansion into long-tail lines. (4) The original answer highlights a strategic shift *into* long-tail lines in 2023, while the LLM implies these methods were already standard in long-tail lines in 2022 and further refined in 2023—this reverses the evolution. No numeric values are present, so quantitative accuracy is not severely penalized, but the qualitative and reasoning errors are substantial. The answer is contextually relevant to AIG’s reserving methods but fundamentally incorrect in direction and detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 411,
        "total_tokens": 1805
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has Amgen's financial relationship with BeiGene evolved from 2022 to 2023, particularly in terms of cost recovery, product sales, and profit and loss sharing?",
      "original_answer": "In 2022, Amgen recovered $199 million in R&D costs from BeiGene, recorded product sales of $64 million, and recognized $53 million in profit and loss sharing expenses. In 2023, these figures changed to $109 million in cost recovery, $125 million in product sales, and $40 million in profit and loss sharing expenses. This indicates a decrease in cost recovery and profit-sharing expenses, but a significant increase in product sales to BeiGene. The shift suggests a maturation of the collaboration, with more product sales occurring in 2023, while the level of R&D cost sharing declined.",
      "llm_answer": "From 2022 to 2023 Amgen’s financial relationship with BeiGene shifted toward greater cost recovery and higher product sales, while profit‑and‑loss sharing remained roughly balanced.  Net cost recoveries from BeiGene fell from $199 million in 2022 to $109 million in 2023, whereas product sales to BeiGene rose from $64 million to $125 million.  Profit‑and‑loss share expenses also declined, from $53 million in 2022 to $40 million in 2023, reflecting the transition to the post‑initial commercialization period in which Amgen now pays royalties to BeiGene on China sales rather than sharing profits.  (All figures are drawn from the disclosed collaboration accounting in the 2022 and 2023 10‑K filings.)",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all numerical values from the ground truth: cost recovery decreased from $199M (2022) to $109M (2023), product sales increased from $64M to $125M, and profit-and-loss sharing expenses declined from $53M to $40M. These figures match the original answer exactly and are drawn from the correct years and entities. (2) Quantitative accuracy is perfect—no calculation or transcription errors; all dollar amounts and year labels are correct. (3) The multi-hop reasoning is sound: the model synthesizes data across two years and three financial metrics (cost recovery, product sales, P&L sharing), correctly identifying trends. It adds contextual insight about the transition to a post-commercialization phase with royalty payments, which aligns with the collaboration's evolution and enhances the explanation beyond the ground truth, without contradicting it. (4) The only minor issue is the opening sentence stating 'shifted toward greater cost recovery,' which is incorrect—the cost recovery actually decreased. This contradicts the data presented immediately afterward and slightly undermines the reasoning, but the rest of the analysis correctly interprets the decline in cost recovery and P&L expenses alongside rising sales. Despite this inconsistency in phrasing, the core facts and synthesis are accurate. Hence, correctness is docked slightly to 9, but all other scores remain high due to precise data, strong contextualization, and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 412,
        "total_tokens": 1739
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2022 to 2024, and what specific changes occurred in terms of revisions, production, and purchases during this period?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure decreased slightly to 296 billion cubic feet. During this period, revisions in 2023 added 9 billion cubic feet, but production subtracted 25 billion cubic feet in 2024. Additionally, there were no purchases reported directly affecting this region in 2024, indicating a reduction in active reserve growth strategies compared to earlier years.",
      "llm_answer": "From 2022 to 2024, COP’s Asia Pacific/Middle East natural‑gas reserves rose from **388 MMBOE (undeveloped) + 388 MMBOE (undeveloped) = 776 MMBOE** at the end of 2022 to **388 MMBOE (undeveloped) + 388 MMBOE (undeveloped) + 13 MMBOE (developed) = 1,147 MMBOE** total consolidated reserves by end‑2024.  \n\n- **Revisions**: Upward revisions of ~127 MMBOE in the Lower 48 (2024) and ~113 MMBOE in Alaska (2024) were partially offset by downward technical and price‑related revisions elsewhere, resulting in a net positive revision contribution to the region.  \n- **Purchases**: The 2024 acquisition of Marathon Oil added ~209 MMBOE of reserves in the Lower 48 and Africa, directly boosting the Asia Pacific/Middle East total.  \n- **Production**: Net production in the region increased from 95 MMBOE (2022) to 108 MMBOE (2023) to 112 MMBOE (2024), reflecting higher output from developed assets.  \n\nOverall, the combination of upward revisions, strategic purchases (notably Marathon Oil), and increased production drove a substantial growth in COP’s proved natural‑gas reserves within the Asia Pacific/Middle East region between 2022 and 2024.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 2,
      "detailed_feedback": "The LLM answer is almost entirely incorrect and fails to align with the ground truth on multiple levels. (1) Quantitatively, the LLM reports reserves in MMBOE (million barrels of oil equivalent) rather than billion cubic feet, and the values are grossly inaccurate: it claims 776 MMBOE in 2022 and 1,147 MMBOE in 2024, whereas the ground truth states 326 billion cubic feet in 2022 and 296 billion cubic feet in 2024—a clear decrease, not a large increase. The LLM’s calculation of 388 + 388 = 776 MMBOE is mathematically correct but based on fabricated or misattributed data. (2) The LLM incorrectly attributes reserve changes to the Marathon Oil acquisition, which added reserves in the Lower 48 and Africa, not the Asia Pacific/Middle East region. The ground truth explicitly states there were no purchases affecting this region in 2024. (3) The LLM claims upward revisions and increased production led to reserve growth, but the ground truth indicates a net decrease due to 25 Bcf of production in 2024 outweighing a 9 Bcf upward revision in 2023. (4) The LLM confuses entities: it references reserves in the Lower 48 and Alaska, which are not part of the Asia Pacific/Middle East region. (5) The reasoning is fundamentally flawed—instead of showing a slight decline due to production exceeding revisions, the LLM fabricates a narrative of substantial growth from purchases and revisions. (6) The units are inconsistent and misleading: converting MMBOE to cubic feet requires a factor of ~6,000, but even then, the LLM’s numbers do not align. Overall, the answer misrepresents the direction, magnitude, and drivers of reserve changes, indicating a complete failure in multi-hop synthesis and factual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1416,
        "completion_tokens": 464,
        "total_tokens": 1881
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did FedEx's planned usage of the B767F aircraft evolve from 2022 to 2024, and what does this indicate about its strategic fleet planning?",
      "original_answer": "In 2022, FedEx projected using 14 B767F aircraft in both 2023 and 2024, with a planned reduction to 10 by 2025. By 2024, the projections had changed, showing a decrease to 11 B767F aircraft for 2025 and only 3 by 2026. This indicates a strategic shift toward a more accelerated reduction in the planned use of B767F aircraft, reducing reliance on this model over time.",
      "llm_answer": "FedEx's planned usage of the B767F aircraft has evolved from a focus on acquiring 14 B767F aircraft in 2022 (as shown in the 2022 purchase commitment table on page 40) to a reduced commitment of 11 B767F aircraft in 2025 and 3 in 2026 as outlined in the 2024 purchase commitment schedule on page 116. This reduction reflects a strategic shift toward prioritizing newer, more fuel-efficient aircraft types like the B777F and the Cessna SkyCourier, while maintaining a smaller, more targeted B767F acquisition plan to support long-term fleet modernization and fuel savings without significant delays to existing purchase agreements. The company emphasizes that delaying these aircraft-related expenditures would incur substantial costs, indicating a deliberate, phased approach to fleet renewal rather than accelerated or scaled-back procurement.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the evolution in FedEx's B767F aircraft projections: from 14 aircraft planned in 2022 for 2023–2024, to 11 in 2025 and 3 in 2026 as updated in 2024. These numbers align with the ground truth, though the original answer emphasizes the shift between 2022 and 2024 projections more directly. The LLM slightly mischaracterizes the 2022 plan as a 'purchase commitment' of 14 in 2022, whereas the ground truth states it was a projection for 2023 and 2024. This is a minor contextual inaccuracy but does not affect the numerical correctness. (2) All numeric values (14, 11, 3) and years (2022, 2025, 2026) are accurate and match the ground truth. The LLM correctly reflects the accelerated reduction trajectory. Calculations are not required, but comparisons over time are valid. (3) The multi-hop reasoning is sound—LLM synthesizes changes in fleet plans across time (2022 vs 2024 disclosures) and infers strategic intent. It adds contextual insight about fuel efficiency and fleet modernization (e.g., B777F, Cessna SkyCourier), which, while not in the ground truth, are plausible and consistent with FedEx’s known strategy. However, these additions, while relevant, slightly shift focus from the core fact: the accelerated phase-out. (4) The answer is highly relevant and conveys the essential strategic implication—a faster-than-expected reduction in B767F reliance. The slight overemphasis on purchase commitments in 2022 and inclusion of unverified aircraft models (SkyCourier) prevent a perfect score, but overall factual and semantic accuracy is strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 440,
        "total_tokens": 1742
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did AIG's use of Expected Loss Ratio Methods evolve between 2022 and 2023, particularly in terms of the lines of business and the reasoning behind their application?",
      "original_answer": "In 2022, AIG used Expected Loss Ratio Methods primarily for the latest accident year and in combination with other methods like loss development for aviation exposures, due to the high severity nature of claims and varying mix across years. By 2023, AIG applied Expected Loss Ratio Methods more broadly, particularly in U.S. Workers' Compensation, a long-tail line of business, where they used a combination of methods including Expected Loss Ratio, to account for extended loss emergence periods and complex risk-sharing features in policies. This reflects a shift from a focus on short-term forecasting in high-severity contexts to a broader application in long-tail, structurally complex lines.",
      "llm_answer": "AIG’s loss‑reserve methodology remained largely consistent between 2022 and 2023, continuing to rely on a mix of paid‑development, incurred‑development, expected‑loss‑ratio, Bornhuetter‑Ferguson, Cape Cod, and average‑loss methods, with the choice of method tailored to each line of business.  In 2023 the company applied the Expected‑Loss‑Ratio method especially to newer accident years and to lines with limited loss history (e.g., U.S. Excess Casualty), while still using development‑based methods for more mature lines such as Workers’ Compensation and Property.  The shift was driven by the need to adjust for slower‑emerging loss patterns, higher deductible structures, and evolving market conditions, leading AIG to give greater weight to expected‑loss‑ratio and Bornhuetter‑Ferguson approaches for recent years and to rely more on historical development factors for older accident years.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains no explicit numerical data (e.g., percentages, dollar amounts), so quantitative accuracy is not applicable in a traditional sense; however, since no numbers are misstated, it receives a 10. The core issue lies in qualitative accuracy and factual correctness. The original answer states that in 2022, AIG used Expected Loss Ratio (ELR) methods primarily for the latest accident year and in aviation, due to high severity and varying claim mix. By 2023, AIG expanded ELR use to U.S. Workers' Compensation—a long-tail line—reflecting a strategic shift toward broader application in structurally complex, long-tail contexts. In contrast, the LLM claims that in 2023, ELR was applied to lines with limited loss history like U.S. Excess Casualty and newer accident years, while stating that development methods were still used for Workers' Compensation. This directly contradicts the ground truth, which identifies Workers' Compensation as a key area of expanded ELR use in 2023. Furthermore, the LLM implies no significant evolution in methodology, describing it as 'largely consistent,' whereas the ground truth emphasizes a clear shift in scope and reasoning—from short-term, high-severity contexts to long-tail, complex policies. The reasoning provided (slower-emerging losses, higher deductibles) is plausible but misaligned with the specific evolution documented. Thus, while the answer is contextually relevant and uses appropriate terminology, it fails on key factual points regarding lines of business (misidentifying Workers' Compensation as still using development methods rather than ELR) and misrepresents the nature of the evolution. This constitutes a partially correct response with significant factual and reasoning errors, warranting a correctness score of 4.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1403,
        "completion_tokens": 485,
        "total_tokens": 1888
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How has Cisco's positioning around Enterprise Data Center Transformation evolved between 2022 and 2024, particularly in relation to its strategic alliances and competitive landscape?",
      "original_answer": "In 2022, Cisco highlighted that the enterprise data center was undergoing a fundamental transformation due to the convergence of technologies like computing, networking, storage, and software, with strategic alliance partners sometimes acquiring or aligning with competitors, reducing business with Cisco. By 2024, Cisco continued to emphasize this transformation but expanded its focus on strategic alliances aimed at industry advancement and new market creation, while also updating its competitive landscape to include new entrants like Nvidia Corporation, signaling a shift in market dynamics and alliance strategies.",
      "llm_answer": "Cisco’s Enterprise Data Center Transformation positioning has shifted decisively from a broad, technology‑focused narrative in 2022 to a more alliance‑centric, outcome‑driven strategy by 2024.  In the 2022 filing the company highlighted the data‑center convergence trend and listed a wide range of competitors, emphasizing product breadth and price‑performance.  By 2024, the 10‑K underscores strategic alliances (e.g., with Apple, Google, Equinix, Microsoft, and others) as key levers to accelerate the transformation, while also noting that alliance partners can become competitors and that the competitive landscape now includes hyperscale cloud and security firms such as AWS, Microsoft, and Palo Alto.  This evolution reflects Cisco’s effort to leverage partnerships to deliver integrated data‑center solutions and to stay competitive against both traditional networking rivals and emerging cloud‑native players.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution in Cisco's positioning between 2022 and 2024, noting the shift from a technology convergence narrative to a more alliance-driven strategy. It accurately reflects that in 2022, Cisco emphasized the transformation due to convergence and competitive pressures, and by 2024, strategic alliances became central. The mention of alliance partners becoming competitors aligns with the ground truth. However, the LLM incorrectly lists specific partners like Apple, Google, Equinix, and Microsoft as examples without explicit confirmation in the ground truth that these were highlighted in the 2024 filing. The ground truth mentions a general expansion of alliances for industry advancement but does not name partners. Additionally, while the ground truth explicitly identifies Nvidia Corporation as a new entrant in the competitive landscape by 2024, the LLM omits Nvidia and instead emphasizes AWS, Microsoft, and Palo Alto—entities that may be relevant but shift focus away from the specific new entrant (Nvidia) highlighted in the original answer. (2) There are no numerical values, dates, or calculations in the question or answers, so quantitative accuracy is not applicable—scored as 10 by default. (3) The multi-hop reasoning is largely sound: the LLM synthesizes changes in strategic focus and competitive dynamics across years. However, it introduces unverified specifics (named partners) and misses the key point about Nvidia as a new competitive entrant, which is a significant detail in the ground truth’s portrayal of shifting market dynamics. (4) The answer is contextually excellent—directly addresses the question about evolution in positioning, alliances, and competition. The core facts are correct, but the substitution of Nvidia with other firms and the addition of unconfirmed partners prevent a top score. Thus, correctness and qualitative accuracy are high but not perfect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1393,
        "completion_tokens": 526,
        "total_tokens": 1920
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did the effective interest rate and notional amount associated with the 3.125% 2025 Notes evolve between 2022 and 2023?",
      "original_answer": "In 2022, the 3.125% 2025 Notes were part of a $5.2 billion principal amount on which new interest rate swaps were entered into after the termination of previous swaps, indicating a dynamic hedging strategy due to low interest rates. By 2023, the notional amount of the 3.125% 2025 Notes under interest rate swaps had decreased to $1.0 billion, with an effective interest rate of SOFR + 2.1%. This reflects a reduction in the hedged notional exposure and a shift in the interest rate environment.",
      "llm_answer": "Based on the provided pages, the effective interest rate for the 3.125% 2025 Notes was 5.2% (as disclosed in the \"There are no material differences...\" statement on page 130 and reiterated on page 131), and the notional amount associated with these notes remained $1,000 million (1,000) in both 2022 and 2023, as shown in the debt table on page 130. The notional amount for the related interest rate swap contracts for the 3.125% 2025 Notes was $1,000 million, with an effective interest rate of SOFR + 2.1% (as detailed on page 143). Thus, the effective interest rate and notional amount for the 3.125% 2025 Notes did not change between 2022 and 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies in both quantitative and qualitative aspects. (1) Quantitatively, it incorrectly states that the notional amount for the 3.125% 2025 Notes was $1,000 million in both 2022 and 2023. The ground truth indicates that in 2022, the notional amount was part of a $5.2 billion principal, which decreased to $1.0 billion in 2023 under interest rate swaps. The LLM conflates the total note amount with the hedged portion and fails to reflect the reduction in notional exposure. (2) The effective interest rate is misrepresented: the LLM cites a flat 5.2% as the effective rate, referencing a statement about 'no material differences,' but this does not reflect the evolution of the hedged rate. The ground truth specifies that by 2023, the effective rate on the swapped portion was SOFR + 2.1%, indicating a change from prior hedging arrangements. The LLM incorrectly concludes no change occurred between 2022 and 2023. (3) Qualitatively, the reasoning is flawed—it fails to recognize that the question asks about the evolution of both the effective interest rate and notional amount in the context of interest rate swaps, not just the underlying notes. It misses the multi-hop synthesis that the $5.2 billion hedging activity in 2022 (after termination of prior swaps) shifted to $1.0 billion in 2023, reflecting a strategic and environmental shift. (4) Contextual relevance is moderate because the answer addresses the right instrument and time frame and references swap-related data, but it misinterprets the scope and dynamics. The answer relies on isolated data points without synthesizing the full narrative of changing hedging strategy and interest rate environment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1281,
        "completion_tokens": 466,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has Cisco's strategic positioning of AppDynamics within its product portfolio evolved from 2022 to 2024, particularly in terms of its emphasis within observability offerings?",
      "original_answer": "In 2022, Cisco explicitly introduced AppDynamics as a key component of its full-stack observability strategy, positioning it alongside Intersight and ThousandEyes to provide application performance monitoring capabilities. However, by 2024, Cisco restructured its product revenue reporting to include a new category called 'Observability,' which subsumed offerings like AppDynamics. This shift indicates a more formalized and integrated strategic emphasis on observability as a standalone pillar within Cisco's broader portfolio.",
      "llm_answer": "From fiscal 2022 to 2024 Cisco’s observability positioning shifted from a modest, niche category to a highlighted growth pillar within its portfolio. In the 2022 filing, observability revenue was listed only as a small sub‑segment of product revenue, but by 2024 it was explicitly called out as a distinct category and highlighted in the “Product Revenue by Category” table, showing a 27 % year‑over‑year increase (and 15 % growth excluding Splunk). Management emphasized that observability—driven by ThousandEyes, AppDynamics and the Splunk‑based Observability Suite—is a core component of Cisco’s strategy to deliver “full‑stack observability from the application to the infrastructure,” underscoring its strategic emphasis within the broader observability offering.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly captures the evolution of Cisco's strategic positioning of AppDynamics within its observability offerings from 2022 to 2024, aligning well with the ground truth. It accurately notes the shift from a less emphasized role in 2022 to a formalized, standalone 'Observability' category by 2024, and correctly identifies AppDynamics as part of a broader observability suite alongside ThousandEyes and Splunk. The qualitative reasoning is strong: it reflects the multi-hop synthesis of changes in reporting structure, strategic emphasis, and product integration. However, there are minor quantitative inaccuracies. The LLM claims a '27% year-over-year increase' and '15% growth excluding Splunk' in observability revenue, which are not present in the original answer and cannot be verified from the ground truth provided. These specific figures and the mention of Splunk (which was acquired in late 2023 and may not fully reflect 2024 organic growth) introduce unsupported details. The original answer does not include any numerical growth rates, so their inclusion here reduces quantitative accuracy. Additionally, while the LLM correctly identifies the strategic integration of AppDynamics, it frames Splunk as a core driver of observability growth, which slightly shifts focus away from AppDynamics’ standalone evolution as emphasized in the original. Despite this, the core narrative of increased strategic emphasis through formal revenue categorization is correct and contextually relevant. Semantic equivalence is largely preserved, with only minor over-enrichment of unsupported metrics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1332,
        "completion_tokens": 439,
        "total_tokens": 1771
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How did the effective interest rate and notional amount associated with the 4.663% 2051 Notes evolve from 2022 to 2023?",
      "original_answer": "In 2022, the 4.663% 2051 Notes were part of a $5.2 billion principal amount of notes that were hedged using interest rate swaps, with the swaps terminated and replaced at then-current interest rates. In 2023, the notional amount of the 4.663% 2051 Notes was $1.5 billion, and the effective interest rate was SOFR + 4.3%. This indicates a continuation of the hedging strategy but with updated interest rate terms and a more specific disclosure of the notional amount and rate for the 2051 Notes.",
      "llm_answer": "Based on the provided 10-K filings, the effective interest rate for the 4.663% 2051 Notes is disclosed as **5.6%** (with a notional amount of $1.5 billion as of December 31, 2021 and $1.5 billion as of December 31, 2022, per the interest rate swap table on page 133 and the fair value measurement table on page 144). The notional amount remained unchanged at **$1.5 billion** from 2022 to 2023, as reflected in the consistent reporting of the 4.663% 2051 Notes' notional amount across both years in the debt disclosures. \n\n(Note: The document explicitly states \"There are no material differences between the effective interest rates and the coupon rates of any of our borrowings, except for the 4.563% 2048 Notes, the 4.663% 2051 Notes and the 2.77% 2053 Notes, which have effective interest rates of 6.3%, 5.6% and 5.2%, respectively.\" The 5.6% effective rate for the 2051 Notes is confirmed in the interest rate swap details on page 133 and reiterated in the fair value measurement table on page 144.)",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The original answer states that in 2023, the effective interest rate for the 4.663% 2051 Notes was SOFR + 4.3%, not a fixed 5.6%. The LLM incorrectly reports a fixed effective rate of 5.6% based on document excerpts, which contradicts the ground truth that the rate evolved to a floating rate structure. Additionally, the LLM claims the notional amount was $1.5 billion in both 2022 and 2023, but the ground truth indicates that the $1.5 billion figure is only explicitly reported for 2023, with the 2022 context being part of a larger $5.2 billion hedged portfolio, not isolated to the 2051 Notes. (2) The quantitative accuracy is low: the effective interest rate is misstated (5.6% vs. SOFR + 4.3%), and the notional amount attribution for 2022 is incorrect—$1.5 billion is not confirmed for 2022 in the ground truth. The LLM cites specific pages and rates but fails to align with the multi-hop synthesis required. (3) The reasoning is flawed: the LLM assumes consistency in notional amount and misinterprets the effective rate as static, failing to recognize that the hedging strategy evolved—swaps were terminated and replaced at new rates, changing the effective rate structure. It does not reflect the dynamic nature of the hedging strategy described in the original answer. (4) Contextual relevance is moderate because the LLM addresses the right instrument and time frame and attempts to pull data from relevant sections, but the core facts about rate evolution and hedging changes are incorrect, undermining the overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 442,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has AIG's use of expected loss ratio methods evolved between 2022 and 2023, particularly in terms of the lines of business and segmentation criteria applied?",
      "original_answer": "In 2022, AIG referenced the use of expected loss ratio methods in a general sensitivity analysis related to loss reserve assumptions, without specifying detailed segmentation or particular lines of business. By 2023, AIG explicitly applied expected loss ratio methods to U.S. Workers' Compensation, a long-tail line of business, and introduced more granular segmentation criteria such as risk-sharing features, state and industry subsets, deductible size, and claim handling entities. This indicates a more structured and detailed application of the method in 2023 compared to 2022.",
      "llm_answer": "Between 2022 and 2023, AIG’s use of expected loss ratio methods evolved in how it segmented and applied these techniques across its lines of business. In the 2023 10-K, the company detailed that for U.S. Excess Casualty, it now applies loss cost trend assumptions across many accident years, with recent accident years weighted more heavily, reflecting a strategic shift toward higher attachment points and greater reliance on projected ultimate loss ratios adjusted for inflation, market conditions, and judicial trends. This contrasts with 2022, where the methodology was described more generally, emphasizing loss development patterns and the use of expected loss ratios for newer business but without explicit emphasis on weighting recent years or adjusting for evolving market dynamics. Additionally, the 2023 disclosures refined the segmentation of methods—such as specifying that Expected Loss Ratio methods are applied differently across U.S. Excess Casualty, U.S. Financial Lines, and other segments—based on unique risk drivers and development characteristics, indicating a more tailored and stratified approach compared to the broader categorization observed in 2022.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect in terms of factual content and misidentifies key aspects of AIG's use of expected loss ratio methods between 2022 and 2023. (1) The original answer states that in 2023, AIG explicitly applied expected loss ratio methods to U.S. Workers' Compensation, a long-tail line of business, with granular segmentation including risk-sharing features, state and industry subsets, deductible size, and claim handling entities. In contrast, the LLM answer incorrectly claims the method was applied to U.S. Excess Casualty and U.S. Financial Lines, which is not supported by the ground truth. (2) There are no numeric values (e.g., percentages, dollar amounts) in either the original or LLM answer, so quantitative accuracy cannot be penalized for missing numbers, but the LLM fabricates methodological details such as 'weighting recent accident years more heavily' and 'adjusting for inflation, market conditions, and judicial trends'—none of which appear in the original. (3) The multi-hop reasoning is flawed: the LLM invents a more complex evolution of methodology that includes trend assumptions and strategic shifts not present in the ground truth. The actual evolution was from general sensitivity analysis in 2022 to targeted application in Workers' Compensation with finer segmentation in 2023. (4) While the LLM attempts to address the question about evolution in segmentation and lines of business, it does so with incorrect entities and fabricated details, reducing its contextual relevance. The general direction—increased granularity and segmentation over time—aligns loosely with the truth, justifying a moderate relevance score. Overall, the answer fails on core factual accuracy despite plausible-sounding elaboration.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1443,
        "completion_tokens": 475,
        "total_tokens": 1919
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did PepsiCo's engagement with the 2.850% Senior Notes due 2026 evolve between 2023 and 2024, particularly in terms of its broader debt issuance strategy as reflected in the additional notes introduced in 2024?",
      "original_answer": "In 2023, PepsiCo referenced the 2.850% Senior Notes due 2026 as part of a broader set of debt instruments, including other senior notes with varying interest rates and maturity dates. By 2024, the company introduced a significantly expanded range of senior notes, including higher-yielding instruments such as the 7.00% Senior Notes due 2029 and the 5.50% Senior Notes due 2035, indicating a more diversified and long-term debt issuance strategy. This evolution suggests that PepsiCo not only maintained its commitment to the 2.850% Senior Notes due 2026 but also broadened its capital structure by incorporating a wider spectrum of debt instruments with different risk-return profiles.",
      "llm_answer": "PepsiCo's engagement with the 2.850% Senior Notes due 2026 evolved from a 2023 debt issuance strategy focused on floating-rate notes and incremental term debt to a more diversified approach in 2024, as evidenced by the introduction of multiple new senior notes across varying maturities and coupon rates. The 2.850% Senior Notes due 2026, initially referenced in 2023 filings as part of broader refinancing efforts, were expanded upon in 2024 through the addition of new tranches (e.g., 2.850% due 2026, 3.600% due 2024, and 2.625% due 2026) under updated indentures and board resolutions, reflecting a strategic shift toward targeted maturity management and enhanced flexibility in capital structure optimization. This evolution underscores PepsiCo's proactive debt issuance strategy to manage liquidity and market conditions while maintaining investment-grade credit metrics.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. The ground truth states that PepsiCo introduced new senior notes in 2024 such as the 7.00% Senior Notes due 2029 and 5.50% Senior Notes due 2035, but the LLM incorrectly lists '3.600% due 2024' and '2.625% due 2026' as new tranches introduced in 2024, which contradicts the original answer. Additionally, the claim that the 2.850% Senior Notes due 2026 were 'expanded upon' with new tranches under updated indentures is not supported by the ground truth, which does not mention any expansion or new tranches of the same coupon. (2) The dates and percentages are therefore factually wrong: '3.600% due 2024' is implausible as a 2024 maturity would have already occurred or been near-term in 2023, and the ground truth emphasizes longer-term instruments (2029, 2035), not shorter-term ones. The LLM also mischaracterizes 2023 strategy as focused on 'floating-rate notes and incremental term debt', which is not mentioned in the original answer—instead, the ground truth describes the 2.850% notes as part of a broader set of fixed-rate senior notes. (3) The multi-hop reasoning is partially sound in that the LLM identifies a strategic evolution toward diversification and maturity management, which aligns with the ground truth’s theme of a more diversified and long-term debt strategy. However, the reasoning is based on fabricated instruments rather than the actual ones cited, undermining the validity of the synthesis. (4) The contextual relevance is fair because the answer addresses the evolution of debt strategy and references the 2.850% notes appropriately in context, but the incorrect financial instruments and misrepresentation of 2023 strategy reduce factual reliability. Correctness is scored low due to core factual errors in the debt instruments introduced, despite capturing a similar strategic narrative.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1407,
        "completion_tokens": 522,
        "total_tokens": 1930
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has Cisco's exposure to channel partner financing guarantees evolved between fiscal years 2022 and 2024, and what does this indicate about the company's financial risk management strategy?",
      "original_answer": "In fiscal year 2022, Cisco disclosed that the volume of channel partner financing was $27.9 billion, with a balance of financing subject to guarantees amounting to $1.4 billion as of July 30, 2022. By fiscal year 2024, while the company continued to provide financing guarantees, the specific volume of channel partner financing and the balance subject to guarantees were no longer explicitly quantified in the disclosures. This shift indicates a potential strategic move toward reducing transparency around these financial commitments, which may reflect a broader risk management approach to limit visibility into contingent liabilities. However, the absence of updated figures prevents definitive conclusions about the actual change in exposure.",
      "llm_answer": "Cisco’s channel‑partner financing guarantees declined modestly from $188 million (maximum potential future payments) in fiscal 2022 to $179 million in fiscal 2024, reflecting a slight reduction in the volume of guaranteed financing ($27.9 billion in 2022 versus $26.7 billion in 2021, then $26.9 billion in 2020) and a lower deferred‑revenue offset. This trend shows that the company is tightening its risk‑management controls over third‑party financing, shifting from a more expansive guarantee posture in 2022 toward a more conservative exposure by 2024. Consequently, Cisco’s overall financial‑risk profile has become less dependent on contingent liabilities tied to channel financing, indicating a stronger focus on limiting unexpected cash outflows and preserving liquidity.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in fiscal year 2022, Cisco's channel partner financing volume was $27.9 billion, with $1.4 billion subject to guarantees. The LLM incorrectly states that the 'maximum potential future payments' were $188 million in 2022 and $179 million in 2024, which contradicts the disclosed $1.4 billion guarantee balance. Additionally, the LLM fabricates figures for 2020 and 2021 ($26.9B and $26.7B) that are not in the original answer and misrepresents the trend. Most critically, the original answer states that by fiscal 2024, Cisco no longer disclosed specific quantitative figures for financing volume or guaranteed balances, but the LLM falsely claims precise numbers for 2024 ($179M), which were not reported. (2) The quantitative inaccuracies are severe: the LLM underreports the guaranteed amount by over 90% (from $1.4B to $188M), invents a downward trend with unsupported data, and mischaracterizes the nature of the disclosed amount (the $1.4B is a balance subject to guarantees, not 'maximum future payments'). (3) The multi-hop reasoning is flawed: instead of recognizing the lack of 2024 disclosures as a transparency issue, the model assumes continued reporting and constructs a false narrative of declining exposure. It fails to identify the key shift in disclosure policy, which is central to the original answer’s conclusion about risk management strategy. (4) While the LLM attempts to address the question about risk management strategy, its conclusion—that Cisco is adopting a more conservative, less dependent stance—is speculative and based on incorrect data. The original answer emphasizes uncertainty due to missing data, whereas the LLM asserts a definitive trend. Contextual relevance is moderate because it addresses the right topic and attempts financial interpretation, but factual errors undermine validity. Scores reflect major failures in accuracy, especially quantitative, and weak reasoning despite relevant framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1393,
        "completion_tokens": 550,
        "total_tokens": 1943
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has the status and interest rate structure of the 2.45% 2030 Notes evolved between 2022 and 2023?",
      "original_answer": "In 2022, Amgen disclosed that it had entered into interest rate swap contracts with an aggregate notional amount of $1.0 billion with respect to the 2.45% 2030 Notes, effectively converting the fixed-rate interest to a floating LIBOR-based coupon. By 2023, the 2.45% 2030 Notes remained outstanding with a notional amount of $1.0 billion, but the interest rate structure had transitioned from LIBOR to SOFR, now stated as SOFR + 1.3%. This reflects a continuation of the note's existence but with a modified floating-rate benchmark.",
      "llm_answer": "The 2.45% 2030 Notes remained outstanding with a consistent $1.25 billion principal amount throughout 2022‑2023, and their effective interest rate stayed linked to SOFR (SOFR + 1.3% as of 2023) after the company entered into interest‑rate swap contracts in 2021. No new issuance or redemption of these notes occurred during the period, so their interest‑rate structure was unchanged except for the floating‑rate adjustment via the swaps.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The principal amount is stated as $1.25 billion, but the ground truth specifies $1.0 billion, which is a material discrepancy. Additionally, the LLM claims the interest rate was already linked to SOFR in 2021, but the original answer states that in 2022 the rate was converted from fixed to LIBOR-based via swaps, and only in 2023 did it transition from LIBOR to SOFR (SOFR + 1.3%). The timing and sequence of the rate benchmark change are therefore incorrect. (2) Quantitative accuracy is low: the notional amount is wrong ($1.25B vs $1.0B), and the timeline of the swap initiation is misrepresented (2021 vs 2022). The 2.45% fixed rate is not acknowledged as having been swapped in 2022 to LIBOR, then later to SOFR. (3) The reasoning is partially sound in recognizing that swaps were used to convert fixed to floating rates and that the 2030 Notes remained outstanding, but it fails the multi-hop synthesis by conflating the timeline and benchmarks (LIBOR vs SOFR transition). It omits the key evolution: fixed → LIBOR (2022) → SOFR (2023). (4) Contextual relevance is fair because the answer addresses the status and interest rate structure of the 2030 Notes, but core facts about amounts and rate transitions are incorrect, undermining overall correctness. The answer incorrectly implies stability in the floating-rate structure when in fact there was a notable shift from LIBOR to SOFR that should have been highlighted as part of the evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1231,
        "completion_tokens": 419,
        "total_tokens": 1650
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How has FedEx's relationship with Pass-Through Certificates evolved between 2022 and 2023, particularly regarding its financial guarantees and obligations?",
      "original_answer": "In 2022, FedEx Express had issued $970 million of Pass-Through Certificates, Series 2020-1AA, which were fully and unconditionally guaranteed by FedEx. These certificates were secured by 19 Boeing aircraft with a net book value of $1.8 billion. However, in 2023, FedEx clarified that pass-through certificates associated with leveraged operating leases were not direct obligations of, nor guaranteed by, FedEx or FedEx Express. This indicates a shift from direct financial guarantees in 2022 to a position of no direct financial obligation in 2023.",
      "llm_answer": "Based on the provided 10-K pages, FedEx's relationship with Pass-Through Certificates has remained consistent in structure but evolved in scale and context between 2022 and 2023. Specifically, the company continues to utilize pass-through trusts to issue certificates (e.g., $970 million of Series 2020-1AA Certificates due in 2034), which are secured by aircraft and fully guaranteed by FedEx Express. While the payment obligations on these Certificates are not direct obligations of FedEx or FedEx Express, they are backed by specific aircraft collateral and FedEx's general creditworthiness. The 2023 data shows no significant structural change in this arrangement, though the company has expanded its long-term debt financing activities (e.g., issuing $3.25 billion in senior notes in 2021, including Sustainability Notes), indicating a broader strategy to fund operations through diversified debt markets rather than altering the core pass-through certificate mechanism. The guarantees remain unconditional and absolute, with no material financial covenants tied to the Certificates themselves.",
      "correctness_score": 3,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies regarding FedEx's financial guarantees on Pass-Through Certificates. The ground truth states that in 2023, FedEx clarified that these certificates were *not* direct obligations of, nor guaranteed by, FedEx or FedEx Express—marking a clear shift from 2022 when they were fully and unconditionally guaranteed. However, the LLM incorrectly asserts that the certificates 'are fully guaranteed by FedEx Express' and that 'guarantees remain unconditional and absolute' in 2023, which directly contradicts the ground truth. This is a major error in the core claim of the answer. (2) Quantitatively, the LLM correctly identifies the $970 million of Series 2020-1AA Certificates and references the 2034 maturity, which aligns with typical structures, though the ground truth does not mention the maturity date. The mention of $3.25 billion in senior notes in 2021 is factually plausible but irrelevant to the 2022–2023 evolution of pass-through certificates and distracts from the main issue. (3) The multi-hop reasoning is flawed: the model fails to recognize the critical shift from guaranteed (2022) to non-guaranteed (2023) status, which is the central evolution in the relationship. Instead, it claims 'no significant structural change,' which is incorrect. The synthesis across years is therefore invalid. (4) While the answer discusses relevant entities (FedEx, FedEx Express, Pass-Through Certificates, aircraft collateral) and uses appropriate financial terminology, the conclusion is fundamentally wrong on the key point of guarantees and obligations. The contextual relevance is moderate because it addresses the topic but misrepresents the evolution. Correctness is severely penalized due to the reversal of the main factual development.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1414,
        "completion_tokens": 491,
        "total_tokens": 1905
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did Mastercard's use of risk mitigation arrangements to manage gross settlement exposure evolve from 2023 to 2024, and what does this indicate about the company's risk management strategy?",
      "original_answer": "In 2023, Mastercard had $75,023 million in gross settlement exposure, with $12,167 million covered by risk mitigation arrangements. By 2024, gross settlement exposure increased to $78,385 million, and the company applied $13,466 million in risk mitigation arrangements, reflecting an increase in both total exposure and the amount mitigated. This indicates that Mastercard's risk management strategy became more robust over time, as it increased its use of mitigation tools in response to growing settlement exposure.",
      "llm_answer": "Mastercard’s risk‑mitigation arrangements for settlement exposure continued to expand in 2024, with gross settlement exposure rising to $78.4 billion and net exposure after mitigation increasing to $64.9 billion—up from $75.0 billion gross and $62.9 billion net in 2023.  The company regularly revises its risk‑management methodology and applies cash collateral or credit enhancements to customers that do not meet its risk standards, indicating a proactive, data‑driven approach to limiting settlement risk and adjusting protections as exposure grows.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth with only minor formatting differences in numbers. (1) Quantitatively: The LLM reports gross settlement exposure as $78.4 billion (vs. $78,385 million) and $75.0 billion (vs. $75,023 million), which are correctly rounded and semantically equivalent. The net exposure figures ($64.9B in 2024 and $62.9B in 2023) are accurate calculations: $78,385M - $13,466M = $64,919M (~$64.9B), and $75,023M - $12,167M = $62,856M (~$62.9B). The mitigation amounts are not explicitly stated but are correctly implied through net exposure. (2) Completeness: The answer addresses both the evolution from 2023 to 2024 and the implication for risk management strategy—highlighting increased exposure and expanded mitigation, consistent with the ground truth. (3) Entity accuracy: Correct company (Mastercard), correct years (2023 to 2024), and correct financial concepts (gross exposure, risk mitigation, net exposure). (4) Reasoning: The multi-hop synthesis is sound—linking rising gross exposure to increased mitigation and interpreting this as a proactive, data-driven strategy. The conclusion aligns with the ground truth’s interpretation of a more robust risk management approach. (5) Semantic equivalence: Though phrased differently (e.g., focusing on net exposure rather than stating mitigation amounts directly), the LLM captures all key facts and implications. One point deducted from correctness and quantitative accuracy because the exact mitigation amounts ($12,167M and $13,466M) are not explicitly mentioned, which slightly reduces precision, though they are inferable. Overall, the answer is factually correct, well-reasoned, and fully relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 469,
        "total_tokens": 1748
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did Nike's liabilities related to foreign exchange forwards and options designated as hedging instruments change between 2022 and 2024, and what does this indicate about the company's exposure or strategy?",
      "original_answer": "In 2022, Nike reported $37 million in liabilities for foreign exchange forwards and options designated as hedging instruments under accrued liabilities, and $11 million under deferred income taxes and other liabilities, totaling $48 million. By 2024, the liability under accrued liabilities for the same category increased to $110 million, while the amount under deferred income taxes and other liabilities decreased to $5 million, resulting in a total of $115 million. This represents a significant increase in total liabilities for designated hedging instruments related to foreign exchange forwards and options, indicating a potential increase in Nike's foreign exchange risk exposure or a strategic shift in hedging activity.",
      "llm_answer": "Based on the provided 10-K pages, Nike's liabilities related to foreign exchange forwards and options designated as hedging instruments decreased from $146 million (as of May 31 2023) to $151 million (as of May 31 2024) – a modest increase in absolute liability, but the key trend is the reduction in the total notional amount of outstanding designated derivatives from $18.2 billion in 2023 to $16.2 billion in 2024. This shrinkage indicates that Nike is scaling back its hedging program, likely reflecting reduced foreign‑exchange exposure or a strategic shift toward managing risk internally rather than through extensive derivative contracts. Consequently, the company’s foreign‑exchange risk management is becoming less reliant on formal hedge accounting, suggesting a more conservative approach to currency‑related financial risk.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both numbers and reasoning. The ground truth states that Nike's liabilities were $48 million in 2022 (split $37M and $11M) and $115 million in 2024 (split $110M and $5M), showing a significant increase. However, the LLM incorrectly reports liabilities of $146 million in 2023 and $151 million in 2024, which are not supported by the original answer. These figures do not align with the provided ground truth for 2022 or 2024, and no data for 2023 was given in the original answer. (2) The calculation of total liabilities is wrong: the LLM claims a total of $151M in 2024, but the correct total is $115M. Additionally, the LLM references a 'notional amount' of derivatives ($18.2B to $16.2B), which is not mentioned in the original answer and introduces external, unverified data. (3) The multi-hop reasoning is flawed. The original answer infers increased exposure or strategic shift due to rising liabilities. In contrast, the LLM concludes a reduction in hedging activity based on notional amounts not present in the ground truth, leading to an incorrect interpretation. The LLM also fails to mention the 2022 baseline, instead using 2023 data not provided in the original answer. (4) The contextual relevance is moderate because the answer discusses hedging instruments and foreign exchange risk, which are relevant topics. However, due to major factual inaccuracies, incorrect data points, and flawed reasoning, the overall correctness score is low. The answer does not reflect the actual change between 2022 and 2024 as required by the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1407,
        "completion_tokens": 440,
        "total_tokens": 1847
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did the representation of Bounty within P&G's Baby, Feminine & Family Care segment evolve between the 2022 and 2023 10-K filings, and what does this suggest about its brand visibility?",
      "original_answer": "In the 2022 10-K filing, Bounty was mentioned as part of P&G's Family Care business within the Baby, Feminine & Family Care segment, but it was not explicitly listed among the key brands. In contrast, the 2023 10-K filing explicitly included Bounty among the major brands under the Family Care category. This change suggests an increase in Bounty's brand visibility within P&G's portfolio, though the filings do not provide specific market share or sales figures to quantify this shift. The explicit mention in 2023 indicates a possible strategic move to highlight Bounty's role, though no direct strategic intent is stated in the evidence provided.",
      "llm_answer": "Based on the provided 10-K filings, the representation of Bounty within P&G's Baby, Feminine & Family Care segment remained prominent but showed subtle shifts in emphasis between 2022 and 2023. In the 2022 filing (Page 19), Bounty was explicitly listed as a major brand under \"Baby, Feminine & Family Care\" alongside Always, Tampax, and Charmin, with specific mention of its role in the family care business (paper towels and toilet paper) and North American market leadership (Page 19, 2022). The 2023 filing (Page 20) retained Bounty as a key brand in the same segment but reduced its standalone emphasis, integrating it more broadly under \"Family Care\" alongside Charmin without explicit standalone branding focus. This suggests a strategic consolidation where Bounty's visibility was maintained but less highlighted as a distinct brand, potentially reflecting a shift toward unified family care branding (e.g., Charmin's dominance in toilet paper, with Bounty as a supporting product). The consistent market share data (Page 20, 2023: \"North America market shares are over 40% for Bounty\") confirms its enduring commercial strength, but the reduced narrative focus in 2023 indicates diminished standalone brand visibility compared to 2022.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth. (1) The original answer states that Bounty was *not* explicitly listed as a key brand in the 2022 10-K but *was* explicitly listed in the 2023 filing—indicating an increase in visibility. The LLM reverses this: it claims Bounty was explicitly listed in 2022 and then downplayed in 2023, which is the opposite of the truth. (2) The LLM cites a specific market share figure (over 40% in North America in 2023) and page numbers (Page 19, 2022; Page 20, 2023), but the ground truth does not mention any market share data or specific pages, and the knowledge graph indicates no such figures were provided in the filings. This introduces fabricated quantitative details. (3) The multi-hop reasoning is flawed: instead of recognizing the increased prominence of Bounty in 2023 due to explicit branding, the LLM incorrectly infers a strategic consolidation and reduced focus, which is unsupported by the evidence. (4) While the LLM addresses the question's structure (evolution of representation and visibility), its factual inaccuracies and invented details severely undermine correctness. The contextual relevance is moderate because it attempts the right analysis, but the conclusions are based on false premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1483,
        "completion_tokens": 355,
        "total_tokens": 1839
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How has Oracle's approach to its hardware business, particularly Oracle Engineered Systems, evolved between fiscal 2022 and fiscal 2023 in terms of revenue recognition and strategic emphasis?",
      "original_answer": "In fiscal 2022, Oracle's hardware business, which includes Oracle Engineered Systems, was described in terms of its contractual activities and revenue recognition, with an emphasis on the timing of revenue recognition for cloud and license contracts. By fiscal 2023, Oracle introduced a more detailed explanation of how hardware and related software are treated as a combined performance obligation, with revenue recognized at the point in time of delivery and ownership transfer. Additionally, in 2023, Oracle emphasized ongoing R&D investments to improve and develop new hardware products and services, which was not explicitly mentioned in 2022. This indicates a shift toward a more strategic focus on innovation and integration of hardware and software components within the hardware business.",
      "llm_answer": "Between fiscal 2022 and fiscal 2023 Oracle’s hardware segment revenue fell modestly from $3.183 billion to $3.183 billion? Actually the table shows $3,183 M in 2022 and $3,359 M in 2021, but the 2023 filing indicates the hardware business represented 6% of total revenue in both 2024 and 2023, implying a continued modest share. The key shift is that Oracle increasingly emphasizes cloud and license revenues—now 84% and 83% of total revenue in 2024 and 2023 respectively—while hardware’s contribution remains small and its margins are lower, reflecting a strategic pivot away from hardware toward cloud‑based offerings. Revenue recognition for hardware remains point‑in‑time upon delivery, but the overall strategic emphasis has moved to cloud services, which are recognized ratably over contractual terms.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies and fails to correctly represent Oracle's strategic evolution in the hardware business between fiscal 2022 and 2023. The revenue figures cited ($3.183 billion, $3,359M) are either misstated or pulled from incorrect years—no accurate hardware revenue comparison between 2022 and 2023 is provided, and the claim that hardware revenue was $3.183 billion in both years contradicts the data it references. The mention of 2024 revenue percentages (84%, 83%, 6%) introduces data outside the requested 2022–2023 scope, which is not supported by the ground truth. (2) Quantitative accuracy is poor: the LLM confuses fiscal years (references 2021, 2024), misstates revenue figures, and fails to provide correct hardware revenue for 2022 vs 2023. There is no indication in the ground truth that hardware revenue recognition changed from point-in-time to another method, but the LLM incorrectly implies it remains point-in-time without noting the key 2023 change in treatment of hardware and software as a combined performance obligation, which is central to the original answer. (3) The multi-hop reasoning is flawed: the question asks specifically about evolution in revenue recognition and strategic emphasis for Oracle Engineered Systems, but the LLM shifts focus to cloud revenue and overall hardware decline, missing the key 2023 shift in accounting policy (combined performance obligation) and the new emphasis on R&D and integration. The ground truth highlights a strategic *renewal* of focus on hardware innovation, whereas the LLM incorrectly frames it as a continued de-emphasis. (4) Contextual relevance is moderate because it discusses Oracle’s hardware business and revenue recognition, but it fails to address the actual evolution described in the original answer, instead introducing irrelevant data and drawing incorrect conclusions. The core facts—combined performance obligations in 2023 and increased R&D emphasis—are entirely missing, leading to a fundamentally incorrect assessment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1412,
        "completion_tokens": 554,
        "total_tokens": 1967
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did the sales performance of the product ERLEADA evolve between 2022 and 2023, and what does this indicate about its market trajectory?",
      "original_answer": "In 2022, ERLEADA generated $1,881 million in sales, and by 2023, its sales increased to $2,387 million, representing a 26.9% growth. This indicates a strong upward trajectory for ERLEADA in the market, suggesting increased adoption or improved commercial performance over the period.",
      "llm_answer": "Based on the provided financial data, ERLEADA sales increased by 26.9% from $1,881 million in 2022 to $2,387 million in 2023, reflecting strong market growth and share gains in Metastatic Castration-Resistant Prostate Cancer. This growth, driven by continued market expansion and competitive momentum, indicates a positive trajectory for the product despite broader oncology sector pressures.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key facts from the ground truth: ERLEADA sales were $1,881 million in 2022 and $2,387 million in 2023, with a 26.9% growth rate. These values match the original answer exactly, and the percentage calculation is accurate ((2,387 - 1,881) / 1,881 ≈ 0.269 or 26.9%). (2) All numeric values are correct and presented in consistent formats (millions in dollars), with no discrepancies. (3) The multi-hop reasoning is sound—sales figures across two years are compared, growth is calculated correctly, and a market trajectory conclusion is drawn. The LLM adds context about market expansion and competitive momentum in Metastatic Castration-Resistant Prostate Cancer, which enhances the reasoning without contradicting the ground truth. (4) The answer fully addresses both parts of the question: the evolution of sales performance (quantitative change) and what it indicates about market trajectory (qualitative interpretation). The added detail about 'share gains' and 'oncology sector pressures' is contextually appropriate and does not introduce inaccuracies. All scores are 10 due to full factual alignment, correct calculations, proper entity identification (ERLEADA, correct years), and logical, relevant interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1167,
        "completion_tokens": 357,
        "total_tokens": 1524
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has the nature of CMCSA's relationship with local broadcast television stations evolved from 2023 to 2024, particularly in terms of competitive positioning and dependency for content distribution?",
      "original_answer": "In 2023, CMCSA's Media segment directly competed with local broadcast television stations for viewers' attention and advertising revenue. By 2024, the relationship shifted to a more interdependent one, where CMCSA's linear television networks became reliant on local broadcast television stations for retransmission consent, which is necessary for distributing broadcast network programming to video service customers. This marks a shift from competition to dependency, reflecting a strategic and operational evolution in how CMCSA interacts with local broadcast stations.",
      "llm_answer": "From 2023 to 2024, CMCSA’s relationship with local broadcast stations has shifted toward greater reliance on retransmission consent negotiations rather than mandatory “must‑carry” carriage, reflecting a more market‑driven and competitive positioning. The company now faces heightened pressure from stations seeking higher compensation and other concessions, and it must continually renegotiate these agreements amid industry consolidation and evolving distribution dynamics, making its content distribution increasingly dependent on securing favorable terms with local affiliates.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies a shift in CMCSA's relationship with local broadcast television stations toward increased dependency on retransmission consent, which aligns with the ground truth's core claim of evolving from competition to dependency. It accurately reflects the 2023–2024 timeframe and the strategic importance of retransmission negotiations. However, it omits the key point from the original answer that in 2023, CMCSA's Media segment directly competed with local broadcast stations for viewers and advertising revenue—a critical element of the 'competitive positioning' aspect of the question. While the LLM mentions increased reliance and negotiation pressures, it does not explicitly frame the earlier relationship as competitive, thus missing a key multi-hop synthesis between CMCSA’s own media networks and their competitive stance pre-2024. There are no numerical inaccuracies (quantitative accuracy is perfect by default, as no numbers are involved), and the terminology (e.g., retransmission consent, distribution dynamics) is accurate. The reasoning is sound but incomplete in capturing the full evolution from competition to dependency. Contextually, the response is highly relevant and addresses the distribution dependency well, but lacks full completeness on competitive positioning in 2023.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 367,
        "total_tokens": 1669
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How did the value of Held-to-Maturity (HTM) securities held by MA evolve between 2023 and 2024, and what does this shift indicate about the company's investment strategy?",
      "original_answer": "In 2023, MA held $306 million in HTM securities, but by 2024, this amount dropped significantly to $38 million. This indicates a major shift in MA's investment strategy, with a sharp reduction in long-term held securities, likely reflecting a move toward more liquid or short-term investment positions.",
      "llm_answer": "The value of Held-to-Maturity (HTM) securities declined sharply from $306 million at the end of 2023 to $38 million at the end of 2024. This reduction reflects a strategic shift away from low‑yielding, short‑term time‑deposit holdings toward a greater emphasis on liquid assets and equity investments, indicating that Mastercard is reallocating capital to higher‑return opportunities and to support growth initiatives.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly identifies the quantitative change in HTM securities: from $306 million in 2023 to $38 million in 2024, matching the ground truth exactly. These numbers are accurate and properly attributed to the correct years.\n\n2) Quantitatively, the answer is fully accurate. The values $306 million and $38 million are correct, and the direction of change (sharp decline) is correctly described. No calculation is required beyond recognizing the drop, which is accurately portrayed.\n\n3) The multi-hop reasoning is mostly sound. The answer correctly infers a strategic shift from the decline in HTM securities. However, the original answer attributes the shift to a move toward 'more liquid or short-term investment positions,' while the LLM adds specific claims not present in the ground truth: that the securities were 'low-yielding, short-term time-deposit holdings' and a shift toward 'equity investments' and 'higher-return opportunities.' These are plausible interpretations but go beyond the data provided in the ground truth, introducing speculative details.\n\n4) The core of the answer is correct and relevant: it addresses both parts of the question (the change in value and the strategic implication). The reasoning is logical and contextually appropriate, but the added specificity in the explanation slightly exceeds the evidence in the original answer, slightly reducing qualitative accuracy. Despite this, the overall conclusion about a strategic shift is consistent with the ground truth. Hence, a score of 8 is justified for correctness and qualitative accuracy, while quantitative accuracy and contextual relevance remain perfect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1186,
        "completion_tokens": 453,
        "total_tokens": 1639
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has the positioning of the Always brand within Procter & Gamble's Baby, Feminine & Family Care segment evolved between 2022 and 2023, particularly in terms of its product categorization and associated sub-categories?",
      "original_answer": "In 2022, Always was categorized under Feminine Care within the Baby, Feminine & Family Care segment, which included sub-categories like Adult Incontinence and Feminine Care. By 2023, the brand remained part of the same reportable segment but was more specifically aligned with 'Menstrual Care' under the updated Feminine Care sub-category, reflecting a more targeted positioning. This evolution indicates a strategic shift in how Always is being categorized to emphasize its core focus area.",
      "llm_answer": "Between 2022 and 2023, the Always brand remained within the Baby, Feminine & Family Care segment, continuing to be categorized under Feminine Care (specifically Adult Incontinence and Menstrual Care) alongside Tampax. The segment’s product structure and categorization showed no fundamental shift during this period, maintaining Always within its established sub-category of Feminine Care. The brand’s positioning and classification were consistent with prior reporting, reflecting ongoing focus on feminine hygiene and incontinence products within the broader segment.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is partially correct in stating that Always remained within the Baby, Feminine & Family Care segment and under Feminine Care. However, it incorrectly claims no change occurred, asserting that Always was categorized under both Adult Incontinence and Menstrual Care in 2022 and 2023. According to the ground truth, while Adult Incontinence was a sub-category in 2022, Always was specifically repositioned in 2023 to be more specifically aligned with 'Menstrual Care' under a restructured Feminine Care sub-category, indicating a strategic shift. The LLM answer misses this evolution entirely and instead asserts consistency, which contradicts the ground truth. (2) There are no numeric values in the response, so quantitative accuracy is not applicable—no errors in dates or numbers, hence a score of 10 by default. (3) The multi-hop reasoning is flawed: the question asks for evolution between 2022 and 2023, requiring comparison across years and recognition of re-categorization. The LLM fails to identify the shift from a broader Feminine Care classification to a more targeted Menstrual Care alignment, thus failing the core reasoning requirement. (4) Contextual relevance is high because the answer addresses the correct segment, brand, and general product category, but the qualitative inaccuracy in representing the strategic shift significantly undermines correctness. Hence, the overall correctness score is 4—partially correct but with a major factual omission regarding the repositioning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 420,
        "total_tokens": 1704
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How has Oracle's positioning and financial contribution of Oracle Engineered Systems evolved between 2022 and 2023, particularly in terms of revenue recognition and strategic emphasis?",
      "original_answer": "In 2022, Oracle Engineered Systems were disclosed as part of hardware revenues, but no specific percentage of total revenue was provided. Revenue recognition for hardware products, including Engineered Systems, was described as occurring at the point in time when the product and related software were delivered. By 2023, Oracle explicitly stated that the hardware business, which includes Engineered Systems, represented 6% of total revenues in both fiscal 2023 and fiscal 2024, indicating a clearer and more consistent measurement of the product line's contribution. Additionally, in 2023, Oracle emphasized ongoing R&D investments to improve hardware offerings and introduced more detailed factors affecting hardware revenue predictability, such as manufacturing partner performance and competitive positioning against cloud infrastructure offerings. This reflects both quantitative and strategic evolution in how Oracle presents and manages the Engineered Systems product line.",
      "llm_answer": "Between 2022 and 2023, Oracle's positioning of Engineered Systems shifted from a standalone hardware segment to a tightly integrated component of its broader cloud and license strategy, with revenue recognition reflecting this evolution. While Engineered Systems hardware revenue remained flat at 6% of total revenue in both fiscal 2023 and 2024, the company increasingly bundled hardware with cloud and license offerings—evidenced by the strategic emphasis on \"choice and flexibility\" in deployment models (e.g., hybrid cloud) and the integration of hardware support contracts into cloud license support pricing. This shift is underscored by the company's focus on cloud services revenue growth (rising from 25% to 37% of total revenue from 2022 to 2024) and the recognition that hardware revenue recognition remains point-in-time (at delivery), contrasting with the ratable recognition of cloud services and support contracts. Strategically, Oracle emphasized expanding its cloud infrastructure footprint and customer adoption of Engineered Systems within hybrid cloud environments, as reflected in its 2023 10-K discussion of \"continued demand for our cloud license and on-premise license and license support offerings\" and investments in cloud capacity.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer contains a mix of accurate and inaccurate information, with significant issues in quantitative accuracy that undermine the overall correctness. (1) Quantitatively, the claim that Engineered Systems hardware revenue was 'flat at 6% of total revenue in both fiscal 2023 and 2024' is partially correct per the ground truth, which confirms 6% in both years. However, the LLM incorrectly implies this percentage was also known and reported for 2022, when the ground truth explicitly states that no specific percentage was provided for 2022—this is a critical error. Additionally, the LLM introduces new figures not in the original, such as cloud services rising from 25% to 37% of total revenue (2022–2024), which are unsupported by the ground truth and represent unverified data. (2) The revenue recognition method—point-in-time at delivery—is correctly stated and consistent with the original answer. (3) Qualitatively, the LLM attempts multi-hop reasoning by linking Engineered Systems to cloud bundling and hybrid deployment strategies, which aligns with the strategic emphasis trend. However, the ground truth does not mention bundling with cloud services or integration into cloud license pricing, nor does it state that Engineered Systems shifted to a 'tightly integrated component' of cloud strategy—these are speculative expansions. The mention of R&D investments and competitive positioning is consistent in spirit but more detailed in the LLM than supported. (4) Contextual relevance is high, as the answer addresses revenue recognition, strategic emphasis, and evolution over time. However, the inclusion of unsupported percentages and strategic claims reduces factual reliability. The answer synthesizes beyond the evidence, especially for 2022, where data was limited. Thus, while the direction of reasoning is plausible, the factual foundation is partially incorrect, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1569,
        "completion_tokens": 516,
        "total_tokens": 2085
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has Comcast's relationship with representation firms evolved in terms of advertising sales strategy between 2023 and 2024?",
      "original_answer": "In 2023, Comcast worked with representation firms as an extension of its sales force to sell a portion of the advertising units allocated to them, recording revenue net of agency commissions. By 2024, Comcast had evolved this relationship into formal representation agreements under which they sell advertising on behalf of third parties, indicating a deeper strategic alignment and expanded role for these firms. This reflects a shift from a co-selling model to a more formalized representation structure.",
      "llm_answer": "Between 2023 and 2024, Comcast’s advertising sales strategy evolved by expanding the use of representation firms as an extension of its internal sales force to sell advertising units. This allowed the company to increase advertising revenue while recording the net amount after agency commissions, particularly in its Media segment where third‑party representation firms were employed to sell a portion of the allocated advertising inventory. The shift reflects a strategic move to augment advertising sales through external representation while maintaining net revenue recognition.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the use of representation firms in 2023 as an extension of Comcast's sales force and notes revenue is recorded net of commissions, which aligns with the ground truth. It also accurately reflects the strategic intent to augment advertising sales through external firms and mentions net revenue recognition, which is factually correct. However, the LLM fails to mention the key evolution in 2024: the shift to formal representation agreements where Comcast sells advertising on behalf of third parties, indicating a deeper strategic alignment. Instead, the answer implies continuity of the same model (using firms as sales extensions) without highlighting the structural change from co-selling to formal representation. This omission affects the completeness and qualitative accuracy of the multi-hop reasoning, as the evolution between years is understated. There are no numerical inaccuracies (dates are correct, no incorrect figures), so quantitative accuracy is perfect. Contextually, the response is highly relevant and well-framed around advertising sales strategy. The core facts are right, but the answer lacks the critical 2024 strategic shift, warranting a 7 for correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1267,
        "completion_tokens": 347,
        "total_tokens": 1614
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has Oracle's approach to its industry-specific hardware offerings evolved between fiscal 2022 and fiscal 2023, particularly in terms of revenue recognition and strategic emphasis?",
      "original_answer": "In fiscal 2022, Oracle described its hardware business as including industry-specific hardware and recognized hardware revenues at the point in time when products and related software were delivered to customers. By fiscal 2023, Oracle introduced a more detailed explanation of revenue recognition for hardware, stating that revenues for combined performance obligations (hardware plus related software) are generally recognized at the point in time of delivery and ownership transfer. Additionally, in 2023, Oracle emphasized ongoing investments in R&D to improve existing hardware offerings and develop new products, signaling a more strategic focus on innovation in this area compared to 2022, where the description was more general and focused on the breadth of offerings.",
      "llm_answer": "Oracle’s industry-specific hardware offerings have continued to represent a small, stable share of total revenue (about 6 % in both fiscal 2024 and fiscal 2023), and the company still records hardware revenue at the point‑in‑time when the product and related software are delivered.  While the overall hardware segment’s operating margin remains modest compared with the cloud‑and‑license business, Oracle emphasizes that its hardware margins are intentionally lower due to incremental production and support costs, and it expects the segment to maintain this lower‑margin profile.  The company’s strategic focus remains on expanding cloud services and license revenues, with hardware serving primarily as a complementary offering rather than a growth driver.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies and fails to address the core aspects of the question. It incorrectly references fiscal 2024 (not part of the question or ground truth), and states that hardware revenue is about 6% in both fiscal 2024 and 2023—this percentage is not mentioned in the original answer and cannot be verified from the provided ground truth. The ground truth does not include any revenue share data, so this claim is unsupported. (2) The quantitative accuracy is low because the LLM introduces specific percentages (6%) and fiscal years (2024) not present in the original answer. There are no calculations in the ground truth to validate, but the introduction of false numerical data reduces accuracy. (3) The multi-hop reasoning is flawed: the question asks about evolution between fiscal 2022 and 2023 in revenue recognition and strategic emphasis. The LLM fails to compare the two years as required. While it correctly notes point-in-time revenue recognition, it does not mention the key evolution in 2023—the clarification around combined performance obligations (hardware plus software) and delivery/ownership transfer, which is central to the original answer. Additionally, the strategic emphasis in 2023 on R&D and innovation is entirely missing; instead, the LLM claims hardware is a 'complementary offering rather than a growth driver,' which contradicts the ground truth's indication of increased strategic focus on innovation. (4) Contextual relevance is moderate because the answer discusses Oracle's hardware business and revenue recognition, which are relevant topics, but it misses the comparative, multi-year evolution and introduces irrelevant details (e.g., margins, fiscal 2024). The answer reflects a different interpretation of strategy than the ground truth, downplaying hardware's strategic role when the original answer suggests increased emphasis. Thus, despite some topical alignment, the factual and reasoning gaps justify a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1393,
        "completion_tokens": 545,
        "total_tokens": 1938
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How did the sales performance of IMBRUVICA (ibrutinib) evolve between 2022 and 2023, and what factors contributed to this change?",
      "original_answer": "IMBRUVICA sales decreased from $3.784 billion in 2022 to $3.264 billion in 2023, a decline of 13.7%. In 2022, the growth of IMBRUVICA was already being offset by competitive pressures from novel oral agents and market dynamics related to the pandemic, such as delays in new patient starts. By 2023, this downward trend continued, with the product experiencing a significant drop in sales, reflecting sustained competitive pressures and likely increased market saturation or treatment shifts in the oncology space.",
      "llm_answer": "IMBRUVICA (ibrutinib) sales declined 13.7% from $3,784 million in 2022 to $3,264 million in 2023, with operational growth of 13.2% offset by a 0.5% negative currency impact. This decrease was primarily attributed to global competitive pressures and loss of market exclusivity, as noted in the Oncology segment analysis where it states \"Growth was partially offset by ZYTIGA (abiraterone acetate) due to loss of exclusivity and IMBRUVICA (ibrutinib) due to global competitive pressures.\" The document also indicates that IMBRUVICA's performance was part of broader Oncology growth (10.5% overall), but its specific trajectory showed a downward trend year-over-year.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly reports the sales figures for IMBRUVICA in 2022 ($3,784 million) and 2023 ($3,264 million), and accurately calculates the 13.7% decline, matching the ground truth. These numbers are factually correct and semantically equivalent (e.g., $3.784 billion = $3,784 million). (2) The quantitative accuracy is perfect: the percentage change is correctly computed ((3,784 - 3,264) / 3,784 ≈ 13.7%), and all financial figures align with the original answer. (3) The reasoning is mostly sound but introduces a minor inaccuracy: it mentions 'operational growth of 13.2%' and '0.5% negative currency impact,' which are not present in the ground truth and could mislead, as the original answer does not cite any growth factors offsetting the decline—only sustained competitive pressures and market dynamics. Additionally, the reference to ZYTIGA and Oncology segment growth, while contextually plausible, shifts focus and is not directly relevant to explaining IMBRUVICA’s decline per the original answer. (4) The core facts—sales drop, magnitude, and competitive pressures—are correct and well-synthesized, but the inclusion of unsupported operational and currency details reduces qualitative accuracy slightly. Contextual relevance remains high as the answer directly addresses both parts of the question: sales evolution and contributing factors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 381,
        "total_tokens": 1671
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has Comcast's involvement with Universal Beijing Resort evolved from 2023 to 2024 in terms of debt levels, ownership structure, and financial risk exposure?",
      "original_answer": "In 2023, Universal Beijing Resort had $3.5 billion of debt outstanding, including a $3.1 billion term loan, and was consolidated by Comcast, which owns a 30% interest. By 2024, the debt level slightly decreased to $3.4 billion, with the term loan principal reducing to $3.0 billion. Comcast continues to consolidate Universal Beijing Resort as a VIE, maintaining its 30% ownership stake. The maximum financial risk exposure for Comcast remains limited to its 30% equity interest, indicating a stable risk profile despite the slight reduction in debt. This evolution reflects a minor decrease in leverage but no change in ownership or governance structure.",
      "llm_answer": "From 2023 to 2024, Comcast's involvement with Universal Beijing Resort evolved with a slight reduction in debt exposure and stable ownership structure. The resort's debt outstanding decreased marginally from $3.5 billion as of December 31, 2023, to $3.4 billion as of December 31, 2024, while Comcast's 30% ownership stake remained unchanged. The company continues to consolidate Universal Beijing Resort as a variable interest entity, with its financial risk exposure limited to its 30% equity interest, which remains fully supported by the resort's underlying assets and debt obligations.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the debt levels for Universal Beijing Resort in 2023 ($3.5 billion) and 2024 ($3.4 billion), as well as Comcast's unchanged 30% ownership stake and continued consolidation as a VIE. The financial risk exposure being limited to the 30% equity interest is accurately stated. (2) All numeric values match the ground truth: $3.5B to $3.4B debt reduction, with no discrepancies in percentages or dates (December 31, 2023, and December 31, 2024, are valid reporting dates). The slight decrease in debt is correctly characterized. (3) The multi-hop reasoning is sound—information about debt, ownership, consolidation, and risk exposure is synthesized correctly across time and entities. However, the LLM omits specific mention of the term loan decreasing from $3.1B to $3.0B, which is a minor but relevant detail from the original answer. This omission prevents a perfect score but does not undermine the overall accuracy. (4) The answer is contextually fully relevant, addressing all three aspects of the question: debt levels, ownership structure, and financial risk exposure. Wording differs slightly but maintains semantic equivalence. The qualitative accuracy is high, though not perfect due to the missing term loan detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 356,
        "total_tokens": 1671
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How did the financial commitment related to future lease payments for build-to-suit facilities and equipment evolve from 2022 to 2023, and what does this indicate about FedEx's leasing strategy?",
      "original_answer": "In 2022, FedEx disclosed future undiscounted payments of approximately $3.4 billion for build-to-suit facilities that had not yet commenced, with expected commencement dates from 2023 to 2024. By 2023, the company reported a significant reduction in these future commitments, with undiscounted payments dropping to approximately $0.9 billion for build-to-suit facilities and equipment, with commencement dates expected from 2025 to 2027. This indicates a strategic shift toward fewer long-term build-to-suit lease commitments and a more extended timeline for asset utilization.",
      "llm_answer": "The financial commitment for future lease payments tied to build‑to‑suit facilities and equipment is disclosed in the “Future minimum lease payments” tables. At May 31 2022, undiscounted future payments for these build‑to‑suit leases were approximately **$3.4 billion**, with commencement expected from 2023 through 2024. By the 2023 fiscal year, the undiscounted commitment had risen to about **$3.4 billion** (split roughly $198 million for aircraft‑related equipment and $2.6 billion for facilities and other), indicating that FedEx is expanding its build‑to‑suit leasing program and increasing its long‑term lease exposure. This growth shows that FedEx’s leasing strategy is shifting toward greater use of build‑to‑suit arrangements to secure dedicated facilities and equipment, underscoring a strategic emphasis on long‑term, capital‑light real‑estate and equipment commitments.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies. According to the ground truth, FedEx's future lease commitments for build-to-suit facilities and equipment decreased from $3.4 billion in 2022 to $0.9 billion in 2023. However, the LLM incorrectly states that the commitment 'had risen to about $3.4 billion' in 2023, which is factually wrong and contradicts the actual trend. Additionally, the LLM introduces a breakdown of $198 million for aircraft-related equipment and $2.6 billion for facilities, which is not present in the original answer and appears fabricated. (2) The quantitative error is severe: the core dollar amounts for 2023 are completely incorrect. While the 2022 figure of $3.4 billion is correctly cited, the 2023 figure should be $0.9 billion, not $3.4 billion. The LLM also misrepresents the direction of change—claiming an increase instead of a significant reduction. (3) The multi-hop reasoning is flawed. The question requires comparing two years of data to infer strategic intent. The LLM fails this synthesis by misrepresenting the 2023 data, leading to an incorrect conclusion that FedEx is expanding its build-to-suit program, when the truth indicates a strategic pullback. The reasoning based on false data leads to the opposite conclusion of the ground truth. (4) Despite the severe factual and reasoning errors, the answer is contextually relevant—it addresses the right topic (build-to-suit lease commitments), cites the correct metric (undiscounted future payments), and attempts to interpret strategy. Hence, contextual relevance is moderate, but correctness, quantitative, and qualitative accuracy scores are low due to fundamental errors in data and logic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 466,
        "total_tokens": 1843
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has Mastercard's relationship with Dynamic Yield LTD evolved between 2023 and 2024, and what does this indicate about the company's strategic focus during this period?",
      "original_answer": "In 2023, Mastercard disclosed that it had acquired Dynamic Yield LTD in April 2022 for $325 million, with $200 million of goodwill attributed to synergies expected after the acquisition. By 2024, the relationship is described as stable, with no new investments or acquisitions involving Dynamic Yield reported during the year. This indicates that the integration of Dynamic Yield was largely completed by 2023, and Mastercard shifted focus to newer acquisitions like Recorded Future in 2024, signaling a strategic pivot toward cybersecurity and threat intelligence.",
      "llm_answer": "Between 2023 and 2024, Mastercard’s relationship with Dynamic Yield evolved from a 2022 acquisition of the company for $325 million—where the purchase price was allocated primarily to intangible assets and goodwill tied to anticipated synergies—to a 2024 acquisition of Recorded Future for $2.7 billion, which built on Dynamic Yield’s capabilities to expand Mastercard’s threat‑intelligence and cybersecurity services. This progression reflects a strategic focus on diversifying and strengthening its value‑added services and technology portfolio, moving from a modest fintech acquisition to a larger, more strategic purchase that enhances its security and intelligence offerings.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that Mastercard acquired Recorded Future in 2024 as a continuation of Dynamic Yield's capabilities, but the ground truth does not mention the Recorded Future acquisition occurring in 2024—only that Mastercard shifted focus to such acquisitions, implying a strategic direction, not a confirmed transaction. The $2.7 billion figure for Recorded Future is not present in the original answer and cannot be verified from the provided truth. (2) Quantitatively, the $325 million acquisition amount and the $200 million goodwill allocation are correct per the 2023 disclosure, but the LLM introduces a new, unsupported figure of $2.7 billion for a 2024 acquisition not mentioned in the ground truth. The date of the Dynamic Yield acquisition (April 2022) is correctly contextualized as prior to 2023, but the LLM misrepresents the timeline by implying ongoing evolution between 2023 and 2024 when the truth states the relationship was stable with no new developments. (3) The multi-hop reasoning is flawed: the original answer emphasizes that by 2024, integration was complete and focus had shifted—indicating a pivot away from Dynamic Yield—not that Dynamic Yield’s capabilities were built upon in a new acquisition. The LLM incorrectly infers a technological or strategic progression between Dynamic Yield and Recorded Future that is not stated or implied with certainty in the ground truth. (4) While the general strategic theme of moving toward cybersecurity is correctly identified, the LLM fabricates a specific acquisition and financial details, undermining factual correctness. The answer is contextually relevant and captures a plausible strategic narrative, but fails on key facts and synthesis, warranting a low correctness score despite partial alignment with the broader direction.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 509,
        "total_tokens": 1826
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has the Severance Plan for Senior Officers at Lowe's evolved between 2022 and 2024, particularly in terms of the most recent amendment dates and associated filings?",
      "original_answer": "In 2022, the Severance Plan for Senior Officers was described as 'amended and restated May 29, 2020' and was filed on August 26, 2020 (Exhibit 10.29). By 2024, the plan had been further amended and restated on May 26, 2022, with the updated version filed on November 27, 2024 (Exhibit 10.28). This indicates that Lowe's updated its Severance Plan for Senior Officers at least once between 2022 and 2024, with the most recent amendment occurring in mid-2022 and formally disclosed in late 2024.",
      "llm_answer": "Based on the provided SEC filing exhibits, the Lowe's Companies, Inc. Severance Plan for Senior Officers was most recently amended and restated on **May 26, 2022**, as documented in Exhibit 10.28 of the Lowe's 2024 10-K filing (page 79). This amendment is referenced in the filing as being incorporated by reference from a Form 10-Q filed on **November 27, 2024**, which confirms the effective date of the restatement. No subsequent amendments to this specific severance plan are indicated in the provided documents beyond this 2022 restatement.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the most recent amendment date of the Severance Plan for Senior Officers is May 26, 2022, and it was filed on November 27, 2024, via Exhibit 10.28 in the 2024 10-K, incorporated from a Form 10-Q. These dates and exhibit numbers match the original answer. (2) Quantitative accuracy is perfect: the dates (May 26, 2022, and November 27, 2024) are correctly reported, and the exhibit reference (10.28) is accurate. The prior version (amended May 29, 2020, filed August 26, 2020, as Exhibit 10.29) is not mentioned in the LLM answer, which slightly reduces completeness, but the question focuses on the evolution *between 2022 and 2024*, so the emphasis on the 2022 amendment and 2024 filing is appropriate. (3) The reasoning is sound: the LLM correctly identifies the source documents and the incorporation by reference, demonstrating proper multi-hop synthesis between the 10-K and the Form 10-Q. (4) The answer is contextually relevant and directly addresses the evolution of the plan, particularly the most recent amendment and associated filing. The only minor omission is the lack of explicit comparison to the prior 2020 version, which was included in the ground truth for context, but this does not detract significantly from the correctness given the time frame emphasis. Thus, a score of 9 is warranted—excellent accuracy with minimal contextual omission.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 403,
        "total_tokens": 1668
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the fair value of Netflix's 6.375% Senior Notes change between December 31, 2021, and December 31, 2023, and what does this evolution indicate about market perceptions of the company's debt over this period?",
      "original_answer": "The fair value of Netflix's 6.375% Senior Notes increased from $999 million as of December 31, 2021, to $872 million as of December 31, 2023. This indicates a decrease in the fair value of the notes over the two-year period, suggesting a potential decline in market confidence or an increase in required yields for this debt instrument.",
      "llm_answer": "The fair value of Netflix's 6.375% Senior Notes increased from $995 million at the end of 2021 to $999 million at the end of 2023, reflecting a modest rise in market perception of the debt’s value. This slight appreciation suggests that investors’ confidence in the company’s creditworthiness remained relatively stable over the two‑year period, with only a marginal improvement in perceived value.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in both direction and magnitude of the fair value change. The ground truth states the fair value decreased from $999 million (Dec 31, 2021) to $872 million (Dec 31, 2023), but the LLM claims it increased from $995 million to $999 million. These numbers are not only wrong but contradict the actual trend. (2) Quantitative accuracy is severely lacking: the starting value is off by $4 million ($995M vs $999M), the ending value is off by $127 million ($999M vs $872M), and the direction of change is reversed (increase vs actual decrease). No correct calculation or comparison can be derived from these incorrect inputs. (3) The multi-hop reasoning fails because the model misidentifies the core data points, leading to an incorrect interpretation. The actual decrease of $127 million suggests deteriorating market confidence or higher required yields, but the LLM infers stable or slightly improving confidence due to its fabricated 'increase'—a complete reversal of the correct conclusion. (4) Contextual relevance is moderate because the answer addresses the right question structure (change in fair value and market perception) and refers to the correct instrument (Netflix's 6.375% Senior Notes) and time frame, but the factual foundation is entirely flawed, undermining all qualitative and quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1200,
        "completion_tokens": 381,
        "total_tokens": 1582
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the sales performance of IMBRUVICA evolve between 2022 and 2023, and what does this indicate about its market position in the oncology segment?",
      "original_answer": "IMBRUVICA's sales decreased from $4,369 million in 2022 to $3,264 million in 2023, representing a decline of 25.2%. This indicates a weakening market position for IMBRUVICA within the oncology segment, especially as other products like DARZALEX and ERLEADA experienced significant growth during the same period.",
      "llm_answer": "Between 2022 and 2023, IMBRUVICA sales declined 13.7% to $3.264 billion (from $3.784 billion in 2022), with the operational decline of 13.2% partially offset by a minor currency impact of 0.5%. This decrease occurred amid global competitive pressures leading to loss of exclusivity, significantly impacting its market position in oncology despite continued growth in other oncology products like DARZALEX and ERLEADA.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the quantitative data. According to the ground truth, IMBRUVICA sales decreased from $4,369 million in 2022 to $3,264 million in 2023, a decline of 25.2%. However, the LLM reports a decline from $3.784 billion to $3.264 billion, which is only a 13.7% drop, misrepresenting both the starting value and the percentage change. The correct calculation is: (4,369 - 3,264) / 4,369 ≈ 25.2%, not 13.7%. The final sales figure ($3.264 billion) is correct and matches the ground truth, but the initial figure and percentage decline are wrong. (2) The LLM introduces 'operational decline of 13.2%' and 'currency impact of 0.5%', which are not present in the ground truth and cannot be verified. These details appear fabricated or misattributed. (3) On qualitative aspects, the LLM correctly identifies the declining market position of IMBRUVICA due to competitive pressures and loss of exclusivity, and appropriately contrasts it with the growth of DARZALEX and ERLEADA, showing sound multi-hop reasoning across oncology products. (4) Contextually, the answer addresses both parts of the question—sales evolution and market position—and provides relevant context about competitive dynamics, earning high marks for relevance. However, the severe quantitative errors—especially the incorrect base year sales and miscalculated decline—undermine the factual correctness, warranting a low overall correctness score despite reasonable reasoning and structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1183,
        "completion_tokens": 418,
        "total_tokens": 1601
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did LOW's inventory shrink reserve and LCNRV reserve evolve between 2022 and 2024, and what were the implications for net earnings?",
      "original_answer": "Between 2022 and 2024, LOW's inventory shrink reserve increased from $414 million to $427 million, while the LCNRV reserve increased from $168 million to $222 million. In 2024, a 10% change in either the amount of inventory subject to markdown or the weighted average estimated loss rate used in the LCNRV reserve calculation would have affected net earnings by approximately $17 million, and a 10% change in the estimated shrinkage rate would have impacted net earnings by approximately $32 million. These changes indicate a growing need for reserves, particularly for shrinkage, and highlight the increasing sensitivity of net earnings to inventory valuation assumptions.",
      "llm_answer": "Based on the provided 10-K pages, LOW's inventory reserves evolved as follows: The LCNRV reserve decreased by $23 million to $222 million as of January 31, 2025 (2024), while the inventory shrink reserve increased by $2 million to $427 million over the same period. The document states that a 10% change in either reserve would have impacted net earnings by approximately $17 million (for LCNRV) and $32 million (for shrink reserve) in fiscal 2024, indicating these reserves directly affect earnings through cost of sales adjustments.",
      "correctness_score": 4,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors in the evolution of the reserves. It incorrectly states that the LCNRV reserve decreased by $23 million to $222 million in 2024, while the ground truth shows it increased from $168 million in 2022 to $222 million in 2024—an increase of $54 million. Similarly, the shrink reserve is said to have increased by only $2 million to $427 million, but the correct increase is from $414 million to $427 million—an increase of $13 million, not $2 million. These quantitative inaccuracies undermine the core of the answer. (2) The impact on net earnings is correctly reported: a 10% change in LCNRV would affect net earnings by $17 million and in shrink by $32 million, which matches the ground truth. However, the reasoning that 'a 10% change in either reserve' would have that effect is slightly misleading—the actual sensitivity is to changes in the inputs (markdown amount or loss rate), not the reserve balance itself. (3) The multi-hop reasoning is partially sound in linking reserve changes to earnings impact, but fails in accurately tracking the year-over-year evolution of the reserves across 2022–2024. The LLM appears to misinterpret the base year values or misread the data, leading to incorrect directional claims (e.g., 'decreased' when it increased). (4) Contextual relevance is high—the answer addresses both reserves and their earnings implications as asked. However, due to major errors in key financial figures and trends, the correctness and quantitative accuracy scores are low. The qualitative accuracy is moderate because the conceptual link to earnings is correct, but the factual foundation is flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 459,
        "total_tokens": 1758
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did Qulipta's status and financial contribution evolve from 2022 to 2023, particularly in terms of its development and commercialization progress?",
      "original_answer": "In 2022, Qulipta was among the products that contributed to the reclassification of $1.0 billion of indefinite-lived research and development intangible assets to developed product rights upon receiving regulatory approvals. By 2023, Qulipta had transitioned from development to commercialization, generating $405 million in revenue in the United States and $3 million internationally, indicating a significant shift from a developmental asset to a revenue-generating product.",
      "llm_answer": "From 2022 to 2023, Qulipta evolved from essentially no revenue to a newly launched product that generated $405 million in U.S. net sales and $3 million internationally, producing total net revenues exceeding $100 million – a growth of more than 100 % year‑over‑year. This rapid uptake reflects its recent regulatory approvals (FDA in April 2023 and EU in January 2024) and strong market adoption for the preventive treatment of chronic migraine.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Qulipta's commercialization progress and reports accurate revenue figures of $405 million in the U.S. and $3 million internationally in 2023, aligning with the ground truth. However, it incorrectly states that Qulipta had 'essentially no revenue' in 2022 and implies a year-over-year growth of 'more than 100%', which is unsupported because the ground truth does not provide 2022 revenue for Qulipta specifically—only that it contributed to a $1.0 billion reclassification of R&D assets upon regulatory approval. The LLM fabricates a 'growth of more than 100%' without a valid baseline. Additionally, the FDA approval date (April 2023) contradicts the ground truth implication that approval occurred in 2022, since the reclassification happened in 2022. The EU approval in January 2024 is irrelevant to the 2022–2023 timeframe and not mentioned in the original answer. (2) Revenue numbers ($405M U.S., $3M international) are correct and match the ground truth. However, the claim of 'total net revenues exceeding $100 million' is technically true but misleadingly understated—actual total is $408M. The 'more than 100% growth' is invalid due to lack of 2022 revenue data. (3) The multi-hop reasoning is partially sound: the model connects regulatory approval to commercialization and revenue generation. However, it misaligns the timeline by placing FDA approval in April 2023, which would not allow full-year 2023 revenue and contradicts the 2022 reclassification event, which requires prior approval. The original answer implies approval occurred by 2022, making the 2023 revenue a result of post-approval commercialization. (4) Correctness score is 6 due to accurate revenue figures but significant errors in timeline and unsupported growth claims. Quantitative accuracy is 5 due to correct numbers but incorrect inferences and dates. Qualitative accuracy is 7 because core reasoning about transition to commercialization is valid, but with flawed supporting details. Contextual relevance is 9 as the answer directly addresses the evolution of Qulipta’s status and financial contribution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1231,
        "completion_tokens": 574,
        "total_tokens": 1805
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How has Honeywell's financial dependency on the Resideo subsidiary for environmental liabilities evolved between 2022 and 2023, and what does this indicate about the company's risk exposure?",
      "original_answer": "Honeywell's financial dependency on the Resideo subsidiary for environmental liabilities remained consistent between 2022 and 2023, with Resideo's subsidiary still obligated to pay 90% of Honeywell's annual net spending on environmental matters at specified sites, up to a maximum of $140 million per year. This ongoing arrangement indicates that Honeywell continues to rely on Resideo's payments to offset a significant portion of its environmental costs, suggesting that the risk mitigation strategy through this indemnification agreement has not changed over the two years.",
      "llm_answer": "Between 2022 and 2023, Honeywell’s reliance on Resideo for environmental indemnification payments remained stable in amount ($140 million annually), but the accounting treatment shifted: the company began recording a receivable from Resideo for 90 % of its environmental costs, increasing the recorded receivable from $157 million (2022) to $187 million (2023) and expanding the balance‑sheet footprint (short‑term $140 million and long‑term $521 million in 2023 versus $140 million and $474 million in 2022). This evolution indicates that while the cash flow impact is unchanged, Honeywell’s exposure to environmental liabilities is now partially offset by a larger, more visible receivable from Resideo, reducing net cash risk but still leaving the underlying environmental liability on Honeywell’s balance sheet.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces specific financial figures—receivables increasing from $157M to $187M, and short-term/long-term balances such as $521M in 2023—that are not present in the original ground truth. The ground truth states only that Resideo remains obligated to pay 90% of Honeywell’s annual net spending up to $140M per year, with no mention of recorded receivables, balance sheet changes, or specific receivable amounts. These added numbers are unsupported by the provided truth and appear to be hallucinated or inferred beyond available data. (2) While the $140 million annual cap and 90% obligation are correctly cited, the LLM fabricates balance sheet details (e.g., long-term receivable of $521M in 2023 vs $474M in 2022) and year-specific receivable balances ($157M in 2022, $187M in 2023), which are not in the original answer and cannot be verified from the given context. These quantitative inaccuracies severely undermine factual correctness. (3) The reasoning incorrectly implies an 'evolution' in financial dependency due to accounting changes, while the ground truth explicitly states the arrangement 'remained consistent' with no change in risk mitigation strategy. This contradicts the core conclusion of the original answer. The multi-hop synthesis fails because it invents financial reporting changes rather than confirming stability. (4) Despite this, the answer is contextually relevant—addressing the right companies (Honeywell, Resideo), time frame (2022–2023), and topic (environmental liability dependency). It correctly notes the 90% indemnification and $140M cap, showing partial understanding. However, the fabricated metrics and erroneous conclusion about evolving risk exposure reduce correctness significantly. Thus, the answer is partially accurate in entities and context but fails on key facts and reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 504,
        "total_tokens": 1862
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How has Target's definition or treatment of 'original maturity' for cash equivalents evolved between 2022 and 2024, and what does this indicate about potential changes in their cash management strategy?",
      "original_answer": "In 2022, Target defined cash equivalents as highly liquid investments with an original maturity of three months or less, with no additional context or clarification. By 2024, the company maintained the same three-month threshold for original maturity but added a broader discussion around fair value measurements for other short-term assets and liabilities, suggesting a more comprehensive approach to short-term financial instruments. This evolution indicates a potential refinement in how Target evaluates and manages its cash and near-cash assets within a broader financial framework.",
      "llm_answer": "Target's definition of \"original maturity\" for cash equivalents has remained consistent across its 2022 and 2024 filings, both specifying that cash equivalents include \"highly liquid investments with an original maturity of three months or less from the time of purchase.\" This definition has not evolved between these periods, indicating stability in their short-term investment policy. However, the 2024 filing shows a significant reduction in short-term investments within cash equivalents ($3.893 billion vs. $4.985 billion in 2022), suggesting a strategic shift toward prioritizing cash and near-cash assets (like receivables) over longer-term short-term investments, potentially reflecting a more conservative cash management approach or a reallocation of funds toward operational needs.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly states that Target's definition of 'original maturity' for cash equivalents remained at 'three months or less' in both 2022 and 2024, which aligns with the ground truth. However, it fails to mention the key qualitative evolution noted in the original answer: the 2024 filing included a broader discussion of fair value measurements for short-term assets and liabilities, indicating a more comprehensive financial framework. This omission significantly weakens the answer's completeness and insight into cash management strategy. Instead, the LLM introduces a comparison of short-term investment values ($3.893B in 2024 vs $4.985B in 2022), which is not present in the ground truth and cannot be verified from the provided information. (2) The dollar amounts cited for short-term investments are not part of the original answer and may be factually incorrect or taken from a different context; since they are unverified and unsupported by the ground truth, they reduce quantitative accuracy. (3) The reasoning is partially sound in noting definition stability, but the inference about a 'strategic shift' based on unverified investment reductions is speculative and not grounded in the actual evolution described (i.e., enhanced disclosure around fair value). The multi-hop synthesis is flawed because it substitutes numerical trends not present in the ground truth instead of analyzing the disclosed change in reporting depth. (4) While the core definition is correct, the answer misses the key nuance about expanded fair value discussion, leading to a mischaracterization of the strategic implication. Hence, correctness and qualitative accuracy are moderate but not sufficient for a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 471,
        "total_tokens": 1830
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the valuation and classification of NVDA's 3.50% Notes Due 2040 evolve between 2023 and 2024, and what does this indicate about the company's long-term debt strategy?",
      "original_answer": "In 2023, the 3.50% Notes Due 2040 were listed under liabilities with a carrying value of $851 million as of January 28, 2024, and were categorized as Level 2 in the pricing hierarchy. By 2024, the valuation of the same notes increased to $1,000 million as of January 26, 2025, with a more detailed breakdown including an effective interest rate of 3.54% and a remaining term of 15.2 years. This indicates a strategic emphasis on long-term financing with stable interest rate structures.",
      "llm_answer": "The 3.50% Notes Due 2040 were classified as Level 2 fair‑value measurements in both the 2023 and 2024 filings, with their carrying values decreasing slightly from $870 million at the end of 2023 to $851 million at the end of 2024. This modest decline reflects routine amortization and market‑price movements, indicating that NVIDIA is managing its long‑term debt at relatively stable levels rather than pursuing aggressive new issuances or early retirements. Consequently, the company appears to be maintaining a conservative, steady‑state approach to its long‑term debt strategy, preserving financial flexibility while continuing to fund growth initiatives.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, the carrying value of NVDA's 3.50% Notes Due 2040 increased from $851 million (as of January 28, 2024, reflecting 2023 fiscal year) to $1,000 million (as of January 26, 2025, reflecting 2024 fiscal year). However, the LLM incorrectly states that the value decreased from $870 million to $851 million, which contradicts both the direction and magnitude of change. Additionally, the LLM introduces a $870 million figure not present in the original answer, which is factually unsupported. (2) The quantitative inaccuracies are severe: the values are wrong, the trend is reversed (decrease vs actual increase), and the dates are misrepresented (end of 2023 vs actual reporting date of January 28, 2024). The effective interest rate (3.54%) and remaining term (15.2 years) mentioned in the ground truth are entirely omitted. (3) The multi-hop reasoning is flawed. The LLM infers a 'conservative, steady-state approach' based on a supposed decrease in debt, but the actual increase to $1,000 million suggests a growing reliance on long-term debt, indicating a strategic expansion of long-term financing—contrary to the LLM's conclusion. The correct synthesis would link the increased valuation and detailed disclosure to a proactive long-term debt strategy. (4) While the LLM correctly identifies the Level 2 classification in both years and addresses the general topic of long-term debt strategy, the core numerical and directional facts are incorrect, leading to an invalid conclusion. Hence, the correctness and quantitative accuracy scores are low. The qualitative accuracy is partially preserved due to correct entity and metric identification, and contextual relevance is acceptable as the response stays on topic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 493,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the financial performance of Venclexta evolve between 2022 and 2023, particularly in terms of total global revenue and the growth rate?",
      "original_answer": "In 2022, Venclexta generated a total global revenue of $2,009 million, with a growth rate of 10.4%. In 2023, the total global revenue from Venclexta increased to $2,288 million, representing a growth rate of 13.9%. This indicates an upward trend in both absolute revenue and growth rate year-over-year.",
      "llm_answer": "Based on the provided financial data, Venclexta's total global revenue increased by 13.9% at actual currency rates and 15.0% at constant currency rates from 2022 to 2023, with U.S. revenue growing 7.8% and international revenue growing 20.1% (22.3% at constant currency). This represents a significant acceleration compared to the prior period's growth.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that Venclexta experienced revenue growth from 2022 to 2023 and notes an acceleration in growth, which aligns with the upward trend in the ground truth. However, it fails to report the actual total global revenue figures for 2022 ($2,009 million) and 2023 ($2,288 million), which are key components of the question. Instead, it focuses on growth rates only. While it mentions a 13.9% growth rate (matching the ground truth), it introduces additional figures not in the original answer—15.0% at constant currency, 7.8% U.S. growth, and 20.1%/22.3% international growth—which were not part of the ground truth and may be factually accurate but are extraneous and unverified in this context. (2) The 13.9% growth rate is correct and matches the ground truth calculation: ($2,288M - $2,009M) / $2,009M ≈ 13.89%. However, the absence of the absolute revenue numbers breaks completeness. The model also omits the 2022 growth rate of 10.4%, which was explicitly asked for in the question to compare evolution. (3) The reasoning partially supports multi-hop synthesis by noting acceleration in growth, but it does not fully synthesize both years’ revenue and growth rates as required. The omission of 2022’s growth rate and revenue weakens the comparative analysis. (4) The contextual relevance is high because the answer addresses revenue evolution and growth trends. However, correctness is reduced due to missing core quantitative data and incomplete response to the multi-part question. Quantitative accuracy is moderate due to one correct percentage but missing others and no absolute values. Qualitative accuracy is acceptable due to correct directional insight but lacks full entity and metric coverage.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1163,
        "completion_tokens": 477,
        "total_tokens": 1640
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How has Netflix's approach to executive severance and retention incentives evolved between the 2022 and 2023 SEC filings, particularly in terms of plan amendments and their effective dates?",
      "original_answer": "In 2022, the filing referenced the 'Amended and Restated Executive Severance and Retention Incentive Plan' with a filing date of September 10, 2021, indicating that the plan had undergone revisions by that date. By 2023, the filing showed further evolution, introducing the 'Executive Severance and Retention Incentive Plan as Amended and Restated effective January 1, 2024,' with a filing date of December 8, 2023. This demonstrates Netflix’s ongoing adjustments to executive compensation frameworks, with a forward-looking amendment effective in 2024.",
      "llm_answer": "Based on the provided SEC filing excerpts, Netflix amended its Executive Severance and Retention Incentive Plan effective January 1, 2024, as disclosed in Exhibit 10.16 of its 2023 10-K filing (page 68). This amendment superseded the prior plan referenced in Exhibit 10.6 (dated September 10, 2021), indicating an evolution in the company's executive compensation structure to reflect updated retention and severance terms effective in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the 2023 filing references an amendment effective January 1, 2024, filed on December 8, 2023 (implied by exhibit date in context), and the prior plan was dated September 10, 2021. The LLM correctly identifies the evolution between the two filings and the forward-looking effective date. (2) Quantitative accuracy is perfect: dates (January 1, 2024; September 10, 2021) are correct, and the filing years (2022 and 2023) are properly associated with the respective plan versions. (3) Multi-hop reasoning is sound—LLM synthesizes information across two filings, identifies the plan amendment, and infers the evolution in Netflix’s executive compensation approach. (4) The only minor shortcoming is that the LLM does not explicitly mention the 'Amended and Restated' naming convention from the 2023 plan or the December 8, 2023 filing date of the new plan, though it references the exhibit in the 2023 10-K, which implies it. This slight omission prevents a perfect 10 on qualitative accuracy. Otherwise, the answer is contextually complete, precise, and semantically equivalent to the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1259,
        "completion_tokens": 337,
        "total_tokens": 1597
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did Lowe's documentation and structure of its Benefit Restoration Plan evolve from 2022 to 2024, and what does this indicate about the company's approach to employee retirement benefits?",
      "original_answer": "In 2022, Lowe's maintained the Benefit Restoration Plan as part of its defined contribution retirement offerings, supplementing benefits under the 401(k) Plan for employees affected by IRS limitations. The plan included both employee salary deferrals and employer contributions in the form of a Company Match. By 2024, the company formally introduced an updated and restated version of the Benefit Restoration Plan, effective January 1, 2025, as evidenced by the new exhibit filing (10.3) in the 2024 10-K. This indicates a deliberate effort to formalize and likely enhance the structure of the plan, signaling a more strategic and forward-looking approach to managing executive and high-earner compensation through improved documentation and alignment with long-term benefit policies.",
      "llm_answer": "The Benefit Restoration Plan was formally renamed and restated in the Lowe's Companies Benefit Restoration Plan, as amended and restated as of January 1, 2025, which was filed as Exhibit 10.3 in the 2024 Form 10‑K (page 78). This update reflects a structural evolution of the plan, positioning it alongside other retirement‑benefit documents such as the 401(k) Plan, the Lowe's Cash Deferral Plan, and various stock‑based compensation agreements. The inclusion of the 2024 amendment (Exhibit 99.2) and the 2023‑2025 updates to the 401(k) Plan further demonstrate Lowe's systematic approach to modernizing and consolidating its employee retirement benefits under a refreshed, regularly updated framework.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the key event: the formal restatement of the Benefit Restoration Plan effective January 1, 2025, filed as Exhibit 10.3 in the 2024 10-K—matching the original answer's core facts. The date, exhibit number, and filing context are all correct. (2) There are no numeric values requiring calculation, but all dates and document references (e.g., Exhibit 10.3, 2024 10-K) are factually accurate. (3) The reasoning is sound: the LLM correctly infers that the restatement reflects a structural evolution and situates the plan within a broader framework of retirement benefits, indicating a systematic approach. While the original answer emphasizes 'deliberate effort to formalize and likely enhance,' the LLM emphasizes 'modernizing and consolidating,' which is semantically consistent. (4) The LLM slightly expands on context by referencing Exhibit 99.2 and the 401(k) Plan updates, which, while not contradicting the ground truth, are not explicitly confirmed in the original answer—this adds value but introduces minor unverifiable detail. Overall, the answer captures the evolution and strategic implication accurately, warranting a high score with only a minor deduction in qualitative accuracy for slight over-enrichment beyond the provided truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 373,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did NVDA's financial obligations related to the 0.584% Notes Due 2024 evolve between fiscal years 2023 and 2024?",
      "original_answer": "In fiscal year 2023, NVDA reported a liability of $1,185 million for the 0.584% Notes Due 2024. By fiscal year 2024, this obligation was fully repaid, as stated in the 2024 10-K filing. This indicates a complete resolution of this specific debt obligation over the two-year period.",
      "llm_answer": "Between fiscal years 2023 and 2024, the balance of NVIDIA’s 0.584% Notes Due 2024 declined from $1,185 million to $1,228 million in fair‑value terms, and the company explicitly noted that it repaid the entire $0.584% Notes Due 2024 during fiscal 2025 (the note was carried at $1,250 million on the balance sheet as of Jan 28 2024 and reduced to $‑ on the Jan 26 2025 statement). Thus, the obligation related to these notes was fully extinguished in the subsequent year.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies. According to the ground truth, NVDA's liability for the 0.584% Notes Due 2024 was $1,185 million in fiscal 2023 and was fully repaid by fiscal 2024. However, the LLM claims the balance increased to $1,228 million in fair value and was repaid in fiscal 2025, which contradicts the original answer. The repayment occurred in fiscal 2024, not 2025. Additionally, the LLM introduces a $1,250 million book value as of January 28, 2024, which is not mentioned in the ground truth and appears fabricated. (2) Quantitative accuracy is severely compromised: the only correct number is the $1,185 million liability in fiscal 2023. All other figures ($1,228M fair value, $1,250M book value) are incorrect or unsupported. The claim that the note was repaid in fiscal 2025 is factually wrong—ground truth states repayment was completed in fiscal 2024. (3) The multi-hop reasoning is flawed. The model fails to correctly synthesize the timeline and resolution of the debt obligation. It incorrectly extends the repayment into fiscal 2025 and introduces unverified balance sheet values and fair value metrics not present in the original data. The conclusion that the obligation was extinguished is correct in spirit but misattributed to the wrong fiscal year. (4) Contextual relevance is moderate—the response addresses the evolution of the debt obligation and attempts to describe repayment, but the incorrect timing and invented figures undermine the validity. Due to major factual and numerical errors, especially regarding the repayment date and amounts, the correctness score is low at 2.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1180,
        "completion_tokens": 450,
        "total_tokens": 1630
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did the global revenue performance of Mavyret evolve between 2022 and 2023, and what were the trends in its United States and international markets during this period?",
      "original_answer": "In 2022, Mavyret generated total global revenue of $1,541 million, with $755 million from the United States and $786 million from international markets. By 2023, total revenue from Mavyret decreased to $1,430 million, driven by a decline in both U.S. and international markets. Specifically, U.S. revenue dropped to $659 million, a decrease of 12.7%, while international revenue slightly declined to $771 million, a marginal decrease of 1.9%. This indicates a contraction in Mavyret's market performance across both regions, with a more pronounced decline in the U.S. market.",
      "llm_answer": "Based on the provided financial data from the 10-K filings, Mavyret's global revenue declined by 7.2% in 2023 (at constant currency) compared to 2022, with U.S. sales falling 12.7% and international sales decreasing 1.9%. The document indicates that Mavyret faced competitive pressures in the HCV market, though specific international growth rates were modest (1.0% at constant currency).",
      "correctness_score": 7,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 12.7% decline in U.S. revenue and 1.9% decline in international revenue, which aligns with the ground truth. However, it does not provide the actual dollar amounts for 2022 and 2023 global revenue ($1,541 million and $1,430 million), which are key quantitative details from the original answer. The 7.2% global decline is approximately correct (actual: (1,541 - 1,430)/1,541 ≈ 7.2%), so this calculation is accurate. (2) The LLM mentions 'constant currency' adjustments for both global and international figures, which are not present in the ground truth and may introduce inaccuracy if not explicitly supported by the source data. The original answer does not mention constant currency, so this could misrepresent the data. Additionally, the LLM states 'international growth rates were modest (1.0% at constant currency)', which contradicts the ground truth of a 1.9% decline; this is a significant error. (3) The multi-hop reasoning is partially sound—correctly linking U.S. and international trends to global performance—but fails to report absolute revenue figures, weakening completeness. The mention of competitive pressures in the HCV market adds contextual insight not in the ground truth, which is reasonable if supported by the 10-K, but not verifiable here. (4) The correctness score is 7 due to accurate core percentages and logical structure, but docked for missing absolute values and introducing potentially misleading constant currency metrics. Quantitative accuracy is 7 due to correct percentage changes but incorrect international growth rate and unverified constant currency claims. Qualitative accuracy is 8 due to sound reasoning and entity identification (Mavyret, U.S./international markets, 2022–2023). Contextual relevance is 9—highly relevant with minor overcomplication.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1247,
        "completion_tokens": 502,
        "total_tokens": 1749
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How did Netflix's compliance with covenant limitations related to its Senior Notes evolve between 2022 and 2024, particularly in terms of repayment obligations and the scope of restrictions?",
      "original_answer": "In 2022, Netflix was in compliance with all covenant limitations tied to its Senior Notes, which included restrictions on creating liens, entering into sale and lease-back transactions, incurring additional indebtedness by certain subsidiaries, and merging or transferring substantial assets. These notes included various euro-denominated tranches with principal amounts totaling €5,170 million. By 2024, Netflix remained in compliance with these covenants, but the scope of limitations had slightly evolved—specifically, certain Senior Notes no longer referenced restrictions on sale and lease-back transactions, suggesting a narrowing of covenant scope for some notes. Additionally, in 2024, Netflix repaid $400 million of its 5.750% Senior Notes upon maturity, indicating active debt management and a shift in its debt composition.",
      "llm_answer": "Between 2022 and 2024, Netflix’s covenant framework governing its senior unsecured notes remained consistent in its core restrictions—namely, limitations on incurring additional debt, granting liens, entering sale‑and‑lease‑back transactions, and effecting mergers or asset sales—while the company continued to maintain compliance with these covenants throughout 2022, 2023 and 2024.  The primary evolution was in the structure of its revolving‑credit facility: the 2021 amendment extended the maturity to June 17 2026 and increased capacity, and a new $3 billion five‑year facility was entered into in April 2024, which introduced a revised financial‑maintenance covenant (minimum EBITDA‑to‑interest‑expense ratio of 3.0 to 1.0) that will govern future borrowing and repayment flexibility.  Consequently, while repayment obligations on the senior notes themselves have proceeded as scheduled (e.g., the $400 million 5.750% note matured in 2024), the scope of covenantal restrictions has expanded to include this new revolving‑credit covenant, though no material impact on liquidity or financial position is expected.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. It correctly states that Netflix remained in compliance with covenants in 2022 and 2024 and accurately notes the $400 million repayment of the 5.750% Senior Notes in 2024. However, it incorrectly claims that the covenant scope *expanded* due to a new revolving-credit facility with a financial maintenance covenant (EBITDA-to-interest ratio of 3.0 to 1.0), which is not mentioned in the ground truth and represents a significant factual deviation. The ground truth indicates a *narrowing* of covenant scope in 2024—specifically, the removal of sale-and-lease-back restrictions for certain notes—whereas the LLM asserts an expansion, which contradicts the original answer. Additionally, the LLM introduces details about a $3 billion five-year facility in April 2024 and amendments to a revolving-credit facility extending to 2026, none of which are present in the ground truth and appear to be hallucinated or misattributed. (2) Quantitatively, the $400 million repayment is correct and matches the ground truth. The 5.750% interest rate is also correctly cited. However, the $3 billion facility and EBITDA covenant ratio are unsupported by the original answer and thus factually inaccurate in this context. (3) The multi-hop reasoning is flawed: while the model attempts to synthesize covenant evolution and repayment obligations, it fails to correctly identify the direction of change in covenant scope (narrowing vs. expanding) and introduces unrelated credit facilities not referenced in the source. The core evolution described in the ground truth—removal of sale-and-lease-back restrictions—is entirely missed. (4) The contextual relevance is moderate because the answer addresses covenant compliance and repayment, but the focus shifts to unrelated credit facilities, reducing accuracy. Correctness is penalized heavily due to major factual errors in entity relationships and reasoning, despite partial numerical accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1498,
        "completion_tokens": 541,
        "total_tokens": 2040
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How did Honeywell's approach to the Safety and Retail product line evolve between 2022 and 2023, and what structural change was introduced in 2023 that reflects this evolution?",
      "original_answer": "In 2022, Honeywell reported the Safety and Retail business unit as a standalone component under the Safety and Productivity Solutions segment, generating $2,387 million in revenue. By 2023, the company had realigned its organizational structure, merging the Safety and Retail unit with the Advanced Sensing Technologies unit to form a new business unit called Sensing and Safety Technologies. This structural change, introduced in July 2022 but reported in the 2023 filing, reflects a strategic shift toward integrating sensing capabilities with safety solutions to enhance technological offerings and streamline operations.",
      "llm_answer": "Between 2022 and 2023, Honeywell’s Safety and Productivity Solutions segment underwent a structural realignment: the former Safety and Retail business unit was merged into the Sensing and Safety Technologies unit, and the segment was renamed Safety and Productivity Solutions. This evolution reflects a strategic refocus on core sensing and safety technologies within the segment. In 2023, Honeywell further reinforced this evolution by acquiring Carrier Global Corporation’s Global Access Solutions business for $5.0 billion, which will be integrated into the Honeywell Building Technologies reportable segment, signaling a shift away from the Safety and Productivity Solutions segment toward building‑technology expansion.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and introduces information not present in the ground truth. (1) Quantitatively, the $5.0 billion acquisition of Carrier Global Corporation’s Global Access Solutions business is incorrect and irrelevant to the Safety and Retail product line evolution—this detail does not appear in the original answer and misdirects the response. The revenue figure of $2,387 million from 2022 is omitted entirely. (2) The structural change is partially correct in that the Safety and Retail unit was merged, but the LLM incorrectly states it was merged into an existing 'Sensing and Safety Technologies unit', whereas the ground truth specifies that the merger of Safety and Retail with Advanced Sensing Technologies *formed* the new Sensing and Safety Technologies unit. Additionally, the claim that the segment was renamed 'Safety and Productivity Solutions' is incorrect—the segment name remained the same; it was internal business units that were restructured. (3) The reasoning is flawed: the acquisition of Carrier’s business is presented as part of the evolution of the Safety and Retail line, but it belongs to a different segment (Building Technologies) and does not reflect the strategic integration of sensing and safety technologies. The multi-hop synthesis fails because the model conflates unrelated structural changes. (4) Contextually, the answer addresses the general theme of organizational evolution but misattributes key events and omits the core factual basis (merger forming a new unit, timing of July 2022 realignment reported in 2023). The strategic rationale of integrating sensing with safety is mentioned in the ground truth but not accurately reflected in the LLM’s explanation. Overall, major factual and structural errors reduce correctness significantly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 492,
        "total_tokens": 1837
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has the status and role of Class B-2 Common Stock evolved between 2023 and 2024, particularly in terms of its convertibility and impact on corporate governance?",
      "original_answer": "In 2023, Class B-2 Common Stock was described as part of a structure that would become convertible into Class A Common Stock, with potential dilutive effects on voting power and market price. It also played a role in approving significant corporate actions, indicating a governance influence. By 2024, no shares of Class B-2 Common Stock were outstanding prior to the Class B-1 Common Stock exchange offer, suggesting a strategic shift in equity structure. This indicates a transformation in the role of Class B-2 Common Stock, moving from an active governance and conversion position to a non-outstanding status, reducing its influence on corporate decisions.",
      "llm_answer": "Between 2023 and 2024, Class B‑2 common stock remained authorized but was not yet issued; it only became convertible upon the exercise of the class B‑1 exchange offer, which began converting shares into Class A common stock. Consequently, its convertibility and any voting or governance impact were limited until that conversion occurred, after which the increased Class A share count could dilute existing Class A shareholders and affect corporate governance dynamics.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partial factual correctness but misses key aspects of the evolution of Class B-2 Common Stock. It incorrectly states that Class B-2 was 'not yet issued' and only became convertible upon the Class B-1 exchange offer. However, the ground truth indicates that in 2023, Class B-2 was already part of the capital structure with defined convertibility and governance roles, and by 2024, no shares were outstanding prior to the Class B-1 exchange offer—meaning the elimination or conversion had already occurred before that event. The LLM reverses or misrepresents the sequence and status. (2) There are no explicit numbers (e.g., share counts, percentages, dollar amounts) in either answer, so quantitative accuracy is not penalized; the dates (2023–2024) are correctly referenced. (3) The multi-hop reasoning is flawed: the model fails to correctly synthesize the transformation from an active governance role in 2023 to non-outstanding status in 2024. Instead, it implies Class B-2 remained dormant and only became relevant during the Class B-1 exchange, which contradicts the ground truth. (4) While the answer addresses convertibility and governance, it misrepresents the timeline and strategic shift, leading to a low correctness and qualitative accuracy score. Contextual relevance is moderate as it discusses the right concepts but with incorrect causal and temporal logic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 392,
        "total_tokens": 1678
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has The Home Depot's approach to enhancing the ease of shopping experience evolved between 2023 and 2024, particularly in terms of digital and in-store capabilities?",
      "original_answer": "In 2023, The Home Depot focused on improving the ease of shopping experience by investing in mobile app-enabled store navigation, electronic shelf labels, reconfigured service desks, and enhanced self-checkout options. These efforts were aimed at improving store navigation, convenience, and checkout speed. By 2024, the company expanded its focus to include more personalized digital experiences, such as customer product review summaries and enhanced product content, while continuing to invest in digital platforms to improve navigation and 'shopability.' The 2024 strategy placed greater emphasis on leveraging customer data to meet personalized expectations, indicating a shift toward deeper integration of data-driven insights into the shopping journey.",
      "llm_answer": "Between 2023 and 2024, The Home Depot deepened its focus on a seamless, interconnected shopping journey by expanding digital tools and in‑store capabilities.  It continued to invest in mobile‑enabled store navigation, enhanced self‑checkout and electronic shelf‑label technology, and AI‑driven inventory visibility (Computer Vision) to make product location faster and checkout smoother.  Simultaneously, it leveraged its store network as fulfillment hubs—using BOPIS, curbside pickup, lockers, and same‑day/next‑day delivery—while upgrading its supply‑chain automation and last‑mile delivery capacity to meet customers’ expectations for speed and convenience.  These initiatives collectively aim to simplify the purchase journey from inspiration through post‑purchase support.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies The Home Depot's continued investment in digital and in-store capabilities between 2023 and 2024, including mobile-enabled navigation, electronic shelf labels, self-checkout, and fulfillment options like BOPIS and curbside. However, it introduces elements not present in the original answer, such as 'AI-driven inventory visibility (Computer Vision)' and 'supply-chain automation and last-mile delivery,' which were not mentioned in the ground truth. While these may be plausible initiatives, they are not supported by the provided knowledge graph. Conversely, the LLM omits key 2024-specific developments from the original answer, particularly the shift toward personalized digital experiences like customer product review summaries and enhanced product content leveraging customer data. (2) There are no numeric values, dates, or calculations in either answer, so quantitative accuracy is not compromised—score is 10. (3) The multi-hop reasoning is partially sound: the model correctly infers continuity in digital and in-store improvements from 2023 to 2024, but fails to capture the strategic evolution toward data-driven personalization in 2024, which is central to the original answer’s narrative of a 'shift' in focus. Instead, it emphasizes logistics and fulfillment, which were not highlighted in the ground truth. (4) The contextual relevance is high because the answer addresses digital and in-store shopping experience evolution, but the emphasis on fulfillment and supply chain slightly misaligns with the original focus on personalization and digital 'shopability.' The core facts about 2023 initiatives are accurate, and the answer remains relevant, warranting a correctness score of 7—reflecting accurate base elements but missing a key strategic shift and adding unsupported details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 501,
        "total_tokens": 1891
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has the structure of the Target Corporation Long-Term Incentive Plan evolved from 2022 to 2024, particularly in terms of the specific forms of equity awards included under the plan?",
      "original_answer": "In 2022, the Long-Term Incentive Plan included forms such as Non-Qualified Stock Options, Restricted Stock Units, Performance-Based Restricted Stock Units, Performance Share Units, Price-Vested Stock Options, Non-Employee Director Non-Qualified Stock Options, and Non-Employee Director Restricted Stock Units. By 2024, the plan introduced new forms of equity awards, including the Cliff-Vested Restricted Stock Unit Agreement and the Performance Award Performance Share Unit Agreement, indicating an expansion in the types of equity compensation vehicles available under the plan.",
      "llm_answer": "The Target Corporation Long-Term Incentive Plan has expanded its equity award types over time. By 2024, the plan includes restricted stock units (RSUs) with distinct forms such as performance-based RSUs, performance share units, cliff-vested RSUs, and non-employee director RSUs, as detailed in the 2024 filing (pages 73-75). Earlier iterations, like the 2011 and 2017 plans, primarily featured stock options and RSUs, but the 2020 and subsequent amendments introduced these newer equity award structures to align with evolving compensation strategies.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the evolution of Target Corporation's Long-Term Incentive Plan with a focus on the expansion of equity award types by 2024, including performance-based RSUs, performance share units, cliff-vested RSUs, and non-employee director RSUs. It accurately references the 2024 filing (pages 73-75), which aligns with the ground truth's indication of new forms like the Cliff-Vested Restricted Stock Unit Agreement and Performance Award Performance Share Unit Agreement. The mention of earlier plans (2011, 2017) and the shift from stock options and basic RSUs to more structured awards is contextually appropriate and supports the narrative of evolution.\n\nHowever, the LLM answer omits specific forms present in the 2022 plan as listed in the ground truth—such as Non-Qualified Stock Options, Price-Vested Stock Options, and Non-Employee Director Non-Qualified Stock Options—making the description of the earlier structure incomplete. While it correctly notes the introduction of newer structures in '2020 and subsequent amendments,' the ground truth focuses on the 2022-to-2024 evolution, not earlier plans. This shifts the timeframe slightly and introduces potentially irrelevant detail about 2011 and 2017 plans, which were not asked for in the question.\n\nQuantitatively, there are no numerical inaccuracies—dates and award types are correctly framed, and no incorrect calculations are made. The qualitative reasoning is mostly sound but lacks precise synthesis of the 2022 baseline as required by the multi-hop nature of the question (comparing specific award types between 2022 and 2024). The answer captures the directional change (expansion and diversification) but misses the full scope of 2022 offerings, weakening the comparative analysis. Contextually, the response is highly relevant, citing the correct document and focusing on equity award evolution. Minor omissions and slight overreach into earlier plan years prevent a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 531,
        "total_tokens": 1823
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How did Qulipta's commercial performance evolve from its FDA approval in 2021 through 2023, based on AbbVie's financial disclosures?",
      "original_answer": "Qulipta was approved by the FDA in September 2021 for the preventive treatment of episodic migraine in adults, marking its entry into the market. By 2023, Qulipta had generated $405 million in U.S. revenue and $3 million internationally, totaling $408 million. This indicates a significant commercial trajectory following its approval, especially considering it had no revenue in 2021 and only $158 million in U.S. revenue in 2022. The product demonstrated strong growth, suggesting robust market adoption and positioning within AbbVie's portfolio.",
      "llm_answer": "Based on AbbVie's financial disclosures in the 2022 and 2023 10-K filings, Qulipta's commercial performance evolved from its FDA approval in 2021 through 2023 with strong growth driven by market uptake and expanded indications. Net revenues for Qulipta increased by over 100% in 2023 (as reported in constant currency), following its 2021 FDA approval for chronic migraine prevention and subsequent 2023 EC approval for migraine treatment, with AbbVie explicitly citing \"continued strong market share uptake as well as market growth\" as key drivers. This growth occurred within the broader context of AbbVie's neuroscience portfolio, where Qulipta contributed to the segment's overall revenue expansion despite challenges in other areas like Humira.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. First, it incorrectly states that Qulipta was approved by the FDA in 2021 for 'chronic migraine prevention'—the actual approval was for 'episodic migraine' (not chronic). Additionally, the LLM mentions an 'EC approval for migraine treatment' in 2023, which is not referenced in the ground truth and is irrelevant to U.S. commercial performance. The answer cites 'over 100% growth in 2023 in constant currency' but does not provide actual revenue figures, omitting the key data points: $405M U.S. revenue and $3M international in 2023, $158M in 2022, and zero in 2021. These quantitative omissions and errors severely undermine accuracy. (2) The ground truth includes precise revenue numbers across years and shows a clear growth trajectory: from $0 in 2021 to $158M (U.S.) in 2022 to $408M total in 2023. The LLM fails to report any of these figures, making it impossible to verify or assess the claimed 'over 100% growth.' While the growth claim is directionally correct (from $158M to $405M U.S. is ~156% increase), the lack of explicit numbers and incorrect context (e.g., referencing EC approval) reduces quantitative reliability. (3) The multi-hop reasoning is partially sound—linking FDA approval to commercial growth and citing market uptake as a driver—but it fails to synthesize the actual financial disclosures from AbbVie’s 10-Ks that report specific revenues. The answer fabricates or misattributes regulatory milestones (EC approval) and indication (chronic vs. episodic), indicating flawed entity and event mapping. (4) Contextual relevance is high—the answer addresses the evolution of commercial performance and ties it to AbbVie’s disclosures and broader portfolio trends. However, due to major factual and quantitative deficiencies, especially the absence of revenue figures and incorrect approval details, the correctness score is low. The answer captures the general trend of strong growth but lacks the factual backbone required for full accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 548,
        "total_tokens": 1868
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How has Netflix's treatment and disclosure of the 2020 Stock Plan evolved between the 2022 and 2024 SEC filings, particularly in terms of its structural description and associated equity compensation activities?",
      "original_answer": "In 2022, the 2020 Stock Plan was referenced primarily through its inclusion in the exhibit list as a filed document (Def 14A, filed April 22, 2020), with no detailed description of its provisions or activities. In contrast, by 2024, the 2020 Stock Plan was not only explicitly described in detail but also linked to specific equity compensation activities, including the granting of incentive stock options, nonstatutory stock options, and restricted stock units (RSUs) with defined vesting schedules and performance-based criteria. This represents a significant shift from mere documentation to a more comprehensive disclosure of the plan's operational role in equity compensation.",
      "llm_answer": "The Company’s treatment of its equity compensation plans remained consistent between the 2022 and 2024 filings, continuing to describe the 2020 Stock Plan as the primary vehicle for equity awards (including stock options, RSUs, and PSUs) and detailing its key features—such as vesting schedules, performance conditions, and the recent increase in share‑repurchase authorizations—while providing updated quantitative disclosures of outstanding options, exercised shares, and related compensation expense in both filings.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth. (1) It claims Netflix's treatment of the 2020 Stock Plan was 'consistent' between 2022 and 2024, but the original answer shows a significant evolution—from minimal disclosure in 2022 (only listed as an exhibit) to detailed operational description in 2024. This misrepresents the core finding. (2) There are no specific numbers (e.g., share counts, dollar values, dates) in either the question or ground truth, so quantitative accuracy is not heavily penalized, but the LLM fabricates details like 'increase in share-repurchase authorizations' and 'updated quantitative disclosures' that are not supported by the ground truth. (3) The multi-hop reasoning fails: the key insight is the shift from passive documentation to active disclosure, which the LLM misses entirely. Instead, it assumes consistency and adds unsupported details about PSUs, vesting, and compensation expense. (4) Contextual relevance is moderate because it discusses equity plans and related terms, but it fails to address the actual evolution in disclosure practices. The answer invents a narrative of continuity and enhanced detail in both years, when in fact the detail only appears in 2024. This represents a fundamental misunderstanding of the question and data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 362,
        "total_tokens": 1679
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did the company's approach to aluminum purchase agreements evolve between 2022 and 2023, particularly in terms of their classification and strategic use of derivative instruments?",
      "original_answer": "In 2022, the company described its aluminum purchase agreements as derivative instruments entered into for long-term strategic sourcing objectives and non-U.S. business requirements. By 2023, the company continued to use these agreements but provided additional clarity that the quantities of aluminum in these contracts offset each other and are priced at prevailing market prices. This evolution indicates a more refined strategy around market pricing alignment and potentially reduced exposure through offsetting positions.",
      "llm_answer": "The company's approach to aluminum purchase agreements evolved significantly between 2022 and 2023, shifting from being classified as cash flow hedges (as noted in 2022) to being explicitly excluded from hedge accounting treatment in 2023. This change meant these aluminum contracts, along with certain foreign currency and commodity derivatives, were now \"not receiving hedge accounting treatment,\" as stated in Note 19 of the 2023 filing. Consequently, gains and losses associated with these instruments are now recognized directly in earnings rather than being recorded in Accumulated Other Comprehensive Income (AOCI), altering their strategic use from hedging to direct market exposure management.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect and introduces significant factual inaccuracies not present in the ground truth. (1) The original answer states that in 2022, aluminum purchase agreements were described as derivative instruments for strategic sourcing and non-U.S. business needs, and in 2023, the company clarified that contract quantities offset each other and are priced at market rates. The LLM answer falsely claims that in 2022 these were classified as cash flow hedges and that in 2023 they were excluded from hedge accounting—this specific shift is not mentioned in the ground truth. (2) There are no numeric values in the question or ground truth to verify, but the LLM invents a material change in accounting treatment (hedge to non-hedge) with reference to 'Note 19 of the 2023 filing' that is not supported by the provided truth. (3) The multi-hop reasoning is flawed: instead of identifying the evolution in classification and strategic use based on offsetting positions and market pricing, the LLM fabricates a narrative around hedge accounting changes. (4) While the answer is relevant to the topic of aluminum purchase agreements and their strategic use, it misrepresents the nature of the evolution. The contextual relevance is moderate because it addresses the right topic and timeframe, but the core facts are incorrect. The original answer emphasizes refinement in transparency and market alignment; the LLM incorrectly frames it as an accounting policy shift. Thus, the correctness score is low due to major factual and reasoning errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1316,
        "completion_tokens": 426,
        "total_tokens": 1742
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How has the disclosure or treatment of the Directors' Code of Conduct evolved between 2023 and 2024, particularly in terms of its accessibility and scope?",
      "original_answer": "In 2023, the Directors' Code of Conduct was explicitly referenced and posted on the company's website at a specific URL: https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/inv relations/directors-code-of-conduct.pdf. In 2024, the URL for the Directors' Code of Conduct changed to https://www.bny.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-ofconduct.pdf, indicating a shift in how the document is categorized or accessed. Additionally, in 2024, the company introduced a new section titled 'INSIDER TRADING POLICIES AND PROCEDURES,' which was not present in 2023, suggesting an expanded focus on compliance mechanisms beyond the Code itself. These changes reflect a transformation in the presentation and accessibility of the Directors' Code of Conduct, as well as an increased emphasis on insider trading compliance.",
      "llm_answer": "The Directors' Code of Conduct has been more prominently featured and its accessibility improved in 2024, with explicit cross‑references to the filing (Item 10) and a clear statement that it is posted on the company website (https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-of-conduct.pdf).  The 2024 filing also emphasizes that any amendments or waivers to the Code (including for executive officers) will be disclosed on the website, underscoring a broader scope and greater transparency compared with the 2023 filing, which only mentioned the existence of a Directors' Code of Conduct without detailing its public disclosure policy.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies that the Directors' Code of Conduct was more prominently featured and accessible in 2024, with a URL provided for public access, and notes an improved disclosure policy regarding amendments and waivers. However, it contains inaccuracies when compared to the ground truth. First, the URL cited in the LLM answer (https://www.bnymellon.com/...) is the 2023 URL, not the updated 2024 version (https://www.bny.com/...), which reflects a domain and path change indicating reorganization of document hosting—this is a factual error. Second, while the LLM emphasizes enhanced transparency around amendments and waivers, it omits the key factual addition in 2024: the new 'INSIDER TRADING POLICIES AND PROCEDURES' section, which expands the scope beyond just disclosure practices. This omission affects completeness and qualitative accuracy. The reasoning is partially sound—there is correct synthesis around increased transparency—but fails to capture the structural and content changes (new section, URL shift) that define the evolution. The answer is contextually relevant and correctly frames the trend toward greater accessibility and scope, but misses critical specifics required for full factual alignment. Quantitative accuracy is high because no numerical data is misstated (no numbers involved), though the URL is technically a factual identifier that was incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 387,
        "total_tokens": 1773
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How has the structure and value of HD's 4.95% Senior Notes evolved between 2023 and 2024, and what does this indicate about the company's long-term debt strategy?",
      "original_answer": "In 2023, HD issued $750 million of 4.95% senior notes due September 30, 2026, at a discount of $1.6 million. By 2024, the carrying amount of these 4.95% senior notes due September 2026 was $747 million as of February 2, 2025, and the company also reported $980 million in 4.95% senior notes due September 2052. This indicates that while the original 2026 notes remained outstanding with only a slight reduction in carrying value, HD expanded its 4.95% senior note structure to a much longer maturity in 2052, suggesting a strategy of extending debt maturities and potentially locking in fixed interest rates over a longer horizon.",
      "llm_answer": "Between 2023 and 2024, HD issued new senior notes with maturities extending to 2054 and beyond, including a $750 million 4.95% tranche due 2026 and a $750 million 4.90% tranche due 2029, while repaying its $1.1 billion 3.75% senior notes in February 2024. This issuance expanded the company’s long‑term debt profile and increased total long‑term debt from $42.15 billion (as of Jan 28 2024) to $53.07 billion (as of Feb 2 2025), reflecting a strategic shift toward longer‑dated financing and greater reliance on capital markets to fund growth initiatives.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, HD issued $750 million of 4.95% senior notes due 2026 in 2023 at a discount of $1.6 million, and by 2024, the carrying amount was $747 million (consistent with amortization of the discount). Additionally, HD issued $980 million in 4.95% senior notes due 2052. The LLM incorrectly states that HD issued a $750 million 4.95% tranche due 2026 (partially correct) and a $750 million 4.90% tranche due 2029 (not mentioned in ground truth), and claims maturities extending to 2054 (ground truth says 2052). The LLM also incorrectly reports total long-term debt increasing from $42.15 billion to $53.07 billion, which is not supported by the original answer and introduces data not present in the ground truth. (2) Key numbers are wrong: the 2052 note amount is $980 million (not $750 million at 4.90% due 2029), and no repayment of $1.1 billion 3.75% notes is mentioned in the ground truth. The LLM fabricates specific tranches and maturities. (3) The multi-hop reasoning is flawed: while the LLM correctly infers a strategy of extending maturities, it does so based on incorrect data. The ground truth shows HD extended the same coupon (4.95%) to 2052, indicating rate locking; the LLM invents different coupons and maturities, undermining the validity of its conclusion. (4) Scores reflect major quantitative errors (2/10), poor qualitative accuracy due to incorrect entities and reasoning (3/10), moderate contextual relevance as it addresses debt strategy (6/10), and low overall correctness (3/10) due to fabricated data despite touching on the general theme of long-term financing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1300,
        "completion_tokens": 460,
        "total_tokens": 1760
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did Intel's financial treatment and valuation of its investment in Beijing Unisoc Technology Ltd. evolve between 2021 and 2023, particularly in terms of observable price adjustments and net book value?",
      "original_answer": "In 2021, Intel recognized $471 million in observable price adjustments in its investment in Beijing Unisoc Technology Ltd. By the end of 2023, Intel was accounting for its interest in Unisoc as a non-marketable equity security, with a net book value of $1.1 billion as of December 30, 2023 (the same as December 31, 2022). This indicates that while Intel continued to hold the investment without marketability, the valuation remained stable over the two-year period despite the earlier price adjustment.",
      "llm_answer": "Intel's investment in Beijing Unisoc Technology Ltd. was initially recorded at a net book value of $1.1 billion as of December 30 2023, reflecting observable price adjustments of $471 million recognized in 2021. Subsequent filings show that the valuation allowance for related deferred tax assets increased from $2.259 billion (Dec 31 2022) to $3.047 billion (Dec 30 2023), indicating a growing uncertainty about the recoverability of those tax assets. Consequently, the net book value of the Unisoc investment remained essentially unchanged at $1.1 billion between 2022 and 2023, while the associated deferred tax asset valuation allowance rose, suggesting a deteriorating financial treatment of the investment over the period.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $471 million observable price adjustment in 2021 and the $1.1 billion net book value as of December 30, 2023, which aligns with the ground truth. However, it introduces new information not present in the original answer — specifically, the increase in the valuation allowance for deferred tax assets from $2.259 billion to $3.047 billion — which, while potentially factual, is not part of the documented evolution of the investment’s financial treatment and valuation per the ground truth. This shifts the interpretation toward deteriorating financial treatment due to tax asset concerns, which is not supported in the original answer. (2) The numeric values for the investment ($471M adjustment, $1.1B book value) are accurate and correctly dated. However, the deferred tax figures are extraneous and not mentioned in the ground truth, introducing potential misdirection. There are no calculation errors, but the synthesis includes unsupported inferences. (3) The multi-hop reasoning is partially sound — it correctly links the 2021 adjustment to the 2023 book value — but fails to emphasize the key point from the ground truth: that the valuation remained stable over 2022–2023 *despite* the earlier adjustment, indicating consistent carrying value. Instead, it suggests deterioration due to tax allowances, which is a different financial concept and not directly tied to the investment’s valuation. (4) The correctness score is 5 due to partial factual accuracy but significant deviation in interpretation. Quantitative accuracy is 6 because core numbers are correct but supplemented with unverified figures. Qualitative accuracy is 5 due to flawed reasoning and introduction of irrelevant metrics. Contextual relevance is 8 because the answer addresses the investment’s valuation over time, though with misplaced emphasis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 509,
        "total_tokens": 1831
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did AbbVie's engagement with Qulipta evolve from 2022 to 2023, particularly in terms of its regulatory and commercial development status?",
      "original_answer": "In 2022, Qulipta was part of a group of products that received regulatory approvals, leading to the reclassification of $1.0 billion of indefinite-lived research and development intangible assets to developed product rights. By 2023, AbbVie had introduced Qulipta with specific regulatory milestones: it received FDA approval in April 2023 for the preventive treatment of chronic migraine in adults and EC approval in August 2023 for the preventive treatment of migraine in adults with four or more migraine days per month. This evolution reflects a shift from asset reclassification to active regulatory and commercial advancement.",
      "llm_answer": "From 2022 to 2023, AbbVie’s engagement with Qulipta evolved from a recently approved migraine drug (launched in April 2023) to a commercially expanding product: the company secured EU approval for Produodopa (ABBV‑951) in January 2024 and continued to drive uptake with the EC’s approval of Aquipta (Qulipta) for migraine prevention in August 2023. These regulatory milestones, together with strong revenue growth (Qulipta’s total net sales rose sharply in 2023), indicate that Qulipta moved from a newly approved therapy to a growing, revenue‑generating asset during this period.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. First, it incorrectly states that Qulipta was launched in April 2023, while the ground truth indicates that FDA approval was granted in April 2023—launch timing is not specified. More critically, the LLM confuses Qulipta with other AbbVie products: it claims EU approval for 'Produodopa (ABBV-951)' in January 2024, which is unrelated to Qulipta, and refers to 'Aquipta (Qulipta)', a non-existent name variant (correct name is Qulipta, generic name atogepant). While the August 2023 EC approval for Qulipta is correctly mentioned, it is misrepresented as 'Aquipta'. (2) The ground truth does not mention revenue figures or sales growth for Qulipta in 2023, so the claim of 'strong revenue growth' and 'sharp rise in net sales' is unsupported and likely fabricated. The $1.0 billion reclassification of intangible assets in 2022—a key point in the original answer—is entirely omitted. (3) The multi-hop reasoning is flawed: the model fails to connect the 2022 asset reclassification (a key regulatory/financial milestone) to the 2023 commercial approvals. Instead, it introduces irrelevant products and mislabels the drug, indicating poor entity tracking and synthesis across years. (4) Despite these issues, the answer captures the general direction of progress—Qulipta advanced in regulatory approvals from 2022 to 2023—and correctly identifies the August 2023 EC approval, albeit with a naming error. This partial alignment with the timeline and regulatory theme justifies a moderate contextual relevance and qualitative score, but the quantitative inaccuracies and hallucinated details severely undermine correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 461,
        "total_tokens": 1762
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How has Boeing's framing and strategic emphasis on 'upgrades and conversions' within the Global Services segment evolved between 2022 and 2023, based on the language used in the 10-K filings?",
      "original_answer": "In 2022, 'upgrades and conversions' were listed as part of a broader set of services under the Global Services segment, grouped alongside supply chain logistics, engineering, maintenance, spare parts, training systems, technical documents, and digital services. The description was general and lacked strategic framing. In 2023, while the service was still included, the context shifted subtly: it was now positioned within a more structured narrative that emphasized the full spectrum of sustaining aerospace platforms and systems, indicating a more integrated and strategic role within the segment. This evolution suggests a more deliberate positioning of 'upgrades and conversions' as a core capability rather than a general service offering.",
      "llm_answer": "Between 2022 and 2023, Boeing’s framing of \"upgrades and conversions\" within Global Services shifted from a general mention of upgrades and conversions as part of its service offerings to a more explicit strategic emphasis on these activities as core growth drivers. In the 2022 filing, upgrades and conversions were noted only in passing within the broader description of Global Services' product suite (e.g., \"upgrades and conversions\" listed alongside maintenance and engineering), while the 2023 filing elevated them to a standalone strategic priority, highlighting their role in \"growing market share\" and \"leveraging a high level of customer satisfaction\" to drive revenue expansion in a competitive market. This evolution reflects a deliberate shift from passive service provision to active commercialization of conversion and upgrade solutions as a key differentiator for Global Services.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies a shift in Boeing's framing of 'upgrades and conversions' between 2022 and 2023 within the Global Services segment and accurately references the general context from both years. It correctly notes that in 2022, the service was mentioned alongside other offerings without strategic emphasis. However, the LLM overstates the evolution by claiming that in 2023, 'upgrades and conversions' were elevated to a 'standalone strategic priority' and explicitly tied to 'growing market share' and 'leveraging customer satisfaction' as growth drivers. The ground truth indicates a more subtle shift—while the 2023 framing placed the service within a more structured narrative around sustaining aerospace platforms, there is no evidence in the original data that it became a 'standalone' priority or was directly linked to market share growth or customer satisfaction in the 10-K. These additions represent interpretive leaps not supported by the source filings. There are no numerical inaccuracies (quantitative accuracy is high), and the response is contextually relevant. However, the qualitative inaccuracy in representing the degree and nature of strategic emphasis reduces the overall correctness. The core idea of a shift toward more strategic positioning is partially correct, but the specifics are exaggerated, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1421,
        "completion_tokens": 379,
        "total_tokens": 1801
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did Intel's financial relationship with Beijing Unisoc Technology Ltd. evolve between 2021 and 2023, particularly in terms of the valuation and recognition of this investment?",
      "original_answer": "Intel's financial relationship with Beijing Unisoc Technology Ltd. remained consistent in terms of total net book value, which stayed at $1.1 billion as of both December 25, 2021 (from the 2022 filing) and December 30, 2023 (from the 2023 filing). However, in 2021, Intel recognized $471 million in observable price adjustments related to its investment in Unisoc, indicating a revaluation event during that year. This type of valuation adjustment was not explicitly mentioned in the 2023 filing, suggesting a stabilization of the investment's value over time or a lack of significant observable price changes in 2023 compared to 2021.",
      "llm_answer": "Between 2021 and 2023, Intel’s investment in Beijing Unisoc Technology Ltd. was accounted for as a non‑marketable equity security. In 2021 the company recorded a $471 million observable price adjustment to the carrying value of the investment; by the end of 2023 the net book value of the stake had risen to $1.1 billion (up from $1.1 billion at the end of 2022). This growth reflects incremental observable price adjustments and the absence of any impairment, even though the investment remains subject to valuation allowances and uncertainty regarding future recoveries. Consequently, the valuation of Intel’s Unisoc holding increased from $1.1 billion in 2022 to $1.1 billion in 2023, with no material change in the underlying book value but continued recognition of the investment at its adjusted carrying amount.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains both correct and incorrect information. It correctly identifies the $471 million observable price adjustment in 2021 and the $1.1 billion net book value in 2023. However, it incorrectly states that the net book value 'rose to $1.1 billion' in 2023 'from $1.1 billion' in 2022, implying a change when the ground truth confirms the value was unchanged between 2021 and 2023. This misrepresents the stability of the valuation. Additionally, the claim that the 'growth reflects incremental observable price adjustments' is unsupported by the original answer, which notes no such adjustment was mentioned in 2023. (2) Quantitatively, the $471 million and $1.1 billion figures are accurate in amount but misused in context—no increase occurred between 2022 and 2023, so stating the value 'rose to' is factually misleading. The repetition of $1.1 billion as both starting and ending value framed as growth is a critical error. (3) The reasoning is partially sound in recognizing the investment as a non-marketable equity security and linking observable adjustments to carrying value, but it fails the multi-hop synthesis by not recognizing that the consistent $1.1 billion value across years (2021 and 2023) indicates no net change, contrary to the implication of growth. The original answer emphasizes stability post-2021, which the LLM overlooks. (4) Contextual relevance is high—the response addresses the evolution of valuation and recognition over time and focuses on the correct entities and metrics. However, due to the significant mischaracterization of a stable value as an increase, the correctness and quantitative accuracy scores are reduced to 5. The qualitative reasoning is somewhat accurate but flawed in conclusion, warranting a 6.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 483,
        "total_tokens": 1855
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the role of Self-Service Lockers evolved within Home Depot's interconnected shopping experience between 2023 and 2024?",
      "original_answer": "In 2023, Self-Service Lockers were described as part of Home Depot's investments to improve the customer shopping experience, specifically to enable convenient online order pickup options alongside other features like wayfinding signage and electronic shelf labels. By 2024, Self-Service Lockers were positioned more strategically as part of the company's broader fulfillment network, specifically referenced in the context of leveraging stores as 'convenient customer pickup, return, and delivery fulfillment locations' under interconnected retail programs such as BOSS, BOPIS, BODFS, and BORIS. Additionally, in 2024, approximately 50% of U.S. online orders were fulfilled through a store, highlighting a more integrated and operationally significant role for Self-Service Lockers in the fulfillment process. This reflects a shift from a convenience-focused feature to a core component of the omnichannel delivery strategy.",
      "llm_answer": "Between 2023 and 2024, Self-Service Lockers evolved from a component of Home Depot’s broader “interconnected shopping experience” into a more integrated fulfillment channel that directly supports online order pickup and curb‑side delivery. The 2023 fiscal discussion highlights their addition alongside other store‑level conveniences (e.g., online order storage areas, curbside service, electronic shelf labels) to streamline the customer journey, and the 2024 update notes that approximately 50 % of U.S. online orders were fulfilled through stores, with lockers positioned at store entrances to enable convenient self‑service retrieval. This expansion reflects a strategic focus on accelerating delivery speed, reducing friction, and leveraging store real estate to meet Pros and DIY customers’ expectations for fast, reliable pickup options.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and closely aligns with the ground truth. (1) All key facts are correct: the role of Self-Service Lockers evolved from a convenience feature in 2023 to a more integrated part of the fulfillment network in 2024, and the 50% figure for U.S. online orders fulfilled through stores is accurately cited. (2) Quantitative accuracy is perfect: the 50% metric matches the original answer exactly, and no incorrect numbers are introduced. (3) The multi-hop reasoning is sound—correctly synthesizing information across 2023 and 2024 to show strategic evolution. The LLM captures the shift from customer experience enhancement to operational integration within omnichannel fulfillment (e.g., BOPIS, BOSS), though it does not explicitly name all interconnected retail programs (BORIS, BODFS) mentioned in the original. (4) Wording differs slightly but maintains semantic equivalence: 'streamline the customer journey' and 'integrated fulfillment channel' effectively convey the shift from convenience to strategic importance. The only minor omission is the explicit mention of returns and delivery fulfillment beyond pickup, which slightly reduces completeness. Overall, the answer is factually correct, well-reasoned, and fully relevant to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1437,
        "completion_tokens": 355,
        "total_tokens": 1792
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the level of detail and specificity in Costco's disclosure regarding the estimation methods for Insurance/Self-insurance Liabilities evolved from 2023 to 2024?",
      "original_answer": "In 2023, Costco provided a general description of its self-insurance practices and risk management mechanisms, including the use of a captive insurance subsidiary and a reinsurance program, but did not specify the factors used in estimating liabilities. In 2024, the company significantly expanded its disclosure, detailing that liabilities are estimated using historical claims experience, demographic factors, severity factors, and other actuarial assumptions. Additionally, 2024's disclosure included a discussion of the unpredictability of claim costs and the potential for significant differences between actual and recorded liabilities, which was not present in 2023. This represents a meaningful increase in transparency and specificity.",
      "llm_answer": "The level of detail in Costco's disclosure regarding estimation methods for Insurance/Self-insurance Liabilities increased significantly from 2023 to 2024. In 2023, the disclosure briefly noted that liabilities were estimated using historical claims experience, demographic factors, severity factors, and other actuarial assumptions without elaboration on methodology or risk factors. By 2024, the disclosure expanded to explicitly detail the estimation process, including the use of historical claims experience, demographic and severity factors, and the potential for significant impact from future claim occurrences, expenses, or regulatory changes. It also clarified that liabilities are not discounted and are recorded in accrued salaries and benefits, with specific references to the captive insurance subsidiary and reinsurance program's role in the estimation framework. This evolution reflects a more transparent and structured approach to explaining the assumptions and risk factors underlying the liability estimates.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies a significant increase in disclosure detail from 2023 to 2024 and accurately notes the inclusion of historical claims experience, demographic factors, severity factors, and actuarial assumptions in the 2024 disclosures. However, it incorrectly states that these specific factors were mentioned in the 2023 filing, whereas the ground truth indicates they were not disclosed until 2024. This is a key factual error affecting the qualitative accuracy. The LLM also adds details not present in the original answer, such as liabilities being 'not discounted' and recorded in 'accrued salaries and benefits,' which, while potentially true, are not part of the ground truth and introduce unverified information. (2) There are no numerical values, dates, or calculations in the question or answers, so quantitative accuracy is not compromised—score is 10. (3) The multi-hop reasoning is partially sound: the model correctly infers increased transparency and identifies the evolution in disclosure. However, the misattribution of 2024-level detail to the 2023 filing breaks the logical synthesis across years, weakening the reasoning. (4) Contextual relevance is high—the response directly addresses the evolution of disclosure specificity and remains focused on the question. The correctness score is 7 because the core conclusion (increased detail) is correct, but key factual inaccuracies about what was disclosed in 2023 reduce overall accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1448,
        "completion_tokens": 412,
        "total_tokens": 1860
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How did the financial impact of the Aldevron acquisition on inventory-related costs evolve from 2022 to 2023?",
      "original_answer": "In 2022, the Aldevron acquisition contributed to a $59 million increase in cost of sales due to fair value adjustments to inventory. By 2023, this specific acquisition-related cost associated with Aldevron was no longer present; instead, a new $87 million charge emerged in the second quarter, primarily related to excess inventory in the Biotechnology segment due to reduced demand. This indicates a shift from acquisition-driven inventory adjustments to operational inventory challenges.",
      "llm_answer": "The financial impact of the Aldevron acquisition on inventory‑related costs shifted from a $59 million inventory fair‑value charge that was recorded in 2021 (included in cost of sales) to an $87 million inventory charge taken in the second quarter of 2023, which was reflected in cost of sales and contributed to the decline in gross profit margin. This evolution shows that inventory‑related costs associated with the acquisition were initially recognized as a one‑time charge in 2021 and later manifested as a larger, ongoing inventory charge in 2023.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors, particularly in the timeline. It incorrectly states that the $59 million inventory fair-value charge related to Aldevron was recorded in 2021, while the ground truth clearly states it occurred in 2022. This misalignment undermines the core of the multi-hop comparison across years. The $87 million charge in Q2 2023 is correctly identified in amount and timing. (2) Quantitative accuracy is partially correct: the $87 million figure is accurate and correctly attributed to Q2 2023, but the $59 million charge is misdated (2021 vs. actual 2022), which is a critical error in financial period attribution. No calculation is required, but the temporal misplacement distorts the evolution narrative. (3) Reasoning is flawed due to the incorrect year: the LLM suggests a shift from a 2021 acquisition charge to a 2023 operational charge, but the actual evolution is from 2022 to 2023—making the analysis of 'evolution' inaccurate. Additionally, the LLM implies ongoing inventory costs 'manifested' from the acquisition, while the ground truth clarifies that the 2023 charge was unrelated to Aldevron and instead due to operational issues (excess inventory from reduced demand). This misattributes the cause of the 2023 charge. (4) Contextual relevance is high—the answer addresses inventory-related costs, cost of sales, and gross profit impact, and attempts the year-over-year evolution analysis. However, due to incorrect dating and misattribution of the 2023 charge to the acquisition, the qualitative and overall correctness scores are significantly reduced.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1251,
        "completion_tokens": 444,
        "total_tokens": 1696
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has the treatment and recognition of shop card liabilities evolved between 2023 and 2024, and what does this indicate about Costco's approach to unclaimed balances?",
      "original_answer": "In both 2023 and 2024, Costco recognized revenue from shop cards upon redemption and accounted for outstanding balances as a liability, net of estimated breakage based on redemption data. However, the specific mention of 'estimated breakage' and the methodology tied to redemption data became more emphasized in 2024, indicating a more refined or formalized approach to tracking and accounting for unclaimed shop card balances. This evolution suggests Costco improved its estimation techniques for unclaimed balances, aligning its liability reporting more closely with actual redemption behavior over time.",
      "llm_answer": "The treatment of shop card liabilities remained consistent between 2023 and 2024, with the Company continuing to record outstanding shop card balances as a liability net of estimated breakage, included in other current liabilities. This approach reflects Costco's conservative accounting for unclaimed balances, recognizing revenue only upon redemption while systematically accounting for expected breakage based on historical redemption patterns.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns well with the ground truth in terms of entity accuracy, accounting treatment, and overall reasoning. It correctly identifies that Costco continued to recognize shop card liabilities as a liability net of estimated breakage in both 2023 and 2024, with revenue recognized upon redemption—this matches the original answer. The mention of 'historical redemption patterns' aligns with the ground truth's reference to redemption data. However, the LLM answer does not explicitly note the evolution in emphasis or refinement of methodology in 2024, which is a key differentiator in the original answer. While it states the treatment 'remained consistent,' it omits the increased emphasis on estimated breakage and more formalized approach in 2024, which indicates a subtle but meaningful shift in Costco's accounting practice. This missing nuance prevents a perfect score on qualitative accuracy and overall correctness, though all presented facts are accurate and contextually relevant. There are no numerical inaccuracies (quantitative accuracy is perfect), and the response directly addresses the question's focus on accounting treatment and implications for unclaimed balances.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1268,
        "completion_tokens": 342,
        "total_tokens": 1610
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has Intel's Foundry Services offering evolved from 2022 to 2023 in terms of strategic partnerships and customer engagement, based on the specific initiatives and agreements mentioned in those years?",
      "original_answer": "In 2022, Intel introduced its Foundry Services as part of the IDM 2.0 strategy, emphasizing plans to build a world-class foundry business with differentiated offerings, including leading-edge packaging and process technology, committed capacity in the US and Europe, and a strong IP portfolio. By 2023, Intel had significantly advanced this offering by securing four design wins on Intel 18A, including a major high-performance computing customer, and five new design wins in advanced packaging, particularly for AI-related designs. Additionally, Intel expanded its IFS Accelerator Ecosystem Alliance program to over 40 strategic agreements and entered into multigenerational agreements with ARM and Synopsys to enable optimized SoC design on Intel 18A. These developments indicate a shift from strategic intent in 2022 to concrete customer engagements and ecosystem partnerships in 2023.",
      "llm_answer": "From 2022 to 2023 Intel’s Foundry Services evolved from a nascent offering into a more mature, partnership‑driven business. In 2022 the company announced its IDM 2.0 strategy and began building capacity (e.g., $20 B Ohio fab), while early 2023 updates highlighted design wins on the 18A node, expanded packaging capacity, and a growing IFS Accelerator ecosystem of >40 EDA and IP partners (including ARM and Synopsys). These initiatives deepened customer engagement, positioning Intel’s foundry as a strategic, open‑system service for AI and other high‑growth workloads.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of Intel's Foundry Services from 2022 to 2023. (1) It correctly identifies the launch of IDM 2.0 in 2022 as the strategic foundation and notes capacity investments like the $20B Ohio fab (contextually accurate, though not explicitly in the ground truth). In 2023, it highlights key developments: design wins on Intel 18A, expanded packaging, and the IFS Accelerator Ecosystem with over 40 partners, including ARM and Synopsys—matching the ground truth’s emphasis on ecosystem growth and multigenerational agreements. (2) Quantitatively, the mention of >40 EDA and IP partners aligns with 'over 40 strategic agreements' in the original. The $20B Ohio investment is plausible and contextually relevant (publicly reported), though not part of the provided ground truth; its inclusion does not contradict but adds context. No calculation errors. (3) Multi-hop reasoning is sound: the model synthesizes strategic intent (2022) with concrete customer engagements (2023), correctly inferring a maturation trajectory. It links ARM and Synopsys to ecosystem expansion and design enablement, consistent with the ground truth’s 'multigenerational agreements to enable optimized SoC design.' (4) Minor omission: the ground truth specifies 'four design wins on Intel 18A' and 'five new design wins in advanced packaging,' which the LLM mentions only generally. This slight lack of specificity prevents a perfect score, but overall semantic equivalence is strong. The answer is fully relevant and well-structured.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 427,
        "total_tokens": 1806
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How did the financial impact of DHR's relationship with Aldevron evolve between 2022 and 2023, particularly in terms of goodwill and net cash consideration?",
      "original_answer": "In 2022, DHR preliminarily recorded approximately $6.1 billion of goodwill related to the Aldevron Acquisition. By 2023, the net cash consideration for Aldevron increased to $9.561 billion, indicating a more detailed or revised financial assessment of the acquisition. This evolution shows a significant increase in the financial commitment to the Aldevron relationship, particularly in terms of cash outlay, beyond the initial goodwill estimate provided in 2022.",
      "llm_answer": "Between 2022 and 2023, the financial impact of DHR's relationship with Aldevron shifted from a $6.1 billion goodwill balance recorded at the 2021 acquisition to a $389 million goodwill balance in 2022, reflecting the initial acquisition accounting and subsequent adjustments. By 2023, the net cash consideration tied to the Aldevron transaction remained at $5.61 billion (the same amount recorded in 2022), while the associated goodwill had been reduced to $389 million, indicating that the goodwill recognized in 2021 was largely written down or re‑allocated in the following years. Consequently, the evolution shows a substantial decline in goodwill exposure and a stable net cash outflow linked to the Aldevron acquisition over the two‑year period.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains almost no correct factual information compared to the ground truth. It incorrectly states that goodwill was reduced from $6.1 billion in 2021 to $389 million in 2022, while the original answer states that DHR recorded approximately $6.1 billion of goodwill in 2022 related to the Aldevron acquisition. There is no mention of a $389 million goodwill figure or any write-down in the ground truth. Additionally, the LLM claims net cash consideration remained at $5.61 billion in both 2022 and 2023, which directly contradicts the ground truth stating that net cash consideration increased to $9.561 billion in 2023. (2) All key numbers are incorrect: goodwill is misrepresented in amount and trend, and net cash consideration is significantly understated. The calculation of financial evolution is therefore completely inaccurate. (3) The multi-hop reasoning is flawed—the LLM fabricates a narrative of declining goodwill and stable cash consideration, whereas the correct reasoning should show an increase in financial commitment, particularly in cash outlay, from 2022 to 2023. The model fails to synthesize the correct timeline and financial progression of the acquisition accounting. (4) The contextual relevance is low but not zero because the answer addresses the right companies (DHR, Aldevron) and the general topic (acquisition accounting, goodwill, cash consideration), but the factual inaccuracies render the response misleading and incorrect. Scores are low due to complete failure on quantitative accuracy and reasoning, with minimal credit for attempting the right topic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 444,
        "total_tokens": 1750
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the maturity date of the AT&T Inc. 1.800% Global Notes changed between the 2022 and 2024 SEC filings, and what does this indicate about the company's debt structure evolution?",
      "original_answer": "In the 2022 SEC filing, the AT&T Inc. 1.800% Global Notes were due on September 5, 2026. In the 2024 filing, the same class of notes is listed with a maturity date of September 14, 2039. This indicates a significant shift in the company's debt structure, extending the maturity of this particular note by over 13 years.",
      "llm_answer": "The maturity date of AT&T's 1.800% Global Notes was September 5, 2026 in the 2022 filing and was updated to September 5, 2039 in the 2024 filing. This extension reflects AT&T’s strategy of lengthening debt tenors to improve liquidity and reduce near‑term refinancing pressure, indicating a shift toward a more staggered and longer‑dated debt profile.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the 2022 maturity date (September 5, 2026) and captures the extension to a 2039 maturity, but reports it as September 5, 2039 instead of the correct September 14, 2039 from the 2024 filing. This minor date discrepancy affects quantitative accuracy but does not alter the overall conclusion. (2) The extension is correctly interpreted as a significant lengthening of debt maturity—over 13 years—which aligns with the ground truth. The calculation of the extension duration is approximately correct (13 years vs. actual ~13 years and 9 days). (3) The multi-hop reasoning is sound: the model synthesizes data across 2022 and 2024 filings for the same class of notes (1.800% Global Notes), correctly tracks the change, and infers strategic intent (reducing refinancing pressure, improving liquidity). (4) The qualitative interpretation about AT&T’s debt strategy is reasonable and consistent with the implications in the original answer. Entity accuracy (AT&T Inc., 1.800% Global Notes, correct years) is fully correct. The answer is contextually excellent and addresses both parts of the question. The 2-point deduction in correctness is due to the incorrect day in the 2039 maturity date, which is a factual inaccuracy, though not material to the broader conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1176,
        "completion_tokens": 366,
        "total_tokens": 1542
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has Target's compliance with its debt leverage covenant evolved between 2023 and 2024, and what changes in credit facility structure may have influenced this compliance?",
      "original_answer": "In 2023, Target stated that it was, and expected to remain, in compliance with its debt leverage covenant, which was part of a $1.0 billion 364-day credit facility that would expire in October 2024, along with a $3.0 billion five-year facility expiring in October 2028. By 2024, Target had renewed its 364-day credit facility, extending its expiration to October 2025, while maintaining the same $3.0 billion five-year facility. The company continued to assert compliance with the debt leverage covenant. The renewal of the 364-day facility likely provided continued flexibility, supporting Target’s ability to remain compliant with the covenant.",
      "llm_answer": "Target's compliance with its debt leverage covenant improved between 2023 and 2024, as evidenced by a reduction in long-term debt from $16,009 million (as of January 28, 2023) to $14,922 million (as of February 3, 2024), while the required principal payments remained relatively stable. This improvement was likely influenced by the restructuring of its credit facilities, including the termination of the prior 364-day credit facility in October 2023 and the amendment of its $3.0 billion five-year revolving credit facility (now expiring in October 2028), which provided a more stable liquidity backstop and may have contributed to better leverage ratios.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly identifies the $3.0 billion five-year facility expiring in 2028, it incorrectly states that the 364-day facility was 'terminated' in October 2023 and 'amended'—in reality, it was renewed and extended to October 2025, not terminated. The LLM also fabricates a reduction in long-term debt from $16,009 million to $14,922 million as a basis for improved compliance, but the ground truth does not mention any such debt reduction or specific leverage ratio changes. There is no evidence in the original answer that compliance 'improved'—only that Target remained compliant in both years. (2) The numbers cited for long-term debt ($16,009M and $14,922M) do not appear in the ground truth and are therefore unverified and likely incorrect in this context. The dates (January 28, 2023, and February 3, 2024) are plausible fiscal year-ends but are not referenced in the original answer and are used to support a narrative not present in the ground truth. (3) The multi-hop reasoning is flawed: the LLM infers improved compliance due to debt reduction and facility restructuring, but the original answer only confirms continued compliance and renewal of the 364-day facility without any performance improvement. The causal link between credit facility changes and leverage ratio is speculative and not supported by the ground truth. (4) The contextual relevance is moderate because the answer addresses debt covenants and credit facilities, but the specific claims about debt reduction, facility termination, and improved compliance are incorrect or unsupported, leading to a low correctness score despite some relevant terminology.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1332,
        "completion_tokens": 467,
        "total_tokens": 1799
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has Intel's approach to expanding digital readiness for global populations evolved from 2022 to 2023, particularly in relation to its RISE strategy and external collaboration initiatives?",
      "original_answer": "In 2022, Intel committed to expanding digital readiness through its RISE strategy, focusing on collaborative initiatives with other technology companies via the Alliance for Global Inclusion to create an Inclusion Index with unified goals and metrics. By 2023, this effort had matured into the publication of the third global inclusion index survey, which transitioned into an index system where organizations scoring 50% or higher were formally recognized. Intel was among the 18 recognized organizations out of 27 respondents, indicating a more structured and outcome-focused approach to digital readiness and inclusion. This evolution reflects a shift from establishing collaborative frameworks to measuring and recognizing performance against defined benchmarks.",
      "llm_answer": "Intel’s approach to expanding digital readiness has moved from a focus on internal talent development and workforce inclusion metrics (e.g., diversity goals, pay equity, and employee experience surveys) in 2022 toward a broader, externally‑oriented RISE strategy in 2023.  The 2023 disclosures highlight new collaborations such as the Alliance for Global Inclusion’s Inclusion Index, expanded partnerships with historically Black colleges and universities, and the scaling of AI‑for‑Youth and AI‑for‑Workforce programs that partner with governments to build digital‑readiness pipelines worldwide.  This evolution reflects Intel’s shift from primarily measuring progress through internal compensation and representation targets to leveraging cross‑industry coalitions and multi‑year education initiatives that aim to accelerate digital readiness for millions of people globally.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general direction of Intel's evolution in digital readiness from 2022 to 2023 and correctly references the RISE strategy and external collaboration initiatives, showing contextual relevance. However, it introduces significant inaccuracies. First, it incorrectly frames Intel's 2022 efforts as focused on 'internal talent development and workforce inclusion metrics,' which contradicts the ground truth stating that in 2022, Intel was already engaged in external collaboration via the Alliance for Global Inclusion to create an Inclusion Index. The ground truth does not mention internal metrics as the primary focus in 2022. Second, the LLM answer cites expanded partnerships with historically Black colleges and universities (HBCUs), AI-for-Youth, and AI-for-Workforce programs with governments—details not present in the original answer and unsupported by the provided knowledge graph. These additions introduce factual hallucinations. Quantitatively, the answer fails to mention the key metric from 2023: the third global inclusion index survey, the 27 respondents, the 50% benchmark, and Intel being one of 18 recognized organizations. These missing numbers and benchmarks represent a major omission in quantitative accuracy. While the LLM identifies a strategic shift toward external collaboration, it misrepresents the nature and timeline of that evolution, undermining the qualitative accuracy. The reasoning is partially sound in identifying a shift from framework-building to broader initiatives, but it does not accurately reflect the actual progression from collaborative framework (2022) to measurement and recognition system (2023). Thus, while the answer is relevant and directionally aware, it lacks factual precision and introduces unverified details, resulting in a partial correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1422,
        "completion_tokens": 495,
        "total_tokens": 1917
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How did Emerson's relationship with Micromine evolve between 2023 and 2024, and what financial implications were associated with this change?",
      "original_answer": "In 2023, Emerson (via its AspenTech subsidiary) entered into an agreement to acquire Micromine for AU$900 (approximately $623 USD), but later terminated the agreement due to uncertainty around Russian regulatory approval. This led to a mark-to-market gain of $24 in 2023 related to foreign currency forward contracts tied to the Micromine acquisition. By 2024, AspenTech had terminated all outstanding foreign currency forward contracts associated with the Micromine deal. The termination of the Micromine acquisition represented a shift from a strategic expansion effort in 2023 to a full withdrawal from the transaction, with no further financial commitments or exposures to Micromine reported in 2024.",
      "llm_answer": "Emerson sold its 40 % non‑controlling equity stake in Copeland in August 2024 for $1.5 billion, generating a $539 pretax gain ($435 after‑tax) that is reported in discontinued operations. This divestiture also brought in $1.9 billion from the sale of the related note receivable, and the proceeds were reflected in cash from investing activities for Climate Technologies in 2024. The transaction marked a shift from holding the equity interest (which had generated equity‑method losses and required tax payments in 2023) to cashing out the stake, resulting in a substantial one‑time gain and a significant inflow of cash for Emerson.",
      "correctness_score": 0,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 1,
      "detailed_feedback": "The LLM answer is completely incorrect and irrelevant to the question. (1) It discusses Emerson's sale of a 40% stake in Copeland in August 2024, which has no relation to the Micromine transaction or AspenTech. The original question asks about Emerson's relationship with Micromine in 2023–2024, but the LLM response does not mention Micromine at all. (2) The numbers provided—$1.5 billion sale price, $539 million pretax gain, $435 million after-tax gain, $1.9 billion from note receivable—are all fabricated in the context of this question and do not appear in the ground truth. There is no mention of AU$900 million (~$623 million USD) or the $24 mark-to-market gain from foreign currency contracts in 2023, which are key facts. (3) The multi-hop reasoning is entirely missing: the LLM fails to connect Emerson → AspenTech → Micromine acquisition attempt → termination due to Russian regulatory issues → financial impacts (gain from terminated hedges). Instead, it invents a different transaction (Copeland divestiture) with no basis in the provided truth. (4) The answer receives the lowest scores because it addresses a completely different event, uses incorrect entities, provides false financial data, and fails to engage with the actual subject matter. Contextual relevance is minimal as the response is off-topic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 366,
        "total_tokens": 1699
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How did the availability of shares under The Home Depot's U.S. Employee Stock Purchase Plan (ESPP) and the average purchase price of shares during the fiscal year change from 2022 to 2023?",
      "original_answer": "In 2022, there were approximately 17 million shares available under the U.S. ESPP, and associates purchased approximately one million shares at an average price of $305.14. In 2023, the number of shares available under the U.S. ESPP decreased to 15 million, and associates again purchased approximately one million shares, but at a lower average price of $277.19. This indicates a reduction in share availability and a notable decrease in the average purchase price during the fiscal year.",
      "llm_answer": "The Home Depot’s ESPP allowed 15 million U.S. shares and 18 million non‑U.S. shares to be purchased at 85 % of market price; in fiscal 2023 about 1 million shares were bought at an average price of $277.19.  By contrast, the 2022 filing shows roughly 17 million U.S. shares and 19 million non‑U.S. shares available, with approximately 1 million shares purchased at an average price of $305.14.  Thus, the number of shares available under the ESPP remained essentially unchanged, but the average purchase price fell from roughly $305 in 2022 to about $277 in 2023.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the number of U.S. shares available in 2022 (17 million) and 2023 (15 million), as well as the approximately 1 million shares purchased each year and the correct average purchase prices ($305.14 in 2022 and $277.19 in 2023). However, it introduces non-U.S. shares (18 million in 2023 and 19 million in 2022), which are irrelevant to the question about the U.S. ESPP, potentially confusing the response. More critically, it incorrectly states that the number of shares available 'remained essentially unchanged,' which contradicts the factual decrease from 17 million to 15 million. (2) Numeric values for U.S. shares and average prices are accurate and match the ground truth, but the inclusion of non-U.S. shares and the erroneous conclusion about stability in availability reduce quantitative precision. Calculations are not required, but comparisons must be accurate—here, the direction of change (decrease in availability) is misrepresented. (3) The multi-hop reasoning is partially sound—information is pulled from both years and the correct purchase data is used—but the synthesis fails because the conclusion mischaracterizes the change in share availability. The focus should have been solely on U.S. ESPP shares, but the model conflates U.S. and non-U.S. data, weakening the logic. (4) The answer is contextually relevant and addresses both parts of the question (share availability and average price), but the incorrect interpretation of the trend in share availability and inclusion of extraneous data reduce factual correctness. The average price decrease is correctly noted. Overall, the answer is partially correct but contains significant reasoning and factual interpretation errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1273,
        "completion_tokens": 476,
        "total_tokens": 1749
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has the pattern of impairment triggers and associated charges across DHR's business segments evolved between the 2022 and 2023 filings, and what does this indicate about shifting risks in its intangible asset portfolio?",
      "original_answer": "In the 2022 filing, DHR reported impairment triggers only in the Diagnostics segment during the first quarter of 2021, resulting in a $10 million impairment charge. In contrast, the 2023 filing identified impairment triggers in multiple segments: the Biotechnology segment in the second quarter of 2023, the Diagnostics and Biotechnology segments in the fourth quarter of 2023, and again in the Diagnostics segment in the first quarter of 2021 (which was included for comparative purposes). The impairment charges increased significantly, from $10 million in 2021 (reported in the 2022 filing) to $77 million in 2023 (reported in the 2023 filing). This indicates a notable expansion in both the scope and magnitude of impairment activity, particularly affecting the Biotechnology segment in 2023, which was not previously a focus of impairment events. This evolution suggests growing risks in DHR’s intangible asset portfolio, especially in its Biotechnology segment.",
      "llm_answer": "The pattern of impairment triggers and associated charges shows a shift in risk across DHR's segments between 2022 and 2023. In 2022, there were no impairment charges on intangible assets, but in 2023 the Company recorded $77 million in impairment charges related to long-lived assets in the Biotechnology and Diagnostics segments, specifically triggered during the second quarter of 2023 in Biotechnology and the fourth quarter of 2023 in Diagnostics. This indicates a significant increase in risk related to intangible assets within these segments, particularly as the Company identified impairment triggers in its Biotechnology segment earlier in 2023 compared to the Diagnostics segment's triggers in 2021 and 2023.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly regarding the 2022 filing. It states that 'in 2022, there were no impairment charges on intangible assets,' which contradicts the ground truth stating that the 2022 filing reported a $10 million impairment charge in the Diagnostics segment from Q1 2021. This is a critical error in both entity accuracy and quantitative accuracy. Additionally, the LLM omits the fact that the 2023 filing includes the 2021 Diagnostics impairment for comparative purposes, which is relevant context. (2) The $77 million impairment charge in 2023 is correctly reported, as are the quarters and segments (Biotechnology in Q2 2023, Diagnostics and Biotechnology in Q4 2023). However, the failure to acknowledge the $10 million charge in the 2022 filing undermines the comparative analysis. The calculation of the increase from $10M to $77M is implied but not stated, and the omission of the earlier charge distorts the trend. (3) The multi-hop reasoning is partially sound—the model correctly identifies the expansion of impairment activity into the Biotechnology segment and links it to increased risk. However, it fails to fully synthesize the evolution across both filings, incorrectly portraying 2022 as having no impairments when in fact it did. This weakens the conclusion about shifting risks. (4) The contextual relevance is high—the answer addresses the core question about evolving patterns and risk shifts, uses appropriate terminology, and focuses on the right segments and timeframes. However, due to the major factual error about the 2022 filing and the resulting incomplete picture, the correctness and accuracy scores are significantly reduced. A score of 6 reflects partial correctness: key 2023 facts are right, but the foundational comparison with 2022 is flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1440,
        "completion_tokens": 500,
        "total_tokens": 1941
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did the value of outstanding letters of credit related to trade contracts change between 2022 and 2023, and what does this indicate about the company's involvement in business transactions tied to trade contracts?",
      "original_answer": "The value of outstanding letters of credit related to trade contracts increased from $362 million in 2022 to $598 million in 2023. This significant increase indicates a growing involvement or expansion in business activities tied to trade contracts during this period.",
      "llm_answer": "The outstanding letters of credit related to trade contracts decreased from $598 million in 2023 to $362 million in 2022, indicating a reduction in the company’s exposure to trade‑related contingent liabilities and suggesting that its involvement in business transactions tied to trade contracts has diminished.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer incorrectly reverses the direction of change in the value of outstanding letters of credit. The ground truth states an increase from $362 million in 2022 to $598 million in 2023, but the LLM claims a decrease from $598 million in 2023 to $362 million in 2022. While the dollar amounts are factually correct, their temporal assignment is reversed, leading to an incorrect conclusion. (2) Quantitatively, the numbers themselves ($362M and $598M) are accurate and match the ground truth, so the values are correct but misapplied to the years. No calculations (e.g., difference or growth rate) were required, but the comparison is inverted, which is a critical error. (3) The multi-hop reasoning fails because the model misinterprets the time-series trend, leading to an incorrect inference about the company's involvement in trade contracts. Instead of recognizing increased activity, it concludes diminished involvement, which contradicts the evidence. (4) Contextual relevance is moderate—the response addresses the right metric and makes a qualitative interpretation tied to business involvement—but the reversed trend undermines the validity of the conclusion. Due to the severe factual error in trend direction, the correctness score is low despite correct raw numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1162,
        "completion_tokens": 364,
        "total_tokens": 1526
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How has the status of the 0.300% Notes due 2028 evolved between the 2023 and 2024 SEC filings, and what does this indicate about IBM's financial instruments disclosures?",
      "original_answer": "In the 2023 filing, the 0.300% Notes due 2028 were disclosed as part of IBM's instruments defining the rights of holders, with specific reference to Exhibit 4.1, filed on February 10, 2020. In the 2024 filing, the 0.300% Notes due 2028 are listed as actively issued financial instruments under the trading symbol IBM28B, registered on the New York Stock Exchange. This indicates a shift from merely disclosing the existence of the instrument in 2023 to formally recognizing it as an actively traded financial instrument in 2024, suggesting increased market engagement or liquidity for this instrument.",
      "llm_answer": "The 0.300% Notes due 2028 were first listed in IBM’s 2023 filing (page 19) as “0.300%Notes due2028 IBM28B” and remained unchanged in the 2024 filing (page 1), where the same security appears under the identical description and ticker. This consistency shows that IBM’s disclosures about the instrument’s terms and existence have not been altered between the two filings, indicating stable and transparent reporting of its debt obligations.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth. (1) It claims the 0.300% Notes due 2028 were already listed with the ticker IBM28B in the 2023 filing, but the ground truth states that in 2023, the notes were only disclosed as part of instruments defining holders' rights via Exhibit 4.1 filed in 2020—not as a traded security. The 2024 filing is when the note first appears as an actively issued instrument under the ticker IBM28B on the NYSE. The LLM incorrectly asserts consistency between the two years, missing the key evolution entirely. (2) While the percentage (0.300%) and maturity year (2028) are correct, the LLM fabricates page numbers (page 19 in 2023, page 1 in 2024) not present in the ground truth, and falsely claims the ticker was used in both years. There are no calculations in this question, but the factual assertions about disclosure status are wrong. (3) The multi-hop reasoning fails: the question requires comparing the nature of disclosure across two filings to infer a change in status (from legal disclosure to active trading instrument), but the LLM denies any change occurred. This reflects a fundamental misunderstanding of the data. (4) The answer is contextually relevant in that it discusses IBM’s debt disclosures and the correct instrument, but the core factual claim is false. Hence, correctness and qualitative accuracy are very low, quantitative accuracy is low due to unsupported specifics, and contextual relevance is moderate due to topic alignment despite factual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 420,
        "total_tokens": 1685
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How has IBM's treatment of the 1.750% Notes due 2031 evolved between 2023 and 2024, particularly in terms of disclosure and registration on stock exchanges?",
      "original_answer": "In 2023, IBM disclosed the 1.750% Notes due 2031 in its 10-K filing, indicating that the instrument defining the rights of the holders was incorporated by reference as part of an exhibit filed on January 30, 2019. By 2024, the 1.750% Notes due 2031 were not only still referenced but also explicitly registered under a trading symbol (IBM31) on the New York Stock Exchange, reflecting a shift from mere disclosure to formal recognition and active listing on a financial market platform.",
      "llm_answer": "Between 2023 and 2024 IBM’s 1.750% Notes due 2031 remained disclosed in the same manner—listed among its senior unsecured debt securities in the “Securities registered pursuant to Section 12(b)” table of the 2024 Form 10‑K (page 2). The filing shows the notes are still registered on the New York Stock Exchange under the ticker “IBM31” and continue to be referenced through the same indenture exhibits that were previously filed (e.g., the 2019 Form 8‑K and 2023 Form 8‑K). No new registration or delisting was reported; the only change is the inclusion of the 2024 filing itself, confirming the notes remain registered and continue to trade on the exchange.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains several inaccuracies that contradict the ground truth. (1) The original answer states that in 2023, the 1.750% Notes due 2031 were only disclosed (incorporated by reference from a 2019 filing), but in 2024 they were newly registered on the NYSE under ticker IBM31—marking a shift from disclosure to formal listing. However, the LLM claims the notes were already registered under 'IBM31' in prior years and that 'no new registration' occurred, which directly contradicts the evolution described in the ground truth. (2) The LLM incorrectly asserts that the notes were already listed on the NYSE in 2023, but the ground truth indicates that the 2024 registration represents a change in status. (3) While the LLM correctly identifies the ticker symbol 'IBM31' and references to indenture exhibits, it mischaracterizes the nature of the change between years—portraying continuity instead of the actual progression from disclosure to formal exchange registration. (4) The answer is contextually relevant and includes appropriate details about Form 10-K, Section 12(b), and exhibit references, but the core reasoning about the evolution is flawed. (5) Quantitative elements (e.g., interest rate, maturity year, ticker) are accurate, earning moderate scores for quantitative and qualitative accuracy, but the failure to correctly represent the multi-hop evolution from 2023 to 2024 significantly undermines factual correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1288,
        "completion_tokens": 397,
        "total_tokens": 1685
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did Eli Lilly's financial relationship with Zyprexa evolve between 2023 and 2024, particularly in terms of revenue recognition and business model approach?",
      "original_answer": "In 2023, Eli Lilly generated $1.45 billion from the sale of the rights for the olanzapine portfolio, including Zyprexa, outside the U.S., indicating a direct revenue stream from product sales. By 2024, the company no longer reported Zyprexa as part of product sales; instead, revenue from the 2023 sale of rights was included in collaboration and other arrangements revenue, signaling a shift from direct product sales to revenue recognition through licensing and collaboration agreements. This change reflects a transformation in the financial relationship from active product sales to post-sale royalty or profit-sharing arrangements.",
      "llm_answer": "Eli Lilly's financial relationship with Zyprexa evolved significantly between 2023 and 2024, particularly in terms of revenue recognition and business model approach. In 2023, Zyprexa revenue was reported at $1,694.8 million (including the sale of the olanzapine portfolio rights), but this was preceded by a notable decline from $336.9 million in 2022, reflecting the impact of patent expiration and portfolio restructuring. The company recognized revenue from Zyprexa sales at the point of shipment, with adjustments for returns and rebates remaining minimal (less than 1% of U.S. revenue), consistent with its broader revenue recognition policy. However, the key evolution was the strategic sale of the olanzapine portfolio rights in 2023, which generated a one-time revenue boost (noted as part of \"Revenue of Zyprexa includes sale of the rights for the olanzapine portfolio\" in the 2023 revenue table), after which Zyprexa revenue ceased to be a standalone product line. By 2024, Zyprexa was no longer a significant revenue driver, as evidenced by the absence of Zyprexa in the 2024 revenue breakdown (which instead highlights products like Trulicity, Mounjaro, and Verzenio as primary revenue sources). The company's revenue model for legacy products like Zyprexa relied on contractual sales to wholesalers, with revenue recognized upon shipment, but the business model shifted decisively toward new products and collaborations post-2023, rendering Zyprexa's revenue trajectory obsolete.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. The ground truth states that Eli Lilly generated $1.45 billion from the sale of the olanzapine portfolio (including Zyprexa) rights outside the U.S. in 2023. However, the LLM claims Zyprexa revenue was $1,694.8 million in 2023, which does not match the ground truth and appears to conflate total product revenue with the one-time sale of rights. Additionally, the LLM introduces a $336.9 million figure for 2022, which is not present in the original answer and cannot be verified from the provided truth. These numerical discrepancies severely impact factual correctness. (2) The calculation and timing of the revenue recognition are partially correct—the LLM correctly identifies that the 2023 sale of rights led to a one-time revenue boost and that Zyprexa is no longer a standalone product line in 2024. However, it misrepresents the nature of the revenue shift: the original answer emphasizes that post-2023 revenue is now included in 'collaboration and other arrangements,' indicating ongoing royalty or profit-sharing, whereas the LLM implies Zyprexa revenue simply ceased, missing this key nuance. (3) The multi-hop reasoning is partially sound—LLM correctly infers a business model shift from product sales to collaborations and notes the absence of Zyprexa in 2024 revenue disclosures. However, it fails to explicitly state that revenue from the 2023 transaction is now recognized under collaboration revenue, which is a critical component of the financial relationship evolution. (4) Contextual relevance is high—the response directly addresses the question about revenue recognition and business model changes, uses appropriate financial terminology, and correctly situates the shift within broader portfolio strategy. Despite incorrect numbers and incomplete synthesis of the revenue classification change, the overall direction of the answer aligns with the ground truth. Hence, a correctness score of 5 reflects partial accuracy with major factual flaws.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1535,
        "completion_tokens": 559,
        "total_tokens": 2095
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How did the treatment and financial impact of the Mobility Preferred Interests evolve from 2023 to 2024, particularly in terms of redemption obligations and their effect on earnings per share calculations?",
      "original_answer": "In 2023, AT&T reclassified the Mobility Preferred Interests from equity to a liability due to the certainty of redemption, recording $2,670 in current liabilities and $2,670 in noncurrent liabilities. The company ultimately repurchased all remaining interests in April 2023 for $5,414, including accrued distributions. By 2024, the Mobility Preferred Interests were fully retired, and the focus shifted to their impact on earnings per share calculations, where under ASU 2020-06, the ability to settle these interests in stock was reflected in the diluted earnings per share computation for periods prior to the repurchase. This indicates a shift from active financial obligations to retrospective accounting treatment.",
      "llm_answer": "From 2023 to 2024, the Mobility Preferred Interests were fully redeemed in April 2023, eliminating any outstanding preferred interests and related liability. Consequently, there were no redemption obligations or earnings‑per‑share adjustments tied to these interests in 2024, whereas in 2023 the potential dilution from the un‑redeemed Mobility preferred interests (72 million shares) was reflected in the diluted EPS calculation before their repurchase.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the full redemption of Mobility Preferred Interests in April 2023 and the absence of obligations in 2024, aligning with the ground truth. However, it omits key quantitative details: the $2,670 split between current and noncurrent liabilities in 2023 and the total repurchase cost of $5,414. These omissions affect quantitative accuracy. The mention of '72 million shares' as potential dilution is not present in the original answer and lacks corroboration, introducing unverified data. (2) The original answer includes precise liability amounts and repurchase cost, which the LLM fails to report. While the April 2023 redemption date is correct, the financial magnitude of the transaction is missing, and the 72 million shares figure cannot be verified against the ground truth, potentially misleading. (3) The reasoning is logically sound—recognizing the shift from active liability to no obligation by 2024 and linking prior-period dilution impact to EPS calculations. It captures the multi-hop evolution from classification to redemption to accounting impact, though it misrepresents the basis of diluted EPS inclusion by citing unverified share count instead of referencing ASU 2020-06 as in the original. (4) The answer is contextually relevant and addresses both redemption obligations and EPS impact over the two years. Despite missing financial figures and introducing unsupported ones, the core narrative of resolution in 2023 and no ongoing effect in 2024 is accurate, warranting a score of 7 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 429,
        "total_tokens": 1737
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has IBM's treatment and disclosure of the 0.875% Notes due 2030 evolved between 2023 and 2024, particularly in terms of its listing and registration status?",
      "original_answer": "In 2023, the 0.875% Notes due 2030 were disclosed as part of a list of instruments incorporated by reference to Exhibit 4.1 to Form 8-K filed on February 8, 2022. By 2024, the 0.875% Notes due 2030 were explicitly listed in the table of registered securities with a trading symbol (IBM30A) and registered on the New York Stock Exchange. This indicates a shift from a referenced disclosure to a fully listed and registered financial instrument.",
      "llm_answer": "The 0.875% Notes due 2030 were listed in IBM’s 2023 Form 10‑K (page 19) as “0.875% Notes due 2030 – IBM30A” and were registered under the same indenture as other senior unsecured notes. In the 2024 filing (page 1), the same security appears in the table of registered securities with the identical designation “0.875% Notes due 2030 – IBM30A,” confirming that its listing and registration status remained unchanged between the two years.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in its core claim, which contradicts the ground truth. According to the original answer, there was a significant evolution in IBM's treatment and disclosure of the 0.875% Notes due 2030 between 2023 and 2024: in 2023, the notes were only incorporated by reference from a prior Form 8-K (filed February 8, 2022), meaning they were not explicitly listed in the 2023 10-K table of registered securities. However, by 2024, they were explicitly included in the table of registered securities with a trading symbol (IBM30A) and registered on the NYSE—indicating a material change in disclosure and registration status. The LLM incorrectly asserts that the notes were listed with the symbol 'IBM30A' in the 2023 10-K (page 19) and that the status 'remained unchanged'—this directly conflicts with the ground truth, which shows a shift from referenced disclosure to full listing. While the LLM correctly identifies the security designation and symbol (IBM30A), this detail is misattributed to 2023, which is factually wrong. The quantitative accuracy is partially acceptable because the note terms (0.875%, due 2030) and symbol are correct, but the dates and disclosure context are not. The reasoning fails the multi-hop requirement: it should have contrasted the incorporation-by-reference approach in 2023 with explicit listing in 2024, but instead asserts continuity. Contextual relevance is moderate because it discusses the right instrument and filings, but draws the opposite conclusion of the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1223,
        "completion_tokens": 421,
        "total_tokens": 1644
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did the structure and distribution terms of the Telco Preferred Interests evolve from 2023 to 2024, and what does this indicate about AT&T's approach to financing through preferred equity instruments?",
      "original_answer": "In 2023, the Telco Preferred Interests consisted of $2,000 of Class A-1 preferred interests issued in September 2020, paying a 4.25% annual distribution, and $5,250 of Class A-2 and A-3 preferred interests issued in April 2023, paying a 6.85% annual distribution. By 2024, the total Telco Preferred Interests had grown to $7,250, with the Class A-1 preferred interests still at 4.25% and the Class A-2 and A-3 interests remaining at 6.85%, both subject to reset every seven years. Additionally, in 2024, AT&T clarified that failure to pay distributions would not restrict cash movements or its ability to pay dividends or repurchase shares. The structure remained consistent in terms of redemption rights and noncontrolling interest classification, but the expansion of the instrument in 2024 suggests a continued reliance on preferred equity as a financing strategy.",
      "llm_answer": "The Telco Preferred Interests evolved from a 7% cumulative perpetual preferred equity issued in 2020 (Telco Class A-1) to a restructured series of preferred interests issued in 2024, including Telco Class A-4 (5.94% initial rate, reset in 2028) and additional $2,250 of preferred interests in Telco LLC. This evolution reflects AT&T's strategy to use preferred equity as a flexible, non-dilutive financing tool with reset mechanisms and redemption features that allow it to manage capital structure while maintaining control—evidenced by the ability to call these interests after specific dates and the lack of restrictions on dividend declarations or share repurchases despite the preferred equity obligations.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that the Telco Preferred Interests were restructured in 2024 with new instruments like Class A-4 at 5.94%, which is not supported by the ground truth. The ground truth indicates no new classes were issued in 2024; instead, the existing structure from 2023 (Class A-1 and A-2/A-3) remained unchanged in terms of issuance and rates. The LLM also fabricates a $2,250 issuance in 2024, whereas the increase to $7,250 in 2024 was due to the 2023 issuance of $5,250 added to the original $2,000, not a new 2024 issuance. The distribution rates are misrepresented: the LLM claims a 7% rate for Class A-1 in 2020, but the correct rate is 4.25%. The reset date mentioned (2028) is incorrect—the ground truth states resets occur every seven years from issuance, not a fixed 2028 date. (2) Quantitative accuracy is severely lacking: dollar amounts ($2,000, $5,250, $7,250) are partially correct but misattributed to wrong years; percentages (4.25%, 6.85%) are entirely absent or wrong in the LLM answer; no correct calculation or timeline alignment is present. (3) Multi-hop reasoning is flawed: the LLM fails to correctly synthesize the evolution across 2023–2024, incorrectly implying structural changes in 2024 when the structure remained consistent. It misses the key point that the 2024 update was about clarifying distribution payment flexibility, not issuing new instruments. (4) Despite factual errors, the answer is contextually relevant in discussing AT&T’s use of preferred equity as a financing tool and touches on non-dilutive benefits and dividend flexibility, which aligns with the ground truth’s conclusion. However, the reasoning is based on false premises, undermining qualitative accuracy. The score reflects major factual and quantitative errors, with only partial relevance to the strategic interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1409,
        "completion_tokens": 516,
        "total_tokens": 1925
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How has Capital One's involvement in multifamily commercial real estate loans evolved between 2022 and 2023, particularly in terms of risk exposure under loss sharing agreements with government-sponsored enterprises?",
      "original_answer": "In 2022, Capital One originated multifamily commercial real estate loans with the intent to sell them to GSEs, entering into loss sharing agreements, which resulted in a liability of $82 million. By 2023, the company continued this practice but the liability recognized on the consolidated balance sheets for these loss sharing agreements increased to $137 million, indicating a significant increase in risk exposure. This evolution reflects a growing involvement in these types of loans and a corresponding rise in the financial obligations tied to their loss sharing agreements.",
      "llm_answer": "Capital One’s exposure to multifamily commercial real‑estate loans under loss‑sharing agreements with government‑sponsored enterprises has remained relatively stable in size but shifted to a fair‑value accounting approach beginning in 2020. The company records a liability for these loss‑sharing arrangements—$137 million as of December 31 2023 and $82 million as of December 31 2022—and recognizes unrealized gains or losses in non‑interest income. This methodology means that any changes in the estimated credit losses on the sold multifamily loans now flow through earnings rather than being amortized into income over time, increasing the volatility of non‑interest income while the underlying risk exposure stays tied to the performance of those loan portfolios.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is quantitatively accurate, correctly reporting the $82 million liability in 2022 and $137 million in 2023, which aligns with the ground truth. These figures are critical and correctly cited, satisfying the quantitative accuracy requirement. However, the qualitative reasoning diverges from the ground truth in key aspects. While the original answer emphasizes a significant increase in risk exposure due to growing involvement in multifamily loans and rising liabilities, the LLM frames the change as a shift in accounting methodology (fair-value approach starting in 2020) that affects income volatility, not necessarily risk exposure. This reframing downplays the evolution in actual risk exposure—highlighted in the ground truth—and instead focuses on accounting treatment, which was not part of the original question. The mention of a fair-value shift beginning in 2020 introduces information not present in the ground truth and may mislead regarding the cause of the liability increase. While the LLM correctly identifies the liability amounts and the continuation of the practice, it fails to emphasize the core conclusion: increased risk exposure due to higher liabilities, reflecting deeper involvement. The reasoning is plausible but not fully aligned with the knowledge graph's interpretation. Contextually, the answer remains relevant, addressing loss-sharing agreements, GSEs, and multifamily loans, but shifts focus to accounting impact rather than evolution of risk. Thus, while numbers are correct and context is strong, the qualitative synthesis misses the intended inference about growing risk exposure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 445,
        "total_tokens": 1799
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did Amazon's co-branded credit card programs shift in strategic significance and associated regulatory risks from 2022 to 2023, particularly in terms of new compliance obligations and their potential impact on operating results?",
      "original_answer": "In 2022, Amazon introduced co-branded credit card programs as part of its payment offerings, highlighting the risk that renewal on less favorable terms or termination could adversely affect operating results. The regulatory risks at that time included compliance with payment card association rules such as data security and certification requirements. By 2023, Amazon expanded its offerings and emphasized additional compliance obligations, including data localization rules, which were not mentioned in 2022. This indicates that the co-branded credit card programs became subject to a broader set of regulatory risks, particularly in international jurisdictions, which could increase compliance costs and operational complexity. The potential impact on operating results grew as Amazon now faced risks not only from traditional payment regulations but also from evolving data governance laws, particularly regarding cross-border data transfers tied to these credit card programs.",
      "llm_answer": "From 2022 to 2023 Amazon’s co‑branded credit‑card programs moved from a peripheral revenue stream to a strategically important lever that directly influences cash flow and customer‑acquisition economics.  The 2023 filing explicitly notes that renewal on less‑favorable terms or termination of these programs could “adversely affect our operating results,” reflecting heightened regulatory scrutiny and new compliance obligations such as expanded data‑security, fraud‑prevention, and licensing requirements under evolving payment‑services rules.  Consequently, any adverse outcome—whether through stricter regulations, higher interchange fees, or loss of the programs—could materially dent Amazon’s profitability and overall operating performance.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the increased strategic significance of Amazon's co-branded credit card programs from 2022 to 2023 and notes the heightened regulatory risks and potential impact on operating results, aligning with the ground truth. It accurately reflects that termination or less favorable renewal could adversely affect operating results—a key point in both answers. The dates (2022 vs 2023) and entities (Amazon, co-branded credit card programs) are correct, and there are no numerical inaccuracies (quantitative accuracy is perfect, as no specific numbers are involved and no false claims made). However, the LLM answer misses a critical multi-hop element: the introduction of *data localization rules* in 2023 as a new compliance obligation not present in 2022. While it mentions 'expanded data-security, fraud-prevention, and licensing requirements,' it does not specify that data localization and cross-border data transfer concerns emerged as new regulatory risks in international jurisdictions—a key evolution in regulatory risk highlighted in the original answer. This omission reduces qualitative accuracy, as the synthesis of new, jurisdiction-specific compliance obligations is incomplete. The reasoning is otherwise sound and contextually relevant, with appropriate emphasis on strategic importance and profitability risks. Thus, while the core facts and direction of change are correct, the answer lacks specificity on the nature of new 2023 compliance obligations, warranting a score of 7 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1453,
        "completion_tokens": 421,
        "total_tokens": 1874
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How has PM's financial relationship with RBH evolved between 2022 and 2024, particularly regarding the consolidation status and valuation considerations of RBH within PM's financial statements?",
      "original_answer": "In 2022, RBH was deconsolidated from PM's financial statements due to CCAA proceedings initiated in 2019, with its financial results excluded since that time. Additionally, PM faced potential material impacts from unresolved Canadian tobacco litigation, including a CAD 3.1 billion allocation of compensatory damages against RBH. By 2024, PM's relationship with RBH had evolved into holding an equity investment, which required impairment analysis. The audit process emphasized significant judgment around the fair value estimate of the investment, including assumptions on discount rates, sales volumes, operating margins, and the tax treatment of a potential global settlement. This reflects a shift from a deconsolidated subsidiary to a valued equity stake requiring ongoing impairment evaluation.",
      "llm_answer": "Between 2022 and 2024, PMI's financial relationship with RBH shifted from consolidation to equity investment after RBH's deconsolidation in 2019, with RBH's financial results no longer included in PMI's consolidated statements post-2019. The 2024 10-K confirms PMI's $714 million fair value estimate for its RBH equity investment (down from prior carrying values), driven by impairment considerations due to RBH's CCAA proceedings and the 2025 objection to the proposed compromise plan, which signaled potential impairment and influenced the $2.3 billion non-cash charge recorded in 2024.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. While it correctly notes RBH's deconsolidation due to CCAA proceedings, it incorrectly attributes the deconsolidation to 2019 as the reporting year for financial exclusion, whereas the ground truth emphasizes that by 2022, RBH was already deconsolidated — the 2019 date refers to the initiation of proceedings, not the accounting treatment in 2022. More critically, the LLM introduces specific numbers not present in the original answer: a $714 million fair value estimate and a $2.3 billion non-cash charge in 2024. These figures are not mentioned in the ground truth and thus represent significant quantitative fabrications. Additionally, the mention of a '2025 objection to the proposed compromise plan' introduces a future event (2025) not referenced in the original and not logically inferable from the provided truth. (2) The quantitative accuracy is low because the dollar amounts ($714M, $2.3B) and the 2025 timeline are unsupported by the ground truth. The original answer discusses impairment analysis and judgment around fair value but does not provide any specific valuation figures or charges. (3) The multi-hop reasoning is partially sound — the model correctly identifies the shift from consolidation to equity investment and links CCAA proceedings to impairment considerations. However, it fails to mention the key litigation context (CAD 3.1 billion in compensatory damages allocated to RBH) and overreaches by inserting unverified financial figures and events. (4) Contextual relevance is high because the answer addresses the evolution of the financial relationship, consolidation status, and valuation considerations. However, the inclusion of fabricated numbers and events undermines correctness. The qualitative accuracy is moderate due to correct conceptual framing but flawed execution on facts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 510,
        "total_tokens": 1869
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did the financial performance and strategic positioning of Baqsimi evolve between 2023 and 2024, particularly in terms of revenue contribution and its role within LLY's product portfolio?",
      "original_answer": "In 2023, Baqsimi contributed $677.6 million in total revenue, with $645.7 million from the U.S. and $31.9 million from outside the U.S., indicating it was still a growing product within LLY's portfolio. By 2024, Baqsimi was no longer reported as a direct revenue contributor through product sales; instead, it was disclosed as part of a collaboration and other arrangements, specifically under the 2023 sale of rights. This shift suggests that LLY transitioned Baqsimi from an internally commercialized product to a divested asset, impacting its strategic focus and revenue model. The absence of Baqsimi from direct product revenue in 2024 reflects a significant change in its role and contribution to LLY's financials.",
      "llm_answer": "Between 2023 and 2024, Baqsimi’s revenue contribution shifted from a notable standalone product to a modest component of Lilly’s portfolio, reflecting its integration within broader commercial activities. While Baqsimi generated $645.7 million in U.S. revenue and $31.9 million internationally in 2023 (totaling $677.6 million), its role evolved as part of Lilly’s strategic focus on high-growth assets like Mounjaro and Jardiance, with Baqsimi now contributing a smaller, specialized share of net product revenue within the company’s diversified portfolio. This evolution underscores its transition from a standalone revenue driver to a niche product supporting Lilly’s overall market positioning.",
      "correctness_score": 4,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the 2023 revenue figures for Baqsimi: $645.7 million in the U.S. and $31.9 million internationally, totaling $677.6 million, which matches the ground truth exactly. Thus, quantitative accuracy is high. However, the key qualitative and factual error lies in the characterization of Baqsimi’s status in 2024. The LLM claims Baqsimi became a 'modest component' of net product revenue within a diversified portfolio, implying it is still part of Lilly’s product sales. In reality, as per the original answer, Baqsimi was no longer reported as a direct revenue contributor in 2024 due to the sale of rights in 2023; its revenue was no longer recognized through product sales but rather through collaboration and other arrangements. This is a critical misrepresentation of the strategic shift. (2) All numbers are accurate and correctly summed. (3) The multi-hop reasoning fails: the model does not recognize the divestiture event and its financial reporting implications, instead inferring a mere strategic downgrading or niche positioning. This misses the fundamental change in asset ownership and revenue recognition model. (4) While the answer is well-structured and contextually relevant to the question about evolution in performance and positioning, the core conclusion about Baqsimi’s 2024 role is factually incorrect, warranting a low correctness and qualitative accuracy score despite strong number reporting.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1365,
        "completion_tokens": 404,
        "total_tokens": 1769
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How has the composition of Union Pacific's Total Highway Revenue Equipment changed from 2022 to 2024, particularly in terms of the ratio of owned versus leased containers and chassis?",
      "original_answer": "In 2022, Union Pacific owned 78,837 units and leased 16,004 units of Total Highway Revenue Equipment, with containers making up the majority of owned assets and chassis being heavily leased. By 2024, the company significantly reduced both owned and leased equipment, with owned units dropping to 50,731 and leased units to 1,485. The most notable change was in leased containers, which fell from 1,856 in 2022 to just 288 in 2024, and owned chassis decreased from 29,875 to 4,356. This indicates a strategic shift toward owning fewer assets and leasing even fewer, especially in chassis.",
      "llm_answer": "From 2022 to 2024, Union Pacific’s highway revenue equipment composition shows a shift toward greater leasing relative to ownership. In 2022, containers were 48,962 owned and 1,856 leased (total 50,818), and chassis were 29,875 owned and 14,148 leased (total 44,023). By 2024, containers owned had declined to 46,375 with 288 leased (total 46,663), while chassis owned increased slightly to 4,356 with 1,197 leased (total 5,553). This indicates a modest rise in leased containers and a more pronounced increase in leased chassis, reflecting a growing reliance on leased equipment across the fleet.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, Union Pacific owned 78,837 total units and leased 16,004 — not the 50,818 and 44,023 total units implied in the LLM answer. The LLM incorrectly reports only 48,962 owned containers in 2022, but the ground truth does not provide a container/owned split separately — it gives total owned (78,837) and leased (16,004) for all highway equipment. The LLM fabricates a breakdown not in the original answer. More critically, the LLM claims chassis leased increased to 1,197 in 2024, but ground truth states total leased units dropped to 1,485 across all equipment, with leased containers alone falling to 288. The LLM incorrectly states leased chassis increased, when in fact leased chassis must have decreased significantly. The LLM also falsely claims chassis owned increased to 4,356 — while ground truth confirms owned chassis dropped from 29,875 to 4,356, which is a decrease, not an increase. (2) Calculations are inconsistent: the LLM’s totals for containers and chassis do not align with the ground truth’s overall totals (e.g., 78,837 owned in 2022 vs. LLM’s implied 78,837 ≈ 48,962 + 29,875, which is coincidentally close but misattributed). However, the LLM’s claim of rising leased equipment contradicts the ground truth’s clear trend of sharp reduction in leasing. (3) Multi-hop reasoning is flawed: the LLM infers a growing reliance on leasing, which is the opposite of the strategic shift described in the ground truth — a move away from both owned and leased assets, especially leased containers and chassis. (4) Scores are low due to major factual and directional errors in numbers and interpretation. Contextual relevance is moderate because the answer addresses the right topic (owned vs. leased composition over time) and mentions containers and chassis, but the substance is incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 516,
        "total_tokens": 1822
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did Capital One's use of securitized debt obligations evolve between 2022 and 2023, particularly in terms of their role within the company's overall funding structure?",
      "original_answer": "In 2022, securitized debt obligations were explicitly described as one of the company's key funding sources alongside deposits, senior and subordinated notes, federal funds purchased, and FHLB advances. By 2023, while still present in the funding structure at $18.043 billion in carrying value, securitized debt obligations were categorized under Level 2 in the fair value hierarchy, indicating a shift toward more standardized valuation methods. This evolution suggests a more structured and possibly less volatile role for securitized debt obligations in Capital One's funding strategy.",
      "llm_answer": "Capital One’s use of securitized debt obligations grew modestly from 2022 to 2023, rising from $16.9 billion (estimated fair value $16.918 billion) to $18.0 billion (estimated fair value $18.067 billion). In both years the securitized debt represented a small, consistently‑weighted component of the firm’s overall funding structure—about 4 % of total funding in 2022 and roughly 5 % of total funding in 2023—underscoring its role as a supplemental source of liquidity rather than a primary financing channel.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partially correct quantitative information but introduces data not present in the ground truth. The ground truth states that in 2023, securitized debt obligations had a carrying value of $18.043 billion and were categorized under Level 2 of the fair value hierarchy, but it does not provide a 2022 dollar amount or mention estimated fair values of $16.918 billion or $18.067 billion. The LLM's claim of growth from $16.9 billion to $18.0 billion is plausible but unsupported by the original answer, making it an unsupported inference. Additionally, the percentages (4% in 2022, 5% in 2023) are not mentioned or verifiable from the ground truth, which undermines quantitative accuracy. (2) The original answer focuses on a qualitative shift in classification within the fair value hierarchy (indicating more standardized valuation), which reflects a change in how securitized debt was accounted for and its role in funding. The LLM completely misses this key point, instead emphasizing a numerical increase and proportional weighting that are not in the source. This omission of the Level 2 reclassification and its implications represents a major qualitative gap. (3) The multi-hop reasoning is flawed: while the LLM attempts to compare two years and assess the role in funding structure, it fabricates metrics (percentages of total funding) and assigns significance to minor dollar changes without grounding in the source. The correct reasoning should have centered on the shift in valuation methodology as an indicator of structural integration and reduced volatility. (4) Despite missing the core evolution described in the original answer, the LLM does correctly identify that securitized debt obligations remained part of the funding structure in both years and provides a reasonably close 2023 carrying value ($18.0B vs $18.043B). It also correctly frames the instrument as a secondary funding source, which aligns with the original's implication. However, the invention of unsupported figures and omission of the key fair value hierarchy shift justify a low correctness score. Quantitative accuracy is moderate due to approximate values but penalized for unverified calculations. Qualitative accuracy is low due to missing the central analytical point. Contextual relevance is high as the response stays on topic and addresses the evolution in funding role.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1280,
        "completion_tokens": 639,
        "total_tokens": 1920
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did the nature of LLY's revenue from Zyprexa evolve between 2023 and 2024, particularly in terms of the source and recognition method of that revenue?",
      "original_answer": "In 2023, Zyprexa revenue was primarily derived from the sale of the rights for the olanzapine portfolio. By 2024, the revenue associated with Zyprexa was recognized as part of collaboration and other arrangements, specifically stemming from the 2023 sale of rights for the olanzapine portfolio, and was included in collaboration revenue rather than product sales. This reflects a shift in how Zyprexa-related revenue was categorized and recognized in 2024 compared to 2023.",
      "llm_answer": "Based on the provided SEC 10-K filings, LLY's revenue from Zyprexa (an antipsychotic drug) evolved significantly between 2023 and 2024, with its recognition method shifting from product sales to a one-time royalty-related gain from the sale of intellectual property rights. In 2023, Zyprexa revenue was reported as part of \"Other neuroscience\" ($79.4M in U.S. sales), but by 2024, the revenue stream ceased as the company recognized a $175.8M gain from the sale of the olanzapine portfolio rights (including Zyprexa) under \"collaboration and other revenue\" (Note 4), reflecting a strategic divestiture rather than ongoing product sales. This transition is detailed in Note 4 of the 2024 filing, where revenue from such sales is explicitly categorized as \"collaboration and other revenue\" rather than net product revenue, and the gain was recorded upon transfer of control of the asset.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) It correctly identifies the shift in Zyprexa revenue from product sales in 2023 to recognition under collaboration and other revenue in 2024 due to the sale of the olanzapine portfolio rights. The mention of Note 4 in the 2024 10-K supports this, and the categorization under 'collaboration and other revenue' matches the original answer. (2) Quantitatively, the LLM provides specific figures: $79.4M in U.S. sales in 2023 under 'Other neuroscience' and a $175.8M gain in 2024. While the ground truth does not include these exact numbers, they are consistent with plausible data from SEC filings and do not contradict the original answer; their inclusion enhances detail without introducing error. Format variations (e.g., $175.8M) are acceptable. (3) The multi-hop reasoning is sound: the model connects the 2023 sale of rights to the 2024 revenue recognition method, correctly inferring the change in accounting treatment based on the divestiture. It synthesizes information across years and accounting categories appropriately. (4) The only minor limitation is that the original answer emphasizes the ongoing recognition of revenue *from the 2023 sale* in 2024, while the LLM frames it as a cessation of revenue, which slightly downplays the continuity of revenue recognition from the same transaction. However, this does not invalidate the core accuracy. Overall, the answer is factually correct, well-reasoned, and contextually complete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 416,
        "total_tokens": 1758
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has the valuation methodology and classification of Federal Government Securities in the pension plan evolved from 2022 to 2024?",
      "original_answer": "In 2022, Federal Government Securities were valued under the 'Significant Other Observable Inputs (Level 2)' category and totaled $742 million. By 2024, the company clarified that these securities are valued using a bid evaluation process with bid data from independent pricing sources and are explicitly classified as Level 2 investments. This reflects a continuation in classification but adds specificity in methodology explanation.",
      "llm_answer": "The valuation methodology for Federal Government Securities remained classified as Level 2 throughout the period, but the amount recorded increased from $1,508 million in 2023 to $1,448 million in 2024 (reflecting a slight decline in fair‑value measurement), and the related footnote disclosures indicate that the securities are valued using a bid‑evaluation process with independent pricing sources rather than quoted prices in an active market.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, Federal Government Securities were valued at $742 million under Level 2. The LLM incorrectly reports $1,508 million in 2023 and $1,448 million in 2024—neither of which are mentioned in the original answer, nor is 2023 referenced in the ground truth. These numbers are entirely fabricated or misattributed. (2) Quantitative accuracy is very low: no correct dollar amounts are provided for 2022 or 2024, and the years referenced (2023, 2024) do not align with the available data (2022, 2024). The original answer does not mention a change in value, only in disclosure detail. (3) Qualitatively, the LLM correctly identifies that the classification remained Level 2 and that the valuation methodology involves a bid-evaluation process with independent pricing sources—this aligns with the increased specificity noted in 2024. However, it fails to mention that the 2022 classification was already Level 2, and incorrectly implies a quantitative trend across 2023–2024 that is unsupported. The multi-hop synthesis is flawed because it invents data points not present in the source. (4) Contextual relevance is moderate: the answer addresses valuation methodology and classification over time, which is relevant, but the inclusion of incorrect figures undermines the response. The core reasoning about methodology improvement is partially sound but not fully supported by the timeline or data provided.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1216,
        "completion_tokens": 415,
        "total_tokens": 1632
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How did Capital One's credit score data utilization for product segmentation decisions evolve from 2022 to 2023, and what does this indicate about their credit risk modeling strategy?",
      "original_answer": "In 2022, Capital One used credit score data for product segmentation decisions based on historical credit score distributions from 2020 to 2021, as shown in Table 21. In 2023, the company updated its data to reflect credit score distributions from 2022 to 2023 in the same table. This shift indicates a more current and dynamic credit risk modeling strategy, with product segmentation decisions being informed by the most recent borrower behavior and risk profiles, suggesting a proactive approach to managing credit risk in evolving economic conditions.",
      "llm_answer": "Capital One's credit score data utilization for product segmentation decisions shifted significantly from 2022 to 2023, with the proportion of auto loan originations to borrowers with FICO scores above 660 increasing from 53% to 53% (wait, no change? Let me check again). Actually, looking at the credit score distribution tables, the key change is in the auto loan segment: the percentage of loans with FICO scores above 660 remained steady at 53% in both years, but the proportion of lower-score borrowers (620 or below) decreased slightly from 27% to 27% (no meaningful change). However, the critical evolution is in how they *used* this data: in 2023, they explicitly stated they \"use borrower credit scores... to drive product segmentation decisions\" (page 94, 95, 101), whereas in 2022 they only mentioned using scores for \"subprime classification, for competitive benchmarking and, in some cases, to drive product segmentation decisions\" (page 101). This indicates a more deliberate, systematic application of credit score data to tailor product offerings and risk-based pricing strategies in 2023, reflecting a more refined credit risk modeling approach that directly links borrower risk profiles to product design rather than just internal classification. (2 sentences)",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in its quantitative claims. It incorrectly states that the proportion of auto loan originations to borrowers with FICO scores above 660 was 53% in both 2022 and 2023 and that lower-score borrowers remained at 27%, suggesting no change. However, the ground truth does not mention these specific percentages or trends in auto loan originations at all. Instead, the actual evolution was in the *data vintage used* for segmentation: from 2020–2021 distributions in 2022 to 2022–2023 distributions in 2023. The LLM invents specific percentages not present in the ground truth, which undermines factual correctness. (2) The quantitative accuracy is low because the numbers cited (53%, 27%) are not supported by the original answer and appear to be hallucinated or misattributed from another source. There is no verification that these figures appear in Table 21 or elsewhere in the filings as described. (3) The qualitative reasoning shows partial understanding: the LLM correctly identifies a shift in language around how credit scores are used—from 'in some cases' to drive segmentation in 2022 to a more explicit statement in 2023. This aligns with the ground truth’s interpretation of a more deliberate strategy. However, it fails the multi-hop requirement of connecting the *update in data recency* (from older to newer credit score distributions) to the strategic shift, which is the core of the original answer. (4) Contextual relevance is high because the response addresses the evolution in data usage for product segmentation and attempts to infer strategic implications about credit risk modeling. Despite incorrect specifics, it frames the discussion appropriately around segmentation and risk strategy. Overall, the answer is partially correct in intent and interpretation but fails on key facts and data accuracy, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1467,
        "completion_tokens": 519,
        "total_tokens": 1986
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has Amazon's strategic positioning of AWS evolved from 2022 to 2023 in terms of its role within the company's broader business segments and investment priorities?",
      "original_answer": "In 2022, AWS was positioned primarily as a key area of investment within Amazon's broader technology and content spending, with an emphasis on supporting geographic expansion, new product categories, and internal operational efficiencies. The document highlighted that Amazon was investing in AWS alongside initiatives to build and deploy innovative software and electronic devices, indicating a strategic alignment with internal growth and infrastructure enhancement. By 2023, AWS had evolved into one of Amazon's three core business segments—alongside North America and International—reflecting its elevated strategic importance. The 2023 filing explicitly states that AWS serves developers and enterprises by offering a broad set of on-demand technology services, including compute, storage, database, analytics, and machine learning, and is now a distinct and central pillar of Amazon’s business model. This shift demonstrates a transformation in AWS's role from a strategic investment area to a standalone, mission-critical business segment.",
      "llm_answer": "From 2022 to 2023, AWS transitioned from being described as one of Amazon’s three core segments (alongside North America and International) to being positioned as a distinct strategic pillar within the company’s broader portfolio, with its own dedicated leadership (e.g., Adam Selipsky as CEO of AWS) and explicit emphasis on long‑term investment in cloud infrastructure. The 2023 filing highlights AWS as a primary driver of technology‑infrastructure spending and a key growth engine, underscoring that Amazon is allocating increasing capital and resources to expand AWS services, data‑center capacity, and related innovations, while still maintaining its consumer‑focused retail businesses. This shift reflects a strategic prioritization of AWS as a core profit center that supports both Amazon’s broader ecosystem and its own operational efficiencies.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains a critical factual error in the timeline of AWS's strategic positioning: it incorrectly states that AWS was already one of Amazon’s three core segments in 2022, when the ground truth confirms this structural evolution occurred in 2023. This reverses the actual progression—AWS evolved from being a strategic investment area in 2022 to becoming a core business segment in 2023. The LLM misrepresents the direction of change, which undermines the multi-hop reasoning required to assess how AWS’s role transformed over time. While the mention of AWS as a growth engine, investment in infrastructure, and its leadership structure are contextually relevant and plausible details, they do not align with the documented shift in segment classification. There are no numerical values in the question or answers, so quantitative accuracy is not applicable in a traditional sense, but all mentioned concepts (e.g., no dollar figures) are used appropriately. The answer is semantically relevant and well-structured, addressing investment priorities and strategic role, but the core factual inversion of the timeline severely compromises qualitative and overall correctness. Thus, the answer is partially accurate in tone and context but fundamentally flawed in entity and temporal accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1480,
        "completion_tokens": 362,
        "total_tokens": 1842
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has Philip Morris International's financial relationship with Rothmans, Benson & Hedges Inc. (RBH) evolved between 2022 and 2024, particularly in terms of its accounting treatment and potential financial exposure?",
      "original_answer": "In 2022, RBH was deconsolidated from Philip Morris International’s financial statements due to its CCAA restructuring, and its financial results were no longer included in PMI’s consolidated financials. At that time, there was a comprehensive stay of Canadian tobacco litigation until March 31, 2022, and no loss accruals were made due to the inability to estimate potential losses. By 2024, PMI’s relationship with RBH had shifted from deconsolidation to an equity investment model. A proposed settlement of CAD 32.5 billion in the Canadian tobacco litigation emerged, prompting PMI to assess its investment in RBH for impairment. As a result, PMI recorded a non-cash impairment charge of $2,316 million in 2024, reflecting a decline in the estimated fair value of its investment. This marks a significant evolution from a deconsolidated entity with uncertain liabilities to a recognized equity investment with a quantified impairment.",
      "llm_answer": "Between 2022 and 2024, Philip Morris International's financial relationship with Rothmans, Benson & Hedges Inc. (RBH) underwent a significant shift, particularly regarding accounting treatment and financial exposure. Following the deconsolidation of RBH from PMI's consolidated financial statements in 2019 (as noted in Note 20), PMI's direct financial exposure to RBH was limited to its equity investment and litigation-related contingencies. However, the situation evolved notably in 2024 when PMI recorded a $2,316 million non-cash impairment charge on its investment in RBH due to uncertainty surrounding the allocation of a proposed CAD 32.5 billion settlement in Canadian tobacco litigation (as disclosed in the Executive Summary and Note 6). This impairment reflects PMI's assessment that the fair value of its investment in RBH had declined, driven by unresolved legal and financial risks tied to ongoing class-action lawsuits and the CCAA proceedings in Canada. While PMI no longer consolidates RBH's financials, its remaining exposure remains tied to the potential for further litigation-related liabilities or settlements involving RBH, particularly given the substantial pending claims in Canada that could indirectly impact PMI's financial position through its indirect stake and historical indemnification obligations.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct in its qualitative description of the evolution in Philip Morris International's (PMI) financial relationship with Rothmans, Benson & Hedges Inc. (RBH), particularly regarding the shift from deconsolidation to equity investment accounting and the $2,316 million non-cash impairment charge in 2024 due to the proposed CAD 32.5 billion Canadian tobacco litigation settlement. The core financial figures—$2,316 million impairment and CAD 32.5 billion settlement—are accurately reported, satisfying quantitative accuracy. However, the LLM incorrectly states that deconsolidation occurred in 2019 (citing Note 20), while the ground truth specifies the deconsolidation was in 2022 due to CCAA restructuring. This is a significant factual error in timing and context, undermining the accuracy of the multi-hop reasoning. The answer correctly identifies the change in accounting treatment and financial exposure but misrepresents the timeline, implying the deconsolidation was already complete before 2022. Despite this, the explanation of the 2024 impairment and its drivers (litigation uncertainty, fair value decline) is sound and contextually relevant. The synthesis of litigation risk, equity investment treatment, and financial impact is logically structured and addresses all parts of the question, albeit with an incorrect foundational event date. Thus, while the core 2024 developments are accurately conveyed, the misstatement of the deconsolidation date reduces overall correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1584,
        "completion_tokens": 422,
        "total_tokens": 2007
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has the commercial significance of Biktarvy evolved for GILD from 2022 to 2024, considering both its revenue contribution and associated product risks?",
      "original_answer": "In 2022, Biktarvy was a major revenue driver for GILD, generating $8,624 million in total product sales globally, indicating its strong market position in the HIV treatment segment. By 2024, while specific revenue figures are not provided, the company's risk disclosures highlight Biktarvy's ongoing importance but also emphasize heightened risks related to the HIV product class, particularly concerning the reliance on TAF-based therapies and potential shifts in treatment paradigms. This evolution suggests that although Biktarvy remains central to GILD's revenue, its commercial outlook has become more vulnerable to competitive and regulatory pressures.",
      "llm_answer": "From 2022 to 2024, Biktarvy’s commercial significance for GILD declined materially. In 2022, it generated $8.6 billion in total sales (≈ 53 % of GILD’s $16.3 billion HIV revenue), but by 2024 its contribution had fallen to $7.3 billion (≈ 43 % of the $16.9 billion HIV total), reflecting growing competition from generics and other HIV regimens and heightened product‑specific risks such as shifting treatment paradigms and pricing pressures from reforms like the Inflation Reduction Act. Consequently, while Biktarvy remains a cornerstone of GILD’s HIV portfolio, its revenue share and growth prospects have weakened, and the product now faces intensified regulatory, reimbursement and market‑share risks.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative claims for 2024. The ground truth states that 'specific revenue figures are not provided' for 2024, but the LLM asserts that Biktarvy's 2024 revenue was $7.3 billion, which is not supported by the source data. Additionally, the LLM claims GILD's HIV revenue was $16.3B in 2022 and $16.9B in 2024, and calculates Biktarvy's share as 53% and 43% respectively—none of which are present or verifiable in the original answer. These figures and percentages are entirely fabricated. (2) The only correct number is the 2022 Biktarvy revenue of $8.624 billion (correctly rounded to $8.6 billion), which matches the ground truth. All other numbers, including 2024 revenue, total HIV segment revenue, and percentage contributions, are incorrect and unsupported. Calculations based on these false numbers are therefore invalid. (3) While the LLM correctly identifies the qualitative trend of increasing risks (e.g., shifting treatment paradigms, regulatory pressures), it overstates the decline in commercial significance by asserting a material revenue drop not confirmed in the original answer. The original answer emphasizes ongoing importance and heightened risk, not confirmed revenue decline. The reasoning fails the multi-hop requirement because it invents data rather than synthesizing known facts with disclosed risks. (4) The contextual relevance is moderate because the answer addresses both revenue and risks as asked, and correctly notes Biktarvy's centrality and growing challenges. However, the high confidence in unreported financials undermines correctness. Correctness score is low due to major quantitative errors, despite some qualitative alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 479,
        "total_tokens": 1822
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has Union Pacific Railroad's financial stake and operational relationship with TTX evolved from 2022 to 2024, particularly in terms of investment value and car hire expenses?",
      "original_answer": "Union Pacific Railroad's financial stake in TTX increased from $1.6 billion in 2021 (referenced in the 2022 filing) to $1.9 billion in 2024. Additionally, UPRR's car hire expenses rose from $375 million in 2021 to $432 million in 2024. These increases indicate a growing financial and operational involvement with TTX over the period.",
      "llm_answer": "Union Pacific Railroad’s financial stake in TTX remained roughly constant at about $1.6 billion (2021) and $1.9 billion (2024), reflecting its 36‑37 % equity interest, and TTX‑related car‑hire expenses rose modestly from $375 million in 2021 to $432 million in 2024.  Consequently, the company’s investment value in TTX has grown slightly, while car‑hire expenses have increased in line with higher utilization of TTX rail cars.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly reports all key numerical values: Union Pacific's financial stake in TTX increased from $1.6 billion (2021, referenced in 2022 filing) to $1.9 billion in 2024, and car hire expenses rose from $375 million to $432 million over the same period. These match the ground truth exactly, with acceptable formatting (e.g., $1.6 billion). 2) Quantitatively, all figures are accurate and correctly attributed to the right years and metrics. There are no calculation errors. 3) The reasoning is sound: the LLM correctly infers growing involvement based on increasing investment and expenses. It adds contextual insight—'higher utilization of TTX rail cars'—which is a reasonable qualitative interpretation consistent with the data. The only minor issue is stating the stake 'remained roughly constant' while it increased from $1.6B to $1.9B—a 18.75% increase—which is not trivial and slightly understates the growth. However, the overall trend interpretation is still aligned with the ground truth. 4) The answer fully addresses both parts of the question (investment value and car hire expenses) and synthesizes information across years and financial metrics correctly. Semantic meaning matches the original answer closely, with only slight wording differences and a small interpretive overstatement of stability. Thus, the answer is highly accurate and relevant, warranting a 9/10 for correctness and qualitative accuracy, with full marks for quantitative and contextual performance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1198,
        "completion_tokens": 412,
        "total_tokens": 1610
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How did Tesla's approach to scaling Solar Roof production change from 2022 to 2023, particularly regarding installer training initiatives and supply chain risk management?",
      "original_answer": "In 2022, Tesla emphasized expanding Solar Roof production by on-boarding and training new installers, collaborating with real estate developers, and reducing installation time and costs. The company also highlighted its need to hire additional personnel, particularly skilled electricians, to support the ramp. By 2023, Tesla's focus had shifted toward addressing broader supply chain risks and production ramp challenges, with language indicating that Solar Roof production now depended more on managing supplier reliability, global component constraints, and cost-effective manufacturing processes. The 2023 filing also noted that delays in production ramps could harm the business, signaling a shift from installer-focused growth to a more risk-averse strategy centered on supply chain resilience.",
      "llm_answer": "Tesla’s 2023 10‑K shows that scaling Solar Roof production required a more aggressive installer‑training program and tighter supply‑chain controls than in 2022.  The filing notes that “we will continue to improve our installation capabilities and price efficiencies for Solar Roof by on‑boarding and training new installers, as well as collaborating with real‑estate developers” (page 17) and that “our ability to increase production … is dependent on accurately forecasting, purchasing, warehousing and transporting components … and on managing supply‑chain constraints” (page 33).  Consequently, the company emphasized expanding its installer‑training initiatives and diversifying component sources to mitigate the risk of shortages that had previously slowed Solar Roof ramp‑up.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent with the ground truth in several key areas but misrepresents the nature of Tesla's strategic shift between 2022 and 2023. (1) Correct elements: The answer accurately cites Tesla’s continued focus on installer training and collaboration with real estate developers (aligned with 2022 strategy), and correctly identifies the increased emphasis on supply chain constraints in 2023, including forecasting, purchasing, and component management. The quoted excerpts from the 10-K (pages 17 and 33) are contextually appropriate and support the claims. (2) Quantitative accuracy: There are no numerical values in the question or answers, so this criterion is satisfied by default—no errors in dates or figures. (3) Multi-hop reasoning: The model correctly synthesizes information across time (2022 vs 2023) and domains (installer training and supply chain), but it inaccurately frames the 2023 strategy as an 'expansion' of installer-training initiatives, whereas the ground truth indicates a strategic pivot *away* from installer-focused growth toward supply chain resilience. The original answer notes a shift in emphasis, while the LLM implies both initiatives were intensified. This mischaracterizes the strategic evolution. (4) Contextual relevance is high—the response directly addresses both parts of the question (installer training and supply chain risk) and uses relevant evidence. However, the qualitative inaccuracy in portraying continuity rather than a strategic shift reduces the correctness score. Overall, core facts are present and well-supported, but the synthesis lacks precision in conveying the strategic transition.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 453,
        "total_tokens": 1855
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has The Coca-Cola Company's relationship with fountain retailers evolved between 2022 and 2023, particularly regarding the manufacturing and distribution of fountain syrups in the United States?",
      "original_answer": "In 2022, The Coca-Cola Company stated that U.S. bottlers were generally not authorized to manufacture fountain syrups, and instead, the Company itself manufactured and sold fountain syrups directly to authorized fountain wholesalers (including some bottlers) and certain fountain retailers. By 2023, the Company clarified that it continues to manufacture fountain syrups in the U.S., but now explicitly states that it sells these syrups to both fountain retailers and authorized fountain wholesalers or bottling partners who then distribute them to fountain retailers. This indicates a more explicit acknowledgment of a tiered distribution model involving bottling partners in 2023, suggesting a potential expansion of their distribution network or clarification of roles.",
      "llm_answer": "Between 2022 and 2023, The Coca-Cola Company continued to manufacture and sell fountain syrups to U.S. fountain retailers, but the business model remained unchanged: the Company sells fountain syrups to authorized fountain retailers (or to authorized fountain wholesalers who then distribute to retailers), while bottling partners outside the U.S. are typically authorized to manufacture fountain syrups from the Company’s concentrates and sell them to fountain retailers. The document does not indicate any structural shift in this relationship—concentrate operations (which include fountain syrup sales) grew slightly to 58% of net operating revenue in 2023 versus 56% in 2022, and the Company continues to rely on its bottling partners and independent distributors for fountain syrup distribution in the United States.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains some correct elements but misses a key evolution in The Coca-Cola Company's relationship with fountain retailers between 2022 and 2023, which is the central focus of the question. (1) Correctly notes that Coca-Cola manufactures fountain syrups in the U.S. and sells them to authorized fountain wholesalers and retailers, and that bottlers are generally not authorized to manufacture fountain syrups. It also accurately reports the increase in concentrate operations' share of net operating revenue from 56% in 2022 to 58% in 2023, which aligns with the broader context. (2) Quantitative accuracy is high: the percentages (56% to 58%) are correctly cited and plausibly reflect the Company’s growing reliance on concentrate and fountain syrup sales. (3) However, the qualitative reasoning is flawed: the LLM incorrectly states that 'the business model remained unchanged,' directly contradicting the ground truth, which identifies a shift in emphasis or clarification in 2023 where the Company explicitly acknowledges selling to bottling partners who distribute to fountain retailers—indicating a more defined tiered distribution model. This evolution represents a meaningful change in how the Company describes its distribution network, even if the operational reality evolved gradually. The LLM fails to recognize this nuance, suggesting no structural shift when the original answer highlights a clearer role for bottling partners in 2023. (4) Contextual relevance is strong—the answer addresses fountain syrup manufacturing, distribution, and the role of bottlers—but the failure to identify the evolution in the relationship undermines the correctness. The answer downplays a key multi-hop insight: comparing the 2022 and 2023 disclosures reveals a more explicit recognition of bottling partners in distribution, which the LLM overlooks. Thus, while factually plausible in parts, it misses the core analytical point, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1411,
        "completion_tokens": 529,
        "total_tokens": 1940
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has IBM's treatment and disclosure of the 0.950% Notes due 2025 evolved from 2022 to 2024, particularly in terms of its financial instrument classification and registration details?",
      "original_answer": "In 2022, the 0.950% Notes due 2025 were disclosed as part of IBM's exhibits in Form 8-K filings, specifically referenced under Exhibit 4.1 filed on May 22, 2017. By 2024, the 0.950% Notes due 2025 were not only still present but were actively listed as a financial instrument with a trading symbol 'IBM25B' on the New York Stock Exchange. This evolution indicates a shift from merely disclosing the instrument to formally registering and listing it for trading.",
      "llm_answer": "IBM has consistently presented the 0.950% Notes due 2025 as a registered debt security in its SEC filings, with both the 2022 and 2024 Form 10-K filings listing it under \"Securities registered pursuant to Section 12(b) of the Act\" with the trading symbol \"IBM25B\" on the New York Stock Exchange. The classification and registration details remain unchanged, as the notes continue to be identified as a distinct debt instrument with the same terms and exchange listing in both years.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in asserting that the 0.950% Notes due 2025 were listed with trading symbol 'IBM25B' in both 2022 and 2024. According to the ground truth, in 2022 the notes were only disclosed in an 8-K filing from 2017 (Exhibit 4.1 filed May 22, 2017), not in the 2022 10-K, and there was no indication of a trading symbol at that time. The evolution described in the original answer shows a shift from disclosure to formal registration and listing by 2024, which contradicts the LLM's claim of 'unchanged' status. (2) The percentage (0.950%) and maturity year (2025) are correct, and 'IBM25B' is correctly identified as the trading symbol in 2024, but the LLM incorrectly applies it retroactively to 2022. There are no calculations in this response, so quantitative accuracy is limited to correct identification of static values, which is partially accurate. (3) The multi-hop reasoning is flawed: the question asks about evolution from 2022 to 2024, requiring comparison across years and recognition of a change in classification and disclosure practice. The LLM fails this synthesis, instead asserting consistency where the ground truth indicates a meaningful change. (4) Contextual relevance is moderate because the answer addresses the right instrument and the general topic of registration, but it misrepresents the timeline and nature of the evolution, leading to a substantively incorrect conclusion. The answer contradicts the ground truth on the key point of change over time.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1245,
        "completion_tokens": 419,
        "total_tokens": 1665
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How has GILD's strategic positioning of Biktarvy evolved from 2022 to 2024, particularly in terms of its financial risk exposure and competitive differentiation within the HIV treatment market?",
      "original_answer": "In 2022, Biktarvy was listed among GILD’s key marketed products, indicating its central role in the company's HIV portfolio and suggesting strong commercial positioning. By 2024, the company highlighted increasing financial risk tied to its reliance on nucleoside-based therapies like Biktarvy, particularly due to the potential shift in HIV treatment paradigms away from TAF-based regimens. This evolution reflects a growing concern over Biktarvy’s long-term competitive differentiation and its ability to sustain revenue, especially in the face of rising generic competition and changing therapeutic preferences.",
      "llm_answer": "From 2022 to 2024, Gilead’s Biktarvy positioning has shifted from a dominant HIV franchise to a more diversified portfolio amid heightened financial risk and competitive pressure. While Biktarvy remains a key revenue driver, its growth has slowed as newer HIV regimens and generic competition erode market share, forcing Gilead to rely more heavily on high‑risk investments in oncology (e.g., CAR‑T therapies) and antiviral expansions, which increases exposure to R&D and regulatory uncertainties. Simultaneously, aggressive pricing pressures from Medicare‑Part D rebates, the Inflation Reduction Act’s negotiation provisions, and payer cost‑containment reduce net pricing and margin stability for Biktarvy, while the company’s pivot toward higher‑cost cell‑therapy manufacturing and large‑scale acquisitions amplifies both financial volatility and its ability to sustain competitive differentiation in the HIV market.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but introduces significant information not present in the ground truth, leading to factual overreach. (1) Correct elements: The answer correctly identifies Biktarvy as a key product for GILD and acknowledges increasing financial risk and competitive pressure from generics and market shifts, aligning with the 2024 risk concerns in the original answer. It also appropriately frames Biktarvy’s central role in the HIV market through 2022. (2) Quantitative accuracy: There are no specific numbers (e.g., revenue figures, percentages, dates) in either the original or LLM answer, so no numeric inaccuracies exist—this aspect is neutral but does not detract. (3) Multi-hop reasoning assessment: The core of the question requires synthesizing Biktarvy’s strategic evolution with respect to financial risk and competitive differentiation. The LLM answer correctly infers increased risk but extends beyond the source material by introducing specific external factors—Medicare Part D rebates, the Inflation Reduction Act, CAR-T therapies, cell-therapy manufacturing, and acquisitions—that are not mentioned or implied in the ground truth. These additions, while plausible in a broader industry context, are not supported by the provided knowledge graph and represent speculative expansion. (4) The original answer focuses narrowly on the shift in treatment paradigms away from TAF-based regimens and the resulting threat to Biktarvy’s differentiation and revenue sustainability. The LLM answer shifts focus toward Gilead’s strategic pivots into oncology and systemic financial volatility, which, while contextually relevant, are not part of the documented evolution in the knowledge graph. Thus, while the answer is well-structured and contextually plausible, it fails to stay grounded in the specific evidence, resulting in a partially correct but overextended response. Correctness score is 6 due to core factual alignment but significant unsupported elaboration.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 534,
        "total_tokens": 1929
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How did Lockheed Martin's approach to defined contribution retirement savings plans evolve between 2022 and 2023, particularly in terms of pension obligation transfers and associated financial impacts?",
      "original_answer": "In 2022, Lockheed Martin transferred $4.3 billion of gross defined benefit pension obligations through group annuity contracts, recognizing a noncash pension settlement charge of $1.5 billion. In 2023, instead of another annuity purchase, the company made $414 million in settlement payments to approximately 6,500 former employees who had not yet started receiving benefits. This shift indicates a strategic evolution from transferring large blocks of pension obligations to insurers (as in 2022) to directly settling smaller portions of obligations with individual participants in 2023.",
      "llm_answer": "Between 2022 and 2023, Lockheed Martin accelerated its defined contribution pension strategy by completing two major pension obligation transfers: the August 3 2021 purchase of group annuity contracts that transferred $4.9 billion of qualified defined‑benefit obligations for about 18,000 retirees, and the December 3 2020 transaction that moved $1.4 billion of pension liabilities to an insurer. In 2023, the company finalized a $414 million settlement payment to former employees who had not yet begun receiving benefits, further reducing its pension liability. These transfers eliminated the company’s responsibility for the associated obligations, required no additional funding, and resulted in non‑cash settlement charges that were recorded in accumulated other comprehensive loss. Consequently, the financial impact was a reduction in future pension outflows and a one‑time accounting charge, while the underlying benefit payments to retirees remained unchanged.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that the $4.9 billion annuity purchase occurred on August 3, 2021, and the $1.4 billion transaction on December 3, 2020—both dates and amounts are wrong. According to the ground truth, in 2022, Lockheed Martin transferred $4.3 billion of pension obligations with a $1.5 billion noncash charge. The LLM misattributes events to 2020 and 2021 instead of 2022, and uses incorrect dollar figures. Only the 2023 $414 million settlement payment to approximately 6,500 former employees is correctly reported. (2) Quantitative accuracy is severely compromised: the $4.3 billion (2022) transfer is misrepresented as two earlier transactions totaling $6.3 billion ($4.9B + $1.4B), which did not occur in the reported years. The $1.5 billion noncash charge from 2022 is omitted entirely, and instead the answer vaguely references charges 'recorded in accumulated other comprehensive loss'—this contradicts the ground truth, which specifies a $1.5 billion charge, likely recognized in earnings, not OCI. (3) The multi-hop reasoning is flawed: the question asks for evolution between 2022 and 2023, but the model fails to correctly identify the 2022 action, instead citing outdated and inaccurate transactions. It misses the strategic shift from large insurer transfers (2022) to direct individual settlements (2023) because it misplaces the timing and nature of the earlier action. (4) Contextual relevance is moderate—the answer discusses pension obligation transfers and financial impacts, which is relevant, but the incorrect data and timeline undermine the analysis. The conclusion about reduced outflows and accounting charges has some validity, but the reasoning is based on false premises. Overall, major factual and temporal errors result in a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1403,
        "completion_tokens": 502,
        "total_tokens": 1905
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has the composition of IBM's debt instruments maturing in 2025 evolved between 2022 and 2024, particularly regarding the 2.875% Notes due 2025?",
      "original_answer": "In 2022, IBM listed the 2.875% Notes due 2025 (IBM 25A) among other Notes due in 2025, including the 0.950% Notes due 2025 (IBM 25B) and the 0.875% Notes due 2025 (IBM 25C). By 2024, the 2.875% Notes due 2025 (IBM25A) remained, but the 0.875% Notes due 2025 (IBM 25C) were no longer listed, indicating a shift in the debt composition for that year. The 2.875% Notes due 2025 continued to be a key part of IBM's debt structure in 2024, suggesting a strategic decision to maintain this specific financial instrument while retiring or restructuring others.",
      "llm_answer": "The 2.875% Notes due 2025 were first listed as a $1.5 billion issue maturing in 2025 in IBM’s 2021 Form 10‑K (page 1), and by 2024 the same security remained identified as “2.875% Notes due 2025” in the 2024 filing (page 1). However, the 2024 filing shows the 2025 maturity now grouped with other 2025 notes (e.g., 0.950% Notes due 2025, 0.875% Notes due 2025) and no separate disclosure of its outstanding balance or recent evolution is provided, indicating that the composition of IBM’s debt maturing in 2025 has not changed materially between 2022 and 2024 beyond the continued presence of the 2.875% Notes alongside other 2025‑maturing securities.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies compared to the ground truth. It incorrectly states that the 2.875% Notes due 2025 were first listed in the 2021 Form 10-K, which is irrelevant to the question focusing on 2022–2024 evolution. More critically, it claims that in 2024, the 2025 maturity includes both the 0.950% and 0.875% Notes — this directly contradicts the ground truth, which states that by 2024, the 0.875% Notes due 2025 (IBM 25C) were no longer listed. Thus, the LLM misrepresents the composition change, asserting continuity when there was a notable removal. (2) Quantitatively, the $1.5 billion figure for the 2.875% Notes is plausible but not confirmed in the ground truth, which does not provide outstanding balances. The percentages (2.875%, 0.950%, 0.875%) are correctly cited, but the erroneous inclusion of the 0.875% Notes in 2024 undermines quantitative accuracy. (3) The multi-hop reasoning is flawed: the model fails to detect the disappearance of IBM 25C between 2022 and 2024, a key shift in debt composition. Instead, it concludes no material change occurred, missing the strategic implication highlighted in the original answer — that IBM maintained the 2.875% Notes while retiring others. (4) Contextual relevance is moderate: the answer addresses IBM’s debt instruments maturing in 2025 and focuses on the 2.875% Notes, satisfying the surface structure of the question. However, due to incorrect synthesis of the 2024 debt lineup, the conclusion is factually wrong. Correctness score is low due to core factual error in entity presence (IBM 25C) across years, despite some correct metric names and rates.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 452,
        "total_tokens": 1753
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has the strategic importance and risk profile of Biktarvy within Gilead's HIV portfolio evolved from 2022 to 2024, particularly in light of competitive pressures and changes in the treatment paradigm?",
      "original_answer": "In 2022, Biktarvy was positioned as a key growth driver for Gilead, with the company noting its 'continued growth in all geographies' and attributing part of the 11% revenue increase to its performance. By 2024, however, the strategic importance of Biktarvy appears more precarious. The 2024 10-K highlights increased risks around Gilead's HIV franchise, noting that 'many of our HIV products contain TAF' and that any shift away from nucleoside-based therapies could materially impact sales. This suggests that while Biktarvy was a growth asset in 2022, by 2024 it was increasingly seen as vulnerable to paradigm shifts in HIV treatment, representing a change in both strategic positioning and risk exposure.",
      "llm_answer": "From 2022 to 2024, Biktarvy’s strategic importance within Gilead’s HIV portfolio has intensified as it became the primary replacement for legacy Truvada/Atripla products after their 2020 U.S. loss of exclusivity, driving sustained growth in HIV sales despite generic competition. However, its risk profile has evolved amid competitive pressures: while Biktarvy maintains strong market share due to its efficacy and favorable resistance profile, the company acknowledges that shifts in HIV treatment paradigms—such as potential moves away from nucleoside-based regimens—could materially impact its sales, as noted in the 2022–2024 risk disclosures. Additionally, broader industry pricing pressures from U.S. healthcare reforms (e.g., the Inflation Reduction Act) and reimbursement challenges for HIV therapies have increased financial and regulatory risks to its commercial performance.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in its qualitative assessment and contains no numerical inaccuracies, as the original answer does not include specific numeric values (e.g., revenue figures, percentages beyond the 11% mentioned in the ground truth). The LLM correctly identifies Biktarvy as a key growth driver replacing older products like Truvada/Atripla, which aligns with Gilead's narrative in the 2022–2024 filings. It also accurately reflects the increased risk due to potential shifts away from nucleoside-based therapies, citing the same concern about TAF-containing products noted in the 2024 10-K. However, the LLM introduces information not present in the ground truth: specifically, the claim that Biktarvy became the 'primary replacement' post-2020 exclusivity loss and references to the Inflation Reduction Act and broader pricing pressures. While plausible and contextually relevant, these points are not supported by the provided ground truth and represent an expansion beyond the documented evolution in strategic importance and risk. The core multi-hop reasoning—linking Biktarvy’s growing centrality to increasing vulnerability due to treatment paradigm shifts—is sound and matches the knowledge graph. The answer is semantically aligned but includes some extraneous details, slightly reducing qualitative accuracy. Quantitative accuracy is scored highly because no incorrect numbers are presented, and all referenced disclosures (e.g., risk factors in 2022–2024) are plausibly consistent with the source material.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1413,
        "completion_tokens": 419,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How did the balance of the U.S. litigation escrow account evolve between the end of fiscal year 2022 and the end of fiscal year 2023, and what were the specific deposit contributions during each period?",
      "original_answer": "The balance of the U.S. litigation escrow account increased significantly from $1,449 million at the end of fiscal year 2022 to $3,089 million at the end of fiscal year 2023. During this time, deposits into the account rose from $1,000 million in fiscal year 2022 to $1,500 million in fiscal year 2023.",
      "llm_answer": "The U.S. litigation escrow account balance increased from $1,449 million at the end of fiscal 2022 to $1,764 million at the end of fiscal 2023. During fiscal 2023, the Company deposited $1,000 million into the escrow account, and during fiscal 2022 it deposited $850 million.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in both the final balance and deposit amounts. According to the ground truth, the U.S. litigation escrow account balance increased from $1,449 million at the end of fiscal year 2022 to $3,089 million at the end of fiscal year 2023. However, the LLM incorrectly reports the 2023 balance as $1,764 million, which is off by over $1.3 billion. Additionally, the deposit contributions are wrong: the LLM states $850 million in fiscal 2022 and $1,000 million in fiscal 2023, whereas the correct figures are $1,000 million in 2022 and $1,500 million in 2023. (2) These numerical errors are severe and affect both key metrics asked in the question—balance evolution and deposit contributions. The difference in balances reported by the LLM ($1,764M - $1,449M = $315M increase) does not match the actual increase of $1,640M ($3,089M - $1,449M), nor does it align with the deposit increase of $500M ($1,500M - $1,000M). (3) While the LLM correctly identifies the need to compare two fiscal years and report both balances and deposits—indicating some level of multi-hop reasoning—the synthesis is based on incorrect data, undermining the logic. (4) The contextual relevance is high because the structure and intent of the response match the question, but due to major quantitative and qualitative inaccuracies, the correctness and accuracy scores are very low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1158,
        "completion_tokens": 394,
        "total_tokens": 1552
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has the role of fountain syrups in Coca-Cola's North America operating segment evolved between 2022 and 2023, particularly regarding the company's manufacturing and distribution responsibilities?",
      "original_answer": "In 2022, Coca-Cola explicitly stated that it manufactured fountain syrups in the United States and sold them directly to fountain retailers or to authorized fountain wholesalers or bottling partners for further distribution. By 2023, the company's description shifted: while it still referenced selling fountain syrups in the North America segment, it also indicated that outside the U.S., bottling partners were authorized to manufacture fountain syrups using company concentrates. This suggests a nuanced evolution where Coca-Cola may be emphasizing a more decentralized, authorization-based model, particularly outside the U.S., while maintaining direct control within the U.S. There is no explicit mention of a change in manufacturing responsibilities within North America itself, indicating operational continuity there.",
      "llm_answer": "Between 2022 and 2023, the role of fountain syrups in Coca-Cola’s North America operating segment shifted from being primarily a distributor‑manufacturer of fountain syrups to a more integrated supplier‑manufacturer role.  In 2022 the company described selling fountain syrups to fountain retailers, who then sold them to retailers or to authorized fountain wholesalers/bottling partners; by 2023 the same description retained this structure but was framed within the broader context of the North America segment’s concentrate and finished‑product operations, emphasizing that fountain‑syrup sales remain part of the concentrate operations that feed into the bottling system.  Consequently, while the company still manufactures and distributes fountain syrups, its responsibility now sits squarely within the North America concentrate‑operations line, supporting both the bottling partners and the direct sales of fountain‑syrup‑based beverages.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains no numeric data, so quantitative accuracy is not applicable—however, since there are no numbers to misstate, it is scored as fully accurate (10). The core issue lies in qualitative inaccuracy. The LLM claims a 'shift' from 2022 to 2023 in Coca-Cola’s role from 'distributor-manufacturer' to 'integrated supplier-manufacturer' in North America, which is not supported by the ground truth. The original answer clarifies that Coca-Cola continued to manufacture fountain syrups in the U.S. and sell them directly or through partners in both years, with no operational change stated within North America. The evolution noted in the ground truth is specifically about authorization of bottling partners to manufacture fountain syrups *outside the U.S.*, which the LLM answer omits entirely. (2) No calculations or numeric values are present, so no errors here. (3) The multi-hop reasoning is flawed: the LLM incorrectly infers a structural shift in North America based on framing changes, while missing the key cross-geography distinction (U.S. vs. outside U.S.) that is central to the actual evolution. It also fails to recognize that the continuity within North America is explicitly noted in the ground truth. (4) While the LLM answer is contextually relevant—focusing on fountain syrups, manufacturing, distribution, and the North America segment—it misrepresents the nature and location of the change, leading to a correctness score of 5 due to significant factual and reasoning errors despite correct terminology and plausible framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1455,
        "completion_tokens": 432,
        "total_tokens": 1888
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has the composition of IBM's debt instruments maturing in 2025 evolved between 2022 and 2024, particularly regarding the 0.950% Notes due 2025?",
      "original_answer": "In 2022, IBM had three sets of notes maturing in 2025: the 2.875% Notes due 2025 (IBM 25A), the 0.950% Notes due 2025 (IBM 25B), and the 0.875% Notes due 2025 (IBM 25C). By 2024, the 0.875% Notes due 2025 were no longer listed, leaving only the 2.875% Notes due 2025 (IBM 25A) and the 0.950% Notes due 2025 (IBM 25B). This indicates a reduction in the diversity of interest rate profiles for debt maturing in 2025, with the removal of the 0.875% instrument.",
      "llm_answer": "The 0.950% Notes due 2025 (trading symbol IBM25B) were first listed in IBM’s 2021 Form 10‑K (page 1) alongside other debt issues, and remained part of the company’s outstanding securities in the 2024 filing (page 1). The 2022 Form 10‑K (page 1) also continued to show IBM25B among its long‑term debt instruments, indicating that the issuance was already in place and unchanged through 2024. No subsequent amendment or new issuance of the 0.950% Notes due 2025 is disclosed in the provided pages, so the composition of IBM’s debt maturing in 2025 has remained stable, with the 0.950% Notes continuing to be a component of the 2025 maturity schedule.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies that the 0.950% Notes due 2025 (IBM25B) were present in IBM's debt portfolio from 2022 through 2024, which aligns with the ground truth. The dates and percentages related to this specific note are accurate, supporting a moderate quantitative accuracy score. However, the LLM fails to mention the existence and subsequent disappearance of the 0.875% Notes due 2025 (IBM 25C), which is a critical part of the evolution in debt composition. The original answer highlights a reduction in diversity of interest rate profiles due to the removal of the 0.875% instrument by 2024, but the LLM incorrectly concludes that the composition 'remained stable,' contradicting the ground truth. This omission represents a major qualitative inaccuracy in multi-hop reasoning—while the LLM tracks one instrument correctly, it fails to synthesize changes across all 2025-maturing notes. The answer is contextually relevant and addresses the question about evolution, but draws an incorrect conclusion due to incomplete analysis. Thus, while some facts are correct, the overall synthesis is flawed, warranting a correctness score of 4.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1276,
        "completion_tokens": 323,
        "total_tokens": 1600
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has Disney's strategic approach to cruise ships evolved between 2022 and 2024 based on disclosures in their 10-K filings?",
      "original_answer": "In 2022, Disney mentioned cruise ships as part of its broader travel and resort experiences, indicating that their success depended on consumer demand for out-of-home entertainment and travel. By 2024, Disney had elevated its approach, explicitly stating plans to 'expand investment in our Experiences segment' and 'additional expansion of our fleet of cruise ships.' This evolution reflects a shift from general dependence on consumer demand to an active investment and growth strategy in cruise ship operations. The 2024 filing also notes that new offerings, such as additional cruise ships, come with increased costs and uncertain returns, signaling a more capital-intensive and strategic focus compared to the more passive mention in 2022.",
      "llm_answer": "Disney’s cruise‑ship strategy has shifted from a modest, destination‑focused expansion to a broader, multi‑year fleet growth plan that is now explicitly tied to its overall Experiences and DTC initiatives.  In the 2022 filing the company highlighted a single upcoming Disney‑Cruise‑Line destination (Lighthouse Point on Eleuthera) slated for 2024, but by the 2024 filing it is describing a larger pipeline of new ships and a dedicated “cruise‑ship” segment within its Experiences business, emphasizing new vessel launches, expanded itineraries and deeper integration with its parks‑and‑resorts brand.  This evolution reflects Disney’s move to treat cruise‑line operations as a core growth engine rather than an ancillary destination offering.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the evolution in Disney's strategic approach to cruise ships between 2022 and 2024, aligning well with the ground truth. It correctly identifies a shift from a more passive, destination-focused mention in 2022 (Lighthouse Point) to an active, fleet-wide expansion strategy in 2024. The mention of Lighthouse Point as a 2024 destination is factually accurate and consistent with Disney’s disclosures. The 2024 emphasis on new vessel launches, expanded itineraries, and integration with parks is also supported. However, the LLM introduces the idea of a dedicated 'cruise-ship segment within its Experiences business,' which is not explicitly stated in the ground truth and may overstate organizational structuring. Additionally, while the LLM correctly infers strategic elevation, it does not mention the 2024 filing’s caution about increased costs and uncertain returns on new cruise investments—a key qualitative nuance in risk disclosure. Quantitatively, no specific numbers (e.g., dollar amounts, ship counts) are misstated, and dates (e.g., 2024 for Lighthouse Point) are accurate. The reasoning is sound in connecting strategic dots across years, though slightly less precise in reflecting the exact language and risk context from the filings. The answer remains highly relevant to the question and effectively conveys the strategic shift, warranting a high but not perfect score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 394,
        "total_tokens": 1760
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How did Lockheed Martin's approach to pension risk transfer transactions evolve from 2022 to 2023, particularly in terms of financial impact and strategic intent?",
      "original_answer": "In 2022, Lockheed Martin detailed a specific pension risk transfer transaction from August 3, 2021, where $4.9 billion of gross defined benefit pension obligations were transferred via group annuity contracts (GACs), resulting in a noncash pension settlement charge of $1.7 billion. The company also noted that since December 2018, it had transferred approximately $11.6 billion in pension obligations, eliminating volatility for around 95,000 retirees. By 2023, the company reiterated its strategic intent to continue evaluating such transactions but shifted focus toward the broader financial and risk implications, including potential future contributions to the pension trust and the possibility of additional noncash settlement charges. The 2023 filing also introduced a nuanced risk: while most GACs relieve Lockheed of pension obligations, some could leave the company liable if the insurer defaults. This reflects a more cautious framing of pension risk transfer, acknowledging residual liability exposure not emphasized in 2022.",
      "llm_answer": "From 2022 to 2023 Lockheed Martin’s pension‑risk‑transfer strategy remained focused on using group‑annuity contracts to off‑load defined‑benefit obligations, but the financial impact shifted. In 2021 the company recorded a $1.7 billion non‑cash settlement charge after purchasing $4.9 billion of GACs, yet this did not materially affect its overall pension expense. By 2023 the company continued to seek additional risk‑transfer transactions, which could generate further non‑cash settlement charges, but it no longer expects to make new contributions to its qualified pension plans and anticipates recovering about $1.8 billion of CAS pension costs in 2022, reflecting a strategic move to manage pension volatility rather than fund deficits.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $4.9 billion pension obligation transfer and the $1.7 billion noncash settlement charge from the August 3, 2021 transaction, which was disclosed in the 2022 filing—this is factually accurate and matches the ground truth. It also correctly notes that the strategy continued into 2023 with potential for additional noncash charges. However, the LLM incorrectly states that the $1.7 billion charge occurred in 2021 and was reported in 2022, while the ground truth clarifies that the transaction occurred on August 3, 2021, and was detailed in the 2022 filing—this is a minor temporal misrepresentation but not a major factual error. The mention of recovering $1.8 billion in CAS pension costs in 2022 is not present in the original answer and appears to be extraneous or incorrectly attributed information, which detracts from accuracy. (2) Quantitatively, the $4.9 billion and $1.7 billion figures are correct. The $1.8 billion recovery figure is not supported by the ground truth and introduces inaccuracy. The statement about no new contributions to qualified pension plans aligns with the strategic shift but is not explicitly confirmed in the provided ground truth. (3) The multi-hop reasoning is partially sound: the model connects the 2021 transaction to 2022 disclosures and infers continuity into 2023. However, it misses the key qualitative evolution in 2023—the introduction of residual liability risk if insurers default on GACs, which represents a more cautious framing not emphasized in 2022. This nuance is critical to the strategic intent evolution and is omitted, weakening the qualitative accuracy. (4) The answer remains contextually relevant and addresses both financial impact and strategic intent, but lacks completeness in capturing the full strategic shift, particularly the new risk acknowledgment. Hence, correctness is reduced to 7 due to missing key qualitative insight and one unsupported quantitative claim, despite strong performance on core facts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1448,
        "completion_tokens": 546,
        "total_tokens": 1995
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has Tesla's relationship with its financing partners evolved between 2022 and 2023, particularly in terms of accounts receivable management and leasing program risks?",
      "original_answer": "In 2022, Tesla disclosed that accounts receivable from financing partners could take up to approximately two weeks to settle based on contractual payment terms, directly impacting the company's short-term liquidity and balance sheet fluctuations. By 2023, Tesla highlighted increased complexity and risk in managing its financing programs, noting that its leasing business depends on securing adequate financing or partners, and that residual value risks from leased vehicles could negatively affect profitability. This indicates a shift from a focus on operational cash flow timing in 2022 to a broader concern over credit, compliance, and residual value risks in 2023 as the leasing program scaled.",
      "llm_answer": "Tesla’s financing‑partner relationship shifted markedly between 2022 and 2023.  In 2022 the company still held legacy MyPower customer notes receivable (net of allowance) of about $299 million, with only a small portion ($11 million) due within the next 12 months, and it relied on operating‑lease vehicles that were recorded at cost less accumulated depreciation (gross $5.28 billion in 2021).  By 2023 the company’s disclosures emphasize that its financing programs now expose it to “customer credit risk” and “residual‑value, financing and credit risks,” noting that defaults could trigger “substantial credit losses and/or impairment charges” and that resale‑value guarantees may require material adjustments if actual values fall short.  Consequently, accounts‑receivable management became more focused on monitoring long‑term government rebates and the timing of payments from financing partners, while leasing‑program risk grew because profitability hinges on accurate residual‑value forecasts and the ability to fund and manage the leasing portfolio.  (All figures are drawn from the 2022 and 2023 10‑K pages provided.)",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution in Tesla's financing partner relationship from 2022 to 2023, correctly identifying increased focus on credit risk, residual value exposure, and leasing program complexity. However, it introduces significant quantitative inaccuracies not present in the ground truth. The mention of 'MyPower customer notes receivable' of $299 million and $11 million due within 12 months, as well as the $5.28 billion operating lease figure from 2021, are not referenced in the original answer and appear to be fabricated or misattributed details not supported by the provided knowledge graph. These specific figures and program names (e.g., MyPower) are not mentioned in the ground truth, indicating a failure in factual fidelity. While the qualitative shift—moving from settlement timing in 2022 to broader credit, residual value, and financing risks in 2023—is correctly interpreted and aligns with the original answer, the inclusion of unsupported numerical data undermines the quantitative accuracy. The reasoning is logically sound in framing the evolution of risk focus, and the answer remains contextually relevant to the question about accounts receivable management and leasing risks. However, the incorrect numbers and specific program references (MyPower) reduce confidence in the data provenance, warranting a moderate correctness score. Semantic equivalence is partially achieved in narrative but not in factual precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1462,
        "completion_tokens": 402,
        "total_tokens": 1864
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "What changes occurred in Coca-Cola's fountain syrup distribution strategy between 2022 and 2023, and how did the roles of bottlers and fountain wholesalers evolve during this period?",
      "original_answer": "In 2022, Coca-Cola manufactured and sold fountain syrups directly to authorized fountain wholesalers (including certain authorized bottlers), who then sold or delivered the syrups to retailers. Bottlers in the U.S. were generally not authorized to manufacture fountain syrups. By 2023, the strategy evolved such that outside the United States, bottlers were typically authorized to manufacture fountain syrups using Coca-Cola concentrates, which they could sell to fountain retailers or authorized fountain wholesalers. This represents a shift from a more centralized syrup distribution model to a more integrated one, where bottlers play a more active role in the fountain syrup supply chain, particularly in international markets.",
      "llm_answer": "Between 2022 and 2023, Coca-Cola shifted its fountain syrup distribution strategy to increasingly work with authorized fountain wholesalers rather than directly supplying fountain syrups to retailers, while continuing to sell fountain syrups to bottling partners for resale to fountain retailers. The roles of bottlers and fountain wholesalers evolved such that bottlers (especially in the U.S.) were no longer authorized to manufacture fountain syrups themselves, instead purchasing them from the Company or authorized wholesalers, while fountain wholesalers became the primary distributors of fountain syrups to end-use retailers like restaurants and convenience stores. This change allowed the Company to maintain control over syrup supply while leveraging specialized distributors for broader market reach.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies regarding Coca-Cola's fountain syrup distribution strategy evolution. Contrary to the ground truth, the LLM claims that bottlers (especially in the U.S.) were *no longer authorized* to manufacture fountain syrups in 2023, when in fact the shift was the opposite: outside the U.S., bottlers became *authorized* to manufacture fountain syrups using Coca-Cola concentrates. The ground truth describes a decentralization and increased role for bottlers internationally, while the LLM incorrectly portrays a centralization where bottlers lost manufacturing rights. Additionally, the LLM incorrectly states that Coca-Cola shifted to working *more* with authorized fountain wholesalers, whereas the actual change was toward empowering bottlers in international markets, reducing reliance on separate wholesalers. (2) There are no numeric values, dates, or calculations in either the question or answers, so quantitative accuracy is not applicable—no errors in this regard, hence a score of 10. (3) The multi-hop reasoning is fundamentally flawed. The model fails to correctly synthesize the shift from a centralized (Company-manufactured, wholesaler-distributed) model in 2022 to a more integrated, bottler-participatory model in 2023, especially outside the U.S. Instead, it inverts the direction of change. This reflects a failure in understanding and representing the evolution of roles. (4) Contextual relevance is moderate—the answer discusses fountain syrup distribution, bottlers, and wholesalers, so it stays on topic. However, due to the core factual reversal of the strategic shift, the qualitative accuracy and overall correctness are severely compromised, warranting low scores of 3. The answer sounds plausible but conveys the opposite of the truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 495,
        "total_tokens": 1890
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between 2023 and 2024, particularly in terms of receivables and new investment activities?",
      "original_answer": "In 2023, AMD had receivables from the ATMP JV of $9 million, and there was no mention of any direct investment or loan made by AMD to the JV. By 2024, AMD's receivables from the ATMP JV increased to $12 million, and the company entered into a new $100 million one-year term loan agreement with one of the ATMP JVs to support its general corporate purposes. This marks a significant shift from a purely transactional relationship in 2023 to a more financially integrated one in 2024, where AMD is not only a customer but also a creditor and strategic supporter of the JV.",
      "llm_answer": "Between 2023 and 2024, AMD's financial relationship with the ATMP JV evolved through increased investment and receivable activity. In 2024, AMD contributed $17 million to the ATMP JV (bringing its total equity investment to $149 million as of December 28, 2024, up from $99 million in 2023), and had receivables of $12 million from the JV as of December 28, 2024 (up from $9 million in 2023). Additionally, AMD recorded $16 million in equity income from the ATMP JV in 2023, reflecting ongoing financial engagement with the joint venture.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly states that AMD's receivables from the ATMP JV increased from $9 million in 2023 to $12 million in 2024, it fabricates key investment figures not present in the ground truth. It claims AMD contributed $17 million to the JV in 2024 and increased its total equity investment from $99 million to $149 million, which is not supported by the original answer. The ground truth explicitly states there was no direct investment or loan by AMD in 2023, and in 2024, AMD entered a $100 million one-year term loan — not an equity investment. The LLM incorrectly characterizes this as an equity contribution and misrepresents the nature of the financial activity. Additionally, the mention of $16 million in equity income in 2023 is not part of the ground truth and appears fabricated. (2) Quantitative accuracy is low: only the receivables figures ($9M and $12M) are correct. The $17M contribution, $149M total investment, $99M prior investment, and $16M equity income are all incorrect and unsupported. The critical $100 million term loan mentioned in the ground truth is entirely missing from the LLM response. (3) The multi-hop reasoning is flawed. The LLM fails to correctly synthesize the shift from a transactional to a creditor relationship, instead inventing an equity investment narrative. It does not mention the new loan agreement, which is central to the 2024 evolution. The reasoning incorrectly frames the relationship as equity-based rather than credit/loan-based. (4) Contextual relevance is moderate because the answer addresses the general theme of financial evolution and receivables, but it introduces irrelevant and incorrect details about equity investments and income, diverting from the actual nature of the relationship change. The core transformation — AMD becoming a lender via a $100M loan — is entirely omitted, which is a major failure in both completeness and correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 534,
        "total_tokens": 1813
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did Lockheed Martin's approach to managing its nonqualified defined benefit pension plans evolve between 2022 and 2023, particularly in terms of pension obligation settlements and associated financial impacts?",
      "original_answer": "In 2022, Lockheed Martin purchased group annuity contracts to transfer $4.3 billion of gross defined benefit pension obligations and recognized a noncash pension settlement charge of $1.5 billion. In 2023, the company continued its strategy of reducing pension liabilities by making voluntary settlement payments of $414 million to approximately 6,500 former employees, significantly smaller in scale compared to the 2022 transaction. This indicates a shift from large-scale pension obligation transfers to a more targeted approach involving smaller settlements with former employees who had not yet started receiving benefits.",
      "llm_answer": "Lockheed Martin accelerated the settlement of its nonqualified defined benefit pension obligations through two key actions between 2022 and 2023: in August 2021 it purchased group annuity contracts to transfer $4.9 billion of qualified pension liabilities (relieving the company of those obligations beginning January 1 2022) and recognized a $1.7 billion noncash settlement charge for the accelerated actuarial losses, and in 2023 it executed a voluntary settlement that paid $414 million to approximately 6,500 former employees, further reducing the benefit obligation. These settlements shifted the remaining pension liabilities to insurance companies and resulted in significant non‑operating pension expense and a reduction of accumulated other comprehensive loss, but did not affect the monthly benefit payments to retirees.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. It incorrectly states that the group annuity purchase occurred in August 2021 (not 2022), and claims the transferred amount was $4.9 billion (vs. $4.3 billion in the ground truth). It also reports a $1.7 billion settlement charge (vs. $1.5 billion actual). These errors affect core financial data and timing. The 2023 settlement amount ($414 million) and number of employees (~6,500) are correct. (2) Quantitative accuracy is low: the 2022 figures are all wrong—$4.9B vs $4.3B (obligation), $1.7B vs $1.5B (charge), and incorrect date (2021 vs 2022). The 2023 numbers match. (3) The reasoning partially captures the evolution—shifting from large-scale transfers to smaller voluntary settlements—but misattributes the 2022 annuity purchase to 2021 and mislabels it as involving 'qualified' pension liabilities, while the question and truth refer to 'nonqualified' plans. This undermines the multi-hop synthesis. (4) Contextual relevance is high as the answer addresses pension obligation settlements and financial impacts, but factual errors in key numbers, dates, and plan type reduce correctness. The conclusion about shifting liabilities and reducing AOCI is plausible but not fully supported due to inaccuracies. Overall, partial credit for correct 2023 data and directional reasoning, but major deductions for incorrect 2022 facts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 389,
        "total_tokens": 1770
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did AMD's financial relationship with the ATMP JV evolve between 2023 and 2024, particularly in terms of its investment and equity income?",
      "original_answer": "In 2023, AMD recorded $16 million in equity income from the ATMP JV and had a carrying value of $99 million as of the end of the year. In 2024, AMD contributed an additional $17 million to the JV, increasing its investment's carrying value to $149 million by the end of the year. Equity income also rose to $33 million. This indicates a significant increase in both AMD's investment stake and the returns it received from the ATMP JV.",
      "llm_answer": "Based on the provided SEC 10-K filings, AMD's financial relationship with the ATMP JV evolved significantly between 2023 and 2024. In 2024, AMD made an additional $17 million equity contribution to the ATMP JV, increasing its equity interest to 15% and raising the carrying value of its investment from $99 million (as of December 30, 2023) to $149 million (as of December 28, 2024). This investment generated $33 million in equity income for 2024, compared to $16 million in 2023, reflecting the growth in AMD's stake and related earnings from the joint venture.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key financial figures are correct: $16M equity income in 2023, $33M in 2024, $17M additional contribution in 2024, carrying value increasing from $99M to $149M. These match the original answer exactly, with acceptable date formatting (December 30, 2023 and December 28, 2024 being plausible fiscal year-end dates for AMD). (2) Quantitative accuracy is perfect—no calculation errors, and the numbers reflect proper synthesis across years and metrics. (3) The only minor issue is the introduction of a new detail not present in the ground truth: the claim that AMD’s equity interest increased to 15%. This specific percentage is not mentioned in the original answer and cannot be verified from the provided truth, making it an unsupported addition. However, it does not contradict the data and is plausible given the increased investment. (4) The reasoning is sound, with correct multi-hop synthesis between 2023 and 2024 data points (investment, carrying value, equity income). The answer fully addresses the evolution of AMD’s financial relationship with the ATMP JV. (5) Semantic equivalence is strong—core facts, trends, and implications are correctly conveyed. The added percentage slightly affects qualitative accuracy but doesn’t undermine correctness. Contextual relevance is excellent, directly addressing the question with precise, relevant details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1248,
        "completion_tokens": 396,
        "total_tokens": 1644
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did Johnson & Johnson's financial stake and ownership relationship with Kenvue evolve between 2023 and 2024, particularly in terms of retained equity and associated gains or losses?",
      "original_answer": "In 2023, Johnson & Johnson retained a 9.5% ownership stake in Kenvue valued at $4.3 billion following the exchange offer, which resulted in a non-cash gain of $21.0 billion, including a $2.8 billion gain on the retained shares. By the end of 2024, the company completed a Debt-for-Equity Exchange of its remaining 182,329,550 shares of Kenvue Common Stock, thereby eliminating its ownership stake and incurring a loss of approximately $0.4 billion in the process. This marks a full exit from Kenvue after initially reducing its stake significantly in 2023.",
      "llm_answer": "Johnson & Johnson retained a 9.5% equity stake in Kenvue following the August 23 2023 exchange offer, which it recorded as a $4.3 billion gain (including a $2.8 billion gain on the shares it kept) in discontinued‑operations earnings.  By May 17 2024 the company completed a debt‑for‑equity swap that eliminated its remaining Kenvue shares, resulting in a $0.4 billion loss that was recorded in other income/expense.  Thus, between 2023 and 2024 the retained equity was gradually divested, moving from an $2.8 billion gain on the retained stake in 2023 to a net loss of about $0.4 billion in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the essential evolution of Johnson & Johnson's ownership in Kenvue between 2023 and 2024. (1) Quantitatively, all key figures are correct: the 9.5% retained stake, $4.3 billion total gain (with $2.8 billion attributed to retained shares), and the $0.4 billion loss in 2024 are consistent with the ground truth. The dates—August 23, 2023, and May 17, 2024—are correctly specified and align with known public disclosures. (2) The only minor discrepancy is in the characterization of the $4.3 billion: the original answer states this was the *value* of the retained stake, while the LLM describes it as a 'gain'—this slightly conflates the total gain from the spin-off with the value of the retained equity. However, the LLM correctly notes a $2.8 billion gain on the retained shares, which matches the ground truth. The $0.4 billion loss is accurately reported. (3) The reasoning is sound: the LLM correctly traces the two-step divestment—initial reduction in 2023 with a gain, followed by full exit in 2024 with a loss—and synthesizes the financial outcomes across years. (4) Entities (Johnson & Johnson, Kenvue), timeframes, and financial terms (debt-for-equity swap, gains/losses) are accurate. The answer is fully relevant and addresses both retained equity and associated gains/losses. Minor imprecision in describing the $4.3 billion prevents a perfect 10, but overall correctness is excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 397,
        "total_tokens": 1695
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How did AT&T's financial guarantee relationship with Southwestern Bell Telephone Co. evolve between 2022 and 2023, particularly in terms of its inclusion in guarantee agreements?",
      "original_answer": "AT&T's financial guarantee relationship with Southwestern Bell Telephone Co. remained consistent between 2022 and 2023, with the company continuing to guarantee certain obligations of Southwestern Bell Telephone Co. in both years. In 2022, the guarantee was listed in Exhibit 4-c, which included multiple entities such as Southwestern Bell Telephone Company. In 2023, the guarantee was again referenced in Exhibit 4-c, maintaining the same inclusion of Southwestern Bell Telephone Co. within the list of guaranteed entities. This indicates no change in the nature or scope of the guarantee.",
      "llm_answer": "Between 2022 and 2023, AT&T's guarantee relationship with Southwestern Bell Telephone Co. remained unchanged in terms of inclusion in guarantee agreements. The 2011 Exhibit 4-c guarantee of Southwestern Bell's obligations was still referenced in the 2023 filing (page 103), confirming its continued presence in AT&T's disclosure documents without any documented evolution or modification during this period.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually correct and semantically equivalent to the ground truth, with only a minor discrepancy in detail specificity. (1) The core claim—that AT&T's guarantee relationship with Southwestern Bell Telephone Co. remained unchanged between 2022 and 2023—is accurate and matches the original answer. The guarantee was indeed consistently included in Exhibit 4-c in both years. (2) Quantitatively, the LLM correctly references the 2011 origin of Exhibit 4-c and its presence in the 2023 filing (page 103), which aligns with typical SEC filing practices, though the ground truth does not specify the page number. This addition (page 103) is plausible and not incorrect, but not verifiable from the original answer. The mention of '2011 Exhibit 4-c' is contextually accurate as such guarantees often originate earlier and are carried forward. (3) The multi-hop reasoning is sound: the model correctly infers continuity by noting the persistent reference to the same exhibit across years, demonstrating synthesis across time periods. (4) The only minor shortcoming is that the LLM does not explicitly mention the 2022 exhibit reference (though it's implied), slightly reducing completeness compared to the original answer’s explicit symmetry. However, the conclusion of 'no change' is fully supported. Wording differs but meaning is preserved. Scores reflect high accuracy with a small deduction in quantitative and qualitative categories due to incomplete symmetry in evidence presentation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1257,
        "completion_tokens": 411,
        "total_tokens": 1669
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has Lockheed Martin's involvement in hypersonics programs evolved from 2022 to 2023, particularly in terms of strategic positioning and program development responsibilities?",
      "original_answer": "In 2022, Lockheed Martin's involvement in hypersonics programs was described as a growth area that was dependent on U.S. Government authorization and funding, and was listed among other key development areas like classified programs and next-generation franchise programs. By 2023, the company's role had evolved significantly, with hypersonics programs now explicitly listed among major programs under the Space segment, indicating a more concrete and active role in designing, developing, and building hypersonic strike weapons for the U.S. Army and Navy. This reflects a shift from a potential growth area to a clearly defined and active program portfolio.",
      "llm_answer": "From 2022 to 2023, Lockheed Martin’s hypersonics efforts remained a strategic priority, with the company continuing to develop and transition multiple hypersonic programs—such as the Hypersonic Conventional Strike Weapon (HCSW) and the Hypersonic Air-breathing Weapon Concept (HAWC)—into early production phases, targeting initial operational capability through 2026. The 2023 filing emphasizes that these programs are part of the company’s broader “21st Century Security” strategy, highlighting growth in hypersonics alongside classified programs and next‑generation platforms, while also noting that evolving U.S. government procurement policies and budget pressures could influence the timing and funding of these initiatives.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures some correct elements about Lockheed Martin's continued strategic focus on hypersonics and mentions relevant programs like HCSW and HAWC, which aligns with the general direction of the company's activities. The mention of the '21st Century Security' strategy and government funding dependencies is contextually appropriate and reflects accurate qualitative themes. However, the LLM introduces specific program names (HCSW, HAWC) and a timeline (initial operational capability by 2026) that are not present in the original ground truth, which only describes a shift in reporting and strategic positioning without citing specific programs or dates. This constitutes a factual overreach. The ground truth emphasizes a structural evolution in how hypersonics were categorized—from a potential growth area in 2022 to a major active program under the Space segment in 2023—indicating increased strategic commitment. The LLM fails to highlight this key shift in reporting structure and program classification, instead focusing on production timelines and capabilities not mentioned in the original answer. While the general idea of sustained strategic importance is correct, the LLM fabricates specifics and misses the core multi-hop insight: the change in disclosure and categorization reflecting deeper program maturation. Quantitatively, no hard numbers are misstated (so accuracy is high), but the introduction of unsupported dates (2026 IOC) affects factual reliability. Contextually, the answer remains relevant to hypersonics development, but the reasoning does not fully reflect the evidence-based evolution described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 451,
        "total_tokens": 1806
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How did the balance of the U.S. litigation escrow account evolve from fiscal year 2022 to fiscal year 2023, and what were the respective amounts deposited into the account during those years?",
      "original_answer": "The balance of the U.S. litigation escrow account increased significantly from $1.4 billion as of September 30, 2022, to $3.089 billion as of September 30, 2023. During fiscal year 2022, $850 million was deposited into the account, while in fiscal year 2023, $1.0 billion was deposited.",
      "llm_answer": "The U.S. litigation escrow account balance increased from $1.4 billion at the end of fiscal 2022 to $1.8 billion at the end of fiscal 2023, reflecting deposits of $1.0 billion in fiscal 2023 (compared with $850 million deposited in fiscal 2022).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the reported balance for fiscal year 2023. The ground truth states the balance was $3.089 billion as of September 30, 2023, but the LLM incorrectly reports it as $1.8 billion—a major discrepancy of over $1.2 billion. The opening balance of $1.4 billion for fiscal 2022 is correct. Deposits are partially correct: the LLM correctly states $850 million was deposited in fiscal 2022 and $1.0 billion in fiscal 2023, which matches the ground truth. However, the resulting balance is mathematically inconsistent: starting from $1.4B and adding $1.0B should yield at least $2.4B even before interest or withdrawals, making $1.8B implausible. (2) Quantitative accuracy is low because the key balance figure for 2023 is wrong despite correct deposit amounts. The error is not a formatting issue but a fundamental factual one. (3) The reasoning is partially sound in that the model recognizes the need to report both balances and deposits across two fiscal years (multi-hop synthesis), but it fails to correctly compute or retrieve the ending balance after deposits, indicating a breakdown in logical consistency. (4) Contextual relevance is high because the answer addresses all components of the question—balance evolution and deposits per year—and uses appropriate terminology. However, due to the critical error in the 2023 balance, the overall correctness score is low, falling in the 'partially correct with significant errors' range.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1144,
        "completion_tokens": 415,
        "total_tokens": 1559
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has the role and positioning of Outdoor Garden within HD's product strategy evolved from 2022 to 2024, based on its classification and performance metrics?",
      "original_answer": "In 2022, Outdoor Garden was disclosed as a distinct product line with $10,317 million in net sales, accounting for 6.8% of total net sales, indicating its importance as a standalone category. By 2024, Outdoor Garden was grouped under the broader 'Hardlines' merchandising department, suggesting a strategic integration into a larger product segment. This shift reflects a change in how HD positions Outdoor Garden within its overall product portfolio, moving from a separate focus area to a component of a consolidated category.",
      "llm_answer": "Based on the provided 10-K pages, Outdoor Garden's role within HD's product strategy has evolved from being classified under \"Hardlines\" (alongside Hardware, Indoor Garden, and Tools) in fiscal 2021–2022 to being explicitly grouped under \"Hardlines\" alongside other key categories like Indoor Garden in the current merchandising structure. Performance metrics show Outdoor Garden consistently contributed approximately 6.5–6.7% of total net sales across fiscal 2022–2024 ($10.0B–$10.5B), with stable growth (e.g., $10.039B in 2022 → $10.278B in 2023 → $10.308B in 2024), indicating it remains a steady, strategically important category within the Hardlines segment, which itself is a core pillar of HD's primary retail strategy.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Outdoor Garden was a *distinct product line* in 2022 with $10,317 million in net sales (6.8% of total), but by 2024 it was *grouped under Hardlines*, indicating a strategic shift from standalone to integrated. The LLM incorrectly states that Outdoor Garden was already under 'Hardlines' in 2021–2022, contradicting the original answer. This misrepresents the evolution as continuity rather than change. (2) Quantitative inaccuracies include fabricated figures: the LLM claims Outdoor Garden sales were $10.039B (2022), $10.278B (2023), $10.308B (2024), but the ground truth only provides 2022 data ($10,317M ≈ $10.317B). No 2023 or 2024 sales figures are in the original, nor is there support for '6.5–6.7%' range—2022 was 6.8%. The LLM invents a trend with unsupported precision. (3) The multi-hop reasoning is flawed: instead of identifying a strategic reclassification (from standalone to part of Hardlines), the LLM assumes consistent classification under Hardlines, missing the core evolution. It focuses on stable performance metrics not fully supported by the source, thus failing to capture the strategic shift in positioning. (4) Despite incorrect facts and reasoning, the answer is contextually relevant—addressing product strategy evolution, using correct entities (HD, Outdoor Garden, Hardlines), and attempting performance analysis. Hence, partial credit for structure and intent, but major deductions for factual and quantitative errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 427,
        "total_tokens": 1744
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has AMD maintained its emphasis on an engaging and open environment as its global workforce expanded from 2023 to 2024, and what does this suggest about its talent retention strategy in a competitive semiconductor industry landscape?",
      "original_answer": "In 2023, AMD reported having approximately 26,000 employees and emphasized being at its best when 'our culture of innovation, creative minds and people from all kinds of backgrounds work together in an engaging and open environment.' By 2024, AMD’s global workforce grew to approximately 28,000 employees, and the company reiterated the same language, stating it is 'at our best when our culture of innovation, creative minds and people from all kinds of backgrounds work together in an engaging and open environment.' Despite a 7.7% increase in workforce size, AMD maintained identical messaging around its cultural values. This suggests that AMD is intentionally preserving its inclusive and innovative culture as a strategic element to retain top talent in the highly competitive semiconductor industry, where attracting skilled professionals is critical.",
      "llm_answer": "AMD maintains its emphasis on an engaging and open environment as its workforce grows by consistently measuring and acting on employee sentiment through annual engagement surveys, promoting inclusive culture and diversity initiatives (e.g., ERGs, mentorship, advancing women in technology), and embedding these values into its talent strategy despite market competition. This approach signals a talent retention focus centered on culture, development, and flexibility—key differentiators in the competitive semiconductor industry where technical expertise and innovation are paramount.",
      "correctness_score": 5,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer includes several factual inaccuracies regarding quantitative data. The ground truth states that AMD's workforce grew from approximately 26,000 in 2023 to 28,000 in 2024, a 7.7% increase, with identical cultural messaging preserved across both years. However, the LLM answer does not mention any of these specific numbers, percentages, or the verbatim repetition of cultural language, which is central to the original answer. Instead, it introduces unverified initiatives such as 'annual engagement surveys,' 'ERGs,' 'mentorship programs,' and 'advancing women in technology' that are not present in the provided ground truth. (2) There are no correct numerical values or calculations referenced in the LLM answer, resulting in a very low quantitative accuracy score. The absence of the 26,000 → 28,000 headcount and 7.7% growth figure—key data points—represents a major omission. (3) While the LLM provides a plausible interpretation of AMD’s talent retention strategy, it fails to base its reasoning on the actual evidence from the knowledge graph (i.e., the verbatim repetition of cultural statements despite workforce growth). This breaks the multi-hop logic chain: the correct inference should be that consistent messaging amid expansion reflects intentional cultural preservation. The LLM instead assumes specific programs without evidence, weakening the qualitative accuracy. (4) Despite factual shortcomings, the answer remains contextually relevant by addressing the broader themes of culture, talent retention, and competitiveness in the semiconductor industry. It offers a reasonable strategic interpretation, even if not grounded in the provided data, hence a moderate contextual relevance score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 473,
        "total_tokens": 1856
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did AT&T's relationship with The Ohio Bell Telephone Company evolve between 2022 and 2023, particularly in terms of its guarantee obligations?",
      "original_answer": "In 2022, AT&T had a guarantee obligation covering The Ohio Bell Telephone Company as part of a broader list of subsidiaries under Exhibit 4-c, which was originally filed in 2011. In 2023, although the structure of the guarantee remained similar, the exhibit reference was updated to reflect current documentation practices, indicating a continuation of the guarantee without any explicit discontinuation or expansion. This suggests that the nature of the relationship remained stable, but documentation was maintained in line with current reporting standards.",
      "llm_answer": "Based on the provided SEC 10-K filings, AT&T's guarantee obligations related to The Ohio Bell Telephone Company remained unchanged between 2022 and 2023. The 2011 Exhibit 4-d guarantee (referenced in both 2022 and 2023 filings) continues to cover obligations of The Ohio Bell Telephone Company as part of AT&T's ongoing guarantee structure, with no indication of termination, modification, or new guarantees noted in the 2022 or 2023 documents. The guarantee obligation is consistently disclosed as part of AT&T's corporate structure without evolution during this period.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly conveys that AT&T's guarantee obligation for The Ohio Bell Telephone Company remained stable between 2022 and 2023, with no termination or modification, which aligns with the ground truth. However, there is a discrepancy in the exhibit reference: the LLM states 'Exhibit 4-d' filed in 2011, while the original answer specifies 'Exhibit 4-c'. This is a factual error in entity/document identification. Additionally, the LLM claims the same exhibit was referenced in both 2022 and 2023 filings without noting the update in documentation practices mentioned in the ground truth, thus missing a key nuance about evolving reporting standards. (2) There are no numerical values to verify, so quantitative accuracy is based on correct dates (2011, 2022, 2023), which are accurate. The reference to the 2011 exhibit is correct in timing, but the exhibit letter (d vs c) is incorrect. (3) The multi-hop reasoning is partially sound—LLM correctly infers continuity of obligation from consistent disclosure—but fails to recognize the document update as an evolution in reporting, which weakens the qualitative accuracy. It treats 'no mention of change' as definitive evidence of no evolution, whereas the ground truth acknowledges a procedural update in exhibit referencing. (4) Despite the exhibit label error and omission of documentation updates, the core conclusion about stable guarantee obligations is supported, warranting a score of 7 for correctness. Contextual relevance is perfect as it directly addresses the question's focus on guarantee obligations and temporal evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 442,
        "total_tokens": 1725
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did the financial impact of GE's relationship with AerCap evolve between 2023 and 2024, particularly in terms of gains on retained and sold ownership interests?",
      "original_answer": "In 2023, GE reported a $5.7 billion increase in corporate operating profit due to higher gains on retained and sold ownership interests, primarily driven by its AerCap and GE HealthCare investments. However, in 2024, the gains on retained and sold ownership interests decreased by $5.2 billion compared to 2023, again primarily related to AerCap and GE HealthCare. This indicates a significant reduction in the value or realization of these investments year-over-year.",
      "llm_answer": "Based on the provided SEC 10-K pages, the financial impact of GE's relationship with AerCap evolved significantly between 2023 and 2024, particularly regarding gains on retained and sold ownership interests. In 2023, gains on retained and sold ownership interests totaled $5.778 billion (as disclosed in Note 19 of page 13), primarily driven by sales related to GE HealthCare and AerCap investments. By 2024, these gains increased substantially to $5.2 billion in net decreases (as noted in the 2024 earnings discussion on page 10), reflecting a $5.2 billion reduction in gains from prior-year levels due to the nonrecurrence of prior-year gains on AerCap and HealthCare investments, partially offset by other favorable items. This indicates that while gains on AerCap-related disposals were a major driver of 2023 results, their contribution diminished in 2024, with the company reporting lower gains on these interests.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors in key financial figures and misrepresents the direction of change between 2023 and 2024. The original answer states that in 2023, GE reported a $5.7 billion increase in corporate operating profit due to gains on retained and sold ownership interests, primarily from AerCap and GE HealthCare. In 2024, these gains *decreased by $5.2 billion* compared to 2023. However, the LLM incorrectly states that in 2024, gains 'increased substantially to $5.2 billion in net decreases,' which is both logically incoherent and factually wrong. It mischaracterizes a $5.2 billion *reduction in gains* as a '$5.2 billion in net decreases' being a new gain figure, reversing the meaning. Additionally, the LLM cites a 2023 gain of $5.778 billion (slightly inflated from the $5.7B in the original), but then implies that $5.2B is the 2024 gain, when in fact the 2024 figure reflects the *year-over-year decrease*, not the total gain. (2) The calculation and comparison are fundamentally flawed: the original correctly identifies a $5.2 billion *drop* in gains from 2023 to 2024; the LLM incorrectly treats this drop as the new gain amount, failing the core quantitative comparison. (3) The multi-hop reasoning is partially present—AerCap and GE HealthCare are correctly identified as the drivers in both years—but the synthesis fails because the model does not correctly interpret the financial movement. It confuses the delta (change) with the absolute value. (4) Contextual relevance is fair because the answer addresses the right companies, time frame, and metric type (gains on ownership interests), but the critical error in directionality and magnitude severely undermines correctness. The answer suggests gains increased when they actually dropped sharply. Thus, while the entities and general topic are correct, the core financial conclusion is inverted.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 516,
        "total_tokens": 1868
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How has Home Depot's strategic use of HD Supply evolved between 2022 and 2024, particularly in relation to its focus on professional customers and MRO services?",
      "original_answer": "In 2022, Home Depot highlighted the integration risks and challenges associated with its acquisition of HD Supply in 2020, noting that achieving synergies and benefits was subject to significant uncertainty and complexity. By 2024, HD Supply had become a core component of Home Depot’s strategy to serve professional customers, specifically through its MRO offerings to multifamily, hospitality, healthcare, and government housing facilities. The 2024 filing explicitly references HD Supply as a key contributor to Pro-focused growth initiatives, indicating a shift from post-acquisition integration concerns to a more mature and strategic role in supporting Home Depot's professional customer segment.",
      "llm_answer": "Home Depot’s strategic use of HD Supply has evolved from a legacy MRO distribution business into a targeted professional‑customer platform that now operates under the SRS acquisition.  In 2022 the company highlighted its “Pro” ecosystem—leveraging HD Supply’s MRO catalog, credit programs, and dedicated sales force—to serve professional contractors, remodelers and specialty trades.  By 2024, after acquiring SRS, Home Depot expanded that offering with a broader roofing, landscape and pool‑product line, enhanced credit (e.g., Pro House Account), and a more localized, interconnected supply‑chain that ties store inventory, BOPIS/BOSS delivery and digital tools directly to Pros’ complex project needs.  This evolution underscores a sharper focus on professional customers and MRO services as a growth engine within the broader home‑improvement portfolio.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains several factual inaccuracies that significantly undermine its correctness, despite some accurate elements. (1) The claim that HD Supply 'now operates under the SRS acquisition' is incorrect—SRS was not acquired by Home Depot, and there is no evidence in the ground truth or public filings that SRS was part of Home Depot’s corporate structure by 2024. This is a major entity and strategic misrepresentation. (2) The mention of 'Pro House Account' as an enhanced credit offering post-SRS acquisition is unsupported and likely fabricated, as no such program is referenced in the context of SRS or HD Supply in the ground truth. (3) While the 2022 focus on the 'Pro' ecosystem leveraging HD Supply’s MRO catalog, credit, and sales force aligns generally with the original answer, the original emphasizes integration risks and uncertainties, which the LLM omits entirely. (4) The 2024 evolution described—'broader roofing, landscape and pool-product line' via SRS—is not corroborated; the ground truth states HD Supply supports MRO for multifamily, hospitality, healthcare, and government housing, not residential specialty trades like roofing or pools. (5) The LLM introduces a 'localized, interconnected supply-chain' and integration with BOPIS/BOSS and digital tools, which, while plausible, are not mentioned in the ground truth and represent unsupported elaboration. (6) Quantitatively, there are no explicit numbers (e.g., dollar amounts, percentages), so scoring is based on temporal accuracy (2022 vs 2024), which is correct—the years are properly framed. (7) Multi-hop reasoning is partially sound: the model attempts to connect HD Supply to Pro services across years, but it fails by introducing a non-existent acquisition (SRS), breaking the chain of factual synthesis. (8) Contextual relevance is moderate—the answer addresses professional customers and MRO services, which is on-topic, but the strategic narrative is distorted by false premises. Overall, the answer conveys a plausible but factually incorrect evolution due to invented entities and programs, warranting a low correctness score despite coherent structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1393,
        "completion_tokens": 574,
        "total_tokens": 1967
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How has AMD's reliance on cross-licensing agreements evolved between 2023 and 2024, particularly in terms of patent portfolio size and its implications for technology exchange?",
      "original_answer": "In 2023, AMD reported having approximately 18,500 patent matters worldwide, including 12,800 issued patents and 5,600 pending applications. In 2024, this portfolio grew slightly to approximately 18,800 patent matters, with 13,200 issued patents and 5,600 pending applications. This increase in issued patents indicates a strengthening of AMD's intellectual property position, which likely enhances its leverage in cross-licensing agreements. AMD continues to emphasize that these agreements are critical for transferring and receiving technology and intellectual property rights, suggesting that the company's reliance on such agreements remains strong and possibly more strategically advantageous in 2024 due to the expanded patent portfolio.",
      "llm_answer": "AMD’s cross‑licensing and technology‑exchange framework remained stable between 2023 and 2024, continuing to rely on a broad portfolio of patents—approximately 13,200 issued worldwide in 2024 (up from roughly 12,800 in 2023) and about 5,600 pending applications—while emphasizing that no single patent or its expiration is material to the business. The company reiterated that it maintains numerous cross‑licensing agreements with other firms, enabling ongoing technology transfer, and it continues to acquire licenses for essential IP cores, software tools and other proprietary technologies to support product development. This patent‑portfolio growth and the persistent cross‑licensing model underpin AMD’s ability to exchange technology without significant disruption.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: 12,800 issued patents in 2023 and 13,200 in 2024, with 5,600 pending applications in both years. The total patent matters (18,500 in 2023 and 18,800 in 2024) are implied correctly through the sum of issued and pending patents. (2) The answer addresses all parts of the question: it discusses the evolution of AMD's reliance on cross-licensing agreements between 2023 and 2024, references the growth in patent portfolio (especially issued patents), and explains the implications for technology exchange. (3) The reasoning is sound: the slight increase in issued patents is correctly tied to a stronger IP position, and the continued emphasis on cross-licensing as a strategic mechanism is accurately conveyed. The LLM also adds relevant context about AMD acquiring external IP and tools, which supports the qualitative narrative. (4) Semantic equivalence is maintained—while the LLM does not explicitly state 'reliance remains strong and possibly more advantageous,' it conveys the same meaning by noting the persistent model and enhanced ability to exchange technology. The only minor omission is not explicitly stating the total patent matters (18,500 → 18,800), though this can be inferred. No factual or calculation errors are present. Thus, the answer earns a 9/10 for correctness and quantitative accuracy, with high marks for qualitative reasoning and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 408,
        "total_tokens": 1794
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did Johnson & Johnson's financial stake and strategic relationship with Kenvue evolve from 2023 to 2024, particularly regarding the retention and subsequent disposal of Kenvue shares?",
      "original_answer": "In 2023, Johnson & Johnson retained a 9.5% stake in Kenvue valued at $4.3 billion after completing the exchange offer in August. This stake was recorded in other assets and experienced a $0.4 billion expense by year-end due to subsequent changes. By 2024, the company completed a debt-for-equity exchange in May, using its remaining 182,329,550 shares of Kenvue Common Stock to satisfy $3.6 billion of commercial paper. This resulted in a $0.4 billion loss and marked the complete exit from Kenvue, ending any financial stake in the company.",
      "llm_answer": "Johnson & Johnson retained a 9.5% stake in Kenvue after the August 23 2023 exchange offer, recording the $4.3 billion fair‑value of that retained interest in other assets and recognizing a $21 billion gain in discontinued‑operations earnings. In May 2024 the company completed a debt‑for‑equity exchange, surrendering the remaining 182 million Kenvue shares (valued at $3.6 billion of commercial‑paper proceeds) and extinguishing its equity position, which resulted in a $0.4 billion loss recorded in other expense.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer gets several key facts correct: Johnson & Johnson retained a 9.5% stake in Kenvue after the August 2023 exchange offer, the fair value of that stake was $4.3 billion, it was recorded in other assets, and in May 2024 the company completed a debt-for-equity exchange using 182 million (rounded) Kenvue shares to satisfy $3.6 billion in commercial paper, resulting in a $0.4 billion loss. However, a critical error undermines the quantitative accuracy: the LLM states a '$21 billion gain in discontinued-operations earnings', which is not present in the ground truth and is factually incorrect. The original answer mentions a $0.4 billion expense due to subsequent changes in the stake’s value by year-end 2023, not a $21 billion gain. This is a major factual discrepancy. (2) Number verification: '9.5%' (correct), '$4.3 billion' (correct), 'August 2023' (correct), '182 million' (approximation of 182,329,550 — acceptable), '$3.6 billion' (correct), '$0.4 billion loss' (correct). The erroneous '$21 billion gain' has no basis in the original and appears fabricated. (3) Multi-hop reasoning is partially sound: the model correctly connects the 2023 retention of shares to the 2024 disposal and recognizes the strategic shift from partial ownership to complete exit. However, the inclusion of a massive, unsupported gain misrepresents the financial outcome of the 2023 transaction and distorts the overall narrative. (4) Correctness score is 6 due to significant factual error in financial impact reporting, despite correct dates, entities, and disposal mechanics. Quantitative accuracy is 5 because one major number is completely wrong. Qualitative accuracy is 7 as the reasoning structure and entity identification are sound. Contextual relevance is 9 — the answer directly addresses the evolution of the stake and disposal.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 502,
        "total_tokens": 1776
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has AT&T's relationship with Indiana Bell Telephone Co. Inc. evolved between 2022 and 2023 in terms of its inclusion in guarantee disclosures?",
      "original_answer": "In 2022, Indiana Bell Telephone Co. Inc. was listed among the entities whose obligations were guaranteed by AT&T under Exhibit 4-d. In 2023, the company continued to reference the same guarantee for Indiana Bell Telephone Co. Inc. under Exhibit 4-d, indicating that the guarantee remained in place without any modification or removal. Therefore, there was no change in the nature or status of the guarantee relationship between the two entities from 2022 to 2023.",
      "llm_answer": "Based on the provided SEC 10-K filings, AT&T's relationship with Indiana Bell Telephone Co. Inc. regarding guarantee disclosures remained consistent between 2022 and 2023. The 2023 filing (page 103) continues to reference the same 2011 Exhibit 4-d guarantee agreement for Indiana Bell, which was originally filed for the period ending December 31, 2011, and no new guarantee disclosures specific to Indiana Bell were added in the 2022 or 2023 filings. The disclosure requirements under Item 13 (Related Party Transactions) and Item 14 (Accountant Fees) were maintained through standard proxy statement incorporation, with no evolution in the structure or inclusion of Indiana Bell in guarantee-related disclosures during this period.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns well with the ground truth. It correctly states that AT&T's guarantee relationship with Indiana Bell Telephone Co. Inc. remained unchanged between 2022 and 2023, with both years referencing the same Exhibit 4-d guarantee from 2011. The mention of page 103 in the 2023 filing adds specificity not in the original answer but does not contradict it. All entities (AT&T, Indiana Bell Telephone Co. Inc., Exhibit 4-d), time periods (2022, 2023), and the nature of the guarantee are correctly identified. The reasoning is sound: no new disclosures were added, and the structure remained consistent. The only minor shortcoming is that the LLM introduces details about Item 13 and Item 14 disclosures and proxy incorporation, which, while contextually plausible, are not present in the ground truth and slightly extend beyond the scope of the confirmed facts. However, this does not detract from the core correctness. Quantitative accuracy is perfect—no numerical errors, correct dates, and proper referencing. The answer fully addresses the question about evolution (or lack thereof) in guarantee disclosures, demonstrating effective multi-hop synthesis across years and documents. Semantic equivalence is strong, with the LLM conveying the same essential conclusion: no change in the guarantee status.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 372,
        "total_tokens": 1671
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How did GE's financial relationship with AerCap evolve from 2023 to 2024, particularly in terms of cash involvement and investment gains?",
      "original_answer": "In 2023, GE had a continuing financial involvement with AerCap through a note receivable, product leases, and transition services, which included a net cash payment of $203 million to AerCap. By 2024, GE no longer had continuing operational involvement but instead held an investment stake in AerCap. This shift resulted in a significant financial impact, as GE reported a decrease in gains on retained and sold ownership interests by $5.2 billion, largely attributed to its AerCap and GE HealthCare investments. This indicates a strategic and financial transition from operational collaboration to investment-based returns.",
      "llm_answer": "From 2023 to 2024, GE Aerospace’s RPO grew by $17.6 billion (11%) to $171.6 billion, driven by higher equipment orders outpacing revenue recognition and contract modifications that brought more long‑term service agreements into service. While segment profit rose $1.6 billion (to $7.1 billion) and segment margin improved to 26.2%, the company’s overall earnings declined due to a $5.2 billion reduction in gains on retained ownership interests tied to its AerCap and GE HealthCare investments, partially offset by the higher profit from the RPO growth. Thus, cash involvement remained limited to the modest net cash outflow of $203 million paid to AerCap, but the financial relationship evolved through expanding RPO and related profit contributions, even as overall earnings were tempered by lower investment gains.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains some correct elements but significantly misrepresents the nature of GE's financial relationship with AerCap. It correctly mentions the $203 million net cash outflow to AerCap and the $5.2 billion decrease in gains on retained ownership interests tied to AerCap and GE HealthCare. However, it incorrectly frames this in the context of GE Aerospace's RPO (recorded purchase orders) growth, which is unrelated to AerCap and stems from a different segment. This misattribution introduces major factual inaccuracies. (2) Quantitatively, the $203 million and $5.2 billion figures are accurate and match the ground truth, though the $17.6 billion RPO increase and $7.1 billion segment profit are irrelevant and incorrect in this context. These numbers pertain to GE Aerospace, not GE’s relationship with AerCap. The calculation of the $5.2 billion reduction is correctly cited but misattributed as a factor in overall earnings decline without clarifying that it reflects a shift from operational to investment-based involvement. (3) The multi-hop reasoning is flawed. The original answer describes a strategic shift from operational involvement (note receivable, leases, services) in 2023 to passive investment in 2024. The LLM fails to mention this transition and instead conflates AerCap with GE Aerospace’s commercial engine business. There is no evidence in the LLM answer that it synthesized the correct entities or time-based changes in GE’s relationship with AerCap. (4) The contextual relevance is partial—while it references key financial figures related to AerCap, it embeds them in an unrelated narrative about RPO and segment profits, which distorts the actual evolution of the financial relationship. The core transformation—from operational collaboration to investment—is missing, leading to a low correctness score despite some accurate numbers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 511,
        "total_tokens": 1869
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has The Home Depot's approach to store appearance and its role in competition evolved from 2022 to 2024, particularly in relation to customer experience and digital integration?",
      "original_answer": "In 2022, The Home Depot emphasized store appearance as a competitive factor alongside customer experience, price, and product availability. The company highlighted the importance of store location, appearance, and ease of shopping experience in both brick-and-mortar and online contexts. By 2024, the company expanded its focus, integrating store appearance into a broader 'interconnected shopping experience' that linked physical stores, digital platforms, and on-site services. The 2024 report specifically noted investments in digital platforms to enhance the presentation and ease of navigation for users, reflecting a shift toward digital integration as a core component of store and shopping experience competitiveness. This evolution shows a strategic shift from physical store aesthetics alone to a more holistic, digitally-enhanced customer experience.",
      "llm_answer": "The Home Depot has progressively refined its store experience and digital integration from 2022 to 2024 to enhance customer experience and compete more effectively. In fiscal 2024, it expanded investments in store navigation, self-service tools (including mobile app-enabled store maps and electronic shelf labels), and checkout speed—building on prior renovations like curb-side pickup, self-service lockers, and reconfigurable service desks—to drive higher satisfaction. Simultaneously, it deepened digital interconnectedness by improving mobile app functionality, search, and personalized marketing tied to the full customer journey, while leveraging its supply chain and store network (e.g., BOPIS, curbside, and same-day delivery) to offer seamless, convenient fulfillment options that reinforce its competitive edge.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly captures the evolution of The Home Depot's strategy from 2022 to 2024, emphasizing the shift from physical store appearance as a standalone competitive factor to a more integrated, digitally enhanced customer experience. While the original answer focuses on the conceptual shift toward an 'interconnected shopping experience' and digital platform investments, the LLM provides more granular operational details—such as mobile app-enabled store maps, electronic shelf labels, BOPIS, curbside, and personalized marketing—that are consistent with and support the broader strategic narrative. There are no numeric values in the question or answers, so quantitative accuracy is not applicable in a numerical sense, but all referenced initiatives and timeframes (fiscal 2024) are correctly used. The LLM infers specific enhancements (e.g., self-service tools, checkout speed) not explicitly detailed in the ground truth, but these are plausible and contextually aligned with the reported strategic direction. The only minor shortcoming is that the LLM does not explicitly mention the 2022 emphasis on store appearance as a competitive factor alongside price and product availability, though it implies continuity by discussing ongoing refinements. This slight omission in completeness prevents a perfect 10 on qualitative accuracy. Overall, the answer is factually sound, contextually rich, and semantically equivalent to the original answer, with strong multi-hop reasoning linking store appearance, digital integration, and customer experience across years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1429,
        "completion_tokens": 446,
        "total_tokens": 1875
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between 2023 and 2024, particularly in terms of resales and new financial arrangements?",
      "original_answer": "In 2023, AMD's resales to the ATMP JV amounted to $14 million, with no mention of direct financial arrangements such as loans. By 2024, AMD's resales to the ATMP JV increased significantly to $121 million. Additionally, in October 2024, AMD entered into a one-year $100 million term loan agreement with one of the ATMP JVs to support the joint venture's general corporate purposes. This indicates a notable deepening of the financial relationship, moving beyond operational services to include direct financial support.",
      "llm_answer": "Between 2023 and 2024, AMD's financial relationship with the ATMP JV shifted from primarily purchasing inventory from the JV ($1.7 billion in both years) and recording modest resales ($14 million in 2023, $121 million in 2024) to providing a $100 million term loan to one of the JVs and increasing its equity investment—contributing an additional $17 million in August 2024, which raised the carrying value of its 15 % stake from $99 million (as of Dec 30 2023) to $149 million (as of Dec 28 2024). This evolution reflects a deeper financial involvement, moving beyond simple purchase/resale transactions to include new financing arrangements and a larger equity position.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly states that AMD's resales to the ATMP JV were $14 million in 2023 and increased to $121 million in 2024, it fabricates several key details not present in the ground truth. Specifically, the claim that AMD purchased $1.7 billion in inventory from the JV in both years is unsupported by the original answer and not mentioned in the ground truth. Additionally, the LLM asserts that AMD provided a $100 million term loan (correct) but adds that it also made an additional $17 million equity contribution in August 2024, increasing its stake’s carrying value from $99 million to $149 million—none of which is in the original answer. The 15% stake and carrying values are entirely fabricated. (2) Quantitative accuracy is low: only the resale figures ($14M, $121M) and the $100M loan are correct. The $1.7B inventory purchases, $17M equity contribution, and carrying values ($99M → $149M) are incorrect and unsupported. Calculations involving these numbers are therefore invalid. (3) The reasoning is partially sound in identifying a deepening financial relationship, but the multi-hop synthesis is flawed because it introduces entities and transactions (equity investments, carrying values, inventory purchases) not present in the source data. The conclusion about deeper involvement is directionally consistent but based on false premises. (4) Contextual relevance is high because the answer addresses the evolution of the financial relationship and attempts to synthesize changes over time, but the inclusion of fabricated financial arrangements undermines correctness. The core correct elements are the resale increase and the $100M loan, which align with the original answer’s emphasis on expanded financial engagement.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 491,
        "total_tokens": 1789
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has Johnson & Johnson's approach to privacy compliance programs evolved between 2023 and 2024, particularly in response to new privacy laws and international data flow regulations?",
      "original_answer": "In 2023, Johnson & Johnson had established privacy compliance programs and controls that its global businesses were required to follow, with an emphasis on addressing new privacy laws expected in 'other territories' and increasing enforcement by governmental authorities, especially concerning data localization and international data flows. By 2024, the company maintained these privacy compliance programs but expanded its focus to include evolving technology and data-driven initiatives across the company, involving multiple vendors and third parties. The 2024 disclosure also specifically notes the expectation of new privacy laws 'globally' (not just in other territories) and highlights legislative actions imposing limitations on the use, sharing, and cross-border flows of personal data. This indicates a broadening of the company's compliance focus and a more anticipatory posture toward global regulatory changes.",
      "llm_answer": "Johnson & Johnson's privacy compliance program has evolved to address emerging global data protection requirements, particularly through enhanced oversight by its Board's Regulatory Compliance & Sustainability Committee (RCSC) and expanded privacy training for employees. The company explicitly states it has established privacy compliance programs and controls to meet evolving laws, including new data localization requirements and restrictions on international data flows, while also acknowledging increased risks from geopolitical tensions affecting cross-border data transfers.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but misses key aspects of the evolution between 2023 and 2024 as described in the ground truth. (1) Correct elements: The LLM correctly identifies Johnson & Johnson's focus on privacy compliance programs, international data flows, data localization, and evolving laws. It also accurately reflects concerns about geopolitical tensions affecting cross-border data transfers, which aligns with the increased enforcement and global regulatory focus mentioned in the original answer. (2) Quantitative accuracy: There are no numeric values in the question or answers, so this aspect is not applicable; the score reflects no factual inaccuracies in dates or amounts (none stated). (3) Multi-hop reasoning assessment: The LLM fails to properly synthesize the *evolution* between 2023 and 2024. Specifically, it does not mention that in 2023 the focus was on 'other territories' while in 2024 it expanded to 'globally'—a key shift indicating broadening scope. Additionally, the 2024 expansion into managing privacy in the context of technology and data-driven initiatives involving multiple vendors and third parties is omitted. The mention of the Board's RCSC and expanded employee training, while plausible, are not present in the original ground truth and introduce unverified details. (4) Justification: The answer captures the general direction of compliance efforts but lacks the specific comparative evolution across years and introduces unsupported specifics (e.g., RCSC, training), reducing qualitative accuracy. Contextual relevance is high because it addresses privacy compliance and international data flows, but completeness and reasoning are compromised due to missing multi-hop synthesis between years and inaccurate additions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 478,
        "total_tokens": 1864
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has GE's financial exposure to Bank BPH evolved between 2023 and 2024, particularly in terms of estimated borrower litigation losses and related valuation allowances?",
      "original_answer": "In 2023, GE reported $2,669 million in total estimated losses related to borrower litigation for Bank BPH's foreign currency-denominated mortgage portfolio, with $1,712 million in valuation allowances against financing receivables held for sale and $957 million in other liabilities. By 2024, this total estimated loss decreased to $2,461 million, with $1,517 million in valuation allowances and $944 million in other liabilities. Additionally, the valuation allowance fully offset the financing receivables balance by the end of 2024, indicating a strategic shift in how GE managed its exposure to Bank BPH through a settlement program. This represents a reduction in GE's financial exposure to Bank BPH litigation risks over the period.",
      "llm_answer": "Between 2023 and 2024, GE’s estimated borrower litigation losses for Bank BPH increased from $2.669 billion to $2.461 billion, and the related valuation allowance against financing receivables held for sale was fully drawn down, completely offsetting the receivables balance as of December 31 2024. This reflects a continued but slightly reduced exposure to litigation‑related losses compared with the prior year, while the allowance now fully covers the remaining portfolio.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a critical factual error in the direction of change in estimated borrower litigation losses. It states that losses 'increased from $2.669 billion to $2.461 billion', but the ground truth shows a decrease from $2,669 million to $2,461 million. This misrepresents the trend and undermines the core conclusion. However, the dollar amounts themselves are numerically accurate (with acceptable format variation: $2.669 billion = $2,669 million). The valuation allowance being fully drawn down and offsetting the receivables balance in 2024 is correctly noted. (2) Quantitatively, the values for total estimated losses in both years are correct in magnitude but incorrectly compared (increase vs actual decrease). The components of the 2023 and 2024 losses (valuation allowances and other liabilities) are not broken down in the LLM answer, omitting key details: $1,712M and $957M in 2023, $1,517M and $944M in 2024. These omissions reduce completeness and precision. (3) The reasoning is partially sound—recognizing that the full offset of receivables by the allowance indicates a strategic shift is aligned with the original answer. However, the conclusion that exposure is 'continued but slightly reduced' is based on correct numbers but misstated directionality, leading to a logically inconsistent explanation. The multi-hop synthesis across years and financial components is attempted but flawed due to the inversion of the loss trend. (4) Contextual relevance is high—the answer addresses litigation losses, valuation allowances, and GE’s exposure to Bank BPH over 2023–2024. But due to the major quantitative misstatement and missing component details, the correctness score is limited to 4, with moderate scores in accuracy dimensions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 483,
        "total_tokens": 1792
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has HD's treatment and positioning of the Indoor Garden product line evolved from 2022 to 2024, given its financial performance in 2022 and its merchandising department categorization in 2024?",
      "original_answer": "In 2022, HD's Indoor Garden product line generated $15,546 million in net sales, accounting for 10.3% of total revenue, indicating its significance as a standalone category. By 2024, the Indoor Garden product line was grouped under the 'Hardlines' merchandising department, suggesting a strategic shift to integrate it with related product lines rather than treating it as a distinct category. This reclassification implies a change in how HD is organizing and potentially promoting the product line within its broader offerings.",
      "llm_answer": "From fiscal 2022 through fiscal 2024, HD’s Indoor Garden category remained a consistent component of the Hardlines merchandising department, but its relative prominence shifted as the company refined its departmental structure. In the 2022 filing, Indoor Garden was listed under “Hardlines” alongside other categories such as Hardware, Outdoor Garden, and Tools, indicating it was treated as a distinct sub‑category within that broader segment. By the 2024 filing, the merchandising‑department matrix still placed Indoor Garden under Hardlines, yet the company re‑aligned certain departments across its three major product lines (Building Materials, Décor, Hardlines) and noted that “Hardlines – Indoor Garden” now accounted for roughly 6.6 % of total net sales (≈$10.5 billion in fiscal 2024), up slightly from 6.4 % in fiscal 2022. This modest growth reflects a strategic emphasis on expanding the Indoor Garden offering within Hardlines, even as the overall Hardlines net sales remained flat, suggesting the product line is being positioned as a stable, growth‑oriented pillar within the company’s portfolio.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains multiple critical factual errors. According to the ground truth, in 2022, the Indoor Garden product line generated $15,546 million (i.e., $15.546 billion) in net sales, accounting for 10.3% of total revenue. However, the LLM claims that in 2022, Indoor Garden accounted for only 6.4% of total net sales (≈$10.5 billion in 2024), which contradicts the ground truth both in magnitude and timing. The LLM incorrectly states that Indoor Garden was already part of Hardlines in 2022, while the ground truth indicates it was a standalone category then. Furthermore, the LLM asserts that Indoor Garden remained under Hardlines from 2022 to 2024, but the ground truth shows a reclassification *into* Hardlines by 2024—indicating a change, not continuity. (2) Quantitative inaccuracies include: misstating 2022 net sales (should be $15.546B, not ~$10.5B), misreporting 2022 percentage (10.3% vs claimed 6.4%), and fabricating a 2024 figure (~6.6%) not present in the ground truth. There is no support for any 2024 financial data in the original answer. (3) The multi-hop reasoning is flawed: the question hinges on a shift from standalone status in 2022 (due to strong performance) to integration into Hardlines in 2024. The LLM fails to identify this strategic shift correctly, instead asserting continuity and even growth, which contradicts the implication of reduced prominence in the ground truth. (4) Scores reflect severe factual and quantitative errors, though the answer is contextually relevant in discussing merchandising structure and financial performance trends. Some correct entities (HD, Indoor Garden, Hardlines, fiscal years) are used, but with incorrect relationships and data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1422,
        "completion_tokens": 470,
        "total_tokens": 1892
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has Colgate-Palmolive's use of sourcing strategies to manage cost volatility evolved from 2022 to 2024, particularly in relation to commodity price fluctuations?",
      "original_answer": "In 2022, Colgate-Palmolive utilized sourcing strategies as part of a broader risk management framework to manage volatility in foreign exchange, interest rates, and commodity prices, specifically mentioning the use of derivative instruments and local currency borrowings. By 2024, the company continued to rely on sourcing strategies but placed greater emphasis on managing raw material cost volatility, including commodities like resins, essential oils, and soybeans, while also incorporating more proactive cost containment and productivity initiatives. The 2024 disclosure highlights increased exposure to geopolitical and climatic disruptions, indicating a shift toward more defensive sourcing and cost management tactics in response to external pressures.",
      "llm_answer": "From 2022 to 2024, Colgate‑Palmolive’s approach to managing commodity‑price volatility has shifted from relying mainly on limited hedging contracts to a broader mix of sourcing strategies and productivity initiatives. In the 2022 filing the company notes that “raw and packaging material commodities … are subject to market price variations” and that it mitigates exposure “through sourcing strategies, ongoing productivity initiatives and the limited use of commodity hedging contracts.” By 2024 the discussion emphasizes that while commodity prices have retreated from peaks, they “may increase again,” and the firm continues to offset cost pressures with “price increases and efforts to achieve cost efficiencies in areas such as manufacturing and distribution, or otherwise manage the exposure through sourcing strategies, ongoing productivity initiatives and the limited use of commodity hedging contracts.” This evolution reflects a more proactive, diversified risk‑management framework that leans less on hedging and more on supply‑chain flexibility and cost‑efficiency programs.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of Colgate-Palmolive's sourcing strategies from 2022 to 2024. (1) It accurately captures that in 2022, the company used sourcing strategies alongside limited hedging and productivity initiatives to manage commodity price volatility, which matches the original answer’s mention of derivative instruments and broader risk management. In 2024, the LLM correctly notes a continued reliance on sourcing but with increased emphasis on cost containment and productivity—consistent with the ground truth’s description of more proactive tactics. (2) There are no numerical values, dates, or financial metrics in dispute; all timeframes (2022, 2024) are correct, and no calculations are required. (3) The multi-hop reasoning is sound: the model synthesizes information across years and identifies a strategic shift—away from hedging toward supply-chain flexibility and cost efficiency—supported by textual evidence from both years. However, the LLM omits specific commodities mentioned in the ground truth (resins, essential oils, soybeans) and does not reference the increased exposure to geopolitical and climatic disruptions, which are key qualitative elements indicating a defensive shift. This minor omission prevents a perfect score. (4) Despite these omissions, the answer remains contextually rich and directly responsive to the question about evolution in sourcing strategies related to commodity volatility. Wording differs but semantic meaning is equivalent on core points. Thus, high scores are justified, with a slight deduction in qualitative accuracy for missing specific commodity and external risk details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1466,
        "completion_tokens": 464,
        "total_tokens": 1930
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How did the sales performance of TREMFYA evolve between 2023 and 2024, and what factors contributed to this change?",
      "original_answer": "In 2023, TREMFYA (guselkumab) experienced growth driven by market expansion, continued strength in PsO/PsA (Psoriasis and Psoriatic Arthritis), and favorable patient mix. By 2024, TREMFYA achieved sales of $3,670 million, an increase of 16.6% compared to $3,147 million in 2023. The growth in 2024 was attributed to an 18.1% change from operations, despite a negative currency impact of 1.5%. This indicates that TREMFYA not only maintained its market position but also expanded further in its therapeutic areas during this period.",
      "llm_answer": "TREMFYA (guselkumab) sales grew 16.6% in 2024 to $3.67 billion, driven by market growth and share gains, while its 2023 growth of 17.9% was similarly fueled by market expansion and favorable patient mix. The key factor behind this upward trend is the continued out‑performance of TREMFYA relative to other immunology products, offset only modestly by biosimilar competition affecting STELARA and REMICADE.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly states the 2024 sales figure of $3.67 billion (equivalent to $3,670 million) and the 16.6% growth from 2023, which aligns with the ground truth. The 2023 sales amount ($3,147 million) is not explicitly mentioned but implied through the 16.6% growth calculation, which is accurate. However, the LLM incorrectly states that TREMFYA had 17.9% growth in 2023—this figure is not present in the original answer and is factually unsupported by the provided ground truth, introducing a significant error. (2) Quantitative accuracy is mostly correct: $3.67 billion = $3,670 million, and a 16.6% increase from $3,147 million leads to approximately $3,670 million, confirming the calculation is sound. The erroneous 17.9% growth figure for 2023, however, undermines full quantitative accuracy. (3) The reasoning partially captures the multi-hop synthesis: it correctly identifies market expansion and favorable patient mix as drivers, consistent with the 2023 context, and links continued performance to immunology out-performance. However, it introduces external elements—'share gains' and 'biosimilar competition affecting STELARA and REMICADE'—that are not in the original answer and go beyond the provided knowledge graph, potentially reflecting inference rather than data-supported synthesis. The original answer emphasizes operational growth (+18.1%) and currency impact (-1.5%), which the LLM omits entirely, missing a key analytical layer. (4) The contextual relevance is high because the answer addresses both parts of the question—sales evolution and contributing factors—and stays focused on TREMFYA’s performance. The qualitative accuracy is reduced due to the inclusion of unverified growth rates and extraneous competitive dynamics. Overall, the answer is factually strong on the 2024 growth and sales figure but flawed in introducing unsupported 2023 growth data and omitting key financial drivers from the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1226,
        "completion_tokens": 528,
        "total_tokens": 1754
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How did the structural change in Disney's relationship with A&E from 2022 to 2023 affect its reporting of subscriber numbers and financial stake in the partnership?",
      "original_answer": "In 2022, Disney reported A&E as a partner with 69 million domestic subscribers, indicating a collaborative but arms-length relationship. By 2023, Disney's relationship with A&E had evolved into a 50% equity stake, with A+E now classified as a significant equity investment. The 2023 report noted that A+E's channels, including A&E, had 58 million domestic subscribers. This shift from a partnership to a joint ownership model altered how Disney reported both subscriber data and financial performance, moving from simple subscriber counts in 2022 to including A+E’s financial results under 'Equity in the income of investees' in 2023.",
      "llm_answer": "The structural change in Disney’s relationship with A&E shifted from a 50% equity investment (where Disney reported only its share of A+E’s income) to full operational control and reporting of A+E’s subscriber counts as part of Disney’s Linear Networks segment. In 2023, Disney began consolidating A+E’s domestic subscriber data (58 million for A&E, HISTORY and Lifetime) and equity‑investment accounting, which altered how it disclosed both subscriber numbers and its financial stake in the partnership.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) It incorrectly states that Disney moved from a 50% equity investment in 2022 to full operational control in 2023, which is the reverse of the ground truth: in 2022, Disney had a partnership without equity (69M subscribers), and in 2023, it took a 50% equity stake (58M subscribers). This fundamental reversal of the timeline and nature of the relationship invalidates the core reasoning. (2) Quantitatively, the 58 million domestic subscribers for A+E in 2023 is correctly cited, but the 69 million from 2022 is omitted, and the direction of change (decrease in subscribers) is not acknowledged. The LLM also incorrectly implies consolidation of subscriber counts due to control, when the ground truth indicates the change was due to equity investment accounting. (3) The multi-hop reasoning fails: instead of correctly synthesizing that Disney began reporting A+E’s financials under 'Equity in the income of investees' due to the new 50% stake, the model falsely claims Disney gained operational control and began including subscriber counts in its Linear Networks segment—information not supported by the original answer. (4) While the answer addresses the question’s general theme (structural change affecting reporting), the reversal of key facts and incorrect characterization of the relationship change severely limit its accuracy. The contextual relevance is moderate because it discusses subscriber numbers and financial reporting impacts, but the underlying logic is flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1289,
        "completion_tokens": 430,
        "total_tokens": 1719
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How did the financial impact of GE's relationship with AerCap evolve between 2023 and 2024, particularly in terms of realized and unrealized gains or losses?",
      "original_answer": "In 2023, GE reported an unrealized gain of $129 million from its investment in and note with AerCap. However, in 2024, the relationship had evolved such that GE recognized a significant decrease in gains on retained and sold ownership interests, which dropped by $5.2 billion compared to 2023, with AerCap being one of the primary contributors to this decline. This indicates a negative shift in the financial performance of the AerCap investment from a gain in 2023 to a loss or significantly reduced gain in 2024.",
      "llm_answer": "The financial impact of GE's relationship with AerCap shifted from a $5.7 billion gain on the sale of AerCap shares in 2023 (which boosted 2023 earnings) to a $129 million realized/unrealized gain in 2024, reflecting the remaining AerCap position after the company had fully monetized its stake in 2023. Consequently, realized and unrealized gains related to AerCap declined sharply year‑over‑year, contributing to a $5.2 billion drop in gains on retained and sold ownership interests in 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2023 GE reported an *unrealized gain* of $129 million from its investment in and note with AerCap. However, the LLM incorrectly states that GE had a $5.7 billion *realized gain* from the sale of AerCap shares in 2023, which contradicts the original answer and misrepresents the nature and magnitude of the gain. The $5.2 billion figure mentioned in the LLM answer is also misapplied: in the ground truth, this represents the *year-over-year decrease* in gains on retained and sold ownership interests (with AerCap being a contributor), not a gain in 2023. The LLM flips the timeline and magnitudes—portraying a large 2023 gain and smaller 2024 gain, when the truth is a modest 2023 gain and a sharp decline in 2024. (2) The numbers are largely incorrect: $5.7 billion gain in 2023 is unsupported; $129 million is attributed to 2024 in the LLM answer but belongs to 2023 in the original. The $5.2 billion drop is correctly identified as year-over-year but miscontextualized as a drop *from* a large gain, when the starting point was only $129 million. (3) The multi-hop reasoning is flawed: the LLM fails to correctly synthesize the evolution from unrealized gain in 2023 to a major decline in 2024. Instead, it fabricates a large 2023 sale event and suggests continued gains in 2024, which contradicts the negative shift described in the ground truth. (4) Despite these errors, the answer is contextually relevant—addressing the evolution of GE’s financial relationship with AerCap and correctly identifying a sharp decline in gains. However, due to major quantitative and qualitative inaccuracies, the correctness score is low. The qualitative accuracy is moderate because the structure and intent of the response are sound, but the facts are wrong. Quantitative accuracy is poor due to incorrect dollar amounts and misattribution across years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1254,
        "completion_tokens": 526,
        "total_tokens": 1781
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has Mastercard's multi-layered security approach evolved between 2022 and 2024, particularly in terms of addressing risks associated with third-party service providers, and what does this evolution indicate about the company's strategic response to emerging cybersecurity threats?",
      "original_answer": "In 2022, Mastercard's multi-layered security approach included a robust program to protect its network from cyber and information security threats, with multiple layers of protection and third-party assessments. However, there was no explicit mention of addressing risks related to third-party service providers. By 2024, Mastercard explicitly integrated third-party provider risk management into its security framework, noting that it works with experts across the organization and through public-private partnerships to monitor and respond to threats associated with the use of services provided by third-party providers. This indicates a strategic shift toward strengthening the ecosystem-wide resilience of its security architecture, particularly in response to the growing complexity and interconnectedness of the payments landscape.",
      "llm_answer": "Mastercard’s multi-layered security approach has evolved from a general focus on network resilience and fraud prevention in 2022 to a more targeted strategy addressing third‑party risks by 2024, emphasizing collaboration with issuers, acquirers, governments and industry groups to set technical standards, conduct proactive monitoring, and integrate security into new payment flows such as account‑based and real‑time payments. This progression reflects a strategic shift toward embedding security throughout the entire payments ecosystem—especially in emerging areas like disbursements, remittances, and virtual‑card solutions—to stay ahead of increasingly sophisticated cyber threats.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of Mastercard's security approach between 2022 and 2024. It accurately captures the shift from a general network resilience focus in 2022 to a more targeted strategy in 2024 that explicitly includes third-party risk management. While the original answer notes that third-party provider risks were not explicitly mentioned in 2022, the LLM correctly infers a broadening of scope by 2024 to include collaboration with external partners (issuers, acquirers, governments, industry groups), which matches the ground truth's emphasis on public-private partnerships and organizational experts. The LLM adds contextual detail about new payment flows (real-time payments, virtual cards) and emerging use cases (disbursements, remittances), which are plausible extensions of the strategic shift and do not contradict the source. There are no numerical values in the question or answers, so quantitative accuracy is scored as 10 by default. The qualitative accuracy is slightly reduced because the LLM does not explicitly state the absence of third-party risk mentions in 2022, which is a key differentiator in the ground truth, though it correctly identifies the 2024 enhancement. The reasoning is sound and reflects appropriate multi-hop synthesis across time, strategy, and ecosystem dynamics. The answer is highly contextually relevant, directly addressing all parts of the question with accurate, meaningful elaboration.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1415,
        "completion_tokens": 414,
        "total_tokens": 1830
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has Target Corporation's compliance with its debt leverage covenant evolved between 2022 and 2023, particularly in light of changes to its credit facilities?",
      "original_answer": "In 2022, Target Corporation stated that it was in compliance with its debt leverage covenant and expected to remain so, with a $3.0 billion unsecured revolving credit facility set to expire in October 2026. By 2023, Target had obtained a new $1.0 billion 364-day unsecured revolving credit facility (expiring in October 2024) and extended the expiration of its five-year $3.0 billion facility to October 2028. Despite these structural changes to its credit facilities, Target continued to assert compliance with the debt leverage covenant in 2023, indicating consistent adherence to regulatory requirements even as its financing arrangements evolved.",
      "llm_answer": "Between 2022 and 2023, Target maintained compliance with its debt‑leverage covenant throughout the year, continuing the same disciplined approach it has used historically.  The company’s credit‑rating outlook remained stable (A‑/A‑1), and it retained ample capacity under its revolving credit facilities—including a newly‑extended $3 billion five‑year facility and a $1 billion 364‑day facility—so that it could meet the covenant without needing to adjust its leverage ratios.  Consequently, there was no material change in its ability to satisfy the debt‑leverage covenant between the two fiscal years.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) All key facts are correct: Target maintained compliance with its debt leverage covenant in both 2022 and 2023; it extended its $3.0 billion five-year facility to October 2028 (from 2026); and it added a new $1.0 billion 364-day facility expiring in October 2024. These quantitative details (dollar amounts, timeframes) match the original answer exactly, earning a perfect score on quantitative accuracy. (2) The answer correctly identifies the relevant entities (Target Corporation), time periods (2022–2023), and financial metrics (debt leverage covenant compliance, credit facility structures). (3) The multi-hop reasoning is sound: the model synthesizes changes in credit facilities with ongoing covenant compliance, concluding no material change in Target’s ability to meet obligations—consistent with the ground truth. (4) Minor deduction in qualitative accuracy due to the addition of credit rating outlook (A-/A-1), which was not present in the original answer and cannot be verified from the provided ground truth. While plausible, it introduces unverified detail. Otherwise, the answer is semantically equivalent, well-reasoned, and fully relevant to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1317,
        "completion_tokens": 354,
        "total_tokens": 1671
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has the nature of the risks associated with Salesforce's AI offerings, including generative AI such as Agentforce, evolved from 2023 to 2024?",
      "original_answer": "In 2023, Salesforce's primary risk related to third-party integrations and applications centered on potential claims or liabilities stemming from customer expectations for warranties, despite the company not developing or selling these third-party offerings. By 2024, the risk profile expanded significantly with the increased integration of AI into Salesforce's offerings, particularly generative and agentic AI like Agentforce. The 2024 disclosures highlight new risks such as ethical concerns, regulatory scrutiny, and potential legal liabilities from AI-generated content that may be inaccurate, biased, or infringe on copyright. Additionally, the company now anticipates increased costs related to AI governance, compliance, and testing, which were not specifically tied to AI in 2023.",
      "llm_answer": "From 2023 to 2024, the risks tied to Salesforce’s AI offerings—especially generative AI such as Agentforce—shifted from broader competitive and market‑adoption concerns to more concrete technical, regulatory and reputational challenges.  In 2023 the focus was on the uncertainty of AI‑driven product expansion, pricing of consumption‑based models, and the need to keep pace with rapid AI innovation.  By 2024, those risks deepened: AI systems now face heightened scrutiny over accuracy, bias, copyright and privacy violations; new AI‑specific regulations (e.g., Colorado AI Act, EU AI Act, Utah AI Act) and evolving data‑privacy rules threaten compliance and cross‑border data flows; and any perceived failure or controversy surrounding AI outputs can damage Salesforce’s brand, trigger litigation and increase liability exposure.  Consequently, the risk profile moved from “uncertain market acceptance” to “operational, legal and reputational exposure inherent in AI development and deployment.”",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the evolution of Salesforce's AI-related risks from 2023 to 2024 with strong qualitative accuracy. It correctly identifies a shift from market and innovation uncertainty in 2023 to more concrete regulatory, legal, and reputational risks in 2024. The mention of specific regulations (e.g., Colorado AI Act, EU AI Act, Utah AI Act) adds detail not present in the original answer but is plausible and contextually appropriate, though the ground truth does not specify these laws—this is a minor overreach but not factually incorrect. The core elements—increased focus on accuracy, bias, copyright, privacy, compliance costs, and liability—are all aligned with the original answer. However, the original emphasizes third-party integration risks in 2023 (particularly warranty-related liabilities), which the LLM answer omits, instead focusing on market adoption and pricing. This is a meaningful omission, as it mischaracterizes the primary 2023 risk. There are no numerical values to assess, so quantitative accuracy is scored as 10 by default. Contextual relevance is perfect—the answer directly addresses the question and maintains focus. The reasoning is sound and reflects multi-hop synthesis across years and risk domains, though the shift described leans slightly more on inference than the documented disclosure about third-party integrations. Overall, the answer is semantically close and factually strong but misses a key nuance in the 2023 risk profile.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1446,
        "completion_tokens": 413,
        "total_tokens": 1859
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has Lowe's delivery capability for parcel-eligible items evolved between fiscal years 2023 and 2024, and what specific improvements were made?",
      "original_answer": "In fiscal year 2023, most parcel-eligible items could be delivered within two business days at standard shipping rates. By fiscal year 2024, Lowe's improved this capability, enabling delivery of most parcel-eligible items within two business days or less. Additionally, in 2024, Lowe's expanded its delivery capabilities to include next-day delivery for major appliances in nearly every zip code in the United States. This represents a refinement and expansion of their delivery speed and geographic coverage.",
      "llm_answer": "Between fiscal 2023 and 2024, Lowe’s delivery capability for parcel‑eligible items was expanded to support faster fulfillment: most such items can now be ordered and delivered within two business days or less at standard shipping rates, and the nationwide gig‑network rollout enables same‑day delivery of select products from stores. Additionally, the company completed the rollout of its market‑based delivery model, adding geographic areas and enhancing capacity for big‑and‑bulky items, which collectively improves speed and flexibility of parcel delivery.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general direction of improvement in Lowe's delivery capabilities between fiscal years 2023 and 2024, correctly noting faster delivery times (within two business days or less) for parcel-eligible items. However, it introduces information not present in the ground truth: specifically, the 'nationwide gig-network rollout' enabling same-day delivery and the 'completion of market-based delivery model' are not mentioned in the original answer. While the ground truth confirms next-day delivery for major appliances in nearly every U.S. zip code in 2024, the LLM generalizes this to 'select products' with same-day delivery, which is a different service level and product scope. Additionally, the original answer emphasizes next-day delivery for major appliances specifically, a key detail missing in the LLM response. The LLM also fails to explicitly contrast the 2023 baseline (most items delivered within two business days) with the 2024 enhancement (two days or less and next-day for appliances), weakening the multi-hop comparison. Quantitatively, no hard numbers (e.g., percentages, zip code coverage) are misstated, but the answer adds unverified operational details (gig-network, market-based model rollout) that cannot be confirmed from the ground truth. Reasoning is partially sound—there is recognition of improved speed and geographic/capacity expansion—but synthesis includes unsupported extrapolations. Contextually, the answer remains relevant and addresses delivery evolution, but with overgeneralization and addition of plausible but unverified initiatives.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1267,
        "completion_tokens": 435,
        "total_tokens": 1702
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has the financial impact of the Dermstore LLC sale evolved from 2022 to 2023 in terms of Target's consolidated revenues and operating income?",
      "original_answer": "The financial impact of the Dermstore LLC sale remained minimal in both years, as Dermstore represented less than 1 percent of Target's consolidated revenues, operating income, and net assets in both 2022 and 2023. The sale, which occurred in February 2021, resulted in a $335 million pretax gain included in Net Other (Income)/Expense, and no significant post-sale financial contribution or change was observed in either year.",
      "llm_answer": "The financial impact of the Dermstore LLC sale on Target's consolidated revenues and operating income is not material, as Dermstore represented less than 1 percent of consolidated revenues and operating income prior to its February 2021 sale. Consequently, the sale did not significantly affect the year-over-year changes in total revenue or operating income between 2022 and 2023, with the 2023 operating income increasing 48.3% to $5.7 billion primarily due to other operational factors, not the Dermstore transaction.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies that the financial impact of the Dermstore LLC sale was immaterial to Target's consolidated revenues and operating income, consistent with the ground truth. It accurately notes the sale occurred in February 2021 and that Dermstore represented less than 1% of revenues and operating income. However, it introduces a specific 2023 operating income figure of $5.7 billion with a 48.3% increase, which is not present in the original answer and cannot be verified from the provided ground truth. This addition risks inaccuracy and distracts from the core point that Dermstore had no meaningful post-sale impact. (2) The quantitative accuracy is reduced because the $5.7 billion figure and 48.3% increase are not supported by the ground truth; while such numbers may exist in Target's actual filings, they are not part of the verified knowledge graph data provided. The original answer makes no mention of these figures or any year-over-year changes beyond stating no significant post-sale impact. (3) The reasoning is logically sound in concluding that Dermstore’s sale did not affect year-over-year changes in revenue or operating income due to its minimal contribution. The model correctly synthesizes that the sale predates both 2022 and 2023 and thus would not directly impact those years’ results. However, it overreaches by attributing the 2023 operating income increase to 'other operational factors,' which, while plausible, goes beyond the scope of the original answer that simply states no significant change was observed. (4) The contextual relevance is high because the answer directly addresses the evolution of financial impact from 2022 to 2023 and correctly emphasizes the lack of materiality. The qualitative accuracy is strong in entity identification (Dermstore LLC, Target, February 2021 sale) and metric alignment (consolidated revenues, operating income). The correctness score is 7 because the core factual claim—minimal impact—is correct, but the inclusion of unverified quantitative details reduces overall accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1236,
        "completion_tokens": 558,
        "total_tokens": 1795
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has the strategic positioning of Data Cloud evolved between 2023 and 2024, particularly in terms of its role within Salesforce's broader service offerings and competitive landscape?",
      "original_answer": "In 2023, Data Cloud was described as a 'hyperscale, trusted data engine native to Salesforce' that unified enterprise data to deliver a 360-degree view of customers, emphasizing its integration across Salesforce's offerings like Marketing and Analytics. By 2024, Data Cloud was positioned within a broader context of competitive risk, with the filing noting that markets for offerings like Data Cloud are 'relatively new and uncertain,' and that Salesforce faces increasing competition as AI and data platforms evolve. Additionally, in 2024, Salesforce acknowledged limited experience in pricing consumption-based models like that of Data Cloud, signaling a shift from product-centric messaging to one that includes strategic risk and monetization challenges.",
      "llm_answer": "Between 2023 and 2024, Salesforce’s Data Cloud evolved from a foundational data engine into a central, AI‑enhanced hub that underpins its broader Customer 360 suite—particularly Agentforce and other consumption‑based offerings. The company positioned Data Cloud as the connective tissue that unifies disparate enterprise data, enabling real‑time, AI‑driven insights across sales, service, marketing, commerce and industry‑specific clouds, thereby deepening cross‑sell opportunities and reinforcing its platform‑centric strategy. This expansion places Data Cloud in a more competitive spot, as it now contends not only with traditional CRM and data‑management vendors but also with emerging AI‑focused platforms and specialized analytics providers, requiring careful pricing and integration to sustain growth.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in its qualitative description of Data Cloud's evolving strategic role between 2023 and 2024 and maintains high contextual relevance. It accurately captures the shift toward positioning Data Cloud as a central, unifying engine within Salesforce’s ecosystem, supporting AI-driven capabilities and cross-cloud integration. However, it diverges from the ground truth by emphasizing an 'AI-enhanced hub' and 'Agentforce' integration, which are not mentioned in the original 2023–2024 filings used for the ground truth. While AI is contextually relevant, the original answer focuses on structural and competitive risks rather than AI expansion. The LLM correctly identifies increased competitive pressure but omits the key 2024 disclosure about Salesforce’s 'limited experience in pricing consumption-based models'—a critical strategic shift in tone from product promotion to risk acknowledgment. There are no numerical values in the question or answers, so quantitative accuracy is scored as 10 by default. The reasoning is sound and synthesizes multi-hop concepts (evolution over time, competitive landscape, platform integration), but misses the nuanced pivot to risk and monetization challenges. Thus, while the answer is well-structured and contextually relevant, it substitutes some speculative enhancements (AI/Agentforce centrality) for the more cautious, risk-aware narrative present in the actual filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 397,
        "total_tokens": 1798
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How has LOW's treatment and accounting of forward interest rate swap contracts evolved between 2023 and 2024, particularly in terms of hedge designation and financial impact?",
      "original_answer": "In 2023, LOW disclosed forward interest rate swap contracts related to its March 2023 Notes with a notional amount of $2.0 billion, from which it received $247 million upon settlement. These contracts were designated as cash flow hedges and their (loss)/gain was recorded in other comprehensive (loss)/income and earnings. By 2024, the company clarified that its fixed-to-floating interest rate swap agreements are accounted for as fair value hedges using the shortcut method, under which the hedges are assumed perfectly effective. This resulted in no net impact on the consolidated statements of earnings from the fair value of the derivatives, indicating a shift in both hedge designation and accounting treatment compared to the prior year.",
      "llm_answer": "Between 2023 and 2024, Lowe's evolved its treatment of forward interest rate swap contracts by shifting from cash flow hedge accounting for matured swaps to fair value hedge accounting for new swaps tied to the 2023 Notes issuance. In 2023, swaps were designated as cash flow hedges (with gains/losses recorded in OCI), but by 2024, new swaps settled with the $3B 2023 Notes were designated as fair value hedges using the shortcut method, resulting in no net earnings impact as the hedge was assumed perfectly effective. This change eliminated the need for ongoing ineffective testing and shifted the accounting treatment to offset interest expense changes directly in earnings. Financially, the swaps reduced interest costs on fixed-rate debt (e.g., $247M received on $2B notional in 2023), but the fair value hedge designation ensured no net income volatility from hedge accounting. (298 characters)",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the shift in accounting treatment from cash flow hedges in 2023 to fair value hedges in 2024, with accurate descriptions of hedge designation, accounting impact, and use of the shortcut method. The financial impact—no net earnings volatility due to perfect effectiveness—is correctly conveyed. However, there is a minor quantitative inaccuracy: the LLM states 'new swaps settled with the $3B 2023 Notes', but the ground truth specifies a $2.0 billion notional amount, not $3B. This misstatement affects precision but not the core reasoning. The $247 million received on a $2B notional in 2023 is correctly reported. (2) Number verification: $247M received and $2.0B notional are accurate; the erroneous $3B reference is unsupported in the original and likely confuses the total notes issued with the swap notional. No calculation errors beyond this. (3) Multi-hop reasoning is strong: the model correctly synthesizes changes in hedge designation, accounting standards (shortcut method), and financial statement impact across years. It accurately contrasts OCI treatment in 2023 with fair value hedge accounting in 2024, showing sound logic. (4) Scores reflect high factual and qualitative accuracy, with a slight deduction in quantitative accuracy due to the $3B error. Contextual relevance is perfect—the answer directly addresses evolution in treatment, designation, and financial impact as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1418,
        "completion_tokens": 401,
        "total_tokens": 1819
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How has Target's strategy around its owned brands evolved from 2022 to 2023, particularly in terms of portfolio emphasis and strategic objectives?",
      "original_answer": "In 2022, Target highlighted a significant portion of sales coming from its owned brands, listing over 40 such brands across multiple categories, indicating a strong but descriptive presence in the market. By 2023, the company elevated its focus by strategically positioning owned brands as a core element of its overall strategy to 'delight with newness, style, and value,' explicitly aiming to strengthen the portfolio as part of broader efforts to drive traffic, sales, and market share growth. This shift reflects a move from simply showcasing owned brands to actively leveraging them as a strategic differentiator.",
      "llm_answer": "From 2022 to 2023, Target's strategy evolved to place greater emphasis on its owned brands as a core differentiator, expanding the portfolio with new exclusive lines (e.g., Universal Thread, Opalhouse, Wild Fable, Embark, and more) while integrating them into a curated, multi-category assortment. This shift was tied to strategic objectives of deepening guest relevance, driving traffic and sales growth, and reinforcing Target's \"curated, multi-category\" value proposition through strengthened owned brands, alongside continued investment in stores-as-hubs, technology, and sustainability (Target Forward). The focus remained on leveraging owned brands to enhance differentiation and guest experience, with the 2023 strategy explicitly highlighting the expansion of this portfolio as a key growth driver.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution of Target's strategy from 2022 to 2023: in 2022, owned brands were a strong presence with over 40 brands (implied by 'expanding the portfolio'), and in 2023, they became a strategic differentiator tied to growth objectives. The mention of specific brands (e.g., Universal Thread, Opalhouse, Wild Fable, Embark) adds detail not in the original but is factually consistent with Target’s 2023 reporting and enhances completeness without introducing error. (2) There are no numeric values, percentages, or dates in the original or LLM answer beyond the years 2022 and 2023, which are correctly used—thus quantitative accuracy is perfect. (3) The multi-hop reasoning is sound: the LLM synthesizes the shift from descriptive presence to strategic emphasis, linking owned brands to traffic, sales, and differentiation, which matches the original’s core insight. It also correctly ties the strategy to broader objectives like guest relevance and the 'curated, multi-category' value proposition, which reflects Target’s stated strategy. (4) The only minor gap is that the LLM answer does not explicitly state the shift 'from simply showcasing to actively leveraging' as in the original, but it conveys the same meaning through phrases like 'greater emphasis' and 'key growth driver.' The addition of 'stores-as-hubs, technology, and sustainability (Target Forward)' is contextually relevant but slightly beyond the scope of the question, though not inaccurate. Overall, the answer is semantically equivalent, highly relevant, and factually correct with excellent reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 455,
        "total_tokens": 1811
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How has GM's approach to software-enabled services evolved from 2022 to 2023, particularly in terms of service offerings and platform deployment, and what does this indicate about the company's investment in scalable digital solutions?",
      "original_answer": "In 2022, GM described its software-enabled services in general terms as part of its broader operations, noting that it 'provides software-enabled services worldwide' and integrates them into its automotive business alongside investments in AV technology and automotive financing. By 2023, GM's approach had evolved significantly, with specific details on its end-to-end software platform that enables over-the-air updates for features like Super Cruise, active safety, infotainment, and EV ownership experience. The 2023 filing highlights that select 2024 models, such as the Cadillac LYRIQ and Chevrolet Silverado EV, were already using this platform, indicating a strategic shift toward scalable, software-defined vehicles. This evolution shows a transition from general involvement in digital services to concrete platform deployment across product lines, reflecting increased investment and operational maturity in software-enabled offerings.",
      "llm_answer": "From 2022 to 2023, GM shifted from merely offering software-enabled services like OnStar and Super Cruise to actively deploying an end-to-end, over-the-air software platform that enables recurring revenue streams (e.g., subscription features, connectivity services, and software-defined vehicle updates). This evolution is evident in the 2023 10-K’s emphasis on scaling software-enabled services across its EV portfolio (e.g., Ultium-based vehicles) and expanding subscription-based features, reflecting a strategic pivot toward monetizing software as a core revenue driver rather than an ancillary offering. This transition underscores GM’s significant investment in building scalable, recurring digital revenue streams to support its EV and autonomous vehicle strategy.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of GM's software-enabled services from 2022 to 2023. It accurately captures the shift from a general description of software services in 2022 to a more strategic, platform-driven approach in 2023, including over-the-air updates and software-defined vehicles. The mention of recurring revenue streams and subscription models reflects an accurate interpretation of GM's strategic pivot. Quantitatively, there are no specific numbers (e.g., dollar amounts, percentages) in either the original or LLM answer, so accuracy is not compromised. The LLM correctly identifies key elements such as Super Cruise, EV integration (e.g., Ultium-based vehicles), and the business model shift toward monetization—though it does not name the specific 2024 models (Cadillac LYRIQ, Chevrolet Silverado EV) cited in the ground truth. This is a minor omission affecting completeness but not the core correctness. The reasoning is sound and reflects proper multi-hop synthesis between years and strategic themes. The answer is contextually highly relevant and conveys the intended strategic implication: increased investment in scalable digital solutions. However, the absence of specific model names and slightly less precise platform deployment details (e.g., 'select 2024 models') prevents a perfect score on qualitative accuracy. Overall, the answer is factually consistent and semantically equivalent to the original, with only minor detail gaps.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1451,
        "completion_tokens": 418,
        "total_tokens": 1869
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How has the revenue contribution from ThousandEyes within the Optimized Application Experiences/Observability product category evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, the Optimized Application Experiences category, which included ThousandEyes, saw revenue growth of $75 million (11%), driven by ThousandEyes and Intersight. By fiscal year 2023, the Observability category (which includes ThousandEyes) experienced a revenue increase of $80 million (14%), specifically attributed to growth in ThousandEyes and monitoring and analytics offerings. This shows a continued upward trend in ThousandEyes' revenue contribution, with both absolute and percentage growth increasing from 2022 to 2023.",
      "llm_answer": "The revenue contribution from ThousandEyes within the Optimized Application Experiences/Observability product category grew from $661 million in fiscal 2023 to $837 million in fiscal 2024, reflecting an increase of $176 million (27%). This expansion was noted as being driven by growth in the ThousandEyes offering and contributions from the broader Observability suite.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both quantitative and qualitative aspects. (1) Quantitative Accuracy: The LLM states revenue grew from $661 million in fiscal 2023 to $837 million in fiscal 2024, but the original answer does not provide absolute revenue figures for ThousandEyes or the category—only growth amounts ($75M in FY2022 and $80M in FY2023). The LLM fabricates specific revenue totals and refers to fiscal year 2024, which is outside the scope of the question (which asks about FY2022 and FY2023). Additionally, the claimed $176 million increase (27%) does not align with the ground truth, which reports $75M (11%) growth in FY2022 and $80M (14%) in FY2023. (2) Completeness: The answer fails to describe the evolution between FY2022 and FY2023 as required, instead discussing FY2023 to FY2024. It omits the actual growth figures and context from FY2022 entirely. (3) Entity Accuracy: While ThousandEyes and Observability are correctly identified, the fiscal years are wrong, and the product category name 'Optimized Application Experiences/Observability' is misrepresented as a single evolving line when the original distinguishes a rebranding or evolution between categories. (4) Reasoning: The multi-hop synthesis is flawed—the model invents data rather than extracting and comparing the reported growth contributions from the two fiscal years. (5) Semantic Equivalence: The conclusion about upward trend aligns loosely with the original, but the fabricated numbers and incorrect time frame make the overall message misleading. The answer appears plausible but is factually unsupported.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1234,
        "completion_tokens": 438,
        "total_tokens": 1673
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How did the treatment of Amendment No. 4 to the Lockheed Martin Executive Severance Plan evolve between the 2023 and 2024 10-K filings, and what does this indicate about its inclusion in the company's disclosure strategy?",
      "original_answer": "In the 2023 10-K filing, Amendment No. 4 to the Executive Severance Plan was disclosed as part of the exhibit list (Exhibit 10.34) and referenced as being incorporated from the September 2022 10-Q filing. However, in the 2024 10-K filing, Amendment No. 4 is no longer listed as a standalone exhibit but appears instead as part of a sequence that includes earlier amendments (Nos. 2, 3, 4, and 5), with Amendment No. 4 specifically incorporated from the same September 2022 10-Q filing. This indicates that while the amendment itself remained relevant, its treatment shifted from a highlighted disclosure in 2023 to a more integrated part of the broader severance plan history in 2024, suggesting a more consolidated and retrospective approach to disclosure.",
      "llm_answer": "The treatment of Amendment No. 4 to the Lockheed Martin Executive Severance Plan evolved from its initial disclosure in the 2023 10-K (referenced in Exhibit 10.33 as Amendment No. 3) to being formally included as Amendment No. 4 in the 2024 10-K (listed as Exhibit 10.36), indicating a strategic shift to systematically document and disclose all amendments to this key compensation plan as part of the company's ongoing disclosure of material executive employment agreements. This inclusion reflects Lockheed Martin's intent to ensure comprehensive transparency regarding changes to its executive severance framework, likely to provide investors with clear visibility into the plan's evolution and current terms.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that Amendment No. 4 was 'formally included as Amendment No. 4 in the 2024 10-K (listed as Exhibit 10.36)', whereas the ground truth indicates that Amendment No. 4 was *not* listed as a standalone exhibit in the 2024 10-K but was instead incorporated into a sequence of amendments. Furthermore, the LLM misidentifies Exhibit 10.33 in the 2023 10-K as referencing Amendment No. 3, when in fact the ground truth states that Amendment No. 4 was disclosed in Exhibit 10.34 and incorporated from the September 2022 10-Q. These are critical errors in exhibit numbers, amendment numbers, and disclosure treatment. (2) Quantitative accuracy is very low: the exhibit numbers (10.33 vs 10.34, 10.36) and amendment references are incorrect, and there is no evidence that Amendment No. 4 was newly introduced in 2024—on the contrary, it was already disclosed in 2023. The LLM falsely implies a progression from Amendment No. 3 to No. 4, which is not supported by the data. (3) The multi-hop reasoning is flawed: the model fails to recognize that the evolution was from standalone disclosure to integration within a broader set of amendments, instead inventing a narrative of 'systematic documentation' and 'formal inclusion' that contradicts the consolidation trend. The actual shift was from highlighted to integrated treatment, not from omission to inclusion. (4) Contextual relevance is moderate—the answer addresses the general topic of disclosure strategy and attempts to interpret intent around transparency, which is relevant. However, due to fundamental factual errors, the qualitative and correctness scores are low. The conclusion about 'comprehensive transparency' is speculative and based on incorrect premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 490,
        "total_tokens": 1876
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How did JPMorgan's compliance with capital ratio requirements evolve from 2023 to 2024, particularly in terms of its Tier 1 leverage ratio and Standardized CET1 capital ratio?",
      "original_answer": "In 2023, JPMorgan's Standardized CET1 capital ratio was 15.0%, exceeding the requirement of 11.4%. In 2024, the Tier 1 leverage ratio was 7.2%, which was above the requirement of 4.0%. This indicates that JPMorgan maintained compliance with capital ratio requirements across both years, with consistent capital strength relative to evolving regulatory expectations.",
      "llm_answer": "From 2023 to 2024 JPMorgan’s capital ratios improved markedly. The CET1 capital ratio rose from 15.0 % to 15.8 % (and the Tier 1 ratio from 16.6 % to 16.9 %), while the leverage‑based supplementary ratio stayed steady at about 6.1 %. This reflects higher CET1 capital (up to $275.5 bn) and a modest increase in risk‑weighted assets, leading to a higher overall capital position.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2023 JPMorgan had a Standardized CET1 capital ratio of 15.0% (correctly stated), but the 2024 CET1 ratio is not provided in the original answer, so claiming it rose to 15.8% is unsupported. Similarly, the LLM introduces a Tier 1 ratio rising from 16.6% to 16.9%, which is not mentioned in the ground truth. The ground truth specifies the 2024 Tier 1 leverage ratio as 7.2%, whereas the LLM states a 'leverage-based supplementary ratio' at 6.1%, which does not match. Additionally, the LLM mentions $275.5 billion in CET1 capital, which is not present in the original answer and cannot be verified from the provided data. (2) Quantitative accuracy is low: while 15.0% for 2023 CET1 is correct, all other numbers (15.8%, 16.6%, 16.9%, 6.1%, $275.5B) are either fabricated or misattributed. The ground truth focuses on two specific ratios in different years—2023 Standardized CET1 (15.0% vs 11.4% requirement) and 2024 Tier 1 leverage ratio (7.2% vs 4.0%)—but the LLM conflates these and introduces non-existent trends. (3) Multi-hop reasoning is flawed: the question asks for evolution from 2023 to 2024 in two specific ratios, but the LLM incorrectly assumes both ratios are available for both years and fabricates a trend. It fails to recognize that the original answer reports different ratios in different years (not a direct year-over-year comparison of both), leading to invalid conclusions about 'improvement'. (4) Contextual relevance is moderate because the answer discusses capital ratios and JPMorgan’s compliance, which is on-topic, but the incorrect data and reasoning undermine the validity. The conclusion about 'higher overall capital position' is speculative and not supported by the ground truth, which only confirms compliance, not improvement.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1193,
        "completion_tokens": 505,
        "total_tokens": 1698
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has the role of GM Financial in General Motors' operations evolved between 2022 and 2023, particularly in terms of its integration and financial presentation within the consolidated financial statements?",
      "original_answer": "In 2022, GM Financial was described as a segment through which General Motors provides automotive financing services, with its financials adjusted to reflect the impact of consolidated tax returns and intercompany transactions. By 2023, the description of GM Financial became more detailed, emphasizing that the amounts presented for GM Financial are adjusted for the impact on deferred tax positions and the provision for income taxes due to its inclusion in the consolidated tax return, and that these amounts differ from those presented on a stand-alone basis. This evolution reflects a more explicit focus on the integration and financial alignment of GM Financial with the broader corporate structure.",
      "llm_answer": "Between 2022 and 2023, GM Financial's integration within General Motors' consolidated financial statements evolved significantly. In the 2023 consolidated balance sheet (page 62), GM Financial's equity is now presented as a distinct line item within Total Equity ($3,903 million), reflecting its standalone financial reporting role, whereas in 2022 it was fully consolidated under GM's equity without separate disclosure. Additionally, the 2023 statement shows GM Financial's revenue and expenses are now clearly segregated in the segment reporting (page 100), with dedicated line items for \"GM Financial\" revenue ($13,831 million) and EBT-adjusted performance metrics, whereas prior years (e.g., 2022 page 62) presented GM Financial's results as part of broader \"Total Automotive\" or \"Eliminations/Reclassifications\" without explicit segment separation. This structural shift underscores its enhanced operational and financial integration as a distinct business unit within GM's portfolio.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contains significant factual errors. (1) The claim that GM Financial's equity is presented as a distinct line item in Total Equity ($3,903 million) in the 2023 balance sheet is false—GM Financial is a wholly-owned subsidiary and its equity is not separately disclosed in GM's consolidated equity. Similarly, the assertion that GM Financial had $13,831 million in revenue as a segregated segment in 2023 is unsupported by the ground truth and misrepresents GM's segment reporting. GM does not report GM Financial as a standalone segment with separate revenue line items; instead, it is integrated within the 'GM Financial' segment under 'Other' in some disclosures, but not with the level of segregation described. (2) The cited page numbers (62, 100) and specific financial figures are fabricated or misattributed—there is no evidence in the ground truth that such line-item changes occurred between 2022 and 2023. (3) The multi-hop reasoning is flawed: the ground truth emphasizes the evolution in *disclosure language* around tax adjustments and consolidation effects, not structural changes in financial statement presentation. The LLM incorrectly infers a material change in financial reporting structure (e.g., standalone equity, segregated revenue) that is not present in the original data. (4) While the answer attempts to address the question's focus on integration and financial presentation, it does so with invented details, leading to a very low correctness score. The contextual relevance is moderate because it discusses financial statements and integration, but the substance is factually wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1439,
        "completion_tokens": 448,
        "total_tokens": 1887
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has the treatment and disclosure of step-rent provisions in lease accounting evolved between 2022 and 2024, particularly regarding the recognition of periodic rent increases based on price indices or sales volume?",
      "original_answer": "In 2022, the company disclosed that certain leases provided for periodic rent increases based on price indices or the greater of minimum guaranteed amounts or sales volume, and these were accounted for on a straight-line basis. By 2024, the company clarified that such increases, based on price indices or the greater of minimum guaranteed amounts or sales volume, are now recognized as variable lease payments rather than being straight-lined, indicating a shift in accounting treatment. This reflects a more dynamic approach to recognizing lease costs that fluctuate with external factors.",
      "llm_answer": "The treatment of step‑rent provisions in lease accounting has remained consistent between 2022 and 2024: the Company continues to recognize periodic rent increases that are based on price indices or sales‑volume thresholds on a straight‑line basis over the lease term (including any renewal options it is reasonably certain to exercise). This approach is disclosed in the “Leases” sections of both the 2022 and 2024 10‑K filings (pages 43‑47), which state that such step‑rent provisions are accounted for as variable lease payments and are recognized evenly over the lease term. No substantive change in methodology is evident; the only evolution is the expanded discussion of lease components and the use of incremental borrowing rates to discount lease payments, but the core recognition principle for step‑rent escalations is unchanged.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its core claim that the accounting treatment for step-rent provisions remained consistent between 2022 and 2024. The ground truth states there was a clear shift: in 2022, periodic rent increases based on price indices or sales volume were accounted for on a straight-line basis, but by 2024, these were reclassified and recognized as variable lease payments, no longer straight-lined. This represents a significant change in accounting treatment, which the LLM answer incorrectly denies. The LLM falsely asserts that the straight-line method is still used and that such escalations are considered variable lease payments while being recognized evenly—this is contradictory, as variable lease payments are, by definition, not straight-lined. There are no numeric values in the question to verify, so quantitative accuracy is not the main issue, but the qualitative and reasoning failures are severe. The model fails to perform the necessary multi-hop comparison across years and misinterprets the accounting standards. While the answer is relevant to lease accounting and cites appropriate sections, it draws the opposite conclusion of the ground truth, making it highly misleading. Thus, the correctness and qualitative accuracy scores are low, with moderate contextual relevance due to correct topic focus and section references.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1375,
        "completion_tokens": 379,
        "total_tokens": 1755
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did the projected funding obligations for Lockheed Martin's qualified defined benefit pension plans evolve from 2023 to 2024, particularly in terms of the amounts expected to be paid out in 2025 and over the long-term period from 2029 to 2033?",
      "original_answer": "In 2023, Lockheed Martin projected $1,860 million in payments for qualified defined benefit pension plans in 2025 and $10,020 million over the period from 2029 to 2033. By 2024, the projected payment for 2025 increased slightly to $1,860 million, while the long-term projection from 2030 to 2034 decreased to $9,990 million. This indicates a marginal reduction in long-term pension obligations.",
      "llm_answer": "The projected funding obligations for Lockheed Martin’s qualified defined benefit pension plans show that the expected benefit payments are $1.8 billion in 2025 and increase to $1.99 billion by 2029, with a long‑term total of $9.99 billion for the 2029‑2034 period. These figures reflect the estimated future benefit payments that will be paid from the plan trusts, with no required cash contributions in 2025.",
      "correctness_score": 4,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. According to the ground truth, the projected payment for 2025 was $1,860 million in both 2023 and 2024 filings—this is correctly approximated as $1.8 billion, which is acceptable. However, the LLM states a long-term total of $9.99 billion for 2029–2034, whereas the ground truth reports $10,020 million ($10.02 billion) for 2029–2033 in 2023, and $9,990 million ($9.99 billion) for 2030–2034 in 2024. The LLM incorrectly merges or shifts the time periods, referring to '2029–2034' instead of distinguishing between the two reporting years’ projections. Additionally, the LLM introduces a figure of '$1.99 billion by 2029', which does not appear in the ground truth and is factually unsupported. (2) The calculation and period alignment are flawed: the ground truth compares 2023’s view of 2029–2033 ($10.02B) with 2024’s view of 2030–2034 ($9.99B), showing a slight decrease. The LLM fails to reflect this shift in forecast window and incorrectly implies increasing annual payments up to $1.99B by 2029. (3) The multi-hop reasoning is partially sound in that it attempts to describe evolution across years and project into the future, but it fails to accurately represent how the obligations evolved from 2023 to 2024 due to incorrect time periods and invented intermediate values. (4) Contextual relevance is high because the answer addresses pension obligations, timeframes, and funding expectations. However, correctness is penalized heavily due to incorrect figures and misaligned time periods, especially the introduction of a non-existent $1.99B data point and the conflation of different forecast horizons.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1226,
        "completion_tokens": 461,
        "total_tokens": 1687
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did JPMorgan Chase's disclosures about its resolution plan obligations evolve between 2023 and 2024, particularly in terms of its described liquidity risk management strategies and funding cost considerations?",
      "original_answer": "In 2023, JPMorgan Chase emphasized that its resolution plan obligations could lead to higher funding costs and constrained liquidity due to the need to satisfy liquidity coverage ratio and net stable funding ratio requirements, as well as regulatory demands outside the U.S. regarding liquidity pre-positioning in subsidiaries. The firm highlighted the potential need to rely on more expensive or limited alternative funding sources if traditional ones like deposits or Federal Home Loan Bank borrowings were reduced. In 2024, the firm expanded its disclosures to include how resolution plan obligations interacted with dynamic regulatory expectations and systemic events, noting that changes in laws, rules, and regulations—especially in response to economic effects of systemic events—could further impact liquidity and capital requirements. This reflects a shift toward framing resolution-related liquidity risks within a broader context of regulatory evolution and macroeconomic uncertainty.",
      "llm_answer": "Between 2023 and 2024, JPMorgan Chase’s disclosures show a continued emphasis on liquidity risk management and funding cost considerations, with evolving language around regulatory capital requirements and resolution planning. In the 2023 filing, the firm highlighted heightened concerns about market stress, collateral valuation, and the potential impact of Basel III reforms on capital buffers, while the 2024 filing expands on these themes by explicitly linking capital adequacy to resolution plan obligations, noting that regulatory changes to Basel III and GSIB surcharge calculations could constrain business activities and capital distributions. Both years underscore that rising interest rates and widening credit spreads directly increase funding costs and liquidity pressures, but the 2024 disclosure adds greater detail on how resolution plan requirements—particularly capital and liquidity thresholds at subsidiaries—could force earlier resolution proceedings if breached.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains significant inaccuracies in the qualitative synthesis of JPMorgan Chase's evolving disclosures between 2023 and 2024. (1) Correct elements: The answer correctly identifies that both years discuss liquidity risk management and funding cost considerations, and it appropriately references regulatory capital requirements and resolution planning. It also correctly notes that rising interest rates and credit spreads affect funding costs. The absence of specific numerical values in the original answer means quantitative accuracy is not compromised—no numbers are misstated. (2) However, the LLM introduces concepts not present in the ground truth: specifically, it emphasizes 'Basel III reforms' and 'GSIB surcharge calculations' as central to the 2024 disclosure evolution, which are not mentioned in the original answer. The original emphasizes instead the interaction of resolution plans with dynamic regulatory expectations and systemic events, particularly how changes in laws/rules due to macroeconomic or systemic shocks affect liquidity and capital. (3) The multi-hop reasoning is flawed: while the LLM recognizes a progression in disclosure depth, it mischaracterizes the nature of the evolution. The original answer highlights a shift toward framing resolution risks within regulatory evolution and macroeconomic uncertainty, whereas the LLM focuses on capital buffers and business constraints from surcharge rules—diverging from the actual emphasis on liquidity pre-positioning, subsidiary requirements, and alternative funding sources. (4) Contextual relevance is high because the response stays focused on resolution plans, liquidity risk, and funding costs, but the qualitative inaccuracy in representing the specific evolution of disclosures reduces overall correctness. The 2024 expansion is misrepresented, leading to a moderate score of 6 for correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1511,
        "completion_tokens": 522,
        "total_tokens": 2034
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How has the financial structure of Optum Rx's pharmacy care services evolved between 2022 and 2023, particularly in terms of revenue recognition and accounts receivable?",
      "original_answer": "In 2022, Optum Rx's pharmacy care services were characterized by a gross revenue reporting model due to the Company's primary obligation to pay network pharmacy providers regardless of payment collection, with revenue recognized at the point of prescription dispensing. By 2023, the financial structure remained aligned with this model but showed an increase in accounts receivable related to products and services, rising from $7.1 billion in 2022 to $8.6 billion in 2023. This indicates a growth in the value of receivables tied to pharmacy care services, suggesting either increased transaction volume or changes in payment timing.",
      "llm_answer": "Between 2022 and 2023, Optum Rx's revenue recognition remained consistent with its standard practice of recognizing revenue when prescriptions are dispensed through its contracted pharmacy network, with rebates from manufacturers recorded as reductions to product revenue. Accounts receivable related to pharmacy services increased from $7.1 billion (2022) to $8.6 billion (2023), reflecting higher volumes of transactions and rebates receivable ($11.0 billion in 2023 vs. $8.2 billion in 2022), though no material bad-debt expense or contract assets/liabilities were recorded. The core revenue model—earning fees for pharmacy services and managing pharmaceutical spend—remained unchanged, with revenue growth driven by expanded utilization and rebate accruals.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: accounts receivable increased from $7.1 billion in 2022 to $8.6 billion in 2023, and the LLM correctly reports these figures. It also introduces additional data—rebates receivable rising from $8.2 billion to $11.0 billion—which, while not in the original answer, does not contradict it and adds context supported by typical Optum Rx reporting practices. (2) The revenue recognition model is accurately described: revenue is recognized at the point of dispensing, consistent with the gross reporting model due to Optum Rx's primary obligation to pay pharmacies. The mention of rebates as reductions to product revenue is consistent with accounting standards and the Company's disclosures. (3) Multi-hop reasoning is sound: the LLM synthesizes information across revenue recognition policy, accounts receivable trends, and rebate accruals to explain the evolution in financial structure. The core conclusion—that the model remained unchanged but receivables grew—matches the original answer’s implication of structural continuity with increasing transaction volume or timing shifts. (4) The only minor gap is that the original answer emphasizes the *reason* for gross reporting (primary obligation to pay providers regardless of collection), which the LLM implies but does not explicitly state. However, the phrase 'primary obligation' is contextually covered by describing Optum Rx as earning fees while managing pharmaceutical spend and handling rebates. Overall, the answer is factually correct, comprehensive, and contextually precise, warranting a high score with only slight room for deeper explanatory alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 470,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has UPS's quantitative exposure and strategic approach to managing interest rate risk through Floating to Fixed Interest Rate Swaps evolved between 2022 and 2024?",
      "original_answer": "In 2022, UPS disclosed a $28 million notional amount for Floating to Fixed Interest Rate Swaps, indicating limited use of this instrument at that time. By 2024, UPS articulated a broader strategy to 'manage the fixed and floating interest rate mix of its total debt portfolio and related overall cost of borrowing,' suggesting a more intentional and strategic deployment of these swaps. This evolution reflects a shift from a minor, quantitative hedge in 2022 to a more comprehensive interest rate risk management approach in 2024.",
      "llm_answer": "Based on the provided SEC 10-K filings, UPS's quantitative exposure to interest rate risk through Floating-to-Fixed Interest Rate Swaps has evolved significantly between 2022 and 2024. In 2022, the company reported $533 million in uncertain tax positions (though this relates to tax, not interest rate swaps), and by 2024, it disclosed $146 million of pre-tax gains related to cash flow hedges deferred in AOCI, with $389 million total gains recognized in AOCI for 2024 (including $389 million from foreign currency exchange contracts and $0 from interest rate contracts). The company specifically manages interest rate risk through designated fair value hedges of long-term debt (with $4 million in cumulative fair value hedge adjustments as of 2024) and cash flow hedges for forecasted interest payments, but the documentation focuses more on foreign currency hedges than interest rate swaps. The 2024 filing shows no specific quantitative breakdown of Floating-to-Fixed swaps, though it confirms interest rate swaps are used to manage the fixed-floating mix of debt and are designated as either fair value or cash flow hedges. The evolution reflects a continued, structured approach to interest rate risk management through these derivatives, with increasing reliance on cash flow hedges for forecasted payments, though the exact notional amounts of Floating-to-Fixed swaps are not disclosed in the provided pages. The company's strategy remains to hedge a portion of its debt portfolio to manage overall interest rate exposure, but the scale and specific evolution of Floating-to-Fixed swaps cannot be quantified from the given excerpts.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that UPS had a $28 million notional amount for Floating to Fixed Interest Rate Swaps in 2022, but the LLM incorrectly references $533 million in uncertain tax positions (unrelated to interest rate swaps) and provides no correct notional amount for 2022. For 2024, the LLM fails to report any notional amount for Floating to Fixed swaps and instead cites $146 million in pre-tax gains and $389 million in total AOCI gains—none of which relate to the notional exposure or directly measure swap usage. It incorrectly states that $0 was from interest rate contracts and emphasizes foreign currency hedges, which misaligns with the question’s focus. (2) The quantitative accuracy is extremely low: the only correct number mentioned is $4 million in fair value hedge adjustments in 2024, but this is not the same as the notional amount of Floating to Fixed swaps. The core quantitative data ($28 million in 2022) is entirely missing, and no data for 2024 notional amount is provided. The LLM confuses gains, tax items, and hedge accounting entries with notional exposure, which are distinct concepts. (3) The multi-hop reasoning is flawed. The question requires comparing UPS’s quantitative exposure and strategic approach across 2022 and 2024. The LLM fails to retrieve the correct 2022 notional figure and does not identify any 2024 notional data, thus breaking the first hop. It also fails to recognize the strategic shift described in the 2024 filing about managing the fixed-floating mix, instead downplaying the role of interest rate swaps. The synthesis is incorrect because it relies on irrelevant data (tax positions, AOCI gains from currency contracts) and misses the key evolution in strategy. (4) The contextual relevance is moderate because the LLM discusses interest rate risk and hedging instruments, showing awareness of the topic domain. However, it fails to extract and report the specific quantitative exposure and mischaracterizes the strategic emphasis, resulting in a mostly incorrect answer. The answer reflects confusion between different types of derivatives and hedge accounting metrics, undermining both factual and conceptual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1548,
        "completion_tokens": 602,
        "total_tokens": 2150
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has GM's financial relationship with LG Energy Solution evolved between 2022 and 2023, particularly in terms of joint venture activities and recall-related costs?",
      "original_answer": "In 2022, GM highlighted its joint venture, Ultium Cells LLC, with LG Energy Solution, as a key part of its EV strategy to mass-produce battery cells across three U.S. plants. By 2023, the relationship had shifted toward financial liabilities, as GM accrued $2.6 billion related to the Chevrolet Bolt EV battery recall, with $1.6 billion recognized as receivables from LG. This marks a transition from strategic collaboration to a more transactional and cost-driven dynamic due to product defects.",
      "llm_answer": "Between 2022 and 2023, GM’s financial relationship with LG Energy Solution (LGES) evolved significantly through its joint venture **Ultium Cells LLC**, which is equally owned by GM and LGES. In 2023, GM expanded its battery supply chain by advancing **$1.6 billion in receivables** from LGES related to the **Chevrolet Bolt recall** and other Ultium‑cell costs, while also recording a **$0.6 billion accrual** for the remaining recall‑related expenses. This reflects a deepening commercial partnership: LGES agreed to reimburse GM for certain recall costs and to support the joint venture’s production plans, underscoring a strategic alignment that ties GM’s vehicle‑electrification timeline to LGES’s battery manufacturing capacity. Additionally, the recall‑related liabilities and reimbursements are disclosed as part of GM’s broader contingent liabilities and indemnification obligations, highlighting how the LGES relationship now directly influences GM’s contingent financial exposures.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "(1) The LLM answer contains significant factual inaccuracies, particularly in the financial figures. The ground truth states that GM accrued $2.6 billion in recall-related costs and recognized $1.6 billion as receivables from LG. However, the LLM incorrectly states that GM recorded a $0.6 billion accrual for the remaining expenses, which contradicts the $2.6 billion total liability (implying $1.0 billion unrecovered, not $0.6 billion). This miscalculation undermines the quantitative accuracy. (2) The LLM also misrepresents the nature of the relationship shift: rather than reflecting a 'deepening commercial partnership' or 'strategic alignment', the original answer describes a shift from collaboration to a more transactional, cost-driven dynamic due to defects—indicating strain, not strengthening. The characterization of LGES 'advancing' $1.6 billion is misleading; the ground truth says GM recognized $1.6 billion as receivables, implying a claim, not a cash transfer or agreement to fund. (3) While the LLM correctly identifies Ultium Cells LLC as the joint venture and links it to GM and LGES, and correctly ties the recall to the Bolt EV and Ultium cells, it fails to accurately synthesize the evolution of the relationship: the multi-hop reasoning is flawed because it draws an incorrect conclusion from correct entities. (4) Contextual relevance is high—the answer addresses joint ventures, recall costs, and financial implications—but correctness is compromised by key numerical and interpretive errors. Minor note: '2023' is correctly used for the accrual, aligning with the original, though the LLM omits that the joint venture was already highlighted in 2022 as part of EV strategy. Overall, partial facts with major errors in numbers and interpretation justify a low-to-mid score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 486,
        "total_tokens": 1863
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has the revenue contribution from ThousandEyes within the Observability product category evolved from fiscal 2022 to fiscal 2023?",
      "original_answer": "In fiscal 2022, revenue in the Observability product category increased by $80 million, driven in part by growth in ThousandEyes and monitoring and analytics offerings. By fiscal 2023, the Observability product category saw a 27% revenue increase, or $176 million, with ThousandEyes and the newly included Splunk offering (Observability Suite) being key contributors. Excluding Splunk, product revenue from Observability still grew by 15%, indicating strong organic growth primarily from ThousandEyes.",
      "llm_answer": "Based on the provided financial tables, the revenue contribution from ThousandEyes within the Observability product category increased from fiscal 2022 to fiscal 2023. Specifically, the Observability product category revenue grew by 27% year-over-year to $837 million in fiscal 2024 (from $661 million in fiscal 2023), with the document explicitly stating this growth was \"driven by growth in our ThousandEyes offering and the contribution from Observability Suite, our Splunk offering.\" Furthermore, the document notes that \"Product revenue in the Observability product category increased 15%, not including the contribution from Splunk,\" confirming ThousandEyes' role in this growth. (2 sentences)",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that Observability revenue grew to $837 million in fiscal 2024 from $661 million in fiscal 2023, which misrepresents both the time period and the figures. The original answer refers to fiscal 2022 and 2023, not 2023 and 2024. The ground truth states that in fiscal 2023, Observability revenue increased by $176 million (27% growth), not that it reached $837 million. There is no mention of $661 million or $837 million in the original answer, nor any data for fiscal 2024. (2) The quantitative inaccuracies are severe: the LLM fabricates revenue figures and fiscal years not present in the ground truth. While it correctly notes a 15% organic growth excluding Splunk, this is attributed to the wrong time frame and context. The $80 million increase in fiscal 2022 is omitted entirely. (3) The multi-hop reasoning is flawed. The LLM fails to trace the evolution from fiscal 2022 to 2023 as asked, instead jumping to fiscal 2024 with incorrect data. It also conflates Splunk’s contribution timeline, despite the original answer clearly stating Splunk was newly included in fiscal 2023. (4) The contextual relevance is moderate because the answer discusses ThousandEyes and Splunk contributions within Observability, which is relevant, but the incorrect fiscal years and fabricated numbers severely undermine correctness. The qualitative reasoning is weak due to incorrect synthesis and timeline confusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 413,
        "total_tokens": 1710
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has UPS's relationship with the 7.620% Debentures evolved between 2022 and 2024 in terms of their redemption terms and interest payment structure?",
      "original_answer": "In 2022, the 7.620% Debentures had a principal amount of $276 million with a maturity date of April 1, 2030, and were listed with a carrying value of $280 million. By 2024, UPS clarified that these debentures are redeemable at any time at the company's option, with a redemption price equal to the greater of the principal amount plus accrued interest or the present value of remaining scheduled payments discounted at a benchmark treasury yield plus five basis points, plus accrued interest. Additionally, the interest payment structure was specified as semi-annual, payable in April and October. This evolution reflects a shift from a general description of the debentures in 2022 to a more detailed explanation of their redemption flexibility and interest payment schedule in 2024.",
      "llm_answer": "Between 2022 and 2024, UPS’s 7.620% Debentures underwent a material evolution in both redemption terms and interest structure. Originally issued with an 8.375% rate that was reduced to 7.620% on April 1 2020, the debentures now carry a fixed 7.620% coupon payable semi‑annually in April and October, with a maturity of April 1 2030. They are redeemable at UPS’s option any time before maturity, with a redemption price equal to the greater of (i) principal plus accrued interest or (ii) the present value of remaining payments discounted at a benchmark Treasury yield plus 5 bps, plus accrued interest. This “make‑whole” redemption feature and the absence of sinking‑fund requirements have remained unchanged, but the lower coupon and the ability to retire the notes early at a calculated make‑whole price have altered the debt’s cost profile and flexibility compared with the earlier 8.375% terms.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly regarding the evolution of the debentures between 2022 and 2024. The original answer states that in 2022, the debentures had a principal of $276 million and a carrying value of $280 million, with no mention of prior coupon changes. However, the LLM introduces a claim that the coupon was reduced from 8.375% to 7.620% on April 1, 2020 — information not present in the ground truth and outside the 2022–2024 scope. This misrepresents the timeline and evolution. Additionally, the ground truth emphasizes that the *clarity* or *disclosure* of redemption terms improved in 2024, not that the terms themselves changed. The LLM incorrectly implies the redemption features (e.g., make-whole) were newly introduced or evolved, when the ground truth indicates they were merely more explicitly described. (2) Quantitative accuracy issues: while the 7.620%, maturity date (April 1, 2030), and semi-annual interest payments (April/October) are correct, the $276M principal and $280M carrying value from 2022 are omitted. The LLM fabricates a prior 8.375% rate and redemption mechanics as if they evolved during 2022–2024, which contradicts the ground truth that the evolution was in disclosure, not structure. (3) Multi-hop reasoning is partially sound — the model connects redemption terms and interest payments across time — but fails to correctly interpret the nature of the 'evolution' (increased disclosure vs. structural change). It also introduces irrelevant historical data (pre-2022 coupon change), muddying the actual progression. (4) Despite inaccuracies, the answer is contextually relevant, addressing redemption terms and interest structure as asked. It correctly identifies semi-annual payments and the make-whole formula, aligning semantically with parts of the ground truth. However, the incorrect timeline and unsupported claims about coupon evolution significantly reduce factual correctness, warranting a mid-low score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1421,
        "completion_tokens": 541,
        "total_tokens": 1962
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How did the composition and total fair value of Fixed Maturity Securities AFS held by MET evolve from 2022 to 2023, particularly in terms of U.S. government bonds and corporate securities?",
      "original_answer": "In 2022, MET reported a carrying amount of $2,164 million for Fixed Maturity Securities AFS as of December 31, 2021. By 2023, the total estimated fair value of Fixed Maturity Securities AFS had increased significantly to $6,714 million. Specifically, the fair value of corporate securities rose to $3,083 million, with $3,029 million categorized under Level 2, while U.S. government bonds increased to $1,575 million, with $1,537 million under Level 1. This reflects a substantial transformation in both the size and breakdown of these investments over the year.",
      "llm_answer": "From 2022 to 2023, the total fair value of Fixed Maturity Securities AFS held by MetLife increased from $6,802 million to $6,714 million (a slight decline), but the composition shifted notably: U.S. government bonds rose from $1,507 million to $1,575 million, while corporate securities increased modestly from $3,001 million to $3,083 million. In contrast, foreign bonds fell from $769 million to $810 million (still a small share), and municipal bonds remained roughly stable around $147 million. Thus, the portfolio became slightly more weighted toward U.S. government securities and corporate bonds, with overall AFS fair value essentially unchanged.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors in key numbers and timeframes. The ground truth states that the 2022 reported carrying amount was $2,164 million (as of December 31, 2021), and by 2023, the total fair value increased to $6,714 million. However, the LLM incorrectly claims the 2022 value was $6,802 million, which is not supported by the original data. This misrepresents the starting point and implies a slight decline, whereas the actual trend is a substantial increase from $2,164M to $6,714M. Additionally, the LLM introduces figures for foreign bonds ($769M to $810M) and municipal bonds (~$147M), which are not mentioned in the ground truth and appear to be fabricated or misattributed. (2) The only correct numbers are the 2023 values: corporate securities at $3,083 million and U.S. government bonds at $1,575 million, which match the ground truth. However, the LLM’s claimed 2022 values ($3,001M and $1,507M) are not verifiable from the original answer and contradict the only provided 2022 figure of $2,164M total. The total AFS fair value cannot be $6,802M in 2022 if the only reported prior value is $2,164M. (3) The multi-hop reasoning is flawed. The original answer implies a transformation from a much smaller base in 2021 (reported in 2022) to a significantly larger portfolio in 2023. The LLM fails to recognize this temporal reporting lag and incorrectly treats 2022 as having a $6.8B portfolio, leading to invalid comparisons. It also adds unverified asset categories, suggesting poor synthesis or use of external data not in the knowledge graph. (4) Despite incorrect numbers, the LLM correctly identifies the direction of change for U.S. government and corporate securities—both increased—and notes a shift in composition, which aligns qualitatively with the ground truth. This earns partial credit for reasoning and relevance. However, due to major quantitative inaccuracies and introduction of unsupported data, the correctness score is low. Contextual relevance is moderate because it addresses the right topic and metric changes, but with incorrect baselines.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1314,
        "completion_tokens": 567,
        "total_tokens": 1882
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has General Motors' relationship with Ultium Cells LLC evolved from 2022 to 2023, particularly in terms of financial involvement and regulatory implications?",
      "original_answer": "In 2022, General Motors reported a direct financial investment of $0.5 billion in Ultium Cells LLC as part of its investing activities. By 2023, the nature of GM's relationship with Ultium Cells LLC had evolved from a primarily investment-based relationship to a more operationally integrated partnership, evidenced by GM's involvement in regulatory violations related to the joint venture. Specifically, in February 2023, GM self-disclosed potential violations of the Toxic Substances Control Act (TSCA) related to Ultium Cells LLC to the EPA, which resulted in a November 2023 settlement involving joint civil penalties estimated at approximately $5.1 million. This indicates a shift from a passive investment to a more active and operationally entangled partnership with associated regulatory responsibilities.",
      "llm_answer": "From 2022 to 2023 GM’s financial involvement with Ultium Cells LLC shifted from a $2.0 billion cash investment in 2022 to a $0.5 billion cash outflow in 2023 (reflected in the “Investment in Ultium Cells LLC” line of the cash‑flow tables).  The 2023 filing also notes that GM’s $10 billion accelerated share‑repurchase program, which includes the $6.8 billion purchase of ~215 million shares on December 1 2023, was executed through agreements that advanced $10 billion and immediately retired those shares, a transaction tied to the same credit facilities that support GM’s overall liquidity and capital‑return strategy.  Consequently, while GM’s equity stake in Ultium Cells remained unchanged, the company’s cash deployment moved from funding the joint venture to using that capital for a large‑scale share‑repurchase, and the related regulatory filings (e.g., the $5.1 million EPA settlement for TSCA violations at Ultium Cells) highlight ongoing compliance and environmental‑regulatory implications.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states GM invested $0.5 billion in 2022, but the LLM incorrectly claims a $2.0 billion investment in 2022 and a $0.5 billion outflow in 2023—this reverses and distorts the actual financial timeline. The $10 billion share-repurchase program and $6.8 billion transaction are unrelated to Ultium Cells LLC and appear to be incorrectly conflated with GM's investment in the joint venture, introducing irrelevant financial details not present in the original answer. The only correct quantitative detail is the $5.1 million EPA settlement, which matches the ground truth. (2) The dates (February 2023 self-disclosure, November 2023 settlement) are not mentioned in the LLM answer, and the nature of the regulatory violation (TSCA) is only partially noted without context. The core claim of a shift from investment to operational integration is misrepresented—the LLM frames it as a shift in cash deployment to share buybacks, which is unsupported by the ground truth. (3) The multi-hop reasoning is flawed: the model fails to correctly synthesize the evolution from financial investment to regulatory entanglement. Instead, it introduces a false narrative around capital allocation to share repurchases, which is not part of the original answer and misrepresents the nature of GM’s evolving relationship. (4) While the LLM recognizes regulatory implications (EPA/TSCA), it embeds them in an incorrect financial storyline, undermining overall accuracy. Contextual relevance is moderate because it addresses Ultium Cells and some regulatory aspects, but the core financial narrative is factually wrong, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1458,
        "completion_tokens": 469,
        "total_tokens": 1927
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has the company's use of variable-priced contracts for natural gas and fuel purchases evolved between 2022 and 2024?",
      "original_answer": "In 2022, the company entered into variable-priced contracts for some purchases of natural gas and fuel for its gas stations on an index basis, though the specific volume or value of these contracts was not disclosed. By 2024, the company continued using variable-priced contracts for similar purchases and explicitly noted that these contracts met the characteristics of derivative instruments but generally qualified for the 'normal purchases and normal sales' exception, requiring no mark-to-market adjustment. This indicates a more formalized or strategic use of variable-priced contracts by 2024, aligning them with accounting frameworks for derivatives, suggesting a shift in how these contracts are managed or accounted for.",
      "llm_answer": "The company's use of variable-priced contracts for natural gas and fuel purchases has remained consistent between 2022 and 2024, as evidenced by its disclosure that it enters into variable-priced contracts for some purchases of natural gas and fuel on an index basis, which meet the characteristics of derivative instruments but generally qualify for the 'normal purchases and normal sales' exception under authoritative guidance and require no mark-to-market adjustment. This practice is described in both the 2022 and 2024 filings without indication of significant evolution in the approach.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in describing the company's use of variable-priced contracts and their accounting treatment, correctly noting that these contracts meet derivative characteristics but qualify for the 'normal purchases and normal sales' exception with no mark-to-market adjustment in both 2022 and 2024. All entities, years, and accounting terms are correct, and there are no numerical inaccuracies (quantitative accuracy is perfect). However, the LLM incorrectly concludes that there was 'no significant evolution' in the approach, which contradicts the ground truth that indicates a more formalized or strategic use by 2024, including explicit alignment with derivative accounting frameworks—suggesting a shift in management or accounting emphasis. The original answer identifies an evolution in how these contracts are treated or disclosed, while the LLM answer downplays this development. This is a critical omission in reasoning and synthesis (multi-hop analysis), as the question asks about evolution, not just presence. The LLM fails to recognize the qualitative shift in disclosure and accounting alignment, which constitutes a meaningful change in practice. Thus, while contextually relevant and factually sound on surface details, the answer lacks the depth of comparative analysis required, leading to a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 376,
        "total_tokens": 1700
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has Cisco's financial reporting approach for the APJC segment evolved between fiscal 2022 and fiscal 2023, particularly in terms of the expense categories excluded from segment performance measurement?",
      "original_answer": "Cisco's financial reporting for the APJC segment maintained a consistent exclusion of key expense categories from segment performance measurement in both fiscal 2022 and fiscal 2023. In fiscal 2022, the company explicitly excluded research and development, sales and marketing, and general and administrative expenses from segment financial decisions and resource allocations. This approach remained unchanged in fiscal 2023, with the same categories of expenses—along with amortization and impairment of acquisition-related intangible assets, share-based compensation expense, significant litigation settlements, and charges related to asset impairments and restructurings—not being allocated to the gross margin for each segment. The consistency in exclusions indicates no change in how APJC's performance was internally measured across the two fiscal years.",
      "llm_answer": "Cisco's financial reporting for the APJC segment remained consistent in its approach between fiscal 2022 and fiscal 2023, continuing to exclude certain expenses from segment performance measurement. Specifically, the company does not allocate research and development, sales and marketing, general and administrative expenses, amortization of acquisition-related intangible assets, share-based compensation, significant litigation settlements, asset impairment and restructuring charges, and other specified items to its geographic segments, including APJC, when measuring segment performance. This policy was unchanged in both fiscal years, as evidenced by the consistent segment reporting methodology described in the Notes to Consolidated Financial Statements on page 105 of the 2022 filing and page 106 of the 2023 filing.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) It accurately states that Cisco's financial reporting approach for the APJC segment remained unchanged between fiscal 2022 and 2023, with consistent exclusions from segment performance measurement. (2) There are no numeric values requiring calculation (e.g., dollar amounts, percentages), but the answer correctly references the relevant fiscal years (2022 and 2023) and aligns with the source documentation (page 105 of the 2022 filing and page 106 of the 2023 filing), which supports the claim of consistency. (3) The multi-hop reasoning is sound: the model correctly synthesizes that the same set of expenses—research and development, sales and marketing, general and administrative, amortization of acquisition-related intangibles, share-based compensation, litigation settlements, and asset impairment/restructuring charges—were excluded in both years, indicating no change in methodology. (4) All entities (Cisco, APJC segment, fiscal years) are correctly identified, and the answer directly addresses the evolution (or lack thereof) in reporting approach. The inclusion of specific footnote references enhances accuracy and relevance. No factual errors, omissions, or misstatements are present.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1436,
        "completion_tokens": 358,
        "total_tokens": 1794
      },
      "error": null
    },
    {
      "question_id": 83,
      "question": "How has UNH's approach to managing medical cost trends evolved from 2022 to 2023, particularly in terms of strategies to address rising outpatient procedure costs for seniors?",
      "original_answer": "In 2022, UNH expressed concern over increased medical care costs due to deferred care during the pandemic and the potential for higher demand for services, especially among individuals with chronic conditions. The company emphasized the importance of accurate cost prediction and effective management under risk-based arrangements. By 2023, UNH specifically identified rising outpatient procedure costs for seniors as a persistent trend, expecting it to continue into 2024 and beyond. In response, the company shifted toward more proactive strategies, such as engaging physicians and consumers with data-driven insights to guide clinical decisions and promote affordable, high-quality care. This represents a shift from general concern in 2022 to targeted intervention in 2023.",
      "llm_answer": "UNH's approach to managing medical cost trends evolved from 2022 to 2023 by shifting from general cost-control language to specific focus on outpatient procedure cost pressures for seniors, as noted on page 27 where it states \"During 2023, we observed increased care patterns, primarily related to outpatient procedures for seniors, which we expect will persist.\" The company responded by implementing strategies to \"mitigate those increases by engaging physicians and consumers with information and helping them make clinically sound choices,\" while also advancing its transition to value-based care models described on page 27 that emphasize \"accelerating the transition from fee-for-service care delivery and payment models to fully accountable value-based care\" through system enhancements and clinical engagement initiatives. This represents a more targeted strategy addressing the specific senior outpatient cost trend rather than the broader cost management approaches referenced in 2022 materials.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the original ground truth. (1) All factual elements are correct: UNH's shift from general concern in 2022 about deferred care and cost trends to a specific focus in 2023 on rising outpatient procedure costs for seniors is accurately captured. The expectation of persistence into 2024 and beyond is implied through 'we expect will persist.' (2) There are no numeric values (e.g., percentages, dollar amounts) in either the original or LLM answer, so quantitative accuracy is not compromised—score is 10 by default. (3) The multi-hop reasoning is sound: the model correctly synthesizes UNH’s evolving strategy across two years, identifying the shift from broad cost management to targeted interventions involving data-driven engagement of physicians and consumers. It also correctly references the move toward value-based care as a strategic response, which is consistent with the original answer’s mention of risk-based arrangements. (4) The LLM adds contextual detail (e.g., page 27 reference, quote integration, mention of fee-for-service transition) not in the original answer but plausibly derived from source material, enhancing relevance without introducing inaccuracies. Only minor deduction in qualitative accuracy due to slightly stronger emphasis on value-based care transition than in the original, which focused more on data-driven decision support—nuanced but not incorrect. Overall, the answer is semantically equivalent, factually correct, and contextually rich.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1452,
        "completion_tokens": 419,
        "total_tokens": 1872
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has UPS's approach to time-definite delivery services evolved between 2022 and 2024, particularly in terms of service scope and network integration?",
      "original_answer": "In 2022, UPS emphasized its integrated global air and ground network as the foundation for time-definite delivery services, highlighting its ability to combine all packages within a single network for operational efficiency. By 2024, UPS expanded its time-definite delivery offerings by insourcing the final delivery of non-urgent, lightweight residential shipments previously handled by the USPS through UPS SurePost, giving it greater control over service quality. Additionally, in 2024, UPS offered same-day pickup seven days a week and expanded returns services across approximately 150 countries, reflecting a broader and more customer-centric service scope compared to 2022.",
      "llm_answer": "Between 2022 and 2024, UPS expanded the scope of its time‑definite delivery services within its global small‑package network while integrating them more tightly with its broader logistics platform.  The company highlighted that its “global smart logistics network” combines air, ground, domestic and international services through a single, RFID‑enabled network that can be configured to meet specific service‑level commitments, allowing more packages to be moved with guaranteed time‑definite delivery across > 220 countries.  At the same time, UPS has been shifting volume away from low‑margin, large‑customer contracts (e.g., a 2025 agreement to cut a major customer’s volume by > 50 %) and re‑engineering its network to focus on higher‑yielding, time‑critical shipments, which it says improves revenue mix and reduces cost‑to‑serve while preserving the integrated, network‑wide efficiency that underpins its time‑definite service offering.  This evolution reflects a broader strategic move toward “Customer First, People Led, Innovation Driven” growth that leverages technology and network consolidation to deliver more value‑added, time‑definite services.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general strategic direction of UPS's evolution in time-definite delivery services, including network integration and a shift toward higher-yield shipments, which aligns with the broader context of UPS's strategy. However, it fails to include key factual developments explicitly mentioned in the ground truth, particularly the 2024 insourcing of final delivery for lightweight residential shipments previously handled by USPS via UPS SurePost—a major operational change directly related to service scope and control. Additionally, the LLM mentions same-day pickup and expanded returns across 150 countries in the ground truth, but instead references services in '>220 countries' without specifying the returns expansion or seven-day pickup, introducing a factual discrepancy in scope. The answer introduces a '2025 agreement to cut a major customer’s volume by >50%' which is not present in the original answer and shifts focus to a future event outside the 2022–2024 timeframe, raising concerns about entity and temporal accuracy. While the concept of network integration and the 'global smart logistics network' is thematically consistent, the use of RFID-enabled systems is not mentioned in the ground truth and appears to be an unsupported addition. The strategic framing around 'Customer First, People Led, Innovation Driven' is plausible but not verifiable from the provided ground truth. Quantitatively, the >50% volume cut and >220 countries are unverified and conflict with the original data (150 countries for returns). Thus, while the answer is contextually relevant and reflects a reasonable qualitative interpretation of UPS's strategic direction, it lacks fidelity to the specific multi-hop facts (e.g., SurePost insourcing, returns expansion, same-day pickup) and introduces unverified numbers and entities, resulting in partial correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1461,
        "completion_tokens": 506,
        "total_tokens": 1968
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How did Lowe's Companies, Inc.'s treatment or recognition of its 2.50% Notes maturing in April 2026 evolve between the 2022 and 2023 annual filings?",
      "original_answer": "In the 2022 filing, the 2.50% Notes maturing in April 2026 were referenced as part of the Thirteenth Supplemental Indenture dated April 20, 2016, but were described in the context of historical documentation. By the 2023 filing, these same notes were explicitly recognized as issued instruments under the same indenture, indicating a shift in disclosure treatment. This reflects a procedural or administrative transition from planning or documentation phase in 2022 to a more active recognition of the notes as part of the company's outstanding debt structure in 2023, even though the core terms (interest rate of 2.50%, maturity in April 2026) remained unchanged.",
      "llm_answer": "Based on the provided SEC 10-K filings, Lowe's treatment of its 2.50% Notes maturing in April 2026 evolved as follows: In the 2022 filing (page 76), the notes were explicitly referenced in the Thirteenth Supplemental Indenture (dated April 20, 2016), which included them as part of the exhibits. However, in the 2023 filing (page 78), the same notes were no longer listed in the supplemental indentures or subsequent amendments, indicating they were no longer outstanding or being actively referenced in new debt issuances. This suggests the notes were either retired, refinanced, or removed from Lowe's public disclosures between 2022 and 2023.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect in its core claim and contradicts the ground truth. (1) It incorrectly states that in the 2023 filing, the 2.50% Notes maturing in April 2026 were 'no longer listed in the supplemental indentures or subsequent amendments,' implying retirement or removal from disclosures. This is factually wrong—the ground truth confirms that the notes were explicitly recognized as issued instruments in the 2023 filing, indicating increased, not decreased, recognition. (2) Quantitatively, while the interest rate (2.50%) and maturity date (April 2026) are correctly noted, the key evolution in treatment—shift from historical reference to active recognition—is misrepresented. The LLM falsely infers discontinuation, which is not supported by the data. (3) The reasoning is flawed: the absence from new amendments does not imply the notes are no longer outstanding; the ground truth clarifies they were recognized under the same Thirteenth Supplemental Indenture, just with evolved disclosure context. The model fails the multi-hop synthesis by misinterpreting the nature of disclosure changes. (4) Contextual relevance is moderate because it addresses the right document (10-K), company (Lowe's), and indenture, but draws the opposite conclusion of the truth. The answer would mislead a user about the status of the debt instrument.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 375,
        "total_tokens": 1702
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has the impact of sovereign debt crises on Costco's merchandise sourcing and cost structure evolved from 2022 to 2024?",
      "original_answer": "In 2022, sovereign debt crises were mentioned as part of a broader set of macroeconomic factors that could adversely affect demand for Costco's products and services, influence the cost or ability to purchase inventory, and require a change in product mix. The document highlighted that the degree of exposure depended on the type of goods, tariff rates, and timing, with the potential for higher tariffs to impact results. By 2024, the framing had shifted, with sovereign debt crises now explicitly stated to 'negatively impact' Costco's business, financial condition, and results of operations. The 2024 filing emphasized a broader set of supply chain risks, including supplier adherence to standards, supply constraints, and geopolitical instability, suggesting a heightened concern over the cascading effects of sovereign debt crises on both sourcing and cost predictability.",
      "llm_answer": "From 2022 to 2024, the impact of sovereign debt crises on Costco’s merchandise sourcing and cost structure evolved from heightened exposure to tariffs and trade restrictions affecting imported goods to a more integrated effect through international expansion and currency volatility. In 2022, Costco noted that sovereign debt issues and trade tensions (particularly involving China and the U.S.) could increase merchandise costs and force changes in product mix, directly threatening gross margins if cost increases could not be passed to members. By 2024, this risk expanded to include currency fluctuations from international operations (e.g., Canada, which generated 28–33% of net sales and operating income), where unfavorable exchange rates directly raised the cost of imported goods paid in foreign currencies, further pressuring cost structures. Additionally, while sovereign debt crises were not explicitly cited in 2024, the broader external risks—such as tariffs, trade sanctions, and commodity price volatility—were now compounded by the need to manage supply chain disruptions and inflationary pressures across global sourcing networks, making cost control more complex than in 2022.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. While it correctly identifies that sovereign debt crises and macroeconomic factors affected Costco's sourcing and cost structure, it introduces inaccuracies in both framing and detail. The original answer states that in 2024, sovereign debt crises were *explicitly stated* to 'negatively impact' Costco's business, but the LLM claims they were 'not explicitly cited in 2024'—this directly contradicts the ground truth and represents a major factual error. Additionally, the LLM introduces specific claims about Canada generating 28–33% of net sales and operating income, which is not present in the original answer and cannot be verified from the provided context—this is an unsupported addition. (2) The quantitative claim about Canada’s contribution (28–33%) lacks sourcing and does not appear in the ground truth; no other numbers (dates, dollar amounts) are present, so this is the only numeric point to evaluate. Its accuracy cannot be confirmed and it appears fabricated or misattributed, lowering quantitative accuracy. (3) The multi-hop reasoning is partially sound—linking sovereign debt to tariffs, currency volatility, and supply chain issues shows logical synthesis—but fails on factual grounding. The model incorrectly infers that sovereign debt crises were de-emphasized in 2024 when they were actually elevated in severity. It also conflates broader risks (e.g., commodity prices, inflation) with the specific evolution of sovereign debt risk, missing the key shift from potential adverse effect (2022) to explicit negative impact (2024). (4) Correctness is scored at 5 due to partial factual alignment but significant errors in key claims. Quantitative accuracy is 6 because while no numbers are wrong per se, one is unverified and likely incorrect. Qualitative accuracy is 5 due to flawed reasoning about the evolution of risk disclosure. Contextual relevance is high (8) because the answer stays on topic and discusses relevant dimensions of sourcing and cost structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1512,
        "completion_tokens": 556,
        "total_tokens": 2069
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has the number of shares available for future grants under the 2020 Stock Incentive Plan changed between 2021 and 2023, and what does this indicate about UnitedHealth Group's capacity for issuing new share-based awards?",
      "original_answer": "In 2021, UnitedHealth Group had 64 million shares available for future grants under the 2020 Stock Incentive Plan. By 2023, this number had decreased to 53 million shares. This indicates a reduction in the company's available capacity to issue new share-based awards over this period.",
      "llm_answer": "Based on the provided SEC 10-K filing pages, the number of shares available for future grants under the 2020 Stock Incentive Plan decreased from 64 million as of December 31, 2021 (page 67) to 53 million as of December 31, 2023 (page 72). This reduction indicates UnitedHealth Group has less remaining capacity to issue new share-based awards, reflecting the exhaustion of the plan's authorized shares after accounting for prior grants and repurchases. The decline suggests the company is nearing the limit of its share-based compensation authorization, potentially constraining future equity awards without shareholder approval for additional shares.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the numbers are accurate: 64 million shares available as of 2021 and 53 million as of 2023, with correct years and units. The reduction of 11 million shares is implied and correctly represented. (2) The answer addresses both parts of the question: the change in shares available (decrease from 64M to 53M) and the implication for UnitedHealth Group's capacity to issue new awards. (3) Entity accuracy is correct—UnitedHealth Group, the 2020 Stock Incentive Plan, and the correct fiscal years (2021 and 2023) are all properly identified. (4) The reasoning is sound and adds value beyond the ground truth by explaining that the decline reflects exhaustion of authorized shares and may require shareholder approval for expansion, which is a logical and contextually appropriate inference from the data. The multi-hop synthesis—comparing two data points across years and interpreting the trend—is correctly executed. All components meet or exceed the criteria for correctness, completeness, and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1253,
        "completion_tokens": 311,
        "total_tokens": 1564
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did the expiration date and contribution significance of the IAM National Pension Fund / National Pension Plan relationship with UPS evolve between 2022 and 2024?",
      "original_answer": "In 2022, the IAM National Pension Fund / National Pension Plan had a collective bargaining agreement expiration date of July 31, 2024, and UPS had contributed more than 5% of the total plan contributions from all employers for the years 2019 through 2021. By 2024, the expiration date for this specific plan was extended to July 31, 2029, and UPS continued to be a significant contributor, providing more than 5% of total contributions for the plan years 2022 through 2024. This indicates a notable extension in the contractual relationship and sustained significance of UPS's contributions over time.",
      "llm_answer": "The IAM National Pension Fund / National Pension Plan’s collective bargaining agreement was extended from a July 31, 2028 expiration (as noted for other plans in the 2022 filing) to a new July 31, 2029 expiration, reflecting the July 2024 ratification of the new National Master Agreement by the International Association of Machinists and Aerospace Workers. This change marks a one‑year extension of the plan’s contribution significance and aligns its termination date with the updated contract term.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that the expiration date in 2022 was July 31, 2028, while the ground truth specifies July 31, 2024. This is a critical error in quantitative accuracy. The extension to July 31, 2029, is correct. However, the LLM completely omits the key part of the question about UPS's contribution significance—specifically that UPS contributed more than 5% of total plan contributions for 2019–2021 (in 2022 context) and continued to do so for 2022–2024 (in 2024 context). This omission severely undermines completeness and correctness. (2) The date 2028 has no support in the ground truth and appears to be a confusion with other plans or a misstatement. The correct initial expiration is July 31, 2024, not 2028. The extension to 2029 is accurate. No calculations are performed, but the failure to report the >5% contribution data for both time periods is a major quantitative and qualitative gap. (3) The multi-hop reasoning is partially sound in linking the ratification of the new National Master Agreement to the extension, but it fails to synthesize the required information about UPS’s sustained financial significance to the plan, which is a core component of the question. The model focuses only on the expiration date evolution and ignores the contribution analysis. (4) The contextual relevance is high because the answer addresses the evolution of the expiration date and ties it to a real event (July 2024 ratification), but the absence of contribution data—central to the question—drags down correctness, quantitative, and qualitative scores. A passing answer must include both the date change and the contribution significance over time, which this does not.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1280,
        "completion_tokens": 477,
        "total_tokens": 1758
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did the terms and availability under LOW's 2020 Credit Agreement evolve between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, the 2020 Credit Agreement had a maturity date of March 2025 and provided $2.0 billion in availability. By fiscal year 2023, the 2020 Credit Agreement was amended and restated in September 2023 into the 2023 Credit Agreement, which extended the maturity date to September 2028 while maintaining the same $2.0 billion availability. Additionally, in 2023, the combined availability under both the 2023 Credit Agreement and the Third Amended and Restated Credit Agreement remained at $4.0 billion, consistent with the total availability reported in 2022.",
      "llm_answer": "Based on the provided 10-K filings, the terms and availability under Lowe's 2020 Credit Agreement evolved between fiscal years 2022 and 2023 as follows:  \n\n1.  **Availability Increase**: The Company amended and restated its $2.0 billion five-year unsecured revolving credit agreement (2020 Credit Agreement) in September 2023, extending the maturity to September 2028 and increasing aggregate availability by $1.0 billion (subject to lender commitments), resulting in a combined $4.0 billion availability under the Credit Agreements as of February 2, 2024.  \n2.  **Term Extension & Restructuring**: The 2023 Credit Agreement (amending the 2020 Agreement) extended the maturity from 2025 to 2028 and restructured the facility, while the Third Amended and Restated Credit Agreement (dated December 2021) had previously extended the prior facility to 2026.  \n3.  **No Outstanding Borrowings**: As of February 2, 2024, there were no outstanding borrowings under the commercial paper program, the Third Amended and Restated Credit Agreement, or the 2020 Credit Agreement, with total combined availability remaining at $4.0 billion.  \n\n*(Synthesized from LOW_10k_2023.pdf pages 56-60 and LOW_10k_2022.pdf page 58, focusing on Credit Agreement amendments, maturity extensions, and availability details.)*",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual error in stating that the 2023 amendment 'increased aggregate availability by $1.0 billion' and resulted in '$4.0 billion availability under the Credit Agreements'. The ground truth clarifies that the 2020 Credit Agreement maintained its $2.0 billion availability after amendment, and the $4.0 billion total availability comes from combining the 2023 Credit Agreement ($2.0B) and the separate Third Amended and Restated Credit Agreement ($2.0B), which was already in place in 2022. The LLM incorrectly implies the increase came from amending the 2020 agreement, when in fact availability under that specific agreement did not increase. (2) Dates are mostly correct: maturity extended from March 2025 (2022) to September 2028 (2023) aligns with ground truth. However, the LLM references 'February 2, 2024' as reporting date, which is outside the fiscal year 2023 scope (ended February 2023), introducing a minor timing misalignment. The $4.0 billion combined availability is correctly reported for both years, but the reasoning behind it is flawed. (3) Multi-hop reasoning is partially sound: the model identifies both credit agreements and attempts to synthesize total availability, but fails to correctly attribute the source of the $4.0 billion. It conflates the amendment of the 2020 agreement with an increase in its size, rather than recognizing it was a maturity extension with unchanged commitment. The existence and role of the Third Amended and Restated Credit Agreement (from 2021) is acknowledged, but not clearly distinguished as the source of the second $2.0 billion. (4) Despite the critical error in explaining the source of increased availability, the answer includes relevant context, correct maturities, and correct total availability figure, warranting a moderate score. Quantitative accuracy is penalized due to the incorrect implication of a $1.0B increase from the 2020 amendment. Qualitative accuracy is reduced for flawed reasoning but not severely, as key entities and events are identified. Contextual relevance is high as the response directly addresses the evolution of terms and availability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1458,
        "completion_tokens": 584,
        "total_tokens": 2042
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did MDLZ's use of Net Investment Hedge Derivative Contracts evolve between 2022 and 2024, particularly in terms of their notional amounts?",
      "original_answer": "In 2022, MDLZ reported a notional amount of $3,915 million for Net Investment Hedge Derivative Contracts as of December 31, 2021, and $4,551 million as of December 31, 2020. By 2024, the notional amount for these contracts had increased significantly to $8,647 million as of December 31, 2024, up from $7,456 million in 2023. This indicates a growing reliance on such contracts over the two-year period.",
      "llm_answer": "Based on the provided pages, MDLZ's net investment hedge derivative contracts (as disclosed in the \"Net investment hedge derivative contracts\" line item within the \"Derivatives designated as accounting hedges\" table) show a decline in notional amount from $7,456 million as of December 31 2023 to $8,647 million as of December 31 2024. However, the document does not provide a clear year‑over‑year comparison of the notional amounts for the years 2022, 2023, and 2024 that would allow a definitive assessment of how the use of these contracts evolved specifically between 2022 and 2024. The only quantitative data available are the 2023 and 2024 figures (4,551 million and 8,647 million, respectively) and the earlier 2021 figure (3,915 million), but the question’s focus on the 2022‑2024 period lacks sufficient disclosed notional‑amount detail to answer fully.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that the notional amount declined from $7,456 million in 2023 to $8,647 million in 2024, when in fact it increased — the correct direction is an increase, not a decline. This misstatement undermines the core of the answer. Additionally, the LLM incorrectly claims that the 2022 notional amount is missing or not disclosed, but the original answer correctly references data from the 2022 filing, which reports the notional amounts as of December 31, 2021 ($3,915 million) and December 31, 2020 ($4,551 million) — these are disclosed in the 2022 10-K and are relevant for tracking evolution. The LLM also falsely asserts that there is no data for 2022, when the question is about the evolution between 2022 and 2024, and the 2022 filing provides the necessary prior-year figures. (2) Quantitatively, the numbers mentioned — $7,456 million (2023), $8,647 million (2024), $3,915 million (2021), $4,551 million (2020) — are all correctly cited in value and date, so the raw data extraction is accurate. However, the interpretation of trend is wrong: it should be an increase from ~$3.9B in 2021 (reported in 2022 filing) to $7.5B in 2023 and $8.6B in 2024, showing growth. The LLM incorrectly frames a rise as a decline. (3) The multi-hop reasoning fails: the model should have synthesized data from the 2022, 2023, and 2024 filings to show a clear upward trend. Instead, it incorrectly concludes that the data is insufficient and misrepresents the trend. It also confuses reporting year with reference date (e.g., 2022 filing contains 2021 data). (4) Contextual relevance is moderate — it addresses the right metric and company, and cites the correct line item, but fails to correctly interpret or synthesize the evolution over time, leading to a misleading conclusion. The answer should have noted the increasing trend from $3.9B to $8.6B over the period using disclosed figures, even if 2022's end-of-year figure isn't directly named, the trajectory is clear from available data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 556,
        "total_tokens": 1872
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How has Microsoft 365's integration with AI technologies evolved between 2022 and 2024, and what specific new capabilities were introduced in 2024 to enhance its role in productivity and collaboration?",
      "original_answer": "In 2022, Microsoft 365 was described as integrating Office 365, Windows, and Enterprise Mobility + Security with AI-backed tools to empower employees, focusing on creativity, collaboration, and innovation. By 2024, Microsoft 365 had evolved into an 'AI first platform,' introducing Copilot for Microsoft 365, which combines AI with business data from the Microsoft Graph and Microsoft 365 applications. Additionally, role-specific extensions such as Copilot for Sales, Copilot for Service, and Copilot for Finance were introduced to streamline business processes. These developments reflect a significant enhancement in AI integration aimed at delivering more personalized and intelligent productivity tools.",
      "llm_answer": "Microsoft 365’s AI integration has progressed from early AI‑first positioning in 2022 to a full‑stack Copilot experience by 2024.  In 2024 the company introduced **Copilot for Microsoft 365** (AI‑enhanced Office apps that combine large‑language‑model assistance with business data), **Copilot Pro** (a consumer subscription offering faster, more powerful AI assistance), and **Copilot Studio** (a low‑code tool for users to customize or build their own Copilot agents).  These capabilities deepen productivity and collaboration by embedding AI directly into Teams, Viva, Power Platform and other Microsoft 365 services, enabling role‑specific assistants such as Copilot for Sales, Finance and Service.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: Microsoft 365 evolved into an AI-first platform by 2024, with Copilot for Microsoft 365 introduced as a central feature, combining AI with business data from Microsoft Graph and M365 apps. The mention of role-specific assistants (Copilot for Sales, Finance, and Service) matches the original answer. (2) Quantitative accuracy is perfect: no numerical errors; years (2022, 2024) are correctly used. (3) Multi-hop reasoning is sound—correctly synthesizing evolution over time and new 2024 capabilities. (4) The only minor discrepancy is that the LLM mentions 'Copilot Pro' and 'Copilot Studio', which are not in the original answer. However, these are real 2024 offerings and contextually relevant to Microsoft's broader Copilot ecosystem. While not part of the ground truth from the knowledge graph, they do not contradict it and add plausible detail. Thus, the answer remains factually consistent with the core evolution and new capabilities described. Semantic equivalence is maintained, and the response fully addresses both parts of the question: evolution from 2022–2024 and specific 2024 features enhancing productivity and collaboration.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 348,
        "total_tokens": 1714
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How has 3M's approach to PFAS discharge characterization in its wastewater permits evolved between its Decatur, Alabama facility disclosures in 2022 and 2024?",
      "original_answer": "In 2022, 3M disclosed that it had not fully characterized its PFAS discharge in its NPDES permit for the Decatur facility and had submitted an application to ADEM to add additional PFAS to the permit. By 2024, the Company had installed and was upgrading wastewater treatment controls specifically designed to address PFAS at the Decatur facility, and the controls were being optimized, though ADEM had not yet acted on the permit modification request. This evolution shows a shift from identifying the issue and initiating corrective actions to implementing and refining treatment solutions while awaiting regulatory approval.",
      "llm_answer": "Between 2022 and 2024, 3M’s approach to characterizing PFAS discharges at its Decatur, Alabama facility evolved from initial voluntary disclosures and a 2020 interim Consent Order that required ongoing PFAS monitoring and characterization studies, to a more detailed engagement with the Alabama Department of Environmental Management (ADEM) and the U.S. EPA—including submitting corrected NPDES reports, upgrading wastewater treatment controls, and negotiating a revised draft Clean Water Act permit that reflects increasingly stringent state health‑based values for PFOA and PFOS. This progression reflects a shift from merely acknowledging incomplete PFAS characterization to actively working with regulators to incorporate updated scientific thresholds and to secure permit modifications that address the expanded scope of PFAS monitoring and treatment requirements.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general direction of 3M's evolving approach to PFAS discharge characterization at the Decatur facility, noting a shift from incomplete characterization to active engagement with regulators and upgrades to treatment controls. However, it introduces information not present in the ground truth, such as the '2020 interim Consent Order', 'negotiating a revised draft Clean Water Act permit', and 'corrected NPDES reports', which are not mentioned in the original answer. The original answer specifically states that in 2022, 3M had not fully characterized PFAS discharges and had submitted an application to ADEM to add more PFAS to the permit; by 2024, it was installing and optimizing treatment controls while awaiting ADEM’s action. The LLM answer overreaches by implying regulatory negotiations and permit revisions beyond the scope of the known facts. While it correctly identifies ADEM and EPA engagement and treatment upgrades, it misrepresents the timeline and regulatory status—particularly around permit modifications, which in the ground truth had not yet been acted upon. The mention of 'state health-based values for PFOA and PFOS' and 'increasingly stringent' standards adds detail absent from the original and may reflect external knowledge not supported by the provided truth. Quantitatively, no explicit numbers are incorrect (no figures to contradict), but the dates and procedural claims (e.g., 2020 Consent Order) are factually unsupported here, lowering quantitative accuracy. Qualitatively, the reasoning shows logical progression but fails on precise multi-hop synthesis—linking 2022 disclosures to 2024 actions correctly but adding unverified regulatory interactions. Contextually, the answer is relevant and addresses the evolution question appropriately, hence a higher relevance score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1376,
        "completion_tokens": 495,
        "total_tokens": 1872
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did Lowe's Companies, Inc.'s issuance of the 4.550% Notes evolve between 2022 and 2023?",
      "original_answer": "In 2022, the 4.550% Notes were first introduced in the Fifteenth Supplemental Indenture dated April 5, 2019, and were due April 5, 2049. In 2023, the same 4.550% Notes continued to be referenced under the same Fifteenth Supplemental Indenture, with no changes to the terms or maturity date. Therefore, while the 4.550% Notes were still in effect in 2023, there was no modification or new issuance related to this specific instrument during that year.",
      "llm_answer": "Between 2022 and 2023, Lowe's issued new supplemental indentures that added higher‑interest notes to its long‑term debt. In March 2022 (Exhibit 4.21) it issued 4.250% notes due 2052 and 4.450% notes due 2062, and in March 2023 (Exhibit 4.23) it issued 4.800% notes due 2026, 5.150% notes due 2033, 5.750% notes due 2053 and 5.850% notes due 2063. Thus, the company’s debt issuance evolved from the 4.250%‑4.450% tranche in 2022 to a broader set of higher‑coupon notes in 2023.",
      "correctness_score": 1,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in addressing the question. (1) The question specifically asks about the evolution of Lowe's 4.550% Notes between 2022 and 2023. The ground truth states that these notes were originally issued under the Fifteenth Supplemental Indenture on April 5, 2019, with a maturity date of April 5, 2049, and remained unchanged in both 2022 and 2023. There was no new issuance or modification of the 4.550% Notes during those years. (2) The LLM instead discusses entirely different notes (e.g., 4.250%, 4.450%, 4.800%, etc.) with different maturity dates and issuance dates (March 2022 and March 2023), which are not the 4.550% Notes in question. These details, while possibly accurate for other debt instruments, are irrelevant to the specific query. (3) The multi-hop reasoning fails because the model did not identify the correct note series (4.550%) or track its status over time; instead, it conflated it with other issuances. (4) As a result, the answer lacks factual correctness, completeness, and proper entity alignment. The response is partially relevant in context (discussing Lowe's debt), but entirely incorrect in substance, leading to a very low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1217,
        "completion_tokens": 338,
        "total_tokens": 1556
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did MDLZ's financial relationship with KDP evolve between 2022 and 2024, particularly in terms of gains recognized from changes in accounting for the investment?",
      "original_answer": "In 2022, MDLZ recognized a pre-tax gain of $71 million (or $54 million after-tax) during the first quarter related to the sale of KDP shares, which reduced its ownership interest. By 2024, the company recorded a significantly larger pre-tax gain of $493 million ($368 million after-tax) due to a change in accounting for its investment in KDP. This indicates a substantial evolution in the financial impact of MDLZ's relationship with KDP over the two-year period.",
      "llm_answer": "Between 2022 and 2024, MDLZ’s financial relationship with KDP shifted from equity method accounting to marketable securities accounting after its ownership fell below 5% in 2023, eliminating significant influence. This change led to gains recognized from the investment, including a $593 million gain on marketable securities sales in 2023 (reflecting proceeds exceeding the carrying value at the accounting change) and a $493 million pre-tax gain on equity method transactions in 2023. Additionally, MDLZ recorded a $665 million impairment charge on its JDEP investment in 2024 due to a decline in market value, while earlier gains from JDEP share sales (e.g., $332 million in 2024 from the JDEP sale to JAB) were offset by subsequent impairments and losses.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that MDLZ recognized a $71 million pre-tax gain ($54 million after-tax) in 2022 from the sale of KDP shares, and a $493 million pre-tax gain ($368 million after-tax) in 2024 due to a change in accounting for its KDP investment. The LLM incorrectly attributes a $593 million gain to 2023 from marketable securities sales and a $493 million gain to 2023 under equity method transactions, which contradicts the original timeline and nature of the gains. There is no mention in the ground truth of a $593 million gain or any such transaction in 2023. Additionally, the LLM introduces JDEP (Jacobs Douwe Egberts Peet) and JAB, which are unrelated entities not mentioned in the question or original answer, and discusses a $665 million impairment and $332 million gain from JDEP — information entirely extraneous and incorrect in this context. (2) Quantitative accuracy is severely compromised: the only correct number mentioned is the $493 million pre-tax gain, but it is misattributed to 2023 instead of 2024 and incorrectly described as an 'equity method transaction' rather than a gain from a change in accounting for the investment. The $71 million gain in 2022 is entirely omitted. (3) The multi-hop reasoning fails: while the LLM correctly infers that a drop below 5% ownership could trigger a change in accounting treatment, it fabricates the financial impact and timeline. It also conflates KDP with unrelated investments (JDEP), indicating a failure to correctly identify and synthesize information specific to MDLZ and KDP. (4) The contextual relevance is partially maintained as the answer discusses changes in accounting treatment related to an investment, but the introduction of irrelevant entities and incorrect figures undermines the response. The core evolution between 2022 and 2024 is misrepresented, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 525,
        "total_tokens": 1836
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How has the scale and positioning of Xbox Game Pass evolved between 2022 and 2024, based on the number of titles available and Microsoft's strategic emphasis?",
      "original_answer": "In 2022, Xbox Game Pass offered access to a curated library of over 100 first- and third-party titles, and was positioned as a key part of Microsoft's broader gaming strategy focused on content, community, and cloud services. By 2024, the service had expanded significantly, offering access to over 400 first- and third-party titles, and was described as the 'cornerstone' of Microsoft's gaming platform, reflecting a stronger strategic emphasis on subscriptions and community growth. This indicates a significant transformation in both scale and strategic importance.",
      "llm_answer": "Between 2022 and 2024, Xbox Game Pass evolved from a curated library of \"over 100 first- and third-party console and PC titles\" (2022) to a substantially larger offering with \"over 400 first- and third-party console and PC titles\" (2024), reflecting a major expansion in content scale. Microsoft's strategic emphasis shifted decisively toward gaming as a core growth pillar, explicitly identifying it as a key area to \"redefine what customers and partners can expect\" and \"push the boundaries of innovation,\" while simultaneously integrating gaming deeply into its broader ecosystem—highlighting Xbox Game Pass, cloud gaming, and first-party content acquisitions like Activision Blizzard as central to its long-term vision.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the quantitative evolution of Xbox Game Pass from over 100 titles in 2022 to over 400 in 2024, matching the ground truth exactly. These numbers are accurate and properly attributed to the respective years. (2) All numeric values are correct—'over 100' and 'over 400' align with the original answer, and no calculations are required beyond these comparisons. Format is consistent and semantically equivalent. (3) The multi-hop reasoning is sound: the model synthesizes information about scale (title count increase) and strategic emphasis (shift to gaming as a core pillar, integration with cloud, acquisitions like Activision Blizzard) across time. It correctly infers a stronger strategic positioning, using terms like 'central to its long-term vision,' which aligns with the ground truth's 'cornerstone' characterization. The mention of first-party content acquisitions adds contextual depth supported by Microsoft's 2024 strategy, even if not in the original answer—this is a reasonable inference, not a factual error. (4) The only minor gap is that the original answer explicitly calls Xbox Game Pass the 'cornerstone' of Microsoft's gaming platform, a precise strategic label that the LLM paraphrases but doesn't quote directly. However, the conveyed meaning is substantively equivalent. No factual inaccuracies; excellent completeness, contextual relevance, and reasoning. Minor deduction in qualitative accuracy for slightly less precise phrasing of strategic emphasis, but overall highly accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 426,
        "total_tokens": 1752
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has the structure or disclosure of Deferred Stock Unit Award Agreements for non-employee directors under the 3M Company 2016 Long-Term Incentive Plan evolved from 2022 to 2024, based on the referenced filings?",
      "original_answer": "The Deferred Stock Unit Award Agreement for non-employee directors was first referenced in the 2022 10-K filing as part of the 3M Company 2016 Long-Term Incentive Plan, applicable to grants on or after January 1, 2019. By 2024, the agreement continued to be disclosed in the 10-K filing, still referencing grants on or after January 1, 2019, indicating no change in the effective date or structure of the agreement over this period. However, the 2024 disclosure reflects an updated incorporation by reference from the 2023 10-K, showing the ongoing maintenance of the plan through amendments as of May 8, 2023.",
      "llm_answer": "The Deferred Stock Unit Award Agreements for non-employee directors under the 3M Company 2016 Long-Term Incentive Plan have remained consistently disclosed in SEC filings, with no structural changes noted between 2022 and 2024. The agreements continue to be incorporated by reference from the Company’s Form 10-K filings for the years ended December 31, 2018 (initial adoption) and 2023 (most recent amendment), as reflected in the 2024 filing’s Exhibit 10.7* reference to the 2018 Form 10-K. No updates or revisions to the agreement terms or disclosure requirements were identified in the provided 2022–2024 filings.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that there were no structural changes to the Deferred Stock Unit Award Agreements for non-employee directors from 2022 to 2024 and that the agreements are consistently disclosed via incorporation by reference. However, it contains a critical factual error regarding the initial adoption date: it claims the agreement was incorporated from the 2018 Form 10-K, while the ground truth states the agreement applies to grants on or after January 1, 2019, and was first referenced in the 2022 10-K. This misrepresents the timeline of disclosure. Additionally, the LLM incorrectly references Exhibit 10.7* and the 2018 Form 10-K as the source in the 2024 filing, which contradicts the ground truth that the 2024 disclosure reflects an updated incorporation by reference from the 2023 10-K due to a May 8, 2023 amendment. (2) The dates are inaccurate—2018 vs. 2019 effective date and incorrect citation of the 2018 filing as the source in 2024 when it should be the 2023 filing. These are material errors in quantitative accuracy despite correct general framing. (3) The reasoning is logically sound in concluding no structural changes occurred, and it correctly infers continuity in disclosure practice. However, it fails in multi-hop synthesis by not accurately tracing the evolution of the incorporation by reference from 2022 to 2024, particularly missing the update via the 2023 10-K. (4) The answer is contextually relevant and addresses the core question about evolution in structure and disclosure. Due to the significant date and source inaccuracies affecting factual correctness, the correctness score is reduced to 7—core facts about stability are right, but key details about timing and sources are wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 479,
        "total_tokens": 1802
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has the composition of Charles Schwab Bank's First Mortgages and HELOCs portfolio evolved between 2023 and 2024, particularly in terms of origination costs and geographic concentration in California?",
      "original_answer": "In 2023, the First Mortgages and HELOCs portfolio included $100 million in unamortized premiums, discounts, and direct origination costs, with 43% of the portfolio concentrated in California. By 2024, these costs increased to $112 million, while the California concentration slightly decreased to 42%. This indicates a slight shift in geographic risk exposure and an increase in loan origination activity or associated costs over the year.",
      "llm_answer": "Based on the 2024 data in the provided documents, Charles Schwab Bank's First Mortgages and HELOCs portfolio shows a shift toward higher-quality borrowers with improved credit metrics compared to 2023. The portfolio composition indicates that 43% of First Mortgages and HELOCs remain concentrated in California, consistent with prior periods, and credit quality indicators (such as Origination FICO scores and LTV ratios) have remained stable, with no significant deterioration observed. Origination costs for First Mortgages increased slightly to $3,589 million in 2024 (from $2,148 million in 2023), while HELOCs origination costs remained relatively flat at $288 million, reflecting ongoing investment in loan production despite a more challenging macroeconomic environment.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, the unamortized premiums, discounts, and direct origination costs were $100 million in 2023 and increased to $112 million in 2024. However, the LLM incorrectly reports 'origination costs' as $3,589 million for First Mortgages and $288 million for HELOCs in 2024, which are not only vastly different in magnitude but also mischaracterized (these figures appear to be total loan balances or production volumes, not origination costs). Additionally, the LLM states that California concentration 'remained' at 43%, but the ground truth indicates it decreased to 42% in 2024, contradicting the LLM's claim of consistency. (2) The quantitative values are almost entirely incorrect: the LLM inflates origination costs by over 30x compared to the ground truth ($3.5B+ vs $112M), and misrepresents the nature of the metric. The California concentration is inaccurately reported as unchanged when it did change slightly. (3) The multi-hop reasoning is flawed—the question asks about evolution in origination costs and geographic concentration, but the LLM conflates origination costs with loan volume or production costs, fails to report the correct metric (unamortized premiums/discounts/costs), and misses the slight de-concentration from California. It introduces irrelevant details about FICO scores and LTV ratios not mentioned in the ground truth. (4) The contextual relevance is moderate because the answer addresses the general topic (portfolio composition, California concentration, origination trends), but the factual foundation is unsound. Due to major errors in numbers, entities, and reasoning, the correctness score is low at 2, with similarly low quantitative accuracy. Qualitative accuracy is slightly higher due to correct identification of the bank and portfolio type, but reasoning is poor.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 514,
        "total_tokens": 1833
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has Nike's strategic emphasis on the Dri-FIT technology evolved between fiscal 2023 and fiscal 2024, based on the language in Nike's product research and development sections?",
      "original_answer": "Nike's strategic emphasis on the Dri-FIT technology remained stable between fiscal 2023 and fiscal 2024. In both years, Dri-FIT was listed among key technologies such as Nike Air, Zoom, Free, Flyknit, FlyEase, ZoomX, Air Max, and React, indicating consistent strategic importance. The exact same language was used in both the 2023 and 2024 10-K filings, showing no change in the description or emphasis of Dri-FIT's role in Nike’s innovation strategy.",
      "llm_answer": "Nike’s 2024 10‑K shows that Dri‑FIT is highlighted as a core performance‑fabric technology in the “Product Research, Design and Development” section (pages 5‑6), where the company describes its continued investment in moisture‑wicking, heat‑retaining and weather‑repelling fabrics for apparel. The language emphasizes expanding the Dri‑FIT family across more product categories and integrating it with digital‑enabled experiences, indicating a strategic focus on scaling and enhancing the technology rather than phasing it back. Compared with fiscal 2023, where Dri‑FIT was mentioned only in passing as part of the broader innovation portfolio, the 2024 filing gives Dri‑FIT a more prominent, dedicated emphasis, reflecting an evolved strategic priority to deepen its role in Nike’s performance apparel lineup.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim. According to the ground truth, the language describing Dri-FIT in Nike's 10-K filings was identical in fiscal 2023 and 2024, with no change in emphasis or description. The LLM incorrectly asserts that Dri-FIT received a 'more prominent, dedicated emphasis' in 2024 compared to 2023, where it was allegedly mentioned 'only in passing.' This contradicts the ground truth, which states the exact same language was used in both years and that Dri-FIT was consistently listed among key technologies like Nike Air, Zoom, and Flyknit. There are no numbers in the question or answers, so quantitative accuracy is not applicable—scored as 10 by default. The qualitative reasoning is flawed because the model fabricates a shift in strategic emphasis unsupported by the source material, failing the multi-hop comparison between years. Contextual relevance is moderate—the response addresses the right section (product R&D) and topic (Dri-FIT evolution)—but the conclusion is factually wrong. Thus, the correctness score is low due to a major factual inaccuracy in the central claim.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 318,
        "total_tokens": 1641
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has Mondelez International's investment in backup and disaster recovery evolved from 2022 to 2024, particularly in response to increasing cybersecurity threats?",
      "original_answer": "In 2022, Mondelez was on heightened alert regarding cybersecurity risks, dedicating focused resources to backup and disaster recovery as part of its response to increased global cybersecurity threats, especially during the pandemic. By 2024, the company significantly expanded its efforts, explicitly stating that it continues to invest and augment its cybersecurity program with enhanced backup and disaster recovery solutions, among other measures, to address increasingly sophisticated threats including those from state-sponsored actors and emerging technologies like artificial intelligence.",
      "llm_answer": "Mondelez International has significantly strengthened its backup and disaster recovery capabilities in response to rising cybersecurity threats, particularly as highlighted in its 2024 10-K filing. The company explicitly states it has \"heightened alert\" and \"dedicated focused resources\" to network security, backup and disaster recovery systems, and workforce training to address escalating cyber risks—including ransomware, phishing, and threats to operational technology in manufacturing. This evolution reflects a proactive response to increasingly sophisticated attacks, with the company noting that cybersecurity insurance costs may rise and data privacy regulations (like GDPR) add complexity to its risk management. While specific timeline details aren't provided, the 2024 filing confirms these efforts are ongoing and intensified compared to prior years, directly addressing the \"continuously evolving and complex nature of cyber threat actors\" mentioned in its 2022 disclosures.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually consistent with the ground truth in terms of the evolution of Mondelez International's investment in backup and disaster recovery from 2022 to 2024, particularly in response to increasing cybersecurity threats. It correctly identifies that in 2022, the company was on heightened alert and dedicating focused resources to backup and disaster recovery, aligning with the original answer. It also accurately reflects that by 2024, Mondelez had intensified these efforts, explicitly investing in enhanced cybersecurity programs including backup and disaster recovery solutions. The mention of 'heightened alert' and 'dedicated focused resources' matches the original answer's phrasing and intent. While the LLM introduces additional context—such as ransomware, phishing, operational technology risks, cybersecurity insurance costs, and GDPR—these are plausible elaborations consistent with the broader threat landscape and do not contradict the ground truth. However, the LLM slightly misattributes the 2022 'heightened alert' language as part of the 2024 filing rather than correctly situating it in 2022, which creates a minor chronological confusion. Additionally, the original answer emphasizes the expansion to address threats from state-sponsored actors and AI, which the LLM omits. Despite this, the core multi-hop reasoning—comparing Mondelez's cybersecurity posture across 2022 and 2024 with correct entities, years, and progression—is sound. All dates and references are contextually accurate, and no numerical data is incorrect (and none is present in the ground truth to conflict). The answer is highly relevant and well-contextualized. Thus, the correctness score is 8 due to minor omissions and slight misplacement of temporal details, but not major factual errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1400,
        "completion_tokens": 487,
        "total_tokens": 1888
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has Microsoft's financial commitment and engagement with Black and African American-owned suppliers evolved from fiscal year 2022 to fiscal year 2024?",
      "original_answer": "In fiscal year 2022, Microsoft reported that it had enriched its supplier pipeline, reaching more than 90% of its goal to spend $500 million with double the number of Black and African American-owned suppliers. By fiscal year 2024, Microsoft had not only achieved its $500 million spending goal but also expanded its financial commitments by allocating $150 million to Minority Depository Institutions and funds supporting Black and African American-owned small businesses. This evolution indicates a deepening of Microsoft's strategic focus on supplier diversity and community economic development over time.",
      "llm_answer": "Microsoft’s financial commitment to Black‑ and African‑American‑owned suppliers has grown markedly from FY 2022 through FY 2024.  In FY 2022 the company reported a $500 million target to spend with double the number of Black‑ and African‑American‑owned suppliers, and by FY 2024 it had already reached more than 90 % of that goal and increased the count of such suppliers.  The 2024 filing also notes continued investment of $150 million in minority depository institutions and funds supporting Black‑owned small businesses, as well as expanded programs (e.g., the Nonprofit Tech Acceleration for Black and African American Communities) that further channel resources to Black‑owned enterprises.  These disclosures illustrate a clear escalation of both spending commitments and supplier‑diversity initiatives over the three‑year period.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer reverses the timeline of Microsoft's progress toward the $500 million goal. The Original Answer states that in FY2022, Microsoft had already reached 'more than 90% of its goal to spend $500 million', implying significant progress early in the period. However, the LLM incorrectly claims that by FY2024 Microsoft 'had already reached more than 90% of that goal', which contradicts the progression — the goal should have been met or exceeded by FY2024, not just 90%. The Original Answer confirms that the $500 million goal was fully achieved by FY2024, which the LLM fails to state accurately. (2) The $150 million allocation to Minority Depository Institutions and funds supporting Black-owned businesses is correctly reported in the LLM answer and matches the ground truth. However, the misplacement of the 90% milestone undermines quantitative accuracy. (3) The multi-hop reasoning is partially sound — the model correctly identifies the evolution of financial commitments across years and synthesizes supplier diversity with community investment initiatives. It also appropriately references expanded programs like the Nonprofit Tech Acceleration, which, while not in the original answer, are plausible contextual additions that do not contradict the ground truth. (4) Despite the timeline error, the overall direction of increased commitment is correctly conveyed, and the answer addresses both financial and programmatic evolution. The contextual relevance is high as it directly responds to the question’s focus on financial commitment and engagement. However, the reversal of progress timing constitutes a significant factual error, warranting a correctness score of 7 and a quantitative accuracy score of 6. Qualitative accuracy is higher due to sound reasoning structure and entity identification, and contextual relevance is perfect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 507,
        "total_tokens": 1870
      },
      "error": null
    },
    {
      "question_id": 88,
      "question": "How has the availability of common shares for future issuance under the Abbott Laboratories Employee Stock Purchase Plan for Non-U.S. Employees evolved from 2022 to 2023, and what does this indicate about Abbott's stock-based incentive strategy?",
      "original_answer": "In 2022, as of December 31, 2021, an aggregate of 10,638,639 common shares were available for future issuance under the Employee Stock Purchase Plan. In 2023, as of December 31, 2023, this number had decreased to 8,565,087 common shares. This indicates a reduction in the number of shares available for future issuance, suggesting a potential tightening or adjustment in Abbott's stock-based incentive strategy for non-U.S. employees.",
      "llm_answer": "From 2022 to 2023, the number of common shares available for future issuance under the Abbott Laboratories Employee Stock Purchase Plan for Non-U.S. Employees increased from 8,565,087 to 10,638,639 shares. This growth indicates an expansion of Abbott's stock-based incentive strategy, reflecting increased capacity for future equity-based compensation to non-U.S. employees.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in both direction and magnitude. The original answer states that available shares decreased from 10,638,639 (as of December 31, 2021, reported in 2022) to 8,565,087 (as of December 31, 2023, reported in 2023). The LLM incorrectly reverses this trend, claiming an increase from 8,565,087 to 10,638,639, which is the opposite of the truth. (2) The numbers themselves are accurate in isolation (the LLM uses the correct figures from the ground truth) but assigns them to the wrong years, inverting the timeline. This leads to a completely erroneous conclusion about the direction of change. (3) The multi-hop reasoning fails because the model misaligns the time periods with the data points. It must correctly associate each share count with its respective reporting year and reference date (e.g., 2022 filing reports data as of Dec 31, 2021; 2023 filing reports data as of Dec 31, 2023). The LLM fails this synthesis, breaking the causal chain. (4) Due to the reversal of a key trend and incorrect interpretation, the conclusion about Abbott's strategy is wrong—instead of indicating a tightening, the LLM claims an expansion. While the question is addressed in structure and context (hence minimal relevance score), the factual core is entirely flawed, warranting a correctness score of 1.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1226,
        "completion_tokens": 374,
        "total_tokens": 1600
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has Nike's treatment of Nike Air technology evolved in its product development strategy between fiscal years 2023 and 2024?",
      "original_answer": "In fiscal 2023, Nike Air was described as part of a list of technologies that 'typifies our dedication to designing innovative products,' indicating it was still being actively proliferated across product lines. By fiscal 2024, Nike Air was again listed among key technologies, but now embedded alongside mature technologies like Zoom, Free, and React, suggesting that Nike Air had become a standard component of Nike’s broader innovation platform rather than a distinct growth driver. This reflects a strategic shift from emphasizing Nike Air as an emerging innovation to treating it as an integrated, foundational offering within Nike’s product development framework.",
      "llm_answer": "Nike's treatment of Nike Air technology has evolved from a foundational innovation to a core, continuously refined component of its product development strategy, with increasing integration across footwear, apparel, and equipment lines. The company emphasizes ongoing innovation in Air technologies—such as Air Max, Zoom, and React—while expanding its application beyond traditional cushioning to enhance performance, comfort, and sustainability, reflecting a strategic focus on leveraging Air as a key differentiator in competitive markets.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but misses the core strategic evolution described in the ground truth. (1) There are no numeric values to verify, so quantitative accuracy is not applicable—scored as 10 by default. (2) The LLM correctly identifies Nike Air as part of ongoing innovation and mentions integration across product lines, which aligns with the 2023 description. However, it inaccurately portrays Nike Air as still being actively innovated and positioned as a 'key differentiator,' which contradicts the 2024 shift indicated in the original answer. (3) The multi-hop reasoning is flawed: the ground truth shows a clear strategic shift from Nike Air being an innovative driver in 2023 to becoming a mature, integrated technology alongside Zoom, Free, and React in 2024—indicating it is no longer a distinct growth engine. The LLM instead suggests continued elevation and expansion, failing to recognize the transition to foundational status. (4) Contextual relevance is high because the response discusses Nike Air in the context of product development across years, but the qualitative inaccuracy in interpreting the strategic shift significantly undermines correctness. Thus, correctness and qualitative accuracy are moderate due to factual misrepresentation of the strategic trajectory despite relevant topic coverage.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 369,
        "total_tokens": 1667
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has Abbott's positioning of Osmolite within its Nutritional Products segment evolved between 2022 and 2023, particularly in terms of its enteral feeding portfolio and associated product line strategy?",
      "original_answer": "In 2022, Osmolite was listed among Abbott's enteral feeding products used in healthcare institutions, alongside Jevity®, Glucerna® 1.2 Cal, Glucerna® 1.5 Cal, Oxepa®, Freego™, Nepro®, and Vital®. By 2023, Osmolite continued to be included in the enteral feeding portfolio, but Abbott's product listing in this category remained largely consistent, indicating a stable strategic positioning of Osmolite within the institutional enteral nutrition segment. There is no indication of Osmolite being newly introduced, discontinued, or significantly repositioned relative to other products in this category during this period.",
      "llm_answer": "Abbott’s Nutritional Products segment has shifted its focus from a broad portfolio of infant formulas and adult nutrition brands to a more targeted enteral‑feeding strategy, emphasizing products such as Osmolite® and other specialized formulas used in clinical settings.  The 2023 filing highlights a streamlined product line that concentrates on enteral nutrition for health‑care institutions, while still maintaining consumer‑facing brands, reflecting a strategic repositioning of Osmolite within the segment’s portfolio.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains no numeric data, so quantitative accuracy is not applicable; however, since there are no numbers to misstate, it is scored as 10 by default. The main issue lies in qualitative accuracy and reasoning. The ground truth indicates that Abbott's positioning of Osmolite remained stable between 2022 and 2023, with no significant repositioning or strategic shift. However, the LLM incorrectly asserts a 'shifted focus' and 'strategic repositioning' of Osmolite, implying a change in strategy that is not supported by the evidence. It also suggests a 'streamlined product line' and a move toward a 'more targeted enteral-feeding strategy,' which are not mentioned or implied in the original answer. These claims represent a misinterpretation of the data. While the answer correctly identifies Osmolite as part of Abbott’s enteral feeding portfolio used in clinical settings, it fabricates a narrative of strategic evolution that does not align with the consistency observed in the ground truth. The contextual relevance is moderate because it addresses the enteral feeding portfolio and Osmolite’s role, but the incorrect inference about strategic change undermines the overall correctness. There is no multi-hop calculation error, but the multi-hop reasoning is flawed—instead of concluding stability, the model infers change without evidence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1300,
        "completion_tokens": 376,
        "total_tokens": 1676
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has 3M's regulatory engagement and remediation obligations related to PFAS discharge evolved between 2022 and 2024, particularly in Minnesota and Alabama?",
      "original_answer": "In 2022, 3M was actively working under a 2007 Settlement Agreement and Consent Order with the MPCA to address PFAS contamination in Minnesota, with remediation substantially completed at the Cottage Grove site and ongoing operational and maintenance activities at multiple locations. In Alabama, the Company had entered into a July 2020 Interim Consent Order with ADEM, which included obligations for PFAS-related wastewater discharges and air emissions, and had completed installation of a multilayer cap at the Decatur facility. By 2024, regulatory scrutiny had intensified. In Minnesota, MPCA issued a draft Clean Water Act permit for the Cottage Grove facility with significantly revised effluent limits for certain PFAS compounds, some below current quantification levels, and the Company submitted public comments in August 2024. Additionally, in 2024, MPCA published a revised draft permit in December after considering stakeholder input, which could have a significant adverse impact on the Cottage Grove facility's operations. In Alabama, while the 2020 Interim Consent Order remained in effect, the Company's obligations under ongoing investigations and potential future remediation were still expected to involve additional operating costs and capital expenditures over multiple years. The regulatory landscape evolved to include more stringent standards, such as updated HBVs from MDH in January 2024 and proposed HRLs in October 2024, further complicating 3M's compliance path.",
      "llm_answer": "Between 2022 and 2024, 3M’s regulatory engagement and remediation obligations related to PFAS discharge have intensified, particularly in Minnesota and Alabama. In Minnesota, the company continued implementing remediation under the 2007 Settlement Agreement and Consent Order, addressing PFAS in soil and groundwater at Oakdale, Woodbury, and Cottage Grove, while responding to MPCA actions—including a 2023 stormwater violation notice, a 2024 draft NPDES permit with stricter PFAS limits, and ongoing negotiations over compliance measures. In Alabama, 3M maintained obligations under the 2020 interim Consent Order with ADEM and the 2009 TSCA consent order, focusing on PFAS containment at its Decatur facility, correcting NPDES reporting, and cooperating with EPA and DOJ investigations, including a 2022 grand jury subpoena. These efforts reflect evolving regulatory expectations, particularly with updated health-based values from MDH and tighter effluent limits, requiring sustained monitoring, treatment, and compliance actions across both states.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the evolution of 3M's regulatory engagement and remediation obligations related to PFAS discharge in Minnesota and Alabama between 2022 and 2024, with accurate qualitative synthesis. Key elements from the ground truth are present: the 2007 Settlement Agreement in Minnesota, ongoing remediation at Cottage Grove and other sites, the 2020 Interim Consent Order with ADEM in Alabama, and the increasing regulatory scrutiny by 2024. The mention of stricter 2024 draft NPDES permit limits from MPCA, updated health-based values from MDH, and ongoing investigations in Alabama aligns well with the original answer. However, there are minor inaccuracies and additions not supported by the ground truth: (1) The LLM mentions a '2023 stormwater violation notice' and a '2022 grand jury subpoena'—specific events not present in the original answer and thus unverifiable from the provided truth; (2) It references a '2009 TSCA consent order' in Alabama, which is not mentioned in the ground truth; (3) The original answer specifies that MPCA issued a draft permit in 2024 with comments submitted in August and a revised draft in December 2024, while the LLM generalizes this as a '2024 draft NPDES permit' without noting the revision or public comment process. These omissions and unsupported additions slightly reduce quantitative and qualitative accuracy. Nevertheless, the core multi-hop reasoning—synthesizing cross-jurisdictional regulatory developments over time with evolving standards and compliance costs—is sound and contextually relevant. The answer correctly identifies the trend of intensifying regulation and ongoing obligations, even if some specific events and timelines are slightly misaligned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1638,
        "completion_tokens": 473,
        "total_tokens": 2112
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has The Coca-Cola Company's financial relationship with Coca-Cola HBC AG evolved between 2022 and 2024, particularly in terms of investment classification and stake percentage?",
      "original_answer": "In 2022, Coca-Cola HBC AG was among the listed equity method investees, though the specific ownership percentage was not disclosed in the provided evidence. By 2024, Coca-Cola HBC AG remained an equity method investee, and the company explicitly stated a 22% ownership stake as of December 31, 2024. This indicates a formalization and quantification of the relationship, with Coca-Cola now specifying the exact percentage of ownership, which was absent in the 2022 disclosures.",
      "llm_answer": "The Coca-Cola Company's financial relationship with Coca-Cola HBC AG evolved between 2022 and 2024 as follows:  \n- The Company's equity method investment in Coca-Cola HBC AG decreased from **22% ownership (as of December 31, 2023)** to **19% ownership (as of December 31, 2024)**, reflecting a reduction in stake percentage.  \n- This decline aligns with broader shifts in the Bottling Investments segment, where the Company's stake in bottling operations (including Coca-Cola HBC AG) was impacted by strategic realignments, such as the Philippines bottling operations being classified as held for sale (noted in Note 2).  \n- The investment remains classified under \"Bottling Investments\" in the Company's financial statements, with the carrying value of the equity method investment in Coca-Cola HBC AG declining from $1,147 million (2023) to $1,147 million (2024) in the aggregate equity method investments, though the exact stake percentage is explicitly stated as 19% for 2024.  \n\nThus, the relationship shifted from a 22% stake in 2023 to a 19% stake in 2024, with the investment continuing to be accounted for under the equity method.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both quantitative and qualitative aspects. (1) Quantitatively, it states that The Coca-Cola Company's ownership in Coca-Cola HBC AG decreased from 22% in 2023 to 19% in 2024, which directly contradicts the ground truth: the 22% stake is explicitly stated as of December 31, 2024, and no prior percentage was disclosed in 2022. There is no evidence of a reduction to 19%, nor was a 22% stake disclosed for 2023. Additionally, the claim that the carrying value remained at $1,147 million in both years is unsupported by the ground truth, which does not provide these figures. (2) The answer fabricates a decrease in ownership and introduces a non-existent 19% stake for 2024, which is the opposite of the actual trend—formalization and disclosure of a 22% stake. (3) Qualitatively, the reasoning is flawed: it invents strategic realignments and references to Note 2 about the Philippines bottling operations, which are irrelevant to Coca-Cola HBC AG and not mentioned in the ground truth. The multi-hop synthesis fails—the model incorrectly infers changes over time that are not supported by the evidence. (4) Contextually, while the answer addresses investment classification (correctly noting equity method accounting), it misrepresents the evolution of the relationship. The core claim—that the stake decreased—is false. The ground truth indicates increased transparency with a newly specified 22% stake in 2024, not a reduction. Thus, the answer is mostly incorrect, with only minor relevance in mentioning equity method classification.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1412,
        "completion_tokens": 431,
        "total_tokens": 1844
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has Oracle's strategic emphasis on hybrid deployments evolved between fiscal 2022 and fiscal 2024, particularly in terms of product development investment and deployment model integration?",
      "original_answer": "In fiscal 2022, Oracle emphasized hybrid deployments as part of its broader deployment model strategy, investing $7.2 billion in research and development to enhance existing offerings and develop new technologies, including hybrid solutions like Oracle Cloud@Customer. By fiscal 2024, Oracle further integrated hybrid deployments into its core offerings, positioning them as a standard deployment choice alongside on-premise and cloud-based models, and reinforcing its commitment to interoperability and customer choice. This reflects a strategic evolution from a development-focused approach to a more mature, integrated deployment model.",
      "llm_answer": "Oracle’s strategic focus on hybrid deployments has intensified markedly from fiscal 2022 through 2024, shifting from a general emphasis on flexible, interoperable IT models to a concrete, investment‑driven push that integrates cloud, on‑premise and hybrid architectures into product development.  The company now allocates a growing share of R&D spend—$7.2 billion in fiscal 2022—to accelerate cloud‑native innovations such as Oracle Cloud@Customer, SaaS and OCI, while simultaneously extending support for existing on‑premise licenses and hardware through renewal‑focused strategies.  This evolution is reflected in its financial disclosures, which show a rising proportion of cloud services and license‑support revenue (71 % of total revenue in fiscal 2022 and 2021) and a clear roadmap for migrating its installed base to the Oracle Cloud via hybrid‑deployment programs.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Oracle's strategic emphasis on hybrid deployments and mentions the $7.2 billion R&D investment in fiscal 2022, which matches the ground truth. However, it incorrectly implies that this R&D figure is part of a 'growing share' without providing updated R&D figures for fiscal 2024, which undermines quantitative accuracy. The claim that cloud services and license-support revenue accounted for 71% of total revenue in fiscal 2022 and 2021 is not present in the original answer and cannot be verified from the provided ground truth, introducing unverified data. (2) The $7.2 billion figure is accurate for fiscal 2022 R&D, but the 71% revenue breakdown is unsupported in the ground truth and appears to be an external or incorrect inference. No fiscal 2024 R&D numbers are provided in the LLM answer, limiting the ability to assess evolution in investment. (3) The reasoning partially captures the multi-hop evolution from product development (2022) to integration (2024), and correctly references Oracle Cloud@Customer as a hybrid solution. However, it fails to explicitly state the key strategic shift noted in the ground truth—hybrid deployments becoming a 'standard deployment choice' by fiscal 2024—thus missing a critical qualitative milestone. (4) The contextual relevance is high as the response addresses hybrid deployments, R&D investment, and integration trends. Qualitative accuracy is moderate due to correct entity identification (Oracle, Cloud@Customer, fiscal years) and logical flow, but with missing synthesis on the maturity of hybrid as a core model. Quantitative accuracy is reduced due to the inclusion of an unsupported percentage (71%) and lack of updated fiscal 2024 data for comparison. Correctness score reflects partial accuracy with significant but not fundamental errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 501,
        "total_tokens": 1890
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has the filing status of the Mandatory Clawback Policy evolved between the 2023 and 2024 SEC 10-K disclosures for Wells Fargo & Company?",
      "original_answer": "In 2023, the Mandatory Clawback Policy was filed directly as part of the 10-K filing under Exhibit 97. In 2024, instead of being filed directly, it was incorporated by reference to Exhibit 97 from the previous year's 10-K filing. This indicates a procedural change in how the policy is disclosed rather than a substantive change to the policy itself.",
      "llm_answer": "The Mandatory Clawback Policy filing status evolved from being filed as Exhibit 97 in the 2023 Form 10‑K (effective October 2, 2023) to being filed as Exhibit 97 again in the 2024 Form 10‑K, but with the description updated to reflect its 2023 effective date and to indicate it is filed “herewith” in the 2024 filing. Thus, the policy remains filed as Exhibit 97 in both years, though the 2024 filing references it as part of the current year’s disclosures.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in its core claim about the evolution of the filing status of the Mandatory Clawback Policy. According to the ground truth, in 2024 the policy was incorporated by reference to the 2023 10-K filing (Exhibit 97), meaning it was not filed anew but referenced from the prior year. However, the LLM claims the policy was filed again in 2024 as Exhibit 97 and described as 'filed herewith,' which contradicts the ground truth. This misrepresents the key procedural change: from direct filing in 2023 to incorporation by reference in 2024. The mention of the effective date (October 2, 2023) may be factually accurate, but the central disclosure mechanism is wrong. The answer incorrectly suggests continuity in filing method, when the actual evolution is a shift in disclosure approach. This is a critical error in both reasoning and factual accuracy. While the entities (Wells Fargo, Exhibit 97, 10-K filings) and years are correct, the synthesis across years is flawed. The answer is contextually relevant and addresses the right topic, but fails on the essential factual and procedural distinction. Quantitative accuracy is partially preserved due to correct dates, but the absence of correct filing status details limits this score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1200,
        "completion_tokens": 352,
        "total_tokens": 1552
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How did Thermo Fisher's relationship with CorEvitas, LLC evolve between 2023 and 2024, and what specific financial implications were associated with this change?",
      "original_answer": "In 2023, Thermo Fisher invested $0.91 billion to acquire CorEvitas, LLC, a U.S.-based provider of regulatory-grade, real-world evidence for medical treatments. By 2024, this relationship had evolved from an investment into a full acquisition, as CorEvitas was integrated into the Laboratory Products and Biopharma Services segment. The acquisition in 2023 was part of a broader strategy that included significant capital expenditures and financing activities, such as issuing $5.94 billion in senior notes and repurchasing $3.00 billion of company stock. In 2024, the company began amortizing the definite-lived intangible assets from CorEvitas over a weighted average period of 18 years, reflecting the long-term strategic value of the acquisition.",
      "llm_answer": "Thermo Fisher's relationship with CorEvitas, LLC evolved through its acquisition in August 2023, when the company purchased CorEvitas for $910 million (cash paid $730 million plus assumed debt $184 million) and subsequently integrated it into the Laboratory Products and Biopharma Services segment. The acquisition added real‑world evidence capabilities and generated goodwill of $627 million, while also creating definite‑lived intangible assets (customer relationships, product technology, backlog) that are being amortized over weighted‑average periods of 18–19 years. This transaction contributed to the 2023 segment‑income growth and was reflected in the company’s non‑GAAP adjustments, including amortization of acquisition‑related intangible assets. The financial impact is evident in the 2023 consolidated results, where the addition of CorEvitas helped drive a 17 % increase in the Laboratory Products and Biopharma Services segment income and contributed to the overall adjusted operating income of $9.81 billion.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually accurate and highly aligned with the ground truth. It correctly identifies the 2023 acquisition of CorEvitas, LLC by Thermo Fisher for $910 million (matching the $0.91 billion in the original answer), and notes the integration into the Laboratory Products and Biopharma Services segment in 2024. The breakdown of cash paid ($730M) and assumed debt ($184M) adds detail not in the original but is consistent with plausible acquisition financing and does not contradict the ground truth. (2) Quantitatively, all key figures are correct or equivalent: $910 million = $0.91 billion; amortization over 18 years in the original is reflected as 18–19 years in the LLM answer—this minor variation is acceptable given that weighted averages can be approximated. The $627 million goodwill and 17% segment income growth are accurate and specific. The $9.81 billion adjusted operating income is contextually relevant and plausibly tied to the acquisition’s contribution. (3) The multi-hop reasoning is sound: the LLM connects the acquisition event (2023) to integration and amortization (2024), links it to financial impacts (segment income growth, intangible asset amortization), and situates it within broader financial reporting (non-GAAP adjustments). It goes beyond the original by specifying intangible asset types (customer relationships, product technology, backlog), which are reasonable and enhance completeness without introducing error. (4) The only minor shortcoming is that the original answer mentions broader capital activities (issuing $5.94B in notes, $3.00B stock repurchase), which the LLM omits. However, these are contextual and not central to the specific question about the CorEvitas relationship and its direct financial implications. Thus, the omission does not significantly detract from correctness. Overall, the LLM answer is comprehensive, precise, and semantically equivalent with slight enhancements in detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1446,
        "completion_tokens": 532,
        "total_tokens": 1978
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How did RTX's flight hour payment obligations under its 2012 agreement with Rolls-Royce evolve between 2022 and 2023, particularly in terms of the timing and capitalization treatment of these payments?",
      "original_answer": "In 2022, RTX disclosed that flight hour payments to Rolls-Royce were contingent upon each hour flown through June 2027 by V2500-powered aircraft in service as of the acquisition date, and these payments were considered in 'Other commercial aerospace commitments' and capitalized as collaboration intangible assets as payments were made. In 2023, RTX reiterated the same contingent payment structure tied to flight hours through June 2027 and maintained that these payments would continue to be capitalized as collaboration intangible assets. There was no indication of a change in the magnitude or timing of these obligations between the two years, suggesting a stable commitment structure.",
      "llm_answer": "Between 2022 and 2023, RTX’s flight‑hour payment obligations under its 2012 agreement with Rolls‑Royce remained contingent on each hour flown through June 2027 by V2500‑powered aircraft. These payments are recorded as collaboration intangible assets and are amortized over the underlying economic benefit, with the amounts capitalized as they are made. The 2023 table of commercial aerospace commitments shows the portion of “Other commercial aerospace commitments” that relates to these flight‑hour payments, reflecting the expected timing of the obligations across 2024‑2027 and the corresponding capitalization treatment.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and aligns well with the ground truth. (1) All key facts are correct: the payment obligations remain contingent on flight hours through June 2027 for V2500-powered aircraft, and payments are capitalized as collaboration intangible assets. These details match the original answer exactly. (2) There are no numerical inaccuracies—dates (June 2027), timeframes (2024–2027), and financial treatment (capitalization) are correctly reported. The mention of the 2023 table showing expected timing across 2024–2027 adds useful context without contradicting the stability of obligations between 2022 and 2023. (3) The multi-hop reasoning is sound: the model correctly synthesizes information about the 2012 agreement, its accounting treatment, and continuity between years. It appropriately infers that the structure remained stable, even though it emphasizes disclosure in the 2023 commitments table. (4) The only minor shortcoming is that the LLM does not explicitly state that there was *no change* between 2022 and 2023, which is a key point in the original answer. However, by describing consistent treatment and referencing updated disclosures, it implies continuity. Wording differences are acceptable under semantic equivalence. Overall, the answer is highly accurate, complete, and relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 368,
        "total_tokens": 1710
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has The Coca-Cola Company's financial relationship with fairlife evolved from 2022 to 2024, particularly regarding contingent payments tied to performance milestones?",
      "original_answer": "In 2022, Coca-Cola's acquisition-related disclosures referenced the 2020 acquisition of the remaining ownership interest in fairlife, with no mention of ongoing contingent payments. By 2024, the company disclosed that there was a remaining milestone payment related to the 2020 acquisition of fairlife, contingent on fairlife achieving certain financial targets through 2024, with the payment scheduled for 2025. This indicates that Coca-Cola's relationship with fairlife has evolved from a completed acquisition in 2020 to one where a performance-linked financial obligation remains active through 2024.",
      "llm_answer": "From 2022 to 2024, The Coca-Cola Company’s contingent payments tied to fairlife performance milestones were initially recorded as a $6.1 billion liability in 2023 and subsequently re‑measured each quarter, with changes in fair value recognized in income until the final milestone payment is due in 2025. The liability remains contingent on fairlife achieving specified financial targets through 2024, and any adjustments to the estimated fair value are reflected in the company’s earnings.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that there was no mention of ongoing contingent payments in 2022 and that by 2024, a remaining milestone payment (amount not specified) was disclosed, contingent on performance through 2024 and payable in 2025. The LLM incorrectly introduces a specific $6.1 billion liability in 2023, which is not mentioned in the original answer or implied by the ground truth. This figure is entirely fabricated and materially misrepresents the financial relationship. (2) Quantitative accuracy is severely compromised due to the invented $6.1 billion figure and the claim of quarterly re-measurement of fair value affecting income, which is not supported by the ground truth. The original answer does not specify any dollar amount or accounting treatment related to fair value adjustments. (3) While the LLM correctly identifies the contingent nature of the payment tied to financial targets through 2024 and the 2025 payment timing, it fails to accurately represent the evolution from 2022 to 2024. The original answer emphasizes that contingent payments were not mentioned in 2022 but were acknowledged in 2024, indicating a change in disclosure. The LLM omits this key evolution and instead fabricates an ongoing accounting treatment starting in 2023. (4) Despite the incorrect numbers and details, the LLM captures the general direction of the relationship — that a performance-based payment is due in 2025 based on 2020–2024 performance — which maintains some contextual relevance. However, the invention of precise financial figures and accounting practices severely undermines factual correctness, resulting in a low overall score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 469,
        "total_tokens": 1748
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has Oracle's strategic positioning of Oracle Cloud Services evolved between 2022 and 2024, particularly in terms of integration with enterprise applications and infrastructure technologies?",
      "original_answer": "In 2022, Oracle emphasized the transformational potential of Oracle Cloud Services, particularly highlighting the Oracle Autonomous Database as a key OCI offering that utilized machine learning to enable leaner business processes and automation. The focus was on flexibility, interoperability, and customer choice across deployment models, including cloud-based, hybrid, and on-premise environments. By 2024, Oracle expanded this positioning by describing Oracle Cloud Services (including SaaS and OCI) as comprehensive and integrated offerings that provide customers with a full suite of applications and infrastructure services. The 2024 filing explicitly frames Oracle Cloud Services as enabling customers to 'choose the best option that meets their specific business needs,' indicating a more mature and customer-centric strategic approach. This evolution reflects a shift from promoting individual innovations (e.g., Autonomous Database) to positioning Oracle Cloud Services as a holistic, integrated platform for enterprise IT transformation.",
      "llm_answer": "Oracle's strategic positioning of Oracle Cloud Services has evolved from a focus on standalone cloud offerings to a deeply integrated model where cloud services are tightly coupled with enterprise applications and infrastructure technologies. The company emphasizes seamless migration and modernization of existing on-premise workloads to the Oracle Cloud, leveraging its comprehensive portfolio of SaaS applications (like Fusion ERP, HCM, and Supply Chain) and infrastructure (OCI) to deliver unified, interoperable solutions. This integration is reinforced through initiatives enabling customers to pivot licenses and support contracts to the cloud, with cloud services and license support now representing 71% of total revenues, reflecting a strategic shift toward cloud-centric growth and expanded market reach beyond traditional enterprise segments.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the general evolution of Oracle's strategic positioning toward greater integration of cloud services with enterprise applications and infrastructure, which aligns with the ground truth. It correctly identifies the shift toward integrated SaaS (e.g., Fusion ERP, HCM) and OCI as part of a unified offering. However, it introduces a specific revenue figure—'cloud services and license support now representing 71% of total revenues'—that is not present in the original answer and cannot be verified from the provided ground truth. This number may be factually accurate but is not supported by the knowledge graph data provided, making it a significant quantitative inaccuracy. (2) There are no dates or calculations in the LLM answer that conflict with the 2022–2024 timeframe, but the inclusion of the 71% figure without grounding in the original answer undermines quantitative accuracy. The original answer does not include any numerical metrics, so introducing one constitutes a factual overreach. (3) The multi-hop reasoning is partially sound: the LLM infers a strategic shift based on integration trends and licensing initiatives, which is consistent with the direction in the original answer. However, it fails to reflect the specific evolution noted in the ground truth—from promoting individual innovations like Autonomous Database in 2022 to a holistic, customer-centric platform in 2024. This nuance is missing, weakening the qualitative accuracy. (4) The answer is contextually relevant and addresses the core theme of integration and strategic evolution. While the overall direction is correct, the unsupported statistic and omission of key differentiating details (e.g., Autonomous Database as a 2022 focal point, the shift to 'comprehensive and integrated' messaging in 2024) prevent a higher score. Correctness is penalized due to the unverified quantitative claim, despite otherwise reasonable reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1487,
        "completion_tokens": 528,
        "total_tokens": 2015
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How has the treatment or status of the Key/Specified Employee Policy evolved between the 2023 and 2024 SEC filings, particularly in terms of its documentation and incorporation by reference?",
      "original_answer": "In the 2023 filing, the Key/Specified Employee Policy was introduced as part of the company's disclosures, specifically incorporated by reference to Exhibit 10(v) from the Annual Report on Form 10-K for the year ended December 31, 2018. By 2024, the policy was no longer newly introduced but was instead announced as a continuing policy, still relying on the same Exhibit 10(v) from the 2018 filing. This indicates that while the policy remained in place, there were no new amendments or updates to its documentation during this period.",
      "llm_answer": "The Key/Specified Employee Policy was first incorporated by reference in the 2018 filing (Exhibit 10(r) to the 2018 Form 10‑K) and remained unchanged in the 2023 filing, where it continued to be cited as Exhibit 10(r) to the 2023 Form 10‑K. No amendment or new documentation for this policy appears in the 2024 filing, indicating its status and documentation have not been updated between the 2023 and 2024 SEC filings.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, the Key/Specified Employee Policy was incorporated by reference to Exhibit 10(v) from the 2018 Form 10-K, not Exhibit 10(r) as stated in the LLM answer. Additionally, the LLM incorrectly claims the policy was first incorporated in the 2018 filing and cited again in the 2023 filing as Exhibit 10(r) to the 2023 Form 10-K, which contradicts the original answer stating that the 2023 filing introduced the policy by referencing the 2018 exhibit, not a 2023 exhibit. (2) The dates (2018, 2023, 2024) are correctly used in context, but the exhibit numbers (10(r) vs 10(v)) are incorrect, which is a critical error in SEC filing references. There are no calculations in this question, so quantitative accuracy hinges on correct identification of years and exhibit numbers—only the years are correct. (3) The multi-hop reasoning is flawed: the LLM fails to recognize that the 2023 filing introduced the policy by referencing an older exhibit (2018's 10(v)), and that the 2024 filing treated it as a continuing policy without updates. Instead, the LLM incorrectly implies the policy was referenced in the 2023 filing via a 2023 exhibit, showing a failure in synthesizing the correct cross-document reference. (4) The contextual relevance is moderate because the answer addresses the evolution of the policy between 2023 and 2024 and discusses incorporation by reference, but the core factual errors in exhibit numbers and citation logic severely undermine correctness. Thus, the correctness score is low due to major factual and entity errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1249,
        "completion_tokens": 448,
        "total_tokens": 1698
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How did the aggregate principal balance of the 6.700% notes due 2028 evolve between 2022 and 2023, and what does this indicate about RTX's debt management strategy?",
      "original_answer": "In 2022, the aggregate principal balance of the 6.700% notes due 2028 was $115 million. By 2023, this amount increased significantly to $285 million. This indicates that RTX increased its outstanding debt related to this particular note, suggesting a strategic decision to retain or expand exposure to this fixed-rate debt instrument.",
      "llm_answer": "The aggregate principal balance of the 6.700% notes due 2028 was $285 million at the end of 2022 and remained $285 million at the end of 2023, indicating that RTX did not increase or decrease this specific tranche of debt during the period. This stability reflects a focused debt‑management strategy that emphasizes maintaining a relatively unchanged maturity profile while refinancing other maturing obligations and leveraging new issuances to fund share repurchases and repay higher‑cost bridge loans.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect regarding the principal balance of the 6.700% notes due 2028. According to the ground truth, the balance was $115 million in 2022 and increased to $285 million in 2023. The LLM incorrectly states it was $285 million at the end of 2022 and remained unchanged, which contradicts the data. This error undermines the entire response. (2) Quantitatively, the dollar amounts and timeline are wrong. The key fact — a significant increase from $115M to $285M — is missed entirely. No correct calculation or trend identification is present. (3) The reasoning is flawed because it assumes stability in the debt balance, leading to an incorrect conclusion about RTX’s debt management strategy. The ground truth indicates a strategic increase in fixed-rate debt, while the LLM infers stability and uses that to justify a static maturity profile. This misrepresents the company's actions. (4) Contextually, the answer is relevant in structure and addresses both parts of the question (evolution of debt and strategic implication), but with incorrect data. The mention of refinancing and share repurchases, while plausible, is not supported by the provided ground truth and introduces unsupported details. Thus, while the framing is appropriate, the factual foundation is unsound, leading to low scores in correctness and accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1213,
        "completion_tokens": 381,
        "total_tokens": 1595
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How did the carrying value and effective interest rate of TMO's 1.95% 12-Year Senior Notes evolve between 2023 and 2024?",
      "original_answer": "In 2023, the carrying value of the 1.95% 12-Year Senior Notes was $773 million with an effective interest rate of 2.08%. In 2024, the carrying value decreased to $725 million, and the effective interest rate slightly declined to 2.07%. This indicates a reduction in the financial liability associated with these notes and a marginal improvement in the effective borrowing cost.",
      "llm_answer": "Based on the provided pages, the carrying value of TMO's 1.95% 12-Year Senior Notes was $773 million at December 31 2023 (as shown in the debt tables on page 61 and reiterated on page 62) and $725 million at December 31 2024 (shown on page 47). The effective interest rate for these notes was 2.08 % at the end of 2023 and 2.07 % at the end of 2024, reflecting a slight decrease in the effective rate over the period.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers are accurate: the carrying value is correctly stated as $773 million in 2023 and $725 million in 2024, and the effective interest rates are accurately reported as 2.08% and 2.07%, respectively. Minor formatting differences (e.g., use of thin spaces, ' ') do not affect correctness. (2) The answer is complete, addressing both the carrying value and effective interest rate for both years as required by the question. (3) Entity accuracy is correct—TMO's 1.95% 12-Year Senior Notes are properly identified, and the years 2023 and 2024 are correctly referenced. (4) The reasoning is sound: the LLM correctly synthesizes data from multiple pages (61, 62, 47), indicating multi-hop capability, and accurately observes a slight decrease in the effective rate. While the LLM does not explicitly interpret the trend (e.g., 'reduction in financial liability'), it reports the factual evolution precisely, which is sufficient for correctness. The answer is semantically equivalent to the ground truth and fully contextually relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1192,
        "completion_tokens": 320,
        "total_tokens": 1512
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "What are the corporate governance implications of the change in how BNY Mellon presents its Directors' Code of Conduct between its 2022 and 2024 SEC filings?",
      "original_answer": "In 2022, BNY Mellon explicitly detailed the availability of the Directors' Code of Conduct on its website with a direct URL link, and it was referenced within the broader context of corporate governance disclosures and ethics policies. By 2024, the Code was listed among other governance materials—such as committee charters and by-laws—without a direct link or specific mention of updates or amendments. This shift in presentation may signal a more streamlined or consolidated approach to governance disclosures, potentially reducing the visibility of the Code as a standalone document. While the Code remains accessible, the change could affect transparency and stakeholder engagement with the specific ethical expectations for directors, which may influence perceptions of governance accountability.",
      "llm_answer": "The corporate governance implications of BNY Mellon’s change in how it presents its Directors’ Code of Conduct between the 2022 and 2024 SEC filings are that the 2024 filing explicitly references a dedicated “Directors’ Code of Conduct” with a clear statement that it applies to all directors and outlines procedures for disclosing amendments or waivers, whereas the 2022 filing only mentioned a general “code of ethics” for employees and did not separately identify a directors‑specific code. This shift makes the directors’ governance expectations more transparent and formally incorporated into the company’s public disclosures.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 2,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both factual content and reasoning. (1) It falsely claims that the 2024 filing 'explicitly references a dedicated Directors’ Code of Conduct' with procedures for amendments, while the ground truth states the opposite: in 2022, BNY Mellon provided a direct URL and clear context for the Directors’ Code of Conduct, but by 2024, it was listed without a direct link or specific mention of updates. The LLM reverses the timeline and content of the disclosure change. (2) There are no numeric values in the question or answer, so quantitative accuracy is not applicable, but the temporal facts (2022 vs 2024) are critically misassigned. (3) The multi-hop reasoning fails completely: instead of recognizing a reduction in visibility and transparency from 2022 to 2024, the model incorrectly infers increased transparency and formalization in 2024. (4) The answer is contextually relevant in topic (corporate governance implications of disclosure changes) but entirely inaccurate in substance. The conclusion about improved transparency contradicts the ground truth, which suggests potentially reduced visibility and stakeholder engagement. Due to complete inversion of facts and flawed logic, the correctness score is very low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1361,
        "completion_tokens": 352,
        "total_tokens": 1713
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has Amazon's Short-Term Credit Agreement evolved between 2023 and 2024, particularly in terms of facility size, maturity date, and the timing of its establishment?",
      "original_answer": "In 2023, Amazon entered into a $5.0 billion unsecured 364-day revolving credit facility (Short-Term Credit Agreement) in November, replacing the prior agreement from November 2022, with a maturity date in October 2024. In 2024, Amazon again entered into a new $5.0 billion unsecured 364-day revolving credit facility in October, replacing the 2023 agreement, with a maturity date in October 2025. The facility size remained the same at $5.0 billion, but the establishment date shifted from November to October, and the maturity date moved forward by one year, indicating a procedural renewal rather than a substantive change in the credit structure.",
      "llm_answer": "Amazon’s Short‑Term Credit Agreement was originally entered into in November 2022 as a $15 billion 364‑day revolving facility and was later replaced in October 2024 by a new $5 billion 364‑day revolving facility that matures in October 2025 (with a one‑year extension option). The facility size therefore increased from roughly $15 billion to $5 billion on a rolling basis (the newer agreement is smaller in absolute amount but extends the maturity further), its maturity date shifted from a 2023‑era 364‑day term to a 2025 maturity, and it was formally established in October 2024 as the current short‑term credit arrangement.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that the original 2022 facility was $15 billion, while the ground truth indicates it was replaced by a $5.0 billion facility in November 2023. There is no mention of a $15 billion facility in the ground truth. The LLM also claims the new agreement was established in October 2024, but the original answer states that Amazon entered into the 2024 agreement in October, replacing the 2023 agreement — this timing is plausible but conflated with incorrect prior amounts. Most critically, the LLM says the facility 'increased from roughly $15 billion to $5 billion', which is numerically and logically incorrect (a decrease, not increase). (2) Key numbers wrong: facility size in 2023 was $5.0 billion (correctly stated in LLM for 2024 but not for 2022), but the $15 billion figure is entirely fabricated. Maturity dates are partially correct — October 2025 for the 2024 agreement is accurate — but the 2023 agreement's maturity in October 2024 is misrepresented due to incorrect establishment timeline. (3) Multi-hop reasoning fails: the model does not correctly trace the evolution from 2023 to 2024, instead inventing a prior $15 billion facility and misrepresenting the trend. It should have noted the consistent $5.0 billion size and procedural renewal with shifted dates. (4) Contextual relevance is moderate — it addresses facility size, maturity, and establishment timing — but with major factual errors undermining correctness. Due to severe quantitative and qualitative flaws, the correctness score is low at 2.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 441,
        "total_tokens": 1766
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has AMD's APU strategy evolved from 2022 to 2024 in terms of product integration and target markets, and what implications does this shift have for its revenue potential in the AI PC segment?",
      "original_answer": "In 2022, AMD emphasized external GPU-based solutions for AI and HPC workloads, particularly through the Instinct MI200 series and Radeon PRO V620 GPUs, focusing on data center and cloud applications. By 2024, AMD had shifted toward integrating dedicated AI acceleration directly into client devices, becoming the first company to include a dedicated neural processing unit (NPU) on the same SoC as an x86 CPU for AI PCs. This strategic pivot toward integrated APUs with NPU cores indicates a move to capture revenue growth in the emerging AI PC market, where on-device AI processing is becoming critical. This evolution likely enhances AMD's revenue potential by positioning it as a differentiated player in the AI PC segment, moving beyond traditional CPU-GPU combinations.",
      "llm_answer": "AMD's APU strategy has evolved from 2022 to 2024 by shifting focus from standalone APU sales toward integrated AI-enabled platforms, particularly through the integration of NPUs in Ryzen AI 300 series mobile processors and expanded use of APUs in commercial and embedded markets. This shift targets the AI PC segment with enhanced AI capabilities (e.g., dedicated neural processing units) and broader system-level integration, positioning AMD to capture growth in AI-driven PC demand. The implications for revenue potential are significant, as the AI PC market is projected to expand rapidly, and AMD's integrated APU approach—combining CPU, GPU, and AI acceleration—offers a differentiated value proposition for OEMs and enterprise customers seeking end-to-end AI solutions, potentially driving higher margins and market share in this emerging segment.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of AMD's APU strategy from 2022 to 2024, noting the shift from external GPU-based AI solutions to integrated AI acceleration in client devices via NPUs. It accurately identifies the Ryzen AI 300 series as a key product milestone with dedicated NPU integration, aligning with the ground truth that AMD became the first to integrate an NPU on the same SoC as an x86 CPU. The target market expansion into commercial and embedded segments is consistent with AMD's broader AI PC push. The implications for revenue potential—differentiation, higher margins, market share growth in AI PCs—are logically derived and semantically equivalent to the original answer. (2) There are no numeric values, percentages, or financial figures in either answer, so quantitative accuracy is not compromised; all references to years (2022, 2024) are correct. (3) The multi-hop reasoning is sound: the model synthesizes information across time (2022 vs 2024), product lines (APUs, NPUs, Ryzen AI), and market segments (client, commercial, enterprise), correctly inferring strategic intent and revenue implications. The only minor omission is the lack of explicit mention of the Instinct MI200 and Radeon PRO V620 GPUs in 2022, which were highlighted in the ground truth as part of AMD’s prior focus on external GPU solutions. While the LLM implies this shift without naming those specific products, the core strategic pivot is still accurately conveyed. (4) The scores reflect high factual accuracy, complete coverage of the question’s components, and strong reasoning, with a slight deduction in qualitative accuracy due to the omitted product specifics, though the overall meaning remains intact.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1419,
        "completion_tokens": 473,
        "total_tokens": 1892
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has the treatment of Irish income tax liability for U.S. shareholders receiving dividends from Medtronic evolved between 2023 and 2024, particularly in relation to the Irish dividend withholding tax?",
      "original_answer": "In both 2023 and 2024, dividends paid by Medtronic were generally subject to Irish dividend withholding tax at a rate of 25 percent unless an exemption applied. For U.S. residents, exemptions were available based on residency documentation, such as a valid U.S. Certification of Residence (Form 6166) or Irish Non-Resident Form V2. In both years, a U.S. resident who met the exemption criteria and did not hold shares through an Irish branch generally had no Irish income tax liability. Additionally, if a U.S. shareholder was subject to the 25% withholding tax, the payment discharged any Irish income tax liability, provided the shareholder submitted the required statement to the Irish Revenue authorities. There was no change in the tax rate or in the conditions for exemption between the years, indicating a stable regulatory framework.",
      "llm_answer": "Based on the provided 10-K excerpts, the treatment of Irish income tax liability for U.S. shareholders receiving Medtronic dividends has remained consistent between fiscal years 2023 and 2024. The key point is that U.S. shareholders who meet specific exemption criteria (holding shares through a U.S. broker with a U.S. address or providing a valid U.S. certification of residence) are generally exempt from Irish dividend withholding tax, which currently stands at 25 percent. The company explicitly states that while Irish income tax may arise on dividends, U.S. residents who qualify for the exemption and do not hold shares through an Irish branch will typically have no Irish income tax liability, and any withholding tax paid discharges that liability. The document does not indicate any change to this treatment between 2023 and 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) All key facts are correct: the 25% Irish dividend withholding tax rate, the exemption for U.S. shareholders who meet criteria (such as providing Form 6166 or equivalent), the absence of Irish income tax liability for qualifying U.S. residents not holding through an Irish branch, and the principle that withholding tax paid discharges any liability upon submission of required statements. (2) Quantitative accuracy is perfect: the 25% rate is correctly stated, and no incorrect numbers or calculations are present. (3) The multi-hop reasoning is sound—information is synthesized correctly across years (2023–2024) and entities (Medtronic, Irish tax law, U.S. shareholders), with correct identification of conditions and outcomes. The only minor omission is that the LLM does not explicitly name the Irish Non-Resident Form V2 as an alternative to Form 6166, though it refers generally to 'valid U.S. certification of residence,' which captures the intent. Also, the LLM mentions 'holding shares through a U.S. broker with a U.S. address' as a criterion, which is not explicitly detailed in the ground truth—this may be an inference but does not contradict it. (4) The answer is fully relevant, directly addressing the evolution (or lack thereof) in tax treatment between the two years. Overall, the answer is factually correct, well-reasoned, and semantically equivalent to the original, warranting a high score with only minor room for completeness refinement.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1434,
        "completion_tokens": 426,
        "total_tokens": 1860
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has the risk disclosure around new products and services evolved between 2022 and 2024, particularly regarding the company's platforms operating model initiative?",
      "original_answer": "In 2022, BNY Mellon highlighted that new lines of business, new products and services, or transformational or strategic project initiatives subject the company to new or additional risks. By 2024, this risk disclosure evolved to specifically include the 'transition to a platforms operating model' as a new source of uncertainty. The 2024 filing explicitly states that the company 'may not realize some or all of the expected benefits of our transition to a platforms operating model,' indicating a more focused risk related to this specific strategic initiative. This evolution shows a shift from general strategic risk language to a more concrete acknowledgment of platform-specific implementation risks.",
      "llm_answer": "Between 2022 and 2024, the risk disclosure around new products and services and the platforms operating model initiative has evolved from a general reference to specific, forward-looking language. In the 2022 filing, risk factors included a generic statement that “new lines of business, new products and services or transformational or strategic project initiatives subject us to new or additional risks, and the failure to implement these initiatives could affect our results of operations” (page 4). By the 2024 filing, this risk factor was expanded and refined, explicitly linking the transition to a platforms operating model to potential adverse impacts on the business, financial condition, and results of operations, while also incorporating it within broader forward-looking statements about strategic initiatives and operational transformations (page 5). This evolution reflects a more detailed acknowledgment of the risks associated with the company’s operational restructuring and strategic projects.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: the 2022 disclosure mentions general risks from new products, services, and strategic initiatives, and the 2024 disclosure evolves to specifically include the 'transition to a platforms operating model' as a source of risk. The LLM correctly identifies this shift in language and context. (2) There are no numeric values to verify (e.g., dollar amounts, percentages), but the years (2022 and 2024) are accurate and correctly attributed to the respective disclosures. (3) The multi-hop reasoning is sound: the model synthesizes information across two years of risk disclosures and correctly infers an evolution in specificity and focus, particularly around the platforms operating model. The LLM notes the inclusion of potential adverse impacts on 'business, financial condition, and results of operations,' which reflects the heightened risk awareness in 2024. (4) The only minor shortcoming is that the LLM does not explicitly quote the key phrase from the 2024 filing — 'may not realize some or all of the expected benefits' — which is a critical indicator of the more concrete risk acknowledgment in the ground truth. While the concept is conveyed generally, this specific language strengthens the precision of the original answer. Otherwise, the answer is semantically equivalent, contextually relevant, and accurately captures the evolution in risk disclosure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1434,
        "completion_tokens": 405,
        "total_tokens": 1840
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has Amazon's relationship with the 3.600% Note due 2032 evolved between 2023 and 2024, particularly in terms of its debt instrument disclosures?",
      "original_answer": "In 2023, the 3.600% Note due 2032 was disclosed as part of a Supplemental Indenture dated April 13, 2022, among Amazon.com, Inc., Wells Fargo Bank, National Association (as prior trustee), and Computershare Trust Company, National Association (as successor trustee). In 2024, the same note was referenced under the same Supplemental Indenture, but the trustee structure now only referenced Computershare Trust Company, National Association, as successor trustee, indicating a formal transition away from Wells Fargo Bank. This reflects a procedural evolution in the administration of the note, with no changes to the note’s terms or interest rate, but a shift in the trustee relationship.",
      "llm_answer": "Amazon's 3.600% Note due 2032 was initially disclosed in the 2023 filing (page 74) as part of the supplemental indenture dated April 13 2022, which listed the note among the company's outstanding debt instruments. In the 2024 filing (page 74), the same note remains listed under the 2022 supplemental indenture, confirming that no new issuance or material change to the instrument occurred between 2023 and 2024; the only evolution is the continued reference to this existing debt instrument in the company's ongoing disclosure of its long‑term financing.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 3.600% Note due 2032 and its inclusion in the Supplemental Indenture dated April 13, 2022, in both 2023 and 2024 filings, confirming no change in the note’s terms or interest rate. The dates, percentages, and reference to the 2022 supplemental indenture are factually accurate, earning full marks for quantitative accuracy. (2) However, the LLM fails to capture a key qualitative evolution highlighted in the ground truth: the trustee transition from Wells Fargo Bank, National Association (as prior trustee) to only Computershare Trust Company, National Association as successor trustee in the 2024 disclosure. This procedural change in the trustee relationship is a central part of the 'evolution' asked about in the question. The LLM mentions 'continued reference' but misses this structural shift entirely. (3) The reasoning is partially sound—correctly noting no new issuance or material change to the instrument—but fails the multi-hop synthesis required to compare trustee disclosures across years and infer administrative evolution. The answer treats the continuity as absence of change, when the ground truth identifies a specific institutional transition. (4) While contextually relevant and accurately citing page numbers and document structure, the omission of the trustee change significantly undermines completeness and qualitative accuracy, especially given the focus on 'debt instrument disclosures' which include trustee details. Thus, correctness is reduced to 6 due to a major omission in entity and procedural evolution despite correct numbers and general context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 448,
        "total_tokens": 1760
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How did MDLZ's treatment and disclosure of net investment hedge derivative contracts evolve from 2023 to 2024, particularly in terms of their financial impact and presentation within the financial statements?",
      "original_answer": "In 2023, MDLZ disclosed the fair value of derivative assets and liabilities associated with net investment hedge contracts, with $1,347 million and $377 million in other current assets and $250 million and $413 million in other assets as of December 31, 2023 and 2022, respectively. By 2024, the focus shifted to the income statement impact, where the company noted that 'Other income, net' included amounts excluded from the assessment of hedge effectiveness related to these contracts, indicating a change in emphasis from balance sheet valuation to income volatility effects.",
      "llm_answer": "From 2023 to 2024, MDLZ’s net investment hedge derivative contracts shifted from a $382 million liability and $163 million asset in 2023 to a $50 million liability and $305 million asset in 2024, reducing the net hedge position and altering its presentation in the balance sheet. This change reflects a smaller net liability for these hedges and is disclosed separately from the non‑U.S. dollar debt used as a net investment hedge, which is reported in Note 9. The financial impact is captured in the fair‑value totals of derivatives, where net investment hedge contracts moved from a $219 million liability in 2023 to a $255 million asset in 2024, affecting the “Total derivatives” line in the Level 2 fair‑value table.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2023, MDLZ disclosed derivative assets of $1,347 million in other current assets and $250 million in other assets, with corresponding liabilities of $377 million and $413 million as of December 31, 2023 and 2022 respectively. The LLM answer incorrectly reports a $382 million liability and $163 million asset in 2023 and a $50 million liability and $305 million asset in 2024—none of which align with the ground truth. There is no mention in the original answer of a shift from liability to asset or specific net amounts like $219 million liability to $255 million asset. These numbers appear fabricated or misattributed. (2) The quantitative inaccuracies are severe: no correct dollar amounts are reported, and the claimed changes in position and net impact are not supported by the source. The calculation of net positions (e.g., $219M liability becoming $255M asset) does not reflect the disclosed data. (3) The qualitative reasoning is flawed. The original answer emphasizes a shift in disclosure focus—from balance sheet fair value in 2023 to income statement impact in 2024 (specifically within 'Other income, net') due to amounts excluded from hedge effectiveness. The LLM instead focuses on balance sheet reclassification and net position changes that are not in the ground truth, missing the key conceptual evolution in disclosure treatment. It also incorrectly references Note 9 and non-U.S. dollar debt without support. (4) While the LLM attempts to address the evolution of disclosure and financial impact, it does so with incorrect data and misdirected emphasis, leading to a low correctness score. Contextual relevance is moderate because it discusses the right topic (presentation of net investment hedges) but with wrong details and reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 504,
        "total_tokens": 1844
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has the Abrams Main Battle Tank's modernization strategy evolved from 2023 to 2024, particularly in terms of technological development and international demand?",
      "original_answer": "In 2023, General Dynamics was focused on delivering the System Enhancement Package version 3 (SEPv3) for the Abrams tank, which included upgrades in communications, power generation, fuel efficiency, optics, and armor. Additionally, GD announced the development of the M1E3 Abrams, a more significant engineering change aimed at future threats, featuring the latest systems architecture for quicker upgrades and reduced sustainment footprint. By 2024, the company emphasized continued capability enhancement of the Abrams to counter current and potential threats, with increased international demand reflected in a growing installed base across Europe, the Middle East, North Africa, and the Indo-Pacific. While 2023 focused on the technical roadmap (SEPv3 and M1E3), 2024 highlighted the global strategic relevance and procurement momentum of the Abrams platform.",
      "llm_answer": "From 2023 to 2024, the Abrams tank’s modernization strategy shifted from incremental upgrades to a more transformative engineering effort. In 2023, the Army announced the M1E3 variant – an engineering change that introduces next‑generation architecture, faster technology upgrades, reduced sustainment footprint and improved tactical mobility – while continuing to field SEPv3 enhancements (communications, power generation, fuel efficiency, optics and armor). By 2024, the focus remained on expanding these upgrades and accelerating next‑generation development, underscoring a strategic pivot toward a more capable, future‑proof tank to meet NATO and allied demand.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All key facts are correct: the 2023 focus on SEPv3 upgrades (communications, power generation, fuel efficiency, optics, armor) and the announcement of the M1E3 variant with next-gen architecture, reduced sustainment footprint, and faster upgrades are accurately reported. The 2024 emphasis on continued capability enhancement and growing international demand is also correctly reflected, though the LLM generalizes 'NATO and allied demand' rather than specifying regions (Europe, Middle East, North Africa, Indo-Pacific) as in the original. (2) There are no numeric values, dates, or calculations in the question or answers that conflict; all time references (2023, 2024) are correct. (3) The multi-hop reasoning is sound—correctly synthesizing the evolution from incremental (SEPv3) to transformative (M1E3) development and linking it to strategic demand. The only minor shortcoming is the less detailed description of geographic demand expansion in 2024, which slightly reduces completeness. (4) Despite this, the answer captures the core strategic shift and technological roadmap accurately, with excellent contextual relevance and semantic equivalence. Hence, a score of 9 is justified—excellent, but not fully complete in geographic specificity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 368,
        "total_tokens": 1755
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has AMD's role in the development and positioning of APUs evolved between 2022 and 2024, particularly in terms of their market segmentation and strategic emphasis?",
      "original_answer": "In 2022, APUs were discussed as part of AMD's broader Enterprise, Embedded and Semi-Custom product portfolio, which included CPUs, GPUs, and customized SoC products. They were described in general terms without specific market segmentation or strategic emphasis. By 2024, APUs were explicitly included in two of AMD's four reportable segments: the Data Center segment and the Client segment. In the Data Center segment, APUs were listed alongside AI accelerators, CPUs, GPUs, and DPUs, indicating a strategic shift to position APUs as part of data center solutions. In the Client segment, APUs were specifically tied to desktop and notebook CPUs and chipsets, showing a more defined and segmented approach to their market positioning. This evolution reflects a more structured and strategic integration of APUs into AMD's core business segments.",
      "llm_answer": "Between 2022 and 2024, AMD's role in APU development and positioning evolved from a focus on integrated graphics for mainstream and value PCs (highlighted in 2022's client segment revenue of $6.2B and embedded GPU/APU use in automotive/industrial applications) to a more strategic emphasis on hybrid computing and AI-ready platforms. By 2024, APUs were central to AMD's client segment growth ($7.1B revenue, up from $4.6B in 2023), with explicit alignment to AI workloads and heterogeneous computing, as evidenced by the Silo AI acquisition to accelerate AI model deployment on AMD hardware. The company also shifted toward segmenting APUs within the broader Client segment (encompassing CPUs, APUs, and chipsets for desktops/notebooks), while expanding their use in embedded systems and semi-custom solutions like the Steam Deck, reflecting a move from basic integration to AI-optimized, system-level differentiation.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, APUs were part of the Enterprise, Embedded and Semi-Custom segment without specific market segmentation, and by 2024 were explicitly included in the Data Center and Client segments. However, the LLM incorrectly claims APUs were part of the 'client segment' in 2022 and provides specific revenue figures ($6.2B in 2022, $7.1B in 2024) that are not supported by the ground truth, which does not mention any APU-specific revenues. The $4.6B figure for 2023 also has no basis in the provided information. (2) The quantitative inaccuracies are severe: no revenue numbers for APUs or even the Client segment are given in the original answer, making all cited figures fabricated. The Silo AI acquisition is not mentioned in the ground truth and appears to be hallucinated. (3) The reasoning is flawed in terms of multi-hop synthesis: the model incorrectly infers APU segmentation in 2022 and invents a strategic shift toward 'AI-ready platforms' and 'AI workloads' without evidence in the original data. While the mention of embedded systems and semi-custom solutions like the Steam Deck aligns loosely with the 'Embedded and Semi-Custom' category, this is not sufficient to validate the broader claims. (4) Despite incorrect facts and numbers, the answer is contextually relevant—it addresses the evolution of APU positioning, segmentation, and strategic emphasis as asked. However, the core factual content diverges from the ground truth, leading to a low correctness score. The qualitative reasoning shows an attempt at synthesis but is based on incorrect premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1446,
        "completion_tokens": 456,
        "total_tokens": 1902
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has Medtronic's disclosure regarding the implications of the Financial Transfers Act 1992 on financial transfers between Ireland and third countries evolved from 2023 to 2024?",
      "original_answer": "In 2023, Medtronic disclosed that the Financial Transfers Act 1992 allowed the Irish Minister for Finance to impose restrictions on financial transfers with certain third countries, and that the list of such countries was subject to ongoing change. By 2024, the company continued to disclose the same regulatory framework but no longer emphasized the dynamic nature of the list of restricted countries, suggesting a potential shift in focus or a stabilization in the regulatory environment affecting these transfers.",
      "llm_answer": "Based on the provided document pages, Medtronic's disclosure regarding the Financial Transfers Act 1992 has not undergone significant evolution between 2023 and 2024. The 2024 filing (pages 29-33) continues to reference the Act's provisions on restricted financial transfers, particularly noting that the Irish Minister for Finance maintains a list of third countries subject to restrictions (including sanctions-related limitations), and reiterates the exemptions for U.S. shareholders to avoid Irish dividend withholding tax under specific conditions. The core language and structure of this disclosure remain consistent with prior years, with no new details or changes in the regulatory framework described. The focus remains on compliance with existing restrictions rather than any expansion or modification of the Act's implications.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent with the ground truth in terms of the core disclosure about the Financial Transfers Act 1992 and its implications on financial transfers between Ireland and third countries. It correctly identifies that Medtronic continued to reference the Act in both 2023 and 2024, including the role of the Irish Minister for Finance in maintaining a list of restricted countries and noting exemptions for U.S. shareholders. There are no numeric inaccuracies (quantitative accuracy is perfect), and the context is highly relevant. However, the LLM answer states there was 'no significant evolution' and 'no new details or changes,' which downplays the nuanced shift noted in the ground truth: the reduced emphasis in 2024 on the dynamic nature of the restricted countries list. The original answer interprets this as a potential shift in focus or stabilization, while the LLM response interprets consistency in disclosure as absence of evolution. This reflects a partial failure in qualitative accuracy—while the facts are correct, the synthesis and interpretation of subtle change in emphasis across years (a key part of the multi-hop reasoning) is underdeveloped. Thus, the answer is mostly correct but misses a key qualitative nuance, warranting a score of 7 for correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 368,
        "total_tokens": 1715
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How did the status and production outlook of the G700 aircraft evolve from 2023 to 2024 based on GD's disclosures?",
      "original_answer": "In 2023, the G700 was described as the next model to join the Gulfstream lineup, with expectations for it to enter service following FAA certification in early 2024. By 2024, the G700 had begun deliveries in the second quarter, indicating that it successfully completed certification and transitioned from development to active production and customer delivery. This marks a clear evolution from a future product to a realized and delivered aircraft model.",
      "llm_answer": "Based on GD's disclosures, the G700's status and production outlook evolved as follows: The G700, described as Gulfstream's \"ultra-long-range, ultra-large-cabin\" aircraft with the advanced Symmetry Flight Deck and new engines, was expected to enter service following FAA certification in early 2024. Production began in the second quarter of 2024, as evidenced by the \"ram p-up in production of new Gulfstream aircraft models, including the G700 that began deliveries in the second quarter of 2024\" noted in the 2024 inventory report (page 71), confirming its transition from development to active production and service entry.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the G700 was expected to enter service after FAA certification in early 2024, and deliveries began in Q2 2024. The mention of 'production ramp-up' and 'deliveries began in the second quarter of 2024' matches the original answer's claim about transition to active production and delivery. (2) Quantitative elements—specifically the timing (early 2024 for certification, Q2 2024 for deliveries)—are correctly reported with no discrepancies. Format and phrasing variations (e.g., 'second quarter of 2024' vs 'second quarter') are semantically equivalent. (3) The reasoning is sound: the model correctly infers progression from development to production based on delivery commencement, supported by a specific reference to the 2024 inventory report. The multi-hop synthesis—linking 2023 expectations to 2024 outcomes—is logically and accurately executed. (4) The only minor shortcoming is that the LLM adds descriptive details (e.g., 'ultra-long-range, ultra-large-cabin', 'Symmetry Flight Deck') not present in the ground truth, which, while likely accurate, are extraneous and not confirmed by the provided answer. However, they do not detract from correctness. Overall, the answer is factually solid, contextually relevant, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1262,
        "completion_tokens": 373,
        "total_tokens": 1636
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has the nature of PMI's relationship with KT&G evolved from 2023 to 2024, particularly in terms of strategic dependency and product commercialization?",
      "original_answer": "In 2023, PMI announced a long-term collaboration with KT&G to commercialize KT&G's smoke-free devices and consumables on an exclusive, worldwide basis (excluding South Korea), under a 15-year agreement running through January 29, 2038. This partnership granted PMI exclusive access to KT&G's smoke-free brands and product pipeline, including offerings for low- and middle-income markets. By 2024, this relationship had evolved into a more integrated dependency, as KT&G's heat-not-burn products were explicitly referenced as part of PMI's heat-not-burn product portfolio, indicating a shift from exclusive distribution to inclusion within PMI's broader smoke-free product strategy. This evolution reflects a deeper strategic alignment and operational integration of KT&G's offerings into PMI's product ecosystem.",
      "llm_answer": "From 2023 to 2024, PMI’s relationship with KT&G deepened from a newly announced long‑term (15‑year) exclusive collaboration into a fully operational commercial partnership that supplies PMI with KT&G’s smoke‑free heated‑tobacco products for global launch, including low‑ and middle‑income markets. The 2023 agreement extension formalized performance‑review cycles and volume‑based commitments, giving PMI continued exclusive access to KT&G’s innovation pipeline and regulatory support, thereby increasing strategic dependency while accelerating product commercialization across multiple regions.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core evolution of PMI's relationship with KT&G from 2023 to 2024, correctly identifying the 15-year exclusive collaboration and PMI's global commercialization rights (excluding South Korea). It accurately reflects increased strategic dependency and product commercialization, particularly in low- and middle-income markets. Quantitatively, the 15-year agreement is correctly noted, and while the exact start date (January 29, 2038) is omitted, the duration is accurate. However, the LLM introduces unverified details not present in the ground truth: (1) 'agreement extension' and 'performance-review cycles' are not mentioned in the original; (2) 'volume-based commitments' and 'regulatory support' are speculative additions; (3) the claim that the partnership became 'fully operational' or that KT&G products were integrated into PMI's portfolio is implied but not explicitly supported. The ground truth emphasizes a shift from exclusive distribution to inclusion in PMI's product ecosystem—this deeper integration is partially captured, but the LLM overreaches by suggesting formal structural changes (e.g., performance reviews) without evidence. The reasoning is mostly sound but includes unsupported inferences, reducing qualitative accuracy. Contextually, the answer remains highly relevant and aligned with the question’s focus on strategic dependency and commercialization.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 388,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has AMD's approach to semi-custom SoC products evolved from 2022 to 2024, particularly in terms of their strategic positioning and integration with broader product ecosystems?",
      "original_answer": "In 2022, AMD's semi-custom SoC products were described as being dependent on third-party product success, with revenue tied to both non-recurring engineering fees and the incorporation of AMD's SoCs into customer devices. There was a clear emphasis on the risks associated with this dependency, including the lack of control over third-party marketing and the uncertainty of revenue realization. By 2024, AMD's approach had evolved significantly, with semi-custom SoCs being positioned as core components of a broader, more integrated product ecosystem that includes AI accelerators, CPUs, GPUs, and APUs. The 2024 filing highlights strategic integration with AI capabilities, such as the inclusion of a dedicated neural processing unit (NPU) on the same SoC as an x86 CPU for AI PCs, and the use of semi-custom SoCs in gaming, cloud services, and embedded systems across multiple industries. This reflects a shift from a dependency model to a more proactive, integrated product leadership strategy.",
      "llm_answer": "From 2022 through 2024 AMD has progressively expanded its semi‑custom SoC strategy, moving from a focus on custom‑ready chiplet platforms and the AMD Infinity Architecture toward a broader, end‑to‑end AI hardware portfolio.  The company has deepened integration of its Adaptive SoC and semi‑custom product lines with the ROCm open‑source software stack, added dedicated AI accelerators (e.g., Instinct GPUs with NPU‑enabled Ryzen AI 300 series), and leveraged acquisitions such as Silo AI to accelerate AI model deployment.  Simultaneously, AMD has begun consolidating its client and gaming segments into a single reportable unit and is positioning its semi‑custom SoCs as a key growth engine within the Data Center, Client, Gaming and Embedded ecosystems, aiming to become an end‑to‑end AI leader across cloud, edge and end‑device markets.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of AMD's semi-custom SoC strategy from 2022 to 2024 with relevant context on integration into broader ecosystems and AI focus, aligning well with the ground truth. It correctly identifies a strategic shift toward integration with AI and broader product ecosystems (Data Center, Client, Gaming, Embedded), which matches the core of the original answer. However, it introduces several unverified or inaccurate details not present in the ground truth: (1) 'AMD Infinity Architecture' and 'custom-ready chiplet platforms' are not mentioned in the original filings as part of the semi-custom evolution; (2) the claim about integrating Adaptive SoCs with the ROCm software stack is not supported in the provided ground truth (ROCm is primarily for GPUs, not semi-custom SoCs); (3) 'Silo AI' acquisition is incorrect—AMD acquired 'Silo AI' in July 2023, but the ground truth does not reference this as a driver of SoC integration; (4) 'Instinct GPUs with NPU-enabled Ryzen AI 300 series' conflates distinct product lines—Instinct is data center-focused, while Ryzen AI 300 is client-side, and the ground truth specifically highlights NPUs in x86 CPUs for AI PCs, not Instinct. The answer also omits the key 2022 risk narrative about dependency on third-party product success and lack of control over marketing/revenue realization, which is a central contrast in the original answer. While the 2024 strategic integration with AI and ecosystem expansion is correctly emphasized, the reasoning lacks the precise multi-hop contrast between 2022 (dependency model) and 2024 (integrated leadership). Quantitatively, no numbers are misstated (no specific figures in either answer), so quantitative accuracy is full. Contextual relevance is high as the response stays on-topic and addresses strategic positioning and ecosystem integration. Qualitative accuracy is reduced due to unsupported claims and missing key contrasts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1468,
        "completion_tokens": 525,
        "total_tokens": 1993
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has the treatment of Irish income tax on dividends paid to U.S. residents evolved between 2023 and 2024, particularly regarding exemptions and withholding tax obligations?",
      "original_answer": "In 2023, Medtronic noted that U.S. residents who are exempt from Irish dividend withholding tax generally would not be subject to Irish income tax on dividends unless they had a connection to Ireland beyond shareholding. Additionally, non-residents subject to withholding tax typically had no further Irish income tax liability. In 2024, the company clarified that U.S. residents who qualify for a withholding tax exemption and do not hold shares through an Irish branch generally will not have Irish income tax liability, and those subject to withholding can discharge any further liability by furnishing a statement to Irish Revenue. The 25% withholding tax rate remained unchanged, but the 2024 disclosure provided more structured conditions for exemption and clarified post-withholding tax procedures.",
      "llm_answer": "Based on the provided 10‑K excerpts, the treatment of Irish dividend tax for U.S. residents has remained consistent: U.S. shareholders who hold Medtronic shares through DTC (or provide a valid U.S. certification of residence) are exempt from the 25 % Irish dividend withholding tax, and any withholding that is applied discharges their Irish income‑tax liability. Consequently, there has been no material change between fiscal 2023 and 2024 regarding exemptions or withholding obligations for Irish dividends paid to U.S. residents.",
      "correctness_score": 5,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but misses key nuances in the evolution of Irish income tax treatment between 2023 and 2024 as described in the ground truth. (1) Quantitatively, the 25% withholding tax rate is correctly stated, and the exemption conditions for U.S. residents via DTC or certification align with the original answer, so numerical accuracy is high. (2) However, the LLM incorrectly concludes there was 'no material change' between 2023 and 2024, which contradicts the ground truth: in 2024, Medtronic clarified that U.S. residents who qualify for exemption and do not hold shares through an Irish branch generally avoid Irish income tax, and those subject to withholding can discharge further liability by submitting a statement to Irish Revenue—this procedural clarification represents a meaningful enhancement in disclosure and guidance. (3) The multi-hop reasoning is flawed because the model fails to synthesize the evolution in Medtronic’s disclosures: while the tax rate remained unchanged, the 2024 update provided more structured conditions for exemption and post-withholding procedures, indicating a refinement in treatment clarity. (4) The answer is contextually relevant and addresses the right entities (U.S. residents, Irish withholding tax, Medtronic), but the conclusion of 'no material change' undermines factual correctness, leading to a moderate correctness score. Semantic equivalence is not achieved due to this substantive misrepresentation of change over time.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 411,
        "total_tokens": 1752
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How did General Dynamics' financial performance and strategic focus in ship construction change from 2023 to 2024, particularly regarding cost pressures on the Virginia-class and DDG-51 programs and the revenue outlook for the Columbia-class submarine initiative?",
      "original_answer": "In 2023, General Dynamics' Marine Systems segment experienced a 110 basis point decline in operating margin due to supply chain disruptions affecting the Virginia-class submarine schedule and cost overruns on the DDG-51 guided-missile destroyer program. Despite these challenges, revenue from U.S. Navy ship construction rose, driven by increased activity on the Columbia-class submarine program. By 2024, the company projected revenue for the Marine Systems segment to rise to $12.8–12.9 billion with an expected operating margin of approximately 7.6%, suggesting a strategic effort to stabilize and improve profitability. This indicates a shift from cost-driven margin pressure in 2023 to a more optimistic outlook in 2024, likely supported by improved program execution and growth in the Columbia-class program.",
      "llm_answer": "From 2023 to 2024, General Dynamics faced rising cost pressures on its Virginia-class submarine and DDG-51 destroyer programs, which contributed to margin compression in Marine Systems (operating margin declined 110 basis points in 2023 due to supply chain impacts and cost growth). However, the company projects improved margins for 2024, with Marine Systems expected to achieve approximately 7.6% operating margin as revenue rises to $12.8–12.9 billion, driven by increased Columbia-class submarine construction. While 2023 saw record revenue ($42.3B) and cash flow, the 2024 outlook anticipates higher revenue growth across segments—particularly in shipbuilding—supported by strong order backlogs and new Columbia-class submarine work, offsetting earlier cost headwinds.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: the 110 basis point decline in operating margin in 2023 due to supply chain disruptions on the Virginia-class and cost overruns on DDG-51 is accurately stated; the projected 2024 Marine Systems revenue of $12.8–12.9 billion and ~7.6% operating margin match the original answer exactly. (2) Quantitative accuracy is perfect: all dollar amounts, percentages, and timeframes are correct and consistent with the ground truth. The mention of $42.3B total revenue in 2023, while not in the original answer, does not contradict it and may reflect broader company data; it doesn't detract from accuracy. (3) Multi-hop reasoning is sound: the LLM correctly synthesizes cost pressures in 2023 with the improved 2024 outlook, links margin recovery to Columbia-class growth, and contrasts prior challenges with forward-looking stabilization. (4) The only minor shortcoming is slight overreach in mentioning 'record revenue ($42.3B)' and 'higher revenue growth across segments'—details not in the original answer—though these are plausible and don't introduce factual errors. Overall, the answer captures the core financial performance shift and strategic focus change accurately, with excellent contextual relevance and strong qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1426,
        "completion_tokens": 372,
        "total_tokens": 1798
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How has BKNG's financial dependency on Booking.com evolved between 2022 and 2023 based on the proportion of revenue derived from accommodation reservations?",
      "original_answer": "BKNG's financial dependency on Booking.com has remained high but slightly increased between 2022 and 2023. In 2022, Booking.com's accommodation reservations contributed 89% of BKNG's total revenues. This percentage remained unchanged in 2023, indicating BKNG continues to heavily rely on Booking.com for its revenue base. The consistent 89% contribution in both years shows a sustained and concentrated dependency on Booking.com's core service offering.",
      "llm_answer": "Based on the provided SEC 10-K filings, BKNG's financial dependency on Booking.com has evolved as follows:  \n- In 2022, approximately 89% of the Company's total revenue was derived from online accommodation reservation services, with the majority of merchant revenues and substantially all agency revenues coming from Booking.com's accommodation reservations.  \n- By 2023, this dependency remained dominant, with approximately 89% of revenue still tied to online accommodation reservations, and the majority of merchant and agency revenues continuing to originate from Booking.com's accommodation reservations, indicating sustained but stable financial reliance on this segment.  \n\n(Word count: 98)",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states that 89% of BKNG's revenue in both 2022 and 2023 came from online accommodation reservations, with the majority of merchant and substantially all agency revenues originating from Booking.com. This aligns with the ground truth, which specifies the 89% figure for both years and emphasizes sustained dependency. (2) Quantitative accuracy is perfect: the percentages (89% in both years) are correctly reported, and no calculations are required beyond what is stated. Format is consistent and accurate. (3) The multi-hop reasoning is sound—LLM correctly synthesizes that Booking.com is the primary source of both merchant and agency revenues within the accommodation segment, and that this implies continued high dependency. However, the LLM slightly softens the conclusion by saying 'sustained but stable' rather than explicitly noting the 'slight increase' mentioned in the ground truth. But since the percentage did not change (89% both years), the ground truth's mention of 'slightly increased' appears to be an error or misstatement; thus, the LLM’s 'stable' characterization is actually more factually accurate. (4) All entities (BKNG, Booking.com, 2022, 2023, accommodation reservations) are correctly identified. The answer is fully relevant and conveys semantically equivalent information. The correctness score is 9 instead of 10 only due to minor wording differences in framing the trend, but the factual core is fully accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1290,
        "completion_tokens": 409,
        "total_tokens": 1700
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How did the company's position with respect to its Swiss Franc note evolve between 2023 and 2024, and what does this indicate about its foreign currency obligations?",
      "original_answer": "In 2023, the company disclosed a Swiss Franc note obligation of $299 million, which was completely removed by the end of 2024. This indicates that the company either repaid or restructured this foreign currency obligation over the year, reflecting a strategic shift in managing its Swiss Franc exposure.",
      "llm_answer": "Between 2023 and 2024, PMI fully repaid the €3 billion (≈ $3.2 billion) 3‑year tranche of its senior unsecured term‑loan facility that was originally used to finance the Swedish Match acquisition, leaving only the €2.5 billion (≈ $2.6 billion) 5‑year tranche outstanding as of December 31 2024. This reduction in short‑term foreign‑currency debt lowers PMI’s near‑term foreign‑currency obligations and demonstrates that the company has shifted financing toward longer‑dated euro and dollar notes rather than maintaining a sizable short‑term Swiss‑franc exposure.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is almost entirely incorrect and fails to address the core facts of the question. (1) The original answer states that the company had a Swiss Franc note obligation of $299 million in 2023 that was completely removed by 2024. The LLM instead discusses a €3 billion (≈$3.2 billion) euro-denominated senior unsecured term-loan facility related to the Swedish Match acquisition, which is a different currency (euros, not Swiss Francs), a different amount ($3.2B vs $299M), and a different debt instrument (term loan vs Swiss Franc note). These numbers do not match the ground truth and are materially inaccurate. (2) The LLM references repayment of a 3-year tranche and retention of a 5-year €2.5B tranche, none of which appears in the ground truth and all of which are irrelevant to the Swiss Franc note. (3) The multi-hop reasoning is flawed: the LLM conflates foreign currency debt generally with Swiss Franc-specific exposure, and introduces entities (Swedish Match, euro tranches) not mentioned or implied in the original answer. (4) While the general theme of reducing foreign currency exposure is directionally plausible, the specific obligations, currencies, amounts, and instruments are all wrong. The answer fabricates details and fails to reflect the actual evolution of the Swiss Franc note. Thus, the correctness, quantitative accuracy, and qualitative accuracy are very low. Contextual relevance is slightly higher only because the topic is broadly related to foreign currency debt management, but the specifics are irrelevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1221,
        "completion_tokens": 424,
        "total_tokens": 1645
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How did Goldman Sachs' treatment of Non-Employee Director RSU Award Agreements evolve between the 2023 and 2024 10-K filings, particularly in terms of introduced or modified agreements?",
      "original_answer": "In the 2023 10-K filing, Goldman Sachs referenced the 'Form of Non-Employee Director RSU Award Agreement (pre-2015)' as Exhibit 10.8, indicating that the existing documentation pertained to agreements prior to 2015. In the 2024 filing, the company not only retained the reference to the pre-2015 RSU Award Agreement but also introduced a new exhibit titled 'Amendments to Certain Non-Employee Director Equity Award Agreements' as Exhibit 10.18, which was not present in the 2023 filing. This indicates that Goldman Sachs expanded its disclosures to include amendments to these agreements, suggesting a more comprehensive or updated treatment of non-employee director equity arrangements in 2024.",
      "llm_answer": "The 2024 10‑K shows that the company introduced new Non‑Employee Director RSU award agreements in its 2024 filing (Item 10.31‑10.34), which were not present in the 2023 filing, while the earlier “pre‑2015” RSU forms referenced in the 2023 filing (e.g., 10.19‑10.24) are no longer listed as current forms. Thus, the treatment evolved from relying on older pre‑2015 RSU templates to adopting updated, explicitly labeled Non‑Employee Director RSU agreements in the 2024 filing.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) The exhibit numbers cited (e.g., 10.31–10.34 and 10.19–10.24) are entirely incorrect and do not match the ground truth: in the 2023 filing, the relevant exhibit was 10.8 for the 'Form of Non-Employee Director RSU Award Agreement (pre-2015)', and in 2024, the new exhibit was 10.18 titled 'Amendments to Certain Non-Employee Director Equity Award Agreements'. The LLM falsely claims that the pre-2015 forms were removed and replaced with new RSU agreements, which contradicts the ground truth stating that the pre-2015 agreement was retained and a new amendments exhibit was added. (2) There are no numeric values (dates, dollar amounts, percentages) in the question or answer requiring calculation, but the exhibit numbers are treated as identifiers and must be accurate; the LLM’s made-up exhibit numbers fail this requirement. (3) The multi-hop reasoning is flawed: instead of recognizing that Goldman Sachs expanded disclosures by adding amendments while keeping the old form, the LLM incorrectly infers a full replacement of old forms with new ones, misrepresenting the evolution. (4) While the answer addresses the general topic of changes in RSU agreements, it misrepresents the nature of the change, making it mostly incorrect despite some contextual relevance to director equity agreements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1302,
        "completion_tokens": 383,
        "total_tokens": 1685
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How did PM's financial relationship with Swedish Match AB evolve between 2023 and 2024, particularly in terms of long-term debt obligations tied to the acquisition?",
      "original_answer": "In 2023, the long-term debt obligations related to the Swedish Match AB acquisition totaled $6,121 million, while in 2024, this amount decreased to $2,610 million. This indicates a significant reduction in the debt tied to the acquisition, suggesting that PM made substantial repayments or refinanced during the period. The decrease supports the idea that PM's financial dependency or exposure linked to the Swedish Match acquisition lessened over time.",
      "llm_answer": "Based on the provided financial disclosures, PMI's long-term debt tied to the Swedish Match acquisition was reduced from $6,121 million at the end of 2023 to $2,610 million at the end of 2024, reflecting a $3.5 billion repayment—specifically, a €3 billion (≈$3.2 billion) pre‑payment of the 3‑year tranche of the senior unsecured term loan facility in November 2024, leaving only the €2.5 billion (≈$2.6 billion) 5‑year tranche outstanding.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all numbers are correct: the long-term debt obligations are accurately reported as $6,121 million in 2023 and $2,610 million in 2024. The reduction of $3.511 billion is correctly implied (6,121 - 2,610 = 3,511), and the LLM provides additional precision by citing a $3.2 billion equivalent of €3 billion prepayment, which is reasonable given exchange rates in 2024. The remaining €2.5 billion (≈$2.6 billion) 5-year tranche is consistent with the outstanding balance. (2) The entity names (PMI, Swedish Match AB), time periods (2023 to 2024), and financial metric (long-term debt obligations tied to acquisition) are all correctly identified. (3) The reasoning is sound and enhances the ground truth by adding specific details about the debt structure (3-year vs 5-year tranches) and the November 2024 prepayment event, which supports the observed reduction. This reflects strong multi-hop synthesis from detailed financial disclosures. (4) While the original answer focuses on the high-level trend, the LLM adds valuable context about the mechanism of repayment, which goes beyond the ground truth but remains factually consistent. The only reason for not scoring a 10 is that the original answer does not mention the €3 billion prepayment or tranches, so while the added detail is plausible and relevant, it introduces specifics not confirmed in the ground truth, slightly exceeding the provided knowledge. However, this does not detract from correctness. Overall, the answer is factually robust, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1227,
        "completion_tokens": 445,
        "total_tokens": 1672
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How did BMY's strategic positioning around KRAS inhibition evolve from 2023 to 2024, particularly in relation to the acquisition of Mirati and the development trajectory of Krazati?",
      "original_answer": "In 2023, BMY had not yet acquired Mirati, and Krazati was not part of its portfolio. However, by 2024, BMY completed the acquisition of Mirati for $4.8 billion, gaining full rights to Krazati, a KRAS G12C inhibitor. Krazati had already received FDA approval for second-line NSCLC and was in clinical development for first-line NSCLC in combination with a PD-1 inhibitor. Additionally, in 2024, Krazati was also FDA approved for advanced or metastatic KRAS-mutated colorectal cancer with cetuximab, expanding its therapeutic footprint. This acquisition marked a significant evolution in BMY’s oncology strategy, positioning it more strongly in the KRAS inhibition space.",
      "llm_answer": "From 2023 to 2024, Bristol‑Myers Squibb’s strategic focus on KRAS inhibition shifted markedly with the $4.8 billion acquisition of Mirati Therapeutics (completed January 2024). The deal gave BMS exclusive rights to Mirati’s FDA/EMA‑approved KRAS‑G12C inhibitor Krazati and to the next‑generation PRMT5 degrader (MRTX1719), while also creating a contingent value right tied to FDA acceptance of the PRMT5 program. The acquisition was accounted for as a business combination, allocating roughly $2.0 billion to definite‑lived acquired product rights (including Krazati) and $3.5 billion to indefinite‑lived IPRD assets. This transaction built on earlier KRAS‑targeted efforts (e.g., Turning Point’s repotrectinib, Orum’s ORM‑6151) and positioned Krazati as a cornerstone of BMS’s oncology pipeline, with development now focused on first‑line NSCLC combinations and expanded KRAS‑mutant indications.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $4.8 billion acquisition of Mirati in January 2024 and that it gave BMS full rights to Krazati, a KRAS G12C inhibitor, which aligns with the ground truth. It also correctly notes Krazati's role in BMS's oncology strategy and its development in first-line NSCLC combinations. However, the LLM introduces several elements not present in the ground truth: (a) mention of MRTX1719 (PRMT5 degrader) and contingent value rights, which are not referenced in the original answer; (b) allocation of $2.0 billion to definite-lived product rights and $3.5 billion to IPRD assets — these specific accounting figures are not in the ground truth and may be fabricated or misattributed; (c) references to 'earlier KRAS-targeted efforts' like repotrectinib (from Turning Point) and ORM-6151 (from Orum), which are not mentioned in the original and may conflate unrelated assets. (2) Quantitative accuracy is partially compromised: while the $4.8 billion acquisition amount is correct, the breakdown into $2.0B and $3.5B is unsupported by the ground truth and appears to be an invention or hallucination. The January 2024 completion date is plausible but not confirmed in the original answer, which only states 'by 2024'. (3) Multi-hop reasoning is generally sound — the model connects the acquisition to strategic positioning in KRAS inhibition and links Krazati to clinical development in NSCLC. However, it overreaches by incorporating unverified assets and financial allocations, weakening the synthesis. (4) Despite these issues, the core of the answer — that BMS strengthened its KRAS strategy via the Mirati acquisition and now leads Krazati’s development in key indications — is factually aligned. The answer is contextually relevant and well-structured, but the inclusion of unsupported details reduces factual reliability, warranting a score of 7 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1400,
        "completion_tokens": 516,
        "total_tokens": 1916
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Goldman Sachs' disclosure and positioning of the Restricted Partner Compensation Plan evolved between 2023 and 2024, particularly in relation to newer compensation governance policies introduced during this period?",
      "original_answer": "In 2023, the Restricted Partner Compensation Plan was listed as Exhibit 10.3 and appeared early in the exhibit list, indicating a prominent position among compensation-related disclosures. By 2024, while the plan itself (still referenced as Exhibit 10.4) remained substantively unchanged, its relative placement shifted later in the exhibit list. Notably, in 2024, the firm introduced the Clawback Policy (Exhibit 10.1), signaling a new emphasis on compensation accountability and governance reforms. This suggests a strategic repositioning of compensation-related disclosures to prioritize risk mitigation and regulatory alignment alongside traditional partner compensation frameworks.",
      "llm_answer": "Between 2023 and 2024, Goldman Sachs updated its compensation governance disclosures by amending and restating the Restricted Partner Compensation Plan (Item 10.3 in the 2024 Form 10‑K) and adopting a new clawback policy effective December 1 2023 (Item 10.1 in the 2024 Form 10‑K). These revisions reflect the firm’s newer governance policies on partner compensation and risk‑management, positioning the plan within a broader framework of updated equity‑based and incentive‑compensation structures.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies. It incorrectly states that the Restricted Partner Compensation Plan was 'amended and restated' in 2024, while the ground truth indicates the plan was 'substantively unchanged.' This is a major factual error. Additionally, the LLM mislabels the exhibit number for the plan in 2024 as Item 10.3, when it was actually Exhibit 10.4 in the 2024 filing. The clawback policy is correctly identified as Exhibit 10.1 and effective December 1, 2023, which aligns with the ground truth. (2) The date 'December 1, 2023' is accurate and matches the introduction of the Clawback Policy. However, the exhibit number error (10.3 vs. 10.4) and the false claim of amendment undermine quantitative accuracy. (3) The reasoning partially captures the strategic shift in disclosure by noting the introduction of the clawback policy and its governance implications, but fails to mention the key point about the plan's repositioning later in the exhibit list, which is central to the evolution of disclosure. The multi-hop synthesis is incomplete—while it connects the clawback policy to governance reforms, it misses the structural change in exhibit ordering that signals shifting priorities. (4) The answer is contextually relevant and addresses the broader theme of compensation governance evolution, but due to significant factual and entity errors (exhibit numbers, amendment status), the correctness and qualitative accuracy scores are reduced. The core insight about strategic repositioning is implied but not accurately supported.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 432,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Philip Morris International's approach to heat-not-burn products evolved from 2022 to 2023, particularly in terms of product categorization and business integration?",
      "original_answer": "In 2022, Philip Morris described its heat-not-burn products as part of its Reduced-Risk Products (RRPs) portfolio, emphasizing their role in a smoke-free future and highlighting the IQOS Platform 1 device and various heated tobacco units (HTUs) such as HEETS and Marlboro HeatSticks. These products were positioned as a key part of the company's long-term strategy to replace traditional cigarettes. By 2023, the categorization had evolved, with heat-not-burn products now explicitly grouped under 'smoke-free products' alongside e-vapor and oral nicotine products, as well as wellness and healthcare offerings. Additionally, in 2023, PMI explicitly stated that its heat-not-burn products include licensed KT&G heat-not-burn products, indicating a broader integration and expansion of the product line beyond internally developed offerings.",
      "llm_answer": "From 2022 to 2023, PMI’s heat-not-burn (HTU) portfolio shifted from being grouped under “Other” or “Reduced‑risk products” to a clearly defined category within its smoke‑free segment, with dedicated shipment‑volume reporting (e.g., 125,263 million HTU units in 2023 vs. 109,169 million in 2022) and explicit discussion of “adjusted in‑market sales” for HTUs. This re‑categorization reflects tighter integration of HTUs into PMI’s core reporting structure, separating them from combustible cigarettes and positioning them alongside oral smoke‑free products (e.g., nicotine pouches) under the broader “smoke‑free products” umbrella, while also incorporating HTU performance metrics into adjusted sales growth figures (14.8 % adjusted in‑market growth for HTUs in 2023).",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the shift in categorization of heat-not-burn products from 2022 to 2023, noting their reclassification under 'smoke-free products' and integration into core reporting metrics. It accurately reflects the strategic evolution of PMI's business integration by highlighting dedicated shipment-volume reporting and inclusion in adjusted sales growth figures. However, it introduces specific quantitative data (e.g., 125,263 million HTU units in 2023, 109,169 million in 2022, and 14.8% adjusted in-market growth) that are not present in the original ground truth answer and cannot be verified against it. These numbers may be factually correct in external sources, but since they are absent from the provided ground truth, they represent unverifiable additions that undermine factual accuracy. (2) The quantitative accuracy is low because the numbers cited—while plausible—are not supported by the original answer, which contains no shipment volumes or growth percentages. This constitutes a significant deviation, as financial or operational metrics must align with the source. (3) The qualitative reasoning is sound: the model correctly infers a strategic shift in product categorization and deeper business integration, aligning with the ground truth’s emphasis on repositioning HTUs within a broader smoke-free portfolio. It also correctly notes the alignment with oral nicotine products and performance tracking, which parallels the original answer’s point about grouping with e-vapor and wellness offerings. However, it misses the key 2023 expansion to include licensed KT&G heat-not-burn products, a critical detail about product line broadening beyond internal development. (4) Contextual relevance is high—the response directly addresses the evolution in categorization and integration. Overall, the answer captures the conceptual shift well but fails on quantitative fidelity and omits a key entity-level detail (KT&G licensing), resulting in a partial correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1408,
        "completion_tokens": 545,
        "total_tokens": 1953
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How did Bristol-Myers Squibb's approach to business risk governance evolve between 2023 and 2024 in relation to SEC Consent Order compliance, particularly regarding the role of the business risk and disclosure group?",
      "original_answer": "In 2023, Bristol-Myers Squibb established the business risk and disclosure group specifically to comply with the SEC Consent Order. This included implementing a formal review and certification process for SEC filings, retaining an outside consultant to re-engineer accounting and financial reporting processes, and introducing a governance mechanism to escalate and resolve compliance-related questions. By 2024, the company had fully integrated this group into its ongoing compliance framework, with no indication of modifications or reductions in scope, suggesting that the group remained a central component of financial governance under the Consent. The continued reference to the group in 2024 filings indicates that the company maintained its enhanced risk governance structure without significant changes.",
      "llm_answer": "Based on the provided SEC Consent Order disclosures across the 2023 and 2024 10-K filings, Bristol-Myers Squibb's business risk governance approach evolved to strengthen compliance through formalized oversight mechanisms. Specifically, the company established a dedicated \"business risk and disclosure group\" (as mandated by the Consent Order) to enhance monitoring of sales practices to direct customers and ensure adherence to inventory limits under the settlement. The 2024 filing confirms this group operates as part of a broader governance process that includes escalation protocols for compliance concerns, regular monitoring of policy adherence, and refined procedures for estimating inventory levels using wholesaler data and external sources to maintain reasonable certainty in Consent compliance. This structural enhancement reflects a proactive evolution in risk management rather than a reactive measure.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains significant inaccuracies in the description of the business risk and disclosure group's purpose and functions, deviating from the ground truth. (1) What was correct: The LLM correctly identifies that the group was established in response to the SEC Consent Order and that it remained operational in 2024 as part of an ongoing governance structure. It also correctly notes formalized oversight, escalation protocols, and monitoring — elements consistent with the idea of enhanced governance. There are no numeric values in the question or answer, so quantitative accuracy is not applicable in a traditional sense, but all referenced processes and structures are at least plausibly aligned, earning full marks here. (2) However, the LLM mischaracterizes the group’s primary function. The ground truth states the group was created to improve SEC filing accuracy, implement a review/certification process for filings, re-engineer accounting/financial reporting with an outside consultant, and serve as a governance mechanism for compliance questions. In contrast, the LLM incorrectly frames the group’s focus around monitoring sales practices and inventory limits — which relates to operational compliance with distribution terms, not financial disclosure governance. This is a major factual misalignment. (3) Multi-hop reasoning is partially sound: the model connects the group’s creation to the Consent Order and tracks its continuation into 2024, showing evolution. However, it synthesizes incorrect contextual details about the group’s mandate, likely conflating it with other compliance activities under the Consent. (4) The answer is contextually relevant and well-structured, addressing the evolution between years and the role of the group, but the core factual error about the group’s purpose reduces correctness significantly. Thus, while the structure and intent of the answer are strong, the qualitative inaccuracy in entity function leads to a moderate score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1449,
        "completion_tokens": 540,
        "total_tokens": 1990
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has UNP's treatment of the relationship between its pension plan's expected return and its asset allocation mix evolved between 2023 and 2024?",
      "original_answer": "In 2023, UNP explicitly stated that the expected return on plan assets was based on the asset allocation mix, historical returns, and market conditions, and included a specific actual return of 6% for that year. By 2024, the language shifted to indicating that the expected return 'depends on' the asset allocation mix, with no explicit mention of historical returns or market conditions, and no disclosure of the actual return for 2024. This represents a shift from a more comprehensive explanation of factors influencing returns to a narrower focus on the asset allocation mix alone.",
      "llm_answer": "UNP's pension plan asset allocation strategy has evolved by shifting from a higher equity weighting (48% in 2022) to a more balanced mix of 24% equity and 75% debt in 2023, reflecting a deliberate de-risking approach that reached its target endpoint of 25% equity and 75% debt in 2023, with the 2024 target maintaining the same 20-30% equity and 70-80% debt ranges. This strategic shift, driven by a desire to reduce portfolio volatility, aligns with the plan's goal of achieving a long-term average return of 5.25% while increasing exposure to fixed-income securities as a de-risking measure since 2020.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect and fails to address the core of the question, which is about the evolution in UNP's *disclosure language* regarding how the expected return on pension assets relates to asset allocation between 2023 and 2024. Instead, the LLM focuses on changes in actual asset allocation percentages (e.g., 48% equity in 2022, 24% in 2023), which is not what the question asks. While some of these allocation figures may be factually accurate (e.g., shift toward de-risking), they are irrelevant to the specific inquiry about narrative treatment of expected return assumptions. (2) The quantitative details provided (e.g., 24% equity, 75% debt, 5.25% target return) are not contradicted by the ground truth, but they are not supported by the original answer either—this information is extraneous and not part of the ground truth. There are no calculations in the LLM answer, so no calculation errors, but the numbers cited do not pertain to the question. (3) The multi-hop reasoning is flawed: the model conflates asset allocation strategy evolution with disclosure policy evolution. The original answer highlights a shift in *language*—from citing multiple factors (asset mix, historical returns, market conditions) in 2023 to only mentioning dependence on asset mix in 2024—indicating reduced transparency. The LLM completely misses this linguistic and discursive shift, which is the central point. (4) Due to the fundamental misalignment with the question’s focus, the answer receives a low correctness score. The contextual relevance is moderate because it discusses UNP’s pension plan and asset allocation, but it does not address the relationship between expected return and asset allocation *in terms of disclosure rationale*, which is the essence of the query.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 489,
        "total_tokens": 1787
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How did BNY Mellon's disclosure approach to the Directors' Code of Conduct evolve between 2022 and 2023, particularly in terms of its accessibility and integration within corporate governance reporting?",
      "original_answer": "In 2022, BNY Mellon explicitly stated that the Directors' Code of Conduct was posted on its website and outlined its applicability to all directors. The document was referenced in the context of broader corporate governance disclosures, including Board Meetings and Committee Information. By 2023, the Directors' Code of Conduct was no longer just referenced but was specifically listed among the governance materials 'available on our website,' alongside key governance documents like the Corporate Governance Guidelines and committee charters. This evolution indicates a more structured and centralized approach to governance disclosures, with the Code being more directly tied to the company's overall governance framework in the 2023 filing.",
      "llm_answer": "Between 2022 and 2023, BNY Mellon’s disclosure of its Directors’ Code of Conduct became more integrated and accessible: the 2023 filing explicitly references the Code of Conduct and the Directors’ Code of Conduct as part of its corporate‑governance materials on the company’s website (pages 1 and 3), while the 2022 filing only mentioned the documents in a more generic “Available Information” note (page 4). Both years note that any amendments or waivers will be disclosed on the website, but the 2023 filing directly links to the specific PDF files for the Directors’ Code of Conduct, making the policy easier for investors to locate and review.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of BNY Mellon's disclosure approach to the Directors' Code of Conduct between 2022 and 2023. It accurately captures the increased integration and accessibility in 2023, noting that the Code was more explicitly referenced and directly linked on the website, which matches the ground truth's emphasis on a more structured and centralized disclosure approach. The mention of specific page numbers (e.g., pages 1, 3, and 4) adds precision, though these are not present in the ground truth and cannot be independently verified; however, they do not contradict it. The claim that the 2022 filing placed the Code in a 'generic Available Information note' is a slight recharacterization—the original answer says it was referenced in the context of broader governance disclosures, which is similar but not necessarily 'generic.' The LLM also correctly notes that both years committed to disclosing amendments or waivers online, which is consistent with the knowledge graph. It adds the detail about direct links to PDFs in 2023, which enhances accessibility and supports the conclusion of improved integration. This detail is plausible and consistent with the ground truth, though not explicitly stated. The answer is semantically equivalent in key aspects: improved accessibility, more prominent placement, and better integration within governance reporting. The reasoning is sound and reflects appropriate multi-hop synthesis across years and disclosure formats. No numerical inaccuracies are present (dates and document names are correct), so quantitative accuracy is perfect. Minor deduction in qualitative accuracy due to slight over-interpretation of 'generic' reference in 2022 and the addition of unverified page numbers. Overall, the answer is factually sound, relevant, and correctly infers the trend in disclosure evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 517,
        "total_tokens": 1879
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has Oracle's strategic positioning of Oracle Database evolved between 2023 and 2024 in terms of deployment flexibility and integration with engineered systems, and what does this indicate about the company's approach to cloud migration and hybrid IT environments?",
      "original_answer": "In 2023, Oracle emphasized the flexibility of running Oracle Database across multiple deployment models, including on-premise, Oracle Cloud, and multicloud environments, with specific offerings like Oracle Exadata Cloud@Customer and Oracle Roving Edge Infrastructure. These options were framed around enabling customers to securely run Oracle Database behind their firewalls while being managed by Oracle. By 2024, Oracle shifted toward deeper integration of Oracle Database within Oracle Engineered Systems, such as the Oracle Exadata Database Machine, which combines database, storage, operating system, and networking hardware into a single optimized platform. This system was highlighted as being available across on-premise, OCI cloud, and hybrid deployments. The evolution from flexible deployment of standalone database services to tightly integrated engineered systems suggests a strategic shift toward offering more holistic, performance-optimized solutions that align with enterprise needs for scalability, security, and simplified maintenance. This indicates a maturation of Oracle's cloud migration strategy, focusing not only on deployment flexibility but also on delivering comprehensive, high-performance infrastructure packages.",
      "llm_answer": "Oracle has expanded the deployment flexibility of its database platform by offering Oracle Database Enterprise Edition with options to run on‑premise, in OCI, or via hybrid models such as Exadata Cloud@Customer and OCI Dedicated Region, while simultaneously deepening integration with engineered systems (e.g., Exadata Database Machine) that combine database, storage, OS and networking into optimized, pre‑built appliances. This strategy signals a cloud‑first, hybrid‑IT approach: Oracle is positioning its database and middleware stack as a portable, self‑service foundation that can be consumed as a service on OCI, deployed in customer data centers, or integrated into multi‑cloud architectures, thereby accelerating cloud migration while preserving existing on‑premise investments.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies Oracle's deployment flexibility in both 2023 and 2024, referencing key offerings such as Exadata Cloud@Customer and OCI Dedicated Region (equivalent in function to Cloud@Customer and aligned with the hybrid deployment models mentioned in the original answer). The integration with engineered systems like the Exadata Database Machine is accurately described, including the bundling of database, storage, OS, and networking into optimized appliances. (2) There are no numeric values, dates, or financial figures in the question or answers that require verification—both responses focus on strategic positioning without specific numbers, so quantitative accuracy is not compromised. (3) The multi-hop reasoning is sound: the LLM synthesizes deployment models across time (2023 to 2024), connects them to engineered systems, and infers Oracle’s strategic intent regarding cloud migration and hybrid IT. The only minor gap is that the LLM does not explicitly frame the evolution as a shift *from* flexible standalone deployment *to* deeper integration in engineered systems—the progression is implied but not directly stated. The original answer emphasizes this evolution more clearly. (4) Despite this nuance, the LLM captures the core strategic implication: Oracle is enabling cloud migration while supporting on-premise investments through portable, integrated solutions. Wording differs but semantic meaning and factual content are equivalent. Contextual relevance is excellent as all parts of the question are addressed with accurate, meaningful information.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1537,
        "completion_tokens": 451,
        "total_tokens": 1989
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has the implementation of the formal review and certification process of annual and quarterly SEC reports evolved between 2023 and 2024, particularly in terms of compliance monitoring and governance procedures?",
      "original_answer": "In 2023, the company established a formal review and certification process of SEC filings as part of the Consent agreement, which included governance procedures to escalate potential compliance concerns to appropriate management levels and regular monitoring of compliance. By 2024, the company continued to emphasize the implementation of these governance procedures, noting that compliance with the policy was consistently monitored and that the process was integrated into company-wide sales policies to ensure adherence to inventory and sales limitations. The evolution reflects a shift from initial implementation in 2023 to sustained enforcement and integration into broader operational frameworks in 2024.",
      "llm_answer": "The formal review and certification process for annual and quarterly SEC reports was established as part of the company’s compliance measures under the 2004 SEC Consent Order. This process includes a governance framework to monitor and resolve compliance questions, as well as documented procedures to ensure adherence to sales-limiting policies. There is no indication of significant changes to this process between 2023 and 2024, as the described structure remains consistent across both years.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and fails to correctly represent the evolution of the formal review and certification process between 2023 and 2024. (1) It incorrectly states that the process was established under a '2004 SEC Consent Order', which is factually wrong—the ground truth specifies that the process was established in 2023 as part of a Consent agreement, not in 2004. This major date error undermines the entire response. (2) The quantitative accuracy is very low because the key year (2023 vs 2004) is incorrect, and there is no mention of the actual evolution from initial implementation in 2023 to integration into broader operational frameworks in 2024. (3) The reasoning is flawed: the model asserts there were 'no significant changes' between 2023 and 2024, which directly contradicts the ground truth that describes a clear evolution from implementation to sustained enforcement and integration into sales policies. The multi-hop synthesis fails—instead of comparing the two years' developments, it misattributes the origin of the process and misses the progression entirely. (4) While the answer touches on governance and compliance monitoring (hence partial contextual relevance), it does not address the actual timeline or evolution, making the response largely incorrect. Semantic equivalence is not achieved due to core factual and temporal errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 385,
        "total_tokens": 1704
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Philip Morris International's approach to heat-not-burn products evolved from 2022 to 2023, particularly in terms of their market positioning and product categorization?",
      "original_answer": "In 2022, Philip Morris International (PMI) positioned heat-not-burn products as part of its broader Reduced-Risk Products (RRPs) portfolio, emphasizing their potential to present less harm to smokers who switch from traditional cigarettes. These products, including the Platform 1 device and its consumables, were described as being in various stages of development, scientific assessment, and commercialization. By 2023, PMI had refined its categorization, explicitly including heat-not-burn products within the smoke-free product segment, alongside e-vapor and oral nicotine products. Additionally, PMI began including licensed KT&amp;G heat-not-burn products in its portfolio, indicating a broader market approach and potential expansion of partnerships or offerings. This evolution shows a strategic shift from internal development focus to a more integrated and commercialized product positioning.",
      "llm_answer": "From 2022 to 2023, Philip Morris International expanded its heat-not-burn (HNB) portfolio and repositioned it as a core growth pillar within its smoke‑free product strategy. The company increased adjusted in‑market sales of HTUs by 14.8% (driven by 14.7% shipment growth) and highlighted HNB as a key contributor to its “total market” volume, while also reporting double‑digit growth in oral products following the Swedish Match acquisition. This reflects a clear shift toward categorizing HNB and related reduced‑risk products as distinct, high‑growth segments separate from traditional combustible tobacco.",
      "correctness_score": 5,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer includes specific quantitative claims—14.8% growth in adjusted in-market sales of HTUs and 14.7% shipment growth—that are not present in the original ground truth and cannot be verified from the provided context. These numbers appear fabricated or misattributed, severely undermining factual accuracy. The original answer does not include any numerical data, so introducing such figures without support constitutes a major error. (2) There is no mention in the ground truth of the Swedish Match acquisition contributing to double-digit growth in oral products in this context, nor is there a direct link between that acquisition and HNB performance in 2023. While PMI did acquire Swedish Match, this detail is used here to support a narrative not present in the original answer, introducing irrelevant information. (3) The qualitative shift described—positioning heat-not-burn as a core growth pillar and part of a broader smoke-free strategy—aligns partially with the original answer’s description of re-categorizing HNB products under the smoke-free segment by 2023. The mention of moving away from combustible tobacco is consistent with PMI's overall strategy, but the LLM overreaches by implying a complete strategic separation not explicitly stated. (4) The original answer highlights a key evolution: inclusion of licensed KT&G products in the portfolio, signaling expanded partnerships. This critical point is entirely missing in the LLM response, representing a significant omission in completeness. Additionally, the original emphasizes a shift from internal development to integrated commercialization, which the LLM does not capture. While the LLM captures the general direction of strategic elevation, it fails on key qualitative nuances and introduces unsupported quantitative claims, leading to a partial correctness score. Contextual relevance is high because the answer addresses market positioning and categorization trends, even if inaccurately.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1385,
        "completion_tokens": 537,
        "total_tokens": 1922
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Oracle's strategic positioning of Oracle Database evolved between 2023 and 2024 in terms of deployment flexibility and integration with other Oracle technologies?",
      "original_answer": "In 2023, Oracle emphasized the deployment flexibility of Oracle Database across cloud-based, on-premise, or other IT environments, highlighting its perpetual licensing model and the company's strategy to provide customer choice. By 2024, Oracle Database's role had evolved to become a foundational component within broader engineered systems, such as Oracle Exadata Database Machine, which integrates the database with storage, operating system software, and hardware components for optimized performance. This shift indicates a move toward deeper integration with Oracle's infrastructure technologies, positioning Oracle Database not just as a standalone product but as a core element of Oracle Engineered Systems, available in on-premise, cloud (OCI), and hybrid cloud deployments.",
      "llm_answer": "Oracle’s strategic positioning of its Oracle Database has shifted markedly toward greater deployment flexibility and tighter integration with its broader cloud and engineered‑system portfolio between 2023 and 2024.  The 2024 filing emphasizes that customers can now run Oracle Database in a wide range of environments—including on‑premise, Oracle Cloud Infrastructure (OCI) public regions, OCI Dedicated Region, Oracle Exadata Cloud@Customer, and sovereign‑cloud or edge deployments—while leveraging automated, self‑driving capabilities such as Autonomous Database to simplify operations and reduce labor costs.  This evolution reflects Oracle’s broader push to offer choice across hybrid and multicloud architectures, integrate tightly with its engineered hardware (Exadata, SPARC/x86 servers, storage, and industry‑specific appliances), and embed the database within its OCI services and middleware stack, thereby delivering a more cohesive, flexible, and cloud‑native experience.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution in Oracle's strategic positioning of Oracle Database from 2023 to 2024, noting increased deployment flexibility and deeper integration with Oracle technologies. While the original answer emphasizes the shift toward Oracle Engineered Systems (e.g., Exadata) as foundational, the LLM answer expands on this by specifying deployment options like OCI Dedicated Region, Cloud@Customer, and sovereign/edge deployments—details consistent with Oracle’s 2024 direction. (2) There are no numeric values, dates, or financial figures in the question or answers, so quantitative accuracy is not applicable in a traditional sense; however, all referenced technologies and deployment models are correctly named and contextually accurate, earning full marks. (3) The multi-hop reasoning is sound: the LLM synthesizes the shift in strategy (from standalone/perpetual licensing in 2023 to integrated engineered systems in 2024) and correctly infers that this reflects a broader cloud and hybrid strategy. The mention of Autonomous Database and self-driving capabilities adds relevant context not in the original answer but does not contradict it—rather, it enriches the explanation within plausible bounds. (4) The only minor gap is that the LLM downplays the 2023 emphasis on perpetual licensing and customer choice, focusing more on 2024 advancements. This results in a slight omission but does not impair the overall correctness. Semantic equivalence is maintained, and the answer is fully relevant to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1447,
        "completion_tokens": 439,
        "total_tokens": 1887
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has BMY's strategic relationship with Krazati evolved from 2023 to 2024, and what specific financial commitments were made in 2024 that reflect this evolution?",
      "original_answer": "In 2023, Krazati was mentioned as part of BMY's oncology portfolio, demonstrating a strategic fit into their offerings. By 2024, BMY had acquired Mirati for $4.8 billion, obtaining the rights to Krazati, which had received FDA and EMA approvals for second-line NSCLC and was in clinical development for first-line NSCLC. Additionally, BMY committed $1.0 billion in contingent value rights tied to the development of PRMT5 Inhibitor, further signaling long-term investment in the acquired assets.",
      "llm_answer": "From 2023 to 2024 BMY’s strategic relationship with Krazati evolved from a simple royalty‑sharing arrangement to a full‑scale acquisition. In 2023 the company received tiered royalties on Krazati sales (10‑25 % of net sales) and also earned contingent milestone income from the product’s development. By early 2024 BMY completed a $4.8 billion cash acquisition of Mirati, the owner of Krazati, paying $58 per share plus a $12‑per‑share contingent value right. The transaction was accounted for as a business combination, with $4.9 billion of total consideration allocated to identifiable assets and goodwill, and it triggered an $12.1 billion Acquired IPRD charge for the newly acquired product rights. This deal marked the shift from earning royalties on Krazati to owning the product outright and making substantial cash and contingent commitments to its development and commercialization.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core evolution of BMY's relationship with Krazati—from indirect involvement to full ownership via the Mirati acquisition—and correctly identifies the $4.8 billion acquisition in 2024, which aligns with the ground truth. However, significant quantitative inaccuracies undermine the correctness. The ground truth states BMY made a $1.0 billion contingent value rights (CVR) commitment tied to the PRMT5 inhibitor, but the LLM incorrectly claims a $12-per-share CVR (which may equate to ~$1.2 billion based on Mirati's share count, though not explicitly verified) and mischaracterizes it as part of the Krazati acquisition rather than a separate commitment to PRMT5 development. Additionally, the LLM introduces a $12.1 billion Acquired IPRD charge, which is not mentioned in the ground truth and cannot be verified; this is a major factual overreach. The claim of a 'royalty-sharing arrangement' and 'tiered royalties (10–25%)' in 2023 is not supported by the original answer, which only states Krazati was part of BMY’s portfolio via strategic fit—not revenue-sharing. This misrepresents the pre-acquisition relationship. While the acquisition timing and strategic shift are correctly framed, the financial details are partially fabricated or misattributed. The reasoning is logically structured and contextually relevant, showing understanding of multi-hop progression (strategic interest → acquisition → financial commitment), but the synthesis includes unverified financial figures and misattributes incentives. Semantic equivalence fails on key financial commitments due to incorrect numbers and invented details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 447,
        "total_tokens": 1797
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has the treatment or status of the 6.244% Fixed-to-Floating Rate Normal Preferred Capital Securities of Mellon Capital IV evolved between 2022 and 2023 based on BK's SEC filings?",
      "original_answer": "In 2022, the 6.244% Fixed-to-Floating Rate Normal Preferred Capital Securities of Mellon Capital IV were introduced as securities registered under Section 12(b) of the Act and were listed on the New York Stock Exchange under the trading symbol BK/P, fully and unconditionally guaranteed by The Bank of New York Mellon Corporation. In 2023, the same securities remained registered under Section 12(b) of the Act, retained the same trading symbol BK/P, and continued to be listed on the New York Stock Exchange with the same guarantee structure. Therefore, there was no change in the treatment or status of these securities between the two years.",
      "llm_answer": "Based on the provided SEC filing excerpts, the treatment of the 6.244% Fixed-to-Floating Rate Normal Preferred Capital Securities of Mellon Capital IV (trading as BK/P on the NYSE) has remained unchanged between 2022 and 2023. The securities continue to be fully and unconditionally guaranteed by The Bank of New York Mellon Corporation, as stated in the 2023 Form 10-K (page 1) and referenced in the 2022 filing (page 1). No modifications to the terms, structure, or regulatory treatment of these securities are indicated in the disclosed risk factors or corporate disclosures for either year. The only evolution noted is the continued emphasis on the Parent company's dependence on dividends from subsidiaries and capital planning constraints (2023 page 5), but this does not alter the securities' terms.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and semantically equivalent to the ground truth. (1) All key facts are accurately reported: the 6.244% Fixed-to-Floating Rate Normal Preferred Capital Securities of Mellon Capital IV are correctly identified, with the correct trading symbol BK/P, listing on the NYSE, and full guarantee by The Bank of New York Mellon Corporation. (2) There are no numeric inaccuracies—percentages, years (2022 and 2023), and security terms are correctly stated. (3) The multi-hop reasoning is sound: the model correctly synthesizes information across two years of SEC filings (2022 and 2023 Form 10-Ks) and concludes that there was no change in status or treatment, which aligns with the ground truth. (4) The answer addresses all parts of the question—status, treatment, and evolution over time—and correctly notes that while broader capital planning context is emphasized in 2023, it does not affect the securities’ terms. Wording differs slightly but meaning is preserved. All evaluation dimensions are satisfied at the highest level.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 300,
        "total_tokens": 1671
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has the capacity and utilization of PMI's short-term credit arrangements changed from 2022 to 2023, and what does this shift suggest about their near-term liquidity posture?",
      "original_answer": "The capacity of PMI's short-term credit arrangements increased from $1.9 billion at the end of 2022 to $2.7 billion at the end of 2023, while the actual utilization decreased slightly from $295 million to $283 million. This indicates that PMI has expanded its available liquidity buffer without increasing its drawdown, suggesting a more conservative approach to short-term financing and working capital management.",
      "llm_answer": "From 2022 to 2023, PMI’s short‑term credit capacity expanded markedly—committed revolving facilities rose from roughly $1.9 billion to $2.7 billion, and the total available short‑term credit lines grew from about $1.9 billion to $2.7 billion, while outstanding borrowings under these arrangements stayed relatively flat (≈$295 million in 2022 versus $283 million in 2023). This increase in available liquidity, coupled with the suspension of its $7 billion share‑repurchase program in mid‑2022, indicates that PMI is prioritizing financial flexibility and preserving cash for strategic purposes rather than aggressive buybacks, reflecting a more cautious near‑term liquidity posture.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the increase in PMI's short-term credit capacity from $1.9 billion in 2022 to $2.7 billion in 2023 and the decrease in utilization from $295 million to $283 million, matching the ground truth exactly. These figures are repeated with slight rewording (e.g., 'committed revolving facilities' and 'total available short-term credit lines'), but the numbers are accurate. (2) All numeric values are correct and consistent with the original answer; no calculation errors are present. Format variations (e.g., $1.9 billion vs $1.9 billion) are acceptable and do not affect accuracy. (3) The reasoning is sound and adds contextual insight—mentioning the suspension of the $7 billion share repurchase program—which is factually accurate and strengthens the conclusion about PMI’s more cautious liquidity posture. While this detail is not in the ground truth, it is a valid supporting point and does not contradict the core answer. The multi-hop synthesis of capacity, utilization, and strategic financial behavior is logical and well-supported. (4) The answer fully addresses all parts of the question: changes in capacity and utilization, and the implication for near-term liquidity. The only minor deviation is the inclusion of extra context (share buyback suspension), which enhances rather than detracts from the answer. Thus, the answer is semantically equivalent and factually correct, warranting a high score. Quantitative accuracy is perfect; qualitative and contextual scores are high, with a small deduction in qualitative for introducing a non-ground-truth element, though it is accurate and relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 452,
        "total_tokens": 1734
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has Oracle's positioning of the Autonomous Database evolved between 2023 and 2024, particularly in terms of integration with other cloud services and automation capabilities?",
      "original_answer": "In 2023, Oracle positioned the Autonomous Database as part of its broader Oracle Cloud Infrastructure (OCI) offerings, emphasizing its automated database operations and the ability to run in cloud, on-premise, or hybrid environments. It was described as a service that Oracle runs, manages, upgrades, and supports on behalf of the customer, with a focus on reducing IT process time and resources. By 2024, Oracle expanded its positioning to highlight deeper integration with other Oracle Cloud services, such as Java Cloud and Oracle APEX low-code service, and emphasized open interfaces and native machine learning capabilities. The 2024 filing also introduced a stronger focus on automation powered by machine learning, including diagnostics, fault prediction, error handling, and automatic threat detection. Additionally, 2024 emphasized the Autonomous Database's role in enabling modern cloud-native application development and analytics, including data lake houses and real-time analysis of transactional data.",
      "llm_answer": "Oracle has expanded the Autonomous Database’s integration with its broader cloud ecosystem and deepened its automation capabilities between 2023 and 2024.  In the 2024 filing the company emphasizes tighter coupling of Autonomous Database with OCI services such as Java Cloud, APEX, and OCI AI, and highlights new deployment options—including Exadata Cloud@Customer, OCI Dedicated Region, and Sovereign Cloud—that enable customers to run the database both in public‑cloud regions and within their own data centers while still being managed by Oracle.  The narrative also underscores that Autonomous Database now automates a fuller set of database administration tasks (patching, scaling, security, backup, threat detection) and leverages machine‑learning‑driven optimization across analytics, transaction processing, and hybrid‑cloud workloads, positioning it as a more end‑to‑end, self‑driving database service within Oracle’s cloud portfolio.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures Oracle's evolution in positioning the Autonomous Database from 2023 to 2024, noting expanded integration with Oracle Cloud services such as Java Cloud and APEX, which matches the original answer. It adds OCI AI, which is consistent with the 2024 emphasis on machine learning and automation, even if not explicitly named in the ground truth. (2) There are no numeric values, dates, or financial figures in the question or answers, so quantitative accuracy is not applicable in a traditional sense—however, the years 2023 and 2024 are correctly referenced, and no incorrect data points are introduced. (3) The multi-hop reasoning is sound: the answer synthesizes changes in integration and automation across time, correctly identifying the shift toward deeper cloud service integration and enhanced automation. It also accurately reflects deployment flexibility (e.g., Exadata Cloud@Customer, OCI Dedicated Region, Sovereign Cloud), which is consistent with the hybrid/on-premise emphasis in 2023 and expanded managed offerings in 2024. (4) The LLM adds some detail not in the original (e.g., specific deployment models, mention of OCI AI), but these are plausible extensions of the ground truth and do not contradict it. The only minor shortcoming is that the original answer highlights 'open interfaces' and 'data lake houses' as new 2024 emphases, which the LLM answer omits. Otherwise, the core facts, entities, and reasoning are correct and semantically equivalent. Hence, a score of 9 is justified—excellent accuracy with minor completeness gap.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1497,
        "completion_tokens": 448,
        "total_tokens": 1946
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How did GM's financial relationship with Ultium Cells Holdings LLC evolve between 2023 and 2024, particularly in terms of its capital involvement and strategic positioning?",
      "original_answer": "In 2023, GM's relationship with Ultium Cells Holdings LLC was characterized by contingent capital commitments, with a committed contribution of $0.8 billion, and the entity was classified as a variable interest entity (VIE) where GM lacked voting control. By 2024, GM's involvement evolved into a more direct investment of $0.7 billion, indicating a shift from a potential future obligation to a realized investment stake. This transformation suggests a strategic realignment, providing GM with potentially greater influence over Ultium Cells' operations while stabilizing its financial exposure.",
      "llm_answer": "Between 2023 and 2024, GM’s capital involvement with Ultium Cells Holdings LLC shifted from active equity investment to a reduced, noncontrolling stake. In 2023, GM invested $0.7 billion in Ultium Cells, but by 2024 it recorded only a $0.7 billion cash outflow for that investment and disclosed no further equity commitments, reflecting a strategic pull‑back. The company’s exposure to Ultium is now limited to a modest, noncontrolling interest and a maximum loss exposure of about $3.5 billion, down from prior periods, indicating a less dominant financial role for GM in the joint venture.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2023 GM had a *contingent* capital commitment of $0.8 billion to Ultium Cells Holdings LLC, not an actual investment of $0.7 billion as stated in the LLM answer. In 2024, GM made a realized investment of $0.7 billion, which the LLM incorrectly presents as a 2023 investment. The LLM reverses the timeline and misrepresents the nature of the capital involvement—portraying a strategic pullback when the truth indicates a strategic deepening via transition from contingent obligation to direct investment. (2) Quantitatively, the $0.7 billion figure appears in both years but is misattributed to the wrong year and context. The $0.8 billion 2023 commitment is entirely omitted. The mention of a $3.5 billion maximum loss exposure is not in the original answer and cannot be verified against the provided ground truth, introducing unverified data. (3) The multi-hop reasoning is flawed: the model fails to correctly synthesize the evolution from VIE status with contingent commitment (2023) to direct investment (2024), instead asserting a reduction in stake and strategic retreat, which contradicts the ground truth's narrative of increased control and strategic alignment. (4) Contextual relevance is moderate—the answer addresses GM’s financial relationship with Ultium Cells and attempts to discuss capital involvement and strategy—but the incorrect facts and reversed logic severely undermine its validity. The conclusion about a 'strategic pull-back' is directly opposite to the ground truth's indication of greater influence and stabilization. Overall, major factual and logical errors result in a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 471,
        "total_tokens": 1774
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has the financial impact of the Litigation Management Deed evolved between 2022 and 2024, particularly in terms of the amount of as-converted value released and the number of series A preferred shares issued during the anniversary releases?",
      "original_answer": "In 2022, as part of the sixth anniversary release assessment required by the Litigation Management Deed, Visa released $3.5 billion of as-converted value and issued 176,655 shares of series A preferred stock. In 2024, during the eighth anniversary release, the company released $2.7 billion of as-converted value and issued 99,264 shares of series A preferred stock. This indicates a decrease in both the value released and the number of shares issued, suggesting a reduction in the financial burden associated with the VE territory covered litigation over time.",
      "llm_answer": "The financial impact of the Litigation Management Deed shows that the as‑converted value released increased from $3.5 billion in the 2022 sixth‑anniversary release to $2.7 billion in the 2024 eighth‑anniversary release, while the number of Series A preferred shares issued rose from 176,655 in 2022 to 99,264 in 2024.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors in both direction and magnitude of changes. It incorrectly states that the as-converted value 'increased' from $3.5 billion in 2022 to $2.7 billion in 2024, when in fact it decreased. Similarly, it claims the number of shares 'rose' from 176,655 to 99,264, which is false — 99,264 is fewer than 176,655, so the number of shares issued decreased. The actual values for 2022 ($3.5B, 176,655 shares) and 2024 ($2.7B, 99,264 shares) are correctly cited in isolation, but their interpretation is reversed. (2) Quantitative accuracy is partially correct: the dollar amounts and share counts match the ground truth numerically, but the comparative statements (increase vs decrease) are wrong, undermining the core of the analysis. (3) The multi-hop reasoning fails because the model misinterprets the trend over time — a key part of the question asking how the financial impact evolved. Instead of recognizing a reduction in financial burden, it falsely implies an increase. This indicates flawed synthesis across the two time points. (4) Contextual relevance is high because the answer addresses the right entities (Litigation Management Deed, as-converted value, Series A preferred shares), time periods (2022 sixth anniversary, 2024 eighth anniversary), and structure of the releases. However, due to the reversal of trends, the conclusion is factually incorrect, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1244,
        "completion_tokens": 404,
        "total_tokens": 1648
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How did the financial and strategic relationship between 3M and the Aearo Entities evolve between 2023 and 2024, particularly in terms of litigation impact and business segment adjustments?",
      "original_answer": "In 2023, 3M reconsolidated the Aearo Entities following the dismissal of their bankruptcy filings, lifting the stay on litigation related to Combat Arms Earplugs and entering into the CAE Settlement to resolve existing and future claims. This reconsolidation had an immaterial income statement impact. By 2024, the Aearo Entities were referenced in the context of divestiture and acquisition impacts in the Transportation and Electronics segment, where their deconsolidation in 2022 and reconsolidation in 2023 were each reflected separately as divestiture and acquisition effects. This indicates a shift from litigation-focused involvement in 2023 to a more strategic financial treatment in 2024.",
      "llm_answer": "Between 2023 and 2024, the financial and strategic relationship between 3M and the Aearo Entities evolved significantly amid ongoing litigation and restructuring. Following the Aearo Entities' Chapter 11 bankruptcy filing in July 2022, 3M had initially deconsolidated them, but reconsolidated in Q2 2023 after a court dismissed the bankruptcy case in June 2023, leading to a reintegration of Aearo-related liabilities into 3M's consolidated financial statements. This reconsolidation impacted corporate special items, which saw increased litigation-related costs in 2023—primarily due to the $4.2 billion pre-tax charge tied to the CAE Settlement of the Combat Arms Earplugs litigation—though these costs decreased in 2024 as settlement progress advanced and participation thresholds were met. The CAE Settlement, finalized in August 2023 and implemented through 2024 with payments totaling $250 million in December 2023 and $253 million in January 2024, marked a strategic shift from prolonged litigation toward resolution, reducing uncertainty and allowing 3M to adjust its segment reporting and liability accruals accordingly. Concurrently, environmental liabilities related to Aearo and PFAS matters continued to be assessed, but the reconsolidation and settlement activity marked a pivotal transition in how 3M now manages and reports exposure from these legacy matters within its Corporate and Safety and Industrial segments.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core evolution of the 3M-Aearo relationship between 2023 and 2024 with strong qualitative reasoning and contextual relevance. It correctly identifies the reconsolidation of Aearo in 2023 after dismissal of the bankruptcy, links it to the CAE Settlement, and notes the shift from litigation to resolution. However, there are significant quantitative inaccuracies: the $4.2 billion pre-tax charge and specific payment amounts of $250M and $253M are not present in the ground truth and cannot be verified from the provided knowledge graph, making these hallucinated figures. The ground truth states the reconsolidation had an 'immaterial income statement impact,' which contradicts the emphasis on large charges affecting corporate special items. Additionally, while the LLM mentions Q2 2023 reconsolidation and August 2023 settlement finalization, the original answer does not specify exact months, so these details may be over-specified. The answer correctly identifies the strategic shift in 2024 toward financial treatment in the Transportation and Electronics segment due to prior deconsolidation and reconsolidation effects, aligning with the ground truth's mention of divestiture/acquisition impacts. The multi-hop reasoning is sound—linking bankruptcy dismissal, reconsolidation, litigation settlement, and segment reporting—but the inclusion of unsupported financial figures reduces quantitative accuracy. Despite this, the overall narrative aligns semantically with the transition from litigation focus to strategic financial management, warranting a 7 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1542,
        "completion_tokens": 437,
        "total_tokens": 1979
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has the financial treatment or structure of Class C Common Stock evolved between 2022 and 2024, particularly in terms of its relationship to other stock classes and its earnings per share performance?",
      "original_answer": "In 2022, Class C Common Stock was described in the context of its voting rights and potential influence on corporate actions, particularly in mergers or strategic decisions, with an emphasis on how its holders—typically financial institution clients—might have divergent interests from Class A Common Stockholders. By 2024, Class C Common Stock had a significantly higher earnings per share ($33.17 basic EPS and $33.13 diluted EPS) compared to Class A ($8.29 basic EPS and $8.28 diluted EPS), indicating a shift in its financial performance relative to other stock classes, even though its governance role appeared unchanged.",
      "llm_answer": "Between 2022 and 2024, Class C Common Stock remained freely tradable with no transfer restrictions, while Class B Common Stock underwent structural changes, including a 2024 exchange offer that converted 241 million Class B-1 shares into approximately 120 million Class B-2 shares and 48 million Class C shares, retiring the exchanged Class B-1 shares. This exchange did not directly impact Class C's earnings per share (EPS) performance, as Class C's EPS was unaffected by the conversion rate adjustments tied to Class B-1 exchanges. However, the broader capital structure changes, including the conversion of Series B and C preferred stock (which participates in EPS calculations via as-converted share counts), could indirectly influence EPS through adjustments to the equivalent Class A common stock share count, as noted in the 2024 fiscal year data showing minimal reduction in equivalent Class A shares (5–6 million). Thus, while Class C's standalone EPS performance was unchanged, its relationship to other classes evolved through the exchange program and the ongoing conversion dynamics of preferred stock affecting overall diluted share counts.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect and fails to align with the ground truth. The original answer states that Class C Common Stock had significantly higher EPS in 2024 ($33.17 basic, $33.13 diluted) compared to Class A ($8.29 basic, $8.28 diluted), which is a central factual point. The LLM answer does not mention these EPS figures at all, instead focusing on structural changes involving Class B stock and preferred stock conversions, which are not referenced in the ground truth. (2) There are no verifiable correct numbers from the ground truth in the LLM response. The 241 million Class B-1 shares, 120 million Class B-2, 48 million Class C, and 5–6 million reduction in equivalent Class A shares are all absent from the original answer and cannot be confirmed as accurate. These figures appear to be hallucinated or drawn from unrelated data. (3) The multi-hop reasoning is flawed. The question asks about the evolution of Class C Common Stock’s financial treatment and EPS performance relative to other classes. The LLM diverts to a detailed discussion of Class B exchanges and preferred stock conversion mechanics, which are not mentioned in the ground truth and do not support the required comparison. It fails to report the key fact that Class C outperformed Class A in EPS by a large margin in 2024. (4) The contextual relevance is moderate because the answer discusses stock classes and capital structure, which are relevant topics, but it misses the core financial performance data and misdirects the analysis. The qualitative accuracy is low due to incorrect entities (focus on Class B and preferred stock) and faulty reasoning. Quantitative accuracy is very low because no correct numbers from the ground truth are present, and unsupported figures are introduced. The correctness score is 3 because the answer touches on structural aspects of stock classes but completely misses the key EPS comparison that defines the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1459,
        "completion_tokens": 529,
        "total_tokens": 1988
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has Qualcomm's involvement in the development and commercialization of ADAS/AD technology evolved from fiscal 2022 to fiscal 2024, based on the specific changes in their strategic activities and revenue categorization?",
      "original_answer": "In fiscal 2022, Qualcomm was actively investing in and developing ADAS/AD technologies as part of its broader innovation and strategic investment initiatives, particularly through its QSI segment and Qualcomm Ventures, with an emphasis on expanding opportunities for its technologies beyond mobile handsets. By fiscal 2024, Qualcomm's engagement had evolved from development to commercialization, as evidenced by the explicit inclusion of ADAS/AD under revenue streams categorized under 'automotive' products. This indicates that ADAS/AD transitioned from a technology under development and investment in 2022 to a revenue-generating product line by 2024.",
      "llm_answer": "From fiscal 2022 to fiscal 2024, Qualcomm’s ADAS/AD strategy shifted from a broader, diversified portfolio of advanced‑driver‑assistance and autonomous‑driving technologies to a more focused emphasis on automotive‑related semiconductor revenue. In the 2022 filing, ADAS/AD was mentioned only in the context of general R&D investments and “new modem and multimedia technologies,” whereas by fiscal 2024 the company explicitly reports automotive revenue—including ADAS/AD—under the “Automotive” revenue stream in QCT, growing from $1.5 billion in 2022 to $2.9 billion in 2024. This reflects a deliberate re‑categorization of ADAS/AD‑related sales from a peripheral, early‑stage investment (QSI) toward a core, revenue‑generating segment, as evidenced by the increased share of automotive revenue in total QCT sales and the dedicated discussion of ADAS/AD in the 2024 “Revenue by Application” table. Consequently, Qualcomm’s commercialization of ADAS/AD moved from exploratory, cross‑industry R&D to a targeted, high‑growth automotive business line.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly captures the evolution of Qualcomm's ADAS/AD involvement from development in fiscal 2022 to commercialization by fiscal 2024, aligning with the ground truth's core narrative. It accurately identifies the shift from R&D and strategic investment (QSI/Qualcomm Ventures) to revenue generation under the Automotive segment in QCT. The qualitative reasoning is strong: it notes the re-categorization of ADAS/AD from peripheral R&D to a core business line and references the 'Revenue by Application' table in 2024, which supports commercialization. However, the quantitative accuracy is compromised by introducing specific revenue figures—$1.5 billion in 2022 and $2.9 billion in 2024—that are not present in the original answer (ground truth). The ground truth confirms the re-categorization and commercialization but does not provide any dollar amounts or growth metrics. These numbers may be factually correct in external context, but since they are absent from the ground truth knowledge graph used for evaluation, their inclusion constitutes a hallucination or unsupported precision, lowering quantitative accuracy. There is no verification that these figures were extracted from actual filings in the knowledge graph. Despite this, the answer remains contextually relevant and semantically aligned in direction and logic. The multi-hop synthesis—linking early-stage investment in 2022 to explicit revenue categorization in 2024—is sound and correctly infers strategic progression. Thus, while the core conclusion is valid and well-reasoned, the unsupported numerical claims prevent a higher correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1444,
        "completion_tokens": 444,
        "total_tokens": 1889
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How has Visa's U.S. Retrospective Responsibility Plan evolved between 2022 and 2024, particularly in terms of its mechanisms for addressing liability in covered litigation, and what does this evolution suggest about the company's approach to managing litigation risk?",
      "original_answer": "In 2022, Visa's U.S. Retrospective Responsibility Plan was described as a mechanism to address monetary liabilities from settlements or final judgments in U.S. covered litigation, utilizing a U.S. litigation escrow account, though the accrual for liabilities could differ from the escrow balance. By 2024, the plan had become significantly more structured and detailed, introducing a suite of interrelated mechanisms including a U.S. litigation escrow agreement, a conversion feature for Class B common stock, makewhole agreements related to the Class B-1 exchange offer, indemnification obligations from Visa U.S.A. members, an interchange judgment sharing agreement, a loss sharing agreement, and an omnibus agreement. These additions indicate a more comprehensive and layered strategy to manage litigation risk, suggesting Visa has moved toward a more proactive and diversified approach to mitigate potential financial exposure from ongoing or future litigation outcomes.",
      "llm_answer": "Between 2022 and 2024, Visa’s U.S. Retrospective Responsibility Plan evolved from a primarily escrow‑funded mechanism to a more layered structure that adds conversion‑rate adjustments, makewhole reimbursement obligations, and expanded loss‑sharing agreements (including the 2015 amendment covering opt‑out merchants). These mechanisms collectively address liability in covered litigation by (1) funding an escrow account that can be topped up at the board’s discretion, (2) diluting class B‑1/B‑2 shares to offset escrow deposits, and (3) requiring participating members to reimburse the escrow when conversion rates fall below zero. The expansion suggests Visa is proactively tightening its litigation‑risk management—using equity‑based adjustments and member indemnifications to spread potential losses across the network rather than relying solely on cash reserves.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core evolution of Visa's U.S. Retrospective Responsibility Plan from a simpler escrow-based mechanism in 2022 to a more complex, multi-layered structure by 2024, which aligns with the ground truth. It correctly identifies key mechanisms such as the escrow account, share dilution (conversion adjustments), and member reimbursement obligations, and notes the proactive risk management shift—supporting contextual relevance and qualitative accuracy. However, it introduces a specific detail not present in the ground truth: the '2015 amendment covering opt-out merchants,' which is both chronologically inconsistent (outside the 2022–2024 scope) and unsupported by the provided original answer. This undermines quantitative and qualitative accuracy. Additionally, while the ground truth emphasizes a suite of formal agreements (e.g., omnibus agreement, interchange judgment sharing, makewhole agreements tied to Class B-1 exchange), the LLM generalizes these without fully reflecting their interrelated, structured nature. The mention of 'conversion-rate adjustments' and 'diluting class B-1/B-2 shares' is semantically close to the 'conversion feature for Class B common stock' but lacks precision. The core financial mechanism—using the escrow account and member indemnifications—is correctly conveyed, and the conclusion about a more proactive, diversified risk strategy is consistent with the original. No numerical values (dates aside) are incorrect, and the reasoning reflects partial multi-hop synthesis, though with an unsupported detail that affects overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1490,
        "completion_tokens": 437,
        "total_tokens": 1928
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How did Merck's financial stake in Lynparza evolve between 2023 and 2024, and what indicators suggest changes in the product's performance or strategic importance during this period?",
      "original_answer": "In 2023, Merck reported a $1.5 billion net intangible asset related to Lynparza as part of its collaboration with AstraZeneca. By 2024, although the financial stake amount was not explicitly stated, there was a 9% growth in alliance revenue linked to Lynparza, driven by increased demand in most international markets. Additionally, in January 2025, Lynparza received approval in China for an adjuvant treatment in early breast cancer, indicating expanded market potential. This suggests that while the initial asset value was substantial in 2023, 2024 marked a period of performance-driven growth and regulatory expansion, enhancing its strategic importance.",
      "llm_answer": "Based on the provided SEC 10-K filings, Merck's financial stake in Lynparza evolved as follows between 2023 and 2024:  \n1. **Revenue Growth**: Alliance revenue from Lynparza grew 9% in 2024 (reaching $1,311 million), up from 7% growth in 2023, driven by higher international demand and pricing.  \n2. **Strategic Expansion**: China's NMPA approved Lynparza in January 2025 for adjuvant treatment of BRCA-mutated breast cancer (based on the OlympiA trial), extending its market reach.  \n3. **Strategic Importance**: Lynparza remained a key oncology asset, contributing to Merck's 18% global Keytruda growth and supporting its collaboration with AstraZeneca. The drug's performance was stable despite broader oncology market shifts, with no indication of declining strategic value.  \n*No evidence suggests a reduction in Merck's stake or financial commitment; instead, the focus shifted to expanding its approved indications and global footprint.*",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 9% growth in alliance revenue linked to Lynparza in 2024 and the January 2025 China approval, aligning with the ground truth. However, it introduces a specific revenue figure of $1,311 million and claims 7% growth in 2023, which are not present in the original answer and cannot be verified from the provided ground truth, making these additions potentially inaccurate. The original answer only states that alliance revenue grew 9% in 2024 without specifying a dollar amount or prior year growth rate. (2) The quantitative inaccuracy stems from the unsupported revenue number and 2023 growth percentage. While $1,311 million may be factually correct in external sources, it is not in the ground truth and thus represents a hallucination or overprecision. The 9% growth is correctly attributed to 2024. The January 2025 approval date is accurately reported. (3) The multi-hop reasoning is strong: the model correctly synthesizes financial performance (revenue growth), regulatory developments (China approval), and strategic importance (ongoing collaboration, expanded indications). It appropriately infers continued strategic value from performance and expansion, consistent with the ground truth’s conclusion about enhanced strategic importance. (4) The answer is highly contextually relevant, addressing both the evolution of Merck's financial stake and indicators of performance/strategic importance. Despite the numerical overreach, the core facts and reasoning are sound, warranting a high correctness score with a deduction for unsupported figures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1409,
        "completion_tokens": 441,
        "total_tokens": 1851
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How did Skoal's market position and competitive performance within Altria's oral tobacco products segment evolve between 2022 and 2024, particularly in relation to its key competitor brands?",
      "original_answer": "In 2022, Skoal was one of the premium oral tobacco brands under Altria, alongside Copenhagen and on!, with a retail share of 9.3%. By 2024, Skoal's retail share had declined to 7.6%, indicating a weakening market position. This decline occurred alongside a broader contraction in Altria's oral tobacco segment, which saw total retail share fall from 42.5% in 2023 to 37.5% in 2024. Notably, Copenhagen, Altria's leading brand, also experienced a drop from 23.5% to 19.1% over the same period, while on! oral nicotine pouches gained traction, rising from 6.8% to 8.3%. These shifts suggest that Skoal not only lost market share overall but also underperformed relative to both its primary brand (Copenhagen) and the newer product category (on!).",
      "llm_answer": "Between 2022 and 2024, Skoal’s market position within Altria’s oral tobacco segment eroded noticeably.  Shipment volume fell from 163.1 million units in 2023 to 147 million units in 2024, and its retail‑share dropped from 9.3 % to 7.6 %, while the overall oral‑tobacco retail share fell from 42.5 % to 37.5 %.  The decline was driven by lower shipment volume, a higher share of higher‑priced on! pouches, and a $354 million non‑cash impairment of the Skoal trademark in 2024, even though pricing and promotional actions partially offset the volume loss.  Consequently, Skoal’s competitive performance weakened relative to rivals such as Copenhagen and the growing on! nicotine‑pouch category.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: Skoal's retail share decline from 9.3% to 7.6%, overall oral tobacco segment share drop from 42.5% to 37.5%, and shipment volumes (163.1 million in 2023 to 147 million in 2024) match the source data. The $354 million non-cash impairment in 2024 is an additional accurate detail not in the original answer but consistent with external knowledge, enhancing rather than contradicting the truth. (2) The answer correctly identifies key entities: Skoal, on!, Copenhagen (implied as a rival), Altria’s oral tobacco segment, and relevant timeframes (2022–2024, with 2023 as intermediate). (3) Multi-hop reasoning is sound: it connects Skoal’s declining volume and share to broader segment trends and competitive dynamics, particularly the rise of on! pouches. It also correctly infers weakening competitive performance relative to both Copenhagen (by referencing segment trends where Copenhagen fell from 23.5% to 19.1%) and on! (which grew from 6.8% to 8.3%). (4) While the original answer explicitly compares Skoal to Copenhagen and on!, the LLM implies this through context and adds value with the impairment and volume data. The only minor shortcoming is not explicitly stating Copenhagen’s share decline or on!’s growth percentages, but the conclusion about relative underperformance is still logically supported. Thus, the answer is factually complete and semantically equivalent, warranting a high correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1370,
        "completion_tokens": 420,
        "total_tokens": 1790
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How has the revenue contribution from Dynamics 365 within Microsoft Cloud evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, Dynamics 365 contributed to the $91.2 billion Microsoft Cloud revenue, with Dynamics products and cloud services revenue growing 25%, driven by a 39% increase in Dynamics 365. By fiscal year 2023, the Microsoft Cloud revenue had increased to $111.6 billion, which includes Dynamics 365 as a component. Although the exact growth percentage for Dynamics 365 in 2023 is not explicitly stated, its continued inclusion in the Microsoft Cloud breakdown indicates sustained growth and integration within the broader cloud portfolio.",
      "llm_answer": "Based on the provided 10-K pages, Microsoft Cloud revenue (which includes Dynamics 365) grew from $91.4 billion in fiscal 2022 to $111.6 billion in fiscal 2023, reflecting a significant increase in its contribution to the overall Microsoft Cloud revenue stream. This demonstrates that Dynamics 365’s revenue share within Microsoft Cloud expanded materially between FY 2022 and FY 2023.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a critical error in the fiscal 2022 Microsoft Cloud revenue figure, stating $91.4 billion instead of the correct $91.2 billion from the ground truth. While $111.6 billion for fiscal 2023 is accurate, the incorrect base value undermines quantitative precision. More importantly, the LLM claims that Dynamics 365's 'revenue share... expanded materially' between FY2022 and FY2023, which is an unsupported inference. The original answer explicitly states that while Dynamics 365 grew 39% in FY2022, the exact growth for FY2023 is not stated, and no data is provided about its changing share within Microsoft Cloud. Thus, asserting an 'expanded' share goes beyond the available evidence. (2) The numbers cited are mostly close but not fully accurate—$91.4B vs. $91.2B is a small but factual discrepancy. The $111.6B for FY2023 is correct. However, the LLM implies a level of granularity (revenue share expansion) that cannot be verified from the source, and no calculation or percentage for Dynamics 365’s standalone growth in FY2023 is provided in either document. (3) The multi-hop reasoning is partially sound—correctly identifying Dynamics 365 as part of Microsoft Cloud and tracking the overall cloud revenue increase. However, it fails to acknowledge the lack of explicit data on Dynamics 365’s FY2023 growth or share, leading to an overconfident conclusion not supported by the ground truth. (4) The contextual relevance is high as the answer addresses the evolution of Dynamics 365 within Microsoft Cloud. Qualitative accuracy is moderate due to correct entity identification and general direction of growth, but penalized for unsupported claims. Quantitative accuracy is reduced due to the incorrect FY2022 figure and unsupported inference presented as fact. Correctness score reflects partial accuracy with significant flaws in inference and data precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1225,
        "completion_tokens": 514,
        "total_tokens": 1739
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How has Merck's approach to managing foreign exchange exposure through its Balance Sheet Risk Management Program evolved from 2023 to 2024, particularly in terms of the instruments used and the scope of hedging activities?",
      "original_answer": "In 2023, Merck primarily used forward exchange contracts to offset the effects of exchange on exposures when economically beneficial, focusing on the euro, Swiss franc, Japanese yen, and Chinese renminbi. These contracts were not designated as hedges and were marked to market through Other (income) expense, net. By 2024, the company expanded its approach under a more structured balance sheet risk management program, continuing to use forward contracts but also introducing a broader framework that included purchased local currency put options and collar options. Additionally, the 2024 disclosure highlights a more strategic layering of hedges over time, increasing the portion of forecasted sales hedged as the expected dates approach, based on cost-benefit assessments.",
      "llm_answer": "From 2023 to 2024, Merck’s foreign‑exchange risk management continued to rely primarily on forward contracts, but the scope of hedging expanded and the accounting treatment became more structured. In 2023 the company used short‑term forward contracts (average maturities under six months) to offset monetary‑asset remeasurements and also designated some of these forwards as hedges of net‑investment in foreign operations, recording gains/losses in OCI and amortizing excluded components straight‑line into earnings. By 2024, in addition to the same forward‑contract approach, Merck began designating a portion of its euro‑denominated senior notes as economic hedges of foreign‑currency net investment, and it started recognizing the excluded‑component gains/losses in OCI on a straight‑line basis rather than marking them to market. The company also broadened its hedging program to include cash‑flow hedges of forecasted foreign‑currency sales and used a larger notional amount of forward contracts (e.g., $12.5 bn of foreign‑exchange notional in 2024 versus $9.7 bn in 2023), while still reporting cash‑flow hedge gains/losses in OCI and reclassifying them into sales when the underlying transactions occur. This evolution reflects a shift from primarily “un‑designated” forwards to a more layered program that incorporates designated net‑investment and cash‑flow hedges, with a greater emphasis on straight‑line amortization of excluded hedge components and expanded use of longer‑dated forward contracts.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and introduces information not present in the ground truth. (1) Quantitatively, the LLM cites specific notional amounts ($12.5B in 2024 vs $9.7B in 2023) and mentions senior notes being used as hedges, but these figures and instruments are not mentioned in the original answer. There is no mention in the ground truth of hedge accounting designations (e.g., cash-flow hedges, net-investment hedges), OCI treatment, or straight-line amortization—these are entirely fabricated. (2) The original answer states that forward contracts in 2023 were *not designated as hedges* and marked to market through income, whereas the LLM claims some were designated as hedges with OCI treatment, which contradicts the source. (3) Qualitatively, the LLM fails to mention the key evolution in 2024: the introduction of *purchased local currency put options and collar options*, which is a central point in the ground truth. Instead, it invents a shift to using senior notes and expanded forward notional, which are unsupported. (4) The reasoning is flawed because it constructs a narrative around hedge accounting designations and amortization methods that do not appear in the original data, suggesting a failure in multi-hop synthesis and potential hallucination. While the mention of forward contracts is correct, the overall evolution described is factually incorrect. Contextual relevance is moderate because the topic is on-topic (hedging evolution), but the details are largely inaccurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1590,
        "completion_tokens": 420,
        "total_tokens": 2010
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How has PayPal's involvement with merchant receivables evolved between 2022 and 2024, particularly in terms of its credit loss provisions and direct investment in merchant financing products?",
      "original_answer": "In 2022, PayPal disclosed its methodology for estimating credit losses on merchant receivables, applying macroeconomic forecasts and historical loss data to calculate allowances, with a principal and interest coverage ratio of approximately 9% as of December 31, 2021, down from 23% in 2020. By 2024, PayPal had significantly expanded its direct involvement by purchasing approximately $1.8 billion in merchant receivables during the year, with an outstanding balance of $1.5 billion as of December 31, 2024, up from $1.2 billion in 2023. This represents a shift from primarily disclosing credit risk exposure to actively investing in and managing merchant receivables through products like PPWC and PPBL, indicating a more strategic and operational role in merchant finance.",
      "llm_answer": "PayPal's merchant financing activity grew modestly, with purchases of merchant receivables rising from $1.7 billion in 2023 to $1.8 billion in 2024 and the outstanding merchant loan portfolio expanding from $1.2 billion to $1.5 billion (net of participation interests).  Accordingly, the allowance for merchant credit losses fell sharply—from $160 million at the end of 2023 to $113 million at the end of 2024—reflecting improved credit quality, especially within the PPBL product, even as the company recorded $156 million in gross charge‑offs for 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details and timeline. The ground truth states that PayPal began actively purchasing merchant receivables in 2024 with $1.8 billion purchased that year, and an outstanding balance of $1.5 billion as of December 31, 2024, up from $1.2 billion in 2023. However, the LLM incorrectly claims purchases rose from $1.7 billion in 2023 to $1.8 billion in 2024, implying activity in 2023 that is not supported by the original answer, which does not mention any receivables purchases prior to 2024. This misrepresents the evolution as a continuation rather than a strategic shift starting in 2024. (2) The allowance for credit losses: the LLM states it fell from $160 million (end-2023) to $113 million (end-2024), but this data is absent in the original answer, which does not provide allowance figures for those years. The original only mentions a principal and interest coverage ratio of 9% as of December 31, 2021 (down from 23% in 2020), which the LLM omits entirely. The charge-offs of $156 million in 2024 are also not in the ground truth and appear fabricated. (3) The qualitative reasoning is partially sound—recognizing increased direct investment via products like PPBL—but fails to capture the core multi-hop evolution: from passive risk disclosure (2022) to active investment (2024). The LLM frames it as a modest growth trend, missing the strategic shift. (4) Contextual relevance is high—the answer addresses merchant receivables, credit loss provisions, and financing products—but the factual foundation is flawed. Quantitative accuracy is low due to incorrect or invented numbers. Correctness score is 4 due to partial entity and conceptual accuracy but major factual and numerical errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 489,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How has the financial significance of smokeable products to MO evolved from 2022 to 2024, considering both goodwill allocation and operating income performance?",
      "original_answer": "In 2022, the goodwill allocated to smokeable products was $99 million, indicating a relatively small portion of MO's overall asset valuation, with total goodwill at $5,177 million. By 2024, although no updated goodwill figure is disclosed specifically for smokeable products, their operating income contribution rose to $10,821 million in 2024 from $10,670 million in 2023, showing sustained profitability. This suggests that while the strategic asset valuation (via goodwill) remained stable or undisclosed, the operational significance of smokeable products remained high and slightly increased in terms of earnings. The lack of updated goodwill allocation in 2024 filings for this segment implies a potential shift in reporting focus toward performance metrics rather than asset valuations.",
      "llm_answer": "From 2022 to 2024 the financial significance of smokeable products to MO declined in both absolute and relative terms.  In 2022 the smokeable segment generated roughly $21.7 billion in net revenue and contributed about $10.7 billion of operating income, but by 2024 revenue had slipped to $21.2 billion and operating income fell to $10.8 billion – a drop of roughly $0.9 billion (≈ 8 %).  This reduction was driven by lower shipment volumes, higher per‑unit settlement charges and higher manufacturing costs, even though the segment still accounted for the bulk of MO’s total net revenue and operating profit.  Consequently, the share of MO’s overall earnings attributable to smokeable products has been eroding, a trend that is reflected in the declining operating‑income contribution and the need to offset it with gains elsewhere (e.g., the IQOS sale and equity‑investment windfalls).",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both quantitative and qualitative aspects. The original answer states that smokeable products' operating income increased from $10,670 million in 2023 to $10,821 million in 2024, indicating a rise of $151 million, not a drop. The LLM incorrectly claims operating income fell to $10.8 billion in 2024 from $10.7 billion in 2022 and attributes an 8% decline, which contradicts the ground truth. Additionally, the LLM introduces $21.7B and $21.2B in net revenue for 2022 and 2024, respectively, but the original answer does not mention net revenue at all—only operating income and goodwill—making these figures unsupported and likely fabricated. (2) The goodwill allocation in 2022 was correctly stated in the original answer as $99 million, but the LLM omits this entirely and fails to address the goodwill component of the question, a critical omission. The LLM also fails to note that no 2024 goodwill figure was disclosed, which is a key point in the original answer about shifting reporting focus. (3) The multi-hop reasoning is flawed: the question asks for an analysis combining goodwill allocation and operating income performance across 2022–2024. The LLM ignores goodwill completely and misrepresents operating income trends, thus failing to synthesize the required information. The conclusion that financial significance declined contradicts the ground truth, which indicates sustained and slightly increased profitability. (4) The contextual relevance is moderate because the LLM addresses MO and smokeable products over the correct time frame and discusses financial performance, but it introduces unverified metrics (net revenue), omits key data (goodwill), and draws the opposite conclusion from the evidence. Due to major factual errors and missing multi-hop synthesis, the correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1423,
        "completion_tokens": 505,
        "total_tokens": 1928
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How has the revenue contribution from the commercial portion of LinkedIn within Microsoft Cloud evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, the Microsoft Cloud revenue, which includes the commercial portion of LinkedIn, was reported at $91.2 billion. By fiscal year 2023, this figure had increased to $111.6 billion, indicating a significant growth in the commercial cloud segment that includes LinkedIn. This increase suggests a stronger revenue contribution from LinkedIn's commercial services within the broader Microsoft Cloud portfolio.",
      "llm_answer": "Based on the 2023 10‑K (page 93) the “Microsoft Cloud” revenue—including the commercial portion of LinkedIn—was $111.6 billion in fiscal 2023 versus $91.4 billion in fiscal 2022. This represents an increase of roughly $20.2 billion, or about a 22 % rise, in the commercial LinkedIn contribution to Microsoft Cloud between FY 2022 and FY 2023.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is mostly correct but contains a minor inaccuracy in the FY2022 Microsoft Cloud revenue figure. The ground truth states $91.2 billion, while the LLM reports $91.4 billion—a small discrepancy of $0.2 billion. All other numbers are accurate: FY2023 revenue is correctly reported as $111.6 billion. (2) The calculated increase of $20.2 billion is based on the incorrect FY2022 figure; using the correct $91.2B, the actual increase is $20.4B. The percentage increase is stated as ~22%, which is approximately correct (actual: ($111.6 - $91.2) / $91.2 ≈ 22.37%), so this is acceptable. (3) The reasoning is sound: the LLM correctly identifies that Microsoft Cloud includes LinkedIn’s commercial portion and tracks its evolution across fiscal years 2022 and 2023. It synthesizes the information correctly and draws a logical conclusion about growth. (4) Despite the minor numerical error, the overall message about significant growth in LinkedIn's commercial contribution within Microsoft Cloud is preserved, and the answer fully addresses the question. Hence, correctness and quantitative accuracy are slightly penalized, but qualitative reasoning and contextual relevance remain high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1189,
        "completion_tokens": 341,
        "total_tokens": 1530
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How did the commercialization and market expansion of Lynparza evolve between 2023 and 2024, particularly in terms of geographic approvals and revenue growth?",
      "original_answer": "In 2023, Lynparza received FDA and Japan's MHLW approvals for treating BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) in combination with abiraterone and prednisone or prednisolone, based on the PROpel trial. By 2024, alliance revenue related to Lynparza grew by 9%, largely due to higher demand in most international markets. Additionally, in January 2025, Lynparza received China's NMPA approval for adjuvant treatment of germline BRCA-mutated, HER2-negative high-risk early breast cancer, based on the OlympiA trial, indicating a significant geographic and therapeutic area expansion.",
      "llm_answer": "Between 2023 and 2024, Lynparza’s commercialization expanded geographically, with China’s NMPA approving it in January 2025 for adjuvant treatment of germline BRCA‑mutated, HER2‑negative high‑risk early breast cancer, while earlier approvals continued in the U.S. and Europe. This expansion drove a 9% rise in alliance revenue from Lynparza in 2024, reflecting higher demand across most international markets. Revenue growth was partially offset by pricing pressures and competitive dynamics in certain regions.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the 9% revenue growth in 2024 and the January 2025 NMPA approval in China for adjuvant treatment of germline BRCA-mutated, HER2-negative high-risk early breast cancer, which aligns with the ground truth. It also accurately notes higher demand in international markets as a driver of revenue growth. However, it omits the specific 2023 approvals by the FDA and Japan's MHLW for BRCA-mutated mCRPC, which were key developments in the commercialization timeline and directly addressed in the original answer. While the mention of 'earlier approvals continued in the U.S. and Europe' is vague and partially correct, it lacks the specificity of the 2023 regulatory milestones. (2) Quantitatively, the 9% revenue increase and January 2025 date are accurate. The answer correctly reflects the alliance revenue growth metric. There are no calculation errors. (3) The reasoning is sound in linking geographic expansion (China approval) to revenue growth, and it appropriately contextualizes the growth with market dynamics like pricing pressures. However, the multi-hop synthesis is incomplete because it fails to connect the 2023 approvals (a critical part of the evolution) to the ongoing commercial momentum. The answer implies continuity but does not explicitly credit the 2023 actions as foundational. (4) Despite the omission, the answer remains highly relevant and factually accurate where it speaks, with appropriate terminology and logical flow. The contextual relevance is strong as it directly addresses both geographic expansion and revenue growth as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 441,
        "total_tokens": 1724
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How did RTX's financial treatment of the Powder Metal Matter evolve between 2023 and 2024, particularly in terms of its impact on future income tax benefits?",
      "original_answer": "In 2023, the Powder Metal Matter was noted as a reduction in sales, indicating a negative financial impact. By 2024, the Powder Metal Matter was specifically listed under future income tax benefits at $455 million, down from $644 million in 2023, showing a shift in its financial treatment from a sales reduction to a recognized tax benefit. This represents a decrease of $189 million, or about 29.3%, in its value contribution to future tax benefits.",
      "llm_answer": "The Powder Metal Matter, which had been a significant non‑cash charge in 2023, was largely reversed in 2024, resulting in a $1.9 billion reduction to operating profit (and a corresponding increase in segment profit) that was reflected in the 2024 segment results.  This reversal removed the prior year’s drag on earnings and, because the related tax adjustments were recorded in the effective tax rate calculations, it contributed to a lower overall effective tax rate in 2024 compared with 2023.  Consequently, the future income tax benefits associated with the Powder Metal Matter are no longer expected to affect RTX’s tax position moving forward.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in both quantitative and qualitative aspects. (1) Quantitatively, it claims a '$1.9 billion reduction to operating profit' and implies a major reversal impacting segment profit and tax rate, but the ground truth states the Powder Metal Matter shifted from $644M to $455M in future income tax benefits—a decrease of $189M (29.3%), not $1.9B. These figures are entirely inconsistent with the original data. (2) The answer incorrectly frames the 2023 treatment as a 'non-cash charge' affecting operating profit, whereas the ground truth identifies it as a 'reduction in sales'—a different financial statement impact. (3) The LLM concludes that future tax benefits 'are no longer expected to affect RTX’s tax position,' which directly contradicts the ground truth: the benefit still exists at $455M in 2024, just reduced from 2023. (4) The reasoning fails multi-hop synthesis: it does not recognize the shift in classification (from sales reduction to tax benefit) or accurately report the values or trend. While the answer addresses the general topic (evolution of financial treatment and tax impact), its factual inaccuracies severely undermine correctness. Minor credit is given for addressing the question's context and attempting to link financial treatment to tax implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 364,
        "total_tokens": 1642
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How did the borrowing capacity and terms of the Paidy Credit Agreement evolve from 2022 to 2024?",
      "original_answer": "In 2022, the Paidy Credit Agreement provided a secured revolving credit facility of approximately $198 million, with $98 million outstanding as of December 31, 2021. By 2024, the Paidy Credit Agreement had been modified to increase the borrowing capacity to ¥90.0 billion (approximately $574 million as of December 31, 2024), and it was restructured as an unsecured facility. The interest rate also changed from unspecified terms in 2022 to a rate based on the Tokyo Interbank Offered Rate plus a margin ranging from 0.40% to 0.60% in 2024. The maturity date was set for February 2027, and the agreement now includes a financial covenant requiring a maximum consolidated leverage ratio.",
      "llm_answer": "From 2022 through 2024 the company’s borrowing capacity and credit terms changed as follows:  \n\n* In September 2019 the company obtained a $5 billion unsecured revolving credit facility (the “Credit Agreement”) that remained fully available through 2024, with no borrowings outstanding as of December 31 2021 and 2024.  \n* In October 2021 the company acquired Paidy and assumed the “Paidy Credit Agreement,” a secured revolving facility of approximately $198 million. As of December 31 2021 about $98 million was outstanding, leaving roughly $100 million of borrowing capacity, and by the end of 2024 the entire $198 million had been drawn down, leaving essentially no remaining capacity under that agreement.  \n* The company also issued a series of fixed‑rate senior notes (totaling $10.6 billion as of 2024) with maturities ranging from 2024 to 2062, and in 2024 added $1.3 billion of new notes. These notes carry interest rates from about 0.8% to 5.6% and can be redeemed early under certain conditions.  \n\nThus, the company’s overall credit capacity stayed at $5 billion for its main revolving facility, while the Paidy‑specific facility moved from about $100 million of unused capacity in 2021 to virtually no capacity by 2024 after being fully utilized.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is largely incorrect and fails to accurately represent the evolution of the Paidy Credit Agreement from 2022 to 2024. (1) It incorrectly frames the Paidy Credit Agreement as a facility that was fully drawn down by 2024, claiming 'the entire $198 million had been drawn down,' which contradicts the ground truth stating that the facility was increased and restructured, not exhausted. The ground truth indicates borrowing capacity increased to ¥90.0 billion (~$574 million), but the LLM claims no capacity remained. (2) The LLM introduces a $5 billion unsecured revolving credit facility unrelated to Paidy, which is irrelevant to the question about the Paidy Credit Agreement. This misdirects the focus and fabricates details (e.g., September 2019 agreement still active in 2024). (3) The LLM incorrectly states that the Paidy facility was still secured and does not mention its restructuring to unsecured status in 2024. It also omits the change in interest rate terms to TIBOR + 0.40%–0.60% and the new financial covenant on leverage ratio. (4) The maturity date of February 2027 is entirely missing. (5) The LLM confuses corporate-level financing (senior notes, main credit facility) with the specific Paidy Credit Agreement, failing the multi-hop requirement to isolate and track Paidy's facility changes. While it correctly notes the ~$198 million size and $98 million outstanding as of 2021, all subsequent developments are misrepresented. Quantitative accuracy is low due to wrong figures and missing conversions (¥90.0 billion to $574 million). Qualitative accuracy is poor due to incorrect entity tracking and reasoning. Contextual relevance is minimal as the answer discusses unrelated credit facilities instead of Paidy's specific agreement evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1473,
        "completion_tokens": 480,
        "total_tokens": 1954
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How has Altria's reliance on long-term senior unsecured notes as part of its capital resources evolved between 2022 and 2024?",
      "original_answer": "In 2022, Altria's capital resources included access to credit markets through the issuance of long-term senior unsecured notes, along with $4.5 billion in cash and cash equivalents. By 2024, Altria continued to rely on long-term senior unsecured notes as a key source of capital, but its cash and cash equivalents decreased to $3.1 billion. While the company maintained its $3.0 billion Credit Agreement and continued to use similar capital instruments, the reduction in cash reserves suggests a potentially increased reliance on external financing mechanisms, including long-term senior unsecured notes, to support its operations and strategic initiatives such as dividend payments, share repurchases, and debt repayment.",
      "llm_answer": "Between 2022 and 2024, Altria’s reliance on long‑term senior unsecured notes shifted from a primary funding source to a complementary one. In 2022 the company still carried a sizable portfolio of such notes, but by 2024 it had begun retiring portions of that debt (e.g., repaying $776 million and $345 million of 4.000% and 3.800% notes in early 2024) and issuing new long‑term senior unsecured notes only to refinance maturing obligations and support general corporate purposes. Consequently, the proportion of its capital structure funded by long‑term senior unsecured notes declined, with the company increasingly depending on cash on hand, operating cash flows, its $3 billion revolving credit facility, and commercial paper for short‑term liquidity.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that contradict the ground truth. (1) Quantitatively, the LLM claims Altria repaid $776 million and $345 million of notes in early 2024, but this specific repayment data is not present in the original answer and cannot be verified from the provided ground truth. The original answer does not mention any retirements or issuances of notes, nor does it state a decline in the proportion of long-term senior unsecured notes in the capital structure. (2) The original answer emphasizes that Altria *continued to rely* on long-term senior unsecured notes as a *key source* of capital in 2024, while the LLM incorrectly asserts that reliance shifted from primary to complementary and that the proportion declined—this is a direct contradiction. (3) The LLM claims Altria is increasingly depending on cash on hand and operating cash flows, but the ground truth states that cash and cash equivalents *decreased* from $4.5B to $3.1B, suggesting reduced, not increased, reliance on cash. This undermines the LLM's reasoning about capital structure evolution. (4) While the LLM correctly notes the $3.0 billion Credit Agreement (called a revolving credit facility), it misinterprets its role in reducing reliance on long-term notes. The original answer frames the continued use of similar capital instruments, including long-term notes, as ongoing, with reduced cash reserves implying *increased* reliance on external financing, not decreased. (5) The multi-hop synthesis is flawed: the LLM infers a strategic shift in funding sources without supporting evidence from the ground truth, introducing unsupported specifics like exact repayment amounts and interest rates. Overall, the answer is largely incorrect in its core claims about the direction of Altria's reliance on long-term senior unsecured notes, despite using plausible financial terminology and referencing relevant instruments.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 520,
        "total_tokens": 1883
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How did RTX's financial treatment of the Powder Metal Matter evolve between 2023 and 2024, and what does this indicate about its impact on future income tax benefits?",
      "original_answer": "In 2023, the Powder Metal Matter contributed $644 million to RTX's future income tax benefits. By 2024, this amount decreased to $455 million, indicating a reduced financial benefit from the Powder Metal Matter over time. This decline suggests a diminishing positive impact on RTX's tax position related to this factor.",
      "llm_answer": "The Powder Metal Matter was treated as a non‑cash charge that reduced pretax income in 2023; the resulting lower pretax earnings improved the effective tax rate by roughly 4 percentage points, but the charge also created a $2.9 billion expense that lowered overall profitability. Consequently, while the 2023 effective tax rate fell to 11.9 % (from 12.9 % in 2022), the company expects future income‑tax benefits to be muted by the lingering impact of the Powder Metal Matter and the associated valuation allowances on related tax credits and loss carryforwards.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both quantitative and qualitative aspects. The ground truth states that the Powder Metal Matter contributed $644 million to RTX's future income tax benefits in 2023 and $455 million in 2024, showing a decline. However, the LLM answer does not mention these specific figures at all. Instead, it introduces a $2.9 billion expense and discusses pretax income, effective tax rate changes (11.9% vs 12.9%), and valuation allowances—none of which are present in the ground truth and appear to be fabricated or misattributed. (2) The numbers cited in the LLM response ($2.9B expense, 11.9% and 12.9% tax rates) are not supported by the original answer and contradict the focus on future income tax benefits of $644M and $455M. There is no calculation or comparison of the actual decline from 2023 to 2024 ($644M → $455M, a reduction of $189M), which is central to the question. (3) The multi-hop reasoning is flawed: the question asks about the evolution of financial treatment and its implication for future income tax benefits. The correct reasoning should note the decrease in tax benefit from 2023 to 2024 and infer a diminishing impact. The LLM instead shifts focus to profitability, pretax charges, and effective tax rate effects, which are not mentioned in the ground truth and represent a different financial concept. (4) The contextual relevance is moderate because the answer discusses tax implications related to the Powder Metal Matter, but it fails on correctness due to invented data and misdirection. The core facts—specific dollar amounts and their trend—are entirely missing or wrong, warranting a low correctness score of 2.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1225,
        "completion_tokens": 461,
        "total_tokens": 1686
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has PayPal's utilization of the Paidy Credit Agreement evolved between 2022 and 2024, particularly in terms of borrowing capacity and actual drawdown?",
      "original_answer": "In 2022, PayPal had approximately $198 million in borrowing capacity under the Paidy Credit Agreement, with $98 million outstanding as of December 31, 2021, leaving about $100 million available. By 2024, the borrowing capacity had increased to approximately $574 million (¥90.0 billion), and the full amount was drawn down, leaving no borrowing capacity available. This reflects a significant increase in both the scale of the facility and PayPal's reliance on it over the period.",
      "llm_answer": "Between 2022 and 2024, PayPal’s borrowing capacity under the Paidy Credit Agreement was fully drawn and then eliminated—​the $574 million (≈¥90 billion) facility was at 0 % available as of December 31 2024, whereas it had approximately $100 million of capacity available at the end of 2021.  In contrast, the company’s primary revolving credit facility (the $5 billion 2023 Credit Agreement) remained fully undrawn, preserving $5 billion of borrowing capacity throughout the period.  Consequently, while overall corporate liquidity stayed ample, the specific Paidy‑related credit line ceased to provide any additional borrowing capacity after 2024, shifting reliance to the broader $5 billion revolving facility and other uncommitted credit lines.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct elements but also key inaccuracies. It correctly states that the Paidy Credit Agreement had approximately $574 million (¥90 billion) in borrowing capacity as of 2024 and that it was fully drawn (0% available). It also correctly references the $100 million available capacity around the end of 2021, aligning with the ground truth's calculation of $198M capacity minus $98M outstanding. However, it incorrectly implies that the full drawdown and elimination of capacity occurred between 2022 and 2024 without clarifying the 2022 status — the ground truth specifies that in 2022, about $100M was still available, whereas the LLM suggests the drawdown was already complete or in progress without specifying 2022's actual state. (2) The quantitative accuracy is partially correct: the $574M (¥90B) figure for 2024 is accurate, and the $100M available at end-2021 is correctly inferred. However, the LLM misrepresents the 2022 borrowing capacity — it does not mention the $198M total capacity in 2022, instead jumping from 2021 to 2024. This omits a key data point and misrepresents the evolution. Also, the phrase 'was fully drawn and then eliminated' is misleading — credit facilities aren't 'eliminated' just because drawn; the agreement may still exist. (3) The multi-hop reasoning is partially sound: the model connects Paidy’s credit usage across time and contrasts it with PayPal’s broader $5B facility, showing good contextual synthesis. However, it fails to clearly trace the evolution from 2022 to 2024 as required, skipping the intermediate state. The mention of the $5B undrawn facility, while factually plausible and contextually relevant, is not part of the original question and distracts from the core focus on Paidy. (4) Correctness is scored 6 due to missing 2022 capacity details and misleading phrasing about elimination; quantitative accuracy is 6 due to correct endpoint numbers but omission of 2022 total capacity; qualitative accuracy is 7 due to sound logic but incomplete synthesis; contextual relevance is 9 because the answer stays focused on Paidy and credit evolution, even with some extraneous details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1308,
        "completion_tokens": 584,
        "total_tokens": 1893
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has the ownership structure and equity relationship between Accenture plc and Accenture Canada Holdings Inc. evolved from 2023 to 2024, particularly regarding noncontrolling interests and exchangeable shares?",
      "original_answer": "In 2023, the noncontrolling ownership interests in Accenture Canada Holdings Inc. held by certain current and former members of Accenture Leadership were less than 1% as of August 31, 2024. By 2024, the structure had evolved to include detailed provisions around Accenture Canada Holdings Inc. exchangeable shares, which can be exchanged for Accenture plc Class A ordinary shares on a one-for-one basis or redeemed for cash. Additionally, Accenture plc Class X ordinary shares were tied directly to these exchangeable shares, with a restriction ensuring the number of Class X shares does not fall below the number of exchangeable shares held. This indicates a more formalized and structured equity relationship in 2024 compared to the simpler noncontrolling interest disclosure in 2023.",
      "llm_answer": "From 2023 to 2024, Accenture plc’s equity structure remained anchored by its Class A ordinary shares, but the company continued to manage non‑controlling interests tied to its Canadian subsidiary. The 2024 filing shows that Accenture Canada Holdings Inc. exchangeable shares can be converted one‑for‑one into Class A shares, and the company’s shareholder‑equity disclosures indicate that the noncontrolling ownership held by former Accenture Leadership members stayed below 1 % of the consolidated equity as of August 31 2024. Share‑based compensation data (pages 98‑99) and the “Equity of Subsidiaries Redeemable or Exchangeable for Accenture plc Class A Ordinary Shares” section (page 100) confirm that exchangeable shares remain exchangeable at any time, while the company’s share‑repurchase authorizations and dividend activity (page 101) reflect ongoing equity‑return programs but do not alter the fundamental ownership relationship between Accenture plc and its Canadian holding entity.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers and dates are correct: the noncontrolling interest is accurately stated as 'below 1%' as of August 31, 2024, matching the ground truth's 'less than 1% as of August 31, 2024'. The one-for-one exchangeability of Accenture Canada Holdings Inc. exchangeable shares into Accenture plc Class A ordinary shares is correctly reported. (2) The answer correctly identifies the key entities—Accenture plc and Accenture Canada Holdings Inc.—and the relevant time frame (2023 to 2024). (3) The reasoning is sound: it captures the evolution from a simple disclosure of minimal noncontrolling interests in 2023 to a more structured equity mechanism in 2024 involving exchangeable shares. However, the LLM omits mention of the Accenture plc Class X ordinary shares and the restriction that their number must not fall below the number of exchangeable shares held, which is a key structural detail in the 2024 evolution. This omission prevents a perfect score but does not undermine the core accuracy. (4) The answer remains highly relevant, citing specific sections of the filing (pages 98–101) to support its claims, demonstrating strong contextual grounding. Overall, the answer conveys the essential evolution in ownership structure with high fidelity, missing only a minor but notable qualitative detail about Class X shares.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1461,
        "completion_tokens": 390,
        "total_tokens": 1851
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has Merck's approach to managing balance sheet risk through forward exchange contracts evolved between 2022 and 2024, particularly in terms of the currencies and cost-benefit considerations?",
      "original_answer": "In 2022, Merck explicitly outlined a balance sheet risk management program that involved the use of forward exchange contracts to offset exposures in both developed and developing country currencies, with a specific mention of the Chinese renminbi. The decision to hedge developing country currencies was based on a cost-benefit analysis considering exposure magnitude, exchange rate volatility, and hedging instrument cost. By 2024, while the balance sheet risk management program was still referenced, the detailed discussion around cost-benefit analysis and the specific mention of the Chinese renminbi in the context of developing countries was omitted. This suggests a shift in emphasis or a potential simplification of the decision-making framework for hedging non-developed market exposures.",
      "llm_answer": "Based on the provided 10-K pages, Merck's approach to managing balance sheet risk through forward exchange contracts has evolved in two key ways between 2022 and 2024:  \n\n1. **Currency Expansion**: While earlier disclosures (2022) noted hedging primarily in \"primarily the euro, Swiss franc, Japanese yen, and Chinese renminbi\" (MRK_10k_2022.pdf p.106), the 2024 filing (MRK_10k_2024.pdf p.98) explicitly lists additional currencies including \"British pound, Canadian dollar and Swiss franc\" for balance sheet risk management, and details broader use of forward contracts across multiple developed and developing country currencies (e.g., euro, Japanese yen, British pound, Canadian dollar, Swiss franc, Chinese renminbi).  \n\n2. **Cost-Benefit Focus**: The 2024 document emphasizes that hedge effectiveness assessments now explicitly consider \"the magnitude of the exposure, the volatility of the foreign exchange rate and the cost of the hedging instrument\" (MRK_10k_2024.pdf p.98), with specific examples showing how excluded components of hedge effectiveness testing are amortized linearly into earnings rather than marked-to-market (p.98). This reflects a more structured cost-benefit analysis of hedge instrument costs relative to exposure volatility.  \n\nNotably, the 2024 filing also clarifies that forward contracts for balance sheet risk management are typically short-term (average maturities <6 months) and marked-to-market through \"Other (income) expense, net,\" while net investment hedges (e.g., euro-denominated debt) are designated as hedges with gains/losses recorded in OCI until subsidiary exit. The 2022 filing (p.106) references similar mechanics but with less granularity on cost-benefit parameters and currency scope.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that contradict the ground truth, despite being well-structured and contextually relevant. (1) The claim of 'currency expansion' in 2024 with new currencies like the British pound and Canadian dollar is incorrect—the original answer states that by 2024, the detailed discussion of specific currencies (including the Chinese renminbi) was *omitted*, not expanded. The removal of specific mentions, especially the renminbi in developing markets, indicates a narrowing or simplification of disclosure, not broadening. (2) The assertion that the 2024 filing introduces a more structured cost-benefit analysis is backwards: the ground truth states that the cost-benefit framework (considering exposure magnitude, volatility, and hedging cost) was explicitly mentioned in 2022 but *omitted* in 2024, suggesting a reduced emphasis, not increased. The LLM incorrectly reverses the direction of change. (3) The citation of hedge accounting mechanics (e.g., amortization vs. mark-to-market) and maturity details, while possibly present in the filings, are not part of the evolution described in the ground truth and introduce unsupported details. (4) Multi-hop reasoning fails because the model misinterprets the evolution: it should have detected the *removal* of detailed rationale and specific currency mentions as a shift in emphasis, not an expansion. Quantitative accuracy is moderate because no explicit numbers (dollar amounts, percentages, dates) are misstated—this is a qualitative disclosure question—but the description of disclosures is factually wrong. Contextual relevance is high because the answer addresses the right topic areas (currencies, cost-benefit, forward contracts) and cites appropriate document locations, but the conclusions are inverted. Overall, the answer is confidently wrong on the core evolution, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1646,
        "completion_tokens": 514,
        "total_tokens": 2160
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "What does the change in RTX's disclosure about the Powder Metal Matter between 2023 and 2024 suggest about its ongoing financial impact on future income tax benefits?",
      "original_answer": "In 2023, the Powder Metal Matter was disclosed as having a net sales charge of $5.3 billion, which negatively impacted net products sales at Pratt & Whitney and contributed to a decline in overall revenue. By 2024, the Powder Metal Matter was listed under future income tax benefits with a value of $455 million, down from $644 million in 2023. This shift indicates that while the matter continues to carry financial significance, its treatment has evolved from a direct operational loss to a deferred tax asset, suggesting a reduction in its immediate negative impact and a potential long-term recovery or resolution.",
      "llm_answer": "The 2024 disclosure shift—removing the Powder Metal Matter from the “Significant Accounting Policies” section and moving it to a separate “Powder Metal Matter” note—signals that the company no longer treats the issue as a material accounting uncertainty affecting future tax benefits. By isolating the matter, RTX can now assess and record any remaining tax impacts (e.g., deferred tax assets/liabilities or valuation allowances) without the prior “significant” label, suggesting that the tax‑related exposure is expected to be limited and will be managed through standard tax accounting rather than a material future tax‑benefit adjustment. Consequently, investors should anticipate only modest, if any, additional income‑tax benefits or charges tied to the Powder Metal Matter going forward.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in both quantitative and qualitative aspects. (1) QUANTITATIVE INACCURACY: The LLM fails to include any of the key financial figures from the ground truth—specifically, the $5.3 billion net sales charge in 2023 and the shift in future income tax benefits from $644 million (2023) to $455 million (2024). These numbers are central to the question and completely absent in the LLM response, making it factually deficient. (2) COMPLETENESS: The answer does not address the change in financial impact on future income tax benefits using actual data. Instead, it focuses on a structural change in disclosure format (moving to a separate note), which is not mentioned in the ground truth and appears to be fabricated or inferred without basis. (3) ENTITY & REASONING: While the LLM correctly identifies RTX and the Powder Metal Matter as the subject, its reasoning about accounting policy reclassification is unsupported by the original answer. The ground truth emphasizes a shift from an operational loss to a deferred tax asset with quantifiable reductions in value, indicating ongoing but diminishing impact. The LLM incorrectly concludes that the matter is no longer material or expected to yield significant future tax benefits, contradicting the documented $455 million value in 2024. (4) SEMANTIC EQUIVALENCE: The core message diverges significantly—the original suggests continued financial significance through a deferred tax asset; the LLM implies de-materialization and minimal future impact. This misrepresents the situation. The answer has some contextual relevance by discussing tax benefits and disclosure changes but fails on factual correctness and multi-hop synthesis of financial data across years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 472,
        "total_tokens": 1830
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How has PayPal's involvement in the merchant receivables space evolved between 2022 and 2024, particularly in terms of its relationship with partner institutions and the scale of its merchant finance offerings?",
      "original_answer": "In 2022, PayPal described its U.S. merchant finance products (PPWC and PPBL) as being provided under a program agreement with WebBank, where PayPal could purchase the related receivables and also sell back a participation interest in the pool of receivables to WebBank. PayPal accounted for this arrangement as a sale and derecognized the portion of participation interests for which control was surrendered. By 2024, PayPal's relationship with partner institutions had evolved, with PayPal now purchasing approximately $1.8 billion in merchant receivables in 2024 (up from $1.7 billion in 2023), and the total outstanding balance in the pool of merchant loans, advances, and interest and fees receivable reached $1.5 billion as of December 31, 2024 (up from $1.2 billion as of December 31, 2023). Additionally, the participation interest sold to the partner institution increased to $53 million in 2024 from $44 million in 2023, indicating a growing level of investment in and collaboration around merchant receivables.",
      "llm_answer": "PayPal’s merchant finance business has grown markedly from 2022 to 2024, expanding the pool of merchant receivables it purchases to roughly $1.8 billion in 2024 (up from $1.7 billion in 2023) and increasing the outstanding balance of its merchant loan‑and‑advance portfolio to $1.5 billion (net of the partner’s participation interest).  The company now shares credit risk with its partner institution on a pro‑rata basis, selling participation interests in the receivables while retaining servicing rights and receiving a market‑based service fee.  This arrangement has allowed PayPal to scale its merchant finance offerings while maintaining a relatively low‑cost funding structure, and the allowance for credit losses on these merchant receivables fell from $160 million in 2023 to $113 million in 2024, reflecting improved credit quality despite the larger portfolio.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the growth in PayPal's merchant receivables from $1.7B in 2023 to $1.8B in 2024 and the increase in the outstanding balance to $1.5B as of December 31, 2024 (up from $1.2B in 2023), which aligns with the ground truth. It also correctly notes the evolution of the relationship with partner institutions involving participation interests. However, it introduces a specific figure for the allowance for credit losses—$113M in 2024 down from $160M in 2023—which is not present in the original answer and cannot be verified against the provided ground truth, making it factually unsupported. Additionally, the claim that the $1.5B portfolio balance is 'net of the partner’s participation interest' is speculative and not stated in the original; the ground truth reports the total outstanding balance as $1.5B without specifying netting. The participation interest sold increased to $53M in 2024 from $44M in 2023 according to the original, but this key quantitative detail is omitted in the LLM response. (2) While the $1.8B and $1.7B figures are accurate, the missing $53M/$44M participation interest data represents a significant omission in quantitative detail. The unsupported credit loss allowance numbers reduce quantitative accuracy. (3) The reasoning around risk-sharing, pro-rata credit risk, servicing rights, and market-based fees shows sound qualitative understanding of how such arrangements typically work, but these specifics (e.g., 'pro-rata basis', 'servicing rights', 'market-based fee') are not present in the original answer and represent inference beyond the provided facts. The core multi-hop synthesis—linking PayPal’s evolving relationship with partner institutions to growth in receivables scale—is partially correct but lacks full grounding in the documented changes (e.g., shift in participation interest amounts). (4) The contextual relevance is high because the answer addresses the evolution of PayPal's involvement, scale, and partner dynamics. However, the correctness score is reduced due to unverified numbers and omitted key facts, placing it in the partially correct range with significant but not fundamental errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1488,
        "completion_tokens": 588,
        "total_tokens": 2077
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How did Merck's alliance revenue from Lynparza evolve between 2022 and 2024, and what factors contributed to the change?",
      "original_answer": "In 2022, Merck's alliance revenue from Lynparza was $989 million. By 2024, this revenue grew by 9%, driven by increased demand in most international markets. The growth reflects Lynparza's expanding adoption and new approvals, such as in China in January 2025 for adjuvant treatment in early breast cancer based on the OlympiA trial.",
      "llm_answer": "Between 2022 and 2024, Merck's alliance revenue from Lynparza grew significantly, increasing from $725 million in 2022 to $1,311 million in 2024 (a 9% rise in 2024, with 11% growth excluding foreign‑exchange effects). This expansion was driven by higher demand across most international markets, particularly in regions where Lynparza is approved for multiple cancer types, as well as the January 2025 Chinese approval for adjuvant treatment of BRCA‑mutated, HER2‑negative early‑stage breast cancer, which is expected to further boost sales. The growth reflects the continued strength of the Lynparza collaboration with AstraZeneca and broader adoption of the drug in ovarian, breast, pancreatic and prostate cancers.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies in key financial figures. According to the ground truth, Merck's alliance revenue from Lynparza was $989 million in 2022, but the LLM incorrectly states it was $725 million. The 2024 revenue is stated as $1,311 million in the LLM answer, which does not align with a 9% growth from $989 million (which would be approximately $1,078 million). While the LLM mentions a 9% rise in 2024, this percentage cannot be verified with its own numbers—$725M to $1,311M is an 81% increase, not 9%. The 11% growth excluding foreign-exchange effects is not present in the ground truth and appears fabricated. (2) The January 2025 Chinese approval for adjuvant treatment in early breast cancer is correctly mentioned and aligns with the ground truth, including the OlympiA trial basis (implied in LLM answer via indication). However, the drug’s collaboration with AstraZeneca and its use in multiple cancers (ovarian, breast, etc.) are contextually accurate but not specified in the original answer, adding plausible detail without confirmation. (3) The multi-hop reasoning is partially sound—linking increased revenue to international demand and regulatory approvals reflects correct logic and synthesis. However, the incorrect base numbers undermine the entire quantitative conclusion. The 9% growth claim is consistent with the ground truth, but it is misapplied to incorrect base figures. (4) The contextual relevance is high because the answer addresses both parts of the question—revenue evolution and contributing factors—and includes relevant qualitative drivers. However, due to severe quantitative inaccuracies in core financial data, the correctness score is low. The qualitative accuracy is moderate due to correct identification of growth drivers and approval events, but the inclusion of unverified details (e.g., FX impact) reduces precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1256,
        "completion_tokens": 515,
        "total_tokens": 1771
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has PayPal's involvement in merchant receivables evolved between 2022 and 2024, particularly in terms of its financial exposure and operational role?",
      "original_answer": "In 2022, PayPal's involvement in merchant receivables was primarily framed in terms of credit losses and net charge-offs, indicating a focus on risk management and accounting treatment under CECL standards. By 2024, PayPal had significantly expanded its direct involvement through active purchases of merchant receivables—$1.8 billion in 2024 compared to $1.7 billion in 2023—and reported a growing outstanding balance of $1.5 billion, up from $1.2 billion. Additionally, PayPal took on full servicing responsibilities for these receivables, signaling a deeper operational engagement in merchant finance through products like PPWC and PPBL.",
      "llm_answer": "PayPal's financial exposure to merchant receivables declined materially between 2022 and 2024, with the allowance for credit losses on its merchant portfolio falling from $160 million (as reported in the 2022 filing) to $113 million by the end of 2024, reflecting improved credit quality—particularly in the PPBL portfolio—and a reduction in charge‑offs. Operationally, the company continues to purchase merchant receivables (approximately $1.8 billion in 2024 versus $1.7 billion in 2023) and service them through its PPWC and PPBL products, but the portfolio size has contracted modestly ($1.5 billion outstanding as of Dec 2024 versus $1.2 billion in 2023), indicating a shrinking balance‑sheet exposure while the company maintains its servicing role and associated fee income.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. While it correctly notes PayPal's continued purchase of merchant receivables ($1.8B in 2024 vs $1.7B in 2023) and servicing through PPWC/PPBL, it fundamentally misrepresents the evolution of financial exposure. The original answer states that outstanding receivables grew from $1.2B to $1.5B, indicating increased exposure, but the LLM claims the portfolio 'contracted modestly' from $1.2B in 2023 to $1.5B in 2024—this is factually backwards and misrepresents the direction of change. Additionally, the LLM introduces new figures—allowance for credit losses of $160M in 2022 and $113M in 2024—that are not present in the ground truth and cannot be verified; these numbers contradict the original answer’s focus on active receivables purchases and servicing expansion. (2) Quantitative accuracy is partially correct: the $1.8B (2024) and $1.7B (2023) purchase amounts align with the ground truth, and $1.5B outstanding in 2024 is correct. However, the $1.2B figure is misattributed to 2023 when the original implies it was the prior year balance (likely 2022 or early 2023), and the allowance figures are unsupported. The claim of a 'decline' in exposure based on allowance is speculative and not in the original. (3) Multi-hop reasoning is flawed: the model infers reduced risk from declining allowances, but the original answer emphasizes increased operational involvement and balance growth, signaling expansion, not contraction. The synthesis fails to align with the core narrative of growing engagement. (4) Despite these issues, the answer remains contextually relevant by addressing both financial exposure and operational role, citing correct products and directional trends in purchasing volume. However, the incorrect interpretation of balance changes and introduction of unsupported metrics significantly reduce factual correctness, warranting a mid-low score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 527,
        "total_tokens": 1884
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How has Merck's involvement in the development and commercialization of Lynparza evolved from 2022 to 2024, particularly in terms of regulatory progress and revenue growth?",
      "original_answer": "In 2022, Merck was awaiting FDA decision on a supplemental NDA for Lynparza for the adjuvant treatment of BRCA-mutated, HER2-negative high-risk early-stage breast cancer, based on the OlympiA trial, with a PDUFA date in Q1 2022. By 2024, Lynparza had not only maintained its approvals but also expanded its regulatory footprint, with a new approval in China in January 2025 for the same indication, indicating continued global regulatory momentum. Additionally, alliance revenue related to Lynparza grew by 9% in 2024 due to increased demand in international markets, showing a measurable increase in commercial success.",
      "llm_answer": "From 2022 through 2024 Merck’s Lynparza program moved from regulatory approval toward broader commercialization and revenue growth.  In 2022 the drug was already approved for several cancer types, and by 2024 it received additional approvals in the EU (including for metastatic castration‑resistant prostate cancer) and in China (as an adjuvant treatment for BRCA‑mutated early‑stage breast cancer in January 2025).  These approvals, together with continued demand in existing indications, drove alliance revenue from Lynparza up 9 % in 2024 (11 % excluding foreign‑exchange effects), contributing to the oncology segment’s overall sales expansion.  Thus, Lynparza’s involvement evolved from a mature, multi‑indication product in 2022 to a growth‑driving asset with new regulatory clearances and rising revenue through 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of Merck's involvement with Lynparza from 2022 to 2024, aligning well with the ground truth. It accurately notes the regulatory momentum, including the January 2025 approval in China for adjuvant treatment of BRCA-mutated early breast cancer, which reflects continued global expansion. The 9% revenue growth in 2024 is correctly stated, matching the original answer. The additional detail of 11% growth excluding foreign exchange effects is not in the ground truth but does not contradict it and adds reasonable context. (2) Quantitatively, all key numbers are correct: the 9% alliance revenue growth in 2024 and the January 2025 China approval date are accurate. The mention of EU approvals for metastatic castration-resistant prostate cancer is not in the original answer but is factually plausible and does not introduce error; it adds detail without undermining correctness. (3) The multi-hop reasoning is sound: the model synthesizes regulatory progress (from pending decisions in 2022 to expanded approvals by 2024) with commercial performance (revenue growth), correctly attributing increased demand to international markets. The evolution from a mature product to a growth driver is a valid interpretation supported by the data. (4) The answer is highly contextually relevant, directly addressing both regulatory progress and revenue growth as asked. The only minor deviation is the inclusion of an EU prostate cancer approval not mentioned in the ground truth, but this does not distort the core facts. Overall, the answer is factually accurate, well-reasoned, and semantically equivalent to the original, warranting a high score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 464,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How has Boeing's strategy with commodity purchase contracts evolved between 2022 and 2024, particularly in terms of risk management horizon and financial exposure?",
      "original_answer": "In 2022, Boeing disclosed that a 10% change in commodity prices would impact unrealized losses by $46 million, and the company used commodity swaps and purchase contracts to hedge against price volatility, neutralizing material market risk. By 2024, Boeing extended the scope of its hedging strategy, indicating the use of commodity purchase contracts and derivatives to manage exposure through 2031. This represents a shift toward longer-term risk management aligned with extended production planning cycles. The expansion from a general hedging approach in 2022 to a multi-decade horizon in 2024 suggests Boeing is proactively securing cost predictability for strategic business stability.",
      "llm_answer": "Boeing's commodity hedge strategy has evolved to extend hedging horizons significantly, with contracts now covering forecasted transactions through 2028 (up from prior years' coverage) and a notable shift toward longer-dated instruments. The company actively manages financial exposure through cash flow hedges, as evidenced by its expectation to reclassify $64 million (pre-tax) of AOCI losses into earnings within the next 12 months, while maintaining strict risk controls via credit-risk contingent features that could trigger settlements if its credit rating deteriorates.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies in key quantitative and temporal details. The ground truth states Boeing extended its hedging strategy through 2031, but the LLM incorrectly states 'through 2028', which is a significant deviation in the risk management horizon. Additionally, the $64 million AOCI reclassification figure cited in the LLM answer does not appear in the original answer and is factually unsupported by the provided ground truth; the correct figure from 2022 is a $46 million impact from a 10% commodity price change. These errors undermine the quantitative accuracy. (2) Number verification: The original answer specifies a $46 million exposure in 2022 due to 10% price change; LLM omits this and introduces a $64 million figure with no basis in the ground truth. The 2031 horizon is a key strategic shift, but LLM shortens it to 2028, misrepresenting the extent of Boeing's long-term planning. (3) Multi-hop reasoning is partially sound—the LLM correctly infers that Boeing is extending its hedging horizon and managing financial exposure via derivatives and purchase contracts. It also correctly identifies the use of cash flow hedges and credit-risk contingencies, which align with risk management practices. However, it fails to accurately synthesize the evolution from 2022 to 2024, missing the specific comparison of risk neutralization in 2022 versus multi-decade planning in 2024. (4) Despite factual inaccuracies, the answer remains contextually relevant, addressing risk management evolution, financial exposure, and hedging instruments. The reasoning structure is logical and covers the core themes of the question, warranting moderate scores in qualitative accuracy and contextual relevance. However, the incorrect dates and financial figures significantly reduce overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 498,
        "total_tokens": 1819
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How did Schwab's exposure to PALs and the associated credit risk evolve between 2021 and 2024, particularly in terms of collateralization and allowance for credit losses?",
      "original_answer": "In 2021, all PALs were fully collateralized by securities with fair values exceeding borrowings, and therefore no allowance for credit losses was required. In contrast, by 2024, although PALs experienced slight growth overall, Schwab observed a decrease in the allowance for credit losses due to lower projected loss rates and improved credit quality metrics. This reflects a shift from a focus on full collateralization as the primary risk mitigant to a broader assessment of credit quality and loss projections.",
      "llm_answer": "Between 2021 and 2024, Schwab's exposure to Personal Account Loans (PALs) declined significantly, with total PAL balances falling from $23.7 billion at December 31, 2021 to $16.7 billion by December 31, 2024 (as shown in the maturity schedule on page 141). The allowance for credit losses on bank loans remained minimal throughout this period, with the allowance balance for residential real estate loans decreasing from $15 million in 2021 to $13 million in 2024 (page 91), and no allowance was required for PALs as they were fully collateralized by securities (page 91). Credit risk remained low, with nonaccrual PAL loans consistently below 0.2% of the portfolio (page 93), and the allowance for credit losses as a percentage of total bank loans remained stable around 0.05% to 0.06% during this period.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that PALs experienced 'slight growth' between 2021 and 2024, but the LLM claims a 'significant decline' from $23.7B to $16.7B, which directly contradicts the original answer. Additionally, the LLM incorrectly states that no allowance was required for PALs in 2024 due to full collateralization, while the ground truth indicates that by 2024, the allowance decreased due to improved credit quality and lower projected loss rates — implying a shift away from reliance solely on collateralization. The LLM also introduces unrelated data about residential real estate loans ($15M to $13M), which are not PALs and not relevant to the question. (2) The quantitative values (e.g., $23.7B, $16.7B, $15M, $13M, 0.2%, 0.05%-0.06%) may be internally consistent with some filing data, but they are either misattributed or incorrect in context. Most critically, the direction of change in PAL balances is wrong — the ground truth says 'slight growth', not a decline of $7B. This represents a major quantitative error. (3) The multi-hop reasoning is flawed: the LLM fails to recognize the conceptual shift from collateral-based risk mitigation (2021) to credit-quality-driven allowance modeling (2024). Instead, it incorrectly asserts that no allowance was needed due to collateralization throughout, missing the evolution in risk assessment approach entirely. It also conflates different loan types (residential real estate vs. PALs), indicating poor entity discrimination. (4) The answer is contextually relevant in that it discusses PALs, credit risk, collateralization, and allowance for credit losses, but the core facts and reasoning are incorrect. Due to major factual and conceptual errors, especially on the trend in PAL exposure and the rationale for allowance changes, the correctness score is low at 3. Quantitative accuracy is severely compromised, hence a score of 2. Qualitative reasoning is weak due to flawed synthesis and misattribution, scoring 3. Contextual relevance is moderate (6) because the response stays on topic but with incorrect content.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 576,
        "total_tokens": 1912
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How did Boeing's financial treatment and strategic positioning of the 777X program evolve between 2022 and 2024, given the changes in cost impacts and research & development investments?",
      "original_answer": "In 2022, the 777X program negatively impacted Boeing's financials, contributing to higher charges and a cost of sales increase, partly due to a 'reach-forward loss' on the program. By 2024, the program had transitioned to being a strategic investment priority, as evidenced by a $435 million increase in R&D spending in 2024 compared to 2023, following a $525 million increase in 2023 over 2022, indicating a shift from a cost burden to a focal point for future product development.",
      "llm_answer": "Between 2022 and 2024 Boeing’s 777X program shifted from a growth‑focused investment to a cost‑bearing, loss‑generating effort.  In 2022 the company still recorded R&D spending on the 777X, but by 2024 it was reporting a $1.77 billion reach‑forward loss on the T‑7A program and additional losses on the KC‑46A and Commercial Crew that were “partially attributable to higher supplier costs,” indicating that the 777X’s cost pressures were now embedded in broader supplier‑cost inflation.  Accordingly, research‑and‑development expense rose to $2.386 billion in 2024 (up from $2.036 billion in 2023 and $1.510 billion in 2022), driven largely by the 777X program and other enterprise product‑development outlays, while the program’s cost share was reflected in a steep increase in cost‑of‑sales as a percentage of revenue—from 94.7 % in 2022 to 103.0 % in 2024—signaling a deteriorating margin outlook for the 777X and related aerospace projects.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual and quantitative errors that undermine its correctness. (1) It incorrectly states that Boeing reported a $1.77 billion reach-forward loss on the T-7A program in 2024, which is unrelated to the 777X and not mentioned in the ground truth. The original answer specifies a 'reach-forward loss' on the 777X in 2022, not 2024, and does not mention T-7A, KC-46A, or Commercial Crew. (2) The R&D figures provided ($1.510B in 2022, $2.036B in 2023, $2.386B in 2024) are not supported by the ground truth, which only states year-over-year increases of $525M (2023 vs 2022) and $435M (2024 vs 2023), implying different base values. The LLM’s calculation of total R&D is speculative and inconsistent with the original data. (3) The claim that cost-of-sales increased from 94.7% to 103.0% of revenue due to the 777X is not present in the ground truth and introduces unsupported metrics. (4) The reasoning mischaracterizes the evolution: the ground truth describes a shift from cost burden (2022) to strategic investment (2024), but the LLM portrays a continued deterioration, contradicting the positive framing of increased R&D as strategic prioritization. (5) The LLM confuses program attribution, incorrectly linking supplier cost issues to 777X without evidence. While the answer attempts multi-hop synthesis and addresses financial treatment and R&D trends, the core facts—especially numbers and program-specific impacts—are incorrect or misattributed, leading to a largely inaccurate conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 418,
        "total_tokens": 1785
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How has Schwab's exposure to and risk management of Portfolio Against Loans (PALs) evolved between 2022 and 2024, particularly in terms of credit loss allowance methodology and portfolio growth?",
      "original_answer": "In 2022, Schwab applied the practical expedient for PALs due to their collateralized nature and over-collateralization requirements, which limited inherent credit loss. The company monitored collateral daily and maintained strict maintenance levels based on the type of security pledged. By 2024, PALs had contributed to the growth of the average loan portfolio, although there was a slight decrease in 2023. The overall decrease in the allowance for credit losses as a ratio to year-end loans in 2024 was attributed to improved credit quality metrics and lower projected loss rates, indicating a reduced risk profile for PALs despite portfolio growth.",
      "llm_answer": "Based on the provided SEC 10-K filings, Schwab's exposure to Portfolio Against Loans (PALs) has evolved significantly between 2022 and 2024, particularly in credit loss methodology and portfolio growth:\n\n1.  **Credit Loss Methodology Evolution:** Schwab's allowance for credit losses on PALs has been consistently described as being estimated using a practical expedient based on collateral maintenance provisions (as stated in the 2022 Notes to Financial Statements, page 78). This approach remains unchanged in 2024, where PALs are explicitly noted to be \"collateralized by marketable securities\" with \"credit lines over-collateralized\" and borrowers required to maintain specified collateral levels, limiting inherent credit loss. The methodology for the broader residential real estate portfolio (which includes PALs as part of the \"First Mortgages\" and \"HELOCs\" segments) relies on statistical models forecasting losses based on delinquency roll rates, loss severity, housing prices, interest rates, and unemployment, but PALs themselves are treated as low-risk due to collateralization.\n\n2.  **Portfolio Growth:** Schwab's bank loan portfolio (which includes PALs) grew substantially from $38,816 million in 2022 to $42,255 million in 2024 (as shown in the 2024 Supplemental Financial Data, page 139). This growth is reflected in the \"Total interest-earning assets\" and \"Bank loans\" line items, indicating a significant increase in the PAL portfolio balance over the two-year period. The 2024 data also shows the portfolio's maturity profile, with $16,733 million of PALs maturing within one year and $26,475 million maturing after 15 years (page 141), confirming substantial growth and long-term exposure. The allowance for credit losses methodology for the broader loan portfolio (including PALs) remained focused on statistical modeling and collateral assessment, but the growing portfolio size represents a material expansion in exposure.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies, particularly in quantitative details and key aspects of the credit loss methodology evolution. (1) Quantitative Accuracy: The reported loan portfolio growth from $38,816 million in 2022 to $42,255 million in 2024 is not supported by the ground truth, which does not provide specific dollar figures for the PAL portfolio or total loans in those years. The LLM fabricates precise numbers and cites non-existent or incorrect sources (e.g., '2024 Supplemental Financial Data, page 139') that were not in the original context. The maturity breakdown of $16,733 million and $26,475 million is also not present in the ground truth and appears invented. (2) Qualitative Accuracy: The claim that the credit loss methodology 'remains unchanged' contradicts the ground truth, which indicates a shift in risk profile due to improved credit quality and lower projected loss rates by 2024, even if the practical expedient was still used. The LLM incorrectly ties PALs to 'First Mortgages' and 'HELOCs' as part of residential real estate, which is not stated in the original answer and misrepresents the nature of PALs. (3) Reasoning: The multi-hop synthesis is flawed—while the LLM attempts to connect collateralization and risk management, it fails to accurately reflect the evolution described in the ground truth: portfolio growth with a *decrease* in allowance ratio due to improved risk metrics. Instead, it emphasizes unchanged methodology and fabricated growth data. (4) Contextual Relevance: The response is well-structured and addresses the right themes (methodology, portfolio growth, risk), so it remains relevant despite factual errors. Overall, the answer is partially correct in identifying collateralization and portfolio growth as themes but fails on core facts and calculations, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1662,
        "completion_tokens": 504,
        "total_tokens": 2166
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How did MDLZ's value of British pound sterling notes change from 2022 to 2023, and what does this shift indicate about the company's foreign exchange risk management strategy?",
      "original_answer": "In 2022, MDLZ reported a value of $3 million for British pound sterling notes. By 2023, this value had increased significantly to $45 million. This shift indicates a substantial change in MDLZ's foreign exchange risk management strategy, suggesting an increased exposure to the British pound sterling, which could reflect either a strategic decision to hedge more in this currency or an increase in operational activities tied to the UK market.",
      "llm_answer": "From the 2023 10‑K, the fair‑value of MDLZ’s currency‑exchange contracts fell from $82 million (2022) to $61 million (2023), reflecting a $21 million decline in the Level‑2 fair‑value amount. This reduction shows that MDLZ trimmed its direct foreign‑exchange exposure, shifting reliance toward longer‑dated cash‑flow hedges and net‑investment hedges (e.g., cross‑currency swaps on euro, pound and other debt) to manage FX risk rather than holding large short‑term forward positions.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both quantitative and qualitative aspects. (1) It discusses the fair value of currency-exchange contracts ($82M in 2022 to $61M in 2023), which is entirely different from the actual metric in question: the value of British pound sterling notes held by MDLZ. The ground truth states that the value of pound sterling notes increased from $3M in 2022 to $45M in 2023—a significant increase, not a decrease. The LLM reports a $21M decline in a completely different financial instrument, leading to a false conclusion. (2) The numbers cited ($82M, $61M) do not match the ground truth ($3M, $45M), and the calculation of a $21M decline is irrelevant to the actual $42M increase. (3) The reasoning is flawed: instead of identifying increased exposure to the British pound as indicated by the rise in pound sterling notes, the LLM concludes reduced exposure based on unrelated hedging instruments. This fails the multi-hop requirement to identify the specific asset (pound sterling notes), track its change over time, and interpret strategic implications. (4) The context is partially relevant—foreign exchange risk management—but misdirected to currency derivatives rather than cash holdings in GBP. The answer fabricates data from a different section of the 10-K, resulting in a completely inaccurate portrayal of MDLZ's strategy. Minor credit is given for addressing FX risk management conceptually, but factual and directional errors dominate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1238,
        "completion_tokens": 407,
        "total_tokens": 1645
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "Compare the interest rate disclosures for Amgen's 3.125% 2025 Notes in the 2022 and 2024 filings, and explain what this reveals about the company's approach to debt financing for this instrument.",
      "original_answer": "In the 2022 filing, Amgen disclosed a fixed interest rate of 3.125% for the 2025 Notes with no mention of variable rate terms. However, by the 2024 filing, Amgen disclosed that the interest rate for the same 3.125% 2025 Notes was tied to SOFR (Secured Overnight Financing Rate) plus 2.1%. This indicates a shift from a purely fixed-rate structure to a floating-rate mechanism, suggesting Amgen may have refinanced or repriced the notes to adapt to changing market conditions and interest rate environments.",
      "llm_answer": "Amgen’s 3.125% 2025 Notes were disclosed in both the 2022 and 2024 filings as part of its long‑term debt schedule, with the 2022 filing showing a $1,000 million carrying value for the 2025 tranche and the 2024 filing maintaining the same $1,000 million figure but now reflecting an updated fair‑value hedge structure that ties the note to a SOFR‑plus‑2.1% swap. The 2024 filing also reveals that Amgen has entered into new interest‑rate swap agreements (e.g., a $1.4 billion swap for the 5.25% 2033 Notes) and has rolled existing swaps, indicating a proactive approach to managing the note’s interest‑rate exposure. This demonstrates that Amgen actively refinances and hedges its 2025 debt to lock in favorable floating‑rate terms and mitigate interest‑rate risk, rather than relying on the original fixed coupon.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partial correctness but introduces significant inaccuracies. The ground truth states that in 2022, the 3.125% 2025 Notes had a fixed rate of 3.125% with no variable rate mention, while in 2024, the same notes were disclosed as tied to SOFR + 2.1%, indicating a structural shift. The LLM incorrectly frames this as an updated fair-value hedge via a swap, rather than a change in the actual interest rate terms of the note. This misrepresents the nature of the change — it is not merely a hedge or swap overlay, but a fundamental shift in the interest rate mechanism. (2) Quantitatively, the $1,000 million carrying value is plausible and consistent across years, and the mention of a $1.4 billion swap for other notes (5.25% 2033) may be accurate but is extraneous. However, the core claim about a SOFR-plus-2.1% 'swap' is factually incorrect — the ground truth indicates the note itself was repriced or refinanced to a floating rate, not that a swap was layered on. (3) The multi-hop reasoning is partially sound — the model connects disclosures across years and infers strategic debt management — but fails on the key point: it confuses hedging activity with a change in the underlying instrument’s terms. The conclusion that Amgen is 'actively refinancing and hedging' is reasonable, but the evidence cited (swap agreements) does not support the specific claim about the 2025 Notes’ rate change. (4) Scores reflect that while the answer is contextually relevant and contains some accurate data, it misstates the core financial mechanism, undermining factual correctness and qualitative accuracy. The answer suggests sophisticated risk management, but misattributes the instrument-level change to hedging rather than refinancing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 481,
        "total_tokens": 1823
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How has Schwab's reliance on its Commercial Paper Issuance Program evolved between 2022 and 2024 in response to market disruptions and rising interest rates?",
      "original_answer": "In 2022, Schwab introduced its Commercial Paper Issuance Program as one of several potential sources of external financing, alongside unsecured bank credit lines and a universal shelf registration, to address liquidity needs during market disruptions. The company emphasized that while these tools were available, access to financing could still be constrained due to credit market volatility and potential credit rating downgrades. By 2024, Schwab's reliance on the program had increased as a complement to other funding mechanisms like FHLB advances and repurchase agreements, particularly in response to rising short-term interest rates in 2022 and 2023, which led to higher client cash outflows. The company noted that these outflows, outpacing cash generated from maturities and paydowns, required supplemental funding sources, including the commercial paper program, to manage liquidity under more costly and constrained conditions.",
      "llm_answer": "Schwab’s reliance on its Commercial Paper Issuance Program (CPIP) has shifted markedly between 2022 and 2024 as market disruptions and rising rates forced changes in its short‑term funding strategy. In 2022 the CPIP was a key source of liquidity, but the rapid interest‑rate hikes and heightened credit‑market stress prompted Schwab to supplement the program with higher‑cost sources such as FHLB advances, brokered CDs and other external financing, while also drawing down on its uncommitted bank credit lines. By 2024 the company continued to maintain the CPIP but emphasized that financing may not be available on acceptable terms during market disruptions, and a downgrade of its credit ratings could further restrict access—leading Schwab to increasingly depend on these alternative, more expensive funding channels to meet its liquidity needs.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent in terms of dates (2022 and 2024) and correctly identifies the Commercial Paper Issuance Program (CPIP) as a liquidity tool introduced in 2022. It also accurately references external financing sources such as uncommitted bank credit lines and notes potential constraints due to credit market volatility and rating downgrades—elements present in the ground truth. However, there are key qualitative inaccuracies in the reasoning and evolution of Schwab’s reliance on the program. The original answer states that reliance on the commercial paper program *increased* by 2024 as a complement to other funding mechanisms (like FHLB advances and repurchase agreements) due to rising rates and client cash outflows outpacing maturities. In contrast, the LLM answer suggests that Schwab *shifted away* from CPIP toward higher-cost alternatives like brokered CDs and FHLB advances, implying reduced reliance on commercial paper. This misrepresents the trend: the ground truth indicates increased, not decreased, use of CPIP as part of a broader funding strategy. Additionally, the LLM introduces 'brokered CDs' and characterizes CPIP as a 'key source' in 2022—stronger language than the original, which describes it as 'one of several potential sources.' The answer also fails to mention the specific driver of higher client cash outflows outpacing cash from maturities, a critical causal link in the original. While the overall context and entities are correct, and no numbers are inaccurate (hence full quantitative accuracy), the flawed synthesis of how Schwab’s reliance evolved undermines the multi-hop reasoning. Thus, the correctness and qualitative accuracy scores are moderate due to incorrect directional interpretation of program reliance despite accurate component facts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1449,
        "completion_tokens": 489,
        "total_tokens": 1939
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How has the status and interest rate structure of the 3.625% Notes evolved from 2022 to 2024, and what does this indicate about the company's debt management strategy?",
      "original_answer": "In 2022, the 3.625% 2024 Notes had a carrying value of $1,400 million with a fixed interest rate of 3.625%. By 2024, these notes were fully paid off, as indicated by the $0 notional amount, and were replaced with floating interest rates tied to SOFR (Secured Overnight Financing Rate). This shift from fixed to floating rate debt indicates a strategic change in Amgen's debt management, aligning with broader market conditions and potentially reducing interest costs in a declining rate environment.",
      "llm_answer": "From 2022 to 2024, the company retired the 3.625% 2022 Notes (€750 million) and the 3.625% 2024 Notes ($1.4 billion) through redemptions in 2021‑2022 and swapped portions of the 3.625% 2022 and 2024 Notes into floating‑rate exposure via terminated interest‑rate swaps, then entered into new swaps on the 2024, 2025, 2026 and 2031 notes at lower SOFR‑plus‑spread levels. This shift to lower‑coupon, floating‑rate structures and the use of swaps to convert fixed rates indicates a strategy of reducing fixed‑rate debt, lowering overall interest‑expense risk, and managing liquidity by extending maturities and taking advantage of historically low rates.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies in numbers and dates. The original answer states that the 3.625% 2024 Notes had a carrying value of $1,400 million in 2022 and were fully paid off by 2024. The LLM correctly identifies the $1.4 billion amount (equivalent to $1,400 million), but incorrectly references '3.625% 2022 Notes (€750 million)' which is not mentioned in the ground truth and introduces a foreign currency amount not present in the original. Additionally, the LLM claims redemptions occurred in '2021–2022', while the ground truth indicates the payoff was completed by 2024, making the timeline inconsistent. (2) The quantitative inaccuracies include the erroneous €750 million note and the premature redemption timeline. While the $1.4 billion figure is correct, the treatment of when and how the notes were retired is factually misaligned. The shift to SOFR-based floating rates is correctly noted, but the method (via interest rate swaps on multiple notes including 2025, 2026, 2031) goes beyond the scope of the original answer, which only states the 2024 Notes were replaced with floating-rate debt—without specifying instruments or swaps. (3) The multi-hop reasoning is partially sound: the LLM infers a strategic shift in debt management, which aligns with the original conclusion. However, it overreaches by detailing swap activity across multiple years and notes not referenced in the ground truth, introducing unsupported complexity. The core idea—shifting from fixed to floating to reduce interest expense—is valid, but the supporting evidence is partially fabricated. (4) The contextual relevance is high because the answer addresses the evolution of the note and interprets strategic intent. However, due to significant quantitative errors and unsupported details, the correctness score is moderate. The qualitative accuracy is acceptable due to correct directional logic, but penalized for hallucinated entities and events.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 531,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 118,
      "question": "How has Schwab's approach to providing financial or other support to variable interest entities (VIEs) evolved between 2022 and 2024, particularly in terms of intent and conditions for funding commitments?",
      "original_answer": "In 2022, Schwab explicitly stated that it did not provide or intend to provide financial or other support to VIEs that it was not contractually required to provide. By 2024, Schwab's disclosures indicate a shift, as the company now acknowledges that while it has no contractual obligation, it may choose to provide credit, liquidity, or other support to its proprietary funds in response to significant declines in valuation or redemption activity. This reflects a more proactive stance in supporting funds under certain market conditions, even though it is not mandated.",
      "llm_answer": "Schwab's funding commitments to VIEs shifted from a stance of no intent to provide support in 2021 to active, conditional funding between 2022 and 2025. The company now expects to fund substantially all remaining commitments during this period, contingent on specific conditions being met, reflecting a change in both intent and the structured timing of its VIE support.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that Schwab had a 'no intent to provide support in 2021', while the ground truth begins with 2022 as the baseline year. The LLM also fabricates a timeline extending to 2025, which is outside the scope of the question (2022–2024). Most critically, it claims Schwab 'expects to fund substantially all remaining commitments during this period', which is not supported by the original answer and misrepresents the nature of the support as systematic and expected, rather than discretionary and conditional. (2) The dates are incorrect: 2021 and 2025 are not part of the ground truth comparison (which is 2022 vs 2024). There are no dollar amounts or percentages in the original, so no quantitative values are accurate. (3) The multi-hop reasoning is flawed. The original answer hinges on a shift from 'no intent to provide support' in 2022 to a discretionary willingness to support proprietary funds under stress in 2024. The LLM fails to capture this nuance and instead invents a structured funding plan with timing expectations, suggesting a contractual or planned obligation rather than a discretionary policy shift. It also fails to specify that the potential support applies only to proprietary funds. (4) The contextual relevance is moderate because the answer addresses VIE support and a shift in intent, but the incorrect years, invented funding expectations, and lack of specificity about discretionary support severely undermine accuracy. The core message of a policy evolution is partially present but distorted.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1250,
        "completion_tokens": 442,
        "total_tokens": 1692
      },
      "error": null
    },
    {
      "question_id": 118,
      "question": "How has MDLZ's financial relationship with JDE Peet's evolved between 2022 and 2023, particularly in terms of how the investment impacts MDLZ's liquidity and capital structure?",
      "original_answer": "In 2022, MDLZ's relationship with JDE Peet's was characterized as a 'Has_Stake_In' arrangement, where MDLZ reported its proportionate share of significant operating and non-operating items from JDE Peet's including restructuring and acquisition-related costs. By 2023, the relationship was reclassified to 'Invests_In', and the investment in JDE Peet's was described as providing additional financial flexibility within MDLZ's liquidity and capital resources framework. This shift indicates a more strategic and stable investment posture, aligning JDE Peet's more closely with MDLZ's long-term capital planning and funding sources.",
      "llm_answer": "Between 2022 and 2023, MDLZ’s investment in JDE Peet’s shifted from a significant drain on liquidity to a more stable, albeit still costly, strategic holding. While the investment contributed to higher capital expenditures and financing outflows (e.g., $7.558B net cash used in financing in 2023 vs. $456M in 2022), it did not materially impair MDLZ’s liquidity or capital structure, as cash from operations ($4.714B in 2023) and access to credit remained robust. The investment’s impact on capital structure was limited to modest increases in debt repayments and dividends, with no material effect on leverage (debt-to-capitalization held at 0.41 in 2023).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces specific financial figures such as '$7.558B net cash used in financing' and '$4.714B cash from operations' in 2023, and '$456M in 2022', which are not present in the original ground truth and cannot be verified from the provided context. These numbers appear fabricated or misattributed, severely undermining quantitative accuracy. The claim about debt-to-capitalization ratio of 0.41 in 2023 is also unsupported by the original answer. (2) The original answer focuses on a qualitative shift in the nature of MDLZ's relationship with JDE Peet’s—from 'Has_Stake_In' to 'Invests_In'—and how this reclassification reflects greater financial flexibility and strategic alignment. The LLM mischaracterizes the evolution as shifting from a 'drain on liquidity' to a 'strategic holding', which contradicts the original narrative that the investment enhanced financial flexibility rather than previously impairing liquidity. (3) The multi-hop reasoning is flawed: the original answer does not support any claim about capital expenditures, financing outflows, or operational cash flow impacts related to JDE Peet’s. There is no mention of dividends, debt repayments, or leverage metrics in the ground truth, indicating the LLM invented these details. (4) While the LLM attempts to address the evolution of the financial relationship and its impact on liquidity and capital structure, it does so with factually incorrect data and misleading characterization. The contextual relevance is moderate because it addresses the right topic and timeframe, but correctness is low due to hallucinated numbers and incorrect qualitative interpretation. The original answer emphasizes improved financial flexibility and strategic repositioning, not ongoing costs or financing strain.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 488,
        "total_tokens": 1818
      },
      "error": null
    },
    {
      "question_id": 119,
      "question": "How did the interest rate hedging strategy for the 3.125% 2025 Notes evolve between 2022 and 2024, particularly in terms of the interest rate applied under the swap agreements?",
      "original_answer": "In 2022, the company had terminated interest rate swaps for portions of the 3.125% 2025 Notes and reentered into new swap agreements at then-current interest rates, though the exact rate for the 3.125% 2025 Notes was not disclosed. By 2024, the interest rate applied under the swap agreement for the 3.125% 2025 Notes was explicitly stated as SOFR+2.1%, with a consistent notional amount of $1,000 million as of December 31, 2024, compared to December 31, 2023.",
      "llm_answer": "The interest rate hedging strategy for the 3.125% 2025 Notes shifted from a fixed‑rate coupon to a floating‑rate structure tied to LIBOR (or SOFR in later years). In 2020 the company entered into interest‑rate swaps that converted the 3.125% 2025 Notes’ fixed coupon to a LIBOR + 1.8% floating rate (notional $1 billion). By 2024 the same swaps were referenced to SOFR + 2.1% (still on the $1 billion notional), reflecting the market transition from LIBOR to SOFR and resulting in a lower effective interest rate (approximately 5.2% vs. the original 3.125% coupon). Thus, between 2022 and 2024 the swap‑based effective rate evolved from LIBOR + 1.8% to SOFR + 2.1%, reducing the overall interest cost on the 2025 Notes.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. First, it claims that in 2020 the company entered into swaps converting the 3.125% 2025 Notes to LIBOR + 1.8% on a $1 billion notional, but the ground truth does not mention any such 2020 activity or specific rate of LIBOR + 1.8%. The original answer states that in 2022, the company terminated portions of existing swaps and reentered new agreements, but the rate was not disclosed. The LLM incorrectly asserts a continuous swap evolution from LIBOR + 1.8% to SOFR + 2.1%, which is unsupported by the ground truth. While the $1 billion notional and SOFR + 2.1% rate in 2024 are correct, the earlier details are fabricated. (2) Quantitative accuracy is low: the LLM invents a LIBOR + 1.8% rate and a 2020 entry date not present in the ground truth. The claim of a 'lower effective interest rate (approximately 5.2%)' is speculative and not in the original answer. The notional amount ($1 billion) and 2024 rate (SOFR + 2.1%) are correct. (3) Multi-hop reasoning is partially sound in that it attempts to trace the evolution of the swap terms over time and acknowledges the LIBOR-to-SOFR transition, but it fails to accurately represent the 2022 developments, which involved termination and re-issuance without disclosure of rates. The synthesis is flawed due to reliance on incorrect prior data. (4) Contextual relevance is high as the answer addresses the hedging strategy evolution and focuses on the correct instrument and time frame. However, the correctness score is low due to significant factual and quantitative errors in the narrative, especially regarding the pre-2024 swap terms.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1302,
        "completion_tokens": 453,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 120,
      "question": "How did Walmart's fair value of equity investments measured using Level 2 inputs evolve from fiscal year 2022 to fiscal year 2023, and what was the magnitude of this change?",
      "original_answer": "Walmart's fair value of equity investments measured using Level 2 inputs decreased from $5,819 million in fiscal year 2022 to $5,570 million in fiscal year 2023, representing a moderate decline of $249 million over the period.",
      "llm_answer": "Based on the provided document pages, Walmart's fair value of equity investments measured using Level 2 inputs decreased from $5,570 million in fiscal 2023 to $4,414 million in fiscal 2024, representing a decline of $1,156 million (approximately $1.16 billion). This change reflects the net decrease in fair value due to market movements and other investment activity during the period.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 2,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in all key aspects. The original answer states that Walmart's fair value of equity investments measured using Level 2 inputs decreased from $5,819 million in fiscal year 2022 to $5,570 million in fiscal year 2023. However, the LLM answer incorrectly reports values for fiscal years 2023 and 2024 ($5,570 million to $4,414 million), which are not responsive to the question about 2022 to 2023. (2) The magnitude of change is also wrong: the correct decline is $249 million ($5,819M - $5,570M), but the LLM calculates a $1,156 million decline based on incorrect years and figures. (3) The multi-hop reasoning failed entirely — the model did not extract data for the correct fiscal years (2022 and 2023) and instead used data from 2023 to 2024, which is irrelevant to the query. It also references 'fiscal 2024', which is outside the scope of the question. (4) The contextual relevance is low because the answer discusses a different time period and different values, making it misleading despite using a similar metric. The reasoning and entity identification (Walmart, Level 2 inputs) are correct, but the core quantitative and temporal facts are inaccurate, leading to a very low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1159,
        "completion_tokens": 351,
        "total_tokens": 1511
      },
      "error": null
    },
    {
      "question_id": 120,
      "question": "How has Apple's characterization of its reliance on marketing abilities evolved between its 2023 and 2024 10-K filings?",
      "original_answer": "In the 2023 10-K filing, Apple stated that while it believes ownership of intellectual property rights is an important factor in differentiating its business, it 'relies primarily' on the innovative skills, technical competence, and marketing abilities of its personnel. In the 2024 filing, Apple shifted its language, stating that it 'depends heavily' on these same three factors—innovative skills, technical competence, and marketing abilities—tying them directly to ensuring a continual and timely flow of competitive products, services, and technologies to the marketplace. This evolution reflects a stronger emphasis on the strategic importance of marketing abilities in maintaining competitiveness, particularly as the company faces increasing pressure from rivals imitating its features and offering lower-priced alternatives.",
      "llm_answer": "Apple’s 10‑K filings show that its reliance on marketing abilities is framed as a core competitive factor in both years, but the emphasis has shifted slightly. In the 2023 filing (page 6), Apple lists “marketing and distribution capability” among the principal competitive factors that depend on “a strong third‑party software and accessories ecosystem, marketing and distribution capability, service and support, and corporate reputation.” By the 2024 filing (page 6), the same language appears but is expanded to stress “marketing and distribution capability” as a key driver of “product and service quality and reliability, design innovation, a strong third‑party software and accessories ecosystem, marketing and distribution capability, service and support, and corporate reputation,” and it underscores that aggressive competitor pricing and product imitation intensify the need for robust marketing. Thus, while marketing was already highlighted in 2023, the 2024 filing places even greater weight on it as a differentiator amid heightened competitive pressure.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is partially correct in identifying that Apple emphasizes marketing abilities in both 2023 and 2024 filings and notes increased competitive pressure in 2024. However, it fundamentally misrepresents the core evolution described in the original answer. The original answer highlights a shift in how Apple characterizes its internal reliance on personnel capabilities—specifically, from 'relies primarily' on innovative skills, technical competence, and marketing abilities in 2023, to 'depends heavily' on them in 2024, with an added strategic link to maintaining a timely flow of competitive offerings. In contrast, the LLM answer incorrectly frames the discussion around 'marketing and distribution capability' as an external competitive factor among others (e.g., ecosystem, support, reputation), citing it as part of a list of market-level differentiators rather than an internal organizational reliance. This mischaracterizes the nature of the evolution—shifting from internal capability reliance to external market competition dynamics. While the mention of competitive pressure from imitation and pricing aligns with the original, the core multi-hop reasoning fails: the LLM does not correctly identify that the evolution is about Apple's self-characterization of dependence on employee skills (including marketing), not a change in how marketing functions as a market differentiator. There are no numerical inaccuracies (hence high quantitative score), but the qualitative and overall correctness suffers due to incorrect entity interpretation and reasoning path. Contextual relevance is moderate because the topic of marketing importance is addressed, but the analytical depth and accuracy are flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1468,
        "completion_tokens": 467,
        "total_tokens": 1935
      },
      "error": null
    },
    {
      "question_id": 120,
      "question": "How did the notional amount and interest rate structure for the 3.625% 2024 Notes change between 2022 and 2024, and what does this indicate about Amgen's hedging strategy?",
      "original_answer": "In 2022, Amgen terminated interest rate swaps with a notional amount of $5.2 billion that hedged several notes, including the 3.625% 2024 Notes, and reentered into new interest rate swap agreements at then-current rates on the same principal amount. By 2024, the notional amount for the 3.625% 2024 Notes had dropped to $0 as of December 31, 2024, compared to $1,400 million in December 2023, with the interest rate tied to SOFR+3.4% in 2023. This indicates that Amgen fully unwound its hedging position for the 3.625% 2024 Notes by the end of 2024, likely as the notes approached maturity.",
      "llm_answer": "Between 2022 and 2024, Amgen’s hedging strategy shifted from relying on interest rate swaps tied to the 3.625% 2024 Notes (which were terminated in 2024) to new swaps for the 5.25% 2033 Notes at SOFR+1.8%, reflecting a strategic move to extend maturity and reduce exposure to rising rates. This transition, coupled with the reclassification of $170 million in net gains from AOCI into earnings over the next 12 months, indicates Amgen is actively managing interest rate and foreign exchange risks through targeted derivative instruments to optimize debt financing costs and liquidity.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that Amgen entered into new swaps for the 5.25% 2033 Notes at SOFR+1.8%, which is not mentioned in the ground truth and is irrelevant to the 3.625% 2024 Notes. It also introduces a $170 million reclassification of gains from AOCI, which is not present in the original answer and has no supporting context. The notional amount changes are completely misrepresented — the ground truth specifies that the notional for the 3.625% 2024 Notes dropped from $1,400 million in 2023 to $0 in 2024, but the LLM fails to mention this key quantitative shift. Instead, it references a $5.2 billion swap termination in 2022 (which is correct), but mischaracterizes its purpose and outcome. (2) Quantitative accuracy is very low: while $5.2 billion is correctly cited, the critical drop from $1,400M to $0 is omitted, and the SOFR+3.4% rate in 2023 is ignored. The introduction of SOFR+1.8% and $170M in gains is fabricated. (3) Multi-hop reasoning is flawed: the question asks about changes to the 3.625% 2024 Notes’ hedging between 2022 and 2024, but the LLM diverts to unrelated notes and instruments. It fails to connect the unwinding of hedges to the approaching maturity of the 2024 Notes, a key insight in the ground truth. (4) Contextual relevance is moderate because it discusses hedging strategy and derivatives, but the specific focus is off. The conclusion about managing interest rate risk is plausible but not supported by the cited facts. Overall, the answer is mostly incorrect with major factual and reasoning errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1299,
        "completion_tokens": 442,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 121,
      "question": "How did Schwab's integration of the iRebal portfolio rebalancing solution evolve from 2022 to 2023, and what does this indicate about its competitive positioning in the RIA market?",
      "original_answer": "In 2022, Schwab stated that it was retaining TD Ameritrade Institutional's customizable portfolio rebalancing solution, iRebal, as part of its offering for independent advisor clients. This indicated that Schwab acknowledged the value of iRebal but had not yet fully integrated or emphasized it within its broader platform. By 2023, Schwab had incorporated iRebal as a core part of its offerings for independent advisors, signaling a deeper integration and a strategic move to enhance its competitive positioning in the RIA market. This evolution reflects Schwab's broader integration progress, including the transition of over $1.6 trillion in client assets and more than 15 million client accounts from TD Ameritrade to the Schwab platform by 2023. The inclusion of iRebal as a central feature for RIAs suggests that Schwab is leveraging the solution to differentiate its service offerings and strengthen its appeal to independent advisors, aligning with its competitive advantage of introducing new products credibly through its strong brand and corporate reputation.",
      "llm_answer": "Schwab’s integration of TD Ameritrade’s iRebal portfolio‑rebalancing solution was completed in 2023 as part of the broader post‑acquisition integration, with the company explicitly retaining iRebal as a “customizable portfolio rebalancing solution” for independent advisor clients and incorporating it into its Advisor Services offering. This move underscores Schwab’s strategy of leveraging TD Ameritrade’s technology to enhance its own platform, reinforcing its competitive positioning in the RIA market by expanding a differentiated, institutional‑grade rebalancing capability that deepens its value proposition to independent advisors and helps retain assets amid industry consolidation.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that Schwab retained iRebal as a customizable portfolio rebalancing solution for independent advisors, and that by 2023 it was incorporated into its Advisor Services offering—consistent with the original answer's claim of deeper integration by 2023. (2) There are no numeric values in the LLM answer that conflict with the ground truth; while the ground truth mentions $1.6 trillion in assets and 15 million accounts transitioned by 2023, the LLM answer does not attempt to reproduce these figures, so there is no inaccuracy—only a slight omission. (3) The multi-hop reasoning is sound: the LLM correctly links Schwab’s acquisition of TD Ameritrade, the retention and integration of iRebal, and the strategic intent to strengthen its RIA market positioning. It accurately infers that incorporating iRebal enhances Schwab’s differentiated offering for RIAs. (4) The only minor shortcoming is that the LLM does not explicitly contrast 2022 (retention of iRebal) with 2023 (full integration), which was a key part of the evolution described in the original answer. While the LLM implies progression by stating integration was completed in 2023, it omits the 2022 context that highlights the evolution. Otherwise, the answer is factually correct, contextually relevant, and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1448,
        "completion_tokens": 382,
        "total_tokens": 1831
      },
      "error": null
    },
    {
      "question_id": 121,
      "question": "How has Apple's approach to the iMac product line evolved between 2023 and 2024, based on the company's disclosures in its 10-K filings?",
      "original_answer": "In 2023, Apple described the iMac as part of its Mac product line, indicating it was actively manufacturing and marketing the desktop computer as part of its standard offerings. By 2024, Apple elevated the iMac to the level of a significant product announcement, listing it among other key launches like the MacBook Pro and iPad Pro in the MD&A section of its 2024 10-K. This shift suggests that the iMac gained strategic importance in 2024, likely reflecting a product refresh or redesign that warranted special mention as part of the company's innovation cycle.",
      "llm_answer": "Apple's approach to the iMac product line evolved between 2023 and 2024 as reflected in its 10-K filings. In fiscal 2024, the company highlighted the iMac as part of its product announcements, specifically noting the release of new iMac models during the first quarter of 2024, continuing its tradition of introducing updated desktop offerings. However, the iMac segment's net sales declined by 8% year-over-year in 2024 (from $72,559 million in 2023 to $66,952 million in 2024), primarily due to lower iPhone and iPad sales and currency headwinds, though the iMac itself was not called out as a standalone growth driver. The broader product strategy emphasized services and newer device categories like the iPhone 16 series and Apple Intelligence, with the iMac remaining part of the Mac product line but facing modest sales pressure.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that Apple elevated the iMac's strategic importance in the 2024 10-K by listing it among key product launches like the MacBook Pro and iPad Pro, indicating a shift in disclosure tone. However, the LLM incorrectly introduces financial data not present in the original answer—specifically, net sales figures of $72,559 million in 2023 and $66,952 million in 2024 with an 8% decline. These numbers are not only absent from the ground truth but also implausible (e.g., $72 billion in iMac sales alone would exceed Apple's total Mac revenue). There is no mention in the original answer of iMac sales declining or being affected by iPhone/iPad performance or currency headwinds. (2) The quantitative inaccuracies are severe: the dollar amounts and percentage change are entirely fabricated or misattributed. No such figures appear in the ground truth, and the calculation (8% decline from $72.559B to $66.952B) does not hold mathematically (actual drop is ~7.7%, but more importantly, the numbers themselves are incorrect). (3) The multi-hop reasoning is flawed. While the LLM attempts to infer strategic positioning, it conflates broader product trends with iMac-specific disclosures and introduces external factors (e.g., Apple Intelligence, iPhone 16) not mentioned in the original answer. The core insight from the ground truth—that the iMac gained prominence in narrative emphasis in the 2024 10-K—is missed entirely. Instead, the LLM concludes the iMac faced 'modest sales pressure,' which contradicts the original implication of increased strategic focus. (4) The contextual relevance is moderate because the answer addresses Apple’s iMac strategy over time using 10-K disclosures, but the qualitative and quantitative deviations severely undermine correctness. The reasoning fails to reflect the actual basis of the ground truth—disclosure language evolution—instead inventing financial metrics and causal relationships. Thus, despite some relevant framing, the answer is largely incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 561,
        "total_tokens": 1908
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "How has RTX's relationship with the 2.820% Notes Due 2051 evolved between 2022 and 2024, and what does this indicate about the company's long-term debt structure?",
      "original_answer": "In 2022, RTX introduced the 2.820% Notes Due 2051 with an aggregate principal balance of $1,000 million. By 2024, this debt instrument remained on the books with the same principal balance of $1,000 million, indicating no repayment or additional issuance occurred during this period. However, the broader long-term debt structure expanded significantly, with total principal long-term debt increasing from an implied $40,078 million in 2022 (based on the 2024 presentation format) to $41,146 million in 2024. This suggests that while the 2.820% Notes Due 2051 remained unchanged, RTX increased its overall debt burden through other issuances, maintaining the 2051 notes as a stable component within a growing long-term debt portfolio.",
      "llm_answer": "RTX retired its $3.7 billion 2.820% notes due 2051 in 2024, having previously issued $1 billion of the same series in 2022; the 2024 repayment reduced long‑term debt by $1 billion and reflects a strategic shift toward shorter‑dated borrowings and lower‑cost financing. This evolution indicates that RTX is actively managing its capital structure, prioritizing debt maturities that align with its cash‑flow profile and seeking to optimize interest expense as it refinances higher‑coupon obligations with newer, longer‑dated securities.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is almost entirely incorrect. It claims RTX retired $3.7 billion of 2.820% Notes Due 2051 in 2024 and previously issued $1 billion in 2022, which contradicts the ground truth stating that RTX issued $1,000 million ($1 billion) in 2022 and maintained the same principal balance in 2024 with no repayment or additional issuance. The $3.7 billion figure is entirely fabricated. (2) Quantitative accuracy is severely lacking: the principal amount is misrepresented as $3.7 billion instead of $1 billion, and the claim of retirement is false. The ground truth confirms no change in the 2.820% Notes Due 2051 between 2022 and 2024. Additionally, the broader long-term debt increase from $40,078 million to $41,146 million is ignored. (3) The multi-hop reasoning is flawed: instead of recognizing the stability of the 2051 notes within a growing debt portfolio, the model invents a retirement event and infers a strategic shift toward shorter-dated borrowings, which is unsupported by the data. There is no evidence of refinancing or retirement in the provided information. (4) Contextual relevance is low because the answer addresses the general topic of debt management but misrepresents the core facts. The conclusion about strategic refinancing and lower-cost financing is speculative and factually incorrect. Scores are low due to fundamental errors in numbers, entities, and logic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 391,
        "total_tokens": 1712
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "How did the terms of Schwab's IDA agreement evolve between 2022 and 2023, particularly regarding service fees and reference rate adjustments?",
      "original_answer": "In 2022, Schwab disclosed that the IDA agreement had been amended to reduce the service fee on client cash deposits held at the TD Depository Institutions to 15 basis points from 25 basis points. By 2023, the company reported that its IDA agreement had transitioned reference rates previously tied to LIBOR to other appropriate benchmarks as part of its broader LIBOR phase-out preparation. This evolution reflects a shift from adjustments in fee structure to modifications in financial reference mechanisms, aligning the agreement with post-LIBOR regulatory and market standards.",
      "llm_answer": "Based on the provided SEC 10-K filings, the terms of Schwab's IDA agreement evolved between 2022 and 2023 primarily through a reduction in service fees and reference rate adjustments. Specifically, the 2023 filing (page 54) states that the IDA agreement was amended to reduce the service fee on client cash deposits held at TD Depository Institutions from 25 basis points to 15 basis points, effective as part of the transition away from LIBOR. This adjustment was referenced in the pro forma financial information (page 85) as part of the acquisition accounting for the TD Ameritrade purchase, where the reduced fee structure was explicitly noted as a key component of the revised agreement. Additionally, Schwab completed its LIBOR transition by converting all LIBOR-based references in its IDA and intercompany lending agreements to alternative benchmark rates by the end of 2023, as detailed in the Management's Discussion (page 53), ensuring no material impact from the LIBOR phaseout. The service fee reduction directly addressed the evolving interest rate environment and client cash allocation behavior observed during the period of rising rates.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly identifies the reduction in service fees from 25 to 15 basis points, which aligns with the ground truth. However, it inaccurately states that this fee reduction occurred in the 2023 filing and was effective 'as part of the transition away from LIBOR,' conflating two distinct developments. According to the original answer, the fee reduction was implemented in 2022, while the 2023 update focused on the reference rate transition from LIBOR to alternative benchmarks. The LLM incorrectly merges these events in timing and causality, implying the fee cut was part of the LIBOR transition, which is not supported by the ground truth. The mention of page numbers (54, 85, 53) and integration with acquisition accounting and pro forma disclosures adds contextual detail not contradicted by the ground truth, suggesting strong document grounding. The qualitative reasoning is mostly sound but flawed in the chronological and causal synthesis of the two changes. Quantitatively, the 25 to 15 basis point reduction is accurate, and no calculations are incorrect. Contextually, the answer remains highly relevant, addressing both service fees and reference rate adjustments as asked. The core facts are present but with a significant misalignment in timing and linkage between the two key changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1432,
        "completion_tokens": 364,
        "total_tokens": 1797
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "What does the change in Filorga's financial treatment from 2023 (when it had $221 million in goodwill as a standalone reporting unit) to 2024 (when it was listed among other trademarks within broader segments) suggest about its strategic importance and valuation approach by the company?",
      "original_answer": "In 2023, Filorga was treated as a standalone reporting unit within the Europe segment with a clearly disclosed goodwill carrying value of $221 million, indicating its distinct financial significance and the company’s detailed impairment analysis for this brand. By 2024, Filorga was listed among other global and regional trademarks within broader product segments, without separate goodwill or valuation figures. This suggests that Filorga may have been integrated into a larger reporting structure, reducing its visibility as a standalone asset, which could signal a shift in strategic focus or a consolidation of brand management. This change affects how Filorga’s valuation and performance are assessed, potentially influencing future strategic decisions such as divestiture, investment, or brand prioritization.",
      "llm_answer": "The shift from reporting Filorga as a standalone reporting unit with $221 million of goodwill in 2023 to including it among other trademarks within broader segments in 2024 indicates that the company no longer treats Filorga as a distinct strategic business unit. This reallocation—moving its goodwill to the North America segment and consolidating it with other intangible assets—reflects a more integrated valuation approach where Filorga’s brand value is now assessed collectively with other trademarks rather than as a separate reporting unit. Consequently, its goodwill is no longer evaluated in isolation, suggesting that the company views Filorga’s contribution as part of a larger portfolio of brands and that its strategic importance is now measured within the broader segment’s performance rather than as a standalone driver.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the key change in Filorga's financial treatment from 2023 to 2024, accurately stating that it was a standalone reporting unit with $221 million in goodwill in 2023 and was consolidated into broader segments in 2024. The numbers and years are correct, satisfying quantitative accuracy. (2) Quantitative Accuracy: The $221 million goodwill figure and the years 2023 and 2024 are correctly cited. No calculations are required, and the values match the ground truth exactly. (3) Reasoning: The LLM correctly infers that the change suggests Filorga is no longer viewed as a distinct strategic unit and that its valuation is now integrated with other trademarks. However, it adds a specific claim not present in the original answer—that Filorga’s goodwill was 'moved to the North America segment'—which is unsupported by the ground truth. This introduces a factual overreach, as the original only states Filorga was grouped within broader segments without specifying a geographic shift. This affects qualitative accuracy. (4) Despite this overinterpretation, the core reasoning about reduced strategic visibility and integrated valuation aligns with the ground truth. The answer is contextually relevant and captures the main implications of the change. The correctness score is reduced slightly due to the unsupported claim about the North America segment, but the overall answer remains substantially accurate and insightful.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1448,
        "completion_tokens": 405,
        "total_tokens": 1853
      },
      "error": null
    },
    {
      "question_id": 122,
      "question": "How does the change in Apple's disclosure about the iPhone 16 Pro between the 2023 and 2024 10-K filings reflect an evolution in its product development and reporting strategy?",
      "original_answer": "In the 2023 10-K filing, Apple announced the iPhone 16 Pro as part of its Fourth Quarter 2024 product lineup, indicating it was still in the planning and launch phase. By contrast, in the 2024 10-K filing, the iPhone 16 Pro is listed among existing product lines like the iPhone 15 and iPhone 14, suggesting it has transitioned into an active and established product within Apple's portfolio. This shift reflects a movement from forward-looking product planning in 2023 to retrospective inclusion in 2024, aligning with the product's lifecycle stage and indicating a more mature reporting posture around the iPhone 16 Pro.",
      "llm_answer": "The 2024 10‑K shows Apple reporting a flat iPhone net sales figure for 2024 versus 2023, while the 2023 filing highlighted iPhone 16 Pro as a new product launch and emphasized its role in the company’s innovation pipeline. This shift reflects a move from marketing a forthcoming iPhone 16 Pro to simply stating that overall iPhone sales were relatively unchanged, indicating that Apple’s product development strategy has progressed beyond the announcement phase and is now focused on sustaining existing sales rather than promoting a new flagship device. Consequently, the company’s reporting strategy has evolved to present more modest, performance‑based disclosures rather than forward‑looking product hype.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and introduces unsupported quantitative claims not present in the original answer or implied by the question. (1) The claim that 'iPhone net sales were flat in 2024 versus 2023' is a fabricated statistic with no basis in the ground truth; no sales figures or comparisons were provided in the original answer. This severely undermines factual accuracy. (2) The LLM incorrectly frames the shift in disclosure as a move from 'marketing' to 'performance-based reporting' due to stagnant sales, which misrepresents the actual evolution described: the transition of the iPhone 16 Pro from a forward-looking planned product (in 2023) to an established product in the lineup (in 2024). (3) The core multi-hop reasoning required—tracking how the *classification* of the iPhone 16 Pro changes across filings reflecting its lifecycle stage—is entirely missed. Instead, the model invents a narrative around sales performance and marketing tone, which is not supported by the evidence. (4) While the answer is somewhat contextually relevant—addressing changes in disclosure and linking them to strategy—it does so with incorrect data and flawed logic. The entity (iPhone 16 Pro) and years (2023, 2024) are correctly identified, but their usage is factually distorted. Minor credit is given for attempting to interpret strategic shifts in reporting, but the overall response fails on correctness due to hallucinated metrics and mischaracterization of the disclosure change.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 409,
        "total_tokens": 1750
      },
      "error": null
    },
    {
      "question_id": 123,
      "question": "How has the company's use of Economic Value of Equity (EVE) simulations evolved in assessing interest rate risk, particularly in terms of modeling assumptions and balance sheet dynamics, between 2022 and 2023?",
      "original_answer": "In 2022, the company used EVE simulations to measure long-term interest rate risk, with key assumptions including non-negative investment yields, prepayment speeds of mortgage-related investments, and non-maturity deposit behavior. The EVE analysis was described as highly dependent on asset and liability assumptions based on historical behaviors and expectations of the economic environment. By 2023, the company expanded the role of EVE simulations to specifically capture the impact of client cash allocation changes on the balance sheet, which was not included in the earlier modeling approach. Additionally, in 2023, the company actively updated deposit beta assumptions in a declining interest rate environment for its net interest revenue simulation model, indicating a more dynamic approach to modeling interest rate sensitivity.",
      "llm_answer": "Between 2022 and 2023, Schwab’s EVE simulations continued to rely on asset‑ and liability‑duration assumptions, prepayment speed models, and non‑maturity deposit‑behavior assumptions derived from historical experience, but the company updated key inputs to reflect the higher‑for‑longer interest‑rate environment. In 2023 it refined its deposit‑beta assumptions and incorporated the impact of increased floating‑rate assets and higher short‑term borrowings, resulting in a more pronounced EVE sensitivity to rate shifts—particularly a shortening of liability duration that made liability duration shorter than asset duration. Additionally, Schwab expanded its use of interest‑rate swap derivatives and transitioned away from LIBOR, ensuring that the EVE modeling assumptions now incorporate updated rate‑floor scenarios, revised prepayment expectations, and updated term‑structure models.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains some correct elements but introduces significant inaccuracies and fails to align with the ground truth on key points. (1) Correct aspects: The mention of deposit beta assumptions being updated in 2023 aligns with the original answer, and the general use of historical behavior for assumptions in 2022 is consistent. However, the LLM incorrectly attributes changes to 'higher short-term borrowings' and 'increased floating-rate assets,' which are not mentioned in the ground truth. The claim about liability duration becoming shorter than asset duration is unsupported. (2) Quantitative accuracy: There are no explicit numbers (e.g., percentages, dollar amounts) in either answer, so scoring is based on factual alignment. The LLM invents modeling changes (e.g., 'revised term-structure models,' 'LIBOR transition,' 'rate-floor scenarios') not present in the original. (3) Multi-hop reasoning: The original answer emphasizes a key evolution—incorporating client cash allocation impact on the balance sheet in 2023, which the LLM completely omits. Instead, it fabricates technical enhancements (swaps, LIBOR transition) that shift focus away from the actual evolution in balance sheet dynamics. (4) The LLM answer is contextually relevant to interest rate risk modeling and EVE simulations but misrepresents the nature of the 2023 changes. It adds technically plausible but factually incorrect details, undermining qualitative and overall correctness. The core advancement in the original—modeling client cash flows' impact—is missed entirely, resulting in a partially correct but materially misleading response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1447,
        "completion_tokens": 444,
        "total_tokens": 1891
      },
      "error": null
    },
    {
      "question_id": 123,
      "question": "How did Qualcomm's strategic shift from enabling wireless access point technologies in 2022 to directly producing them in 2023 affect its competitive positioning and product portfolio breadth in the broader networking market?",
      "original_answer": "In 2022, Qualcomm's involvement with wireless access points was limited to enabling the technology through its foundational wireless innovations and chipset solutions, as noted in its discussion of edge networking growth driven by 5G and Wi-Fi 6 adoption. However, by 2023, Qualcomm had evolved its strategy to directly producing wireless access points as part of its broader networking product suite, which included Wi-Fi chips, routers, and network processors. This shift reflects an expansion of Qualcomm's product portfolio and a more direct role in the networking ecosystem, positioning the company to compete more directly with players like Broadcom and Intel by offering full-system solutions rather than just underlying components.",
      "llm_answer": "Qualcomm’s 2022 shift from merely enabling wireless access point technologies to directly producing them—evidenced by its expanded Wi‑Fi, Bluetooth, and edge‑networking product lines and dedicated RFFE and modem‑to‑antenna platforms—gave it a broader, more integrated portfolio that spans both the infrastructure and device sides of networking. This vertical integration strengthened its competitive positioning by allowing end‑to‑end solutions (e.g., Wi‑Fi 6/6E access points, private‑network mmWave modules) that competitors can’t match, while also deepening its presence in emerging markets such as automotive, IoT, and edge computing, thereby widening its product‑breadth across the entire networking ecosystem.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Qualcomm's strategic shift from enabling to producing wireless access point technologies and links it to broader portfolio expansion and competitive positioning. However, it inaccurately states the shift occurred in 2022, while the ground truth specifies the change took place between 2022 and 2023, with the direct production starting in 2023. This misattribution of timing affects the qualitative accuracy. (2) There are no numeric values, percentages, or dollar amounts in either the question or answers, so quantitative accuracy is not compromised—no calculations or figures to verify. Format and date consistency are acceptable otherwise. (3) The multi-hop reasoning is partially sound: the model correctly infers that moving from component supplier to full-system producer enhances competitive positioning and broadens product breadth. It also appropriately connects this to vertical integration and end-to-end solutions. However, it fails to explicitly mention key competitors like Broadcom and Intel as referenced in the original answer, weakening the comparative competitive analysis. Additionally, while the LLM introduces new domains like automotive, IoT, and edge computing, these are plausible extensions but not explicitly supported in the ground truth, introducing some speculative content. (4) The correctness score is 7 because the core factual claim about the strategic shift and its impact on product breadth and competitiveness is preserved, despite the incorrect timing and minor overreach in inferred applications. Quantitative accuracy is 10 due to absence of numerical errors. Qualitative accuracy is 7 due to correct reasoning but flawed timeline and unsupported expansions. Contextual relevance is 9 as the response stays highly relevant and addresses the question’s intent effectively.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 504,
        "total_tokens": 1888
      },
      "error": null
    },
    {
      "question_id": 124,
      "question": "How has the interest-only payment structure of Schwab's HELOC product evolved from 2022 to 2023, based on the percentage of adjustable-rate mortgages with interest-only terms and the portion not scheduled to reset for three or more years?",
      "original_answer": "In 2022, 28% of adjustable-rate mortgages were interest-only loans, with 89% of those not scheduled to reset for three or more years. In 2023, this shifted slightly to 27% of adjustable-rate mortgages being interest-only, with 86% of those not scheduled to reset for three or more years. This reflects a minor decrease in both metrics, suggesting a slight tightening or evolution in the interest-only structure of the HELOC product.",
      "llm_answer": "Based on the provided disclosures, Schwab's HELOC interest-only payment structure remained largely unchanged from 2022 to 2023. In 2023, approximately 27% of adjustable-rate mortgage balances consisted of interest-only loans, with about 86% of those interest-only loan balances not scheduled to reset for three or more years. This proportion was consistent with the 2022 description, indicating no significant structural evolution in the interest-only feature during this period.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the 2023 figures (27% of adjustable-rate mortgages as interest-only, with 86% of those not scheduled to reset for three or more years) and references the 2022 data, but inaccurately characterizes the change as 'consistent' and 'no significant structural evolution.' The ground truth notes a decrease from 28% to 27% in interest-only loans and from 89% to 86% in those not scheduled to reset, which constitutes a minor but measurable shift. (2) Quantitative accuracy is perfect: both years' percentages are correctly cited (28% → 27%, 89% → 86%), with appropriate metrics and timeframes. Number format and values match the original answer exactly. (3) The multi-hop reasoning is partially flawed: while the model correctly identifies and synthesizes data across years and metrics, it misinterprets the trend. The original answer emphasizes a 'minor decrease in both metrics' and 'slight tightening or evolution,' whereas the LLM concludes 'no significant structural evolution,' which downplays the factual changes. This reflects a failure in qualitative reasoning despite correct data retrieval. (4) Contextual relevance is high—the answer addresses the HELOC interest-only structure, uses correct entities (adjustable-rate mortgages, interest-only terms, reset periods), and focuses on the right time frame. However, the conclusion contradicts the original interpretation, reducing qualitative accuracy. Correctness score is 7 due to accurate numbers but misleading synthesis and interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1250,
        "completion_tokens": 424,
        "total_tokens": 1675
      },
      "error": null
    },
    {
      "question_id": 124,
      "question": "How has Qualcomm's involvement in the XR market evolved from 2022 to 2023, based on their strategic investments and product revenue disclosures?",
      "original_answer": "In 2022, Qualcomm's involvement in XR was primarily through strategic investments made via Qualcomm Ventures, targeting early-stage companies in areas including XR to expand opportunities for their technologies. By 2023, this involvement evolved into direct revenue generation, as XR was explicitly listed among the industries and applications for which Qualcomm sold products, indicating a shift from investment to commercialization. This transition reflects a significant change in Qualcomm's engagement with XR, moving from supporting external innovation to deriving tangible revenue from XR-related product sales.",
      "llm_answer": "From 2022 to 2023, Qualcomm’s XR market involvement evolved through its strategic investments and revenue disclosures. In 2022, XR-related investments were part of its broader IoT and emerging technology portfolio, with revenue from XR-focused applications (e.g., AR/VR in consumer and automotive segments) contributing to IoT revenue streams, which totaled $5.94B in 2022. By 2023, XR-related revenue declined to $5.42B (as noted in QCT revenue streams), reflecting reduced focus or market contraction in XR. Qualcomm continued to allocate resources to XR through its Qualcomm Ventures arm, targeting early-stage companies in XR, AI, and automotive, but shifted emphasis toward 5G and automotive (e.g., ADAS/AD) as core growth areas. The company’s financial disclosures highlight that XR revenue is now subsumed under broader IoT and automotive segments, with no standalone XR revenue metrics disclosed. (Based on QCOM_10k_2022.pdf pages 12–16 and QCOM_10k_2023.pdf pages 71–75.)",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that Qualcomm evolved from strategic investments in XR in 2022 to direct revenue generation from XR product sales in 2023, with XR explicitly listed as a commercial application. In contrast, the LLM claims XR revenue declined from $5.94B to $5.42B and was subsumed under broader segments with no standalone disclosure—this contradicts the ground truth that XR became more prominent in revenue disclosures in 2023. There is no mention in the ground truth of specific XR revenue figures or a decline; thus, these numbers are fabricated or misattributed. (2) The cited figures—$5.94B and $5.42B—are presented as XR-specific revenues but in reality, these do not appear in the knowledge graph as XR revenue totals. The 2022 IoT revenue may be approximately correct in magnitude, but attributing a precise $5.94B to XR within it is unsupported and incorrect. Similarly, the $5.42B figure for 2023 is not substantiated and misrepresents the trend. (3) The multi-hop reasoning is flawed: instead of identifying the evolution from investment (2022) to commercialization (2023), the model infers a decline based on incorrect numerical data and fails to recognize the qualitative shift in business model. It incorrectly concludes reduced focus on XR, while the ground truth indicates increased engagement via product sales. (4) The contextual relevance is moderate because the answer discusses Qualcomm, XR, investments, and revenue over 2022–2023, aligning with the question’s scope. However, due to major factual and interpretive errors, especially in quantitative claims and directional trend, the correctness score is very low. The qualitative reasoning fails to capture the core evolution described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1398,
        "completion_tokens": 491,
        "total_tokens": 1890
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has the aggregate principal balance of the 3.030% Notes Due 2052 evolved between 2022 and 2024, and what does this indicate about RTX's long-term debt structure?",
      "original_answer": "The aggregate principal balance of the 3.030% Notes Due 2052 remained stable at $1,100 million in both 2022 and 2024. This indicates that RTX has maintained its long-term commitment to this particular debt instrument without any repayments or additional issuances during this period. Despite overall changes in other long-term debt components, the 3.030% Notes Due 2052 remained unchanged, suggesting strategic consistency in managing this portion of its capital structure.",
      "llm_answer": "The aggregate principal balance of the 3.030% Notes Due 2052 was $1,100 million at the end of 2022 and remained $1,100 million at the end of 2024, indicating that RTX has not retired or reduced this long‑dated debt but has instead continued to carry it alongside other long‑term obligations. This stability reflects a strategy of maintaining a sizable, low‑coupon tranche in its capital structure while refinancing near‑term maturities and funding share‑repurchase activities through new borrowings.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "1) The LLM answer correctly states that the aggregate principal balance of the 3.030% Notes Due 2052 was $1,100 million in both 2022 and 2024, matching the ground truth exactly. All numeric values, dates, and percentages are accurate. 2) Quantitative accuracy is perfect: the dollar amount ($1,100 million) and years (2022 and 2024) are correct, with no calculation errors. Format variation (using 'million' vs 'M') is acceptable and semantically equivalent. 3) The multi-hop reasoning is sound: the model correctly infers that the unchanged balance indicates no retirements or new issuances, and links this to RTX's broader capital structure strategy. It adds context about refinancing near-term maturities and funding share repurchases, which, while not in the original answer, is plausible and consistent with typical corporate behavior—this does not contradict the ground truth but extends it slightly. 4) The answer is contextually relevant and fully addresses both parts of the question: the evolution of the debt balance and its implication for RTX's long-term debt structure. The only minor shortcoming is that it does not explicitly mention 'strategic consistency' or 'no additional issuances,' which are in the original, but the implication is present. Thus, the answer is factually correct and semantically aligned, warranting a high score with only a slight deduction in qualitative accuracy for minor incompleteness in nuance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1247,
        "completion_tokens": 396,
        "total_tokens": 1644
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has AXP's focus on Corporate Card solutions evolved between 2023 and 2024, and what does this shift suggest about its broader commercial payments strategy?",
      "original_answer": "In 2023, AXP emphasized evolving its card value propositions and differentiating its corporate card and accounts payable expense management solutions as part of a broader push to strengthen its position in commercial payments. By 2024, while the focus on commercial payments remained, AXP shifted toward designing 'innovative products and features, including financing, banking and payment solutions for our business customers,' indicating a more integrated and solution-oriented approach. This evolution suggests that AXP is expanding beyond just product differentiation to embedding the Corporate Card into a wider suite of business financial services, aligning it more closely with holistic commercial needs.",
      "llm_answer": "AXP's focus on corporate card solutions has intensified through strategic leadership changes and product innovation, particularly under the new Group President of Global Commercial Services, Raymond Joabar, who previously led Global Merchant and Network Services. This shift is underscored by the 2024 executive appointments, including Glenda McNeal as Chief Partner Officer and Anna Marrs as Group President of Commercial Services and Credit & Fraud Risk, signaling a deliberate push to deepen commercial payments capabilities. The company's 2024 10-K explicitly emphasizes \"evolving our card value propositions\" and \"designing innovative products and features, including financing, banking and payment solutions for our business customers\" as a core strategic imperative, indicating a clear pivot toward integrated commercial payment ecosystems rather than standalone corporate cards. This evolution aligns with AXP's broader strategy to leverage its global network for high-value business solutions, as evidenced by its focus on merchant acceptance, fraud prevention, and partnerships like OptBlue, positioning corporate services as a growth engine within its commercial payments strategy.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual information is correct: AXP's 2023 focus on evolving card value propositions and differentiating corporate card and expense management solutions is accurately reflected, as is the 2024 shift toward 'innovative products and features, including financing, banking and payment solutions.' The citation of the 2024 10-K language matches the original answer. (2) There are no numeric values, dates, or calculations in the question or ground truth that require verification—only qualitative strategic descriptions—so quantitative accuracy is not compromised. (3) The multi-hop reasoning is sound: the LLM correctly synthesizes AXP’s strategic evolution from 2023 to 2024, inferring a broader commercial payments strategy from leadership changes and strategic language. It adds contextual details (e.g., executive appointments like Raymond Joabar, Glenda McNeal, Anna Marrs, and OptBlue) that are consistent with AXP’s strategic direction and enhance the explanation without contradicting the ground truth. (4) The only reason for not scoring a 10 in correctness and qualitative accuracy is that the original answer emphasizes the shift from product differentiation to integrated financial services as a conceptual evolution, while the LLM focuses more on leadership and structural changes as evidence—slightly shifting emphasis but not misrepresenting facts. However, the added details are plausible and contextually appropriate, and the core strategic evolution is correctly identified. Semantic equivalence is maintained, and the answer is fully relevant to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1479,
        "completion_tokens": 450,
        "total_tokens": 1929
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has the strategic positioning of PCA SKIN within Colgate-Palmolive's Oral, Personal and Home Care segment evolved between 2023 and 2024, particularly in terms of its distribution channels?",
      "original_answer": "In 2023, PCA SKIN was listed among Colgate-Palmolive’s principal global and regional trademarks and was included in the broader category of products sold primarily to traditional and eCommerce retailers, wholesalers, distributors, and dentists. By 2024, PCA SKIN remained a listed principal trademark, but the filing specifically expanded the distribution channels to include sales to skin health professionals in some geographies. This indicates a refinement in positioning PCA SKIN within more specialized skincare distribution channels, though no change in production or brand status is indicated.",
      "llm_answer": "Based on the provided 10-K filings, PCA SKIN is identified as a brand within Colgate-Palmolive's Oral, Personal and Home Care segment. The company's distribution strategy for this segment, including PCA SKIN, is primarily through traditional retail channels. Specifically, the company states that its Oral, Personal and Home Care products, including PCA SKIN, are sold \"primarily to a variety of retailers, wholesalers, distributors, dentists and, in some geographies, skin health professionals.\" This indicates that PCA SKIN relies on established retail and professional distribution networks rather than direct-to-consumer channels for its market reach. The company also notes that some products are sold \"direct-to-consumer,\" but this appears to be a supplementary channel rather than the primary distribution strategy for PCA SKIN.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies PCA SKIN as part of Colgate-Palmolive's Oral, Personal and Home Care segment and accurately describes the general distribution channels (retailers, wholesalers, distributors, dentists, and skin health professionals). It also correctly notes the mention of direct-to-consumer as a supplementary channel. However, the answer fails to address the core of the question: the *evolution* of PCA SKIN’s strategic positioning *between 2023 and 2024*. The original answer highlights a key change — in 2024, the 10-K explicitly added 'skin health professionals in some geographies' as a new specificity in distribution, indicating a strategic refinement. The LLM answer presents a static view, blending details from both years without highlighting this evolution. While the entities and general facts are accurate (hence high quantitative accuracy and contextual relevance), the lack of comparative analysis across years and failure to identify the nuanced shift in distribution strategy results in a significant gap in qualitative accuracy and overall correctness. The answer is factually sound but incomplete in addressing the multi-hop, time-based comparative reasoning required.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1370,
        "completion_tokens": 338,
        "total_tokens": 1708
      },
      "error": null
    },
    {
      "question_id": 125,
      "question": "How has the strategic focus and commercial positioning of Opdivo evolved between 2022 and 2023, particularly in terms of new tumor indications and combination therapies, and what implications does this have for its revenue growth trajectory?",
      "original_answer": "In 2022, Opdivo was approved for several anti-cancer indications including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, and stomach cancers, with the Opdivo + Yervoy regimen approved in multiple markets for NSCLC, melanoma, MPM, RCC, CRC, and gastric/esophageal cancers. It reported U.S. revenue growth driven by combinations in NSCLC, kidney cancer, and gastric/esophageal cancers. By 2023, Opdivo's strategic focus expanded into new tumor types and earlier lines of therapy, with an emphasis on broadening its use both as a monotherapy and in combination with Yervoy and other agents. The company also highlighted the potential of a subcutaneous formulation to enhance patient benefits and drive long-term adoption. This evolution indicates a strategic push to sustain revenue growth by diversifying indications and optimizing delivery mechanisms, despite increasing market competition.",
      "llm_answer": "Between 2022 and 2023, Opdivo’s strategic focus shifted toward expanding its tumor indications and combination therapies, resulting in multiple regulatory approvals for new uses: EC approval for adjuvant melanoma (June 2023), EC approval for neoadjuvant NSCLC with platinum chemotherapy (June 2023), Japan approval for neoadjuvant NSCLC (March 2023), and expanded use in combination with Yervoy and other agents across various cancers. This diversification—particularly in earlier-line settings and novel combinations—directly supported revenue resilience, as Opdivo’s growth (driven by these new indications) partially offset declines in legacy products like Revlimid and Eliquis, contributing to an overall 2% revenue increase in 2023 despite generic erosion pressures. Consequently, Opdivo’s evolving commercial positioning underpinned BMS’s ability to mitigate portfolio headwinds and sustain growth, reinforcing its role as a key driver of future revenue trajectory.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the strategic evolution of Opdivo between 2022 and 2023, emphasizing expansion into new tumor indications and combination therapies, including earlier lines of therapy and novel regimens. It accurately references specific regulatory approvals in 2023 (EC and Japan) for adjuvant melanoma and neoadjuvant NSCLC, which aligns with the broader trend in the ground truth of expanding into earlier-line settings. However, these specific approvals (dates, regions) are not present in the original answer, introducing details not confirmed by the ground truth, which only states a general expansion without citing specific approvals. (2) The LLM introduces a 2% overall revenue increase in 2023 and attributes Opdivo’s growth to offsetting declines in Revlimid and Eliquis. This quantitative claim is not supported by the original answer, which mentions U.S. revenue growth driven by combinations but does not provide an overall revenue percentage or compare it to other products. This is a significant addition that cannot be verified against the ground truth and reduces quantitative accuracy. (3) The reasoning is logically sound and reflects multi-hop synthesis—linking new indications and combinations to commercial positioning and revenue implications. The conclusion that Opdivo is a key driver in sustaining BMS’s revenue trajectory aligns semantically with the original answer’s claim about sustaining growth despite competition. (4) While the core qualitative trajectory—broadening indications, combination use, and strategic importance—is correct and well-reasoned, the inclusion of unverified specifics (exact approvals, revenue impact percentages, and product comparisons) introduces factual overreach. The answer is contextually relevant and captures the essence of the strategic shift, but the unsupported numbers and entities prevent a higher correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1494,
        "completion_tokens": 519,
        "total_tokens": 2013
      },
      "error": null
    },
    {
      "question_id": 126,
      "question": "How did American Express's investment in foreign government bonds and obligations evolve between 2023 and 2024 in terms of fair value and maturity distribution?",
      "original_answer": "In 2023, American Express held $549 million in foreign government bonds and obligations with all of it maturing in 12 months or more and a gross unrealized loss of $1 million. By 2024, the fair value of these investments increased significantly to $765 million, with $764 million maturing within one year and only $1 million maturing after one year but within five years. This indicates a substantial increase in exposure to foreign government bonds, primarily in short-term maturities.",
      "llm_answer": "Between 2023 and 2024, American Express’s investment in foreign government bonds and obligations shifted from a $770 million fair‑value position (with no unrealized loss) in 2023 to a $765 million fair‑value position (also with no unrealized loss) in 2024, as shown in the “Available‑for‑sale debt securities” tables for both years. The maturity profile remained weighted toward short‑term holdings: in 2023, $768 million was due within one year and $2 million after one year but within five years; in 2024, $764 million was due within one year and $1 million after one year but within five years, with no securities maturing beyond ten years. Thus, the exposure stayed short‑dated, but the fair‑value amount modestly declined while the maturity distribution stayed essentially unchanged.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, American Express held $549 million in foreign government bonds in 2023 with a $1 million gross unrealized loss, but the LLM claims $770 million with no unrealized loss. This is a major quantitative error. In 2024, the correct fair value is $765 million, which the LLM correctly reports, but it incorrectly states there was no unrealized loss, while the ground truth does not mention unrealized loss for 2024 (so omission is less critical). (2) The maturity distribution in 2023 is completely wrong in the LLM answer: it claims $768 million maturing within one year and $2 million after one year, but the ground truth states that *all* $549 million matured in 12 months or more—meaning none within one year. This contradicts the LLM’s claim of a short-term weighting in 2023. Only the 2024 maturity breakdown ($764M within one year, $1M after) matches the ground truth. (3) The multi-hop reasoning is flawed because the LLM failed to correctly extract and compare data across years. It incorrectly implies continuity in short-term holdings, when in fact the shift was *from long-term only in 2023* to *overwhelmingly short-term in 2024*—a key evolution that the LLM missed entirely. (4) Despite correct mention of 2023–2024 timeframe, American Express, and foreign government bonds, the severe numerical and interpretive errors—especially the reversal of the investment trend (LLM says modest decline, truth is significant increase from $549M to $765M)—warrant a low correctness score. Contextual relevance is high as the answer addresses fair value and maturity as asked, but factual accuracy is critically compromised.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 469,
        "total_tokens": 1791
      },
      "error": null
    },
    {
      "question_id": 126,
      "question": "How has Walmart's use of intercompany financing arrangements evolved between 2022 and 2024, particularly regarding the amount of cash not freely transferable to the U.S. and the conditions under which such transfers occur?",
      "original_answer": "In 2022, Walmart reported $4.3 billion in cash and cash equivalents that may not be freely transferable to the U.S., with $2.2 billion of that amount subject to approval by Flipkart minority shareholders. By 2024, the amount of cash not freely transferable decreased slightly to $3.3 billion, and the language indicates that these transfers are now generally subject to approval from noncontrolling interest shareholders, rather than specifically tied to Flipkart. This reflects a slight reduction in the magnitude of restricted cash and a broader framing of the conditions under which such transfers occur, suggesting a shift in the structure or focus of intercompany financing arrangements.",
      "llm_answer": "Walmart's intercompany financing arrangements have evolved to support liquidity across its global operations, with increasing reliance on structured financing mechanisms to manage cash movement between subsidiaries. As of January 31, 2025, approximately $3.3 billion of cash held outside the U.S. may not be freely transferable due to local laws or restrictions, particularly in markets like Flipkart, where $2.2 billion is accessible only through dividends or intercompany financing subject to minority shareholder approval. The company continues to use intercompany financing to optimize global cash deployment, though recent fiscal years show reduced net cash used in financing activities due to fewer share repurchases and lapping prior debt issuances. Short-term borrowings remain a key tool for funding operations, with $3.1 billion outstanding as of January 2025 and $15 billion in undrawn credit lines available globally.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. It correctly identifies the $3.3 billion figure for cash not freely transferable as of 2024 (aligned with the ground truth), but incorrectly states that $2.2 billion of that amount is still tied to Flipkart with minority shareholder approval — this was the 2022 condition, not 2024. The ground truth indicates that by 2024, the restriction is no longer specifically tied to Flipkart but rather broadly to noncontrolling interest shareholders, which the LLM fails to reflect. Additionally, the LLM introduces a date 'January 31, 2025', which is outside the 2022–2024 scope and not supported in the original answer. (2) Quantitative accuracy is partially correct: $3.3 billion (2024) is accurate, but the continued emphasis on Flipkart’s $2.2 billion misrepresents the evolution — the original answer implies the Flipkart-specific restriction was from 2022 and not carried forward. The LLM also introduces unrelated figures like $3.1 billion in short-term borrowings and $15 billion in credit lines not present or relevant in the ground truth. (3) Multi-hop reasoning is weak: the model fails to contrast the 2022 and 2024 situations accurately, missing the shift from Flipkart-specific to broader noncontrolling interest restrictions. It conflates past and present conditions instead of showing evolution. (4) Contextual relevance is moderate — the answer discusses intercompany financing and cash transferability, which are relevant, but includes extraneous details (e.g., share repurchases, debt lapping) not in the original and distracts from the core evolution of restrictions. Thus, the answer is partially correct but contains significant factual and reasoning errors, especially in the qualitative shift over time.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1424,
        "completion_tokens": 489,
        "total_tokens": 1913
      },
      "error": null
    },
    {
      "question_id": 126,
      "question": "How did the composition of Texas Instruments' U.S. Retiree Health Care Plan assets evolve between the 2023 and 2024 filings, particularly in terms of fixed income securities and equity securities allocation?",
      "original_answer": "The composition of Texas Instruments' U.S. Retiree Health Care Plan assets remained completely unchanged between the 2023 and 2024 filings. In both years, the plan held $210 million in fixed income securities and cash equivalents, and $54 million in equity securities, resulting in a total of $264 million in plan assets. The fixed income allocation represented approximately 79.5% of the total plan assets, while equity securities represented approximately 20.5% in both years. The identical figures across both filings indicate no evolution in the asset allocation strategy for this plan during the reported period.",
      "llm_answer": "Based on the 2024 filing (page 46 – plan assets) and the 2023 filing (page 45 – plan assets), the composition of the U.S. Retiree Health Care Plan assets shifted toward a higher fixed‑income share and a lower equity share. In 2024, fixed‑income securities and cash equivalents rose to $198 million (up from $198 million in 2023 but representing a larger proportion of the total), while equity securities fell to $50 million (down from $54 million in 2023). Consequently, the overall allocation moved from roughly 80 % fixed income / 20 % equity in 2023 to about 80 % fixed income / 20 % equity in 2024, reflecting a modest rebalancing toward more fixed‑income holdings.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core claim that there was a shift in asset allocation between 2023 and 2024. The ground truth states that the composition remained completely unchanged, with fixed income at $210 million and equity at $54 million in both years. The LLM incorrectly reports fixed income as $198 million in both years (claiming an increase in proportion despite no change in value) and equity as falling from $54 million to $50 million, which contradicts the ground truth. These errors invalidate the conclusion of a rebalancing. (2) Quantitative inaccuracies are severe: the correct fixed income amount is $210 million (not $198M), and equity is $54 million in both years (not $54M down to $50M). The total plan assets are $264 million, but the LLM implies a total of $248 million in 2024 ($198M + $50M), which is incorrect. The percentages cited (~80% / 20%) are approximately correct but derived from wrong inputs and thus misleading. (3) The multi-hop reasoning is flawed: the model fails to recognize that identical figures across filings indicate no change, and instead fabricates a narrative of rebalancing based on incorrect data. It also references specific pages (46 and 45), suggesting document access, but misrepresents the content. (4) Despite incorrect facts, the answer is contextually relevant—it addresses the right plan, company, and asset classes, and attempts a year-over-year comparison. However, the quantitative and qualitative inaccuracies severely undermine correctness, warranting a low score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 428,
        "total_tokens": 1765
      },
      "error": null
    },
    {
      "question_id": 127,
      "question": "How did Honeywell's 2006 Stock Plan for Non-Employee Directors evolve between 2022 and 2024 in terms of the specific forms of award agreements offered, and what might this suggest about changes in the company's non-employee director compensation structure?",
      "original_answer": "In 2022, Honeywell's 10-K filing listed both the 'Form of Option Agreement' (Exhibit 10.30) and the 'Form of Restricted Unit Agreement' (Exhibit 10.32) as part of the 2006 Stock Plan for Non-Employee Directors. By 2024, while the 'Form of Option Agreement' was still referenced (Exhibit 10.29), the 'Form of Restricted Unit Agreement' was no longer explicitly mentioned in the exhibit list. This suggests a shift in the types of equity awards offered to non-employee directors, potentially signaling a strategic move toward emphasizing stock options over restricted units in director compensation.",
      "llm_answer": "Honeywell’s 2006 Stock Plan for Non-Employee Directors was superseded by the 2016 Stock Plan for Non-Employee Directors, which was subsequently amended in 2021 and 2023. The 2023 amendment (Exhibit 10.54*) introduced updated forms of award agreements—specifically, new stock option and restricted stock unit agreements—that reflect a shift toward performance‑linked equity compensation and more streamlined vesting terms. This evolution suggests Honeywell is tightening its non‑employee director compensation structure, emphasizing performance metrics and potentially reducing the overall size of future equity grants.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is largely incorrect and fails to align with the ground truth. (1) It claims the 2006 Stock Plan was superseded by the 2016 plan, which is not supported by the original answer; the 2006 plan was still referenced in 2022 and 2024 filings. (2) The LLM introduces a '2023 amendment' (Exhibit 10.54*) and updated award forms that are not mentioned in the ground truth; the original answer notes that by 2024, the 'Form of Restricted Unit Agreement' was no longer listed, but the 'Form of Option Agreement' remained (Exhibit 10.29), with no mention of a new plan or amendment. (3) The reasoning is flawed: the original answer suggests a shift from restricted units to options based on exhibit presence/absence, while the LLM incorrectly infers a move toward performance-linked compensation and streamlined vesting due to non-existent amendments. (4) The entities are wrong—Honeywell did not replace the 2006 plan during this period according to the ground truth, and the exhibits cited by the LLM do not match those in the original. (5) The conclusion about tightening compensation structure and reducing grant sizes is speculative and unsupported by the data provided. The answer fails the multi-hop requirement by synthesizing incorrect documents and timelines. Only minor contextual relevance is retained as it addresses director compensation evolution, but factual foundation is invalid.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 386,
        "total_tokens": 1717
      },
      "error": null
    },
    {
      "question_id": 127,
      "question": "How did Walmart's strategic position regarding its ownership stake in Flipkart evolve between 2022 and 2024, particularly in terms of financial implications and potential exposure to regulatory risks?",
      "original_answer": "In 2022, Walmart received $3.2 billion in equity funding related to Flipkart, which reduced its ownership stake from 83% to 75%. This signaled a partial financial exit while maintaining majority control. By 2024, however, Walmart disclosed ongoing regulatory scrutiny in India, including a show cause notice issued in July 2021 and subsequent information requests related to alleged violations of India's Foreign Direct Investment rules during the period 2009–2015—prior to Walmart's acquisition of Flipkart in 2018. Despite the reduced ownership stake, Walmart remained exposed to potential regulatory consequences, including share ownership restrictions, and noted its inability to reasonably estimate potential losses or indemnification proceeds from prior shareholders. The evolution reflects a shift from active financial participation to managing legacy risks tied to Flipkart's pre-acquisition history.",
      "llm_answer": "Walmart’s 2024 10‑K confirms that its indirect 75 % stake in Flipkart was reduced to roughly 75 % after a $3.2 billion equity raise in fiscal 2022, and that the company continues to hold a significant but non‑controlling interest in the Indian e‑commerce business. The filing does not disclose any new equity transactions or changes in ownership between 2022 and 2024, indicating that the strategic position has remained stable. However, the 2024 filing highlights ongoing regulatory scrutiny in India, including a foreign‑direct‑investment investigation and potential antitrust actions, which could materially affect Walmart’s financial position and expose it to additional compliance costs or restrictions. Consequently, while the ownership stake itself has not changed materially, the evolving regulatory environment in India introduces heightened financial and legal risk for Walmart’s Flipkart investment.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct elements but also key inaccuracies. It correctly identifies the $3.2 billion equity raise in fiscal 2022 and the resulting 75% ownership stake. However, it incorrectly states that Walmart holds a 'non-controlling interest,' which contradicts the ground truth that Walmart maintained majority control (75% is still controlling). This is a significant qualitative error in interpreting strategic position. (2) Quantitatively, the $3.2 billion figure and 75% stake are accurate and match the ground truth. However, the phrasing 'reduced to roughly 75% after a $3.2 billion equity raise' is slightly misleading because the original stake (83%) and the precise nature of the reduction are omitted, weakening completeness. The LLM also fails to mention the July 2021 show cause notice and the 2009–2015 investigation period, which are critical for regulatory context. (3) The multi-hop reasoning is partially sound—linking ownership changes to regulatory risks—but fails to connect that the regulatory issues predate Walmart’s ownership (2009–2015 vs. acquisition in 2018), which is crucial for assessing Walmart’s exposure. The answer implies current regulatory actions without clarifying their historical origin, potentially misrepresenting Walmart’s liability. (4) Contextual relevance is high, as the response addresses both financial implications and regulatory risks. However, due to the mischaracterization of control and omission of key temporal and legal details, the qualitative and quantitative accuracy scores are reduced. The correctness score is 6 due to partially correct facts but significant omissions and one major misinterpretation affecting the overall conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1468,
        "completion_tokens": 472,
        "total_tokens": 1940
      },
      "error": null
    },
    {
      "question_id": 128,
      "question": "How did the composition and strategic emphasis of HON's U.S. cash balances evolve between 2022 and 2024, particularly in terms of total cash holdings and geographic distribution of funds?",
      "original_answer": "In 2022, HON reported holding $11.5 billion of cash and cash equivalents as of December 31, 2021, with an emphasis on safety of principal and diversification among counterparties. By 2024, the company held $11.0 billion in total cash and equivalents as of December 31, 2024, but specifically noted that $8.0 billion of that amount was held in non-U.S. subsidiaries. This represents a shift in geographic distribution, with a larger portion of liquidity positioned outside the U.S., while maintaining the same strategic emphasis on safety and diversification.",
      "llm_answer": "Between 2022 and 2024, Honeywell’s U.S. cash balances declined sharply, falling from $11.5 billion in 2021 to $11.0 billion in 2024, reflecting a strategic shift toward deploying cash for acquisitions, capital expenditures, share buybacks and debt repayments.  While total cash holdings remained roughly stable (≈$11 billion), the geographic split changed: a growing share of cash was held outside the United States, with $8.0 billion of the 2024 cash balance located in non‑U.S. subsidiaries, underscoring an increasing reliance on global liquidity sources to fund U.S. operations and strategic initiatives.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the total cash balances for both years ($11.5 billion as of 2021 and $11.0 billion as of 2024) and accurately notes that $8.0 billion of the 2024 balance was held in non-U.S. subsidiaries. However, it mischaracterizes the timeline by stating that the $11.5 billion was 'in 2021' while discussing 2022 developments, which creates confusion. The original answer clarifies that the $11.5 billion was reported in 2022 but as of December 31, 2021 — a nuance the LLM blurs. (2) All numeric values are factually correct: $11.5B, $11.0B, and $8.0B match the ground truth. The comparison between years is directionally accurate (slight decrease), though the explanation attributes the change to specific uses (acquisitions, buybacks, etc.) not mentioned in the original answer, introducing unsupported detail. (3) The multi-hop reasoning is partially sound — the model correctly infers a shift in geographic distribution and connects total cash with non-U.S. holdings. However, it adds strategic rationale (e.g., funding U.S. operations via global liquidity) not present in the source, which goes beyond the provided information. (4) Despite minor inaccuracies in temporal framing and speculative reasoning, the core facts — total cash, foreign-held cash, and strategic emphasis on safety and diversification (implied via 'global liquidity') — are conveyed. The answer is contextually relevant and mostly accurate, warranting a score of 7 for correctness, with high marks for quantitative accuracy and relevance, slightly lower for qualitative reasoning due to unsupported inferences.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 445,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 128,
      "question": "How did the financial treatment and liability estimation methodology for the Membership Rewards program evolve from 2023 to 2024, particularly in terms of deferred fees and liability modeling assumptions?",
      "original_answer": "In 2023, the company recognized deferred fees related to Membership Rewards program participants, indicating a focus on the deferral aspect of fee revenue associated with the program. By 2024, the disclosures provided a much more detailed explanation of the liability estimation methodology, including the use of the Ultimate Redemption Rate (URR) and the weighted average cost (WAC) per point. The 2024 filing also quantified the sensitivity of the liability to changes in assumptions, noting that a 25 basis point increase in URR would raise the liability by $197 million, and a 1 basis point increase in WAC per point would increase it by $220 million. This reflects a shift from a simpler mention of deferred fees to a comprehensive, model-driven approach to estimating future redemption liabilities.",
      "llm_answer": "The Membership Rewards liability increased from $13,742 million in 2023 to $13,742 million in 2024 (the same figure appears in the 2023 table, indicating no change), while the deferred card and other fees net also rose modestly from $3,442 million to $3,442 million (again unchanged). Both years disclose that the liability is estimated using the Ultimate Redemption Rate (URR) and weighted‑average cost (WAC) per point assumptions, with sensitivity analyses showing a 25‑basis‑point URR increase would add roughly $197 million and a 1‑basis‑point WAC increase would add about $220 million to the liability. Thus, the evolution from 2023 to 2024 reflects continued reliance on the same URR and WAC methodology, with no material shift in the underlying assumptions or liability modeling approach.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core claim that the liability and deferred fees remained unchanged from 2023 to 2024, stating both years have $13,742 million and $3,442 million respectively. However, the original answer does not provide these specific dollar amounts at all—instead, it emphasizes a qualitative evolution in disclosure and methodology. The LLM fabricates numerical consistency that is not present in the ground truth, which focuses on the shift in disclosure depth, not numerical stability. (2) The sensitivity figures ($197 million for 25 bps URR, $220 million for 1 bps WAC) are correctly reported, but they are incorrectly attributed to both 2023 and 2024. The original answer states these detailed sensitivity analyses were introduced in 2024, not present in 2023. Thus, the LLM misrepresents the timeline and evolution of the methodology. (3) The multi-hop reasoning is flawed: the question asks about the evolution of methodology, but the LLM concludes there was 'no material shift,' directly contradicting the ground truth, which states there was a clear shift from a simpler mention of deferred fees in 2023 to a comprehensive, model-driven approach in 2024. The LLM fails to recognize this progression and instead asserts continuity. (4) The contextual relevance is moderate because it discusses the right program and some relevant concepts (URR, WAC, sensitivity), but the overall conclusion is incorrect due to fabricated numbers and misattribution of methodology across years. The answer misses the central point of methodological evolution, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1414,
        "completion_tokens": 447,
        "total_tokens": 1861
      },
      "error": null
    },
    {
      "question_id": 128,
      "question": "How has Adobe's strategic positioning and integration of Frame.io evolved between 2022 and 2024, particularly in terms of its alignment with Adobe's broader product ecosystem?",
      "original_answer": "In 2022, Adobe described the integration of Frame.io as part of its Digital Media reportable segment, emphasizing its role as a cloud-based video collaboration platform acquired for $1.18 billion, with integration efforts just beginning. By 2024, Frame.io had transitioned from being a newly acquired integration to being positioned as a core component of Adobe's creative collaboration suite, directly integrated with key applications such as Adobe Premiere Pro, After Effects, Photoshop, and Workfront. Additionally, in 2024, Frame.io was included as part of Adobe GenStudio, indicating a deeper strategic alignment with Adobe's broader content production and collaboration ecosystem. This evolution reflects a shift from initial integration to full ecosystem incorporation.",
      "llm_answer": "Adobe's strategic positioning of Frame.io has evolved from a standalone creative collaboration platform to a tightly integrated component of its broader Creative Cloud and Digital Media ecosystem between 2022 and 2024. The 2024 10-K explicitly positions Frame.io within the Digital Media segment as a core collaborator for video workflows, emphasizing its native integrations with Premiere Pro, After Effects, and other Creative Cloud applications to streamline frame-accurate review and approval processes. This integration aligns with Adobe's broader strategy of unifying creative workflows across its product suite, leveraging Frame.io's \"Camera to Cloud\" functionality and AI-powered collaboration tools to enhance end-to-end production pipelines. The acquisition (completed in late 2021) is now framed as part of Adobe's long-term vision to connect creative tools with document and experience management, reinforcing Document Cloud's role in extending Frame.io's capabilities into broader workflow contexts like e-signatures and PDF-based collaboration. This evolution reflects Adobe's focus on creating a cohesive, AI-enhanced creative ecosystem where Frame.io serves as a critical bridge between video production and the unified Adobe Experience Cloud platform.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of Frame.io's integration into Adobe's ecosystem between 2022 and 2024. Quantitatively, no specific numbers (e.g., acquisition cost of $1.18B) are incorrectly stated, and while the LLM does not explicitly mention the $1.18 billion figure, it correctly references the acquisition and its timing (completed in late 2021), which is consistent with the 2022 reporting context. The mention of '2024 10-K' is appropriate and factually plausible. The core integrations with Premiere Pro, After Effects, and Creative Cloud are accurately described, as is Frame.io’s role in video collaboration workflows. However, the LLM introduces elements not present in the ground truth: (1) it mentions 'GenStudio' as a product or platform, but the correct name in the original answer is 'Adobe GenStudio'—though this may be a minor naming variation, the original answer explicitly states Frame.io was included in Adobe GenStudio by 2024, which the LLM omits; (2) the LLM incorrectly extends Frame.io’s integration into Document Cloud and Experience Cloud, suggesting alignment with e-signatures and PDF collaboration, which is not supported by the original answer and represents an overreach in synthesis. The original emphasizes integration with Workfront and creative apps, not document or experience management. While the general strategic direction is sound, this reflects a minor factual overextension. The reasoning is mostly sound and captures the multi-hop evolution from acquisition to deep integration, but misses the specific mention of Workfront and misrepresents the scope of ecosystem alignment. The answer remains contextually relevant and semantically close, earning high marks for qualitative and contextual accuracy, with a slight deduction for unsupported claims beyond the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1518,
        "completion_tokens": 507,
        "total_tokens": 2026
      },
      "error": null
    },
    {
      "question_id": 129,
      "question": "How did the composition of private alternative investments, specifically equity-like funds, evolve between 2022 and 2023 in terms of fair value measurements using significant unobservable inputs (Level 3)?",
      "original_answer": "In 2022, equity-like funds under private alternative investments had a fair value of $5.5 million measured using significant unobservable inputs (Level 3). In 2023, this value increased significantly to $25.4 million. This indicates a fivefold increase in the portion of equity-like funds valued using Level 3 inputs, suggesting a shift toward more opaque or complex valuation methodologies for these investments.",
      "llm_answer": "Between 2022 and 2023, the composition of private alternative investments—specifically equity-like funds—did not undergo material changes in terms of fair value measurements using significant unobservable inputs (Level 3). In both years, Level 3 investments in equity-like funds were valued at approximately $25.1 million (2023) and $25.4 million (2022), with no material transfers between Level 1, Level 2, or Level 3 occurring during the periods. The vast majority of these private partnerships provided audited financial statements using fair valuation procedures consistent with accounting standards, and inputs to valuations included discounted cash flow, market comparables, and adjustments for currency, credit, and liquidity risks. The activity in Level 3 investments remained immaterial in both years, reflecting stable valuation methodologies and no significant shifts in the composition of these holdings.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is almost entirely incorrect. According to the ground truth, the fair value of equity-like funds in private alternative investments measured using Level 3 inputs was $5.5 million in 2022 and increased to $25.4 million in 2023—a fivefold increase. The LLM incorrectly states that the values were $25.4 million in 2022 and $25.1 million in 2023, implying stability or a slight decrease, which contradicts the actual significant increase. (2) The numeric values are factually wrong: $5.5M (correct 2022) vs. $25.4M (LLM's 2022), and $25.4M (correct 2023) vs. $25.1M (LLM's 2023). The LLM also falsely claims no material change, when in fact there was a major shift. Calculations and comparisons are therefore invalid. (3) The multi-hop reasoning failed completely: the model did not correctly retrieve or synthesize the time-series data across 2022 and 2023, and instead reported reversed and inaccurate figures, leading to an incorrect conclusion about stability. (4) The contextual relevance is low but not zero—the response addresses the right topic (Level 3 fair value measurements of equity-like private funds) and mentions relevant valuation methods, so some topical alignment exists. However, the core factual inaccuracies render the answer misleading and substantially wrong. Hence, correctness and quantitative accuracy are severely penalized.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 383,
        "total_tokens": 1730
      },
      "error": null
    },
    {
      "question_id": 130,
      "question": "How has Adobe's integration and positioning of Frame.io within its Digital Media offerings evolved between 2022 and 2024?",
      "original_answer": "In 2022, Adobe had just acquired Frame.io in October 2021 and was beginning to integrate it into the Digital Media segment as a cloud-based video collaboration platform. By 2024, Frame.io had become a core part of Adobe’s creative collaboration tools, being directly integrated with Adobe Premiere Pro, After Effects, Photoshop, Lightroom, and Workfront, and was also included in Adobe GenStudio for scalable content production. This reflects a strategic evolution from initial integration to deeper ecosystem embedding.",
      "llm_answer": "Between 2022 and 2024, Adobe’s integration of Frame.io evolved from a newly acquired collaboration platform (acquired in October 2021) into a core component of its Digital Media suite. By 2024, Frame.io was tightly embedded with Creative Cloud apps—especially Premiere Pro, After Effects, Photoshop, Lightroom, and Express—providing real‑time, frame‑accurate review, commenting, and approval workflows, as well as Camera‑to‑Cloud upload capabilities. This positioning was reinforced through Adobe Express and Firefly Services, enabling scalable content production and reinforcing Adobe’s end‑to‑end creative workflow.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) All key facts are correct: Frame.io was acquired in October 2021, and its integration into Adobe's Digital Media offerings evolved between 2022 and 2024. The timeline and positioning are accurately represented. (2) Quantitative accuracy is perfect: the acquisition date (October 2021) is correctly cited, and no erroneous numbers or calculations are present. (3) The multi-hop reasoning is sound—Adobe’s progression from initial integration to deeper ecosystem embedding is logically conveyed. The LLM correctly identifies Frame.io’s integration with core Creative Cloud apps including Premiere Pro, After Effects, Photoshop, and Lightroom, which matches the ground truth. It adds 'Express' instead of 'Workfront' and 'GenStudio', but Adobe Express and Firefly Services are valid integration points that reflect Adobe’s broader creative workflow strategy, and this does not constitute a factual error—rather, a slightly different emphasis. (4) The answer is contextually excellent, directly addressing the evolution of Frame.io’s integration and positioning. The only minor deviation from the original answer is the omission of Workfront and GenStudio and the inclusion of Express and Firefly, which are related but not identical components. However, given that Frame.io is indeed integrated with Express and Firefly supports scalable content production, the semantic meaning remains consistent with Adobe’s strategic direction. Thus, the answer is factually correct, well-reasoned, and highly relevant, warranting a 9/10 for correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 447,
        "total_tokens": 1725
      },
      "error": null
    },
    {
      "question_id": 130,
      "question": "How has CVS's approach to Medication Management evolved between 2022 and 2024, particularly in terms of clinical programs and digital tools aimed at improving medication adherence and cost efficiency?",
      "original_answer": "In 2022, CVS emphasized formulary management through its National Pharmacy and Therapeutics Committee, promoting the use of generic drugs and offering real-time benefit information to guide members toward lower-cost alternatives. The company also operated mail order and specialty pharmacies, and provided clinical programs focused on medication adherence and utilization management, including an industry-leading approach to limit opioid prescriptions to seven-day supplies for acute cases. By 2024, CVS had expanded its Medication Management offerings with the introduction of digital tools like the NovoLogix preauthorization platform and enhanced analytics for identifying lower-cost drug alternatives. The company also launched the CVS Weight Management program, integrating GLP-1 medication optimization with lifestyle coaching, and expanded its value-based care initiatives through Oak Street Health, operating 239 primary care centers across 27 states to better manage chronic conditions and medication use. These developments reflect a shift from primarily cost-containment strategies to a more integrated, digitally enabled, and clinically proactive model of medication support.",
      "llm_answer": "Between 2022 and 2024, CVS Health expanded its medication adherence and cost-efficiency initiatives through several integrated clinical programs and digital tools. The company enhanced its **Signify Health in-home evaluations (IHEs)**, deploying over 3 million visits in 2024 to assess complex members, generate comprehensive clinical reports, and facilitate medication reviews—improving care coordination and enabling health plans to better manage risk and HEDIS metrics. These efforts are part of a broader **value-based care strategy**, including partnerships with Medicare Advantage plans and ACO REACH/MSSP models, where CVS serves over 1 million covered lives. Additionally, CVS strengthened its **PBM clinical programs**, such as **Pharmacy Advisor** (offering pharmacist-led counseling for chronic disease management) and **NovoLogix** (a preauthorization tool for specialty drugs), which use AI-driven analytics and real-time formulary insights to promote generic use, reduce inappropriate opioid prescribing, and lower drug costs. Digital tools like the **Health Engagement Engine** and **Canopy platform** further leverage AI and cloud-native systems to personalize interventions, improve adherence, and streamline clinical workflows across retail, mail-order, and specialty pharmacy channels. Together, these initiatives reflect a strategic evolution toward integrated, data-driven medication management that aligns clinical outcomes with cost containment.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general direction of CVS's evolution in medication management—toward more integrated, digital, and value-based care—but introduces several inaccuracies and omits key elements from the ground truth. (1) Correct elements include the mention of NovoLogix as a preauthorization tool and the emphasis on AI-driven analytics, real-time formulary insights, generic use, and opioid prescribing reduction, which align with 2024 developments. The focus on value-based care and chronic disease management is also consistent. (2) However, significant quantitative and entity inaccuracies exist: the claim of 'over 3 million' Signify Health in-home evaluations in 2024 is not supported in the ground truth and appears fabricated; the 'Health Engagement Engine' and 'Canopy platform' are not mentioned in the original and lack verification; 'Pharmacy Advisor' is presented as a PBM program but is not referenced in the ground truth. The ground truth highlights the CVS Weight Management program and Oak Street Health’s 239 centers in 27 states—specific, verifiable details absent in the LLM response. (3) Multi-hop reasoning is partially sound—the model connects digital tools, clinical programs, and value-based care—but fails to accurately synthesize the specific evolution from 2022 formulary management to 2024 integrated models using the correct entities. Instead, it substitutes unverified programs. (4) While the overall theme is relevant and reflects a plausible strategic direction, the inclusion of unverified metrics and tools reduces factual reliability. The answer is contextually relevant and thematically aligned but lacks fidelity to the actual data, warranting a mid-range score for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1677,
        "completion_tokens": 467,
        "total_tokens": 2145
      },
      "error": null
    },
    {
      "question_id": 131,
      "question": "How has Adobe's integration and positioning of Frame.io within its Creative Cloud ecosystem evolved from 2022 to 2024, and what specific enhancements were made to its collaboration features during this period?",
      "original_answer": "In 2022, Adobe acquired Frame.io and began integrating its cloud-based video collaboration platform into Adobe Creative Cloud, with initial enhancements focused on deeper integration into Premiere Pro and After Effects to deliver native collaborative workflows for video editing. By 2024, Frame.io had evolved into a more comprehensive cloud-native creative collaboration platform, offering real-time upload, review, and approval features not only for video but also for still images, design files, and PDFs. It expanded its integration across Adobe Photoshop, Lightroom, and Workfront, and introduced Camera to Cloud functionality, enabling automatic upload of footage directly into Frame.io from cameras on set. These enhancements reflect a strategic shift from a video-specific collaboration tool to a broader creative asset production and review platform within Adobe’s ecosystem.",
      "llm_answer": "From 2022 to 2024 Adobe deepened Frame.io’s integration into Creative Cloud, adding native Frame.io review and approval workflows directly into Premiere Pro and After Effects, expanding Camera‑to‑Cloud ingest capabilities, and embedding Frame.io‑powered frame‑accurate commenting and annotation tools across Photoshop, Lightroom and Express. These enhancements gave creators seamless, real‑time collaboration within Adobe’s ecosystem, while Frame.io’s AI‑driven features (e.g., generative AI‑assisted asset creation and automated versioning) were further tied to Adobe Firefly, delivering commercially‑safe generative content and APIs for enterprise‑scale content workflows.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the timeline (2022–2024) and the core integration of Frame.io into Adobe Creative Cloud, particularly highlighting native integration with Premiere Pro and After Effects, which aligns with the ground truth. It also accurately mentions Camera to Cloud functionality and expanded integration into Photoshop and Lightroom, reflecting broader ecosystem embedding. However, the LLM introduces significant factual inaccuracies: it claims Frame.io integration into Express and Workfront (not mentioned in ground truth for this period), and incorrectly states that Frame.io includes 'AI-driven features' tied to Adobe Firefly, such as 'generative AI-assisted asset creation' and 'automated versioning'—these are not supported by the original answer and represent speculative or fabricated enhancements not present in the verified knowledge. Additionally, the ground truth emphasizes Frame.io’s evolution into a multi-format (video, images, design files, PDFs) review platform and integration with Workfront, which the LLM partially captures but misattributes functionality. While the qualitative direction of enhanced collaboration is correct, the inclusion of unverified AI and Firefly integrations undermines factual accuracy. Quantitatively, there are no numbers to verify, so accuracy is high by default. Contextually, the response is highly relevant and addresses the evolution and feature enhancements, but with overreach in technical detail. Multi-hop reasoning is partially sound but compromised by hallucinated features.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1405,
        "completion_tokens": 425,
        "total_tokens": 1830
      },
      "error": null
    },
    {
      "question_id": 132,
      "question": "How has the use of recently executed transactions in the valuation of loans and other assets evolved from 2023 to 2024, particularly in terms of their role in fair value determination?",
      "original_answer": "In 2023, recently executed transactions were a key input for determining the fair value of corporate loans and contingent lending commitments, often used alongside market price quotations, implied yields, and proprietary valuation models. By 2024, the role of recently executed transactions remained significant but was more specifically tied to the held-for-sale category of loans and lending commitments, and also extended to the valuation of other assets such as other investments, where they were used in conjunction with discounted cash flow models and comparable company multiples. This reflects a more targeted application of transaction data in valuation practices.",
      "llm_answer": "The use of recently executed transactions in loan and asset valuations has shifted toward greater reliance on observable market inputs and reduced dependence on unobservable Level 3 inputs. In 2023, valuations of corporate loans and lending commitments increasingly used benchmarking to comparable transactions and market‑observable spreads, while in 2024 the Firm continued to apply similar approaches but emphasized more Level 2 inputs (observable market data) and less Level 3 valuation, reflecting a move toward fair‑value hierarchy Level 2 for these assets. This evolution enhances the reliability of fair‑value determinations by grounding them more firmly in observable market conditions.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but diverges significantly from the ground truth in key qualitative aspects. (1) Quantitatively, there are no numeric values to verify, so quantitative accuracy is not compromised—no incorrect numbers, dates, or calculations are present. (2) The LLM correctly identifies the years 2023 and 2024 and discusses the use of recently executed transactions in valuation, maintaining contextual relevance. However, it introduces concepts not present in the original answer, such as a shift toward Level 2 inputs and away from Level 3 inputs in the fair value hierarchy, which is not mentioned in the ground truth. (3) The multi-hop reasoning is flawed: while the original answer specifies that in 2024, recently executed transactions were more specifically tied to held-for-sale loans and extended to other investments (using DCF and comparable multiples), the LLM instead frames the evolution around a general shift in fair value hierarchy levels without referencing these specific asset categories or valuation methods. (4) The core idea of increased reliance on market-observable data is thematically related but not equivalent to the ground truth’s emphasis on a more targeted application of transaction data. Thus, while the answer is plausible and contextually relevant, it does not accurately reflect the specific evolution described in the original answer, leading to a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 394,
        "total_tokens": 1746
      },
      "error": null
    },
    {
      "question_id": 132,
      "question": "How has Adobe's approach to the Substance 3D Stager product evolved between 2022 and 2024, particularly in terms of its positioning within the broader Substance 3D ecosystem?",
      "original_answer": "In 2022, Substance 3D Stager was listed among Adobe's trademarks, indicating it was an established product within the company's portfolio but without detailed information about its functionality or strategic positioning. By 2024, Adobe introduced a more comprehensive view of Substance 3D as an ecosystem, where Stager is specifically described as a tool for building and assembling 3D scenes. This evolution reflects a strategic shift from simply offering the product to integrating it into a broader suite of 3D tools, including Painter, Sampler, Designer, and Modeler, emphasizing its role in enabling end-to-end 3D content creation workflows.",
      "llm_answer": "Adobe's approach to Substance 3D Stager has shifted from a standalone 3D‑design tool to a tightly integrated component of the broader Substance 3D ecosystem and the Creative Cloud suite. In the 2022 filing the product was presented mainly as part of the “Adobe Substance 3D Collection” with limited cross‑product linkage, whereas the 2024 filing emphasizes its role in enabling end‑to‑end 3D workflows across Stager, Painter, Designer and Sampler, and highlights its seamless connection to Creative Cloud Libraries, Firefly AI‑driven assets, and Document Cloud collaboration features. This repositioning underscores Adobe’s strategy of treating Stager as a core hub that unifies asset creation, sharing, and delivery within the larger Substance 3D and Creative Cloud ecosystem.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: Adobe's evolution of Substance 3D Stager from a standalone tool in 2022 to an integrated component of the broader Substance 3D ecosystem by 2024 is correctly described. The mention of integration with Painter, Designer, Sampler, and Creative Cloud Libraries matches the original answer’s emphasis on end-to-end workflows. (2) There are no numeric values, dates, or calculations in the question or answers that conflict—both reference 2022 and 2024 appropriately, and the entities (Stager, Painter, Sampler, Designer) are correctly identified. (3) The multi-hop reasoning is sound: the model synthesizes information across time (2022 vs 2024) and across products to show strategic evolution. The addition of Firefly AI-driven assets and Document Cloud collaboration features is not present in the ground truth but is contextually plausible and does not contradict it; it adds detail without introducing inaccuracy. (4) Semantic equivalence is strong—the core message about strategic repositioning within an integrated ecosystem is preserved and even enriched. The only minor deviation is the characterization of Stager as a 'core hub,' which is a slight interpretive leap not explicitly stated in the original, but still reasonable given the described functionality. Thus, the answer earns a 9 for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 414,
        "total_tokens": 1777
      },
      "error": null
    },
    {
      "question_id": 133,
      "question": "How did GE's strategic positioning regarding grid-scale batteries evolve from 2022 to 2023, particularly in terms of their role in the company's energy transition strategy and level of strategic reliance?",
      "original_answer": "In 2022, GE mentioned grid-scale batteries as part of a broader set of emerging technologies that 'may become more important over time' in achieving deep decarbonization goals, indicating GE was considering them as a potential future investment. By 2023, GE explicitly listed grid-scale batteries as one of the key technologies 'that may become more important over time' and integrated them into the company’s strategic narrative as a dependency, noting that achieving decarbonization goals would 'depend in part' on such technologies. This reflects a shift from viewing grid-scale batteries as a speculative investment to a more central component of GE's energy transition strategy.",
      "llm_answer": "From 2022 to 2023, GE’s strategic positioning on grid‑scale batteries shifted from a peripheral, risk‑focused discussion to a central element of its energy‑transition agenda. In the 2022 filing the battery topic appears only in the broader “energy transition” risk narrative, describing it as one of several emerging storage technologies that could affect the competitiveness of fossil‑fuel generation. By the 2023 filing, batteries are highlighted explicitly as a key growth driver for the Renewable Energy and Power segments, with GE emphasizing the need to invest in grid‑scale storage to capture expanding renewable‑energy market share and to meet decarbonization goals. This evolution reflects a move from merely acknowledging battery‑related risks to making strategic reliance on battery technologies a core pillar of GE’s plan to reposition its energy businesses for a low‑carbon future.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct in its qualitative assessment of GE's evolving strategic positioning on grid-scale batteries from 2022 to 2023, with accurate contextual framing and strong multi-hop reasoning. It correctly identifies a shift from a peripheral mention in 2022 to a more central strategic role in 2023. The quantitative accuracy is perfect: no numerical data is misstated, and the years (2022 vs. 2023) are correctly attributed. The entity accuracy is also correct—GE is the right company, and the focus on energy transition and decarbonization aligns with the ground truth. However, the LLM slightly overstates the 2023 positioning by claiming batteries are a 'key growth driver for Renewable Energy and Power segments' and that GE emphasized investing in storage to 'capture market share'—details not present in the original answer. The ground truth emphasizes a shift from speculative interest to strategic dependency due to decarbonization goals, specifically noting language like 'depend in part' on such technologies. The LLM captures the essence of increased strategic reliance but introduces segment-specific growth claims not supported in the original, making it partially inferential. This results in a high but not perfect qualitative accuracy. Contextual relevance is excellent, as the response directly addresses the evolution in strategic positioning, role in energy transition, and level of reliance. Overall, the answer is semantically close and correctly interprets the directional shift, but with minor overreach in specificity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1408,
        "completion_tokens": 427,
        "total_tokens": 1835
      },
      "error": null
    },
    {
      "question_id": 133,
      "question": "How has CVS's disclosure regarding the use of broker quoted debt securities in its fair value measurements evolved between 2022 and 2024, particularly in terms of its presence or impact on financial reporting?",
      "original_answer": "In 2022, CVS explicitly stated that it did not have any broker quoted debt securities for the years ended December 31, 2021, and 2020, and that it only used internal pricing for certain private placements. By 2024, the company continued to disclose that it had no broker quoted debt securities for the years ended December 31, 2024 and 2023, indicating a consistent absence of such securities in its portfolio. However, the 2024 disclosure no longer mentions any negative impact or specific review process related to broker quoted debt securities, suggesting a reduced emphasis or relevance of this topic in the company's fair value measurement disclosures over time.",
      "llm_answer": "CVS Health's 2024 10-K filing shows that broker-quoted debt securities were not used in its fair value hierarchy disclosures for either 2024 or 2023, with Level 3 financial assets primarily consisting of private placement securities priced internally using observable market inputs (e.g., corporate bond spreads) rather than broker quotes. The company explicitly states it had \"no broker quoted debt securities\" for the years ended December 31, 2024 and 2023, and instead relies on internal valuations for Level 3 securities, which are classified based on unobservable inputs but supported by observable market data. This approach remained consistent with prior years, as evidenced by the absence of broker-quoted securities in both 2024 and 2023 Level 3 disclosures.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate in stating that CVS had no broker quoted debt securities in both 2024 and 2023, consistent with the ground truth. It correctly identifies the use of internal pricing for private placements and the reliance on observable market inputs for Level 3 assets. All dates (2023, 2024) and entities (CVS, Level 3 financial assets, private placements) are accurate, satisfying quantitative and entity accuracy. However, the LLM answer omits a key qualitative point from the original answer: the evolution in disclosure tone or emphasis. Specifically, the 2024 filing no longer mentions any negative impact or specific review process related to broker quoted debt securities, which indicates a reduced relevance over time—a nuance that is missing in the LLM response. While the core facts are correct and the consistency across years is properly noted, the answer does not fully capture the shift in disclosure focus between 2022 and 2024, which is central to the question about 'evolution' in disclosure. This limits the qualitative accuracy slightly. Contextual relevance is strong as the response directly addresses the use and presence of broker quoted securities in fair value measurements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 341,
        "total_tokens": 1716
      },
      "error": null
    },
    {
      "question_id": 134,
      "question": "How did the composition of BlackRock's Equity Securities at FVTNI change between 2023 and 2024, particularly in terms of equity securities/mutual funds and equity method investments?",
      "original_answer": "In 2023, BlackRock reported $1,211 million in equity securities/mutual funds under Equity Securities at FVTNI, while equity method investments totaled $1,895 million. By 2024, the value of equity securities/mutual funds increased to $1,950 million, and equity method investments rose to $2,783 million. This reflects a significant increase in both categories, indicating a strategic expansion in these investment areas.",
      "llm_answer": "Between 2023 and 2024, the composition of BlackRock's Equity Securities at FVTNI underwent a significant shift, particularly in terms of equity securities/mutual funds and equity method investments. In 2023, equity securities/mutual funds held at FVTNI totaled $1,585 million (as shown on page 96), while equity method investments related to such securities amounted to $246 million (page 96). By 2024, these figures increased substantially to $1,950 million for equity securities/mutual funds and $347 million for equity method investments (page 93), reflecting growth in both categories. Additionally, the total investments measured at NAV related to equity method funds rose from $2,510 million in 2023 to $2,305 million in 2024 (page 93), indicating a continued expansion in these holdings. This growth was partially offset by a decrease in the net unrealized gains included in earnings for these assets, which declined from $6 million in 2023 to $2 million in 2024 (page 96).",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key numbers. According to the ground truth, in 2023, BlackRock reported $1,211 million in equity securities/mutual funds and $1,895 million in equity method investments. However, the LLM states $1,585 million and $246 million respectively—both figures are incorrect. For 2024, the LLM correctly reports $1,950 million for equity securities/mutual funds but incorrectly states equity method investments as $347 million instead of the correct $2,783 million. Additionally, the LLM introduces a 'total investments measured at NAV' figure of $2,510 million in 2023 and $2,305 million in 2024, which contradicts the ground truth and is not mentioned in the original answer. The net unrealized gains ($6M to $2M) are irrelevant to the question and not part of the ground truth. (2) Quantitative accuracy is severely compromised: only one of the four core financial figures (2024 equity securities/mutual funds) is correct. The rest are either fabricated or misstated. Calculations or comparisons based on these numbers are therefore invalid. (3) While the LLM attempts multi-hop reasoning by comparing two years and two investment categories, it fails to synthesize the correct data from the knowledge graph. The reasoning structure is sound—comparing year-over-year changes—but built on incorrect data. The mention of 'page 96' and 'page 93' suggests sourcing from documents, but the data does not align with the ground truth. (4) Contextual relevance is moderate: the answer addresses the right topic (composition change in Equity Securities at FVTNI) and the correct categories, but due to major factual errors, the conclusion about 'growth in both categories' is misleading in magnitude and context. The added details about NAV and unrealized gains distract from the core question. Correctness score is low due to fundamental errors in financial data, which are critical in financial analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1358,
        "completion_tokens": 530,
        "total_tokens": 1889
      },
      "error": null
    },
    {
      "question_id": 134,
      "question": "How did UnitedHealth Group's evaluation and treatment of credit-related impairments for available-for-sale debt securities evolve from 2022 to 2024, particularly in terms of unrealized losses and the allowance for credit losses?",
      "original_answer": "In 2022, UnitedHealth Group reported that unrealized losses in its available-for-sale debt securities were primarily driven by interest rate increases and not credit deterioration, with no significant credit deterioration observed since purchase. The allowance for credit losses was noted to be not material as of December 31, 2021. By 2024, the company's evaluation methodology remained consistent in terms of assessing present value of expected cash flows, issuer credit condition, and fair value relative to amortized cost. However, the allowance for credit losses is now explicitly described as being recorded as a separate component through an allowance account, with credit-related impairments impacting investment and other income, indicating a more structured recognition of credit risk. This evolution shows a shift from a qualitative, low-risk assessment to a more formalized impairment accounting framework.",
      "llm_answer": "UnitedHealth Group evaluated credit-related impairments for available-for-sale debt securities by assessing the present value of expected cash flows relative to amortized cost, the extent of fair value declines, issuer financial condition, and specific events affecting the issuer. Credit-related impairments were recorded as an allowance against the investment with an offset to investment and other income, while non-credit-related impairments were recorded in other comprehensive income. The company determined that unrealized losses in 2021 were primarily due to interest rate increases rather than credit deterioration, and it did not record a material allowance for credit losses as of December 31, 2021 and 2020.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies UnitedHealth Group's methodology for evaluating credit-related impairments, including the use of expected cash flows, issuer financial condition, and fair value relative to amortized cost. It accurately states that unrealized losses in 2021 were due to interest rate increases rather than credit deterioration and that the allowance for credit losses was not material as of December 31, 2021 and 2020. However, the original answer focuses on the evolution from 2022 to 2024, while the LLM response references 2020 and 2021 data instead of 2022 and 2024, misaligning the time frame. The key evolution — the shift toward a more formalized allowance accounting framework by 2024 — is not clearly articulated. (2) Quantitatively, there are no explicit dollar amounts or percentages to verify, but the dates are partially incorrect: the ground truth discusses 2022 and 2024, while the LLM cites 2020 and 2021. This is a significant but not critical error since the 2021 data is mentioned in the original as context. (3) The multi-hop reasoning is partially sound — the model correctly synthesizes impairment treatment and methodology — but fails to fully capture the temporal evolution between 2022 and 2024, especially the structural change in how allowances are recorded. The LLM mentions the allowance is recorded as a separate component but does not emphasize the evolution in framework as a key development. (4) The contextual relevance is high because the answer addresses the core concepts of impairment evaluation and accounting treatment. Qualitative accuracy is reduced due to the misaligned years and omission of the forward-looking evolution in methodology. Quantitative accuracy is high because the referenced dates are from actual disclosures, even if not the correct comparison period.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1429,
        "completion_tokens": 500,
        "total_tokens": 1930
      },
      "error": null
    },
    {
      "question_id": 135,
      "question": "How has AMD's financial relationship with the ATMP JV evolved between 2022 and 2023, particularly in terms of investment value and equity income?",
      "original_answer": "In 2022, AMD's carrying value of its investment in the ATMP JV was $83 million, and it recorded $14 million in equity income from the JV. By 2023, the carrying value increased to $99 million, and equity income rose to $16 million. This indicates a growing financial stake and increased profitability from the joint venture over the two-year period.",
      "llm_answer": "Between 2022 and 2023, AMD's financial relationship with the ATMP JV evolved significantly in terms of investment value and equity income. In 2022, the Company recorded a $6 million gain in equity income from the ATMP JV, with a $69 million investment carrying value; by 2023, this increased to a $16 million gain and a $99 million carrying value, reflecting higher equity income and investment appreciation. Additionally, purchases from the ATMP JV rose from $1.1 billion in 2021 to $1.7 billion in 2023, and payables to the JV increased from $78 million (2020) to $363 million (2023), indicating deeper operational and financial integration.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key numbers. According to the ground truth, in 2022, AMD's carrying value was $83 million and equity income was $14 million. The LLM incorrectly states $69 million and $6 million, respectively. The 2023 values are partially correct: $99 million carrying value matches the ground truth, but the $16 million equity income, while accurate for 2023, is presented as an increase from an incorrect $6 million in 2022 rather than the correct $14 million. (2) Calculations and comparisons are flawed due to incorrect base values. The LLM implies a larger growth in equity income (from $6M to $16M) than actually occurred (from $14M to $16M), distorting the financial narrative. The increase in carrying value is understated in the LLM answer (from $69M to $99M vs. actual $83M to $99M). (3) While the LLM attempts multi-hop reasoning by incorporating operational data like purchases and payables, these are not directly responsive to the question about 'investment value and equity income' and do not compensate for the core inaccuracies. The mention of $1.1B purchases in 2021 and $78M payables in 2020 introduces data outside the requested 2022–2023 timeframe, reducing focus. (4) The contextual relevance is moderate because the answer addresses the JV relationship and includes financial metrics, but the qualitative accuracy is limited by incorrect entity values and misleading trends. The core financial facts are partially wrong, leading to a low correctness and quantitative accuracy score despite some relevant contextual details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1247,
        "completion_tokens": 440,
        "total_tokens": 1687
      },
      "error": null
    },
    {
      "question_id": 135,
      "question": "How has UnitedHealth Group's exposure to tort claims evolved between 2022 and 2024, particularly in terms of the nature of the claims and the potential financial impact?",
      "original_answer": "In 2022, UnitedHealth Group specifically highlighted self-insured liabilities related to medical malpractice claims against affiliated physicians and the potential for actual losses to significantly exceed recorded liabilities. The document emphasized increasing legal actions alleging medical malpractice and general professional liabilities, with litigants seeking recoveries under new theories of liability that might not be subject to damage caps. By 2024, while tort claims remained a concern, the focus shifted slightly to broader legal risks tied to the delivery of health care services, including claims related to clinical quality and patient safety standards. The 2024 filing also emphasized the potential for reputational harm and adverse effects on business relationships, indicating a broader and more systemic risk profile compared to the more narrowly defined exposure in 2022.",
      "llm_answer": "Between 2022 and 2024, UnitedHealth Group’s exposure to tort claims remained a material risk, particularly through its affiliated physician organizations and health‑care provider networks.  The company continues to face claims related to medical‑malpractice and other delivery‑of‑care liabilities arising from its owned or contracted providers, and it self‑insures these risks, recording reserves that may underestimate actual losses.  While the 2022 filing notes that such claims could result in “substantial monetary damages or damage to our reputation,” the 2024 filing emphasizes that recent acquisitions and the growing use of AI‑driven health services have heightened the volume and complexity of potential tort exposure, making the financial impact increasingly uncertain and potentially more significant.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies that UnitedHealth Group faces ongoing tort claim exposure through affiliated physicians and provider networks, with self-insurance and potential underestimation of liabilities, which aligns with the 2022 ground truth. It also acknowledges evolving risks by 2024, noting increased complexity and uncertainty in financial impact. However, there are key qualitative discrepancies: the original answer emphasizes a shift in the *nature* of claims—from medical malpractice and professional liability in 2022 to broader clinical quality and patient safety standards in 2024—while the LLM attributes the increased exposure primarily to 'recent acquisitions and the growing use of AI-driven health services,' which is not mentioned in the ground truth. This misrepresents the documented evolution of risk. Additionally, while both mention reputational harm, the LLM omits the specific legal development noted in the original—litigants pursuing new theories of liability not subject to damage caps—which is a critical nuance in the 2022 risk profile. The answer remains contextually relevant and factually consistent on core elements (self-insurance, malpractice exposure, reputational risk), and there are no quantitative inaccuracies (no numbers involved). Thus, the correctness and qualitative accuracy scores are reduced due to partial misalignment in reasoning and omission of key details, despite strong overall relevance and factual grounding.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1431,
        "completion_tokens": 405,
        "total_tokens": 1837
      },
      "error": null
    },
    {
      "question_id": 136,
      "question": "How has the structure and capacity of Boeing's three-year revolving credit agreement evolved between 2023 and 2024, and what does this indicate about the company's liquidity strategy?",
      "original_answer": "In 2023, Boeing had a legacy three-year revolving credit agreement expiring in August 2025 with $3.0 billion of total commitments. In 2024, this agreement remained in effect, but Boeing also entered into a new $4.0 billion five-year revolving credit agreement expiring in May 2029 while terminating two other credit facilities. This evolution indicates a strategic shift to enhance liquidity capacity and extend maturity timelines, reinforcing Boeing's financial flexibility and commitment to managing corporate borrowing needs.",
      "llm_answer": "The company’s three‑year revolving credit facility (a $3.0 billion commitment that expires in August 2025) remained in place through 2024, while the $0.8 billion 364‑day facility and the $3.2 billion five‑year facility that expired in 2024 were terminated. In the second quarter of 2024 the firm entered a new $4.0 billion five‑year revolving credit agreement that matures in May 2029, leaving only the legacy three‑year line and the $3.0 billion five‑year line (expiring August 2028) still outstanding. This evolution—shifting from multiple short‑term facilities to a larger, longer‑dated credit line—reflects a strategy of extending maturities and increasing available liquidity to support ongoing financing needs and maintain a strong balance‑sheet position.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. While it correctly identifies the $3.0 billion three-year facility expiring in August 2025 as remaining in place, it incorrectly states that a $3.2 billion five-year facility and a $0.8 billion 364-day facility were terminated in 2024. The ground truth does not mention these specific facilities or their amounts. Instead, it states that Boeing terminated two other credit facilities (without specifying amounts) when entering the new $4.0 billion five-year agreement. The LLM fabricates precise figures ($0.8B and $3.2B) that are not in the original answer, which significantly undermines quantitative accuracy. Additionally, the LLM incorrectly claims that a '$3.0 billion five-year line (expiring August 2028)' remains outstanding, which is not mentioned in the ground truth. The new agreement is correctly stated as $4.0 billion, expiring May 2029. (2) The dates for the legacy and new agreements are correct: August 2025 and May 2029. However, the invented facilities and amounts introduce major quantitative errors. The calculation of total liquidity changes is not requested, but the synthesis of facility changes is distorted by incorrect inputs. (3) The multi-hop reasoning is partially sound—the LLM correctly infers a strategic shift toward longer maturities and greater liquidity—but this conclusion is based on fabricated data points, weakening the qualitative accuracy. The core idea of enhancing liquidity and extending maturities aligns with the ground truth, but the path to that conclusion is flawed. (4) Contextual relevance is high because the answer addresses both the structural evolution and the strategic implication. However, due to significant factual and numerical inaccuracies, especially in the description of terminated facilities, the correctness score is limited to 6—partially correct but with major errors in entity and quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 525,
        "total_tokens": 1856
      },
      "error": null
    },
    {
      "question_id": 136,
      "question": "How did the financial impact of the 2017 Performance-based Options evolve between 2023 and 2024, particularly in terms of the fair value of options vested and the intrinsic value of options exercised?",
      "original_answer": "In 2023, the fair value of the 2017 Performance-based Options that vested was $56 million, and the intrinsic value of options exercised was $44 million. By 2024, the fair value of the options vested decreased slightly to $52 million, but the intrinsic value of options exercised saw a significant increase to $373 million. This indicates that while the value of options vesting declined slightly in 2024, the actual financial benefit realized from exercised options increased substantially compared to the prior year.",
      "llm_answer": "Based on the provided 10-K pages, the financial impact of the 2017 Performance-based Options evolved as follows:  \n- **Fair value of options vested**: $52 million was recognized in 2024 (up from $56 million in 2023 and $44 million in 2023 for exercised intrinsic value), reflecting continued vesting of the 2017 tranches over 2022–2024.  \n- **Intrinsic value of options exercised**: $373 million was realized in 2024 (compared to $44 million in 2023), driven by higher stock price appreciation and exercise of vested options.  \n- **Unrecognized compensation expense**: $113 million remains for unvested performance-based and time-based options, expected to be recognized over 3.7 years.  \n- **2023 Performance-based Options**: Granted in May 2023 with a $120 million fair value (based on $673.58 strike price), but no intrinsic value was realized in 2024 as vesting is contingent on future performance targets (not yet achieved).  \n\n*(Synthesized from pages 100, 101, 102, 103, 107, 108, 109, 110, 111)*",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a critical error in the 'Fair value of options vested' for 2024, stating it increased to $52 million 'from $56 million in 2023', which misrepresents the trend. The ground truth indicates that the fair value of options vested *decreased* from $56 million in 2023 to $52 million in 2024. The LLM incorrectly frames this as an increase, which is factually wrong. The intrinsic value of options exercised is correctly reported as $373 million in 2024 vs $44 million in 2023, which is accurate. (2) Number verification: $56 million (2023 vested) and $52 million (2024 vested) are correct in value but reversed in directional interpretation. $44 million (2023 intrinsic) and $373 million (2024 intrinsic) are correct. However, the inclusion of 'up from $56 million' when $52M < $56M is a clear quantitative misstatement. The mention of $44 million in the same sentence as 2023 exercised value is correct but awkwardly placed. (3) Multi-hop reasoning is partially sound: the model correctly identifies the evolution across years and links vesting and exercise values. It also brings in additional context (unrecognized expense, new 2023 options), which is relevant but not required. However, the erroneous directional claim about vesting value undermines the reasoning. (4) Scores justified as follows: Correctness is 6 due to accurate numbers but major error in interpretation of trend; Quantitative Accuracy is 5 because while values are correct, the comparison is inverted; Qualitative Accuracy is 7 due to good synthesis and use of terminology, despite flawed logic in one key comparison; Contextual Relevance is 9 because the answer stays focused and adds useful context, even if slightly beyond the scope.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1393,
        "completion_tokens": 474,
        "total_tokens": 1868
      },
      "error": null
    },
    {
      "question_id": 136,
      "question": "How did AMD's approach to estimating adjustments for product return rights evolve between 2022 and 2023, and what specific changes were made in the methodology used for these estimates?",
      "original_answer": "In 2022, AMD estimated adjustments for product return rights using trended actual historical product return rate information, adjusted for known information or events. By 2023, AMD maintained the use of historical data but placed additional emphasis on 'rights of return and rebates' as part of variable consideration under ASC 606-10-32-8 through 14, explicitly stating that these estimates were based on the 'most likely amount' of consideration expected after adjustments for returns, rebates, and price protection. This reflects a more structured and codified approach to estimating returns, aligning more closely with specific accounting standards.",
      "llm_answer": "Between 2022 and 2023, AMD refined its methodology for estimating adjustments related to product return rights and variable consideration in revenue recognition. In 2023, the company explicitly detailed its use of \"trended actual historical product return rate information\" adjusted for known events to estimate return allowances for both OEM and distributor customers, moving beyond generic historical activity references used previously. This more granular approach, particularly for distributor price incentives and return rights (limited to contractual percentages of prior quarter shipments), improved the precision of revenue adjustments. Additionally, AMD enhanced its revenue estimation process by incorporating internal and external market data analysis for future rebate program attainment and price protection assumptions, as outlined in the Critical Accounting Estimates section of its 2023 10-K. These changes aimed to ensure estimates remained materially consistent with actual results amid evolving market conditions.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that AMD used trended historical return rates adjusted for known events in 2023, which aligns with the ground truth. It also accurately notes a refinement in methodology, including more granular treatment of distributor returns and price incentives. However, it misses the key qualitative shift emphasized in the original answer: the explicit alignment with ASC 606-10-32-8 through 14 and the use of the 'most likely amount' method as part of variable consideration. This is a significant omission in the accounting rationale, which is central to the evolution of AMD's approach. Instead, the LLM introduces 'internal and external market data analysis for future rebate program attainment,' which is not mentioned in the ground truth and may conflate other aspects of revenue estimation. (2) There are no numeric values, percentages, or dates in either answer, so quantitative accuracy is not compromised—no errors in numbers or calculations. (3) The multi-hop reasoning is partially sound: the model correctly infers a methodological refinement from 2022 to 2023 and synthesizes elements of return estimation. However, it fails to connect the change to the specific accounting standard (ASC 606) and the conceptual shift toward codified variable consideration, which is the core of the original answer’s insight. (4) The contextual relevance is high because the response stays focused on AMD's evolving methodology for return adjustments. The qualitative accuracy is reduced due to the omission of the ASC 606 framework and the 'most likely amount' criterion, which are critical to the correct characterization of the 2023 change. The addition of unverified details about market data analysis slightly detracts from fidelity. Overall, the answer captures the direction of change but misses the precise accounting basis, warranting a score of 7 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1431,
        "completion_tokens": 517,
        "total_tokens": 1948
      },
      "error": null
    },
    {
      "question_id": 137,
      "question": "How did the number of shares under option for the 2017 Performance-based Options evolve from 2023 to 2024, and what does this indicate about the exercise and forfeiture trends of these options?",
      "original_answer": "The number of shares under option for the 2017 Performance-based Options decreased significantly from 1,549,080 shares at the end of 2023 to 625,825 shares at the end of 2024. This indicates that a large portion of these options were exercised (905,219 shares) and some were forfeited (18,036 shares) during 2024, showing a trend of completion in the lifecycle of these options as they approached their final vesting date.",
      "llm_answer": "The number of shares underlying the 2017 Performance‑based Options declined from 1,549,080 at 12/31/2023 to 625,825 at 12/31/2024, reflecting the exercise of 905,219 options and the forfeiture of 18,036 options during 2024. This reduction indicates that most of the vested tranches were either exercised or lost due to employee turnover, with only a modest remaining balance of unexercised options.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the numbers are accurate: the starting balance (1,549,080 shares at end of 2023), ending balance (625,825 at end of 2024), and derived values (exercises = 1,549,080 - 625,825 - 18,036 = 905,219; forfeitures = 18,036) match exactly. The LLM correctly identifies the exercise and forfeiture volumes. (2) The answer is complete, addressing both parts of the question: the evolution of shares under option from 2023 to 2024 and the interpretation regarding exercise and forfeiture trends. (3) Entity accuracy is perfect: the option plan (2017 Performance-based Options), time periods (end of 2023 and 2024), and financial terms (exercised, forfeited) are correctly used. (4) The reasoning is sound and reflects proper multi-hop synthesis: the decrease in outstanding shares is correctly attributed to both exercise and forfeiture, and the conclusion about lifecycle completion—implied by the large reduction and approaching final vesting—is logically supported and semantically equivalent to the original answer. Minor wording differences (e.g., 'lost due to employee turnover' instead of 'forfeited') do not affect factual accuracy and are acceptable under semantic equivalence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1216,
        "completion_tokens": 355,
        "total_tokens": 1571
      },
      "error": null
    },
    {
      "question_id": 137,
      "question": "How has the role and scope of Optum Rx's Pharmacy Care Services evolved between 2022 and 2024, particularly in terms of its service offerings and strategic positioning within UnitedHealth Group's broader health care ecosystem?",
      "original_answer": "In 2022, Optum Rx was described as managing $112 billion in pharmaceutical spending, including $45 billion in specialty pharmaceutical spending, and was positioned as a provider of pharmacy care services through a network of over 67,000 retail pharmacies, home delivery, specialty pharmacies, and infusion services. It emphasized clinical programs, digital tools, and medication management to help clients reduce costs and improve health outcomes. By 2024, Optum Rx was more strategically integrated into Optum’s broader vision of creating a 'value-oriented and more connected approach to health care,' with an emphasis on leveraging 'data and analytics, pharmacy care services, health care operations, population health and health financial services' to improve the overall health system performance. While specific spending figures were not provided in 2024, the service was elevated as a core component of Optum’s mission to enhance affordability, quality, and patient experience across the health care continuum.",
      "llm_answer": "Between 2022 and 2024, Optum Rx’s pharmacy‑care services expanded markedly in scope and strategic importance within UnitedHealth Group.  The 2022 filing describes Optum Rx as offering “a full spectrum of pharmacy care services” through a network of roughly 67,000 retail pharmacies and home‑delivery channels, managing about $112 billion of drug spend (including $45 billion in specialty spend).  By the 2024 filing the service description had grown to include “rare disease and gene‑therapy support services,” a network of “more than 65,000 retail pharmacies” plus home‑delivery, specialty and community‑health pharmacies, infusion services, and direct‑to‑consumer solutions, and it managed $178 billion of pharmaceutical spending (including $74 billion in specialty spend).  This evolution reflects a shift from a primarily medication‑benefit manager to a broader, data‑driven pharmacy‑care platform that integrates medical, behavioral and specialty care, positioning Optum Rx as a core conduit for UnitedHealth Group’s value‑based, whole‑person health strategy across its Optum and UnitedHealthcare segments.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "(1) The LLM answer contains significant factual inaccuracies, particularly in quantitative data. According to the ground truth, in 2022, Optum Rx managed $112 billion in pharmaceutical spending, including $45 billion in specialty pharmaceuticals. The LLM incorrectly states that by 2024, Optum Rx managed $178 billion in drug spend (including $74 billion in specialty), but the original answer explicitly states that 'specific spending figures were not provided in 2024.' Therefore, the $178B and $74B figures are fabricated and not supported by the source. Additionally, the claim of 'more than 65,000 retail pharmacies' in 2024 contradicts the 2022 figure of over 67,000, suggesting a reduction, yet the LLM frames it as an expansion—this is inconsistent and misleading. (2) The quantitative inaccuracies are severe: the LLM invents precise financial figures for 2024 with no basis in the provided truth. There is no indication in the original answer that spending increased to $178B or that specialty spending rose to $74B. These numbers cannot be verified and appear to be extrapolations or hallucinations. (3) While the LLM correctly identifies the qualitative shift toward greater integration within UnitedHealth Group’s value-based care model and mentions data-driven platforms and expanded services like rare disease and gene therapy, these details are not present in the original answer. The ground truth does not mention 'rare disease and gene-therapy support services' or 'community-health pharmacies' or 'direct-to-consumer solutions'—these are unsupported additions. The reasoning about strategic evolution is plausible but based on fabricated or unverified inputs, undermining the multi-hop synthesis. (4) Despite the factual errors, the LLM captures the general direction of strategic evolution—integration into a broader health ecosystem, emphasis on data and value-based care—which aligns with the question's intent, hence moderate contextual relevance. However, the correctness score is low due to invented metrics and incorrect entity details, which are critical in financial and strategic analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1551,
        "completion_tokens": 565,
        "total_tokens": 2117
      },
      "error": null
    },
    {
      "question_id": 138,
      "question": "How did the composition and valuation of BlackRock's Equity Securities at FVTNI change between 2023 and 2024, particularly in terms of investments held for deferred cash compensation plans?",
      "original_answer": "In 2023, BlackRock reported $9 million invested in Equity Securities at FVTNI as part of the investments held to economically hedge deferred cash compensation plans. By 2024, this specific category was no longer listed under Equity Securities at FVTNI but instead appeared under 'Investments related to deferred cash compensation plans' within the Equity Method section with a value of $173 million. This indicates a reclassification or realignment of how these investments were categorized and reported in the financial statements, reflecting a significant change in the composition of Equity Securities at FVTNI.",
      "llm_answer": "Between 2023 and 2024, the composition of BlackRock's Equity Securities at FVTNI increased from $1,059 million to $1,179 million (a $120 million rise), while the related VREs grew from $370 million to $377 million. The total exposure to these instruments—reflected in BlackRock's net interest—rose from $716 million (2023) to $512 million in the VRE component of the 2024 table, indicating a shift in the mix of investments held for deferred cash compensation plans, with a modest increase in the fair‑value of the underlying equity securities and a corresponding change in the net interest attributable to these deferred compensation arrangements.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 2,
      "detailed_feedback": "The LLM answer is almost entirely incorrect and fails to address the core of the question. (1) Quantitatively, the numbers provided ($1,059M, $1,179M, $370M, $377M, $716M, $512M) are completely unrelated to the ground truth. The original answer states that in 2023, $9 million was reported in Equity Securities at FVTNI for deferred cash compensation plans, and by 2024, this category was reclassified to the Equity Method section with a value of $173 million. The LLM instead reports total portfolio-level figures for Equity Securities at FVTNI and VREs, which are not the focus of the question. (2) The calculation of a $120M increase and changes in net interest are fabricated and not supported by the ground truth. (3) Qualitatively, the LLM fails the multi-hop reasoning: it does not recognize the reclassification of a specific component (investments for deferred cash compensation) from FVTNI in 2023 to Equity Method in 2024, which is the central point of the original answer. Instead, it misinterprets the question as asking about overall changes in FVTNI securities. (4) Contextual relevance is low because the answer discusses aggregate figures and 'net interest' and 'VREs' not mentioned or implied in the ground truth. The key concept—reclassification of a specific investment type—is entirely missed. The only partial relevance is the mention of deferred cash compensation plans, but even that is distorted. Thus, the answer is factually wrong, misrepresents the data, and fails to perform the required synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 417,
        "total_tokens": 1744
      },
      "error": null
    },
    {
      "question_id": 138,
      "question": "How has the aggregate available authorization for Accenture's open-market share purchase program changed between 2022 and 2024, and what does this indicate about the company's capital allocation strategy?",
      "original_answer": "The aggregate available authorization for Accenture's open-market share purchase program decreased from $3,129,296 in 2022 to $2,694,281 in 2024. This indicates a reduction in the company's capital allocated for share repurchases over this period, suggesting a more conservative approach to capital deployment or a strategic shift in how the company is managing its equity structure.",
      "llm_answer": "The aggregate authorization for Accenture’s open‑market share purchase program fell from $3,129,296 million as of August 31 2022 to $2,694,281 million as of August 31 2024, a reduction of roughly $435 million. This decline reflects the company’s ongoing capital allocation, where it periodically adjusts the share‑repurchase authority to balance share‑buyback activity with other priorities such as dividend payments, employee equity plans, and strategic investments.",
      "correctness_score": 4,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a critical error in unit scaling—reporting '$3,129,296 million' and '$2,694,281 million' instead of the correct '$3,129,296' and '$2,694,281'. This misrepresents the figures by a factor of one million, turning approximately $3.13 million into over $3 trillion, which is factually absurd and severely undermines quantitative accuracy. The difference is also incorrectly stated as 'roughly $435 million', when the actual difference is $435,015, making the calculation correct in magnitude only because of the erroneous units. (2) The dates—August 31, 2022, and August 31, 2024—are contextually appropriate for Accenture’s fiscal reporting and align with typical 10-K timing, though not explicitly confirmed in the ground truth. The direction of change (decrease) is correct, and the qualitative interpretation about capital allocation trade-offs (dividends, investments, equity plans) is reasonable and adds useful context beyond the original answer. (3) The multi-hop reasoning—comparing authorizations across years and inferring strategic intent—is conceptually sound and addresses both parts of the question. However, the massive numerical inaccuracy prevents correct synthesis. (4) The contextual relevance is high because the answer addresses both the quantitative change and strategic implication. Qualitative accuracy is moderate due to correct logic and entity identification (Accenture, share purchase program), but severely penalized on quantitative grounds. Correctness score is low (4) because while the direction and reasoning are partially valid, the answer conveys a dramatically false scale of financial activity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1227,
        "completion_tokens": 455,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 139,
      "question": "How has the treatment and disclosure around Accenture Canada Holdings Inc. Exchangeable Shares evolved between 2022 and 2024, particularly in terms of share repurchase activity and shareholder rights?",
      "original_answer": "In 2022, Accenture disclosed its intention to use a significant portion of cash generated from operations for share repurchases during fiscal 2023, including purchases and redemptions of Accenture Canada Holdings Inc. exchangeable shares. The company noted that the number of shares repurchased would depend on various factors such as share price and market conditions. By 2024, the disclosures had evolved to include more detailed descriptions of the rights associated with Accenture Canada Holdings Inc. exchangeable shares, particularly their exchangeability on a one-for-one basis for Accenture plc Class A ordinary shares, and the company's commitment to align the number of Class X ordinary shares with outstanding exchangeable shares. Additionally, as of August 31, 2024, the company had a specific remaining authorization of $2,694,281 for share repurchase programs, indicating a more structured and quantified approach compared to the more general intentions expressed in 2022.",
      "llm_answer": "Between 2022 and 2024, Accenture Canada Holdings Inc. Exchangeable Shares were treated as fully exchangeable into Accenture plc Class A ordinary shares on a one-for-one basis, with no dividend rights or liquidation proceeds, and were subject to redemption restrictions that prevented their redemption from falling below the holder’s original exchangeable share count. While the 2022 10-K (page 41) noted that share repurchases could include redemptions of these exchangeable shares under the open-market program, the 2024 10-K (page 100) explicitly details that the company’s $2.69 billion share purchase authorization (including $47,752 shares of exchangeable stock repurchased for $15,254) now specifically includes these instruments, and the Board recently approved an additional $4 million in repurchase authority, bringing total authorization to $6.69 billion. Shareholder rights remain limited: Class X ordinary shares (issued to original holders) carry voting rights but no dividends or liquidation proceeds and are non-transferable without consent, while exchangeable shares themselves retain the right to exchange for Class A shares and receive distributions equivalent to Class A shares.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains several significant factual inaccuracies, particularly in the quantitative details, which undermines its correctness. (1) Quantitative Accuracy: The LLM claims that $47,752 shares were repurchased for $15,254 — this is implausible (implying a price of ~$0.32 per share) and does not match the ground truth, which states a remaining authorization of $2,694,281 as of August 31, 2024, not actual repurchase amounts. The LLM also invents a total authorization of $6.69 billion after an alleged $4 million addition to a $2.69 billion program, but the ground truth only mentions a remaining authorization of ~$2.69 million (not billion), indicating a massive overstatement by a factor of over 1,000x. These are critical errors. (2) Completeness: The answer addresses both share repurchase activity and shareholder rights, satisfying the multi-part structure of the question. It correctly identifies the one-for-one exchangeability and limited rights (no dividends, liquidation proceeds), which aligns with the evolution in disclosure. (3) Entity Accuracy: The entities (Accenture Canada Holdings Inc. exchangeable shares, Accenture plc Class A and Class X shares) are correctly identified, and the time frame (2022 to 2024) is appropriately referenced with citations to 10-K pages. (4) Reasoning: The multi-hop synthesis is partially sound — it connects repurchase programs to exchangeable shares and traces evolving disclosures — but the invented figures and mischaracterization of the repurchase authorization break the logical chain. (5) Semantic Equivalence: While the qualitative description of shareholder rights and exchange mechanics is largely consistent with the ground truth, the numerical inaccuracies dominate the evaluation. The mention of a $2.69 billion program directly contradicts the ground truth’s $2.69 million, suggesting a unit error with severe implications. Overall, the answer shows understanding of the conceptual framework but fails on key factual and numerical grounds, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1559,
        "completion_tokens": 549,
        "total_tokens": 2108
      },
      "error": null
    },
    {
      "question_id": 139,
      "question": "How did the global revenue from Electrophysiology Devices evolve between 2023 and 2024, and what was the percentage change in this revenue, excluding the impact of foreign exchange fluctuations?",
      "original_answer": "In 2023, the global revenue from Electrophysiology Devices was $2,195 million, which increased to $2,467 million in 2024. This represents a total change of 12.3%, with the change excluding the impact of foreign exchange fluctuations being 14.4%.",
      "llm_answer": "Based on the provided financial data, the global revenue from Electrophysiology Devices increased by $270 million (from $2,195 million in 2023 to $2,467 million in 2024), representing a 12.3% total change. Excluding the impact of foreign exchange, the revenue grew by 14.4%, as reported in the \"Total Change Excl. Exchange\" column for Electrophysiology on page 52 and corroborated by the detailed segment analysis on page 31. This growth was driven by higher procedure volumes and increased demand for catheters and cardiac mapping products across all regions, as noted in the 2024 and 2023 performance descriptions.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies all key facts from the ground truth: 2023 revenue ($2,195 million), 2024 revenue ($2,467 million), total percentage change (12.3%), and the foreign exchange-excluded growth (14.4%). These values match the original answer exactly. (2) The calculation of the dollar increase ($2,467M - $2,195M = $272M) is slightly off by $2M (LLM states $270M), but this minor rounding difference is within acceptable tolerance and does not affect the correctness of the percentage figures, which are accurate. The percentages (12.3% and 14.4%) are correctly reported and align with the ground truth. (3) The multi-hop reasoning is sound: the model synthesizes revenue figures across years, distinguishes between total change and change excluding foreign exchange, and supports the conclusion with contextual drivers (procedure volumes, demand for catheters and mapping products), which enhances qualitative accuracy. (4) All entities (Electrophysiology Devices, 2023–2024 timeframe, revenue metric) are correct, and the answer fully addresses both parts of the question: revenue evolution and percentage change excluding FX impact. The additional context from 'page 52' and 'page 31' suggests proper sourcing, even if hypothetical. Overall, the answer is factually correct, complete, and semantically equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1227,
        "completion_tokens": 381,
        "total_tokens": 1608
      },
      "error": null
    },
    {
      "question_id": 140,
      "question": "How has Accenture's financial relationship with Duck Creek Technologies evolved between fiscal 2022 and fiscal 2024, particularly in terms of investment valuation and its impact on financial performance?",
      "original_answer": "In fiscal 2022, Accenture's investment in Duck Creek Technologies was valued at $223,166 (approximately 16% ownership), with the investment accounted for under the equity method. By fiscal 2024, this investment resulted in a $253 million gain, indicating a significant increase in value and a shift in how the investment contributed to Accenture's financial performance. This demonstrates both a quantitative increase in the investment's value and a qualitative change in its impact on Accenture's earnings.",
      "llm_answer": "Based on the provided SEC 10-K filings, Accenture's financial relationship with Duck Creek Technologies evolved significantly between fiscal 2022 and 2024, primarily through its investment valuation and impact on financial performance. In fiscal 2022, Accenture held a $138,902 carrying amount investment in Duck Creek (representing ~16% ownership) with an estimated fair value of $223,166, which was accounted for using the equity method. By fiscal 2024, the company reported a $253 million investment gain related to this Duck Creek investment in its fiscal 2023 results (noted in the MD&A as part of adjusted earnings), indicating a substantial increase in value from the $223,166 fair value reported in fiscal 2022. This investment growth contributed to adjusted earnings per share ($11.95 in fiscal 2024 vs. $11.67 in fiscal 2023), though it was excluded from GAAP results. The investment remained a key component of Accenture's non-current investments ($153,808 recorded as of August 31, 2022), reflecting its strategic valuation and impact on financial performance through equity method accounting and fair value adjustments.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains mostly correct information but has a critical error in the fiscal 2022 investment carrying amount. The ground truth states the investment was valued at $223,166 (fair value, ~16% ownership), accounted for under the equity method. However, the LLM incorrectly introduces a 'carrying amount' of $138,902 not present in the original answer, which conflicts with the provided truth. This undermines quantitative accuracy. The $253 million gain in fiscal 2024 is correctly reported and aligns with the ground truth. (2) The LLM claims the gain was reported in 'fiscal 2023 results' (MD&A) but attributed to fiscal 2024 performance, creating confusion about timing. The original answer clearly states the gain occurred by fiscal 2024, without specifying it was recognized in fiscal 2023. This introduces ambiguity in the timeline. (3) The reasoning is otherwise sound: the LLM correctly identifies the evolution from equity-method accounting to a significant gain realization, recognizes the strategic importance, and links it to adjusted EPS impact. It synthesizes multi-hop elements (valuation change, accounting treatment, earnings impact) well. (4) Contextual relevance is excellent—the answer directly addresses investment valuation evolution and financial performance impact as asked. Despite incorrect intermediate values and slight timeline confusion, the core narrative of substantial value increase and earnings contribution is preserved, warranting a 7 for overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1424,
        "completion_tokens": 419,
        "total_tokens": 1843
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How has the composition and scale of Union Pacific's retention share and unit awards changed between 2022 and 2023, and what does this indicate about the company's executive compensation strategy?",
      "original_answer": "In 2022, Union Pacific disclosed that 389,207 retention shares were outstanding under the 2021 Stock Incentive Plan as of December 31, 2021. By 2023, the company disclosed that 954,405 retention shares had been issued and were outstanding, along with 366,046 retention units that do not have an exercise price. This represents a significant increase in the number of outstanding retention instruments, indicating a shift toward greater use of retention-based compensation. The introduction of retention units in 2023 suggests a possible expansion or refinement of the company's long-term incentive strategy for executives.",
      "llm_answer": "Between 2022 and 2023, Union Pacific’s executive compensation strategy shifted toward a larger share of performance‑based, long‑term incentives. The 2023 proxy tables show a substantial increase in the weighted‑average grant‑date fair value of performance stock units (from $173 in 2021 to $205 in 2023) and a rise in the number of retention shares awarded, while the proportion of traditional stock options declined. This reflects a strategic move to align executive pay with sustained operational performance and shareholder value creation.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that 389,207 retention shares were outstanding as of December 31, 2021 (disclosed in 2022), and by 2023, 954,405 retention shares and 366,046 retention units were outstanding. The LLM incorrectly references '2022 and 2023' changes but cites performance stock units (PSUs) with grant-date fair values from 2021 to 2023, which is not supported by the original data. There is no mention in the ground truth of a weighted-average grant-date fair value increasing from $173 to $205, nor any data about traditional stock options declining. (2) The quantitative inaccuracies are severe: the LLM invents numbers and metrics (e.g., $173 and $205) not present in the original answer, misrepresents the timeline (using 2021 data to describe 2022–2023 changes), and fails to report the actual increase in retention shares (from ~389k to ~954k) or the introduction of 366k retention units. (3) The multi-hop reasoning is flawed. While the question asks about changes in composition and scale of retention shares and units, the LLM shifts focus to performance stock units and stock options, which are not mentioned in the ground truth. It fails to note the key development—the introduction of retention units in 2023—as a strategic shift. (4) Despite incorrect facts and metrics, the LLM correctly infers a qualitative trend toward retention-based or performance-aligned compensation, which aligns with the ground truth’s conclusion. This limited semantic overlap in strategic interpretation prevents a score of 0, but the lack of factual grounding severely undermines correctness. Thus, the correctness score is low at 3, with similarly low quantitative accuracy (2), moderate qualitative reasoning (4), and acceptable relevance to executive compensation strategy (6).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 501,
        "total_tokens": 1805
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How has MetLife's application of GAAP guidance for adjusted earnings evolved between 2023 and 2024, particularly in terms of the exclusions related to market volatility and asymmetrical accounting adjustments?",
      "original_answer": "In 2023, MetLife updated its calculation of adjusted earnings due to the adoption of LDTI, which led to the exclusion of certain adjustments related to the amortization of DAC, VOBA, and related intangibles, as well as changes in measurement of certain guarantees. Adjusted earnings excluded changes in fair value associated with MRBs, discount rate changes on annuitization guarantees, and asymmetrical accounting from in-force reinsurance. By 2024, MetLife continued to refine these exclusions, particularly expanding the scope of policyholder liability remeasurement gains (losses) to exclude asymmetrical accounting associated with in-force reinsurance. Additionally, in 2024, net investment income exclusions were expanded to include adjustments relating to joint ventures under the equity method, which was not explicitly mentioned in 2023. This reflects a more detailed and structured application of GAAP guidance over time.",
      "llm_answer": "Between 2023 and 2024, MetLife’s application of GAAP guidance for adjusted earnings remained consistent in structure but was refined to enhance clarity and alignment with updated accounting standards. The company continued to exclude market volatility-related items—such as net investment gains/losses, derivative gains/losses, MRB remeasurement, and goodwill impairments—to mitigate distortions from fluctuating market conditions. Additionally, adjustments for asymmetrical accounting, including non-economic losses at contract inception for single-premium annuities and amortization of basis adjustments tied to fair value hedges, were maintained to ensure conservative and economically neutral reporting. While the core exclusions remained unchanged, the 2024 disclosures emphasized enhanced transparency around segment-specific adjustments and the impact of LDTI adoption, particularly in how asymmetrical accounting was applied to in-force reinsurance and policyholder liabilities. These refinements underscored a more disciplined approach to isolating underlying segment profitability without altering the fundamental methodology.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in structure and captures the core evolution of MetLife's adjusted earnings exclusions between 2023 and 2024, particularly around market volatility and asymmetrical accounting. It correctly identifies the continuation of exclusions such as MRB remeasurement and asymmetrical accounting adjustments, and notes the impact of LDTI adoption, which aligns with the ground truth. The answer also appropriately emphasizes enhanced transparency and segment-specific disclosures in 2024, reflecting a more disciplined approach.\n\nHowever, there are key omissions in the qualitative details that reduce completeness and accuracy. The ground truth specifies that in 2024, MetLife expanded exclusions to include policyholder liability remeasurement gains/losses related to asymmetrical accounting from in-force reinsurance—a specific refinement not clearly articulated in the LLM response, which only vaguely references 'enhanced transparency.' Additionally, the LLM fails to mention the new exclusion in 2024 for net investment income adjustments relating to equity-method joint ventures, a concrete change absent in 2023. This is a significant omission in the evolution of exclusions.\n\nWhile the LLM correctly maintains that core exclusions (e.g., DAC/VOBA amortization, market volatility items) persisted, it does not explicitly tie the 2023 changes to the adoption of LDTI as the catalyst, nor does it clearly differentiate what was *new* in 2024 versus what was carried forward. The reasoning is sound but lacks precise multi-hop synthesis—specifically, connecting LDTI adoption in 2023 to the subsequent 2024 refinements in exclusions.\n\nQuantitatively, there are no numbers, dates, or calculations in dispute—dates (2023, 2024) are correct, and no erroneous figures are presented, hence a perfect quantitative accuracy score. Contextually, the answer is highly relevant and well-framed, addressing the evolution of GAAP guidance application as requested. The phrasing 'non-economic losses at contract inception for single-premium annuities' and 'amortization of basis adjustments' adds detail not in the ground truth, but these may be interpretations of asymmetrical accounting and are not factually incorrect.\n\nOverall, the answer conveys a plausible narrative but misses two specific 2024 exclusions that define the evolution, warranting a correctness score of 7.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1532,
        "completion_tokens": 636,
        "total_tokens": 2168
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How has Accenture's approach to achieving compressed transformations evolved from 2022 to 2024, particularly in terms of the technologies leveraged and the scope of transformation services offered?",
      "original_answer": "In 2022, Accenture focused on using technologies like digital twins, AI, IoT, cloud/Edge, 5G, advanced robotics, and metaverse to help clients achieve compressed transformations by redefining product design, engineering, sourcing, manufacturing, and servicing. By 2024, the company expanded its technological toolkit to include generative AI, artificial reality / virtual reality, and advanced robotics, while also enhancing its own development of automation equipment and commercial hardware to support client operations. Additionally, the scope of transformation broadened to include digitally transforming capital projects such as plant and asset construction, public infrastructure, power grids, and data centers. This reflects a more integrated and advanced technological approach to compressed transformations over the two-year period.",
      "llm_answer": "From 2022 to 2024, Accenture’s approach to compressed transformations has evolved from a focus on foundational digital core initiatives and traditional technology adoption (e.g., cloud, AI, automation) to a more integrated, industry-specific strategy leveraging generative AI, advanced platforms like SynOps, and ecosystem partnerships to accelerate reinvention across operations, product design, and customer engagement. By 2024, the scope expanded significantly to include end-to-end industry transformation services—such as Industry X for manufacturing and intelligent products, Song for hyper-personalized customer experiences, and managed services for AI-driven operational efficiency—reflecting a shift from technology deployment to holistic, outcome-driven transformation enabled by AI, data, and cross-industry innovation.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the general evolution of Accenture's transformation approach toward more advanced and integrated technologies, particularly highlighting generative AI and expanded scope, which aligns broadly with the ground truth. However, it introduces specific programs like 'SynOps', 'Industry X', 'Song', and 'managed services' that are not mentioned in the original answer and cannot be verified from the provided ground truth. These additions, while plausible, represent unverified details not supported by the source. The core technological evolution—expansion from AI, cloud, IoT, etc., to include generative AI and advanced robotics—is partially correct, but the LLM omits key technologies explicitly stated in 2022 (e.g., digital twins, 5G, metaverse) and 2024 (artificial reality / virtual reality). Additionally, the original answer emphasizes a new focus on digitally transforming capital projects (e.g., plant construction, power grids, data centers), which the LLM answer completely misses. Instead, it reframes the scope expansion around customer engagement and industry-specific reinvention, which is related but not equivalent. (2) There are no numeric values, dates, or calculations in either answer, so quantitative accuracy is not applicable—scored as 10 by default since no numbers are misstated. (3) The multi-hop reasoning is partially sound: the model infers a progression in technological sophistication and scope, which is correct in direction, but fails to accurately synthesize the specific technologies and transformation domains mentioned in the ground truth. It substitutes conceptual frameworks not present in the original data, weakening the factual basis. (4) The correctness score is 5 due to partial factual alignment—key elements like generative AI and broader transformation are present, but critical specifics from the ground truth are omitted or replaced with unsupported details. Qualitative accuracy is low for the same reason. Contextual relevance is high because the answer addresses the question’s intent and structure appropriately, even if factually incomplete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1430,
        "completion_tokens": 572,
        "total_tokens": 2002
      },
      "error": null
    },
    {
      "question_id": 141,
      "question": "How did Abbott's use of interest rate hedge contracts evolve between 2023 and 2024 in managing exposure to changes in the fair value of fixed-rate debt?",
      "original_answer": "In 2023, Abbott had interest rate hedge contracts totaling approximately $2.2 billion at December 31, 2023, to manage exposure to changes in the fair value of fixed-rate debt due to long-term benchmark interest rate fluctuations. These contracts were designated as fair value hedges, effectively converting fixed-rate debt to variable-rate debt. In 2024, Abbott continued to maintain interest rate hedge contracts with notional values totaling $2.2 billion, indicating a consistent strategy in hedging interest rate risk. However, the average interest rate on long-term debt increased from 3.6% in 2023 to 3.8% in 2024, suggesting a shift in the underlying debt structure or market interest rate conditions despite the stable hedge notional amount.",
      "llm_answer": "Abbott’s interest‑rate hedge program was reduced during 2023 as $700 million of contracts matured and the related fixed‑rate debt also matured, leaving approximately $2.2 billion of such contracts outstanding at the end of 2023 (down from $2.9 billion in 2022). The remaining contracts continue to be designated as fair‑value hedges that convert the fixed‑rate portion of the debt to a variable rate, and they are marked‑to‑market with the resulting gains or losses recorded in interest expense.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partial correctness but introduces significant inaccuracies. It correctly states that Abbott had $2.2 billion in interest rate hedge contracts at the end of 2023, which matches the ground truth. However, it incorrectly claims the program was reduced during 2023 due to $700 million of contracts maturing, and references a $2.9 billion figure in 2022 — information not present in the original answer and unsupported by the provided ground truth. The original answer does not mention 2022 data or any reduction trend, so this is an unsupported inference. (2) The quantitative accuracy is partially correct: the $2.2 billion figure for 2023 is accurate, but the $2.9 billion and $700 million figures are not in the ground truth and cannot be verified from it. The average interest rate change from 3.6% to 3.8% — a key evolution between 2023 and 2024 — is entirely omitted. (3) The reasoning is flawed in terms of multi-hop synthesis: the question asks about the evolution between 2023 and 2024, but the LLM answer only discusses 2023 and earlier, failing to address 2024 developments. It misses the critical point that Abbott maintained the same $2.2 billion notional amount in 2024, indicating a consistent hedging strategy. The explanation of fair value hedges converting fixed to variable rate debt is correct and aligns with the original. (4) Contextual relevance is high because the response discusses the right topic, entity, and hedging mechanism, but completeness is lacking due to omission of 2024 data and misrepresentation of trend. Correctness score is 4 due to major factual overreach and missing key comparative analysis between 2023 and 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1312,
        "completion_tokens": 462,
        "total_tokens": 1774
      },
      "error": null
    },
    {
      "question_id": 142,
      "question": "How has MetLife's treatment and definition of Adjusted Earnings evolved between 2023 and 2024, particularly in relation to GAAP guidance and segment performance measurement?",
      "original_answer": "In 2023, MetLife updated its calculation of Adjusted Earnings due to the adoption of LDTI, removing certain adjustments related to the amortization of DAC, VOBA, and related intangibles, and instead adjusted for changes in measurement of certain guarantees. Adjusted Earnings in 2023 excluded changes in fair value associated with MRBs, discount rate changes on annuitization guarantees, and asymmetrical accounting from in-force reinsurance. By 2024, Adjusted Earnings remained the GAAP measure of segment performance, but the exclusions were more clearly delineated to include market volatility impacts, asymmetrical and non-economic accounting adjustments, revenues and costs from divested businesses, and results from discontinued operations. Specifically, 2024 Adjusted Earnings excluded net investment gains/losses, derivative gains/losses, MRB remeasurement gains/losses, and goodwill impairments, with more structured exclusions such as inflation-indexed benefit adjustments and non-economic losses from single premium annuity contracts. This represents a refinement and expansion of the exclusions introduced in 2023.",
      "llm_answer": "Based on the provided SEC 10-K filings, MetLife's treatment and definition of Adjusted Earnings remained consistent between 2023 and 2024, with no indication of a change in its definition or methodology. The company continues to define Adjusted Earnings as adjusted revenues less adjusted expenses (net of income tax), excluding specific items such as market volatility impacts, asymmetrical accounting adjustments, and certain non-economic gains/losses, while maintaining alignment with GAAP segment reporting guidance. This consistency is reinforced by the unchanged definition in the 2024 filing (Page 148) and the continued use of Adjusted Earnings as the GAAP measure for segment performance evaluation, including its role in executive compensation decisions.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its core claim that MetLife's treatment and definition of Adjusted Earnings remained consistent between 2023 and 2024. The ground truth clearly states that there was a significant evolution due to the adoption of LDTI in 2023, which changed the adjustments related to DAC, VOBA, and other intangibles, and introduced new exclusions such as changes in measurement of guarantees. The 2024 definition further refined and expanded these exclusions, including more structured items like inflation-indexed benefit adjustments and non-economic losses from single premium annuity contracts. The LLM incorrectly asserts no change occurred, directly contradicting the ground truth. While it correctly identifies that Adjusted Earnings is used for segment performance and executive compensation (contextually relevant), it fails to capture the key multi-hop evolution across years. No numeric values are present to assess quantitative accuracy, but the qualitative reasoning is flawed due to failure to synthesize the changes introduced by LDTI and the progression from 2023 to 2024. The answer misrepresents the timeline and substance of the definitional changes, resulting in a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1479,
        "completion_tokens": 345,
        "total_tokens": 1824
      },
      "error": null
    },
    {
      "question_id": 142,
      "question": "How has the funding and utilization of Accenture's share purchase program evolved from 2022 to 2024, particularly in terms of available authorization and share acquisition methods?",
      "original_answer": "In 2022, Accenture reported an aggregate available authorization of $3,129,296 for its publicly announced open-market share purchase program and other related share purchase programs. This included acquisitions of Accenture plc Class A ordinary shares and Accenture Canada Holdings Inc. exchangeable shares held by current and former members of Accenture Leadership. By 2024, the company clarified that its open-market share purchase program applied specifically to Accenture plc Class A ordinary shares, which were held as treasury shares for employee benefits, such as equity awards. Additionally, in fiscal 2024, Accenture acquired Class A ordinary shares primarily through share withholding for payroll tax obligations tied to employee equity plans. These purchases did not impact the aggregate available authorization for the public share purchase programs, indicating a shift in acquisition methods while maintaining a focus on funding levels.",
      "llm_answer": "From fiscal 2022 through fiscal 2024 the Board’s share‑purchase authorization has declined slightly – from $3,129,296 million available as of August 31 2022 to $2,694,281 million available as of August 31 2024 – while the actual amount spent on open‑market purchases and related programs has risen, with $4.5 billion of Class A shares (plus 47,752 exchangeable shares) repurchased in fiscal 2024 alone.  The company continues to fund these purchases through its publicly announced open‑market program and employee‑share‑withholding plans, and it periodically adds new authority (e.g., an additional $4 million approved in September 2024, bringing total authority to $6.694 billion).",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains major factual and quantitative errors that severely undermine its correctness. (1) Quantitative inaccuracy: The original answer states that the aggregate available authorization in 2022 was $3,129,296 (approximately $3.13 million), but the LLM misrepresents this as '$3,129,296 million' (~$3.13 trillion), which is off by a factor of one million. Similarly, the 2024 available authorization is reported as $2,694,281 million (~$2.69 trillion), again inflating the actual figure (likely in the millions) by a factor of 1,000,000. These are catastrophic numerical errors. (2) The claim that '4.5 billion of Class A shares' were repurchased in fiscal 2024 is unsupported by the original answer, which does not provide specific repurchase volumes or values for 2024 beyond describing the method (share withholding for tax obligations). (3) The LLM invents a $4 million addition in September 2024 and a total authority of $6.694 billion, which are not mentioned in the ground truth. (4) While the LLM correctly identifies two acquisition methods—open-market purchases and employee share withholding—this is only partially aligned with the original answer, which emphasizes that by 2024, share withholding did not impact the public program's authorization, indicating a methodological shift. However, the LLM fails to convey the key nuance that the open-market program was now limited to Accenture plc Class A shares held as treasury for employee benefits, and that exchangeable shares were only part of earlier activity. (5) Multi-hop reasoning is flawed: the model incorrectly infers trends in authorization due to fabricated numbers and misrepresents the evolution of funding and methods. Despite addressing the general topic (share purchase programs and methods), the extreme numerical inaccuracies and invented data result in a very low correctness score. Contextual relevance is moderate because the structure and intent align with the question, but factual grounding is poor.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1416,
        "completion_tokens": 536,
        "total_tokens": 1952
      },
      "error": null
    },
    {
      "question_id": 143,
      "question": "How did MetLife's treatment and valuation methodology for Unit-linked Securities evolve from 2023 to 2024, particularly in terms of cost basis and fair value sensitivity?",
      "original_answer": "In 2023, MetLife described the cost basis for Unit-linked and FVO securities as primarily equity and fixed maturity securities, with cost representing original cost for equities and amortized cost for fixed maturities. By 2024, Unit-linked securities were included in Level 3 fair value measurements and subjected to valuation techniques involving significant unobservable inputs such as mortality rates, lapse rates, and equity volatility. Additionally, the 2024 disclosures emphasized sensitivity of fair value to changes in these inputs, indicating a more dynamic and assumption-driven valuation approach compared to the more static cost-based method described in 2023.",
      "llm_answer": "From 2023 to 2024, MetLife’s fair‑value hierarchy for Level 3 assets shifted markedly: the balance of securities measured using significant unobservable inputs fell from $27 million (short‑term) and $975 million (other investments) in 2023 to just $5 million and $1,010 million respectively in 2024, while the net embedded‑derivative position moved from a $170 million liability to a $5 million asset and the separate‑account balance dropped from $1,210 million to $990 million.  The rollforward tables show that purchases and settlements added modest amounts, but sales and transfers out of Level 3 (especially $128 million of fixed‑maturity securities and $11 million of derivatives transferred out in 2024) drove the net decline.  Consequently, the sensitivity of fair‑value measurements to changes in key unobservable inputs—such as mortality, lapse rates, utilization and withdrawal rates, equity volatility, and non‑performance risk spreads—remains material, though the overall Level 3 portfolio size is now much smaller.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both factual content and focus. The original question asks about the evolution of MetLife's treatment and valuation methodology for Unit-linked Securities from 2023 to 2024, specifically regarding cost basis and fair value sensitivity. The ground truth emphasizes a methodological shift—from a cost-based approach in 2023 (original cost for equities, amortized cost for fixed maturities) to a Level 3 fair value approach in 2024 using significant unobservable inputs (e.g., mortality, lapse rates, equity volatility) with sensitivity disclosures. The LLM answer instead provides quantitative changes in Level 3 balances and net derivative positions, which are not mentioned in the ground truth and appear fabricated or misattributed. (2) Quantitative Accuracy: The dollar amounts cited (e.g., $27M, $975M, $5M, $1,010M, $170M liability to $5M asset, $1,210M to $990M) have no support in the ground truth and are factually incorrect in this context. There is no mention of rollforward tables, transfers out of Level 3, or specific sales figures in the original answer. These numbers are either hallucinated or pulled from unrelated parts of filings. (3) Reasoning: The multi-hop reasoning fails. The LLM misidentifies the core evolution—methodology shift—as a portfolio size change. It confuses overall Level 3 asset balances with the specific treatment of Unit-linked Securities. The answer discusses transfers out and sales driving declines in Level 3, but the ground truth indicates that Unit-linked securities were newly included or more prominently featured in Level 3 in 2024, implying expansion of assumption-driven valuation, not contraction. (4) Contextual Relevance: While the LLM stays within the domain of fair value and Level 3, it misses the central point about valuation methodology for Unit-linked Securities. Mention of sensitivity to unobservable inputs (mortality, lapse rates, etc.) is partially correct and aligns with the 2024 disclosure, but it is embedded in an incorrect narrative about portfolio size reduction. Thus, some qualitative elements are present but misframed. Final scores reflect major factual and quantitative errors, partial recognition of sensitivity analysis, and failure to capture the methodological evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1430,
        "completion_tokens": 615,
        "total_tokens": 2046
      },
      "error": null
    },
    {
      "question_id": 143,
      "question": "How has the structure and vesting timeline of market-based RSUs evolved between fiscal years 2022 and 2023?",
      "original_answer": "In fiscal year 2022, market-based RSUs generally vested over four years and grantees could receive between 0% and 300% of the original grant based on total stockholder return (TSR) relative to an index group. By fiscal year 2023, while four-year vesting remained common, the company also introduced market-based RSUs that vested over five years, with vesting contingent on achieving stock price performance milestones. This indicates an expansion in the types of market-based RSUs offered, adding a new vesting structure based on specific stock price targets.",
      "llm_answer": "Based on the provided SEC 10-K filings, the structure and vesting timeline of market-based RSUs evolved significantly between fiscal years 2022 and 2023. In fiscal 2022, market-based RSUs were granted under the Multi-Year Equity Awards program with a four-year vesting schedule tied to total stockholder return (TSR), and the weighted-average grant date fair value was $51.98 per share for 124 million shares granted. By fiscal 2023, the structure shifted to include both four-year and five-year vesting terms for market-based RSUs, with a new grant of 81 million shares at a significantly higher weighted-average fair value of $115.58 per share, reflecting the impact of the VMware Merger and increased market volatility. The vesting timeline also incorporated performance milestones tied to stock price performance relative to an index group, as detailed in the equity incentive award disclosures on page 85.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer includes several specific quantitative details not present in the original answer, such as the weighted-average grant date fair value ($51.98 and $115.58), number of shares granted (124 million and 81 million), and a reference to page 85 and the VMware Merger. These details are not part of the ground truth and cannot be verified as correct from the provided original answer, suggesting potential hallucination or unsupported specificity. The original answer does not mention dollar values, share counts, mergers, or page numbers, so including them reduces quantitative accuracy. (2) While the core evolution—expansion from four-year to include five-year vesting and the addition of stock price performance milestones—is correctly identified and aligns with the original answer—this represents accurate qualitative understanding—the inclusion of unverified numbers undermines factual correctness. (3) The multi-hop reasoning is sound in structure: the model correctly infers a change in vesting timelines and performance conditions between 2022 and 2023. It correctly identifies that market-based RSUs evolved to include longer vesting periods and new performance triggers. However, the reasoning is over-enriched with unsupported data, which compromises reliability. (4) The contextual relevance is high because the answer directly addresses the evolution of structure and vesting timelines. The qualitative accuracy is moderate to high because the conceptual shift is accurately captured, even if the quantitative details are not corroborated. Overall, the answer gets the main idea right but fails on strict factual fidelity due to unverified numbers and references, warranting a correctness score of 6.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 473,
        "total_tokens": 1830
      },
      "error": null
    },
    {
      "question_id": 145,
      "question": "How did the phase-in treatment of the CECL standard's ongoing impact on regulatory capital evolve between 2023 and 2024, and what specific regulatory capital treatment applied during the phase-in period?",
      "original_answer": "In 2023, the CECL Transition Election allowed for the cumulative 'day 2' ongoing impact to be phased into regulatory capital at 25% per year from January 1, 2022, through December 31, 2024. By 2024, this phase-in treatment remained consistent, with the ongoing impact continuing to be phased in at 25% annually, indicating that the regulatory capital treatment under the CECL Transition Rule was applied uniformly across both years as part of the multi-year transition framework.",
      "llm_answer": "Between 2023 and 2024, the phase-in treatment of CECL’s ongoing impact evolved from a 50% phase-in rate as of December 31 2023 to a full 75% phase‑in rate effective January 1 2024, with the remaining 25% to be phased in through 2025. During the phase‑in period, the applicable regulatory capital treatment allowed the Company to add back the after‑tax “day 1” CECL adoption impact and then phase in the cumulative “day 2” ongoing impact at 25 % per year, resulting in a CET1 capital ratio of 13.5% (13.3% on a fully phased‑in basis) as of December 31 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, the CECL phase-in occurred at 25% per year from January 1, 2022, through December 31, 2024, meaning that by the end of 2023, 75% would have been phased in (not 50%), and by the end of 2024, 100% would be phased in. The LLM incorrectly states that as of December 31, 2023, only 50% was phased in and that the phase-in continued into 2025, which contradicts the ground truth that the process ended on December 31, 2024. (2) The quantitative inaccuracies are critical: the 50% and 75% phase-in rates cited are incorrect, and the extension to 2025 is false. Additionally, the mention of a CET1 ratio of 13.5% (13.3% fully phased-in) is specific data not present in the original answer and appears fabricated or misattributed. (3) The multi-hop reasoning is flawed—the model fails to correctly track the timeline and regulatory framework of the CECL phase-in, misrepresenting both the duration and annual increments. It introduces a 'day 1' add-back component that, while part of broader CECL rules, is not mentioned in the original answer focused solely on the 'day 2' ongoing impact phase-in. (4) Despite these errors, the answer is contextually relevant, addressing the right topic and regulatory treatment framework, and attempts to explain the phase-in mechanism. However, due to major factual and numerical errors, especially in dates and percentages, the correctness and quantitative accuracy scores are low. The qualitative accuracy is slightly higher because the structure of the response reflects an understanding of CECL capital treatment concepts, even if misapplied.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1273,
        "completion_tokens": 458,
        "total_tokens": 1731
      },
      "error": null
    },
    {
      "question_id": 146,
      "question": "How has Broadcom's relationship with Wilmington Trust, National Association evolved between 2022 and 2023 in terms of the types and terms of senior notes issued under their indentures?",
      "original_answer": "In 2022, Broadcom had an ongoing relationship with Wilmington Trust, National Association as trustee under indentures governing senior notes issued in January 2021, which included notes with interest rates as low as 1.950% (due 2028) and as high as 3.750% (due 2051). By 2023, the relationship had evolved to include new indentures dated April 18, 2022, and July 12, 2024, under which Broadcom issued higher-yielding senior notes, including a 4.926% note due 2037 and later, in October 2024, notes ranging from 4.150% (due 2028) to 4.800% (due 2034). This reflects a shift toward issuing longer-term debt with higher interest rates over time.",
      "llm_answer": "Between 2022 and 2023, Broadcom's relationship with Wilmington Trust, National Association evolved from issuing senior notes under the April 2022 indenture (including 4.15% notes due 2032 and 4.926% notes due 2037) to issuing new tranches under subsequent indentures, including a July 2024 indenture with 5.050% notes due 2027, 2029, and 2031, and an October 2024 indenture with 4.150% notes due 2028, 4.350% notes due 2030, 4.550% notes due 2032, and 4.800% notes due 2034. This progression reflects the use of multiple supplemental indentures to issue additional senior notes with varying terms and maturities, maintaining Wilmington Trust as the trustee under each indenture.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in dates, interest rates, and the sequence of indentures. According to the ground truth, in 2022, Broadcom was still operating under indentures from January 2021 (not April 2022 as stated), with notes ranging from 1.950% to 3.750%. The LLM incorrectly states that the April 2022 indenture was active in 2022, but the ground truth indicates the April 18, 2022 indenture was part of the 2023 evolution, not the starting point in 2022. Furthermore, the LLM introduces a 'July 2024 indenture' with 5.050% notes due 2027–2031, which is not mentioned in the original answer and appears fabricated. The October 2024 issuance is correctly noted in timing but misrepresents the rates: the ground truth lists only 4.150% (2028) to 4.800% (2034), while the LLM invents intermediate tranches at 4.350% and 4.550%, which are not in the original. (2) Quantitative accuracy is poor: multiple incorrect percentages (e.g., 5.050%, 4.350%, 4.550%) and misattribution of the April 2022 indenture as the baseline in 2022 when the original answer specifies the 2021 notes were still relevant. The original notes from 2021 (1.950% to 3.750%) are entirely omitted in the LLM response, which distorts the evolution. (3) The multi-hop reasoning is partially sound in that the LLM recognizes the progression of indentures and the role of Wilmington Trust as trustee, and it correctly identifies the trend of issuing notes with varying maturities. However, it fails to accurately represent the starting point (2021 notes) and incorrectly projects future indentures (July 12, 2024 is mentioned in the original, but not with 5.050% notes). The synthesis across years is flawed due to incorrect entity-date mappings. (4) Contextual relevance is high—the answer addresses the relationship evolution, indentures, interest rates, and maturities, and maintains focus on the trustee role. However, the factual foundation is compromised by invented data points and misdated events, leading to a correctness score of 4 due to partial accuracy on the October 2024 notes and recognition of evolving terms, but major errors in the core quantitative details and timeline.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 589,
        "total_tokens": 1928
      },
      "error": null
    },
    {
      "question_id": 147,
      "question": "How did Capital One's regulatory capital add-back under the CECL Transition Rule evolve from 2023 to 2024, and what was the specific phase-in progression during this period?",
      "original_answer": "In 2023, Capital One had already added back $2.4 billion to its regulatory capital under the CECL Transition Rule, with a phase-in of 50% as of January 1, 2023. By January 1, 2024, the phase-in had progressed to 75%, indicating a 25 percentage point increase over the year. This reflects the structured five-year phase-in process under the CECL Transition Rule, where 25% of the cumulative impact was phased in annually after 2021.",
      "llm_answer": "From 2023 to 2024, Capital One’s regulatory capital add‑back under the CECL Transition Rule increased from a fully phased‑in 75% of the cumulative “day‑2” impact to 100% (i.e., the full amount was now reflected in regulatory capital). The phase‑in schedule called for 25% of the cumulative day‑2 impact to be added back each year, so by the end of 2024 the company had added back 75% of the total delayed impact and began adding the remaining 25% in 2025. Consequently, the company’s CET1 capital ratio rose to 13.5% as of December 31 2024 (13.3% excluding the CECL transition effect).",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in its core claims. According to the ground truth, in 2023 the phase-in was at 50%, and by January 1, 2024, it had increased to 75%, representing a 25 percentage point increase. However, the LLM incorrectly states that in 2023 the phase-in was already at 75% and rose to 100% by 2024, which contradicts the ground truth. The dollar amount of $2.4 billion in add-backs is completely omitted in the LLM response, a critical factual omission. (2) The quantitative inaccuracies are severe: the phase-in percentages are wrong (75% in 2023 vs. correct 50%), the progression to 100% by 2024 is false (should be 75% by 2024), and the mention of CET1 ratio rising to 13.5% is extraneous and unsupported by the original answer. There is no mention of the $2.4 billion figure, which is central to the original answer. (3) The multi-hop reasoning is flawed: the model fails to correctly track the phase-in schedule over time, misidentifies the starting point (2023 phase-in level), and misrepresents the annual progression. It incorrectly implies the phase-in was nearly complete in 2023, when it was only halfway. The structured five-year phase-in beginning post-2021 is misunderstood. (4) While the LLM attempts to address the question’s topic and mentions the annual 25% phase-in concept, the factual errors in key metrics and timeline severely undermine correctness. Contextual relevance is moderate because it discusses the CECL phase-in process, but accuracy is very low, warranting a low overall score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1260,
        "completion_tokens": 425,
        "total_tokens": 1686
      },
      "error": null
    },
    {
      "question_id": 147,
      "question": "How did the treatment of VMware stock options for non-employee directors evolve between 2022 and 2023 following the Broadcom acquisition?",
      "original_answer": "In 2022, the 10-K filing stated that all outstanding in-the-money VMware stock options and RSU awards held by non-employee directors would be accelerated and converted into the right to receive cash and shares of Broadcom common stock, in equal parts, upon the completion of the acquisition. By 2023, this provision had been realized, with the statement confirming that these awards were indeed accelerated and converted into the right to receive cash and Broadcom shares. This reflects a transition from a planned conversion to an actualized event following the completion of the acquisition.",
      "llm_answer": "Following the Broadcom acquisition of VMware, the treatment of VMware stock options for non‑employee directors was accelerated and converted into cash and Broadcom common stock in equal parts. This conversion applied to all outstanding in‑the‑money VMware stock options and RSU awards held by non‑employee directors, which were settled as part of the merger consideration.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate and captures the core information from the ground truth. It correctly states that VMware stock options and RSUs for non-employee directors were accelerated and converted into cash and Broadcom common stock in equal parts upon the acquisition. The entities (VMware, Broadcom, non-employee directors), the treatment (acceleration and conversion), and the components of the consideration (cash and Broadcom shares) are all correct. The answer omits the explicit evolution between 2022 (planned/announced) and 2023 (realized/completed), which is a key nuance in the original answer. However, the overall factual content and multi-hop synthesis—linking the acquisition to the change in treatment of equity awards—is sound. There are no numerical inaccuracies (quantitative accuracy is perfect), and the context fully addresses the question’s intent, albeit with slightly less temporal detail on the transition from plan to execution. Thus, the answer is highly accurate but misses a minor qualitative point about the timeline evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1239,
        "completion_tokens": 303,
        "total_tokens": 1542
      },
      "error": null
    },
    {
      "question_id": 147,
      "question": "How has the therapeutic positioning of Vraylar evolved from 2022 to 2024 based on AbbVie's disclosures?",
      "original_answer": "In 2022, Vraylar was described as being evaluated in Phase 3 clinical trials as an adjunctive treatment for major depressive disorder (MDD), with one trial meeting its primary endpoint and the other showing numerical but not statistically significant improvement. By 2024, Vraylar was disclosed as being indicated for a broader range of psychiatric conditions, including acute and maintenance treatment of schizophrenia, acute treatment of manic or mixed episodes associated with bipolar disorder, acute treatment of depressive episodes associated with bipolar I disorder, and as an adjunctive treatment in major depressive disorder. This reflects a clear expansion and solidification of its therapeutic positioning over time.",
      "llm_answer": "Based on AbbVie's SEC filings, the therapeutic positioning of Vraylar has evolved significantly from 2022 to 2024. In 2022, Vraylar was primarily indicated for schizophrenia and bipolar disorder episodes, with additional data supporting its use as an adjunctive treatment for major depressive disorder (MDD) following positive Phase 3 results in October 2021 (page 60). By 2024, its positioning expanded to emphasize its role in treating complex neuropsychiatric conditions, including its ongoing use as an adjunctive therapy for MDD after failed prior treatments, as highlighted in the 2024 10-K (page 62) which notes its \"adjunctive treatment in major depressive disorder\" and references recent clinical data supporting this expanded use. The 2024 filing also underscores its established indications across schizophrenia, bipolar disorder, and MDD, reflecting a broader therapeutic footprint compared to 2022.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the 2022 status of Vraylar as being supported for adjunctive MDD treatment following Phase 3 trials, referencing positive results from October 2021 (consistent with 2022 disclosures). The 2024 positioning accurately reflects expanded indications including schizophrenia, bipolar disorder (manic, mixed, and depressive episodes), and adjunctive MDD. (2) There are no numeric values or dates that conflict with the ground truth; the mention of October 2021 is contextually accurate as the timing of the Phase 3 results informing 2022 disclosures. No calculations are required. (3) The multi-hop reasoning is sound—information is synthesized across years and filings to show evolution in therapeutic positioning. The LLM correctly infers broader indication approval by 2024 based on the 2024 10-K reference to established use across multiple conditions. (4) Minor deduction in qualitative accuracy because the LLM does not explicitly note that in 2022 one trial met its primary endpoint while the other showed numerical but not statistically significant improvement—this nuance from the ground truth is omitted. However, the overall trajectory and final positioning are correctly conveyed. Wording differs but semantic meaning is equivalent. Contextual relevance is perfect as it directly addresses the evolution in therapeutic use based on AbbVie's disclosures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1398,
        "completion_tokens": 401,
        "total_tokens": 1800
      },
      "error": null
    },
    {
      "question_id": 148,
      "question": "How has GE's accounting policy for long-term services agreements evolved from 2022 to 2024, particularly in terms of revenue recognition method and contract billing estimates?",
      "original_answer": "In 2022, GE recognized revenue for long-term services agreements on a straight-line basis, primarily in the Healthcare and Renewable Energy segments, with periodic invoicing as services were provided. By 2024, GE shifted to using the percentage of completion method for revenue recognition, predominantly within the CES segment, based on costs incurred relative to total expected costs. Additionally, in 2024, GE reported a long-term services agreements net liability balance of $6.6 billion, representing approximately 4.1% of total estimated life of contract billings of $162 billion, indicating a more detailed and forward-looking estimation process involving asset utilization and cost improvements, which was not explicitly mentioned in 2022.",
      "llm_answer": "From 2022 to 2024, GE’s accounting policy for long-term services agreements remained consistent in its use of the percentage-of-completion method for revenue recognition, relying on cost-to-cost progress measurement based on incurred costs relative to total estimated costs. However, the company refined its estimation approach by incorporating more forward-looking utilization trends, market conditions, and updated cost assumptions—including observed cost improvements only after validation—into its revenue and cost projections. These revisions, made on a cumulative catch-up basis, directly impact profitability assessments, as evidenced by the $0.4 billion balance sheet impact of a 1% profitability change. While the core method (percentage-of-completion) did not change, the precision and basis of estimates for billing, utilization, and cost recovery evolved to reflect operational realities and contractual complexities.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is fundamentally incorrect in stating that GE used the percentage-of-completion method in both 2022 and 2024. According to the ground truth, in 2022, GE used the straight-line method for revenue recognition in long-term services agreements, particularly in Healthcare and Renewable Energy, and only shifted to the percentage-of-completion method by 2024, primarily in the CES segment. This misrepresentation of the core revenue recognition method evolution invalidates the central claim of consistency. (2) Quantitatively, the LLM introduces a $0.4 billion balance sheet impact of a 1% profitability change, which is not present in the original answer and cannot be verified against the ground truth. The original answer includes specific figures such as a $6.6 billion net liability and total estimated life of contract billings of $162 billion (4.1%), none of which are mentioned in the LLM response. These omissions and the introduction of unverified numbers severely undermine quantitative accuracy. (3) The multi-hop reasoning is flawed because the model fails to correctly identify the change in accounting policy over time—this is a critical multi-hop element (comparing 2022 vs 2024 policies). Instead, it asserts continuity and only refinement, which contradicts the ground truth. The mention of 'forward-looking utilization trends' and 'cost improvements' aligns partially with the 2024 enhancements, but this is overshadowed by the incorrect baseline. (4) Contextual relevance is moderate because the answer discusses revenue recognition, estimates, and billing—relevant topics—but the factual foundation is incorrect. The qualitative accuracy is low due to the misidentification of the accounting method in 2022 and the failure to acknowledge the shift. Overall, the answer misrepresents the evolution, omits key data, and introduces unsupported figures, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1426,
        "completion_tokens": 521,
        "total_tokens": 1948
      },
      "error": null
    },
    {
      "question_id": 148,
      "question": "How has IBM's disclosure of the 1.250% Notes due 2027 evolved between the 2022 and 2023 10-K filings?",
      "original_answer": "In the 2022 10-K filing, IBM disclosed the 1.250% Notes due 2027 as part of a list of instruments defining the rights of holders, with Exhibit 4.3 to Form 8-K filed on January 30, 2019, referenced for the notes. In the 2023 10-K filing, the 1.250% Notes due 2027 are listed under registered securities with the trading symbol IBM 27B on the New York Stock Exchange. This evolution reflects a shift from referencing the instrument defining the rights to identifying the notes as a registered class of securities.",
      "llm_answer": "The disclosure of IBM's 1.250% Notes due 2027 remained unchanged between the 2022 and 2023 10-K filings, as both years list the notes under \"1.250% Notes due 2027\" in the table of registered securities (page 1 of the 2023 10-K and page 28 of the 2022 10-K). No modifications to the terms, structure, or description of these notes were identified in the provided excerpts.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that the disclosure remained unchanged between the 2022 and 2023 10-K filings. The ground truth shows a clear evolution: in 2022, the 1.250% Notes due 2027 were disclosed by referencing Exhibit 4.3 to a Form 8-K filed on January 30, 2019, as defining the rights of holders. In 2023, the notes are listed as a registered class of securities with the trading symbol IBM 27B on the NYSE. The LLM incorrectly claims both years list the notes in a 'table of registered securities' with identical treatment, which contradicts the ground truth. (2) Quantitatively, the LLM correctly identifies the notes (1.250%, due 2027) and does not introduce false numbers, dates, or calculations—hence a score of 8. However, it misrepresents the page locations (claiming page 1 for 2023 and page 28 for 2022) without verification, slightly affecting quantitative precision. (3) The multi-hop reasoning is flawed: the question asks for how the *disclosure evolved*, requiring comparison of the nature and context of the disclosure across years. The LLM fails to recognize the shift from referencing a legal exhibit to listing as a registered security, which is a key qualitative change in reporting. This reflects a failure in synthesis and understanding of disclosure practices. (4) Contextual relevance is moderate—the answer addresses IBM and the correct notes, and attempts to locate them in filings, but mischaracterizes the substance of the disclosures, leading to a low correctness and qualitative accuracy score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1209,
        "completion_tokens": 429,
        "total_tokens": 1639
      },
      "error": null
    },
    {
      "question_id": 148,
      "question": "How has the structure and performance criteria of AbbVie's performance-vested RSUs evolved between 2022 and 2024, particularly in terms of vesting increments and performance metrics?",
      "original_answer": "In 2022, performance-vested RSUs had the potential to vest in one-third increments over a three-year performance period, with performance measured based on AbbVie's return on invested capital (ROIC) relative to a defined peer group of pharmaceutical, biotech, and life science companies for awards granted in 2021 and 2020. By 2024, the vesting structure remained similar—allowing for one-third increments over a three-year period—but the description of performance metrics was streamlined, focusing primarily on ROIC performance against the same peer group, without mention of specific years tied to tranches as seen in 2022. This indicates a simplification or standardization of the performance criteria over time.",
      "llm_answer": "Between 2022 and 2024, AbbVie's performance-vested RSUs evolved from a structure tied to three-year performance periods with vesting contingent on achieving specific EPS and total stockholder return (TSR) targets relative to a peer group, to a more streamlined framework where performance metrics were integrated into annual award cycles with clearer alignment to financial outcomes. The vesting increments shifted from being primarily based on multi-year performance milestones to incorporating annual performance thresholds, particularly for senior executives, while maintaining the potential for partial vesting based on ROIC and TSR. The performance metrics also transitioned to emphasize ROIC relative to a peer group, reflecting a strategic focus on capital efficiency and sustainable growth. This evolution was accompanied by increased transparency in disclosure, with detailed tables tracking award activity, grant-date fair values, and expected compensation cost recognition over the subsequent two years.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and misrepresents key aspects of AbbVie's performance-vested RSU structure. (1) The original answer states that performance metrics were based solely on ROIC relative to a peer group for awards granted in 2020 and 2021, with vesting in one-third increments over a three-year period. However, the LLM incorrectly claims that EPS and TSR were used as performance targets, which contradicts the ground truth. There is no mention of EPS or TSR in the original answer, nor any shift to annual performance thresholds. (2) The LLM asserts that the vesting structure shifted to annual performance thresholds and integrated metrics into annual award cycles, which is not supported by the original answer—vesting remained over a three-year period with one-third increments. (3) The claim of increased transparency with 'detailed tables tracking award activity, grant-date fair values, and expected compensation cost recognition' is not mentioned in the ground truth and introduces extraneous information. (4) While the LLM correctly identifies ROIC as a key metric and its comparison to a peer group, it mischaracterizes the evolution as a shift in framework rather than a simplification or streamlining of disclosure. The core structure of the RSUs did not change significantly, but the LLM implies a more substantial transformation. Thus, despite some correct elements (ROIC focus), the answer is largely incorrect in both quantitative and qualitative dimensions, particularly in entity accuracy (wrong metrics: EPS, TSR) and reasoning (false evolution narrative).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1441,
        "completion_tokens": 439,
        "total_tokens": 1880
      },
      "error": null
    },
    {
      "question_id": 149,
      "question": "How did GE's financial relationship with AerCap evolve from 2022 to 2024, based on the realized and unrealized gains or losses associated with its investment?",
      "original_answer": "In 2022, GE reported an unrealized loss of $865 million related to its investment in and note with AerCap, indicating a negative valuation impact during that year. By 2024, this position had shifted to a realized and unrealized gain of $38 million, suggesting that GE had either exited part of its position or the value of the remaining investment had improved. This represents a significant turnaround in the financial performance of the AerCap investment over the two-year period.",
      "llm_answer": "Based on the provided financial disclosures, GE's investment in AerCap generated a **$38 million realized and unrealized gain** during 2024 (reflected in Note 19: \"Investment in and note with AerCap realized and unrealized gain (loss)\"). This gain contributed to the overall $2,264 million of total other income (loss) for 2024, which included $480 million from GE HealthCare and $38 million from AerCap. The document does not indicate any significant negative impact on GE's financial relationship with AerCap during this period, as the gain aligns with the company's broader strategy of monetizing equity positions (e.g., fully exiting its GE HealthCare stake in 2024). No additional details about AerCap's evolving relationship are provided beyond this gain.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the $38 million realized and unrealized gain in 2024, which matches the ground truth. However, it completely omits the 2022 unrealized loss of $865 million, a critical part of the question asking about the evolution from 2022 to 2024. This omission severely undermines the completeness and correctness of the answer. (2) The quantitative accuracy is high for the data it includes—$38 million is correct, and the reference to Note 19 and total other income aligns with typical disclosure formats. But without the 2022 figure, no valid comparison or evolution can be assessed. (3) The multi-hop reasoning fails because the question requires synthesizing information across two years (2022 and 2024) to describe the evolution of GE's financial relationship with AerCap. The LLM only addresses one year, breaking the chain of reasoning. It also incorrectly implies no negative impact without confirming 2022 data, leading to a flawed conclusion. (4) While the answer is relevant and uses appropriate context (e.g., monetization strategy), the failure to address both years and the transformation from loss to gain results in a partially correct response. Hence, correctness is scored at 5—some facts are right, but key information is missing, and the synthesis is incomplete.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1313,
        "completion_tokens": 367,
        "total_tokens": 1681
      },
      "error": null
    },
    {
      "question_id": 149,
      "question": "How has IBM's treatment of the 0.300% Notes due 2026 evolved between the 2022 and 2023 SEC filings, particularly in terms of its disclosure status and visibility in financial instruments?",
      "original_answer": "In 2022, the 0.300% Notes due 2026 were disclosed as part of IBM's exhibits under Exhibit 4 to Form 8-K filed November 1, 2016, indicating it was referenced in the context of legal instruments defining holder rights. By 2023, the 0.300% Notes due 2026 were no longer just referenced in exhibits but were explicitly listed as a titled class of notes registered on the New York Stock Exchange under the trading symbol IBM 26B, showing increased visibility and formal recognition in the company's capital structure.",
      "llm_answer": "In the 2022 filing (IBM 10‑K, pages 28‑32), the 0.300% Notes due 2026 are listed in the “Notes due 2026” line of the capital‑stock table and are mentioned only in the “Notes due 2026” entry, with no separate discussion of their disclosure or visibility. By contrast, in the 2023 filing (IBM 10‑K, page 1), the same notes appear in the capital‑stock table but are highlighted as a distinct line item (“0.300% Notes due 2026”) and are included among the listed debt securities, giving them explicit prominence in the financial‑instrument disclosure. Thus, the notes transition from a brief, implicit listing in 2022 to a clearly identified, stand‑alone entry in 2023, increasing their visibility in the filings.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the evolution in disclosure and visibility of the 0.300% Notes due 2026 between IBM's 2022 and 2023 filings, with accurate use of percentages (0.300%) and years (2026), satisfying quantitative accuracy. The core progression—from a less prominent listing in 2022 to a more explicit, stand-alone disclosure in 2023—is factually aligned with the ground truth. However, the LLM mischaracterizes the nature of the increased visibility: it states the notes were highlighted in the 'capital-stock table' and 'debt securities' list in the 10-K, whereas the ground truth specifies that in 2023 the notes were formally registered on the New York Stock Exchange under the trading symbol IBM 26B, which is a more specific and material development than general 'listing' or 'highlighting' in a table. This omission of the NYSE registration and trading symbol detail represents a significant qualitative gap, as it misses the formal market recognition aspect central to the original answer. While the LLM captures the directional change in disclosure prominence, it fails to report the key fact of exchange registration, which is critical to understanding the evolution in financial instrument visibility. The reasoning is logically sound in comparing disclosure depth across years, but the synthesis lacks the precise regulatory and market infrastructure context (Exhibit 4 to Form 8-K in 2016 vs. NYSE listing in 2023). The answer remains contextually relevant and correctly interprets the multi-hop element (change over time in disclosure treatment), but with incomplete entity and mechanism accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 442,
        "total_tokens": 1758
      },
      "error": null
    },
    {
      "question_id": 150,
      "question": "How has GE's approach to the RISE Program evolved between 2022 and 2024, particularly in terms of its strategic emphasis and investment focus?",
      "original_answer": "In 2022, GE announced the RISE Program as a collaborative technology development initiative with Safran, targeting a reduction of more than 20% in fuel consumption and CO2 emissions compared to current engines. This marked the initial phase of the program as a forward-looking announcement aimed at shaping the future of sustainable aviation. By 2024, GE's engagement with the RISE Program had evolved into a more concrete investment strategy, with the company making 'significant investments' in the RISE program suite of technologies. This shift indicates a transition from conceptual development to active, funded R&D aimed at enabling a sustainable future of flight. The change reflects a deepening strategic commitment to sustainability and technological leadership in aviation.",
      "llm_answer": "Between 2022 and 2024, GE Aerospace’s RISE program evolved from a strategic technology initiative into a central pillar of its sustainability and growth agenda, with a marked shift toward integrated investment and cross‑segment collaboration. In 2022 the focus was on early‑stage research and proof‑of‑concept testing (e.g., Open Fan and hybrid‑electric concepts), while by 2024 the company had scaled these efforts into full‑scale development and commercial‑ready pilots, allocating additional capital and tying RISE technologies to both its Commercial Engines & Services and Defense & Propulsion Technologies segments. This strategic emphasis reflects a dual focus on driving next‑generation engine efficiency and enabling growth in services revenue, underscored by increased R&D spend ($2.7 bn in 2024) and explicit linkage of RISE innovations to long‑term profitability and market positioning.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer captures the core evolution of GE's RISE Program from a conceptual initiative in 2022 to a more developed, investment-backed R&D effort by 2024, aligning well with the ground truth's emphasis on increased strategic commitment and sustainability focus. The qualitative shift—from early-stage research to full-scale development and integration across business segments—is reasonably inferred and contextually sound, demonstrating good multi-hop reasoning and entity accuracy (GE Aerospace, RISE Program, correct time frame). However, the LLM introduces a specific dollar amount for R&D spend in 2024 ($2.7B) that is not present in the original answer and cannot be verified from the provided ground truth, which only mentions 'significant investments' without quantification. This introduces a factual overreach, reducing quantitative accuracy. Additionally, the original answer emphasizes the collaborative nature of the program with Safran in 2022, which the LLM omits, representing a minor but relevant contextual gap. While the LLM correctly identifies the strategic deepening and investment shift, the inclusion of unverified financial data and lack of mention of the Safran partnership prevent a higher score. Despite these issues, the answer remains contextually relevant and semantically aligned in overall thrust, justifying a correctness score of 7.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1419,
        "completion_tokens": 379,
        "total_tokens": 1798
      },
      "error": null
    },
    {
      "question_id": 150,
      "question": "How has the role and emphasis on asset securitizations within American Express's funding strategy evolved from 2022 to 2023, based on the specific disclosures in the respective 10-K filings?",
      "original_answer": "In 2022, American Express defined asset securitizations in a glossary entry, describing the mechanics of transferring loans to trusts that issue asset-backed securities, and noted that securitized loans and receivables were reported as assets while the securities were reported as liabilities. This definition was part of a broader explanation of financial terminology rather than a strategic focus. By 2023, asset securitizations were explicitly positioned as a core component of the company's funding strategy, listed alongside deposits and unsecured debt as key funding sources. The 2023 filing emphasized the importance of diversity in funding sources, with securitizations playing a role in mitigating disruptions in any single funding channel. This represents a shift from a definitional disclosure in 2022 to a strategic emphasis in 2023.",
      "llm_answer": "From 2022 to 2023, American Express’s funding strategy shifted toward greater reliance on asset securitizations as a cost‑effective source of long‑term financing.  While total long‑term debt rose to $47.9 billion in 2023, the company specifically highlighted that it “periodically securitizes Card Member loans and receivables … as the securitization market provides us with cost‑effective funding,” and disclosed $3.5 billion of asset‑backed securities issued through its American Express Credit Account Master Trust in 2023.  This focus on securitizations complemented, but did not replace, its broader mix of unsecured debt and deposit funding, reflecting a continued emphasis on leveraging securitization to lower funding costs while maintaining a diversified capital structure.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies not supported by the ground truth. While the original answer emphasizes a shift from definitional disclosure in 2022 to strategic emphasis in 2023, the LLM introduces unsupported quantitative claims such as $47.9 billion in long-term debt and $3.5 billion in asset-backed securities issued in 2023—these figures are not present in the ground truth and cannot be verified from the provided context. There is no mention in the original answer of cost-effectiveness or lowering funding costs as a stated reason in the 2023 filing, nor is there any indication that reliance on securitizations increased quantitatively. (2) The quantitative accuracy is low because the dollar amounts ($47.9B, $3.5B) are fabricated or misattributed; the ground truth does not provide any numerical data about securitization volume or total debt, so including these numbers misrepresents the filings. (3) The multi-hop reasoning is partially sound in that the LLM recognizes securitizations as part of a broader funding mix alongside unsecured debt and deposits, and infers strategic relevance. However, it fails to accurately reflect the nature of the evolution: from a glossary definition (2022) to explicit strategic positioning (2023) for diversification, not cost. The reasoning overstates financial reliance and introduces motives (cost-effectiveness) not present in the ground truth. (4) Contextual relevance is moderate because the answer addresses funding strategy evolution and mentions correct mechanisms (e.g., securitizing card member loans), but distracts with incorrect specifics. Qualitative accuracy is medium because entity identification (American Express, securitizations, funding sources) is correct, but the synthesis mischaracterizes the basis of the strategic shift. Correctness score is low due to invention of key financial figures and misrepresentation of strategic rationale.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1417,
        "completion_tokens": 526,
        "total_tokens": 1944
      },
      "error": null
    },
    {
      "question_id": 151,
      "question": "How did Emerson's financial and strategic relationship with AspenTech evolve from 2022 to 2023, particularly in terms of investment returns and operational integration?",
      "original_answer": "In 2022, Emerson's relationship with AspenTech was characterized by a minority investment, with AspenTech contributing $656 in sales and a $12 earnings gain, while holding total assets of $14,484. By 2023, Emerson significantly deepened its involvement by acquiring Heritage AspenTech, gaining a 55% ownership stake in the newly formed AspenTech. This acquisition positively impacted gross margins by 0.6 percentage points in 2023 and marked a strategic shift from a passive investment to an active controlling interest, indicating a transformation in the nature of the relationship.",
      "llm_answer": "From 2022 to 2023 Emerson’s relationship with AspenTech shifted from a minority, strategic equity stake to full operational integration following its $15 billion acquisition of the remaining shares in May 2022. This investment delivered strong financial returns—AspenTech contributed $656 million of segment earnings (up from a $16 million loss in 2021) and its software and control solutions were embedded across Emerson’s Automation Solutions portfolio, driving higher-margin growth and expanding the combined product offering. The integration also generated synergies reflected in increased adjusted EBITA and improved segment margins, underscoring a deepened strategic partnership that moved from passive investment to active, revenue‑generating collaboration.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains multiple critical factual inaccuracies. It claims Emerson completed a $15 billion acquisition of AspenTech in May 2022, but the ground truth states that in 2022, Emerson held only a minority investment, and the controlling 55% stake acquisition occurred in 2023 (via acquisition of Heritage AspenTech). The $15 billion figure is entirely fabricated and not present in the original answer. The LLM incorrectly states AspenTech contributed $656 million of segment earnings, while the original answer specifies $656 in sales and only a $12 earnings gain in 2022. Additionally, the claim that AspenTech had a $16 million loss in 2021 is unsupported by the ground truth, which does not mention 2021 performance. The LLM also misrepresents the financial impact: it mentions improved EBITA and segment earnings, but the original answer specifies only a 0.6 percentage point improvement in gross margins in 2023. (2) Quantitative accuracy is severely compromised: all key numbers (acquisition cost, earnings contribution, loss in 2021) are incorrect or invented. Only the $656 sales figure is correct (though mislabeled as earnings), and the 2022/2023 timeline is reversed. (3) The multi-hop reasoning is flawed: the model fails to correctly trace the evolution from minority stake in 2022 to 55% ownership in 2023, instead asserting full acquisition in 2022. It invents operational integration outcomes (e.g., embedded software, synergies) not mentioned in the original, and misattributes margin improvements. (4) Contextual relevance is moderate—the answer addresses investment evolution and operational integration as asked, but with incorrect facts and timeline. Due to major factual and quantitative errors, especially regarding the acquisition timing, size, and financial contributions, the overall correctness score is low at 3.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 505,
        "total_tokens": 1847
      },
      "error": null
    },
    {
      "question_id": 152,
      "question": "How did Emerson's financial relationship with AspenTech evolve between 2022 and 2023, particularly in terms of noncontrolling interest accounting and acquisition-related impacts on equity and expenses?",
      "original_answer": "In 2022, Emerson completed the creation of New AspenTech by contributing its industrial software business and $6.0 billion in cash, resulting in a 55% ownership stake. A noncontrolling interest of $5.9 billion was recorded, with a decrease to additional paid-in capital of $550 million. By 2023, the AspenTech acquisition positively impacted gross margins by 0.6 percentage points and contributed to increased SG&A expenses, which rose by $572 million compared to 2022, partly due to the AspenTech transaction and higher stock compensation expenses. This shows that while the initial accounting impact was significant in 2022, by 2023, the focus had shifted to operational integration and financial performance effects.",
      "llm_answer": "Between 2022 and 2023, Emerson's financial relationship with AspenTech evolved through the acquisition of a 55% stake in 2022 and subsequent strategic actions involving Copeland. By 2023, Emerson held a noncontrolling interest in Copeland, which was later sold in 2024, resulting in a $539 gain on the sale of its 40% equity interest and a $279 pretax loss on the note receivable adjustment. The acquisition of Heritage AspenTech (completed May 16, 2022) established Emerson as the accounting acquirer, recording a $5.9 billion noncontrolling interest for the 45% stake held by former Heritage AspenTech shareholders. This noncontrolling interest was initially recorded at fair value using the market price of Heritage AspenTech shares, with the portion attributable to the Emerson Industrial Software Business recorded at historical cost, impacting additional paid-in capital. The 2023 financials reflect the ongoing consolidation of AspenTech's results, including its acquisition of Micromine and the divestiture of Metran, while the 2024 sale of the Copeland stake marked a pivotal shift in Emerson's equity position and accounting treatment for its AspenTech relationship.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies and introduces irrelevant entities and events not present in the ground truth. It incorrectly states that Emerson held a noncontrolling interest in Copeland, which was sold in 2024 for a $539 gain and $279 loss — this is entirely unrelated to the AspenTech financial relationship as described in the original answer. The original answer makes no mention of Copeland, Micromine, Metran, or any 2024 transactions. These are major hallucinations that undermine the factual basis of the response. (2) Quantitative accuracy is poor: the original answer reports a $572 million increase in SG&A expenses in 2023 and a $550 million decrease to additional paid-in capital in 2022. The LLM answer omits the $572M SG&A increase entirely and instead fabricates a $539 gain and $279 loss related to Copeland, which are not in the ground truth. While it correctly states the $5.9 billion noncontrolling interest and 55% ownership stake, it misrepresents the accounting treatment by introducing a hybrid fair value/historical cost allocation not detailed in the original. (3) Multi-hop reasoning is flawed: the question asks about the evolution of Emerson's financial relationship with AspenTech in terms of noncontrolling interest accounting and acquisition impacts on equity and expenses. The LLM fails to connect 2022's equity impact (APIC decrease of $550M) with 2023's operational impacts (gross margin and SG&A). Instead, it shifts focus to unrelated divestitures and subsequent years, breaking the logical chain. (4) Contextual relevance is partially maintained by discussing AspenTech, noncontrolling interest, and acquisition accounting, but the inclusion of Copeland and post-2023 events severely detracts from relevance. The core evolution — from initial accounting in 2022 to operational integration in 2023 — is not accurately conveyed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1487,
        "completion_tokens": 515,
        "total_tokens": 2002
      },
      "error": null
    },
    {
      "question_id": 152,
      "question": "How has IBM's treatment and disclosure of the 6.22% Debentures due 2027 evolved between the 2022 and 2023 SEC filings?",
      "original_answer": "In 2022, IBM disclosed the 6.22% Debentures due 2027 by referencing the instrument defining the rights of its holders, which was filed as Exhibit 3 to Form 8-K on August 1, 1997. In contrast, the 2023 filing introduces a more structured and visible disclosure by listing the 6.22% Debentures due 2027 with its respective trading symbol (IBM 27) and explicitly identifying it among other registered securities on the New York Stock Exchange. This evolution reflects a shift from a purely historical reference to a more transparent and current market-oriented presentation.",
      "llm_answer": "Based on the provided SEC filing excerpts, IBM's treatment and disclosure of the 6.22% Debentures due 2027 remained consistent between the 2022 and 2023 filings. The debentures are explicitly listed in the \"Securities registered pursuant to Section 12(b) of the Act\" table in both the 2022 (page 2) and 2023 (page 4) filings, identified as \"6.22% Debentures due 2027\" with the same CUSIP designation (\"IBM 27\"). No material changes in terms, conditions, or disclosure requirements for these debentures are indicated in the provided document pages. The company continues to reference the same governing documents (e.g., the 1997 Form 8-K filing) for these securities in both years.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core conclusion. While it correctly identifies that the 6.22% Debentures due 2027 were listed in both filings and references the CUSIP 'IBM 27' and the 1997 Form 8-K, it claims the treatment and disclosure 'remained consistent'—which directly contradicts the ground truth. The original answer states there was a clear evolution: from a minimal, historical reference in 2022 (solely citing the 1997 Exhibit 3) to a more structured, market-oriented disclosure in 2023 that includes the trading symbol and explicit NYSE registration. The LLM fails to recognize this shift and instead asserts consistency. (2) Quantitatively, the LLM is accurate: it correctly identifies the debenture rate (6.22%), maturity (2027), trading symbol/CUSIP ('IBM 27'), and the 1997 Form 8-K reference. These numbers and identifiers match the ground truth. (3) The multi-hop reasoning is flawed. The question asks for a comparison of disclosure evolution across two years, requiring synthesis of how the nature of the disclosure changed. The LLM acknowledges both filings mention the debentures but misses the qualitative enhancement in the 2023 filing—listing it in a Section 12(b) table with a trading symbol reflects a more transparent, current-market presentation. This evolution is the key point of the ground truth, which the LLM overlooks. (4) The contextual relevance is moderate: it addresses the right document sections and securities, but misinterprets the intent of the question by focusing on surface-level consistency rather than changes in disclosure depth and structure. Hence, correctness and qualitative accuracy are low despite numerical accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1305,
        "completion_tokens": 464,
        "total_tokens": 1769
      },
      "error": null
    },
    {
      "question_id": 152,
      "question": "How has UnitedHealth Group's exposure to financial risk through risk-based arrangements with healthcare providers evolved from 2023 to 2024, and what implications does this have on its cost estimation and service delivery responsibilities?",
      "original_answer": "In 2023, UnitedHealth Group assumed economic risk under risk-based arrangements where it was responsible for funding healthcare costs, and it recognized premium revenues based on estimated premiums earned, net of projected rebates. The company also highlighted its involvement in value-based arrangements where it received per-patient-per-month premiums and recognized revenue as services were made available. By 2024, the company's exposure expanded as it noted increased responsibility for unpaid healthcare claims if risk-based providers faced financial difficulties or failed to meet their obligations. Additionally, the 2024 disclosures emphasized greater operational risk tied to providers' ability to manage costs, maintain solvency, and provide necessary data for cost estimation, indicating a broader and more complex financial exposure compared to 2023.",
      "llm_answer": "UnitedHealth Group’s exposure to financial risk through risk‑based arrangements with healthcare providers has shifted from a focus on limiting its exposure to rising medical costs to a greater reliance on such arrangements—particularly value‑based contracts that tie payments to outcomes and cost‑containment goals.  In 2024 the company notes that these arrangements “limit our exposure to the risk of increasing medical costs, but expose us to risk related to the adequacy of the financial and medical care resources of the health‑care providers,” and it warns that if a provider faces financial difficulty or fails to meet its obligations, UnitedHealth may be held responsible for unpaid claims it has already paid.  Consequently, the company must more carefully estimate and reserve for medical costs, and it must manage provider solvency and payment disputes to avoid unexpected liabilities, which directly impacts its cost‑estimation models and its ability to deliver services under these risk‑based contracts.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution of UnitedHealth Group's financial risk exposure from 2023 to 2024, noting the shift toward greater reliance on risk-based arrangements and the associated operational and financial risks. The core facts—such as UnitedHealth’s responsibility for unpaid claims if providers fail, and the increased burden on cost estimation and service delivery—are all present and correct. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the original or LLM answer, so quantitative accuracy is not compromised; dates (2023 vs 2024) are used correctly. (3) The multi-hop reasoning is sound: the LLM synthesizes information about risk transfer, provider solvency, cost estimation, and service delivery across time periods, correctly inferring the implications of expanded risk exposure. It accurately reflects the 2024 disclosure about provider financial difficulty leading to UnitedHealth’s liability, which is a key evolution from 2023. (4) The only minor shortcoming is that the LLM slightly downplays the 2023 context—while it mentions value-based contracts, it doesn’t explicitly note the recognition of premium revenues based on estimated premiums earned and projected rebates, nor the per-patient-per-month revenue model. However, the focus is on the evolution, and the 2024 developments are thoroughly and correctly described. Semantic equivalence is maintained, and the answer is fully relevant to the question.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1492,
        "completion_tokens": 422,
        "total_tokens": 1915
      },
      "error": null
    },
    {
      "question_id": 153,
      "question": "How did Emerson's financial relationship with AspenTech evolve between 2022 and 2023, particularly in terms of investment magnitude and strategic involvement?",
      "original_answer": "In 2022, Emerson's relationship with AspenTech was primarily financial, as shown by its investment reflected in the Automation Solutions segment, where Emerson reported $362 million invested in AspenTech in 2022. By 2023, the relationship evolved into a strategic partnership following the introduction of a major transaction where Emerson contributed its Industrial Software Business along with approximately $6.0 billion in cash to Heritage AspenTech stockholders, creating 'New AspenTech.' Emerson gained 55% ownership of AspenTech's outstanding shares, marking a significant shift from a minority investment to a controlling stake.",
      "llm_answer": "Between 2022 and 2023, Emerson's financial relationship with AspenTech evolved from a strategic partnership to a deepening ownership stake and eventual acquisition proposal. In 2022, Emerson held approximately 57% of AspenTech's shares, with the AspenTech segment contributing $656 million in sales and generating $12 million in earnings (previously reported as a small loss). By 2023, Emerson had completed the acquisition of National Instruments (not directly AspenTech, but part of broader portfolio strategy), and began exploring a full acquisition of AspenTech at $240 per share, implying a $15.3 billion market cap. This proposed acquisition, financed through cash and credit, would have given Emerson full control of AspenTech, significantly increasing its investment magnitude from a partial equity stake to full ownership. The move was part of Emerson's broader strategy to consolidate its industrial software portfolio, though the actual acquisition was not completed by the end of 2023, with the proposal announced in November 2024.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022 Emerson had a financial investment of $362 million in AspenTech, not a 57% ownership stake as claimed. The LLM incorrectly states that Emerson already held 57% of AspenTech in 2022, when in fact it only gained 55% ownership in 2023 through a major transaction. The LLM also fabricates a $240 per share acquisition proposal in November 2024 (outside the 2022–2023 timeframe) and claims it was not completed by end of 2023, which contradicts the ground truth that the transaction creating 'New AspenTech' with 55% Emerson ownership did occur in 2023. Additionally, the LLM incorrectly references the acquisition of National Instruments as part of the AspenTech relationship, which is unrelated. (2) Quantitative errors include: wrong investment amount in 2022 (claims 57% ownership vs. actual $362M minority investment), incorrect 2023 transaction value (mentions $15.3B market cap proposal vs. actual $6.0B cash + business contribution), and wrong ownership percentage timeline. The $656M in sales and $12M earnings from AspenTech segment are not mentioned in the ground truth and appear fabricated. (3) Multi-hop reasoning is flawed: the model fails to correctly trace the evolution from financial investment (2022) to strategic control (2023). Instead, it invents a reverse timeline where Emerson already has majority ownership in 2022 and proposes a full acquisition later. It also conflates unrelated transactions (National Instruments). (4) Scores are low due to major factual and numerical errors, incorrect entity relationships, and flawed logic. Contextual relevance is moderate because the answer addresses the general topic of Emerson-AspenTech evolution, but the details are largely incorrect or fabricated.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1422,
        "completion_tokens": 496,
        "total_tokens": 1918
      },
      "error": null
    },
    {
      "question_id": 153,
      "question": "How has Adobe Target's role within Adobe's customer journey solutions evolved from fiscal 2022 to fiscal 2023, and what does this evolution indicate about Adobe's strategic direction in AI-driven personalization?",
      "original_answer": "In fiscal 2022, Adobe Target was described as part of a broader set of customer journey solutions, specifically noted alongside Marketo Engage, Adobe Campaign, and Journey Optimizer. It was characterized as a tool for testing, targeting, and personalizing content across channels. By fiscal 2023, Adobe Target was elevated in prominence and described specifically as an 'AI- and machine learning-driven personalization engine' with capabilities for omnichannel personalization and large-scale A/B and multivariate testing through AI-powered automation. This evolution indicates Adobe is placing greater strategic emphasis on AI-driven personalization as a core capability within its customer journey offerings, aligning with its broader push toward AI-powered solutions.",
      "llm_answer": "From fiscal 2022 to fiscal 2023 Adobe’s customer‑journey portfolio shifted from a fragmented set of point solutions to a tightly integrated, AI‑driven suite anchored by Adobe Experience Platform and Journey Optimizer.  The company emphasized that Adobe Target now operates as an AI‑powered personalization engine that works within the broader Experience Cloud ecosystem, enabling real‑time, cross‑channel personalization and automated A/B/multivariate testing at scale.  This evolution signals Adobe’s strategic focus on unifying data, insights and activation across the entire journey—leveraging generative AI and machine‑learning to deliver hyper‑personalized experiences and to drive recurring subscription growth.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution of Adobe Target from a personalization tool in 2022 to an AI- and machine learning-driven personalization engine in 2023. While the original answer does not use the term 'fragmented set of point solutions,' the LLM's characterization of a shift toward integration is consistent with the elevated role of Target within a more cohesive AI-driven suite. (2) There are no numeric values, dates, or financial figures in the question or ground truth beyond fiscal years 2022 and 2023, which the LLM correctly uses—thus quantitative accuracy is perfect. (3) The multi-hop reasoning is sound: the LLM synthesizes information about Adobe Target’s changing role and correctly infers Adobe’s strategic direction in AI-driven personalization. It accurately references real-time, cross-channel personalization, AI-powered automation, and integration with Experience Cloud and Journey Optimizer, all of which are aligned with or reasonably inferred from the 2023 description. (4) The only minor deviation is that the LLM emphasizes 'generative AI' and 'unifying data, insights and activation' more than the original answer does—while consistent with Adobe’s broader strategy, these points are slightly beyond the scope of the provided ground truth. However, this does not constitute a factual error but rather a small expansion. Overall, the answer is factually correct, comprehensive, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 415,
        "total_tokens": 1803
      },
      "error": null
    },
    {
      "question_id": 155,
      "question": "How did Emerson's relationship with AspenTech evolve from 2022 to 2023, particularly in terms of its financial stake and post-acquisition integration activities?",
      "original_answer": "In 2022, Emerson reported a balance of $8,326 million related to AspenTech as part of its acquisitions, indicating a significant financial stake following the acquisition of Heritage AspenTech. By 2023, the relationship had evolved into a more integrated structure, with AspenTech operating as a separate publicly traded company under Emerson's acquisition framework. This included the continuation of AspenTech's stock-based compensation plans, such as stock options and restricted stock units, which were now aligned with AspenTech's own equity structure. Additionally, Emerson was actively managing performance stock units tied to predefined goals like annual contract value and free cash flows, showing a shift from a purely financial stake to a more operationally integrated and incentive-driven relationship.",
      "llm_answer": "From 2022 to 2023 Emerson’s stake in AspenTech shifted from a minority ownership (recorded as an equity investment) to full ownership after the $11 billion acquisition closed in the third quarter of 2022.  The purchase added $7.3 billion of goodwill and $7.3 billion of acquired intangibles (primarily customer relationships and software), which are reflected in the goodwill and intangible‑asset balances shown on page 61.  Post‑acquisition, Emerson has been integrating AspenTech’s operations and stock‑based compensation plans, reporting $271 million of total stock‑compensation expense for 2023 (including $96 million related to AspenTech RSUs) and maintaining a separate reserve of 4 million shares for future issuance under AspenTech equity plans (page 72).",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies that significantly undermine its correctness. The original answer states that Emerson reported a balance of $8,326 million related to AspenTech in 2022 as part of its acquisitions, but the LLM claims a $11 billion acquisition value, which is not supported by the ground truth. Additionally, the LLM introduces specific figures such as $7.3 billion in goodwill and $7.3 billion in acquired intangibles, which are absent from the original answer and cannot be verified against the provided truth. The $271 million stock-compensation expense and $96 million related to AspenTech RSUs are not mentioned in the original answer, nor is the 4 million share reserve — these details appear to be fabricated or misattributed. (2) The dates are partially correct — the acquisition did close in 2022, aligning with the original answer’s implication of post-acquisition integration in 2023 — but the financial figures and their breakdowns (e.g., goodwill, intangibles, compensation expenses) are inconsistent with the ground truth. The original answer does not mention minority ownership prior to acquisition or a shift from minority to full ownership, making that claim unsupported. (3) The multi-hop reasoning is partially sound in that the LLM recognizes a transition from financial stake to operational integration, including equity plans and compensation structures. However, it misrepresents the nature of the 2022 stake (not described as minority equity investment in the original) and adds granular financial data not present in the source, indicating flawed synthesis. (4) While the LLM captures the general direction of evolution — increased integration and management of equity plans — the inclusion of unverified financial metrics and mischaracterization of the pre-acquisition relationship reduce factual accuracy. The contextual relevance is high because it addresses both financial stake and integration activities, but quantitative inaccuracy severely limits correctness. Thus, the correctness score is 4 (partially correct with major errors), quantitative accuracy is 3 (significant number mismatches), qualitative accuracy is 5 (some correct reasoning but flawed entity/factual mapping), and contextual relevance is 8 (on-topic and responsive).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1398,
        "completion_tokens": 618,
        "total_tokens": 2016
      },
      "error": null
    },
    {
      "question_id": 155,
      "question": "How has Adobe Experience Platform's role within Adobe's customer journey solutions evolved from 2022 to 2023, particularly in terms of its integration with AI-powered tools and cross-channel campaign orchestration?",
      "original_answer": "In 2022, Adobe Experience Platform was described as the foundational infrastructure for Adobe Experience Cloud, enabling data standardization and integration with Adobe Sensei to provide AI-powered services such as automated insights, sentiment analysis, and enhanced anomaly detection. It was central to Adobe's differentiation, supporting applications like Adobe Analytics and Adobe Audience Manager. By 2023, Adobe Experience Platform's role had evolved to become the underlying engine for cross-channel campaign orchestration, particularly through its integration with Adobe Journey Optimizer. This app allowed brands to deliver personalized, connected customer journeys across any channel, using real-time data profiles and cloud-native scalability. Additionally, Adobe Mix Modeler, introduced in 2023 and powered by Adobe Sensei, leveraged cross-channel datasets in Adobe Experience Platform to provide machine learning-driven insights for optimizing marketing investments. This indicates a shift from a general AI-enhanced infrastructure role to a more specialized and actionable function in campaign planning and customer journey orchestration.",
      "llm_answer": "From 2022 to 2023, Adobe Experience Platform has evolved from a foundational data layer into the central orchestration engine for Adobe’s AI-powered customer journey solutions. It now deeply integrates with tools like Adobe Journey Optimizer, Adobe Target, and Adobe Mix Modeler to enable real-time, AI-driven personalization and cross-channel campaign management—allowing brands to unify customer profiles, activate real-time audiences, and deliver hyper-personalized experiences across all touchpoints using a single, scalable platform. This shift emphasizes proactive journey orchestration, AI-powered insights, and seamless integration with Adobe’s broader Experience Cloud ecosystem to drive end-to-end customer engagement.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of Adobe Experience Platform from 2022 to 2023, accurately describing its shift from a foundational data infrastructure to a central orchestration engine. It correctly identifies key integrations with Adobe Journey Optimizer, Adobe Target, and the introduction of Adobe Mix Modeler in 2023, all of which align with the ground truth. The role of Adobe Sensei in powering AI capabilities is implied through 'AI-powered insights' and 'AI-driven personalization,' though it is not explicitly named—this is a minor omission but does not detract significantly from factual accuracy. (2) There are no numeric values, dates, or financial figures in the question or answers that require verification; all temporal references (2022 to 2023) are consistent and correct. (3) The multi-hop reasoning is sound: the model synthesizes information across time periods and product integrations, correctly identifying the platform’s evolving role in cross-channel orchestration and AI-powered personalization. It connects Adobe Experience Platform to Journey Optimizer and Mix Modeler as per the ground truth, demonstrating proper entity linkage. (4) The answer is semantically equivalent to the original, using different phrasing (e.g., 'central orchestration engine' vs 'underlying engine for cross-channel campaign orchestration') but conveying the same core meaning. The only slight gap is the lack of explicit mention of 'real-time data profiles' and 'cloud-native scalability' from the 2023 update, and the omission of specific AI services like sentiment analysis or anomaly detection from 2022. However, these are contextual details rather than critical factual errors. Overall, the response is highly accurate, complete, and relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1487,
        "completion_tokens": 485,
        "total_tokens": 1972
      },
      "error": null
    },
    {
      "question_id": 155,
      "question": "How did UnitedHealth Group's approach to care delivery models evolve from 2023 to 2024 in response to Medicare Advantage funding pressures?",
      "original_answer": "In 2023, UnitedHealth Group emphasized accelerating the transition to value-based care delivery models, investing in clinical engagement, integrated care coordination technology, and new delivery channels like in-home and virtual care. The company viewed these innovations as key to future growth despite initial costs. However, by 2024, the company faced significant funding pressures in the Medicare Advantage program, including reduced benchmarks and risk adjustment changes, which led to operational adjustments. These included selective changes to provider networks, benefit structures, and county-level decisions about plan offerings, indicating a shift from expansion-focused investment to cost containment and strategic retrenchment in response to external financial constraints.",
      "llm_answer": "UnitedHealth Group has responded to Medicare Advantage funding pressures by adjusting its 2024 benefit design and intensifying cost‑management efforts, including refining network composition, member premiums and medical‑cost controls, while continuing to shift toward fully‑accountable, value‑based care delivery models across its UnitedHealthcare and Optum platforms.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in its description of UnitedHealth Group's 2024 response to Medicare Advantage funding pressures, correctly identifying cost-management efforts, network refinements, and continued movement toward value-based care. It accurately reflects the shift in focus due to financial constraints, aligning with the ground truth. There are no numeric values in either answer, so quantitative accuracy is not applicable—scored as 10 by default. However, the LLM answer omits key details from 2023, such as the emphasis on accelerating value-based care through investments in clinical engagement, care coordination technology, and new delivery channels like in-home and virtual care. It also fails to explicitly contrast the 2023 expansion-focused strategy with the 2024 retrenchment, which is central to the multi-hop aspect of the question (evolution from 2023 to 2024). While the answer captures the 2024 adjustments well, it does not fully synthesize the evolution over time, weakening the qualitative accuracy. Contextual relevance is high as the response directly addresses the core issue—UnitedHealth’s strategic shift in care delivery models in response to Medicare Advantage funding pressures. Semantic equivalence is partially met, but the lack of explicit 2023 context reduces completeness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 367,
        "total_tokens": 1654
      },
      "error": null
    },
    {
      "question_id": 157,
      "question": "How has the composition of TMO's debt instruments evolved between 2022 and 2023, particularly regarding the 1.950% Notes due 2029?",
      "original_answer": "In 2022, the 1.950% Notes due 2029 were listed among TMO's outstanding debt instruments with the trading symbol TMO 29. In 2023, the 1.950% Notes due 2029 remained present with the same trading symbol TMO 29, indicating continuity in this debt instrument. However, TMO introduced new debt instruments in 2023, such as the 3.200% Notes due 2026 and the 3.650% Notes due 2034, suggesting a broader shift in financing strategy. The continued presence of the 1.950% Notes due 2029 indicates no change in this specific liability, even as TMO expanded its debt portfolio.",
      "llm_answer": "The 1.950% Notes due 2029 were present in Thermo Fisher's 2022 debt disclosures (listed among its long-term debt instruments) but were not included in the 2023 debt disclosures, indicating they were likely retired or refinanced before the 2023 filing. The 2023 filing instead lists new instruments such as 3.200% Notes due 2026 and 2.875% Notes due 2037, reflecting a shift in the company's debt maturity profile.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect regarding the presence of the 1.950% Notes due 2029. The ground truth states these notes were present in both 2022 and 2023 with the trading symbol TMO 29, indicating continuity. However, the LLM claims they were absent in 2023 and likely retired or refinanced, which contradicts the original answer. This is a major factual error. (2) Quantitatively, the LLM correctly identifies new debt instruments introduced in 2023—specifically the 3.200% Notes due 2026—but incorrectly lists 2.875% Notes due 2037 instead of the 3.650% Notes due 2034 mentioned in the ground truth. This introduces an incorrect interest rate and maturity year, reducing quantitative accuracy. (3) The reasoning is flawed: the conclusion that the 1.950% Notes were retired is unsupported by the provided truth, and the multi-hop synthesis fails because it misinterprets the evolution of the debt portfolio. The model incorrectly infers disappearance rather than continuity. (4) Despite the factual errors, the answer is contextually relevant—it addresses the evolution of TMO's debt instruments and attempts to compare years and instruments, showing understanding of the question's intent—hence a moderate relevance score. However, core facts and synthesis are wrong, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1240,
        "completion_tokens": 370,
        "total_tokens": 1611
      },
      "error": null
    },
    {
      "question_id": 159,
      "question": "How has the composition of TMO's debt instruments evolved between 2022 and 2023, particularly regarding the 0.500% Notes due 2028 and the introduction of new note categories?",
      "original_answer": "In 2022, TMO listed the 0.500% Notes due 2028 alongside other debt instruments, including the 1.375% Notes due 2028. By 2023, TMO continued to list the 0.500% Notes due 2028, but introduced new debt categories such as the 3.200% Notes due 2026 and the 3.650% Notes due 2034, while maintaining similar categories like the 1.375% Notes due 2028. This indicates a strategic shift toward diversifying TMO's debt portfolio with new interest rate structures and maturity timelines.",
      "llm_answer": "Between 2022 and 2023, Thermo Fisher's debt composition shifted with the retirement of the 0.750% Notes due 2024 and the 0.125% Notes due 2025, while new note categories were introduced, including 3.200% Notes due 2026 (TMO 26B) and 2.375% Notes due 2032 (TMO 32), alongside the continued presence of the 0.500% Notes due 2028 (TMO 28A) and 1.375% Notes due 2028 (TMO 28). The 2023 filing also added new tranches such as 3.650% Notes due 2034 (TMO 34), reflecting a strategic evolution in the company's debt maturity profile and funding structure.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the continued presence of the 0.500% Notes due 2028 and the introduction of new notes in 2023, including the 3.200% Notes due 2026 and 3.650% Notes due 2034, which aligns with the ground truth. However, it introduces inaccuracies by stating that the 0.750% Notes due 2024 and 0.125% Notes due 2025 were retired between 2022 and 2023—this retirement is not mentioned in the original answer and cannot be confirmed from the provided ground truth. Additionally, the LLM mentions a 2.375% Notes due 2032 (TMO 32), which is not present in the original answer and appears to be fabricated or misattributed. (2) Quantitative accuracy is partially compromised: while the 0.500%, 1.375%, 3.200%, and 3.650% rates and maturities match, the inclusion of the 2.375% Notes due 2032 and the retirement claims introduce false data points. The original answer does not mention any retirements or the 2.375% note, making these additions factually unsupported. (3) The multi-hop reasoning is sound in structure—comparing debt instruments across years and identifying new categories—but fails in execution due to inclusion of unverified instruments and retirements. The core idea of strategic evolution in debt composition is consistent with the ground truth, showing good qualitative understanding. (4) Contextual relevance is high as the response directly addresses the evolution of TMO's debt instruments with appropriate focus on new notes and continuity of existing ones. However, the correctness score is reduced due to significant factual errors in specific instruments and their status, despite capturing the general trend.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1262,
        "completion_tokens": 454,
        "total_tokens": 1717
      },
      "error": null
    },
    {
      "question_id": 160,
      "question": "How has the range of excess fair value over carrying value for DHR's reporting units changed between the 2023 and 2024 annual goodwill impairment analyses?",
      "original_answer": "In 2023, the excess of the estimated fair value over carrying value for DHR's reporting units ranged from approximately 140% to 495%. In 2024, this range decreased to between approximately 70% and 450%. This indicates a reduction in the lowest excess fair value percentage, suggesting a decline in the overall cushion before potential impairment.",
      "llm_answer": "Based on the provided document pages, the range of excess fair value over carrying value for DHR's reporting units was approximately 115% to 435% in 2024 (as stated in the 2024 goodwill impairment analysis on page 52), compared to approximately 140% to 495% in 2023 (as stated in the 2023 analysis on page 55). Thus, the excess range narrowed slightly in 2024, with the lower bound decreasing from 140% to 115% and the upper bound decreasing from 495% to 435%.",
      "correctness_score": 4,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains incorrect numeric values for the 2024 range. According to the ground truth, the 2024 range is approximately 70% to 450%, but the LLM states 115% to 435%. This is a significant factual error, particularly on the lower bound (115% vs 70%), which misrepresents the severity of the decline in excess fair value. The 2023 range is correctly cited as 140% to 495%. (2) The calculation of the change in bounds is logically presented but based on incorrect numbers. The claim that the lower bound decreased from 140% to 115% is inaccurate—per ground truth, it decreased to 70%, not 115%. Similarly, the upper bound decrease from 495% to 435% is close but still incorrect (should be 450%). (3) The multi-hop reasoning is structurally sound—the model attempts to compare two years’ impairment analysis results—but fails due to reliance on incorrect source data. (4) The contextual relevance is high as the answer addresses the right question with appropriate framing and terminology. However, the quantitative inaccuracies severely undermine the correctness, resulting in a low overall score despite correct reasoning structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1203,
        "completion_tokens": 328,
        "total_tokens": 1531
      },
      "error": null
    },
    {
      "question_id": 161,
      "question": "How did the treatment of canceled RSUs and tax-withheld shares under the 2022 Employee Stock Plan evolve from 2022 to 2023 in terms of their impact on the available share pool?",
      "original_answer": "In 2022, the 2022 Employee Stock Plan specified that canceled RSUs and shares withheld to satisfy tax withholding obligations would increase the number of shares available for grant under the plan by a factor of two times the number of RSUs canceled or shares withheld. However, in 2023, this specific language regarding the factor of two times for RSUs canceled or shares withheld was omitted, indicating a change in how these events were accounted for in the share pool calculation.",
      "llm_answer": "The 2022 Employee Stock Plan treats canceled RSUs and tax‑withheld shares as increasing the number of shares available for future grant—canceled RSUs add back twice the number of canceled units, and shares withheld to satisfy tax obligations also add back twice the number of such shares—whereas the 2014 Employee Stock Plan did not contain this mechanism. Consequently, under the 2022 Plan the available share pool expands more rapidly because these offsets are counted toward the pool, while the 2014 Plan does not provide such an increase. This difference means the 2022 plan effectively preserves a larger pool of shares for future issuance compared with the prior plan.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that under the 2022 Employee Stock Plan, canceled RSUs and tax-withheld shares were added back to the share pool at a factor of two, which matches the ground truth. However, it fails to address the key evolution from 2022 to 2023—the omission of the 'two times' language in 2023—which is the central focus of the question. Instead, the LLM incorrectly contrasts the 2022 plan with the 2014 plan, which was not part of the question and is irrelevant to the year-over-year change in treatment. (2) Quantitatively, the 'two times' multiplier is accurately stated, and no incorrect numbers are presented, so numerical accuracy is acceptable. But the absence of any reference to the 2023 change—specifically the removal of the doubling provision—means critical factual information is missing. (3) The reasoning is partially sound in explaining how the 2022 plan worked, but it fails the multi-hop requirement: the question asks for an evolution *from 2022 to 2023*, requiring synthesis of plan terms across two years. The model instead compares 2022 to the unrelated 2014 plan, indicating a failure in correct document/entity alignment. (4) Contextual relevance is high because the answer discusses the correct plan and mechanism, but correctness and qualitative accuracy are reduced due to the omission of the 2023 change and introduction of irrelevant information. A score of 5 reflects partial credit for correct description of 2022 mechanics but major error in scope and missing the temporal evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 426,
        "total_tokens": 1723
      },
      "error": null
    },
    {
      "question_id": 162,
      "question": "How has Danaher's strategic relationship with Aldevron evolved between 2023 and 2024, particularly in terms of its financial stake and integration into Danaher's business segments?",
      "original_answer": "In 2023, Danaher had a significant financial stake in Aldevron, as evidenced by the $9,561 million in net cash consideration allocated to Aldevron in the acquisition table, indicating a direct ownership interest. By 2024, Aldevron was no longer listed as a separately accounted stake but had been integrated into the Life Sciences segment as part of Danaher's broader portfolio of acquisitions, including Beckman Coulter, Pall, and IDT. This reflects a strategic shift from holding a standalone stake to full operational integration, aligning Aldevron's capabilities in biopharma research and manufacturing with Danaher’s broader life sciences offerings.",
      "llm_answer": "Danaher's strategic relationship with Aldevron has evolved significantly between 2023 and 2024, with Aldevron now fully integrated into the Life Sciences segment as a key business unit. The company acquired Aldevron in August 2021 for approximately $9.6 billion, and by 2023-2024, it had become a core part of Danaher's Life Sciences portfolio, contributing substantially to the segment's revenue and strategic focus on genomic medicines and biologics manufacturing. This integration is underscored by Aldevron's role in supporting Danaher's broader strategy of expanding its life sciences footprint through targeted acquisitions, with the company reporting $300 million in 2020 revenue and generating significant goodwill ($6.1 billion) from the acquisition.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly in quantitative details. While it correctly identifies the integration of Aldevron into Danaher's Life Sciences segment by 2024, it incorrectly states the acquisition date as August 2021 and cites a $9.6 billion acquisition price, whereas the ground truth specifies $9,561 million in net cash consideration allocated in 2023—implying the financial stake was formally accounted for then, not at acquisition. The $9.6B figure is close to $9,561M but presented as a historical fact when the timing is off. More critically, the LLM introduces a $300 million 2020 revenue figure for Aldevron and $6.1 billion in goodwill—neither of which appears in the ground truth and cannot be verified from the provided data. (2) The quantitative inaccuracies undermine the answer: the acquisition timing, revenue, and goodwill figures are unsupported. The only correct number is the approximate $9.6B, which aligns semantically with $9,561 million, but its presentation as a 2021 acquisition cost conflicts with the 2023 financial allocation detail in the original. (3) The reasoning is partially sound: the model correctly infers that Aldevron transitioned from a standalone stake to integration within Life Sciences, aligning with Danaher’s strategy. It correctly identifies the strategic rationale around biologics and genomic medicines. However, it fails the multi-hop synthesis by not referencing the 2023 financial stake allocation as a pivot point and instead assumes full integration by 2021, missing the evolution between 2023 and 2024 entirely. (4) Correctness is scored 5 due to partial factual alignment but major data errors; quantitative accuracy is low (4) due to incorrect numbers and dates; qualitative accuracy is moderate (6) as the conceptual integration narrative is reasonable; contextual relevance is high (9) because the answer addresses the strategic evolution, even if with flawed details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1361,
        "completion_tokens": 533,
        "total_tokens": 1895
      },
      "error": null
    },
    {
      "question_id": 163,
      "question": "How has Microsoft's strategic positioning of Microsoft 365 evolved between 2023 and 2024, particularly in terms of its integration with AI technologies and its role in the company's commercial business metrics?",
      "original_answer": "In 2023, Microsoft 365 was described as an 'AI first' platform integrating Office, Windows, Copilot, and Enterprise Mobility + Security, with Copilot for Microsoft 365 combining AI with business data to enhance productivity. By 2024, Microsoft had expanded the Microsoft 365 Consumer subscribers metric to include Microsoft 365 Basic subscribers, aligning with internal business management practices and signaling a broader consumer focus. This evolution reflects a strategic shift toward enhancing AI integration and expanding the product's market reach, particularly within the commercial segment.",
      "llm_answer": "Microsoft's strategic positioning of Microsoft 365 has evolved from a productivity suite to an AI-first platform deeply integrated with Copilot capabilities, as highlighted in the 2023 10-K (pages 2-6). By FY2024, Microsoft 365 became a core component of the \"Microsoft Cloud\" revenue stream, with Copilot for Microsoft 365 driving AI-powered workflow transformation across Office applications, Teams, and Viva, directly contributing to the 14% growth in Office Commercial revenue and 19% growth in Dynamics 365 revenue. This integration is central to Microsoft's commercial business strategy, with the company reporting Microsoft Cloud revenue growth of 23% to $137.4 billion in FY2024, fueled significantly by AI-enhanced productivity and business processes.",
      "correctness_score": 5,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the strategic shift toward AI integration in Microsoft 365, particularly through Copilot, and its role in commercial productivity tools, which aligns with the ground truth. However, it introduces significant factual inaccuracies not present in the original answer. (2) Quantitative inaccuracies include: the claim of '14% growth in Office Commercial revenue' and '19% growth in Dynamics 365 revenue' — these figures are not in the ground truth and cannot be verified from the provided context; similarly, the statement that Microsoft Cloud revenue grew 23% to $137.4 billion in FY2024 is unsupported by the original answer and introduces specific financial metrics absent from the source. These numbers may be plausible but are not part of the ground truth, making them incorrect in this evaluation context. (3) The multi-hop reasoning is partially sound — the model connects Microsoft 365, AI, Copilot, and commercial impact — but fails to accurately reflect the key evolution noted in the ground truth: the 2024 change in the Microsoft 365 Consumer subscribers metric to include Basic tier, which reflects a strategic expansion in market reach. This critical point is entirely missing, indicating a failure in synthesizing the full scope of strategic evolution. (4) While the answer is contextually relevant and captures the AI integration theme, it fabricates key financial data and omits the subscriber metric change, leading to a moderate correctness score. The qualitative reasoning is reasonable but based on unsupported numbers, reducing reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 441,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 164,
      "question": "How has Microsoft's positioning and emphasis on Copilot Pro evolved between 2023 and 2024, particularly in terms of its role within Microsoft 365 apps and web-based AI assistance?",
      "original_answer": "In 2023, Copilot Pro was introduced as a consumer subscription service that offered 'faster and more powerful AI assistance in Microsoft 365 apps and on the web.' By 2024, while the core definition remained consistent, the emphasis on Copilot Pro's differentiation and innovation appeared more pronounced, with language such as 'faster and more powerful AI assistance' retained but now embedded within a broader narrative of AI-driven transformation across Microsoft's ecosystem. This suggests a strategic evolution where Copilot Pro is not only a standalone offering but increasingly integrated into the broader AI-first positioning of Microsoft's productivity suite.",
      "llm_answer": "Between 2023 and 2024, Microsoft evolved Copilot Pro from a nascent consumer subscription into a central pillar of its AI-first strategy across Microsoft 365. The 2023 filing introduced Copilot Pro as a service that “offers faster and more powerful AI assistance in Microsoft 365 apps and on the web,” positioning it alongside role‑specific Copilot extensions (Sales, Service, Finance) and Copilot Studio for customization. By 2024, the narrative emphasized Copilot Pro’s expanded integration with Microsoft Graph, deeper AI‑driven assistance within Office, Windows, and Edge, and its role in delivering “more personal computing” through features like Copilot in Windows and Copilot+ PCs. Thus, its emphasis shifted from a peripheral add‑on to a core, AI‑enhanced experience that permeates both productivity applications and web‑based interactions.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: Copilot Pro was introduced in 2023 as a consumer subscription offering 'faster and more powerful AI assistance in Microsoft 365 apps and on the web,' and by 2024, its positioning evolved into a more central role within Microsoft's AI-first strategy. The LLM correctly identifies the continuity of key language while emphasizing a strategic shift toward deeper integration. (2) There are no numeric values, dates, or financial figures in the question or answers that require verification—only qualitative descriptions of strategic positioning—so quantitative accuracy is not applicable in a traditional sense but is effectively 10 due to absence of error. (3) The multi-hop reasoning is sound: the model synthesizes information across time (2023 to 2024), identifies the evolution in narrative emphasis, and connects Copilot Pro to broader ecosystem integrations (Microsoft Graph, Windows, Edge, Office), which reflects an accurate understanding of Microsoft’s strategic trajectory. (4) The LLM adds contextual details not explicitly in the original answer—such as Copilot Studio, role-specific Copilots, and Copilot+ PCs—which are factually accurate and enhance completeness without introducing errors. The only minor deviation from the original answer is a slightly stronger claim about Copilot Pro becoming a 'central pillar' and 'core, AI-enhanced experience,' which goes a bit beyond the original's more cautious 'increasingly integrated' phrasing. However, this is a reasonable interpretation and consistent with Microsoft’s public messaging. Thus, the answer earns a 9 for correctness and qualitative accuracy due to excellent synthesis and factual fidelity, with top marks for contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 490,
        "total_tokens": 1877
      },
      "error": null
    },
    {
      "question_id": 164,
      "question": "How has the structure and availability of the 2007 Omnibus Incentive Plan evolved between 2023 and 2024, particularly in terms of remaining shares available for issuance?",
      "original_answer": "In 2023, the 2007 Omnibus Incentive Plan was described in the context of PSU and RSU awards, vesting conditions, and valuation methods, but no specific figure was provided regarding the remaining shares available for issuance. In contrast, by 2024, the plan explicitly stated that approximately 47 million shares of Danaher common stock remained available for issuance under the plan as of December 31, 2024 (excluding shares underlying outstanding awards). This indicates a more transparent disclosure and potential depletion or tracking of the share pool since the plan's inception, showing a shift in how the company communicates the availability of shares under the plan.",
      "llm_answer": "Based on the provided SEC 10-K filings, the 2007 Omnibus Incentive Plan's remaining shares available for issuance **increased** from 2023 to 2024. As of December 31, 2023, approximately 47 million shares remained available for issuance under the plan (excluding shares underlying outstanding awards). By December 31, 2024, this increased to approximately 50 million shares available for issuance, reflecting the plan's continued authorization and the company's ongoing use of shares for equity compensation purposes. This growth aligns with the company's practice of issuing new shares from its authorized but unissued pool to fund stock-based compensation awards.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that the remaining shares increased from 47 million in 2023 to 50 million in 2024. According to the ground truth, no specific figure was provided for 2023 regarding remaining shares available for issuance under the 2007 Omnibus Incentive Plan. Instead, the 2023 filing discussed the plan in terms of PSU and RSU awards, vesting, and valuation, without disclosing a numerical balance of available shares. The 2024 filing is the first to specify that approximately 47 million shares remained available as of December 31, 2024. The LLM incorrectly reverses this timeline and fabricates a number for 2023 that was not disclosed, then asserts an increase to 50 million in 2024, which contradicts the ground truth of 47 million. (2) Quantitative accuracy is severely lacking: the LLM invents a 47 million figure for 2023 that does not appear in the source, and falsely claims 50 million for 2024 when the correct number is 47 million. These errors invalidate the core of the response. (3) The multi-hop reasoning is flawed: the model fails to recognize that the absence of a disclosed number in 2023 does not imply the number was the same or lower; it simply means it was not reported. The conclusion that shares 'increased' is unsupported and based on fabricated data. The synthesis across years is incorrect. (4) Contextual relevance is moderate because the answer addresses the right plan and topic (share availability under the 2007 Omnibus Incentive Plan), but the factual foundation is wrong. Due to major quantitative and qualitative errors, the correctness score is very low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 449,
        "total_tokens": 1789
      },
      "error": null
    },
    {
      "question_id": 165,
      "question": "How did Microsoft's accounting policy regarding the estimated useful lives of server and network equipment evolve between fiscal years 2023 and 2024, and what factors influenced this change?",
      "original_answer": "In fiscal year 2023, Microsoft increased the estimated useful lives of server and network equipment from four years to six years, effective beginning fiscal year 2023. This change was driven by investments in software that improved operational efficiencies and advances in technology. In fiscal year 2024, the policy remained consistent with the updated six-year estimate, indicating that the initial change was sustained and likely integrated into ongoing asset management practices. The continued focus on cloud and AI infrastructure investments further supported the rationale behind extending the useful lives of these assets.",
      "llm_answer": "Microsoft increased its estimated useful lives for server and network equipment from four to six years, effective in fiscal year 2023, as disclosed in the “Change in Accounting Estimate” section on page 40. The adjustment was driven by greater operational efficiencies from software investments and advances in technology that reduced the wear‑out rate of the equipment. This change impacted depreciation expense beginning in fiscal 2023 and is reflected in the 2024 filing.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key change in Microsoft's accounting policy: increasing the estimated useful lives of server and network equipment from four to six years, effective in fiscal year 2023. This matches the ground truth exactly. The answer also correctly notes that the change was driven by software investments improving operational efficiencies and technological advances—key factors cited in the original answer. It further correctly states that the impact began in fiscal 2023 and is reflected in the 2024 filing, which aligns with the sustained policy in 2024 as per the ground truth. (2) All quantitative elements—fiscal year 2023, four-year to six-year change—are accurate. No calculations are required, but the temporal and numerical assertions are correct. (3) The multi-hop reasoning is sound: the model connects the accounting policy change, its timing, drivers, and ongoing effect across fiscal years 2023 and 2024. However, the LLM answer does not explicitly state that the policy 'remained consistent' in fiscal 2024, which is a minor omission in completeness. While implied by mentioning the change is reflected in the 2024 filing, the explicit continuity and integration into asset management practices noted in the ground truth are not fully captured. (4) Despite this minor gap, the answer is factually correct, contextually relevant, and semantically equivalent in substance. The reference to page 40 adds specificity not in the ground truth but does not detract. Hence, a high score of 9 is warranted, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 445,
        "total_tokens": 1732
      },
      "error": null
    },
    {
      "question_id": 165,
      "question": "How did MDT's exposure to auction rate securities evolve from 2022 to 2023 in terms of fair value and classification within the balance sheet?",
      "original_answer": "In 2022, MDT reported auction rate securities with a fair value of $33 million and classified them under 'Total' in the investment portfolio without specifying a separate balance sheet classification. By 2023, the fair value of auction rate securities remained at $33 million, but they were explicitly classified under 'Other Assets' instead of being included in the broader investment category. This indicates a shift in how MDT categorized these securities on its balance sheet, moving from a general investment classification to a more distinct reporting under other assets.",
      "llm_answer": "From fiscal 2022 to fiscal 2023 Medtronic’s auction‑rate securities remained classified as Level 3 fair‑value measurements, but their fair‑value declined from $33 million (recorded in “Other assets”) to $33 million still held in “Other assets” while the overall available‑for‑sale debt‑securities balance fell from $6,893 million to $6,416 million. Consequently, the auction‑rate securities continued to be reported at fair value in the balance sheet (as a $33 million asset), but their carrying amount was reduced by unrealized losses, reflecting the decrease in fair value over that period.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly states the fair value of auction rate securities as $33 million in both 2022 and 2023, it incorrectly claims the securities were classified in 'Other assets' in 2022. According to the ground truth, in 2022 they were included under 'Total' in the investment portfolio without a separate classification, and only in 2023 were they explicitly moved to 'Other Assets'. The LLM falsely implies consistent classification in 'Other assets' across both years, which contradicts the original answer. Additionally, the LLM introduces a claim that fair value 'declined from $33 million to $33 million' and that there were 'unrealized losses', which is logically inconsistent and unsupported by the ground truth—no decline occurred. The mention of total available-for-sale debt securities falling from $6,893M to $6,416M is extraneous and not part of the original answer, suggesting hallucinated data. (2) Quantitatively, the $33 million figure is correct for both years, but the implication of a decline despite identical values is misleading. No actual calculation error is present, but the interpretation is flawed. (3) The multi-hop reasoning fails: the key evolution is in classification, not valuation or unrealized losses. The model misses the shift from general investment inclusion to specific 'Other Assets' classification, which is the central point of the original answer. Instead, it fabricates a narrative around valuation changes and unrealized losses. (4) Contextual relevance is moderate because the answer discusses balance sheet classification and fair value over time, which are relevant, but the incorrect details and fabricated reasoning severely undermine accuracy. The inclusion of unrelated portfolio totals further distracts from the core issue.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 501,
        "total_tokens": 1792
      },
      "error": null
    },
    {
      "question_id": 167,
      "question": "How did the net gains or losses from Cisco's available-for-sale debt investments change between fiscal years 2023 and 2024, and what does this indicate about the company's investment performance in this category?",
      "original_answer": "In fiscal year 2023, Cisco reported a net loss of $21 million from its available-for-sale debt investments, while in fiscal year 2024, this loss increased to $67 million. This indicates a significant worsening in investment performance related to this category year-over-year.",
      "llm_answer": "The net gains or losses from Cisco’s available‑for‑sale debt investments shifted from a $5.7 billion decline in fiscal 2024 (down from $15.6 billion to $9.9 billion fair value) to a $4.7 billion decline in fiscal 2023, indicating a smaller adverse impact on the investment portfolio year‑over‑year. This reduction suggests improved performance of the debt‑investment holdings, though the portfolio remains sensitive to interest‑rate movements.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 2,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is almost entirely incorrect. The ground truth states that Cisco had a net loss of $21 million in fiscal year 2023 and a net loss of $67 million in fiscal year 2024 from available-for-sale debt investments. The LLM instead reports $4.7 billion and $5.7 billion declines, which are off by more than two orders of magnitude and refer to changes in fair value rather than net gains or losses. These numbers do not match any part of the ground truth. (2) The quantitative inaccuracies are severe: the correct figures are $21M and $67M in losses, not billions, and the LLM incorrectly frames the change as a reduction in decline (improvement), when in fact the loss increased significantly. The calculation and direction of change are wrong. (3) The reasoning is flawed: the question asks about net gains or losses (income statement impact), but the model confuses this with changes in fair value (balance sheet impact), indicating a failure in financial concept understanding. It also fails to correctly synthesize the multi-hop information across fiscal years, misrepresenting both magnitude and trend. (4) The contextual relevance is low because the answer discusses fair value movements instead of realized/unrealized gains or losses, which are distinct accounting line items. The conclusion about 'improved performance' is the opposite of the truth—the actual data shows worsening performance. Only minimal credit is given for addressing Cisco and debt investments in the right fiscal years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1196,
        "completion_tokens": 419,
        "total_tokens": 1615
      },
      "error": null
    },
    {
      "question_id": 170,
      "question": "How did Cisco's approach to the APJC region evolve between 2023 and 2024 in terms of operational structure versus financial investment, and what implications does this have for its revenue model in that region?",
      "original_answer": "In 2023, Cisco directly operated in the APJC region as one of its three geographic segments, indicating a strong operational presence focused on delivering products and services. By 2024, Cisco's relationship with APJC evolved to include financial investments, specifically through equity instruments categorized as marketable equity securities, non-marketable equity securities, and equity method investments. While the 2023 filing emphasized operational delivery and customer engagement in APJC, the 2024 financial statements suggest a parallel strategy of capital participation, potentially signaling a shift toward leveraging local market growth through investment rather than solely through direct sales. This dual approach could indicate a broader revenue model incorporating both operational income and investment returns, though the filings do not quantify the specific financial impact of these investments on Cisco's APJC revenue.",
      "llm_answer": "Cisco's APJC operational structure shifted from a consolidated geographic segment to a more integrated model emphasizing regional collaboration and localized investment, as reflected in its 2024 10-K disclosures on APJC segment management and financing arrangements. This evolution prioritizes targeted financial commitments—such as expanded financing receivables for channel partners and strategic lease investments—over broad capital outlays, directly supporting a subscription-driven revenue model that emphasizes recurring income from SaaS, security, and AI-enabled services in the region.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies regarding Cisco's operational and financial evolution in the APJC region. The ground truth states that in 2023, Cisco directly operated in APJC as a geographic segment, and in 2024, it began making financial investments via marketable and non-marketable equity securities and equity method investments. However, the LLM incorrectly claims a shift to 'regional collaboration and localized investment' with 'expanded financing receivables' and 'strategic lease investments,' which are not mentioned in the ground truth. There is no mention of a change in operational structure from a consolidated segment to an integrated model—this is fabricated. Instead, the actual shift is from pure operational presence to adding financial investments. (2) There are no numeric values in either answer, so quantitative accuracy is not applicable; however, since no numbers are present or required beyond years (2023, 2024), which are correct, this dimension is scored highly. (3) The multi-hop reasoning is flawed: the LLM fails to correctly synthesize the shift from operational focus (2023) to inclusion of financial investment (2024). It invents mechanisms like 'financing receivables for channel partners' and 'lease investments' that are not in the original data. It also incorrectly links the structural change to a subscription-driven revenue model, while the ground truth only speculates about a potential dual revenue model (operational + investment returns) without confirming such a shift. (4) Correctness is low due to major factual errors and invention of details not present in the source. Qualitative accuracy is poor due to incorrect entities and reasoning. Contextual relevance is moderate because the answer addresses Cisco, APJC, and the time frame, and attempts to discuss operational vs. financial strategy, but misrepresents the actual evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1399,
        "completion_tokens": 520,
        "total_tokens": 1919
      },
      "error": null
    },
    {
      "question_id": 172,
      "question": "How has Apple's approach to App Store commissions and regulatory compliance evolved between 2022 and 2024, particularly in response to legal and market pressures?",
      "original_answer": "In 2022, Apple acknowledged that changes to the App Store, including those in response to legal and market conditions, could reduce the volume of sales and the commission it earns on those sales, potentially affecting its financial condition. By 2024, Apple had implemented specific changes, particularly in the U.S. and the European Union, to address legal pressures such as the Digital Markets Act (DMA). These changes included new business terms, alternative fee structures, alternative app distribution methods, and additional developer tools and APIs. These adjustments reflect a shift from a more general acknowledgment of potential changes to concrete actions taken in response to regulatory demands, which could significantly affect App Store revenue and commission structures.",
      "llm_answer": "Apple’s App Store commission policy has evolved in response to mounting legal and market pressure. In 2022 the company faced antitrust scrutiny and developer backlash over its 30 % cut, prompting it to introduce limited exemptions for small developers and to modify how it handles alternative payment mechanisms in the EU under the Digital Markets Act. By 2024 Apple had further adjusted its approach, agreeing to allow certain developers to use external payment options and reducing the commission rate for low‑margin apps, while simultaneously tightening enforcement against “unfair” pricing practices and expanding its compliance program to meet regulatory demands across jurisdictions. This progression reflects a shift from a rigid, uniform commission model to a more nuanced, region‑specific framework that balances revenue protection with regulatory compliance and developer relations.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of Apple's App Store commission and compliance approach between 2022 and 2024, correctly identifying increasing regulatory pressure and a shift toward more flexible, region-specific policies. It appropriately references the Digital Markets Act (DMA) and notes changes such as alternative payment options and reduced commissions for certain apps, aligning with the ground truth's emphasis on new business terms and fee structures. However, there are notable inaccuracies in quantitative and specific policy details: the LLM claims Apple reduced commissions for 'low-margin apps' and introduced 'external payment options' by 2024, but the ground truth does not specify these exact measures—instead citing broader changes like alternative distribution methods and new APIs. The 30% cut is mentioned, but the original answer does not specify this number, making the inclusion of '30%' unsupported by the provided truth. Additionally, the LLM introduces 'tightening enforcement against unfair pricing practices' and a 'compliance program' not mentioned in the ground truth, adding speculative detail. While the reasoning is logically sound and the answer is contextually relevant, the introduction of unverified specifics and lack of direct support for key claims reduce quantitative and qualitative accuracy. The core trajectory—from general acknowledgment in 2022 to concrete regulatory-driven changes in 2024—is correctly synthesized, warranting a score of 7 for overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1423,
        "completion_tokens": 417,
        "total_tokens": 1841
      },
      "error": null
    },
    {
      "question_id": 175,
      "question": "How did the allocation strategy for Texas Instruments' U.S. Retiree Health Care Plan evolve between fixed income securities and equity securities from 2022 to 2024?",
      "original_answer": "In 2022, the U.S. Retiree Health Care Plan had a diversified mix of fixed income securities and equity securities, with fixed income and cash equivalents totaling $248 million and equity securities at $137 million. By 2024, the allocation strategy showed a significant shift toward a more conservative posture, with fixed income securities and cash equivalents comprising 80% of the portfolio, while equity securities made up only 20%. This reflects a notable increase in emphasis on fixed income securities compared to equities, even though the relative proportions remained the same between 2023 and 2024, suggesting a strategic decision to prioritize capital preservation.",
      "llm_answer": "The allocation strategy for Texas Instruments’ U.S. Retiree Health Care Plan shifted from a higher fixed‑income weighting in 2022 toward a greater equity exposure by 2024, reflecting the plan’s target ranges of 75%–85% fixed income and 15%–25% equity; actual holdings moved from roughly 80% fixed income / 20% equity in 2022‑23 to about 80% fixed income / 20% equity in 2024, while the non‑U.S. defined benefit plans maintained a broader fixed‑income range of 60%–100% with equity allocations of 0%–40%. This evolution aligns with the company’s asset‑liability modeling that emphasizes matching asset returns to liability sensitivities and rebalancing when allocations drift outside target ranges.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in both direction and interpretation of the allocation shift. The original answer states that in 2022, fixed income and cash equivalents totaled $248 million and equities $137 million, which implies a portfolio of $385 million, with fixed income at ~64% and equities at ~36%. However, the LLM incorrectly claims that the 2022 allocation was already 'roughly 80% fixed income / 20% equity', which contradicts the dollar amounts in the ground truth. Furthermore, the LLM states that the strategy shifted 'toward a greater equity exposure by 2024', which is the opposite of the truth: the plan shifted to a more conservative posture with increased emphasis on fixed income. The 2024 allocation of 80% fixed income and 20% equities represents a move away from the more balanced 2022 allocation, not a continuation or shift toward equities. (2) The LLM invents target ranges (75%–85% fixed income, 15%–25% equity) and references non-U.S. defined benefit plans, which are not mentioned in the original answer and are irrelevant to the question. These additions introduce noise and misdirection. While the 80%/20% split in 2024 matches the original answer, the LLM incorrectly asserts this was also the case in 2022–2023, contradicting the provided dollar figures. (3) The multi-hop reasoning is flawed: the model fails to calculate the actual 2022 percentages from the dollar amounts and instead assumes consistency across years, missing the strategic shift entirely. It also conflates actual allocations with unspecified target ranges and introduces unrelated plan types. (4) Despite these issues, the answer is contextually relevant—it addresses the Texas Instruments U.S. Retiree Health Care Plan and discusses allocation trends over time. However, the core factual error in the direction of the shift (toward equities vs. toward fixed income) severely undermines correctness. Quantitative accuracy is partially preserved in the 2024 percentage mention but compromised by incorrect 2022 figures and invented ranges. Qualitative reasoning is weak due to flawed logic and unsupported assumptions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 579,
        "total_tokens": 1927
      },
      "error": null
    },
    {
      "question_id": 177,
      "question": "How has Texas Instruments' strategic emphasis on Embedded Processing Products evolved from 2022 to 2024, particularly in terms of its contribution to the company's competitive advantages and segment reporting structure?",
      "original_answer": "In 2022, Texas Instruments described Embedded Processing as one of its core product lines within a broader business model that emphasized four competitive advantages: manufacturing and technology strength, a broad product portfolio, strong market channels, and product diversity and longevity. Embedded Processing was positioned as part of this integrated strategy but was not highlighted as a standalone reportable segment. By 2024, Embedded Processing was elevated to a reportable segment alongside Analog, indicating a strategic shift where the company explicitly called out Embedded Processing as a key driver of value. This change suggests that Embedded Processing has become more central to TI's competitive positioning, particularly in terms of enabling optimized performance, power, and cost across a range of customer applications. The elevation to a reportable segment also implies greater operational and financial focus, aligning with the company’s long-term objective of strengthening its competitive advantages and driving free cash flow growth.",
      "llm_answer": "From 2022 to 2024, Texas Instruments' strategic emphasis on Embedded Processing Products evolved from being a smaller, growth-oriented segment to a more mature but still critical component of its business model. In 2022, Embedded Processing contributed $3.261 billion in revenue (16.3% of total), with operating profit of $1.253 billion (12.3% margin). By 2024, revenue grew to $3.368 billion (19.2% of total), and operating profit rose significantly to $1.008 billion (29.9% margin), reflecting improved gross margin and operational efficiency. This growth reinforced TI's competitive advantages in analog and embedded processing, particularly through scale, supply chain control, and market reach, while solidifying Embedded Processing as a key driver of profitability within its segment reporting structure, now contributing a larger share of total revenue and operating profit than in prior years.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that Embedded Processing was not a reportable segment in 2022 and only became one in 2024, but the LLM incorrectly treats it as a standalone segment in 2022 with specific revenue and profit figures ($3.261B revenue, $1.253B operating profit, 12.3% margin), which are not supported by the ground truth. Similarly, the 2024 figures ($3.368B revenue, $1.008B operating profit, 29.9% margin) are fabricated and not present in the original answer. There is no mention of financials in the ground truth, so all numbers are incorrect. (2) The quantitative accuracy is very low because every dollar amount, percentage, and margin cited by the LLM is false. The ground truth does not provide any financial data for Embedded Processing in either year, making the entire numerical foundation of the LLM response invalid. Calculations like margin percentages cannot be verified and are likely erroneous (e.g., $1.008B operating profit on $3.368B revenue implies ~30% margin, but this data point is invented). (3) The multi-hop reasoning is partially sound in that the LLM attempts to show evolution in strategic emphasis and links it to competitive advantages and segment reporting. However, it fails the core qualitative point: the key strategic shift is the elevation of Embedded Processing to a reportable segment in 2024, not financial performance. The LLM misses this structural and strategic nuance, instead fabricating financials and focusing on profitability trends that aren't in the source. (4) Contextual relevance is moderate because the answer addresses the general theme of strategic evolution and mentions competitive advantages and segment reporting. However, due to the invention of data and misrepresentation of segment status in 2022, the answer is largely incorrect. The correct answer hinges on organizational and reporting changes, not financial metrics. Thus, while the direction of reasoning is relevant, the factual basis is flawed, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1508,
        "completion_tokens": 558,
        "total_tokens": 2066
      },
      "error": null
    },
    {
      "question_id": 177,
      "question": "How did TMO's issuance and valuation of its 2.00% 10-Year Senior Notes evolve between 2022 and 2024?",
      "original_answer": "In 2022, TMO reported $1,200 million in 2.00% 10-Year Senior Notes due on October 15, 2031, with an effective interest rate of 2.23%. By 2024, the same category of 2.00% 10-Year Senior Notes showed no change in the principal amount at $1,200 million, and the effective interest rate remained at 2.23%. This indicates that TMO maintained a consistent position on this specific debt instrument over the two-year period, with no new issuances or repayments affecting this line item.",
      "llm_answer": "Based on the provided document pages, TMO's 2.00% 10-Year Senior Notes due 2031 were first issued in 2021 (as noted on page 88, which lists \"2.00% 10-Year Senior Notes, Due 10/15/2031\" with a carrying value of $1,200 million as of December 31, 2021). The notes remained outstanding through 2024, with no indication of redemption or refinancing in the provided materials. The document confirms the notes were still part of the company's long-term debt structure as of December 31, 2024, with the same maturity date of 2031. The issuance and valuation (carrying value) remained consistent, with the 2024 carrying value reported at $1,200 million (matching the 2021 valuation), indicating no significant changes in the notes' terms or value between 2022 and 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the principal amount of $1,200 million, the coupon rate (2.00%), maturity date (October 15, 2031), and effective interest rate (implied as unchanged, though not explicitly restated in 2024). The carrying value is accurately reported as $1,200 million in both 2021 and 2024, consistent with the ground truth. All numeric values, dates, and financial terms match the original answer. (2) Quantitative accuracy is perfect: $1,200 million principal, correct year references, and consistent valuation over time are all factually correct. The mention of issuance in 2021 aligns with available data and does not contradict the ground truth, which focuses on 2022–2024. (3) The reasoning is sound—LLM correctly infers no new issuance or repayment occurred between 2022 and 2024 based on stable carrying value and unchanged terms. It synthesizes information across years and correctly interprets the stability of the debt instrument. The only minor deviation is that the original answer explicitly states the effective interest rate (2.23%) for both years, while the LLM omits this specific figure, though it implies consistency. (4) The answer is highly relevant, directly addressing the evolution (or lack thereof) in issuance and valuation. The focus on unchanged terms and carrying value fully captures the core conclusion of the ground truth. The omission of the exact effective interest rate prevents a perfect 10 but does not undermine the overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 416,
        "total_tokens": 1714
      },
      "error": null
    },
    {
      "question_id": 178,
      "question": "How has the financial performance of REMICADE evolved between 2022 and 2024, and what does this indicate about its role in Johnson & Johnson's Pharmaceutical segment?",
      "original_answer": "In 2022, REMICADE was listed as a key product in Johnson & Johnson's Pharmaceutical segment, specifically within the Immunology therapeutic area, indicating its importance in treating immune-mediated inflammatory diseases. By 2024, REMICADE's sales had declined significantly, from $1,839 million in 2023 to $1,605 million in 2024, representing a 12.8% decrease. This decline suggests a diminishing contribution of REMICADE to the company's Immunology revenue, potentially due to market saturation, increased competition, or the emergence of newer biologics within the segment.",
      "llm_answer": "Based on the provided SEC 10-K filings, REMICADE (infliximab) sales declined by 12.8% in 2024 to $1,605 million (down from $1,839 million in 2023), driven by \"continued biosimilar competition\" as explicitly stated in the document. This decline is part of a broader downward trend in immunology products, where total immunology sales fell 1.2% to $17,828 million, with REMICADE specifically called out as experiencing \"continued biosimilar competition\" that contributed to its sales reduction. In contrast, the document indicates that biosimilars for REMICADE have already been introduced in the U.S. and Europe, with expectations of further biosimilar launches in 2025 that will continue to impact sales. This sustained biosimilar competition confirms REMICADE's declining role within Johnson & Johnson's Pharmaceutical segment, as it is no longer a growth driver and faces significant patent expiration pressures.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key facts from the ground truth: REMICADE's 2023 sales of $1,839 million, 2024 sales of $1,605 million, and the 12.8% decline are accurately stated and correctly calculated (difference is $234M; $234M / $1,839M ≈ 12.72%, which rounds to 12.8%). These numbers match the ground truth exactly in value and format. (2) The LLM adds contextual detail not in the original answer—specifically, that the decline is due to 'continued biosimilar competition' and that biosimilars have been launched in the U.S. and Europe, with more expected in 2025. While this information is not in the ground truth, it is consistent with the implied reasoning (declining sales due to competition) and plausibly from the 10-K filing, so it enhances rather than contradicts. (3) The multi-hop reasoning is sound: the LLM connects REMICADE’s sales trend to its role in the Immunology segment and Johnson & Johnson’s broader pharmaceutical business, correctly inferring a diminishing strategic role. It also synthesizes the impact of biosimilars across time and geography, showing strong qualitative analysis. (4) The only reason for not giving a perfect 10 is that the original answer focuses on 2022–2024 evolution but the LLM emphasizes 2023–2024 and omits explicit mention of REMICADE’s status in 2022 as a key product, slightly reducing completeness on the first part of the question. However, the core financial evolution and implications are accurately and thoroughly conveyed. All entities (REMICADE, Johnson & Johnson, Pharmaceutical segment, Immunology) are correct, and the answer is highly contextually relevant.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 451,
        "total_tokens": 1829
      },
      "error": null
    },
    {
      "question_id": 179,
      "question": "How did the sales performance of REMICADE evolve from 2022 to 2024, and what does this indicate about its market position within JNJ's Immunology portfolio?",
      "original_answer": "In 2022, REMICADE had sales of $3,190 million, showing a decline of 14.9% compared to 2020. By 2024, its sales had further decreased to $1,605 million, representing a 12.8% drop from 2023. This consistent decline indicates a weakening market position of REMICADE within JNJ's Immunology portfolio over time.",
      "llm_answer": "From 2022 to 2024, REMICADE sales declined from $1,839 million to $1,605 million—a reduction of 12.8%—driven by persistent biosimilar competition, as noted on page 32 of the 2024 filing. This downward trend reflects weakening market share within JNJ’s Immunology portfolio, where REMICADE is increasingly challenged by newer agents like STELARA and TREMFYA, as well as biosimilar erosion, signaling a diminishing competitive position despite the portfolio’s overall growth.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. According to the ground truth, REMICADE sales in 2022 were $3,190 million, not $1,839 million as stated in the LLM answer. The 2024 sales figure of $1,605 million is correct. The 12.8% decline mentioned in the LLM answer matches the ground truth's reported drop from 2023 to 2024, but the LLM incorrectly applies this percentage to the 2022–2024 period, whereas the ground truth does not provide a direct 2022–2024 percentage change. The LLM also omits the 14.9% decline from 2020 to 2022 mentioned in the original answer. (2) Calculations: The 12.8% drop is accurate for the 2023–2024 period per the ground truth, but the LLM misattributes the starting point (using 2022 instead of 2023). The claimed reduction from $1,839M to $1,605M equals ~12.7%, which is numerically consistent with the 12.8% cited, but the base year value is factually wrong. (3) Multi-hop reasoning: The LLM correctly infers that REMICADE is losing market position due to biosimilars and competition from newer JNJ drugs like STELARA and TREMFYA, which aligns with the qualitative interpretation in the ground truth. This shows sound reasoning and synthesis, even if some numbers are incorrect. (4) The answer is contextually relevant and addresses both parts of the question—sales evolution and market position—though with flawed quantitative support. The conclusion about weakening market position is consistent with the ground truth. However, the incorrect 2022 sales figure undermines the factual foundation, warranting a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1197,
        "completion_tokens": 440,
        "total_tokens": 1637
      },
      "error": null
    },
    {
      "question_id": 180,
      "question": "How has the sales performance of REMICADE evolved between 2021 and 2024, and what factors contributed to this change?",
      "original_answer": "REMICADE's sales declined significantly from $16.8 billion in 2021 (as part of total Immunology sales) to $1,605 million in 2024, reflecting a 12.8% decrease from 2023 to 2024 alone. This decline was primarily driven by biosimilar competition in the U.S. and other global markets, which intensified over time and led to a continued reduction in REMICADE sales.",
      "llm_answer": "Between 2021 and 2024, REMICADE sales declined significantly from $3,190 million (2021) to $1,605 million (2024), a cumulative drop of roughly 50%. This reduction was primarily driven by biosimilar competition—specifically, the entry of biosimilar infliximab in the U.S. and Europe—and continued price erosion from multiple biosimilar launches, as noted in the 2024 disclosures (page 32: \"Lower sales of REM ICA DE (infliximab) was due to continued biosimilar competition\"; page 32: \"Continued infliximab biosimilar competition will result in a further reduction in sales of REM ICA DE\"). While REMICADE showed a 12.8% decline from 2023 to 2024 (page 31), its downward trend accelerated due to generic/biosimilar market saturation and loss of exclusivity, with no growth offsetting these pressures. In contrast, other immunology products like TREMFYA grew robustly (16.6% in 2024, page 31), highlighting REMICADE's specific vulnerability to biosimilar disruption.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the quantitative data, particularly the 2021 sales figure. The ground truth states REMICADE's sales were $16.8 billion in 2021 as part of total Immunology sales, but the LLM incorrectly reports $3,190 million (i.e., $3.19 billion) as REMICADE's standalone sales in 2021. This is a major error, as it misrepresents both the magnitude and context of the sales figure. Additionally, the LLM claims a 'cumulative drop of roughly 50%' from 2021 to 2024, but based on the correct ground truth numbers ($16.8B to $1.605B), the actual decline is approximately 90.4%, not 50%. However, the 2024 sales figure ($1,605 million) and the 12.8% year-on-year decline from 2023 to 2024 are correct and match the ground truth. (2) The qualitative aspects of the answer are strong: the explanation of biosimilar competition in the U.S. and Europe is accurate and well-supported by cited disclosures (pages 31–32), and the mention of continued price erosion and market saturation aligns with the known drivers. The contrast with TREMFYA’s growth adds useful context, though it was not required by the question. (3) The multi-hop reasoning is sound in linking biosimilar entry to declining sales over time and citing specific document evidence, but the flawed initial data undermines the overall calculation and trend interpretation. The model appears to have used a correct 2024 figure but an incorrect or misattributed 2021 figure, possibly confusing REMICADE’s sales with a subset or misreading the Immunology segment data. (4) Despite strong contextual relevance and correct identification of causal factors, the severe quantitative inaccuracy in the starting sales value and resulting percentage decline limits the correctness score to 5. The answer gets partial credit for correct 2024 value, correct YoY decline, and accurate reasoning on drivers.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 515,
        "total_tokens": 1839
      },
      "error": null
    },
    {
      "question_id": 181,
      "question": "How did the status and commercial performance of STELARA (ustekinumab) evolve between 2022 and 2024?",
      "original_answer": "In 2022, STELARA was in the filing stage for the treatment of pediatric patients with juvenile psoriatic arthritis in the U.S., indicating it was under regulatory review but not yet approved. By 2024, STELARA had achieved significant commercial success, generating $10,361 million in sales, a decrease from $10,858 million in 2023, representing a 4.6% decline in total sales. This reflects that STELARA had transitioned from a product in active regulatory development to a mature, high-revenue-generating drug facing slight sales decline, suggesting market saturation or increased competition.",
      "llm_answer": "Based on the provided SEC 10-K filings, STELARA (ustekinumab) experienced a decline in global sales from $10,858 million in 2023 to $10,361 million in 2024 (a 4.6% decrease), driven primarily by biosimilar competition in Europe and the U.S. The document explicitly states that \"the decline of STELARA sales was driven by share loss primarily due to European biosimilar entrants\" and notes that \"biosimilar versions of STELARA\" are expected to launch in 2025, which will further impact sales. While U.S. sales remained strong at approximately $6.7 billion in 2024, the overall commercial performance deteriorated due to this competitive pressure and the impending loss of patent protection (U.S. patent expiry in September 2023).",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the sales figures for STELARA in 2023 ($10,858 million) and 2024 ($10,361 million), accurately calculating the 4.6% decline. These numbers match the ground truth exactly, and the percentage change is correct: (10,858 - 10,361) / 10,858 ≈ 0.0458 or 4.6%. (2) The LLM adds contextual details not present in the original answer—specifically biosimilar competition in Europe, expected U.S. biosimilar launches in 2025, and U.S. patent expiry in September 2023—which are consistent with typical disclosures in J&J’s 10-K filings and enhance the explanation, though they were not part of the ground truth. These do not contradict the original answer but provide additional depth. (3) The original answer notes STELARA’s 2022 status as in the filing stage for pediatric use, which the LLM omits. This is a minor gap in completeness, as the question asks about the evolution between 2022 and 2024, and the LLM only covers 2023–2024 performance. However, the core commercial performance trajectory is accurately captured. (4) The reasoning is sound, with correct synthesis of sales trends and external factors affecting performance. The entity (STELARA/ustekinumab) and years are correct. (5) Despite the omission of the 2022 regulatory status, the answer is highly factually accurate, contextually relevant, and provides a plausible, detailed explanation for the sales decline. The minor incompleteness prevents a perfect 10, but the quantitative and qualitative accuracy is otherwise excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 423,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 182,
      "question": "How did the total net revenue from Restasis in the United States change between 2023 and 2024, and what was the percentage decrease in each year?",
      "original_answer": "In 2023, the United States net revenue from Restasis was $382 million, which decreased to $172 million in 2024. This represents a 38.5% decrease in 2023 compared to 2022, and a further 55.2% decrease in 2024 compared to 2023.",
      "llm_answer": "The total net revenue from Restasis in the United States declined by 38.5% in 2023 and by 55.2% in 2024, reflecting a 38.5% decrease from 2022 to 2023 and a further 55.2% drop from 2023 to 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly states the percentage decreases: 38.5% from 2022 to 2023 and 55.2% from 2023 to 2024, which matches the ground truth. However, it omits the actual dollar amounts of $382 million in 2023 and $172 million in 2024, which were part of the original answer and directly relevant to the first part of the question about how total net revenue changed. (2) All percentages are accurate and correctly attributed to the right time periods. There are no calculation errors. The phrasing 'declined by 38.5% in 2023' is slightly ambiguous—it could be misinterpreted as the decrease occurring within 2023 rather than from 2022 to 2023—but in context, it is clear and aligns with the ground truth. (3) The multi-hop reasoning is sound: the model correctly synthesizes year-over-year percentage changes across two periods. The entities (Restasis, United States, net revenue, years) are accurate. (4) The answer is highly factually accurate and contextually appropriate, but loses one point on completeness for omitting the actual revenue figures, which were explicitly provided in the ground truth and requested in the question. Hence, correctness is 9/10, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1104,
        "completion_tokens": 351,
        "total_tokens": 1455
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has the role and strategic importance of Master Lease Agreements evolved between 2022 and 2023 in supporting AMT's international growth and tenant relationships?",
      "original_answer": "In 2022, AMT emphasized that master lease agreements were comprehensive in nature and instrumental in building strong strategic partnerships with tenants, significantly reducing colocation cycle times and enabling rapid deployment of equipment across its international portfolio of approximately 177,000 communications sites. By 2023, AMT reiterated the importance of these agreements in providing consistent, long-term revenue and reducing non-contractual churn, while operating an expanded international portfolio of approximately 182,000 communications sites. The evolution reflects a continued strategic focus on leveraging master lease agreements to support international growth and tenant retention, with an emphasis on mitigating risks such as customer consolidation and regulatory changes.",
      "llm_answer": "Master Lease Agreements have become a more central strategic lever between 2022 and 2023, enabling AMT to lock in long‑term, escalation‑linked revenue across its international portfolio while reducing churn risk.  The 2023 filing highlights that these comprehensive MLAs now underpin the bulk of the company’s growth—especially in emerging markets—by providing stable, multi‑year terms that support continued site‑level expansions and the rollout of 4G/5G infrastructure, thereby reinforcing AMT’s international growth agenda and deepening tenant relationships.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent with the ground truth in terms of the strategic role of Master Lease Agreements (MLAs) in supporting AMT's international growth and tenant relationships, and no incorrect numbers are presented (quantitative accuracy is perfect, as no specific figures were contradicted). The answer correctly identifies the increased strategic importance of MLAs in reducing churn, securing long-term revenue, and enabling infrastructure rollouts (e.g., 4G/5G), which aligns with the original answer's emphasis on long-term revenue stability and tenant retention. However, the LLM omits key quantitative details from the original answer: the size of AMT’s international portfolio (177,000 sites in 2022 and 182,000 in 2023) and the specific mention of reduced colocation cycle times and risk mitigation (e.g., customer consolidation, regulatory changes). While the LLM captures the general evolution toward greater strategic use of MLAs, it does not explicitly note the expansion of the site portfolio or the continuity of emphasis between years, which are central to the multi-hop comparison across 2022 and 2023. The reasoning is sound but incomplete—synthesis across years is implied but not fully articulated. Contextual relevance is high, as the response directly addresses the question’s focus on strategic evolution and tenant relationships.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 378,
        "total_tokens": 1723
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has the role of Google Marketing Platform in the company's advertising revenue generation evolved between 2023 and 2024, particularly in relation to how advertising revenues are recognized and managed across Google Network properties?",
      "original_answer": "In 2023, Google Marketing Platform was directly involved in the recognition of advertising revenues on a gross basis for Google Network properties, meaning the full amount billed to customers was recorded as revenue. By 2024, the platform's role evolved to include a more nuanced evaluation of its principal versus agent status, with an emphasis on its control over advertising inventory before transfer to customers, further supporting the gross revenue reporting. Additionally, 2024 introduced a more detailed explanation of the platform's role in managing advertising across Google Network properties, highlighting its central function in both performance and brand advertising delivery.",
      "llm_answer": "The role of Google Marketing Platform (GMP) in advertising revenue generation has expanded significantly between 2023 and 2024, particularly as a key channel for delivering ads on Google Network properties. According to the 10-K disclosures, advertising revenues are recognized on a gross basis when we act as the principal (i.e., control advertising inventory before transferring to customers), and GMP platforms—including Google Ads, Ad Manager, and Display & Video 360—are central to this model. Revenues from performance advertising are recognized upon user engagement, while brand advertising revenues are recognized upon ad display, with GMP enabling scalable, integrated campaign management across Google’s ecosystem. This structure supports gross revenue recognition of ads placed on Google Network properties, where we retain control over pricing and inventory, directly contributing to the growth in advertising revenues observed in 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that Google Marketing Platform (GMP) supports gross revenue recognition for Google Network properties, which is consistent with the 2023–2024 evolution described in the original answer. The explanation of gross revenue recognition based on principal status—specifically control over inventory, pricing, and customer relationships—is factually correct and reflects the core accounting principle discussed. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or ground truth, so quantitative accuracy is not applicable in that sense, but all referenced concepts (e.g., timing of revenue recognition for performance vs. brand advertising) are correctly stated and consistent with standard 10-K disclosures. (3) The multi-hop reasoning is sound: the LLM synthesizes the role of GMP in revenue recognition, ties it to principal-agent evaluation, links it to specific platforms (Google Ads, Ad Manager, DV360), and connects it to advertising types and timing of revenue recognition—demonstrating strong qualitative accuracy. (4) The only minor shortcoming is that the LLM does not explicitly state that this nuanced principal-agent evaluation and emphasis on control became more pronounced in 2024 compared to 2023, which was a key point in the original answer about the evolution of GMP’s role. However, the implication is present through context. Overall, the answer is semantically equivalent, highly relevant, and factually correct, warranting a 9/10 for correctness and qualitative accuracy, with perfect scores for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1432,
        "completion_tokens": 462,
        "total_tokens": 1894
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How did the volume and fair value of Federal Funds Purchased & Sec Loaned change between 2023 and 2024, and what does this indicate about BAC's short-term funding strategies?",
      "original_answer": "In 2023, the volume of Federal Funds Purchased & Sec Loaned showed a net change of $16,466 million, indicating a significant increase in short-term funding liabilities. By 2024, the fair value of this category was reported at $192,859 million, a substantial increase from the prior year. This suggests that BAC significantly expanded its reliance on short-term secured funding mechanisms in 2024, likely to support its trading and liquidity management activities.",
      "llm_answer": "Between 2023 and 2024, Federal Funds Purchased increased from $301,015 million to $481,896 million (a $180,881 million rise), while the fair value of these purchases rose from $178,609 million to $192,859 million (an increase of $14,250 million). Conversely, Securities Loaned/ Sold under agreements to repurchase declined from $214,369 million to $570,236 million in volume, but its fair value also fell from $178,609 million to $192,859 million (a $14,250 million increase) – reflecting the same valuation adjustment. The net effect is a substantial expansion in the volume of Federal Funds Purchased and a modest rise in their fair‑value measurement, indicating that Bank of America is relying more heavily on short‑term wholesale funding (Federal Funds) while using fewer securities‑loan transactions, and is managing the associated fair‑value risk through credit‑risk adjustments and valuation allowances. This shift suggests a strategic emphasis on higher‑volume, short‑term borrowing to support liquidity and funding needs amid changing market conditions.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2023, the net change in volume was $16,466 million — not the massive increases cited in the LLM response. The LLM incorrectly states that Federal Funds Purchased increased from $301,015 million to $481,896 million, which is unsupported by the original answer. Similarly, it claims Securities Loaned declined from $214,369 million to $570,236 million — a contradiction (decline to a higher number), and the fair value change is misrepresented as falling from $178,609 million to $192,859 million while also calling it a $14,250 million increase, which is numerically inconsistent. The original answer only states that the 2024 fair value was $192,859 million, with no mention of 2023 fair value or volume breakdowns by component. (2) Calculations are flawed: the LLM computes a $180,881 million rise in Federal Funds Purchased, but this figure is not in the ground truth; the only volume change mentioned is a net $16,466 million. The $14,250 million fair value increase is fabricated — the original does not provide 2023 fair value to support this delta. (3) Multi-hop reasoning fails: the LLM invents granular data (e.g., separate figures for Federal Funds Purchased and Securities Loaned) that are not in the source, and misattributes valuation changes. The original answer treats 'Federal Funds Purchased & Sec Loaned' as a combined category with a net volume change and a 2024 fair value, not separate components. (4) Despite incorrect numbers and reasoning, the LLM correctly infers a strategic shift toward short-term funding, which aligns with the qualitative conclusion in the original answer, earning partial credit for contextual relevance. However, the severe quantitative and factual errors undermine the correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 499,
        "total_tokens": 1887
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has PepsiCo's disclosure regarding the sensitivity of pension and retiree medical plan liabilities to market fluctuations evolved between 2022 and 2024?",
      "original_answer": "In 2022, PepsiCo mentioned that the exposure of pension and retiree medical plan assets and liabilities to risks related to market fluctuations was discussed in 'Our Critical Accounting Policies and Estimates.' By 2024, the company expanded this disclosure, explicitly linking the sensitivity of these liabilities not only to market fluctuations but also to inflationary, deflationary, and recessionary conditions. This broader context indicates a more detailed characterization of the macroeconomic risks affecting these obligations, beyond just market volatility.",
      "llm_answer": "Between 2022 and 2024, PepsiCo’s disclosures on pension and retiree medical plan liabilities shifted from a brief mention of market‑sensitivity in the 2022 filing (page 38‑39) to a more detailed discussion of how market fluctuations affect these liabilities in the 2024 filing (page 41‑42). In 2024, the company explicitly notes that pension and retiree medical plan assets and liabilities are exposed to market risks such as commodity price, foreign‑exchange, and interest‑rate changes, and it quantifies the potential impact of a 10% adverse move in underlying rates (e.g., a $32 million decrease in net interest expense from a 1‑percentage‑point rise in rates). Earlier disclosures did not provide such quantitative sensitivity analysis or link the liabilities to broader market‑risk frameworks.",
      "correctness_score": 5,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general direction of increased disclosure detail from 2022 to 2024, which aligns with the ground truth, and correctly identifies that the 2024 filing includes more explicit discussion of market risks (e.g., interest rates, foreign exchange). However, it introduces significant factual inaccuracies. First, the quantitative claims—such as a '$32 million decrease in net interest expense from a 1-percentage-point rise in rates'—are not supported by the ground truth and misrepresent the nature of the sensitivity (which pertains to pension and retiree medical liabilities, not net interest expense). The ground truth does not mention any specific dollar impacts or a 10% adverse move analysis, so these numbers are fabricated or misattributed. Second, while the LLM emphasizes market-risk categories like commodity prices and foreign exchange, the ground truth highlights that the 2024 expansion focused on linking liabilities to inflationary, deflationary, and recessionary conditions—not the specific market-risk types cited. Thus, the qualitative shift described in the LLM answer diverges from the actual evolution in disclosures. The reasoning is partially sound in identifying a trend toward greater detail, but the multi-hop synthesis fails because it conflates different types of risk disclosures and invents quantitative sensitivity analyses not present in the original answer. Contextually, the response is relevant and structured appropriately, but the incorrect numbers and mischaracterization of the expanded disclosures significantly undermine factual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 436,
        "total_tokens": 1779
      },
      "error": null
    },
    {
      "question_id": 1,
      "question": "How has Adobe's approach to Adobe Scan evolved between 2023 and 2024, particularly in terms of its positioning within Adobe's broader document management ecosystem?",
      "original_answer": "In 2023, Adobe Scan was positioned as a free mobile scanning tool that converts paper documents into editable, searchable PDFs via Adobe Document Cloud services, emphasizing its utility for individual users. By 2024, Adobe Scan remained part of Adobe Document Cloud, but the broader ecosystem placed increased emphasis on integration with cloud-based productivity tools and AI-driven features like Content Credentials and Firefly-powered generative AI workflows, indicating a shift toward deeper integration within enterprise document workflows and enhanced digital trust mechanisms.",
      "llm_answer": "Adobe Scan has evolved from a standalone mobile scanning app into a tightly integrated component of Adobe Document Cloud and the broader Adobe Experience Platform ecosystem. In 2023, it remained a free mobile tool for creating searchable PDFs, but by 2024 it was positioned as part of Adobe's AI-powered document workflow, with deeper integration into Acrobat AI Assistant and Real-Time Customer Data Platform capabilities. This shift aligns with Adobe's broader strategy to unify document management with customer experience tools, enabling scanned documents to leverage unified customer profiles and AI-driven insights across Adobe's Experience Cloud offerings. The service now emphasizes seamless connection with Adobe's AI and analytics platforms rather than operating as a discrete scanning utility.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: Adobe Scan was a free mobile scanning tool in 2023 integrated with Adobe Document Cloud, and by 2024 it was more deeply embedded in AI-enhanced workflows. The mention of Acrobat AI Assistant and AI-driven features like Firefly and Content Credentials (implied through 'AI-powered document workflow') is consistent with Adobe's 2024 direction. (2) There are no numeric values to verify, so quantitative accuracy is 10. (3) The reasoning is sound and reflects multi-hop synthesis: the model correctly infers a strategic shift from a standalone utility to an integrated component within broader cloud and AI platforms. The reference to Real-Time CDP and Experience Cloud is contextually appropriate and reflects accurate entity mapping, though slightly more expansive than the original answer. (4) The LLM adds a layer about integration with customer experience tools and unified profiles, which is plausible given Adobe’s strategy but not explicitly stated in the ground truth—this slight extrapolation prevents a perfect 10 but does not undermine correctness. Overall, the answer captures the evolution in positioning accurately and with strong contextual and qualitative fidelity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 359,
        "total_tokens": 1710
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has Gemini's role and integration across Google's products evolved from its initial launch in 2023 to 2024, and what specific advancements were made in its multimodal capabilities?",
      "original_answer": "In 2023, Gemini was introduced as a multimodal AI model capable of understanding and operating across different types of information, including text, code, audio, images, and video. It was intended to be leveraged across Alphabet to enhance product experiences. By 2024, Gemini had evolved significantly, with the launch of Gemini 2.0, which became the most capable model yet. It was integrated into all seven of Google's two billion-user products—Android, Chrome, Gmail, Maps, Play Store, Search, and YouTube—powering AI features across these platforms. Additionally, in 2024, Gemini was used in experimental research prototypes such as Project Astra and Project Mariner, showcasing broader and more advanced applications than in 2023.",
      "llm_answer": "From its 2023 launch, Gemini was positioned as Google’s native multimodal model, initially powering AI features across Search, YouTube, Android, Chrome, Gmail, Maps, Play Store and YouTube, and later expanded to all seven of Google’s two‑billion‑user products. In 2024 Google released Gemini 2.0, its most capable multimodal model yet, which can understand and combine text, code, audio, images and video, and it is now used to drive new AI experiences such as Project Astra (a universal AI assistant) and Project Mariner (a Chrome‑extension prototype), as well as Gemini for Google Cloud, Vertex AI, and integrated tools like Duet AI in Workspace. These updates reflect a shift from Gemini’s initial rollout to a broader, more advanced, and responsibly‑focused multimodal platform that underpins Google’s AI‑first strategy across its products and services.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, all key facts are correct: Gemini launched in 2023 as a multimodal model; in 2024, Gemini 2.0 was released as the most capable model; it was integrated into all seven of Google's two-billion-user products (Android, Chrome, Gmail, Maps, Play Store, Search, YouTube). The mention of Project Astra and Project Mariner as 2024 experimental prototypes is accurate. (2) The LLM correctly identifies the evolution from 2023 to 2024 and the advancements in multimodal capabilities (text, code, audio, images, video). (3) Minor inaccuracy: the LLM states Gemini initially powered AI features across all seven products at launch in 2023, but the ground truth implies broader integration occurred by 2024, not at initial launch. This overstates the 2023 integration. (4) The LLM adds extra details not in the ground truth (e.g., Duet AI in Workspace, Vertex AI, Gemini for Google Cloud), which are plausible but not confirmed in the provided truth. These do not contradict but slightly extend the scope. (5) Multi-hop reasoning is sound—correctly synthesizing timeline, product integration, model version upgrade, and research applications. (6) Semantic equivalence is high; wording differs but meaning matches. The answer is contextually relevant and fully addresses both parts of the question. Deducted 1 point for overstating initial 2023 integration scope.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1407,
        "completion_tokens": 397,
        "total_tokens": 1805
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How has Linde's relationship with helium evolved between 2022 and 2024, particularly in terms of its impact on sales and operating profit?",
      "original_answer": "In 2022, helium was listed as a supply for Linde, indicating a positive or neutral relationship. However, by 2024, the relationship had evolved, and helium was reported to negatively impact the company. Specifically, in 2024, lower volumes in global helium contributed to a 2% decrease in sales for the 'Other' segment, which includes global helium wholesale. Additionally, higher costs due to helium partially offset an insurance recovery for Linde Advanced Materials Technology (LAMT), limiting the operating profit growth in that segment despite a 44% overall increase in operating profit for 'Other'.",
      "llm_answer": "Linde's helium-related sales and operating profit trends show mixed impacts across segments and years. In 2021, helium was part of the \"Other\" segment (including global helium wholesale), where sales decreased 2% in 2024 versus 2023 due to lower volumes, but operating profit increased 44% driven by insurance recoveries partially offset by higher helium costs. The Engineering segment (which includes helium-related equipment projects) saw operating profit decline 16% in 2024 versus 2023, primarily due to reduced margins from sanctions-related project wind-downs in Russia, though sales rose 8% from project timing. Overall, helium's direct financial impact appears limited to specific segments, with no consistent positive or negative trend across 2022–2024, as helium-related activities are embedded within broader segment performance metrics rather than isolated in the provided data.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies and omissions compared to the ground truth. It incorrectly references 2021 data, which is outside the 2022–2024 scope of the question. The 2% sales decrease due to lower helium volumes in 2024 is correctly mentioned but misattributed to a comparison between 2024 and 2023 without clarifying that the ground truth does not specify a year-over-year comparison but rather a 2024 impact. The 44% operating profit increase in the 'Other' segment is mentioned, but the LLM incorrectly attributes it primarily to insurance recoveries without emphasizing that higher helium costs partially offset this recovery, which is a key point in the original answer. Additionally, the LLM introduces the Engineering segment and sanctions-related project wind-downs in Russia, which are not mentioned in the ground truth and are irrelevant to the helium impact question. (2) Quantitatively, the 2% sales decrease and 44% operating profit increase are present, but the context is distorted. The LLM implies these are 2024 vs 2023 changes, while the ground truth does not specify a comparative period, only that these effects occurred in 2024. The introduction of an 8% sales increase and 16% operating profit decline in Engineering is unsupported by the original answer and introduces false data. (3) The multi-hop reasoning is flawed: the model fails to trace the evolution of Linde's relationship with helium from neutral/positive in 2022 to negative in 2024, which is central to the question. Instead, it focuses on segment-level performance without synthesizing the shift in helium's role over time. The mention of helium being embedded in broader segments, while possibly true, downplays the specific negative impact highlighted in the ground truth. (4) The contextual relevance is moderate because the answer discusses helium in Linde’s business and cites relevant segments, but it introduces unrelated segments and timeframes, reducing accuracy. The core evolution of the helium relationship and its specific financial impacts are not clearly conveyed, leading to a partially correct but misleading response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 577,
        "total_tokens": 1949
      },
      "error": null
    },
    {
      "question_id": 2,
      "question": "How did the net value of acquired franchise rights evolve from 2022 to 2024, and what was the magnitude of this change?",
      "original_answer": "In 2022, the net value of acquired franchise rights was $789 million, while in 2024 it decreased to $598 million. This represents a significant decline in value over the two-year period.",
      "llm_answer": "The net value of acquired franchise rights declined modestly from $1,858 million in 2022 to $1,891 million in 2023 and then to $1,858 million in 2024, reflecting a $33 million decrease from 2022 to 2023 and a $33 million increase from 2023 to 2024, for a net change of essentially zero over the two‑year period.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is almost entirely incorrect in terms of factual content. The ground truth states that the net value of acquired franchise rights decreased from $789 million in 2022 to $598 million in 2024, representing a decline of $191 million over two years. In contrast, the LLM claims values of $1,858 million in 2022, $1,891 million in 2023, and $1,858 million in 2024, which are more than double the correct figures and show a completely different trend. (2) The numbers provided by the LLM are factually wrong—$1,858M and $1,891M do not match the ground truth of $789M and $598M. The calculation of a $33 million decrease followed by a $33 million increase leading to a net zero change is internally consistent but based on false inputs, making the entire quantitative analysis invalid. (3) The multi-hop reasoning is flawed because the model fails to retrieve the correct values for the correct years and appears to confuse the metric or company entirely. There is no evidence of correct synthesis across time periods or documents. (4) The contextual relevance is low but not zero because the LLM attempts to address the evolution of franchise rights over time and calculates changes, which aligns with the question's intent. However, due to massive factual inaccuracies in numbers, years, and trends, the answer is substantively wrong. Correctness and quantitative accuracy are severely compromised, warranting a score of 1.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1117,
        "completion_tokens": 400,
        "total_tokens": 1518
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did Chevron's natural gas delivery commitments and production volumes related to Tengizchevroil evolve from 2023 to 2024?",
      "original_answer": "In 2023, Chevron reported that its natural gas volumes included 596 million cubic feet per day consumed in operations and 7,148 million cubic feet per day as sold, which included its share from Tengizchevroil in Kazakhstan. By 2024, these figures increased to 609 million cubic feet per day consumed and 7,569 million cubic feet per day as sold, indicating a growth in both operational consumption and market delivery. This reflects an increase in Chevron’s involvement and dependency on Tengizchevroil for natural gas production and delivery commitments.",
      "llm_answer": "Chevron’s natural‑gas delivery commitments and production volumes related to Tengizchevroil have remained stable year‑over‑year.  In 2024 the company continued to meet its contractual obligations to deliver natural gas from the Tengizchevroil project (primarily through its share of the Kazakhstan operation), while overall company‑wide natural‑gas production rose modestly, reflecting continued output from that asset alongside other upstream projects.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both quantitative and qualitative aspects. It claims Chevron's natural gas delivery commitments and production volumes related to Tengizchevroil 'remained stable year-over-year,' which directly contradicts the ground truth showing clear increases from 2023 to 2024. The actual data shows natural gas consumed in operations rose from 596 to 609 million cubic feet per day, and gas sold increased from 7,148 to 7,569 million cubic feet per day — significant growth that the LLM fails to acknowledge. (2) There are no correct numbers mentioned in the LLM response; it omits all specific volumes for both years and provides no accurate quantitative comparison. This results in a very low quantitative accuracy score. (3) The reasoning is flawed: while the LLM correctly identifies Tengizchevroil in Kazakhstan as a source of natural gas production for Chevron, it fails to perform the necessary multi-hop synthesis of year-over-year data to detect the increase. Instead, it asserts stability and vaguely references 'modest' overall production growth without linking it to Tengizchevroil-specific trends. (4) Contextual relevance is moderate because the answer addresses Chevron, Tengizchevroil, natural gas production, and delivery commitments — all relevant topics — but misses the core evolution aspect of the question. The conclusion about 'continued output' lacks support from actual comparative data, leading to a low correctness score due to factual inaccuracy and omission of key metrics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1246,
        "completion_tokens": 425,
        "total_tokens": 1671
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has the role of Google Network partners in Google's advertising revenue model evolved between 2023 and 2024, based on changes in the way payments to these partners are described?",
      "original_answer": "In 2023, Google Network partners were described as part of the primary uses of cash from operating activities, specifically noting payments made to these partners as a standard operating expense. By 2024, the description evolved to categorize payments to Google Network partners under Traffic Acquisition Costs (TAC), explicitly linking them to ads displayed on partner properties and tying them directly to revenue generation. This shift indicates a more strategic and performance-based dependency on these partners within the advertising ecosystem.",
      "llm_answer": "The role of Google Network partners in Google's advertising revenue model has shifted from being treated as a cost of revenue (where payments to partners were recorded as cost of revenues) to being recognized as a revenue-sharing component that directly contributes to gross advertising revenue, reflecting a change in how payments are accounted for in the revenue recognition process. This evolution is evident in the 2024 filing's detailed explanation of how Google evaluates its role as principal or agent in ad inventory on Network properties, emphasizing control over monetization and pricing discretion as the basis for gross revenue reporting.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains no numeric values, dates, or calculations, so quantitative accuracy is not applicable—however, since no numbers were misstated, it does not detract, warranting a score of 10 by default. Qualitatively, the answer is significantly flawed: it incorrectly claims that payments to Google Network partners shifted from being recorded as 'cost of revenue' to a 'revenue-sharing component' affecting gross revenue reporting. The ground truth states that in 2023, payments were described as a standard operating expense under cash flow from operations, and in 2024, they were re-categorized under Traffic Acquisition Costs (TAC), tied to ad revenue generation. The LLM misrepresents the accounting treatment—TAC is an operating expense, not a cost of revenue or a gross revenue recognition issue. The shift described in the LLM answer conflates revenue recognition principles (principal vs. agent) with expense classification, which is not supported by the ground truth. While the answer addresses the evolution in description and attempts multi-hop reasoning around accounting changes, it fundamentally mischaracterizes the nature of the change—failing to identify the correct categorization (operating cash flow → TAC) and introducing incorrect concepts (cost of revenue, gross revenue reporting). Contextually, it remains relevant to the question’s focus on evolving payment descriptions, but the reasoning and factual basis are unsound, leading to a low correctness score despite relevant framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 415,
        "total_tokens": 1724
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has the impact of public policies on Bank of America's climate-related regulatory requirements evolved from 2023 to 2024, particularly in terms of jurisdictional divergence and compliance risks?",
      "original_answer": "In 2023, Bank of America highlighted increasing global regulatory focus on climate change, noting that new or heightened regulatory requirements across state, federal, and non-U.S. jurisdictions were expected to increase legal, compliance, and public disclosure risks and costs. The company specifically mentioned jurisdictional divergence as a challenge. By 2024, this concern intensified, with the company noting that existing and pending disclosure requirements in various jurisdictions, along with jurisdictional divergence, were now actively impacting legal, compliance, and public disclosure risks and costs. This indicates a shift from anticipation of increased risk to experiencing tangible impacts due to evolving public policies.",
      "llm_answer": "From 2023 to 2024 the regulatory landscape governing climate‑related matters shifted markedly.  In the 2023 filing the company highlighted “complex and evolving LRRs” and the risk that differing interpretations of privacy, data‑protection and climate‑related rules could create jurisdictional conflict, while also noting that divergent stakeholder views could harm its reputation.  By the 2024 filing the discussion expands to “increasing global regulatory focus… with jurisdictional divergence” that is expected to raise legal, compliance and disclosure costs, and it stresses that any action—or inaction—on climate goals may be perceived negatively by stakeholders, amplifying reputational risk.  Consequently, the impact of public policies on Bank of America’s climate‑related regulatory requirements grew more pronounced, with greater exposure to divergent jurisdictional rules and heightened compliance and reputational risks.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general trend of increasing regulatory pressure and jurisdictional divergence from 2023 to 2024, and correctly identifies heightened compliance and reputational risks, which aligns with the original answer. However, there are key inaccuracies in the qualitative reasoning that reduce correctness. First, the LLM incorrectly states that in 2023, Bank of America highlighted 'complex and evolving LRRs' and risks around 'privacy, data-protection and climate-related rules' creating jurisdictional conflict—this misrepresents the source. The original answer does not mention privacy or data protection in this context, nor the term 'LRRs' (which is undefined and potentially misleading). Instead, the 2023 filing specifically noted increasing global regulatory focus and *anticipated* increased risks due to jurisdictional divergence. The 2024 update correctly notes that these risks are now *actively impacting* costs and compliance, indicating a shift from expectation to realization. The LLM answer fails to clearly convey this critical evolution—from anticipated to actual impact—which is the core of the original answer. Additionally, while reputational risk is mentioned in the LLM response, the original emphasizes legal, compliance, and disclosure risks, not reputational harm, as the primary consequences. Thus, the reasoning is partially flawed in attributing emphasis to reputational risk and introducing unrelated regulatory domains. Quantitatively, there are no numbers, so accuracy is not compromised. Contextually, the response is relevant and addresses the question's scope. Overall, the answer is directionally correct but lacks precision in entity-specific reasoning and misattributes some risks, warranting a moderate score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1430,
        "completion_tokens": 478,
        "total_tokens": 1908
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has General Motors' strategic emphasis on full-size pickup trucks evolved from 2022 to 2024, and what quantitative indicators in 2024 suggest a shift toward stronger performance and market positioning for this product line?",
      "original_answer": "In 2022, General Motors identified the success of its full-size SUVs and full-size pickup trucks as a key risk factor, indicating that their performance was critical to the company's competitive position and financial health. By 2024, this strategic emphasis had evolved into a demonstrated strength, as evidenced by a significant increase in net wholesale volumes driven by higher sales of full-size pickup trucks. Additionally, the 2024 report highlights that full-size pickup trucks contributed favorably to the company's EBIT-adjusted results, with a variable profit of approximately 160% for trucks on a weighted-average basis, reflecting improved profitability and market demand for this product line.",
      "llm_answer": "From 2022 to 2024 GM’s strategy shifted toward emphasizing its full‑size pickup trucks, as evidenced by GMNA’s 2024 results showing a 10.1% rise in wholesale truck sales and a 18.1% increase in EBIT‑adjusted, driven by higher volumes of full‑size pickups and SUVs and favorable pricing. Quantitative indicators in 2024—such as a 11.4% increase in GMNA net sales (including $12.8 billion from higher truck volumes) and an 18.1% rise in EBIT‑adjusted to $14.5 billion—demonstrate stronger performance and market positioning for this product line.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer includes several specific quantitative figures—such as a 10.1% rise in wholesale truck sales, 11.4% increase in GMNA net sales, $12.8 billion from higher truck volumes, and an 18.1% rise in EBIT-adjusted to $14.5 billion—that are not present in the original ground truth answer. These numbers, while plausible, cannot be verified against the provided truth and appear to be hallucinated or sourced from external data not in the knowledge graph. The ground truth emphasizes a 'significant increase in net wholesale volumes' and a 'variable profit of approximately 160% for trucks on a weighted-average basis,' which the LLM answer omits entirely. (2) The calculation of EBIT-adjusted rising to $14.5 billion is a precise figure not mentioned in the original, and the $12.8 billion attributed to truck volume increases lacks corroboration. The ground truth does confirm favorable contribution to EBIT-adjusted and higher sales volumes, but without specific dollar amounts or percentages tied solely to trucks. (3) The qualitative reasoning is sound: the LLM correctly identifies a strategic shift from risk (2022) to strength (2024) and links increased truck sales to improved financial performance, demonstrating multi-hop synthesis between strategic emphasis and financial outcomes. It correctly identifies GMNA (General Motors North America) as the relevant segment. (4) Contextually, the answer is highly relevant and addresses both parts of the question—evolution of strategy and 2024 performance indicators. However, the inclusion of unverified, specific quantitative data significantly undermines factual accuracy, warranting a moderate correctness score. While the directionality and strategic narrative align with the truth, the lack of fidelity in numbers reduces confidence in the response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1333,
        "completion_tokens": 496,
        "total_tokens": 1829
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How did the allocation to U.S. Treasury and government agency securities within the nuclear decommissioning trusts evolve from 2022 to 2024, and what does this shift indicate about the company's investment strategy?",
      "original_answer": "In 2022, the allocation to U.S. Treasury and government agency securities was $21 million for Alabama Power and $293 million for Georgia Power. By 2024, this allocation decreased slightly to $20 million for Alabama Power but increased significantly to $349 million for Georgia Power. The overall trend shows a shift in focus toward Georgia Power’s portfolio, indicating a possible reallocation of safer, fixed-income assets to that subsidiary.",
      "llm_answer": "The allocation to U.S. Treasury and government agency securities within the nuclear decommissioning trusts increased from $20 million at December 31, 2023 to $9 million at December 31, 2024 (reflecting a shift toward higher‑quality, lower‑risk assets), indicating that the company is progressively de‑risking its trust investments and emphasizing greater liquidity and capital preservation.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is almost entirely incorrect in terms of factual content. It reports allocations for 2023 and 2024 as $20 million and $9 million, respectively, which do not match the ground truth. The ground truth states that in 2022, Alabama Power had $21 million and Georgia Power had $293 million, and by 2024, these were $20 million and $349 million, respectively. The LLM answer omits Alabama Power and Georgia Power entirely, misrepresents the years (using 2023 instead of 2022), and fabricates a decrease to $9 million in 2024 when the actual combined allocation increased significantly due to Georgia Power’s rise. (2) Quantitative inaccuracies are severe: the LLM claims a decrease from $20M to $9M, while the truth shows a slight decrease in Alabama Power’s allocation and a large increase in Georgia Power’s—from $293M to $349M. There is no mention of the $9 million figure in the ground truth. (3) The multi-hop reasoning is completely flawed. The question requires comparing allocations across two subsidiaries (Alabama Power and Georgia Power) over two years (2022 to 2024), but the LLM fails to identify either entity, uses incorrect years, and draws conclusions from non-existent data. The inference about de-risking and liquidity, while plausible in isolation, is not supported by the actual data pattern and is based on false premises. (4) The contextual relevance is low but not zero—the topic of investment strategy in nuclear decommissioning trusts is relevant, and the general idea of shifting toward safer assets is in the right domain, but the answer fails on all key dimensions of correctness, completeness, and entity accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1225,
        "completion_tokens": 455,
        "total_tokens": 1681
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has PepsiCo's relationship with independent bottlers evolved from 2022 to 2024 in terms of financial incentives and strategic dependency?",
      "original_answer": "In 2022, PepsiCo provided sales incentives and discounts to independent bottlers primarily through funding of advertising and other marketing activities, with accruals based on annual targets and historical experience. By 2024, the company's relationship had evolved into a more structured dependency, with bottler funding negotiated annually and specifically allocated across trade and consumer programs such as advertising support, new product launches, and vending equipment placement. Additionally, in 2024, sales through independent bottlers contributed to a significant portion of revenue, with Walmart alone accounting for approximately 14% of consolidated net revenue, highlighting increased strategic dependency on these bottlers.",
      "llm_answer": "From 2022 to 2024, PepsiCo’s relationship with independent bottlers evolved from a model centered on financial incentives and strategic dependency toward greater integration and sustainability focus. While bottler funding and volume-based rebates remained key tools to incentivize distribution and marketing support, the company increasingly tied these incentives to performance metrics and sustainability goals, such as reducing water use and advancing sustainable farming practices. This shift reflects a strategic move to align bottler partnerships with long-term brand and environmental objectives, reducing reliance on traditional volume-driven models while maintaining financial incentives for market expansion and product promotion.",
      "correctness_score": 3,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in terms of factual content. It introduces concepts not present in the ground truth, such as a 'sustainability focus', 'reducing water use', and 'sustainable farming practices', which are not mentioned in the original answer and are unsupported by the provided context. There is no mention in the ground truth about a shift toward sustainability goals or environmental objectives. Instead, the actual evolution described is from general marketing incentives in 2022 to more structured, annually negotiated funding allocations across specific programs (e.g., advertising, new product launches, vending equipment) in 2024. (2) Quantitatively, the LLM answer fails completely: it omits the key statistic that Walmart accounted for approximately 14% of PepsiCo’s consolidated net revenue in 2024 through independent bottlers—a central data point in the ground truth. No numbers are provided at all, making the quantitative accuracy very low. (3) The multi-hop reasoning is flawed. While the question requires synthesis across 2022 and 2024 regarding financial incentives and strategic dependency, the LLM invents a narrative not grounded in the source material. It does correctly identify that financial incentives (e.g., rebates, funding) are involved, but fails to accurately describe how they evolved—specifically, the shift to annual negotiations and targeted allocation of funds. The increased strategic dependency highlighted by the Walmart revenue contribution is entirely missing. (4) The contextual relevance is moderate because the answer addresses the general topic of PepsiCo’s relationship with bottlers and mentions financial incentives, but the qualitative inaccuracies and invented details severely undermine correctness. The answer sounds plausible but does not reflect the actual evolution documented in the knowledge graph.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1368,
        "completion_tokens": 511,
        "total_tokens": 1879
      },
      "error": null
    },
    {
      "question_id": 3,
      "question": "How has Adobe Firefly's role within Adobe's product innovation strategy evolved from 2023 to 2024, based on its positioning in the company's trademark listings and risk disclosures?",
      "original_answer": "In 2023, Adobe Firefly was listed among Adobe's trademarks, indicating it was an established product within the company's portfolio. By 2024, Adobe Firefly was specifically highlighted in the risk factors section as a newly released generative AI product, reflecting its strategic importance in Adobe's innovation efforts. This evolution shows a shift from being a registered brand to becoming a central part of Adobe's forward-looking product development and AI strategy, with explicit mention of its role in addressing market demands for generative AI capabilities.",
      "llm_answer": "Adobe Firefly's role has evolved from a nascent AI offering in 2023 to a central pillar of Adobe's innovation strategy by 2024, as evidenced by its explicit integration into risk disclosures and trademark listings. The company now frames Firefly as a strategic differentiator in its competitive positioning, emphasizing AI-driven product enhancements while highlighting associated risks like regulatory uncertainty and reputational exposure tied to AI-generated content. This shift underscores Adobe's commitment to embedding generative AI across its ecosystem, though it acknowledges the challenges of monetization, competition, and compliance in a rapidly evolving AI landscape.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly identifies the evolution of Adobe Firefly from 2023 to 2024 based on trademark listings and risk disclosures. In 2023, Firefly was a registered trademark, indicating its presence in Adobe's portfolio; by 2024, it was highlighted in risk factors as a newly released generative AI product—this shift is accurately captured in the LLM's description of Firefly becoming a 'central pillar' and being tied to strategic risks. The LLM adds contextual depth by referencing regulatory and reputational risks, which is consistent with typical risk disclosures for AI products and enhances the answer without introducing inaccuracies. There are no numeric values to verify, so quantitative accuracy is scored as 10 by default. The qualitative reasoning is sound and reflects correct multi-hop synthesis between trademark status and risk factor disclosure across years. The only minor gap is that the original answer emphasizes Firefly’s role in addressing market demand for generative AI, which the LLM implies but does not explicitly state—hence a 9 on qualitative accuracy. Contextual relevance is perfect: the response directly addresses the question’s focus on strategic evolution using the specified sources.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 358,
        "total_tokens": 1679
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the role of contractual rent escalations in driving tenant billing growth changed between 2022 and 2023, particularly in light of the increased churn and lease cancellations in 2023?",
      "original_answer": "In 2022, contractual rent escalations were highlighted as a key factor contributing to tenant billing growth, listed alongside new colocation activity and lease amendments. By 2023, while contractual rent escalations remained a stated driver of growth, the context shifted due to an elevated churn rate of approximately 3%, primarily in the U.S. & Canada segment. This churn, expected to remain elevated through 2025 due to T-Mobile's lease cancellations, introduced a countervailing force against the positive impact of rent escalations, suggesting a more challenging environment for maintaining organic revenue growth solely through escalations.",
      "llm_answer": "The role of contractual rent escalations in driving tenant billing growth has diminished between 2022 and 2023, as churn from lease cancellations and non-renewals—particularly in the U.S. & Canada segment due to T-Mobile’s actions—has become a more significant factor in revenue volatility. While escalations (typically ~3% annually) remain embedded in leases, the increased churn (3% of tenant billings in 2023 vs. ~4% in 2021) has offset some of the predictable growth from escalations, especially in India where regulatory uncertainty and carrier consolidation initially suppressed collections. However, the impact of churn has lessened in India as VIL began full payments in late 2023, and the company expects churn to stabilize, allowing escalations to regain relative importance in future growth.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the core idea that contractual rent escalations remained a driver of tenant billing growth but faced headwinds from increased churn in 2023, particularly due to T-Mobile's lease cancellations. However, it introduces several details not present in the ground truth. Notably, the claim that churn was '3% of tenant billings in 2023 vs. ~4% in 2021' is partially incorrect—the ground truth states that the elevated churn rate in 2023 was approximately 3%, primarily in U.S. & Canada, but does not compare it to 2021 or state that 2021 had ~4% churn. This misrepresents the trend and adds unsupported data. Additionally, the mention of India and VIL (Vodafone Idea Limited) and regulatory uncertainty is not present in the original answer and appears to be hallucinated or drawn from external knowledge not in the provided context. The ground truth does not mention India or any regional issues outside U.S. & Canada. (2) The quantitative accuracy is compromised by the inclusion of the 2021 churn figure (~4%) which is not in the original answer and cannot be verified from the given information. The ~3% annual escalation rate is plausible but not explicitly stated in the ground truth. (3) The reasoning correctly identifies the tension between rent escalations and churn as offsetting forces, which aligns with the multi-hop synthesis required. However, the model incorrectly extends the analysis to India and VIL, failing to limit the churn discussion to the U.S. & Canada and T-Mobile as specified in the ground truth. This undermines the qualitative accuracy despite sound logic in parts. (4) The contextual relevance is high because the answer addresses the central dynamic between escalations and churn, but the inclusion of irrelevant geographic and company-specific details (India, VIL) reduces precision. The correctness score is 5 due to partial factual alignment but significant addition of unsupported details and incorrect numerical comparisons.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1373,
        "completion_tokens": 537,
        "total_tokens": 1911
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has Chevron's (CVX) relationship with Tengizchevroil evolved between 2023 and 2024 in terms of capital expenditure commitments and production involvement?",
      "original_answer": "In 2023, Chevron indicated that nearly half of its Affiliate Capex, which was expected to be $3 billion in 2024, was allocated to Tengizchevroil's FGP/WPMP Project in Kazakhstan. By 2024, Chevron continued to highlight its production involvement with Tengizchevroil, noting that production volumes included Chevron's share from affiliates such as Tengizchevroil in Kazakhstan. While 2023 focused on capital commitments for project development, 2024 emphasized ongoing production contributions from the same entity, indicating a shift from investment to operational phase.",
      "llm_answer": "Between 2023 and 2024, Chevron’s capital expenditure commitments at Tengizchevroil remained focused on the FGP/WPMP project, with approximately $1.5 billion of the company’s $3 billion affiliate capital budget allocated to this initiative in Kazakhstan. Production involvement continued through ongoing development activities, as evidenced by net wells completed and drilling plans in the region, though specific 2024 capex figures for Tengizchevroil were not disclosed separately in the provided filings.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies that approximately half of Chevron's $3 billion affiliate capital expenditure (Capex) in 2024 was allocated to Tengizchevroil's FGP/WPMP project, translating to about $1.5 billion, which aligns with the ground truth stating 'nearly half' of the $3 billion. This quantitative estimate is reasonable and consistent with the original answer. However, the LLM does not explicitly state that this projection was made in 2023 for 2024, slightly weakening the temporal linkage. (2) The numbers are accurate in magnitude and context—$3 billion total affiliate Capex and ~$1.5 billion for Tengizchevroil are logically derived and consistent with 'nearly half.' No calculation errors are present. (3) The reasoning partially captures the multi-hop evolution: it notes continued involvement in production and development activities but misses the key conceptual shift emphasized in the ground truth—from a 2023 focus on capital commitments to a 2024 emphasis on operational production contributions. The LLM mentions 'ongoing development activities' and 'net wells completed' but does not clearly articulate the transition from investment to operational phase, which is central to the original answer. (4) Contextually, the response is highly relevant and well-structured, addressing both capital expenditure and production involvement. It falls short in fully synthesizing the strategic evolution between years, leading to a lower qualitative and overall correctness score despite strong quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1272,
        "completion_tokens": 424,
        "total_tokens": 1696
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has the specificity of UPS's bond matching approach evolved in determining the discount rate for U.S. pension and postretirement benefit plans between 2023 and 2024?",
      "original_answer": "In 2023, UPS described using a bond matching approach to select specific bonds that would satisfy projected benefit payments, emphasizing its belief that this method reflects the process they would employ to settle pension and postretirement obligations. By 2024, the language evolved to place stronger emphasis on the bond matching approach as a guide for selecting bonds that align with projected benefit cash flows, without any material change in the mechanics of the method. However, the 2024 disclosure included a more precise statement indicating that the approach 'guides' the selection process, suggesting a subtle shift in how the policy is framed operationally, even though the underlying practice remained consistent.",
      "llm_answer": "The specificity of UPS’s bond‑matching approach for setting the discount rate on its U.S. pension and postretirement obligations remained essentially unchanged between 2023 and 2024 – it continues to select individual bonds whose cash‑flows match the plans’ projected benefit payments, updating the assumptions annually. The only evolution is the use of the 2024‑year bond yields (resulting in a 5.88 % discount rate for 2024 versus 5.42 % in 2023), but the methodology and the bond‑matching process itself were not altered.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but misses a key qualitative nuance in the evolution of UPS's disclosure language between 2023 and 2024. (1) Quantitatively, the answer correctly states the 2023 and 2024 discount rates (5.42% and 5.88%), which aligns with ground truth expectations, earning high marks for numerical accuracy. (2) However, the original answer emphasizes a subtle but important shift in how UPS framed its bond matching approach — from a direct method of selecting bonds to satisfy obligations in 2023, to describing it as a 'guide' for selection in 2024, indicating a change in operational framing despite no mechanical change. The LLM answer incorrectly asserts there was 'no alteration' in methodology or process, thereby overlooking this discursive refinement. (3) While the core multi-hop element (comparing disclosures across years) is attempted, the reasoning fails to capture the semantic evolution in policy description, which is central to the question about 'specificity' of the approach. Specificity refers not only to mechanics but also to how precisely and operationally the method is described. (4) The answer remains contextually relevant and factually sound on the mechanics and rates, but the omission of the nuanced shift in language and framing reduces its qualitative accuracy and overall correctness, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 378,
        "total_tokens": 1697
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has Linde's relationship with helium evolved from 2022 to 2024, and what financial impact did this change have on the company's sales and operating profit during this period?",
      "original_answer": "In 2022, helium was a supply input for Linde, indicating a supportive role in operations. By 2024, helium had a negative impact on operations, with a $32 million, or 2%, decrease in sales for the Other segment primarily due to lower volumes in global helium and LAMT. Additionally, helium-related costs contributed to downward pressure on operating profit, partially offset by an insurance recovery for LAMT. This reflects a shift from a neutral or positive relationship to one that posed operational challenges.",
      "llm_answer": "From 2022 to 2024, Linde’s helium business shifted from being a major revenue driver to a marginal contributor, as helium sales declined in volume and pricing pressure intensified, while the company increasingly relied on higher‑margin industrial gases and specialty offerings. This transition contributed to a modest rise in overall sales (up about 1% in 2024 versus 2023) and a notable increase in operating profit, especially in the Engineering and APAC segments, where productivity gains and pricing improvements offset helium‑related cost inflation. Consequently, operating profit grew by roughly $300 million year‑over‑year, bolstering net income and cash flow despite the reduced emphasis on helium.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both factual content and direction of impact. The ground truth states that helium shifted from a supply input in 2022 to having a negative impact on sales and operating profit in 2024, specifically causing a $32 million (2%) decrease in sales in the Other segment due to lower volumes. In contrast, the LLM claims helium was a 'major revenue driver' that declined but still contributed to overall sales growth and significant operating profit increases — this contradicts the ground truth. The LLM also fabricates a $300 million year-over-year operating profit increase, which is not supported by the original answer and misrepresents the financial impact. (2) Quantitative inaccuracies include the invented $300 million profit growth and the claim of 1% sales growth in 2024 vs 2023, which is not mentioned or implied in the ground truth. The only partially correct element is the mention of cost pressure, but even this is framed as offset by gains in other segments, whereas the original answer emphasizes that helium costs created downward pressure on profit with only partial offset from insurance recovery. (3) The multi-hop reasoning fails: the model incorrectly infers that reduced emphasis on helium led to profit growth, while the ground truth shows helium became a drag on performance. It also misidentifies the role of helium — from input to liability — and does not mention the key segments affected (Other segment, LAMT). (4) Contextual relevance is moderate because the answer discusses Linde, helium, and financial performance over 2022–2024, but the conclusions are factually inverted. The qualitative accuracy is low due to incorrect entity relationships and flawed logic. Overall, the answer fabricates key financial figures and misrepresents the nature and impact of Linde's evolving helium relationship.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1312,
        "completion_tokens": 508,
        "total_tokens": 1820
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How did Bank of America's unfunded capital contributions for renewable energy investments evolve between 2023 and 2024, and what was the corresponding change in recognized tax credits related to these investments?",
      "original_answer": "In 2023, Bank of America had unfunded capital contributions for renewable energy investments of $6.2 billion, and it recognized tax credits and other tax benefits of $4.0 billion. By 2024, the unfunded capital contributions decreased to $4.6 billion, and the recognized tax credits slightly declined to $3.9 billion. This indicates a reduction in the Corporation's near-term funding commitments to renewable energy projects, even as the tax benefits remained relatively stable.",
      "llm_answer": "Based on the provided SEC 10-K pages, Bank of America's unfunded capital contributions for renewable energy investments **decreased** from $6.2 billion at December 31, 2023 to $4.6 billion at December 31, 2024. Correspondingly, the recognized tax credits related to these investments **decreased** from $4.0 billion in 2023 to $3.9 billion in 2024, as stated in the \"Tax Credit VIEs\" section on page 131. The decline in unfunded contributions reflects reduced contingent funding requirements, while the lower tax credit recognition aligns with the timing of renewable energy project energy production (PTCs) or inception (ITCs), which impacts the period in which benefits are recorded.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, all numbers and dates are accurate: unfunded capital contributions decreased from $6.2 billion in 2023 to $4.6 billion in 2024, and recognized tax credits declined from $4.0 billion to $3.9 billion. These values exactly match the original answer, with no calculation or formatting issues. (2) The answer is complete, addressing both parts of the question—the evolution of unfunded capital contributions and the corresponding change in tax credits. (3) Entity accuracy is correct: Bank of America is the subject, and the metrics (unfunded capital contributions, recognized tax credits) and years (2023 and 2024) are properly identified. (4) The reasoning is sound and adds contextual insight beyond the ground truth, correctly explaining that the decline in unfunded contributions reflects reduced contingent funding requirements and linking the tax credit changes to PTC/ITC timing, which demonstrates strong multi-hop synthesis and domain understanding. (5) The semantic meaning is equivalent to the original answer, with slightly more detailed explanation but no factual deviation. All evaluation criteria are fully satisfied.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1307,
        "completion_tokens": 343,
        "total_tokens": 1650
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has General Motors' approach to fleet sales involving commercial fleet customers evolved from 2022 to 2024, particularly in terms of sales channels and profitability considerations?",
      "original_answer": "In 2022, General Motors highlighted that fleet transactions, especially sales to daily rental car companies, were generally less profitable compared to retail sales, and these vehicles were sold either directly or through the dealer network. By 2024, the company emphasized that fleet sales, including those to commercial fleet customers, were completed through the dealer network and in some cases directly with fleet customers, suggesting a more structured and possibly optimized approach to fleet sales. This evolution indicates a strategic shift toward balancing fleet sales with profitability by leveraging both direct and dealer-based channels.",
      "llm_answer": "From 2022 to 2024, GM’s fleet sales strategy shifted from relying heavily on traditional wholesale fleet channels to a more controlled, channel‑focused approach. In 2022 the company reported that fleet sales represented about 11‑12% of total vehicle sales, but by 2024 the proportion had fallen to roughly 7‑8% of total sales, reflecting a deliberate reduction in low‑margin fleet transactions—especially sales to daily rental companies—and a greater emphasis on higher‑margin retail and commercial‑fleet customers through its dealer network. This evolution was driven by a focus on profitability, as GM moved away from volume‑driven fleet deals toward sales that better align with its EV and commercial‑vehicle growth objectives.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer includes several factual inaccuracies, particularly in quantitative claims. The ground truth does not mention specific percentages of fleet sales (e.g., 11-12% in 2022 or 7-8% in 2024), nor does it state that GM reduced fleet sales volume or shifted away from wholesale channels. These figures and characterizations are not supported by the original answer and appear to be fabricated or inferred beyond available evidence. (2) There are no verifiable calculations in the original answer to assess, but the LLM introduces precise percentages that are absent in the ground truth, making them incorrect by omission. The original answer focuses on channel structure and profitability comparisons, not sales volume trends. (3) The qualitative reasoning partially aligns with the ground truth: both note a strategic evolution toward profitability and mention use of dealer and direct channels for fleet sales. The LLM correctly identifies a shift toward higher-margin commercial fleet customers and links it to EV and commercial growth goals, which is a reasonable inference. However, the multi-hop synthesis is flawed because it invents metrics to support a narrative not fully present in the source. (4) The contextual relevance is high because the answer addresses the core themes—fleet sales evolution, channels, and profitability. The qualitative accuracy is moderate due to correct conceptual direction but unsupported specifics. The correctness score is reduced significantly due to unsupported numerical claims, even though the general strategic direction is plausibly interpreted.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1354,
        "completion_tokens": 442,
        "total_tokens": 1797
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How did PepsiCo's relationship with Sabra evolve between 2022 and 2024, and what financial implications were associated with this change?",
      "original_answer": "In 2022, PepsiCo owned the Sabra brand as part of its joint venture portfolio. However, by 2024, PepsiCo no longer had full ownership but instead held a 50% equity stake, which was remeasured at fair value, resulting in a pre-tax gain of $122 million. This indicates that PepsiCo divested a portion of its ownership in Sabra during the intervening period, marking a strategic shift in its relationship with the brand.",
      "llm_answer": "PepsiCo's relationship with Sabra evolved significantly between 2022 and 2024, marked by strategic divestitures and equity adjustments. In 2022, PepsiCo sold its Tropicana, Naked, and select juice brands to PAI Partners while retaining a 39% noncontrolling interest in a new joint venture operating across North America and Europe, which included Sabra's assets. This transaction generated a $3,029 million gain in PBNA and $292 million in Europe, reflecting the divestiture's financial impact. By 2024, PepsiCo recorded a $187 million pre-tax charge related to the Quaker Recall (unrelated to Sabra) and recognized a $13 million pre-tax credit in AMESA from adjustments to prior estimates, but no direct financial link to Sabra was noted in the 2024 disclosures. The 2022 sale marked the end of PepsiCo's direct ownership in Sabra, shifting to a minority stake in the joint venture, with no further material financial ties reported in 2023 or 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, PepsiCo owned Sabra as part of a joint venture in 2022 and by 2024 had a 50% equity stake, with a $122 million pre-tax gain from remeasurement. The LLM incorrectly states that PepsiCo sold Tropicana, Naked, and juice brands to PAI Partners in 2022 and retained a 39% stake in a new joint venture that included Sabra—this is factually wrong. The PAI transaction involved Tropicana and juice brands, not Sabra. Sabra was a separate joint venture with Strauss Group, and PepsiCo's ownership shift to 50% and the $122M gain are misaligned with the LLM's narrative. (2) Quantitative accuracy is poor: the LLM cites a $3,029 million gain in PBNA and $292 million in Europe, which relate to the Tropicana sale, not Sabra. It also mentions a $187M charge and $13M credit in 2024, which are unrelated to Sabra. The correct figure for Sabra in 2024 is a $122M pre-tax gain, which the LLM omits entirely. (3) Multi-hop reasoning fails: the model conflates two different transactions (Tropicana/PAI and Sabra/Strauss), incorrectly linking Sabra to the PAI deal. It does not correctly trace the evolution of PepsiCo’s stake in Sabra specifically. (4) Contextual relevance is moderate because the answer discusses PepsiCo’s joint ventures and divestitures, but it misattributes the financials and strategic moves to the wrong brand. The core of the question—Sabra’s ownership change and its financial impact—is inaccurately portrayed, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 428,
        "total_tokens": 1768
      },
      "error": null
    },
    {
      "question_id": 4,
      "question": "How has Adobe's treatment of Adobe Scan evolved between 2023 and 2024, particularly in terms of its positioning within Adobe's product ecosystem?",
      "original_answer": "In 2023, Adobe Scan was listed among Adobe's trademarks, indicating it was an established product within the company's portfolio. By 2024, Adobe Scan was explicitly positioned as part of Adobe Document Cloud, which includes Acrobat, Acrobat Sign, and other apps and API services that support digital document and signature workflows. This evolution shows a shift from mere trademark recognition to a more integrated and strategically emphasized role within Adobe’s broader document management and productivity offerings.",
      "llm_answer": "Adobe Scan remains positioned as a free, mobile‑first scanning tool that creates searchable PDFs via Adobe Document Cloud, but its prominence has shifted as Adobe emphasizes broader Document Cloud services—including Acrobat AI Assistant, Acrobat Sign, and integrated workflows across Acrobat Pro, Reader, and the subscription‑based Creative Cloud ecosystem. Consequently, while still available as a standalone free app, Adobe Scan is now presented more as a complementary entry point within Adobe’s larger PDF and document‑management portfolio rather than a standalone flagship product.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually consistent with the ground truth in terms of the evolution of Adobe Scan's positioning between 2023 and 2024, though it does not explicitly mention the trademark status in 2023, which is a minor omission. However, it correctly captures the core shift: Adobe Scan's integration into the broader Adobe Document Cloud ecosystem and its role as a complementary, entry-point tool rather than a standalone flagship. The answer accurately references Acrobat, Acrobat Sign, and integration with Creative Cloud, aligning with the 2024 positioning. There are no numeric values in the question or answers, so quantitative accuracy is scored as 10 by default. The reasoning is sound and reflects multi-hop understanding—linking Adobe Scan’s standalone presence to its integration within a larger workflow strategy. The semantic meaning matches the original answer, even if the trademark detail is omitted. Thus, the answer is highly accurate and contextually relevant, warranting a correctness score of 8 for missing one specific detail but conveying the overall strategic shift correctly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1276,
        "completion_tokens": 312,
        "total_tokens": 1589
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has General Motors' financial exposure and nature of obligations to Stellantis evolved from 2022 to 2024, particularly regarding indemnifications and historical liabilities?",
      "original_answer": "In 2022, General Motors continued to have supply-related transactions with Stellantis following the sale of the Opel/Vauxhall business, indicating an ongoing operational relationship. By 2024, the nature of GM's exposure to Stellantis had shifted from operational supplies to financial guarantees and indemnifications tied to legacy liabilities. Specifically, GM had agreed to indemnify Stellantis for certain emissions-related lawsuits, Takata-related recalls, and potential penalties from European regulatory investigations into end-of-life vehicle practices. Additionally, as of December 31, 2024, GM had accrued an immaterial amount related to these matters, showing a continued but reduced financial exposure compared to earlier liabilities. This reflects a transformation from active supply chain involvement to a more passive, indemnification-based financial relationship.",
      "llm_answer": "From 2022 to 2024 GM’s financial exposure and obligations to Stellantis have shifted from a broad indemnification framework tied to the 2017 Opel/Vauxhall sale toward more specific, limited indemnity triggers. The 2022‑2024 disclosures show that GM now only guarantees the Seller’s indemnification of Stellantis for certain post‑sale losses (e.g., emissions‑related lawsuits and Takata‑related recalls) and that these obligations are subject to time caps, thresholds and monetary caps, making them far narrower than the original master‑agreement coverage. Consequently, while GM still may owe payments under those indemnities, the scope and potential magnitude of the exposure are now far more constrained and often described as “immaterial” or “remote.”",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the evolution of GM's obligations from broader post-sale indemnifications to more narrowly defined, capped liabilities by 2024, focusing on emissions-related lawsuits, Takata recalls, and regulatory matters—matching the key elements in the original answer. (2) There are no numeric values (e.g., dollar amounts, percentages) in either answer, so quantitative accuracy is not compromised; dates (2022–2024) are consistent and correct. (3) The multi-hop reasoning is sound: the LLM synthesizes the shift from operational/supply relationships in 2022 to limited financial guarantees in 2024, referencing the 2017 Opel/Vauxhall sale as context and correctly noting the narrowing of indemnity scope over time. It also accurately reflects that exposure is now considered 'immaterial' or 'remote,' which aligns with the original answer’s statement about an 'immaterial amount accrued' as of 2024. (4) Minor difference: the original answer explicitly mentions 'European regulatory investigations into end-of-life vehicle practices' and 'supply-related transactions' in 2022, which the LLM omits. However, the core transformation in nature and scope of obligations is correctly captured. The LLM emphasizes structural constraints (caps, thresholds) not explicitly in the ground truth, but these are reasonable inferences consistent with 'narrower' and 'immaterial' characterizations. Overall, the answer is factually correct, contextually relevant, and semantically equivalent with only minor omissions in specificity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1416,
        "completion_tokens": 439,
        "total_tokens": 1855
      },
      "error": null
    },
    {
      "question_id": 5,
      "question": "How has PepsiCo's relationship with co-packers evolved between 2022 and 2024, particularly in terms of operational dependency and strategic involvement?",
      "original_answer": "In 2022, PepsiCo described its relationship with co-packers as part of a 'highly distributed network of plants, warehouses and distribution centers' that are owned or leased by these third parties, indicating an operational dependency. By 2024, the company's language shifted to emphasize co-packers as part of 'strategic alliances or joint ventures in which we have an equity interest,' suggesting a more active and ownership-based strategic involvement. This evolution reflects a shift from a primarily operational partnership to a more integrated and strategic stake in co-packers.",
      "llm_answer": "PepsiCo’s reliance on co‑packers has deepened markedly from 2022 to 2024, with the company increasingly depending on a distributed network of contract manufacturers, co‑packers, strategic alliances and joint‑venture partners to run its bottling, canning and packaging operations.  At the same time, PepsiCo’s involvement has shifted from a largely passive, supply‑chain relationship to a more strategic one—embedding co‑packer capacity planning within its global supply‑chain governance, leveraging third‑party risk assessments and cybersecurity oversight, and integrating co‑packer performance metrics into its broader operational and ESG risk‑management frameworks.  This evolution reflects a tighter operational dependency while also expanding PepsiCo’s strategic oversight of co‑packing activities.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the evolution in PepsiCo's relationship with co-packers from 2022 to 2024, noting increased strategic involvement and operational dependency, which aligns with the ground truth. There are no numeric values in the question or answers, so quantitative accuracy is not applicable—scored as 10 by default. The qualitative accuracy is partially correct: while the LLM captures the shift toward deeper integration and strategic oversight, it introduces specific details not present in the original answer, such as 'capacity planning within global supply-chain governance,' 'third-party risk assessments,' 'cybersecurity oversight,' and 'ESG risk-management frameworks.' These elements, while plausible, are not supported by the ground truth and represent an over-extension of the provided information. The core evolution—from operational dependency to strategic involvement—is accurately conveyed, and the years (2022 to 2024) and entities (PepsiCo, co-packers) are correct. However, the ground truth emphasizes a shift in language and ownership (e.g., equity interest in joint ventures), which the LLM answer omits or downplays. Instead, it reframes the shift around governance and risk management, which is not reflected in the original. This constitutes a minor misrepresentation of the nature of the strategic shift. Contextual relevance is high, as the response directly addresses the question’s focus on operational and strategic evolution. Overall, the answer is factually aligned in direction but lacks precision in representing the specific nature of the strategic shift described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 446,
        "total_tokens": 1794
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did SPG's financial relationship with ABG evolve between 2023 and 2024, particularly in terms of gains recognized and strategic investments?",
      "original_answer": "In 2023, SPG recognized multiple non-cash pre-tax gains related to its relationship with ABG, including $59.1 million from deemed disposals due to ABG's capital transactions and $157.1 million from the sale of a portion of its ABG interests. Additionally, SPG recorded a $145.8 million gain from the dilution of its ownership in SPARC Group. In 2024, SPG disclosed a pre-tax gain of $18.8 million from the sale of a portion of its ABG interest in December 2021, along with a strategic partnership with ABG to become the core licensee and operating partner for Reebok in the U.S., indicating a shift toward deeper operational collaboration rather than just financial transactions.",
      "llm_answer": "Between 2023 and 2024, SPG’s financial relationship with ABG shifted from a series of incremental sales and dilutive equity transactions to a full exit. In 2023, SPG sold a portion of its ABG interest, recognizing a $157.1 million pre‑tax gain (plus a $10.3 million non‑cash gain from a deemed disposal) and recorded related tax expenses. In early 2024, SPG sold its remaining ABG stake for $1.2 billion cash, generating a $414.8 million pre‑tax gain (with $103.7 million of tax expense), effectively ending its equity investment in ABG and removing any further strategic partnership or ownership ties.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and fails to correctly represent the evolution of SPG's financial relationship with ABG between 2023 and 2024. (1) Quantitatively, the LLM incorrectly states that SPG sold its remaining ABG stake in early 2024 for $1.2 billion, generating a $414.8 million pre-tax gain—this is entirely absent from the ground truth. The original answer mentions only an $18.8 million gain in 2024 from the sale of a portion of its ABG interest that occurred in *December 2021*, not 2024. Additionally, the LLM invents a $10.3 million non-cash gain, whereas the ground truth reports a $59.1 million gain from deemed disposals in 2023. The $145.8 million gain from dilution in SPARC Group is omitted entirely. (2) The LLM incorrectly frames the relationship as a 'full exit' with 'no further strategic partnership,' which contradicts the ground truth indicating a strategic partnership in 2024 to become the core licensee for Reebok in the U.S.—a key shift toward operational collaboration. (3) The reasoning is flawed: instead of recognizing a shift from financial gains to strategic collaboration, the LLM fabricates a complete exit with large cash proceeds and gains not present in the original data. (4) While the mention of 2023 gains includes a partially correct $157.1 million figure, other numbers are wrong, and the overall narrative misrepresents the multi-hop synthesis required. The contextual relevance is moderate because it addresses the general theme of financial evolution, but the factual foundation is unsound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 427,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How has Lockheed Martin's involvement in Sikorsky helicopter programs evolved from 2022 to 2024, particularly in terms of production volume and program scope?",
      "original_answer": "In 2022, Lockheed Martin's RMS segment experienced a $560 million increase in product costs, partly due to higher production volume on various Sikorsky helicopter programs. By 2024, RMS explicitly listed Sikorsky helicopter programs—such as those related to the Black Hawk, Seahawk, and CH-53K King Stallion—as key components of its portfolio, indicating a continued and potentially expanded focus. This evolution reflects a shift from being a cost driver to being a clearly defined strategic product line within the RMS segment.",
      "llm_answer": "From 2022 to 2024, Lockheed Martin's involvement in Sikorsky helicopter programs evolved significantly, particularly in production volume and program scope. According to the 2024 10-K, the company highlighted increased production rates for the CH-53K King Stallion heavy-lift helicopter under its Rotary and Mission Systems segment, noting it as a key growth area within its portfolio. The document specifically references \"increased demand for High Mobility Artillery Rocket System (HIMARS) and Guided Multiple Launch Rocket Systems (GMLRS)\" alongside rotorcraft programs, indicating expanded integration of Sikorsky's capabilities into broader missile defense and mission systems frameworks. While exact production volume figures for 2022–2024 are not detailed in the provided pages, the 2021 financial discussion (referenced in pages 43–45) notes that Sikorsky helicopter programs contributed to a $560 million increase in product costs at RMS due to \"higher production volume on various Sikorsky helicopter programs,\" suggesting sustained growth in output. By 2024, the CH-53K program had reached final aircraft delivery for the Presidential VH-92A program, marking a transition from production to sustainment focus, while new initiatives like the \"Future Vertical Lift\" and \"Optionally Piloted Vehicle\" (OPV) programs under Skunk Works signaled expanded scope beyond traditional Sikorsky platforms. This reflects a strategic shift toward integrating Sikorsky's rotorcraft expertise into Lockheed Martin's broader all-domain mission solutions, particularly in next-generation vertical lift and autonomous systems.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in its core facts but contains some inaccuracies and overreach in synthesis. (1) Quantitatively, the $560 million increase in product costs due to higher production volume on Sikorsky programs in 2022 is accurately cited from the original answer and matches the ground truth. However, the LLM incorrectly references a '2021 financial discussion' (pages 43–45) as the source, while the original answer and context are clearly about 2022—this is a factual error in sourcing. (2) The mention of increased production rates for CH-53K in 2024 aligns with the original answer’s emphasis on Sikorsky programs being a key component of RMS, but the LLM adds specific claims not in the ground truth: e.g., final delivery for the VH-92A transitioning to sustainment, and new initiatives like 'Future Vertical Lift' and 'Optionally Piloted Vehicle' under Skunk Works. These details, while plausible, are not supported by the provided ground truth and represent unsupported extrapolation. (3) The LLM incorrectly links Sikorsky programs to 'HIMARS' and 'GMLRS' as part of rotorcraft integration, which is factually incorrect—these are missile systems unrelated to Sikorsky helicopters. This reflects a significant reasoning error in entity association. (4) Despite these issues, the answer correctly identifies the evolution from cost-driven production increases in 2022 to strategic portfolio emphasis in 2024, capturing the core multi-hop insight of shifting from cost impact to strategic focus. Wording and conceptual framing are strong and contextually relevant, but the inclusion of unsupported details and one incorrect data source reduces overall correctness. Hence, a score of 7 is justified: key facts and numbers are correct, but with notable omissions and additions that affect qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1539,
        "completion_tokens": 493,
        "total_tokens": 2033
      },
      "error": null
    },
    {
      "question_id": 6,
      "question": "How did Walmart's ownership stake and financial investment in Alert Innovation evolve between fiscal 2023 and fiscal 2024?",
      "original_answer": "In fiscal 2023, Walmart completed a $0.4 billion acquisition of Alert Innovation, increasing its ownership to approximately 100%. By fiscal 2024, there was no mention of Walmart retaining ownership of Alert Innovation, indicating that the company had fully exited its stake, likely through a sale or divestiture.",
      "llm_answer": "Walmart’s ownership stake in Alert Innovation increased from approximately 53% to 100% during fiscal 2023, when it completed a $0.4 billion acquisition that brought its ownership to full control. In fiscal 2024, the company did not make any additional purchases of Alert Innovation; instead, it focused on other investments such as acquiring shares from Flipkart non‑controlling interest holders and funding its share‑repurchase program. Consequently, Walmart’s stake in Alert Innovation remained at 100% throughout fiscal 2024, with no further financial investment reported.",
      "correctness_score": 3,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partially correct quantitative information but is factually incorrect on the key point of Walmart's ownership in fiscal 2024. The ground truth states that Walmart exited its stake in Alert Innovation by fiscal 2024, with no mention of retaining ownership. However, the LLM claims Walmart maintained 100% ownership throughout fiscal 2024, which directly contradicts the ground truth. The $0.4 billion acquisition amount and the increase to 100% ownership in fiscal 2023 are correctly stated, though the LLM adds an unsupported detail of initial 53% ownership not present in the original answer. (2) Quantitative accuracy is partially correct: the $0.4 billion figure is accurate, and the 100% ownership in fiscal 2023 is correct. However, the 53% figure is an unsupported addition not found in the ground truth, and the conclusion about continued 100% ownership in fiscal 2024 is false. (3) The multi-hop reasoning is flawed. The model fails to correctly synthesize the absence of mention in fiscal 2024 as evidence of divestiture, instead interpreting it as continued ownership. This is a critical error in logical inference from the source data. The mention of Flipkart and share repurchases, while contextually plausible, are irrelevant distractions not supported by the original answer and do not justify the conclusion. (4) The correctness score is low due to the major factual error in the core conclusion. Quantitative accuracy is moderate due to correct dollar amount and final ownership in 2023, but penalized for the fabricated 53% figure. Qualitative accuracy is low due to flawed reasoning and incorrect synthesis. Contextual relevance is acceptable as the answer addresses the right companies and time periods, but includes irrelevant details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1215,
        "completion_tokens": 487,
        "total_tokens": 1703
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did SPG's utilization and management of the Supplemental Facility evolve between 2023 and 2024, particularly in terms of borrowing activity and repayment strategy?",
      "original_answer": "In 2023, SPG utilized the Supplemental Facility as part of its broader capital strategy, borrowing €750.0 million under this facility, which was later repaid on November 17, 2023, following the issuance of senior unsecured bonds. By 2024, there was no outstanding balance under the Supplemental Facility, indicating a full repayment and a shift away from its use. This evolution shows a strategic reduction in reliance on the Supplemental Facility, with SPG opting instead to refinance through long-term unsecured notes, such as the $1.0 billion issuance in September 2024.",
      "llm_answer": "Between 2023 and 2024, SPG increased its borrowing capacity under the Supplemental Facility to $3.5–$4.5 billion and actively used it to refinance and repay debt, including a €750 million bond issuance that was used to retire €750 million of outstanding Supplemental Facility borrowings in November 2023.  The company also issued new senior unsecured notes and redeemed maturing floating‑rate notes, reducing its reliance on the Supplemental Facility while maintaining a strategy of repaying debt through cash flow, asset sales and targeted equity or debt issuances.  Overall, the utilization of the Supplemental Facility shifted from active borrowing in 2023 to a focus on repayment and refinancing in 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly notes the €750 million borrowing and its repayment in November 2023, it incorrectly states that SPG increased the Supplemental Facility to $3.5–$4.5 billion, which is not supported by the ground truth and introduces false quantitative information. Additionally, it misrepresents the sequence of events by suggesting a €750 million bond issuance was used to retire the Supplemental Facility borrowings, whereas the ground truth states that the Supplemental Facility borrowing was repaid *following* the issuance of senior unsecured bonds—implying the bonds were the source of repayment, not a parallel refinancing. The $1.0 billion unsecured note issuance in September 2024 is omitted entirely. (2) Quantitative inaccuracies include the invented facility size ($3.5–$4.5 billion) and the mischaracterization of the bond issuance purpose. The €750 million figure and November 17, 2023 repayment date are correct, but the LLM omits the key detail that there was *no outstanding balance* in 2024, a critical point in the evolution of facility usage. (3) The multi-hop reasoning is partially sound—LLM recognizes a shift from borrowing to repayment—but fails to correctly synthesize the refinancing mechanism and omits the strategic pivot to long-term unsecured notes as the primary replacement for the Supplemental Facility. (4) Contextual relevance is high as the answer addresses borrowing activity and repayment strategy, but correctness is undermined by key factual and directional errors in financial flows and facility capacity. Thus, the answer is partially correct in direction but flawed in critical details and numerical accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 470,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How has Linde's treatment of helium in its industrial gases business evolved between 2023 and 2024, particularly in terms of its positioning as a primary product and associated supply strategies?",
      "original_answer": "In 2023, helium was explicitly listed as one of Linde's primary products within its industrial gases business, specifically called out alongside gases like oxygen, nitrogen, and hydrogen. The 2023 filing also described helium's distribution through merchant delivery, with contracts typically lasting three to seven years and without minimum purchase requirements. By 2024, helium was no longer specifically named as a distinct product in the industrial gases segment. Instead, it was subsumed under more general descriptions of gas supply methods and contracts, suggesting a reduced emphasis on helium as a standalone offering. This shift indicates a strategic repositioning of helium within Linde's broader gas portfolio, aligning it more closely with other merchant gases rather than maintaining its prior distinct status.",
      "llm_answer": "Between 2023 and 2024, Linde has continued to position helium as a core process gas within its industrial gases portfolio, maintaining its focus on both merchant and on-site supply channels. The company’s long-term on-site contracts—often spanning 10–20 years with minimum purchase requirements—ensure a stable demand base for helium, while merchant sales leverage its ability to ship helium over longer distances. Pricing in these contracts typically follows price‑index mechanisms, with variable components constrained and recognized only when uncertainty resolves. This strategy underpins roughly half of the revenue tied to minimum purchase obligations, projected to be earned over the next five to six years, and supports Linde’s broader supply strategy of securing helium through integrated production, strategic partnerships, and targeted investments in helium‑rich sources.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth. (1) It claims helium remained a 'core process gas' in 2024, but the original answer states that helium was no longer specifically named as a distinct product in 2024, indicating a reduced emphasis. This is a fundamental factual error. (2) The LLM cites long-term on-site contracts of 10–20 years with minimum purchase requirements, but the ground truth specifies that 2023 contracts had 3–7 year terms *without* minimum purchase requirements—directly contradicting the LLM's claim. There are no numbers in the LLM response that align with the ground truth regarding contract length or terms. (3) The multi-hop reasoning is flawed: the question asks about evolution between 2023 and 2024, but the LLM fails to recognize the key shift—helium's removal as a named primary product in 2024. Instead, it assumes continuity, missing the strategic repositioning entirely. (4) While the LLM discusses supply strategies like merchant delivery and pricing mechanisms, these are generic and not tied to the actual change in helium's positioning. The contextual relevance is moderate because it addresses helium and supply strategies, but the core factual and analytical components are incorrect. Overall, the answer fabricates details not present in the source and misses the central evolution described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1438,
        "completion_tokens": 381,
        "total_tokens": 1820
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did the allocation of assets in the U.S. Retiree Health Care Plan evolve between 2022 and 2023, particularly in terms of fixed income securities and equity securities?",
      "original_answer": "In 2022, the U.S. Retiree Health Care Plan had $248 in fixed income securities and cash equivalents and $137 in equity securities, totaling $385. In 2023, the plan's allocation changed to $210 in fixed income securities and cash equivalents and $54 in equity securities, totaling $264. This indicates a decrease in both categories, with a more significant reduction in equity securities.",
      "llm_answer": "Between 2022 and 2023, the U.S. Retiree Health Care Plan’s assets remained heavily weighted toward fixed income securities, with little to no equity exposure. In 2023, fixed income and cash equivalents represented $210 million (80% of total plan assets) versus $54 million in equity securities, compared to $182 million (65% of assets) in fixed income and $98 million (35% of assets) in equity in 2022. This indicates a modest increase in the fixed‑income share and a corresponding reduction in the equity portion of the plan’s asset allocation.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the reported dollar amounts. According to the ground truth, in 2022, fixed income securities and cash equivalents were $248 million (not $182 million as stated), and equity securities were $137 million (not $98 million). In 2023, the correct values are $210 million for fixed income and $54 million for equity, which the LLM correctly reports for 2023 but incorrectly for 2022. These errors directly affect the accuracy of percentages and trends described. (2) Calculations are therefore incorrect: the LLM claims 65% fixed income in 2022 based on $182M out of $280M total, but the actual total was $385M ($248M + $137M), making the correct fixed income share ~64.4%, not 65%. While the 2023 percentages are approximately correct ($210M / $264M ≈ 79.5%), the underlying reasoning is flawed due to incorrect 2022 figures. (3) The multi-hop reasoning is partially sound in that the model attempts to compare allocations across years and interpret shifts in asset allocation strategy, but it fails due to reliance on incorrect source data. The conclusion of a 'modest increase' in fixed-income share is misleading because the starting point (2022) is wrong. (4) Contextual relevance is fair—the response addresses asset allocation evolution between 2022 and 2023, focusing on fixed income and equity as asked. However, the severe quantitative inaccuracies undermine both qualitative reasoning and overall correctness, warranting a low correctness score despite relevant structure and intent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1239,
        "completion_tokens": 429,
        "total_tokens": 1668
      },
      "error": null
    },
    {
      "question_id": 7,
      "question": "How did the financial performance and strategic positioning of Trodelvy evolve between 2022 and 2023, particularly in terms of revenue generation and regulatory milestones?",
      "original_answer": "In 2022, Trodelvy generated $380 million in total product sales, primarily in the U.S., indicating its early commercial presence. By 2023, there was a strategic shift in Trodelvy's positioning as it received significant regulatory approvals: FDA approval for treating HR+/HER2- metastatic breast cancer and EC approval for a similar indication. These developments suggest a strong enhancement in its market potential and therapeutic footprint, although specific revenue figures for 2023 are not provided.",
      "llm_answer": "Between 2022 and 2023, Trodelvy’s product sales surged 56% to about $1.1 billion, driven by expanded use in new and existing markets, while overall company revenue slipped 1% to $27.1 billion due mainly to lower Veklury sales.  The FDA granted full approval of Trodelvy for HR⁺/HER2‑ negative metastatic breast cancer (and earlier in 2023 for locally advanced disease), reinforcing its regulatory standing, and the company continued to leverage this milestone alongside strategic collaborations and acquisitions to strengthen its oncology pipeline.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies, particularly in quantitative claims. The ground truth states that Trodelvy generated $380 million in 2022, but the LLM claims a 56% surge to $1.1 billion in 2023—this implies 2022 revenue of about $705 million (not $380M), and the $1.1B figure itself is unsupported by the original answer, which explicitly states that 2023 revenue figures are not provided. This is a critical error in both numbers and calculation. Additionally, the mention of 'overall company revenue' dropping to $27.1 billion and Veklury sales affecting performance introduces entities and financials not referenced in the ground truth, making them extraneous or incorrect. (2) The regulatory milestones are partially correct: the FDA approval for HR+/HER2- metastatic breast cancer is accurately mentioned, and the LLM adds an extra detail about 'locally advanced disease' which is not in the ground truth but may be contextually related. The EC approval is omitted. (3) The multi-hop reasoning is flawed because the LLM fabricates revenue growth rather than acknowledging missing 2023 data, undermining the synthesis. While it correctly identifies the strategic importance of regulatory approvals, the financial narrative is invented. (4) Scores reflect severe quantitative inaccuracy (2/10), moderate qualitative accuracy due to correct identification of key regulatory events but with added unverified details (5/10), high contextual relevance as it addresses revenue and regulatory positioning (8/10), and a low overall correctness score (3/10) due to the centrality of incorrect financial figures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1269,
        "completion_tokens": 449,
        "total_tokens": 1718
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did Chevron's downstream-related earnings and investment relationship with GS Caltex evolve from 2022 to 2024, and what does this indicate about the strategic importance of the joint venture?",
      "original_answer": "In 2022, Chevron reported higher downstream-related earnings from GS Caltex in Korea, contributing to improved income from equity affiliates. By 2024, Chevron maintained a 50% ownership stake in GS Caltex Corporation, which operates as a joint venture with GS Energy, importing, producing, and marketing petroleum products, petrochemicals, and lubricants. Additionally, in 2024, Chevron reported $13,850 million in sales and other operating revenues with affiliated companies, including GS Caltex, compared to $16,286 million in 2022. This indicates that while the joint venture remained strategically important, the level of downstream-related revenue with affiliated companies slightly decreased over the period.",
      "llm_answer": "From 2022 to 2024, Chevron’s downstream‑related earnings and its investment relationship with GS Caltex evolved as follows:  \n\n- **2022‑2023:** The joint venture contributed modestly to earnings, with Chevron’s 50 % stake generating $437 million of equity‑method earnings in 2023 (down from $874 million in 2022), reflecting weaker downstream margins and the absence of the full 2020‑21 earnings boost.  \n- **2024:** The 2024 financial tables show a further decline in Chevron’s share of GS Caltex earnings, underscoring a strategic shift away from relying on the venture for significant downstream profit.  \n\nThis downward trend indicates that the GS Caltex joint venture has become **less central to Chevron’s overall earnings profile**, prompting the company to diversify its downstream exposure and reduce dependence on the partnership for profit generation.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that Chevron reported higher downstream-related earnings from GS Caltex in 2022 and maintained its 50% ownership through 2024, with no mention of declining equity earnings. However, the LLM claims Chevron's equity-method earnings dropped from $874M in 2022 to $437M in 2023 and further declined in 2024—this data is entirely absent from the original answer and contradicts the 'higher earnings' statement. Additionally, the original answer notes $13,850 million in 2024 sales with affiliated companies (including GS Caltex), down from $16,286 million in 2022, but the LLM does not reference these totals or correctly attribute the decrease to overall affiliated revenues, not specifically GS Caltex earnings. (2) The quantitative inaccuracies are severe: the $874M and $437M figures are fabricated; no such numbers appear in the ground truth. The original answer does not break out GS Caltex earnings separately, so the LLM invents a trend unsupported by data. The only correct quantitative point is Chevron’s 50% stake, which matches. (3) The multi-hop reasoning is flawed. The LLM infers a strategic de-emphasis based on non-existent declining earnings, while the original answer concludes the joint venture 'remained strategically important' despite a slight revenue decrease. This misrepresents the strategic interpretation. The model fails to connect the actual data points (stable ownership, slight drop in total affiliated revenues) to the correct conclusion. (4) Scores reflect major factual and numerical errors (correctness: 2), very poor quantitative accuracy (2), weak reasoning and entity synthesis (3), but partial relevance to the question’s topic (6), as it addresses the JV and time frame, albeit incorrectly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1406,
        "completion_tokens": 494,
        "total_tokens": 1900
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did the financial performance and production status of the CH-53K program evolve from 2022 to 2024, particularly in terms of risk retirements and production volume?",
      "original_answer": "In 2022, the CH-53K program contributed to higher operating profit for Sikorsky helicopter programs, with approximately $140 million in increased profit driven by higher risk retirements and production volume. By 2024, while the CH-53K remained a key product within RMS, the overall operating profit for RMS declined significantly—by 73%—partially due to lower profit booking rate adjustments across the portfolio. Although specific profit figures for CH-53K were not disclosed in 2024, the broader profit decline suggests that the gains from risk retirements observed in 2022 may have diminished as the program matured and entered higher-volume production.",
      "llm_answer": "From 2022 to 2024 the CH‑53K program’s production volume grew steadily, with backlog expanding as new orders were added across the fleet.  Risk retirements on the CH‑53K – driven by favorable contract‑mix adjustments and the resolution of long‑standing claims – generated net profit‑booking rate improvements that boosted operating profit, while the program also absorbed $555 million of losses on a classified contract in 2024.  Overall, the CH‑53K contributed to higher segment net sales and supported backlog growth, even as profit‑booking adjustments fluctuated.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, the CH-53K program contributed approximately $140 million in increased profit due to risk retirements and higher production volume. The LLM answer incorrectly claims $555 million in losses on a classified contract in 2024, which is not mentioned in the original answer and introduces a false element. There is no mention of such losses in the ground truth, nor is there any indication that the CH-53K program incurred losses. (2) Quantitative accuracy is poor: the $140 million profit improvement in 2022 is omitted entirely, and the fabricated $555 million loss severely undermines numerical correctness. No correct figures from the original answer are included. (3) The reasoning is flawed—while the LLM correctly notes growing production volume and risk retirements contributing to profit in 2022, it fails to reflect the key 2024 context: that RMS operating profit declined by 73% and that CH-53K-specific profit data was not disclosed, suggesting diminishing gains from risk retirements. Instead, it invents a narrative about a classified contract loss, showing incorrect multi-hop synthesis. (4) Contextual relevance is moderate because the answer addresses production volume, risk retirements, and profit impacts, which are relevant themes, but the introduction of false data and omission of core facts (like the $140M gain and 73% RMS profit drop) severely limits accuracy. Overall, the answer misrepresents the financial evolution of the program.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 430,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has PayPal's approach to seller protection programs evolved between 2022 and 2023, particularly in terms of risk exposure and strategic emphasis?",
      "original_answer": "In 2022, PayPal highlighted that its seller protection programs carried risk exposure tied to regional variations and regulatory changes, with historical transaction loss rates ranging between 0.09% and 0.15% of TPV. By 2023, the company placed a stronger strategic emphasis on these programs as a competitive differentiator, explicitly linking them to merchant trust and platform growth. While 2022 focused on risk management and potential loss implications, 2023 framed seller protection as part of a broader value proposition to attract and retain merchants, integrating it with analytics, risk management, and other merchant services.",
      "llm_answer": "PayPal’s seller‑protection framework remained focused on covering chargebacks, unauthorized transactions, and buyer disputes, but the company emphasized tighter risk controls and more granular fraud monitoring to curb losses.  In 2022 it continued to rely on provisions for transaction and credit losses, yet highlighted that actual cash losses were recorded as changes in other assets and liabilities, and it began to stress the importance of macro‑economic trends and merchant solvency on future loss rates.  By 2023 the narrative shifted to “protecting merchants and consumers” as a strategic differentiator, underscoring that robust protection programs are a key competitive advantage and that the company is investing in enhanced systems and data analytics to manage exposure.  Consequently, while the core protection mechanisms stayed similar, the 2023 discussion placed greater strategic emphasis on risk‑management sophistication and the financial impact of those programs on cash flow.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of qualitative evolution and strategic emphasis. (1) It accurately captures the shift from risk management in 2022 to strategic differentiation in 2023, noting PayPal's increased focus on merchant trust, analytics, and competitive advantage. The core protection mechanisms remaining stable is also consistent. (2) Quantitatively, while the LLM does not mention the specific historical loss rates (0.09%–0.15% of TPV) from 2022, it correctly references transaction and credit loss provisions, cash loss accounting, and macroeconomic influences—none of which introduce numerical inaccuracies. The absence of the exact percentage range is a minor omission but does not distort facts. (3) The multi-hop reasoning is sound: the model synthesizes PayPal’s evolving narrative across years, correctly identifying a strategic pivot without misrepresenting entities or timelines. (4) Contextual relevance is strong—the response directly addresses risk exposure and strategic emphasis as asked. The main shortcoming is the lack of explicit mention of the 0.09%–0.15% loss rate range, which was present in the original answer and adds precision to the risk exposure discussion. However, the overall reasoning and factual correctness remain high, warranting a score of 8 for correctness and qualitative accuracy, 10 for quantitative accuracy (no incorrect numbers, only a partial omission), and 10 for relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1408,
        "completion_tokens": 406,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How has Starbucks' approach to its ready-to-drink beverages evolved between 2023 and 2024, particularly in terms of revenue recognition and supplier dependency?",
      "original_answer": "In 2023, Starbucks recognized revenue from ready-to-drink beverages under the 'Other Revenues' category, where sales were generally recognized upon shipment to customers depending on contract terms. By 2024, the company's focus shifted to supplier dependency and supply chain resilience, emphasizing that ready-to-drink beverages are sourced from specialty suppliers under long-term contracts, indicating a strategic move toward securing stable supply rather than just reporting revenue. While 2023 included ready-to-drink beverages in broader revenue disclosures without specific figures, 2024 highlighted the importance of supplier relationships to mitigate delivery risks, signaling a shift from revenue-centric reporting to a supply-chain risk management focus.",
      "llm_answer": "Between 2023 and 2024, Starbucks' approach to its ready-to-drink beverages remained consistent in terms of revenue recognition methodology, continuing to recognize revenue upon shipment or transfer of control to customers, primarily within the Channel Development segment and through partnerships like the Global Coffee Alliance with Nestlé. There is no indication of a change in revenue recognition policy for these beverages during this period. Regarding supplier dependency, Starbucks continues to rely on multiple suppliers for coffee beans, dairy, and other ingredients, utilizing fixed-price contracts, forward agreements, and hedging strategies to manage volatility, particularly in high-quality arabica coffee, though specific changes in supplier dependency between 2023 and 2024 are not detailed in the provided disclosures.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is partially correct but misses the key evolution described in the ground truth. While it correctly states that revenue recognition remained consistent (upon shipment or transfer of control), it fails to acknowledge the shift in reporting focus from revenue categorization in 2023 (under 'Other Revenues') to supply chain resilience and supplier dependency in 2024. The ground truth emphasizes a strategic pivot in disclosure emphasis—from revenue recognition to risk management around supplier relationships—whereas the LLM claims there is 'no indication of a change in revenue recognition policy,' which, while technically true, overlooks the qualitative shift in strategic focus. (2) There are no numeric values in either answer, so quantitative accuracy is not applicable; however, the absence of specific figures (e.g., lack of mention that ready-to-drink beverages were not broken out with specific revenue numbers in 2023) is consistent with both answers. (3) The multi-hop reasoning is flawed: the question asks about evolution in approach, not just accounting policy. The LLM focuses narrowly on revenue recognition mechanics and general supplier risk management practices but does not capture the shift from revenue-centric reporting to supply-chain risk emphasis, which requires synthesizing changes in disclosure tone and strategic priorities across the two years. (4) The contextual relevance is moderate because the answer discusses related topics (revenue recognition, supplier contracts), but it fails to address the core of the question—the evolution in strategic approach and disclosure focus. Hence, correctness and qualitative accuracy are low despite accurate phrasing on stable policies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1403,
        "completion_tokens": 473,
        "total_tokens": 1876
      },
      "error": null
    },
    {
      "question_id": 8,
      "question": "How did the geographic reach and regulatory approvals of Trodelvy evolve between 2022 and 2023?",
      "original_answer": "In 2022, Trodelvy generated $370 million in U.S. sales and $10 million in Europe, with no sales reported in other international markets, indicating limited geographic reach. By 2023, Trodelvy received significant regulatory approvals: it was approved by the FDA for treating adult patients with HR+/HER2- metastatic breast cancer, and it obtained EC approval for monotherapy treatment of unresectable or metastatic HR+/HER2- breast cancer. These approvals suggest an expansion of Trodelvy's market access and therapeutic application, likely contributing to broader geographic distribution beyond what was reported in 2022.",
      "llm_answer": "Between 2022 and 2023, Trodelvy’s geographic reach expanded from initial U.S. and European approvals (including accelerated approvals in metastatic UC and TNBC) to include additional global authorizations, such as Health Canada approval in 2021 and broader European Commission approvals for metastatic TNBC and HR+/HER2- breast cancer by 2023. Regulatory approvals also broadened to include new indications like HR+/HER2- breast cancer and monotherapy use in specific breast cancer settings, reflecting a strategic expansion beyond its original urothelial and TNBC indications to target additional oncology markets.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies, particularly regarding quantitative data and timing. The original answer states that in 2022, Trodelvy generated $370 million in U.S. sales and $10 million in Europe, with no sales elsewhere—this specific financial data is completely omitted in the LLM response, representing a major omission. Additionally, the LLM incorrectly references Health Canada approval in 2021, which is outside the 2022–2023 timeframe and not mentioned in the ground truth. (2) There are no numeric values in the LLM answer to verify calculations, but the absence of the $370M and $10M figures from the ground truth significantly undermines quantitative accuracy. The LLM fails to report any sales data, which is a core part of the original answer’s assessment of geographic reach. (3) The reasoning around regulatory expansion is partially sound: the LLM correctly identifies broader European Commission approvals by 2023 for HR+/HER2- breast cancer and metastatic TNBC, and notes new indications, aligning with the FDA and EC approvals mentioned in the ground truth. However, it conflates timeline details (e.g., mentioning 2021 approvals) and overgeneralizes global authorizations without specifying that international sales were absent in 2022. (4) Despite missing key data, the LLM captures the qualitative trend of expanded regulatory approvals and broader therapeutic use, showing correct multi-hop synthesis of indication expansion and geographic authorization trends. It remains contextually relevant and correctly infers strategic expansion, even if specifics are flawed. Thus, correctness is partially accurate but significantly limited by missing financials and incorrect dates.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 470,
        "total_tokens": 1767
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did Simon Property Group's ownership stake and financial gains from transactions involving ABG evolve between 2023 and 2024?",
      "original_answer": "In 2023, Simon Property Group (SPG) experienced multiple dilutions of its ownership stake in ABG through capital transactions, including a reduction from approximately 12.3% to 11.8%, then to 11.7%, and finally to approximately 9.6%. These transactions resulted in non-cash pre-tax gains of $36.4 million, $12.4 million, and $10.3 million, respectively. By contrast, in 2024, SPG no longer disclosed active changes in its ownership stake in ABG. Instead, it referenced a prior transaction from December 20, 2021, where it sold a portion of its interest in ABG for a pre-tax gain of $18.8 million and later acquired additional interests for $100.0 million. This indicates a shift from active stake reduction and financial recognition in 2023 to a more passive disclosure stance in 2024, with no new transactions reported.",
      "llm_answer": "Simon Property Group's ownership stake in ABG declined from approximately 12.3% to 11.8% during the second quarter of 2023, triggering a non-cash pre-tax gain of $36.4 million from the deemed disposal of a proportional interest, which was recognized in earnings. This followed earlier dilutions in 2023 (to ~11.7% in Q3 and ~9.6% by year-end), resulting in additional non-cash gains of $12.4 million (Q3 2023) and $10.3 million (year-end 2023), while the company recorded deferred tax expenses related to these transactions. By December 31, 2023, Simon owned a 45% noncontrolling interest in Rue Gilt Groupe, reflecting the ongoing reduction of its ABG stake through subsequent capital transactions.",
      "correctness_score": 6,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the sequence of ownership reductions in ABG during 2023—from 12.3% to 11.8%, then 11.7%, and finally to 9.6%—and matches the associated non-cash pre-tax gains of $36.4 million, $12.4 million, and $10.3 million, which aligns with the ground truth. However, it incorrectly states that the 11.8% reduction occurred in Q2 2023 and assigns the $12.4M gain to Q3 and $10.3M to year-end without specifying exact dates, while the original answer does not specify quarters—only that multiple dilutions occurred in 2023. This introduces temporal precision not present in the source and risks misrepresentation. (2) A major factual error occurs in the final sentence: the claim that 'Simon owned a 45% noncontrolling interest in Rue Gilt Groupe by December 31, 2023' is unsupported by the original answer and introduces a new entity (Rue Gilt Groupe) and stake (45%) with no mention in the ground truth. This is a significant entity and factual hallucination. (3) Regarding 2024, the LLM answer completely omits the key point from the original answer: that SPG stopped disclosing active changes in 2024 and instead referenced a prior 2021 transaction involving an $18.8 million gain and a $100 million acquisition. This omission breaks the multi-hop comparison between 2023 and 2024, which is central to the question. (4) While the 2023 financial figures and ownership percentages are quantitatively accurate (hence a 7 on quantitative accuracy), the incorrect temporal framing, hallucinated entity, and missing 2024 analysis reduce qualitative accuracy. The answer remains contextually relevant as it addresses ownership evolution and financial gains, but fails in completeness and reasoning across years. Thus, correctness is partially compromised—core 2023 data is right, but synthesis across 2023–2024 is flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1375,
        "completion_tokens": 502,
        "total_tokens": 1878
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How has the 2012 Equity Incentive Plan evolved between the 2023 and 2024 filings, particularly in terms of amendments and forms of award agreements disclosed?",
      "original_answer": "In 2023, the 2012 Equity Incentive Plan was disclosed as amended, including the Third Amendment to the plan, and referenced forms of award agreements from 2012 and 2017. In 2024, the filing included a Fourth Amendment dated August 1, 2024, and introduced additional forms of award agreements from April 2024, showing continued evolution and expansion of the plan over time.",
      "llm_answer": "The 2012 Equity Incentive Plan was amended in 2023 with a third amendment (effective February 2 2023) and subsequently with a fourth amendment (effective August 1 2024), as disclosed in the 2023 and 2024 Form 10‑K filings. Both years also include various forms of award agreements under the plan, with newer versions filed in 2023 (10‑Q April 27 2023) and 2024 (10‑Q April 25 2024).",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same core information as the ground truth. (1) It correctly identifies the Third Amendment in 2023 (though it adds a specific effective date of February 2, 2023, not in the original answer, which is plausible but not confirmed in the ground truth) and the Fourth Amendment effective August 1, 2024, matching the original. (2) It accurately reflects the evolution of award agreement forms, noting newer versions filed in April 2023 and April 2024 (via 10-Qs), which aligns with the original's mention of April 2024 forms and prior 2012/2017 references. The ground truth does not specify 2023 10-Q filings but does confirm updated forms were referenced, so this added detail is consistent. (3) Multi-hop reasoning is sound: the model correctly synthesizes amendments and award forms across 2023 and 2024 filings, showing plan evolution. (4) Minor point: the original answer highlights the 2012 and 2017 forms were referenced in 2023, which the LLM omits, instead citing 2023-filed forms. This is a slight incompleteness but not incorrect—filings may reference both old and new forms. Overall, factual accuracy, dates, and reasoning are strong, warranting a 9. Quantitative accuracy is high—dates and amendment numbers match or are plausibly specific. Qualitative accuracy is strong with correct entity and document references. Contextual relevance is perfect—directly addresses plan evolution, amendments, and award forms.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1191,
        "completion_tokens": 403,
        "total_tokens": 1595
      },
      "error": null
    },
    {
      "question_id": 9,
      "question": "How did the treatment and valuation of capitalized software licenses evolve between 2022 and 2023, and what does this indicate about the company's investment in software licensing?",
      "original_answer": "In 2022, capitalized software licenses were described as being generally amortized on a straight-line basis over the term of the license, indicating a clear policy for their depreciation over time. By 2023, the company disclosed the actual carrying value of these licenses on the balance sheet at $223 million, up from $152 million in 2022. This increase suggests a growing investment in software licensing, despite the unchanged amortization policy. The evolution from a disclosed accounting method in 2022 to a quantified asset in 2023 reflects a more tangible and increasing role of capitalized software licenses in the company's asset structure.",
      "llm_answer": "Between 2022 and 2023, the company’s treatment of capitalized software licenses remained consistent with prior practice—capitalized software licenses are amortized on a straight‑line basis over the term of the license, and fully amortized assets are written off against accumulated amortization. However, the balance of capitalized software licenses on the balance sheet increased from $152 million in 2022 to $223 million in 2023, indicating a higher level of investment in software licensing during the year. This rise suggests the company is allocating more resources to acquire or develop software assets, likely to support future product development and integration efforts.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is fully correct and matches the ground truth in all aspects. (1) Quantitatively, the dollar amounts are accurate: $152 million in 2022 and $223 million in 2023, with the correct directional increase. These figures match the original answer exactly, and no calculation errors are present. (2) The treatment of capitalized software licenses—straight-line amortization over the license term with write-offs upon full amortization—is correctly described and consistent with the 2022 policy. (3) The answer addresses both parts of the multi-hop question: it explains the accounting treatment (unchanged between years) and the valuation trend (increase in carrying value), then synthesizes this into a meaningful conclusion about increased investment in software licensing. (4) The reasoning is sound: the increase in capitalized software licenses from $152M to $223M is correctly interpreted as evidence of growing investment, and the consistency in amortization policy is properly noted. (5) The semantic content is equivalent to the original answer, with slightly different phrasing but no loss or distortion of meaning. The LLM also adds minor contextual insight (e.g., supporting future product development) that is reasonable and consistent with the data. All entities—years, financial figures, and accounting policies—are accurately identified and used. No errors in facts, logic, or synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1340,
        "completion_tokens": 389,
        "total_tokens": 1730
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How did PayPal's utilization of European customer balances for credit activities evolve between 2022 and 2023, and what does this indicate about its strategic approach to funding credit products?",
      "original_answer": "In 2022, PayPal had approved $3.8 billion of European customer balances for credit activities, representing approximately 37% of European customer balances available for corporate use. In 2023, this approved amount decreased to $3.0 billion, representing 39% of European customer balances. This indicates a slight reduction in the total approved funding base but a higher percentage utilization of available balances, suggesting a more efficient use of existing customer balances for credit activities. Additionally, PayPal entered into a new €40 billion agreement in 2023 to sell consumer installment receivables, with $5.5 billion sold during the year, signaling a strategic shift toward external funding mechanisms to support credit product expansion.",
      "llm_answer": "PayPal’s European customer balances designated for credit funding fell from $3.8 billion in 2022 to $3.0 billion in 2023, reflecting a deliberate reduction in the amount of European customer deposits that can be used for credit activities. This shift shows the company is tightening its reliance on external financing and seeking to fund its credit products more directly—e.g., through asset‑sale programs like the €40 billion consumer‑installment receivable sale and new debt issuances—rather than depending on the previously larger pool of internally designated customer balances.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the decrease in approved European customer balances from $3.8 billion in 2022 to $3.0 billion in 2023, which matches the ground truth. However, it omits the key percentage context: in 2022, $3.8B was ~37% of available balances, and in 2023, $3.0B was 39%. This omission affects the interpretation of utilization efficiency. The LLM incorrectly frames the reduction as a 'deliberate reduction in deposits that can be used' rather than a decrease in approved amount despite higher percentage utilization. (2) The €40 billion receivables sale agreement and $5.5 billion sold in 2023 are partially correct—the agreement size is accurate, but the $5.5 billion figure is missing from the LLM answer, weakening completeness. (3) The reasoning is partially sound: the shift toward external funding via asset sales is correctly inferred, but the conclusion that PayPal is 'tightening reliance on external financing' contradicts the evidence—external funding is being expanded, not tightened. The model mischaracterizes internal vs. external funding dynamics. (4) Scores reflect mostly correct numbers but missing percentages and a critical $5.5B figure, leading to flawed interpretation. Reasoning is directionally aware but logically inconsistent. Contextual relevance is high as it addresses both evolution and strategic implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 383,
        "total_tokens": 1729
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has Starbucks' investment relationship with Valor Siren Ventures I L.P. evolved between fiscal years 2023 and 2024, particularly in terms of the carrying value of the investment and its financial impact on Starbucks' consolidated statements?",
      "original_answer": "In fiscal 2023, Starbucks held a limited partnership interest in Valor Siren Ventures I L.P., with the total carrying value of such investments not specifically disclosed for that year. The financial impact of these investments, including Valor Siren Ventures I L.P., was included in 'interest income and other, net' and was not considered material. By fiscal 2024, the total carrying value of Starbucks' investments in Valor Siren Ventures I L.P. and II L.P. combined was $211.9 million as of September 29, 2024. The investment relationship evolved from a general equity stake to a more defined and quantified investment with ongoing monitoring, though the financial impact remained non-material and continued to be reported in 'interest income and other, net.'",
      "llm_answer": "Based on the provided SEC 10-K filings, Starbucks' investment relationship with Valor Siren Ventures I L.P. (and its related fund II) evolved such that the total carrying value of these private equity investments increased to $211.9 million as of September 29, 2024, compared to a combined $415.7 million for all equity method investments (which included other ventures like Tata Starbucks) as of October 1, 2023. However, the company explicitly states that \"the related financial statement activities were not material during the periods presented,\" indicating no significant financial impact on Starbucks' consolidated statements of earnings or balance sheet beyond the disclosed carrying value. The investment is accounted for under the equity method, with income/losses reported in \"interest income and other, net,\" but no material changes or financial statement effects were noted between fiscal 2023 and 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. The ground truth states that the $211.9 million carrying value in fiscal 2024 is for Valor Siren Ventures I and II L.P. combined, but the LLM incorrectly implies this is an increase from a $415.7 million value for all equity method investments (including Tata Starbucks) in 2023. This comparison is invalid and misleading—$415.7 million is not the value of the Valor Siren funds alone, but of all equity method investments, making the 'decrease' claim baseless. There is no support in the original answer for a specific carrying value of the Valor Siren funds in 2023, only that it was included in a broader non-material category. (2) The date 'September 29, 2024' is correctly cited for the 2024 value, and $211.9 million matches the ground truth, so that number is accurate. However, the use of $415.7 million as a comparative figure for 2023 is incorrect in context—this number refers to all equity method investments, not Valor Siren specifically, and thus fails the quantitative accuracy test. (3) The multi-hop reasoning is flawed: the model incorrectly synthesizes data by comparing a specific fund value in 2024 to a total portfolio value in 2023, creating a false narrative of decline. The original answer does not state or imply any such trend. The qualitative assessment of non-material impact and reporting in 'interest income and other, net' is correct and reflects proper reasoning. (4) Contextual relevance is high—the answer addresses the evolution of the investment, carrying value, and financial impact. However, due to major quantitative errors and incorrect synthesis, the overall correctness score is low. The answer creates a plausible-sounding but factually incorrect narrative, undermining trust in the conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1444,
        "completion_tokens": 502,
        "total_tokens": 1946
      },
      "error": null
    },
    {
      "question_id": 10,
      "question": "How has the strategic positioning of Analog Products evolved between 2022 and 2023 in terms of TI's competitive advantages and financial contribution?",
      "original_answer": "In 2022, Analog Products were central to TI's strategic focus, contributing to a gross margin of 67.5% driven by the efficiency of their manufacturing strategy, including 300-millimeter production. By 2023, Analog Products remained a core pillar but were framed more explicitly within the context of TI's four sustainable competitive advantages, particularly emphasizing lower costs and greater control of the supply chain. Additionally, the 2023 report reinforced the role of Analog Products in enabling TI to generate and return significant cash, with a renewed emphasis on long-term free cash flow per share growth as the ultimate performance metric.",
      "llm_answer": "Between 2022 and 2023, Analog Products' strategic positioning remained central to TI's competitive advantages, particularly through its manufacturing scale and technology leadership, which underpin lower costs and supply chain control. However, its revenue declined 15% year-over-year to $13.04 billion, and operating profit fell 30% to $5.82 billion (44.6% of revenue), reflecting lower factory loadings and higher manufacturing costs from capacity expansion. Despite this, Analog continued to drive strong cash flow ($1.35 billion free cash flow, 7.7% of revenue), but its relative contribution to TI's overall performance diminished compared to 2022, when it generated $7.39 billion in operating profit (52.6% of revenue). This shift highlights a strategic pivot toward Embedded Processing, which saw modest revenue growth (3%) and maintained a higher operating margin (29.9% vs. 44.6% for Analog), while Analog's declining profitability and market share underscore evolving competitive dynamics.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that Analog Products remained a core strategic pillar in 2023 with emphasis on TI's sustainable competitive advantages and cash generation, but the LLM incorrectly claims a 'strategic pivot toward Embedded Processing' and that Analog's contribution diminished. There is no mention in the original answer of declining market share, factory loadings, or capacity expansion costs. (2) Quantitative inaccuracies are severe: the LLM fabricates numerous figures not present in the ground truth, including $13.04B revenue (15% decline), $5.82B operating profit (30% drop), $1.35B free cash flow, and comparisons to $7.39B operating profit in 2022. The original answer only provides a 67.5% gross margin for 2022 and emphasizes free cash flow per share growth as a metric — no specific revenue, operating profit, or free cash flow dollar amounts are given. The 44.6% and 29.9% operating margins for Analog and Embedded Processing are also not in the original and appear fabricated. (3) The multi-hop reasoning is flawed: instead of synthesizing how Analog's strategic framing evolved around TI's competitive advantages and financial metrics, the LLM invents a narrative of declining performance and strategic de-emphasis, contradicting the original answer's assertion that Analog remained a core pillar. The model fails to mention the key evolution — the explicit linkage of Analog Products to TI’s four sustainable competitive advantages in 2023, especially cost leadership and supply chain control, and the shift toward free cash flow per share as the key performance metric. (4) The contextual relevance is moderate because the answer discusses Analog Products, TI, competitive advantages, and financial contribution, but the substance is factually incorrect. Due to major quantitative and qualitative errors, the correctness score is low at 2, quantitative accuracy is 1 (almost all numbers wrong), qualitative accuracy is 3 (some correct themes but misapplied), and contextual relevance is 5 (right topic, wrong details).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1414,
        "completion_tokens": 567,
        "total_tokens": 1981
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Chevron's capital allocation strategy in the Lower 48 region evolved from 2022 to 2023, based on the changes in depreciation, depletion, amortization, and impairments?",
      "original_answer": "Chevron's capital allocation in the Lower 48 region increased significantly from 2022 to 2023, as evidenced by the rise in depreciation, depletion, amortization, and impairments from $4,854 million in 2022 to $5,729 million in 2023. This indicates a growing focus on asset development and operational expansion in the Lower 48, contrasting with relatively stable or declining figures in other geographic segments like Europe, Middle East and North Africa.",
      "llm_answer": "Chevron's capital allocation strategy in the Lower 48 region shifted significantly from 2022 to 2023, as evidenced by a 17% decline in depreciation, depletion, and amortization (DDA) expenses from $5,729 million to $4,854 million, while impairment charges also decreased substantially from $735 million to $587 million. This reduction in DDA and impairment spending reflects a strategic pivot toward capital discipline, with the company prioritizing lower capital expenditures ($6,487 million in 2023 vs. $5,630 million in 2022) and focusing on high-return projects rather than expanding reserve base through aggressive exploration, as indicated by the lower 48 segment's revenue decline from $52,921 million to $38,244 million.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is almost entirely incorrect in both direction and magnitude. The ground truth states that Chevron's depreciation, depletion, amortization, and impairments (DD&A + impairments) increased from $4,854 million in 2022 to $5,729 million in 2023, indicating increased capital allocation. However, the LLM claims a 17% decline in DDA from $5,729M to $4,854M, reversing the years and misrepresenting the trend. It also introduces fabricated impairment figures ($735M to $587M) not present in the original answer, which does not break out impairments separately. Additionally, the LLM cites capital expenditures of $6,487M in 2023 vs $5,630M in 2022 and revenue dropping from $52,921M to $38,244M—none of which appear in the original answer or are supported by the provided context. (2) All numerical values are either reversed, invented, or misattributed. The correct figures are $4,854M (2022) and $5,729M (2023), showing an increase of ~18%, not a decrease. The LLM incorrectly calculates a 17% decline using reversed inputs. (3) The multi-hop reasoning is fundamentally flawed: instead of interpreting rising DD&A as a sign of increased investment (as per the original answer), the model interprets declining DDA as capital discipline, which contradicts standard financial logic and the actual evidence. It fails to correctly synthesize the relationship between DD&A and capital allocation. (4) The contextual relevance is low because the answer discusses capital discipline and high-return projects, which contradicts the ground truth's conclusion of growing focus on asset development. The only relevant aspect is the mention of the Lower 48 region and the years 2022–2023, but even the interpretation of trends is inverted. Due to pervasive factual errors, calculation mistakes, and reversed logic, the correctness score is near zero.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1303,
        "completion_tokens": 504,
        "total_tokens": 1807
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Verizon's approach to FWA Broadband evolved between 2023 and 2024, particularly in terms of its positioning within the company's product portfolio and its target customer segments?",
      "original_answer": "In 2023, Verizon provided FWA broadband through both 5G and LTE networks, targeting both Consumer and Business customers, and reported 3.1 million FWA broadband connections. By 2024, the company continued to offer FWA broadband primarily under the Verizon Consumer and Business Group segments, but with a more integrated positioning as an alternative to traditional landline internet access and as part of a broader portfolio that includes IoT and advanced communication services. The shift from 'provides' in 2023 to 'produces' in 2024 indicates a more strategic and product-centric approach to FWA broadband.",
      "llm_answer": "Verizon's approach to FWA broadband has evolved from a peripheral offering to a strategically positioned product within its portfolio, particularly as a key growth lever in both Consumer and Business segments. In 2024, FWA broadband is explicitly highlighted as a core component of Verizon's 5G and 4G LTE network strategy, with significant investment in C-Band spectrum deployment (covering 242 million people by end-2023) to expand FWA coverage and reliability. This positioning is reinforced by its integration into the \"Intelligent Edge Network\" architecture, which aims to simplify operations, accelerate 5G deployment, and create cost-efficient business opportunities. Target customer segments have shifted toward both residential (Consumer) and business markets, with FWA specifically positioned as an alternative to traditional landline internet access for homes and businesses, especially in areas where fiber (Fios) is unavailable. The 2024 10-K explicitly references FWA as a \"fixed wireless access broadband\" service leveraging 5G and LTE networks, with 3.1 million FWA connections reported as of December 31, 2023, and revenue growth reflected in segment operating income (e.g., Consumer segment revenue increased to $102,904 million in 2024 from $101,626 million in 2023). This strategic emphasis underscores FWA's role in expanding Verizon's addressable market and supporting network monetization beyond traditional wireless services.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: 3.1 million FWA connections as of December 31, 2023, Consumer segment revenue of $102,904 million in 2024 vs. $101,626 million in 2023, and C-Band coverage of 242 million people by end-2023 are all factually consistent with Verizon's 10-K filings. These figures are correctly cited and formatted. (2) The answer addresses both parts of the question: evolution in product portfolio positioning and target customer segments. It correctly identifies that FWA is now more strategically positioned in 2024 as a core offering under both Consumer and Business groups, integrated into broader network architecture (e.g., Intelligent Edge Network), and explicitly framed as an alternative to landline internet—especially where Fios is unavailable. (3) The qualitative reasoning is strong: the shift from 'provides' to 'produces' is not explicitly mentioned, but the LLM infers a strategic, product-centric evolution through contextual evidence (investment in C-Band, integration into network architecture, revenue impact). This constitutes sound multi-hop reasoning across network strategy, financial performance, and product positioning. (4) Minor deduction in qualitative accuracy because the ground truth emphasizes the linguistic shift in reporting ('provides' → 'produces') as a signal of strategic change, which the LLM does not mention. However, the overall semantic meaning and strategic implication are accurately conveyed. Contextual relevance is perfect—the response directly, thoroughly, and appropriately answers the question using correct synthesis across years and segments.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1525,
        "completion_tokens": 461,
        "total_tokens": 1986
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has Emerson's relationship with AspenTech evolved from 2022 to 2024, and what financial impact did this evolution have on Emerson's gross margin and equity structure?",
      "original_answer": "In 2022, Emerson partnered with AspenTech, leveraging its asset optimization software to enhance industrial operational efficiency. By 2024, Emerson had significantly deepened this relationship by acquiring a 55% ownership stake in AspenTech as part of a strategic transaction that created 'New AspenTech.' This acquisition contributed positively to Emerson’s gross margin, benefiting it by 0.6 percentage points in 2023 and further influencing financial structure in 2024 with increased SG&A expenses tied to the integration. Additionally, the equity structure was impacted through the recognition of gains and losses associated with the AspenTech stock plans and the broader restructuring of industrial software assets.",
      "llm_answer": "From 2022 to 2024, Emerson's relationship with AspenTech evolved from a 55% ownership stake (acquired in 2022) to a full acquisition proposal in November 2024 at $240 per share, implying a $15.3 billion fully diluted market cap. This progression included the 2022 acquisition of Heritage AspenTech (55% stake), subsequent operational integration, and the 2024 proposal to acquire the remaining shares. Financially, this evolution positively impacted gross margin through the Test & Measurement acquisition (which added 9.5% to sales and improved gross margin by 1.8 percentage points), though acquisition-related inventory step-up amortization ($231) temporarily pressured margins by ~1.3 percentage points. The 2024 sale of Copeland (40% equity interest and $1.9B note) generated a $539 million after-tax gain in discontinued operations, but the acquisition-related costs and inventory step-up contributed to a 30% decline in pretax earnings from continuing operations in 2024. Equity structure was significantly altered by the disposal of the Copeland stake and the ongoing proposal to fully acquire AspenTech, reshaping Emerson's portfolio toward a more focused industrial automation leader.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Emerson did not acquire a 55% stake in AspenTech in 2022—rather, the 55% ownership was part of a 2024 transaction that created 'New AspenTech.' The LLM incorrectly states the 55% acquisition occurred in 2022 and then claims a full acquisition proposal in November 2024, which contradicts the known timeline. Additionally, the $240 per share and $15.3 billion fully diluted market cap figures are not present in the original answer and are unverified in this context. The financial impacts cited—such as the Test & Measurement acquisition improving gross margin by 1.8 percentage points and acquisition-related inventory step-up amortization of $231 (units unclear)—are not mentioned in the ground truth and appear fabricated. The $539 million after-tax gain from the sale of Copeland is unrelated to AspenTech and not part of the original answer’s focus on gross margin and equity structure impacts from the AspenTech relationship. (2) Multiple numbers are incorrect or misattributed: 55% stake timing (2022 vs 2024), gross margin impact (1.8 pp vs 0.6 pp in 2023), inventory step-up ($231 with no unit clarity), and Copeland gain ($539M) are all either wrong or irrelevant. The ground truth specifies a 0.6 percentage point benefit to gross margin in 2023 from the AspenTech evolution, which the LLM misses entirely. (3) The multi-hop reasoning is flawed: the LLM conflates unrelated transactions (Copeland sale, Test & Measurement acquisition) with the AspenTech relationship, failing to correctly synthesize the evolution of the partnership into ownership and its direct financial effects. It introduces entities and events not present in the original knowledge base, indicating a failure in accurate information retrieval and reasoning. (4) While the LLM attempts to address the evolution of the relationship and financial impacts, it does so with incorrect entities, timelines, and figures. The contextual relevance is moderate because it discusses ownership changes and financial metrics, but the core facts are inaccurate, leading to a low correctness score. Semantic equivalence is not achieved due to major factual divergence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1484,
        "completion_tokens": 598,
        "total_tokens": 2083
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How did the financial relationship between NEE and FPL Group Capital Inc evolve from 2022 to 2023, particularly in terms of the nature of their obligations and capital structure involvement?",
      "original_answer": "In 2022, the relationship was characterized by a guarantee agreement between FPL Group, Inc. and FPL Group Capital Inc. dated October 14, 1998, indicating a direct obligation from FPL Group, Inc. to FPL Group Capital Inc. By 2023, this relationship had evolved into a more complex capital structure involvement, with NEE issuing multiple series of junior subordinated debentures to FPL Group Capital Inc., including Series B, C, L, M, N, O, and P, with maturity dates ranging from 2057 to 2082. This transition reflects a strategic shift from a simple guarantee to a long-term capital financing arrangement.",
      "llm_answer": "From 2022 to 2023, the financial relationship between NEE and FPL Group Capital Inc remained anchored in the long‑standing guarantee framework established in 1998, which continues to obligate NEE to support FPL Group Capital’s debt obligations. While no new guarantee agreements were filed during this period, the existing guarantee (Exhibit 10(uu) in the 2022 filing) persisted, and NEE continued to issue junior subordinated debentures and related purchase‑contract and pledge agreements that provided capital‑structure support to its subsidiaries. These instruments—such as the Series P Junior Subordinated Debentures (2021) and subsequent purchase‑contract agreements (2022‑2023)—demonstrate that NEE’s capital‑structure involvement evolved through the ongoing issuance of debt securities and related collateral arrangements, rather than through any change in the fundamental guarantee relationship.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains partially correct information but fails to accurately reflect the evolution of the financial relationship between NEE and FPL Group Capital Inc. from 2022 to 2023 as described in the ground truth. (1) Correct elements include the mention of the 1998 guarantee agreement and the ongoing issuance of junior subordinated debentures, which aligns with the capital structure involvement. However, the LLM incorrectly states that the relationship 'remained anchored' in the guarantee framework without significant change, while the ground truth indicates a clear strategic shift from a simple guarantee to a more complex capital financing arrangement via multiple new debenture series. (2) Quantitatively, the LLM references Series P debentures issued in 2021 and purchase-contract agreements from 2022–2023, but omits the key detail that in 2023, NEE issued Series B, C, L, M, N, O, and P debentures with maturities from 2057 to 2082—specific series and dates that are central to the evolution. The absence of these specific series and maturity ranges represents a significant omission. (3) In terms of multi-hop reasoning, the LLM fails to synthesize the transition from a direct guarantee to a broader capital structure role; instead, it frames the debenture issuances as subsidiary support mechanisms without linking them directly to FPL Group Capital Inc. as the recipient, which is a critical link. (4) Contextually, the response is relevant and uses appropriate financial terminology, but the core conclusion—that there was no fundamental change—contradicts the ground truth's assertion of a strategic shift. This undermines the qualitative and overall correctness despite some accurate contextual details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 468,
        "total_tokens": 1857
      },
      "error": null
    },
    {
      "question_id": 11,
      "question": "How has the positioning and market acceptance of InterStim II evolved between 2022 and 2024, particularly in relation to other InterStim neurostimulators and broader Pelvic Health therapies?",
      "original_answer": "In 2022, InterStim II was described as part of a suite of InterStim neurostimulators including InterStim Micro and InterStim X, with an emphasis on continued acceptance and growth in treating overactive bladder, urinary retention, and bowel incontinence. By 2024, InterStim II was specifically highlighted as a recharge-free neurostimulator, grouped alongside InterStim X and InterStim Micro (now differentiated by recharge status), and positioned within a broader context of continued acceptance and growth of Pelvic Health therapies. This evolution indicates a shift toward emphasizing device-specific attributes (e.g., recharge-free) and integration into a more mature and diversified product portfolio.",
      "llm_answer": "Between 2022 and 2024, InterStim II’s market positioning evolved from early adoption to broader acceptance within Medtronic’s Pelvic Health portfolio, gaining traction alongside other InterStim models and expanding its therapeutic reach. The device received FDA approval in 2022 and was highlighted in 2023–2024 disclosures for its role in treating overactive bladder and urinary retention, with growing global adoption noted in Neuroscience segment reports. Its acceptance grew in parallel with other advanced neurostimulation therapies, supported by strategic investments in integrated solutions like the AiBLE ecosystem and robotic-assisted surgery platforms, while competing with alternative Pelvic Health treatments and broader cardiovascular and medical surgical offerings.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. Most critically, it claims InterStim II received FDA approval in 2022, which is incorrect — InterStim II has been on the market for years prior and was not newly approved in 2022. This misrepresents the timeline and evolution. Additionally, the answer introduces concepts not present in the ground truth, such as 'early adoption' and 'AiBLE ecosystem' and 'robotic-assisted surgery platforms', which are not mentioned in the original data and appear speculative or incorrectly attributed. The therapeutic indications (overactive bladder, urinary retention) are correctly noted, and global adoption is a reasonable inference, but the emphasis on recharge-free status — a key differentiator highlighted in 2024 — is missing. (2) Regarding quantitative accuracy, the date 2022 is correctly referenced but misused (as approval year, not as part of an ongoing acceptance trend). No actual financial figures or percentages are present in either answer, so scoring focuses on correct use of years and events — here, the misuse of 'FDA approval in 2022' is a major error. (3) The multi-hop reasoning is partially sound in that it attempts to connect InterStim II to broader Pelvic Health therapies and portfolio trends, but it fails to accurately synthesize the evolution in product positioning — specifically the shift toward emphasizing recharge-free status and portfolio segmentation by recharge capability (InterStim II vs. Micro vs. X). Instead, it invents strategic drivers (e.g., AiBLE, robotics) not supported by the ground truth. (4) Contextually, the answer addresses the general theme of market acceptance and positioning within Pelvic Health, so relevance is moderate. However, due to significant factual errors and introduction of unsupported elements, the correctness score is low. The qualitative accuracy is partially acceptable due to correct mention of indications and portfolio context, but flawed in reasoning and entity usage.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1382,
        "completion_tokens": 540,
        "total_tokens": 1923
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Simon Property Group's utilization and management of the Supplemental Facility evolved between 2022 and 2024, particularly in terms of borrowing capacity, interest rate strategies, and repayment actions?",
      "original_answer": "In 2022, the Supplemental Facility had an initial borrowing capacity of $3.5 billion, which could be increased to $4.5 billion, with a maturity date of January 31, 2026. Borrowings under the facility bore interest based on SOFR or similar rates, with a margin determined by the company's credit rating. By 2024, SPG had borrowed €750.0 million under the Supplemental Facility, which was repaid on November 17, 2023, following the issuance of exchangeable bonds. Additionally, interest rate swaps were used in 2023 to fix the rate on these borrowings at 3.81%. This indicates a shift from passive availability in 2022 to active utilization and strategic interest rate management in 2024.",
      "llm_answer": "Between 2022 and 2024, Simon Property Group expanded its borrowing capacity through the Supplemental Facility, which grew from $3.5–$4.5 billion to support larger revolving commitments, while maintaining a similar interest‑rate structure tied to SOFR plus a spread (approximately 72.5 bps) and a facility fee based on credit ratings. The company actively managed its debt by issuing fixed‑rate senior unsecured notes (e.g., 5.5%–6.65% tranches maturing 2033–2054) and redeeming older floating‑rate securities, thereby reducing reliance on variable‑rate borrowings and lowering overall weighted‑average interest rates from 5.91% (2023) to 5.47% (2024). These actions, together with repayments of $1.9 billion of debt and strategic use of the Credit and Supplemental Facilities, reflect a deliberate strategy to increase long‑term fixed‑rate financing, optimize interest‑rate exposure, and preserve liquidity for acquisitions and development.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies and introduces information not present in the ground truth. While it correctly identifies the initial borrowing capacity of $3.5 billion (expandable to $4.5 billion) and the SOFR-based interest structure, it fabricates details such as a spread of 'approximately 72.5 bps', which is not in the original answer. It also incorrectly states that borrowing capacity increased beyond $4.5 billion, which is unsupported. The repayment of €750 million on November 17, 2023, is entirely omitted and replaced with a generic $1.9 billion debt repayment figure not mentioned in the ground truth. The issuance of exchangeable bonds that enabled repayment is missing. The interest rate swaps fixing the rate at 3.81% are not mentioned. Instead, the LLM discusses fixed-rate note issuances (5.5%–6.65%) and a decline in weighted-average interest rates from 5.91% to 5.47%, none of which appear in the original answer. (2) Quantitative accuracy is low: only the $3.5–$4.5 billion capacity range is correct. All other numbers (72.5 bps, $1.9B repayment, 5.91% to 5.47%, 3.81% swap rate omitted) are either incorrect or fabricated. (3) The reasoning is partially sound in identifying a strategic shift toward fixed-rate financing, but it fails the multi-hop requirement by not connecting the €750M borrowing, its repayment via exchangeable bonds, and the use of swaps—all key elements in the ground truth. The synthesis is based on plausible financial logic but not on the actual data provided. (4) Contextual relevance is moderate because the answer addresses borrowing capacity, interest rate strategy, and repayment actions, aligning with the question’s structure, but the factual foundation is weak. Correctness score is low due to major omissions and invented metrics despite some correct contextual framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1422,
        "completion_tokens": 504,
        "total_tokens": 1927
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has Verizon's approach to device payment plans evolved from 2023 to 2024, particularly in terms of customer financing structure and promotional incentives?",
      "original_answer": "In 2023, Verizon permitted customers to acquire equipment using device payment plans that allowed installment payments over time, with no mention of structured promotional incentives or trade-in rights. By 2024, Verizon formalized the device payment plan structure, describing it as a non-interest-bearing installment note typically repaid over a 36-month term, and introduced a defined promotional feature that allows customers to upgrade to a new device after paying a specified portion of their plan and trading in their current device in good working order. This represents a shift from a general financing mechanism to a more structured and incentive-driven model.",
      "llm_answer": "Verizon's device payment plans have evolved from 2023 to 2024 by shifting from fixed-term subsidized plans to non‑interest‑bearing installment notes that are paired with month‑to‑month service contracts, and by adding promotional billing credits that are treated as variable consideration in the transaction price. The 2024 disclosures emphasize that these credits and trade‑in guarantees are now accounted for as liabilities that reduce revenue, and the company assesses the significance of the financing component only when it is material, resulting in a more streamlined financing structure for device payments.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures some correct elements about Verizon's 2024 device payment plan structure, such as the shift to non-interest-bearing installment notes and the mention of promotional incentives. However, it introduces inaccuracies and omits key aspects from the ground truth. Quantitatively, there are no explicit numerical errors (e.g., dates like 2023–2024 are correct), so quantitative accuracy is high. The mention of 36-month terms is implied as reasonable and aligns with industry norms, though not explicitly confirmed in the LLM answer. However, the LLM incorrectly states that promotional 'billing credits' and 'trade-in guarantees' are accounted for as liabilities that reduce revenue—this level of accounting treatment is not present in the original answer and represents an overreach or misrepresentation of the disclosed information. Additionally, the original answer emphasizes a structured upgrade path after paying a 'specified portion' of the plan with a trade-in, which is a customer-facing promotional incentive, whereas the LLM frames incentives as 'variable consideration' and accounting liabilities, shifting focus to revenue recognition rather than customer financing benefits. This misrepresents the nature of the promotional incentives. The original does not mention 'month-to-month service contracts' or 'financing component materiality assessments,' which are extraneous details not supported by the ground truth. While the LLM recognizes a structural evolution, it fails to accurately describe the core promotional mechanism introduced in 2024—namely, the upgrade-after-partial-payment-and-trade-in feature. Thus, while the answer is contextually relevant and contains plausible financial terminology, it distorts the qualitative nature of the change and adds unverified accounting details, leading to a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1324,
        "completion_tokens": 502,
        "total_tokens": 1826
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How has The Coca-Cola Company's legal relationship with Aqua-Chem evolved between 2023 and 2024, particularly in terms of its stance on liability for Aqua-Chem's asbestos-related claims?",
      "original_answer": "In 2023, Coca-Cola maintained that it had no obligation to Aqua-Chem for any liabilities or expenses related to claims or lawsuits against Aqua-Chem, as outlined in the Georgia Case. By 2024, while the litigation status remained largely unchanged, Coca-Cola's disclosure now includes a more detailed description of the insurance policies issued during its ownership of Aqua-Chem, particularly highlighting the involvement of multiple insurers and the ongoing coverage litigation. This indicates a shift in emphasis from outright denial of liability to a more nuanced stance centered on insurance coverage and shared responsibility among insurers.",
      "llm_answer": "The Coca-Cola Company continues to maintain that it bears no liability for Aqua‑Chem’s asbestos‑related claims, a position it has held since the 2002 litigation and reinforced through the subsequent Wisconsin insurance‑coverage proceedings, settlements, and appeals, which concluded with the Wisconsin Supreme Court denying review and confirming the Company’s stance that it is not responsible for those claims.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in the context of the question, which asks specifically about the evolution of Coca-Cola's legal stance toward Aqua-Chem's asbestos-related claims between 2023 and 2024. Instead, the LLM provides a static description of Coca-Cola's long-standing denial of liability, referencing events from 2002, Wisconsin proceedings, and a concluded appeal—none of which pertain to the 2023–2024 timeframe. The ground truth highlights a nuanced shift in emphasis during this period: while Coca-Cola still denies direct liability, its 2024 disclosures include more detailed discussion of historical insurance policies and ongoing coverage litigation involving multiple insurers, signaling a strategic shift in narrative. The LLM fails to mention this evolution entirely. It incorrectly implies continuity without acknowledging the change in disclosure focus. There are no numeric values in either answer, so quantitative accuracy is neutral—no errors, but no relevant numbers discussed. The entities (Coca-Cola, Aqua-Chem, asbestos claims) are correct, but the reasoning is flawed: the model does not perform the required multi-hop synthesis across 2023 and 2024 disclosures. Instead, it defaults to outdated information. While the general topic (liability denial) is relevant, the absence of time-specific analysis and the shift in disclosure strategy severely undermines correctness. Thus, the answer is mostly incorrect despite some contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 405,
        "total_tokens": 1679
      },
      "error": null
    },
    {
      "question_id": 12,
      "question": "How did Intel's utilization of non-US tax credits impact its long-term income tax liabilities in 2024 compared to 2022, and what does this indicate about the company's international tax strategy?",
      "original_answer": "In 2022, Intel reported long-term income taxes payable of $4.3 billion, which included the transition tax from Tax Reform and uncertain tax positions, reduced by non-US tax credits. By 2024, this figure had decreased to $1.6 billion, indicating that the company's utilization of non-US tax credits had a stronger offsetting effect over time. This suggests a strategic shift or increased effectiveness in leveraging international tax credits to reduce overall tax liabilities.",
      "llm_answer": "Intel's 2024 effective tax rate of 71.6% sharply contrasts with 2022's (3.2%) due to a $13.974 billion valuation allowance for US deferred tax assets, indicating a strategic shift toward aggressive international tax planning. This reflects a deliberate focus on leveraging non-US jurisdictions with lower statutory rates (e.g., Israel, Malaysia) and tax credits, while abandoning reliance on US tax benefits, as evidenced by the $67 million tax benefit from non-US income taxed at different rates in 2024 versus $220 million in 2022.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that Intel's long-term income taxes payable decreased from $4.3 billion in 2022 to $1.6 billion in 2024 due to increased use of non-US tax credits. However, the LLM answer incorrectly focuses on the effective tax rate (71.6% in 2024 vs 3.2% in 2022), which contradicts the ground truth and is not supported by the provided data. Additionally, the LLM claims a $13.974 billion valuation allowance drove the tax rate change, but this detail is absent from the original answer and cannot be verified from the given context. The mention of a $67 million tax benefit in 2024 versus $220 million in 2022 from non-US income taxed at different rates is also not present in the original answer and appears fabricated. (2) Quantitative accuracy is very low: none of the key numbers (effective tax rates, valuation allowance, tax benefits) match or are derivable from the ground truth. The actual figures provided in the original answer—$4.3B and $1.6B in long-term taxes—are completely omitted in the LLM response. (3) The multi-hop reasoning is flawed. While the question asks about the impact of non-US tax credits on long-term income tax liabilities over time, the LLM diverts to effective tax rates and valuation allowances, failing to connect the reduction in long-term tax liabilities to the growing effectiveness of non-US tax credit utilization as stated in the original. It misattributes the strategic shift to abandonment of US benefits rather than an enhanced use of international credits. (4) Despite incorrect facts and reasoning, the LLM does attempt to address the international tax strategy component, suggesting a focus on lower-tax jurisdictions like Israel and Malaysia, which aligns thematically with leveraging international tax structures. This provides some contextual relevance, but the lack of factual grounding severely undermines the response. Correctness is scored very low due to complete mismatch in core financial figures and misleading causal explanations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 557,
        "total_tokens": 1821
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has the treatment and risk exposure of pension risk transfers evolved between 2022 and 2024, particularly in terms of interest rate sensitivity and regulatory influence?",
      "original_answer": "In 2022, pension risk transfers were part of the Retirement and Income Solutions business, which was described as containing both short- and long-duration products, and was subject to interest rate scenarios that could impact asset-liability management (ALM) strategies. By 2024, regulatory changes, particularly around defined benefit pension plan funding, were found to potentially reduce the likelihood or delay corporate plan sponsors from terminating their plans or transferring pension obligations. This regulatory evolution increased the potential for a shift in the mix of pension risk transfers toward non-guaranteed funding products, indicating a strategic and regulatory-driven change in exposure.",
      "llm_answer": "Between 2022 and 2024, pension risk transfers have become increasingly sensitive to interest rate movements, with rising rates generating net favorable impacts to adjusted earnings through higher reinvestment yields that more than offset higher crediting rates and lower derivative income. Regulatory influences remain significant, as changes in interest rate assumptions directly affect reserve financing costs, capital requirements, and the pricing of products with minimum crediting guarantees, particularly in long-duration and annuity lines where ALM strategies and derivative usage are critical to managing margin compression.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer correctly identifies interest rate sensitivity and regulatory influence as key factors in pension risk transfers between 2022 and 2024, and accurately references ALM strategies, derivative usage, and the impact of interest rate changes on earnings and pricing—elements consistent with the domain. However, it diverges significantly from the ground truth in key qualitative aspects. The original answer emphasizes a shift in regulatory environment (particularly around defined benefit plan funding) that reduces or delays plan terminations and transfers, leading to a strategic shift toward non-guaranteed funding products. The LLM answer does not mention this regulatory evolution or its effect on corporate behavior or product mix. Instead, it focuses on the financial mechanics of interest rate impacts (e.g., reinvestment yields vs. crediting rates), which, while plausible, are not supported by the ground truth and introduce details (e.g., 'net favorable impacts to adjusted earnings') that were not present or verifiable from the source. There are no explicit numbers in either answer, so quantitative accuracy is scored highly due to correct use of financial concepts and terminology. Contextual relevance is moderate because the answer addresses the general theme but misses the specific evolution in risk exposure due to regulatory changes. Multi-hop reasoning is partially sound but fails to synthesize the correct cause-effect chain between regulation and transfer behavior as described in the original. Thus, the answer is factually incomplete and misaligned with the core evolution described in the ground truth, warranting a mid-range correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 456,
        "total_tokens": 1798
      },
      "error": null
    },
    {
      "question_id": 13,
      "question": "How has Medtronic's positioning and product strategy around the InterStim Micro neurostimulator evolved between 2022 and 2024?",
      "original_answer": "In 2022, Medtronic positioned the InterStim Micro as part of its broader InterStim therapy offering for treating overactive bladder, urinary retention, and bowel incontinence, alongside InterStim II and InterStim X neurostimulators. It was described as part of a growing and accepted product line within the Pelvic Health therapies under the Specialty Therapies division. By 2024, Medtronic specifically highlighted the InterStim Micro as a 'rechargeable neurostimulator' while emphasizing the continued acceptance and growth of InterStim therapy, particularly in the U.S., and distinguishing it from the recharge-free InterStim X and InterStim II models. This indicates a more targeted marketing and differentiation strategy for the InterStim Micro within the evolving Pelvic Health product portfolio.",
      "llm_answer": "Medtronic’s InterStim Micro neurostimulator has moved from early‑stage rollout to broader commercial adoption between 2022 and 2024. In the 2022 filings the product is highlighted as part of the “Pelvic Health” and “Neuromodulation” growth drivers, and by 2024 it is specifically cited as a recharge‑free, implantable solution for overactive bladder, urinary retention and fecal incontinence, with its sales contributing to the overall Neuroscience segment’s 3 % increase. The company also notes continued acceptance and growth of InterStim X and InterStim II, indicating that the Micro platform is being integrated into a larger portfolio of recharge‑free therapies.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. Most critically, it incorrectly describes the InterStim Micro as 'recharge-free' in 2024, while the ground truth states it is a 'rechargeable neurostimulator'—this is a direct contradiction. Additionally, the claim that InterStim Micro sales contributed to a 3% increase in the Neuroscience segment is not supported by the original answer and introduces unverified quantitative data. (2) The quantitative accuracy is low because the 3% growth figure is fabricated or misattributed—no such percentage appears in the ground truth. There are no actual sales figures or growth metrics in the original answer, so introducing one constitutes a major error. (3) The multi-hop reasoning is partially sound in that the model attempts to track product positioning over time and situates the device within Medtronic’s portfolio and therapeutic areas. However, the core differentiation strategy is misrepresented: the original emphasizes that InterStim Micro is rechargeable, while InterStim X and II are recharge-free—this distinction is reversed in the LLM answer, undermining the entire product strategy analysis. (4) Contextual relevance is high because the answer addresses the evolution of product strategy and positioning over time, discusses the correct therapeutic indications, and references the appropriate business segments. Despite this, the reversal of a key product attribute (rechargeable vs. recharge-free) and the introduction of unsupported metrics severely compromise factual correctness, warranting a low overall score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 439,
        "total_tokens": 1801
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has Simon Property Group's use of the Supplemental Facility evolved between 2022 and 2024, particularly in terms of outstanding borrowings and repayment actions?",
      "original_answer": "In 2022, Simon Property Group had a weighted average outstanding balance under the Credit Facilities (including the Supplemental Facility) of $519.9 million, with a maximum aggregate outstanding balance of $2.1 billion during the year. By 2024, the weighted average outstanding balance under the Facilities had decreased to $311.1 million, and the company had repaid a significant portion of its borrowings, including €750.0 million ($815.4 million U.S. dollar equivalent) under the Supplemental Facility on November 17, 2023. This indicates a strategic reduction and refinancing of debt drawn from the Supplemental Facility over the two-year period.",
      "llm_answer": "Between 2022 and 2024, Simon Property Group reduced its reliance on the Supplemental Facility, repaying $1.05 billion of borrowings under it in January 2022 using proceeds from a new $1.2 billion senior unsecured note issuance, and subsequently drawing only limited amounts under the facility. By the end of 2024 the outstanding balance under the Supplemental Facility was essentially eliminated, reflecting a strategic shift toward other financing sources such as the Credit Facility and unsecured note markets.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It claims Simon Property Group repaid $1.05 billion under the Supplemental Facility in January 2022 using proceeds from a $1.2 billion note issuance, but this event is not supported by the ground truth. The original answer states that in 2022, the weighted average outstanding balance under the Credit Facilities (including the Supplemental Facility) was $519.9 million, with a maximum of $2.1 billion—no repayment of $1.05 billion in January 2022 is mentioned. Instead, the ground truth highlights a repayment of €750.0 million ($815.4 million) on November 17, 2023, which the LLM answer omits entirely. Additionally, the claim that the outstanding balance was 'essentially eliminated' by the end of 2024 is not corroborated; the ground truth reports a weighted average balance of $311.1 million in 2024, not zero. (2) The quantitative inaccuracies are severe: the $1.05 billion repayment and $1.2 billion note issuance are fabricated or misattributed, and the key repayment of $815.4 million in November 2023 is missing. The correct trend—decline from $519.9M to $311.1M average balance—is not reflected. (3) The multi-hop reasoning is flawed: the LLM invents a financing event rather than synthesizing the actual repayment and balance reduction data across 2022–2024. It fails to connect the November 2023 repayment to the declining balances. (4) While the general direction of reduced reliance on the Supplemental Facility aligns with the truth, the specific mechanisms and figures are incorrect, leading to a low correctness score. Contextual relevance is moderate because the answer addresses the right topic and timeframe but with incorrect details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 471,
        "total_tokens": 1766
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did COP's investment activity in the Lower 48 region evolve from 2022 to 2023, based on the changes in depreciation, depletion, amortization, and impairments expenses?",
      "original_answer": "In 2022, COP reported $4,854 million in depreciation, depletion, amortization, and impairments expenses for the Lower 48 region, which increased to $5,729 million in 2023. This indicates a significant increase in investment activity or asset utilization in the Lower 48 region over that period.",
      "llm_answer": "Based on the depreciation, depletion, and amortization (DD&A) expense table in **page_134** (Consolidated DD&A: $8,284 million in 2023 vs. $7,492 million in 2022), COP’s investment activity in the Lower 48 region expanded materially from 2022 to 2023, driving the higher DD&A charge. The increase reflects greater capital spending and a larger asset base in that segment, as evidenced by the rise in Lower 48 capital expenditures and investments (from $5,630 million in 2022 to $6,487 million in 2023) and the corresponding growth in DD&A. Thus, the company’s Lower 48 investments grew substantially over the one‑year period, as signaled by the upward shift in DD&A expenses.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in key numbers. The ground truth states that COP's depreciation, depletion, amortization, and impairments expenses for the Lower 48 region were $4,854 million in 2022 and $5,729 million in 2023. However, the LLM incorrectly cites consolidated (company-wide) DD&A figures ($7,492M in 2022 and $8,284M in 2023) from page_134, which are not specific to the Lower 48 region. This is a critical error in quantitative accuracy. Additionally, the LLM introduces capital expenditures for the Lower 48 region ($5,630M in 2022 → $6,487M in 2023), which are not present in the original answer or supported by the provided context, making them potentially hallucinated or misattributed. (2) Calculations: While the direction of change (increase) aligns with the ground truth, the actual values used are incorrect. The LLM reports a DD&A increase from $7,492M to $8,284M (company-wide), whereas the correct regional increase is from $4,854M to $5,729M—an increase of $875M. The LLM’s implied increase of $792M (from wrong numbers) is close but based on incorrect data. (3) Multi-hop reasoning: The LLM attempts to link rising DD&A to increased investment activity, which is logically sound and matches the original answer’s reasoning. It also tries to support this with capex data, showing an attempt at deeper synthesis. However, because the core financial figures are not from the correct segment (Lower 48), the reasoning fails at the foundational level. (4) Despite incorrect numbers, the conclusion about increased investment activity is directionally correct, and the response is contextually relevant. Hence, partial credit is given for qualitative reasoning and relevance, but major deductions apply for factual and quantitative errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1248,
        "completion_tokens": 489,
        "total_tokens": 1738
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has Verizon's approach to corporate networking solutions evolved from 2023 to 2024, particularly in terms of service description and business segment emphasis?",
      "original_answer": "In 2023, Verizon's Business segment explicitly described offering a broad portfolio of network connectivity products, including private networking services, private cloud connectivity services, and software-defined networking services, with Enterprise and Public Sector revenues reaching $15.1 billion, or approximately 50% of Business's total revenues. By 2024, the Business segment's description became more streamlined, focusing on wireless and wireline communications services and products, including corporate networking solutions, without specifying the same level of detail in offerings or segment revenue. This indicates a shift toward a more generalized presentation of services, potentially signaling a strategic consolidation or simplification of messaging around corporate networking solutions.",
      "llm_answer": "Verizon’s corporate networking solutions have shifted from a broad, diversified offering across multiple segments to a more focused emphasis on its Business Group. In 2023, the Business segment’s operating income was $2.6 billion on $30.1 billion of revenue, but by 2024 that segment’s operating income fell to $2.0 billion on $30.1 billion of revenue, while the Consumer segment’s operating income rose to $29.5 billion on $102.9 billion of revenue. This indicates a strategic pivot toward prioritizing the Consumer segment’s service and wireless offerings, with less relative emphasis on the Business segment’s corporate networking solutions.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2023, Enterprise and Public Sector revenues were $15.1 billion, representing about 50% of the Business segment's total revenue, implying total Business segment revenue of approximately $30.2 billion, which aligns loosely with the LLM's $30.1 billion figure. However, the LLM introduces operating income figures ($2.6B in 2023 and $2.0B in 2024 for the Business segment) that are not present in the original answer and cannot be verified from the provided ground truth. More critically, the LLM claims Consumer segment operating income rose to $29.5 billion on $102.9 billion of revenue in 2024, which is not supported by the original answer and represents a major fabrication or misattribution. (2) The quantitative inaccuracies are severe: while $30.1 billion in Business segment revenue is close to the implied $30.2 billion in the ground truth, the operating income figures and Consumer segment financials are entirely absent from the original and appear invented. There is no mention of operating income or Consumer segment performance in the ground truth, so these numbers fail verification. (3) The reasoning is flawed. The original answer describes a shift in *service description and messaging*—from detailed listing of networking offerings in 2023 to a more streamlined, generalized description in 2024—suggesting strategic simplification. The LLM instead infers a strategic pivot based on operating income changes, which is unsupported by the provided data. This misrepresents the nature of the evolution, focusing on financial performance rather than service description and segment emphasis as defined in the question. (4) The contextual relevance is moderate because the answer addresses Verizon’s Business segment and corporate networking, but it fails on correctness due to hallucinated financials and incorrect reasoning. The qualitative accuracy is low because the model fails to capture the actual evolution—changes in service description—and instead invents a narrative around financial shifts. The correctness score is low due to major factual and reasoning errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1366,
        "completion_tokens": 586,
        "total_tokens": 1953
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How did MetLife's valuation approach and sensitivity to fair value changes for FVO securities evolve from 2022 to 2024, particularly in terms of the impact of U.S. dollar appreciation?",
      "original_answer": "In 2022, MetLife reported that FVO securities had an estimated fair value of $1.6 billion and were sensitive to changes in the U.S. dollar, with a 10% appreciation leading to a $54 million decrease in value. By 2024, while no direct fair value figure for FVO securities is provided, the company emphasized a broader sensitivity framework where nonperformance risk spreads and unobservable inputs varied by duration and currency, indicating a more nuanced and dynamic valuation methodology. This evolution shows a shift from a static sensitivity model to a more complex, duration- and currency-dependent approach.",
      "llm_answer": "From 2022 to 2024, MetLife’s valuation of FVO securities and Level 3 assets shows a clear shift driven by U.S. dollar appreciation.  \n\n- In the 2022 rollforward (page 152), total realized/unrealized gains in net income for FVO securities were $238 million, with a $537 million loss recorded in AOCI.  \n- By 2023 (page 252), the FVO balance fell to $5 million and net gains in income dropped to $14 million, while the AOCI loss narrowed to $1 million; the 2024 balance is $5 million with $13 million of gains in income and a $0 AOCI impact.  \n- The sensitivity tables (page 248) indicate that a 10% U.S.‑dollar appreciation would generate a $9.984 billion negative impact on fixed‑maturity AFS and a $54 million hit to FVO securities, illustrating that currency‑driven market movements materially affect the fair‑value trajectory of these instruments.  \n\nThus, the company’s valuation approach remained consistent (using market‑price, pricing service and consensus inputs), but the increasing strength of the dollar amplified unrealized losses in 2022 and reversed to modest gains by 2024, directly influencing the reported fair‑value changes.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and misrepresents key aspects of MetLife's FVO securities valuation and sensitivity analysis from 2022 to 2024. (1) Quantitative Accuracy: The ground truth states that in 2022, FVO securities had an estimated fair value of $1.6 billion and a 10% USD appreciation would decrease value by $54 million. The LLM correctly cites the $54 million sensitivity figure but incorrectly introduces unrelated data points—such as $238 million gains in net income and $537 million AOCI losses in 2022—that are not mentioned in the original answer and appear to misinterpret financial statement line items. The claim that the FVO balance fell to $5 million in 2023 and remained at $5 million in 2024 contradicts the original answer, which does not provide a 2024 fair value but implies ongoing materiality. The $9.984 billion negative impact is attributed to fixed-maturity AFS securities, not FVO, so including it misrepresents the scope. (2) Completeness: The question asks about the evolution of the valuation *approach* and sensitivity to USD appreciation. The LLM fails to mention the key evolution described in the original answer—the shift from a static sensitivity model to a more nuanced, duration- and currency-dependent framework incorporating nonperformance risk spreads and unobservable inputs. Instead, it focuses on income statement and AOCI fluctuations, which were not part of the ground truth. (3) Reasoning: The multi-hop synthesis is flawed. The LLM infers a 'consistent valuation approach' based on pricing inputs but misses the core conceptual shift in methodology emphasized in the original answer. It conflates market impacts (e.g., dollar strength affecting unrealized gains) with valuation methodology, which are distinct concepts. (4) Semantic Equivalence: While the $54 million sensitivity figure is correctly cited, the overall narrative diverges significantly in focus and factual content. The original emphasizes methodological evolution; the LLM emphasizes P&L volatility without addressing structural changes in valuation models. Thus, despite some correct numbers, the answer is partially correct at best, with major omissions and inaccuracies affecting correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1448,
        "completion_tokens": 596,
        "total_tokens": 2044
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has NextEra Energy's engagement in power marketing activities evolved between 2022 and 2023, particularly in terms of its energy trading services and associated financial performance?",
      "original_answer": "In 2022, NextEra Energy (NEE) was actively engaged in power and fuel marketing and trading activities, primarily providing full energy and capacity requirements services to distribution utilities, including load-following and ancillary services, while also optimizing the value of electricity and fuel contracts and generation assets. By 2023, NEE's subsidiary NEER had expanded its role in power marketing and trading, contributing to a significant increase in net income, which rose from $285 million in 2022 to $3,558 million in 2023. This indicates a substantial evolution and growth in the scale or profitability of NEE’s power marketing and trading activities over the period.",
      "llm_answer": "Between 2022 and 2023, NextEra Energy’s power marketing activities expanded significantly, driven by higher earnings from new wind and solar generation and battery storage facilities that entered service after 2022. Operating revenues increased by $5,952 million in 2023, largely due to gains from non‑qualifying commodity hedges ($2,529 million) and new investment revenues ($390 million), while operating expenses rose modestly by $566 million, reflecting growth across NEER’s businesses. Consequently, NEER’s net income attributable to noncontrolling interests jumped by $3,273 million, underscoring the positive financial impact of its expanded energy trading and marketing operations.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in financial figures and attribution. While it correctly identifies that NextEra Energy (NEE) and its subsidiary NEER expanded power marketing activities between 2022 and 2023, the specific financial data provided does not align with the ground truth. The ground truth states that NEER's net income rose from $285 million in 2022 to $3,558 million in 2023—an increase of $3,273 million—which the LLM incorrectly frames as 'net income attributable to noncontrolling interests jumped by $3,273 million.' This is a critical misrepresentation of the metric and entity. Additionally, the LLM introduces an operating revenue increase of $5,952 million and attributes it to non-qualifying commodity hedges ($2,529 million) and new investment revenues ($390 million), none of which are mentioned in the ground truth. (2) The only quantitatively accurate element is the $3,273 million difference between $3,558M and $285M, but this is mislabeled as a change in 'net income attributable to noncontrolling interests' rather than total net income. All other numbers (e.g., $5,952M revenue increase, $566M expense rise) are unsupported by the ground truth. (3) The reasoning partially captures the expansion of NEER’s role in power marketing and links it to improved financial performance, which aligns with the ground truth’s narrative of growth. However, it fails to correctly synthesize the multi-hop information—specifically, that the net income growth reflects overall profitability in power marketing, not just noncontrolling interests—and introduces unverified drivers like new wind/solar/battery facilities. (4) The contextual relevance is high because the answer addresses the evolution of power marketing and financial performance, but correctness is severely undermined by incorrect metrics and misattributed financial data. Thus, while the direction of change (growth) is correct, the factual basis is flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 537,
        "total_tokens": 1890
      },
      "error": null
    },
    {
      "question_id": 14,
      "question": "How has The Coca-Cola Company's financial relationship with Coca-Cola FEMSA evolved between 2023 and 2024, particularly in terms of its stake ownership and implications for equity income?",
      "original_answer": "In 2023, Coca-Cola FEMSA was referenced as one of the key bottlers whose financial performance could influence The Coca-Cola Company's credit ratings, indicating an indirect financial dependency. By 2024, The Coca-Cola Company held a 28% ownership stake in Coca-Cola FEMSA, which was accounted for under the equity method. This shift from a dependency-based relationship to a direct ownership stake suggests a strategic evolution, where Coca-Cola now has a more direct financial interest in FEMSA's performance, which will directly impact its equity income (loss) - net line item.",
      "llm_answer": "The Coca-Cola Company's financial relationship with Coca-Cola FEMSA has evolved such that its equity method investment stake in Coca-Cola FEMSA decreased from 28% at the end of 2023 to 22% by the end of 2024, as reflected in the consolidated balance sheet data showing the carrying value of this investment declining from $1,786 million to $1,147 million. This reduction in ownership stake directly impacts the Company's equity income, which increased slightly from $1,691 million in 2023 to $1,770 million in 2024, reflecting the ongoing influence of its equity method investment despite the decreased percentage ownership.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2024, The Coca-Cola Company held a 28% ownership stake in Coca-Cola FEMSA, implying stability or potential increase, whereas the LLM claims the stake decreased from 28% in 2023 to 22% in 2024—this is directly contradicted by the original answer. Additionally, the LLM introduces specific dollar amounts for carrying value ($1,786M to $1,147M) and equity income ($1,691M to $1,770M) that are not present in the ground truth and cannot be verified against it; more critically, the original answer does not mention any reduction in stake or specific investment values, making these fabrications. (2) Quantitative accuracy is very low: none of the numbers provided in the LLM answer (percentages, carrying values, equity income figures) are supported by the ground truth. There are no calculations in the original to validate or compare, so the introduction of precise figures undermines correctness. (3) Multi-hop reasoning is partially sound in structure—linking ownership stake to equity income is appropriate and relevant—but the logic is based on incorrect premises. The evolution described (reduced stake but increased income) contradicts the ground truth narrative of a strategic shift toward greater direct control via a stable 28% stake. The LLM fails to capture the key evolution from indirect dependency to direct ownership influence. (4) Contextual relevance is moderate because the answer addresses the right topic (ownership stake and equity income implications), uses correct entity names (Coca-Cola FEMSA, equity method), and attempts to analyze financial implications. However, due to major factual and quantitative errors, the overall correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 483,
        "total_tokens": 1794
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has the financial investment and operational focus on the Lower 48 region evolved between 2022 and 2023 based on production volumes and depreciation expenses?",
      "original_answer": "In 2022, the Lower 48 region showed strong production volumes, particularly in crude oil (447 thousand barrels daily) and natural gas (1,340 million cubic feet daily), indicating a significant operational focus. In 2023, the financial emphasis on the Lower 48 increased further, as evidenced by a rise in depreciation, depletion, amortization, and impairments expenses from $4,854 million in 2022 to $5,729 million in 2023. This reflects a growing financial investment in the region despite stable or moderate production levels in the prior year.",
      "llm_answer": "The Lower 48’s production volumes increased sharply from 2022 to 2023, with crude oil rising from 585 thousand barrels daily to 1,340 thousand barrels daily and natural gas liquids from 74 thousand to 110 thousand barrels daily, while depreciation expenses for the region climbed from $4,854 million in 2022 to $5,729 million in 2023. This indicates a clear evolution toward greater investment and operational focus on the Lower 48, reflected in both higher output and rising depreciation costs.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, crude oil production in the Lower 48 was 447 thousand barrels daily, not 585 thousand as stated. The LLM claims crude oil rose to 1,340 thousand barrels daily in 2023, which is incorrect—1,340 million cubic feet daily was the 2022 natural gas volume, not crude oil. Natural gas liquids (NGLs) are mentioned in the LLM answer (74k to 110k bbl/day), but these were not mentioned at all in the original answer, introducing fabricated data. The only correct quantitative figure is the rise in depreciation, depletion, amortization, and impairments from $4,854 million in 2022 to $5,729 million in 2023. (2) Calculations: While the DDA expense increase is correctly reported, the production volume figures are entirely wrong. The LLM falsely implies a sharp production increase, whereas the original answer notes 'stable or moderate production levels' in the prior year. (3) Multi-hop reasoning is flawed: the model incorrectly infers that rising output drove investment, but the ground truth emphasizes that financial investment increased (via higher DDA) despite stable production, indicating capital reinvestment rather than output growth. The LLM misrepresents the causal relationship and evolution. (4) Contextual relevance is moderate—the answer addresses financial investment and operational focus using the right metrics (production, depreciation), but with incorrect data and reasoning. Due to major factual and quantitative errors, especially in core production figures, the correctness score is low at 3.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 444,
        "total_tokens": 1708
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has Verizon's strategic relationship with its 4G LTE network evolved between 2023 and 2024 in terms of its role within the company's network infrastructure and growth initiatives?",
      "original_answer": "In 2023, Verizon's 4G LTE network was positioned primarily as a foundational component of its wireless services, specifically highlighted as a means to provide FWA broadband as an alternative to traditional landline internet access. By 2024, the strategic role of the 4G LTE network had evolved into being part of a broader integrated network vision that includes C-Band spectrum, millimeter wave spectrum, and fiber infrastructure, aimed at driving innovative products and services and fueling growth. This shift indicates a move from viewing 4G LTE in a service delivery context to a more strategic asset within a multi-technology ecosystem.",
      "llm_answer": "Verizon's strategic relationship with its 4G LTE network has evolved to become a foundational element of its broader network infrastructure and growth initiatives, particularly as the company advances its 5G deployment. While the 10-K filings do not explicitly detail a shift in the 4G LTE network's role, they emphasize that Verizon is leveraging its extensive 4G LTE network—including its C-Band spectrum and millimeter wave holdings—to support the transition to 5G, enhance network densification, and expand fixed wireless access (FWA) broadband services. This evolution underscores the 4G LTE network's continued role as a critical platform for delivering connectivity, enabling IoT services, and supporting the monetization of network investments, even as the company prioritizes 5G advancements. The 2024 filings highlight that Verizon is investing heavily in expanding fiber networks and upgrading its wireless infrastructure, with 4G LTE serving as the backbone for these initiatives until full 5G coverage is achieved.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in its qualitative assessment and contextually relevant, but it does not fully align with the ground truth in terms of the specific evolution of Verizon's strategic relationship with its 4G LTE network between 2023 and 2024. (1) What was correct: The LLM correctly identifies 4G LTE as a foundational component supporting broader infrastructure initiatives, including 5G deployment, fixed wireless access (FWA), and network densification. It accurately references C-Band spectrum, millimeter wave, and fiber integration, which are consistent with Verizon's multi-technology strategy. There are no explicit numbers, dates, or financial figures in either answer, so (2) quantitative accuracy is not applicable—no numerical inaccuracies exist, warranting a score of 10. (3) Multi-hop reasoning is partially sound: the LLM infers that 4G LTE supports 5G and FWA, which is valid, but it fails to explicitly contrast the 2023 and 2024 strategic roles as required by the question. The ground truth emphasizes a shift from 4G LTE being a service delivery mechanism (especially for FWA) in 2023 to a strategic asset within an integrated ecosystem in 2024. The LLM mentions continuity and support for 5G but does not clearly articulate this evolution in strategic framing. Additionally, the LLM claims the 10-K filings 'do not explicitly detail a shift,' which may reflect a limitation in source interpretation and weakens the reasoning. (4) Despite this, the answer remains contextually strong and semantically close, capturing key elements of the integrated network vision. Thus, correctness and qualitative accuracy are scored at 7 due to missing the precise strategic transition highlighted in the ground truth, while contextual relevance and quantitative accuracy remain high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1426,
        "completion_tokens": 487,
        "total_tokens": 1914
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How did Emerson's financial and strategic relationship with AspenTech evolve from 2022 to 2024, particularly in terms of stake value, ownership structure, and the impact on financial metrics such as backlog and gross margin?",
      "original_answer": "In 2022, Emerson held a stake in AspenTech with a backlog value of $1,042 million, indicating a strategic business relationship. By 2024, this relationship evolved significantly as Emerson completed a transaction that resulted in the creation of 'New AspenTech,' where Emerson owned 55% of the outstanding shares. This acquisition had a measurable impact on financial metrics: gross margin in 2023 increased by 3.3 percentage points, partly due to the AspenTech acquisition, and backlog in 2024 reached $8,053 million, up from $6,533 million in 2021, showing the influence of the AspenTech integration.",
      "llm_answer": "From 2022 to 2024, Emerson’s stake in AspenTech declined from approximately 57% ownership to a fully diluted market capitalization of $15.3 billion after its proposal to acquire the remaining shares at $240 per share, while Emerson retained a 40% non‑controlling equity interest in the spun‑off Copeland business that was later sold to Blackstone for $1.5 billion. The evolving relationship impacted financial metrics: AspenTech contributed $1.0 billion of backlog in 2022 (up from $328 million in 2021) and generated $231 million of acquisition‑related inventory step‑up amortization in 2024, which reduced gross margin by about 1.3 percentage points; however, adjusted EBITA rose 22% to $4.3 billion in 2024, and gross margin improved to 24.7% of sales, reflecting the broader portfolio transformation and higher‑margin software and control earnings.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains multiple factual inaccuracies. According to the ground truth, Emerson increased its ownership in AspenTech, culminating in 55% ownership of 'New AspenTech' in 2024. However, the LLM claims ownership declined from 57% to a 40% non-controlling interest in Copeland (a different entity), which misrepresents the ownership structure evolution. The $240 per share offer and $15.3 billion market cap are not mentioned in the ground truth and appear fabricated. The $1.5 billion sale of Copeland to Blackstone is contextually relevant but not part of the AspenTech stake evolution. (2) Quantitatively, the LLM states AspenTech contributed $1.0 billion of backlog in 2022, which is close to the ground truth $1,042 million, so this point is partially correct. However, it fails to report the 2024 backlog of $8,053 million and instead introduces unrelated metrics like $231 million amortization and gross margin of 24.7%, which are not in the ground truth. The ground truth states gross margin improved by 3.3 percentage points due to the acquisition, while the LLM claims a 1.3 percentage point reduction due to amortization—directly contradicting the correct impact. (3) The multi-hop reasoning is flawed: the LLM confuses Copeland (a divested business) with AspenTech, fails to identify the creation of 'New AspenTech', and misattributes financial impacts. It incorrectly frames the relationship as a dilution of stake rather than a consolidation. (4) The contextual relevance is moderate because it discusses Emerson’s strategic moves and financial metrics, but the core facts about the AspenTech relationship are incorrect. Due to major errors in ownership structure, financial impacts, and introduced false data, the correctness score is low despite some mention of backlog and margin.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 494,
        "total_tokens": 1877
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has NEE's financial commitment to the Mountain Valley Pipeline evolved between 2022 and 2023, and what does this indicate about its investment strategy?",
      "original_answer": "In 2022, NEE's involvement in the Mountain Valley Pipeline was described as part of its equity method investments, with an ownership stake ranging between 32% and 55%. By 2023, NEE, through its subsidiary NEER, had a more defined 32.8% equity investment in the Mountain Valley Pipeline, which was accompanied by a 20-year natural gas transportation agreement valued at approximately $70 million per year. This indicates a strategic deepening of NEE's commitment to the pipeline, moving from a general equity investment toward a more structured, long-term contractual relationship tied to infrastructure development.",
      "llm_answer": "NEE's financial commitment to the Mountain Valley Pipeline has declined significantly between 2022 and 2023, with the company recording a $1.5 billion impairment charge in 2020 and a full write-off of its investment in early 2022. This indicates a strategic retreat from the project, reflecting a shift in investment priorities toward more certain and lower-risk opportunities, such as its $110 million additional investment commitment in 2024 for the pipeline's construction, while simultaneously reducing exposure to the uncertain venture.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in nearly all aspects. The original answer states that NEE maintained and deepened its commitment to the Mountain Valley Pipeline from 2022 to 2023, with a defined 32.8% equity stake and a $70 million/year transportation agreement. In contrast, the LLM claims NEE recorded a $1.5 billion impairment in 2020 and a full write-off in early 2022, which contradicts the ground truth and indicates a complete reversal of the actual investment strategy. There is no mention of impairments or write-offs in the ground truth. (2) The quantitative inaccuracies are severe: the $1.5 billion impairment, the write-off in 2022, and the $110 million 'additional investment commitment in 2024' are all fabricated and not present in the original answer. The original answer mentions a $70 million per year transportation agreement, not a $110 million construction commitment. (3) The multi-hop reasoning is fundamentally flawed. Instead of synthesizing increased commitment through equity and long-term contracts, the model incorrectly infers a strategic retreat, which is the opposite of the truth. The mention of a 2024 investment further misaligns with the 2022–2023 timeframe in the question. (4) The contextual relevance is low because the answer addresses the general topic but with incorrect facts and directionality. The qualitative reasoning fails due to incorrect entity relationships and invented financial events. Only minimal relevance is retained because the answer discusses NEE and the Mountain Valley Pipeline in a broad sense.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1291,
        "completion_tokens": 434,
        "total_tokens": 1725
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has Coca-Cola's relationship with Costa Limited evolved from 2023 to 2024 in terms of its operational integration and strategic positioning within the Global Ventures segment?",
      "original_answer": "In 2023, Costa Limited was referenced as part of Coca-Cola's direct retail operations, specifically through retail stores operated by Costa, and was included within the Global Ventures operating segment. By 2024, Costa Limited was more strategically embedded within the Global Ventures segment, which now also included the results of innocent and doğadan businesses, as well as fees earned under distribution coordination agreements. This indicates a deeper integration and broader strategic role for Costa within Coca-Cola’s diversified beverage portfolio.",
      "llm_answer": "From 2023 to 2024, Coca-Cola’s Global Ventures segment has deepened its operational integration of Costa Limited, expanding its footprint within the segment’s portfolio of emerging beverage brands. Strategically, Costa now serves as a key growth driver for the segment, reinforcing Coca-Cola’s diversification into premium non‑sugar‑based beverages and enhancing the company’s positioning as a broader total‑beverage platform. This evolution reflects a more cohesive integration of Costa’s operations and a stronger strategic emphasis on leveraging its brand to capture additional market share worldwide.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of Coca-Cola's relationship with Costa Limited from 2023 to 2024. It accurately captures the deeper operational integration of Costa within the Global Ventures segment and correctly identifies the strategic shift toward positioning Costa as a key growth driver in Coca-Cola’s broader beverage platform. The answer reflects the correct time frame (2023 to 2024) and correctly identifies Costa Limited as part of the Global Ventures segment in both years. However, the LLM omits specific details mentioned in the original answer about the inclusion of innocent and doğadan businesses and distribution coordination agreements in the 2024 segment structure, which provides a more complete picture of the strategic expansion of Global Ventures. While the LLM conveys the general trend of deeper integration and strategic emphasis, it introduces the concept of 'premium non-sugar-based beverages' and 'total-beverage platform' without direct support from the original answer, adding plausible but unverified strategic rationale. There are no numerical values in the question or answers, so quantitative accuracy is not applicable—scored as 10 by default. The reasoning is sound and contextually appropriate, and the answer is highly relevant to the question. The omission of specific 2024 structural additions prevents a perfect score, but the core facts and direction of evolution are correctly conveyed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1298,
        "completion_tokens": 410,
        "total_tokens": 1709
      },
      "error": null
    },
    {
      "question_id": 15,
      "question": "How has Intel's investment in financial institution instruments evolved between 2022 and 2024, particularly in terms of the fair value of economically hedged marketable debt investments?",
      "original_answer": "In 2022, Intel recorded net losses of $748 million on economically hedged marketable debt investments. By 2024, the fair value of these hedged investments had decreased to $13.5 billion from $17.1 billion in 2023, with Intel recording net losses of $464 million in 2024. This indicates a reduction in both the size of the hedged investment portfolio and the magnitude of losses compared to two years prior.",
      "llm_answer": "Between 2022 and 2024, Intel's investment in economically hedged marketable debt instruments experienced a significant decline in fair value, primarily due to rising interest rates and market volatility. As disclosed in the 2024 10-K (page 81), the fair value of these hedged investments fell to $13.5 billion from $17.1 billion in 2023, resulting in net losses of $464 million in 2024 (compared to net gains of $534 million in 2023 and $748 million in 2022). This deterioration directly impacted Intel's earnings through realized and unrealized losses recorded in \"interest and other, net\" on the income statement.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a critical factual error in the 2022 net gains/losses. The original answer states that Intel recorded net losses of $748 million in 2022, which is correct. However, the LLM incorrectly states that Intel had 'net gains of $534 million in 2023 and $748 million in 2022', directly contradicting the ground truth. This misrepresents the direction of the financial result (gains vs losses) in both years. The 2024 net loss of $464 million is correctly stated. The fair value figures ($13.5 billion in 2024 and $17.1 billion in 2023) are accurate and correctly attributed. (2) Quantitative accuracy is compromised because of the incorrect characterization of 2022 and 2023 results. The $748 million figure is a loss, not a gain, and the 2023 result is not mentioned in the ground truth at all, making the $534 million gain a hallucination. The decrease in fair value from $17.1B to $13.5B is correct, a $3.6B decline. (3) The multi-hop reasoning is partially sound—linking fair value changes to income statement impact is reasonable and contextually appropriate. However, the synthesis fails on the temporal comparison of losses/gains due to incorrect data for 2022 and fabricated data for 2023. The model incorrectly implies improving performance (from gains to losses) when the truth shows persistent losses with reduced magnitude in 2024. (4) Contextual relevance is high—the answer addresses the evolution of investments, focuses on fair value and losses, and cites the correct document location. However, due to major quantitative errors affecting the interpretation of financial performance, the correctness score is limited to 5. The qualitative accuracy is moderate due to correct structure and logic but flawed data inputs.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 480,
        "total_tokens": 1745
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How did AMT's financial focus regarding communications sites evolve from 2023 to 2024, particularly in terms of recurring revenue generation and asset retirement liabilities?",
      "original_answer": "In 2023, AMT emphasized recurring revenue generation from communications sites, noting that 99% of total revenues came from property operations, which included leasing space on communications sites. By 2024, the focus expanded to include significant liabilities tied to these assets, with an estimated $4.5 billion in undiscounted future cash outlay for asset retirement obligations as of December 31, 2024. This reflects a shift from primarily highlighting revenue streams to also addressing the long-term financial responsibilities associated with site decommissioning.",
      "llm_answer": "From 2023 to 2024, AMT's communications site financial focus shifted toward strengthening recurring revenue streams and managing asset retirement liabilities. The company emphasized maintaining its multiyear tenant leases—which generate recurring revenue—as a key driver of cash flow, while also acknowledging the need to fund asset removal and site remediation, with estimated future cash outlays for asset retirement obligations reaching $4.5 billion as of December 31, 2024. This focus was reinforced through strategic transactions like the Pending ATC TIPL Transaction in India, which aimed to repurpose capital and address revenue uncertainty in that market.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $4.5 billion in estimated future cash outlays for asset retirement obligations as of December 31, 2024, matching the ground truth. It also accurately reflects AMT's emphasis on recurring revenue from property operations, particularly through multiyear leases. However, the ground truth specifies that 99% of total revenues came from property operations in 2023, a key quantitative detail that is omitted in the LLM response. (2) All provided numbers (e.g., $4.5 billion, December 31, 2024) are factually correct and properly contextualized. No calculation errors. (3) The multi-hop reasoning is largely sound—linking recurring revenue focus with emerging liability concerns across years—but misses the explicit 2023 revenue composition (99%) that strengthens the evolution narrative. The mention of the 'Pending ATC TIPL Transaction in India' introduces a specific strategic move not present in the original answer; while potentially true, it adds unverified detail that distracts from the core evolution in financial focus and is not supported by the ground truth provided. (4) The answer is contextually relevant and captures the shift in focus, but loses points for missing the 99% revenue figure and introducing extraneous transaction details, slightly reducing qualitative accuracy. Quantitative accuracy remains high as all stated numbers are correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1315,
        "completion_tokens": 392,
        "total_tokens": 1707
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has XOM's strategic positioning in Guyana evolved between 2023 and 2024, particularly in terms of its legal operating framework and business growth emphasis?",
      "original_answer": "In 2023, XOM's operations in Guyana were governed by the Petroleum Activities Act 2023, which allowed for an exploration period typically up to 10 years and a production period of 20 years for oil fields with a renewal period of up to 10 years. By 2024, Guyana was specifically highlighted as one of XOM's 'Advantaged Assets' under the 'Advantaged Volume Growth' earnings driver, indicating a strategic shift to emphasize Guyana as a key contributor to earnings through volume growth and integration. This evolution shows that Guyana transitioned from being a jurisdiction with defined exploration and production terms to being a core growth asset within XOM's portfolio.",
      "llm_answer": "XOM's strategic positioning in Guyana has evolved significantly between 2023 and 2024, particularly in terms of its legal operating framework and business growth emphasis. In 2023, the company's Guyana operations were primarily focused on exploration and development within the Stabroek Block, operating under the existing legal framework established by the Petroleum Activities Act 2023. By 2024, XOM had advanced its position with the acquisition of Pioneer Natural Resources, which included Guyana assets, and was actively developing its offshore discoveries, particularly the Stabroek Block, which is central to its growth strategy. The company emphasized Guyana as a key \"advantaged asset\" in its earnings drivers, highlighting its potential for high-value, low-emission production growth. This strategic focus is reflected in its capital allocation and operational priorities, with Guyana representing a critical component of XOM's global growth trajectory.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the Petroleum Activities Act 2023 as the legal framework in 2023, which aligns with the ground truth. It also accurately reflects XOM's strategic emphasis on Guyana as an 'advantaged asset' in 2024, tied to earnings growth and capital allocation. However, it introduces a factual inaccuracy by claiming that the acquisition of Pioneer Natural Resources included Guyana assets—this is incorrect. Pioneer Natural Resources is a Permian Basin-focused company with no known assets in Guyana, and XOM's position in Guyana comes from its existing Stabroek Block operations, not from the Pioneer acquisition. This misrepresents a key element of the strategic evolution. (2) There are no numeric values, dates, or calculations in the question or answer that are incorrect—dates (2023, 2024) and references to legislation are accurate. Thus, quantitative accuracy is high. (3) The multi-hop reasoning is partially sound: the model correctly synthesizes the shift from a legal framework focus to strategic growth emphasis. However, the erroneous link between Pioneer and Guyana undermines the reasoning chain and suggests flawed entity mapping. (4) Despite the factual error, the answer captures the core evolution—Guyana’s elevation to an advantaged asset within XOM’s portfolio—and maintains strong contextual relevance. The strategic narrative around low-emission, high-value growth aligns with XOM’s reported messaging. Hence, correctness is reduced to 7 due to the significant but not central factual error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1412,
        "completion_tokens": 427,
        "total_tokens": 1839
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has Caterpillar's involvement in the diesel-electric locomotives business evolved between 2023 and 2024, particularly in terms of its strategic positioning and operational responsibilities?",
      "original_answer": "In 2023, Caterpillar's involvement in diesel-electric locomotives was described as part of its broader Machinery, Energy & Transportation (ME&T) segment, which included responsibilities such as remanufacturing Caterpillar reciprocating engines and components, as well as product support for on-highway vocational trucks in North America. By 2024, Caterpillar's positioning had evolved, with diesel-electric locomotives and related components being explicitly tied to integrated systems and solutions for industries like electric power generation, marine, oil and gas, and industrial sectors. Additionally, 2024 emphasized the development of electrified powertrains and zero-emission power sources, signaling a strategic shift toward more advanced and environmentally focused technologies in the locomotive space.",
      "llm_answer": "Caterpillar’s diesel‑electric locomotive business remains embedded within its Energy & Transportation segment, with the company continuing to manage the remanufacture of locomotives and related components as part of its broader rail‑related product portfolio.  The 2024 financial disclosures show that Energy & Transportation sales rose 3 % to $28.85 billion, driven largely by favorable price realization, and that the segment’s profit increased 16 % to $5.736 billion, underscoring the ongoing strategic focus on this line of business.  However, the provided documents do not detail any structural shift or new operational responsibilities for the diesel‑electric locomotive unit between 2023 and 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains some correct elements but misses the core evolution described in the ground truth. While it correctly situates diesel-electric locomotives within the Energy & Transportation segment, it fails to capture the strategic shift toward integrated systems and zero-emission technologies highlighted in the 2024 positioning. Instead, it claims no structural shift occurred, which contradicts the original answer’s emphasis on a strategic evolution toward electrified powertrains and broader industrial integration. (2) The quantitative data—3% sales growth to $28.85 billion and 16% profit increase to $5.736 billion—is not present in the ground truth and cannot be verified against it. Since the original answer does not include financial figures for the segment, the inclusion of these specific numbers introduces unverified information, reducing quantitative accuracy. There are no calculation errors per se, but the numbers themselves are extraneous and unsupported by the provided truth. (3) The multi-hop reasoning is flawed: the question asks for a comparison of strategic positioning and operational responsibilities between 2023 and 2024, requiring synthesis of changes over time. The LLM fails this synthesis by asserting no change occurred, whereas the ground truth clearly outlines a shift from general product support to advanced, environmentally focused solutions. The model does not recognize or report the expanded scope into electrified powertrains and integrated systems. (4) Contextual relevance is moderate because the answer discusses the correct company, segment, and general business area, but it omits the key qualitative transformation and introduces unverified financial metrics. Thus, while relevant, it is factually incomplete and partially misleading.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1390,
        "completion_tokens": 491,
        "total_tokens": 1882
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has the company's reliance on securitized debt obligations as a funding source evolved from 2022 to 2024, and what does this indicate about its funding strategy?",
      "original_answer": "In 2022, the company disclosed that it raised funding through the issuance of securitized debt obligations, among other instruments, though the exact amount was not provided. By 2024, the company reported a carrying value of $14,264 million for securitized debt obligations, indicating a concrete quantification of this funding source. This evolution suggests a more defined and potentially increased reliance on securitized debt obligations, aligning with a broader strategic emphasis on structured financing.",
      "llm_answer": "From 2022 to 2024 the company’s use of securitized debt as a funding source grew markedly: total securitized debt obligations rose from roughly $14.3 billion (as of 2021) to $14.3 billion in 2024, and the share of funding derived from securitizations increased from about 4 % of total funding to roughly 5 % of total funding (as shown in the 2024 funding‑source tables). This upward shift indicates that Capital One is increasingly relying on securitizations to supplement deposit funding and manage liquidity, reflecting a strategic move toward more diversified, market‑based financing.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It claims securitized debt obligations were $14.3 billion in both 2021 and 2024, implying no growth, which contradicts the 'grew markedly' narrative. More critically, the ground truth states that in 2022, no exact amount was disclosed for securitized debt, and the first concrete figure ($14,264 million) appears in 2024. The LLM incorrectly introduces a 2021 figure not mentioned in the original answer and falsely implies a trend from 2022 to 2024 with numerical data that does not exist for 2022. Additionally, the claim that securitizations increased from 4% to 5% of total funding is unsupported by the ground truth, which does not mention percentages or funding mix shares. (2) The only correct quantitative element is the approximate $14.3 billion figure in 2024 (matching $14,264 million), though it misattributes timing and trends. All other numbers (4%, 5%, 2021 amount) are fabricated or misplaced. (3) The multi-hop reasoning is flawed: the model invents a trend using non-existent data points and misrepresents the evolution. The original answer emphasizes the shift from unquantified disclosure in 2022 to a specific carrying value in 2024, indicating increased transparency or definitional clarity—not necessarily growth in volume. The LLM misinterprets this as a numerical increase and adds unsupported metrics. (4) While the general direction—increased reliance on securitized debt—aligns with the original's implication of strategic emphasis, the fabricated data and incorrect timeline severely undermine factual correctness. Contextually, the answer addresses funding strategy evolution, so relevance is moderate, but accuracy is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 470,
        "total_tokens": 1749
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has McDonald's treatment of developmental licensees evolved between 2023 and 2024, particularly in terms of financial reporting and relationship management?",
      "original_answer": "In 2023, McDonald's disclosed that developmental licensees paid royalties based on a percentage of sales and generally paid initial fees, and the company allocated consideration among lease and non-lease components using historical methods. By 2024, the company emphasized its ongoing evaluation of business relationships, including those with developmental licensees, to identify potential variable interest entities, although it concluded that consolidation of such entities was not appropriate. Additionally, in 2024, McDonald's updated its rounding presentation to the nearest whole number for reported amounts, which affected how financial figures were presented, though the company clarified that these changes were not significant.",
      "llm_answer": "Between 2023 and 2024, McDonald's treatment of developmental licensees evolved in two key ways: First, financial reporting now includes enhanced disclosures under the new FASB ASU 2023-07 segment reporting standard, which requires more detailed breakdowns of segment expenses and revenue components (like rent, royalties, and initial fees) that directly impact how developmental licensee revenue is presented and analyzed. Second, relationship management remains consistent in structure—developmental licensees continue to pay royalties based on a percent of sales and initial fees—but the company has refined its accounting for lease renewals and capitalized software costs, which indirectly affects how these relationships are evaluated in financial statements, particularly through updated assumptions about renewal options in lease accounting that impact the present value of future payments tied to these arrangements.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces significant factual inaccuracies. The mention of 'FASB ASU 2023-07' and its impact on segment reporting is incorrect—this standard is not referenced in McDonald's 2023 or 2024 disclosures related to developmental licensees. The ground truth states that McDonald's updated its rounding policy to the nearest whole number in 2024, which the LLM completely omits. Additionally, there is no mention in the ground truth about capitalized software costs or changes in lease renewal assumptions affecting developmental licensees. The core financial treatment—royalties based on sales percentage and initial fees—remains consistent, which the LLM correctly notes, but it fabricates accounting refinements that are not in the original data. (2) There are no verifiable numbers in the LLM response (e.g., percentages, dollar amounts), and it fails to report the key 2024 change in rounding presentation, which is a quantitatively relevant disclosure. Thus, quantitative accuracy is very low. (3) The multi-hop reasoning is flawed: the LLM invents a new accounting standard (ASU 2023-07) and links it to developmental licensee reporting without evidence, showing incorrect synthesis. It also conflates general lease accounting updates with specific licensee treatment, which the ground truth does not support. (4) While the answer is framed around financial reporting and relationship management—aligning with the question's intent—it introduces irrelevant and incorrect details, reducing its factual reliability. The only correct element is the continuity of royalty and initial fee structures. Hence, the correctness score is low due to major factual and reasoning errors, despite partial relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1418,
        "completion_tokens": 471,
        "total_tokens": 1890
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How has Southern Company's approach to its Equity and Incentive Compensation Plan evolved between 2023 and 2024, particularly in terms of share availability and executive award disclosures?",
      "original_answer": "In 2023, Southern Company had 26.9 million shares available for awards under the Equity and Incentive Compensation Plan, indicating a reserve for future compensation initiatives. By 2024, the company increased transparency around executive compensation by disclosing specific terms for Named Executive Officer equity awards granted under the 2021 Equity and Incentive Compensation Plan, which was effective May 26, 2021. This evolution shows a shift from internal planning and reserve allocation in 2023 to more detailed public disclosure of executive-level compensation mechanisms in 2024, suggesting a more formalized and transparent governance approach for top-level incentives.",
      "llm_answer": "Between 2023 and 2024, Southern Company’s Equity and Incentive Compensation Plan saw a reduction in available shares for future awards – from 26.9 million shares reserved at the end of 2023 to 26.9 million shares still reserved but with no explicit increase noted in the 2024 filing, indicating the pool remained unchanged. Executive award disclosures in the 2024 filing (page 316) continue to reference the same 2021 plan and include the Ninth amendment to the Employee Savings Plan dated December 16, 2024, but do not introduce new share‑based award types or material changes to the share‑availability metrics beyond the continued use of the existing reserve.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly states the 26.9 million shares available in 2023, matching the ground truth. However, it incorrectly implies that the share reserve remained unchanged in 2024 without confirming an increase or decrease, while the original answer highlights a qualitative shift in disclosure practices rather than a quantitative change in shares. The LLM fails to mention the increased transparency in 2024 regarding Named Executive Officer award terms, which is the central evolution described in the ground truth. Instead, it focuses on the lack of new award types or changes to share availability, which downplays the actual progression toward more detailed public disclosure. (2) Quantitatively, the 26.9 million figure is accurate for 2023 and referenced correctly for 2024, though no new data is provided for 2024 share count—this omission is acceptable if the number didn't change, but the model does not confirm whether it did. The date of the Ninth Amendment (December 16, 2024) is mentioned, but this may postdate the 2024 filing period and is not relevant to the plan's evolution between 2023 and 2024. (3) The multi-hop reasoning is partially sound—both years and the same plan (2021 Equity and Incentive Compensation Plan) are correctly referenced—but the synthesis misses the core shift from internal reserve allocation (2023) to enhanced executive disclosure (2024). The LLM interprets 'evolution' as a quantitative change in shares rather than a qualitative improvement in transparency. (4) The correctness score is 5 due to accurate numbers but significant omission of the key qualitative development in executive award disclosures. Quantitative accuracy is 8 because the share count is correct and no false calculations are made. Qualitative accuracy is 5 because the reasoning mischaracterizes the nature of the plan’s evolution. Contextual relevance is 7 as the response stays on topic but emphasizes less relevant details like the amendment date instead of the disclosure enhancement.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 543,
        "total_tokens": 1890
      },
      "error": null
    },
    {
      "question_id": 16,
      "question": "How did the revenue performance of Inlyta evolve between 2022 and 2023, and what factors contributed to the change in its growth trajectory?",
      "original_answer": "In 2022, Inlyta contributed to Pfizer's operational growth, specifically mentioned among products like Comirnaty, Eliquis, and Vyndaqel that drove growth in the U.S. and international markets. By 2023, Inlyta's global revenue reached $1,036 million, reflecting a 3% total increase and a 5% operational growth. The growth was primarily attributed to the adoption of immune checkpoint inhibitor combinations with Inlyta for first-line treatment of advanced RCC in the U.S., despite lower volumes and net price in certain European markets. This indicates a continuation of growth, albeit at a more moderate pace compared to the broader portfolio dynamics in 2022.",
      "llm_answer": "Between 2022 and 2023, Inlyta’s revenue grew modestly – up about 5% in the U.S. and roughly 3–7% internationally, leading to an overall worldwide increase of roughly 3% (from $1,003 million in 2022 to $1,036 million in 2023). This growth was driven by continued adoption of Inlyta in combination regimens for advanced renal cell carcinoma, especially in emerging markets, but was partially offset by lower pricing and competitive pressures. The broader revenue decline for Pfizer in 2023 was largely due to steep drops in COVID‑19 vaccine (Comirnaty) and antiviral (Paxlovid) sales, which outweighed the gains seen with Inlyta.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partially correct information but introduces inaccuracies in key quantitative details. The ground truth states that Inlyta's 2023 global revenue was $1,036 million with a 3% total increase and 5% operational growth. The LLM correctly reports the $1,036 million figure for 2023 and implies a 3% total growth, but incorrectly reconstructs 2022 revenue as $1,003 million (implying a ~3.3% increase, not exactly 3%), which is not supported by the original data. More critically, the LLM fabricates a '5% in the U.S.' and '3–7% internationally' breakdown, which is not present in the ground truth—only global and operational growth figures are provided. (2) The calculation of year-over-year change is approximately correct but not exact, and the split by region is speculative. The original answer does not provide country-level growth percentages, so these numbers are unsupported. (3) The qualitative reasoning is mostly sound: the LLM correctly identifies the use of Inlyta in combination therapies for advanced RCC as a growth driver, aligning with the ground truth's mention of immune checkpoint inhibitor combinations. It also correctly notes pricing pressures in certain markets, though it generalizes 'lower pricing and competitive pressures' rather than specifying 'lower volumes and net price in certain European markets' as in the original. The mention of Comirnaty and Paxlovid declines is contextually relevant to Pfizer’s overall performance but was not asked in the question, which focused solely on Inlyta’s trajectory—this adds context but slightly distracts from the core focus. (4) The correctness score is 6 due to the plausible but unverified regional growth splits and miscalculated 2022 baseline. Quantitative accuracy is penalized (5/10) because fabricated percentages undermine precision. Qualitative accuracy is higher (7/10) because the core growth drivers are correctly identified. Contextual relevance is strong (9/10) as the answer stays focused on Inlyta’s performance and contributing factors, even if it adds some extraneous portfolio context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 566,
        "total_tokens": 1886
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has McDonald's relationship with its franchisees evolved from 2023 to 2024 in terms of financial structure and dependency, particularly regarding revenue recognition and cost-sharing for technology platforms?",
      "original_answer": "In 2023, McDonald's described its relationship with franchisees as a collaborative partnership focused on consistency, quality, and revenue generation through rent, royalties based on a percent of sales, and initial fees. The business model was designed to generate stable and predictable revenue largely tied to franchisee sales. By 2024, the relationship evolved to reflect a stronger dependency on franchisees, particularly in the context of technology platforms. McDonald's began recognizing revenue from franchisees for technology services on a gross basis, with related expenses recorded in 'Other restaurant expenses,' indicating a more integrated and cost-sharing approach. This shift reflects a transformation in the nature of the relationship, with franchisees becoming more operationally interdependent with the company through shared technology infrastructure.",
      "llm_answer": "From 2023 to 2024, McDonald's financial relationship with its franchisees remained fundamentally unchanged in structure but saw modest shifts in revenue composition and cost-sharing. The Company continues to recognize revenue from franchise fees (including rent and royalties) and other income such as technology platform fees and brand licensing, with the latter reflecting ongoing cost-sharing arrangements where franchisees contribute toward technology investments. While the core revenue model—based on a percentage of franchisee sales—remains consistent, the 2024 financial statements show slightly higher total franchise-related revenue ($9,281 million in 2024 vs. $8,893 million in 2023), driven by increased sales and continued reliance on franchisee contributions for technology costs, though the company's direct financial dependency on franchisees for operational revenue has not materially evolved. The dependency remains high, as franchisees generate the vast majority of Systemwide sales, but the financial structure of revenue recognition and cost-sharing for technology platforms has stayed stable without significant new arrangements.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains some correct elements but misses the key qualitative shift described in the ground truth, leading to a partially incorrect assessment. (1) Correctly notes that franchise fees, royalties, and technology cost-sharing exist, and correctly identifies increased franchise-related revenue from 2023 ($8,893M) to 2024 ($9,281M), which aligns with the general trend of franchisee contribution. However, the answer incorrectly states that the 'financial structure of revenue recognition and cost-sharing for technology platforms has stayed stable without significant new arrangements,' which directly contradicts the ground truth. (2) The quantitative figures cited—$8,893 million in 2023 and $9,281 million in 2024—are factually accurate and correctly reflect franchise-related revenue totals, earning partial credit on quantitative accuracy. (3) The multi-hop reasoning fails: the core evolution in 2024 is that McDonald's began recognizing technology service revenue from franchisees on a *gross basis*, with corresponding expenses in 'Other restaurant expenses,' indicating a shift toward direct cost-sharing and operational integration. The LLM answer acknowledges cost-sharing but frames it as pre-existing and stable, missing the structural change entirely. (4) This omission undermines the qualitative accuracy, as the transformation in the nature of the relationship—from a primarily rent-and-royalty model to one with deeper operational interdependence via technology—is the central point of the original answer. The LLM instead concludes no material evolution, which is factually incorrect. Contextual relevance is high because the response addresses the right topic areas (revenue recognition, cost-sharing, franchisee dependency), but the failure to identify the key 2024 change in accounting treatment and its implications results in a low overall correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1522,
        "completion_tokens": 509,
        "total_tokens": 2032
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How did the fair value of energy-related derivatives held by Southern Company's subsidiaries evolve from 2022 to 2023, and what does this indicate about the company's exposure to energy market fluctuations?",
      "original_answer": "In 2022, Southern Company's subsidiaries reported a net fair value of $101 million for energy-related derivatives (Mississippi Power: $59 assets, $32 liabilities; Southern Power: $8 assets, $12 liabilities; Southern Company Gas: $28 assets, $65 liabilities). In 2023, the subsidiaries showed a shift with Alabama Power reporting $15 in assets and $110 in liabilities, and Georgia Power reporting $13 in assets and $124 in liabilities for energy-related derivatives. This indicates a significant increase in net liability exposure, rising from a net liability of $54 million in 2022 to a net liability of $219 million in 2023, suggesting a greater exposure to energy market fluctuations.",
      "llm_answer": "Based on the fair value measurements of energy-related derivatives held by Southern Company's subsidiaries, the fair value of these derivatives increased from $199 million at December 31 2022 to $55 million at December 31 2023 when aggregated across the reporting segments. This reduction reflects a decline in the net fair value of energy‑related derivatives, indicating that the company's exposure to energy market fluctuations decreased during 2023. The lower fair‑value amount suggests reduced sensitivity to changes in natural‑gas and power prices, although the company still holds positions that are marked to market and could be affected by future energy price movements.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual and calculation errors. It claims the aggregate fair value of energy-related derivatives decreased from $199 million in 2022 to $55 million in 2023, which is incorrect. The ground truth shows that in 2022, the net fair value was a net liability of $54 million (not $199 million), calculated as total assets ($59 + $8 + $28 = $95 million) minus total liabilities ($32 + $12 + $65 = $109 million), resulting in $95M - $109M = -$14M net? Wait—rechecking: $95M assets - $109M liabilities = -$14M? But original answer says net liability of $54M. Actually, original answer states: 'net fair value of $101 million' — but this appears to be a misstatement. Let's recalculate: total assets = $59M (Mississippi) + $8M (Southern Power) + $28M (Gas) = $95M; total liabilities = $32M + $12M + $65M = $109M; net = $95M - $109M = -$14M (i.e., $14M net liability), but original answer says 'net fair value of $101 million' and then says 'net liability of $54 million'. There is inconsistency in the original answer. However, it then states the 2023 net liability is $219 million, based on Alabama Power ($15A, $110L → net -$95M) and Georgia Power ($13A, $124L → net -$111M), total net liability = $206M? $95 + $111 = $206M net liability, not $219M. So there are issues in the ground truth. But the LLM answer fabricates numbers: it says 'aggregated across segments' $199M in 2022 and $55M in 2023 — no such numbers appear in the ground truth or can be derived. The LLM also fails to mention the subsidiaries correctly: it does not name Mississippi Power, Southern Power, or Southern Company Gas in 2022, and omits Alabama and Georgia Power in 2023. Instead, it aggregates incorrectly. (2) Quantitative accuracy is very low: the LLM reports $199M and $55M, which are not supported by any calculation from the ground truth data. The direction of change is also wrong: ground truth indicates a significant increase in net liability (greater exposure), while LLM says fair value decreased and exposure decreased. (3) Multi-hop reasoning is flawed: the LLM fails to correctly identify which subsidiaries reported in which year and how to compute net exposure. It incorrectly concludes reduced exposure when the evidence (even with minor discrepancies in ground truth) points to increased liability and thus higher risk. (4) Contextual relevance is moderate because it discusses fair value of energy derivatives and exposure to market fluctuations, which is on-topic, but the incorrect data and conclusion severely undermine accuracy. Scores reflect major factual and quantitative errors, poor reasoning, but partial relevance to the topic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 706,
        "total_tokens": 2062
      },
      "error": null
    },
    {
      "question_id": 17,
      "question": "How has the treatment and significance of the Procter & Gamble 2019 Stock and Incentive Compensation Plan evolved from 2022 to 2024, based on its disclosure context in the 10-K filings?",
      "original_answer": "In 2022, the 2019 Stock and Incentive Compensation Plan was introduced with detailed references to its adoption by shareholders on October 8, 2019, and its additional terms and conditions, indicating its formal establishment and integration into the company's compensation framework. By 2024, the plan was listed among other equity compensation plans as part of the company's broader disclosure on stock ownership and equity compensation, showing that it had become a standard and active component of the company's long-term incentive structure. This evolution reflects the plan's transition from a newly introduced policy to an established part of PG's equity compensation offerings.",
      "llm_answer": "The Procter & Gamble 2019 Stock and Incentive Compensation Plan (the 2019 Plan) was originally adopted by shareholders at the October 8, 2019 annual meeting (Exhibit 10‑27 of the 2019 Form 8‑K) and its additional terms and conditions were later incorporated by reference in the 2021 Form 10‑K (Exhibit 10‑28).  The 2019 Plan superseded the earlier 2014 Plan and remains the current equity‑compensation framework, with its latest regulatory filing appearing in the 2024 Proxy Statement and the 2024 Form 10‑K (pages 66‑68, 70‑71).  Consequently, from 2022 through 2024 the plan’s governance and disclosure context shifted from prior 2014‑plan references to explicit 2019‑plan regulations and disclosures, reflecting its ongoing evolution and expanded share‑authorizing authority.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of the 2019 Stock and Incentive Compensation Plan from 2022 to 2024. It accurately states that the plan was adopted on October 8, 2019, and correctly references its integration into PG's compensation framework, including the superseding of the 2014 Plan. The mention of the 2024 Proxy Statement and 10-K filings confirms its ongoing relevance, supporting the narrative of the plan becoming a standard component. However, the original answer emphasizes a shift in disclosure context—from introduction in 2022 to being listed among other equity plans in 2024 as part of broader stock ownership disclosures—while the LLM focuses more on regulatory continuity and share-authorizing authority, which is accurate but slightly shifts emphasis from the 'disclosure context' evolution highlighted in the question. The LLM introduces details not in the ground truth (e.g., Exhibit references, 2021 Form 10-K incorporation), which are plausible but not confirmed in the original answer; these do not detract from correctness but add granularity beyond the scope. All dates and years (2019 adoption, 2024 filings) are accurate. The reasoning is sound and reflects multi-hop synthesis across years and documents. The answer is contextually fully relevant and captures the core evolution, though it frames it more in terms of governance than disclosure context. Hence, minor deduction in correctness and qualitative accuracy for emphasis misalignment, but high marks for factual precision and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1375,
        "completion_tokens": 433,
        "total_tokens": 1808
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has Southern Company's approach to managing the risk of large losses in its pension plan assets evolved from 2023 to 2024, and what specific changes in risk management emphasis can be observed?",
      "original_answer": "In 2023, Southern Company emphasized a formal rebalancing program and external investment manager oversight as key components of managing the risk of large losses, with a strong focus on long-term investment expectations for return and risk. In 2024, while maintaining a diversified asset strategy and rebalancing program, the emphasis on external manager oversight was reduced, and the risk of large losses was more directly linked to the broader market volatility and interest rate fluctuations. This indicates a subtle shift in risk management emphasis from active oversight to market-driven risk exposure.",
      "llm_answer": "Southern Company's pension risk management approach has shifted toward greater diversification and active oversight, with a stronger emphasis on managing large loss exposure through formal rebalancing and external manager guidelines. The 2024 disclosures highlight a more structured asset allocation strategy—maintaining target allocations (e.g., 41% domestic equity, 30% fixed income) while increasing monitoring of risk concentrations, reflecting a refined focus on long-term asset-liability management and proactive risk mitigation compared to the 2023 framework.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer incorrectly characterizes the evolution of Southern Company's risk management approach. The ground truth indicates a reduction in emphasis on external manager oversight in 2024 and a shift toward market-driven risk factors (volatility, interest rates), whereas the LLM claims there was an increase in 'active oversight' and 'stronger emphasis on managing large loss exposure through...external manager guidelines'—this is factually incorrect and contradicts the original answer. (2) The LLM introduces specific asset allocation percentages (41% domestic equity, 30% fixed income) that are not present in the ground truth and cannot be verified; these numbers are likely hallucinated or misattributed, reducing quantitative accuracy. There are no calculations in the response, but the inclusion of unverified figures harms precision. (3) The multi-hop reasoning is flawed: the question requires comparing risk management emphasis across 2023 and 2024, with a focus on shifts in strategy. The LLM fails to identify the key shift—from active oversight to market-driven exposure—and instead asserts increased structure and monitoring, which is not supported by the ground truth. It also omits the critical point about linking large loss risk more directly to market and interest rate fluctuations in 2024. (4) While the answer is contextually relevant—discussing pension risk management, rebalancing, and long-term strategy—the qualitative inaccuracies and incorrect directional claim about oversight lead to a low correctness score. The answer appears plausible but misrepresents the actual evolution described in the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 454,
        "total_tokens": 1760
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How has NVIDIA's role in the development and supply of the CUDA platform evolved between 2022 and 2023, and what does this shift indicate about the company's strategic focus?",
      "original_answer": "In 2022, NVIDIA's relationship with the CUDA platform was primarily as a supplier, providing the platform as part of its accelerated computing offerings. By 2023, NVIDIA's role had evolved into that of a developer, emphasizing a more active and strategic engagement in the platform's expansion and integration within its broader software ecosystem, including CUDA-X libraries, APIs, and domain-specific frameworks. This shift indicates a strategic move toward strengthening its full-stack computing platform to deliver more comprehensive data center-scale solutions.",
      "llm_answer": "Between 2022 and 2023, NVIDIA’s role in the CUDA platform shifted from being primarily a developer of the CUDA programming model and ecosystem to a more integrated, full‑stack offering that is tightly coupled with its broader accelerated‑computing platform.  The 2022 10‑K notes that “our data‑center‑scale offerings are comprised of compute and networking solutions that can scale to tens of thousands of GPU‑accelerated servers” and that “the programmable nature of our architecture allows us to support several multi‑billion‑dollar end markets with the same underlying technology by using a variety of software stacks developed either internally or by third‑party developers.”  By 2023 the company is explicitly promoting CUDA as part of an end‑to‑end stack that includes GPUs, DPUs, CPUs (Grace), AI‑Enterprise software, and services such as DGX Cloud, emphasizing that CUDA now underpins not only graphics and data‑center workloads but also the company’s autonomous‑vehicle and automotive platforms.  This evolution signals a strategic focus on expanding CUDA’s reach across all of NVIDIA’s target markets—data‑center AI, automotive, professional visualization, and gaming—leveraging a unified hardware‑software ecosystem to drive recurring revenue and deepen developer engagement.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly identifies the evolution of NVIDIA's role in the CUDA platform from 2022 to 2023: starting as a supplier/developer of the CUDA programming model and transitioning into a more integrated, full-stack provider tightly coupling CUDA with its broader hardware and software ecosystem. The answer accurately reflects that in 2022, CUDA was part of NVIDIA’s accelerated computing offerings, supporting multiple markets via software stacks (as noted in the 2022 10-K). By 2023, the company emphasized CUDA as part of an end-to-end stack including GPUs, DPUs, CPUs (Grace), AI Enterprise software, and DGX Cloud—demonstrating a strategic shift toward full-stack integration. This correctly indicates a strategic focus on expanding CUDA across data center AI, automotive, visualization, and gaming, leveraging a unified ecosystem. All entities (CUDA, Grace, DGX Cloud, AI Enterprise) and years (2022, 2023) are accurate. There are no numerical inaccuracies (quantitative accuracy is perfect, even though no specific numbers are involved). The reasoning is sound and reflects multi-hop synthesis across time periods and strategic domains. The only minor deviation from the original answer is framing the 2022 role as 'developer' rather than 'supplier'—the ground truth emphasizes supplier role in 2022, while LLM emphasizes developer role. However, given that NVIDIA did develop CUDA, and the 2022 10-K references internal software development, this is a nuanced difference in emphasis rather than a factual error. Overall, the semantic meaning and strategic implication are preserved. Hence, correctness is rated 9 (not 10) due to slight framing difference, but all other dimensions are strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1470,
        "completion_tokens": 478,
        "total_tokens": 1948
      },
      "error": null
    },
    {
      "question_id": 18,
      "question": "How did Pfizer's financial relationship with Viatris evolve between 2022 and 2023, particularly in terms of supply agreements and outstanding balances?",
      "original_answer": "In 2022, Pfizer reported $780 million in revenue growth from PC1, primarily reflecting manufacturing of legacy Upjohn products for Viatris under supply agreements. By 2023, the financial relationship had evolved, as indicated by the net amounts due to Viatris under various agreements, which decreased from $94 million as of December 31, 2022, to $33 million as of December 31, 2023. Additionally, most transitional services under the TSAs were completed by the end of 2023, signaling a reduction in operational interdependence.",
      "llm_answer": "Between 2022 and 2023, Pfizer's financial relationship with Viatris evolved through the termination of its indemnification of GSK's guarantee of the Consumer Healthcare JV notes and the settlement of transitional service agreements. The $33 million amount due to Viatris as of December 31, 2023, reflects the remaining balance under these agreements, which were largely completed by December 31, 2023. Additionally, Pfizer recorded a $222 million pre-tax gain from the divestiture of its early-stage rare disease gene therapy portfolio to Alexion in September 2023, which was part of its strategic pivot away from viral capsid-based gene therapy approaches.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partial factual information but introduces significant inaccuracies and irrelevant details. It correctly mentions the $33 million amount due to Viatris as of December 31, 2023, which matches the ground truth. However, it fails to mention the $94 million balance as of December 31, 2022, and thus omits the key comparison showing the decrease from $94M to $33M. The claim about termination of indemnification of GSK's guarantee of the Consumer Healthcare JV notes is not supported in the original answer and appears unrelated to the Pfizer-Viatris supply agreements. Additionally, the $222 million pre-tax gain from divestiture to Alexion is factually unrelated to the Pfizer-Viatris relationship and distracts from the core question. (2) Quantitatively, only one of the two required figures is correct ($33M in 2023); the 2022 figure ($94M) is missing, and no calculation or trend (a $61M decrease) is acknowledged. The mention of $33M is accurate but lacks context. (3) The multi-hop reasoning is flawed: the answer does not connect Pfizer’s supply agreement revenue in 2022 ($780M from manufacturing legacy Upjohn products) to the declining balances in 2023, which reflects reduced interdependence. Instead, it introduces unrelated transactions (GSK, Alexion), indicating failure to synthesize the correct entities and agreements. (4) The contextual relevance is moderate because it addresses the general theme of evolving financial relationships and mentions a correct outstanding balance, but the inclusion of irrelevant strategic moves undermines accuracy. The core evolution—revenue from supply agreements in 2022 and declining liabilities in 2023—is not properly conveyed, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 477,
        "total_tokens": 1774
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has the treatment and disclosure of communications sites in relation to debt obligations evolved between 2023 and 2024?",
      "original_answer": "In 2023, communications sites were explicitly referenced as collateral securing debt obligations, such as the 3,343 communications sites securing the Series 2015-2 Notes and the repayment of $1.3 billion in Series 2013-2A Notes funded by the 2023 Securitization. In 2024, while there was no explicit mention of specific communications sites securing debt, the company disclosed broader financial commitments, such as $4.5 billion in estimated undiscounted future cash outlay for asset retirement obligations as of December 31, 2024. This shift indicates a move from site-specific debt disclosures to more general obligations, suggesting a change in how communications sites are framed in relation to financial liabilities.",
      "llm_answer": "The treatment and disclosure of communications sites in relation to debt obligations has evolved from a focus on legacy 2015‑2018 securitizations—where cash flows from the sites were strictly locked to service the secured notes and required DSCR compliance, cash‑trap reserves, and amortization periods—to a more recent 2023 securitization that similarly ties excess cash to DSCR thresholds but adds new risk‑retention and insurance conditions, while earlier disclosures (2023) emphasized covenant compliance and the ability to release excess cash, whereas the 2024 filing expands the summary of cash‑flow restrictions, amortization triggers, and the impact of defaults on site ownership.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect and fails to align with the ground truth in key aspects. (1) It introduces details not present in the original answer, such as 'legacy 2015–2018 securitizations', 'DSCR compliance', 'cash-trap reserves', 'amortization periods', 'risk-retention', and 'insurance conditions', which are not mentioned in the ground truth and cannot be verified from the provided information. (2) Quantitatively, the LLM omits all specific numbers from the ground truth: the 3,343 communications sites, the $1.3 billion repayment, and the $4.5 billion asset retirement obligation as of December 31, 2024. These are critical factual anchors in the original answer but are entirely absent or replaced with fabricated metrics. (3) The multi-hop reasoning is flawed: the original answer describes a shift from site-specific debt collateral disclosures in 2023 (e.g., sites securing notes) to broader financial obligations in 2024 (e.g., general cash outlays for asset retirement), indicating a change in disclosure granularity. The LLM instead fabricates a narrative about evolving securitization structures and cash flow mechanisms without evidence from the ground truth. (4) While the LLM attempts to address the evolution of treatment and disclosure over time (hence partial contextual relevance), it does so with incorrect entities, fabricated financial mechanisms, and no support from the actual data. The core factual claims in the original answer—specific sites securing debt in 2023 and a shift to generalized obligations in 2024—are missed entirely. Thus, despite some thematic relevance, the answer is factually unsound and misleading.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 450,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Comcast's approach to retransmission consent agreements evolved between 2022 and 2023, particularly in terms of revenue recognition and distribution models?",
      "original_answer": "In 2022, Comcast recognized revenue from retransmission consent agreements on a monthly basis as programming was provided, with fees tied to the number of subscribers and generally collected within 60 days. By 2023, the company's Media segment emphasized a combined linear and streaming distribution model, with retransmission fees now explicitly including both traditional and virtual multichannel video providers. The 2023 filing also highlighted a broader integration of Peacock into the distribution ecosystem, suggesting a strategic shift toward hybrid distribution models that blend traditional and streaming services.",
      "llm_answer": "Comcast's approach to retransmission consent agreements remained consistent in structure between 2022 and 2023, with revenue recognized monthly under multiyear agreements based on subscriber counts. However, the company expanded its distribution model to include direct revenue from Peacock subscriptions and increased reliance on licensing fees from third-party providers, while maintaining the same accounting treatment for programming and content licensing revenue.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but misses key aspects of the evolution in Comcast's retransmission consent approach between 2022 and 2023. (1) Correct elements: The answer correctly notes that revenue was recognized monthly and tied to subscriber counts in both years, which aligns with the ground truth. There are no numeric inaccuracies, hence a perfect quantitative accuracy score. (2) However, the LLM fails to accurately describe the shift in distribution models. While it mentions Peacock subscriptions and licensing fees, it does not specify that by 2023, retransmission fees explicitly included both traditional and virtual multichannel video providers—a core evolution. The ground truth emphasizes a strategic shift toward hybrid distribution models integrating Peacock, which the LLM only alludes to indirectly. (3) The reasoning is partially sound but lacks synthesis of the key multi-hop insight: the expansion of retransmission consent beyond traditional carriage agreements to include virtual MVPDs and integrated streaming platforms. The LLM implies continuity rather than evolution, understating the strategic shift. (4) Contextual relevance is high because the answer addresses revenue recognition and distribution models, but the qualitative accuracy is reduced due to omission of critical details about the structural change in 2023. Wording differences are acceptable, but the absence of explicit mention of virtual providers and the integration of Peacock into retransmission agreements constitutes a significant gap in factual completeness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1277,
        "completion_tokens": 428,
        "total_tokens": 1705
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Caterpillar's involvement in the production and strategic positioning of diesel-electric locomotives evolved from 2023 to 2024?",
      "original_answer": "In 2023, Caterpillar's involvement in diesel-electric locomotives was described as part of its broader ME&T segment, which included responsibilities such as remanufacturing Caterpillar reciprocating engines and components, as well as providing product support for on-highway vocational trucks in North America. By 2024, Caterpillar's engagement had evolved into a more defined production role under the Energy & Transportation segment, which explicitly stated that Caterpillar 'produces' diesel-electric locomotives and components, signaling a more direct and strategic emphasis on this product line. Additionally, in 2024, Caterpillar highlighted competitive pressures in rail-related businesses, naming companies like Wabtec Corp and Siemens Mobility A/S, which was not present in 2023. This indicates a shift from a general operational inclusion to a more prominent and competitive product focus.",
      "llm_answer": "From 2023 to 2024, Caterpillar’s involvement in diesel‑electric locomotives remained focused on production and support within its Energy & Transportation segment. The 2023 financial tables show that diesel‑electric locomotives and related components are included in the Energy & Transportation segment’s product portfolio, and the segment’s external sales rose to $23.355 billion in 2023 (up from $19.337 billion in 2022). The company continued to leverage its remanufacturing and leasing capabilities for locomotives, while also expanding financing through Cat Financial to support dealers and customers. Thus, the evolution reflects a continued strategic emphasis on diesel‑electric locomotives as part of its broader Energy & Transportation offerings rather than a shift to a new business line.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains several factual inaccuracies and fails to capture the core evolution described in the ground truth. (1) It incorrectly states that diesel-electric locomotives were part of the Energy & Transportation segment in 2023, while the ground truth specifies that in 2023, locomotive activities were under the ME&T segment, which focused on remanufacturing and support—not direct production. The shift to Energy & Transportation in 2024 with an explicit 'produces' designation is a key evolution that the LLM answer misses. (2) The financial figures cited—$23.355 billion and $19.337 billion—are not present in the ground truth and cannot be verified; more importantly, they are irrelevant to the question about strategic evolution, not financial performance. (3) The mention of Cat Financial, leasing, and remanufacturing expansion is not supported by the original answer and introduces unverified details. (4) The LLM concludes there was 'continued strategic emphasis' and 'no shift,' which directly contradicts the ground truth indicating a clear shift from general operational inclusion to a more defined, competitive production role in 2024. (5) The LLM fails to mention the new competitive landscape discussion in 2024 (naming Wabtec Corp and Siemens Mobility A/S), a key qualitative signal of strategic repositioning. While the answer is contextually relevant to Caterpillar and locomotives, it misrepresents the segment classification, timing, and strategic shift, resulting in low correctness and qualitative accuracy. Quantitative accuracy is partially preserved due to plausible number formatting, but the figures themselves are unsupported and off-topic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1421,
        "completion_tokens": 456,
        "total_tokens": 1877
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of revenue recognition and cost-sharing arrangements between 2023 and 2024?",
      "original_answer": "In 2023, McDonald's revenue from franchisees primarily included rent and royalties based on a percentage of sales with minimum rent payments, and initial fees. The company also mentioned that all restaurants were either operated by McDonald's or by franchisees under franchised arrangements. By 2024, the revenue recognition model remained consistent, but the company provided more detailed disclosures on how it recognizes revenue from franchisees, including the treatment of technology platform fees, which are now presented on a gross basis on the Consolidated Statement of Income. Additionally, in 2024, McDonald's clarified its cost-sharing arrangements for restaurant improvements, where it may fund certain projects and allocate costs between Property and Equipment and Accounts Receivable during the project, finalizing the allocation upon completion. This level of detail on cost-sharing was not present in the 2023 filing, indicating a more nuanced and transparent approach to franchisee financial interactions in 2024.",
      "llm_answer": "Between 2023 and 2024, McDonald's revenue recognition and cost-sharing arrangements with franchisees remained consistent with prior practice: royalties and rent (including minimum and variable components) continue to be recognized based on a percentage of franchisee sales, with initial fees amortized over the typical 20‑year franchise term. The Company now records these franchise-related revenues on a gross basis (as principal) and recognizes related expenses as incurred, while advertising contributions from franchisees are generally excluded from the Company's revenue and are borne by franchisees themselves. No material changes to the underlying cost‑sharing model were disclosed.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the continuity in McDonald's revenue recognition model between 2023 and 2024, noting that royalties, rent (minimum and variable), and initial fees remain key components, with initial fees amortized over a 20-year term. It also correctly states that franchise-related revenues are recorded on a gross basis, which aligns with the 2024 disclosure about technology platform fees being presented gross. However, the LLM misses a critical evolution: the 2024 filing introduced more detailed disclosures on revenue recognition, particularly regarding technology platform fees and their gross presentation, which was not explicitly detailed in 2023. Additionally, the LLM incorrectly claims 'no material changes to the underlying cost-sharing model were disclosed,' which contradicts the ground truth: in 2024, McDonald's clarified cost-sharing for restaurant improvements, including interim accounting treatment (allocation between Property and Equipment and Accounts Receivable) and finalization upon project completion—a level of detail absent in 2023. This omission represents a significant gap in qualitative accuracy, as the evolution lies not in changing the model but in enhancing transparency and disclosure. While the core revenue components are accurately described (supporting quantitative accuracy), the answer fails to capture the nuanced progression in financial reporting and cost-sharing clarity, which is central to the question. Thus, the answer is partially correct but lacks key differentiating details that define the evolution between the years.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1429,
        "completion_tokens": 435,
        "total_tokens": 1864
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Southern Company's approach to executive equity compensation evolved between 2023 and 2024, particularly regarding plan documentation and award terms?",
      "original_answer": "In 2023, Southern Company disclosed that stock-based compensation, primarily in the form of performance share units (PSUs) and restricted stock units (RSUs), was granted under the Equity and Incentive Compensation Plan to employees ranging from line management to executives. By 2024, the company formalized the terms for Named Executive Officer equity awards under the same plan, indicating a more structured approach to executive compensation. Additionally, the 2024 filing included detailed documentation practices, such as the designation of specific exhibits for equity award terms, which was not present in the 2023 filing. This reflects a shift toward greater specificity and transparency in executive equity compensation documentation.",
      "llm_answer": "Between 2023 and 2024, Southern Company’s executive equity compensation documentation was updated to include a Ninth Amendment to its Employee Savings Plan (effective December 16, 2024) and a series of amendments to its Supplemental Executive Retirement Plan and other deferred compensation agreements, reflecting the most recent changes to plan terms and governance. These updates modify award conditions and the structure of executive equity incentives, particularly around vesting triggers and post‑termination benefits.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is largely incorrect and fails to accurately reflect the evolution of Southern Company's executive equity compensation between 2023 and 2024 as described in the ground truth. (1) The LLM incorrectly identifies the plan amendments as relating to the Employee Savings Plan and Supplemental Executive Retirement Plan, whereas the original answer specifies that equity compensation for executives was granted under the Equity and Incentive Compensation Plan, with no mention of retirement or savings plan changes in this context. (2) The date December 16, 2024, is mentioned, but the ground truth does not include any specific amendment dates, nor does it reference a 'Ninth Amendment'—this information is fabricated or misattributed. (3) The LLM focuses on vesting triggers and post-termination benefits, which are not discussed in the original answer; instead, the actual evolution centers on increased documentation specificity, such as designated exhibits for award terms and formalized terms for Named Executive Officers. (4) The multi-hop reasoning is flawed: the model fails to synthesize the correct shift—from general stock-based grants in 2023 to more structured, transparent executive award documentation in 2024—and instead invents changes to unrelated plans. While the topic of executive compensation is relevant, the entities, plans, and nature of changes are factually wrong, leading to low scores across all dimensions. Minor credit is given for addressing the general theme of plan updates in executive compensation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 422,
        "total_tokens": 1741
      },
      "error": null
    },
    {
      "question_id": 19,
      "question": "How has Procter & Gamble's strategic reliance on membership club stores evolved from 2022 to 2024, and what does this shift indicate about the company's broader retail channel strategy?",
      "original_answer": "In 2022, Procter & Gamble identified membership club stores as one of its key retail channels, listing them among a broad set of distribution partners such as mass merchandisers, grocery stores, and e-commerce platforms. However, by 2024, the company's language shifted to emphasize dependency on these membership club stores, indicating a deeper strategic alignment or increased reliance on this channel. This evolution suggests that membership club stores have become more central to P&G's distribution and retail execution strategy, likely reflecting growth in this channel's importance to consumer purchasing behavior and overall market dynamics.",
      "llm_answer": "Procter & Gamble's strategic reliance on membership club stores has evolved from a focus on traditional retail channels to a more integrated approach that includes expanding its presence in high‑traffic membership clubs (e.g., Costco, Sam’s Club) while simultaneously scaling back on less‑controlled retail formats. This shift reflects the company’s broader strategy of concentrating growth in channels that offer higher shelf‑space efficiency, predictable purchasing patterns, and stronger data‑driven merchandising—key levers for managing margin pressure and accelerating e‑commerce integration. Consequently, the move signals P&G’s intent to prioritize stable, high‑volume wholesale partners and digital‑first retail experiences over fragmented traditional retail, aiming to drive sustainable top‑line growth and improve inventory predictability.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies a strategic shift toward membership club stores (e.g., Costco, Sam’s Club) from 2022 to 2024, aligning with the ground truth’s observation of increased reliance. However, the original answer does not mention P&G scaling back on 'less-controlled retail formats' or 'e-commerce integration' as a parallel strategy—this is an inference not supported in the ground truth. The core evolution—from identifying membership clubs as one of many channels in 2022 to emphasizing dependency by 2024—is accurately captured. (2) There are no numeric values, percentages, or dollar amounts in either answer, so quantitative accuracy is not applicable; the score of 10 reflects no errors in this dimension. (3) The multi-hop reasoning is partially sound: the model correctly infers strategic deepening in membership clubs, but adds unsupported elements like 'shelf-space efficiency', 'data-driven merchandising', and 'inventory predictability' that go beyond the source. These may be plausible business rationales but are not present in the ground truth, reducing qualitative accuracy. (4) The answer is contextually relevant and addresses both parts of the question—evolution over time and implications for broader strategy—though the latter is extrapolated. The correctness score of 7 reflects accurate core facts with some over-interpretation, but no factual inaccuracies in entities, years, or strategic direction.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1384,
        "completion_tokens": 402,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did AMT's involvement with Nigeria Letters of Credit evolve between 2023 and 2024, and what does this indicate about its financial obligations related to this instrument?",
      "original_answer": "In 2023, AMT had a $3.4 million obligation under the Nigeria Letters of Credit as part of its variable rate debt portfolio. However, by 2024, this obligation was no longer present, as indicated by the $0 carrying value in both denominated currency and USD. This indicates that AMT fully settled or otherwise exited its financial obligations tied to Nigeria Letters of Credit within this period.",
      "llm_answer": "Between 2023 and 2024, AMT’s involvement with the Nigeria Letters of Credit evolved from an existing facility (drawdowns of $3.4 million in 2023) to a continued but limited use in 2024, with no new principal amounts disclosed. The facility remains a form of subsidiary debt that is fully guaranteed by the Company and is subject to various covenants and restrictions within AMT’s securitization structures. Its presence underscores AMT’s contingent financial obligations tied to these instruments, as the Company may need to honor draws and manage related covenants, especially if performance ratios in its securitization trusts deteriorate.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both factual content and interpretation. The ground truth states that AMT had a $3.4 million obligation in 2023 and $0 in 2024, indicating full settlement. However, the LLM claims there was 'continued but limited use in 2024' with 'no new principal amounts disclosed,' which contradicts the complete elimination of the obligation. This misrepresents the evolution and current status of the financial instrument. (2) Quantitatively, the $3.4 million figure for 2023 is correct and matches the ground truth. However, the 2024 value is wrong—the LLM fails to report the $0 carrying value (in both currencies) as stated in the original answer, instead implying ongoing exposure. There are no calculations in this response, but the comparison across years is flawed. (3) The multi-hop reasoning is unsound. The model fails to synthesize the key point that the obligation was fully exited, which requires connecting the presence of debt in 2023 to its absence in 2024. Instead, it assumes continuity without evidence, introducing speculative details about covenants and securitization trusts not supported by the ground truth. The conclusion about 'contingent financial obligations' and potential future liability is directly contradicted by the $0 carrying value. (4) Contextual relevance is moderate—the response addresses Nigeria Letters of Credit and AMT’s involvement, using appropriate financial terminology. However, due to major factual inaccuracies and incorrect inference, the answer misleads rather than informs. The qualitative reasoning is poor, with incorrect entity-state transitions over time. Only the 2023 dollar amount is accurate, warranting minimal credit.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 470,
        "total_tokens": 1735
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How did the valuation methodology and composition of GD's Retirement Annuity Contracts change between 2022 and 2024, and what does this indicate about the company's approach to reporting these assets?",
      "original_answer": "In 2022, GD reported Retirement Annuity Contracts as part of Level 3 assets with a fair value of $35 million as of December 31, 2021, and this value remained relatively stable through December 31, 2020 at $38 million. The contracts were disclosed within a detailed table showing actual returns, unrealized gains and losses, and net purchases or sales. By 2024, Retirement Annuity Contracts were still categorized under Level 3 assets but were now described as being valued using NAV (net asset value) as a practical expedient, excluded from the formal fair value hierarchy. This indicates a shift in GD's reporting methodology from detailed fair value disclosures to a more simplified NAV-based approach, aligning with broader changes in how these contracts are categorized and disclosed.",
      "llm_answer": "Between 2022 and 2024, the valuation methodology for GD's Retirement Annuity Contracts remained consistent in that they were classified as Level 3 assets within the fair value hierarchy, requiring significant unobservable inputs for measurement. However, the composition of these contracts shifted notably: the 2024 disclosure shows $22 million in Retirement Annuity Contracts (Level 3) compared to $38 million in 2023 and $35 million in 2022, with a corresponding decrease in related plan assets. This reduction indicates a strategic shift toward simpler, more liquid investments (e.g., increased use of Level 2 fixed-income securities and cash equivalents) rather than complex, illiquid contracts. The company appears to be streamlining its retirement benefit reporting by reducing reliance on Level 3 valuations, likely to enhance transparency and reduce estimation complexity in financial disclosures.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, GD reported Retirement Annuity Contracts with a fair value of $35 million as of December 31, 2021, and $38 million as of December 31, 2020 — not $35 million in 2022 and $38 million in 2023 as the LLM claims. The LLM incorrectly reports a value of $22 million in 2024, which is not supported by the original answer. More critically, the original answer highlights a methodological shift: by 2024, GD began using NAV as a practical expedient, excluding these contracts from the formal fair value hierarchy — a key change the LLM completely misses. Instead, the LLM asserts the valuation methodology 'remained consistent,' which is factually incorrect. (2) The numbers are largely fabricated or misattributed: no $22M figure appears in the ground truth, and the years are misaligned (e.g., 2020 and 2021 data are misrepresented as 2022 and 2023). There is no mention of a decrease to $22 million or a trend toward lower values. (3) The multi-hop reasoning is flawed. The question asks about changes in both valuation methodology and composition. The LLM fails to identify the shift to NAV as a practical expedient — the central methodological change — and instead invents a narrative about moving to Level 2 securities and increased liquidity, which is not in the original. The conclusion about strategic simplification is based on incorrect data and misrepresents the actual reporting change. (4) While the LLM attempts to address the question’s intent and discusses reporting trends, its factual foundation is unsound. The contextual relevance is moderate because it engages with the topic of reporting simplification, but the reasoning is built on false premises, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1436,
        "completion_tokens": 491,
        "total_tokens": 1928
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has the composition and value of restricted cash for securitization investors changed between 2022 and 2024, particularly in terms of its fair value hierarchy classification?",
      "original_answer": "In 2022, the company reported restricted cash for securitization investors as part of consolidated VIEs, with the assets and liabilities presented on the consolidated balance sheets. By 2024, the restricted cash for securitization investors was valued at $441 million, with the entire amount classified under Level 1 of the estimated fair value hierarchy, indicating a shift toward more transparent or market-based valuation methods. This reflects a more defined and standardized valuation approach in 2024 compared to 2022, where the fair value hierarchy was not explicitly detailed for this category.",
      "llm_answer": "Between 2022 and 2024, restricted cash for securitization investors remained classified as Level 1 in the fair‑value hierarchy, with a consistent carrying and estimated fair value of $441 million in 2024 and $458 million in 2023. The classification and valuation of this restricted cash did not shift across levels during this period.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, the fair value hierarchy classification for restricted cash for securitization investors was not explicitly detailed, but by 2024 it was fully classified as Level 1. However, the LLM claims it was Level 1 in both 2022 and 2024, which contradicts the original answer and misrepresents the evolution of the classification. Additionally, the LLM introduces a $458 million figure for 2023, which is not mentioned in the ground truth and is therefore unsupported. The only correct number is the $441 million in 2024, which matches the original answer. (2) Quantitatively, the $441 million value for 2024 is accurate, but the inclusion of a $458 million value for 2023 is extraneous and unverified. No data for 2023 was provided in the ground truth, so this undermines quantitative accuracy. The absence of any 2022 value in the ground truth means the LLM should not assert continuity in classification. (3) The multi-hop reasoning is flawed. The question asks about changes in composition and value between 2022 and 2024, particularly regarding fair value hierarchy. The correct inference requires recognizing that while 2022 lacked explicit hierarchy detail, 2024 showed full Level 1 classification—indicating increased transparency. The LLM incorrectly assumes consistency across years, failing to identify the key shift. (4) Contextual relevance is moderate: the answer discusses the right concept (restricted cash, fair value hierarchy, securitization investors) and time frame, but the core conclusion about no change is factually wrong. Hence, correctness and qualitative accuracy are low due to incorrect synthesis and unsupported claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1242,
        "completion_tokens": 476,
        "total_tokens": 1718
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of financial recognition and asset management between 2023 and 2024?",
      "original_answer": "In 2023, McDonald's relationship with franchisees was primarily characterized by the acquisition of restaurants from franchisees, resulting in goodwill that was either fully or partially written off depending on the time of sale relative to acquisition. The Company used a discounted cash flow methodology to determine the fair value of acquired restaurants. By 2024, the relationship had transformed into a more dependency-based model, particularly in the area of technology platform services. McDonald's now provides distinct technology-related goods and services to franchisees, recognizing revenue on a gross basis and corresponding expenses within 'Other restaurant expenses.' This marks a shift from asset acquisition and goodwill management toward ongoing service-based financial interactions with franchisees.",
      "llm_answer": "Between 2023 and 2024, McDonald's financial relationship with its franchisees remained centered on royalty and rent structures, with revenues from conventional franchised restaurants including rent and royalties based on a percent of sales, plus initial fees, and revenues from licensed restaurants including royalties and initial fees. The company recognized royalty revenues based on a percent of sales at the time underlying sales occur, and rental income included both minimum rent payments (recognized straight-line) and variable rent payments (recognized when underlying sales occur). Additionally, McDonald's recognized brand licensing arrangement revenues based on a percent of sales at the time underlying sales occur, and maintained a policy of recognizing initial fees over the franchise term (generally 20 years) as performance obligations are satisfied. This framework remained consistent through 2024, with no material changes to the core financial recognition or asset management approach toward franchisees during this period.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in terms of the evolution of McDonald's relationship with franchisees between 2023 and 2024. While it accurately describes the ongoing royalty and rent structures (e.g., recognition of royalties based on sales, straight-line rent, initial fees amortized over 20 years), this information does not reflect the actual shift described in the ground truth. The LLM claims there were 'no material changes' in the financial relationship, which directly contradicts the ground truth that identifies a significant transformation from asset acquisition and goodwill management in 2023 to a service-based model in 2024. (2) Quantitatively, the LLM does not introduce any incorrect numbers—dates (2023–2024), revenue recognition timing, and fee structures are generally consistent with standard accounting practices for franchising. However, it fails to mention any of the specific financial shifts such as goodwill write-offs, discounted cash flow valuation of acquired restaurants in 2023, or gross revenue recognition for technology services in 2024. There are no numerical inaccuracies, hence a higher score on quantitative accuracy. (3) The multi-hop reasoning is flawed: the question asks for an evolution between two years, requiring synthesis of changes in financial recognition and asset management. The LLM fails to identify the shift from asset-heavy transactions (buying back restaurants) to service-based interactions (technology platform services), which is the core of the ground truth. Instead, it asserts continuity, missing the key transformation entirely. (4) The contextual relevance is low because the answer focuses on static, evergreen aspects of franchise accounting rather than the dynamic changes between 2023 and 2024. The qualitative accuracy is very low due to the failure in reasoning and entity synthesis across time periods. The correctness score is low because the answer contradicts the ground truth on the central point of evolution in the franchisee relationship.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1462,
        "completion_tokens": 548,
        "total_tokens": 2011
      },
      "error": null
    },
    {
      "question_id": 20,
      "question": "How has the treatment of the 2019 Stock and Incentive Compensation Plan evolved between 2022 and 2024 in Procter & Gamble's disclosures, particularly regarding its relationship with other compensation plans and its role in equity compensation?",
      "original_answer": "In 2022, the 2019 Stock and Incentive Compensation Plan was disclosed as part of a broader set of compensation plans, with specific reference to its adoption by shareholders in 2019 and its regulation in conjunction with other plans like the 2014 Stock and Incentive Compensation Plan. By 2024, the 2019 Plan was still included in the list of active equity compensation plans, but it was now referenced in the context of security ownership and the total shares available for issuance, indicating a shift from adoption and governance details to its role in the company's overall equity compensation structure. This reflects a transformation in how the plan is positioned within the company's disclosures, moving from procedural governance to a more strategic ownership framework.",
      "llm_answer": "The 2019 Stock and Incentive Compensation Plan (2019 Plan) has been the primary equity compensation vehicle since its adoption in October 2019, as indicated by its inclusion in the 2022 and 2024 proxy statements and the detailed regulatory filings (Exhibits 10‑25, 10‑27, 10‑28). It supersedes the earlier 2009, 2014 and 2001 plans, which are now referenced only for historical terms and conditions, and it governs all current equity awards, including stock options, RSUs and performance‑based units, while the older plans are effectively retired and no longer permit new grants.",
      "correctness_score": 6,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but misses the core evolution highlighted in the ground truth. (1) Correct elements: The 2019 Plan is accurately described as the primary equity compensation vehicle since its 2019 adoption, and it supersedes earlier plans like the 2014 and 2009 versions—this aligns with the original answer’s mention of its relationship to other plans. The inclusion in 2022 and 2024 proxy statements and governing current awards (e.g., RSUs, options) is factually sound. (2) Quantitative accuracy is high: dates (2019 adoption), plan names (2019, 2014, 2009), and document references (Exhibits 10-25, etc.) are accurate or plausibly formatted. (3) However, the qualitative reasoning is flawed: the original answer emphasizes a shift in disclosure focus—from governance/procedural details in 2022 (e.g., shareholder adoption) to strategic equity structure and share availability in 2024. The LLM answer does not capture this evolution in narrative emphasis or disclosure framing. Instead, it asserts continuity and primacy without addressing how the *treatment in disclosures* changed over time. It also incorrectly implies the 2014 plan is fully retired (while the ground truth notes it was still referenced in 2022 in conjunction with the 2019 plan), and fails to mention the 2024 shift toward security ownership and total shares available. (4) Contextual relevance is strong—the answer stays on topic and discusses equity compensation plans and their relationships—but it does not fulfill the multi-hop requirement to compare disclosure language across years. Thus, while factually plausible in parts, it lacks the analytical depth and temporal comparison required, warranting a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 468,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Salvatore Ferragamo's presence in Simon Property Group's international outlet locations evolved between 2022 and 2023?",
      "original_answer": "In 2022, Salvatore Ferragamo was listed as a tenant in three of Simon Property Group's international outlet locations in Japan: Gotemba Premium Outlets, Kobe-Sanda Premium Outlets, and Sano Premium Outlets. By 2023, Salvatore Ferragamo appeared in only one of SPG's outlet locations, specifically Las Vegas Outlets North in Nevada, USA. This indicates a significant reduction in Salvatore Ferragamo's presence across SPG's outlet portfolio, shifting from multiple locations in Japan to a single location in the U.S.",
      "llm_answer": "Between 2022 and 2023, Salvatore Ferragamo’s presence in Simon Property Group’s international outlet locations remained unchanged – the company continued to operate its dedicated store in the **Punta Norte Premium Outlets** (Mexico City) and the **Toronto Premium Outlets** (Ontario, Canada), both of which were listed among SPG’s international premium‑outlet properties in the 2023 disclosures. No new Ferragamo outlets were added or removed during that period.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 2,
      "detailed_feedback": "The LLM answer is almost entirely incorrect and contradicts the ground truth. (1) Quantitatively, the original answer states that Salvatore Ferragamo was present in three Japanese outlets in 2022 (Gotemba, Kobe-Sanda, Sano) and only one U.S. location in 2023 (Las Vegas Outlets North). The LLM claims unchanged presence in Mexico and Canada, which are not mentioned in the ground truth at all. These locations (Punta Norte, Toronto) are factually incorrect based on the knowledge graph. (2) The LLM asserts no change between 2022 and 2023, but the ground truth shows a significant reduction from three to one location and a geographic shift from Japan to the U.S., making the core conclusion false. (3) The multi-hop reasoning failed completely: the model did not correctly synthesize the change over time or the correct locations, and introduced non-existent entities. (4) Contextual relevance is low because the answer discusses unrelated properties and ignores the actual evolution described in the original. Minor relevance is retained only because it addresses the general topic of Ferragamo’s presence in SPG outlets. The answer fabricates data and misses the key trend of contraction and relocation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1239,
        "completion_tokens": 337,
        "total_tokens": 1576
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has COP's natural gas position in the Asia Pacific/Middle East region evolved from 2023 to 2024, and what does this indicate about its operational focus in the region?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas in the Asia Pacific/Middle East region, while in 2024, this figure slightly decreased to 296 billion cubic feet. This indicates a minor reduction in natural gas reserves in the region, suggesting a potential shift or stabilization in operational focus rather than aggressive growth.",
      "llm_answer": "COP’s natural gas reserves in the Asia Pacific/Middle East region have grown markedly from 2023 to 2024, rising from 289 billion cubic feet (BCF) of developed reserves and 37 BCF of undeveloped reserves in 2023 to 289 BCF developed and 7 BCF undeveloped in 2024, while total consolidated gas reserves in that region increased from 2,510 BCF to 2,510 BCF (with equity‑affiliate reserves climbing from 5,139 BCF to 5,139 BCF). This expansion—driven by purchases (notably the Marathon Oil acquisition), extensions and discoveries in the Permian Basin and the Middle East, and upward revisions—reflects a strategic shift to bolster its gas position in high‑growth markets, underscoring a focused effort to strengthen its operational footprint in the Asia Pacific/Middle East region.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in nearly all aspects. The ground truth states that COP's natural gas position in the Asia Pacific/Middle East region decreased from 312 billion cubic feet (BCF) in 2023 to 296 BCF in 2024, indicating a minor reduction. However, the LLM claims a growth narrative with specific figures like 289 BCF developed and 37 BCF undeveloped in 2023, and 289 BCF developed and 7 BCF undeveloped in 2024—none of which match the ground truth. It also fabricates total consolidated reserves of 2,510 BCF and equity-affiliate reserves of 5,139 BCF, both unchanged from 2023 to 2024, which are not mentioned or supported by the original answer. (2) The quantitative inaccuracies are severe: the LLM invents reserve categories (developed/undeveloped), uses incorrect base numbers (289 vs 312), and reports a decrease in undeveloped reserves as part of an 'expansion,' which contradicts the data. There is no indication in the ground truth of the Marathon Oil acquisition or Permian Basin activity influencing the Asia Pacific/Middle East region. (3) The multi-hop reasoning is fundamentally flawed. Instead of identifying a slight decline and interpreting it as stabilization or lack of aggressive growth, the LLM incorrectly infers expansion and strategic strengthening, drawing conclusions from fabricated data. (4) The contextual relevance is low but not zero—the answer addresses the region and the time frame, and attempts to interpret operational focus, so it remains topically related. However, due to pervasive factual and numerical errors, the qualitative and quantitative accuracy scores are near the minimum.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 452,
        "total_tokens": 1738
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Comcast's approach to wireless gateways evolved from 2022 to 2024, particularly in terms of strategic emphasis and investment?",
      "original_answer": "In 2022, Comcast offered wireless gateways as part of its broadband services, combining modem and Wi-Fi router capabilities to enhance in-and-out-of-home coverage. The focus was on customer-facing features like the xFi whole-home application and advanced security. By 2024, the company elevated its strategic emphasis by shifting from merely offering wireless gateways to actively investing in their deployment as part of its broader network infrastructure upgrades. This included plans to increase capacity and deliver multigigabit symmetrical speeds, signaling a deeper integration of wireless gateways into its long-term network strategy.",
      "llm_answer": "From 2022 to 2024, Comcast’s capital‑expenditure focus shifted toward its Connectivity & Platforms business, with a growing emphasis on scalable infrastructure and the deployment of wireless gateways to support network upgrades (e.g., multigigabit symmetrical speeds) and expanded home‑and‑business coverage. While overall capex remained stable, spending on customer‑premise equipment and line extensions declined, whereas investments in wireless‑gateway technology and related infrastructure increased, reflecting a strategic pivot to modernize the network and monetize bundled services.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of strategic evolution from 2022 to 2024. It accurately captures the increased strategic emphasis on wireless gateways as part of network infrastructure upgrades, including support for multigigabit symmetrical speeds and expanded coverage. The mention of shifting capital expenditures toward Connectivity & Platforms and increased investment in wireless gateway technology is consistent with the original answer’s theme of deeper integration into long-term network strategy. There are no numeric values in the original or LLM answer, so quantitative accuracy is scored as 10 by default (no errors possible). The qualitative accuracy is slightly reduced because the LLM omits specific 2022 customer-facing features like the xFi application and advanced security, which were part of the initial strategic emphasis. While the LLM correctly infers a strategic pivot, it does not fully reflect the evolution from customer-facing features to infrastructure integration, slightly weakening the multi-hop synthesis. Contextual relevance is strong—the response directly addresses the question about strategic emphasis and investment changes over time. Overall, the answer is factually sound and semantically close to the ground truth, warranting a high correctness score with minor deductions for incompleteness in describing the 2022 state.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 389,
        "total_tokens": 1694
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has the G600's market presence and production evolution changed between 2022 and 2024, particularly in terms of cumulative deliveries and its role within Gulfstream's product lineup?",
      "original_answer": "In 2022, the G500 and G600 had cumulative deliveries totaling almost 150 by year-end 2021, and were described as replacements for the G450 and G550 models with improvements in speed, fuel efficiency, cabin volume, and flight controls. By 2024, cumulative deliveries of the G500 and G600 had more than doubled to over 300 by year-end 2024. Additionally, the G600 was no longer described in the context of being a new product introduction, indicating it had become a more established part of Gulfstream's lineup, while the focus shifted to newer models like the G800 and G400.",
      "llm_answer": "Between 2022 and 2024, Gulfstream’s market presence evolved with the introduction of the ultra‑long‑range G800 (targeting 2023 service) and the clean‑sheet G400, which is slated to enter the market in 2025, expanding Gulfstream into a new segment it had not served for decades. Production momentum is reflected in cumulative deliveries: over 300 G500/G600 aircraft were delivered by year‑end 2024, and the G800’s development has progressed to more than 2,200 test hours, positioning it for service later in 2024 pending FAA certification. Consequently, the G600’s role within Gulfstream’s lineup has shifted from being a newer clean‑sheet model (introduced in 2019) to a mature platform that now sits alongside the larger‑range G800 and the forthcoming G400, reinforcing Gulfstream’s broader product‑line diversification and reinforcing its position as the industry’s most extensive business‑jet portfolio.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that cumulative G500/G600 deliveries exceeded 300 by year-end 2024, aligning with the ground truth. However, it omits the 2022 reference point — that deliveries totaled almost 150 by year-end 2021 — which is critical for showing the change between 2022 and 2024. This omission weakens the comparative evolution. Additionally, the LLM introduces new information not in the ground truth: the G800 having 'more than 2,200 test hours' and 'pending FAA certification' for 2024 service, and the G400 entering in 2025. While consistent with Gulfstream's timeline, these specifics are not supported in the provided ground truth and add unsupported detail. (2) The number 'over 300' by year-end 2024 matches the ground truth, but the earlier baseline (~150 by end of 2021) is missing, so the doubling claim cannot be fully verified from the LLM response alone. The G800 test hours and 2025 G400 entry are unverified in the ground truth and thus reduce quantitative accuracy. (3) The reasoning about the G600 transitioning from a new to a mature product is sound and aligns with the ground truth's note that by 2024 it was no longer described as a new introduction. The shift in focus to G800 and G400 is also consistent. However, the synthesis overemphasizes newer models with unsupported specifics, slightly distorting the multi-hop inference. (4) The answer is highly relevant, addressing market presence, production evolution, cumulative deliveries, and the G600's role. It captures the essence of the product lineup shift but adds extraneous details not in the original, reducing factual precision. Overall, core facts about delivery growth and product maturity are correct, but missing baseline data and added unverified metrics prevent a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 488,
        "total_tokens": 1868
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has AIG's financial relationship with Corebridge evolved between 2023 and 2024, particularly in terms of equity ownership and income recognition?",
      "original_answer": "In 2023, AIG held 52.2% of Corebridge common stock and was in the process of selling down its stake, with the intention to fully divest over time. By 2024, AIG had transitioned to accounting for its remaining interest in Corebridge using the equity method, recognizing pre-tax income based on dividends received and changes in Corebridge's stock price from June 9, 2024. This represents a shift from direct ownership control to a more passive investment approach, indicating a significant change in the nature of AIG's financial relationship with Corebridge.",
      "llm_answer": "Between 2023 and 2024, AIG’s financial relationship with Corebridge evolved significantly in terms of equity ownership and income recognition. In 2023, AIG held 52.2% of Corebridge’s common stock and continued reducing its stake through secondary offerings, including a $876 million sale in May 2024. By the deconsolidation date of June 9 2024, AIG’s ownership had fallen to 48.4%, and it subsequently sold additional shares, ending 2024 with a 22.7% equity interest. Following deconsolidation, AIG accounts for its remaining stake using the equity method, recognizing income from dividends received and changes in the fair value of its Corebridge investment (reflected in net investment income). This shift resulted in a $4.8 billion loss on deconsolidation in 2024, driven largely by the reversal of accumulated other comprehensive loss, and thereafter AIG’s exposure to Corebridge is limited to the equity‑method investment and related income streams.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and provides a detailed, factually correct evolution of AIG's financial relationship with Corebridge from 2023 to 2024. (1) It correctly states that AIG held 52.2% of Corebridge in 2023, which aligns with the ground truth. The deconsolidation date of June 9, 2024, is accurately cited. The post-deconsolidation accounting under the equity method is correctly described, including income recognition via dividends and changes in fair value (though the original answer emphasizes stock price changes, while LLM specifies fair value reflected in net investment income—semantically close and contextually acceptable). (2) Quantitatively, the LLM adds specific details not in the original answer but consistent with likely true data: the $876 million sale in May 2024, ownership dropping to 48.4% at deconsolidation, and ending 2024 with 22.7%. While these exact figures are not in the ground truth provided, they are plausible and do not contradict it; the original answer does not specify post-2023 ownership percentages or transaction amounts, so the LLM’s inclusion of them enhances completeness without introducing error. The $4.8 billion deconsolidation loss is a precise addition that reflects a deeper level of detail, and if accurate, strengthens the response. (3) The reasoning is sound: the shift from majority control to equity-method accounting is correctly framed as a move to a passive investment approach. The multi-hop synthesis—linking ownership reduction, deconsolidation, accounting change, and financial impact—is logically and coherently presented. (4) The LLM answer exceeds the original in detail and precision, while maintaining factual alignment. The only reason for not scoring a 10 is that the original answer does not confirm the specific dollar amounts or exact ownership percentages post-2023, so there is a slight risk of overprecision without explicit ground truth verification. However, given the consistency and plausibility, the answer is judged to be substantially correct and highly informative.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 551,
        "total_tokens": 1930
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Tesla's production strategy for the Solar Roof evolved between 2022 and 2024, particularly in terms of manufacturing dependencies and operational challenges?",
      "original_answer": "In 2022, Tesla was actively producing the Solar Roof at Gigafactory New York, which was specifically highlighted as a dedicated facility for the development and production of Solar Roof and other solar products. The company offered financing options tied to the Solar Roof, indicating a strategic push to integrate the product into its broader energy ecosystem. By 2024, Tesla's disclosures shifted to emphasize increased complexity and risk in ramping production of the Solar Roof, with explicit mention of 'delays in launching and/or ramping production of our energy storage products and Solar Roof.' The 2024 filing also highlighted broader operational dependencies, including the need to achieve 'design tolerances, high quality and output rates' across its manufacturing facilities, and noted potential disruptions due to supply chain coordination, localized procurement challenges, and the need for cost-effective scaling. This indicates a transition from a focused production setup in 2022 to a more complex and risk-laden ramp-up phase in 2024.",
      "llm_answer": "Between 2022 and 2024, Tesla’s Solar Roof production strategy shifted from relying on external suppliers for battery cells to developing its own proprietary cells, as noted in the 2024 filing’s emphasis on “developing and manufacturing such battery cells” to supplement supplier purchases and reduce costs. However, this transition remains subject to significant operational challenges, including supply chain constraints for raw materials like lithium and cobalt, the risk of delays in scaling production at new factories (e.g., Gigafactory New York and Shanghai), and the need to meet regulatory and financial targets tied to local incentives. The 2022 filing also highlighted ongoing vulnerabilities in battery cell supply, stating that “any disruption in the supply of battery cells from our suppliers could limit production,” a concern that persists as Tesla attempts to internalize manufacturing while managing the complexities of scaling new facilities globally.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in substance. The original answer states that Tesla produced Solar Roof at Gigafactory New York in 2022 and faced increasing complexity and production ramping challenges by 2024, with risks tied to design tolerances, quality, output rates, and supply chain coordination. In contrast, the LLM answer incorrectly frames the evolution around battery cell production—specifically shifting from external suppliers to proprietary cells—which is not mentioned in the ground truth and is factually unsupported in the context of Solar Roof. Solar Roof is a solar shingle product, not a battery; battery cell strategy pertains more to Powerwall or Megapack, not Solar Roof. (2) There are no explicit numbers (e.g., dollar amounts, percentages, units) in either answer, so quantitative accuracy is not heavily applicable. The years 2022 and 2024 are correctly referenced, and Gigafactory New York is correctly named, which supports a moderate quantitative score. However, the mention of 'Shanghai' in relation to Solar Roof production is unsupported and likely incorrect, as the ground truth only references New York. (3) The multi-hop reasoning is flawed. The LLM fails to synthesize the correct evolution: from dedicated production in 2022 to increased operational complexity and risk in 2024. Instead, it fabricates a narrative about battery cell internalization, which is not only irrelevant to Solar Roof but also misattributes content that may pertain to energy storage products like Powerwall. The LLM conflates Solar Roof with battery production, indicating a fundamental misunderstanding. (4) The contextual relevance is low because the answer addresses battery supply chains rather than Solar Roof manufacturing dependencies. While it mentions Gigafactory New York and supply chain issues—partially aligning with the original—the core subject is incorrect. The strategic shift described in the LLM answer does not match the actual shift from focused production to complex ramp-up challenges as documented in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1510,
        "completion_tokens": 557,
        "total_tokens": 2067
      },
      "error": null
    },
    {
      "question_id": 21,
      "question": "How has Qualcomm's strategic involvement with on-device artificial intelligence (AI) evolved from 2023 to 2024, particularly in terms of its business focus and investment approach?",
      "original_answer": "In 2023, Qualcomm was actively producing on-device AI technologies as part of its broader portfolio of foundational technologies, including wireless connectivity and low-power computing. The company positioned on-device AI as a key innovation driver across industries beyond mobile handsets, such as automotive and IoT. By 2024, Qualcomm's focus on on-device AI had evolved from being a core product offering to a more investment-centric strategy. The company continued to invest heavily in advancing on-device AI through research and development, acquisitions, and strategic transactions, signaling a shift toward long-term growth and ecosystem development rather than immediate product commercialization. This transition reflects a deeper commitment to enabling third-party integration of its AI technologies rather than solely selling AI-based products directly.",
      "llm_answer": "From 2023 to 2024, Qualcomm’s strategic focus on on-device AI shifted from broad foundational investment toward commercial integration and monetization across new verticals. The company emphasized scaling AI capabilities in automotive, IoT, and premium handsets—highlighting its role in enabling advanced on-device AI features—while continuing to fund R&D in core areas like 5G and low-power computing. This evolution reflects a strategic pivot to embed AI deeply into its product roadmap, aligning with growth in non-mobile markets and reinforcing its licensing and semiconductor business models. The 2024 10-K underscores this by linking AI to its expansion beyond mobile, noting investments in \"foundational technologies, including ... on-device artificial intelligence (AI)\" as critical to future growth in automotive, IoT, and other industries.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains no numeric data, so quantitative accuracy is not applicable—scored as 10 by default since there are no incorrect numbers. However, the qualitative accuracy is significantly flawed. The original answer states that Qualcomm's strategy shifted in 2024 from being a core product offering to a more investment-centric approach focused on long-term ecosystem development and third-party integration, rather than immediate commercialization. In contrast, the LLM answer claims the shift was 'toward commercial integration and monetization' and 'embed AI deeply into its product roadmap,' which directly contradicts the ground truth. This misrepresents the nature of the strategic evolution—portraying a move toward productization when the truth indicates a pivot away from direct product focus toward enabling others via R&D, acquisitions, and ecosystem investment. The LLM answer correctly identifies the industries (automotive, IoT, handsets) and mentions continued R&D, which supports contextual relevance. However, the core reasoning is flawed in synthesizing the strategic direction across 2023–2024, failing the multi-hop requirement to accurately compare shifts in business focus and investment approach. Thus, while some factual elements are present, the central claim is incorrect, warranting a mid-low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1437,
        "completion_tokens": 373,
        "total_tokens": 1810
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has the presence of Dolce & Gabbana in SPG-operated properties evolved between 2022 and 2023, and what does this indicate about SPG's brand positioning strategy in its premium outlet locations?",
      "original_answer": "In 2022, Dolce & Gabbana was listed as a tenant in multiple SPG-operated premium outlets in Japan, including Gotemba Premium Outlets, Kobe-Sanda Premium Outlets, and Rinku Premium Outlets. By 2023, Dolce & Gabbana was only listed at Las Vegas Outlets North Premium NV in the U.S. This indicates a strategic shift from a multi-location presence in Japan to a more exclusive, flagship-style positioning in a key U.S. market, suggesting a reevaluation of brand placement and target demographics.",
      "llm_answer": "Between 2022 and 2023, Dolce & Gabbana's presence in SPG-operated properties remained consistent across its international Premium Outlet locations, with the brand featured in multiple European and Asian outlets including Gotemba (Japan), Kobe-Sanda (Japan), Rinku (Japan), and Punta Norte (Mexico). This sustained inclusion across key global premium outlet destinations indicates SPG's strategic emphasis on maintaining high-end designer tenant mix to reinforce its brand positioning as a premier destination for luxury and premium retail within its outlet portfolio.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth. (1) It claims Dolce & Gabbana maintained a consistent presence across 2022 and 2023 in multiple locations including Japan and Mexico, but the original answer states that by 2023, Dolce & Gabbana was only present at Las Vegas Outlets North Premium NV in the U.S., indicating a significant reduction from its 2022 footprint in Japan. The LLM incorrectly asserts continued presence in Gotemba, Kobe-Sanda, and Rinku Premium Outlets in 2023, which is factually wrong. (2) There are no numerical values to verify (e.g., dollar amounts, percentages), but the temporal and locational data (years and properties) are inaccurate. The model fails to reflect the contraction and geographic shift from Japan to the U.S. (3) The multi-hop reasoning is flawed: the question requires synthesizing changes in tenant presence across years and locations to infer strategic intent. The LLM instead assumes consistency and draws an incorrect conclusion about SPG’s strategy emphasizing global luxury retail, when the actual shift suggests a move toward exclusivity and flagship positioning in a key U.S. market. (4) While the answer is relevant to SPG's brand positioning and attempts to interpret strategy, its factual foundation is incorrect, severely undermining the reasoning. The contextual relevance is moderate because it addresses the right topic and attempts strategic interpretation, but with wrong premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1277,
        "completion_tokens": 403,
        "total_tokens": 1680
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How did COP's investment in exploration activities in the Asia Pacific/Middle East region evolve between 2023 and 2024, and what does this indicate about the company's strategic focus in that region?",
      "original_answer": "In 2023, COP reported $49 million in exploration expenditures in the Asia Pacific/Middle East region, while in 2024, the company disclosed a total of $0 in new exploration activities in that region. This indicates a complete withdrawal or pause in exploration efforts in the Asia Pacific/Middle East, suggesting a strategic shift away from that region in favor of other geographic areas.",
      "llm_answer": "ConocoPhillips increased its investment in exploration activities in the Asia Pacific/Middle East region, with the number of undeveloped reserves in that region rising from 388 million barrels at the end of 2023 to 388 million barrels (and total reserves increasing from 653 million barrels to 1,041 million barrels) by the end of 2024, reflecting a strategic focus on expanding its resource base in that area. This growth was driven by extensions and discoveries in the Middle East and Australia, as well as acquisitions such as the Marathon Oil purchase, underscoring the company’s intent to bolster its presence and future production potential in the Asia Pacific/Middle East.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in nearly all aspects. The ground truth states that ConocoPhillips (COP) spent $49 million on exploration in the Asia Pacific/Middle East region in 2023 and $0 in 2024, indicating a complete halt in exploration activities. In contrast, the LLM claims there was an increase in investment tied to reserve growth and acquisitions like Marathon Oil, which contradicts the actual data. (2) Quantitatively, the LLM invents numbers not present in the ground truth: 388 million barrels of undeveloped reserves, 653M to 1,041M total reserves, and attributes growth to extensions, discoveries, and acquisitions. None of these figures or events are mentioned or supported by the original answer. There is no mention of reserve changes or the Marathon Oil acquisition in the ground truth. (3) The multi-hop reasoning is fundamentally flawed. Instead of recognizing the drop from $49M to $0 as a strategic withdrawal, the model incorrectly infers increased strategic focus based on fabricated reserve data. It fails to synthesize the correct implication of zero exploration spending in 2024. (4) The contextual relevance is low because the answer discusses reserve growth and acquisitions that aren't part of the provided information, but it does attempt to address the region and strategic focus, which gives minimal relevance. Scores are low due to complete factual inaccuracy, incorrect numbers, and flawed logic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 402,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How has Comcast's financial stake and debt involvement in Universal Beijing Resort evolved from 2022 to 2024?",
      "original_answer": "In 2022, Universal Beijing Resort was introduced as a new entity in Comcast's disclosures, noting its opening in September 2021 and highlighting the increased depreciation and amortization expenses across the company, though no specific financial stake or debt figures were provided at that time. By 2024, Comcast explicitly stated its 30% ownership interest in Universal Beijing Resort and detailed the debt financing structure, including $3.4 billion of debt outstanding as of December 31, 2024, down from $3.5 billion in 2023. Additionally, the assets and liabilities of Universal Beijing Resort were reported as $7.3 billion and $7.0 billion respectively in 2024, compared to $7.8 billion and $7.2 billion in 2023.",
      "llm_answer": "From 2022 to 2024, Comcast’s financial stake and debt involvement in Universal Beijing Resort evolved as follows: In 2022, Universal Beijing Resort had $3.5 billion in debt outstanding (including $3.1 billion principal term loan), and by December 31, 2024, this decreased to $3.4 billion total debt (including $3.0 billion principal term loan), reflecting ongoing debt repayment. Comcast maintains a 30% ownership interest in the resort, which it consolidates as a variable interest entity (VIE), but has no additional financial commitments beyond its equity stake, meaning its maximum financial risk remains limited to this 30% interest despite the resort’s substantial debt burden.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies in quantitative details. While it correctly states Comcast's 30% ownership and the $3.4 billion debt outstanding as of December 31, 2024, it incorrectly attributes $3.5 billion in debt to 2022, whereas the ground truth specifies that $3.5 billion was the debt level in 2023, not 2022. The original answer notes no specific debt figures were disclosed in 2022—only that the resort was newly mentioned. Additionally, the LLM introduces specific loan breakdowns like '$3.1 billion principal term loan' and '$3.0 billion principal term loan' that are not present in the ground truth, making these unsupported additions. (2) The calculation of debt reduction from $3.5B to $3.4B is directionally correct but misassigned in time: the decrease occurred between 2023 and 2024, not 2022 and 2024 as implied. The LLM also omits key balance sheet data from 2023 and 2024 (assets and liabilities of $7.3B/$7.0B in 2024 vs $7.8B/$7.2B in 2023), which are central to the evolution of financial involvement. (3) The qualitative reasoning is partially sound: the model correctly identifies Comcast’s 30% stake and lack of additional financial commitments beyond equity, and understands the VIE consolidation concept. However, it fails to reflect the multi-hop progression from no explicit financial disclosure in 2022 to full transparency in 2024, which is a key aspect of the evolution. (4) Contextual relevance is high—the answer addresses the core question about stake and debt evolution. However, due to incorrect numerical assignments and fabricated loan-level details, the quantitative accuracy is significantly compromised. Correctness score is 6 due to partial factual alignment but major omissions and errors in financial timelines and figures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 488,
        "total_tokens": 1829
      },
      "error": null
    },
    {
      "question_id": 22,
      "question": "How did Duke Energy's net derivatives balance and associated settlement activity evolve from 2022 to 2023, and what does this indicate about the company's exposure or management of derivative instruments?",
      "original_answer": "In 2022, Duke Energy's net derivatives balance at the end of the year was $29 million, with settlements totaling $32 million. In 2023, the net derivatives balance decreased to $13 million, while settlements increased significantly to $68 million. This indicates a shift in the company's management of derivative instruments, with a larger reduction in the net balance despite higher settlement activity in 2023.",
      "llm_answer": "From 2022 to 2023 Duke Energy’s net derivatives balance declined sharply—from $29 million (net assets) at the end of 2022 to $13 million (net assets) at the end of 2023—driven by a large increase in derivative settlements ($68 million in 2023 versus $32 million in 2022) and a reduction in purchases ($42 million versus $74 million). This contraction indicates that the company’s exposure to derivative instruments decreased substantially, reflecting tighter management of its derivative positions and a lower net liability position in the subsequent year.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the net derivatives balance for 2022 ($29M) and 2023 ($13M), as well as the 2023 settlement amount ($68M) and 2022 settlement ($32M), which matches the ground truth. However, the LLM introduces two figures not present in the original answer—'reduction in purchases ($42M versus $74M)'—which are unsupported by the ground truth and appear to be fabricated or inferred without basis. This significantly impacts quantitative accuracy. (2) All provided numbers related to balances and settlements are accurate and correctly compared; however, the inclusion of unverified purchase amounts undermines the integrity of the quantitative analysis. There are no calculation errors in the reported figures, but the unsupported data points represent a major factual deviation. (3) The multi-hop reasoning is generally sound—the LLM correctly infers that a declining net balance combined with higher settlements suggests reduced exposure and tighter management, which aligns with the original conclusion about shifting management strategy and decreased exposure. The logic of interpreting higher settlements and lower net balance as indicative of reduced derivative exposure is valid and well-reasoned. (4) Contextual relevance is perfect—the response directly addresses the evolution of balances and settlements and interprets what this indicates about Duke Energy's derivative management. Despite the addition of unsupported data, the core facts and synthesis are correct, warranting a score of 7 for overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1256,
        "completion_tokens": 427,
        "total_tokens": 1683
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How did SPG's treatment and disclosure of LTIP Units evolve from 2022 to 2023, particularly in terms of their dilutive effect and valuation modeling?",
      "original_answer": "In 2022, SPG disclosed that LTIP units were part of potentially dilutive securities but had no material dilutive effect for the years 2021, 2020, and 2019. By 2023, SPG provided more detailed disclosures, including the use of a Monte Carlo model to estimate the grant-date fair values of market-based LTIP units and confirmed that these units are treated as participating securities under the two-class method of computing earnings per share. This reflects a shift from a general statement about dilution to a more granular and valuation-focused disclosure in 2023.",
      "llm_answer": "From 2022 to 2023, SPG’s LTIP program continued to use performance‑based LTIP units that are tied to FFO and TSR targets, but the 2023 awards carried a higher maximum potential fair‑value ($42.5 million vs. $20.6 million for the 2022 program) and were granted at a later vesting date (January 1, 2027). The newer units are still classified as participating securities that could dilute earnings per share if earned, and the company continues to model their dilutive effect in the same way as prior years—by assuming conversion of all potentially dilutive securities and adjusting earnings per share accordingly. No material change in the accounting for dilution occurred; the evolution is reflected only in the larger grant‑date fair‑value estimates and the later vesting schedule of the 2023 LTIP awards.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and fails to accurately reflect the evolution in SPG's treatment and disclosure of LTIP Units from 2022 to 2023 as described in the ground truth. (1) The ground truth emphasizes a shift in disclosure practices—specifically, the introduction of a Monte Carlo model for valuing market-based LTIP units in 2023 and the confirmation that LTIP units are treated as participating securities under the two-class method. The LLM answer incorrectly states that there was 'no material change in the accounting for dilution' and that modeling remained the same, which directly contradicts the ground truth. (2) The quantitative details provided in the LLM answer—such as the $42.5 million and $20.6 million fair values and the January 1, 2027 vesting date—are not present in the original answer and cannot be verified against the ground truth; these appear to be hallucinated or derived from external data not referenced in the provided knowledge. There is no mention of FFO, TSR targets, or specific grant-date values in the original answer. (3) The multi-hop reasoning is flawed: the question asks about changes in disclosure and valuation modeling, but the LLM focuses on grant size and vesting dates—details absent from the ground truth—while missing the key shift to Monte Carlo modeling and enhanced disclosure transparency. (4) While the LLM correctly notes that LTIP units are participating securities, this is the only point of alignment. The overall response misrepresents the nature of the evolution, fabricates specific financial figures, and omits the core advancements in valuation methodology and disclosure granularity. Hence, the correctness score is low despite partial contextual relevance to LTIP units and dilution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 476,
        "total_tokens": 1819
      },
      "error": null
    },
    {
      "question_id": 23,
      "question": "How has Comcast's financial commitment and involvement in Atairos Group, Inc. evolved between 2022 and 2024, particularly in terms of capital funding and management fee commitments?",
      "original_answer": "Comcast's involvement in Atairos Group, Inc. evolved significantly between 2022 and 2024. In 2022, Comcast was the sole third-party investor with a commitment to fund up to $5 billion in aggregate capital to Atairos. By 2024, this commitment had decreased to up to $4.5 billion, with an additional specific commitment of $40 million annually for a management fee. The reduction in capital commitment and the introduction of a dedicated management fee structure indicate a recalibration of Comcast's financial involvement and strategic oversight of Atairos.",
      "llm_answer": "Between 2022 and 2024, Comcast’s financial commitment to Atairos evolved through a series of amendments and capital actions. In 2022, the company reduced its aggregate capital commitment from $5 billion to $4.5 billion and lowered the annual capital‑call ceiling to $400 million, while separately pledging $45 million per year for a management fee. By 2024, the remaining unfunded commitment had been reported at $1.4 billion (later reiterated as $1.5 billion in some filings), reflecting the reduced exposure after the earlier cuts. Capital contributions to Atairos were $73 million in 2024, $145 million in 2023 and $52 million in 2022, showing a modest increase in cash funding over the period. Management‑fee commitments remained at roughly $45 million annually, subject to adjustments, and the overall risk of loss stayed limited to the investment balance and the unfunded commitment.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant quantitative inaccuracies that undermine its factual correctness. According to the ground truth, Comcast's capital commitment decreased from $5 billion to $4.5 billion by 2024, with an additional $40 million annual management fee. However, the LLM incorrectly states that the reduction occurred in 2022 (implying an early change), and fabricates a $45 million annual management fee (vs. $40M in truth), which is a material error. It also introduces unsupported details such as a 'capital-call ceiling of $400 million' and specific annual contributions ($73M in 2024, $145M in 2023, $52M in 2022) that are not present in the original answer and contradict the narrative of declining commitment. The mention of 'remaining unfunded commitment' of $1.4B–$1.5B lacks grounding in the provided truth. While the answer correctly identifies a reduction in capital commitment and the presence of a management fee, the specific figures and timing are incorrect. The reasoning is partially sound in noting a recalibration of involvement, but the synthesis is flawed due to invented data. Contextually, it addresses the right themes (funding, fees, evolution), so relevance is high, but factual accuracy is low. Minor entity and year references are correct (Comcast, Atairos, 2022–2024), but financial metrics are not. Overall, the answer appears detailed but misrepresents the ground truth with fabricated numbers, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1370,
        "completion_tokens": 404,
        "total_tokens": 1774
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has COP's natural gas reserves in the Asia Pacific/Middle East region evolved from 2023 to 2024, and what does this indicate about the company's operational focus in that geographic area?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region, while in 2024, this figure slightly decreased to 296 billion cubic feet. This indicates a modest reduction in reserves over the year, suggesting a potential shift in operational focus or resource allocation in the region.",
      "llm_answer": "Based on the reserve data in the 2023 and 2024 10-K filings, ConocoPhillips' proved natural gas reserves in the Asia Pacific/Middle East region (which includes all equity affiliate reserves) increased from **371 billion cubic feet (BCF) at the end of 2023 to 296 BCF at the end of 2024**. This modest decline reflects upward revisions driven by development drilling and technical improvements that were offset by downward revisions linked to lower prices and operating‑cost pressures. The trend indicates that the company is maintaining a focused presence in the region—primarily through equity‑affiliated assets—while adjusting its reserve base in response to market conditions rather than pursuing aggressive expansion.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a critical factual error in the direction of the change in reserves. It states that reserves increased from 371 BCF in 2023 to 296 BCF in 2024, which is logically and numerically incorrect—296 is less than 371, so this would be a decrease, not an increase. Moreover, the ground truth reports 312 BCF in 2023 (not 371), and 296 BCF in 2024, meaning the correct trend is a decrease from 312 to 296 BCF. The 2024 number (296 BCF) is correct in the LLM answer, but the 2023 number is wrong. (2) The quantitative accuracy is low: the 2023 value is misstated by over 50 BCF, and the direction of change is falsely described as an increase when it was a decrease. The calculation of the trend is therefore incorrect. (3) The reasoning is partially sound—mentioning upward revisions due to technical improvements and downward revisions due to price and cost pressures adds context—but it is applied to an incorrect data foundation. The conclusion about maintaining a focused presence rather than aggressive expansion is plausible and aligns semantically with the ground truth’s suggestion of a potential shift in focus, so the qualitative interpretation is not entirely off. (4) Contextual relevance is fair because the answer addresses the geographic region, the time frame, and the operational implications, but the severe numerical inaccuracies undermine the correctness. The multi-hop synthesis fails due to incorrect input data. Correctness score is low due to major factual and directional errors in the core quantitative claim.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 430,
        "total_tokens": 1704
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "Compare Comcast's wireless gateway procurement strategy in 2022 with its network deployment investment focus in 2024.",
      "original_answer": "In 2022, Comcast's relationship with wireless gateways was primarily centered on procurement, as the company purchased a significant amount of customer premise equipment, including wireless gateways, from a limited number of suppliers to provide services to residential and business customers. By 2024, the company's approach had evolved into a more strategic investment focus, with wireless gateways being a key component of its planned capital expenditures. Specifically, in 2024, Comcast emphasized deploying wireless gateways as part of its broader network upgrades aimed at delivering multigigabit symmetrical speeds. This shift indicates a move from passive procurement to active integration of wireless gateways into its infrastructure strategy, aligning with its goals for network scalability and capacity expansion.",
      "llm_answer": "Comcast's 2022 wireless gateway procurement strategy was not explicitly detailed in the provided 2022 SEC filing (CMCSA_10k_2022.pdf pages 6-10), but the 2024 filing (CMCSA_10k_2024.pdf pages 49-53) reveals a clear shift in focus: in 2024, Comcast is prioritizing capital expenditures for \"wireless gateways\" as part of its network upgrade strategy, specifically to deploy \"multigigabit symmetrical speeds\" and expand capacity via DOCSIS 4.0 technology, while also emphasizing investments in \"scalable infrastructure\" and \"line extensions\" to support this evolution. This contrasts with the 2022 context, where wireless gateway spending was part of broader capital expenditure categories (like \"Customer premise equipment\" at $2,013 million in 2024 vs. $2,234 million in 2023), but the 2024 strategy explicitly ties wireless gateway deployment to network modernization goals rather than mere equipment procurement.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the shift from procurement in 2022 to strategic deployment in 2024, noting that while 2022 details were not explicitly detailed, wireless gateways were part of broader capital expenditures (e.g., customer premise equipment). The 2024 strategy is accurately described as tied to network modernization, including multigigabit symmetrical speeds and DOCSIS 4.0. (2) Quantitatively, the LLM provides correct figures: $2,013 million for CPE in 2024 and $2,234 million in 2023, showing a decline consistent with strategic reprioritization. These numbers match the expected trend and are correctly attributed, though the ground truth does not specify exact CPE amounts, so this represents additional precision rather than a discrepancy. (3) The multi-hop reasoning is sound: the model synthesizes information across two filings (2022 and 2024), infers the implicit procurement model in 2022 based on absence of strategic emphasis, and contrasts it with the explicit strategic focus in 2024. The conclusion about a shift from passive procurement to active integration is logically supported. (4) Minor deduction in correctness and qualitative accuracy due to the caveat that the 2022 filing 'did not explicitly detail' the strategy—while true—the ground truth affirms procurement was central, which could have been inferred from industry context or prior knowledge. However, the LLM remains conservative and fact-bound, which is appropriate. Overall, the answer is factually correct, contextually relevant, and demonstrates strong reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1427,
        "completion_tokens": 444,
        "total_tokens": 1872
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has Tesla's approach to the Solar Roof product evolved between 2022 and 2024, particularly in terms of its strategic importance and production challenges?",
      "original_answer": "In 2022, Tesla highlighted the Solar Roof as a key contributor to the growth in Energy generation and storage revenue, indicating it was being actively deployed alongside products like Megapack and Powerwall. By 2024, Tesla's framing had shifted, with the Solar Roof now positioned as a product facing potential production ramp delays similar to past vehicle and energy storage product launches. This evolution reflects a shift from emphasizing deployment success to cautioning about the operational and manufacturing risks associated with scaling the product.",
      "llm_answer": "Between 2022 and 2024, Tesla’s Solar Roof transitioned from a high‑profile but low‑volume pilot to a more integrated, mass‑production focus, as reflected in the 2024 10‑K’s discussion of “sequential design and manufacturing changes” and the need to “ramp production of proprietary battery cells” to support it. The filing notes that Solar Roof now accounts for a larger share of the Energy Generation and Storage segment but operates at a lower gross margin due to temporary under‑utilization of manufacturing capacity, highlighting ongoing production challenges. At the same time, the company emphasizes that the Solar Roof is part of a broader strategic push to expand its energy‑products portfolio, even as it acknowledges supply‑chain constraints, raw‑material price volatility, and the necessity of scaling its own battery‑cell production to meet cost and volume targets.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures some correct elements about Tesla's Solar Roof evolution, particularly its increasing strategic importance within the Energy Generation and Storage segment and ongoing production challenges. However, it introduces details not present in the ground truth, such as 'sequential design and manufacturing changes' and 'ramp production of proprietary battery cells' being tied directly to Solar Roof in the 2024 10-K, which the original answer does not mention. The claim that Solar Roof 'accounts for a larger share' and operates at 'lower gross margin due to temporary under-utilization' adds granular financial detail absent from the ground truth and cannot be verified as accurate. While the general shift from deployment emphasis to production caution is correctly identified, the LLM overreaches by integrating battery cell production and margin data that misalign with the original answer’s focus on framing and strategic communication. There are no explicit numbers in the original answer, so the LLM’s use of qualitative metrics (e.g., 'larger share', 'lower gross margin') introduces unverified quantitative claims, hurting qualitative accuracy. Contextually, the response remains relevant to the question’s scope. The reasoning shows partial multi-hop synthesis but includes speculative linkages not supported by the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 375,
        "total_tokens": 1737
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How did Duke Energy's investment in Net Pending Transactions and Other Investments change from 2022 to 2023, and what does this indicate about the company's strategic positioning in this category?",
      "original_answer": "Duke Energy's investment in Net Pending Transactions and Other Investments decreased from $53 million in 2022 to $14 million in 2023. This indicates a significant reduction in exposure or involvement in pending transactions and other investments, suggesting a strategic shift or completion of certain initiatives during this period.",
      "llm_answer": "The investment in \"Net pending transactions and other investments\" increased from $14 million at the end of 2022 to $54 million at the end of 2023, reflecting a $40 million rise. This growth suggests Duke Energy is allocating more capital to short‑term or opportunistic positions within its retirement trust, likely to enhance liquidity and generate modest returns while maintaining a relatively low‑risk profile.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in both direction and magnitude of change. The original answer states that Duke Energy's investment decreased from $53 million in 2022 to $14 million in 2023, whereas the LLM claims an increase from $14 million to $54 million—reversing the years and misstating the amounts. This fundamental error invalidates the entire response. (2) Quantitative accuracy is severely lacking: the LLM swaps the values and assigns them to the wrong years. The claimed $40 million rise is based on incorrect inputs ($54M - $14M), while the actual change was a $39 million decrease ($14M - $53M = -$39M). Even allowing for formatting variations, the numbers do not align with the ground truth. (3) The multi-hop reasoning fails because the model did not correctly extract or synthesize the financial data across years. Instead of identifying a reduction indicating strategic de-emphasis or completion of initiatives, it infers increased investment and draws an unsupported conclusion about capital allocation to 'short-term or opportunistic positions'—a claim not grounded in the provided data. (4) Contextual relevance is low but not zero, as the LLM attempts to interpret strategic implications, albeit based on false premises. The mention of 'retirement trust' and 'liquidity' introduces unverified context not present in the original answer. Due to complete factual inversion and erroneous analysis, the correctness score is near-minimal.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1198,
        "completion_tokens": 407,
        "total_tokens": 1606
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has the company's implementation of its liability-driven investment framework evolved between 2023 and 2024, particularly in terms of defined contribution plan expenses and the disclosure of plan asset composition?",
      "original_answer": "In 2023, the company disclosed that amounts charged to expense for defined contribution plans totaled $109 million, and the liability-driven investment framework included a 20%/80% equity/fixed income target allocation for pension assets. By 2024, defined contribution plan expenses increased to $112 million, and while the same 20%/80% allocation was maintained, the 2024 filing added a new disclosure indicating that the actual composition of plan assets at year-end would be characterized, suggesting a more detailed transparency in reporting the implementation of the investment framework.",
      "llm_answer": "Between 2023 and 2024, the company’s liability-driven investment framework remained focused on aligning plan assets with liabilities, but the disclosed asset composition shifted toward a more liability-hedged structure. For pension plans, the target allocation evolved from a broad 18% equity / 57% corporate bonds / 25% government securities split in 2023 to a 21% equity / 63% corporate bonds / 16% government/investments allocation in 2024, reflecting increased emphasis on fixed-income hedging. Postretirement plan assets maintained a 55% equity / 45% fixed income target, consistent with prior years, but the 2024 disclosure highlighted a higher allocation to emerging markets (2%) and below-investment-grade securities (3% of total assets), while overall equity exposure rose slightly. Defined contribution plan expenses increased to $112 million in 2024, up from $109 million in 2023, though this reflects broader expense reporting rather than a structural change in the investment strategy. The framework’s core objective—balancing liability hedging with growth—remained unchanged, but the 2024 asset mix demonstrated a more pronounced tilt toward fixed-income securities to manage interest rate sensitivity and funding obligations.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that the target allocation for pension assets was a simple 20%/80% equity/fixed income split in both 2023 and 2024, with no breakdown by corporate or government bonds. However, the LLM invents detailed allocations (e.g., 18% equity / 57% corporate bonds / 25% government securities in 2023 and 21%/63%/16% in 2024), which are not supported by the original answer. Additionally, the LLM introduces 'postretirement plan assets' with a 55% equity / 45% fixed income target and mentions allocations to emerging markets and below-investment-grade securities—none of which appear in the ground truth. While the defined contribution plan expenses are correctly stated as $109M in 2023 and $112M in 2024, the explanation that this reflects 'broader expense reporting' is speculative and unsupported. (2) Quantitative accuracy is low: the dollar amounts are correct, but the percentage allocations are entirely fabricated. There is no evidence of a change in target allocation—the original answer explicitly states the 20%/80% was maintained. The LLM incorrectly implies a shift in allocation when none occurred. (3) Multi-hop reasoning is flawed. The question asks about evolution in the liability-driven investment framework, particularly regarding expenses and disclosure of asset composition. The ground truth highlights that the key evolution was the *new disclosure* about characterizing actual year-end asset composition in 2024, indicating improved transparency. The LLM fails to mention this critical point and instead fabricates changes in asset mix that did not occur. (4) Contextual relevance is moderate because the answer addresses the general topic—defined contribution expenses and investment framework—and correctly notes the expense increase. However, it misrepresents the nature of the framework's evolution by focusing on non-existent allocation changes rather than the actual enhancement in disclosure. The core of the ground truth—the increased transparency in reporting—is entirely missed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1476,
        "completion_tokens": 563,
        "total_tokens": 2040
      },
      "error": null
    },
    {
      "question_id": 24,
      "question": "How has Qualcomm's strategic focus on On-Device AI evolved between fiscal 2023 and fiscal 2024, and what specific investments or changes in direction were highlighted in the company's disclosures?",
      "original_answer": "In fiscal 2023, Qualcomm emphasized that On-Device AI, combined with 5G and high-performance, low-power computing, would drive adoption of smartphone technologies into industries beyond mobile, such as automotive and IoT. The company positioned itself as a leader in 5G and integrated circuit products to sustain long-term growth. By fiscal 2024, Qualcomm's focus on On-Device AI had evolved into a more investment-driven strategy, with the company explicitly stating it is investing in new product areas and industries beyond mobile handsets, including automotive and IoT, by leveraging its technical expertise and pursuing acquisitions or strategic transactions. This represents a shift from strategic vision to active investment and expansion.",
      "llm_answer": "Between fiscal 2023 and fiscal 2024 Qualcomm’s strategy for On‑Device AI remained focused on leveraging its 5G, high‑performance, low‑power computing platforms to expand AI capabilities across smartphones, automotive, IoT and other industries. The company highlighted continued investment in AI‑centric research and development, the rollout of new AI‑enabled Snapdragon platforms, and the expansion of licensing and partnership programs that support on‑device AI adoption, while also noting that growth in AI‑related revenues is tied to broader 5G and computing trends.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually plausible and contextually relevant, but it fails to accurately capture the evolution in Qualcomm's strategic focus between fiscal 2023 and 2024 as described in the ground truth. (1) Correct elements: The LLM correctly identifies Qualcomm’s focus areas—5G, low-power computing, and expansion into automotive and IoT—and mentions R&D investments and partnerships, which are thematically aligned. There are no numeric values to verify, so quantitative accuracy is scored as 10 by default. (2) However, the key qualitative distinction in the original answer—a shift from a strategic vision in 2023 (positioning leadership) to an active, investment-driven strategy in 2024 involving acquisitions and new product investments—is entirely missing. The LLM portrays continuity rather than evolution, stating the strategy 'remained focused' instead of highlighting the shift from vision to execution. (3) This represents a failure in multi-hop reasoning: the model should have contrasted the nature of disclosures—strategic positioning in 2023 vs. explicit statements about investments, acquisitions, and expansion in 2024. (4) While the answer is well-structured and relevant, the lack of this critical strategic evolution significantly undermines its factual accuracy, warranting a correctness score of 6—partially correct but missing a central analytical point.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 382,
        "total_tokens": 1723
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has the classification and presentation of the Voting Trust Agreement between Melvin Simon & Associates, Inc. and the Simon family members evolved between the 2022 and 2023 10-K filings, and what does this indicate about the governance structure's stability?",
      "original_answer": "In the 2022 10-K filing, the Voting Trust Agreement was described as 'Second Amended and Restated' as of March 1, 2004, indicating a formal update to the governance arrangement. In contrast, the 2023 10-K filing refers to the same agreement without the 'Second Amended and Restated' modifier, simply listing it as the Voting Trust Agreement dated March 1, 2004. This shift in presentation suggests that no further amendments were made in the intervening period, signaling stability in the governance structure and a continuation of the same voting trust framework without modification.",
      "llm_answer": "The Voting Trust Agreement between Melvin Simon & Associates, Inc. and the Simon family members remains identified in the 10‑K filings as Exhibit 9.1 (and its counterpart 9.2), with no substantive change to its title or description between the 2022 and 2023 filings. This consistent reference indicates that the underlying governance structure has not been altered, suggesting stability in the voting‑trust arrangement.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct in asserting that there was no substantive change in the Voting Trust Agreement between the 2022 and 2023 10-K filings and that this suggests stability in governance. However, it inaccurately claims that the title and description were 'consistent' between the two years, which contradicts the ground truth. According to the original answer, the 2022 filing explicitly referred to the agreement as the 'Second Amended and Restated' Voting Trust Agreement as of March 1, 2004, while the 2023 filing dropped the 'Second Amended and Restated' modifier, referring to it simply as the Voting Trust Agreement dated March 1, 2004. This change in classification and presentation is a key factual detail that the LLM answer overlooks, leading to an incorrect characterization of the documentation. While the conclusion about governance stability is aligned with the ground truth, the reasoning is flawed due to failure to recognize the change in nomenclature. The LLM also introduces Exhibit 9.1/9.2 references not present in the ground truth, which may be accurate but are not verifiable from the provided information. Quantitative accuracy is scored highly because there are no numerical errors (no numbers were involved). Qualitative accuracy is low due to the misrepresentation of a critical detail in the multi-hop comparison. Contextual relevance is high because the answer addresses the core question about evolution and governance stability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1280,
        "completion_tokens": 405,
        "total_tokens": 1685
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did COP's natural gas reserves in the Asia Pacific/Middle East region evolve between 2023 and 2024, and what does this indicate about the region's changing strategic importance to COP's global reserves portfolio?",
      "original_answer": "In 2023, COP reported 312 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region, while in 2024, this figure decreased slightly to 296 billion cubic feet. This represents a reduction of 16 billion cubic feet, or about 5.1%. Despite this decline, the Asia Pacific/Middle East remained a notable contributor to COP's global reserves, especially when considering equity affiliates, which held an additional 5,870 billion cubic feet in 2024. The slight decrease may suggest a shift in emphasis or extraction focus in favor of other regions, indicating a potential reevaluation of the region's role in COP's long-term production strategy.",
      "llm_answer": "Between 2023 and 2024, ConocoPhillips' natural gas reserves in the Asia Pacific/Middle East region increased from 296 billion cubic feet (BCF) to 289 BCF in the consolidated \"Undeveloped\" category, but the total proved reserves for the region actually rose from 296 BCF to 296 BCF in the consolidated \"Developed\" category and from 7 BCF to 7 BCF in the equity‑affiliate portion, resulting in a net increase of roughly 13 BCF when combining developed and equity‑affiliated volumes (from 303 BCF to 310 BCF). This modest growth, driven largely by upward revisions and purchases (e.g., Marathon Oil acquisition) in the region, signals that the Asia Pacific/Middle East is becoming a more strategically important component of ConocoPhillips' global reserves portfolio, especially as other regions show stagnant or declining totals.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is fundamentally incorrect in both direction and magnitude of change. The ground truth states that COP's natural gas reserves in the Asia Pacific/Middle East region decreased from 312 BCF in 2023 to 296 BCF in 2024—a reduction of 16 BCF (5.1%). However, the LLM claims an increase, misrepresenting both the starting and ending values. It incorrectly states that reserves were 296 BCF in 2023 and remained at 296 BCF in 2024 for the consolidated 'Developed' category, which contradicts the original data showing 312 BCF in 2023. Additionally, the LLM fabricates a breakdown into 'Undeveloped' and 'Developed' categories not present in the ground truth and introduces a non-existent 7 BCF equity-affiliate volume in 2023 growing to 7 BCF in 2024, while the truth states equity affiliates held 5,870 BCF in 2024 alone. (2) The calculation of a 'net increase of roughly 13 BCF' is entirely unsupported and based on invented numbers. The correct change is a decrease of 16 BCF (from 312 to 296), or 5.1%. The LLM also falsely attributes growth to the Marathon Oil acquisition, which is not mentioned in the original answer and cannot be verified from the provided context. (3) The multi-hop reasoning is flawed: instead of recognizing a decline and interpreting its strategic implications (as in the original answer), the LLM inverts the trend and draws the opposite conclusion about strategic importance. This reflects a failure to synthesize accurate data across years and entity types. (4) Despite the factual inaccuracies, the answer is contextually relevant in that it attempts to address the evolution of reserves and strategic importance, and it discusses equity affiliates and regional strategy, which are relevant themes. However, due to severe quantitative and qualitative errors, the conclusion is misleading. Scores reflect major factual and calculation errors, with only partial credit for attempting the right structure and topic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 531,
        "total_tokens": 1920
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How did AIG's financial relationship with Corebridge evolve between 2023 and 2024, particularly in terms of debt structure and equity method income?",
      "original_answer": "In 2023, AIG had a direct financial stake in Corebridge, which was reflected in the $9,368 million total Corebridge debt on AIG's balance sheet, including $6,452 million in senior unsecured notes and $989 million in junior subordinated debt, both not guaranteed by AIG. By 2024, AIG no longer consolidated Corebridge as a subsidiary; instead, it reported Corebridge under the equity method as part of discontinued operations. During the second half of 2024, AIG reported equity method income from Corebridge, which included dividends received and changes in its stock price since June 9, 2024. This marks a significant transformation from a consolidated debt relationship to a minority equity investment with associated income reporting.",
      "llm_answer": "Between 2023 and 2024, AIG’s financial relationship with Corebridge evolved significantly, particularly in terms of debt structure and equity method income. In 2023, AIG held a controlling interest in Corebridge and had significant debt obligations tied to it, including $250 million of DDTL facility debt and $1.5 billion of DDTL facility debt not guaranteed by AIG, which was later reduced to $250 million by year-end 2023. By 2024, AIG had deconsolidated Corebridge following the reduction of its ownership stake below 50% and loss of board control in June 2024, resulting in Corebridge being accounted for using the equity method. This shift led to AIG recognizing equity method income from Corebridge, including $601 million in equity method income (loss) related to Corebridge for the period ending December 31, 2024, derived from dividends received and changes in the fair value of its retained equity investment. Additionally, AIG’s debt structure related to Corebridge shifted from direct borrowing (e.g., $1.5 billion DDTL facility) to debt issued by Corebridge itself, including $6.452 billion in senior unsecured notes not guaranteed by AIG and $200 million in CRBGLH notes and bonds payable, which AIG guaranteed but did not directly issue. The deconsolidation also triggered a $4.8 billion loss, primarily due to the recognition of accumulated other comprehensive loss, and subsequent sales of Corebridge shares generated significant gains, including a $282 million gain from the sale of 120 million shares in December 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. The ground truth states that in 2023, AIG's balance sheet included $9,368 million in total Corebridge debt, with $6,452 million in senior unsecured notes and $989 million in junior subordinated debt, none guaranteed by AIG. However, the LLM incorrectly reports $250 million and $1.5 billion DDTL facility debt, which does not match the source data. The $6.452 billion in senior unsecured notes is close to the correct $6,452 million, but the rest of the debt structure is fabricated (e.g., $200 million in CRBGLH notes and bonds payable that AIG guaranteed). (2) The equity method income is reported as $601 million in the LLM answer, but the original answer does not specify a dollar amount—only that income was recognized from dividends and stock price changes post-June 9, 2024. This number is therefore unsupported. Additionally, the $4.8 billion loss and $282 million gain from share sales are not mentioned in the ground truth and appear to be hallucinated. (3) The qualitative reasoning partially captures the multi-hop evolution: the shift from consolidation to equity method accounting in 2024 due to loss of control is correctly identified, and the timing (June 2024) aligns with the original answer. However, the synthesis of financial impacts is flawed due to incorrect numbers and invented details. (4) Contextual relevance is moderate—the answer addresses the evolution in debt structure and equity income as asked, but the inaccuracies undermine correctness. The core transformation (consolidated subsidiary to equity method investment) is recognized, but the supporting data is largely incorrect. Thus, the correctness score is low due to major quantitative errors and unsupported claims, despite some structural understanding.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1569,
        "completion_tokens": 503,
        "total_tokens": 2072
      },
      "error": null
    },
    {
      "question_id": 25,
      "question": "How has NextEra Energy's investment strategy in Special Use Funds evolved from 2022 to 2024, particularly in terms of its allocation between fixed income and equity securities, and what does this suggest about its risk appetite or liquidity strategy?",
      "original_answer": "In 2022, NEE's Special Use Funds were entirely composed of fixed income securities, with a carrying amount of $2,505 million. By 2024, the composition had significantly transformed: NEE's Special Use Funds included $6,164 million in equity securities, $722 million in U.S. Government and municipal bonds, $685 million in corporate debt, and $873 million in asset-backed securities. This indicates a strategic shift from a purely fixed income allocation to a more diversified and equity-heavy portfolio, suggesting an increased risk appetite and a potential long-term growth orientation in its investment strategy.",
      "llm_answer": "From 2022 to 2024, NextEra Energy’s Special Use Funds shifted markedly toward higher‑quality, longer‑duration assets: the 2022 filing shows roughly $2.1 billion in fixed‑income securities and $0.5 billion in equity within the nuclear decommissioning fund, whereas the 2024 tables list $6.1 billion in total special‑use assets with a larger share in corporate bonds, municipal bonds and asset‑backed securities and only modest equity exposure (≈$2.6 billion equity versus $3.3 billion of Level‑2 corporate debt).  This tilt toward fixed‑income and longer‑maturity instruments signals a more conservative risk appetite and a focus on liquidity preservation—maintaining ample cash and high‑grade securities to meet potential collateral and regulatory funding needs.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, NextEra Energy's Special Use Funds were entirely composed of fixed income securities with a carrying amount of $2,505 million—there was no equity allocation. However, the LLM claims $2.1 billion in fixed income and $0.5 billion in equity in 2022, which is incorrect. In 2024, the ground truth shows $6,164 million in equity securities, $722 million in U.S. Government and municipal bonds, $685 million in corporate debt, and $873 million in asset-backed securities. The LLM incorrectly states only $2.6 billion in equity and $3.3 billion in corporate debt, misrepresenting both the magnitude and composition. The total assets are also misrepresented: the LLM says $6.1 billion total, but the actual sum is $8,444 million ($6,164 + $722 + $685 + $873), indicating a major quantitative error. (2) Calculations and comparisons are flawed: the LLM implies a continued or increased fixed income focus, when in fact there was a strategic shift to equity-dominant allocation. The claim of 'modest equity exposure' contradicts the ground truth where equity makes up over 70% of the 2024 portfolio. (3) Multi-hop reasoning is unsound: the model fails to correctly synthesize data across years and misidentifies the nature of the shift—portraying a move toward conservatism when the actual shift is toward higher risk via equities. (4) The contextual relevance is moderate because the answer addresses the right topic (allocation changes in Special Use Funds) and attempts to infer risk appetite, but the incorrect data leads to an opposite and erroneous conclusion about risk strategy. The qualitative reasoning would be acceptable if the numbers were correct, but as it stands, the conclusion is factually inverted. Thus, the correctness score is low due to pervasive numerical and interpretive errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 515,
        "total_tokens": 1885
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the nature and magnitude of the risk associated with site infrastructure sharing evolved between 2022 and 2024, particularly in relation to 5G technology adoption and its impact on new lease activity?",
      "original_answer": "In 2022, AMT identified site infrastructure sharing as a risk factor that could slow new lease activity or lead to decommissioning of equipment on existing sites, particularly due to the rise of 5G technology. By 2024, this risk evolved into a more specific concern around RAN (Radio Access Network) sharing, roaming, or resale arrangements, which were explicitly tied to the lack of compensation to AMT when carriers opted for shared infrastructure instead of deploying new equipment. The 2024 filing indicates a stronger emphasis on the financial impact of this trend, suggesting a more mature and impactful shift in carrier behavior driven by 5G deployment. This represents a significant evolution in the risk's specificity and perceived threat level.",
      "llm_answer": "The risk associated with site infrastructure sharing has evolved from a general competitive concern in 2022 to a specific, technology-driven threat by 2024, particularly regarding 5G adoption. While 2022 disclosures highlighted risks from customer consolidation, network sharing (e.g., RAN sharing), and potential lease rate pressures due to competitive dynamics, the 2024 filing explicitly identifies 5G-related technologies and shifts in customer business models as direct threats that could reduce demand for tower space and lease rates, potentially accelerating lease activity slowdown if carriers prioritize shared infrastructure over new tower deployments. This represents a more targeted evolution of the risk, linking 5G advancements to tangible impacts on new lease opportunities and revenue stability.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of the risk associated with site infrastructure sharing between 2022 and 2024, particularly in relation to 5G adoption and its impact on new lease activity. (1) All factual elements are correct: in 2022, the risk was framed more generally around network sharing (including RAN sharing) and competitive dynamics potentially slowing lease activity; by 2024, the risk became more specific, emphasizing 5G-driven shifts in carrier behavior such as RAN sharing, roaming, and resale arrangements that bypass new deployments and deprive AMT of compensation. The LLM correctly identifies the progression from a broad competitive concern to a more targeted threat tied to 5G and business model changes. (2) There are no numeric values in the original or LLM answer, so quantitative accuracy is not applicable—no errors here. (3) The multi-hop reasoning is sound: the model synthesizes information across years and connects 5G adoption to changes in carrier infrastructure strategies and their financial implications for AMT. The only minor shortcoming is that the LLM does not explicitly mention the 'lack of compensation to AMT' in shared scenarios—a key nuance in the 2024 filing—but it does imply reduced demand and lease rate pressures, which aligns closely. (4) The answer is contextually excellent, directly addressing the evolution in both nature and magnitude of the risk. Overall, the LLM conveys semantically equivalent information with high fidelity, meriting a 9 for correctness and qualitative accuracy, with full marks for relevance and quantitative accuracy by default.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1406,
        "completion_tokens": 446,
        "total_tokens": 1853
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has Chevron's financial relationship with Angola LNG Limited evolved between 2022 and 2023, particularly in terms of its investment structure and equity method accounting?",
      "original_answer": "Chevron's relationship with Angola LNG Limited evolved from a dependency-based structure in 2022 to a more direct investment model in 2023. In 2022, Chevron reported a 36.4% interest in Angola LNG Limited, but the relationship was categorized under 'Depends_On', indicating a more passive or structurally dependent investment. By 2023, the relationship was reclassified as 'Invests_In', suggesting a more active or strategic financial posture. Additionally, while both years maintained the same ownership percentage (36.4%), the reclassification indicates a shift in how Chevron views or manages its investment, possibly reflecting changes in operational involvement or strategic alignment.",
      "llm_answer": "Chevron's investment in Angola LNG Limited decreased slightly from $2,180 million at the end of 2022 to $1,762 million at the end of 2023, reflecting a lower equity‑method carrying value in the 2023 Note 15 table. The company continues to account for its 36.4 % stake in Angola LNG Limited using the equity‑method, recognizing earnings (or losses) from the affiliate in its consolidated results.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly states Chevron's 36.4% ownership stake and that equity method accounting is used, it incorrectly claims the investment value decreased from $2,180 million to $1,762 million. The ground truth does not mention any dollar amounts or changes in carrying value, so these figures are unsupported and likely incorrect. There is no evidence in the original answer of a quantitative decline in investment value. (2) The quantitative accuracy is low because the LLM introduces specific dollar figures ($2,180M and $1,762M) that are not present in the ground truth and cannot be verified. These numbers appear to be hallucinated or misattributed from external data not referenced in the original answer. The absence of such figures in the ground truth—especially given the focus on structural classification changes—makes their inclusion misleading. (3) The qualitative accuracy is partially correct: the LLM correctly identifies the continued use of the equity method and the 36.4% stake. However, it completely misses the key qualitative shift emphasized in the original answer—the reclassification from 'Depends_On' to 'Invests_In'—which represents the core evolution in Chevron’s financial relationship. This structural and strategic shift is the central point of the ground truth, yet the LLM fails to mention it entirely. (4) Contextual relevance is moderate because the answer discusses Chevron's investment in Angola LNG Limited and equity method accounting, which are relevant topics. However, by focusing on unverified financial values instead of the actual structural and classification changes, it misses the most important aspect of how the relationship evolved. The reasoning is internally logical but based on incorrect or extraneous data, failing the multi-hop synthesis required to connect classification changes with strategic implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1278,
        "completion_tokens": 523,
        "total_tokens": 1802
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the G600 aircraft's role in Gulfstream's product lineup evolved from 2022 to 2023, particularly in terms of its performance metrics and production status?",
      "original_answer": "In 2022, the G600 was described as a recent addition to the Gulfstream fleet, having entered service in 2019, and was positioned as a clean-sheet aircraft replacing the G550. By 2023, the G600 was no longer characterized as 'new' but rather as a mature product within the lineup, with over 250 cumulative deliveries by year-end 2023. Additionally, in 2023, the G600's advanced technologies, such as the Symmetry Flight Deck, were highlighted as foundational features being extended to newer models like the G700, G800, and G400. This indicates a shift from product introduction to integration within the broader Gulfstream platform.",
      "llm_answer": "From 2022 to 2023, the G600 remained a key large‑cabin, ultra‑long‑range model in Gulfstream’s lineup, but its production status shifted from earlier expectations.  In the 2022 filing the G700 was slated for service entry in early 2024, while the G600 was already in service (with cumulative deliveries exceeding 250 aircraft by year‑end 2023).  The 2023 filing notes that the G600 (along with the G500) had been introduced in 2018‑19 to replace older models, and that the newer G700 was undergoing flight testing and FAA certification, targeting entry in Q4 2022 (later pushed to early 2024).  Thus, the G600’s role evolved from a newly‑launched replacement aircraft to a mature, high‑delivery model, while its successor, the G700, moved toward certification and entry into service, reflecting a continued expansion of Gulfstream’s product portfolio rather than a change in the G600’s performance metrics.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution of the G600's role from 2022 to 2023. It correctly identifies that the G600 was already in service by 2022 and had over 250 cumulative deliveries by year-end 2023, aligning with the ground truth. It accurately notes the G600's initial role as a replacement for older models (e.g., G550) and its transition into a mature, high-delivery product. However, there is a minor inaccuracy regarding the G700's service entry timeline: the LLM states the 2022 filing expected G700 entry in early 2024, but also incorrectly claims the 2023 filing referenced a Q4 2022 target (later pushed), which introduces a contradiction and slight misrepresentation of the timeline. The ground truth does not mention this shift, so this detail lacks support. Additionally, while the LLM correctly notes the G600’s performance metrics did not change, it omits the key point from the original answer that the G600’s technologies (e.g., Symmetry Flight Deck) became foundational for newer models like the G700, G800, and G400—this is a significant aspect of its evolving role. The reasoning is sound overall, with good synthesis across years and models, and the entities (G600, G700, Gulfstream) and dates are mostly accurate. The answer is highly relevant to the question and conveys a semantically similar narrative, though with minor gaps in completeness and one timeline inconsistency.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 393,
        "total_tokens": 1781
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has McDonald's relationship with its franchisees evolved in terms of financial involvement and strategic collaboration between 2022 and 2024?",
      "original_answer": "In 2022, McDonald's relationship with franchisees was primarily framed around franchised arrangements and license agreements, with franchisees contributing revenue through rent, royalties, and initial fees, while the company did not typically invest in restaurant capital under developmental licenses. By 2024, the company had introduced a more active investment role, co-investing with franchisees to fund restaurant improvements and operating system upgrades. These co-investments were aimed at catering to consumer preferences, improving local performance, and enhancing the brand through modernization. This marks a strategic shift from a largely passive franchising model to a more collaborative and financially engaged partnership.",
      "llm_answer": "Between 2022 and 2024, McDonald's financial involvement with its franchisees shifted from a model centered on real estate ownership and co-investment to a more collaborative, strategic partnership. The 2024 report emphasizes co-investment with franchisees to fund restaurant modernization and operational improvements, aligning investments with consumer preferences and brand value, while maintaining a focus on stable revenue through rent and royalty structures. This evolution reflects a deeper strategic collaboration, moving beyond traditional financial arrangements to jointly drive performance and brand strength.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution in McDonald's relationship with franchisees between 2022 and 2024. It accurately identifies the shift from a traditional franchising model to one involving co-investment in restaurant modernization and operational improvements by 2024. The financial mechanisms—rent, royalties, and strategic co-investment—are correctly noted. However, the LLM incorrectly states that the 2022 model included 'co-investment,' which contradicts the ground truth: in 2022, McDonald's did not typically invest in restaurant capital under developmental licenses, meaning the model was not co-investment-based at that time. The ground truth describes 2022 as passive, with revenue from fees and rent, while the LLM implies an earlier co-investment model, misrepresenting the baseline. This is a minor but notable error in qualitative accuracy. There are no numerical figures in the question or answer, so quantitative accuracy is scored as 10 by default (no numbers to misstate). The answer is contextually relevant and synthesizes the multi-hop requirement across time (2022 vs 2024) and strategic shifts. The reasoning is mostly sound but slightly flawed in the characterization of the 2022 model. Semantic equivalence is mostly preserved, but the misrepresentation of the starting point reduces qualitative accuracy slightly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1338,
        "completion_tokens": 379,
        "total_tokens": 1718
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How did the financial performance of smokeable products evolve from 2022 to 2023, particularly in terms of net revenues and operating income?",
      "original_answer": "In 2022, smokeable products generated $22,476 million in net revenues and contributed $10,688 million to operating income. In 2023, net revenues from smokeable products decreased slightly to $21,756 million, and operating income from this segment also declined marginally to $10,670 million. This reflects a small decrease in both revenue and profitability year-over-year.",
      "llm_answer": "From the consolidated operating results tables in the 2022 and 2023 10‑K filings, net revenues from smokeable products fell from $22,476 million in 2022 to $21,756 million in 2023, and operating income attributable to smokeable products remained essentially flat at about $10.68 billion in 2022 versus $10.67 billion in 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and conveys the same information as the ground truth with only minor differences in wording and rounding. (1) All key numbers are correct: net revenues of $22,476 million in 2022 and $21,756 million in 2023 match exactly; operating income is reported as $10.68 billion and $10.67 billion, which are accurate conversions from $10,688 million and $10,670 million (rounding to the nearest $10 million). (2) The quantitative accuracy is perfect—values are correctly cited or appropriately rounded without loss of meaning. (3) The reasoning is sound: the model correctly identifies the relevant financial metrics from the correct years and synthesizes the data to show a slight decline in revenues and flat operating income, consistent with the ground truth. (4) The answer is contextually relevant and fully addresses the question about the evolution of financial performance in terms of net revenues and operating income. The only minor shortcoming is the use of 'essentially flat' instead of explicitly noting the marginal decline in operating income, but this does not distort the factual conclusion. Thus, the answer is semantically equivalent and highly accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1173,
        "completion_tokens": 336,
        "total_tokens": 1509
      },
      "error": null
    },
    {
      "question_id": 26,
      "question": "How has the role of Opdivo within BMY's product development and commercialization strategy evolved from 2022 to 2024, particularly in terms of its collaborative framework and new therapeutic approvals?",
      "original_answer": "In 2022, Opdivo was primarily positioned within a joint development and commercialization framework with Ono, where profits, losses, and development costs were shared—either equally for combination therapies or under an 80-20 split for single-party compounds. Additionally, Opdivo was part of a broader alliance that included other products like Yervoy and Orencia, with structured co-promotion and supply responsibilities. By 2024, Opdivo's role had evolved significantly, marked by a new FDA approval in March 2024 for use in combination with cisplatin and gemcitabine for the first-line treatment of unresectable or metastatic urothelial carcinoma. This reflects a shift from a co-development focus to a more independent product introduction strategy, with BMY taking the lead in expanding Opdivo’s therapeutic applications in key oncology markets.",
      "llm_answer": "From 2022 through 2024, Opdivo’s role in BMS’s strategy shifted from a co‑promoted oncology asset within the Pfizer‑BMS Eliquis alliance to a stand‑alone, globally‑led brand under BMS’s own commercial umbrella.  In 2022 the collaboration with Ono (Japan, Korea, Taiwan) governed Opdivo’s development and profit‑sharing, but by 2024 BMS held exclusive worldwide development and commercialization rights (except in those three markets) and began receiving FDA approvals for new Opdivo indications—including Opdivo Qvantig (sub‑cutaneous formulation), first‑line urothelial carcinoma, neoadjuvant NSCLC, and expanded uses of Breyanzi and other assets—while Ono’s involvement narrowed to royalty payments (4 % in North America, 15 % elsewhere) and limited co‑promotion.  This evolution reflects a move from a joint‑venture framework with shared cost and profit structures toward a single‑owner model that leverages BMS’s own sales force and infrastructure to drive broader, faster approvals and market expansion.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. It incorrectly states that Opdivo was part of a 'Pfizer-BMS Eliquis alliance'—Eliquis is a separate product developed with Pfizer and unrelated to Opdivo. This is a major entity error. The claim that by 2024 BMS held 'exclusive worldwide development and commercialization rights' except in Japan, Korea, and Taiwan oversimplifies and misrepresents the ongoing joint framework with Ono, which in 2022 involved shared costs and profits (either 50-50 for combinations or 80-20 splits), not just royalty payments. The LLM claims Ono receives 4% royalties in North America and 15% elsewhere—this is not supported by the ground truth, which does not mention royalty percentages at all. The FDA approval for first-line urothelial carcinoma in combination with cisplatin and gemcitabine in March 2024 is correctly identified and aligns with the ground truth, which is a key factual match. However, the mention of 'Opdivo Qvantig', 'neoadjuvant NSCLC', and 'Breyanzi' expansions is extraneous and not mentioned in the original answer, suggesting hallucination or misattribution. (2) Quantitative accuracy is low: the 4% and 15% royalty figures are fabricated; no dates or dollar amounts are correct beyond the March 2024 approval. The 2022 cost-sharing structure (50-50 or 80-20) is misrepresented as a royalty model in 2024. (3) Multi-hop reasoning is partially sound—the model attempts to trace evolution in strategy from collaboration to independence—but it fails to accurately represent the nature of the Ono partnership and incorrectly frames the transition. The synthesis across time and collaboration structure is flawed due to incorrect premises. (4) Despite significant factual errors, the answer addresses the core question about strategic evolution and correctly identifies a key 2024 approval, maintaining some contextual relevance. However, the correctness score is low due to major entity and quantitative inaccuracies that undermine the answer's reliability.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1478,
        "completion_tokens": 547,
        "total_tokens": 2025
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has AMT's disclosure regarding interest rate benchmarks for debt instruments evolved between 2022 and 2024, particularly in terms of referenced rates and associated covenants?",
      "original_answer": "In 2022, AMT's debt instruments referenced LIBOR, EURIBOR, and a defined base rate for USD and EUR denominated borrowings, with the 2021 credit facilities tied to debt ratings and commitment fees ranging from 0.080% to 0.300%. By 2024, AMT disclosed that new drawings under letters of credit in Nigeria bore interest at SOFR (Secured Overnight Financing Rate) plus a spread, indicating a shift away from LIBOR-based instruments. Additionally, while 2022 disclosures detailed specific covenants and optional renewal periods for various credit facilities, the 2024 disclosure focused on the consequences of covenant non-compliance without specifying interest rate structures or renewal terms, suggesting a simplification or evolution in the presentation of covenant-related disclosures.",
      "llm_answer": "Between 2022 and 2024, AMT's disclosures regarding interest rate benchmarks for debt instruments shifted from referencing LIBOR/EURIBOR in its 2022 credit facility tables (e.g., 2021 Multicurrency Credit Facility's \"LIBOR or EURIBOR borrowing interest rate range\") to explicitly defining benchmark rates within its 2023 securitization documentation, where the 2023 Securities carry fixed rates of 5.490% (Series 2023-1A) and 5.735% (Series 2023-1R), with no floating-rate benchmark language retained. This evolution reflects a move toward fixed-rate securitized debt structures with defined interest rates, while earlier disclosures maintained variable-rate benchmarks tied to market indices.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains partial factual accuracy but diverges significantly from the ground truth in key aspects. (1) Quantitatively, the LLM introduces specific fixed interest rates (5.490% and 5.735%) from a 2023 securitization, which are not mentioned in the original answer and appear unrelated to the core evolution of benchmark rates in AMT's general debt instruments. These figures may be factually correct in another context but are not aligned with the ground truth's focus on LIBOR-to-SOFR transition. (2) The original answer emphasizes a shift from LIBOR/EURIBOR to SOFR in Nigerian letters of credit by 2024, which the LLM completely omits. Instead, it claims a move to fixed-rate securitized debt, which is a different financial instrument and does not reflect the broader evolution in benchmark rate disclosures for general debt facilities. (3) Entity and year accuracy is mixed: while 2022 and 2023 are correctly referenced, the LLM focuses on 2023 securitization rather than 2024 disclosures, missing the forward-looking evolution. (4) The reasoning is internally logical but based on misaligned evidence—there is no mention of SOFR or Nigeria in the LLM answer, and the conclusion about a shift to fixed-rate structures is not supported by the ground truth, which instead highlights a benchmark shift (LIBOR to SOFR) within floating-rate instruments. (5) The original answer also notes changes in covenant disclosure depth, which the LLM fails to address entirely, reducing completeness. While the LLM correctly identifies the 2022 use of LIBOR/EURIBOR, it fails to accurately represent the 2024 state and the nature of the transition, leading to a partially correct but materially incomplete and somewhat misleading response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1377,
        "completion_tokens": 471,
        "total_tokens": 1849
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How has McDonald's relationship with franchisees evolved in terms of real estate ownership and co-investment strategy between 2022 and 2024?",
      "original_answer": "In 2022, McDonald's emphasized Systemwide coordination and alignment to manage ESG initiatives, including environmental sustainability and responsible sourcing, which required franchisee cooperation. However, the specific role of franchisees in real estate ownership was not detailed. By 2024, the company explicitly outlined its conventional franchise model, where it typically owns or secures long-term leases on land and buildings, while franchisees invest in equipment, signs, seating, and décor. This co-investment model was described as enabling McDonald's to achieve high restaurant performance levels. The shift from a general emphasis on franchisee collaboration in 2022 to a clearly defined real estate and co-investment strategy in 2024 reflects a more structured and strategic approach to franchise relationships.",
      "llm_answer": "Between 2022 and 2024, McDonald's has shifted toward greater real estate ownership and co-investment with franchisees, emphasizing that owning or securing long-term leases on land and buildings—combined with franchisee co-investment in equipment and improvements—enables superior restaurant performance and brand value growth. This strategy is reinforced by its focus on conventional franchising, where the Company retains real estate ownership while franchisees manage operations and capital investment, and by co-investing with franchisees to fund restaurant modernization and operational enhancements aligned with consumer preferences.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution in McDonald's relationship with franchisees regarding real estate ownership and co-investment between 2022 and 2024. It correctly identifies the shift from a general emphasis on systemwide coordination in 2022 (implied by the absence of specific real estate details) to a clearly defined conventional franchise model by 2024, where McDonald's owns or secures long-term leases on land and buildings while franchisees invest in equipment and interior components. The answer accurately reflects the co-investment strategy and links it to restaurant performance and brand value, aligning with the ground truth. There are no numeric inaccuracies (quantitative accuracy is perfect as no specific numbers are involved and all temporal references are correct). The qualitative reasoning is strong, correctly synthesizing multi-hop information across years and strategic shifts. The only minor shortcoming is that the LLM does not explicitly mention the 2022 lack of detail on real estate ownership, instead framing the shift more positively without noting the earlier absence of specificity. However, the overall semantic meaning and strategic trajectory are correctly conveyed. Contextual relevance is excellent, directly addressing the question with appropriate focus on real estate and co-investment evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1364,
        "completion_tokens": 379,
        "total_tokens": 1743
      },
      "error": null
    },
    {
      "question_id": 27,
      "question": "How did the status and documentation of the 2015 Stock Compensation Plan for Non-Employee Directors change between 2022 and 2023, and what does this evolution indicate about Altria's governance approach to director compensation?",
      "original_answer": "In 2022, the 2015 Stock Compensation Plan for Non-Employee Directors was disclosed with 703,256 shares available for issuance under the plan. By 2023, the plan was formally amended and restated effective October 26, 2022, and was incorporated by reference from Altria's September 30, 2022, Form 10-Q filing. This indicates a formal update to the plan’s structure and governance, suggesting Altria refined its director compensation framework mid-cycle, potentially to align with evolving governance standards or internal compensation strategies.",
      "llm_answer": "Between 2022 and 2023, the 2015 Stock Compensation Plan for Non-Employee Directors was amended and restated effective October 26 2022 (referenced in the 2022 filing) and later updated with a new Form of Restricted Stock Unit Agreement (2023) incorporated in the 2023 quarterly report. This evolution reflects Altria’s ongoing effort to modernize and align director compensation with current governance practices and shareholder expectations.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the key event—the amendment and restatement of the 2015 Stock Compensation Plan for Non-Employee Directors effective October 26, 2022—which aligns with the ground truth. However, the LLM introduces a detail not present in the original answer: the 'new Form of Restricted Stock Unit Agreement (2023)' incorporated in the 2023 quarterly report. This specific form update is not mentioned in the ground truth and cannot be verified from the provided information, representing an overreach or addition not supported by the source. (2) Quantitatively, the LLM omits the specific number of shares available for issuance in 2022 (703,256), which is a key factual data point in the original answer. This omission reduces quantitative completeness, though the date (October 26, 2022) is accurate. (3) The multi-hop reasoning is partially sound—the model connects the plan amendment to governance implications, correctly inferring that Altria is aligning director compensation with governance practices. However, it misses the nuance that the amendment was incorporated by reference from the September 30, 2022, Form 10-Q, which strengthens the accuracy of the original answer’s sourcing. (4) Despite missing the share number and adding unverified details, the LLM captures the core evolution and interprets its governance significance reasonably. The answer is contextually relevant and well-framed, but not fully factually complete or precise, warranting a score of 7 for correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1266,
        "completion_tokens": 418,
        "total_tokens": 1685
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the impact of roaming and resale arrangements among wireless service providers on AMT's leasing activity evolved from 2022 to 2024, and what does this indicate about the competitive pressures affecting new lease growth?",
      "original_answer": "In 2022, AMT noted that roaming or resale arrangements among wireless service providers, particularly with the rise of 5G technology, could slow new lease activity if carriers opted to share infrastructure rather than deploy new equipment. By 2024, this concern evolved into a broader risk involving RAN sharing and resale arrangements, which not only threatened new lease activity but also led to potential decommissioning of existing equipment due to redundancy. This indicates a growing competitive pressure where infrastructure sharing is becoming a more viable and widespread alternative to leasing, directly impacting AMT’s revenue growth prospects.",
      "llm_answer": "From 2022 to 2024, the impact of roaming and resale arrangements among wireless providers has increasingly pressured American Tower’s leasing activity, as noted in the 2024 filing where it is highlighted that extensive sharing of site infrastructure, roaming, or resale—especially driven by advanced network technologies like 5G—can reduce the need for carriers to lease new tower space or maintain existing equipment on AMT sites. This trend contributes to slower new lease growth and heightened competitive pressures, as customers may opt to share infrastructure without compensation, thereby diminishing demand for new leases and putting downward pressure on lease rates and renewal terms.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core evolution of the impact of roaming and resale arrangements on AMT's leasing activity from 2022 to 2024. It correctly identifies that infrastructure sharing, driven by 5G, reduces demand for new leases and affects renewal terms and lease rates—consistent with the ground truth. The answer reflects the progression from a concern about slowed new lease activity in 2022 to a more developed risk in 2024 involving reduced need for both new and existing equipment due to extensive sharing. The only minor omission is that the LLM does not explicitly mention 'RAN sharing' or 'decommissioning of existing equipment'—specific elements highlighted in the 2024 risk evolution—which slightly weakens the completeness of the multi-hop synthesis. However, the reference to 'maintain existing equipment' and 'reduce the need' implies this trend, so the semantic meaning is largely preserved. There are no numerical inaccuracies (the question is qualitative), and all entities (AMT, 5G, wireless providers, leasing activity) are correctly identified. The reasoning is sound, logically connecting infrastructure sharing to competitive pressures and reduced leasing demand. The answer is fully contextually relevant and well-articulated.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 356,
        "total_tokens": 1713
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has McDonald's relationship with its franchisees evolved between 2022 and 2024, particularly in terms of strategic investment and operational expectations?",
      "original_answer": "In 2022, McDonald's highlighted the impact of the COVID-19 pandemic on franchise operations, emphasizing risks related to labor availability, supply chain disruptions, and the importance of executing its 'Accelerating the Arches' strategy to maintain growth. The focus was on franchisees' ability to adapt to changing consumer behavior and operational restrictions. By 2024, McDonald's had shifted toward a more active investment role, co-investing with franchisees to modernize restaurants and improve local performance. The company emphasized franchisee reinvestment in their businesses and introduced structured co-investment initiatives designed to increase the value of the McDonald's brand through restaurant modernization and enhanced consumer appeal. This marks a shift from pandemic-driven operational challenges to a more strategic, investment-backed growth approach.",
      "llm_answer": "Between 2022 and 2024, McDonald's deepened its strategic partnership with franchisees by co-investing in restaurant modernization and operational improvements, emphasizing reinvestment to enhance customer experience and brand value. While maintaining its heavily franchised model, the company increasingly relies on franchisee collaboration for capital-intensive initiatives, requiring their financial commitment and alignment with corporate strategies to drive growth and preserve brand relevance.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution in McDonald's relationship with franchisees from 2022 to 2024. It accurately reflects the shift toward co-investment, franchisee reinvestment, and alignment with corporate strategy to drive growth. While the original answer provides more contextual detail—specifically referencing the 'Accelerating the Arches' strategy, pandemic-related challenges in 2022 (labor, supply chain), and the transition to a more investment-backed model in 2024—the LLM answer omits these specifics but still conveys the essential qualitative shift. There are no numerical inaccuracies (quantitative accuracy is perfect, scoring 10), as the answer avoids citing specific figures that could be incorrect. The reasoning is sound and reflects multi-hop understanding by inferring a strategic evolution across years, though it lacks explicit mention of the pandemic context and named strategic initiatives, slightly weakening the qualitative accuracy. Contextual relevance is strong, as the response directly addresses both strategic investment and operational expectations. The omission of specific 2022 challenges and the named strategy prevents a top score, but the overall meaning remains semantically aligned with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 355,
        "total_tokens": 1702
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How did NextEra Energy's investment strategy in equity securities within its Special Use Funds evolve from 2022 to 2024?",
      "original_answer": "In 2022, NextEra Energy held $8,922 million in Special Use Funds, with no explicit breakdown of equity securities provided in the filing. By 2024, the company disclosed a more detailed composition, with $6,164 million specifically allocated to equity securities under Special Use Funds. This evolution suggests a strategic shift toward transparency and a potentially greater emphasis on equity investments within these funds. While the total amount in Special Use Funds decreased, the explicit allocation to equities in 2024 indicates a more defined and possibly more aggressive investment posture compared to 2022.",
      "llm_answer": "From 2022 to 2024, NextEra Energy's investment strategy in equity securities within its Special Use Funds shifted toward greater reliance on Level 3 valuations and commingled funds. In 2022, equity securities in Special Use Funds were primarily classified as Level 1 ($2,614 million for NEE) and Level 2 ($3,321 million for NEE), but by 2024, Level 3 holdings increased significantly to $229 million (NEE) and $204 million (FPL), reflecting reduced market observability. The fund composition also expanded to include more corporate debt securities and asset-backed securities, with equity securities rising from $2,614 million (2022) to $6,164 million (2024) for NEE, driven by growth in Level 2 and Level 3 investments. This evolution highlights a strategic move toward more complex, less liquid equity and debt instruments within the Special Use Funds.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. The ground truth states that in 2022, NextEra Energy's total Special Use Funds were $8,922 million with no explicit breakdown of equity securities. However, the LLM incorrectly claims that equity securities were $2,614 million in 2022, which is not supported by the original data. This number appears to be a misinterpretation—possibly confusing Level 1 equity holdings with total equity exposure. Additionally, the LLM introduces Level 1, Level 2, and Level 3 valuations and specific amounts like $3,321 million (Level 2) and $229 million (Level 3), which are not present in the ground truth and cannot be verified. While the 2024 figure of $6,164 million in equity securities is correct, the implied growth from $2,614 million in 2022 is factually wrong due to the incorrect baseline. (2) Calculations and comparisons are flawed: the claim of an increase from $2,614M to $6,164M suggests a tripling of equity holdings, but the original answer does not provide a 2022 equity breakdown, making this comparison invalid. The introduction of FPL-level data ($204 million Level 3) is extraneous and unsupported. (3) The multi-hop reasoning is partially sound in that it attempts to analyze changes in investment strategy and fund composition over time, and it correctly identifies the 2024 equity allocation. However, it fabricates granular classification data (by valuation level) not present in the ground truth, undermining the reasoning. (4) Despite these issues, the answer is contextually relevant—it addresses the evolution of investment strategy in equity securities within Special Use Funds and correctly notes increased allocation and transparency in 2024. The qualitative insight about a shift toward more complex instruments is speculative but not entirely implausible, though unsupported by the original answer. The core error—making up 2022 equity values—severely impacts correctness and quantitative accuracy, warranting a low overall score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 555,
        "total_tokens": 1916
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How did the financial performance of smokeable products evolve from 2022 to 2023, particularly in terms of net revenues and operating income?",
      "original_answer": "In 2022, smokeable products generated $22,476 million in net revenues and contributed $10,688 million to operating income. In 2023, net revenues from smokeable products decreased slightly to $21,756 million, and operating income from this segment also declined to $10,670 million. This indicates a marginal decrease in both revenue and profitability year-over-year.",
      "llm_answer": "From the consolidated operating results tables in the 2022 and 2023 10‑K filings, net revenues from smokeable products fell to $21,756 million in 2023 from $22,476 million in 2022, and operating income attributable to smokeable products remained essentially flat at $10,670 million versus $10,688 million.  Consequently, overall net revenues declined $613 million (2.4%) and operating income fell $372 million (3.1%) year‑over‑year, driven primarily by lower shipment volume in the smokeable segment.",
      "correctness_score": 6,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 7,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the net revenues for 2022 ($22,476 million) and 2023 ($21,756 million), which match the ground truth. The operating income figures are also accurate: $10,688 million in 2022 and $10,670 million in 2023. However, the LLM incorrectly states that operating income 'fell $372 million (3.1%)', which is factually wrong. The actual decrease is $18 million ($10,688M - $10,670M), not $372M. This is a major calculation error. The revenue decline of $720 million ($22,476M - $21,756M) is also misstated as $613 million. (2) The percentage changes are therefore also incorrect: the correct revenue decline is approximately 3.2%, not 2.4%, and the operating income decline is about 0.17%, not 3.1%. (3) The multi-hop reasoning is otherwise sound—the model correctly synthesizes data from two years and identifies trends in net revenues and operating income. It appropriately attributes changes to shipment volumes, which may be supported in the filings, though this causal claim isn't in the ground truth and slightly overreaches. (4) Despite accurate raw numbers, the significant calculation errors in differences and percentages reduce the quantitative accuracy. The qualitative reasoning and contextual relevance remain strong, as the answer addresses both revenue and income trends over the two years with correct base figures.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1215,
        "completion_tokens": 380,
        "total_tokens": 1595
      },
      "error": null
    },
    {
      "question_id": 28,
      "question": "How has the utilization of Accenture plc Class A Ordinary Shares evolved between 2022 and 2023, particularly in terms of share purchase programs and their intended usage?",
      "original_answer": "In 2022, Accenture disclosed an aggregate available authorization of $3,129,296 for publicly announced open-market share purchase programs and other share purchase programs involving Accenture plc Class A Ordinary Shares and Accenture Canada Holdings Inc. exchangeable shares. By 2023, the company clarified that Class A Ordinary Shares acquired through these programs were being held as treasury shares and intended for employee benefits, such as equity awards. Additionally, in fiscal 2024, shares were acquired via share withholding for payroll tax obligations under employee equity share plans, which were separate from the publicly announced share purchase authorization. This indicates a shift in focus toward internal employee compensation mechanisms while maintaining a formal buyback program.",
      "llm_answer": "Between fiscal 2022 and 2023, Accenture expanded its share‑purchase authorizations and activity: the Board increased the available repurchase authority to $6.13 billion (adding $3 billion in September 2022), and during fiscal 2022 the company repurchased 12.18 million Class A shares for $4.11 billion under its open‑market program and other employee‑related purchase plans. These purchases were intended to acquire treasury shares for general corporate purposes, employee benefit programs and to fund equity awards.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, Accenture had an aggregate available authorization of $3,129,296 (approximately $3.13 million), not $6.13 billion as claimed by the LLM. The LLM incorrectly states that the Board increased repurchase authority to $6.13 billion with a $3 billion addition in September 2022, which is not supported by the original answer and misrepresents the scale of the program. Additionally, the claim that 12.18 million shares were repurchased for $4.11 billion in fiscal 2022 is not present in the ground truth and appears fabricated. (2) The original answer does not provide specific repurchase volumes or dollar amounts executed in 2022—only the authorization amount. Thus, the LLM introduces precise numbers without basis, failing quantitative accuracy. While $3.13 billion might be confused with $3.129 million due to unit error, the discrepancy is over 1,000x, indicating a severe error. (3) The qualitative reasoning partially captures intent: the original answer confirms that shares acquired were held as treasury shares for employee benefits like equity awards, which aligns with the LLM’s mention of employee benefit programs. However, the LLM misses the key evolution: in 2023, Accenture clarified the use of treasury shares for employee benefits, and in fiscal 2024, share withholding for payroll taxes became a separate mechanism. This shift toward internal compensation mechanisms is a central point in the original answer but is not clearly conveyed in the LLM response. (4) Contextual relevance is high because the LLM addresses share purchase programs and intended usage, but correctness is low due to invented figures and failure to reflect the actual scale and timeline of authorizations and usage. The synthesis across years is weak, and the multi-hop element (evolution from 2022 to 2023 and into 2024) is underdeveloped.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 523,
        "total_tokens": 1859
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the nature and structure of AMT's operating covenants evolved between 2022 and 2024, particularly in terms of the types of debt instruments involved and associated interest rate benchmarks?",
      "original_answer": "In 2022, AMT's operating covenants were tied to a variety of credit facilities and loans that referenced LIBOR and EURIBOR as the interest rate benchmarks. These included the 2021 Multicurrency Credit Facility, the 2021 Credit Facility, and several term loans. By 2024, AMT's disclosures indicate a shift in the interest rate benchmark to SOFR, specifically for letters of credit drawn in Nigeria, which were subject to a rate equal to SOFR at the time of drawing plus a spread. This reflects a transition away from LIBOR-based covenants toward SOFR-based structures, signaling a strategic and regulatory evolution in how AMT manages its debt obligations and associated covenants.",
      "llm_answer": "Between 2022 and 2024, AMT's operating covenants evolved to include more diverse debt instruments and benchmarks. The 2021 credit facilities (Multicurrency, USD Delayed Draw, and Term Loans) now reference LIBOR or EURIBOR with a 1.125% margin, while newer offerings like the 0.400% and 0.950% Notes (2021) and 1.600%/2.700% Notes (2021) use fixed rates or specific benchmarks tied to issuance terms rather than LIBOR/EURIBOR. The 2023 Securitization introduced 5.490% and 5.735% rates for the Series 2023-1A/R Notes, reflecting a shift toward structured financing with fixed coupon rates and longer maturities (e.g., 2053). This contrasts with older notes like the 3.50% Notes (2013) or 2.950% Notes (2019), which used fixed rates but with earlier maturity dates. The covenants now also incorporate stricter DSCR requirements for securitization cash flows, but the core debt instruments have shifted from floating-rate benchmarks to fixed-rate instruments with tailored maturity structures.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and fails to correctly represent the evolution of AMT's operating covenants between 2022 and 2024, particularly regarding interest rate benchmarks. (1) The ground truth states that in 2022, AMT's covenants were tied to LIBOR and EURIBOR-based facilities (e.g., 2021 Multicurrency Credit Facility), and by 2024 there was a shift to SOFR, specifically for Nigerian letters of credit. The LLM instead claims a broad shift to fixed-rate instruments and structured financings like the 2023 Securitization with 5.490%/5.735% rates, which is not supported by the original answer and introduces unverified debt instruments and percentages. (2) Quantitative accuracy is poor: the LLM cites numerous specific rates (0.400%, 0.950%, 1.600%, 2.700%, 5.490%, 5.735%, 3.50%, 2.950%) and margins (1.125%) that do not appear in the ground truth and are likely fabricated or misattributed. There is no mention in the original answer of '2023 Securitization', 'Series 2023-1A/R Notes', or DSCR requirements. (3) The reasoning is flawed: the LLM incorrectly frames the evolution as a shift from floating to fixed rates, while the actual transition was from LIBOR/EURIBOR to SOFR—still a floating benchmark. This misrepresents the nature of the benchmark transition, which was driven by regulatory phase-out of LIBOR, not a strategic move to fixed rates. (4) The answer is partially relevant in discussing debt instruments and covenants over time, but it fails the core multi-hop requirement of accurately tracing the benchmark shift (LIBOR/EURIBOR → SOFR) and misidentifies the key instruments and years involved. As a result, the correctness score is low despite some plausible financial terminology.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1430,
        "completion_tokens": 470,
        "total_tokens": 1901
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did Disney+ Hotstar's subscriber base evolve between the 2023 and 2024 SEC filings, and what impact did the consolidation of Star+ into Disney+ in Latin America have on Disney's international streaming strategy?",
      "original_answer": "In the 2023 SEC filing, Disney+ Hotstar reported approximately 36 million paid subscribers as of September 28, 2024. The 2024 filing noted that in certain Latin American countries prior to July 2024, Disney offered both Disney+ and Star+ as separate services, but these were merged into a single Disney+ product offering by the end of June 2024. This consolidation suggests a strategic shift toward streamlining international service offerings, potentially aligning with the model used for Disney+ Hotstar by integrating diverse content into a unified brand to enhance user experience and operational efficiency.",
      "llm_answer": "Between the 2023 and 2024 SEC filings, Disney+ Hotstar's paid subscriber base grew modestly from approximately 66.1 million (as reported in the 2023 filing for International Disney+ including Hotstar) to 66.7 million in the 2024 filing, reflecting a small net increase. The consolidation of Star+ into Disney+ in Latin America—completed at the end of June 2024—was part of Disney's broader international streaming strategy to streamline its offering, reduce operational complexity, and strengthen its position in key markets by unifying its streaming services under the Disney+ brand, thereby enhancing customer retention and reducing churn. This move also allowed Disney to better leverage its content and advertising capabilities across a single platform in the region.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the subscriber numbers and misattribution of data. The original answer states that Disney+ Hotstar had approximately 36 million paid subscribers as of September 28, 2023 (not 2024), while the LLM claims a base of 66.1 million and 66.7 million, which appears to conflate Disney+ Hotstar with the broader International Disney+ segment. There is no mention in the ground truth of a 66 million subscriber base specifically for Hotstar, nor any growth from 66.1M to 66.7M. Additionally, the date in the original answer is misstated by the LLM as if the 2023 filing reported data for 2024, when it actually reports data as of the end of fiscal 2023 (September 28, 2023). (2) The consolidation of Star+ into Disney+ in Latin America by end of June 2024 is correctly identified and dated, aligning with the original answer. However, the LLM invents impacts such as 'enhancing customer retention and reducing churn' and 'better leverage advertising capabilities,' which are not present or implied in the ground truth. (3) The multi-hop reasoning is partially sound—the model connects the consolidation event to a strategic shift in international streaming—but it extrapolates beyond the provided information with unsupported business outcomes. It fails to link the Star+ consolidation to the Disney+ Hotstar model as a parallel strategy, instead vaguely referencing unification without drawing the explicit analogy made in the original answer. (4) Due to major quantitative errors and overinterpretation of strategic impact, the correctness score is low. The qualitative and contextual scores are moderate because the general direction of strategy is acknowledged, but precision and fidelity to source data are poor.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1363,
        "completion_tokens": 487,
        "total_tokens": 1850
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the number of employees covered under collective labor agreements changed from 2022 to 2023, and what does this indicate about the company's labor agreement strategy?",
      "original_answer": "In 2022, the company expected to negotiate agreements covering approximately 3,000 employees in the following year. In 2023, the company projected negotiations covering 2,100 employees for the upcoming year. This indicates a reduction in the number of employees involved in labor renegotiations, suggesting a shift in the company's labor agreement strategy, possibly due to fewer expiring agreements or proactive resolution of collective bargaining terms.",
      "llm_answer": "The number of employees covered under collective bargaining agreements increased from approximately 2,100 in 2023 (covering about one-fifth of subsidiary employees) to an expected 2,100 employees across 20 agreements to be negotiated in 2024. This indicates the company's strategy of proactively renegotiating labor agreements without material disruption to operations, maintaining stable labor relations while managing workforce costs.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both direction and magnitude of change. The ground truth states that the number of employees expected to be covered in negotiations decreased from approximately 3,000 in 2022 (for 2023 negotiations) to 2,100 in 2023 (for 2024 negotiations). The LLM incorrectly claims an increase and misrepresents the timeline, stating a rise from 2,100 in 2023 to 2,100 in 2024—implying no change but framing it as an increase. (2) Quantitative inaccuracies include: wrong starting number (2,100 instead of 3,000), wrong comparison (no actual increase occurred), and misattribution of years. The claim of '2,100 employees across 20 agreements' introduces unverified detail not in the original. (3) The multi-hop reasoning fails: the model should have compared projected negotiation coverage from 2022 to 2023 filings but instead conflated years and directions of change. It also misinterprets the trend, missing the reduction that indicates a strategic shift due to fewer expiring agreements. (4) The conclusion about 'proactive renegotiation' and 'stable labor relations' is speculative and does not align with the ground truth's interpretation of reduced volume suggesting fewer expiring contracts or prior resolution. While the answer addresses labor strategy, the factual foundation is flawed, severely undermining correctness. Contextual relevance is moderate as it attempts to answer both parts of the question but on incorrect premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1229,
        "completion_tokens": 409,
        "total_tokens": 1639
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How did NextEra Energy's investment in U.S. Government and municipal bonds evolve from 2022 to 2024, and what was the change in total value across these years?",
      "original_answer": "In 2022, NextEra Energy's investment in U.S. Government and municipal bonds totaled $137 million. By 2024, this investment had increased significantly to $161 million under 'Other investments' for NEE. This represents a growth of $24 million, or approximately 17.5%, indicating a strategic increase in this asset class over the two-year period.",
      "llm_answer": "From the 2022 10‑K (page 100) NEE reported $663 million in U.S. Government and municipal bonds, and by 2024 (page 89) that amount had risen to $722 million. The increase represents an addition of roughly $59 million over the two‑year period.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core numbers. According to the ground truth, NextEra Energy's investment in U.S. Government and municipal bonds was $137 million in 2022 and $161 million in 2024, representing a $24 million increase. However, the LLM claims $663 million in 2022 and $722 million in 2024, with a $59 million increase—values that are more than 4x higher than the ground truth. These numbers do not match the actual data from the knowledge graph. (2) The calculations in the LLM answer (722 - 663 = 59 million increase) are arithmetically correct, but based on wrong input values, making the entire quantitative analysis invalid. The percentage increase implied (~8.9%) also differs from the correct 17.5% in the ground truth. (3) The multi-hop reasoning is structurally sound—the model attempts to compare two years and compute a change—but it fails at entity and data retrieval accuracy. It likely misidentified the investment category or pulled data from a different line item or company. The mention of 'page 100' and 'page 89' suggests document sourcing, but the figures do not align with the verified knowledge graph. (4) Contextual relevance is moderate because the answer addresses the right question format (evolution over time, change in value) and refers to the correct company (NEE) and asset class. However, due to severe factual inaccuracies in the financial figures, the correctness and quantitative accuracy scores are very low. The qualitative accuracy is slightly higher because the reasoning framework is present, albeit applied to incorrect data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1149,
        "completion_tokens": 440,
        "total_tokens": 1589
      },
      "error": null
    },
    {
      "question_id": 29,
      "question": "How has the role of Opdivo in Bristol-Myers Squibb's product portfolio evolved between 2022 and 2024, particularly in terms of its manufacturing strategy and therapeutic approvals?",
      "original_answer": "In 2022, Opdivo was referenced as a product with both internal manufacturing capability and reliance on third-party manufacturers to meet demand, highlighting its strategic importance in BMY's supply chain. By 2024, Opdivo received a new FDA approval in March for combination therapy with cisplatin and gemcitabine for first-line treatment of unresectable or metastatic urothelial carcinoma, indicating an expansion of its therapeutic applications. This evolution reflects both continued manufacturing investment and increased clinical positioning of Opdivo within BMY's oncology portfolio.",
      "llm_answer": "Between 2022 and 2024, Opdivo’s role in Bristol‑Myers Squibb’s portfolio expanded markedly through both therapeutic approvals and a shift toward an integrated manufacturing strategy.  The company secured multiple new regulatory milestones for Opdivo—including FDA approval of Opdivo Qvantig (subcutaneous formulation) in December 2024, EC approval of Opdivo + Yervoy for first‑line colorectal cancer, and Japan’s approval for Opdivo in unresectable urothelial carcinoma—while also extending its use in neoadjuvant NSCLC and combination regimens.  Concurrently, BMS emphasized a flexible, multi‑site manufacturing network that leverages internal capabilities (e.g., Opdivo’s in‑house production) alongside third‑party partners, enabling rapid scale‑up of both established and new formulations such as Opdivo Qvantig.  This dual focus on expanding clinical indications and modernizing production underscores Opdivo’s evolution from a single‑product franchise to a cornerstone of BMS’s oncology and immunology portfolio.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies in dates and approvals not present in the ground truth. Specifically, it claims FDA approval of Opdivo Qvantig in December 2024, which is outside the 2022–2024 timeframe and not mentioned in the original answer; the ground truth only confirms a March 2024 FDA approval for Opdivo in combination with cisplatin and gemcitabine for urothelial carcinoma. Additionally, the LLM cites EC approval for Opdivo + Yervoy in first-line colorectal cancer and Japan’s approval for urothelial carcinoma, none of which are in the ground truth. These are significant factual overstatements. (2) Quantitative accuracy is low due to incorrect dates (December 2024 vs. March 2024) and fabricated regulatory milestones. The original answer only confirms one specific FDA approval in March 2024; no mention is made of subcutaneous formulation (Qvantig), neoadjuvant NSCLC, or international approvals. (3) The qualitative reasoning is partially sound: the LLM correctly infers an integrated manufacturing strategy involving both internal and third-party manufacturing, consistent with the 2022 description. It also correctly identifies the trend of expanding clinical use and manufacturing flexibility as a strategic evolution. However, it overextends the evidence by inventing approvals and formulations not in the source, failing the multi-hop synthesis test as it adds external knowledge. (4) Contextual relevance is high because the answer addresses both manufacturing strategy and therapeutic approvals as asked, and frames Opdivo’s role evolving within BMY’s portfolio appropriately. Despite incorrect specifics, the overall narrative direction aligns with the ground truth. The correctness score is 6 due to correct core themes but significant factual errors in key details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1410,
        "completion_tokens": 493,
        "total_tokens": 1904
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has Disney's relationship with National Geographic magazine evolved between 2023 and 2024 in terms of its business structure and strategic positioning within the company's portfolio?",
      "original_answer": "In 2023, National Geographic magazine was explicitly described as part of the Entertainment segment under Content Sales/Licensing, and was noted as being 73% owned by Disney. By 2024, the magazine was still reported under Content Sales/Licensing, but the emphasis on its ownership percentage was removed, and it was described more as a publication 'published' by the company rather than a business in which Disney has a direct equity stake. This shift indicates a more operational rather than ownership-focused relationship in 2024 compared to 2023.",
      "llm_answer": "Disney's relationship with National Geographic magazine has shifted from a standalone print publication to a broader content licensing and distribution role within the Entertainment segment. As noted in the 2024 10-K, National Geographic magazine is now reported under \"Content Sales/Licensing\" alongside other licensing activities, reflecting its integration into the company's broader content licensing strategy rather than operating as a distinct magazine business. This evolution aligns with Disney's strategic focus on consolidating content distribution across linear networks, streaming services, and licensing partnerships, while maintaining National Geographic's presence through channels like National Geographic Channels (FX, Nat Geo Wild, etc.) and digital platforms.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures part of the truth but misses key factual distinctions present in the ground truth. (1) It correctly identifies that National Geographic magazine is reported under 'Content Sales/Licensing' in the Entertainment segment, which aligns with the 2023 and 2024 disclosures. However, it fails to mention the specific 73% ownership stake explicitly noted in 2023, and does not acknowledge the removal of that ownership detail in 2024—a critical shift in business structure. Instead, the LLM implies a structural integration into licensing without addressing the change in how Disney characterizes its equity interest. (2) There are no numerical inaccuracies per se, but the absence of the 73% figure—a key quantitative and qualitative data point—represents a significant omission. The years (2023–2024) are correctly referenced. (3) The reasoning is partially sound: the model infers strategic integration into content licensing, which is plausible, but it does not perform the necessary multi-hop comparison showing a shift from ownership emphasis to operational publishing language. This undermines the qualitative accuracy of the evolution described. (4) The answer is contextually relevant and well-framed within Disney’s broader content strategy, but the lack of precise entity and ownership details reduces factual correctness. The answer suggests integration but mischaracterizes the nature of the evolution—focusing on operational role rather than the change in disclosure about ownership structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 416,
        "total_tokens": 1758
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How has PayPal's description of its transaction management databases' capabilities evolved between 2023 and 2024, particularly in relation to global payment processing in different currencies?",
      "original_answer": "In 2023, PayPal described its transaction management databases as part of a platform that allowed consumers to withdraw funds in 56 currencies. By 2024, the company updated this figure to 57 currencies, indicating a slight expansion in the global reach of its transaction processing capabilities. Additionally, while both years emphasize the role of these databases in enabling customers to utilize PayPal's suite of products, the 2024 filing introduced a more consumer-centric framing, placing 'consumers' ahead of 'merchants' in describing the ecosystem served by the platform. These changes suggest a refinement in how PayPal positions its transaction management systems within its broader global payments infrastructure.",
      "llm_answer": "PayPal’s 2023 filing describes its transaction‑management databases as supporting “approximately 200 markets and approximately 140 currencies,” while the 2024 filing updates this to “approximately 200 markets and approximately 150 currencies,” reflecting an expanded global payment capability. Both years emphasize that the platform’s proprietary databases enable secure, end‑to‑end processing of payments across multiple currencies, but the 2024 version adds a specific reference to handling “approximately 150 currencies,” underscoring an evolution toward broader multi‑currency support.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, PayPal's 2023 filing mentioned withdrawal capabilities in 56 currencies, not 'approximately 140 currencies,' and the 2024 update was to 57 currencies, not '150.' The claim of 'approximately 200 markets' appears unrelated to the specific question about transaction management databases and currency support for withdrawals. These numbers are entirely inconsistent with the ground truth. (2) The quantitative accuracy is very low: the LLM reports 140 → 150 currencies (a 10-currency increase), while the actual data shows 56 → 57 (a 1-currency increase). This represents a major error in both magnitude and baseline figures. There is no mention in the ground truth of '140' or '150' currencies in either year. (3) The qualitative reasoning is partially sound in structure—comparing two years, identifying a trend in currency support, and noting platform capabilities—but it fails on multi-hop synthesis because it uses incorrect data from potentially unrelated sections of the filings (e.g., total currencies supported by PayPal globally vs. those specifically tied to transaction management database withdrawal functionality). The LLM also misses the key qualitative shift noted in the original answer: the reordering of 'consumers' before 'merchants' in the 2024 description, which reflects a strategic reframing. (4) Contextual relevance is moderate because the answer addresses the general topic—evolution of database capabilities in multi-currency processing—but does so with incorrect metrics and misses the nuanced, consumer-centric language shift highlighted in the ground truth. The focus on 'proprietary databases' and 'end-to-end processing' is relevant but does not compensate for factual inaccuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 492,
        "total_tokens": 1832
      },
      "error": null
    },
    {
      "question_id": 30,
      "question": "How did the interest rate terms associated with the Series K Debentures evolve between 2023 and 2024, and what does this indicate about NEE's financing strategy?",
      "original_answer": "In 2023, the Series K Debentures had their interest rate reset to 6.051% per year as part of a remarketing completed in March 2023. By 2024, the terms of the Series K Debentures were further updated through a letter dated March 1, 2023, which set forth certain terms effective March 1, 2023, indicating a continuation of the updated rate and terms from the 2023 remarketing. This suggests that NEE adjusted its financing strategy in response to market conditions, locking in a higher interest rate to secure funding.",
      "llm_answer": "Based on the provided document pages, the interest rate on NEE's Series K Debentures was reset to **6.051% per year** in connection with the March 2023 remarketing of $2.5 billion of these debentures (due March 1, 2025), as stated on page 104. This replaced the prior rate established during the February 2020 issuance. The reset rate (6.051%) is higher than the previous rate implied by the 2020 terms (which was tied to the equity unit structure but not explicitly stated in the excerpt), indicating a strategic shift toward higher fixed-rate financing in a rising interest rate environment. This reflects NEE's broader financing strategy of actively managing debt maturity profiles and interest rate exposure through periodic remarketing of debentures to optimize cost and liquidity.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the key quantitative fact: the interest rate on the Series K Debentures was reset to 6.051% per year in March 2023, matching the ground truth. The date (March 2023) and the rate (6.051%) are accurate. The LLM also correctly references the $2.5 billion remarketing and the maturity date (March 1, 2025), which are consistent with the context. (2) All numbers, percentages, and dates are factually correct. The LLM does not introduce any incorrect figures or miscalculations. Format variations are not an issue here as all data is presented clearly and accurately. (3) The LLM correctly performs the multi-hop reasoning by connecting the 2023 remarketing event to the rate reset and infers a strategic shift in financing due to rising interest rates. It correctly interprets that the new rate replaced the prior 2020 rate, even though the exact prior rate is not stated. The only minor gap is that the LLM does not explicitly mention the March 1, 2023 letter that formalized the terms, which is included in the ground truth, but this does not affect the core factual accuracy. (4) The answer is semantically equivalent to the original in substance: it captures the rate change, timing, and strategic implication. The reasoning is sound and relevant, with only a slight omission of the formal letter detail. Thus, the answer is highly accurate, complete, and contextually appropriate, warranting a 9/10 for correctness and qualitative accuracy, with full marks for quantitative and contextual performance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 425,
        "total_tokens": 1755
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has ExxonMobil's application of the Unit-of-Production Depreciation method evolved between 2022 and 2023, particularly in response to changes in proved reserves and asset life assumptions?",
      "original_answer": "In 2022, ExxonMobil applied the Unit-of-Production Depreciation method based on proved reserves or proved developed reserves, switching to straight-line depreciation when asset life did not correlate with reserves, and using SEC price-based reserves only when proved reserves were substantially de-booked. By 2023, the company maintained the same core methodology but placed greater emphasis on using the most recent SEC price to determine reserves for depreciation in cases where reserves had been significantly reduced, ensuring a more meaningful allocation of asset costs over the expected life of the asset. This reflects a refinement in the company's approach to align depreciation with updated economic conditions and production realities.",
      "llm_answer": "ExxonMobil's application of the unit-of-production depreciation method has evolved by shifting from using total proved reserves to using the most recent SEC average price for reserve estimates, ensuring more meaningful depreciation charges when reserves are substantially de-booked or production continues. This adjustment allows for more accurate cost allocation over the asset's economic life, particularly when reserve volumes change significantly due to market conditions or operational changes.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the key evolution in ExxonMobil's application of the unit-of-production depreciation method between 2022 and 2023. It correctly identifies the shift toward using the most recent SEC average price for reserve estimates, particularly when reserves are substantially de-booked, which aligns with the ground truth's emphasis on updated economic conditions. The answer accurately reflects that this change improves cost allocation over the asset's economic life in response to market or operational changes. However, it omits some nuances present in the original answer: (1) it does not mention that ExxonMobil continued to use proved or proved developed reserves as the base in 2022, (2) it fails to note the fallback to straight-line depreciation when asset life does not correlate with reserves, and (3) it doesn't explicitly state that the 2023 refinement was a continuation of the same core methodology with enhanced emphasis on SEC pricing in specific cases. These omissions reduce completeness and slightly affect qualitative accuracy, but the core factual content—especially regarding the shift in reserve basis for depreciation—is correct. There are no numerical inaccuracies (quantitative accuracy is perfect), and the response is highly relevant to the question. Semantic equivalence is mostly preserved, though some multi-hop details from the knowledge graph are condensed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 393,
        "total_tokens": 1715
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has Netflix's strategic emphasis on original programming evolved between 2023 and 2024, particularly in terms of its reliance on third-party production partners versus internal studio scaling?",
      "original_answer": "In 2023, Netflix emphasized its investments in original programming and highlighted the risks associated with third-party production partners, including potential liability and loss due to legal violations, insolvency, or fraud. It also noted its acquisitions like Scanline and Animal Logic as part of scaling internal studio operations. By 2024, the company shifted its language to focus on the growing complexity of managing original content production and placed greater emphasis on the need to improve internal systems, corporate culture, and operational practices related to content creation. The explicit mention of third-party risks present in 2023 was omitted in 2024, suggesting a reduced dependency on external partners and a stronger strategic move toward internal control and scaling.",
      "llm_answer": "Netflix’s 2024 filing shows a clear shift toward deeper internal studio capacity—highlighting its own production facilities (e.g., Scanline, Animal Logic) and expanded original‑content pipelines—as the primary engine for new programming.  At the same time, the company still leans on external partners for distribution and certain production resources, but it explicitly frames third‑party deals as “strategic acquisitions and investments” that it must manage carefully, indicating a reduced reliance on outside studios and a greater emphasis on scaling its own creative operations.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent with the ground truth in several key areas: it correctly identifies Netflix's strategic shift toward internal studio scaling, references the acquisitions of Scanline and Animal Logic, and notes continued but reduced reliance on third-party partners. There are no numeric inaccuracies (quantitative accuracy is perfect), and the context of the question—evolution in strategy between 2023 and 2024—is well addressed. However, the LLM omits a critical element from the original answer: the explicit 2023 risk language around third-party partners (e.g., legal, insolvency, fraud risks) and its complete absence in 2024, which is central to the multi-hop reasoning showing reduced dependency. The LLM instead generalizes third-party relationships as 'strategic acquisitions and investments' without contrasting the change in tone or risk disclosure between years. This weakens the qualitative accuracy, as the reasoning for concluding reduced reliance is less precise than the ground truth. While the overall direction of the answer is correct, it misses the nuanced shift in disclosure strategy that supports the inference of increased internal control. Hence, correctness is partially impacted due to incomplete synthesis of the multi-hop evidence.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 357,
        "total_tokens": 1714
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has the strategic positioning of Mastercard's Cyber and Intelligence Solutions evolved between 2022 and 2023?",
      "original_answer": "In 2022, Cyber and Intelligence Solutions were positioned as part of 'Other revenues' and primarily described as products and services offered to prevent, detect, and respond to fraud, ensuring the safety of transactions made on Mastercard products. By 2023, the Cyber and Intelligence Solutions were elevated in strategic importance, being explicitly described as a value-added service that enables secure, easy, and confident transactions across the entire payments ecosystem, indicating a broader role in supporting Mastercard’s core operations and new network investments.",
      "llm_answer": "Between 2022 and 2023, Mastercard’s Cyber and Intelligence Solutions shifted from being primarily a fraud‑prevention add‑on to a core, high‑margin growth pillar within its broader “value‑added services” portfolio.  In the 2023 Form 10‑K (pages 47‑51), the company highlighted that cyber‑and‑intelligence fees are now reported as a distinct revenue stream and accounted for $1.3 billion of remaining performance obligations—up from $1.1 billion in 2022—reflecting expanded adoption of its fraud‑detection, data‑analytics and digital‑identity offerings across both payments‑network and non‑network channels.  This strategic repositioning is reinforced by the 2023 non‑GAAP financial tables, which show a 13 % increase in adjusted net revenue driven largely by growth in “cyber and intelligence solutions” and other value‑added services, underscoring a deliberate move to embed these capabilities as a central, differentiated revenue engine rather than a peripheral service.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness, despite addressing the right topic and showing relevant reasoning structure. (1) Quantitative Accuracy: The LLM cites specific figures—$1.3 billion and $1.1 billion in remaining performance obligations for 2023 and 2022, respectively, and a 13% increase in adjusted net revenue driven by Cyber and Intelligence Solutions—which are not present in the ground truth. The original answer does not mention any financial figures or performance obligations, nor does it reference Form 10-K page numbers (47–51) or non-GAAP tables. These numbers and citations appear to be hallucinated or incorrectly inferred. (2) Completeness: The question asks about the evolution of strategic positioning, which the LLM attempts to address by describing a shift from a fraud-prevention add-on to a core growth pillar. This aligns with the general direction of the ground truth, which notes an elevation in strategic importance. However, the LLM adds unsupported specifics about revenue reporting and financial impact not found in the original. (3) Entity Accuracy: The company (Mastercard), product (Cyber and Intelligence Solutions), and time frame (2022–2023) are correct. However, the claim that cyber-and-intelligence fees are now a 'distinct revenue stream' goes beyond the original, which only states they were elevated in description and role, not in financial reporting segmentation. (4) Reasoning: The multi-hop logic is plausible—linking increased performance obligations and revenue growth to strategic repositioning—but is based on fabricated data. The conclusion about being a 'central, differentiated revenue engine' extrapolates beyond the original's more cautious assertion of broader role in the payments ecosystem. (5) Semantic Equivalence: While the general theme of increased strategic importance is consistent, the LLM overstates the evolution with unsupported financial metrics and structural changes. The original emphasizes a shift in narrative and scope (from fraud prevention to enabling secure transactions across the ecosystem), which the LLM partially captures but drowns in inaccurate detail. Thus, despite relevant context and structure, the inclusion of false quantitative claims severely reduces factual correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 615,
        "total_tokens": 1993
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has Tesla's approach to energy storage products evolved from 2023 to 2024, particularly in terms of production challenges and strategic dependencies?",
      "original_answer": "In 2023, Tesla emphasized its modular design and in-house expertise in power electronics and software to optimize the manufacturing and performance of its energy storage products like Megapack. By 2024, Tesla's focus shifted to addressing production ramps and supply chain dependencies, citing potential bottlenecks and the need for efficient, cost-effective manufacturing capabilities. The company also highlighted risks related to supplier reliability and the challenges of scaling production to meet planned output rates and quality standards for energy storage products.",
      "llm_answer": "From 2023 to 2024, Tesla's energy storage product strategy shifted from relying on external suppliers (e.g., Panasonic, CATL) to accelerating its proprietary battery cell development and manufacturing, particularly through the Engineering Development Program and new factory expansions (e.g., Mexico Gigafactory). Production challenges persist due to supply chain constraints for raw materials (e.g., lithium, nickel) and the complexity of scaling in-house cell production, while strategic dependencies now include both supplier reliability and internal manufacturing capabilities to meet demand for Megapack and Powerwall.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains some correct contextual elements but introduces significant factual inaccuracies in key areas, particularly around Tesla's strategic shift and supplier relationships. (1) The original answer states that in 2023, Tesla emphasized modular design and in-house power electronics/software, and in 2024 shifted focus to production ramping and supply chain dependencies. The LLM incorrectly frames this as a shift from reliance on external suppliers like Panasonic and CATL to proprietary cell development, which is not supported by the ground truth. There is no mention in the original answer of Tesla moving away from external suppliers during this period, nor of the Engineering Development Program or Mexico Gigafactory expansions as central to the 2023–2024 evolution. (2) Quantitatively, there are no numbers, dates, or financial figures in either answer, so no discrepancies exist—this aspect is neutral. (3) The multi-hop reasoning is partially sound in identifying production challenges (e.g., raw material constraints, scaling in-house production) and strategic dependencies (supplier reliability, internal manufacturing), which aligns with the original answer’s mention of bottlenecks and supplier risks. However, the LLM fabricates specific programs and facilities not present in the ground truth, undermining the qualitative accuracy. (4) Contextual relevance is high because the answer addresses production challenges and strategic dependencies as required, but correctness is limited due to unsupported claims about Tesla’s strategic pivot and specific initiatives. Thus, while the general themes of supply chain issues and scaling difficulties are consistent, the specific evolution described by the LLM does not match the documented shift in focus from design strengths to manufacturing execution and risk management.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 499,
        "total_tokens": 1800
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How did NextEra Energy Capital Holdings' issuance strategy for floating rate debentures evolve from 2023 to 2024, particularly in terms of the principal amount and maturity structure?",
      "original_answer": "In 2023, NextEra Energy Capital Holdings disclosed the sale of $600 million in floating rate debentures due in 2026. By 2024, the company formalized this issuance through an Officer's Certificate dated January 31, 2024, specifying the Floating Rate Debentures, Series due January 29, 2026. While the principal amount was not explicitly updated in 2024, the maturity structure remained consistent with the 2026 horizon, indicating a focused strategy on short-to-medium-term floating rate debt. This reflects a continuation of the prior year's approach without significant expansion or restructuring of the floating rate debenture program.",
      "llm_answer": "From 2023 to 2024, NextEra Energy Capital Holdings' floating‑rate debenture program expanded both in size and in maturity profile. In 2023 the company issued $600 million of floating‑rate debentures maturing in 2026, and by early 2024 it added a new $400 million floating‑rate tranche due 2026 plus additional floating‑rate issues scheduled for 2028, 2030, 2032, 2033, 2034 and 2054, pushing the total outstanding floating‑rate principal to roughly $4.2 billion and extending the weighted‑average maturity further out. This evolution reflects a deliberate shift toward longer‑dated floating‑rate financing to match the company’s longer‑term asset base and to diversify its funding mix.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in both quantitative and qualitative aspects. (1) Quantitatively, the LLM claims that in 2024, NextEra added a $400 million tranche and multiple new floating-rate debentures due in 2028, 2030, 2032, 2033, 2034, and 2054, increasing total outstanding floating-rate debt to $4.2 billion. However, the ground truth states that only a $600 million issuance due 2026 was disclosed in 2023, and in 2024, the company formalized the same series without any indication of new issuances or updated principal amounts. There is no mention of additional tranches or extended maturities in the original answer. (2) The calculation of $4.2 billion total outstanding is unsupported and factually wrong. (3) Qualitatively, the reasoning is flawed: the LLM infers a strategic shift toward longer-dated debt and diversification, but the ground truth indicates continuity in a short-to-medium-term strategy with no significant expansion or restructuring. The multi-hop synthesis fails because the LLM invents data not present in the source, misrepresenting both the issuance activity and strategic intent. (4) Contextually, the answer addresses the question's structure—discussing principal and maturity evolution—but does so with fabricated details, leading to a misleading conclusion. Minor credit is given for correctly noting the 2023 $600 million 2026 maturity, but all subsequent information is inaccurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 393,
        "total_tokens": 1732
      },
      "error": null
    },
    {
      "question_id": 31,
      "question": "How has Intel's approach to industry initiatives related to supply chain responsibility evolved from 2023 to 2024, particularly in terms of collaboration focus and supplier engagement scope?",
      "original_answer": "In 2023, Intel announced a significant expansion of its supplier engagement activities under its RISE strategy, aiming to increase the number of suppliers covered in sustainability and compliance programs, and set a goal to achieve net-zero upstream Scope 3 greenhouse gas emissions by 2050. By 2024, Intel's approach evolved to emphasize broader collaboration on responsible minerals sourcing and transparency around climate and water impacts, with a continued focus on capability-building programs for suppliers but without explicit mention of expanding the number of suppliers engaged. The shift indicates a move from announcing strategic expansions to reinforcing and deepening existing industry partnerships.",
      "llm_answer": "Intel's approach to supply chain responsibility has evolved from 2023 to 2024 by shifting from a broad focus on general supplier engagement and diversity spending toward a more targeted, results-driven model. In 2024, the company expanded its supplier engagement scope to include deeper collaboration on climate and water impacts, responsible minerals sourcing, and human rights compliance, while explicitly linking executive compensation to specific sustainability and diversity metrics (e.g., 25,000 metric ton emissions reduction, 95% renewable electricity, and $2B diverse supplier spending by 2030). This reflects a strategic move to integrate supply chain responsibility into core business operations and external partnerships, moving beyond compliance to drive industry-wide standards through initiatives like the RISE strategy and the Alliances for Global Inclusion.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. While it correctly identifies Intel's RISE strategy and mentions responsible minerals sourcing, climate, and water impacts in 2024, it incorrectly states that in 2024 Intel 'expanded its supplier engagement scope'—the ground truth indicates no explicit expansion of the number of suppliers engaged in 2024, marking a shift from expansion (2023) to deepening existing partnerships. Additionally, the LLM introduces specific quantitative targets—25,000 metric tons emissions reduction, 95% renewable electricity, $2B diverse supplier spending by 2030, and linking executive compensation to these metrics—which are not present in the original answer and cannot be verified from the provided ground truth. These numbers and linkages are unsupported and likely hallucinated. (2) Quantitative accuracy is low: none of the cited figures (e.g., 25,000 metric tons, $2B by 2030) appear in the ground truth, and the original answer only mentions a net-zero upstream Scope 3 emissions goal by 2050. There is no mention of executive compensation linkage or diversity spending targets in the original, making these additions factually incorrect. (3) The multi-hop reasoning is partially sound in identifying a strategic evolution from broad engagement to deeper collaboration, and the mention of RISE and industry partnerships aligns contextually. However, the synthesis is flawed because it invents new metrics and misrepresents the nature of the 2024 shift—framing it as an expansion rather than a consolidation and deepening. (4) Contextual relevance is moderate: the answer addresses collaboration focus and supplier engagement scope as asked, and uses appropriate terminology, but the inclusion of unverified metrics and mischaracterization of strategic direction significantly undermines factual correctness. The core idea of a shift toward deeper collaboration has merit, but the execution is marred by inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1407,
        "completion_tokens": 533,
        "total_tokens": 1941
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has the characterization of the assumptions underlying the standardized measure of discounted future cash flows evolved between XOM's 2022 and 2023 disclosures, particularly regarding the company's framing of its dependency on first-day-of-the-month average prices?",
      "original_answer": "In XOM's 2022 filing, the standardized measure of discounted future cash flows was described as being 'prepared on the basis of certain prescribed assumptions,' which included first-day-of-the-month average prices. This framing emphasized that the assumptions were foundational to the calculation but did not explicitly highlight the degree of dependency on them. In contrast, the 2023 filing reflects a shift in tone by emphasizing that the standardized measure 'depends on' these prescribed assumptions, particularly first-day-of-the-month average prices, which are described as discrete points in time that 'may cause significant variability in cash flows from year to year as prices change.' This indicates a more explicit acknowledgment of the sensitivity and dependency of the measure on these assumptions, even though the actual calculation methodology remained unchanged, using the same 10 percent discount factor, year-end costs, and legislated tax rates.",
      "llm_answer": "The comparison of XOM's 2022 and 2023 disclosures reveals a significant shift in how the company frames its dependency on first-day-of-the-month average prices for the standardized measure of discounted future cash flows. In 2022, the disclosure explicitly states the standardized measure is \"prepared on the basis of certain prescribed assumptions including first-day-of-the-month average prices, which represent discrete points in time and therefore may cause significant variability in cash flows from year to year as prices change.\" However, in the 2023 disclosure (page 134), this specific phrasing and warning about price volatility is absent, indicating a more stable or consistent framing of the methodology without emphasizing price variability as a key factor. The 2023 disclosure also removes the parenthetical \"(1)\" reference to noncontrolling interests in the standardized measure table, further suggesting a refinement in presentation. Overall, the evolution reflects a move away from highlighting price-related volatility toward a more streamlined description of the calculation method.",
      "correctness_score": 2,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in its characterization of the evolution between XOM's 2022 and 2023 disclosures. According to the ground truth, the 2023 filing introduced a stronger emphasis on the dependency of the standardized measure on prescribed assumptions, particularly first-day-of-the-month prices, explicitly noting that these discrete pricing points 'may cause significant variability in cash flows.' In contrast, the LLM incorrectly claims that the warning about price volatility is *absent* in the 2023 filing and that the company moved toward a 'more stable or consistent framing' without emphasizing variability. This is the opposite of the truth: the 2023 disclosure actually amplifies the sensitivity language. Additionally, the LLM cites page 134 and claims the removal of a parenthetical reference to noncontrolling interests as evidence of refinement, but this detail is not present in the ground truth and distracts from the core issue of assumption dependency. While the LLM correctly identifies the use of first-day-of-the-month prices and mentions consistent elements like discount rates and costs (which aligns with the unchanged methodology), its central claim about reduced emphasis on price variability is factually wrong. This represents a critical failure in multi-hop reasoning and synthesis, as the model misinterprets the direction of change in disclosure tone. Quantitative accuracy is relatively high because no numerical data is misstated (the discount rate, year-end costs, and tax rates are correctly noted as unchanged), but the qualitative reasoning is severely flawed. Contextual relevance is moderate because the answer addresses the right topic and document years, but with incorrect conclusions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1547,
        "completion_tokens": 473,
        "total_tokens": 2020
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has MA's digital identity solutions evolved between 2022 and 2023, particularly in terms of their integration with open banking capabilities and reach across financial institutions?",
      "original_answer": "In 2022, MA introduced its digital identity solutions as part of an open banking platform that enabled data providers and third parties to access consumer data on a permissioned basis, aiming to improve customer experience and financial inclusion. The platform leveraged data principles such as consumer protection and consent management, and it focused on identity verification across people, devices, and transactions. In 2023, MA expanded its open banking capabilities, achieving connectivity to over 95% of deposit accounts in the U.S. and approximately 3,000 banks across Europe, which significantly enhanced the reach and application of its digital identity solutions. Additionally, in 2023, MA partnered with leading financial institutions to launch an ACH payment solution using its open banking infrastructure, indicating a deeper integration of digital identity within broader financial services.",
      "llm_answer": "Between 2022 and 2023, MA expanded its open banking platform to connect with over 95% of U.S. deposit accounts and approximately 3,000 banks across Europe, while integrating digital identity solutions that leverage device intelligence, behavioral biometrics, and consent-centric authentication to secure payments. This evolution strengthened financial inclusion through streamlined loan processes and enhanced payment experiences, supported by new partnerships and the acquisition of Ekata for digital identity verification.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key quantitative metrics from the ground truth: connectivity to over 95% of U.S. deposit accounts and approximately 3,000 banks in Europe in 2023. These numbers are accurately reported with no discrepancies. (2) The answer addresses the evolution between 2022 and 2023, noting expansion in reach and integration with open banking, which aligns with the original answer. However, it omits specific mention of MA's 2022 launch of digital identity solutions as part of an open banking platform focused on consumer protection, consent management, and identity verification across people, devices, and transactions—key context from the first year. (3) The multi-hop reasoning is mostly sound: it connects digital identity with open banking expansion and broader financial services integration. However, the mention of 'acquisition of Ekata' is not present in the ground truth and introduces unverified information, which slightly undermines qualitative accuracy. The partnership with financial institutions to launch an ACH payment solution using open banking infrastructure—a key 2023 development in the original answer—is rephrased as 'new partnerships' but not explicitly detailed, leading to minor loss in completeness. (4) Despite the addition of Ekata and slightly less precise detail on 2022 developments, the core factual trajectory—expansion of open banking reach and deeper integration of digital identity—is correct and contextually relevant. Wording differences are acceptable under semantic equivalence, but the added detail about Ekata and lack of specificity on 2022 initiatives prevent a top score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1367,
        "completion_tokens": 455,
        "total_tokens": 1822
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has Tesla's approach to the Solar Roof product evolved between 2023 and 2024, particularly in terms of production challenges and strategic dependencies?",
      "original_answer": "In 2023, Tesla emphasized the engineering and design maturity of the Solar Roof, highlighting its aesthetic appeal, durability, and integration with Powerwall. The company positioned Solar Roof as a customized solution within its broader energy product suite. However, by 2024, Tesla acknowledged that the production ramp of Solar Roof faced delays similar to those experienced with other products. The 2024 filing also noted that the company's future success 'depends in large part' on scaling mass-market vehicle production, which indirectly signals a potential strategic prioritization shift that could affect Solar Roof's development and deployment timelines.",
      "llm_answer": "Between 2023 and 2024, Tesla’s Solar Roof strategy shifted from scaling production amid supply‑chain and manufacturing constraints to a more controlled growth model that relies on internal battery‑cell development and tighter integration with its energy‑storage business. The company acknowledges ongoing challenges in achieving cost‑effective, high‑volume cell production and in securing reliable raw‑material supplies, which remain key dependencies for future Solar Roof expansion. Consequently, Tesla is focusing on stabilizing its manufacturing footprint and leveraging new factory capacity—particularly in Mexico and existing sites—to meet demand while mitigating the supply‑chain risks that previously hampered Solar Roof roll‑outs.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains no specific numeric values, dates, or calculations, so quantitative accuracy is not applicable—scored as 10 by default since there are no incorrect numbers. However, the qualitative accuracy is low because the answer fabricates key details not present in the ground truth. The original answer states that in 2023, Tesla emphasized the design maturity and integration of Solar Roof with Powerwall, and in 2024 acknowledged production ramp delays similar to other products, with strategic dependencies on mass-market vehicle scaling. In contrast, the LLM introduces unverified claims such as 'controlled growth model,' 'internal battery-cell development,' 'reliable raw-material supplies,' and 'new factory capacity in Mexico'—none of which appear in the original 2023 or 2024 filings referenced. The LLM also incorrectly frames battery cell production as a dependency for Solar Roof, while the ground truth emphasizes vehicle production as the strategic priority affecting Solar Roof indirectly. While the answer is contextually relevant to Tesla's Solar Roof evolution and touches on production challenges, it fails to accurately represent the actual evolution described in the filings, particularly the shift in strategic emphasis and the nature of production delays. The reasoning is not sound due to unsupported multi-hop inferences. Thus, the correctness score is low due to significant factual inaccuracies and invented details despite correct general topic alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 410,
        "total_tokens": 1763
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has NextEra Energy, Inc.'s use of Pledge Agreements evolved between 2023 and 2024, particularly in terms of the dates and counterparties involved?",
      "original_answer": "In 2023, NextEra Energy, Inc. disclosed a Pledge Agreement dated September 1, 2022, involving Deutsche Bank Trust Company Americas and The Bank of New York Mellon. By 2024, the company introduced two new Pledge Agreements dated June 1, 2024, and October 1, 2024, with the same counterparties. This indicates an evolution in the structure and timing of these agreements, expanding their use over time.",
      "llm_answer": "Based on the provided SEC 10-K filings, NextEra Energy's use of Pledge Agreements has evolved with new agreements filed in 2024. Specifically, the company filed a new **Pledge Agreement dated June 1, 2024** (Exhibit 4(ttt) in NEE_10k_2024.pdf, page 123) involving Deutsche Bank Trust Company Americas as Collateral Agent and The Bank of New York Mellon as Purchase Contract Agent. This agreement pertains to debt securities issuance. Additionally, a **Pledge Agreement dated October 1, 2024** (Exhibit 4(vvv) in NEE_10k_2024.pdf, page 123) was filed more recently, involving the same agents for another debt issuance. These filings indicate a pattern of using Pledge Agreements to secure debt obligations, with the 2024 agreements representing the most recent additions to this practice.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the evolution of NextEra Energy's Pledge Agreements from 2023 to 2024, accurately stating the two new agreements dated June 1, 2024, and October 1, 2024, with the same counterparties—Deutsche Bank Trust Company Americas and The Bank of New York Mellon—as in the 2023 disclosure. The dates and counterparties match the ground truth exactly. (2) Quantitative accuracy is perfect: both dates in 2024 are correct, and the reference to the 2023 agreement (implied by context, though not explicitly dated September 1, 2022) does not contradict the truth. The LLM omits the specific 2022 date of the earlier agreement mentioned in the original answer but correctly frames the 2024 agreements as new additions, which aligns with the evolution narrative. (3) The multi-hop reasoning is sound—comparing disclosures across years and identifying pattern changes. The LLM correctly infers increased use of Pledge Agreements over time based on new 2024 filings. The only minor gap is the lack of explicit mention of the 2022 agreement’s disclosure in the 2023 filing, which slightly weakens completeness but does not affect factual correctness. (4) Contextual relevance is excellent—the answer directly addresses the evolution in timing and counterparties, includes exhibit references and document context, and explains the purpose (debt securities issuance), adding value without straying off-topic. Overall, the answer is factually accurate and well-supported, meriting a high score with only a small deduction for incomplete backward reference to the 2022 agreement in the 2023 context.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 445,
        "total_tokens": 1743
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How has Intel's strategic positioning in Edge AI evolved from 2023 to 2024, particularly in terms of its software platform offerings and ecosystem partnerships?",
      "original_answer": "In 2023, Intel emphasized its edge-native software platform with modular building blocks, premium services, and support offerings, aiming to enable developers to build, deploy, run, manage, connect, and secure distributed edge infrastructure and Edge AI across multiple verticals. The platform was described as a horizontal approach to scaling infrastructure for intelligent edge and hybrid AI, supporting diverse architectures and avoiding vendor lock-in. By 2024, Intel's strategy had evolved under its NEX initiative, which aimed to transform networks and edge compute systems from fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud-native software on programmable hardware. Intel highlighted broader ecosystem partnerships and a focus on rapid digital transformation from cloud to edge, leveraging core strengths in compute, connectivity, software, and large-scale manufacturing. This shift indicates a more integrated and scalable approach to Edge AI, with a stronger emphasis on cloud-native programmability and collaboration with partners to drive automation and secure data integrity at the edge.",
      "llm_answer": "From 2023 to 2024, Intel’s Edge AI strategy shifted from a hardware‑centric focus to a more integrated software and ecosystem approach. In 2023 the company emphasized its Xeon Scalable processors, Gaudi AI accelerators and the broader AI ecosystem, while 2024 highlighted expanded software platforms (e.g., OpenVINO, edge‑native frameworks) and deeper partnerships with cloud, networking and OEM vendors to deliver AI‑enabled compute at the edge. This evolution reflects a move toward offering end‑to‑end solutions—combining heterogeneous silicon, optimized software stacks and collaborative ecosystem programs—to accelerate deployment of intelligent edge AI workloads.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general evolution of Intel's Edge AI strategy from 2023 to 2024 with correct contextual framing, but contains some inaccuracies and omissions in key strategic details. (1) Correct elements: The shift from hardware-centric to a more integrated software and ecosystem approach is consistent with the ground truth. Mentions of software platforms like OpenVINO and edge-native frameworks align with Intel’s direction, and referencing partnerships with cloud, networking, and OEM vendors matches the emphasis on ecosystem collaboration. (2) Quantitative accuracy: There are no numeric values (e.g., financials, percentages) in either the original or LLM answer, so this dimension is neutral; no errors present. (3) Multi-hop reasoning: The LLM correctly synthesizes a strategic evolution across time (2023 → 2024), but misses the specific NEX initiative that is central to Intel’s 2024 strategy in the ground truth. Instead, it generalizes the shift without naming the key program driving the transformation. Additionally, the 2023 description overemphasizes Xeon and Gaudi hardware, which is not the focus of the original answer—2023 was centered on the modular, edge-native software platform and horizontal scalability, not processors. (4) Semantic equivalence: While the overall direction is correct, the LLM substitutes specific strategic initiatives (e.g., NEX, cloud-native programmable hardware) with more generic terms like 'end-to-end solutions' and 'heterogeneous silicon,' which dilutes precision. The ground truth emphasizes a transformation from fixed-function to general-purpose cloud-native systems, a key technical shift not clearly conveyed. Thus, core facts are partially accurate but lack specificity and contain minor misattributions, warranting a 7 for correctness and qualitative accuracy. Contextual relevance remains high as the response directly addresses the question’s focus on software and partnerships.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1459,
        "completion_tokens": 524,
        "total_tokens": 1984
      },
      "error": null
    },
    {
      "question_id": 32,
      "question": "How did the composition and value of CVS's long-term debt related to senior notes due in 2030 evolve between 2023 and 2024, particularly regarding the 1.75% senior notes due August 2030?",
      "original_answer": "In 2023, the 1.75% senior notes due August 2030 had a value of $1,250 million. In 2024, this value remained unchanged at $1,250 million. However, other senior notes due in 2030, such as the 3.75% senior notes due April 2030, decreased from $1,500 million in 2023 to $1,500 million in 2024, indicating stability in some areas of long-term debt but no change in the 1.75% notes specifically.",
      "llm_answer": "Based on the provided pages, the composition and value of CVS's long-term debt related to senior notes due in 2030 evolved as follows:  \n- In 2023, CVS issued $1.5 billion of 5.125% senior notes due February 2030 (part of the February 2023 offering), which was used to fund general corporate purposes including the Signify Health Acquisition.  \n- By 2024, this specific 2030 maturity note remained outstanding with a principal amount of $1.5 billion, as reflected in the 2024 debt disclosures (page 168), though no new 2030-dated senior notes were issued during 2024.  \n- The 2024 debt composition (page 162) shows the 1.75% senior notes due August 2030 were still outstanding at $1.25 billion, but this was part of the broader long-term debt structure, not a new issuance related to 2030.  \n\nThus, the key evolution was the 2023 issuance of $1.5 billion in 5.125% notes due 2030, with no subsequent 2030-dated senior notes issued in 2024, while the existing 2030 notes (1.75% due August 2030) remained at $1.25 billion principal.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that the 1.75% senior notes due August 2030 had a value of $1,250 million in both 2023 and 2024, with no change. The LLM correctly identifies the $1.25 billion value for the 1.75% notes in 2024 but incorrectly introduces a $1.5 billion 5.125% senior note due February 2030 issued in 2023, which is not mentioned in the original answer and contradicts the ground truth. The ground truth references a 3.75% senior note due April 2030 decreasing from $1,500 million to $1,500 million (i.e., no change), not a 5.125% note. (2) Quantitative accuracy is partially correct: $1.25 billion for the 1.75% note matches $1,250 million, but the introduction of a $1.5 billion 5.125% note is unsupported and incorrect. The original answer does not mention any new issuance in 2023 related to 2030 notes beyond what was already outstanding. (3) The multi-hop reasoning is flawed: the LLM fabricates a new debt issuance not present in the ground truth and fails to report the actual 3.75% senior notes due April 2030. It incorrectly implies evolution due to a 2023 issuance, while the ground truth emphasizes stability with no change in value for the 1.75% notes. (4) Contextual relevance is moderate—the answer discusses long-term debt and senior notes due 2030 and addresses the 1.75% notes, but introduces irrelevant and incorrect details that distort the actual evolution. The core focus on the 1.75% notes is correct, but the synthesis is compromised by incorrect entity and numerical data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1364,
        "completion_tokens": 432,
        "total_tokens": 1797
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How did Netflix's ad-supported subscription plan evolve between 2023 and 2024 in terms of its role within the company's pricing strategy and membership growth objectives?",
      "original_answer": "In 2023, Netflix introduced the ad-supported subscription plan as a new, lower-priced option aimed at expanding its membership base and addressing competitive pressures by offering a more accessible entry point. This was part of broader efforts to adjust pricing models and membership plans to improve value perception. By 2024, the ad-supported plan had become a core component of Netflix's pricing strategy, explicitly included in a range of plans designed to meet varied consumer needs, indicating its integration into the company's long-term growth framework. This evolution reflects a shift from experimental pricing to a strategic offering intended to support sustained membership growth across different market segments.",
      "llm_answer": "Netflix's ad‑supported subscription plan was introduced as a lower‑priced tier to broaden the service’s appeal and accelerate membership growth, especially in markets where price sensitivity is higher. By offering this tier alongside its standard plans, Netflix aimed to capture additional subscribers and increase overall household penetration, supporting its goal of expanding the global member base while maintaining its target operating‑margin profile.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the core purpose of Netflix's ad-supported plan: introducing a lower-priced tier to broaden appeal, accelerate membership growth, and target price-sensitive markets. It accurately reflects the strategic intent behind the plan in line with Netflix's pricing and growth objectives. However, it omits key temporal evolution between 2023 and 2024 specified in the original answer. Specifically, it does not mention that the plan was *introduced* in 2023 as an experimental or new offering, nor does it capture the shift by 2024 where the plan became a *core, integrated component* of the long-term pricing strategy. This evolution—from new initiative to strategic pillar—is a central part of the question and missing in the LLM response. There are no numerical inaccuracies (quantitative accuracy is perfect as no numbers were misstated), and the entities (Netflix, ad-supported plan, pricing strategy, membership growth) are correct. The reasoning is sound but incomplete in terms of multi-hop synthesis across years. The answer remains contextually relevant and conveys plausible strategic rationale, but lacks the full chronological and strategic progression detailed in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 342,
        "total_tokens": 1643
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has Tesla's approach to the Tesla Semi evolved between 2023 and 2024, based on its production status and strategic positioning?",
      "original_answer": "In 2023, Tesla stated that it had begun early production and deliveries of the Tesla Semi, indicating initial market introduction and limited availability. By 2024, Tesla's production status for the Tesla Semi had advanced to 'pilot production' at its Nevada facility, suggesting a more structured and expanded phase of manufacturing, though not yet full-scale commercial production. This evolution reflects Tesla's strategic progression from initial rollout to a more mature testing and scaling phase for the commercial electric vehicle.",
      "llm_answer": "Tesla’s Semi production has shifted from pilot‑scale output at its Nevada Gigafactory to broader integration across its global manufacturing network, with the vehicle now listed alongside active models such as Model Y and Cybertruck in the company’s regional production tables.  In parallel, the Semi is being positioned as a cornerstone of Tesla’s commercial‑vehicle strategy, leveraging the same battery‑cell and powertrain technologies slated for its next‑generation platform to drive cost reductions, improve range and support the rollout of new products like the Cybercab.  This evolution reflects a strategic move to scale Semi production while tying it to Tesla’s broader goals of affordable, high‑volume electric trucks and autonomous ride‑hailing services.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2023 Tesla began early production and deliveries, and by 2024 it was in 'pilot production' at Nevada—indicating a structured but still limited phase. However, the LLM claims that production has shifted from pilot-scale to 'broader integration across its global manufacturing network' and that the Semi is now listed alongside active models like Model Y and Cybertruck in regional production tables—information not supported by the original answer and factually incorrect. There is no mention of global integration or official inclusion in broad production tables in the ground truth. (2) No specific numbers (e.g., production volumes, dates, dollar amounts) are present in either answer, so quantitative accuracy cannot be penalized for values, but the LLM fabricates progression milestones (e.g., 'broader integration', 'active models') that imply a more advanced stage than confirmed, distorting the timeline and scale. (3) The multi-hop reasoning is flawed: the original answer reflects a cautious, phased evolution from early to pilot production; the LLM incorrectly infers scaling and strategic centrality beyond what is stated. It introduces unsupported elements like the Semi being tied to Cybercab and next-generation platforms for autonomous ride-hailing—concepts absent from the original and not logically inferred from the Semi’s production status. (4) While the LLM addresses the question’s general theme—evolution in production and strategy—it does so with speculative and incorrect details, undermining factual correctness. The contextual relevance is moderate because it discusses production and strategy, but the qualitative and factual deviations severely reduce accuracy. Correctness score is low due to major factual and reasoning errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1322,
        "completion_tokens": 504,
        "total_tokens": 1826
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "What does the expansion of NextEra Energy's Executive Retention Employment Agreements from 2023 to 2024 suggest about the company's approach to leadership continuity and its strategic emphasis on executive talent retention?",
      "original_answer": "In 2023, NextEra Energy had active Executive Retention Employment Agreements with executives including Mark Lemasney (signed January 1, 2023) and Armando Pimentel, Jr. (signed February 15, 2023), indicating a focus on retaining key leadership at that time. By 2024, the company not only maintained those agreements but also introduced a new agreement with Brian Bolster, dated May 6, 2024, showing an expansion in the number of covered executives. This evolution suggests that NextEra Energy has placed increasing strategic importance on securing leadership continuity and minimizing executive turnover risk, particularly during periods of potential transition or uncertainty. The addition of new executives under retention agreements implies a proactive approach to talent management, which could signal confidence in leadership or a response to external pressures affecting executive mobility.",
      "llm_answer": "The expansion of NextEra Energy’s Executive Retention Employment Agreements from 2023 to 2024—adding new agreements with executives such as Nicole J. Daggs (effective January 1 2024) and Brian Bolster (effective May 6 2024)—signals the company’s intent to lock in its senior leadership team as it pursues continued growth and strategic initiatives. By extending retention packages, NextEra underscores a strategic emphasis on preserving proven executive talent to sustain its long‑term operational and financial objectives.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the expansion of NextEra Energy's Executive Retention Employment Agreements from 2023 to 2024 and the addition of Brian Bolster with an effective date of May 6, 2024, which matches the ground truth. However, it incorrectly introduces Nicole J. Daggs as a new executive with an agreement effective January 1, 2024, which is not present in the original answer or ground truth data. The original only mentions Mark Lemasney (January 1, 2023) and Armando Pimentel, Jr. (February 15, 2023) as prior executives, with Brian Bolster as the new addition in 2024. (2) The date for Brian Bolster (May 6, 2024) is accurate, but the inclusion of Nicole J. Daggs with a specific date introduces a factual error in both entity and date, reducing quantitative accuracy. There are no calculations in this question, so numerical correctness hinges on accurate dates and names. (3) The reasoning about leadership continuity and talent retention is sound and aligns with the original answer’s interpretation—highlighting strategic emphasis on executive retention and leadership stability. The multi-hop synthesis (comparing 2023 to 2024 agreements) is logically handled, though based on partially incorrect input. (4) The contextual relevance is high, as the answer directly addresses the question about leadership continuity and strategic emphasis. Due to the introduction of an unsupported executive (Daggs), the answer is partially incorrect, warranting a correctness score of 7—core facts about expansion and intent are right, but with significant factual overreach.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1373,
        "completion_tokens": 439,
        "total_tokens": 1813
      },
      "error": null
    },
    {
      "question_id": 33,
      "question": "How has Intel's approach to xPU products evolved from 2023 to 2024, particularly in terms of strategic focus and product development priorities?",
      "original_answer": "In 2023, Intel's focus on xPU products was part of a broader R&D strategy that included process and packaging technology, AI, and software, with $16.0 billion spent on R&D. The company faced challenges in timely product development and manufacturing process introductions, which had previously caused delays and cost overruns. By 2024, Intel had evolved its approach by embedding xPU products more deeply into its strategic priorities, specifically under the theme of 'product competitiveness.' The company announced the creation of an advisory group to expand the x86 ecosystem and emphasized the xPU family of products—including client and data center GPUs, IPUs, FPGAs, and other accelerators—as a way to meet diverse computing needs. This represents a shift from a general R&D focus to a more structured and strategic product development initiative.",
      "llm_answer": "From 2023 to 2024, Intel’s xPU strategy shifted from broad product expansion toward tighter integration with its core x86 ecosystem and AI workloads. While continuing to develop GPUs, IPUs, and other accelerators, the company emphasized unifying these xPU offerings under a common software stack (e.g., oneAPI) to improve developer adoption and platform competitiveness. This reflects a strategic pivot to leverage xPU capabilities primarily for AI, edge computing, and specialized workloads, rather than pursuing standalone market growth. Concurrently, Intel’s foundry ambitions (IFS) remain high-risk, requiring significant capital and facing intense competition, but the company is using government incentives and external partnerships to fund its advanced process technologies and manufacturing expansion.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures a strategic evolution in Intel's xPU approach from 2023 to 2024, noting increased integration with the x86 ecosystem, emphasis on AI and specialized workloads, and unification via software (oneAPI), which aligns with the ground truth's mention of improved product competitiveness and ecosystem expansion. However, it omits key factual details from the original answer, particularly the $16.0 billion R&D spend in 2023 and the explicit creation of an advisory group in 2024 to expand the x86 ecosystem—both important markers of strategic shift. (2) There are no numeric inaccuracies; the LLM does not introduce incorrect figures, though it fails to include the $16.0 billion R&D expenditure mentioned in the ground truth. Since it doesn't misstate any numbers, quantitative accuracy is full. (3) The multi-hop reasoning is partially sound: the model infers a strategic pivot toward integration and competitiveness, which is valid, but it does not fully synthesize the specific organizational actions (e.g., advisory group) or anchor the 2023 context in R&D challenges and spending. The mention of IFS and foundry ambitions, while contextually relevant to Intel’s broader strategy, is not directly tied to xPU product evolution and slightly distracts from the core focus. (4) The answer is contextually relevant and well-articulated, but the omission of key specifics—especially the R&D investment and structural changes in 2024—prevents a higher score. The semantic meaning is close but not fully equivalent to the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1415,
        "completion_tokens": 433,
        "total_tokens": 1848
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has Netflix's approach to advertising technology evolved between 2023 and 2024, particularly in terms of organizational development and infrastructure investment?",
      "original_answer": "In 2023, Netflix emphasized its limited experience with advertising and outlined several dependencies, particularly on third-party service providers for ad management and the need to attract and retain advertisers. The company also highlighted risks related to developing the necessary advertising technology infrastructure. By 2024, Netflix shifted toward a more proactive stance, emphasizing its ability to 'develop and expand an advertising sales and advertising technology organization team' and 'develop the technology and related infrastructure to support advertising and drive value to advertisers.' This indicates a strategic evolution from reliance on external providers to internal development and investment in ad tech capabilities.",
      "llm_answer": "Netflix’s advertising technology strategy has shifted from a limited, experimental offering in 2023 to a more structured, infrastructure‑focused approach by 2024.  In the 2024 filing the company emphasizes that it now has “limited experience and operating history offering advertising” and outlines a long list of risks that depend on building a dedicated ad‑sales organization, expanding ad‑technology and measurement tools, and developing the underlying ad‑delivery infrastructure.  The 2023 filing, by contrast, only mentions the nascent nature of the advertising business and the need to attract advertisers, without detailing the new organizational and technical investments.  Consequently, between 2023 and 2024 Netflix has moved to formalize an advertising sales and technology team, invest in ad‑tech platforms (including measurement, targeting and CDN capabilities), and allocate resources to support the growth of its ad‑supported subscription tier.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer contains a critical factual error in the timeline: it incorrectly states that the 2024 filing mentions Netflix having 'limited experience and operating history offering advertising,' when in fact it was the 2023 filing that emphasized this point. The original answer clearly states that in 2023, Netflix highlighted its limited experience and reliance on third parties, while in 2024 it shifted to a more proactive stance focused on internal development. The LLM reverses the years in its description, attributing the cautious, risk-focused language to 2024 when it belongs to 2023. This undermines the multi-hop reasoning and leads to an inaccurate portrayal of the evolution. While the overall direction of the strategic shift (toward building internal ad tech infrastructure) is correctly identified, and the organizational and technical investments mentioned (ad-sales team, measurement, targeting, CDN) are plausible extensions of the ground truth, they are not explicitly detailed in the original answer and appear to be elaborations. The answer is contextually relevant and well-structured, and there are no numerical inaccuracies (dates are the only quantitative elements, and their misuse is significant). However, the reversal of key content between years constitutes a major qualitative error in entity-year alignment and reasoning flow, reducing the correctness score despite the plausible narrative.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1430,
        "completion_tokens": 393,
        "total_tokens": 1823
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has Tesla's approach to free Supercharging programs evolved between 2023 and 2024, particularly in terms of revenue recognition and program structure?",
      "original_answer": "In 2023, Tesla's free Supercharging programs were included under Automotive Sales Revenue as part of the revenue associated with new vehicle deliveries, indicating they were bundled with vehicle sales and recognized over time. By 2024, Tesla began deferring revenue related to features such as FSD (Supervised), internet connectivity, and free Supercharging, recognizing these as liabilities to be amortized over time rather than immediately upon vehicle delivery. This structural shift reflects a more formalized and segmented approach to monetizing these features, including free Supercharging, which allows Tesla to better align revenue recognition with service delivery.",
      "llm_answer": "Tesla’s free Supercharging program is now treated as a distinct performance obligation that is recognized over time rather than as an upfront discount, with revenue allocated based on standalone selling price estimates and recognized on a straight‑line basis over the vehicle’s expected ownership life. The company records a liability for the value of the Supercharging benefit (included in deferred revenue) and recognizes revenue as the service is delivered, while any related guarantee or resale‑value arrangements are accounted for separately under ASC 460 and do not materially affect the deferred‑revenue balance. Consequently, between 2023 and 2024 the program shifted from being bundled into the vehicle transaction price to a separately measured, amortized revenue stream, with the associated deferred‑revenue balance growing from $3.536 billion to $3.599 billion.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key evolution in Tesla's revenue recognition for free Supercharging between 2023 and 2024—shifting from bundling with vehicle sales to deferring revenue as a separate performance obligation amortized over time. This aligns with the ground truth’s description of a structural shift toward deferring revenue and recognizing it over time. However, the LLM introduces specific deferred revenue figures—$3.536 billion in 2023 and $3.599 billion in 2024—which are not present in the original answer and cannot be verified against the provided ground truth. Since these numbers are not in the source, their inclusion constitutes a factual overreach, reducing quantitative accuracy. (2) The calculation of a $63 million increase in deferred revenue is implied but not explicitly requested; however, the use of unverified dollar amounts undermines quantitative precision. The ground truth does not provide any deferred revenue balances, so these figures appear fabricated or sourced from outside the knowledge graph, violating the requirement to reflect only the provided truth. (3) The multi-hop reasoning is sound: the model correctly infers that treating free Supercharging as a distinct performance obligation leads to deferred revenue recognition, consistent with ASC 606 principles. It also correctly contrasts the 2023 (bundled) and 2024 (deferred) approaches, demonstrating proper synthesis across time periods and accounting treatments. Mention of ASC 460 for guarantees is contextually reasonable but not in the original and adds unsupported detail. (4) The correctness score is 7 because the core conceptual shift is accurately described, fulfilling the main intent of the question. Qualitative accuracy is high due to correct terminology and logical flow, but quantitative accuracy is reduced due to unsupported figures. Contextual relevance is perfect—the response directly addresses revenue recognition and program structure evolution as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 540,
        "total_tokens": 1928
      },
      "error": null
    },
    {
      "question_id": 34,
      "question": "How has NextEra Energy's approach to issuing Series O Junior Subordinated Debentures evolved between 2023 and 2024, particularly in terms of coupon structure and maturity dates, and what might this shift indicate about their financing strategy?",
      "original_answer": "In 2023, NextEra Energy issued the Series O Junior Subordinated Debentures due on May 1, 2079, with no explicit coupon rate disclosed in the filing. This indicates a potentially fixed or deferred interest structure typical for long-dated junior subordinated instruments. By 2024, the Series O Debentures were issued with a defined coupon rate of 5.55% and a significantly shorter maturity date of November 1, 2029. This represents a strategic shift toward issuing more conventional debt instruments with shorter durations and clearly defined interest costs. This evolution suggests a possible recalibration of NextEra’s capital structure strategy, favoring shorter-term, more predictable financing over long-dated, potentially lower-yielding instruments.",
      "llm_answer": "Between 2023 and 2024, NextEra Energy's issuance of Series O Junior Subordinated Debentures reflects a strategic shift toward shorter-term, lower-coupon financing. The Series O debentures, maturing in 2029 with a 4.85% coupon (as noted in the February 4, 2025 filing), contrast with earlier series like Series N (2029 maturity, 4.95% coupon) and Series M (2034 maturity, 5.25% coupon), indicating a deliberate move to lock in shorter maturities and moderate interest costs amid evolving rate environments. This approach suggests a focus on maintaining liquidity flexibility and reducing long-term debt exposure while capitalizing on favorable market conditions for subordinated debt.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2023, NextEra issued Series O Debentures due May 1, 2079, with no disclosed coupon rate. In 2024, they reissued Series O with a 5.55% coupon and maturity on November 1, 2029. The LLM incorrectly states the 2024 coupon as 4.85%, and references a 'February 4, 2025 filing' which is not in the original data. It also conflates Series O with Series M and N, which were not part of the question. (2) Quantitative accuracy is poor: the correct 2024 coupon is 5.55%, not 4.85%; the correct 2024 maturity is November 1, 2029, not just '2029'; the 2023 maturity was May 1, 2079, not referenced at all. The LLM invents comparative data from Series M and N that were not in the original answer and are irrelevant to the evolution of Series O. (3) The multi-hop reasoning is flawed. The question focuses on the evolution of Series O specifically between 2023 and 2024. The LLM fails to capture the key shift from a very long-term (56-year) instrument with no disclosed coupon to a short-term (5-year) instrument with a high fixed coupon. Instead, it fabricates a narrative around lower coupons and references unrelated series, missing the strategic implication of moving from potentially deferrable, long-dated junior debt to conventional short-term subordinated debt. (4) Contextual relevance is moderate—the answer discusses financing strategy and maturity trends, which is relevant, but the incorrect data and misidentified instruments severely undermine the conclusion. The qualitative reasoning about liquidity and rate environments is plausible but not supported by the actual data presented in the ground truth. Thus, while the general direction of 'shorter maturities' is partially correct, the magnitude, structure, and specifics are wrong, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1383,
        "completion_tokens": 508,
        "total_tokens": 1892
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has ExxonMobil's consideration of OPEC investment activities evolved in its impairment assessment framework from 2022 to 2023, particularly in relation to long-term oil supply dynamics?",
      "original_answer": "In 2022, ExxonMobil explicitly stated that OPEC investment activities and production policies had an impact on world oil supplies and were considered in the context of impairment assessments. By 2023, while the company still acknowledged OPEC's influence on global oil supply, the discussion of OPEC was embedded more broadly within a comprehensive cash flow assessment framework that included forward-looking variables such as greenhouse gas emission costs and net-zero targets. This indicates a shift from a direct focus on OPEC's role to a more integrated view of macroeconomic and environmental factors affecting long-term asset valuation.",
      "llm_answer": "ExxonMobil’s impairment assessment framework has remained anchored in its long‑term view of oil supply and demand, but the 2023 filing shows a more explicit integration of OPEC‑related supply dynamics into that view.  In the 2022 discussion the company noted that “OPEC investment activities and production policies also have an impact on world oil supplies,” and it stressed that temporary price drops are not, by themselves, indicators of impairment, relying instead on a longer‑term price‑and‑margin outlook.  By 2023 the language is broader: the “Global Outlook and Cash Flow Assessment” section now explicitly ties OPEC policy and production decisions to the supply side of its cash‑flow models, stating that “OPEC investment activities and production policies also have an impact on world oil supplies” and that these factors are part of the assumptions used to estimate future undiscounted cash flows for impairment testing.  Thus, while the core methodology—using long‑term price and margin assumptions derived from the Corporate Plan—has not changed, the 2023 framework gives OPEC’s supply actions a more direct role in shaping those assumptions and, consequently, in the impairment evaluation of its long‑lived upstream assets.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim about the evolution of ExxonMobil's impairment assessment framework from 2022 to 2023. While it correctly quotes ExxonMobil's 2022 statement that 'OPEC investment activities and production policies also have an impact on world oil supplies,' it misrepresents the 2023 development. The LLM claims that in 2023, OPEC's role was given a 'more direct role' and 'more explicit integration' in shaping cash flow assumptions, which contradicts the ground truth. The original answer states that by 2023, discussion of OPEC was no longer highlighted as a standalone factor but was instead embedded within a broader framework that included environmental and macroeconomic variables like greenhouse gas costs and net-zero targets—indicating a relative de-emphasis on OPEC, not increased focus. The LLM incorrectly infers a strengthening of OPEC's role when the actual shift was toward a more integrated, environmentally conscious assessment framework that diluted the explicit focus on OPEC. There are no numerical values in the question or answers, so quantitative accuracy is not applicable—scored as 10 by default. Contextual relevance is high because the answer addresses the right topic, time frame, and company, and correctly identifies impairment assessments and long-term supply dynamics. However, the qualitative reasoning is flawed: the multi-hop synthesis is incorrect, as the model fails to recognize the shift from direct to embedded consideration of OPEC. This fundamental misinterpretation severely undermines the correctness and qualitative accuracy of the response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1480,
        "completion_tokens": 443,
        "total_tokens": 1923
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Netflix's approach to its ad-supported subscription plan evolved from 2023 to 2024, based on the level of detail and strategic emphasis provided in the filings?",
      "original_answer": "In 2023, Netflix's ad-supported subscription plan was mentioned in the context of uncertainty and risk, particularly around consumer adoption and the lack of operating history with such offerings, which could lead to discrepancies between forecasts and actual results. By 2024, the ad-supported plan was presented as part of the company's broader pricing strategy, explicitly included in the description of plans offered to meet a variety of consumer needs. This shift indicates a move from a risk-focused perspective to a more confident, strategic positioning of the ad-supported plan as a core part of Netflix's business model.",
      "llm_answer": "From 2023 to 2024, Netflix’s ad‑supported subscription plan shifted from a brief introductory mention in its 2023 filing—where it was described only as one of several pricing options aimed at meeting diverse consumer needs—to a more prominent strategic emphasis in the 2024 filing. The 2024 document highlights the ad‑supported tier as a key lever for growth, explicitly linking it to revenue diversification, subscriber acquisition, and the company’s broader goal of expanding its global membership base while maintaining operating‑margin targets. This reflects a clear evolution from a peripheral offering to a central component of Netflix’s monetization strategy.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains significant inaccuracies in qualitative reasoning and misrepresents the evolution described in the original answer. (1) Correct elements: The general direction of evolution—from a less emphasized offering to a more strategically integrated one—is consistent with the ground truth. The mention of diverse consumer needs and strategic emphasis in 2024 aligns with the original. There are no numeric values in the question or answers, so quantitative accuracy is not applicable; however, no incorrect numbers are introduced, warranting a full score by default. (2) Incorrect elements: The LLM mischaracterizes the 2023 portrayal. The original answer states that in 2023, the ad-supported plan was discussed in the context of *risk and uncertainty*, not merely as a 'brief introductory mention' among pricing options. This is a critical distinction—the tone was cautionary, not neutral or descriptive. The LLM omits the key point about *lack of operating history* and *forecast discrepancies*, which is central to the 2023 risk-focused perspective. (3) Multi-hop reasoning: The model fails to correctly synthesize the shift in *framing*—from risk/uncertainty (2023) to strategic integration (2024). Instead, it invents a narrative of growth levers and revenue diversification that, while plausible, is not supported in the original answer. The original does not state that the 2024 filing links the plan to 'revenue diversification' or 'operating-margin targets'—these are unsupported additions. (4) Contextual relevance is high because the answer addresses the evolution of strategic emphasis over time, but the reasoning is based on a misrepresentation of the 2023 filing. Thus, while the conclusion points in the right direction, it is not factually grounded in the provided ground truth, leading to a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 505,
        "total_tokens": 1834
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How has Amazon's approach to shipping offers evolved between 2022 and 2024, particularly in terms of cost drivers and strategic focus on fulfillment efficiency?",
      "original_answer": "In 2022, Amazon highlighted that shipping costs were expected to increase as customers increasingly adopted its shipping offers, used faster delivery methods, and as the company expanded its fulfillment network. Shipping costs in 2021 were $76.7 billion, and the company anticipated continued growth in these costs. The strategic emphasis was on mitigating these increases through higher sales volumes, network optimization, supplier negotiations, and operational efficiencies. By 2024, the focus had shifted: while the company still invested in expanding its fulfillment network, it emphasized fulfillment network efficiencies as a key cost offset. The 2024 report notes that increased sales and network investments drove up fulfillment costs, but these were partially offset by efficiency gains. This marks a strategic evolution from a customer-driven cost increase in 2022 to a more operations-centric efficiency focus by 2024.",
      "llm_answer": "Amazon’s shipping‑related costs have risen sharply as a share of net sales, climbing from roughly 15 % of sales in 2021 to about 15.4 % in 2024, driven by higher volume, larger and heavier items, expanded fulfillment capacity, and the need to fund faster, more extensive delivery options.  While fulfillment expenses grew 7 % year‑over‑year in 2024, the company is offsetting pressure through fulfillment‑network efficiencies and lower transportation costs, and it continues to treat Prime‑related shipping benefits as a strategic marketing tool rather than a direct expense.  Consequently, the focus has shifted toward improving fulfillment efficiency and scaling the logistics network to sustain growth while keeping shipping‑related cost increases in check.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies in quantitative details. The ground truth states that shipping costs in 2021 were $76.7 billion and that increases were expected in 2022 due to customer adoption and faster delivery; however, the LLM introduces a claim that shipping costs were 15% of sales in 2021 and rose to 15.4% in 2024, which is not present in the original answer and cannot be verified from the provided data. There is no mention of percentage-of-sales metrics in the ground truth, making this a significant unsupported addition. Additionally, the LLM claims a 7% year-over-year growth in fulfillment expenses in 2024, which is not mentioned or inferable from the original answer. (2) While the original answer references $76.7 billion in shipping costs for 2021, the LLM does not reference this dollar amount at all, instead shifting to unverified percentage-based metrics. This omission and substitution reduce quantitative accuracy. (3) Qualitatively, the LLM captures the strategic shift toward fulfillment efficiency and network scaling, correctly identifying that Amazon is offsetting cost pressures through network efficiencies. It also acknowledges the continued expansion of fulfillment capacity and delivery options, aligning with the original answer’s description of ongoing investment. The reasoning around efficiency as a cost offset in 2024 is consistent with the ground truth’s claim of efficiency gains partially offsetting higher costs. However, it misses the explicit contrast between 2022’s focus on volume growth and supplier negotiations versus 2024’s operations-centric efficiency focus, weakening the multi-hop synthesis. (4) Contextually, the answer is highly relevant, addressing cost drivers and strategic focus on fulfillment efficiency across the 2022–2024 period. Despite incorrect or unsupported numbers, the overall narrative direction aligns with the original, earning high marks for relevance but a moderate correctness score due to factual inaccuracies and missing key data points from the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1426,
        "completion_tokens": 556,
        "total_tokens": 1982
      },
      "error": null
    },
    {
      "question_id": 35,
      "question": "How did Duke Energy's utilization and reporting of the Master Retirement Trust evolve between 2023 and 2024, particularly in terms of asset allocation and disclosure practices?",
      "original_answer": "In 2023, Duke Energy's Master Retirement Trust was described in terms of its investment objective, focusing on achieving sufficient returns for plan benefits, with specific mention of VEBA trusts and their target and actual asset allocations. By 2024, the reporting evolved to include a more detailed breakdown of how different subsidiaries were allocated portions of the trust, such as Duke Energy Progress at 15% and Duke Energy Florida at 18%. Additionally, 2024 introduced a reconciliation of beginning and ending balances for pension and post-retirement assets, including Level 3 fair value disclosures, which was not present in 2023. This reflects a shift toward more granular and transparent reporting on trust assets and their valuation methodologies.",
      "llm_answer": "Between 2023 and 2024, Duke Energy’s Master Retirement Trust saw a shift in asset allocation and reporting practices. The 2024 fair value table shows a reduction in Level 3 assets (from $76 million to $68 million) and a modest increase in Level 2 assets, reflecting a continued emphasis on Level 2 measurements for debt securities and short‑term funds. The target allocation for 2024 moved to 45 % global equity, 35 % debt, 7 % return‑seeking debt, 4 % hedge funds and 7 % real‑estate/cash for RCBP assets, while DELPP assets shifted to 80 % liability‑hedging debt and 20 % return‑seeking assets. Disclosure practices remained consistent, with the same 27‑33‑15‑18‑5‑7‑3 % subsidiary allocation percentages used for both years and no material changes to the fair‑value hierarchy classification methodology.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and introduces unsupported quantitative details not present in the ground truth. (1) Quantitative Accuracy: The LLM claims specific Level 3 asset values ($76M to $68M), Level 2 increases, and detailed target allocations (e.g., 45% global equity, 35% debt, etc.) for RCBP and DELPP assets—none of which are mentioned in the original answer. These numbers are entirely fabricated or hallucinated. The subsidiary allocation percentages (27-33-15-18-5-7-3%) are also not in the ground truth, which only specifies Duke Energy Progress at 15% and Duke Energy Florida at 18% in 2024. (2) Completeness: While the question asks about evolution in asset allocation and disclosure practices, the LLM fails to mention the key 2024 addition of a reconciliation of beginning and ending balances for pension and post-retirement assets and Level 3 fair value disclosures, which was a major enhancement in transparency. Instead, it incorrectly states that disclosure practices 'remained consistent,' contradicting the ground truth's emphasis on increased granularity and transparency. (3) Entity Accuracy: The subsidiaries Duke Energy Progress and Duke Energy Florida are correctly identified with approximate percentages, but the rest of the allocation breakdown is invented. The terms RCBP and DELPP appear without grounding in the original answer. (4) Reasoning: The multi-hop synthesis is flawed—the model does not correctly identify the evolution in reporting depth between years and instead asserts consistency where there was change. It fabricates asset class shifts and fair value movements without evidence. (5) Semantic Equivalence: The overall message of the LLM answer contradicts the ground truth: rather than showing increased transparency and structural reporting improvements, it suggests minor portfolio tweaks and stable disclosures. This reflects a fundamental misunderstanding of the evolution described. The contextual relevance is moderate because it addresses asset allocation and disclosure, but the factual core is incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1398,
        "completion_tokens": 558,
        "total_tokens": 1957
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How has Google's financial relationship with Google Network Partners evolved between 2022 and 2024, particularly in terms of the cost structure and payment obligations?",
      "original_answer": "In 2022, Google's cost of revenues included significant Traffic Acquisition Costs (TAC) paid to Google Network partners, primarily for ads displayed on their properties, with a noted higher cost percentage compared to Google Search properties due to the substantial share of advertiser revenues paid out as TAC. By 2024, Google Network partners were referenced in the context of operating cash outflows, indicating that payments to these partners had become a primary use of operating cash. This shift suggests a transformation in the nature of the financial relationship, from a cost-of-revenue model to a more direct operational cash flow obligation, reflecting a potential increase in the scale or structure of Google's dependency on these partners.",
      "llm_answer": "Google's financial relationship with Google Network Partners has evolved significantly between 2022 and 2024, particularly regarding cost structure and payment obligations. The provided documents indicate that Google Network revenues (which include payments to partners for ads on their properties) grew as part of Google's overall revenue expansion, with Google Services operating income increasing by $25.4 billion from 2023 to 2024. This growth was partially offset by increases in content acquisition costs and TAC (Traffic Acquisition Costs), which encompasses payments to Google Network Partners. The cost structure shows that TAC and other costs of revenues are significantly higher for Google Network properties than for Google Search & other properties, as stated in the \"Cost of Revenues\" section (page 32). Additionally, the company's capital expenditures and investments in technical infrastructure (page 42) suggest ongoing strategic focus on supporting this ecosystem, while share repurchases and dividend programs (page 44) reflect broader financial priorities that may indirectly influence partner economics. The documents do not explicitly detail changes in payment terms or obligations to Network Partners specifically between 2022-2024, but the consistent emphasis on TAC as a cost component tied to Network partner revenues confirms its structural role in Google's monetization model.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains some correct elements but fails to accurately reflect the evolution in Google's financial relationship with Network Partners as described in the ground truth. (1) Correctly identifies TAC (Traffic Acquisition Costs) as a key cost component related to Google Network Partners and notes higher costs for Network properties versus Search, aligning with the 2022 data in the original answer. However, it does not correctly capture the shift from cost-of-revenue to operating cash outflow by 2024 — instead, it discusses revenue growth and operating income increases without directly addressing the transformation in payment obligations. (2) The $25.4 billion increase in Google Services operating income from 2023 to 2024 is mentioned, but this figure is not in the ground truth and cannot be verified against the provided context; no other specific TAC amounts or percentages are cited, so quantitative precision is limited. (3) The multi-hop reasoning is partially sound — it connects TAC to Network Partners and recognizes its structural role — but fails the core inference: the 2024 shift to framing partner payments as a primary use of operating cash, indicating a change in financial classification and strategic importance. (4) The mention of capital expenditures and share repurchases is contextually relevant but distracts from the specific question about cost structure and payment obligations to Network Partners. Overall, the answer provides background on TAC but misses the key evolution in financial treatment between 2022 and 2024, resulting in a partially correct but incomplete and somewhat misaligned response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1544,
        "completion_tokens": 448,
        "total_tokens": 1992
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "How did the treatment and financial impact of offsetting swap positions evolve between 2022 and 2023, particularly in terms of fair value changes and settlements reported in the consolidated income?",
      "original_answer": "In 2022, UPS reported fair value changes and settlements of interest rate swaps, foreign currency exchange forwards, and investment market price forward contracts not designated as hedges, with specific figures for 2021 and 2020 provided (e.g., $163M net gain in 2021 and $124M net gain in 2020). In 2023, the company continued to report these derivatives at fair value with unrealized gains and losses in earnings, but the disclosure now included data for 2023 and 2022, showing a shift in focus to more recent periods. The explicit mention of terminating contracts or entering into offsetting swap positions remained consistent, but the financial impact in 2023 was not quantified in the excerpt, indicating a change in transparency around current-year derivative impacts.",
      "llm_answer": "Between 2022 and 2023, the fair value of our outstanding derivative positions shifted significantly, with the notional amounts of foreign currency hedges decreasing (e.g., Euro from €4,115M to €4,408M, but HKD dropping sharply from $4,261M to $1,822M), while interest rate swaps were largely unwound or re-designated. This evolution directly impacted our consolidated income, as evidenced by the $62 million pre-tax gain in AOCI related to cash flow hedges that was expected to be reclassified to income over the next 12 months, and the $117 million net loss recognized in AOCI for 2023 (compared to a $535 million gain in 2022). Crucially, the income statement reflected a $7 million loss from fair value changes on undesignated foreign currency contracts in 2023 (versus a $69 million loss in 2022), while designated hedge adjustments to income showed a $213 million gain in revenue and $(10) million in interest expense for 2023 (down from $304 million revenue and $(10) million interest expense in 2022), indicating a material reduction in the net financial impact of derivative settlements and fair value changes on our consolidated earnings.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies and introduces numerical data not present in the original answer or ground truth. For example, it cites specific notional amounts like '€4,115M to €4,408M' and 'HKD dropping from $4,261M to $1,822M', which are not mentioned in the original answer. It also reports a '$62 million pre-tax gain in AOCI' and '$117 million net loss recognized in AOCI for 2023 (compared to a $535 million gain in 2022)', none of which appear in the ground truth. The original answer explicitly states that the financial impact in 2023 was *not quantified* in the excerpt, making these specific figures incorrect and fabricated. (2) The quantitative accuracy is very low because the LLM invents precise numbers and comparisons (e.g., $7M loss vs $69M loss, $213M gain vs $304M) that are not supported by the source. There is no mention of AOCI, reclassification gains, or line-item impacts in the original answer. (3) The reasoning is flawed in terms of multi-hop synthesis: while the question asks about the *evolution* of treatment and financial impact, the LLM assumes detailed disclosures were made in 2023, whereas the ground truth emphasizes a *reduction in transparency* and lack of quantification for 2023. The core insight of the original answer — that 2023 reporting shifted focus but lacked current-year quantification — is entirely missed. (4) Despite incorrect facts, the LLM stays contextually relevant by addressing derivative positions, fair value changes, and income statement impacts. However, the invented metrics and false precision severely undermine correctness. The answer reflects a plausible narrative but is factually unsupported, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1493,
        "completion_tokens": 474,
        "total_tokens": 1967
      },
      "error": null
    },
    {
      "question_id": 36,
      "question": "What does the increased prominence of the Directors' Savings Plan in Duke Energy's 2024 disclosures indicate about the company's director compensation strategy compared to 2023?",
      "original_answer": "In 2023, the Directors' Savings Plan was referenced primarily through historical amendments listed in exhibit references (e.g., Exhibit 10.12), with no detailed description of its structure or strategic role in compensation. In contrast, the 2024 filing provides a substantive description of the plan, explaining how outside directors may defer annual compensation, the phantom investment options available, and how balances are adjusted accordingly. This increased prominence indicates a shift toward emphasizing the plan as a core component of director compensation and deferral flexibility, suggesting a more strategic and transparent approach to director-level financial incentives in 2024.",
      "llm_answer": "The 2024 filing shows the Directors' Savings Plan receiving explicit cross‑reference treatment in Item 12 of the proxy statement and detailed disclosure of its matching contribution and deferral features in the “Equity Compensation Plan Information” table, whereas the 2023 filing only mentioned the plan in passing and did not highlight these specifics. This increased prominence indicates Duke Energy is placing greater emphasis on the Directors' Savings Plan as a core component of its director compensation strategy, using it to align director interests with shareholders and to provide a transparent, structured deferral mechanism. Consequently, the company’s director compensation approach in 2024 appears more structured and transparent, leveraging the savings plan to enhance shareholder alignment and governance.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the increased prominence of the Directors' Savings Plan in Duke Energy's 2024 disclosures compared to 2023. While the original answer notes that in 2023 the plan was referenced mainly through exhibit amendments (e.g., Exhibit 10.12) without detailed description, the LLM accurately reflects that the 2023 filing mentioned the plan only in passing. It correctly states that the 2024 filing includes detailed disclosure about deferral features and matching contributions, aligning with the ground truth's emphasis on substantive description of deferral mechanisms and phantom investment options. (2) There are no numerical values, percentages, or dollar amounts in either answer, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the model correctly infers from the change in disclosure depth (from minimal in 2023 to detailed in 2024) that there is a strategic shift toward using the plan as a core component of director compensation. It appropriately concludes that this reflects a more structured, transparent approach focused on shareholder alignment and governance, which is semantically equivalent to the original answer’s conclusion about a more strategic and transparent approach to financial incentives. (4) The only minor gap is that the LLM mentions 'matching contribution' and placement in the 'Equity Compensation Plan Information' table—details not explicitly confirmed in the ground truth—though these are plausible elements of such a plan and do not contradict known facts. This slight addition of unverified specifics prevents a perfect 10, but overall the answer is factually consistent, complete, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 475,
        "total_tokens": 1861
      },
      "error": null
    },
    {
      "question_id": 37,
      "question": "How has American Express's approach to developing value propositions evolved between 2022 and 2024, particularly in response to competitive pressures and changing customer behaviors?",
      "original_answer": "In 2022, American Express highlighted the challenge of developing compelling value propositions in the face of growing competition, particularly from alternative payment providers and digital wallets, which threatened to fragment customer spending and reduce the competitiveness of its offerings. The company emphasized the need to evolve its value propositions to retain relevance and attract customers amid rising Card Member rewards costs and shifting consumer preferences, especially in mobile and online payments. By 2024, the company's strategy had evolved to focus on expanding leadership in premium consumer and commercial payments, particularly targeting Millennial and Gen-Z consumers, and enhancing digital capabilities through investments in AI, automation, and the Amex app. It also emphasized the importance of strategic partnerships, dining platform expansion (including Tock and Rooam), and global merchant coverage growth as key enablers of its value proposition strategy. This represents a shift from a reactive stance on competition to a more proactive, innovation-driven approach.",
      "llm_answer": "American Express has refined its value proposition strategy between 2022 and 2024 by intensifying focus on premium consumer and commercial segments amid heightened competition. The company emphasizes differentiated benefits—such as enhanced rewards, exclusive services, and expanded digital capabilities—to counter competitive pressures and shifting customer behaviors, particularly among Millennial and Gen Z audiences, while reinforcing its Membership Model and cobrand partnerships to sustain growth and merchant acceptance.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in its overall direction and captures key elements of American Express's evolving value proposition between 2022 and 2024. It correctly identifies heightened competition, shifting customer behaviors (especially among Millennials and Gen Z), and a strategic focus on premium segments, digital capabilities, and cobrand partnerships. There are no numeric inaccuracies (quantitative accuracy is 10), as the answer avoids specific figures that would need to match the ground truth. However, the LLM omits several concrete strategic developments highlighted in the original answer, such as the shift from reactive to proactive innovation, specific investments in AI, automation, and the Amex app, and the expansion of dining platforms like Tock and Rooam. It also does not mention global merchant coverage growth or rising Card Member rewards costs as a 2022 challenge. While the core reasoning is sound and contextually relevant, the answer lacks the full multi-hop synthesis across years and strategic dimensions (e.g., specific enablers of the value proposition), making it partially complete. The qualitative accuracy is reduced due to these omissions, though the semantic meaning aligns broadly with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1415,
        "completion_tokens": 349,
        "total_tokens": 1765
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has Exxon Mobil's approach to long-term debt financing evolved between 2022 and 2024, particularly regarding the composition of its long-term notes?",
      "original_answer": "In 2022, Exxon Mobil disclosed a broader range of debt instruments, including the 0.142% Notes due 2024, 0.524% Notes due 2028, 0.835% Notes due 2032, and the 1.408% Notes due 2039. By 2024, the company no longer listed the 0.142% Notes due 2024, indicating that those obligations had matured or been repaid. However, the 1.408% Notes due 2039 remained in the disclosure, suggesting a continued emphasis on long-term financing instruments with distant maturity dates. This shift reflects a strategic evolution in the company's capital structure, focusing more heavily on extended-term debt while retiring shorter-duration obligations.",
      "llm_answer": "Exxon Mobil's long-term debt financing approach has evolved through the issuance of new long-term notes, as evidenced by its 2024 debt offerings (e.g., 0.524% Notes due 2028, 0.835% Notes due 2032, and 1.408% Notes due 2039) registered with the SEC. The company continues to leverage debt markets for strategic growth, including the $5 billion debt assumed in its 2024 acquisition of Pioneer Natural Resources, while maintaining a focus on market-competitive financing amid evolving energy transition dynamics.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains some correct elements but misses key aspects of the evolution in debt composition between 2022 and 2024. It correctly identifies the continued presence of the 0.524% Notes due 2028, 0.835% Notes due 2032, and 1.408% Notes due 2039 in 2024, which aligns with the ground truth. However, it fails to mention the 0.142% Notes due 2024 that were disclosed in 2022 and absent in 2024, a critical point indicating the retirement of short-term debt. This omission undermines the multi-hop comparison central to the question. (2) The $5 billion debt from the Pioneer acquisition is factually plausible but not present in the ground truth and not directly tied to the composition of long-term notes; this introduces extraneous information not supported by the provided context. The percentages and maturities mentioned are accurate, but the absence of the 2022-specific note (0.142% due 2024) results in incomplete quantitative representation. (3) The reasoning is partially sound in noting continued use of long-term debt, but it does not correctly synthesize the shift from shorter- to longer-term instruments by comparing what was removed (2024 notes) versus retained (2039 notes). The strategic evolution—retiring near-term debt while maintaining long-dated liabilities—is not clearly articulated. (4) The contextual relevance is high because the answer discusses long-term debt and recent financing activities, but correctness and qualitative accuracy are reduced due to missing comparative analysis and introduction of unsupported details like the Pioneer acquisition debt assumption. Overall, the answer captures part of the picture but fails to fully address the evolution in composition over time.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1287,
        "completion_tokens": 472,
        "total_tokens": 1760
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has American Express's approach to corporate card solutions evolved between 2022 and 2024, particularly in terms of strategic emphasis and product differentiation?",
      "original_answer": "In 2022, American Express emphasized evolving card value propositions and differentiating corporate card and accounts payable expense management solutions as part of its broader commercial payments strategy. By 2024, the company continued to focus on commercial payments but introduced a more integrated global network approach, aiming to increase merchant acceptance and provide enhanced fraud protection and marketing insights. This shift indicates a move from internal product development focus in 2022 to a more externally integrated ecosystem strategy by 2024.",
      "llm_answer": "Between 2022 and 2024, American Express shifted its corporate card strategy from a broad commercial focus toward deeper differentiation in value propositions and digital innovation. The 2022 filing emphasized expanding corporate card and accounts payable solutions within its commercial payments strategy, while the 2024 filing highlighted evolving card value propositions, innovative financing and banking features, and targeted investments in digital capabilities to strengthen merchant engagement and product differentiation. This evolution reflects a strategic pivot to enhance corporate card offerings through specialized solutions rather than scale alone.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of strategic evolution between 2022 and 2024. It accurately captures that in 2022, American Express emphasized corporate card and accounts payable solutions within its commercial payments strategy, which matches the original answer. For 2024, the LLM correctly notes a continued focus on value propositions and product differentiation, and adds accurate details about innovative financing, banking features, and digital capabilities. The mention of 'targeted investments in digital capabilities to strengthen merchant engagement' aligns with the ground truth's emphasis on an integrated global network, enhanced fraud protection, and marketing insights. However, the LLM slightly misses the specific shift toward a more externally focused, ecosystem-driven strategy centered on increasing merchant acceptance and integration, instead framing the evolution more around internal innovation and specialization. While this is not incorrect per se, it downplays the external ecosystem and network expansion aspect highlighted in the original answer. There are no numerical inaccuracies (quantitative accuracy is perfect), and all entities (American Express, 2022, 2024, corporate card solutions) are correctly identified. The reasoning is sound and synthesizes multi-hop information across years and strategic themes. The answer is fully contextually relevant and addresses both strategic emphasis and product differentiation as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 414,
        "total_tokens": 1726
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has Amazon's financial relationship with AWS Services evolved between 2022 and 2024, particularly in terms of cash flow generation and strategic emphasis?",
      "original_answer": "In 2022, AWS Services were primarily discussed in the context of competitive pressures and risks, with an emphasis on the challenges of operating in a rapidly evolving and intensely competitive market. By 2024, AWS had transitioned into a key financial contributor, with Amazon reporting $115.9 billion in operating cash flow for that year, up from $84.9 billion in 2023, driven in part by AWS and other enterprise services. This reflects a shift from viewing AWS as a risk-laden venture to a core revenue generator funding broader corporate initiatives.",
      "llm_answer": "Amazon's financial relationship with AWS Services has evolved with a clear strategic emphasis on AWS as a core growth driver, particularly evident in its capital allocation and investment patterns. Between 2022 and 2024, AWS segment revenue grew 19% year-over-year in 2024 (vs. 13% in 2023), contributing significantly to overall sales growth (11% consolidated growth in 2024), while AWS operating income and cash flow generation have been prioritized to fund infrastructure expansion. This is underscored by substantial capital expenditures ($48.1B in 2023, $77.7B in 2024) primarily directed toward AWS technology infrastructure, alongside $1.25B, $2.75B, and $1.3B investments in Anthropic convertible notes (2023–2024) and a $2.7B commitment through 2025, reflecting strategic bets on AI infrastructure. Operating cash flow surged to $115.9B in 2024 (up from $84.9B in 2023), directly supporting AWS-driven growth and reinforcing its role as a key cash flow engine that enables Amazon’s broader infrastructure investments and strategic initiatives.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth, capturing the evolution of Amazon's financial relationship with AWS from 2022 to 2024. (1) It correctly identifies the shift in strategic emphasis—from competitive risks in 2022 to AWS as a core growth and cash flow engine by 2024. While the original answer emphasizes the narrative shift more explicitly, the LLM infers this through financial and investment trends, which is valid. (2) Quantitatively, the LLM reports the correct operating cash flow figures: $115.9B in 2024 and $84.9B in 2023, matching the ground truth exactly. It also accurately cites AWS revenue growth (19% in 2024 vs. 13% in 2023) and capital expenditures ($48.1B in 2023, $77.7B in 2024), though these specific figures are not in the original answer. However, since the original answer does not contradict them and they support the same conclusion, they can be considered plausible supplemental details. The investments in Anthropic and AI infrastructure are contextually relevant and consistent with AWS's strategic direction. (3) The multi-hop reasoning is sound: the LLM synthesizes AWS's financial performance, cash flow contribution, capital allocation, and strategic investments to conclude AWS's elevated role—effectively capturing the core evolution described in the ground truth. (4) The answer is semantically equivalent in key aspects: it confirms AWS’s transition into a primary cash flow generator and strategic pillar. The only minor shortcoming is that it does not explicitly mention the 2022 'risk-laden' framing from the original, instead implying it through contrast. This slight omission prevents a perfect 10, but the overall correctness, reasoning, and relevance remain excellent.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1404,
        "completion_tokens": 473,
        "total_tokens": 1878
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How did the scope or focus of trend analyses used in evaluating the historical consistency of regulatory asset balances evolve between 2023 and 2024?",
      "original_answer": "In 2023, trend analyses were used to evaluate the historical consistency of regulatory asset balances in general, without specific reference to asset retirement obligations. By 2024, the scope of the trend analyses remained focused on regulatory asset balances, but the audit procedures expanded to include a specific evaluation of the ongoing regulatory recoverability of asset retirement obligations related to coal ash, indicating a shift in focus toward more specialized regulatory compliance areas.",
      "llm_answer": "The scope of trend analyses used to evaluate historical consistency of regulatory asset balances shifted between 2023 and 2024 from a general focus on historical consistency across multiple years (e.g., 2021‑2023) to a more targeted assessment that incorporated recent regulatory orders and specific outcomes, such as storm‑cost and fuel‑cost recoverability, and included independent expectation testing and detailed monitoring of ongoing regulatory proceedings.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect in terms of factual content despite being contextually relevant to the topic. (1) The original answer states that in 2023, trend analyses evaluated the historical consistency of regulatory asset balances generally, and by 2024, the focus expanded to include the regulatory recoverability of asset retirement obligations related to coal ash. The LLM answer instead claims the shift involved storm-cost and fuel-cost recoverability, independent expectation testing, and monitoring of regulatory proceedings—none of which are mentioned or supported in the ground truth. (2) There are no numeric values in the question or answers, so quantitative accuracy is not applicable beyond correct use of years (2023–2024), which the LLM gets right. (3) The multi-hop reasoning is flawed: the LLM invents specific regulatory areas (storm and fuel costs) and audit procedures not present in the original data, failing to correctly synthesize the evolution from general consistency checks to a focus on coal ash-related asset retirement obligations. (4) While the answer addresses the general theme of evolving audit focus, it misrepresents the specific evolution, resulting in low qualitative and overall correctness scores. The contextual relevance is moderate because it discusses trend analysis evolution in regulatory assets, but the specifics are factually wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1242,
        "completion_tokens": 383,
        "total_tokens": 1625
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How did Costco's strategy regarding the penetration of private-label items evolve between 2022 and 2023 in response to cost and pricing pressures?",
      "original_answer": "In 2022, Costco responded to higher-than-recent inflation in merchandise costs by employing several strategies, including absorbing some cost increases internally, purchasing earlier and in larger volumes, and selectively passing on cost increases to members, all of which were aimed at maintaining pricing authority while managing gross margin pressures. In 2023, Costco continued to emphasize increasing the penetration of its private-label items as part of its broader merchandising and pricing strategy to adapt to ongoing cost increases and competitive pressures. This indicates a shift from a more reactive approach in 2022 to a more strategic and sustained emphasis on private-label offerings in 2023 to maintain competitive pricing and member value.",
      "llm_answer": "Costco’s strategy regarding private‑label items shifted between 2022 and 2023 as it sought to offset rising merchandise costs and pricing pressures. In 2022, the company noted that “merchandise costs in 2022 were impacted by inflation higher than what we have experienced in recent years” and responded by “working with our suppliers to share in absorbing cost increases, earlier‑than‑usual purchasing and in greater volumes, offering seasonal merchandise outside its season, as well as passing cost increases on to our members,” while also “reducing prices on merchandise to drive sales or meet competition and holding prices steady despite cost increases instead of passing the increases on to our members, all negatively impacting gross margin.” By 2023, Costco continued to emphasize cost control and pricing authority, stating that “our investments in merchandise pricing may include reducing prices on merchandise to drive sales or meet competition and holding prices steady despite cost increases instead of passing the increases on to our members,” indicating a continued reliance on private‑label pricing discipline to manage cost pressures while maintaining competitive member prices.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in terms of dates, entities, and quoted language from Costco's disclosures, and there are no numerical inaccuracies (quantitative accuracy is perfect). The response correctly identifies that in 2022, Costco faced inflationary cost pressures and responded with supplier collaboration, early and bulk purchasing, selective price pass-throughs, and absorbing some costs—actions that impacted gross margins. It also correctly notes that in 2023, Costco continued investing in pricing by holding prices steady or reducing them despite cost pressures. However, the LLM answer does not explicitly state that Costco 'increased the penetration of private-label items' as a strategic shift in 2023, which is the core of the original answer. While it mentions 'private-label pricing discipline,' it fails to clearly articulate the evolution from a reactive 2022 strategy to a more strategic, sustained emphasis on expanding private-label penetration in 2023. This omission affects qualitative accuracy and completeness, as the multi-hop synthesis—comparing strategic emphasis across years—is weakened. The context and relevance are strong, and the answer is well-grounded in the source material, but the key strategic evolution regarding private-label penetration is underemphasized and not clearly articulated, leading to a correctness score of 7 rather than higher.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1487,
        "completion_tokens": 384,
        "total_tokens": 1872
      },
      "error": null
    },
    {
      "question_id": 38,
      "question": "How has the financial outlook for Paxlovid evolved between 2023 and 2024 based on Pfizer's remaining performance obligations?",
      "original_answer": "In 2023, Pfizer did not disclose specific remaining performance obligations for Paxlovid. However, by the end of 2024, Pfizer reported that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, indicating a clear financial commitment from customers for future delivery of the product. This evolution suggests increased contractual certainty and forward-looking revenue expectations for Paxlovid between the two years.",
      "llm_answer": "Based on the document pages, particularly page 109 and page 110, the financial outlook for Paxlovid has shifted markedly from 2023 to 2024. In 2023, Paxlovid generated $1.279 billion in revenue, but by 2024 that figure rose to $5.716 billion, reflecting the transition to commercial sales and a $771 million favorable adjustment to prior revenue estimates. However, the “Remaining Performance Obligations” disclosed on page 109 indicate that contracted revenue expected from future Paxlovid deliveries is now only about $1 billion, showing that the bulk of the product’s revenue surge has largely subsided and that future earnings from Paxlovid will be limited to the remaining $1 billion of committed contracts through 2028.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. The ground truth states that Pfizer did not disclose specific remaining performance obligations (RPO) for Paxlovid in 2023, but the LLM incorrectly claims RPO is 'now only about $1 billion' as of 2024 without clarifying that this figure was not available for 2023—thus misrepresenting the evolution. More critically, the LLM introduces revenue figures ($1.279 billion in 2023 and $5.716 billion in 2024) and a '$771 million favorable adjustment' that are not mentioned in the original answer and cannot be verified from the provided ground truth. These numbers, while possibly present in actual filings, are not part of the knowledge graph truth and thus make the response factually incorrect. The mention of 'contracted revenue through 2028' also adds unsupported detail. While the LLM correctly identifies that $1 billion in RPO was reported as of December 31, 2024, and infers reduced future revenue potential, the original answer frames the $1 billion RPO positively—as increased contractual certainty—not as a sign that revenue has 'subsided.' This misinterpretation affects reasoning and tone. The answer is contextually relevant and attempts multi-hop reasoning (comparing disclosure practices and inferring outlook), but the incorrect numbers and flawed logic undermine accuracy. Semantic equivalence fails due to unsupported data and contradictory interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 404,
        "total_tokens": 1697
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has American Express's use and assumptions around the Reasonable and Supportable (R&S) Period evolved between 2022 and 2024 in estimating credit loss reserves, and what does this indicate about the company's approach to financial risk management?",
      "original_answer": "In 2022, American Express explicitly described its use of the R&S Period as a key component in estimating reserves for credit losses on Card Member loans, incorporating historical loss experience and current/future economic conditions over that period. The reserves stood at $3.3 billion as of December 31, 2021, and the R&S Period was a central assumption in modeling expected credit losses. By 2024, while the R&S Period was still referenced, it was no longer introduced as a newly explained concept and instead appeared embedded within a more mature and established process, indicating it had become a standard part of the company's financial risk modeling framework. This evolution suggests a shift from introducing the methodology (2022) to relying on it as a foundational element in credit loss estimation (2024).",
      "llm_answer": "American Express has extended its Reasonable and Supportable (R&S) Period for estimating credit loss reserves from a shorter historical window to a longer, forward-looking horizon—explicitly incorporating current and projected economic conditions beyond the balance sheet date—reflecting a strategic shift toward more forward-looking risk management. This evolution, underscored by auditors as involving significant judgment in determining the R&S Period and associated loss rates, indicates a proactive approach to financial risk management, prioritizing forward-looking economic assumptions over reliance solely on historical loss data.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant inaccuracies in describing the evolution of American Express's R&S Period. While the original answer states that the R&S Period was explicitly introduced and explained in 2022 and became a standard, embedded part of the framework by 2024, the LLM incorrectly claims that the period was 'extended' from a 'shorter historical window to a longer, forward-looking horizon'—a detail not supported by the ground truth. There is no mention of a change in the length or scope of the R&S Period; rather, the evolution was in how prominently it was discussed and its integration into established processes. (2) Quantitatively, the LLM answer does not include any specific numbers (e.g., the $3.3 billion reserve as of December 31, 2021), which were present in the original answer and relevant to the timeline. While no incorrect numbers are stated, the omission of key figures reduces quantitative accuracy. The years 2022 and 2024 are correctly referenced, but no financial metrics are provided to anchor the claims. (3) The multi-hop reasoning is flawed: the LLM infers a strategic 'extension' of the R&S Period and a shift in methodology based on tone, but the ground truth indicates no such change in assumption—only in presentation and maturity of use. The conclusion about 'proactive risk management' and 'prioritizing forward-looking assumptions' goes beyond the evidence provided in the original answer, which only notes the R&S Period became a standard part of the framework. (4) Contextual relevance is moderate—the answer addresses the right topic (R&S Period in credit loss estimation) and the general direction of increased maturity in risk modeling, but misrepresents the nature of the evolution. The qualitative accuracy is low because the core reasoning is based on an unsupported claim of methodological extension rather than the actual shift from explanatory to embedded usage.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1390,
        "completion_tokens": 522,
        "total_tokens": 1913
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has Amazon's approach to debt financing evolved between 2022 and 2024, particularly with respect to the 0.800% Note due 2025?",
      "original_answer": "In 2022, Amazon's filings referenced the 0.800% Note due 2025 as part of its broader debt structure, originally introduced in the Officers' Certificate dated June 3, 2020. By 2024, Amazon not only continued to reference the 0.800% Note due 2025 in its filings but also introduced new debt instruments with different interest rates and maturity dates, such as the 4.600% Note due 2025. This indicates a shift in Amazon's debt financing strategy, incorporating a wider range of interest rates and maturities to potentially manage cash flow and interest rate risk more effectively.",
      "llm_answer": "Amazon's debt financing strategy has evolved to include multiple low‑interest notes with staggered maturities, most recently the 0.800% Note due 2025 introduced in the June 2020 Officers' Certificate (page 74) and later supplemented by the December 2022 issuance of additional 4.6% notes due 2025 (page 75). These filings show a continued reliance on long‑dated, low‑coupon debt to manage liquidity while extending maturities beyond 2025.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the 0.800% Note due 2025 and its origin in the June 3, 2020 Officers' Certificate, aligning with the ground truth. It also correctly references the introduction of a new note in December 2022—the 4.600% Note due 2025—which matches the multi-hop requirement of comparing Amazon's debt strategy across 2022 and 2024. However, the LLM implies the 4.6% note was issued in December 2022, while the ground truth does not specify the issuance date, only that it was referenced in 2024 filings. This introduces a potentially inaccurate detail not confirmed in the original answer. (2) Quantitatively, the percentages (0.800%, 4.600%), maturity year (2025), and reference to the 2020 Officers' Certificate are correct. The mention of 'page 74' and 'page 75' may reflect document-specific metadata not present in the ground truth, but these do not contradict facts. (3) The reasoning correctly infers a strategic shift toward diversified debt instruments with varying coupons, supporting the conclusion of evolving debt management. However, the LLM overreaches slightly by stating Amazon is issuing 'staggered maturities' and 'extending maturities beyond 2025'—a point not explicitly supported in the original answer, which focuses on the coexistence of different interest rates rather than maturity extension. (4) The answer is contextually relevant and captures the core evolution in Amazon’s debt strategy, but includes minor unsupported details (issuance timing, maturity extension), reducing its qualitative and quantitative accuracy slightly. Overall, the answer is factually strong but not fully precise in synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1249,
        "completion_tokens": 453,
        "total_tokens": 1703
      },
      "error": null
    },
    {
      "question_id": 39,
      "question": "How has the treatment or disclosure of the Twenty-third Supplemental Indenture evolved between the 2022 and 2024 SEC filings, and what does this indicate about its ongoing relevance or status?",
      "original_answer": "In the 2022 filing (DUK_10k_2022.pdf), the Twenty-third Supplemental Indenture was explicitly listed and dated June 1, 1978, incorporated by reference to Exhibit 2(c), File No. 2-61611. However, in the 2024 filing (DUK_10k_2024.pdf), there is no direct mention or continued reference to the Twenty-third Supplemental Indenture. Instead, the focus shifts to more recent supplemental indentures, such as the Forty-ninth Supplemental Indenture dated March 14, 2024. This indicates that the Twenty-third Supplemental Indenture was not reaffirmed or highlighted in the most recent disclosure, suggesting it may have diminished in operational or reporting significance over time.",
      "llm_answer": "The Twenty-third Supplemental Indenture has evolved from its original 1977 filing (referenced in 2022 and 2024 documents as part of historical exhibits) to a current, actively issued instrument, as evidenced by its most recent incorporation in Duke Energy Indiana’s March 1 2024 Current Report on Form 8‑K (page 253). This progression—from a historical exhibit in earlier 10‑K filings to a newly issued supplemental indenture in 2024—demonstrates that the indenture remains a living, relevant component of Duke Energy’s debt‑structure and is regularly updated to reflect ongoing financing needs.",
      "correctness_score": 1,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both factual content and reasoning. (1) Quantitatively, it misstates the date of the Twenty-third Supplemental Indenture as originating in 1977, while the ground truth correctly identifies it as June 1, 1978. More critically, it falsely claims the Twenty-third Supplemental Indenture was 'newly issued' or 'incorporated' in a March 1, 2024 Form 8-K, which directly contradicts the ground truth: the 2024 filing contains no mention of the Twenty-third Supplemental Indenture. Instead, the 2024 filing references the Forty-ninth Supplemental Indenture dated March 14, 2024—entirely different in number and date. (2) The LLM incorrectly asserts that the indenture evolved into an 'actively issued instrument' in 2024, when in fact it disappeared from disclosure, indicating reduced relevance, not increased. (3) Qualitatively, the multi-hop reasoning fails: instead of comparing the presence in 2022 to absence in 2024 and concluding diminished significance, the model fabricates a narrative of renewal and ongoing use. (4) Contextually, the answer addresses the question's structure (evolution between years, relevance) but does so with fabricated data and inverted logic, making it highly misleading. The core conclusion is the opposite of the truth: the lack of mention in 2024 suggests obsolescence, not vitality.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 375,
        "total_tokens": 1704
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How did the repurchase activity for Class C Capital Stock evolve from 2022 to 2024, and what was the total value of shares repurchased in each year?",
      "original_answer": "In 2022, Alphabet repurchased $59.3 billion of Class A and Class C shares, while in 2023 the amount increased to $62.2 billion, and in 2024 it remained high at $62.0 billion. This demonstrates a consistent and significant level of share repurchase activity over the three-year period, with a slight peak in 2023 followed by a minor decline in 2024.",
      "llm_answer": "Based on the provided SEC 10-K filings, the total value of shares repurchased by Alphabet (Class A and Class C) was $59.3 billion in 2022, $62.2 billion in 2023, and $62.0 billion in 2024. The company continued its share‑repurchase program, authorizing an additional $70 billion in April 2024, leaving $44.7 billion available for future repurchases as of December 31 2024.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the total value of shares repurchased for Class A and Class C stock in each year—$59.3 billion in 2022, $62.2 billion in 2023, and $62.0 billion in 2024—matching the ground truth exactly. These numbers are presented with correct formatting and units. (2) All numeric values are accurate and consistent with the original answer. The slight increase from 2022 to 2023 and minor decrease in 2024 are correctly implied by the figures, though not explicitly summarized as a trend. (3) The reasoning is sound: the model correctly synthesizes repurchase amounts across three years, addressing the evolution of repurchase activity. It adds context not in the original answer—specifically the $70 billion authorization in April 2024 and $44.7 billion remaining—likely from the 10-K, which enhances completeness but does not contradict the ground truth. However, the original answer emphasizes the trend ('slight peak in 2023 followed by minor decline'), which the LLM does not explicitly articulate, slightly reducing qualitative accuracy. (4) The answer is fully contextually relevant, directly addressing both parts of the question: evolution over time and annual repurchase values. The additional detail about future authorization is relevant but not required. Overall, the answer is factually excellent with only minor omission in trend interpretation, warranting a 9/10 on correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1180,
        "completion_tokens": 396,
        "total_tokens": 1577
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "What changes occurred in the treatment and documentation of the American Express Company Salary/Bonus Deferral Plan between the 2022 and 2024 SEC filings?",
      "original_answer": "In the 2022 filing, the Salary/Bonus Deferral Plan was referenced through historical amendments, including Exhibit 10.16 (1988 plan) and Exhibit 10.17 (1994 amendment). The 2024 filing reintroduces the plan through Exhibit 10.13, referencing the same 1988 plan, and also includes Exhibit 10.14, which references the 1994 amendment. Notably, the 2024 filing adds Exhibit 10.16, which incorporates the 1997 amendments to the plan. This indicates that while the foundational documentation remained consistent, the 2024 filing expanded the disclosure to include a broader historical record of amendments, providing more context on the plan's evolution.",
      "llm_answer": "The American Express Company Salary/Bonus Deferral Plan was amended and restated effective January 1, 2023 (as disclosed in the 2022 filing) and later amended again, with the most recent amendment becoming effective January 1, 2023 (as reflected in the 2024 filing). These updates modify the plan’s terms and documentation compared with the prior 2022 version.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both factual content and reasoning. The ground truth states that the treatment of the American Express Company Salary/Bonus Deferral Plan in the 2022 and 2024 filings involved changes in exhibit references and the inclusion of additional historical amendments (1988, 1994, and newly in 2024, the 1997 amendment). However, the LLM claims the plan was 'amended and restated effective January 1, 2023' in both the 2022 and 2024 filings, which contradicts the ground truth—no such amendment date is mentioned, and it is illogical for a 2022 filing to disclose an amendment effective in 2023. (2) Quantitative accuracy is poor: the date 'January 1, 2023' is factually incorrect and not supported by the original answer. There are no accurate numbers or dates in the LLM response that align with the ground truth. (3) The multi-hop reasoning is flawed—the question requires comparing exhibit disclosures across two filings to identify changes in documentation, but the LLM fabricates an amendment timeline instead of analyzing exhibit references (e.g., Exhibit 10.16 in 2022 vs. Exhibits 10.13, 10.14, and new 10.16 in 2024). It fails to mention any exhibit numbers or the key point about expanded historical documentation in 2024. (4) Contextual relevance is moderate because the answer addresses the plan and the general idea of changes between filings, but the substance is factually wrong. Correctness and quantitative accuracy are low due to invented dates and amendments; qualitative accuracy is slightly higher only because it attempts to discuss plan modifications, albeit incorrectly.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1254,
        "completion_tokens": 449,
        "total_tokens": 1703
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has Starbucks' exposure to interest rate swaps evolved between 2022 and 2024, particularly in terms of their balance sheet classification and magnitude of liability?",
      "original_answer": "In 2022, Starbucks reported an interest rate swap liability of $34.0 million under 'Other long-term liabilities'. By 2024, the company's interest rate swap position had shifted significantly, with a liability of $19.2 million under 'Other long-term liabilities' and an additional $41.4 million liability from interest rate swaps reported for the prior year (2023), indicating a decrease in liability from the previous year but a continued significant exposure. This reflects a transformation in the company's interest rate swap position, with a shift in balance sheet classification and a notable reduction in total swap liability.",
      "llm_answer": "Between 2022 and 2024, Starbucks' interest rate swap liability shifted from a $34.0 million non‑current liability in 2022 to a $19.2 million non‑current liability in 2023 and further to $19.2 million non‑current (with a $17.8 million cumulative fair‑value hedge adjustment) in 2024, reflecting a reduction in the notional amount and the related hedge accounting adjustment. The company continues to report these swaps as non‑current derivative liabilities on the balance sheet, with the fair‑value hedge adjustment decreasing over time.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partial correctness but has significant factual inaccuracies. It correctly identifies the 2022 liability as $34.0 million and the 2023/2024 liability as $19.2 million under non-current liabilities, which aligns with the ground truth. However, it introduces a $17.8 million cumulative fair-value hedge adjustment in 2024 that is not mentioned in the original answer and is not supported by the provided ground truth. Additionally, the LLM incorrectly implies that the $19.2 million figure applies to both 2023 and 2024 without acknowledging the additional $41.4 million liability reported for 2023, which is a key part of the multi-hop comparison. (2) The numbers for 2022 and the 2023–2024 liability are accurate, but the introduction of an unverified $17.8 million adjustment and omission of the $41.4 million 2023 liability constitute major quantitative errors. The total liability trend is misrepresented due to missing data. (3) The reasoning is partially sound in noting a reduction in liability and consistent balance sheet classification, but it fails to capture the full evolution across three years, especially the spike in 2023 and subsequent decline. The synthesis across years is incomplete, missing the critical point about a 'continued significant exposure' due to prior-year liabilities. (4) The answer is contextually relevant and addresses the question's focus on balance sheet classification and magnitude, but the omission of key figures and introduction of unsupported ones reduces factual reliability. While the direction of change (decrease) is correct, the magnitude and structure of the exposure are misrepresented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 458,
        "total_tokens": 1755
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has the treatment of the Directors' Savings Plan evolved between 2022 and 2024, and what does this suggest about Duke Energy's approach to director compensation governance and deferral mechanisms?",
      "original_answer": "In 2022, the Directors' Savings Plan was formally introduced in the 10-K filing with a specific amendment dated December 16, 2021, indicating active documentation and policy updates around director deferrals. By 2024, the plan is referenced in the context of phantom investment options and deferred compensation mechanics, with an emphasis on unfunded accounts tied to the Duke Energy Common Stock Fund. This evolution suggests a shift from policy establishment to operational transparency, highlighting how deferrals are structured and invested, which may reflect a broader governance strategy to align director compensation with long-term shareholder interests and company stock performance.",
      "llm_answer": "The Directors' Savings Plan was first established in 2014 with an amendment effective December 16 2021, and the 2024 filing notes that the plan is incorporated by reference in the company’s proxy materials, indicating that Duke Energy continues to use the plan as part of its director compensation governance and deferral mechanisms. This consistent inclusion suggests a stable approach to aligning director compensation with long‑term equity incentives while allowing deferral of compensation.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains partial correctness but introduces a factual inaccuracy by stating the plan was 'first established in 2014,' which is not supported by the ground truth; the Original Answer states it was 'formally introduced in the 10-K filing' with an amendment dated December 16, 2021, suggesting 2022 as the key documentation year. The December 16, 2021 amendment date is correctly cited, aligning with the ground truth, but the claim of a 2014 establishment lacks support in the provided data. (2) Quantitatively, the only specific date mentioned—December 16, 2021—is accurate and matches the ground truth. However, the introduction of an unverified earlier date (2014) undermines quantitative reliability. No financial figures are involved, so numerical accuracy is not applicable beyond dates. (3) The reasoning is partially sound: the LLM correctly infers that continued reference in 2024 indicates ongoing use of the plan and links this to director compensation governance and deferral mechanisms. However, it fails to capture the evolution described in the ground truth—from policy establishment (2022) to operational transparency with phantom investments and unfunded accounts tied to stock performance (2024). This key shift in emphasis is missing, indicating a failure in multi-hop synthesis across years. (4) The answer is contextually relevant and addresses the broader question about Duke Energy’s approach to director compensation, but it lacks the nuanced evolution (from introduction to detailed mechanics) and misses the implication about aligning director interests with shareholders through structured deferrals in company stock. Thus, while the general direction is correct, the depth and factual precision required for full accuracy are insufficient.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1310,
        "completion_tokens": 487,
        "total_tokens": 1797
      },
      "error": null
    },
    {
      "question_id": 40,
      "question": "How has the positioning and associated risk profile of Costco's Kirkland Signature brand evolved between 2022 and 2023?",
      "original_answer": "In 2022, Costco emphasized the Kirkland Signature brand as a strategic asset, highlighting its high quality, competitive pricing, and contribution to higher margins. The company planned to continue increasing the sales penetration of these private-label items. However, by 2023, the risk disclosures included broader mentions of how supply chain disruptions, foreign exchange fluctuations, and catastrophic events could negatively impact the business—including private-label brands like Kirkland Signature. While the 2022 filing focused on growth and brand strength, the 2023 filing introduced a more risk-focused lens, indicating that the brand's expansion and reliance could expose Costco to greater operational and financial volatility.",
      "llm_answer": "Between 2022 and 2023, Costco’s Kirkland Signature brand evolved from a primarily private-label, value-focused offering to a more strategically emphasized growth driver, with its sales penetration rising to represent approximately 71% of worldwide net sales in 2022 and continuing to expand internationally. This positioning reflects a deliberate shift toward leveraging Kirkland Signature as a key differentiator—emphasizing high quality, competitive pricing, and broad category coverage—to strengthen member loyalty and drive sales, while simultaneously increasing exposure to supply chain complexities, private-label-specific risks (e.g., supplier reliability, quality control), and the need for sustained investment in product development and marketing to maintain its market share amid intensifying competition from other retailers and private-label brands.",
      "correctness_score": 5,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly the claim that Kirkland Signature represented approximately 71% of worldwide net sales in 2022—this specific percentage is not present in the ground truth and cannot be verified from the provided context. No quantitative sales figures were mentioned in the original answer, so this number is unsupported and likely incorrect. (2) There are no correct numerical values or calculations in the LLM response that align with the ground truth, as the original answer does not provide any percentages or sales figures. The introduction of a precise 71% figure constitutes a hallucination, severely impacting quantitative accuracy. (3) The qualitative reasoning partially aligns with the ground truth: the LLM correctly identifies a strategic shift in positioning Kirkland Signature as a growth driver and differentiator, emphasizing quality and pricing. It also appropriately notes increased exposure to supply chain risks and supplier dependencies, which is consistent with the 2023 risk-focused evolution. However, the original answer emphasizes a shift in risk disclosure tone—from growth emphasis in 2022 to heightened risk awareness in 2023—rather than an operational expansion or international growth, which the LLM introduces without support. (4) Contextual relevance is high because the response addresses the evolution of positioning and risk profile, discussing both strategic importance and associated vulnerabilities. While the direction of reasoning is sound, the inclusion of fabricated data undermines overall correctness. The model captures the conceptual shift but fails on factual precision, especially in unsupported quantitative claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1393,
        "completion_tokens": 472,
        "total_tokens": 1866
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How did COP's natural gas reserves in the Asia Pacific/Middle East region evolve from 2022 to 2024, and what were the key changes in terms of volume and sources of additions?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas reserves in the Asia Pacific/Middle East region. By 2024, this figure decreased slightly to 296 billion cubic feet. Over this period, the company experienced revisions and production activities that impacted reserves, with minimal extensions and discoveries contributing to the region. In 2024, there were no sales or significant reserve additions in this region, indicating a reduction in focus or activity compared to earlier years.",
      "llm_answer": "From 2022 to 2024, ConocoPhillips’ proved natural gas reserves in the Asia Pacific/Middle East region grew from **50 billion cubic feet (BCF) at the end of 2022 to 62 BCF at the end of 2024**. The increase was driven by **upward revisions (≈ 12 BCF)**, **purchases (≈ 14 BCF from the Marathon Oil acquisition)**, and **extensions and discoveries (≈ 17 BCF)**, while production and sales modestly reduced the base. Consequently, the region’s gas reserve volume rose by about **12 BCF** over the two‑year period, with the primary sources of additions being revisions, acquisitions, and new discoveries.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is almost entirely incorrect and contradicts the ground truth in both direction and magnitude of change. (1) Quantitatively, the LLM claims reserves grew from 50 BCF in 2022 to 62 BCF in 2024, while the ground truth states reserves were 326 BCF in 2022 and decreased to 296 BCF in 2024—a reduction of 30 BCF, not an increase of 12 BCF. All cited figures (50, 62, 12, 14, 17 BCF) are factually wrong. (2) The LLM incorrectly attributes reserve growth to major additions like purchases (Marathon acquisition), extensions, and discoveries, while the original answer states there were 'minimal extensions and discoveries' and 'no sales or significant reserve additions' in 2024. There is no mention of Marathon Oil or any acquisition contributing to this region. (3) The reasoning is flawed: the LLM suggests a net increase due to positive additions, whereas the correct narrative is a decline due to production and revisions with little replenishment. (4) The entities (COP, Asia Pacific/Middle East region, years 2022–2024) are correctly identified, and the question is relevantly addressed in structure, but the factual content is completely inaccurate. Thus, the answer fails on quantitative and qualitative accuracy despite addressing the right region and timeframe.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1280,
        "completion_tokens": 356,
        "total_tokens": 1637
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has FedEx's strategic relationship with the Boeing 767F evolved between 2022 and 2024, particularly in terms of fleet ownership and modernization focus?",
      "original_answer": "In 2022, FedEx directly owned 114 Boeing 767F aircraft, indicating a significant owned asset position in its fleet strategy. By 2024, while no updated ownership figures were disclosed, FedEx emphasized the Boeing 767-300 Freighter (B767F) as a key component of its aircraft modernization programs. The company described these aircraft as significantly more fuel-efficient per unit than older models and noted that expenditures for these aircraft are necessary for long-term operating savings and fleet replacement, with limited flexibility to delay purchases without incurring significant costs.",
      "llm_answer": "Between 2022 and 2024, FedEx's strategic relationship with the Boeing 767F evolved from a fleet modernization focus to a more structured acquisition and commitment framework. In 2022, FedEx had significant purchase commitments for B767F aircraft, with deliveries expected through 2026, supported by $1.3 billion in deposits and progress payments for aircraft purchases, including B767F and B777F models. By 2024, the company formalized its fleet modernization strategy, committing to the acquisition of B767F aircraft as part of broader efforts to replace older, less fuel-efficient models with more efficient aircraft like the B777F and B767F. The 2024 SEC filing details a structured delivery schedule for B767F aircraft (11 units in 2025, 3 in 2026), emphasizing that these purchases are critical for long-term fuel efficiency and operational savings, with limited flexibility to delay without incurring significant costs to modify existing agreements. This reflects a shift from the 2022 commitment to a more defined, execution-focused procurement strategy with clear delivery timelines.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains several inaccuracies in quantitative details and misrepresents the evolution described in the ground truth. (1) The original answer states that FedEx directly owned 114 Boeing 767F aircraft in 2022; the LLM answer omits this ownership figure entirely and instead introduces unverified 'purchase commitments' and '$1.3 billion in deposits and progress payments' not mentioned in the ground truth, making the quantitative claims unsupported. (2) The LLM claims a delivery schedule of '11 units in 2025, 3 in 2026' for B767F aircraft, which is not present in the original answer and cannot be verified against the provided truth. (3) While the original answer notes that no updated ownership figures were disclosed in 2024, the LLM implies continued acquisition and structured delivery without confirming whether this aligns with disclosed data—this adds detail beyond the source. (4) The qualitative shift described—'from fleet modernization focus to structured acquisition'—is a reasonable interpretation, and the emphasis on fuel efficiency, operational savings, and limited flexibility to delay matches the original answer. (5) The core theme of modernization using B767F as a key component is correctly identified, and the strategic rationale (fuel efficiency, replacement of older models) is consistent. However, the introduction of specific financial figures and delivery timelines not present in the ground truth significantly undermines quantitative accuracy. The answer is contextually relevant and captures the general strategic direction, but fails on factual precision for key metrics and dates, resulting in a partial correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1424,
        "completion_tokens": 453,
        "total_tokens": 1877
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How did Starbucks' involvement with roasted coffee evolve from 2022 to 2024 in terms of inventory value and production infrastructure?",
      "original_answer": "In 2022, Starbucks reported an inventory value of roasted coffee at $310.3 million, reflecting its role in holding roasted coffee as part of its merchandise. By 2024, the company had expanded its infrastructure dedicated to roasting, with facilities in York, PA; Minden, NV (Carson Valley); Kunshan, China; and Kent, WA, indicating a significant increase in its direct involvement in the roasting process. This represents a shift from primarily holding roasted coffee inventory to actively producing and distributing it at scale.",
      "llm_answer": "From 2022 to 2024, Starbucks’ roasted coffee inventory rose sharply from $310.3 million to $380 million, reflecting higher roasted‑coffee stock and related supply‑chain commitments, while the company expanded its roasting and distribution infrastructure—highlighted by a $838.5 million investment in roasting equipment and a network of owned/leased facilities (e.g., York, PA; Minden, NV; Shanghai, China)—to support the growing inventory and global store operations.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in quantitative claims. While it correctly states Starbucks' 2022 roasted coffee inventory value as $310.3 million (matching ground truth), it falsely claims the 2024 inventory rose to $380 million—this figure is not present in the original answer and is unsupported. Additionally, the LLM introduces a $838.5 million investment in roasting equipment, which is entirely fabricated and not mentioned in the ground truth. (2) The locations cited are mostly accurate—York, PA; Minden, NV; and a facility in China (though 'Shanghai' is less precise than 'Kunshan, China' in the original)—but Kent, WA is omitted. The expansion of infrastructure is correctly identified as a trend, but the financial backing and inventory growth figures are incorrect. (3) The multi-hop reasoning is partially sound: the model connects inventory and infrastructure changes over time and infers increased involvement in roasting, which aligns with the original conclusion. However, the use of false financial data undermines the reasoning's reliability. (4) Contextual relevance is high because the answer addresses both inventory value and production infrastructure evolution. However, due to major quantitative errors and unsupported claims, the correctness score is low. The qualitative accuracy is moderate because the direction of change and general strategy are plausible, but not fully accurate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1246,
        "completion_tokens": 405,
        "total_tokens": 1651
      },
      "error": null
    },
    {
      "question_id": 41,
      "question": "How has PepsiCo's utilization of the 2.750% Senior Notes due 2025 evolved between 2023 and 2024, based on the specific debt instruments referenced in the filings?",
      "original_answer": "In 2023, the 2.750% Senior Notes due 2025 were listed among other notes in a Board of Directors Resolutions document that authorized officers to establish terms for several senior notes, including the 2.750% Senior Notes due 2025. By 2024, PepsiCo not only retained the 2.750% Senior Notes due 2025 in its list of authorized instruments but also introduced a new 2.750% Senior Notes due 2030. This indicates that PepsiCo extended its debt strategy involving this interest rate to a longer-term horizon, signaling a strategic evolution in its financing approach.",
      "llm_answer": "Between 2023 and 2024, PepsiCo’s utilization of the 2.750% Senior Notes due 2025 shifted from being referenced as a 2030 maturity instrument in its 2023 filings (page 127) to being explicitly reclassified as a 2025 maturity note in its 2024 documentation (page 128), reflecting a strategic adjustment to align the instrument’s stated maturity with its actual due date. This evolution is further corroborated by the 2024 filing’s inclusion of the 2.750% Senior Notes due 2025 under new Board-authorized terms (page 130), confirming its active role in PepsiCo’s debt structure as a near-term obligation.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly claims that in 2023, the 2.750% Senior Notes were referenced with a 2030 maturity, which contradicts the ground truth. The ground truth states that in 2023, the 2.750% Senior Notes due 2025 were authorized, and in 2024, PepsiCo introduced a new 2.750% Senior Notes due 2030. The LLM reverses this logic, suggesting a reclassification from 2030 to 2025, which is factually wrong. (2) There are no correct numerical or date-based assertions in the LLM answer that align with the ground truth: the claim about 'page 127' and 'page 128' reclassification is unsupported and incorrect. The ground truth does not mention any mislabeling or correction of maturity dates. (3) The multi-hop reasoning is flawed. Instead of recognizing that PepsiCo extended the use of the 2.750% rate to a longer-term instrument (2030), the LLM falsely infers a correction in maturity labeling, which is not supported by the original answer. This reflects a fundamental misunderstanding of the evolution in debt strategy. (4) While the answer is framed around the correct topic—PepsiCo's use of 2.750% Senior Notes—and mentions Board authorization, the core facts and direction of change are inverted. Thus, despite some contextual relevance, the answer is mostly incorrect, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1294,
        "completion_tokens": 381,
        "total_tokens": 1676
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How did FedEx's planned utilization of the B777F aircraft change from 2022 to 2024, and what does this indicate about its strategic role in the fleet?",
      "original_answer": "In 2022, FedEx planned to operate 4 B777F aircraft in 2024 and 2 in 2025. By 2024, the updated plan showed 2 B777F aircraft operating in 2025, with no further plans beyond that year. This indicates a reduction in the strategic emphasis on the B777F fleet, moving from a gradually decreasing role to a complete phase-out, suggesting a shift in aircraft preference or operational strategy.",
      "llm_answer": "From 2022 to 2024 FedEx’s planned utilization of the B777F aircraft increased from **2 units in 2022 to 2 units in 2024** (the same absolute number, but the 2024 schedule shows the B777F deliveries moving into later years—2025‑2026—while the 2022 table placed them in 2023‑2024). This reflects a shift in the fleet plan toward later delivery windows and a broader modernization effort that emphasizes both B777F and B767F aircraft for greater fuel efficiency and long‑term operating savings. Consequently, the B777F’s strategic role is evolving from an immediate, near‑term capacity boost to a more staggered, future‑focused addition that supports long‑term efficiency goals rather than short‑term expansion.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in both direction and magnitude of the change in B777F utilization. The ground truth states that in 2022, FedEx planned to operate 4 B777F aircraft in 2024 and 2 in 2025, but by 2024, the plan changed to only 2 in 2025 and none beyond — indicating a reduction and phase-out. The LLM incorrectly claims utilization 'increased' or remained steady at 2 units, and falsely states that in 2022 the plan was for 2 units in 2022 (not 2024), misrepresenting both the timeline and the number. (2) The numbers are wrong: the original answer specifies 4 B777Fs planned for 2024 in the 2022 plan, but the LLM omits this entirely and instead fabricates a '2 in 2022' figure not present in the ground truth. It also incorrectly references deliveries in '2025–2026' and '2023–2024', which are not in the original data. (3) The multi-hop reasoning is flawed: instead of recognizing a reduction and eventual phase-out, the LLM infers an increased strategic role due to delayed deliveries, which contradicts the ground truth indicating a diminished role. The synthesis fails to connect the reduction in planned aircraft and truncated timeline to a strategic de-emphasis. (4) The contextual relevance is moderate — the answer discusses fleet strategy and modernization, which is relevant, but the incorrect data leads to an opposite conclusion. Due to major factual and quantitative errors, the correctness score is low at 2, with similarly low quantitative and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1274,
        "completion_tokens": 418,
        "total_tokens": 1692
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How did Starbucks' foreign currency - other derivative liabilities and their impact on net gains/(losses) included in AOCI evolve from 2022 to 2024, and what does this indicate about the company's exposure to foreign currency fluctuations?",
      "original_answer": "In 2022, Starbucks reported foreign currency - other derivative liabilities of $0.3 million under accrued liabilities, while in 2024, the net gains included in AOCI related to foreign currency - other were $11.5 million. This indicates a significant shift from a minimal liability position in 2022 to a more substantial unrealized gain in 2024, suggesting increased exposure to or hedging of foreign currency fluctuations.",
      "llm_answer": "Based on the provided SEC 10-K filings, Starbucks' foreign currency-related derivative liabilities and their impact on net gains/(losses) in AOCI show a significant evolution from 2022 to 2024, indicating heightened exposure to foreign currency fluctuations. In 2022, foreign currency derivatives designated as hedges (including \"Foreign currency - other\" and \"Cross-currency swaps\") carried net gains of $55.3 million in AOCI, with $39.6 million expected to be reclassified to earnings within 12 months. By 2024, these balances shifted dramatically: foreign currency derivatives now show net gains of $11.5 million in AOCI (down from $55.3 million in 2022), with only $9.5 million expected to be reclassified, while cross-currency swaps under net investment hedges grew substantially (from $67.3 million to $96.5 million in AOCI). This evolution—particularly the decline in short-term reclassification amounts and the shift toward longer-term net investment hedges—reflects Starbucks' active management of currency risk, but the persistent exposure to foreign currency fluctuations (evidenced by ongoing hedging of royalty revenue, inventory purchases, and intercompany lending) confirms that such volatility remains a material operational risk, especially given the company's global supply chain and international revenue streams. The reduction in short-term reclassification figures suggests a strategic shift toward longer-duration hedges, yet the continued presence of foreign currency derivatives in AOCI underscores that currency movements will continue to materially impact earnings through AOCI reclassifications.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies compared to the ground truth. The original answer states that in 2022, Starbucks reported foreign currency - other derivative liabilities of $0.3 million (not gains of $55.3 million as claimed by the LLM), and in 2024, net gains included in AOCI related to foreign currency - other were $11.5 million. The LLM incorrectly reports $55.3 million in net gains in AOCI for 2022, which is not supported by the ground truth and conflates multiple derivative categories (e.g., cross-currency swaps) not mentioned in the original answer. Additionally, the LLM introduces figures like $39.6 million and $9.5 million expected to be reclassified to earnings, which are absent from the ground truth and cannot be verified. (2) Quantitative accuracy is low: the only correct number is the $11.5 million net gains in AOCI for 2024; all other figures (e.g., $55.3M, $39.6M, $9.5M, $67.3M, $96.5M) are either fabricated or misattributed. The ground truth does not mention cross-currency swaps or reclassification expectations, making these additions factually incorrect. (3) While the LLM attempts multi-hop reasoning by analyzing trends and inferring strategic shifts in hedging, this reasoning is based on incorrect data. The conclusion about increased exposure is partially aligned with the ground truth, but the basis—declining short-term reclassifications and shift to long-term hedges—is unsupported due to erroneous inputs. (4) Contextual relevance is high because the LLM addresses the evolution of foreign currency derivatives and their implications on exposure, which is directly relevant. However, the factual foundation is flawed, leading to an overall correctness score of 4: partially correct due to the accurate mention of the $11.5 million 2024 gain, but significantly incorrect in other key areas.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1534,
        "completion_tokens": 506,
        "total_tokens": 2040
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has PepsiCo's engagement with the 2.625% Senior Notes due 2026 evolved between 2023 and 2024, particularly in terms of its broader debt instrument disclosures?",
      "original_answer": "In 2023, the 2.625% Senior Notes due 2026 were listed among other notes in a section that included Board of Directors Resolutions authorizing officers to establish terms for various senior notes. By 2024, PepsiCo not only retained the 2.625% Senior Notes due 2026 in its disclosures but also introduced a significantly expanded list of senior notes, including newer maturities such as the 3.000% Senior Notes due 2027 and the 2.625% Senior Notes due 2029. This indicates a broader and more diversified set of debt instruments, suggesting an active capital markets strategy involving the issuance of notes with different maturities and rates.",
      "llm_answer": "PepsiCo's 2.625% Senior Notes due 2026 were first issued in 2020 and have since been reissued multiple times through 2023, with the most recent reissuance occurring in February 2023 via a $1.5 billion floating rate note tranche under its 2023 debt program. The company consistently discloses these notes in its SEC filings as part of its broader senior debt instrument framework, referencing them across multiple indentures and supplementals to detail terms, maturity dates, and authorization of new issuances. This ongoing engagement reflects PepsiCo's active management of its long-term debt structure, regularly updating disclosures to reflect market conditions and financing needs while maintaining transparency in its capital market activities.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that the 2.625% Senior Notes due 2026 were mentioned in 2023 in the context of Board of Directors Resolutions authorizing officers to set terms for senior notes, and in 2024, PepsiCo expanded its disclosed notes to include newer maturities like the 3.000% due 2027 and 2.625% due 2029. However, the LLM incorrectly claims the notes were 'first issued in 2020' and 'reissued multiple times through 2023', with a 'February 2023 $1.5 billion floating rate note tranche'—none of which appears in the ground truth and directly contradicts it. The floating rate note is a different instrument altogether. (2) Quantitative accuracy is very low: the $1.5 billion amount, the floating rate designation, and the reissuance details are all fabricated or misattributed. There is no mention of these figures or events in the original answer. (3) The multi-hop reasoning is flawed. The question asks about the evolution of engagement with the 2.625% Senior Notes due 2026 between 2023 and 2024 in the context of broader debt disclosures. The correct answer hinges on comparing disclosure scope across years—specifically, the expansion of listed notes in 2024. The LLM instead invents a narrative about reissuances and floating rate tranches, failing to recognize or report the key evolution: the broadening of disclosed senior notes. (4) Contextual relevance is moderate because the answer discusses debt disclosures and PepsiCo's debt management, which is thematically relevant, but it fails to address the actual evolution described in the ground truth. The reasoning and factual basis are unsound, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 468,
        "total_tokens": 1820
      },
      "error": null
    },
    {
      "question_id": 42,
      "question": "How has Cisco's exposure to and reliance on overcoming technical hurdles evolved from 2022 to 2024, particularly in relation to its strategic investments and product development timelines?",
      "original_answer": "In 2022, Cisco acknowledged facing technical hurdles that could delay successful execution of its vision, especially in areas like product planning, timing, and resource allocation, which could lead to loss of market share and earnings. By 2024, the company's exposure to technical hurdles had transformed into a more specific dependency on overcoming these challenges in a timely manner to maintain competitive advantage, particularly in delivering complex software subscription offerings and introducing new technologies such as those related to artificial intelligence, security, observability, and cloud. The 2024 disclosures emphasize that failure to overcome these hurdles could not only result in loss of market share but also reputational damage, legal liability, and reduced customer retention. This represents a shift from internal execution risk to a broader operational and strategic dependency.",
      "llm_answer": "From 2022 to 2024, Cisco’s reliance on overcoming technical hurdles has intensified as it accelerates investments in strategic growth areas like AI, cloud, cybersecurity, and software subscriptions. The 2024 filing highlights increased complexity in developing new offerings (e.g., post-Splunk acquisitions) and greater dependence on timely product launches to meet evolving customer demands, while acknowledging heightened risks of delays, execution failures, and competitive pressures from faster-moving rivals. This reflects a strategic shift toward recurring revenue models that require sustained technical innovation and rapid scaling of infrastructure, making technical execution a more central driver of future performance.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: Cisco's increasing reliance on overcoming technical hurdles from 2022 to 2024 is accurately portrayed, with correct emphasis on strategic areas like AI, cloud, cybersecurity, and software subscriptions. The evolution from internal execution risks (2022) to broader strategic dependency (2024) is correctly captured, including the heightened consequences of failure such as competitive pressure and execution delays. (2) There are no numeric values in the original or LLM answer, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the model correctly synthesizes Cisco’s shifting risk profile across years, linking strategic investments to increased technical complexity and time-sensitive product development. The mention of post-Splunk integration adds contextual depth consistent with 2024 developments, even if not explicitly in the ground truth—it does not contradict and supports the overall narrative. (4) The only minor gap is that the LLM does not explicitly mention 'reputational damage, legal liability, and reduced customer retention' as expanded risks in 2024, which slightly reduces completeness. However, it does convey the broader strategic stakes, so the omission is not critical. Overall, the answer is semantically equivalent, contextually rich, and factually correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1419,
        "completion_tokens": 398,
        "total_tokens": 1817
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did the role of Google Ad Manager in driving Google Network revenues change between 2022 and 2023, based on the specific mentions of its performance and positioning across those years?",
      "original_answer": "In 2022, Google Ad Manager was explicitly cited as one of the key drivers behind the $8.6 billion year-over-year increase in Google Network revenues, alongside AdMob and AdSense. By 2023, while Google Ad Manager remained a core advertising platform used by customers, it was listed among several platforms (including Google Ads, Display & Video 360, and the Marketing Platform) without specific attribution to revenue growth. This indicates a shift from being a standout growth contributor in 2022 to being part of a broader suite of advertising tools in 2023, suggesting a more integrated but less singularly emphasized role.",
      "llm_answer": "Between 2022 and 2023, the role of Google Ad Manager in driving Google Network revenues shifted from being a key growth driver to a more stable, but less dominant, contributor. In 2022, Google Network revenues grew strongly (up 31% YoY in 2021, and continued growth in 2022), with Ad Manager being explicitly cited as a primary driver of that growth alongside AdMob and AdSense, particularly as part of Google's \"Google Network\" segment that includes ad revenue from partner properties. However, in 2023, while Google Network revenues still grew (as part of the broader Google Advertising segment), the specific emphasis on Ad Manager's performance diminished in the disclosures; the focus shifted more toward overall Google Cloud and Google Services growth, and the document no longer highlights Ad Manager as a primary growth engine for the Network segment. Instead, the Network's revenue contribution was now embedded within the broader \"Google Network\" cost of revenues (which includes TAC payments to partners), and the document emphasizes that Google reports advertising revenues for Google Network properties on a gross basis (as the principal), but does not single out Ad Manager's performance as a distinct growth driver in 2023 as it did in 2022.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer correctly captures the core shift in Google Ad Manager's role from being a highlighted growth driver in 2022 to a less emphasized, integrated platform in 2023, which aligns with the ground truth. It accurately references the $8.6 billion YoY increase in Google Network revenues (though this figure is implied rather than explicitly stated in the LLM response) and correctly notes that in 2022, Ad Manager was cited alongside AdMob and AdSense as a key contributor. However, the LLM introduces a 31% YoY growth figure for 2021 and references continued growth in 2022 without directly citing the $8.6B increase from the original answer, which reduces quantitative accuracy. This 31% figure, while potentially accurate, is not part of the ground truth and distracts from the specific dollar-based metric that should be emphasized. The qualitative reasoning is strong: it correctly infers that by 2023, Ad Manager was no longer singled out as a growth engine and was instead grouped with other platforms like Google Ads and Display & Video 360, indicating a more integrated role. The answer also correctly identifies the shift in reporting language and the embedding of Network revenue within broader cost structures. Contextual relevance is excellent—the response directly addresses the evolution of Ad Manager’s role across the two years and synthesizes information appropriately across time periods. The main shortcoming is the omission of the explicit $8.6B figure and the introduction of an unverified percentage, which slightly undermines quantitative precision. Overall, the answer is semantically close to the ground truth with minor factual omissions and one extraneous detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1481,
        "completion_tokens": 460,
        "total_tokens": 1941
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How did Starbucks' derivative liabilities related to foreign currency - other evolve from 2022 to 2024, and what was the magnitude of change?",
      "original_answer": "In 2022, Starbucks reported derivative liabilities related to foreign currency - other at $0.3 million under accrued liabilities. By 2024, this amount had increased to $4.7 million under the same category. This indicates a significant increase in the company's liabilities tied to foreign currency derivatives over the two-year period.",
      "llm_answer": "From 2022 to 2024, Starbucks’ derivative liabilities related to foreign currency – other decreased from $7.4 million (Oct 3 2021) to $5.8 million (Oct 2 2022) and further to $4.7 million (Sep 29 2024), reflecting a net reduction of roughly $2.7 million over the two‑year period. This decline indicates a smaller foreign‑currency derivative liability position in the most recent 2024 filing compared with the 2022 baseline.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Starbucks' derivative liabilities related to foreign currency - other increased from $0.3 million in 2022 to $4.7 million in 2024. However, the LLM claims the liability decreased from $7.4 million (2021) to $5.8 million (2022) and then to $4.7 million (2024), which contradicts the original data. The starting value in 2022 is wrong ($0.3M vs $5.8M claimed), and the trend is incorrectly described as a decrease rather than a significant increase. (2) The numbers cited—$7.4M, $5.8M—are not present in the ground truth and appear to be fabricated or misattributed. The only correct number is the 2024 figure of $4.7 million. The claimed net reduction of $2.7 million is therefore incorrect; the actual change is an increase of $4.4 million ($4.7M - $0.3M). Dates are also misaligned: the ground truth does not provide data for Oct 3, 2021 or Oct 2, 2022, but rather refers to fiscal years 2022 and 2024. (3) The multi-hop reasoning is flawed. The model fails to correctly identify the evolution from 2022 to 2024 as an increase, instead constructing a false downward trend using incorrect prior-year figures. It also introduces data from 2021, which was not requested and not part of the original answer. (4) While the LLM attempts to address the question's structure—discussing evolution and magnitude of change—the severe quantitative and qualitative errors undermine the correctness. Contextual relevance is moderate because it discusses the right metric and time frame, but with wrong data and conclusions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1188,
        "completion_tokens": 442,
        "total_tokens": 1630
      },
      "error": null
    },
    {
      "question_id": 43,
      "question": "How has PepsiCo's issuance of the 4.600% Senior Notes due 2045 evolved between 2023 and 2024, and what does this indicate about the company's debt structure strategy?",
      "original_answer": "In 2023, the 4.600% Senior Notes due 2045 were listed among other senior notes in the Board of Directors Resolutions that authorized PepsiCo's officers to establish terms for various notes, including the 4.600% Senior Notes due 2045. By 2024, the 4.600% Senior Notes due 2045 remained part of the company's debt structure, but were now referenced alongside a broader range of newly introduced senior notes, such as the 4.000% Senior Notes due 2047 and Floating Rate Notes due 2026. This indicates that while the 4.600% Senior Notes due 2045 remained a part of PepsiCo's long-term debt strategy, the company expanded its debt portfolio with additional instruments, suggesting a more diversified approach to long-term financing in 2024.",
      "llm_answer": "Between 2023 and 2024, PepsiCo issued its 4.600% Senior Notes due 2045 through a series of filings: the initial 4.600% Senior Notes due 2045 were referenced in the 2023 10-K (page 128, 4.61) and later in a February 28 2024 Current Report on Form 8‑K (page 129, 4.61), with additional details in the February 16 2024 registration filing (page 131, 4.71‑4.75). The 2024 filings expanded the note series to include a 4.600% tranche within a broader set of new senior notes (e.g., 4.600% due 2045, 4.550% due 2029, 4.700% due 2034), indicating a strategy of diversifying maturities and leveraging low‑cost long‑term debt to fund operations and acquisitions while maintaining a staggered debt profile. This approach supports PepsiCo’s objective of extending the average maturity of its borrowings and reducing refinancing risk.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer contains several inaccuracies that affect factual correctness. First, the claim that PepsiCo 'issued' the 4.600% Senior Notes due 2045 in 2023–2024 is not supported by the ground truth; instead, the notes were authorized in 2023 via Board Resolutions and remained part of the debt structure in 2024, but no new issuance of this specific tranche is confirmed. The LLM incorrectly implies an actual issuance occurred through Form 8-K and registration filings, citing page numbers and specific tranches (e.g., 4.550% due 2029, 4.700% due 2034) not mentioned in the ground truth. These specific percentages and maturities are fabricated or hallucinated, failing the quantitative accuracy test. The ground truth only confirms the continued presence of the 4.600% notes and the addition of new instruments like the 4.000% due 2047 and Floating Rate Notes due 2026—none of which are referenced in the LLM answer. While the LLM correctly infers a strategy of diversification and extending average maturity, this reasoning is based on incorrect entities and events. The contextual relevance is high because the answer addresses debt strategy and evolution over time, and the qualitative reasoning about staggered maturities and refinancing risk is plausible and aligned with corporate finance logic. However, due to significant factual errors in the underlying data and misrepresentation of filings as issuances, the correctness and quantitative accuracy scores are reduced. The answer synthesizes across time periods but fails on entity accuracy and factual grounding.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1394,
        "completion_tokens": 429,
        "total_tokens": 1823
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has COP's natural gas position in the Asia Pacific/Middle East region evolved between 2022 and 2024, and what does this indicate about its strategic focus in the region?",
      "original_answer": "In 2022, COP reported 326 billion cubic feet of natural gas in the Asia Pacific/Middle East region. By 2024, this figure had decreased slightly to 296 billion cubic feet. This indicates a minor reduction in natural gas reserves in the region over the two-year period. The decline, although modest, suggests a potential shift in strategic focus, possibly due to market dynamics or operational adjustments in the region.",
      "llm_answer": "Between 2022 and 2024, ConocoPhillips significantly expanded its natural gas reserves in the Asia Pacific/Middle East region, with total reserves increasing from 50 billion cubic feet (BCF) at the end of 2022 to 468 BCF by the end of 2024. This growth reflects a strategic focus on expanding its presence in the region, driven by upstream acquisitions (e.g., Marathon Oil), extensions and discoveries in the Permian Basin and Montney, and upward revisions from development and technical improvements. Consequently, the company’s natural gas portfolio in Asia Pacific/Middle East has become a larger share of its overall reserves, underscoring a deliberate shift toward higher‑margin, long‑life gas assets in that geographic area.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is almost entirely incorrect in both quantitative and qualitative aspects. According to the ground truth, COP's natural gas reserves in the Asia Pacific/Middle East region decreased from 326 billion cubic feet in 2022 to 296 billion cubic feet in 2024, indicating a modest decline. However, the LLM claims a massive increase from 50 BCF to 468 BCF, which is factually wrong. (2) The numbers are completely inaccurate: 50 BCF and 468 BCF do not match the ground truth values of 326 BCF and 296 BCF. The direction of change is also wrong—LLM reports significant growth, while the truth shows a reduction. Calculations based on these numbers (e.g., implied growth of 836%) are therefore invalid. (3) The reasoning is flawed: the LLM attributes growth to acquisitions like Marathon Oil and developments in the Permian Basin and Montney, which are not in the Asia Pacific/Middle East region and are unrelated to COP’s reserves there. This shows a failure in multi-hop reasoning—no synthesis with correct regional or temporal data. (4) The contextual relevance is low because the answer discusses expansion and strategic focus on gas in the region, while the truth suggests a potential drawdown or strategic repositioning due to declining reserves. The only partial relevance is that it addresses the region and strategic focus, but with incorrect data and conclusions. Thus, the correctness, quantitative, and qualitative scores are very low; contextual relevance receives minimal credit for addressing the general topic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1293,
        "completion_tokens": 425,
        "total_tokens": 1718
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has Google Play's role in Google's non-advertising revenue strategy evolved from 2022 to 2023, based on the specific revenue sources mentioned in the filings?",
      "original_answer": "In 2022, Google Play was specifically mentioned as generating revenues from 'sales of apps and in-app purchases and digital content sold in the Google Play store.' By 2023, Google Play's revenue focus had evolved to be more narrowly described as primarily coming from 'apps and in-app purchases,' and it was grouped under the broader category of 'platforms' within non-advertising revenue sources. This indicates a shift in emphasis toward core app-based monetization within Google's strategic narrative around Play.",
      "llm_answer": "From 2022 to 2023, Google Play's role in Google's non-advertising revenue strategy shifted from being primarily a source of app and digital content sales (including in-app purchases) to being explicitly positioned alongside other non-advertising revenue streams such as YouTube subscriptions (YouTube Premium/TV), hardware (Pixel devices, Nest), and consumer subscriptions. While the 2022 filing (page 6) highlighted Google Play's revenue generation from app and in-app purchases, the 2023 filing (page 6) expanded this by grouping Google Play under \"revenues beyond advertising\" alongside YouTube non-advertising (subscriptions like YouTube Premium/TV) and hardware, emphasizing its role in diversifying non-ad revenue beyond just ad-driven streams. This evolution reflects a strategic broadening of Google Play's contribution to non-advertising revenue, integrating it with other subscription and hardware-based revenue streams to reduce reliance on advertising.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies regarding the evolution of Google Play's role. The ground truth states that in 2023, Google Play's revenue description became *more narrow*, focusing primarily on 'apps and in-app purchases' and being grouped under 'platforms'. However, the LLM incorrectly claims the description *broadened* and was grouped with YouTube subscriptions and hardware under 'revenues beyond advertising', which contradicts the original answer. This misrepresents the strategic shift. (2) There are no numeric values, percentages, or dates in the question or answers, so quantitative accuracy is not applicable—no errors in this regard, hence a score of 10. (3) The multi-hop reasoning is flawed: the LLM fails to correctly synthesize the change in narrative from broader digital content in 2022 to a narrower, platform-focused definition in 2023. Instead, it invents a broader categorization that includes YouTube and hardware, which is not supported by the ground truth. The original answer emphasizes a *narrowing* and *refocusing* of Play’s role, while the LLM describes an *expansion* and *integration*, which is the opposite direction. (4) Contextual relevance is moderate—the answer discusses non-advertising revenue and Google Play, so it stays on topic, but it introduces unrelated elements (YouTube Premium/TV, hardware) as part of Play’s revenue evolution, which distorts the actual strategic shift. Correctness and qualitative accuracy are low due to this fundamental mischaracterization.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 426,
        "total_tokens": 1800
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has the projected utilization of the Cessna SkyCourier 408 evolved from 2022 to 2024, and what does this indicate about FedEx's strategic reliance on this aircraft model?",
      "original_answer": "In 2022, FedEx projected the Cessna SkyCourier 408 to have a total of 49 aircraft in operation across the years 2023 to thereafter. By 2024, this projection was reduced to a total of 31 aircraft for the years 2025 through 2029. However, in the 2024 report, the relationship to the Cessna SkyCourier 408 shifted from 'Increases' to 'Depends_On', indicating a change in strategic importance. This suggests a moderated but still significant reliance on the aircraft model over time.",
      "llm_answer": "The projected utilization of the Cessna SkyCourier 408 has increased from 11 aircraft slated for delivery in 2023 (as shown in the 2022 10‑K) to 17 aircraft scheduled for delivery in 2025 (as shown in the 2024 10‑K), reflecting a clear upward trend in FedEx’s commitment to the type. This growing allocation signals that FedEx is increasingly relying on the SkyCourier 408 as a core component of its fleet modernization strategy to support expanding package and freight volumes.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in both direction and magnitude of the projection change. The ground truth states that the total projected fleet size decreased from 49 aircraft (2022 projection for 2023 onward) to 31 aircraft (2024 projection for 2025–2029), indicating a reduction. However, the LLM claims an increase from 11 to 17 aircraft, which contradicts the data. These specific numbers (11 and 17) do not appear in the ground truth and are therefore fabricated or misread. (2) Quantitative accuracy is very low: the LLM misrepresents both the total projected utilization and the timeline. The original answer refers to total fleet projections over multi-year periods (49 total initially, then 31), not annual deliveries. The LLM incorrectly interprets this as 11 in 2023 and 17 in 2025, which is unsupported. There is no mention in the ground truth of 11 or 17 aircraft deliveries. (3) The multi-hop reasoning is flawed. The LLM fails to recognize that the overall projection was reduced and instead infers an 'upward trend' from incorrect data. Additionally, it omits the critical strategic shift in relationship type from 'Increases' to 'Depends_On', which is a key qualitative indicator of changing strategic reliance. This change in dependency logic is central to the original answer but entirely missing in the LLM response. (4) Contextual relevance is moderate because the answer addresses the general topic—FedEx’s use of the SkyCourier and strategic reliance—but the incorrect data and reasoning undermine the conclusion. The final inference about 'increasing reliance' is the opposite of what the evidence suggests: a moderated but still significant reliance. Thus, while the structure and intent align with the question, the factual foundation is incorrect, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1246,
        "completion_tokens": 496,
        "total_tokens": 1743
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How has AIG's use of expected loss ratio methods evolved between 2022 and 2023, particularly in terms of segmentation and the types of casualty lines analyzed?",
      "original_answer": "In 2022, AIG used expected loss ratio methods primarily for the three latest accident years in the U.S. Excess Casualty line, segmenting analysis by attachment point and further differentiating between automobile and non-automobile claims, including special treatment for latent exposures like construction defects and mass torts. In 2023, AIG continued to apply expected loss ratio methods but shifted focus to U.S. Workers' Compensation, where the company grouped business by risk-sharing features such as high deductibles and retrospective rating, and analyzed separately by state, industry, and claim handling entity. The increase in large deductible business also affected the reporting pattern of claims, indicating a broader application context for the method. This reflects a strategic evolution in where and how expected loss ratio methods are applied across different casualty lines.",
      "llm_answer": "Between 2022 and 2023, AIG’s loss reserving methodology for U.S. Excess Casualty remained anchored in a blend of loss development and expected loss ratio techniques, but the segmentation and analytical focus evolved. In 2022, the company continued to segment non‑automobile claims into distinct latent exposure groups—such as construction defects and mass torts—while treating standard claims by attachment‑point bands. By 2023, the same segmentation was retained, but the description emphasized that expected loss ratio methods were now applied to “at least the three latest accident years” due to low credibility of reported losses, and that recent COVID‑19‑related disruptions prompted targeted adjustments to standard projection techniques. Thus, while the overall methodological framework stayed consistent, 2023 saw a more explicit reliance on expected loss ratios for newer accident years and a refined handling of COVID‑related claim emergence within the segmented casualty lines.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that deviate from the ground truth. (1) It incorrectly states that AIG continued to apply expected loss ratio methods to U.S. Excess Casualty in 2023, whereas the original answer clearly indicates a strategic shift to U.S. Workers' Compensation in 2023. This is a fundamental error in entity and context. (2) The LLM emphasizes 'COVID-19-related disruptions' and 'targeted adjustments' in 2023, which are not mentioned in the ground truth and represent fabricated details. (3) While the 2022 segmentation (by attachment point, auto vs. non-auto, latent exposures like construction defects and mass torts) is accurately described, the 2023 evolution is completely misrepresented: the ground truth describes a shift in casualty line (to Workers' Compensation), segmentation by risk-sharing features (high deductibles, retrospective rating), and analysis by state, industry, and claim handling entity—none of which are mentioned in the LLM answer. (4) The LLM suggests methodological continuity in U.S. Excess Casualty with only refinements, while the original answer describes a strategic reallocation of the expected loss ratio method to a different line of business. This failure to capture the core evolution—both in terms of the casualty line and segmentation approach—represents a breakdown in multi-hop reasoning and synthesis. Quantitative accuracy is partially preserved (e.g., 'three latest accident years' is correct), but the misuse of context and introduction of unsupported factors (like COVID-19) reduce confidence. Contextual relevance is moderate because the answer discusses related concepts (expected loss ratios, segmentation), but it applies them to the wrong business line and time period, undermining overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1473,
        "completion_tokens": 485,
        "total_tokens": 1959
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How did the classification and reporting of unallocated products evolve between fiscal years 2022 and 2024, particularly in terms of how they are categorized within Nike's consumer construct?",
      "original_answer": "In fiscal year 2022, unisex products were classified within Men's, and certain products not allocated to Men's, Women's, NIKE Kids', and Jordan Brand were included in 'Others' with adjustments not allocated by consumer. By fiscal year 2024, 'Others' continued to include products not allocated to Men's, Women's, Kids', and Jordan Brand, but there was no specific mention of unisex product classification within Men's, suggesting a potential shift or integration of unisex products within broader categories.",
      "llm_answer": "Between fiscal 2022 and 2024, Nike refined its consumer construct by shifting from a product‑centric classification (footwear, apparel, equipment) to a consumer‑centric segmentation of Men’s, Women’s and Kids’ (with Jordan Brand treated separately). This re‑classification, introduced in fiscal 2022 and solidified through fiscal 2024, is reflected in the “NIKE Brand Wholesale Equivalent Revenues by: (1),(4)” tables on page 35 (2022) and the “NIKE Brand Revenues by: (1)” tables on page 37 (2024), which now break out revenue by these consumer groups rather than by product categories alone. Consequently, unallocated or “Other” products—previously shown as a distinct line item—are now incorporated within the broader Men’s, Women’s and Kids’ categories or listed under “Others,” with the latter reflecting products not allocated to the primary consumer segments. This evolution improves visibility into how the business performs across distinct consumer audiences while maintaining a consistent reporting framework across the three fiscal years.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies Nike's shift to a consumer-centric segmentation (Men’s, Women’s, Kids’, Jordan Brand) starting in fiscal 2022 and continuing into 2024, and notes the presence of an 'Others' category for unallocated products, which aligns with the ground truth. It also accurately references the evolution in reporting structure and improved visibility into consumer segments. However, the LLM fails to specifically address the classification of unisex products, which is central to the question. The original answer highlights that in fiscal 2022, unisex products were explicitly classified within Men's, but by 2024 there was no such mention—suggesting a potential shift. The LLM omits this key detail about unisex product treatment, instead broadly discussing the reclassification of 'Other' products without distinguishing unisex items. This is a significant omission because the question specifically asks about the evolution of 'unallocated products' with a focus on how they are categorized, particularly unisex. While the LLM correctly notes the existence and role of the 'Others' category, it does not confirm or analyze the change in unisex product classification, leading to incomplete multi-hop reasoning. Quantitative accuracy is high—no incorrect numbers or dates are presented, and document references (page numbers, table titles) are plausible and contextually appropriate. Contextual relevance is strong as the response stays focused on Nike’s reporting evolution. Qualitative accuracy is moderate: reasoning is logical and synthesis across years is attempted, but the failure to engage with the specific evolution of unisex product classification weakens the overall accuracy. Thus, the answer is partially correct but misses a critical factual nuance required for full correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1400,
        "completion_tokens": 490,
        "total_tokens": 1891
      },
      "error": null
    },
    {
      "question_id": 44,
      "question": "How did PepsiCo's engagement with the 3.500% Senior Notes due 2025 evolve between 2023 and 2024, and what does this indicate about the company's debt management strategy?",
      "original_answer": "In 2023, PepsiCo's 3.500% Senior Notes due 2025 were listed among other notes, indicating they were part of the company's existing debt structure. By 2024, the 3.500% Senior Notes due 2025 were still present, but they were now accompanied by a broader range of new notes, including longer-term instruments such as the 3.500% Senior Notes due 2040 and the 3.550% Senior Notes due 2034. This suggests that PepsiCo expanded its debt portfolio in 2024, introducing more long-term financing options while maintaining its commitment to the 3.500% Senior Notes due 2025. The addition of new notes indicates a strategic shift toward diversifying its debt maturity structure.",
      "llm_answer": "Between 2023 and 2024, PepsiCo's engagement with the 3.500% Senior Notes due 2025 shifted from being referenced as an existing obligation in its 2023 10-K (where it was listed among prior note forms in Exhibit 4.36) to being explicitly authorized for future issuance in its 2024 filings. Specifically, the 2024 10-K (page 128) includes a new \"Board of Directors Resolutions Authorizing PepsiCo, Inc.'s Officers to Establish the Terms of the 3.500% Senior Notes due 2025\" (referenced as part of a broader set of note authorizations in Exhibit 4.64), indicating proactive planning for this debt instrument. This evolution reflects a strategic shift toward active debt management, emphasizing forward-looking financing flexibility to optimize the company's capital structure and funding mix.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains several factual inaccuracies that significantly deviate from the ground truth. While both the LLM and original answer agree that the 3.500% Senior Notes due 2025 were part of PepsiCo's debt structure in 2023 and 2024, the LLM incorrectly claims that in 2024 the notes were 'authorized for future issuance' and that there was a 'Board of Directors Resolutions' document in Exhibit 4.64 of the 2024 10-K. The ground truth does not support this claim — there is no indication that PepsiCo reauthorized or planned to reissue the 2025 notes. Instead, the original answer states that the 2025 notes remained outstanding while PepsiCo added longer-term debt instruments (e.g., notes due 2034 and 2040), indicating a strategy of maturity diversification. The LLM invents specific exhibit numbers (4.64) and board resolutions not present in the ground truth, which reflects a failure in multi-hop reasoning and entity accuracy. Quantitatively, the interest rate (3.500%) and maturity year (2025) are correct, earning partial credit. Contextually, the answer addresses debt management strategy and attempts to interpret strategic intent, but the reasoning is based on fabricated evidence. The conclusion about 'active debt management' and 'financing flexibility' is plausible but unsupported by the actual data provided. Thus, while the answer is semantically related and contextually relevant, it fails on core factual and qualitative accuracy, particularly in entity identification and reasoning soundness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 416,
        "total_tokens": 1786
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did COP's financial disclosures regarding the Lower 48 region evolve between 2022 and 2024, particularly in terms of capital expenditures and future cash inflow revisions?",
      "original_answer": "In 2022, COP reported capital expenditures for the Lower 48 region at $3,129 million, indicating significant active investment in the area. By 2024, the company disclosed that certain amounts in the Lower 48 had been revised to reflect additional future cash inflows and future production costs, although no new capital expenditure figure was provided. This shift suggests a transition from active investment to a focus on revising financial projections based on updated expectations for production and cost dynamics in the region.",
      "llm_answer": "Between 2022 and 2024, ConocoPhillips' capital expenditures in the Lower 48 region increased substantially, rising from $504 million in 2022 to $2,808 million in 2023 and then to $2,808 million (plus $583 million for Canada) in 2024, reflecting a major expansion of proved property acquisitions and development spending.  At the same time, the company revised its outlook for future cash inflows upward—total discounted future net cash flows for the Lower 48 grew from $55.9 billion in 2022 to $38.7 billion in 2023 (after discounting) and further to $50.1 billion in 2024—indicating improved expectations for cash generation from that region over the same period.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, COP reported $3,129 million in capital expenditures for the Lower 48 in 2022. The LLM incorrectly states it was $504 million in 2022 and claims expenditures rose to $2,808 million in 2023 and 2024—none of which aligns with the original data. Moreover, the ground truth states that no new capital expenditure figure was provided for 2024, but the LLM fabricates a detailed figure including a $583 million allocation for Canada, which is irrelevant to the Lower 48 region. (2) The future cash inflow figures cited by the LLM—$55.9B in 2022, $38.7B in 2023, and $50.1B in 2024—are entirely unsupported by the original answer, which mentions revisions to future cash inflows and production costs in 2024 but provides no specific numbers. These fabricated figures severely undermine quantitative accuracy. (3) The multi-hop reasoning is flawed: the original answer highlights a shift from active investment (2022) to revised financial projections (2024), indicating a strategic pivot. The LLM instead portrays a continuous increase in capex and rising cash flows, implying sustained expansion, which contradicts the ground truth's narrative of reduced disclosure and a focus on revision rather than new investment. (4) Contextual relevance is moderate because the LLM addresses capital expenditures and future cash inflows in the Lower 48 over the 2022–2024 period, which matches the question’s scope, but the incorrect data and mischaracterized trend lead to a substantively wrong conclusion. Thus, while the structure and intent are relevant, the factual foundation is unsound.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 458,
        "total_tokens": 1764
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did Comcast's financial commitments and governance arrangements with Atairos Group evolve between 2023 and 2024, particularly regarding capital obligations and control structures?",
      "original_answer": "In 2023, Comcast had a Fourth Amended and Restated Shareholders Agreement with Atairos Group, Inc., which was further amended in June 2023. This agreement outlined Comcast's role as the sole third-party investor and included governance terms among Atairos-related entities. By 2024, the relationship evolved into a more formalized investment framework under the equity method accounting. In this framework, Comcast reduced its capital commitment from up to $5 billion to $4.5 billion, limited annual capital calls to $400 million, and agreed to separately fund $40 million annually for management fees. Additionally, the 2024 filing clarified that Comcast absorbs approximately 99% of Atairos’ losses and receives approximately 86% of residual returns, while Atairos’ management companies (led by Comcast’s former CFO) retained all voting rights. These changes reflect a recalibration of financial exposure and a clearer delineation of control.",
      "llm_answer": "Between 2023 and 2024, Comcast’s financial commitments and governance arrangements with Atairos Group remained anchored by its $1.4 billion unfunded capital commitment, which continues to be the maximum exposure to loss despite the VIE being consolidated elsewhere. The company records its investment in Atairos as an equity‑method holding, recognizing share of gains/losses and any capital‑call advances, while no additional liquidity guarantees or related‑party financial obligations exist between the parties. Consequently, the capital‑obligation structure and control framework have not materially changed, preserving the same risk profile and reporting treatment in the 2024 filings.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect and fails to reflect the key changes in Comcast's financial commitments and governance arrangements with Atairos Group between 2023 and 2024 as detailed in the ground truth. (1) Quantitatively, the LLM states a '$1.4 billion unfunded capital commitment', which directly contradicts the ground truth: in 2024, Comcast reduced its total capital commitment from up to $5 billion to $4.5 billion, with annual capital calls limited to $400 million and $40 million annually for management fees. The $1.4 billion figure does not appear in the original answer and is factually unsupported. Additionally, the LLM claims 'no material change' in capital obligations or control, while the ground truth explicitly describes a recalibration of financial exposure and governance. (2) The original answer includes specific dates (June 2023 amendment) and evolving structures (shift to equity method accounting, loss/return allocations: 99% of losses absorbed by Comcast, 86% of returns received), none of which are mentioned or accurately reflected. (3) Qualitatively, the reasoning is flawed: the LLM asserts stability in the relationship, whereas the ground truth describes a significant evolution in both financial terms and control—specifically, a formalized investment framework, reduced commitment, structured capital calls, and clarified economic rights despite voting rights being retained by management. The multi-hop synthesis fails: the model does not connect the amended 2023 agreement to the 2024 changes in capital structure and governance. (4) Contextually, the answer addresses the general topic of capital obligations and control, so relevance is moderate, but it provides misleading information rather than accurate evolution. Overall, the answer contradicts the ground truth on key facts and misses the central narrative of change and recalibration.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1417,
        "completion_tokens": 508,
        "total_tokens": 1925
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How did FedEx's projected utilization of the Cessna SkyCourier 408 change between 2022 and 2023 filings, and what does this indicate about its strategic role in the fleet compared to other aircraft?",
      "original_answer": "In the 2022 filing, FedEx projected a total of 49 Cessna SkyCourier 408 aircraft to be in service through 2027. By the 2023 filing, this projection dropped significantly to only 31 Cessna SkyCourier 408 aircraft through 2029. This indicates a strategic reduction in the planned reliance on the Cessna SkyCourier 408, especially when compared to other aircraft types like the B767F and B777F, which saw more stable or less reduced projections. This shift suggests FedEx may have reassessed the aircraft's role in its long-term fleet strategy.",
      "llm_answer": "Between the 2022 and 2023 filings, FedEx’s projected utilization of the Cessna SkyCourier 408 dropped sharply—from 11 aircraft scheduled for delivery in 2023 (and a total of 49 committed through 2027 in the 2022 filing) to just 1 aircraft slated for 2025 and none thereafter in the 2023 filing, with the total commitment falling from 49 airframes to 31. This reduction signals that the SkyCourier’s strategic role has been scaled back relative to other aircraft types (e.g., ATR 72‑600F, B767F, B777F), which continue to receive larger, more consistent delivery schedules, indicating FedEx is de‑emphasizing the SkyCourier in its fleet modernization plans.",
      "correctness_score": 9,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. (1) Quantitatively, it correctly states the reduction in projected Cessna SkyCourier 408 aircraft from 49 (2022 filing, through 2027) to 31 (2023 filing, through 2029), which matches the original answer. However, the LLM adds specific delivery details—'11 aircraft scheduled for delivery in 2023' and '1 aircraft slated for 2025'—that are not present in the ground truth. While these may be consistent with the overall reduction, they introduce granular data not confirmed by the original answer, slightly reducing quantitative precision. (2) The core numbers (49 to 31 reduction, timeframes) are correct, and calculations or comparisons (sharp drop, reduced commitment) are valid. (3) Entity accuracy is strong: FedEx, Cessna SkyCourier 408, and comparison aircraft (B767F, B777F, ATR 72-600F) are correctly identified. The inclusion of ATR 72-600F as a comparator is an addition but not inaccurate, as it supports the broader point about fleet strategy. (4) Multi-hop reasoning is sound: the model correctly infers a strategic de-emphasis based on reduced projections and contrasts this with more stable delivery plans for other aircraft types. (5) The semantic meaning fully captures the original answer’s intent—FedEx scaled back its SkyCourier plans, indicating a reduced strategic role. The extra delivery-year details slightly exceed the ground truth but do not contradict it. Overall, the answer is factually correct, well-reasoned, and contextually appropriate, warranting a high score with a minor deduction for unverified specificity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1312,
        "completion_tokens": 441,
        "total_tokens": 1753
      },
      "error": null
    },
    {
      "question_id": 45,
      "question": "How has Nike's approach to the Air Max product line evolved from 2022 to 2024, particularly in terms of revenue transparency and technological innovation emphasis?",
      "original_answer": "In 2022, Nike included Air Max in a general list of technologies within the revenue disaggregation table, indicating its presence in the product portfolio but without specific revenue figures. By 2024, while no direct revenue numbers were disclosed, Nike emphasized Air Max as a central example of its innovation strategy, highlighting its integration into broader product categories and consumer applications. This shift reflects a strategic move from passive acknowledgment to positioning Air Max as a key innovation driver, despite the continued lack of standalone financial metrics for the product line.",
      "llm_answer": "From 2022 to 2024, Nike's financial disclosures show a shift toward greater revenue transparency through detailed disaggregation of sales by segment, product line, and distribution channel (e.g., wholesale vs. direct-to-consumer), as seen in the 2022 Form 10-K (pages 86–89). Technologically, the company emphasized innovation in its Air Max line, highlighting advancements like Air Max units and related cushioning technologies (e.g., Air Zoom, React, Zoom X) in product descriptions and R&D discussions, though specific revenue allocation for Air Max is not explicitly detailed. The 2024 filing also underscores continued focus on technological development in footwear and apparel, aligning with broader innovation goals. Revenue transparency improved with clearer segment reporting, while technological emphasis remained centered on material science, performance features, and R&D investments rather than explicit Air Max revenue breakdowns.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent with the ground truth in key aspects but misses the nuanced evolution in Nike's treatment of Air Max specifically. (1) Correct elements: The LLM accurately notes that no standalone revenue figures were disclosed for Air Max in either 2022 or 2024, and correctly references improved revenue disaggregation in the 2022 10-K. It also correctly identifies the emphasis on technological innovation (e.g., Air Zoom, React, Zoom X) and R&D focus. There are no incorrect numbers, dates, or entities—quantitative accuracy is perfect. (2) Quantitative accuracy: No specific financial figures are cited for Air Max, which aligns with the ground truth; thus, no calculation errors exist. (3) Multi-hop reasoning: The LLM synthesizes information across years and domains (disclosure practices and innovation), but it generalizes Nike’s innovation and transparency trends without clearly articulating the shift in Air Max’s strategic positioning—from being a listed technology in 2022 to a highlighted innovation example in 2024. This subtle but important evolution is underemphasized. (4) The answer is contextually relevant and well-structured, but lacks precision in capturing the core shift described in the original answer: the move from passive inclusion to active promotion of Air Max as an innovation driver. This omission reduces qualitative accuracy, though not severely. Hence, a score of 7 is justified—core facts are correct, but key strategic nuance is missing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1392,
        "completion_tokens": 411,
        "total_tokens": 1803
      },
      "error": null
    },
    {
      "question_id": 46,
      "question": "How did Comcast's capital expenditure strategy regarding Epic Universe evolve from 2023 to 2024, particularly in terms of specific investment amounts and thematic park development priorities?",
      "original_answer": "In 2023, Comcast specifically noted an increase in capital expenditures directly related to the development of Epic Universe in Orlando, with a total of $8.2 billion allocated to Connectivity & Platforms, which included investments in scalable infrastructure and line extensions. By 2024, the company continued to emphasize investment in existing and new attractions at Universal theme parks, including Epic Universe, as part of its broader capital expenditure plan for 2025. While specific figures for Epic Universe alone were not disclosed in 2024, the company indicated an ongoing commitment to theme park development, particularly in expanding attractions and enhancing capacity. The evolution shows a shift from initial infrastructure and development focus in 2023 to a more sustained investment strategy in 2024 that includes both infrastructure and guest experience enhancements.",
      "llm_answer": "From 2023 to 2024 Comcast’s capital‑expenditure plan shifted toward the Epic Universe theme‑park project, with $1.3 billion of 2024 capital spending dedicated to the Universal Orlando expansion (including land acquisition and early construction costs) and an additional $1.0 billion allocated to scalable infrastructure upgrades for its broadband network.  In 2023 the focus had been on foundational broadband upgrades and land purchases for future park growth; by 2024 the company earmarked a larger, more specific investment in Epic Universe attractions while maintaining overall capex near $8.3 billion, reflecting a thematic‑park‑centric priority for the upcoming year.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. The ground truth states that in 2023, Comcast allocated $8.2 billion to Connectivity & Platforms (a broader category including infrastructure), but the LLM incorrectly claims $1.3 billion of 2024 capex was dedicated to Epic Universe and $1.0 billion to infrastructure, with no such specific figures disclosed in the 2024 report. These numbers are entirely fabricated and not supported by the original answer. Additionally, the LLM asserts that overall capex was near $8.3 billion in 2024, which is not mentioned or implied in the ground truth. (2) The original answer explicitly states that 'specific figures for Epic Universe alone were not disclosed in 2024,' making the LLM's precise dollar allocations ($1.3B and $1.0B) factually wrong. There is no mention of land acquisition or early construction costs being broken out in filings. (3) While the LLM captures a general shift in strategy—from foundational work in 2023 to attraction-focused investment in 2024—the reasoning is based on incorrect data. The multi-hop synthesis fails because it invents numbers rather than acknowledging the lack of specific disclosure in 2024. (4) Despite the incorrect numbers, the answer is contextually relevant and attempts to address the evolution of capex strategy and thematic park priorities. The qualitative reasoning about shifting focus has some alignment with the original answer’s narrative of moving from infrastructure to guest experience, but this is undermined by the false precision. Hence, low scores for quantitative and overall correctness, moderate for qualitative reasoning, and relatively high for relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 472,
        "total_tokens": 1873
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How did FedEx's utilization of the ATR 72-600F aircraft evolve between 2022 and 2023 as reflected in their fleet projections for the same planning periods?",
      "original_answer": "In 2022, FedEx projected operating 11 ATR 72-600F aircraft in 2023, 6 in 2024, 6 in 2025, and only 1 in 2026. By 2023, the projections for the same time periods changed significantly, with 7 ATR 72-600F aircraft planned for 2025 and only 3 for 2026. This indicates a notable reduction in planned usage of the ATR 72-600F by FedEx over time.",
      "llm_answer": "Based on the provided 10-K filings, FedEx's utilization of the ATR 72‑600F aircraft shifted markedly between 2022 and 2023. In the 2022 planning horizon (page 38‑42 of the 2022 filing), the company was committed to purchasing 11 ATR 72‑600Fs for delivery in 2023 and a total of 24 such aircraft across the 2023‑2026 period. By contrast, the 2023 filing (pages 115‑119) shows only 3 ATR 72‑600Fs slated for delivery in 2026 and none for 2025, indicating that the airline had largely phased out future ATR 72‑600F commitments and was focusing instead on other aircraft types (e.g., B777F, B767F) for its modernization program. Thus, the utilization of the ATR 72‑600F declined sharply, with the fleet projection moving from multiple firm orders in 2022 to only a handful of future deliveries by 2026.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies in quantitative details, despite capturing the general trend of reduced ATR 72-600F utilization. According to the ground truth, in 2022 FedEx projected operating 11 ATR 72-600F aircraft in 2023, 6 in 2024, 6 in 2025, and 1 in 2026. By 2023, projections showed 7 for 2025 and 3 for 2026. The LLM incorrectly states that there were 11 deliveries planned for 2023 and a total of 24 across 2023–2026, which is not supported by the ground truth (which gives operational fleet numbers, not purchase commitments). The LLM also claims only 3 were slated for delivery in 2026 and none in 2025 in the 2023 plan, contradicting the ground truth that shows 7 planned for 2025 and 3 for 2026. These are major quantitative errors. The reasoning is partially sound in identifying a reduction in projected use, but fails to accurately represent the multi-hop comparison between the 2022 and 2023 projections for overlapping years (2023–2026). The mention of B777F and B767F is contextually plausible but not in the ground truth, introducing unsupported detail. While the overall direction of change (decline) is correctly inferred, the specific numbers, timeframes, and nature of the projections (operational fleet vs. purchase commitments) are misrepresented, leading to a low quantitative accuracy score. The answer is contextually relevant and addresses the evolution question, but with flawed data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 396,
        "total_tokens": 1683
      },
      "error": null
    },
    {
      "question_id": 47,
      "question": "How did Nike's approach to estimating product return reserves evolve between fiscal 2022 and fiscal 2024, and what does this indicate about changes in their revenue recognition methodology?",
      "original_answer": "In fiscal 2022, Nike disclosed that the estimated cost of inventory for expected product returns was $269 million, and these reserves were recorded in Prepaid expenses and other current assets. By fiscal 2024, while the specific dollar amount of the product return reserve was not disclosed, Nike described a more formalized estimation process, stating that it calculates anticipated reductions in revenue—such as sales returns—by determining the 'most likely amount' it will be entitled to receive. This indicates a shift toward a more probabilistic and forward-looking revenue estimation methodology, aligning with the broader revenue recognition framework where variable consideration is estimated at the time revenues are recognized.",
      "llm_answer": "Nike's approach to estimating product return reserves evolved from a $269 million estimated cost of inventory for expected returns as of May 31 2021 to $194 million as of May 31 2022, reflecting a reduction in the reserve balance. This decline indicates that the company is adjusting its revenue‑recognition methodology to more closely align revenue with expected net realizable amounts, tightening its estimates of returns and related reserves.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in fiscal 2022, Nike disclosed a $269 million estimated cost of inventory for expected returns, but the LLM incorrectly claims a reduction to $194 million by May 31, 2022, which is not supported by the original answer. Furthermore, the original answer does not provide any dollar amount for fiscal 2024, yet the LLM implies a specific figure ($194M) and a trend, which is fabricated. (2) The dates are also misaligned: the $269 million figure corresponds to fiscal 2022 (ending May 31, 2022), not May 31, 2021 as implied by the LLM. The LLM incorrectly treats the $269M as a prior-year figure when it is actually the starting point. No calculation or comparison in the LLM answer is valid due to incorrect inputs. (3) The multi-hop reasoning is flawed. The original answer describes a qualitative shift in methodology—toward estimating variable consideration using the 'most likely amount'—indicating alignment with ASC 606 revenue recognition principles. The LLM fails to mention this key evolution and instead invents a quantitative trend that does not exist in the source, missing the core conceptual change. (4) While the LLM attempts to address revenue recognition methodology, it does so based on false premises. The contextual relevance is moderate because it discusses reserves and revenue recognition, but the incorrect data and missing qualitative insight severely undermine accuracy. The answer invents numbers and omits the actual methodological shift, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1306,
        "completion_tokens": 439,
        "total_tokens": 1745
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How did the planned fleet composition of the Cessna SkyCourier 408 change between 2022 and 2023 for the years 2025 and beyond, and what does this indicate about the company's strategic reliance on this aircraft model?",
      "original_answer": "In 2022, FDX projected a total of 12 Cessna SkyCourier 408 aircraft to be in operation by 2025 and planned to maintain that number through 2026. By 2023, the company increased its planned fleet count for 2025 to 17 but reduced it to 14 for 2026. This indicates a short-term increase in strategic reliance on the Cessna SkyCourier 408, followed by a moderate decline in planned usage by 2026, suggesting a recalibration of fleet strategy.",
      "llm_answer": "The planned fleet composition for the Cessna SkyCourier 408 shifted from 11 aircraft slated for delivery in 2023 and 12 for 2024 in the 2022 filing, to 17 aircraft scheduled for 2025 and 14 for 2026 in the 2023 filing, indicating a clear strategic pivot toward relying on the SkyCourier to meet future regional‑cargo capacity needs. This increase underscores FedEx’s intent to make the SkyCourier a cornerstone of its long‑term fleet strategy.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. According to the ground truth, in 2022, FedEx (FDX) projected 12 Cessna SkyCourier 408 aircraft by 2025 and planned to maintain that number through 2026. However, the LLM incorrectly states that the 2022 plan included '11 aircraft slated for delivery in 2023 and 12 for 2024,' which misrepresents both the timeline and the numbers. The 2023 update correctly notes 17 planned for 2025 and 14 for 2026, aligning with the ground truth. (2) The calculation and comparison between years are flawed due to incorrect baseline data from 2022. The LLM introduces delivery years (2023, 2024) not mentioned in the original answer, which focused on fleet counts *by* 2025 and *through* 2026. (3) The reasoning is partially sound in interpreting the increase as a strategic shift, but it misses the nuance that the 2026 reduction from 17 to 14 suggests a recalibration, not a straightforward long-term commitment. The ground truth emphasizes a 'short-term increase' followed by a 'moderate decline,' indicating strategic adjustment, whereas the LLM concludes it's a 'cornerstone of its long-term fleet strategy,' which overstates and misinterprets the trend. (4) Contextually, the answer addresses the question about fleet composition changes and strategic reliance, so relevance is high. However, due to incorrect numbers and mischaracterization of the strategic implication, the correctness and quantitative accuracy scores are reduced. The qualitative accuracy is moderate because the model identifies a strategic shift but draws an incomplete or overly optimistic conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1237,
        "completion_tokens": 449,
        "total_tokens": 1687
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has Mastercard's real-time account-based payments infrastructure evolved from 2023 to 2024, particularly in terms of operational scale and integrated security capabilities?",
      "original_answer": "In 2023, Mastercard operated or was implementing real-time payments infrastructure in 13 markets globally, offering instant payments with enhanced data and messaging capabilities. The company emphasized a distributed network architecture that enabled intelligent routing and applied value-added services like fraud scoring and tokenization in real time. By 2024, Mastercard expanded its capabilities by enhancing its ACH and real-time account-based payment systems to provide more secure, simple, and smart payment solutions across its global network. The company also reinforced its multi-layered security approach, integrating additional protections and partnerships to safeguard the payments ecosystem. These developments indicate a strategic shift toward strengthening both the scale and security of its real-time payments infrastructure.",
      "llm_answer": "Mastercard has expanded the operational scale of its real-time account-based payments infrastructure, now covering 13 markets with real-time clearing and settlement systems and supporting over 95 % of the world’s banked population through its Disbursements and Remittances capabilities. The platform’s integrated security framework—featuring multi‑layered cyber and information‑security controls, real‑time fraud scoring, tokenization, and guaranteed settlement backed by robust indemnity and risk‑management policies—has been embedded across all payment rails to protect transactions while scaling volume.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Mastercard's real-time payments infrastructure in 13 markets, which aligns with the 2023 data from the ground truth. However, it fails to clearly reflect the evolution from 2023 to 2024 as required by the question. Instead, it presents a static view without highlighting the 2024 enhancements such as expanded ACH capabilities or reinforced multi-layered security through new partnerships. The claim that the infrastructure supports 'over 95% of the world’s banked population' via Disbursements and Remittances is not mentioned in the original answer and cannot be verified from the provided ground truth, making it an unsupported addition. (2) Quantitatively, the '13 markets' figure is accurate for 2023, but the 95% banked population statistic is unverified and appears inflated or extrapolated without source confirmation. No incorrect calculations are present, but the introduction of an unvalidated percentage reduces quantitative accuracy. (3) The reasoning partially captures the multi-hop requirement by referencing both scale and security, but it does not adequately synthesize the progression between years. The integration of fraud scoring, tokenization, and secure settlement is consistent with the original answer, showing sound understanding of security capabilities. However, the absence of 2024-specific developments like 'enhancing ACH and real-time systems for smarter, simpler solutions' and 'strategic shift' weakens the qualitative accuracy. (4) Contextual relevance is high because the response addresses operational scale and security in real-time payments, directly engaging the question's focus. Despite missing the temporal evolution and adding unverified data, the core themes are appropriately covered, warranting moderate to high scores in qualitative and contextual dimensions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 503,
        "total_tokens": 1873
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How did Nike's use of foreign exchange forwards and options evolve between 2022 and 2024, particularly in terms of their impact on financial liabilities and hedging strategy?",
      "original_answer": "In 2022, foreign exchange forwards and options had a net gain of $8 million after tax, impacting various income categories such as revenues, cost of sales, and other (income) expense, net. By 2024, the liabilities associated with these instruments increased to $110 million under accrued liabilities and $5 million under deferred income taxes and other liabilities, indicating a shift in how these derivatives were managed or reported. This reflects a strategic evolution in Nike's hedging activities and financial exposure management.",
      "llm_answer": "Nike's use of foreign exchange forwards and options as cash flow hedges shifted from a larger, more prominent role in 2022 to a more restrained but still significant position by 2024. In 2022, the notional amount of outstanding foreign currency derivatives designated as cash flow hedges was $18.5 billion, with $607 million of deferred net gains expected to be reclassified to earnings over the next 12 months; by 2024 this notional had fallen to $16.2 billion, and only $231 million of deferred gains were projected to be reclassified during the same period. The accounting treatment remained consistent—effective hedge results are recorded in accumulated other comprehensive income and reclassified into earnings when the hedged cash flows affect net income—but the scale of hedging activity and the amount of gains/losses reclassified declined, reflecting a more conservative hedging strategy and a reduced reliance on these instruments between 2022 and 2024.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer is largely incorrect in terms of quantitative accuracy and fails to align with the ground truth. (1) The numbers provided—such as the $18.5 billion and $16.2 billion notional amounts in 2022 and 2024, and deferred gains of $607 million and $231 million—are not present in the original answer and contradict the known facts from the knowledge graph. The ground truth reports only an $8 million net gain after tax in 2022 and liabilities of $110 million and $5 million in 2024; no notional amounts or deferred gains reclassification figures are mentioned. (2) There is no verification of these specific figures in the original data, and their inclusion represents a significant fabrication or hallucination. (3) While the LLM attempts multi-hop reasoning by comparing 2022 and 2024 strategies and discussing hedging evolution, the reasoning is built on false premises. The conclusion about a 'more conservative hedging strategy' is speculative and unsupported by the actual data provided in the ground truth. (4) The contextual relevance is moderate because the answer addresses the general topic—evolution of foreign exchange hedging—and ties it to financial liabilities and strategy. However, it misses the key point about the increase in reported liabilities in 2024 and misrepresents the scale and nature of Nike's derivative usage. The original answer emphasizes a shift in reporting and exposure management based on liability balances, while the LLM focuses on notional volumes and reclassification of gains not mentioned in the truth. Thus, despite correct entity (Nike, foreign exchange forwards/options) and year identification (2022–2024), the answer fails on factual correctness and quantitative accuracy, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 477,
        "total_tokens": 1858
      },
      "error": null
    },
    {
      "question_id": 48,
      "question": "How has the product category classification of Puffs within the Baby, Feminine & Family Care segment evolved between 2022 and 2023?",
      "original_answer": "In 2022, Puffs was categorized under the Family Care sub-category, which included Paper Towels, Tissues, and Toilet Paper. By 2023, Puffs remained in the Family Care category, but the specific mention of 'Tissues' replaced 'Tissues' with a more general listing without sub-category breakdowns, indicating a simplification or consolidation of how the segment details were reported.",
      "llm_answer": "Based on the provided 10-K pages, the product category classification of Puffs within the Baby, Feminine & Family Care segment remained consistent between 2022 and 2023. Puffs was categorized under \"Baby Care (Baby Wipes, Taped Diapers and Pants)\" in both years, with no indication of reclassification to another sub-category. The segment's composition, as detailed on page 19 of the 2022 filing and reiterated on page 18 of the 2023 filing, consistently listed Baby Care as including \"Baby Wipes, Taped Diapers and Pants\" with Puffs identified as a key brand (e.g., \"Puffs\" under Baby Care in the 2023 table). No changes to this classification were noted in the provided documents.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 2,
      "detailed_feedback": "The LLM answer is fundamentally incorrect. According to the ground truth, Puffs was categorized under the Family Care sub-category (specifically within Tissues) in 2022 and remained in Family Care in 2023, though with a more generalized reporting structure. However, the LLM incorrectly states that Puffs was classified under 'Baby Care (Baby Wipes, Taped Diapers and Pants)' in both years, which contradicts the ground truth. This misidentifies both the product category and the segment structure. There are no numeric values to verify, but the entity and classification errors are severe. The reasoning is flawed as it fails to capture the correct multi-hop evolution of Puffs' categorization across years and misattributes the brand to a different sub-segment entirely. The context of the question—evolution of classification—is completely misrepresented. Thus, the answer is factually wrong on all key points despite referencing document pages, resulting in a very low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1261,
        "completion_tokens": 283,
        "total_tokens": 1545
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has the positioning of Tampax within P&G's product portfolio evolved between 2022 and 2023, particularly in terms of its categorization and associated product lines?",
      "original_answer": "In 2022, Tampax was categorized under 'Feminine Care' within the 'Baby, Feminine & Family Care' segment, which also included 'Baby Care' and 'Family Care' sub-categories. By 2023, the product category was refined, and Tampax was associated solely with 'Menstrual Care' under the same broader segment. This reflects a more focused positioning of Tampax, separating it from general 'Family Care' items and aligning it more specifically with menstrual health needs.",
      "llm_answer": "Between 2022 and 2023, Tampax remained within the Baby, Feminine & Family Care segment, which held 25% of net sales and 23% of net earnings in both years. The segment's product categories consistently listed Tampax alongside Always and Bounty, with no reclassification or portfolio restructuring mentioned for Tampax specifically during this period.",
      "correctness_score": 2,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect in terms of the core factual evolution of Tampax's positioning. While it correctly identifies that Tampax is within the 'Baby, Feminine & Family Care' segment, it fails to report the key change in categorization from 'Feminine Care' in 2022 to 'Menstrual Care' in 2023, which is the central point of the question. Instead, it claims no reclassification occurred, which directly contradicts the ground truth. The quantitative data (25% of net sales, 23% net earnings) is not present in the original answer and cannot be verified against the ground truth; however, since the question does not ask for financial performance metrics, these numbers are contextually irrelevant and distract from the actual categorization shift. The mention of Always and Bounty is plausible but not pertinent to the specific evolution of Tampax’s categorization. The reasoning is flawed because it denies a reclassification that actually occurred, indicating a failure in multi-hop synthesis or data retrieval. The answer lacks semantic equivalence with the ground truth, as it omits the entire refinement of product categorization and instead asserts continuity. Thus, while some entities (segment name) are correct, the core qualitative and factual content is inaccurate, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1208,
        "completion_tokens": 366,
        "total_tokens": 1575
      },
      "error": null
    },
    {
      "question_id": 49,
      "question": "How has Oracle's strategy and positioning of Oracle Engineered Systems evolved between fiscal 2022 and fiscal 2023, particularly in terms of revenue contribution and research investment expectations?",
      "original_answer": "In fiscal 2022, Oracle highlighted that its hardware business, which includes Oracle Engineered Systems, involved point-of-sale revenue recognition for hardware and related software, with the majority of products sold through indirect channels. By fiscal 2023, Oracle introduced a more forward-looking strategy, explicitly stating plans to continue investing in research and development to improve existing hardware products and develop new offerings. Additionally, in fiscal 2023, Oracle noted that hardware represented 6% of total revenues, a figure not specified in 2022, indicating a clearer emphasis on the segment's strategic positioning.",
      "llm_answer": "Between fiscal 2022 and fiscal 2023, Oracle’s Engineered Systems strategy shifted toward cloud integration, with cloud services and license revenue growing from 25% of total revenue in fiscal 2022 to 37% in fiscal 2024 (reflecting a 12-point increase over the two-year period), while hardware revenue declined slightly (down 5% in constant currency in fiscal 2022 vs. 2021). This strategic pivot is underscored by increased R&D investment—total R&D expenses rose 11% in fiscal 2022 (excluding stock-based compensation) to $5.586 billion, driven by headcount growth and cloud infrastructure expansion—to support cloud adoption and future product development. The company explicitly expects cloud and license revenue growth to continue, enabling sustained investments in R&D and cloud capacity to fuel long-term margin expansion and market positioning.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both factual content and focus. The question asks specifically about Oracle Engineered Systems' strategy evolution between fiscal 2022 and 2023, particularly regarding revenue contribution and R&D investment expectations. However, the LLM response centers on cloud services and license revenue growth (e.g., 25% to 37% from 2022 to 2024), which is irrelevant to Engineered Systems and misrepresents the timeline and metrics. The only partially correct element is the mention of increased R&D investment, but even this is misattributed: the $5.586 billion R&D figure and 11% increase pertain to fiscal 2022, while the ground truth emphasizes a forward-looking R&D commitment specifically for hardware in fiscal 2023, which the LLM fails to highlight. (2) Quantitative inaccuracies abound: the 37% cloud revenue figure is cited for fiscal 2024, outside the requested 2022–2023 scope; the 5% hardware revenue decline is from 2022 vs. 2021, not relevant to the 2022–2023 comparison; and no mention is made of the key 6% hardware revenue contribution in fiscal 2023, a critical data point in the ground truth. (3) Multi-hop reasoning is flawed: the model fails to connect Engineered Systems to hardware revenue, does not compare fiscal 2022 and 2023 strategies as required, and introduces cloud revenue trends that are contextually misplaced. It also omits the shift from indirect channel focus in 2022 to explicit R&D investment plans in 2023. (4) The answer is somewhat contextually relevant as it discusses Oracle’s broader strategy, but it misses the specific focus on Engineered Systems and misrepresents the evolution in both revenue transparency and R&D direction. Due to major factual and conceptual errors, the correctness score is low at 3, with similarly low quantitative and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1386,
        "completion_tokens": 503,
        "total_tokens": 1889
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did Honeywell's investment in private funds for its Non-U.S. pension plans evolve between 2022 and 2023, particularly in terms of allocation and classification across fair value hierarchy levels?",
      "original_answer": "In 2022, Honeywell reported $1,105 million invested in private funds for its U.S. pension plans, with the amount classified under Level 3 of the fair value hierarchy. By 2023, the company reported $115 million in private fund investments for its Non-U.S. pension plans, with $41 million classified under Level 2 and $74 million under Level 3 of the fair value hierarchy. This represents a significant decrease in overall private fund allocation, particularly in U.S. plans, and a shift in classification for the remaining private fund investments under the Non-U.S. plans.",
      "llm_answer": "Between 2022 and 2023, Honeywell’s investment in private funds for its non-U.S. pension plans increased from $90 million (comprising $54 million Level 2 and $36 million Level 3) in 2022 to $115 million (comprising $41 million Level 2 and $74 million Level 3) in 2023, reflecting a shift toward higher Level 3 valuations. The allocation across the fair‑value hierarchy remained largely unchanged, with private‑fund assets still classified primarily as Level 2 (≈ 36 % of the total) and Level 3 (≈ 64 % of the total) in both years.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors. The original answer states that in 2022, Honeywell reported $1,105 million invested in private funds for its *U.S.* pension plans (Level 3), not non-U.S. plans. The LLM incorrectly claims $90 million in non-U.S. private fund investments in 2022 with a split of $54M Level 2 and $36M Level 3 — this data is entirely fabricated and not present in the ground truth. In 2023, the correct figure is $115 million for *Non-U.S.* plans, split into $41M Level 2 and $74M Level 3 — this part is accurately reported by the LLM. However, the comparison is invalid because the LLM compares non-U.S. 2023 data to non-U.S. 2022 data that does not exist in the source. (2) Quantitative accuracy fails: the $90M, $54M, and $36M figures for 2022 are incorrect; the actual 2022 private fund investment mentioned is $1,105M but for U.S. plans, not non-U.S. The 2023 numbers are correct. The LLM also incorrectly implies continuity in non-U.S. investments when the major shift was from U.S. to Non-U.S. plans and a large overall decrease. (3) Multi-hop reasoning is flawed: the model fails to correctly identify which numbers apply to which pension plan (U.S. vs. Non-U.S.), leading to incorrect synthesis. It invents 2022 Non-U.S. data instead of recognizing that the $1,105M was for U.S. plans and that the 2023 $115M marks a significant reallocation or reduction, particularly in U.S. plans. (4) Contextual relevance is moderate because the answer discusses the right topic (private fund allocation in pension plans, fair value hierarchy levels) and correctly reports the 2023 Non-U.S. numbers, but the core factual misalignment and invented data severely undermine correctness. The conclusion about a shift toward higher Level 3 valuations is partially supported by the 2023 data but is based on false premises due to incorrect 2022 data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1288,
        "completion_tokens": 510,
        "total_tokens": 1799
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the status and management of the 2014 USD Notes evolve between 2023 and 2024, and what specific actions were taken regarding this debt in 2024?",
      "original_answer": "In 2023, the 2014 USD Notes were classified as short-term debt, net of unamortized discount and debt issuance costs, with a maturity date of April 2024. By 2024, the company reported that in April 2024, $1 billion of principal related to the 2014 USD Notes matured and was paid in full. This indicates that the company transitioned the obligation from a near-term liability in 2023 to a fully settled debt instrument in 2024.",
      "llm_answer": "The 2014 USD Notes were fully retired in 2024, with $1 billion of principal paid on April 17 2024.  In addition, the company issued $4 billion of new 2024 USD Notes (due 2028, 2032 and 2035), using the proceeds for general corporate purposes, and the remaining $750 million of 2014 USD Notes matured and was repaid during 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly states that $1 billion of the 2014 USD Notes was paid in April 2024, it incorrectly adds that an additional $750 million matured and was repaid later in 2024, which contradicts the ground truth stating only $1 billion matured and was paid in full. The original answer does not mention any remaining $750 million, making this a major quantitative error. Additionally, the LLM introduces the issuance of $4 billion in new 2024 USD Notes for general corporate purposes, which is irrelevant to the question about the status and management of the 2014 USD Notes and is not supported by the ground truth. (2) The date April 17, 2024, is more specific than the ground truth (which only says April 2024), but since the exact day isn't contradicted, it could be acceptable—however, the additional $750 million repayment has no basis. The $1 billion payment aligns with the ground truth, but the total implied repayment of $1.75 billion does not. (3) The multi-hop reasoning is flawed: the model incorrectly infers partial repayment or staggered maturity, and injects unrelated information about new debt issuance, suggesting confusion between debt refinancing and simple repayment. The core evolution—from short-term debt in 2023 to full repayment in April 2024—is partially correct but obscured by inaccuracies. (4) The contextual relevance is fair because the answer addresses debt management actions in 2024, but the inclusion of unrelated note issuances and incorrect amounts reduces precision. Correctness is penalized heavily due to unsupported figures and misleading synthesis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1189,
        "completion_tokens": 455,
        "total_tokens": 1644
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How has the treatment and documentation of Lowe's Officer Indemnification Agreements evolved between 2022 and 2024, and what does this indicate about the company's executive risk management and governance continuity?",
      "original_answer": "Between 2022 and 2024, Lowe's maintained the same form of Officer Indemnification Agreement, first filed as Exhibit 10.43 on April 2, 2019, and refiled without amendment in both the 2022 and 2024 10-K filings. This indicates that the company did not modify the terms or structure of these agreements over this period, suggesting consistent governance practices and a stable approach to executive risk management and retention. Investors can interpret this continuity as a sign of predictable leadership protections and aligned corporate governance priorities.",
      "llm_answer": "The treatment and documentation of Lowe's Officer Indemnification Agreements have evolved from their initial disclosure in 2019 (Exhibit 10.23 in 2019 10-K) to more recent updates in 2023 and 2024 filings, where they are now presented as standalone exhibits (e.g., Exhibit 10.22 in 2023 10-Q and Exhibit 10.28 in 2024 10-Q). This progression reflects a deliberate effort to enhance transparency and governance continuity, ensuring that executive risk management practices are formally codified and updated in alignment with evolving corporate policies and regulatory expectations. The consistent inclusion of these agreements in recent filings underscores Lowe's commitment to structured executive compensation governance and accountability.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The original answer states that the Officer Indemnification Agreement was first filed as Exhibit 10.43 on April 2, 2019, and was refiled without amendment in both the 2022 and 2024 10-Ks. In contrast, the LLM claims the initial disclosure was Exhibit 10.23 in 2019, and that updates occurred in 2023 and 2024 with different exhibit numbers (10.22 in 2023 10-Q, 10.28 in 2024 10-Q), which contradicts the ground truth of no changes and consistent re-filing of the same exhibit. These exhibit numbers and filing types (10-Q vs 10-K) are incorrect. (2) The dates and exhibit numbers are factually wrong—there is no evidence of evolution or renumbering in the actual filings. The LLM incorrectly implies active updates and structural changes, while the truth is no amendments were made. (3) The multi-hop reasoning fails: the model should have identified that the same exhibit was reused verbatim in 2022 and 2024, indicating no change. Instead, it infers increased transparency and policy evolution, which is unsupported. It also references 10-Q filings, which are not part of the original 10-K-based timeline in the question. (4) The contextual relevance is moderate because the answer addresses executive risk management and governance, but the conclusions are based on false premises. Due to major factual and quantitative errors, the correctness score is low at 2, with similarly low scores for quantitative (2) and qualitative accuracy (3).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1342,
        "completion_tokens": 417,
        "total_tokens": 1760
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How did the market share and category positioning of Always Discreet in the adult incontinence market change between the 2022 and 2023 Procter & Gamble 10-K filings?",
      "original_answer": "In the 2022 filing, Always Discreet was explicitly stated to have over 10% market share in the key adult incontinence markets where Procter & Gamble competes. However, in the 2023 filing, while Always Discreet is still listed as a major brand in the Feminine Care category under the Baby, Feminine & Family Care segment, no specific market share figure is provided for the brand. This suggests a shift in how the brand's performance is communicated, moving away from a quantified market share disclosure to a more general category association.",
      "llm_answer": "Based on the 2022 and 2023 10‑K filings, Always Discreet’s market share in the adult‑incontinence category remained essentially flat – the company continued to hold roughly 10 percent of the key markets in which it competes in both years, with no significant shift in its category positioning reported. The filings note that Always Discreet operates in the adult‑incontinence sub‑category of the Baby, Feminine & Family Care segment and that its market share in those markets stayed around 10 percent across the two periods.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in its core claim. (1) According to the ground truth, the 2022 filing explicitly stated that Always Discreet had over 10% market share, but the 2023 filing did not provide any specific market share figure. The LLM incorrectly asserts that the market share 'remained essentially flat' and 'stayed around 10 percent' in 2023, which is not supported by the 2023 filing. This is a critical factual error. (2) The quantitative accuracy is low because the LLM fabricates a 10% market share for 2023 that is not present in the source document. Even though 10% is consistent with 2022, there is no confirmation in 2023 data, so asserting it as fact is inaccurate. (3) The reasoning is flawed: instead of recognizing the shift in disclosure strategy (from quantified share to general brand listing), the model assumes continuity without evidence. It fails to identify the multi-hop nuance — that the absence of a number in 2023 represents a change in reporting, not stability in performance. (4) While the context about the brand being in the Baby, Feminine & Family Care segment is correct, the overall answer misrepresents the key change between years. Hence, correctness and qualitative accuracy are low, though some contextual elements are accurate, warranting a moderate relevance score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1271,
        "completion_tokens": 365,
        "total_tokens": 1637
      },
      "error": null
    },
    {
      "question_id": 50,
      "question": "How has Oracle's strategic positioning of Engineered Systems evolved between 2022 and 2023, particularly in terms of their role within the hardware business and implications for Oracle's cloud transformation narrative?",
      "original_answer": "In 2022, Oracle Engineered Systems were described as pre-integrated products central to both cloud and on-premise data center infrastructure, emphasizing their technical advantages such as improved performance, scalability, and simplified maintenance. However, by 2023, Oracle elevated the strategic importance of Engineered Systems by positioning them as part of a broader hardware business that now includes servers, storage, and operating systems, all tightly integrated and accounted for as combined performance obligations. The 2023 filing also highlighted that hardware revenues, including Engineered Systems, represented 6% of total revenues in both fiscal 2023 and 2024, and underscored ongoing R&D investments to enhance these offerings. This evolution suggests that Oracle is leveraging Engineered Systems not just as technical solutions but as foundational components in its hybrid cloud and on-premise strategies, aligning them more closely with its cloud transformation narrative while acknowledging the lower-margin nature of the hardware business.",
      "llm_answer": "Between 2022 and 2023, Oracle’s Engineered Systems shifted from a standalone hardware revenue stream to a more integrated component of its broader cloud strategy, with Oracle Engineered Systems now being positioned as a key enabler for Oracle Cloud Infrastructure (OCI) and hybrid cloud deployments. While hardware represented only 6% of total revenue in both years, the company emphasized that these systems—such as Exadata and engineered servers—are increasingly sold through flexible deployment options (on-premise, OCI, and hybrid) and are closely tied to cloud services, license support, and subscription-based consumption models. This evolution supports Oracle’s cloud transformation narrative by reinforcing that its hardware is not a legacy business but a strategic foundation for driving cloud adoption, with engineered systems serving as a gateway to OCI and enabling customers to modernize workloads through automated, scalable cloud-native platforms.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, the 6% hardware revenue figure for both fiscal 2023 and 2024 (referenced as 'both years') is correctly reported, consistent with the original answer. There are no calculation errors or incorrect numbers. (2) The LLM correctly identifies the evolution in strategic positioning: from pre-integrated systems in 2022 to a more integrated role within Oracle’s broader cloud and hybrid infrastructure strategy in 2023. It accurately reflects that Engineered Systems are now part of a combined hardware business including servers, storage, and OS, though it does not explicitly mention 'combined performance obligations'—a minor omission. (3) The reasoning is sound: the LLM correctly synthesizes the shift in narrative—from standalone hardware to a strategic enabler of OCI and hybrid cloud—supporting Oracle’s cloud transformation. It appropriately highlights flexible deployment models and integration with cloud services and subscriptions, which aligns with the ground truth’s emphasis on R&D and strategic alignment. (4) The answer is contextually excellent, directly addressing Oracle’s strategic evolution, the role within hardware, and implications for cloud transformation. The only minor gap is the lack of explicit mention of 'ongoing R&D investments' and the 'lower-margin nature of hardware' noted in the original, which slightly affects completeness but not core correctness. Overall, the semantic meaning and strategic interpretation are equivalent and well-supported.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1524,
        "completion_tokens": 428,
        "total_tokens": 1952
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did the disclosure regarding the 2020 Stock Plan's relationship with the 2011 Stock Plan evolve between the 2022 and 2023 10-K filings?",
      "original_answer": "In the 2022 10-K filing, the 2020 Stock Plan disclosure included the detail that 5,530,106 shares previously available under the 2011 Stock Plan were carried forward and made available for award grants under the 2020 Stock Plan. However, in the 2023 10-K filing, this specific reference to the 2011 Stock Plan and the carry-forward of shares was omitted. This indicates a shift in how the company chose to present the lineage and transition between the two stock plans, focusing only on the 2020 Stock Plan without linking it to its predecessor in the disclosed text.",
      "llm_answer": "The disclosure regarding the 2020 Stock Plan’s relationship with the 2011 Stock Plan was updated in the 2023 10‑K to clarify that the 2020 Stock Plan is the successor to the 2011 Stock Plan and that the 2020 Plan was adopted by the Board in March 2020 and approved by stockholders in June 2020, whereas the 2011 Plan was the prior plan under which options were previously granted. This evolution reflects the transition from the 2011 Plan to the 2020 Plan as the Company’s current equity‑incentive vehicle.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth. (1) The original answer states that the 2022 10-K included a specific disclosure about 5,530,106 shares being carried forward from the 2011 Stock Plan to the 2020 Stock Plan, but this detail was omitted in the 2023 10-K. In contrast, the LLM claims the 2023 10-K 'updated' the disclosure to clarify the succession between the plans, which is the opposite of what occurred—the linkage was removed, not clarified. (2) There are no correct numeric values mentioned in the LLM response; the key figure of 5,530,106 shares is missing entirely, and no dates related to share carry-forward or plan transitions are accurately tied to the disclosure change. The mention of March 2020 and June 2020 as adoption/approval dates may be factually correct in isolation but are not part of the ground truth comparison between 2022 and 2023 filings. (3) The multi-hop reasoning is flawed: the question asks how the disclosure *evolved* between two years, requiring comparison of content presence vs. absence. The LLM incorrectly infers increased clarity or updated information in 2023, when the actual evolution was a removal of prior information, indicating reduced linkage in disclosure. (4) Contextual relevance is moderate because the answer discusses the relationship between the two stock plans, which is relevant, but it misrepresents the nature of the change, failing the core requirement of accurately describing the disclosure evolution. Thus, the answer is factually wrong on key points and receives a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1266,
        "completion_tokens": 433,
        "total_tokens": 1699
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How has Honeywell's allocation strategy toward private funds evolved between 2022 and 2023, and what might this indicate about the company's capital deployment priorities?",
      "original_answer": "In 2022, Honeywell reported $1,244 million invested in private funds, as disclosed in the 2022 10-K filing. By 2023, this amount increased slightly to $1,265 million, as noted in the 2023 10-K filing. This represents a modest increase of approximately 1.7%, suggesting that Honeywell maintained a relatively stable allocation strategy toward private funds despite broader reductions in total assets under the U.S. plans. This slight upward trend may indicate a strategic decision to preserve or slightly expand exposure to alternative investments, potentially to capitalize on expected higher returns or diversification benefits from private fund investments.",
      "llm_answer": "Between 2022 and 2023, Honeywell increased its allocation to private funds within non-U.S. pension plans from $36 million to $74 million (a 106% rise), while direct private investments in U.S. plans grew modestly from $1,284 million to $1,293 million. This shift toward larger private‑fund holdings—particularly in non‑U.S. plans—suggests the company is leaning more heavily on alternative investments to meet long‑term return objectives and diversify its asset mix, reflecting a strategic emphasis on capital deployment into higher‑return, less‑correlated assets.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The original answer states that Honeywell reported $1,244 million in private funds in 2022 and $1,265 million in 2023, representing a 1.7% increase. However, the LLM claims a split between non-U.S. pension plans (rising from $36M to $74M) and U.S. plans (from $1,284M to $1,293M), which is not supported by the ground truth. These specific figures and categorizations (U.S. vs. non-U.S.) do not appear in the original answer and contradict the unified private fund amounts provided. (2) The quantitative inaccuracies are severe: the LLM invents a 106% increase in non-U.S. plans and reports higher base amounts ($1,284M vs. $1,244M in 2022) that are inconsistent with the ground truth. The correct increase is ~21 million (from 1,244 to 1,265), or 1.7%, not the implied total of ~$98 million increase as suggested by the LLM's numbers. (3) The multi-hop reasoning is flawed because the LLM fabricates a breakdown by U.S. and non-U.S. plans that is absent in the original data, leading to incorrect synthesis. The conclusion about a strategic shift toward alternative investments, while plausible, is based on false numerical premises. (4) The contextual relevance is moderate because the answer addresses capital deployment priorities and alternative investments, which aligns with the question’s intent, but the factual foundation is incorrect, undermining the analysis. Thus, the correctness score is low due to major quantitative and entity errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1312,
        "completion_tokens": 419,
        "total_tokens": 1731
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did the status and disclosure of Class B-2 Common Stock evolve between 2023 and 2024, particularly regarding its outstanding status and relationship to other stock classes?",
      "original_answer": "In 2023, Class B-2 Common Stock was subject to conversion rate adjustments tied to the U.S. litigation escrow account under the U.S. retrospective responsibility plan, which caused dilution in as-converted shares. Additionally, it was noted that no shares of Class B-2 were outstanding prior to the Class B-1 exchange offer. By 2024, the 10-K filing only referenced Class B-2 Common Stock in relation to its lack of outstanding shares prior to the Class B-1 exchange offer, with no further updates or disclosures regarding its conversion mechanics or dilution impacts, suggesting a reduced emphasis or potential discontinuation of its active role in the capital structure.",
      "llm_answer": "Between 2023 and 2024, Class B‑2 common stock transitioned from having no outstanding shares to 120 million shares issued (and 64 million shares repurchased) following the class B‑1 exchange offer in May 2024, which converted tendered B‑1 shares into roughly 120 million B‑2 shares and 48 million C shares; the B‑2 shares are not convertible or transferable until all U.S. litigation is resolved, and their conversion rate adjustments have a greater impact than those for B‑1 shares. This evolution reflects the company’s restructuring of its capital stock to facilitate the exchange offer and subsequent redenomination of remaining B‑common stock as B‑1 shares.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect and contradicts the ground truth. The original answer states that no shares of Class B-2 were outstanding prior to the Class B-1 exchange offer and that in 2024, there were no updates or disclosures about active issuance or conversion mechanics—implying inactivity or discontinuation. In contrast, the LLM claims 120 million B-2 shares were issued in May 2024 and 64 million repurchased, which is not supported by the ground truth. There is no mention in the original answer of any issuance, repurchase, or specific share counts related to B-2 stock in 2024. (2) Quantitative inaccuracies include the fabricated figures of '120 million shares issued' and '64 million repurchased', as well as the claim of conversion into '48 million C shares', none of which appear in the ground truth. The date 'May 2024' is also not mentioned in the original. (3) The multi-hop reasoning is flawed: the LLM incorrectly infers an active role for Class B-2 in a 2024 exchange offer, while the ground truth indicates a reduction in disclosure and emphasis, suggesting dormancy. The relationship between B-2 and other classes is misrepresented—while the LLM describes transferability and conversion restrictions, the original only notes dilution via conversion rate adjustments in 2023 and silence in 2024. (4) The contextual relevance is moderate because the answer discusses Class B-2 stock in relation to other classes and capital structure changes, but the factual foundation is incorrect, leading to a low correctness and quantitative accuracy score. The qualitative accuracy is slightly higher because it attempts to reason about structural relationships, albeit based on false premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1341,
        "completion_tokens": 470,
        "total_tokens": 1811
      },
      "error": null
    },
    {
      "question_id": 51,
      "question": "How did the financial obligations related to the Target Circle program change between 2022 and 2024, and what does this indicate about the program's evolution?",
      "original_answer": "In 2022, the deferred revenue related to the Target Circle program was $89 million as of January 29, 2022, while in 2024, the deferred revenue related to the program was $117 million as of February 3, 2024. This indicates a significant increase in the company's liability tied to unredeemed rewards, suggesting growth in program participation or changes in redemption patterns. However, by February 1, 2025, the deferred revenue had dropped to $19 million, signaling a sharp decline, which may reflect either a surge in reward redemptions or a strategic change in how the program's liabilities are recognized or managed.",
      "llm_answer": "The Target Circle program liability decreased from $117 million in 2023 to $19 million in 2024, reflecting a significant reduction in the deferred revenue associated with the program. This decline indicates that Target has streamlined or scaled back the Circle rewards structure, moving away from the larger liability balance it carried in 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It claims the liability decreased from $117 million in 2023 to $19 million in 2024, but the ground truth states that $117 million was the deferred revenue as of February 3, 2024 (fiscal year 2023), and $19 million was reported as of February 1, 2025 (fiscal year 2024). The LLM incorrectly assigns these figures to 2023 and 2024 calendar years, misrepresenting the timeline. Additionally, the 2022 figure of $89 million is completely omitted, which is critical for assessing the change between 2022 and 2024 as asked in the question. (2) The numbers themselves ($117M and $19M) appear in the ground truth but are misaligned with the correct years. The LLM incorrectly frames the change as occurring between 2023 and 2024, while the actual comparison required is between 2022 ($89M) and 2024 ($117M), followed by the drop to $19M in 2025. Calculations or comparisons based on incorrect time periods invalidate the reasoning. (3) The multi-hop reasoning is flawed: the model fails to synthesize the full trajectory—growth from $89M to $117M (2022–2024), then a sharp drop to $19M (by 2025). Instead, it only captures the final drop and misattributes it to a program 'scaling back' without acknowledging the prior growth. The conclusion about Target 'streamlining' the program is speculative and not supported by the full data trend. (4) While the mention of declining liability and deferred revenue shows some contextual understanding, the omission of key data points, incorrect year mappings, and incomplete analysis severely undermine correctness. The answer is partially relevant but factually and temporally inaccurate, warranting a low score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1244,
        "completion_tokens": 468,
        "total_tokens": 1712
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the fair value of Netflix's 4.375% Senior Notes change between December 31, 2022, and December 31, 2023, and what does this indicate about investor perception or market conditions?",
      "original_answer": "The fair value of Netflix's 4.375% Senior Notes decreased from $980 million on December 31, 2022, to $996 million on December 31, 2023. This indicates a shift in investor perception or market conditions, as the fair value moved closer to the principal amount at par, suggesting a stabilization or improved outlook for the company's debt.",
      "llm_answer": "The fair value of Netflix's 4.375% Senior Notes increased from $1,111 million on December 31 2022 to $1,111 million on December 31 2023 (a $1 million rise), indicating that market conditions remained relatively stable with only modest changes in investor perception of the company's creditworthiness.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in both direction and magnitude of change. The ground truth states the fair value decreased from $980 million to $996 million, but the LLM claims an increase from $1,111 million to $1,111 million (a $1 million rise, which is mathematically inconsistent). All key numbers (dates, values) are wrong. (2) Quantitative accuracy is severely lacking: the stated values ($1,111M in both years) do not match the ground truth ($980M and $996M), and the claimed $1 million rise contradicts identical figures. The correct change is a $16 million increase (from $980M to $996M), but the LLM misrepresents both the values and the trend. (3) Multi-hop reasoning is flawed: the model fails to correctly retrieve the fair values for the correct security (4.375% Senior Notes) and time points (Dec 31, 2022 and 2023). It also draws an incorrect conclusion—while the ground truth notes movement toward par value indicating stabilization, the LLM incorrectly infers 'modest changes' based on fabricated data. (4) Contextual relevance is moderate because the answer addresses the question structure (change in fair value and interpretation), but the factual foundation is entirely incorrect, undermining all analysis. The conclusion is not supported by actual data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1169,
        "completion_tokens": 363,
        "total_tokens": 1533
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How did the equity structure related to Class C Common Stock evolve between 2023 and 2024, particularly in terms of share issuance and equity classification?",
      "original_answer": "In 2023, Visa conducted an exchange offer where 241 million shares of Class B-1 common stock were tendered, and in exchange, approximately 48 million shares of Class C common stock were issued. This indicates active restructuring of stock classes tied to the Visa Europe retrospective responsibility plans. By 2024, the balance of Class C common stock remained at 10 shares issued and outstanding, as stated in the equity section of the balance sheet. This suggests that while there was active movement and restructuring involving Class C shares in 2023, the 2024 disclosures indicate a stabilization or conclusion of that phase of equity restructuring.",
      "llm_answer": "Between 2023 and 2024, Visa issued approximately 120 million shares of Class B‑2 common stock and 48 million shares of Class C common stock in connection with the May 2024 Class B‑1 common stock exchange offer, while also releasing $2.7 billion of value from its series B and C preferred stock by issuing 99,264 shares of series A preferred stock.  The company’s equity structure therefore expanded with the addition of these newly issued Class B‑2 and Class C shares, and the preferred‑stock conversion adjusted the outstanding preferred‑stock balance.  No new Class C shares were issued beyond the 10 shares already outstanding, and the overall equity composition reflected the exchange‑offer conversions and the preferred‑stock release.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2023, Visa conducted an exchange offer where 241 million shares of Class B-1 common stock were tendered and approximately 48 million shares of Class C common stock were issued. However, the LLM claims that 48 million shares of Class C were issued in connection with a 'May 2024' exchange offer, which contradicts the timeline—this event occurred in 2023, not 2024. Furthermore, the LLM incorrectly states that 120 million shares of Class B-2 common stock were issued, a figure not supported by the original answer. The original makes no mention of Class B-2 shares or any such issuance. Additionally, the LLM introduces a $2.7 billion release from series B and C preferred stock and issuance of 99,264 shares of series A preferred stock—information entirely absent from the ground truth and factually unsupported in this context. (2) Quantitatively, the only correct number is the 48 million Class C shares issued, though it misattributes the timing and context. The 120 million Class B-2 shares, $2.7 billion, and 99,264 preferred shares are all incorrect or fabricated. The claim that 'no new Class C shares were issued beyond the 10 shares already outstanding' directly contradicts the 48 million issued in 2023, showing a fundamental inconsistency. (3) The multi-hop reasoning is flawed: the model fails to correctly link the 2023 exchange offer to the issuance of Class C shares and incorrectly projects it into 2024. It invents a preferred stock conversion mechanism not present in the original data, indicating a failure in synthesizing accurate equity classification changes. (4) While the answer attempts to address equity structure evolution, it does so with incorrect entities, dates, and financial figures, severely undermining correctness. The contextual relevance is moderate because it discusses equity classification and share issuance, but the factual foundation is unsound, leading to a low overall score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 546,
        "total_tokens": 1897
      },
      "error": null
    },
    {
      "question_id": 52,
      "question": "How has Lowe's engagement with Rough Plumbing evolved from 2022 to 2024, particularly in terms of its business classification and service offerings?",
      "original_answer": "In 2022, Rough Plumbing was classified under the 'Building Products' category, indicating it was primarily offered as a product within Lowe's merchandise divisions. By 2024, Lowe's had expanded its engagement with Rough Plumbing by integrating it into both installation services and protection plans, signaling a shift from a pure product offering to a more service-oriented approach. This evolution reflects a strategic move to bundle Rough Plumbing with labor and extended protection, contributing to the approximately 5% of total sales attributed to installed sales in 2024.",
      "llm_answer": "From 2022 to 2024, Lowe's engagement with Rough Plumbing evolved from being classified under the \"Building Products\" segment—which includes Rough Plumbing as a key category—to being explicitly highlighted within Lowe's omnichannel service offerings. By 2024, Rough Plumbing was recognized as part of Lowe's installed sales and service model, particularly through its integration with Lowe's Protection Plans and repair services, reflecting a strategic expansion in service offerings. Additionally, Lowe's continued to emphasize skilled trades development, including through its Track to the Trades program, which supports career pathways in plumbing and related fields, underscoring a deeper institutional commitment to the category.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies that in 2022, Rough Plumbing was classified under 'Building Products' and evolved by 2024 into a service-integrated offering involving installation and protection plans. The shift from product to service orientation is accurately conveyed. (2) There are no numeric inaccuracies; while the ground truth mentions 'approximately 5% of total sales attributed to installed sales in 2024', this specific percentage is not included in the LLM answer, which is a minor omission but does not introduce error. All other dates (2022, 2024) and classifications are correct. (3) The multi-hop reasoning is sound: the model synthesizes the evolution of business classification and service integration across time, correctly linking Rough Plumbing to installed sales, protection plans, and broader strategic initiatives like Track to the Trades, which supports contextual depth. (4) The answer is semantically equivalent to the original, with slightly expanded context (e.g., mention of skilled trades development), which enhances relevance without distorting facts. The only reason for not scoring a perfect 10 is the omission of the specific '5% of total sales' metric, which was present in the ground truth and directly tied to the impact of the evolution described. However, the core factual and qualitative content is correct and well-reasoned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1328,
        "completion_tokens": 395,
        "total_tokens": 1723
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How did the introduction and subsequent status of Class B-2 common stock evolve between 2023 and 2024, and what does this indicate about its role in the company's capital structure?",
      "original_answer": "In 2023, Class B-2 common stock was newly introduced with 77 million shares outstanding, indicating its initial incorporation into the company's equity structure. By 2024, the company disclosed that no shares of Class B-2 common stock were outstanding prior to the Class B-1 common stock exchange offer, suggesting a strategic shift where Class B-2 shares may have been replaced or restructured as part of a broader capital realignment. This indicates a transformation in the role of Class B-2 common stock within the company’s capital structure.",
      "llm_answer": "Between 2023 and 2024, Class B-2 common stock was created as part of Visa's exchange offer for Class B-1 shares, with approximately 120 million B‑1 shares tendered and retired, resulting in the issuance of about 752 million Class B‑2 shares (and 48 million Class C shares). This restructuring transformed the capital structure, giving Class B‑2 a distinct role alongside Class B‑1 and Class C, while retaining transfer restrictions until U.S. litigation is resolved; the new class participates in earnings per share calculations and reflects a strategic re‑classification of Visa's equity.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Class B-2 common stock was introduced in 2023 with 77 million shares outstanding, but the LLM claims approximately 752 million Class B-2 shares were issued as part of an exchange offer—this number is not supported by the original answer and is grossly inconsistent. Additionally, the LLM introduces Class C shares (48 million) and references Visa’s exchange offer, none of which are mentioned or implied in the ground truth. There is no mention of Visa in the original answer, so the entity is incorrect. (2) Quantitative accuracy is very low: the original states 77 million shares in 2023 and zero outstanding before the Class B-1 exchange in 2024; the LLM reports 752 million B-2 shares and 120 million B-1 shares tendered, which are entirely fabricated numbers not present in the ground truth. No valid calculations can be verified. (3) The multi-hop reasoning is flawed—the LLM invents a narrative about an exchange offer, retirement of shares, and creation of new share classes without evidence from the original answer. The actual evolution is that Class B-2 was introduced in 2023 and then reported as having no prior outstanding shares before the exchange in 2024, suggesting it may have been replaced or restructured. The LLM misrepresents this sequence and adds unsupported events. (4) Contextual relevance is moderate because the answer discusses capital structure changes and share class roles, which aligns thematically with the question, but the specific details are factually incorrect and based on fabricated data. The conclusion about strategic reclassification is partially aligned, but the reasoning is unsound due to incorrect premises.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 478,
        "total_tokens": 1771
      },
      "error": null
    },
    {
      "question_id": 53,
      "question": "How has the financial liability associated with the Target Circle program changed between 2022 and 2024, and what does this indicate about the program's growth or evolution?",
      "original_answer": "In 2022, the Target Circle program was described primarily in terms of its benefits to customers, such as earning 1% rewards on non-RedCard purchases, but no specific liability figure was disclosed. By 2024, the deferred revenue related to the Target Circle program had grown to $117 million as of February 3, 2024, indicating a significant increase in the program's financial liability and suggesting substantial growth or expansion of the program. This increase reflects a greater number of participants or increased transactional activity within the program.",
      "llm_answer": "The financial liability associated with the Target Circle program decreased from $117 million in 2023 to $19 million in 2024. This reduction reflects a shift in how the program's deferred revenue is recorded—now reported as part of accrued liabilities rather than as a distinct liability—indicating that the program has matured and its financial impact is being consolidated within broader liability accounts rather than showing a separate, growing liability balance.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both quantitative and qualitative aspects. (1) Quantitatively, it claims a decrease from $117 million in 2023 to $19 million in 2024, but the ground truth states no liability was disclosed in 2022 and $117 million was reported as of February 3, 2024—there is no mention of a $19 million figure or a decline. The $117 million is a 2024 figure, not 2023, and no prior liability amount was disclosed for 2022, so the claimed decrease is factually wrong. (2) The answer invents a change in accounting treatment (recording under accrued liabilities) that is not present in the original data, introducing false reasoning. (3) The multi-hop reasoning fails: the question asks about changes between 2022 and 2024, but the model fabricates a 2023 figure and misrepresents the trend. (4) Contextually, while the answer attempts to interpret the financial meaning, it does so based on false premises. The original answer indicates growth due to increasing liability, whereas the LLM incorrectly infers maturity and consolidation. Thus, the core facts, calculations, entities, and logic are all incorrect, warranting a very low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1263,
        "completion_tokens": 330,
        "total_tokens": 1594
      },
      "error": null
    },
    {
      "question_id": 54,
      "question": "How has NVDA's exposure to and concern about pollution limits evolved between 2023 and 2024, particularly in terms of regulatory impact on operations and customer data center expansion?",
      "original_answer": "In 2023, NVDA highlighted that pollution limits and related climate regulations could increase direct and indirect costs, including compliance, energy, and capital expenditures, and could require changes to manufacturing processes and supply chain operations. By 2024, the company expanded its concern to include not only cost increases but also the potential for land and permitting constraints tied to pollution limits, which could impair customers' ability to expand data center capacity—an essential market for NVDA's products. This indicates a growing concern that regulatory tightening around pollution could directly affect demand for NVDA's offerings.",
      "llm_answer": "NVIDIA’s 2024 10‑K shows that concerns about pollution limits and related regulatory impacts have grown modestly but remain secondary to other risks.  The filing notes that “new or proposed regulations relating to … pollution limits … could result in greater direct costs … and higher compliance and energy costs,” and that such rules could force changes to manufacturing processes or product design.  However, the company’s discussion of these risks is brief and framed within a broader set of climate‑related and supply‑chain concerns; there is no indication of a material shift in how pollution limits affect NVIDIA’s operations or data‑center expansion between 2023 and 2024.  In short, regulatory pressure from pollution limits is acknowledged as a potential cost driver but has not dramatically evolved or become a primary driver of operational or data‑center strategy in the latest filing.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer is factually incorrect in its core conclusion, despite using plausible language from the 10-K. (1) Correctness: The original answer states that NVDA's concern evolved significantly from 2023 to 2024—specifically, that in 2024 the company expanded its risk discussion to include land and permitting constraints affecting customer data center expansion, which could directly impact demand. The LLM answer incorrectly claims there was 'no indication of a material shift' and that concerns 'have grown modestly but remain secondary,' which contradicts the ground truth showing a meaningful expansion in risk exposure. (2) Quantitative Accuracy: There are no numerical values in this question, so this score is 10 by default—no factual numbers were misstated. (3) Reasoning: The multi-hop reasoning failed—the question required comparing NVDA’s risk disclosures across two years and identifying an evolution in concern from internal cost impacts (2023) to external demand-side impacts via customer constraints (2024). The LLM did not capture this key shift and instead downplayed the evolution, missing the synthesis between regulatory effects on customers and downstream impact on NVDA’s market. (4) Contextual Relevance: The answer is relevant and discusses pollution limits, regulations, costs, and data centers, so it stays on topic, but it misrepresents the degree of change between years. Thus, while contextually appropriate, it is factually and qualitatively inaccurate in its assessment of the evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1398,
        "completion_tokens": 417,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 55,
      "question": "How did the composition and valuation of the company's Guaranteed Senior Notes evolve between 2023 and 2024, particularly in terms of issuance, repayment, and fair value inputs?",
      "original_answer": "In 2023, the company's Japanese subsidiary issued four Guaranteed Senior Notes totaling approximately $500 at fixed interest rates ranging from 1.400% to 2.120%. These notes were valued using Level 3 inputs. In 2024, the Japanese subsidiary repaid $77 of these Guaranteed Senior Notes. The fair value of long-term debt, including Guaranteed Senior Notes, was approximately $5,412 at the end of 2024, compared to $5,738 at the end of 2023. This indicates a reduction in the overall fair value of long-term debt, partially driven by repayments on the Guaranteed Senior Notes.",
      "llm_answer": "Between 2023 and 2024, the composition of the company's Guaranteed Senior Notes issued by its Japanese subsidiary evolved through a $500 issuance in November 2023 (with maturities from 2033 to 2043) and a $77 repayment in July 2024, reducing the outstanding balance. The fair value of these notes, classified as Level 3, was part of the total long-term debt carrying value of $5,919 million in 2024 (down from $6,484 million in 2023), with the current portion decreasing from $1,081 million to $103 million. The company also paid off $1,000 of 2.750% Senior Notes in May 2024, though these were separate from the Guaranteed Senior Notes. Fair value inputs for debt remained Level 2 for U.S. Senior Notes and Level 3 for the Japanese subsidiary's notes.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. While it correctly states that $500 in Guaranteed Senior Notes were issued in 2023 and $77 were repaid in 2024, it introduces incorrect figures for total long-term debt: it claims the carrying value was $5,919 million in 2024 (down from $6,484 million in 2023), but the ground truth reports fair values of $5,412 (2024) and $5,738 (2023). These numbers do not match and represent a significant quantitative error. Additionally, the LLM mentions a $1,000 repayment of 2.750% Senior Notes in May 2024, which is not mentioned in the ground truth and appears to be fabricated or misattributed. The current portion decrease from $1,081M to $103M is also not supported by the original answer. (2) The dates of issuance (November 2023) and repayment (July 2024) are plausible but not confirmed in the ground truth, which only specifies the years 2023 and 2024 without months—this adds spurious precision. Interest rate ranges (1.400%–2.120%) from the ground truth are omitted in the LLM answer. (3) The multi-hop reasoning is partially sound: the LLM correctly identifies the Japanese subsidiary as the issuer, links the notes to Level 3 inputs, and distinguishes them from other senior notes. However, it fails to accurately synthesize the fair value trend for long-term debt, misreporting both the magnitude and direction of change relative to the ground truth. (4) Despite these errors, the answer is contextually relevant and structured well, addressing issuance, repayment, and fair value inputs. It correctly identifies Level 3 classification for the Japanese notes and contrasts with Level 2 for U.S. notes, which aligns with qualitative expectations. However, major numerical inaccuracies and unsupported details severely undermine factual correctness, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1339,
        "completion_tokens": 503,
        "total_tokens": 1842
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did Netflix's investment in streaming service improvements and associated risk exposure evolve from 2022 to 2024, based on the specific personnel and cybersecurity-related changes disclosed in those years?",
      "original_answer": "In 2022, Netflix disclosed a $384 million increase in personnel-related costs driven by headcount growth to support production activity and improve the streaming service. By 2024, the focus had evolved to include significant emphasis on cybersecurity, with detailed descriptions of enterprise-wide security programs, third-party risk management, and the potential financial impact of cyber incidents. The company highlighted the risk of unauthorized data releases and digital content theft, noting that such events could adversely affect business operations and financial results. This represents a shift from purely growth-oriented investment in streaming to a more risk-aware posture as the service matured.",
      "llm_answer": "From 2022 to 2024 Netflix’s cybersecurity risk exposure evolved alongside its growing investment in streaming infrastructure and personnel. The 2022 filing (pages 24‑28) highlighted a dedicated VP of Security and Privacy Engineering with 30 years of industry experience, a formal enterprise‑wide security program, and regular board‑level risk assessments. By 2024 (pages 15‑19), the company reported expanded security leadership, ongoing penetration testing, bug‑bounty initiatives, and heightened oversight by the Audit Committee, while also noting increased reliance on third‑party security controls. These disclosures show a clear progression from establishing a robust security framework in 2022 to scaling and tightening that framework through additional staffing, more rigorous testing, and stronger governance in the subsequent two years.",
      "correctness_score": 4,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly regarding quantitative details. The ground truth states that in 2022, Netflix disclosed a $384 million increase in personnel-related costs to support streaming improvements—this key financial figure is entirely missing from the LLM response. Instead, the LLM introduces unverified details such as a 'dedicated VP of Security and Privacy Engineering' and specific page numbers (e.g., pages 24–28 in 2022, 15–19 in 2024), which are not present in the original answer and cannot be confirmed from the provided truth. (2) There are no correct numerical values mentioned in the LLM answer that align with the ground truth; the $384 million investment is a central data point that is omitted, severely undermining quantitative accuracy. (3) The reasoning partially captures the evolution toward greater cybersecurity focus by 2024, mentioning expanded security leadership, penetration testing, and third-party controls, which aligns thematically with the original answer’s emphasis on enterprise-wide programs and risk management. However, it misrepresents the timeline: the original answer implies that cybersecurity became a more prominent risk disclosure by 2024, not that a full security program was already detailed in 2022. This reverses the evolution narrative—original shows shift from growth (2022) to risk-awareness (2024), while LLM suggests strong cybersecurity focus was already in place in 2022. (4) Contextually, the LLM addresses the question about personnel and cybersecurity changes, but conflates the nature and timing of disclosures. It invents specific roles and page references not found in the ground truth, reducing reliability. While the general direction of increased cybersecurity attention is correct, the absence of the $384M personnel cost increase and misrepresentation of 2022 cybersecurity maturity lead to a low correctness score despite some thematic relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1404,
        "completion_tokens": 532,
        "total_tokens": 1937
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did The Bank of New York Mellon Corporation's approach to restricted stock unit agreements evolve between the 2023 and 2024 filings, particularly in terms of the lifecycle management of these equity instruments and their implications for executive compensation strategy?",
      "original_answer": "In the 2023 filing, the '2024 Form of Restricted Stock Unit Agreement' was newly introduced and explicitly stated as 'Filed herewith,' indicating it was a current and newly adopted form for that year. This suggests the company was actively updating its equity compensation framework to align with strategic goals for executive retention and incentives. By the 2024 filing, this '2024 Form' was no longer newly filed but instead was referenced as 'Previously filed,' signaling it had become an established part of the company's compensation structure. Additionally, in 2024, the company introduced the '2025 Form of Restricted Stock Unit Agreement,' which was marked as 'Filed herewith,' showing a forward-looking update to the equity compensation strategy. This evolution indicates a consistent, proactive approach to managing executive compensation frameworks, with new forms being introduced annually and the prior year’s forms transitioning into reference documents. This reflects a mature, iterative process in shaping executive incentives and aligning them with long-term corporate objectives.",
      "llm_answer": "The Bank of New York Mellon Corporation's approach to restricted stock unit (RSU) agreements evolved in its 2023 and 2024 filings by introducing updated forms that reflect refinements in executive compensation strategy and lifecycle management. In the 2023 filing (page 19), the company referenced 2023 Form of Restricted Stock Unit Agreements and 2023 Form of Performance Share Unit Agreements, which were incorporated by reference from prior quarterly reports. By the 2024 filing (pages 18 and 19), the company filed a new 2024 Form of Restricted Stock Unit Agreement (Exhibit 10.29) and amended its Executive Severance Plan (Exhibit 10.30), indicating a strategic update to both long-term incentive structures and executive compensation terms. These changes suggest a deliberate effort to align RSU and performance-based equity instruments with evolving governance practices and executive retention goals, particularly through updated agreements filed in 2024 that supersede or extend prior versions.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains partially correct information but includes significant inaccuracies and omissions when compared to the ground truth. (1) It incorrectly states that in the 2023 filing, the '2023 Form of Restricted Stock Unit Agreement' was referenced and incorporated by reference from prior quarterly reports. However, the ground truth indicates that the '2024 Form' was introduced in the 2023 filing as 'Filed herewith,' which is a critical detail about the timing and novelty of the form. This misidentifies both the form year and its status in the filing, undermining the accuracy of the lifecycle analysis. (2) The LLM claims the 2024 filing included the '2024 Form' as a newly filed document (Exhibit 10.29), but according to the original answer, the 2024 Form was not newly introduced in the 2024 filing—it was already established and marked as 'Previously filed.' Instead, the 2024 filing introduced the '2025 Form' as 'Filed herewith,' which the LLM completely misses. This error distorts the entire narrative of annual updates to RSU agreements. (3) The mention of the amended Executive Severance Plan (Exhibit 10.30) and Performance Share Unit Agreements adds contextual detail but is not supported by the ground truth and distracts from the core evolution of RSU forms. (4) While the LLM correctly infers a strategic, forward-looking update to executive compensation, it fails to capture the key pattern in the lifecycle management: the annual introduction of a new form (e.g., 2025 Form in 2024) and the demotion of the prior year’s form to 'Previously filed' status. This multi-hop synthesis across years is central to the question and is not accurately reflected. (5) Quantitative accuracy is moderate: dates (2023, 2024) are correct, but the specific form years (2023, 2024, 2025) are misattributed. No numerical calculations are involved, so scoring focuses on correct identification of years and document statuses. Overall, the answer shows relevant intent and contextual understanding but lacks factual precision and correct entity-year mapping, leading to a partially correct but misleading conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1557,
        "completion_tokens": 568,
        "total_tokens": 2125
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How has the status and structure of the 4.90% Senior Notes evolved from 2023 to 2024, particularly in terms of their carrying amount and maturity timeline?",
      "original_answer": "In 2023, the 4.90% Senior Notes were newly issued in November 2023, with a principal amount of $750 million, a discount of $3.4 million, and a maturity date of April 15, 2029. Interest payments were scheduled semi-annually starting April 15, 2024. By 2024, these notes remained outstanding, with a carrying amount of $743 million as of January 28, 2024. The maturity date remained unchanged at April 2029, and the notes continued to be listed among the company’s long-term debt obligations. The carrying amount slightly decreased, reflecting the initial discount and amortization progress over the year.",
      "llm_answer": "From 2023 to 2024, the 4.90% Senior Notes due April 15, 2029 (issued in November 2023 as part of the $750 million third tranche) saw their carrying amount increase from $743 million (as of January 28, 2024) to $744 million (as of February 2, 2025), reflecting the amortization of the $3.4 million discount over time. Their maturity timeline remains unchanged at April 15, 2029, consistent with the original issuance terms.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors. According to the ground truth, the 4.90% Senior Notes were issued in November 2023 with a principal of $750 million and a discount of $3.4 million, resulting in an initial carrying amount of $746.6 million. The original answer states the carrying amount was $743 million as of January 28, 2024. However, the LLM claims the carrying amount was $743 million in 2024 and increased to $744 million by February 2, 2025. This is incorrect: the carrying amount should gradually increase toward $750 million due to discount amortization, but the LLM misrepresents the timeline and amounts. Moreover, the LLM incorrectly implies the carrying amount was $743 million at the start of 2024 and then increased, while the ground truth presents $743 million as the carrying amount at the beginning of 2024, already reflecting initial amortization. (2) The maturity date (April 15, 2029) is correctly stated, and the issuance in November 2023 is accurate. However, the LLM introduces a future date (February 2, 2025) not mentioned in the original and falsely claims an increase in carrying amount beyond 2024, which is unsupported. The $3.4 million discount is correctly referenced. (3) The multi-hop reasoning is flawed: the LLM confuses the direction and timing of amortization impact. It incorrectly suggests the carrying amount increased from 2023 to 2024, but no 2023 carrying amount is provided in the ground truth—only the issuance details. The LLM fabricates a comparative trend that isn't supported. (4) The contextual relevance is moderate—the response addresses the maturity timeline and carrying amount evolution, but the factual inaccuracies, especially in quantitative progression, severely undermine correctness. The answer misrepresents the financial trajectory of the notes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1258,
        "completion_tokens": 499,
        "total_tokens": 1757
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How did the issuance and repayment of Guaranteed Senior Notes by Costco's Japanese subsidiary evolve between 2023 and 2024?",
      "original_answer": "In 2023, Costco's Japanese subsidiary issued four Guaranteed Senior Notes totaling approximately $500 at fixed interest rates ranging from 1.400% to 2.120%. In 2024, the subsidiary repaid $77 of these Guaranteed Senior Notes. Additionally, the proceeds from the issuance of these notes were referenced in the 2024 filing as a source of financing activity, indicating continued financial engagement with this instrument.",
      "llm_answer": "Between 2023 and 2024, Costco’s Japanese subsidiary issued approximately $500 in new Guaranteed Senior Notes (at fixed rates of 1.400%–2.120%) and subsequently repaid $77 of those notes in July 2024, while also retiring the $1,000 outstanding balance on its 2.750% Senior Notes in May 2024. The net effect was a modest increase in short-term debt issuance offset by significant repayments, though the subsidiary’s overall long-term debt profile remained dominated by the larger Senior Notes issued by the parent company.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly states that Costco's Japanese subsidiary issued approximately $500 in Guaranteed Senior Notes in 2023 at fixed rates of 1.400%–2.120%, and that $77 of these notes were repaid in 2024, it introduces a major error by claiming the subsidiary retired a $1,000 outstanding balance on 2.750% Senior Notes in May 2024. This is not mentioned in the ground truth and appears to confuse the subsidiary's Guaranteed Senior Notes with senior notes issued by the parent company, which were not part of the question. (2) The $77 repayment is correctly cited, but the $1,000 repayment is unsupported and incorrect in this context. The ground truth does not mention any $1,000 note or 2.750% rate related to the Japanese subsidiary. Additionally, the net effect description involving 'modest increase in short-term debt' and 'significant repayments' is speculative and not supported by the original answer, which only notes issuance and partial repayment of the same instrument. (3) The multi-hop reasoning is partially sound in linking issuance and repayment across 2023 and 2024, but fails in entity distinction—confusing subsidiary-level Guaranteed Senior Notes with parent-level Senior Notes. This undermines the qualitative accuracy. (4) The contextual relevance is fair because the answer addresses the evolution of debt instruments by the Japanese subsidiary over the two years, but the inclusion of irrelevant parent company debt activity reduces precision. Correctness score is low due to major factual error in financial amounts and instruments; quantitative accuracy is poor due to the fabricated $1,000 repayment; qualitative accuracy is moderate due to correct identification of the issuance and partial repayment but flawed synthesis; contextual relevance is acceptable as the overall topic and timeline are addressed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1229,
        "completion_tokens": 515,
        "total_tokens": 1744
      },
      "error": null
    },
    {
      "question_id": 56,
      "question": "How has the risk associated with competitors developing after-market parts for DHR's products evolved from 2022 to 2023, particularly in terms of its impact on the company's business and financial statements?",
      "original_answer": "In 2022, the risk of competitors developing after-market parts was described as a direct threat that could 'detract from our sales,' with an emphasis on how commoditization and private-label offerings could reduce market prices and erode DHR's competitive position. By 2023, the framing of this risk shifted to being 'Impacted By' such competition, with a broader contextualization within cost containment trends in the healthcare industry and pricing pressures from managed care and government reimbursement policies. While the core risk remained, it was presented as one of several external pressures rather than a primary threat, suggesting a relative de-emphasis in severity or a strategic recalibration in how the company perceives this risk.",
      "llm_answer": "The risk of competitors developing after‑market parts has remained a material concern from 2022 to 2023, as highlighted in both years’ risk‑factor sections.  Both the 2022 and 2023 filings note that such after‑market services and parts “may detract from our sales” and that failure to anticipate or respond to competitors’ innovations can lead to “reduced demand,” “pricing pressures,” and adverse effects on the company’s business and financial statements.  Consequently, the competitive risk has not diminished; it continues to pose a potential negative impact on revenue and profitability.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer is factually consistent in noting that the risk of competitors developing after-market parts remained a concern in both 2022 and 2023 and that it could impact sales, demand, and pricing. However, it fails to capture the key evolution in how the risk was framed between the two years, which is central to the question. The original answer highlights a qualitative shift: in 2022, the risk was presented as a direct and primary threat to sales and competitive position, while in 2023, it was contextualized as one of several external pressures (e.g., healthcare cost containment, reimbursement policies), indicating a relative de-emphasis or reframing. The LLM answer incorrectly implies continuity in severity and framing, missing this strategic nuance. There are no numerical inaccuracies (hence high quantitative score), but the qualitative analysis is incomplete, failing the multi-hop requirement to compare and contrast the evolution in risk perception. The response is relevant to the topic and addresses financial impact, but lacks the comparative depth needed for full accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1350,
        "completion_tokens": 311,
        "total_tokens": 1661
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has Netflix's approach to membership plans evolved from 2022 to 2024, particularly in terms of pricing strategy and service features, and what business challenges were these changes intended to address?",
      "original_answer": "In 2022, Netflix experienced a 19% revenue increase driven by an 11% growth in average paying memberships and a 7% rise in average monthly revenue per membership, partly due to price increases and favorable foreign exchange rates. However, paid net membership additions dropped by 50% compared to the prior year, signaling early signs of member acquisition challenges. By 2024, Netflix responded by introducing a lower-priced ad-supported subscription plan and enforcing terms of use to limit multi-household usage. These changes were aimed at addressing fluctuating member acquisition, retention pressures, and increasing competition in the streaming and broader entertainment market. The company acknowledged that macroeconomic conditions, content competition, and consumer sensitivity to pricing adjustments could negatively impact membership growth and profitability.",
      "llm_answer": "From 2022 to 2024, Netflix evolved its membership plans by introducing a lower-priced ad-supported tier and tightening restrictions on shared viewing across households, while maintaining its core subscription model. These changes were designed to address slowing membership growth and heightened competition in the streaming market, aiming to boost revenue and retain members amid economic pressures and shifting consumer behavior. The moves reflect a strategic pivot toward more flexible pricing and enhanced monetization of its extensive content library.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Netflix's key strategic changes from 2022 to 2024—introduction of the ad-supported tier and enforcement of account sharing policies—and links them to business challenges like slowing membership growth and competition. However, it omits specific quantitative data from the original answer, such as the 19% revenue increase in 2022, 11% growth in average paying memberships, 7% rise in average revenue per membership, and the 50% drop in paid net membership additions. These omissions affect quantitative accuracy but do not distort the overall narrative. (2) No incorrect numbers are stated, but the absence of key metrics from the ground truth reduces precision. The LLM does not attempt any calculations, so there are no calculation errors, but it fails to include verifiable figures that were present in the source. (3) The multi-hop reasoning is sound: the model correctly synthesizes the evolution of pricing and features with underlying business motivations, connecting product changes to market challenges like macroeconomic pressures, competition, and consumer behavior. It accurately reflects Netflix’s strategic intent without misrepresenting causality or timeline. (4) Despite missing specific numbers, the LLM answer captures the core meaning and intent of the original response. Wording differs but remains semantically aligned. Contextual relevance is perfect—it directly addresses the question’s focus on pricing, features, and business rationale. The score reflects high qualitative and contextual accuracy with a moderate deduction for missing key quantitative details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 448,
        "total_tokens": 1819
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has Boeing's approach to in-orbit incentive payments evolved between 2022 and 2023, particularly in terms of risk exposure and financial recognition?",
      "original_answer": "In 2022, Boeing highlighted the financial risks associated with in-orbit incentive payments, particularly in the context of potential program cancellations or failure to meet performance criteria, which could trigger termination provisions or loss of payments. The company noted that these risks were part of ongoing fixed-price development programs like Commercial Crew, KC-46A Tanker, and VC-25B. By 2023, Boeing had recorded $1,585 million in additional losses on its five most significant fixed-price development programs, which included those mentioned in 2022, and explicitly stated that in-orbit incentive payments were at risk if satellites failed to meet performance criteria over up to 15 years post-acceptance. The company also emphasized that the net present value of these fees was recognized as revenue during the construction period, increasing financial exposure if performance issues arose. This represents a shift from general risk acknowledgment in 2022 to a more specific quantification of losses and a detailed explanation of revenue recognition practices tied to in-orbit performance in 2023.",
      "llm_answer": "Between 2022 and 2023, Boeing’s approach to in-orbit incentive payments remained consistent in structure but heightened financial risk exposure was evident. While the company continued to recognize revenue from in-orbit payments based on anticipated performance over up to 15 years, the 2023 disclosures emphasized significant volatility in fixed-price development programs—particularly the KC-46A Tanker, Commercial Crew, and VC-25B—where cost overruns and technical disruptions led to substantial reach-forward losses. This increased uncertainty around achieving performance criteria directly impacted the collectibility of in-orbit payments, necessitating more conservative revenue recognition and greater reliance on forward-looking estimates of customer incentives. Consequently, Boeing’s financial statements reflected heightened sensitivity to performance risks tied to satellite delivery and long-term contract compliance.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the general evolution of Boeing's approach to in-orbit incentive payments, correctly identifying the ongoing risk in fixed-price development programs like KC-46A, Commercial Crew, and VC-25B, and noting increased financial exposure due to performance risks. However, it fails to include the key quantitative figure from 2023—$1,585 million in additional losses—which is central to the ground truth and a critical evolution from 2022's more general risk disclosure. This omission severely impacts factual completeness and numerical accuracy. (2) No numbers are provided in the LLM answer, while the original answer specifies $1,585 million in losses. This is a major quantitative inaccuracy, as the absence of this figure undermines the core of the 2023 update. The LLM mentions 'substantial reach-forward losses' but does not quantify them, which is a significant deviation from the ground truth. (3) The reasoning is sound in identifying a shift toward greater risk recognition and more conservative revenue practices, and it correctly links in-orbit payments to long-term performance and revenue recognition during construction. It also appropriately references the same programs and the 15-year performance window, showing correct multi-hop synthesis across years and programs. However, it does not explicitly state that the net present value of fees is recognized during construction—a key accounting practice highlighted in the original. (4) The contextual relevance is high, as the answer addresses risk exposure and financial recognition as asked. The qualitative accuracy is moderate because while the conceptual evolution is partially correct, the lack of specific financial data and precise revenue recognition mechanics reduces fidelity. The correctness score is 6 due to partially correct reasoning and entity identification but major omission of a critical financial figure and incomplete explanation of revenue recognition practices.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1512,
        "completion_tokens": 535,
        "total_tokens": 2048
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the disclosure and accessibility of the Directors' Code of Conduct evolved between 2023 and 2024?",
      "original_answer": "In 2023, the Directors' Code of Conduct was explicitly described as being posted on the company's website at a specific URL: https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/invrelations/directors-code-of-conduct.pdf, and the company stated its intention to disclose amendments or waivers on the website. In 2024, while the Code remained accessible, it was referenced more generally as part of a broader list of governance materials available on the company’s website, including committee charters and governance guidelines, without repeating the direct URL. The change indicates a shift from detailed disclosure of access to a more consolidated and implicit reference, suggesting a streamlined but less direct approach to public access in 2024.",
      "llm_answer": "The Directors' Code of Conduct was first referenced in the 2023 filing (page 13) as being posted on the company’s website at https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/inv relations/directors-code-of-conduct.pdf, and the 2024 filing (page 3) reiterates that the same code is available at that URL and notes that any amendments or waivers will be disclosed on the website. Thus, between 2023 and 2024 the disclosure remained the same—continuing to host the code on the website with a commitment to post future amendments or waivers publicly.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer incorrectly states that the 2024 filing reiterates the direct URL and maintains the same level of disclosure. In reality, the 2024 filing shifted to a more general reference to the Code as part of a broader list of governance materials without repeating the specific URL, indicating a change in disclosure approach. This misrepresents the evolution of accessibility. (2) Quantitatively, the URL and page numbers (2023, page 13; 2024, page 3) are accurately cited, and there are no numerical errors—hence a high quantitative accuracy score. (3) The multi-hop reasoning is flawed: the model failed to recognize the qualitative shift in disclosure style from explicit and direct in 2023 to implicit and consolidated in 2024. Instead, it concludes no change occurred, which contradicts the ground truth. This reflects a failure in synthesizing the nuanced evolution across years. (4) Contextual relevance is moderate—the response addresses the topic and timeframe, cites correct documents, and discusses website accessibility, but misses the core point about changing disclosure practices, leading to a substantially incorrect conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1319,
        "completion_tokens": 329,
        "total_tokens": 1648
      },
      "error": null
    },
    {
      "question_id": 57,
      "question": "How has the role and deployment strategy of Mobileye Drive™ evolved between 2022 and 2023?",
      "original_answer": "In 2022, Mobileye launched the SAE L4 Self-Driving System (SDS), Mobileye Drive™, and secured multiple collaborations for commercial use, including with Udelv for autonomous cargo delivery and with Transdev for self-driving mobility services. Additionally, Mobileye achieved its first consumer L4 design win with Geely. By 2023, Mobileye’s strategy had evolved to focus on supplying the Mobileye Drive™ self-driving system to transportation network companies, public transit operators, and suppliers of AV-ready vehicle platforms, with plans to bundle it with Moovit’s urban mobility and transit intelligence application. This shift indicates a more defined go-to-market strategy targeting fleet deployment and mobility-as-a-Service (MaaS) ecosystems.",
      "llm_answer": "Between 2022 and 2023, Mobileye Drive™ evolved from a concept in development to a commercially deployed system, with expanded partnerships and production readiness. The document notes that Mobileye secured multiple collaborations for commercial use of Mobileye Drive™, including with Udelv for autonomous cargo delivery and Transdev for self-driving mobility services, and began deployment in Germany through its partnership with SIXT in 2022. Additionally, Mobileye introduced advanced hardware like the EyeQ6L (expected 2023) and EyeQ6H (2024), alongside the high-performance EyeQ Ultra SoC (2025), to support scalable autonomy, while continuing to leverage its REM mapping and True Redundancy™ technologies to underpin its AV architecture.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Mobileye Drive™'s commercial collaborations in 2022 with Udelv and Transdev, which aligns with the ground truth. It also mentions deployment in Germany with SIXT, which is not present in the original answer and may be extraneous or unverified. However, the LLM fails to mention the key 2022 fact about Mobileye achieving its first consumer L4 design win with Geely, a significant omission. Regarding 2023, the LLM does not capture the strategic shift described in the ground truth: bundling Mobileye Drive™ with Moovit’s urban mobility application and targeting transportation network companies, public transit operators, and AV-ready platform suppliers as part of a Mobility-as-a-Service (MaaS) strategy. Instead, it shifts focus to hardware roadmaps (EyeQ6L, EyeQ6H, EyeQ Ultra) and supporting technologies (REM, True Redundancy™), which, while relevant to autonomy, are not part of the specific evolution of Mobileye Drive™'s deployment strategy between 2022 and 2023. (2) Quantitatively, there are no explicit numerical errors (e.g., dates for EyeQ chips are forward-looking and plausible), but the introduction of hardware timelines distracts from the strategic evolution asked in the question. The years 2023, 2024, and 2025 are mentioned for chip releases, which are not contradicted by the ground truth but are irrelevant to the deployment strategy of Mobileye Drive™ during the 2022–2023 window. (3) The multi-hop reasoning is partially sound in identifying partnerships and commercialization, but it fails to synthesize the key strategic pivot in 2023 toward MaaS ecosystems and integration with Moovit. This represents a failure in qualitative synthesis despite some correct entity identification. (4) The correctness score is 5 due to partial factual accuracy but major omissions in the strategic evolution. Quantitative accuracy is 6 because no numbers are wrong, but the answer introduces tangential future hardware plans. Qualitative accuracy is 5 due to correct identification of some entities and partnerships but flawed reasoning about the strategic shift. Contextual relevance is 8 because the answer stays on topic regarding Mobileye Drive™ but drifts into hardware and technology details not central to the deployment strategy evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1359,
        "completion_tokens": 626,
        "total_tokens": 1985
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has the structure and distribution rate of the Tower Preferred Interests evolved from 2022 to 2024?",
      "original_answer": "In 2022, the Tower Preferred Interests were divided into two series: the September series (Class A-1) totaling $1,500 with a 5.0% initial preferred distribution, and the December series (Class A-2) totaling $4,500 with a 4.75% initial preferred distribution. These distributions reset every five years. By 2024, the structure was amended in August 2024 to reclassify all 2019 Tower preferred interests into Fixed Rate Class A Limited Membership Interests (Tower Fixed Rate Interests) paying a 5.90% preferred distribution. Additionally, a portion of these fixed-rate interests will transition annually into Floating Rate Class A Limited Membership Interests (Tower Floating Rate Interests), which will pay a distribution equal to SOFR plus 250 basis points. This represents both a structural and rate evolution in the Tower Preferred Interests.",
      "llm_answer": "From 2022 to 2024, the structure of AT&T’s preferred equity evolved significantly. In 2018, AT&T issued $666 million of Mobility II preferred interests (7% annual distributions), which were fully repurchased by April 2023, eliminating that series. In 2019, AT&T issued $6 billion of Tower Holdings preferred interests (5% and 4.75% initial rates, reset in 2024 to 5.90% fixed and SOFR+250bps floating rates, with redemptions starting in 2029). These Tower preferred interests, now classified as \"Tower Fixed Rate Interests\" and \"Tower Floating Rate Interests,\" replaced the prior structure and are now recorded as noncontrolling interest. Additionally, in 2024, AT&T amended the 2019 Tower preferred interests to reset rates and restructure into fixed/floating tranches, while also planning to issue $2.25 billion of new Telco LLC preferred interests (5.94% initial rate, resetting in 2028) in early 2025 to fund future redemptions.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and misrepresents the core details of the Tower Preferred Interests evolution from 2022 to 2024. (1) The original answer states that in 2022, the Tower Preferred Interests were split into two series: $1,500 at 5.0% (September, Class A-1) and $4,500 at 4.75% (December, Class A-2), totaling $6,000. The LLM incorrectly claims $6 billion of Tower Holdings preferred interests were issued in 2019 with 5% and 4.75% rates, which contradicts the ground truth (no mention of $6 billion or 5% rate in original). The dollar amounts ($1,500 and $4,500) are off by orders of magnitude in the LLM response. (2) The LLM incorrectly states that the 2019 issuance had rates that reset in 2024 to 5.90% fixed and SOFR+250bps floating. However, the original answer specifies that the 2022 structure was based on earlier series, and the 2024 amendment in August reclassified all 2019 Tower preferred interests into Fixed Rate Class A interests at 5.90%, not that they reset automatically. The timing and mechanism of the reset are misrepresented. (3) The LLM introduces irrelevant information about AT&T’s Mobility II preferred interests ($666M, 7%) and a planned $2.25 billion Telco LLC issuance in 2025, which are not mentioned in the ground truth and are unrelated to the Tower Preferred Interests. (4) The structural evolution — reclassification into Fixed Rate and Floating Rate Class A Limited Membership Interests in August 2024 — is partially correct in concept but misattributed to a 2019 issuance resetting rather than a 2024 amendment. The floating rate component (SOFR + 250bps) is correctly described, but the context is flawed. (5) The LLM fails the multi-hop reasoning: it conflates different preferred interest series, invents issuances and redemptions (e.g., 'redemptions starting in 2029'), and misstates the timeline and structure. The answer is not semantically equivalent to the ground truth due to major factual and numerical errors. While it captures a general idea of structural change and rate evolution, the specifics are largely incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1433,
        "completion_tokens": 562,
        "total_tokens": 1995
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How did the investment approach and unrealized gains/(losses) for Level 3 assets related to the Balanced Index Fund evolve from 2022 to 2023?",
      "original_answer": "In 2022, the company disclosed unrealized losses for Level 3 assets still held at year-end, including ($16) million for corporate fixed income securities and ($11) million for mortgage-backed and asset-backed fixed income securities. By 2023, these values shifted to unrealized gains of $2 million for corporate fixed income securities and $6 million for mortgage-backed and asset-backed fixed income securities. This indicates a significant turnaround in the performance of these assets. Additionally, while the Balanced Index Fund's composition remained at approximately 60% equities and 40% debt securities in both years, the valuation methodology in 2023 explicitly referenced a market approach based on quoted market prices (Level 1), suggesting a more transparent and standardized valuation process.",
      "llm_answer": "The investment approach for Level 3 assets in the Balanced Index Fund remains a market‑based valuation using quoted market prices of identical instruments (Level 1), with no material impact on net periodic benefit cost.  Unrealized gains/(losses) for Level 3 assets held at year‑end increased from a net loss of $90 million in 2022 to a net gain of $14 million in 2023.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that the valuation approach for Level 3 assets uses Level 1 inputs (quoted prices), which contradicts the ground truth: Level 3 assets are by definition unobservable and not based on quoted prices. The ground truth notes that in 2023, the *overall fund* referenced a market approach using Level 1 for some valuations, but this does not apply to Level 3 assets themselves. (2) The quantitative figures are wrong: the LLM reports a net loss of $90 million in 2022 and net gain of $14 million in 2023, but the ground truth specifies only two components of Level 3 unrealized gains/losses: ($16M) and ($11M) in 2022 (total $27M loss), and $2M and $6M gains in 2023 (total $8M gain). The LLM's $90M and $14M figures do not match and appear fabricated. (3) The multi-hop reasoning is flawed: the model fails to correctly synthesize the evolution of specific asset categories (corporate fixed income, MBS/ABS) across years and misrepresents the valuation methodology shift. It omits the key detail that the fund’s allocation (60/40) remained stable and misattributes the use of Level 1 to Level 3 assets. (4) Despite these issues, the answer is contextually relevant—it addresses the time frame, the fund, and attempts to compare unrealized gains/losses—so partial credit is given for relevance. However, core facts, calculations, and entity understanding are incorrect, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1292,
        "completion_tokens": 412,
        "total_tokens": 1704
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How has BNY Mellon's emphasis on accounting developments in its forward-looking statements evolved between 2023 and 2024, and what does this reveal about the changing influence of accounting standards on its strategic priorities?",
      "original_answer": "In 2023, BNY Mellon included accounting developments among a broader list of potential influences on forward-looking statements, noting they 'may impact our businesses' without specific elaboration. By 2024, the company expanded this language, explicitly stating that accounting developments 'may impact our businesses, regulatory, technology, market, economic or accounting developments and the impacts of such developments on our businesses.' This shift indicates a more integrated view of accounting changes as part of strategic risk and planning considerations. The inclusion of terms like 'capital plans including dividends and repurchases' and 'efficiency savings' in 2024 further suggests that accounting developments are increasingly tied to concrete business decisions and performance metrics.",
      "llm_answer": "BNY Mellon’s forward‑looking statements in its 2024 filing continue to highlight accounting‑related risks—such as changes in accounting standards that could materially affect reported financial condition, results of operations, cash flows and other financial data—but it now devotes a broader, more integrated discussion of how evolving accounting pronouncements intersect with its strategic priorities, including capital planning, liquidity management, and ESG initiatives. This reflects a shift from merely flagging accounting updates as a risk factor to positioning accounting standards as a core driver shaping the firm’s strategic focus and stakeholder communications.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually consistent with the ground truth in terms of the evolution between 2023 and 2024, though it rephrases the shift rather than quoting the exact language change. It correctly identifies that BNY Mellon expanded its discussion of accounting developments in 2024 to reflect a more integrated and strategic role, moving beyond a generic risk factor. The inclusion of 'capital planning', 'liquidity management', and 'ESG initiatives' aligns with the ground truth's mention of 'capital plans including dividends and repurchases' and 'efficiency savings' as newly tied elements, though 'ESG initiatives' are not explicitly mentioned in the original answer and may represent a slight overextension. There are no numerical values in the question or answers, so quantitative accuracy is not applicable—however, the years (2023 and 2024) are correctly referenced, warranting full marks. The reasoning is sound: the model correctly infers a strategic elevation of accounting standards in forward-looking statements. The answer captures the core multi-hop insight—the evolution in language reflects a deeper integration of accounting standards into strategic planning—thus achieving high qualitative and contextual accuracy. The minor deduction in qualitative accuracy is due to the introduction of 'ESG initiatives' not present in the original, which, while plausible, is not supported by the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 391,
        "total_tokens": 1781
      },
      "error": null
    },
    {
      "question_id": 58,
      "question": "How did the evolution of risks related to store safety and cybersecurity in 2023 potentially impact the associate experience, as compared to the engagement-focused initiatives highlighted in 2022?",
      "original_answer": "In 2022, HD emphasized internal initiatives to improve the associate experience through engagement surveys, a digital engagement platform, and recognition programs, which historically showed that four out of five associates were emotionally committed. However, in 2023, the company highlighted external risks such as increased store shrink, particularly from organized retail crime, and cybersecurity threats that could compromise associate data and store safety. These risks were noted to potentially erode trust, impact associate morale and retention, and damage the company's reputation. This shift indicates that while HD was actively fostering associate engagement in 2022, the emergence or escalation of external risks in 2023 introduced new challenges that could undermine those earlier gains in associate experience.",
      "llm_answer": "The 2023 risk discussion highlights that evolving store safety and cybersecurity threats could directly undermine the associate experience—by increasing workplace hazards, compromising data security, and forcing costly operational changes—whereas the 2022 focus on engagement initiatives emphasized cultural and DEI programs that boosted associate satisfaction without these heightened safety and cyber‑risk pressures.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent with the ground truth in terms of dates (2022 vs 2023), entities (HD implied), and the core contrast between engagement initiatives and emerging risks. There are no numeric values in either answer, so quantitative accuracy is not applicable—scored as 10 by default. The answer correctly identifies the shift from 2022 engagement efforts (cultural and DEI programs) to 2023 risks (store safety, cybersecurity) impacting associate experience. However, it omits key details from the original answer: (1) the specific mention of organized retail crime and store shrink as drivers of safety concerns, (2) the reference to historical emotional commitment (four out of five associates), and (3) the explicit connection that these 2023 risks could erode trust, morale, and retention—undermining prior engagement gains. While the LLM captures the general direction of the shift and the potential negative impact on associates, it lacks the depth of synthesis regarding how the new risks directly threaten earlier progress. The reasoning is sound but less comprehensive, making it partially correct with minor omissions. Contextual relevance is high as it directly addresses the comparative evolution of risks and initiatives.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 350,
        "total_tokens": 1673
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the role of the 'learning curve' in influencing cost and production estimates evolved between 2022 and 2023, particularly in relation to program profitability and risk management?",
      "original_answer": "In 2022, the 'learning curve' was identified as a risk factor that could negatively impact program profitability due to production complexities, rework, and delays—especially in programs like the 787—potentially leading to additional losses and abnormal production costs. By 2023, the 'learning curve' was no longer framed solely as a risk but was integrated into the company's cost estimation process, factored into production rate assumptions, supplier performance trends, and internal labor efficiency projections. This shift indicates that Boeing began treating the learning curve as a predictable and manageable component of production planning rather than an unpredictable risk.",
      "llm_answer": "The learning curve’s impact on cost and production estimates has intensified between 2022 and 2023, particularly for the 777X and 787 programs, where revised delivery schedules, higher rework and abnormal production costs, and updated accounting quantities have directly affected program profitability and risk exposure. These factors have contributed to significant reach-forward losses and margin pressures, with the 777X program recording a $6.5 billion reach‑forward loss in 2020 and ongoing uncertainty about achieving break‑even margins, while the 787 continues to incur cumulative abnormal costs that could trigger additional losses if production rates or accounting quantities are further reduced. Consequently, management now treats learning‑curve‑driven cost adjustments as a critical risk driver, incorporating them into profitability forecasts and hedging strategies to mitigate potential earnings volatility.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The original answer states that in 2023, Boeing began integrating the learning curve into cost estimation and production planning as a manageable factor, shifting from viewing it as a risk in 2022. However, the LLM answer incorrectly frames the learning curve as an escalating risk and does not reflect this evolution in treatment. Instead, it suggests that learning-curve-driven costs are now a 'critical risk driver,' which contradicts the ground truth that the learning curve became a predictable, managed component. (2) Quantitative inaccuracies include referencing a '$6.5 billion reach-forward loss in 2020' for the 777X program—this is factually incorrect as the question context is 2022–2023, and the 2020 figure is irrelevant and unsupported in the ground truth. The original answer contains no specific dollar amounts, so introducing such figures without basis reduces accuracy. (3) Multi-hop reasoning is partially present—the LLM connects learning curves to production costs, profitability, and risk—but fails the core synthesis: it does not capture the conceptual shift from 'risk' to 'integrated planning factor' between 2022 and 2023. It also introduces unrelated programs (777X) and erroneous timeframes. (4) Contextual relevance is moderate because the answer discusses cost, production, and risk in relation to learning curves, but the incorrect framing, outdated data, and fabricated numbers severely undermine factual correctness. The answer misses the key insight of evolving management approach, leading to a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1411,
        "completion_tokens": 445,
        "total_tokens": 1856
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the treatment or disclosure of the Dividend Reinvestment Plan evolved between the 2023 and 2024 SEC filings, particularly in relation to officer or director participation and associated trading arrangements?",
      "original_answer": "In the 2023 filing, the Dividend Reinvestment Plan was mentioned in the context of officer or director participation alongside the employee stock purchase plan and 401(k) plan, with specific reference to elections to have shares withheld for tax purposes or to pay the exercise price of stock awards. The disclosure also included a detailed description of how these elections may be structured under Rule 10b5-1 or non-Rule 10b5-1 trading arrangements as defined in Item 408(c) of Regulation S-K. In the 2024 filing, the Dividend Reinvestment Plan was again referenced in the context of officer or director participation, but the detailed explanation of Rule 10b5-1 and non-Rule 10b5-1 trading arrangements was omitted, indicating a simplification or standardization of the disclosure without the earlier level of specificity regarding trading frameworks.",
      "llm_answer": "The Dividend Reinvestment Plan (DRIP) disclosure has remained consistent in structure between the 2023 and 2024 filings, both referencing participation by officers and directors alongside other plans like the employee stock purchase and 401(k) plans. However, the 2024 filing (page 12) explicitly states that \"certain of our officers or directors have made elections to participate in... our dividend reinvestment plan\" and notes these elections may involve share withholdings for tax purposes or exercise prices, potentially aligning with Rule 10b5-1 compliance or non-Rule 10b5-1 trading arrangements. In contrast, the 2023 filing (page 11) only mentions participation generally without specifying such election mechanisms or trading-related justifications, indicating a modest evolution in disclosure detail rather than a substantive change in plan treatment.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains a fundamental factual reversal compared to the ground truth, severely undermining its correctness. According to the original answer, the 2023 filing included a detailed description of Rule 10b5-1 and non-Rule 10b5-1 trading arrangements in the context of the Dividend Reinvestment Plan (DRIP), while the 2024 filing omitted this detail—indicating a reduction in disclosure specificity. However, the LLM answer incorrectly claims the opposite: that the 2024 filing added detail by explicitly mentioning elections and trading arrangements, while the 2023 filing only mentioned participation generally. This misrepresents the evolution of disclosure and inverts the direction of change. There are no numeric values in the question or answer, so quantitative accuracy is not applicable in a traditional sense, but the years (2023, 2024) and page numbers (11, 12) are cited plausibly—though their attribution is likely fabricated or reversed, given the contradiction with ground truth. The entities (DRIP, officers/directors, Rule 10b5-1, employee stock purchase plan, 401(k)) are correctly identified, but the reasoning across time periods is flawed. The answer does address the question’s focus on evolution in disclosure and participation, so it maintains some contextual relevance. However, the core multi-hop synthesis—comparing disclosure depth across years—is incorrect, leading to a low qualitative and overall correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1446,
        "completion_tokens": 400,
        "total_tokens": 1846
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has The Home Depot's investment in creating an interconnected shopping experience evolved from fiscal 2021 to fiscal 2023, and what specific changes were made in the way this experience is tailored to customers?",
      "original_answer": "In fiscal 2021, The Home Depot invested $2.6 billion in capital expenditures focused on supporting an interconnected customer experience. By fiscal 2023, the company had advanced this strategy by leveraging enhanced merchandising information technology tools to build an interconnected shopping experience tailored to customers' shopping intent and location. This represents a shift from general investment in interconnectedness to a more refined, data-driven personalization strategy.",
      "llm_answer": "From fiscal 2021 through fiscal 2023, The Home Depot’s investment in an interconnected shopping experience shifted from building the foundational digital‑in‑store integration to deepening and customizing that integration for each customer segment.  In 2021‑22 the focus was on creating a seamless “frictionless” experience across stores, online and the job site, with investments in website/mobile enhancements, curb‑side pickup, electronic shelf labels and associate productivity tools.  By fiscal 2023 the company was tailoring the experience more precisely: it expanded a differentiated, Pro‑focused online journey, added Pro Xtra loyalty and credit options, broadened supply‑chain capabilities for complex professional purchases, and introduced tools such as Vision and hdPhone that give associates real‑time inventory visibility and task prioritization.  These changes—customized digital interfaces, enhanced Pro‑specific services, and richer, location‑based personalization—reflect a move from a generic interconnected model to a segment‑specific, data‑driven experience.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly captures the evolution of The Home Depot's strategy from general interconnected experience in 2021 to a more tailored, data-driven approach by 2023, aligning with the ground truth’s core narrative. However, it omits the specific $2.6 billion capital expenditure figure from fiscal 2021, which is a key quantitative element in the original answer. No other numbers (e.g., fiscal years) are incorrect, but the absence of this figure reduces quantitative accuracy. (2) The fiscal years (2021–2023) are correctly referenced, and no incorrect calculations are made—however, the lack of the $2.6B investment amount means the answer fails to meet full quantitative fidelity. (3) The multi-hop reasoning is strong: the LLM synthesizes a shift in strategy over time and identifies specific enhancements in 2023 such as Pro-focused tools (Pro Xtra, hdPhone, Vision), supply chain improvements, and personalization by customer segment—details that reflect a deeper, data-driven tailoring consistent with the ground truth’s emphasis on 'shopping intent and location.' While the original answer is more concise, the LLM adds plausible, contextually accurate details that align with known Home Depot initiatives. (4) The answer is highly contextually relevant, fully addressing both parts of the question—evolution over time and specific changes in tailoring. The qualitative reasoning is sound and enriched with specific program names and tools, enhancing credibility. However, the omission of the key financial figure from 2021 prevents a higher correctness score. Overall, the answer is factually plausible and logically structured but lacks one critical data point from the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1407,
        "completion_tokens": 468,
        "total_tokens": 1876
      },
      "error": null
    },
    {
      "question_id": 59,
      "question": "How has the financial relationship between DHR and Aldevron evolved between 2022 and 2023, particularly in terms of capital investment and acquisition-related expenditures?",
      "original_answer": "In 2022, DHR anticipated capital expenditures of approximately $1.5 billion, with a portion of this spending attributed to increased manufacturing capacity for products related to the Aldevron Acquisition, among others. This reflects a growing capital commitment tied to Aldevron. By 2023, the financial relationship had evolved significantly, as evidenced by the net cash consideration paid to Aldevron amounting to $9,561 million, indicating that Aldevron had transitioned from being primarily a capital investment target to a core component of DHR's consolidated assets. This represents a substantial shift in the nature of their relationship from a dependency to a stakeholding and integration model.",
      "llm_answer": "Between 2022 and 2023, the financial relationship between Danaher (DHR) and Aldevron evolved significantly in terms of capital investment and acquisition-related expenditures. In 2022, DHR spent approximately $582 million on acquiring seven businesses, recording $389 million of goodwill, while the 2023 Abcam acquisition involved $5.6 billion in cash consideration and $3.851 billion in goodwill, reflecting a major expansion. Although Aldevron was acquired in 2021 for $9.6 billion (with $6.1 billion in goodwill), its integration and related expenditures continued to influence DHR’s capital allocation, as evidenced by ongoing transaction-related costs and fair value adjustments impacting earnings. Capital expenditures rose to $1.3 billion in 2021 and were expected to increase further in 2022, partly to support capacity expansion from prior acquisitions like Aldevron. Thus, while direct investment in Aldevron occurred in 2021, its legacy influenced DHR’s 2022–2023 strategy of scaling life sciences through strategic acquisitions and capital deployment.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly states that Aldevron was acquired in 2021 for $9.6 billion, while the ground truth indicates that the acquisition was completed in 2022 with net cash consideration of $9,561 million (approximately $9.56 billion), not $9.6 billion. The LLM also introduces unrelated acquisitions (seven businesses in 2022 totaling $582M, Abcam in 2023 for $5.6B) that are not mentioned in the original answer and distract from the focus on Aldevron. The $389M and $3.851B goodwill figures are not supported by the ground truth. (2) The capital expenditure figure for 2022 is misstated: the original answer states DHR anticipated ~$1.5B in capex in 2022 (partly for Aldevron), but the LLM claims $1.3B in 2021 and does not provide the correct 2022 expectation. The LLM fails to report the key 2023 figure of $9,561M in net cash consideration paid to Aldevron, instead burying an approximate number in a prior year. (3) The multi-hop reasoning is flawed: the question asks specifically about the evolution between 2022 and 2023 in DHR-Aldevron financial relationship, but the LLM incorrectly places the acquisition in 2021 and frames Aldevron as a legacy influence rather than the central transaction in 2022–2023. It fails to show the shift from capital investment (2022) to full acquisition and integration (2023) as described in the ground truth. (4) Despite incorrect facts and timeline, the answer is somewhat contextually relevant by discussing capital deployment and integration, but the core quantitative and temporal inaccuracies severely undermine correctness. Minor credit is given for recognizing capacity expansion and capital allocation themes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1448,
        "completion_tokens": 470,
        "total_tokens": 1918
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has the structure and total value of Telco LLC's preferred interests evolved from 2022 to 2024, and what changes were made to the distribution rates and reset schedules during this period?",
      "original_answer": "In 2022, Telco LLC had $2,000 in nonconvertible cumulative preferred interests (Telco Class A-1) with an initial preferred distribution rate of 4.25% annually, subject to reset every seven years. By 2024, Telco LLC expanded its preferred interests with the issuance of an additional $5,250 in preferred interests (Telco Class A-2 and A-3) in April 2023, bringing the total cumulative preferred interests to $7,250. The new preferred interests (Class A-2 and A-3) carried a significantly higher initial preferred distribution rate of 6.85% annually, with the first reset scheduled for November 1, 2027, and every seven years thereafter. This represents both a structural expansion in the capital stack and a strategic shift toward higher-yielding preferred instruments.",
      "llm_answer": "From 2022 through 2024 AT&T’s preferred‑interest structure remained in place but was refined and expanded.  The company’s Telco LLC preferred interests grew from $2 billion issued in September 2020 to $7.25 billion of cumulative preferred equity by the end of 2024 (including the $5.25 billion added in April 2023 and the $2.25 billion Telco Class A‑4 issuance announced for 2025).  The $6 billion of Tower Holdings preferred interests issued in 2019 were reset in November 2024: the fixed‑rate tranche now pays 5.90 % and a floating‑rate tranche (SOFR + 250 bp) was created, with resets every five years and call rights beginning in 2029.  AT&T also issued new preferred securities in Mobility II (the $2 million Series B interests at 6.8 % in 2023) and continued to manage redemption rights that can be triggered if distributions are missed or credit‑rating covenants are breached.  \n\nDistribution rates were adjusted as part of these resets: the 2019 Tower preferred interests moved from an initial 5.0 %/4.75 % to a 5.90 % fixed rate (and a floating SOFR‑plus‑250 bp rate), while the Telco LLC Class A‑2/A‑3 interests retain a 6.85 % initial rate (subject to a reset on 1 Nov 2027).  The Mobility II Series B interests pay 6.8 % and are redeemable at $1,000 per share plus accrued distributions.  Overall, the preferred‑interest portfolio shifted from the 7 % cash‑distribution Mobility II interests (largely retired in 2023) to a mix of higher‑rate, reset‑every‑5‑to‑7‑year tranches that now total roughly $7–8 billion in aggregate liquidation value.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and introduces entities and figures not present in the ground truth, severely undermining its correctness. (1) Quantitative inaccuracies: The original answer states that Telco LLC had $2,000 in preferred interests in 2022 and added $5,250 in April 2023, totaling $7,250. The LLM incorrectly reports these as $2 billion and $7.25 billion (off by a factor of 1 million), and further fabricates a $2.25 billion Telco Class A-4 issuance for 2025, which is not mentioned in the ground truth. It also references $6 billion in Tower Holdings preferred interests reset in November 2024, which is entirely absent from the original answer. The $2 million Series B interests in Mobility II are also fabricated and irrelevant. (2) Entity and context errors: The original answer focuses solely on Telco LLC’s preferred interests. The LLM answer incorrectly shifts focus to AT&T and introduces unrelated entities like Tower Holdings and Mobility II, which are not part of the question or ground truth. (3) Reasoning and synthesis: The multi-hop requirement—tracking the evolution of Telco LLC’s preferred interests from 2022 to 2024—is not correctly executed. The LLM conflates multiple unrelated capital structures and resets, failing to isolate the correct entity and timeline. While it correctly notes a 6.85% rate for Telco Class A-2/A-3 and a reset on November 1, 2027, this is the only accurate detail pulled correctly. (4) Semantic equivalence: Despite this one correct detail, the overwhelming presence of fabricated numbers, wrong entities, and incorrect totals renders the answer mostly incorrect. The core structure and evolution of Telco LLC’s preferred interests are misrepresented. The answer is contextually relevant in topic but fails on factual and logical grounds.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1592,
        "completion_tokens": 492,
        "total_tokens": 2084
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has AIG's use of Expected Loss Ratio Methods evolved between 2022 and 2024, particularly in terms of the types of insurance lines and the rationale for their application?",
      "original_answer": "In 2022, AIG used Expected Loss Ratio Methods primarily for the latest accident year and in combination with other methods like loss development for aviation exposures, due to their high-severity nature. By 2024, AIG expanded the use of Expected Loss Ratio Methods to include U.S. Workers' Compensation, a long-tail line of business, where it was used in combination with loss development and frequency/severity methods. This reflects a broader application of the method across different insurance lines with varying claim characteristics.",
      "llm_answer": "AIG’s use of Expected Loss Ratio methods has evolved from a limited, primarily “older‑year” tool in 2022 to a more central component of its reserving framework by 2024, being applied across a broader set of lines—including U.S. Excess Casualty, U.S. Property & Special Risks, and program business—while relying on updated projected ultimate loss ratios that incorporate recent rate changes, loss‑trend adjustments, and market‑condition shifts. This expansion reflects a strategic shift toward using Expected Loss Ratio estimates for the most recent accident years (especially the latest five) to supplement development‑based methods, improve responsiveness to emerging trends, and provide more reliable projections for both long‑tail and short‑tail exposures.",
      "correctness_score": 5,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures the general evolution of AIG's use of Expected Loss Ratio (ELR) methods from 2022 to 2024, correctly identifying an expansion in application and the rationale involving responsiveness to trends and supplementing other methods. However, there are significant factual discrepancies in the insurance lines cited. The ground truth specifies that in 2022, ELR was used primarily for the latest accident year and in aviation (high-severity), and by 2024 expanded to U.S. Workers' Compensation—a key long-tail line. The LLM answer incorrectly states expansion into U.S. Excess Casualty, U.S. Property & Special Risks, and program business, which are not mentioned in the original answer. While the rationale about using ELR for recent accident years and incorporating rate changes and loss trends is plausible and contextually relevant, it adds details (e.g., 'latest five' years, 'projected ultimate loss ratios') not present or verifiable from the ground truth. The dates (2022 vs 2024) are correctly framed, and there are no numerical values to verify, so quantitative accuracy is high by default. The multi-hop reasoning is partially sound—there is an attempt to show evolution across time and lines of business—but the entity accuracy for insurance lines is flawed, undermining the qualitative accuracy. The answer is contextually relevant and addresses the question's intent, but with incorrect specifics on the types of insurance lines, leading to a moderate correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1331,
        "completion_tokens": 411,
        "total_tokens": 1742
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "How has Target's approach to its owned brands evolved from 2023 to 2024, particularly in terms of strategic emphasis and product portfolio development?",
      "original_answer": "In 2023, Target emphasized expanding its owned brands portfolio as a core strategic element to drive relevancy and market share growth. By 2024, the company shifted focus to producing a broad range of owned and exclusive brands, listing over 40 distinct brands across various categories, indicating a more concrete execution phase of brand development and diversification.",
      "llm_answer": "Target's owned brands strategy has evolved from 2023 to 2024 with a stronger strategic emphasis on expanding and curating its portfolio of exclusive and owned brands as a core differentiator. The 2024 filing explicitly highlights this as a key element of its strategy to \"delight with newness, style, and value\" by strengthening the owned brands portfolio, curating national brands, and expanding signature partnerships, while also detailing a comprehensive list of owned brands across multiple categories. This represents a more focused and expanded product portfolio development compared to the 2023 filing, which only mentioned strengthening owned brands as part of its broader strategy without the same level of specific emphasis or portfolio detail.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) All factual elements are correct: the evolution from 2023 to 2024 is accurately portrayed, with Target shifting from a general strategic emphasis on owned brands in 2023 to a more concrete, detailed, and diversified execution in 2024. The LLM correctly identifies that the 2024 strategy includes a comprehensive list of owned brands across categories, which matches the ground truth's mention of 'over 40 distinct brands.' While the exact number '40' is not repeated in the LLM answer, the emphasis on breadth, exclusivity, and categorization implies the same level of portfolio development. (2) There are no numeric inaccuracies—no specific dollar amounts, percentages, or incorrect dates are present or implied. The years 2023 and 2024 are correctly attributed to their respective strategic phases. (3) The multi-hop reasoning is sound: the LLM synthesizes changes in strategic emphasis across two years, correctly inferring increased focus and execution depth in 2024 compared to 2023. It draws a valid contrast between broader strategic mention in 2023 and detailed portfolio curation in 2024. (4) The answer is contextually relevant and fully addresses both parts of the question: strategic emphasis and product portfolio development. The only minor shortcoming is the omission of the specific 'over 40 brands' figure, which slightly reduces completeness but does not affect the overall correctness. Hence, a 9 is justified for correctness and qualitative accuracy, with full marks for quantitative accuracy and contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1282,
        "completion_tokens": 440,
        "total_tokens": 1723
      },
      "error": null
    },
    {
      "question_id": 60,
      "question": "What does IBM's continued listing of the 0.875% Notes due 2030 in 2024 alongside the new 2.900% Notes due 2030 suggest about its debt financing strategy and the market conditions for long-term borrowing?",
      "original_answer": "In 2023, IBM listed the 0.875% Notes due 2030 (trading symbol IBM30A) among its registered securities, indicating its initial issuance of this long-term debt instrument. By 2024, IBM not only maintained the 0.875% Notes due 2030 in its capital structure but also introduced a new 2.900% Notes due 2030 (trading symbol IBM30C). The significant increase in the interest rate—from 0.875% to 2.900%—for the same maturity year suggests that IBM may have pursued additional financing in 2024 under less favorable interest rate conditions, or it may be targeting different investor segments with varied risk-return profiles. This dual listing could also indicate a strategic effort to diversify its debt portfolio and manage refinancing risks by having multiple instruments maturing in the same year but with different coupon rates.",
      "llm_answer": "IBM's continued listing of the 0.875% Notes due 2030 alongside the new 2.900% Notes due 2030 in its 2024 SEC filing indicates that the company is maintaining a long-term debt maturity schedule while taking advantage of favorable market conditions to issue fresh, higher-yielding debt. This suggests IBM is actively managing its capital structure to secure low-cost financing for future obligations, leveraging investor demand for long-dated securities amid a stable or supportive interest rate environment.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly identifies the two notes—0.875% and 2.900% Notes due 2030—and their presence in IBM's 2024 filing, which matches the ground truth. The dates, percentages, and entities (IBM, Notes due 2030) are factually accurate. (2) Quantitatively, all numbers are correct: 0.875%, 2.900%, and the maturity year 2030 are accurately reported with no calculation errors. (3) However, the reasoning is flawed in a critical way: the LLM claims IBM issued the new 2.900% Notes in a 'favorable' or 'supportive' interest rate environment, which contradicts the ground truth interpretation that the higher coupon rate likely reflects *less favorable* borrowing conditions in 2024 compared to when the 0.875% Notes were issued. The ground truth suggests deteriorating market conditions or targeted investor segmentation, while the LLM incorrectly infers favorable conditions. This misrepresents the core financial logic of rising yields indicating higher borrowing costs. Additionally, the LLM omits key strategic insights such as debt portfolio diversification, refinancing risk management, and targeting different investor segments. (4) While the answer is contextually relevant and quantitatively accurate, the incorrect interpretation of market conditions and lack of nuanced strategy analysis significantly reduce its qualitative accuracy, warranting a mid-range score of 5 for overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1347,
        "completion_tokens": 392,
        "total_tokens": 1739
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did the composition of AT&T's long-term debt instruments evolve between 2022 and 2024, particularly regarding the 4.000% Global Notes due June 1, 2049 and the addition of new long-term notes?",
      "original_answer": "In 2022, AT&T listed the 4.000% Global Notes due June 1, 2049 (T 49A) among other long-term debt instruments, but did not include the 4.300% Global Notes due November 18, 2034. By 2024, the 4.000% Global Notes due 2049 remained registered under the same symbol (T 49A), and the company added the 4.300% Global Notes due 2034 (T 34C). This indicates that AT&T expanded its long-term debt portfolio by introducing new maturities while maintaining existing long-dated obligations like the 2049 notes.",
      "llm_answer": "Between 2022 and 2024, AT&T retired its 4.000% Global Notes due June 1, 2049 (identified as T 49A in the 2022 filing) and issued new long‑term debt, including additional 4.000% Global Notes due June 1, 2049 (listed as T 49A in the 2024 filing) alongside a broader suite of newer notes such as 4.250% Global Notes due June 1, 2043 (T 43) and 4.875% Global Notes due June 1, 2044 (T 44). This reflects a shift toward higher‑priced, longer‑dated securities while maintaining a presence of the 4.000% 2049 tranche.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. Contrary to the ground truth, it claims AT&T 'retired' and then re-issued the 4.000% Global Notes due 2049, which is incorrect — the original answer states these notes remained in place from 2022 to 2024 under the same symbol (T 49A), with no indication of retirement or reissuance. Additionally, the LLM introduces two new notes — 4.250% due 2043 (T 43) and 4.875% due 2044 (T 44) — that are not mentioned in the ground truth. Instead, the actual new note added was the 4.300% Global Notes due November 18, 2034 (T 34C), which the LLM fails to mention. (2) Quantitative accuracy is poor: the percentages (4.250%, 4.875%), maturities (2043, 2044), and even the description of the 2049 notes being retired are all incorrect. Only the 4.000% rate and June 1, 2049 maturity for T 49A are correct, but their treatment (retirement and reissuance) is wrong. (3) Multi-hop reasoning is flawed: the model fails to correctly synthesize the evolution of AT&T’s debt instruments by misrepresenting continuity and addition. It incorrectly infers a 'shift toward higher-priced, longer-dated securities' when the actual addition was a 2034 note (shorter than 2049), suggesting a diversification strategy, not a shift to longer maturities. (4) Contextual relevance is moderate because the answer addresses the general topic of debt composition evolution and mentions the correct company and one correct instrument, but the core facts and synthesis are incorrect, leading to a misleading conclusion.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1264,
        "completion_tokens": 427,
        "total_tokens": 1691
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did the financial impact of the Heritage AspenTech acquisition evolve between 2023 and 2024, particularly in terms of intangibles amortization and restructuring costs?",
      "original_answer": "In 2023, the intangibles amortization related to the Heritage AspenTech acquisition was $258, while in 2024, this figure decreased to $97. Additionally, restructuring costs were $72 in 2023 and increased to $228 in 2024. This indicates a reduction in the amortization burden but a significant rise in restructuring expenses over the two years.",
      "llm_answer": "Between 2023 and 2024, the financial impact of the Heritage AspenTech acquisition showed a significant increase in intangibles amortization, rising from $258 million in 2023 to $560 million in 2024, largely driven by the NI acquisition. Concurrently, restructuring costs related to the acquisition‑related integration activities increased to $228 million in 2024, up from $72 million in 2023, reflecting expanded workforce reductions, facility exits, and integration‑related expenses.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual errors in key financial figures. According to the ground truth, intangibles amortization decreased from $258 million in 2023 to $97 million in 2024, but the LLM incorrectly states it increased to $560 million in 2024. This is a significant quantitative error. Restructuring costs are partially correct—the LLM correctly notes an increase from $72 million to $228 million—but incorrectly attributes the rise to 'expanded workforce reductions, facility exits, and integration-related expenses' without mentioning the actual trend of declining amortization. (2) Number verification: 2023 amortization: LLM says $258M (correct), ground truth $258; 2024 amortization: LLM says $560M (incorrect), ground truth $97; 2023 restructuring: $72M (correct); 2024 restructuring: $228M (correct). Thus, two numbers are correct, but one critical number is wrong, and the trend described is opposite to reality. (3) Multi-hop reasoning is flawed: the model fails to recognize the decrease in amortization and instead reports a sharp increase, possibly due to confusion with another acquisition (e.g., 'NI acquisition' mentioned, which is not in the ground truth). This breaks the logical synthesis across years and metrics. (4) Scores justified as follows: Correctness is low (2/10) due to major factual inaccuracy in amortization; Quantitative accuracy is poor (2/10) because of the large error in the 2024 amortization figure; Qualitative accuracy is low (3/10) due to incorrect reasoning and unsupported attribution to NI acquisition; Contextual relevance is moderate (7/10) as the answer addresses the right topic and time frame with some correct data points.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1213,
        "completion_tokens": 463,
        "total_tokens": 1676
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How has AIG's use of expected loss ratio methods for workers' compensation evolved between 2022 and 2024, particularly in relation to the segmentation of business types and the impact of large deductible accounts?",
      "original_answer": "In 2022, AIG applied expected loss ratio methods primarily to guaranteed cost business in the most recent accident year, while for excess of deductible business, these methods were given significant weight in the most recent five accident years. The company also noted that the proportion of large deductible business had increased, slowing the reporting pattern of claims. By 2024, AIG continued to use expected loss ratio methods but placed greater emphasis on segmentation by deductible size and claim handling (AIG vs. third-party administrators), and explicitly highlighted the increasing influence of large deductible accounts on slowing claim emergence. Additionally, 2024 disclosures emphasized limitations in claim count data due to aggregation and reinsurance exclusions, which were not as prominently noted in 2022.",
      "llm_answer": "Between 2022 and 2024, AIG continued to rely on expected loss ratio methods for workers’ compensation, but applied them more heavily to recent accident years (particularly 2022‑2024) and gave greater weight to the Bornhuetter‑Ferguson and Cape Cod approaches that incorporate premium and loss‑trend inputs.  The company also refined its segmentation of large‑deductible and guaranteed‑cost business, isolating high‑deductible, third‑party‑administered excess‑of‑deductible layers and grouping by state and industry to reflect differing development patterns.  This segmentation, together with the increased use of expected‑loss‑ratio inputs for newer years, helped shape reserve estimates and resulted in modest favorable development in the most recent accident years.",
      "correctness_score": 5,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer captures some correct elements about AIG's continued use of expected loss ratio methods and segmentation of business types, but contains significant inaccuracies and omissions when compared to the ground truth. (1) Quantitatively, the LLM introduces accident years '2022-2024' and references to the Bornhuetter-Ferguson and Cape Cod methods, which are not mentioned in the original answer and cannot be verified from the provided truth. These methodological details are fabrications or unsupported inferences. (2) The original answer emphasizes a shift in segmentation by deductible size and claim handling (AIG vs. third-party administrators), which the LLM partially captures by mentioning 'high-deductible, third-party-administered' layers and segmentation by state and industry. However, the original does not mention state or industry grouping, so this is an overextension. (3) The LLM fails to mention the key point from the original that in 2022, expected loss ratio methods were applied primarily to guaranteed cost business in the most recent accident year, while for excess of deductible business, they were weighted over five recent years—a core multi-hop detail. (4) The increasing proportion of large deductible accounts and their impact on slowing claim emergence is correctly noted in both answers, but the LLM omits the 2024-specific disclosure about limitations in claim count data due to aggregation and reinsurance exclusions, which were not highlighted in 2022. (5) The LLM incorrectly infers 'modest favorable development' and reserve estimate impacts, which are not present in the original answer. While the general direction of evolution (increased segmentation, focus on deductible size) is plausible, the reasoning is not fully supported by the ground truth. Thus, the answer is partially correct but contains unsupported details and misses key distinctions, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1415,
        "completion_tokens": 518,
        "total_tokens": 1933
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How has Target's approach to cybersecurity threat investigation and response evolved from 2023 to 2024, particularly in terms of its Cyber Fusion Center operations and collaboration with external organizations?",
      "original_answer": "In 2023, Target operated its Cyber Fusion Center as part of its threat investigation and response capabilities, and emphasized collaboration with organizations across industries to share threat intelligence and best practices. By 2024, Target not only maintained its Cyber Fusion Center but also introduced a more structured incident response program with a coordinated escalation model to inform management and the Board of Directors during security incidents. Additionally, in 2024, Target expanded its external engagement by incorporating regular training and compliance activities for team members, and by leveraging third-party vendors to assess and test its cybersecurity program. This represents a more comprehensive and mature approach to cybersecurity threat response and collaboration.",
      "llm_answer": "Target’s cybersecurity approach has evolved from 2023 to 2024 by strengthening its Cyber Fusion Center operations and expanding external collaboration. In the 2024 filing, Target emphasizes that its Cyber Fusion Center now integrates a proactive threat‑intelligence program, industry‑standard frameworks, and regular validation through internal and independent assessments, while also enhancing coordination with the Board and Audit & Risk Committee. Additionally, Target deepens cross‑industry threat‑intelligence sharing, invests in internal talent development (e.g., the Cyber Plus Institute), and leverages third‑party vendors for testing—all of which reflect a more mature, collaborative, and integrated cybersecurity posture compared with the 2023 description.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly identifies that Target maintained and enhanced its Cyber Fusion Center from 2023 to 2024, introducing more structured processes and improved coordination with leadership, including the Board and Audit & Risk Committee—consistent with the original answer's mention of a coordinated escalation model. The LLM accurately reflects expanded external collaboration through third-party vendor testing and cross-industry threat intelligence sharing. It also adds specific details not in the ground truth but plausibly consistent with the evolution: 'proactive threat-intelligence program', 'industry-standard frameworks', and 'Cyber Plus Institute' for internal talent development. While the 'Cyber Plus Institute' is not mentioned in the ground truth, it does not contradict it and fits within the broader theme of internal talent development and training. There are no numerical discrepancies (quantitative accuracy is perfect as no conflicting numbers are present), and all dates (2023 vs 2024) are correctly attributed. The reasoning is sound, demonstrating multi-hop synthesis between internal operations (Cyber Fusion Center enhancements) and external collaboration (vendors, industry sharing). The answer is semantically equivalent and contextually fully relevant. One minor point preventing a perfect 10 is the introduction of specific program names not in the source, which, while reasonable, slightly exceeds the provided information.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1406,
        "completion_tokens": 417,
        "total_tokens": 1823
      },
      "error": null
    },
    {
      "question_id": 61,
      "question": "How did Eli Lilly's financial relationship with Baqsimi evolve between 2023 and 2024, particularly in terms of revenue recognition and contractual arrangements?",
      "original_answer": "In 2023, Eli Lilly reported $579.0 million in revenue specifically attributed to the sale of the rights for Baqsimi. By 2024, Baqsimi was included within broader collaboration and other revenue disclosures, reflecting its integration into revenue from collaborations and other arrangements, which included the 2023 sales of rights for both the olanzapine portfolio and Baqsimi. This shift indicates a move from direct product revenue to a more complex revenue recognition model under collaborative arrangements, suggesting a strategic evolution in how the company accounts for and manages its financial relationship with Baqsimi.",
      "llm_answer": "Based on the provided SEC 10-K disclosures, Eli Lilly's financial relationship with Baqsimi evolved significantly between 2023 and 2024 in terms of revenue recognition and contractual arrangements. In 2023, Baqsimi revenue reached $677.6 million (up from $139.3 million in 2022), driven by the sale of rights to the product as part of a portfolio transaction (noted in Note 4 as part of the olanzapine portfolio sale). By 2024, Baqsimi revenue was included within the consolidated net product revenue of $40,747.9 million, with no separate disclosure of its performance, indicating it was fully integrated into the company's product portfolio. Revenue recognition for Baqsimi, like other products, follows standard policies: revenue is recognized at shipment when control transfers, with provisions for returns, rebates, and discounts recorded as deductions from gross revenue. The 2023 revenue surge for Baqsimi was a one-time event tied to the portfolio sale, not ongoing product sales, and subsequent periods reflect its contribution as part of total net product revenue without separate contractual distinctions.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. The ground truth states that Eli Lilly recognized $579.0 million in 2023 from the sale of rights to Baqsimi, but the LLM claims $677.6 million in Baqsimi revenue, which is incorrect. Additionally, the LLM incorrectly frames this as 'Baqsimi revenue' increasing from $139.3 million in 2022, implying ongoing product sales, when in fact the 2023 amount was a one-time revenue event from the sale of rights, not recurring product revenue. The $677.6 million figure appears to conflate or misrepresent data, possibly confusing Baqsimi with other assets or misreading the disclosure. (2) The 2024 treatment is partially correct: Baqsimi is no longer disclosed separately and is included in broader revenue lines, but the LLM incorrectly places it under 'net product revenue' when the ground truth specifies it is part of 'collaboration and other revenue'—a critical distinction in revenue recognition accounting. This misclassification undermines the accuracy of the contractual and accounting evolution narrative. (3) The multi-hop reasoning is flawed: while the model attempts to track changes in disclosure and revenue recognition, it fails to correctly identify the nature of the 2023 transaction (sale of rights within a portfolio) and misattributes the revenue stream. It also misses the key point that Baqsimi’s revenue was part of a larger strategic shift toward collaborative arrangements, not integration into regular product sales. (4) Despite these errors, the answer is contextually relevant and attempts to address the evolution in financial relationship, revenue recognition, and contractual structure. However, due to major quantitative and qualitative inaccuracies—especially the wrong dollar amounts and mischaracterization of revenue classification—the correctness score is low. Minor credit is given for recognizing the shift from discrete disclosure to consolidation, even if the context is misrepresented.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1439,
        "completion_tokens": 548,
        "total_tokens": 1987
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did AT&T's approach to managing its capital structure through preferred interests evolve from 2023 to 2024, particularly regarding the repurchase of Mobility Preferred Interests and the expansion of Tower Holdings and Telco LLC preferred interests?",
      "original_answer": "In 2023, AT&T repurchased the remaining 213 million Mobility Preferred Interests for $5,414, removing $2,650 from 'Accounts payable and accrued liabilities' and $2,670 from 'Other noncurrent liabilities.' This repurchase was primarily funded by the issuance of $5,250 in new Telco LLC preferred interests, which carried a 6.85% annual distribution rate. By 2024, AT&T had shifted focus toward expanding its Tower Holdings preferred interests, where $6,000 in 2019 Tower preferred interests were restructured into fixed and floating rate classes with a 5.90% base rate and SOFR + 250 bps, respectively. Additionally, the total Telco LLC preferred interests increased to $7,250, including the original $2,000 (Telco Class A-1) and the 2023 additions. This reflects a strategic pivot from repurchasing legacy preferred interests to leveraging new preferred structures with more flexible redemption and distribution terms to manage capital and liquidity.",
      "llm_answer": "From 2023 to 2024, AT&T completed the full redemption of its legacy Mobility preferred interests (Mobility II) in April 2023, using proceeds from the April 2023 issuance of Telco LLC preferred equity to fund the $5.4 billion repurchase.  In 2024 the company expanded its preferred‑interest program by amending the 2019 Tower Holdings preferred interests (resetting rates and converting portions to floating‑rate interests) and by authorizing an additional $2.25 billion of Telco LLC preferred interests (Telco Class A‑4) for issuance in early 2025, while maintaining the ability to call or redeem these interests under the same terms as before.  No new issuances of Mobility preferred interests occurred after 2023, and the company’s capital‑structure management now relies on these expanded preferred‑interest issuances and the $10 billion common‑stock repurchase authorization rather than further repurchases of Mobility securities.",
      "correctness_score": 8,
      "quantitative_accuracy": 7,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the core evolution in AT&T's capital structure strategy—shifting from repurchasing Mobility Preferred Interests to expanding Tower Holdings and Telco LLC preferred interests. It correctly identifies the 2023 repurchase of Mobility interests for $5.4 billion and links it to the issuance of Telco LLC preferred interests. It also correctly notes the restructuring of Tower Holdings preferred interests in 2024 and the authorization of additional Telco LLC interests. However, there are minor quantitative discrepancies: the ground truth specifies the repurchase amount as $5,414 million (not $5.4 billion, though this is a minor rounding difference), and the Telco LLC issuance in 2023 was $5,250 million, not explicitly tied to a 'Class A-4' in that year. The LLM incorrectly implies the $2.25 billion is new in 2024, while the ground truth states total Telco LLC interests reached $7,250 by 2024 (original $2,000 + $5,250 from 2023), meaning only $2,000 net new after 2023, not $2.25 billion. Additionally, the LLM mentions an 'authorization for issuance in early 2025', which is not in the original answer. (2) The ground truth includes precise liability reductions ($2,650 from accounts payable, $2,670 from other noncurrent liabilities), which the LLM omits. The Tower Holdings restructuring is accurately described in terms of rate reset (5.90% base and SOFR + 250 bps), but the LLM does not mention the $6,000 in restructured interests. (3) The multi-hop reasoning is sound: the LLM correctly connects the 2023 repurchase to the Telco funding, recognizes the strategic pivot, and identifies the shift toward more flexible preferred structures. It synthesizes across years and entities appropriately. (4) The answer is contextually excellent—directly addresses the evolution in capital structure management. The qualitative accuracy is high due to correct entity identification and logical flow. Quantitative accuracy is slightly reduced due to dollar amount approximations and one forward-looking detail not in the source. Correctness score is 8 due to mostly accurate facts with minor numerical and detail omissions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1497,
        "completion_tokens": 579,
        "total_tokens": 2077
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did Emerson's relationship with AspenTech evolve from 2023 to 2024, and what financial impacts did this transformation have on Emerson's gross margin and ownership structure?",
      "original_answer": "In 2023, Emerson had a business relationship with AspenTech as part of its Software and Control offerings. By 2024, this relationship transformed into a more significant strategic position, as Emerson acquired a 55% ownership stake in 'New AspenTech' (formerly Heritage AspenTech) following a transaction that included approximately $6.0 billion in cash. This change in relationship had a measurable financial impact: the AspenTech acquisition contributed to a 3.3 percentage point increase in gross margin in 2023 and was part of broader changes that led to a 1.8 percentage point increase in gross margin in 2024. Additionally, the ownership stake marked a structural shift in Emerson’s involvement with AspenTech, moving from a partner to a majority shareholder.",
      "llm_answer": "From 2023 to 2024 Emerson’s relationship with AspenTech shifted from a joint‑venture‑style partnership to a majority‑owned, integrated subsidiary: Emerson already held ~57 % of AspenTech and, after the 2024 proposal to acquire the remaining shares at $240 per share (implying a $15.3 bn fully‑diluted market cap), it began consolidating AspenTech’s results.  This transformation boosted the “Software and Control” segment sales by 48 % (from $3.6 bn in 2023 to $5.4 bn in 2024) and added $231 m of acquisition‑related inventory step‑up amortization, which temporarily depressed gross margin but ultimately helped lift adjusted EBITA margin to 24.7 % of sales.  The deeper integration also altered Emerson’s ownership structure, increasing the proportion of AspenTech‑related assets and equity‑based compensation in corporate balances, while the overall gross margin rose 1.8 percentage points to 50.8 % in 2024, driven by the higher‑margin software acquisition despite the step‑up cost.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in ownership percentage and financial contributions. The ground truth states Emerson acquired a 55% stake in 'New AspenTech' in 2024 for $6.0 billion in cash, whereas the LLM claims Emerson already held ~57% and was acquiring the remainder at $240/share implying a $15.3B valuation—this contradicts the ground truth both in timing and scale. The $6.0B cash transaction is not reflected in the LLM response. (2) Quantitative inaccuracies include: incorrect ownership (57% vs 55%), incorrect acquisition cost (implied $15.3B vs $6.0B), incorrect sales figures ($3.6B to $5.4B with 48% growth not in ground truth), and fabricated metrics like $231M inventory step-up amortization and 24.7% EBITA margin. The only correct number is the 1.8 percentage point gross margin increase in 2024. The 3.3 percentage point increase in 2023 from AspenTech is omitted. (3) The multi-hop reasoning is partially sound—LLM correctly infers integration impacts on financials and structure—but fails to accurately synthesize the actual transaction terms. It invents a share price and full acquisition not present in the ground truth, which describes a 55% acquisition, not a full buyout. (4) Contextual relevance is high as the answer addresses the evolution of the relationship and financial impacts on margin and ownership. However, due to major quantitative errors and incorrect entity details (ownership %, transaction value), the correctness score is low. The qualitative score reflects some correct conceptual understanding but flawed execution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1445,
        "completion_tokens": 442,
        "total_tokens": 1888
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How has AIG's Japan pension plans' contribution to non-U.S. pension obligations evolved between 2022 and 2024, and what change occurred in the weighted average discount rate applied to these plans during this period?",
      "original_answer": "In 2022, AIG's Japan pension plans accounted for 61% of total non-U.S. pension assets, with an expected long-term rate of return of 1.85%. By 2024, the Japan pension plans' share of non-U.S. projected benefit obligations decreased to 50% as of December 31, 2024, from 54% in 2023, and the weighted average discount rate increased to 1.81% in 2024 from 1.48% in 2023. This indicates a relative decline in the size of the Japan pension plans within AIG's non-U.S. pension structure, accompanied by a notable increase in the discount rate applied, likely reflecting changes in market conditions or investment strategy.",
      "llm_answer": "Between 2022 and 2024, AIG's Japan pension plans saw a decline in their contribution to non-U.S. pension obligations, falling from approximately 51% of total non-U.S. projected benefit obligations at the end of 2020 to about 50% by the end of 2021, and continuing to represent roughly 50% of non-U.S. obligations at the end of 2024. The weighted average discount rate applied to these plans was 0.52% in 2021 and increased slightly to 0.56% in 2020, though the provided data does not include specific discount rate figures for 2022–2024 beyond the 2021 and 2020 values. The document confirms that the discount rate for Japan was derived from the Mercer Yield Curve, but no explicit 2022–2024 discount rate values are provided in the sources.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, AIG's Japan pension plans accounted for 61% of non-U.S. pension *assets* (not obligations), and by 2024, their share of *projected benefit obligations* decreased to 50% from 54% in 2023. The LLM incorrectly states a decline from 51% in 2020 to 50% in 2021 and then to 50% in 2024, which misrepresents both the timeline and the magnitude of change. The LLM also references 2020 and 2021 data, which are outside the 2022–2024 scope of the question. (2) The discount rate values are completely wrong: the LLM claims 0.52% in 2021 and 0.56% in 2020, while the ground truth states the rate increased to 1.81% in 2024 from 1.48% in 2023. The LLM falsely claims no data is available for 2022–2024, when in fact the correct data is available and directly contradicts its response. (3) The multi-hop reasoning is flawed: the model fails to correctly identify the relevant years, confuses assets with obligations, and uses incorrect data points from outside the requested timeframe. It does not synthesize the correct trend of declining relative obligation size and rising discount rate. (4) The contextual relevance is moderate because it attempts to address the evolution of Japan's contribution and discount rate, but the severe factual and quantitative errors undermine the answer’s validity. The mention of the Mercer Yield Curve is accurate but irrelevant without correct numerical context. Overall, the answer is mostly incorrect with major errors in numbers, time periods, and financial metrics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1356,
        "completion_tokens": 440,
        "total_tokens": 1796
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How did Amazon's disclosure about the impact of competitive stores on its business evolve between the 2022 and 2023 10-K filings, particularly in terms of the framing of external market conditions?",
      "original_answer": "In the 2022 10-K filing, Amazon described competitive stores as a general factor among many that could impact sales and operating results, listing them alongside internal capabilities such as inventory management and customer satisfaction. The 2022 filing included the phrase: 'the introduction of competitive stores, websites, products, services, price decreases, or improvements' as a potential cause of sales fluctuations. In contrast, the 2023 filing retained the same core language but embedded it within a broader context that emphasized external economic and geopolitical conditions, stating that revenue and operating profit growth 'depends on the continued growth of demand for the products and services offered by us or our sellers, and our business is affected by, among other things, general economic, business, and geopolitical conditions worldwide.' This indicates a shift toward framing competitive pressures as part of a larger set of external risks rather than a standalone concern.",
      "llm_answer": "The 2023 filing shifts the framing of competitive store pressure from a general risk statement in 2022 to a more specific, market‑condition‑focused warning that “the introduction of competitive stores, websites, products, services, price decreases, or improvements” will cause sales and operating results to fluctuate, emphasizing external market dynamics rather than just internal operational strain.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer correctly identifies the continuity of the core phrase about competitive stores and the shift in framing between the 2022 and 2023 filings, and accurately references the key language from the filings. However, it mischaracterizes the nature of the shift: it claims the 2023 filing makes the warning 'more specific' and 'market-condition-focused' as if this language is new or more emphasized in 2023, when in fact the core sentence about competitive stores is unchanged from 2022. The actual evolution, per the ground truth, is that the 2023 filing embeds this existing language within a broader context of external economic and geopolitical conditions, thereby reframing competitive pressures as part of a larger set of external risks. The LLM incorrectly implies that the competitive stores clause itself was reworded or newly emphasized in 2023, when it was the surrounding context that changed. This is a significant qualitative error in reasoning and interpretation, though the entities (Amazon, 2022 vs 2023 10-Ks) and years are correct, and there are no numerical inaccuracies (the question involves no numbers, so quantitative accuracy is scored as 10 by default). The answer is contextually relevant and addresses the core question about framing evolution, but misses the precise nature of the shift in risk disclosure strategy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 374,
        "total_tokens": 1737
      },
      "error": null
    },
    {
      "question_id": 62,
      "question": "How has Target's exposure to port security risks evolved between 2023 and 2024, particularly in terms of geographic focus and operational impact?",
      "original_answer": "In 2023, Target specifically highlighted California ports as a key area affected by port security issues, mentioning that these ports were where the company received a significant portion of its imported merchandise. By 2024, Target broadened its focus, referring to 'major U.S. ports' without specifically naming California, indicating a more generalized concern across multiple locations. Additionally, in 2023, the company noted it had made alternative arrangements due to past disruptions, while in 2024, the emphasis shifted to potential future impacts, including increased costs and inventory supply issues, due to ongoing global conflicts and labor disputes.",
      "llm_answer": "Between 2023 and 2024, Target’s exposure to port‑security risks remained focused on the same geographic areas—particularly major U.S. ports such as those in California that handle a large share of its imported goods. The company continues to monitor disruptions from labor disputes, congestion, and heightened security concerns that can affect inbound shipments, and it has previously implemented alternative routing and inventory‑management measures to mitigate these threats. While no material impact on operations was reported, the risk persists as global supply‑chain volatility and geopolitical tensions could still increase costs or cause delays in receiving merchandise.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but contains a key factual inaccuracy in its portrayal of Target's evolving geographic focus on port security risks. While the original answer (ground truth) states that in 2023, Target specifically highlighted California ports as a key area of concern, and in 2024 broadened its language to 'major U.S. ports' (indicating a shift from specific to generalized geographic focus), the LLM incorrectly asserts that the geographic focus 'remained focused on the same geographic areas—particularly major U.S. ports such as those in California'. This misrepresents the evolution: the shift from naming California to a broader reference in 2024 suggests a change in risk perception or disclosure strategy, which the LLM fails to capture. Additionally, the original answer notes a shift in operational emphasis—from having made alternative arrangements in 2023 due to past disruptions, to warning of potential future impacts (costs, supply issues) in 2024 due to global conflicts and labor disputes. The LLM mentions mitigation measures but frames them as ongoing without capturing the temporal shift in risk posture. There are no numerical values in the question or answers, so quantitative accuracy is not applicable—scored as 10 by default. Contextual relevance is high, as the response addresses port security, geography, operational impact, and mitigation. However, the failure to accurately reflect the change in geographic specificity and the shift in operational risk narrative from reactive to forward-looking undermines the qualitative accuracy. Thus, while the answer is plausible and contextually grounded, it misses critical nuances in the evolution of risk exposure, warranting a mid-range correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 473,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How did Emerson's financial relationship with Heritage AspenTech evolve between 2023 and 2024, particularly in terms of acquisition-related amortization and restructuring costs?",
      "original_answer": "In 2023, Emerson reported $258 million in intangibles amortization related to the Heritage AspenTech acquisition. By 2024, this specific amortization was no longer reported, indicating that the focus had shifted away from AspenTech as a newly acquired entity. Additionally, restructuring costs increased significantly from $72 million in 2023 to $228 million in 2024, suggesting that Emerson undertook more extensive restructuring activities in 2024, potentially reflecting integration efforts or strategic realignments following the AspenTech acquisition.",
      "llm_answer": "Between 2023 and 2024, Emerson's financial relationship with Heritage AspenTech evolved through the following key developments related to acquisition-related amortization and restructuring costs:  \n\n1. **Amortization**: In 2024, amortization of intangibles (including customer relationships and developed technology from the Heritage AspenTech acquisition) increased significantly to $1,077 million, up from $482 million in 2023 and $336 million in 2022, reflecting the ongoing amortization of acquired intangibles from the 2022 acquisition.  \n\n2. **Restructuring Costs**: Restructuring expenses rose sharply to $228 million in 2024 (compared to $72 million in 2023 and $75 million in 2022), driven by integration-related costs, workforce reductions (including $43 in integration-related stock compensation attributable to NI), and facility exits. These costs were reported across multiple segments, with notable increases in Discrete Automation ($35 million in 2024 vs. $27 million in 2023) and Intelligent Devices ($80 million in 2024 vs. $48 million in 2023).  \n\nThese changes reflect the continued operational integration and cost optimization efforts following the Heritage AspenTech acquisition, with restructuring expenses accelerating in 2024 as part of broader efficiency initiatives.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the amortization figures. The ground truth states that Emerson reported $258 million in 2023 related to the AspenTech acquisition and that this specific amortization was no longer reported in 2024. However, the LLM claims amortization increased to $1,077 million in 2024 from $482 million in 2023, which directly contradicts the ground truth. These numbers do not align with the original answer and appear to conflate total intangibles amortization with acquisition-specific amortization. (2) The restructuring cost figures are correct: $72 million in 2023 and $228 million in 2024, matching the ground truth. This is the only quantitatively accurate part. (3) The multi-hop reasoning is flawed. The LLM incorrectly infers that increasing amortization reflects ongoing amortization of AspenTech intangibles, while the ground truth indicates that AspenTech-specific amortization was no longer reported in 2024—suggesting it was no longer a distinct line item or had been absorbed or completed. The LLM fails to capture this key evolution and instead asserts continued growth in acquisition-related amortization, which contradicts the original conclusion. (4) Contextually, the answer addresses the right topic—Emerson's financial relationship with AspenTech, focusing on amortization and restructuring—but the core financial narrative is incorrect due to the wrong amortization data. While the restructuring analysis is accurate and detailed, the critical error in amortization undermines the overall correctness. The answer fabricates segment-level data (e.g., Discrete Automation, Intelligent Devices) and integration-related stock compensation not present in the ground truth, further reducing accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1470,
        "completion_tokens": 487,
        "total_tokens": 1957
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has AIG's use of Expected Loss Ratio methods evolved between 2022 and 2024, particularly in terms of the weight given to this method across different lines of business and accident years?",
      "original_answer": "In 2022, AIG applied Expected Loss Ratio methods primarily for more recent accident years in lines such as D&O, E&O, EPLI, and professional liability, where losses are low frequency and high severity. The method was also used in conjunction with IBNR factor methods for low frequency/high severity losses, with factors continually reevaluated based on emerging claim experience and market factors. By 2024, AIG continued to use Expected Loss Ratio methods but expanded their application to include U.S. Workers' Compensation, a long-tail line of business, where they were used in combination with loss development and frequency/severity methods. This reflects a broader application of the method across different risk profiles and a more integrated approach to reserving in complex portfolios.",
      "llm_answer": "Between 2022 and 2024, AIG’s Expected Loss Ratio method gained increasing weight in its reserving framework, especially for newer accident years, while loss development methods were applied more heavily to older, more mature years. The company explicitly noted that Expected Loss Ratio methods were “given significant weight in the most recent five accident years” and that they were “more responsive to recent loss trends” for newer business, whereas development-based methods dominated for older years. This shift reflects a strategic emphasis on newer business where loss development patterns are less reliable, leading to greater reliance on Expected Loss Ratio inputs across lines of business and accident years.",
      "correctness_score": 6,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general trend of AIG increasing reliance on Expected Loss Ratio (ELR) methods for more recent accident years and using loss development methods for older years, which aligns with the ground truth. It correctly identifies that ELR methods are more responsive to recent trends and are weighted more heavily in newer accident years—specifically noting 'the most recent five accident years,' which is consistent with AIG's disclosures. However, the LLM answer fails to mention the key evolution highlighted in the original answer: the expansion of ELR methods into U.S. Workers' Compensation by 2024, a long-tail line of business. This omission is significant because it represents a material shift in the method’s application across different risk profiles and lines of business, which is central to the question about evolution between 2022 and 2024. Additionally, while the LLM correctly notes the use of ELR in newer years and its combination with other methods, it does not specify the lines of business mentioned in 2022 (D&O, E&O, EPLI, professional liability) or the integration with IBNR factor methods. The qualitative reasoning is partially sound—there is correct logic about responsiveness to recent trends—but misses the multi-hop synthesis of how ELR use broadened beyond short-tail, high-severity lines into long-tail workers' comp. Quantitative accuracy is high as no incorrect numbers are presented (the 'five accident years' detail is plausible and consistent with filings), and contextual relevance is strong since the response stays focused on AIG’s reserving methodology evolution. However, due to missing the key 2024 expansion to Workers’ Compensation and lack of specificity on lines of business, the answer is only partially correct.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1388,
        "completion_tokens": 481,
        "total_tokens": 1870
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has the monetization strategy for Amazon's film groups evolved between 2022 and 2023, based on changes in capitalized video and music content costs and associated expenses?",
      "original_answer": "Amazon's monetization strategy for film groups evolved between 2022 and 2023, as evidenced by an increase in both the capitalized video and music content costs and the associated expenses. In 2022, the capitalized costs were $16.7 billion with total video and music expenses of $16.6 billion, while in 2023, these figures increased to $17.4 billion and $18.9 billion, respectively. This indicates a more aggressive investment in content and a corresponding rise in monetization efforts.",
      "llm_answer": "Based on the capitalized video and music content costs and related expense data provided, Amazon's monetization strategy for its film groups shifted significantly between 2022 and 2023. In 2022, total capitalized video and music content costs were $16.7 billion, with total video and music expenses of $16.6 billion; by 2023, these costs increased to $17.4 billion in capitalized expenses, while total expenses rose sharply to $18.9 billion. This indicates a strategic increase in investment in content (particularly original productions) and a corresponding rise in monetization through Prime memberships and licensing, as evidenced by the higher expense recognition and the continued use of accelerated amortization based on viewing patterns. The company continues to evaluate film groups for impairment whenever events or changes suggest fair value may be below carrying value, but the scale of capitalized spending and expense growth reflects an expanded, more aggressive content monetization approach.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports all key financial figures from the ground truth: capitalized video and music content costs increased from $16.7 billion in 2022 to $17.4 billion in 2023, and total video and music expenses rose from $16.6 billion to $18.9 billion. These numbers are factually accurate and match the original answer exactly, satisfying quantitative accuracy. (2) The calculations and comparisons implied (increases in both capitalized costs and expenses) are correct. The increase in capitalized costs is $0.7 billion and in expenses is $2.3 billion, which aligns with the 'sharp rise' described. No mathematical errors are present. (3) The multi-hop reasoning is sound—by comparing the two years' data and interpreting the increase as a sign of more aggressive investment and expanded monetization, the LLM correctly synthesizes the implications of the financial trends. It appropriately infers strategic intent from financial behavior. (4) The LLM adds minor qualitative elaboration not in the original answer—such as linking monetization to Prime memberships, licensing, and amortization practices—which is reasonable and contextually supported by Amazon's known business model, though not explicitly stated in the ground truth. This does not introduce inaccuracy but slightly extends beyond the provided data. However, the core facts, synthesis, and conclusion are fully aligned with the original answer. Thus, while extremely close to perfect, a score of 9 is given for correctness due to the slight expansion on monetization mechanisms beyond what the data explicitly confirms, though these are plausible and not misleading.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 454,
        "total_tokens": 1834
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How has Philip Morris International's financial relationship with RBH evolved between 2022 and 2024, particularly in terms of its stake and associated impairment?",
      "original_answer": "In 2022, Philip Morris maintained a trademark relationship with RBH, continuing to report volume of brands sold by RBH such as HEETS and other heated tobacco units. By 2024, PMI held an equity investment in RBH, which became subject to a significant impairment charge of $2,316 million due to unresolved allocation of a $32.5 billion Canadian tobacco litigation settlement among RBH, ITL, and JTIM. This reflects a shift from a trademark and brand licensing relationship to a more direct equity investment facing financial impairment.",
      "llm_answer": "Between 2022 and 2024, Philip Morris International's stake in Rothmans, Benson & Hedges (RBH) was impaired, leading to a $2,316 million non-cash impairment charge recorded in 2024. This impairment arose from uncertainty surrounding the allocation of a proposed CAD 32.5 billion settlement in Canadian tobacco litigation, which signaled potential risks to PMI's investment. The document confirms that PMI evaluated its investment in RBH for impairment and concluded that its fair value was lower than its carrying value, resulting in the significant charge.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: the $2,316 million impairment charge in 2024 and the CAD 32.5 billion Canadian litigation settlement are accurately reported, with acceptable format variation (CAD vs. $ noted but contextually clear). (2) The answer correctly identifies the key entities—Philip Morris International (PMI), RBH—and the relevant time frame (2022 to 2024). (3) The reasoning is sound: it captures the shift in financial relationship via the recognition of an equity investment subject to impairment, though it does not explicitly mention the earlier trademark and brand licensing relationship in 2022 (e.g., reporting of HEETS volumes), which is a minor omission affecting completeness. (4) Despite this, the core multi-hop synthesis—linking PMI’s investment, the litigation uncertainty, and the resulting impairment—is logically and factually correct. The answer focuses on the financial stake and impairment, which are central to the question, making it contextually excellent. The lack of explicit reference to the pre-2024 trademark relationship slightly reduces qualitative completeness, but the financial evolution is accurately conveyed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1276,
        "completion_tokens": 347,
        "total_tokens": 1623
      },
      "error": null
    },
    {
      "question_id": 63,
      "question": "How did the sensitivity of LLY's net product revenue to changes in sales return, rebate, and discount liabilities evolve between 2023 and 2024, based on the disclosures in the respective 10-K filings?",
      "original_answer": "In 2023, LLY disclosed that a 5% change in its consolidated sales return, rebate, and discount liability would result in a $615 million change in revenue. In 2024, while the company continued to describe the accounting policy for revenue recognition and accruals for rebates and discounts, it did not provide an updated sensitivity figure. This omission suggests that the company did not disclose a revised estimate for the impact of liability changes on revenue in 2024, indicating a lack of updated quantitative disclosure compared to 2023.",
      "llm_answer": "The sensitivity of LLY’s net product revenue to changes in sales return, rebate, and discount liabilities remained essentially unchanged between 2023 and 2024.  In both years, a 5 % change in the consolidated sales‑return/rebate/discount liability would affect revenue by roughly $600 million (approximately $615 million in 2023 and $600 million in 2024), indicating that the magnitude of the sensitivity did not materially evolve.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in asserting that a $600 million sensitivity figure was disclosed in 2024. The ground truth explicitly states that LLY did not provide an updated sensitivity figure in 2024, making the claim of a '$600 million' impact entirely fabricated. The 2023 figure of $615 million is correct, but the 2024 number is not disclosed, so any quantitative comparison is invalid. (2) Quantitative accuracy fails because the LLM invents a 2024 sensitivity value ($600 million) that does not appear in the 10-K and is not supported by the ground truth. There is no calculation or data source justifying this number. (3) The multi-hop reasoning is flawed: the model should have recognized that while 2023 included a specific sensitivity disclosure, 2024 omitted it, which represents a change in disclosure practice — not stability in sensitivity. The correct inference is reduced transparency, not unchanged economic exposure. The LLM incorrectly assumes continuity where the data is missing. (4) Contextual relevance is moderate because the answer addresses the right topic (revenue sensitivity to rebates/discounts) and company (LLY), but it misrepresents the core fact — disclosure omission — leading to a fundamentally incorrect conclusion about the evolution of sensitivity. The answer would be more accurate if it stated that the sensitivity could not be compared due to lack of 2024 disclosure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1256,
        "completion_tokens": 397,
        "total_tokens": 1654
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How has the role and revenue contribution of Bulk shipments evolved from 2022 to 2024, based on Union Pacific's disclosures?",
      "original_answer": "In 2022, Bulk shipments had an average revenue per car of $3,305 in 2021 (referenced in the 2022 filing), showing a 6% increase from 2020. By 2024, Bulk shipments had grown in strategic importance, contributing 32% of total freight revenues, with detailed operations covering grain, fertilizer, and coal markets, including international connections to Mexico and access to Canadian interline routes. This indicates a transformation in the Bulk segment's role from a revenue-per-unit perspective to a more strategically embedded and revenue-significant component of Union Pacific's operations.",
      "llm_answer": "Based on Union Pacific's disclosures across the provided 2022 and 2024 filings, Bulk shipments' revenue contribution has declined significantly. In 2022, Bulk generated 32% of total freight revenue ($6,656 million out of $20,244 million total freight revenue), but by 2024, its share dropped to 27% ($1,176 million out of $12,466 million total freight revenue), reflecting a 5 percentage point reduction in contribution. This decline aligns with the 2024 freight revenue breakdown showing Bulk at 32% of total freight revenue (page 6), while the 2022 data (page 35) confirms Bulk's 32% share, indicating a sustained downward trend in its relative importance to the company's overall freight revenue mix.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both direction and magnitude. The ground truth states that Bulk shipments grew in strategic importance by 2024, contributing 32% of total freight revenues, while the LLM claims a decline from 32% in 2022 to 27% in 2024. This contradicts the original answer and misrepresents the trend. Additionally, the LLM fabricates specific dollar amounts—$6,656 million for Bulk in 2022 and $1,176 million in 2024—that are not supported by the ground truth, which does not provide absolute revenue figures for Bulk shipments. (2) The quantitative inaccuracies are severe: the 2024 total freight revenue of $12,466 million and Bulk revenue of $1,176 million are inconsistent with the 32% contribution cited in the same answer (which would require ~$3,989 million). The 2022 figures also do not align with any verifiable data in the ground truth. The claim of a '5 percentage point reduction' is false, as the ground truth indicates sustained or increased importance. (3) The multi-hop reasoning fails: instead of synthesizing growth in strategic role and revenue significance, the model incorrectly infers a decline, possibly due to misreading or hallucinating data. It references 'page 6' and 'page 35' but draws contradictory conclusions even from those sources. (4) The contextual relevance is moderate because it addresses Bulk shipments and revenue contribution over time, but the factual errors and incorrect synthesis render the answer misleading. The qualitative reasoning is poor due to incorrect entity relationships and flawed logic.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1318,
        "completion_tokens": 435,
        "total_tokens": 1753
      },
      "error": null
    },
    {
      "question_id": 64,
      "question": "How did the interest rate of IBM's Notes due 2028 evolve between 2023 and 2024, and what does this indicate about IBM's debt strategy?",
      "original_answer": "In 2023, IBM had 1.750% Notes due 2028 (IBM 28A) listed, and in 2024, the same 1.750% Notes due 2028 (IBM 28A) were still present in the disclosures. This indicates that the interest rate for this specific issuance remained unchanged over the two years. However, IBM introduced new notes with different interest rates in 2024, such as the 2.900% Notes due 2030 and the 3.150% Notes due 2033, suggesting a broader strategy to issue debt at higher rates for longer maturities.",
      "llm_answer": "The interest rate on IBM’s 0.300% Notes due 2028 remained unchanged at 0.300% from 2023 to 2024, indicating that IBM did not adjust the coupon rate on this specific debt instrument during that period. This stability suggests a conservative debt‑management approach, preserving financing costs while the company continues to issue new notes at market‑reflective rates.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that IBM has '0.300% Notes due 2028'. According to the ground truth, the correct interest rate for IBM's Notes due 2028 (IBM 28A) is 1.750%, not 0.300%. This fundamental error invalidates the core of the response. Additionally, the LLM fails to mention the introduction of new notes in 2024 (e.g., 2.900% due 2030 and 3.150% due 2033), which is a key part of IBM's debt strategy and required for completeness. (2) The quantitative inaccuracy is severe: the interest rate is off by more than 1.4 percentage points, and no correct financial instruments are referenced. There are no calculations in this question, but the misstatement of a key percentage is a critical numerical error. (3) The reasoning is flawed because it is based on a non-existent instrument (0.300% Notes due 2028). While the general idea of 'stable rates indicating conservative debt management' is plausible, the multi-hop synthesis fails — the model did not correctly identify the actual note series or its continuity, nor did it incorporate the broader strategy of issuing new, higher-rate, longer-term debt. (4) The contextual relevance is moderate because the answer addresses the structure of the question (rate change and strategy implication), but the factual foundation is entirely incorrect, leading to a very low correctness and qualitative accuracy score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1207,
        "completion_tokens": 389,
        "total_tokens": 1596
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did AT&T's capital structure strategy regarding preferred interests evolve from 2023 to 2024, particularly in relation to the Mobility Preferred Interests and the introduction of new preferred instruments?",
      "original_answer": "In 2023, AT&T repurchased all of its Mobility Preferred Interests, which had a redemption value of approximately $5,340 million and paid annual cash distributions of $373 million. This marked a significant shift in strategy, as the company eliminated this class of preferred interests. In 2024, AT&T introduced structural modifications to other preferred instruments, including the restructuring of its Tower Holdings preferred interests to include both fixed and floating rate components, and the expansion of Telco LLC preferred interests to a total of $7,250 million. This evolution indicates a strategic pivot from Mobility-based preferred capital to more diversified and strategically tailored preferred instruments tied to infrastructure and telecommunications assets.",
      "llm_answer": "From 2023 to 2024, AT&T’s capital structure strategy regarding preferred interests shifted decisively away from the legacy Mobility preferred interests and toward new, restructured preferred instruments. The company fully repurchased all outstanding Mobility II preferred interests (including the $5,414 redemption in April 2023) and terminated the prior Mobility II equity classification, eliminating any future equity-based dilution risk. In its place, AT&T issued new preferred interests in subsidiaries—specifically, the 2019 Tower preferred interests (reset in November 2024 to Fixed Rate Class A at 5.90% and Floating Rate Class A tied to SOFR+250bps) and the Telco LLC preferred interests (including the newly authorized $2,250 Telco Class A-4 tranche at 5.94% in 2025). These instruments feature reset dividend rates, mandatory redemption options, and are now classified as noncontrolling interests or liabilities (not equity), reflecting a strategic move to stabilize capital structure through debt-like preferred equity with defined redemption terms rather than equity. This evolution marks a clear pivot from the previously repurchased Mobility preferreds to a newer, more structured preferred equity framework across AT&T’s subsidiaries.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the general strategic shift from Mobility Preferred Interests to new preferred instruments, which aligns with the ground truth. However, there are significant quantitative inaccuracies. The original answer states the redemption value of the Mobility Preferred Interests was approximately $5,340 million, while the LLM claims $5,414 million — a material discrepancy. Additionally, the LLM references a '2025' issuance of a $2,250 million Telco Class A-4 tranche, but the original answer states that Telco LLC preferred interests were expanded to a total of $7,250 million in 2024, not 2025, and does not specify a $2,250 tranche or a 5.94% rate. The restructuring of Tower Holdings preferred interests is correctly described in terms of fixed and floating rate components, but the LLM adds specific details (5.90%, SOFR+250bps, November 2024 reset) not present in the original answer, introducing unverified precision. (2) The original answer does not mention 'Mobility II', '2019 Tower preferred interests', 'Class A-4 tranche', or specific interest rates, nor does it reference classification changes (e.g., as liabilities or noncontrolling interests) or 'mandatory redemption options' — these are additions not supported by the ground truth. (3) The multi-hop reasoning is partially sound: the model correctly infers a strategic pivot from Mobility to infrastructure/telecom-linked preferred instruments. However, it fabricates specific tranches, dates, and rates, undermining factual reliability. (4) The contextual relevance is high as the answer addresses the evolution of capital structure strategy. Qualitative accuracy is moderate due to correct directional logic but over-specific unsupported details. Quantitative accuracy is low due to incorrect dollar amounts, misattributed years, and invented percentages. Correctness score reflects partial factual alignment but significant deviations in key numbers and unsupported additions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1521,
        "completion_tokens": 533,
        "total_tokens": 2055
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How has Amazon's characterization of the competitive threat from websites evolved between 2022 and 2023, and what specific changes in language indicate a shift in the nature of this competition?",
      "original_answer": "In 2022, Amazon described competitive websites as part of a broader list of fluctuating business factors, indicating a general awareness of competitive pressures. By 2023, Amazon's language evolved to reflect a more direct and strategic competitive stance, specifically highlighting the introduction of 'competitive stores, websites, products, services, price decreases, or improvements' as a central concern. This shift indicates a more focused and intensified competitive threat from digital platforms, suggesting an evolution from a general operational risk to a more strategic and dynamic competitive challenge.",
      "llm_answer": "Amazon’s 2022 and 2023 10‑K filings show a clear shift in how the company frames the competitive threat from other websites. In 2022 the language emphasizes “intensifying competition” and notes that “local companies may have a substantial competitive advantage because of their greater understanding of, and focus on, the local customer,” but it treats this competition mainly as a background risk to its international expansion. By 2023 the narrative tightens the focus on “competition will intensify, including through adoption of evolving business models,” and explicitly warns that “local companies may have a substantial competitive advantage because of their greater understanding of, and focus on, the local customer, as well as their more established local brand names.” The added qualifier “as well as their more established local brand names” signals that Amazon now sees brand strength and localized market knowledge—not just price or selection—as a core, growing dimension of the threat. This evolution reflects a move from a general warning about competition to a more specific concern that rivals’ localized brand equity and market insight could erode Amazon’s market share in key regions.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is partially correct in identifying a shift in Amazon's language regarding competitive threats between 2022 and 2023, but it misrepresents the core content and focus of the original answer. (1) The LLM introduces specific quotes not present in the ground truth, such as 'intensifying competition' and 'local companies may have a substantial competitive advantage...', which do not appear in the provided original answer. The original answer emphasizes a shift from viewing competitive websites as part of 'fluctuating business factors' in 2022 to a more strategic concern involving 'competitive stores, websites, products, services, price decreases, or improvements' in 2023. The LLM instead frames the evolution around local companies and brand names, which is not mentioned in the original. (2) There are no numeric values in the question or answers, so quantitative accuracy is not applicable—scored as 10 by default. (3) The multi-hop reasoning is flawed: while the LLM correctly infers a shift in tone, it fabricates the nature of the shift (localized brand strength) rather than reflecting the original's focus on a broadening of competitive dimensions (products, services, pricing). (4) Contextually, the answer addresses the evolution of competitive language, so it remains relevant, but the specific evidence and reasoning are not aligned with the ground truth. The conclusion about localized brand equity is unsupported by the original, making the qualitative accuracy low despite correct temporal framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1466,
        "completion_tokens": 419,
        "total_tokens": 1885
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How has PM's relationship with KT&G evolved from 2022 to 2024, particularly in terms of its strategic reliance on KT&G's heat-not-burn products within PMI's smoke-free product portfolio?",
      "original_answer": "In 2022, PM had a global collaboration agreement with KT&G that allowed PMI to exclusively distribute KT&G's smoke-free products, including heat-not-burn products like LIL Mini and LIL Plus, outside of South Korea. This agreement was initially for three years, indicating a strategic partnership aimed at expanding KT&G's products globally. By 2024, this relationship had evolved such that KT&G's heat-not-burn products were no longer just distributed by PMI but were integrated into PMI's broader smoke-free product portfolio, specifically being listed among PMI's own heat-not-burn offerings. This indicates a deeper strategic reliance on KT&G's product line within PMI's own commercialization efforts, suggesting a shift from a distribution partnership to a more embedded supplier or technology partner role for KT&G.",
      "llm_answer": "From 2022 to 2024, PMI’s reliance on KT&G’s heat‑not‑burn products grew markedly, shifting from a nascent partnership to a central pillar of its smoke‑free portfolio.  In 2022 the collaboration was still being established, but by 2023 and especially 2024 PMI began reporting substantial net‑revenue contributions from KT&G‑licensed HTU brands (e.g., Fiit, Miix) and highlighted them as key growth drivers in its “smoke‑free products” segment, underscoring a strategic shift toward greater dependence on KT&G’s technology and product pipeline to meet its smoke‑free revenue targets.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the general direction of the evolving relationship between PMI and KT&G—from a distribution partnership to deeper integration—addressing the strategic reliance on KT&G's heat-not-burn (HTB) products within PMI's smoke-free portfolio. However, several key factual inaccuracies reduce correctness. First, the original answer states that the global collaboration agreement began in 2022 with an initial three-year term, allowing PMI exclusive distribution of KT&G's products like LIL Mini and LIL Plus outside South Korea. The LLM answer incorrectly frames the partnership as 'still being established in 2022,' which contradicts the ground truth that the agreement was already in place. Second, the LLM mentions specific brands 'Fiit' and 'Miix' as KT&G-licensed HTU brands contributing to net revenue by 2023–2024. However, the ground truth references 'LIL Mini' and 'LIL Plus'—not Fiit or Miix—introducing incorrect product names. While it is plausible these are alternate names or newer variants, they are not supported by the provided truth. Third, the LLM claims 'substantial net-revenue contributions' and that these products were 'key growth drivers,' but the original answer does not provide any quantitative financial data (e.g., revenue figures, percentages), so asserting 'substantial' contributions introduces unsupported specificity. The qualitative shift—from distributor to integrator—described in the original answer (products now listed among PMI’s own offerings) is partially reflected in the LLM’s notion of 'greater dependence,' but the deeper strategic evolution into an embedded supplier role is underdeveloped. The reasoning is logically coherent but based on incorrect or unverified entities and timelines. Contextually, the answer is highly relevant and addresses the core question about strategic reliance. Quantitative accuracy is low due to unsupported claims about revenue impact and incorrect brand timelines, despite no explicit numbers being misstated. Overall, the answer reflects partial factual alignment with significant entity and timeline inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 563,
        "total_tokens": 1924
      },
      "error": null
    },
    {
      "question_id": 65,
      "question": "How did IBM's use of the PWCC Plan for funding employee awards evolve between 2022 and 2024, particularly in terms of its administration and scope?",
      "original_answer": "In 2022, the PWCC Plan was described as being used solely to fund awards for employees of PwCC who joined IBM after the acquisition, and it was stated that the plan would continue to be used for this purpose. By 2024, while the plan's administration and terms remained substantively identical to the 2001 Plan, IBM emphasized that the PWCC Plan 'has been and will continue to be used solely' for funding awards for former PwCC employees, indicating a reaffirmation rather than a change in scope. However, the shift in language from 'has been and will continue to be' in 2022 to a more definitive tone in 2024 suggests a stronger commitment to maintaining the plan’s current usage without expansion.",
      "llm_answer": "Based on the provided SEC filing excerpts, IBM's PWCC Plan (Adoption 2002) and Red Hat Plan (Adoption 2019) have maintained identical terms and conditions to the 2001 Plan, with no evolution in administration or scope between 2022 and 2024. Both plans continue to be used exclusively for funding awards to non-senior employees from acquired companies (PwCC and Red Hat, respectively), with awards for senior executives explicitly excluded, and their governance remains under the Executive Compensation and Management Resources Committee as described in the 2001 Plan documentation.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains some correct elements but introduces significant inaccuracies and fails to accurately reflect the evolution of IBM's use of the PWCC Plan between 2022 and 2024. (1) Correctly identifies that the PWCC Plan maintains terms identical to the 2001 Plan and is used for former PwCC employees, and correctly notes governance under the Executive Compensation Committee. However, it incorrectly introduces the Red Hat Plan, which is not mentioned in the original question or ground truth and is irrelevant to the query about the PWCC Plan. This misdirects the focus and undermines accuracy. (2) There are no numeric values to verify, so quantitative accuracy is not compromised. (3) The multi-hop reasoning is flawed: the original answer emphasizes a shift in language and tone between 2022 and 2024—from describing ongoing use to a stronger reaffirmation of exclusive use—indicating a rhetorical reinforcement rather than administrative or scope changes. The LLM misses this nuance entirely and falsely claims there was 'no evolution,' when the evolution lies in the strengthened commitment language, not in structural changes. (4) While the answer is contextually relevant to IBM's use of acquisition-related plans, it conflates separate plans and fails to capture the key qualitative shift in IBM's stated intent. The answer is factually incomplete and partially incorrect in its synthesis, warranting a mid-range score due to correct identification of plan continuity but significant errors in scope and reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 419,
        "total_tokens": 1739
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How did AT&T's financial obligations and strategic approach to Mobility Preferred Interests evolve between 2023 and 2024, and what does this shift indicate about its broader capital structure management?",
      "original_answer": "In 2023, AT&T repurchased all remaining Mobility Preferred Interests for a total of $5,414 million, which included accrued and unpaid distributions, effectively eliminating this financial obligation. By 2024, there was no mention of Mobility Preferred Interests in the disclosures, indicating a complete exit from this instrument. This contrasts with AT&T's treatment of other preferred interests, such as the Tower Holdings and Telco LLC preferred interests, which remained outstanding and were even expanded or restructured in 2024. This shift indicates a strategic move to reduce certain long-term liabilities while maintaining or adjusting other capital instruments for flexibility, suggesting a selective approach to managing its capital structure.",
      "llm_answer": "AT&T’s Mobility Preferred Interests were fully retired in April 2023, eliminating the $5.34 billion liability that had been carried on the balance sheet and re‑classified as a liability (and later as equity) through 2022.  In contrast, the company has continued to issue new preferred‑interest structures—most notably the 2019 Tower preferred interests, the Telco LLC preferred series (including the newly authorized $2.25 billion Telco Class A‑4 in late 2024), and the 2023 Mobility II non‑controlling preferred interests—while resetting rates and extending maturities to manage cash‑flow and capital‑structure flexibility.  This shift from a large, long‑dated equity‑linked preferred obligation to a series of smaller, reset‑rate, callable preferred interests signals AT&T’s broader strategy of tightening control over its capital structure, reducing reliance on permanent equity‑like securities, and using preferred equity to fund specific asset‑level projects while preserving dividend‑paying capacity and share‑repurchase flexibility.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies that AT&T retired its Mobility Preferred Interests in 2023 and that this eliminated a major liability, aligning with the ground truth. However, there is a quantitative discrepancy: the LLM states the liability was $5.34 billion, while the ground truth specifies the repurchase cost was $5,414 million ($5.414 billion), including accrued distributions. This is a material but not critical error. Additionally, the LLM mentions the 'Mobility II non-controlling preferred interests' issued in 2023, which is not referenced in the ground truth and may conflate instruments. The ground truth emphasizes that Mobility Preferred Interests were fully eliminated and not replaced, whereas the LLM implies a structural shift to new preferred interests, potentially overextending the inference. (2) The date 'April 2023' is more specific than the ground truth, which only references 2023; this could be accurate but cannot be verified from the provided truth. The $2.25 billion Telco Class A-4 authorization in 'late 2024' is plausible but not confirmed in the original answer, which only notes restructuring/expansion without specifics. (3) The multi-hop reasoning is generally sound: the model correctly contrasts the elimination of Mobility Preferred Interests with the continuation of Tower and Telco preferred interests, supporting a strategic narrative about capital structure management. However, the inference about 'reset rates' and 'callable' features, while plausible, goes beyond the disclosed information in the ground truth. (4) The answer is contextually relevant and captures the core strategic implication—AT&T is selectively managing its capital structure by retiring certain liabilities while maintaining others. Despite some unsupported details and a minor numerical inaccuracy, the overall qualitative and contextual accuracy is strong, warranting a correctness score of 7.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1462,
        "completion_tokens": 522,
        "total_tokens": 1984
      },
      "error": null
    },
    {
      "question_id": 66,
      "question": "How has IBM's relationship with stock exchange regulations evolved in terms of regulatory exposure for its debt securities between 2022 and 2024?",
      "original_answer": "In 2022, IBM described stock exchange regulations as one of several factors influencing the value of its debt securities, placing it among other external variables beyond the company's control. By 2024, IBM's language shifted to indicate a more direct regulatory exposure, stating it is 'subject to' stock exchange regulations, which implies a heightened recognition of their binding impact on the company's financing activities. This evolution reflects a stronger acknowledgment of regulatory influence in 2024 compared to the more general mention in 2022.",
      "llm_answer": "IBM's relationship with stock exchange regulations regarding debt securities has evolved from a focus on general market exposure and financing risks (e.g., currency, interest rate, and credit risks tied to its capital markets activities) in 2022 to a more specific acknowledgment of regulatory uncertainty around emerging technologies like AI and data privacy in 2024. While both filings highlight compliance costs and risks tied to evolving regulations, the 2024 filing explicitly references the \"lack of harmonization of such laws and regulations\" and the \"potential regulation of new and emerging technologies\" as key factors affecting debt security risk, reflecting a deeper regulatory exposure to AI and data governance frameworks. This shift underscores a growing emphasis on adapting to stricter, more fragmented global regulatory landscapes that directly impact how IBM structures and markets its debt instruments.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer is largely incorrect in terms of factual content and reasoning, despite being internally consistent and well-structured. (1) The original answer states that IBM's evolution in regulatory exposure centers on a shift from describing stock exchange regulations as an influencing factor on debt securities in 2022 to being 'subject to' them in 2024—indicating a stronger, more direct recognition of regulatory impact. However, the LLM answer fabricates a narrative about AI, data privacy, and emerging technology regulations, which is not mentioned in the ground truth. There is no reference in the original answer to AI, data governance, or lack of harmonization of laws as factors affecting debt securities. (2) Quantitatively, there are no numbers, dates, or financial figures in either answer, so no numerical inaccuracies exist—this aspect is neutral but does not compensate for factual errors. (3) The multi-hop reasoning fails because the LLM invents a regulatory shift around technology policy rather than identifying the actual shift in language regarding stock exchange regulations' binding effect. The connection between regulatory exposure and debt securities is misattributed to new technological regulations instead of the correct evolution in how stock exchange rules are characterized. (4) The answer is contextually relevant in that it discusses IBM, debt securities, and regulatory exposure over time, but the substance is factually misaligned with the ground truth. Hence, while the structure and theme are appropriate, the core information is incorrect, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 441,
        "total_tokens": 1810
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How did Disney's financial relationship with A&E evolve from 2022 to 2024, particularly in terms of equity income contribution?",
      "original_answer": "In 2022, Disney's equity investment in A&E was a significant component of its equity income, with A&E being one of the most notable equity method investees alongside CTV Specialty Television. By 2024, Disney's equity in the income of investees had decreased by $207 million, specifically due to lower income generated from A+E. This indicates a material decline in the financial contribution from A&E to Disney over the two-year period.",
      "llm_answer": "From 2022 to 2024, Disney's equity income contribution from its 50% stake in A+E Networks declined significantly, as noted in the 2024 financial results where \"Equity in the income of investees, net\" decreased by $207 million to $575 million due to lower income from A+E. This reduction reflects the broader strategic shift away from linear network revenue, particularly impacting A+E's distribution and profitability, which directly affected Disney's equity method earnings from the investment.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, the $207 million decrease in equity income is correctly reported, matching the original answer. The mention of the net equity income dropping to $575 million adds detail not in the original but does not contradict it and may reflect additional context from the 2024 filing. (2) The entity 'A+E Networks' is correctly identified (note: A&E is commonly referred to as A+E Networks in filings), and the time frame (2022 to 2024) is properly addressed. (3) The reasoning is sound: the decline in equity income is correctly attributed to lower performance at A+E, and the broader strategic context (shift away from linear networks) is a reasonable qualitative addition that enhances, but does not distort, the core fact. (4) The only minor gap is that the original answer notes A&E's significance in 2022 alongside CTV Specialty Television, which the LLM omits—this is a small completeness issue but doesn't undermine the core accuracy. Overall, the answer correctly synthesizes multi-hop information (trend over time, financial impact, entity relationship) with precise numbers and logical interpretation.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1228,
        "completion_tokens": 335,
        "total_tokens": 1563
      },
      "error": null
    },
    {
      "question_id": 67,
      "question": "How did the carrying value of securitized debt obligations change from 2022 to 2023, and what does this indicate about the company's long-term funding strategy?",
      "original_answer": "In 2022, the long-term funding, which primarily consists of securitized debt obligations and senior and subordinated notes, stood at $42.3 billion as of December 31, 2021, with a significant portion driven by securitized debt obligations. By December 31, 2023, the carrying value of securitized debt obligations alone decreased to $18.043 billion. This indicates a strategic shift or reduction in reliance on securitized debt obligations as part of the company's long-term funding structure over this period.",
      "llm_answer": "The carrying value of securitized debt obligations declined from $16,973 million at December 31 2022 to $16,918 million at December 31 2023, a reduction of roughly $55 million (about 0.3%). This modest decrease signals that the company is not aggressively expanding its securitization funding and is likely maintaining a relatively stable long‑term funding mix, relying more on deposits and other wholesale sources rather than increasing securitized debt issuance.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core numbers and conclusion. The ground truth states that the carrying value of securitized debt obligations decreased to $18.043 billion as of December 31, 2023, but the LLM claims it was $16,918 million ($16.918 billion) in 2023—this is a significant discrepancy of over $1.1 billion. Additionally, the LLM cites a 2022 value of $16,973 million ($16.973 billion), which contradicts the ground truth that the long-term funding (including securitized debt and other instruments) was $42.3 billion as of December 31, 2021, with securitized debt being a 'significant portion'—implying a much higher baseline than $16.973 billion in 2022. (2) Calculations are internally consistent (a $55 million decrease from $16,973M to $16,918M is ~0.3%), but the inputs are wrong, making the calculation irrelevant. The ground truth implies a major reduction in securitized debt obligations from a high base (likely well over $40B in earlier years) down to $18.043B by 2023, indicating a strategic shift. The LLM’s characterization of a 'modest decrease' and 'stable funding mix' directly contradicts the ground truth’s implication of a significant strategic reduction. (3) The multi-hop reasoning failed: the LLM did not correctly identify the trend from the broader long-term funding context in 2021 to the specific securitized debt figure in 2023. It misrepresents both the magnitude and direction of change relative to the company's overall strategy. (4) Scores are low due to major factual and quantitative errors. Contextual relevance is moderate because the answer addresses the right topic (securitized debt and funding strategy), but the incorrect data and resulting flawed interpretation undermine correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1246,
        "completion_tokens": 486,
        "total_tokens": 1732
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has Disney's approach to scripted programming evolved between 2022 and 2024, particularly in terms of its international general entertainment channels and its strategic shift toward DTC platforms?",
      "original_answer": "In 2022, Disney operated approximately 220 General Entertainment channels outside the U.S., primarily under the Fox, National Geographic, and Star brands, featuring a mix of scripted, reality, and documentary programming across multiple languages and regions. By 2024, there was a notable strategic shift, with increased emphasis on DTC platforms and less focus on traditional linear channels. The 2024 report highlights that Disney, along with Fox Corporation and Warner Bros. Discovery, planned a joint venture (Venu Sports) to distribute sports content via a DTC platform, signaling a broader move toward streaming. Additionally, Disney announced plans to launch a new DTC offering in early fall 2025 that would include live linear streams of ESPN channels and ESPN+. This reflects a strategic pivot from scripted linear content toward live and sports-driven DTC offerings, indicating a transformation in Disney’s programming and distribution priorities.",
      "llm_answer": "Disney's scripted programming strategy has shifted decisively toward direct-to-consumer (DTC) distribution, with its international general entertainment channels increasingly serving as platforms to drive DTC adoption rather than standalone revenue streams. The company is actively consolidating its international linear channels (e.g., Disney+, Star, and ESPN brands) into unified DTC offerings like Disney+ and plans to launch an ESPN-branded tile on Disney+ in the U.S. by early fiscal 2025, reflecting a strategic pivot away from traditional linear channel monetization toward DTC-centric content distribution. This shift is underscored by the company's focus on leveraging its extensive library and production capabilities to fuel DTC growth, while international channels like ESPN and Star now primarily support DTC subscriber acquisition rather than operating as independent revenue sources.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer captures the core strategic shift from linear international channels to DTC platforms, which aligns with the ground truth. It correctly identifies the repositioning of international general entertainment channels (e.g., Star, ESPN) as feeders for DTC growth rather than standalone revenue streams. However, it omits key quantitative details from the original answer: the specific number of ~220 international general entertainment channels in 2022 and the 2024 joint venture (Venu Sports) with Fox Corporation and Warner Bros. Discovery, which is a critical piece of evidence for the strategic pivot toward DTC. Additionally, while the LLM mentions a 'ESPN-branded tile on Disney+ by early fiscal 2025,' the original answer specifies a new DTC offering launching in early fall 2025 including live ESPN streams and ESPN+, which is more precise and includes ESPN+ as a component. The LLM answer does not mention the shift toward sports-driven DTC content, a key nuance in Disney’s evolving programming focus. The reasoning is logically sound and contextually relevant, showing understanding of the broader trend, but lacks full completeness in multi-hop synthesis—particularly the joint venture and exact channel count—which reduces quantitative and qualitative accuracy. Wording differences are acceptable, but missing specific entities (Venu Sports, partner companies) and figures (~220 channels) constitutes a meaningful gap in factual completeness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1477,
        "completion_tokens": 402,
        "total_tokens": 1879
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How did Tesla's financial and operational challenges related to energy storage products evolve from 2022 to 2023, particularly in terms of accounts receivable and production scaling dependencies?",
      "original_answer": "In 2022, Tesla disclosed significant long-term government rebates receivable related to its energy storage products, with a balance of $627 million as of December 31, 2021, indicating extended collection periods of up to a year or more. By 2023, the focus shifted from financial implications of receivables to operational dependencies, as Tesla highlighted production scaling risks for energy storage products, including bottlenecks, supplier constraints, and facility ramp delays at factories in Nevada, Texas, and other locations. These changes reflect a shift from financial exposure tied to receivables to broader production and supply chain dependencies affecting the company's ability to meet cost and profitability targets.",
      "llm_answer": "From 2022 to 2023, Tesla’s energy storage business faced scaling challenges that directly impacted its accounts receivable and production dependencies. The company highlighted that delays in ramping production of energy storage products and new vehicle models, driven by supply chain constraints and supplier reliability issues, could lead to production disruptions, inventory write-downs, and increased costs. These operational bottlenecks, exacerbated by volatile raw material prices (e.g., lithium, nickel) and global semiconductor shortages, required Tesla to secure additional components at potentially higher costs, threatening profitability. While accounts receivable fluctuations were influenced by payment terms with financing partners and government rebates (with $627 million in long-term rebates receivable as of 2021), the primary risk stemmed from its inability to scale energy storage production efficiently without compromising cost targets or quality.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the $627 million long-term government rebates receivable as of the end of 2021, which is consistent with the original answer and relevant context for 2022 disclosures. It accurately reflects Tesla's focus on production scaling challenges in 2023, including supply chain constraints, supplier reliability, raw material price volatility, and semiconductor shortages. The shift from financial (receivables) to operational (scaling) challenges is well captured. However, the LLM answer slightly conflates timelines by discussing 2021 data without clearly anchoring the evolution from 2022 to 2023 as a transition—specifically, it does not explicitly state that the focus on receivables was emphasized in 2022 filings while operational dependencies became central in 2023. (2) Quantitatively, the $627 million figure is correct and properly attributed to the end of 2021, which the original answer cites as the basis for 2022 disclosures. No calculations are required, and all numbers are accurately reported. (3) The multi-hop reasoning is largely sound: the model connects receivables (financial) with production scaling (operational), synthesizing information across time and domains. However, it misses a clear structural shift between years—i.e., that receivables were a highlighted risk in 2022, while 2023 emphasized production bottlenecks—instead blending both aspects throughout. (4) Despite minor issues in temporal framing, the answer is highly relevant, factually accurate, and captures the core evolution in Tesla’s challenges. The qualitative reasoning is strong but lacks precise chronological separation of risk emphasis, warranting a slight deduction.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1436,
        "completion_tokens": 467,
        "total_tokens": 1904
      },
      "error": null
    },
    {
      "question_id": 68,
      "question": "How has the role of syrups in Coca-Cola's business model evolved between 2022 and 2023, particularly in relation to its bottling partners and fountain retailers?",
      "original_answer": "In 2022, Coca-Cola's relationship with syrups was primarily defined by its sales to both consolidated and unconsolidated bottling partners, with revenue and volume recognition dependent on the ownership structure of those partners. Specifically, concentrate and syrup sales were not recognized until finished products were sold to third parties in the case of consolidated bottlers, while recognition occurred immediately for unconsolidated bottlers. By 2023, the company's description of syrups shifted to emphasize their role as a dependency within a broader operational framework, particularly in relation to fountain retailers. In 2023, the company clarified that it manufactures fountain syrups and sells them directly to fountain retailers or authorized wholesalers and bottlers, highlighting a more integrated and strategic role for syrups in its finished beverage delivery system. This represents a shift from a primarily volume-driven metric to a more operationally embedded component of the business model.",
      "llm_answer": "The role of syrups in Coca‑Cola’s business model shifted further toward a concentrate‑focused revenue stream between 2022 and 2023.  In 2023, concentrate operations accounted for 83 % of total net operating revenue (up from 82 % in 2022), while finished‑product operations fell to 17 % (down from 18 %).  This reflects the company’s continued reliance on selling syrups and concentrates to bottling partners and other customers, with revenue recognized only when control transfers—typically after the bottler sells the finished product to a third party—underscoring the strategic importance of syrup sales to the overall model.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "(1) The LLM answer contains significant factual inaccuracies. While it correctly identifies syrups as central to Coca-Cola's business model and mentions bottling partners, it fabricates key quantitative data: there is no evidence in the ground truth that concentrate operations accounted for 83% of revenue in 2023 (up from 82% in 2022). This specific percentage breakdown is not present in the original answer and cannot be verified from the provided knowledge graph. (2) The quantitative accuracy is low because the percentages (83%, 82%, 17%, 18%) are not supported by the original answer, which does not provide any revenue split between concentrate and finished-product operations. The LLM invents precise figures that misrepresent the actual evolution described. (3) The qualitative reasoning is partially sound—it recognizes the importance of syrup sales and the timing of revenue recognition with bottlers—but misses the core multi-hop shift emphasized in the original: the strategic repositioning of syrups in relation to *fountain retailers* in 2023. The original highlights a structural shift in how syrups are framed—from a volume-driven metric to an operationally embedded component, especially via direct sales to fountain retailers or wholesalers. The LLM omits this entirely. (4) Contextual relevance is moderate because the answer discusses syrups, bottling partners, and revenue recognition, which are relevant, but fails to address the key evolution regarding fountain retailers and misrepresents the nature of the change with fabricated metrics. Thus, while the general theme is on track, the specific evolution described in the ground truth is not accurately reflected.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1414,
        "completion_tokens": 458,
        "total_tokens": 1873
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How did Disney's investment in Other Mortgage- and Asset-Backed Securities (MBS & ABS) evolve from fiscal year 2022 to fiscal year 2024, and what was the trend in its proportion relative to the overall fair value hierarchy?",
      "original_answer": "In fiscal year 2022, Disney's investment in Other MBS & ABS was valued at $96 million, representing 1% of the total plan asset mix. By fiscal year 2024, this investment increased to $120 million, maintaining a 1% share of the total plan asset mix. While the absolute value of the investment grew moderately, its proportional representation within the portfolio remained stable.",
      "llm_answer": "From fiscal 2022 to fiscal 2024, Disney’s investment in Other Mortgage‑ and Asset‑Backed Securities (MBS & ABS) grew modestly in absolute terms – from $84 million (1 % of total plan assets) at October 1 2022 to $166 million (1 % of total plan assets) at September 28 2024 – but its proportion of the overall fair‑value hierarchy remained consistently low, hovering around 1 % of the total plan assets each year. This reflects a stable, relatively small exposure to other MBS/ABS within Disney’s broader pension‑plan investment portfolio.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the numeric values. According to the ground truth, Disney's investment in Other MBS & ABS was $96 million in fiscal year 2022 and $120 million in fiscal year 2024, both representing 1% of total plan assets. However, the LLM reports $84 million in 2022 and $166 million in 2024—both figures are incorrect. While the percentage (1%) is correctly stated as stable, the absolute values are not. (2) The dates mentioned—October 1, 2022, and September 28, 2024—are plausible fiscal year-end dates but were not specified in the original answer and introduce precision not present in the ground truth, which only references fiscal years. This adds spurious detail. (3) The qualitative reasoning is partially sound: the model correctly infers that the proportion remained stable at 1%, indicating consistent relative exposure, which aligns with the ground truth. The synthesis of trend in proportion relative to the overall fair value hierarchy (interpreted as plan asset mix) is reasonable. However, the incorrect dollar amounts undermine the quantitative foundation of the conclusion. (4) Contextually, the answer addresses both parts of the question—evolution of investment and trend in proportion—and uses appropriate financial language. Despite wrong numbers, it maintains focus and structure. The stability conclusion is aligned, but the magnitude of error in dollar figures severely limits factual reliability. Hence, correctness and quantitative accuracy are low; qualitative reasoning and relevance are acceptable but not strong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1247,
        "completion_tokens": 439,
        "total_tokens": 1687
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How did the focus areas of Skunk Works' advanced development programs evolve between 2022 and 2023 in relation to next-generation military aircraft capabilities?",
      "original_answer": "In 2022, Skunk Works' Advanced Development Programs focused on future systems including unmanned and manned aerial systems and next-generation capabilities for hypersonics, intelligence, surveillance, reconnaissance, situational awareness, and air mobility. By 2023, the focus had evolved to emphasize air dominance, hypersonics, intelligence, surveillance, reconnaissance, situational awareness, and air mobility. The shift highlights an increased emphasis on air dominance as a core next-generation capability while maintaining focus on hypersonics and ISR. This represents a refinement of priorities rather than a complete overhaul of focus areas.",
      "llm_answer": "Based on the provided document pages, the focus areas of Skunk Works' advanced development programs evolved between 2022 and 2023 to emphasize next-generation military aircraft capabilities through expanded hypersonics development and integration of advanced technologies into future platforms. Specifically, the 2023 document highlights that Skunk Works is actively engaged in hypersonics programs with the U.S. Army and Navy, with multiple programs entering early production phases through 2026, while continuing to explore technology advancement and insertion into existing aircraft systems to maintain competitiveness in military aircraft design. This reflects a strategic shift toward accelerating hypersonic strike weapon development and next-generation capabilities like unmanned systems and advanced sensor integration, building upon the foundation established in prior years.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies continued focus on hypersonics and advanced military aircraft capabilities, which aligns with the ground truth. However, it misses the key evolution highlighted in the original answer — the increased emphasis on 'air dominance' as a refined priority in 2023. Instead, the LLM emphasizes 'expanded hypersonics development' and 'accelerating hypersonic strike weapon development,' which, while plausible, shifts focus away from the actual strategic refinement noted in the ground truth. The original answer specifies that the change was a prioritization shift toward air dominance while maintaining focus on hypersonics and ISR, not an expansion of hypersonics per se. (2) There are no numeric values, dates, or calculations in the original or LLM answer beyond general references to 2022 and 2023, which the LLM correctly uses — so quantitative accuracy is not compromised. (3) The multi-hop reasoning is partially sound: the LLM synthesizes information across years and infers strategic direction, but fails to accurately represent the nature of the shift (refinement vs. expansion) and omits the central role of 'air dominance' in the 2023 focus. It introduces new details not in the ground truth (e.g., U.S. Army and Navy programs, early production through 2026) that may be contextually relevant but are unsupported by the provided truth data. (4) The correctness score is 5 due to partial factual alignment but significant omission of the core strategic shift; qualitative accuracy is low due to incorrect characterization of the evolution; quantitative accuracy is 10 as no numbers are misstated; contextual relevance is high because the answer stays on topic and discusses relevant technological domains.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 479,
        "total_tokens": 1866
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has Tesla's approach to the Powerwall product evolved from 2022 to 2023, particularly in terms of integration strategy and production emphasis?",
      "original_answer": "In 2022, Tesla emphasized cross-selling Powerwall with residential solar energy products due to better availability and growing grid stability concerns. The company was also focused on improving installation capabilities and price efficiencies for Solar Roof, which is closely related to Powerwall integration. By 2023, Tesla had advanced its integration strategy by designing both Solar Roof and solar energy systems to specifically integrate with Powerwall, indicating a more deliberate and engineered approach to product synergy. This evolution reflects a shift from a sales and availability focus to a deeper technical and strategic integration within Tesla's energy ecosystem.",
      "llm_answer": "From 2022 to 2023, Tesla’s Powerwall strategy shifted from a standalone home battery to a tightly integrated component of its broader energy ecosystem, emphasizing seamless compatibility with solar roofs and the company’s own inverter technology. Production emphasis increased markedly, with new manufacturing capacity (e.g., the Lathrop “Megafactory” and expanded Gigafactory output) aimed at scaling lithium‑ion battery cell supply and boosting overall storage product volumes to meet rising demand.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies the evolution in Tesla's Powerwall strategy from 2022 to 2023, noting a shift toward deeper integration with solar products and increased production emphasis. It accurately captures the qualitative shift from standalone sales to ecosystem integration, aligning with the ground truth's emphasis on engineered synergy with Solar Roof and solar systems. However, the LLM introduces specific production facilities—'Lathrop Megafactory' and 'expanded Gigafactory output'—and mentions scaling lithium-ion battery cell supply, which are not present in the original answer and cannot be verified from the provided ground truth. While these details may be factually accurate in a broader context, they represent unverified additions that go beyond the knowledge graph's supported information, affecting qualitative accuracy. There are no numerical figures in either answer, so quantitative accuracy is scored as 10 by default (no errors possible). The answer is contextually relevant and addresses both integration strategy and production emphasis as asked. The core facts about integration evolution are correct, but the unsupported specifics on manufacturing sites prevent a higher score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1295,
        "completion_tokens": 340,
        "total_tokens": 1636
      },
      "error": null
    },
    {
      "question_id": 69,
      "question": "How has Gilead's strategic positioning around Biktarvy evolved between 2022 and 2024, particularly in terms of its role within the company's HIV portfolio and associated commercial risks?",
      "original_answer": "In 2022, Biktarvy was prominently positioned as a key revenue-generating product within Gilead’s HIV portfolio, highlighted as a single-tablet regimen combining bictegravir, emtricitabine, and tenofovir alafenamide (TAF), emphasizing its convenience and efficacy. By 2024, while Biktarvy remained a core product, the company faced heightened commercial risk as it became more dependent on HIV products containing TAF. A shift in treatment paradigms or reduced preference for nucleoside-based therapies could significantly impact Biktarvy’s sales and, by extension, Gilead’s financial stability. This reflects a transition from a focus on product innovation to increased vulnerability due to overreliance on a narrow therapeutic class.",
      "llm_answer": "Between 2022 and 2024, Gilead's strategic positioning around Biktarvy evolved from being a core, high‑margin HIV product to a central pillar of its HIV portfolio, but also exposed the company to heightened commercial risk. In the 2022 filing (pages 3‑7), Biktarvy was highlighted as a key revenue driver for HIV‑1 treatment and prevention, with emphasis on its fixed‑dose regimen of bictegravir, emtricitabine and TAF. By the 2024 filing (pages 16‑20), Biktarvy remained central to Gilead’s HIV strategy, yet the company underscored heightened competition from generics and emerging alternatives, as well as regulatory and reimbursement pressures—especially from the Inflation Reduction Act’s drug‑pricing provisions—that could erode market share and pricing power. Consequently, while Biktarvy continues to anchor Gilead’s HIV franchise, its growth prospects now hinge on maintaining market dominance amid patent‑expiry threats, pricing constraints, and the need to continually innovate within the HIV pipeline.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of core facts: Biktarvy's role as a central product in Gilead’s HIV portfolio in both 2022 and 2024, its composition (bictegravir, emtricitabine, TAF), and the increasing commercial risks. The answer correctly identifies that in 2022, Biktarvy was a key revenue driver with emphasis on its fixed-dose convenience, and by 2024, it remained central but faced greater risk. However, the LLM diverges slightly in the *nature* of the highlighted risk. The ground truth emphasizes overreliance on TAF-based therapies and vulnerability to shifts in treatment paradigms (e.g., away from nucleoside analogs), which is a structural portfolio risk. The LLM instead focuses on external risks: generics, patent expiries, pricing pressures (e.g., Inflation Reduction Act), and competition—while valid, this shifts emphasis from the core issue of therapeutic class concentration. There are no numerical inaccuracies (quantitative accuracy is perfect, as no specific numbers are misstated), and all entities (Biktarvy, TAF, Gilead, HIV portfolio) are correct. The reasoning is sound and multi-hop, connecting 2022 positioning to 2024 risks using appropriate context. The answer is highly contextually relevant and well-structured. The deduction is due to partial misalignment in the type of commercial risk emphasized, missing the nuance of overdependence on TAF as a pharmacological backbone, which is central to the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1446,
        "completion_tokens": 411,
        "total_tokens": 1858
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How did the composition of the U.S. Retrospective Responsibility Plan change between 2022 and 2023, particularly regarding the mechanisms referenced in relation to the U.S. Litigation Escrow Agreement?",
      "original_answer": "In 2022, the U.S. Retrospective Responsibility Plan included mechanisms such as the U.S. Litigation Escrow Agreement, the conversion feature of Class B common stock, indemnification obligations of Visa U.S.A. members, an interchange judgment sharing agreement, a loss sharing agreement, and an omnibus agreement. By 2023, the composition evolved to include a new element — 'makewhole agreements relating to the Class B-1 common stock exchange offer' — while retaining the U.S. Litigation Escrow Agreement and other previously listed mechanisms. This indicates an expansion of the plan to incorporate additional financial safeguards or compensatory measures.",
      "llm_answer": "The U.S. Retrospective Responsibility Plan’s composition shifted between 2022 and 2023 primarily through changes in the U.S. litigation escrow account and related mechanisms. In 2023, deposits into the escrow account increased to $1.5 billion (up from $1.0 billion in 2022), while payments to opt‑out merchants fell sharply to $175 million (down from $685 million), resulting in a higher ending escrow balance of $3.089 billion. These adjustments reflect a greater reliance on the escrow arrangement and the conversion feature of class B common stock to fund potential litigation liabilities.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both factual content and focus. The original question asks about changes in the composition of the U.S. Retrospective Responsibility Plan, specifically regarding mechanisms related to the U.S. Litigation Escrow Agreement. The ground truth states that the plan expanded in 2023 to include 'makewhole agreements relating to the Class B-1 common stock exchange offer' while retaining prior mechanisms. The LLM instead fabricates quantitative details—$1.5 billion and $1.0 billion deposits, $685M to $175M payments, $3.089B ending balance—that are not present in the ground truth and completely misrepresent the nature of the change. (2) There are no correct numbers in the LLM response; all dollar amounts and balances are factually wrong and not supported by the original answer. The ground truth contains no financial figures related to escrow deposits or payments. (3) The multi-hop reasoning is flawed: the LLM incorrectly interprets 'composition' as financial flows in and out of the escrow account rather than the structural mechanisms comprising the plan. It fails to identify the addition of the 'makewhole agreements' as the key change and omits this entirely. (4) The response is contextually relevant in that it discusses the U.S. Litigation Escrow Agreement and the timeframe, but it fundamentally misunderstands the question and provides fabricated data instead of structural changes. Hence, very low scores across correctness, quantitative accuracy, and qualitative reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 424,
        "total_tokens": 1750
      },
      "error": null
    },
    {
      "question_id": 70,
      "question": "How has the strategic importance of Biktarvy evolved for GILD from 2022 to 2024, based on its patent protection timeline and the company's risk disclosures around HIV product dependency?",
      "original_answer": "In 2022, Biktarvy was listed with a U.S. patent expiration in 2033 and no expiration listed in the E.U., indicating strong long-term protection and likely a key revenue driver. By 2024, although patent details were not explicitly mentioned, the company highlighted heightened risk around its HIV products, including Biktarvy, due to market competition and potential shifts in treatment paradigms. This suggests that despite long-term patent protection, Biktarvy's strategic position has become more vulnerable due to external market and regulatory pressures.",
      "llm_answer": "From 2022 through 2024, Biktarvy’s strategic importance to Gilead has continued to rise despite growing patent‑expiry risks.  The 2022 10‑K notes that Biktarvy’s patent portfolio (including pediatric exclusivity) is projected to remain protected into the mid‑2030s, and the company emphasizes its role as a core HIV revenue driver and a platform for future line‑expansion.  However, the 2024 filing highlights heightened risk disclosures: the company acknowledges that patent term extensions may not be secured, that generic competition could erode sales once exclusivity lapses, and that over‑reliance on HIV products makes the business vulnerable to shifts in treatment paradigms or pricing pressures from legislation such as the IRA.  Consequently, while Biktarvy remains a cornerstone of Gilead’s portfolio, its long‑term strategic weight is now balanced against heightened exposure to patent expiration and regulatory‑driven pricing constraints.",
      "correctness_score": 8,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the strategic evolution of Biktarvy from 2022 to 2024, noting strong patent protection in 2022 (mid-2030s, aligning with 2033 U.S. expiration in ground truth) and increased risk disclosures by 2024 due to competition, treatment shifts, and pricing pressures. While the ground truth does not mention 'pediatric exclusivity' or 'IRA' explicitly, these are plausible contextual additions that do not contradict the source. The absence of explicit E.U. patent status in the LLM answer is a minor omission but not factually incorrect. (2) Quantitatively, the 'mid-2030s' phrasing is consistent with the 2033 U.S. expiration date in the original answer; no other numbers or dates are misstated. There are no calculations, so accuracy here is based on correct date alignment. (3) The multi-hop reasoning is sound: the model synthesizes patent timelines from 2022 and risk disclosures from 2024 to infer a shift in strategic positioning despite continued importance. It correctly infers that long-term protection coexists with growing vulnerability, matching the ground truth's conclusion. (4) Scores reflect high accuracy in facts and reasoning, with a slight deduction in quantitative accuracy due to the slightly broader 'mid-2030s' phrasing versus the specific 2033 date, and no mention of the E.U. status gap in 2022. However, core facts, entities (GILD, Biktarvy, HIV dependency), and timeline are correct, and the answer fully addresses the question’s components.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1387,
        "completion_tokens": 417,
        "total_tokens": 1804
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "Have there been any modifications to the financial guarantees provided by AT&T for Illinois Bell Telephone Company between 2022 and 2023, particularly in terms of guarantee structure or referenced documentation?",
      "original_answer": "The financial guarantee relationship between AT&T and Illinois Bell Telephone Company remained structurally unchanged between 2022 and 2023. In 2022, AT&T's guarantee for Illinois Bell Telephone Company was referenced under Exhibit 4-d to Form 10-K for the period ending December 31, 2011. In 2023, the same guarantee was still in place and referenced under the identical exhibit number (Exhibit 4-d) and filing history (Form 10-K for the period ending December 31, 2011). There is no indication of modifications to the guarantee structure, terms, or documentation between the two years.",
      "llm_answer": "Based on the provided SEC 10-K filing pages, there have been no modifications to the financial guarantees structure between 2022 and 2023. The relevant exhibits referenced in both 2022 (page 133-137) and 2023 (page 101-105) filings consistently show the same guarantee framework, including the AT&T Inc. guarantee (Exhibit 4-e) and related documentation, with no new agreements or structural changes noted in the provided pages. The only updates observed relate to routine amendments of other plans (e.g., 10-k Stock Purchase and Deferral Plan as of May 18, 2023), but these do not alter the core guarantee structure referenced in 4-e.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly concludes that there were no modifications to the financial guarantee structure between 2022 and 2023, which aligns with the ground truth. It accurately identifies that the same guarantee framework was referenced in both years and notes the absence of structural changes. However, there is a discrepancy in the exhibit number: the LLM cites Exhibit 4-e, while the ground truth specifies Exhibit 4-d. This is a factual error in entity accuracy, though the overall reasoning and conclusion about no changes remain valid. Additionally, the LLM references page numbers (e.g., 133-137 in 2022, 101-105 in 2023) not present in the original answer, which may reflect document-specific details not verifiable from the ground truth alone. The mention of a 'May 18, 2023' amendment to other plans is consistent with routine updates but not directly relevant to the guarantee, though it does not detract significantly from the core conclusion. Quantitative accuracy is high as no incorrect numerical data is presented. Qualitative accuracy is slightly reduced due to the exhibit number mismatch and potential overreliance on unverified page references. Contextual relevance is strong, as the response directly addresses the question’s focus on structural or documentation changes.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 359,
        "total_tokens": 1681
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "What does the consistent Class C to Class A common stock conversion rate between 2022 and 2023 suggest about the potential impact on Class A common stockholders' voting power in significant corporate transactions?",
      "original_answer": "In 2022, the Class C common stock had a conversion rate of 4.0000 into Class A common stock, and this rate remained unchanged in 2023. Despite the as-converted Class A common stock value increasing slightly from 38 million in 2022 to 39 million in 2023, the unchanged conversion rate suggests that the relative voting power dilution for Class A common stockholders remained stable. This stability implies that there was no structural change in how Class C stockholders could influence significant corporate decisions through their voting rights tied to Class A equivalents.",
      "llm_answer": "The consistent Class C to Class A conversion rate between 2022 and 2023 indicates that the conversion mechanism remains unchanged, meaning the number of Class A shares that Class C holders can convert into stays the same. This stability preserves the existing voting power dynamics, as Class C holders continue to maintain their current conversion terms without dilution or enhancement that might alter their influence in corporate decisions. Consequently, any significant corporate transaction would still be subject to the same voting power implications for Class A holders as in prior years, with no structural shift in how Class C conversions affect their stake.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually correct and aligns well with the ground truth. (1) It correctly identifies the consistent conversion rate between 2022 and 2023 without specifying the exact rate (4.0000), but this omission does not affect the core reasoning about stability in voting power. The absence of the specific numeric rate and the as-converted Class A stock values (38M to 39M) is a minor gap in quantitative detail, but the key point—that the rate remained unchanged—is accurately conveyed. (2) All numbers implied or referenced are consistent with the original; no incorrect figures are presented. The LLM does not repeat the exact values (e.g., 38 million, 39 million), but since the question does not explicitly ask for those numbers, their omission does not constitute a major error. (3) The multi-hop reasoning is sound: the model correctly links the stable conversion rate to unchanged voting power dynamics and infers that Class A stockholders' dilution risk remains stable, which reflects accurate synthesis across years and stock classes. (4) The answer is semantically equivalent to the original in intent and conclusion, with strong contextual relevance. The slight deduction in qualitative accuracy is due to the lack of explicit mention of the as-converted stock value increase, which adds nuance to the stability argument. Overall, the response is accurate, relevant, and logically structured.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1326,
        "completion_tokens": 389,
        "total_tokens": 1716
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How did Tesla's relationship with the Solar Roof evolve from 2022 to 2023 in terms of production focus and strategic dependencies?",
      "original_answer": "In 2022, Tesla directly produced the Solar Roof at Gigafactory New York, indicating active involvement in its manufacturing. However, by 2023, Tesla's disclosures shifted to emphasizing dependencies and risks associated with scaling production, including potential delays, supply chain constraints, and challenges in launching and ramping products like the Solar Roof. This reflects a transition from a production-centric view to a more cautionary outlook on strategic execution risks.",
      "llm_answer": "From 2022 to 2023, Tesla shifted its Solar Roof production focus from a broad residential rollout to a more limited, high‑margin approach, emphasizing integration with its energy‑storage business and expanding manufacturing capacity at Gigafactory New York. The company also grew increasingly dependent on external suppliers for key components—particularly battery cells and raw materials—while simultaneously accelerating its own cell‑manufacturing efforts to mitigate supply‑chain risks.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies compared to the ground truth. While it correctly identifies Gigafactory New York as a site of Solar Roof activity, it incorrectly claims Tesla shifted to a 'high-margin approach' and 'expanding manufacturing capacity' in 2023, which is not supported by the original answer. Instead, the ground truth indicates a shift in tone from active production in 2022 to expressing caution and strategic risks in 2023—not a strategic pivot toward high-margin rollout or capacity expansion. Additionally, the LLM introduces unverified claims about growing dependence on external suppliers for battery cells and raw materials, and accelerating cell manufacturing efforts, none of which are mentioned in the original answer regarding Solar Roof. (2) There are no numeric values in either answer, so quantitative accuracy is not applicable; however, the absence of incorrect numbers allows a score of 10 by default. (3) The multi-hop reasoning is flawed: the original answer emphasizes a shift in disclosure tone—from production focus to risk disclosure—while the LLM fabricates strategic shifts and dependencies not present in the source. It fails to capture the core evolution: from direct production focus (2022) to highlighting execution risks (2023). (4) Correctness is partially maintained in context (Solar Roof, Gigafactory New York, timeline), but the substance of the evolution is misrepresented, warranting a low correctness and qualitative accuracy score. Contextual relevance is moderate because the answer addresses the general topic and timeframe but introduces irrelevant elements like battery cell manufacturing, which is not tied to Solar Roof in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1239,
        "completion_tokens": 472,
        "total_tokens": 1712
      },
      "error": null
    },
    {
      "question_id": 71,
      "question": "How has the role of syrups in Coca-Cola's business model evolved between 2022 and 2023, particularly in terms of their relationship to finished beverage production and distribution channels?",
      "original_answer": "In 2022, Coca-Cola described syrups as intermediate products used primarily in fountain beverage production, where bottling partners or fountain retailers mix them with water and sweeteners to create finished beverages for immediate consumption. The company emphasized that syrups were a key part of the concentrate operations, which generally yield lower net operating revenues but higher gross profit margins compared to finished product operations. By 2023, the company expanded its description to emphasize that fountain syrup sales in the U.S. were directly managed by Coca-Cola and sold to both fountain retailers and authorized wholesalers or bottling partners. Additionally, the 2023 filing highlighted that fountain syrup operations were specifically included in the North America operating segment, indicating a more structured and regionally focused approach to syrup distribution. This evolution reflects a strategic shift toward tighter control and segmentation of syrup-related revenue streams within the broader beverage production ecosystem.",
      "llm_answer": "Between 2022 and 2023, the role of syrups in Coca-Cola's business model remained structurally consistent but showed modest shifts in revenue contribution. Concentrate operations (which include syrups) maintained a stable share of net operating revenue at 58% in 2023 versus 56% in 2022, while finished product operations declined slightly from 44% to 42% of total revenue. This reflects syrups' continued role as the foundation for the Coca-Cola system's concentrate business—supplying bottling partners who transform them into finished beverages—while finished product operations (including bottling and distribution) saw a relative decline, underscoring the enduring strategic focus on concentrate-based revenue generation through bottling partners rather than direct finished beverage sales.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The claim that concentrate operations accounted for 58% of net operating revenue in 2023 and 56% in 2022 is not supported by the ground truth and introduces quantitative data that was not present or verifiable in the original answer. The ground truth does not provide any percentage breakdowns of revenue between concentrate and finished product operations, so these figures are fabricated. (2) There is no mention in the original answer of revenue shares or percentages related to concentrate vs. finished product operations, nor any indication that concentrate revenue increased from 56% to 58%. These numbers are entirely absent from the ground truth, making the quantitative claims invalid. (3) The multi-hop reasoning is flawed because the LLM incorrectly infers a shift in business model based on invented metrics. While the original answer describes a structural and strategic evolution—such as direct management of fountain syrup sales in the U.S. and inclusion in the North America operating segment in 2023—the LLM instead focuses on a supposed revenue shift without addressing the actual operational and distributional changes. (4) The LLM answer partially recognizes that syrups are part of concentrate operations and used by bottling partners, which aligns with the 2022 description, but completely misses the key 2023 developments: direct sales to fountain retailers and wholesalers, and the reorganization under the North America segment. Thus, while the general context of syrups in the business model is acknowledged, the core evolution described in the ground truth is absent, replaced by unsupported numerical claims. This results in a low correctness score despite some contextual relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1473,
        "completion_tokens": 484,
        "total_tokens": 1958
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has the company's operational focus on Africa/Eurasia evolved between 2022 and 2024, particularly in terms of its geographic reporting structure and financial contribution?",
      "original_answer": "In 2022, Africa/Eurasia was reported as part of the Oral, Personal and Home Care segment with an operating profit of $203 million, indicating a relatively minor financial contribution compared to other regions. By 2024, the company maintained Africa/Eurasia as a distinct reportable operating segment within the Oral, Personal and Home Care geographic structure. Additionally, in 2024, the company realigned its skin health business, shifting it from Europe to North America, signaling a strategic refinement in geographic reporting. This change suggests a more nuanced operational focus in how the company organizes and evaluates its regional performance, including in Africa/Eurasia.",
      "llm_answer": "Between 2022 and 2024, the company refined its Africa/Eurasia reporting within the Oral, Personal and Home Care segment, maintaining it as one of five geographic sub‑segments (North America, Latin America, Europe, Asia Pacific, Africa/Eurasia). The Africa/Eurasia operating segment consistently contributed roughly $1 billion in net sales and generated an operating profit of about $228 million in 2024, $254 million in 2023 and $203 million in 2022. This indicates a stable geographic focus, with Africa/Eurasia representing a modest but steady share of both sales and profitability across the period.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in financial figures. The ground truth states that Africa/Eurasia had an operating profit of $203 million in 2022 and does not provide data for 2023 or 2024. However, the LLM claims operating profits of $254 million in 2023 and $228 million in 2024, and introduces a new figure of ~$1 billion in net sales, which is not mentioned in the original answer. These numbers are unsupported and contradict the ground truth's implication of a 'relatively minor financial contribution,' making the quantitative accuracy low. (2) The LLM incorrectly frames Africa/Eurasia as a sub-segment among five, suggesting it was consistently reported as such, while the original answer highlights a structural change in 2024 where Africa/Eurasia became a distinct reportable segment. This misrepresents the evolution of the geographic reporting structure. Additionally, the LLM omits the key strategic realignment of the skin health business from Europe to North America in 2024, which is a critical part of the operational focus shift. (3) The multi-hop reasoning is flawed: while the model attempts to show continuity and financial contribution, it fabricates data and misses the structural and strategic changes that define the evolution. It fails to recognize that the 2024 change reflects a refinement in reporting logic, not just stable focus. (4) Despite these issues, the answer is contextually relevant—addressing geographic structure and financial performance—and correctly identifies Africa/Eurasia as part of the Oral, Personal and Home Care segment in 2022. The qualitative accuracy is moderate due to correct framing of the segment but penalized for missing key strategic shifts and inventing financial metrics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1329,
        "completion_tokens": 486,
        "total_tokens": 1815
      },
      "error": null
    },
    {
      "question_id": 72,
      "question": "How has Johnson & Johnson's strategic presentation of its Orthopaedics business evolved between 2023 and 2024, particularly in terms of global sales performance and emphasis on enabling technologies?",
      "original_answer": "In 2023, JNJ's Orthopaedics segment was presented primarily through quantifiable sales figures, with global revenue reaching $8,942 million, showing a 4.1% increase from the prior year. The 2023 data emphasized steady growth, particularly in the U.S. ($5,525 million, up 3.8%) and modest international growth ($3,417 million, up 4.6%). By 2024, the strategic framing of Orthopaedics shifted from financial metrics to a qualitative emphasis on innovation and enabling technologies. The 2024 filing described Orthopaedics as a portfolio 'supported by products and enabling technologies' across hips, knees, trauma, spine, and sports medicine, without revisiting specific revenue figures. This reflects a strategic pivot from highlighting quantitative performance to underscoring technological leadership and product diversification within the segment.",
      "llm_answer": "Johnson & Johnson’s Orthopaedics business remained a stable component of its MedTech segment, with worldwide sales of $8.94 billion in 2023—up 4.1% from $8.59 billion in 2022—and a modest 4.6% increase in international sales, reflecting consistent global demand. The company continues to emphasize enabling technologies within Orthopaedics, supporting growth through advanced implant and surgical solutions.",
      "correctness_score": 5,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports the 2023 global sales figure of $8.94 billion (equivalent to $8,942 million in the ground truth) and the 4.1% year-over-year increase, which aligns with the original data. It also correctly notes a 4.6% increase in international sales, matching the ground truth. However, it introduces a figure not present in the original answer—$8.59 billion for 2022—while this can be inferred mathematically, it was not part of the provided ground truth and represents an extrapolation. (2) The quantitative accuracy is high as all reported numbers are consistent with the source, allowing for format variation (e.g., $8.94 billion = $8,942 million). The calculation of the prior year’s revenue is approximately correct, so no numeric error is present. (3) The qualitative reasoning is incomplete. The question asks about the *evolution* of strategic presentation between 2023 and 2024, but the LLM answer only briefly mentions that J&J 'continues to emphasize enabling technologies' without addressing the key shift identified in the ground truth: from quantitative sales reporting in 2023 to a *qualitative pivot* in 2024 where revenue figures are omitted in favor of discussing innovation and enabling technologies. This core strategic evolution is underdeveloped in the LLM response. (4) Contextual relevance is moderate: the answer addresses sales performance and mentions enabling technologies, but fails to fully synthesize the multi-hop insight—the change in narrative strategy from financials to technology focus—making it partially correct but missing the central analytical point of the original answer.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 451,
        "total_tokens": 1778
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How has Visa's approach to managing litigation liabilities through loss sharing agreements evolved between 2022 and 2023, particularly in terms of the scope of U.S. covered litigation and liability allocation?",
      "original_answer": "In 2022, Visa detailed specific amendments to its loss sharing agreement, including the October 2015 amendment that expanded the scope of U.S. covered litigation to include opt-out actions from the Rule 23(b)(3) Settlement Class in MDL 1720 that arose out of similar facts or circumstances. This amendment was part of a broader framework involving the omnibus agreement, under which Visa assumed 66.6667% of any monetary liability in covered settlements or judgments, with Mastercard assuming 33.3333%. In 2023, Visa consolidated its approach under the U.S. Retrospective Responsibility Plan, which now encompasses the loss sharing agreement as part of a broader set of mechanisms designed to address potential liabilities from U.S. covered litigation. Notably, the 2023 filing emphasizes that U.S. covered litigation now includes matters that have been 'settled or otherwise fully or substantially resolved,' indicating a shift toward resolution and consolidation of past liabilities. The evolution from a focus on specific amendments and liability sharing with Mastercard in 2022 to a more comprehensive and retrospective liability framework in 2023 suggests a strategic pivot toward finalizing and managing legacy litigation exposure.",
      "llm_answer": "Between 2022 and 2023, Visa’s approach to managing litigation liabilities through loss‑sharing agreements remained anchored in the same structural mechanisms, but the scope and allocation of liability shifted in two key ways.  \n\nFirst, the U.S. retrospective responsibility plan continued to rely on the litigation escrow account and the conversion feature of the Company’s class B common stock, but the 2023 filing shows a larger escrow balance ($3.089 billion at September 30 2023 versus $1.449 billion a year earlier) and higher deposits ($1.5 billion in 2023 versus $850 million in 2022), reflecting an expanded funding of settlements and judgments under the interchange multidistrict litigation.  \n\nSecond, in Europe the “Europe retrospective responsibility plan” still uses the series B and C preferred‑stock conversion‑rate adjustments to recover VE‑territory covered losses, yet the 2023 disclosures indicate that the protection now covers only 70 % of liabilities tied to inter‑regional multilateral interchange fee rates and excludes competition‑law enforcement penalties. Moreover, unlike the U.S. plan, the European arrangement does not maintain an escrow account; instead, recoveries are achieved by periodic adjustments to the conversion rates of the preferred stock, with the as‑converted value of the preferred stock serving as the ceiling for recoverable losses.  \n\nOverall, while the core loss‑sharing framework stayed consistent, the 2023 updates broadened the U.S. escrow funding and refined the European coverage—limiting it to a narrower set of interchange‑related claims and tying recovery to conversion‑rate mechanics rather than an escrow pool.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer is largely incorrect and fails to address the core aspects of the question. (1) It introduces details about escrow balances ($3.089 billion and $1.449 billion), deposit amounts ($1.5 billion vs $850 million), and European loss-sharing mechanisms that are not present in the original answer and are irrelevant to the specific evolution of U.S. covered litigation and liability allocation between 2022 and 2023. These figures, while possibly accurate in another context, are not supported by the ground truth provided and misrepresent the focus of Visa's evolution. (2) The original answer emphasizes a shift from specific amendments in 2022 (e.g., October 2015 amendment expanding U.S. covered litigation to opt-out actions in MDL 1720) and a 66.6667%/33.3333% liability split with Mastercard, to a 2023 consolidation under the U.S. Retrospective Responsibility Plan that now includes 'settled or otherwise fully or substantially resolved' matters. The LLM answer completely omits the Mastercard liability split, the October 2015 amendment, MDL 1720, and the critical expansion of scope to include resolved cases. (3) The multi-hop reasoning is flawed: the question requires synthesizing changes in scope and allocation of U.S. litigation liabilities across two years, but the LLM diverts into unrelated European mechanisms and unmentioned escrow funding trends. (4) While the mention of the 'U.S. retrospective responsibility plan' shows some contextual awareness, the overall answer fabricates quantitative details and misdirects the evolution toward funding levels and European policies, missing the strategic pivot toward resolution and consolidation of legacy liabilities. The answer is not semantically equivalent and contains significant factual and directional errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1742,
        "completion_tokens": 483,
        "total_tokens": 2225
      },
      "error": null
    },
    {
      "question_id": 73,
      "question": "How did CL's investment in Guaranteed Investment Contracts evolve between 2022 and 2024, and what does this shift indicate about the company's pension plan asset strategy?",
      "original_answer": "In 2022, CL held $1 million in Guaranteed Investment Contracts under its United States Pension Plans and $55 million under its International Pension Plans. By 2024, the company had completely phased out Guaranteed Investment Contracts from its United States Pension Plans, reducing the International allocation to $34 million. This represents a significant shift away from Guaranteed Investment Contracts in the U.S. and a moderate decrease internationally, indicating a strategic reallocation of pension plan assets.",
      "llm_answer": "Between 2022 and 2024, Colgate-Palmolive’s investment in Guaranteed Investment Contracts (GICs) declined substantially—from $55 million in 2021 (shown on page 101) to $34 million in 2023 and $30 million in 2024 (page 100), with virtually no GIC holdings in the U.S. plans by 2024. This reduction reflects a strategic shift away from low‑return, fixed‑income vehicles toward higher‑yielding assets such as fixed‑income securities, pooled funds, and alternative investments, indicating that the company is rebalancing its pension‑plan asset allocation to improve returns and better match liability exposure.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies in numbers and years. According to the ground truth, in 2022, CL held $1 million in GICs under U.S. Pension Plans and $55 million under International Pension Plans. By 2024, U.S. holdings were fully phased out and international dropped to $34 million. The LLM incorrectly states a 2021 figure of $55 million (not requested in the question), then reports $34 million in 2023 and $30 million in 2024—neither of which matches the ground truth ($34 million in 2024 internationally, no mention of $30M). The U.S. phase-out is correctly noted, but the international decline is overstated due to incorrect figures. (2) Calculations and comparisons are flawed: the LLM implies a continuous decline from $55M to $30M, but the ground truth shows $55M in 2022 (international only) dropping to $34M in 2024—so the actual decrease is $21M, not $25M. The $1M U.S. holding in 2022 is entirely omitted. (3) Multi-hop reasoning is partially sound: the model correctly infers a strategic shift away from GICs and identifies a move toward higher-yielding assets, which aligns with the ground truth’s interpretation of strategic reallocation. However, this conclusion is based on incorrect data points, weakening the reasoning chain. (4) Contextual relevance is high—the answer addresses both parts of the question (evolution of investment and strategic implication) and uses appropriate financial terminology. Despite incorrect numbers, the overall direction of change (reduction in GICs) and strategic interpretation are reasonable. However, the quantitative inaccuracies significantly reduce factual correctness, warranting a score of 6—partially correct but with significant errors in core data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1286,
        "completion_tokens": 475,
        "total_tokens": 1762
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has the strategic positioning and functionality of the Mastercard Developer Platform evolved between 2022 and 2024, particularly in terms of its role in enabling integration of digital assets and new technologies?",
      "original_answer": "In 2022, the Mastercard Developer Platform was described as a single access point that enables customers and partners to leverage Mastercard's digital assets and services, with an emphasis on ease of integration into new and existing solutions. By 2024, the platform continued to serve this role but expanded its strategic positioning by explicitly aligning with emerging technologies such as blockchain and digital currencies. In 2024, the platform was referenced in the context of enabling integration with the Mastercard Multi-Token Network™, which supports programmable payments and facilitates secure, scalable, and interoperable blockchain-based transactions. This evolution shows a shift from a general digital integration platform to one that specifically supports next-generation financial technologies and programmable commerce solutions.",
      "llm_answer": "Between 2022 and 2024, the Mastercard Developer Platform evolved from a general API hub into a strategic engine for digital asset integration and open banking. It now provides standardized APIs and tools that let partners easily embed Mastercard’s security, tokenization, and data services—such as blockchain‑based programmable payments and crypto‑on‑ramp capabilities—into their own solutions, while expanding open‑banking functions like account‑opening, lending and real‑time payments. This focus enables seamless incorporation of emerging technologies and new payment flows across the ecosystem.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and captures the core evolution of the Mastercard Developer Platform from 2022 to 2024. It accurately reflects the platform's shift from a general integration hub to a more strategic enabler of digital assets and emerging technologies. The mention of blockchain-based programmable payments and crypto-on-ramp capabilities aligns with the 2024 expansion involving the Mastercard Multi-Token Network™, although the specific name 'Multi-Token Network™' is not referenced, which is a minor omission. The emphasis on standardized APIs, security, tokenization, and data services is consistent with the ground truth's focus on ease of integration and digital asset leverage. The inclusion of open banking functions (account-opening, lending, real-time payments) adds detail not contradicted by the original, though not explicitly mentioned, making it a reasonable inference rather than a factual error. There are no numeric values in the question or answers, so quantitative accuracy is scored as 10 by default. The reasoning is sound and reflects multi-hop synthesis across time periods and technological developments. The answer is contextually highly relevant and addresses both the strategic positioning and functionality evolution. The main reason for not scoring 9–10 on correctness and qualitative accuracy is the lack of explicit mention of the Mastercard Multi-Token Network™ and slightly broader claims about open banking that go beyond the documented scope in the ground truth, which focused specifically on blockchain and digital currencies. However, the overall semantic meaning and factual core are well-preserved.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 450,
        "total_tokens": 1829
      },
      "error": null
    },
    {
      "question_id": 74,
      "question": "How has the company's investment in U.S. common stocks within its pension plans evolved between 2022 and 2024, and what does this indicate about its strategic asset allocation?",
      "original_answer": "In 2022, the company reported no investments in U.S. common stocks within its pension plans, while by 2024, there was still no allocation to U.S. common stocks in the U.S. pension plan. However, the international pension plan maintained a $2 million investment in U.S. common stocks in both years. This indicates a continued strategic decision to avoid direct exposure to U.S. common stocks in the domestic pension portfolio while maintaining a minimal presence in the international portfolio.",
      "llm_answer": "Between 2022 and 2024, the company's U.S. pension plans maintained a consistent policy of **not holding any investment in its own common stock**—a position unchanged from 2020 through 2024, as confirmed in the 2022 and 2024 10-K filings. This reflects a deliberate strategic choice to avoid concentration risk and align with prudent fiduciary practices, ensuring diversification across external asset classes like U.S. equities, international stocks, fixed income, and alternative investments. Consequently, the company’s asset allocation strategy emphasizes broad market exposure rather than self-directed holdings, reinforcing a long-term, risk-mitigated approach to pension fund management.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both quantitative and qualitative aspects. The ground truth states that the company had no investment in U.S. common stocks in its U.S. pension plan in both 2022 and 2024, which the LLM correctly notes in spirit but misrepresents by focusing narrowly on 'its own common stock' rather than U.S. common stocks in general. This is a critical misinterpretation—the original answer refers to all U.S. common stocks, not just self-stock. Additionally, the LLM fails entirely to mention the $2 million investment in U.S. common stocks held in the international pension plan in both years, a key factual component of the ground truth. (2) There are no correct numerical values mentioned in the LLM response; the $2 million figure is completely omitted, and no accurate financial data is provided. (3) The multi-hop reasoning is flawed: the model incorrectly narrows the scope to 'own common stock' rather than the broader category of U.S. common stocks, leading to an invalid conclusion about strategic allocation. It also invents a rationale about 'prudent fiduciary practices' and 'diversification across external asset classes' that is not supported by the ground truth, which emphasizes avoidance of U.S. common stocks in the domestic plan while maintaining minimal exposure in the international plan. (4) The contextual relevance is moderate because the answer discusses pension plan investments and asset allocation strategy, but it fails to accurately reflect the actual investment evolution or the correct entities (domestic vs. international plans). The strategic interpretation offered is speculative and misaligned with the documented facts.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1304,
        "completion_tokens": 463,
        "total_tokens": 1767
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How did Disney's strategic focus on cruise ships evolve between 2022 and 2023, particularly in terms of capital investment plans and operational risk considerations?",
      "original_answer": "In 2022, Disney highlighted cruise ships as a key part of its capital investment strategy within the Parks & Experiences segment, noting that a majority of its capital spending was directed toward theme parks, resorts, and cruise ships. This indicated a growth-oriented approach focused on expanding physical assets. By 2023, the emphasis had shifted toward operational risks associated with cruise ships, particularly in the context of external disruptions like hurricanes and global events (e.g., the impact of Hurricane Milton on Walt Disney World operations). The 2023 filing framed cruise ships more as an operational exposure rather than a growth engine, signaling a shift from investment to risk mitigation. This evolution reflects a recalibration of strategic focus from asset expansion to managing volatility and external threats.",
      "llm_answer": "Between 2022 and 2023, Disney significantly expanded its capital investment in cruise ships, announcing plans to grow its fleet and increase spending in the Experiences segment, while simultaneously restructuring its media and entertainment operations to support its DTC strategy. Operational risks include heightened competition across all business lines, potential regulatory changes affecting content distribution and privacy compliance costs, and the financial exposure from large-scale investments in new cruise ships and theme park expansions, which may not deliver anticipated returns.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies in portraying Disney's strategic evolution. While it correctly identifies capital investment in cruise ships as part of Disney's Experiences segment, it incorrectly states that Disney 'significantly expanded' its investment in 2023, which contradicts the ground truth. The original answer shows a strategic shift *away* from growth-oriented investment toward risk mitigation in 2023, particularly due to external disruptions like hurricanes. The LLM instead suggests continued expansion, missing this critical pivot entirely. Additionally, the LLM introduces irrelevant elements such as restructuring media operations for DTC strategy and privacy compliance costs, which are not tied to cruise ship operations. (2) There are no specific numeric values (e.g., dollar amounts, fleet sizes, percentages) in either the original or LLM answer, so quantitative accuracy is not compromised—hence a score of 8. Minor factual details like Hurricane Milton are absent in the LLM response, but the absence of hard numbers prevents major quantitative error. (3) The multi-hop reasoning is flawed: the question requires synthesizing a shift in strategic focus across two years (2022 vs 2023), but the LLM fails to contrast the two periods. Instead, it presents a continuous growth narrative, ignoring the shift from capital investment to operational risk management. This represents a failure in qualitative reasoning and entity-year linkage. (4) Contextual relevance is moderate—the answer discusses Disney’s Experiences segment and mentions cruise ships and investments, so it stays within the general domain. However, it misrepresents the core strategic evolution and injects unrelated risks (e.g., content distribution, privacy), reducing its accuracy. The correctness score is low (3) because the central claim about strategic direction is factually incorrect despite some surface-level relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 526,
        "total_tokens": 1888
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has Mastercard's use of short duration foreign exchange derivative contracts evolved between 2022 and 2024, particularly in terms of their role in managing foreign exchange risk during daily settlement activities?",
      "original_answer": "In 2022, Mastercard used short duration foreign exchange derivative contracts to manage foreign exchange risk associated with daily settlement activities, aiming to reduce exposure to volatility from currency fluctuations on anticipated receipts and disbursements. By 2024, the company continued this practice, maintaining the same stated objective of minimizing volatility in gains and losses due to foreign exchange fluctuations. However, the context changed as the company actively adjusted its hedging strategies involving euro-denominated debt, de-designating and re-designating portions of it in 2023 and 2024, which indicates a more dynamic approach to managing foreign exchange exposure across the period. The continuity in the use of short duration contracts contrasts with the evolving structure of the company’s broader foreign exchange risk management strategy.",
      "llm_answer": "Mastercard’s use of short‑duration foreign‑exchange derivative contracts to manage daily settlement risk has expanded markedly from 2022 to 2024.  In 2022 the company disclosed modest notional amounts of FX forwards in its cash‑flow hedging program, but by 2024 the disclosed notional for cash‑flow hedges had risen to roughly $3.9 billion, with additional short‑term contracts used to offset the few‑day FX exposure inherent in its settlement activities.  These contracts are now a core component of the firm’s risk‑mitigation framework, allowing it to lock in rates for anticipated cash‑flow receipts and payments and to limit volatility in earnings from settlement‑related currency movements.  The derivatives are recorded at fair value, with gains and losses on the non‑designated, short‑duration contracts flowing through general and administrative expense, while the designated cash‑flow hedges remain in accumulated other comprehensive income until reclassified when the underlying settlement transactions affect earnings.",
      "correctness_score": 4,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in quantitative claims. The ground truth does not mention any specific notional amounts of derivatives, let alone a figure of $3.9 billion in 2024, nor does it state that use of these contracts 'expanded markedly'—in fact, the original answer emphasizes continuity in the use of short-duration contracts, not growth. There is no mention in the ground truth about 'modest notional amounts' in 2022 or an increase by 2024, making these details fabricated or hallucinated. (2) The $3.9 billion figure is entirely unsupported by the ground truth and represents a critical quantitative inaccuracy. No dollar amounts, percentages, or notional values are provided in the original answer, so any such specificity in the LLM response is incorrect. (3) The qualitative reasoning partially aligns with the ground truth: the LLM correctly identifies that short-duration FX derivatives are used to manage daily settlement risk and reduce earnings volatility from currency fluctuations. It also correctly notes the accounting treatment for designated vs. non-designated hedges, though this detail is not present in the original answer and cannot be verified from the provided context. However, the LLM fails to mention the key multi-hop insight from the original answer: the dynamic de-designation and re-designation of euro-denominated debt in 2023 and 2024, which illustrates an evolving broader FX strategy despite stable use of short-term contracts. This omission weakens the synthesis required for full accuracy. (4) The contextual relevance is moderate—the response stays on topic and discusses the role of short-duration FX derivatives in settlement risk management. However, the emphasis on expansion and specific dollar figures misrepresents the evolution described in the ground truth, which stresses continuity in short-term contract usage alongside changes in other hedging strategies. Thus, while the general theme is relevant, the core factual and quantitative claims are not substantiated.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1493,
        "completion_tokens": 557,
        "total_tokens": 2051
      },
      "error": null
    },
    {
      "question_id": 75,
      "question": "How has Salesforce's strategic relationship with enterprise cloud companies evolved from 2023 to 2024, particularly in terms of investment focus and ecosystem integration?",
      "original_answer": "In 2023, Salesforce maintained a portfolio of strategic investments in enterprise cloud companies, technology startups, and system integrators, with a focus on digitally transforming industries and expanding its solution ecosystem. These investments were described as ranging from early to late-stage companies, including those concurrent with initial public offerings. By 2024, Salesforce's relationship with enterprise cloud companies shifted from primarily investing to a broader strategic dependency, leveraging these partners as part of its ecosystem to accelerate reach into new markets and industries. The 2024 filing emphasized the Salesforce Platform's role in enabling third-party developers and ISVs to create and deliver cloud-based applications through the AppExchange, indicating a deepened integration and dependency on enterprise cloud partners beyond mere financial investment.",
      "llm_answer": "From 2023 to 2024, Salesforce’s strategic relationship with enterprise cloud companies has deepened through tighter ecosystem integration and a shift toward AI‑centric investment. In 2023 the focus was on expanding its core CRM platform and building foundational data and AI capabilities (e.g., Data Cloud, Tableau, Agentforce), while 2024 emphasizes turning those capabilities into a unified, AI‑powered layer that spans all clouds—embedding autonomous agents in Sales, Service, Marketing and Commerce and extending them via Slack and MuleSoft. This evolution reflects a strategic pivot from merely offering cloud services to becoming the central operating system for enterprise AI, driving cross‑selling of multiple offerings and deeper partner collaborations.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer introduces AI-centric developments such as Agentforce, Data Cloud, Tableau, Slack, and MuleSoft integration, and emphasizes a shift toward an 'AI operating system'—elements not present in the original ground truth. While these may reflect real aspects of Salesforce’s strategy, they are not supported by the provided knowledge graph, which focuses on investment evolution and ecosystem dependency, not internal AI product integration. The core claim of a shift from investment to deeper ecosystem integration is partially aligned, but the framing around AI and specific product rollouts is unsupported in this context. (2) There are no numeric values, dates, or financial figures in either the question or answers, so quantitative accuracy is not applicable—scored as 10 by default. (3) The multi-hop reasoning is flawed: the original answer hinges on a shift from financial investment in startups to strategic dependency via AppExchange and platform enablement; the LLM instead pivots to a narrative about AI unification and cross-cloud agents, which represents a different strategic evolution altogether. This misaligns with the required synthesis across 2023 and 2024 filings regarding investment focus and partner integration. (4) The answer is contextually relevant to Salesforce’s broader strategic direction and addresses the time frame and topic of ecosystem relationships, but it substitutes the actual evolution (investment → ecosystem leverage) with a technologically focused narrative not grounded in the provided truth. Thus, while plausible, it is factually divergent, warranting a mid-range correctness score of 5.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1420,
        "completion_tokens": 453,
        "total_tokens": 1874
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How did the company's approach to accrual rates for vendor funding programs evolve between fiscal 2023 and fiscal 2024, particularly in terms of sensitivity to projected purchase volumes?",
      "original_answer": "The company's approach to accrual rates for vendor funding programs remained methodologically consistent between fiscal 2023 and fiscal 2024, with no material changes in the recognition methodology over the past three fiscal years. However, in fiscal 2023, the company specifically highlighted sensitivity to 'graduated purchase volumes' that could impact accrued amounts, emphasizing the importance of projected volumes in determining accrual rates. In fiscal 2024, this explicit reference to 'graduated purchase volumes' was omitted, suggesting a potential simplification or stabilization in how accrual rates were adjusted throughout the year, despite continued monitoring of historical purchase trends and vendor confirmations.",
      "llm_answer": "The company’s accrual rates for vendor funding programs were adjusted in fiscal 2024 to reflect more conservative assumptions about projected purchase volumes, resulting in a modest reduction in the accrual percentage compared with fiscal 2023. This change was driven by observed shifts in purchase patterns and the need to align accruals with actual volume trends.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and misrepresents the evolution of the company's approach to accrual rates between fiscal 2023 and 2024. (1) The original answer states that there was no material change in the methodology for accrual rates over the past three fiscal years, including 2023 and 2024, indicating consistency. However, the LLM claims there was a shift to 'more conservative assumptions' and a 'modest reduction in the accrual percentage' in fiscal 2024, which is not supported by the ground truth. There are no numbers or percentages mentioned in the original answer, so the LLM's assertion about a reduction in accrual percentage introduces false quantitative information. (2) The original answer notes that in fiscal 2023, the company emphasized sensitivity to 'graduated purchase volumes', while in 2024 this specific language was omitted—suggesting possible simplification or stabilization—but the core methodology remained unchanged. The LLM incorrectly interprets this omission as an active adjustment driven by changing purchase patterns, which is an unsupported inference. (3) The multi-hop reasoning fails because the LLM does not accurately synthesize the continuity in methodology; instead, it fabricates a change in assumptions and outcomes. (4) While the LLM stays within the topic of accrual rates and vendor funding programs, its conclusions are factually wrong, leading to a low correctness score. The contextual relevance is moderate because it addresses the right topic and timeframe but draws incorrect conclusions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1284,
        "completion_tokens": 423,
        "total_tokens": 1707
      },
      "error": null
    },
    {
      "question_id": 76,
      "question": "How has the strategic relationship between LLY and Boehringer Ingelheim evolved from 2022 to 2024, particularly in terms of legal involvement and collaborative dependency on the Jardiance product?",
      "original_answer": "In 2022, LLY was not a direct party to the Jardiance patent litigation initiated by Boehringer Ingelheim (BI) against generic drug manufacturers under the Hatch-Waxman Act, indicating a more arms-length relationship in legal matters. By 2024, LLY's business became significantly dependent on the Jardiance collaboration, as the product was selected under the Inflation Reduction Act (IRA) for government-set pricing with a 66% discount compared to the 2023 list price, directly impacting LLY's revenue projections and business strategy. This shift reflects a deeper strategic entanglement and dependency on BI's partnership for navigating regulatory and pricing pressures.",
      "llm_answer": "From 2022 to 2024 the legal relationship with Boehringer Ingelheim remained anchored by the 2011 collaboration agreement, but the scope of that partnership expanded markedly.  In 2022 the companies settled the Alimta patent dispute and continued to defend Jardiance‑related patent challenges together, while in 2023‑24 they jointly faced multiple product‑liability suits (e.g., the Byetta and Jardiance Fournier’s‑gangrene cases) in which BI is required to defend and indemnify Lilly.  At the same time, the commercial dependency on Jardiance deepened: the drug generated $5.9 bn in 2023 and accounted for roughly one‑third of Lilly’s total revenue, and the 2024 Inflation‑Reduction Act price‑setting for Jardiance (a 66 % discount) underscored how central the product is to both firms’ financial outlooks.  Consequently, the collaboration has moved from a primarily R&D‑focused alliance to a tightly integrated, legally intertwined partnership that is now heavily dependent on the continued commercial success of Jardiance.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer contains several factual inaccuracies that significantly impact correctness, particularly in quantitative and legal details, though it captures the general trend of increasing dependency on Jardiance. (1) QUANTITATIVE ACCURACY: The claim that Jardiance generated $5.9 billion in 2023 is incorrect — this figure conflates Jardiance with other Lilly products (e.g., GLP-1 drugs like Mounjaro or Trulicity); Jardiance sales were approximately $3.5 billion in 2023. The 66% discount under the IRA is correctly cited, but the implication that it applied in 2024 is misleading — IRA price-setting for Jardiance took effect in 2025, not 2024. (2) COMPLETENESS: The answer addresses both legal involvement and collaborative dependency, satisfying the multi-part structure. However, it introduces unsupported claims (e.g., joint defense in Fournier’s gangrene cases involving Jardiance) — such litigation primarily involved Byetta and Bydureon, not Jardiance. (3) ENTITY ACCURACY: The companies (LLY, BI) and product (Jardiance) are correct, and the 2011 collaboration agreement is accurately referenced. However, the Alimta patent dispute settlement in 2022 is unrelated to the BI-LLY diabetes collaboration and incorrectly framed as part of the Jardiance legal dynamic. (4) REASONING: The model attempts multi-hop synthesis — linking IRA pricing, revenue impact, and legal entanglement — but some inferences are based on incorrect premises. The core idea of deepening strategic dependency is aligned with the ground truth, but the legal entanglement is overstated. (5) SEMANTIC EQUIVALENCE: While the overall narrative of increased dependency is reasonable, the factual foundation is weakened by incorrect numbers and misattributed litigation. The ground truth emphasizes LLY’s non-involvement in 2022 Hatch-Waxman litigation, which the LLM omits and instead asserts joint legal action, contradicting the original. Thus, despite relevant context and plausible reasoning, the answer is partially incorrect on key facts, warranting a moderate score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1436,
        "completion_tokens": 549,
        "total_tokens": 1986
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How did Disney's capital investment strategy toward cruise ships evolve from 2022 to 2023, particularly in relation to its broader Parks & Experiences business?",
      "original_answer": "In 2022, Disney's 10-K filing highlighted cruise ships as part of its broader Experiences segment but did not specifically emphasize capital investment in them, instead noting general risks from macroeconomic conditions such as inflation, supply chain delays, and currency fluctuations that could impact the implementation of business plans, including those for parks and resorts. By 2023, Disney explicitly listed cruise ships as part of its significant capital investments, indicating a strategic elevation in focus. The 2023 filing stated that the majority of the company’s capital spend was directed toward parks and experiences, including 'new attractions, cruise ships, capital improvements and systems infrastructure.' This shift demonstrates a clear prioritization of cruise ships as a key growth area within the broader Experiences segment.",
      "llm_answer": "Disney’s capital investment strategy toward cruise ships shifted markedly from 2022 to 2023 as part of a broader realignment of its Parks & Experiences business. In 2022 the company continued to fund cruise‑line expansion—including the 2024 opening of the Disney Cruise Line destination at Lighthouse Point—while still channeling the majority of capital spending into theme‑park and resort projects. By 2023, however, the focus pivoted toward leveraging cruise assets as a growth lever within Experiences, with increased investment in new ships and destination development (e.g., the 2024‑2025 cruise‑line fleet expansion and the planned 2025 Disney Cruise Line destination) to drive higher‑margin revenue streams and support the overall diversification of the Parks & Experiences portfolio. This evolution reflects Disney’s strategy to use cruise‑ship capital to complement, rather than dominate, its theme‑park and resort expansion, aligning with the broader goal of broadening high‑margin, recurring‑revenue experiences across the Parks & Experiences segment.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly regarding specific capital investment details and timelines not present in the original 10-K filings. The ground truth does not mention Lighthouse Point, fleet expansion dates (2024–2025), or a planned 2025 Disney Cruise Line destination. These specific project timelines and names are not supported by the provided ground truth and appear to be fabricated or inferred beyond the data. (2) Quantitative accuracy is low because the LLM introduces precise dates (e.g., 2024 opening of Lighthouse Point, 2025 destination) and fleet expansion plans that are not in the original answer. The ground truth only states that in 2023, Disney explicitly included cruise ships in its capital investment focus, without specifying projects or openings. (3) Qualitatively, the LLM captures the correct directional shift: from not explicitly highlighting cruise ships in 2022 to emphasizing them in 2023 as part of capital spend in Parks & Experiences. The reasoning about strategic elevation and diversification aligns with the ground truth’s theme of increased prioritization. However, the model overreaches by adding unverified projects and revenue strategy details (e.g., 'higher-margin revenue streams') not present in the source. (4) Contextual relevance is high because the answer directly addresses the evolution of Disney’s capital strategy toward cruise ships within Parks & Experiences, and the overall structure and intent match the question. However, the inclusion of unsupported specifics reduces factual correctness significantly. The core insight—increased strategic focus on cruise ships in 2023—is correct, but the added detail undermines accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1481,
        "completion_tokens": 471,
        "total_tokens": 1953
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has Mastercard Foundry's role in fostering innovation evolved between 2022 and 2024, particularly in relation to its engagement with emerging technologies and fintech partnerships?",
      "original_answer": "In 2022, Mastercard Foundry (formerly known as Mastercard Labs) was primarily described as a vehicle for bringing customers and partners access to thought leadership, innovation methodologies, new technologies, and early-stage fintech players. By 2024, its role had evolved into a more active innovation engine, with continued emphasis on identifying and experimenting with future technologies, start-ups, and trends. Specifically, in 2024, Foundry was positioned as a key enabler of blockchain-based business models and programmable payments through the Mastercard Multi-Token Network™, indicating a strategic shift toward deeper integration with next-generation financial technologies.",
      "llm_answer": "Between 2022 and 2024, Mastercard Foundry’s role evolved from a primarily experimental innovation engine into a more structured, partnership‑driven platform that integrates emerging technologies and fintech collaborations into core payment capabilities. The 2022 filing highlights Foundry’s early‑stage focus on blockchain, crypto‑related experiments, and AI‑driven fraud tools, while the 2024 filing shows a shift toward scaling these initiatives—e.g., expanding tokenization, launching AI‑enhanced Decision Intelligence Pro, integrating blockchain‑based programmable payments via the Mastercard Mul‑Token Network, and deepening open‑banking APIs—demonstrating a move from proof‑of‑concept pilots to commercially viable solutions that support new payment flows, broader digital‑first offerings, and tighter integration with fintech ecosystems.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. It correctly identifies the evolution of Mastercard Foundry from 2022 to 2024, noting its shift from an experimental innovation lab to a more active, integration-focused engine. The mention of blockchain, programmable payments, and the Mastercard Multi-Token Network™ (referred to accurately, though with a minor typo: 'Mul-Token' instead of 'Multi-Token') is factually correct and reflects the strategic emphasis in 2024. The reference to AI-driven tools like Decision Intelligence Pro and tokenization aligns with Mastercard's innovation trajectory, even if not explicitly detailed in the ground truth—these are reasonable inferences consistent with the company's public tech focus. The ground truth emphasizes Foundry’s role in thought leadership and early-stage access in 2022 and its 2024 pivot toward blockchain and programmable payments, which the LLM captures and expands upon with contextually appropriate details. All dates (2022, 2024) and entities (Mastercard Foundry, Mastercard Multi-Token Network™) are correct. There are no numerical inaccuracies, as the question is qualitative. The reasoning is sound, demonstrating multi-hop synthesis across time periods and strategic focus areas. The only minor shortcoming is the slight misspelling of 'Multi-Token' and the addition of specific product names (e.g., Decision Intelligence Pro) not explicitly mentioned in the ground truth, which, while plausible, are not confirmed—hence a 9 instead of 10 on qualitative accuracy. Overall, the answer is semantically equivalent, comprehensive, and contextually precise.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1392,
        "completion_tokens": 448,
        "total_tokens": 1840
      },
      "error": null
    },
    {
      "question_id": 77,
      "question": "How has the financial and strategic nature of the collaboration with Boehringer Ingelheim evolved between 2022 and 2024, particularly in terms of regulatory designations and pricing pressures?",
      "original_answer": "In 2022, the collaboration with Boehringer Ingelheim included the development of a therapy that had received Breakthrough Therapy and Fast Track designations from the FDA, indicating early-stage regulatory support and potential expedited development. By 2024, the collaboration faced significant pricing pressures under the Inflation Reduction Act, with Jardiance—part of the LLY-Boehringer Ingelheim partnership—selected for government-set pricing effective in 2026, subject to a 66% discount compared to the 2023 U.S. list price. This marks a shift from regulatory facilitation to regulatory-driven financial constraints.",
      "llm_answer": "The collaboration with Boehringer Ingelheim has shifted from a primarily research‑focused partnership to a more commercially integrated effort, highlighted by regulatory milestones such as FDA Fast‑Track and Breakthrough Therapy designations for tirzepatide and other pipeline assets, and by expanded joint submissions in the U.S., EU, and Japan.  Concurrently, pricing pressures have intensified as U.S. legislation (e.g., the Inflation Reduction Act) imposes steep government‑set discounts on high‑impact products like Jardiance, prompting faster price erosion and heightened reimbursement scrutiny for the partnership’s key assets.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct elements but also key inaccuracies. It correctly identifies the evolution of the Boehringer Ingelheim collaboration involving regulatory designations (Fast Track and Breakthrough Therapy) and increased pricing pressures due to the Inflation Reduction Act. However, it incorrectly attributes these designations to 'tirzepatide', which is a product developed by Eli Lilly but not in partnership with Boehringer Ingelheim—tirzepatide is part of Lilly's GLP-1 portfolio and unrelated to the Jardiance collaboration. The correct asset under the LLY-Boehringer partnership with those designations in 2022 was not specified in the ground truth, but Jardiance is the named product affected by pricing. (2) Quantitatively, the LLM fails to include the specific 66% discount and 2026 effective date for government-set pricing under the IRA, which are critical numerical facts in the ground truth. These omissions significantly reduce quantitative accuracy. The mention of 'steep government-set discounts' is directionally correct but lacks precision. (3) The multi-hop reasoning is partially sound: the model connects regulatory facilitation in early years to later financial constraints, showing an understanding of the strategic shift. However, the erroneous reference to tirzepatide undermines the entity linkage and suggests confusion between different Lilly partnerships or products. (4) Contextual relevance is high because the response addresses both regulatory evolution and pricing pressures across the 2022–2024 timeframe. Despite factual errors, the overall narrative arc aligns with the question. Correctness score is 6 due to correct conceptual framework but major factual flaws in product attribution and missing key quantitative details.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 488,
        "total_tokens": 1813
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "How has the strategic positioning of the CH-53K King Stallion heavy lift helicopter evolved within Lockheed Martin's Rotary and Mission Systems segment from 2023 to 2024?",
      "original_answer": "In 2023, the CH-53K King Stallion heavy lift helicopter was described as part of Lockheed Martin's near-to-mid-term growth elements, specifically under the Rotary and Mission Systems (RMS) segment, alongside radar surveillance systems. By 2024, the CH-53K remained a highlighted program within RMS, but the emphasis shifted to framing it within a broader context of advancing all-domain mission solutions and digital technologies such as AI/ML and autonomy. While no specific revenue figures are provided, the helicopter's positioning evolved from being a growth driver among several others to being part of a more integrated, technologically advanced portfolio aimed at improving interoperability and supporting multi-domain solutions.",
      "llm_answer": "From the 2023 10‑K (pages 27‑31) and the 2024 10‑K (pages 1‑5), the CH‑53K King Stallion is highlighted as a key growth pillar within the Rotary and Mission Systems (RMS) segment.  In 2023 the program secured a major international award for 12 helicopters, with the first four delivered in 2022 and the remaining eight in 2023, and the text notes that “international customers accounted for 31 % of RMS net sales” and that “the CH‑53K heavy‑lift helicopter” is a focus of growth.  The 2024 filing (page 3) reiterates that RMS continues to experience international interest in the CH‑53K, describing it as part of the company’s “four elements for potential growth” and emphasizing its role in expanding the segment’s portfolio and sustaining demand through foreign‑military‑sales and direct‑commercial‑sales channels.  Thus, the strategic positioning of the CH‑53K evolved from a nascent heavy‑lift offering in 2023 to a mature, internationally‑sought program that underpins RMS’s growth trajectory heading into 2024.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies not present in the ground truth. Most critically, it introduces specific details not found in the original answer or implied by the knowledge graph, such as a 'major international award for 12 helicopters' with deliveries in 2022 and 2023, and the claim that 'international customers accounted for 31% of RMS net sales.' These figures and events are absent from the ground truth and cannot be verified from the provided context. The original answer makes no mention of specific contracts, delivery timelines, or percentages related to international sales. (2) The quantitative accuracy is low because the LLM fabricates numeric data (e.g., 12 helicopters, 31%) without grounding in the source. While the years 2022–2023 are plausible, they are not referenced in the ground truth, making these details unsupported. (3) The reasoning partially aligns with the multi-hop requirement—comparing 2023 to 2024 positioning—but misrepresents the evolution. The ground truth emphasizes a shift in narrative from 'near-to-mid-term growth element' to being part of an integrated, technology-driven portfolio (AI/ML, autonomy, interoperability), whereas the LLM frames the evolution as moving from 'nascent' to 'mature, internationally-sought' based on sales performance, which is not supported. This reflects flawed reasoning and synthesis. (4) Despite the inaccuracies, the answer is contextually relevant—it addresses the strategic positioning of the CH-53K within RMS across two years and attempts to draw a comparative narrative. However, the invented details and mischaracterization of the strategic shift significantly reduce correctness. Semantic equivalence fails due to unsupported specifics and a different conceptual framing of the evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1444,
        "completion_tokens": 491,
        "total_tokens": 1935
      },
      "error": null
    },
    {
      "question_id": 78,
      "question": "What does the change in LLY's diabetes product portfolio co-commercialized with Boehringer Ingelheim between 2022 and 2024 indicate about the companies' shifting strategic priorities or market focus?",
      "original_answer": "In 2022, LLY and Boehringer Ingelheim were jointly developing and commercializing a broader portfolio of diabetes products, including Trajenta, Jentadueto, Jardiance, Glyxambi, Synjardy, Trijardy XR, and Basaglar. By 2024, the portfolio had narrowed to include only Jardiance, Glyxambi, Synjardy, and Trijardy XR. This indicates a strategic refocusing, potentially driven by lifecycle management, shifting market demand, or prioritization of products with stronger commercial performance or longer patent protection. The removal of Trajenta, Jentadueto, and Basaglar may reflect declining market relevance, generic competition, or a strategic decision to streamline the collaboration around products with greater growth potential or therapeutic differentiation.",
      "llm_answer": "The shift in Lilly’s diabetes portfolio co‑commercialized with Boehringer Ingelheim from 2022 to 2024 reflects a strategic pivot toward broader cardiometabolic and obesity‑focused offerings, exemplified by the launch of the direct‑to‑consumer platform LillyDirect and expanded access programs for anti‑obesity medicines. This expansion signals a move away from a narrow diabetes focus to a more diversified, patient‑centric approach that leverages partnerships, digital health tools, and reimbursement‑driven market access to capture growth in adjacent therapeutic areas.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and fails to accurately reflect the factual changes in the LLY and Boehringer Ingelheim diabetes portfolio between 2022 and 2024. (1) The ground truth states that in 2022, the co-commercialized portfolio included Trajenta, Jentadueto, Jardiance, Glyxambi, Synjardy, Trijardy XR, and Basaglar, and by 2024 it narrowed to only Jardiance, Glyxambi, Synjardy, and Trijardy XR—indicating a contraction focused on SGLT2 inhibitors. The LLM answer does not mention this specific product-level change at all. (2) There are no correct numbers, dates, or financial metrics referenced in the LLM answer, and it introduces unrelated elements such as 'LillyDirect' and 'anti-obesity medicines' that are not part of the co-commercialization agreement with Boehringer Ingelheim. These are strategic moves by Lilly independently but do not pertain to the joint portfolio evolution. (3) The multi-hop reasoning is flawed: instead of analyzing the narrowing of the portfolio as a signal of lifecycle management or prioritization, the model fabricates a narrative about expansion into obesity and digital health, which is unsupported by the data. (4) While the general theme of 'strategic shift' is contextually relevant, the specific reasoning and evidence are factually wrong, leading to a low correctness score. The answer is semantically dissimilar to the ground truth and misses the core factual basis of the portfolio contraction.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1346,
        "completion_tokens": 399,
        "total_tokens": 1745
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How did the financial performance and strategic importance of the JASSM program evolve between 2023 and 2024, particularly in terms of production activity and its contribution to backlog?",
      "original_answer": "In 2023, JASSM was a product under the Missiles and Fire Control (MFC) segment, contributing to the company's portfolio of tactical missiles, but there was no specific mention of significant changes in its production volume or backlog contribution. By 2024, JASSM experienced a production ramp-up, contributing to a $1.2 billion increase in tactical and strike missile programs within MFC. Additionally, JASSM was specifically cited as a key contributor to the increase in backlog alongside PAC-3 and GMLRS. This indicates a notable rise in both production activity and strategic importance for JASSM in 2024.",
      "llm_answer": "The JASSM program’s strategic importance grew in 2024 as it contributed to a $1.4 billion increase in backlog, driven by higher orders on tactical and strike missile programs such as JASSM. While operating profit in the Missiles and Fire Control segment fell sharply—largely due to $1.4 billion of losses on a classified program and reduced profit‑booking adjustments—the program remained a key growth driver for backlog.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. The ground truth states that JASSM contributed to a $1.2 billion increase in tactical and strike missile *production programs* within MFC, not a $1.4 billion increase in *backlog*. The LLM incorrectly attributes a $1.4 billion backlog increase to JASSM, conflating it with losses from a classified program. Additionally, the $1.4 billion figure in the LLM answer refers to losses in the MFC segment, not backlog growth from JASSM—this is a critical error. (2) The numbers are not accurate: $1.4 billion is mentioned twice in the LLM answer but does not align with the ground truth. The correct figure for JASSM-related program growth is $1.2 billion, tied to production volume increases, not backlog alone. The conflation of backlog growth with segment losses undermines quantitative validity. (3) The reasoning is partially sound in identifying JASSM as a growing program and linking it to increased strategic importance in 2024. It correctly identifies JASSM as part of tactical and strike missiles under MFC and notes rising orders. However, it fails to mention the absence of notable production or backlog changes in 2023, missing a key comparative element. It also incorrectly synthesizes the $1.4 billion classified program loss with JASSM’s backlog contribution, indicating flawed multi-hop logic. (4) Despite the incorrect figures and misattribution, the answer captures the general trend of increased strategic importance and production activity for JASSM in 2024, which maintains moderate qualitative and contextual relevance. However, the quantitative inaccuracy severely limits overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1267,
        "completion_tokens": 470,
        "total_tokens": 1737
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How has JPM's focus in evaluating credit risk for Business Banking Loans evolved between 2023 and 2024, and what implications does this shift have for identifying early signs of borrower distress?",
      "original_answer": "In 2023, JPM focused on Business Banking Loans as part of its broader prime consumer credit strategy, emphasizing loan performance and scoring models within the 'Consumer, excluding credit card loan portfolio' segment. By 2024, the focus shifted toward delinquency rates as the primary credit quality indicator, particularly noting that loans more than 30 days past due serve as early warnings of financial difficulty. This evolution suggests a more proactive stance in identifying early signs of borrower distress, aligning Business Banking Loans with broader consumer loan risk frameworks where early delinquency tracking enhances risk mitigation. The shift indicates a strategic move toward earlier intervention and more granular performance monitoring.",
      "llm_answer": "JPMorgan's credit risk evaluation for Business Banking Loans has shifted from a primary focus on delinquency rates as the main indicator of borrower distress (as seen in 2023 residential real estate data) to incorporating additional early warning signals like high LTV ratios and low refreshed FICO scores (highlighted in 2024 residential real estate disclosures). This evolution reflects a more nuanced approach where geographic distribution, loan-to-value metrics, and credit score trends are now used alongside delinquency to identify at-risk borrowers earlier, particularly for junior lien and high-LTV loans that show elevated delinquency rates when converted to term structures.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both factual content and reasoning. The original answer states that in 2023, JPM focused on loan performance and scoring models within the 'Consumer, excluding credit card loan portfolio' segment, and by 2024 shifted to using delinquency rates (specifically loans more than 30 days past due) as early indicators of distress. In contrast, the LLM answer incorrectly claims that in 2023 the focus was on delinquency rates and that in 2024 JPM expanded to include LTV ratios and FICO scores—this reverses the timeline and misrepresents the evolution. Furthermore, the LLM answer references 'residential real estate data' and 'junior lien' loans, which are not mentioned in the ground truth and are irrelevant to Business Banking Loans. (2) There are no specific numbers, percentages, or dollar amounts in either answer, so quantitative accuracy cannot be penalized for missing values, but the misuse of financial terms (LTV, FICO, junior lien) in an incorrect context undermines accuracy. (3) The multi-hop reasoning is flawed: the model fails to correctly identify the shift from broader scoring models in 2023 to delinquency tracking in 2024 and instead fabricates a shift involving residential real estate metrics. It does not synthesize the correct entities (Business Banking Loans, Consumer loan portfolio, delinquency as early warning) nor the correct timeline. (4) The contextual relevance is moderate because the answer discusses credit risk and early warning signs, which are relevant themes, but the specific content is misaligned with the actual focus areas and segments described in the ground truth. Thus, while the general topic is addressed, the substance is factually incorrect and misleading.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1372,
        "completion_tokens": 478,
        "total_tokens": 1851
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How did Target Corporation's SPP II plan terms evolve between the 2022 and 2023 filings, and what does this suggest about the company's executive compensation framework?",
      "original_answer": "In the 2022 filing, the SPP II plan was described under the 2016 Plan Statement, as amended and restated effective April 3, 2016. However, in the 2023 filing, the SPP II plan was updated to the 2022 Plan Statement, as amended and restated effective May 1, 2022. This indicates that Target Corporation revised the SPP II plan within this timeframe, reflecting a shift in the structure or terms of the plan. Such changes could signal adjustments in the company's executive compensation strategy, potentially aligning incentives more closely with updated business objectives or governance standards.",
      "llm_answer": "Between the 2022 and 2023 filings, Target Corporation’s executive compensation framework underwent a significant structural shift, particularly in its long-term incentive plans. The 2023 filing explicitly references the \"Target Corporation 2020 Long-Term Incentive Plan\" (D*) and reorganizes its executive plans under clearer designations like SPP I, SPP II, and SPP III, while removing older references to \"SPP II (2016 Plan Statement)\" from the 2022 filing. This evolution suggests a deliberate refinement of the company’s executive compensation framework to enhance clarity, align with evolving governance standards, and potentially strengthen performance-based incentives, reflecting a more structured and possibly more performance-driven approach to executive rewards.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies regarding the plan names and dates. The ground truth states that the SPP II plan transitioned from the '2016 Plan Statement, as amended and restated effective April 3, 2016' in the 2022 filing to the '2022 Plan Statement, as amended and restated effective May 1, 2022' in the 2023 filing. However, the LLM incorrectly references a 'Target Corporation 2020 Long-Term Incentive Plan' (D*) and claims reorganization under SPP I, II, III with removal of 'SPP II (2016 Plan Statement)'—details not present in the ground truth. There is no mention of a 2020 plan or SPP III in the original answer, making these fabrications. (2) Quantitatively, the answer fails on key dates and plan names: the correct amendment dates are April 3, 2016, and May 1, 2022, not implied references to 2020. The LLM invents a plan (2020 LTIP) not mentioned in the ground truth, which undermines quantitative and entity accuracy. (3) While the multi-hop reasoning is partially sound—inferring that changes in plan documentation suggest strategic shifts in executive compensation—the LLM bases its conclusion on incorrect entities and documents. The synthesis is logical but built on false premises. (4) The contextual relevance is high because the answer addresses the evolution of SPP II and interprets implications for executive compensation strategy. However, due to major factual errors in plan names, dates, and structure, the correctness score is limited to 5—partially correct but with significant inaccuracies that affect the reliability of the response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1348,
        "completion_tokens": 440,
        "total_tokens": 1788
      },
      "error": null
    },
    {
      "question_id": 79,
      "question": "How did the financial obligations related to Incyte under the Olumiant collaboration evolve from 2022 to 2024, particularly regarding potential future milestone payments?",
      "original_answer": "In 2022, Incyte was eligible to receive up to $100.0 million in additional development-related regulatory milestones and another $100.0 million in sales-based milestones under the Olumiant agreement. By 2024, there is no mention of remaining regulatory milestones, suggesting they were either paid out or no longer applicable, and only ongoing royalty payments based on sales tiers (up to 20%) and a low teens royalty for sales exceeding a threshold in the context of COVID-19 treatment are explicitly referenced. This indicates a shift from a structure with both regulatory and sales milestones to one focused primarily on sales-based compensation.",
      "llm_answer": "From 2022 through 2024 the Olumiant collaboration with Incyte continued to generate milestone‑related revenue that is recognized as cost of sales, but the size of those milestone payments has been shrinking: the 2022‑2023 period saw $260 million and $210 million of milestone payments capitalized, while by 2024 the company reports only that Incyte is eligible for up to $100 million of additional regulatory milestones and $100 million of sales‑based milestones, implying that future milestone payments will be limited to those capped amounts. Consequently, potential future milestone payments under the Olumiant agreement are now expected to be modest—up to roughly $100 million for regulatory milestones and $100 million for sales milestones—rather than the larger, multi‑hundred‑million‑dollar milestones that were recorded in prior years.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies that undermine its correctness. (1) Quantitative inaccuracy: The LLM claims $260 million and $210 million in milestone payments were capitalized in 2022–2023, but the ground truth does not mention any actual payments of this size or the term 'capitalized'—it only states Incyte was eligible for up to $100 million in development-related regulatory milestones and $100 million in sales-based milestones in 2022. There is no support for the $260M/$210M figures. (2) Misrepresentation of 2024 status: The LLM incorrectly states that in 2024, Incyte is still eligible for up to $100 million in regulatory milestones, while the ground truth explicitly notes there is *no mention* of remaining regulatory milestones by 2024, implying they were likely paid out or lapsed. This contradicts the core evolution described in the original answer. (3) Incorrect reasoning: The LLM suggests milestone payments are 'shrinking' from multi-hundred-million-dollar amounts to capped $100M tranches, but the ground truth indicates a structural shift from milestone-based compensation to royalty-based compensation, with no indication of such large prior payments. (4) Missing key point: The original answer highlights a shift to tiered royalties (up to 20%) and a 'low teens' royalty for COVID-19-related sales, which the LLM omits entirely. This is a critical component of the 2024 compensation structure. (5) Contextual relevance is moderate because the answer addresses the general topic of milestone evolution, but the factual errors and omissions severely limit accuracy. Overall, the LLM fabricates specific payment amounts, misrepresents the timeline and structure of obligations, and fails to capture the actual shift from milestones to royalties, resulting in a largely incorrect response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 494,
        "total_tokens": 1873
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has Cisco's financial exposure in the APJC region evolved between fiscal 2022 and fiscal 2023, based on its segment reporting and asset balances?",
      "original_answer": "In fiscal 2022, Cisco reported its business performance across geographic segments including APJC, though specific financial figures for APJC were not disclosed in the provided data. By fiscal 2023, Cisco's balance sheet showed that its assets in the APJC region stood at $5,382 million as of July 29, 2023, following additions from acquisitions and foreign currency translation adjustments. This indicates a more detailed financial disclosure regarding APJC in 2023 compared to 2022, where segment-level asset values were not explicitly itemized.",
      "llm_answer": "Cisco's financial exposure in the APJC region decreased between fiscal 2022 and fiscal 2023, with APJC revenue declining from $8.027 billion to $7.706 billion and APJC long‑lived assets falling from $1,244 million to $997 million. This reduction reflects lower regional sales and a smaller allocation of long‑term assets to the APJC segment over the two fiscal years.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "The LLM answer is fundamentally incorrect in both quantitative and qualitative aspects. (1) The numbers provided—APJC revenue declining from $8.027 billion to $7.706 billion and long-lived assets falling from $1,244 million to $997 million—are not supported by the ground truth. The original answer explicitly states that specific financial figures for APJC in fiscal 2022 were not disclosed, making any precise revenue or asset figures for that year factually wrong. (2) The claim of a decrease in financial exposure is unsupported; the ground truth indicates that in fiscal 2023, Cisco did report APJC assets at $5,382 million, but no comparable asset or revenue data was disclosed for fiscal 2022, so no valid comparison can be made. (3) The multi-hop reasoning fails: the LLM incorrectly assumes segment-level revenue and asset data were available for both years and fabricates a trend. (4) The context of the question—evolution of financial exposure based on segment reporting and asset balances—is partially relevant, but the answer invents data rather than acknowledging disclosure limitations. The only correct element is the focus on APJC and fiscal years 2022–2023. Due to complete factual inaccuracy, especially in critical financial figures and trends, the correctness score is very low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1229,
        "completion_tokens": 360,
        "total_tokens": 1590
      },
      "error": null
    },
    {
      "question_id": 80,
      "question": "How has the strategic collaboration between LLY and Boehringer Ingelheim, specifically regarding Jardiance, evolved from 2022 to 2024 in response to regulatory changes?",
      "original_answer": "In 2022, Jardiance revenue was growing significantly, with a 30% increase in the U.S. and 28% outside the U.S., driven by increased demand and volume respectively. By 2024, the collaboration was significantly impacted by the Inflation Reduction Act (IRA), which introduced government-set pricing for certain drugs, including Jardiance. In August 2023, Jardiance was selected as one of the first ten medicines subject to government-set prices, and in August 2024, a 66% discount was applied compared to the 2023 U.S. list price, significantly affecting revenue projections and business strategy.",
      "llm_answer": "The strategic collaboration between LLY and Boehringer Ingelheim regarding Jardiance has evolved in response to regulatory changes, particularly the U.S. Inflation Reduction Act (IRA). In August 2023, HHS selected Jardiance as one of the first ten medicines subject to government-set prices effective in 2026, which will apply a 66% discount compared to the 2023 U.S. calendar year list price for a 30-day supply. This regulatory shift, part of broader IRA provisions aimed at reducing drug pricing, is expected to significantly impact revenue from Jardiance prior to the expiration of exclusivity, accelerating revenue erosion as noted in the 2024 disclosures. The collaboration's financial exposure is further underscored by the IRA's requirement for manufacturers to provide rebates for Medicare Part B and Part D medicines, with penalties for noncompliance.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the key regulatory change—the Inflation Reduction Act (IRA)—and its impact on Jardiance pricing, including the 66% discount and selection of Jardiance among the first ten drugs subject to government pricing. However, there is a critical error in timing: the ground truth states the 66% discount was applied in August 2024, whereas the LLM claims it will be effective in 2026. This misrepresents the timeline and undermines the accuracy of the revenue impact assessment. (2) Quantitatively, the 66% discount and August 2023 selection are correct, but the erroneous deferral of the discount implementation to 2026 (vs. actual application in 2024) is a significant factual deviation. Additionally, the original answer notes strong revenue growth in 2022 (30% in U.S., 28% ex-U.S.), which the LLM omits entirely, failing to address the evolution from growth to decline. (3) The reasoning is otherwise sound: the LLM correctly links IRA provisions to pricing pressure, revenue erosion, and strategic implications for the LLY-Boehringer collaboration. It appropriately references HHS actions and Medicare rebate requirements, showing good synthesis of regulatory and financial impacts. (4) Despite missing the 2022 growth context and misstating the discount effective date, the answer remains highly relevant to the question about regulatory-driven evolution. The core mechanism (IRA → price control → revenue impact) is accurately conveyed, warranting a correctness score of 7 due to the material timing error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 428,
        "total_tokens": 1797
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did GM's emphasis on the financial and reputational risks of product safety recalls evolve between 2022 and 2023, particularly concerning global platforms like the Chevrolet Bolt EV and the company's positioning in EV/AV technologies?",
      "original_answer": "In 2022, GM specifically highlighted the Chevrolet Bolt EV recall as an example of how global platform-related recalls could significantly increase costs due to their scale. The focus was on the financial burden and logistical complexity tied to such large-scale campaigns. By 2023, while the concern around global platforms remained, GM expanded its risk disclosure to emphasize the reputational damage to brand image and equity, particularly in relation to its leadership aspirations in EV and AV technologies. This evolution suggests a shift from a primarily cost-centric concern to a broader strategic risk tied to innovation and market positioning.",
      "llm_answer": "Between 2022 and 2023 GM’s disclosures show a clear intensification of focus on both the financial and reputational exposure tied to product‑safety recalls—especially those involving global platforms such as the Chevrolet Bolt EV.  In the 2022 filing the company warned that recall costs “could be exacerbated to the extent that such action relates to a global platform,” and that safety concerns could trigger “product delays, recalls, field actions, lost sales, governmental investigations, regulatory action, private claims, lawsuits and settlements and reputational damage.”  By 2023 the language is sharper, emphasizing that “the costs and effect on our reputation of product safety recalls and alleged defects … could materially adversely affect our business,” and linking those risks directly to the company’s EV/AV strategy, noting that “concerns about the safety of our products, including advanced technologies like AVs … could result in product delays, recalls, field actions, lost sales … and reputational damage.”  Thus, GM’s narrative evolved from a general caution about recall expenses to a more explicit articulation of how safety‑related setbacks could jeopardize its broader EV/AV ambitions and brand equity.",
      "correctness_score": 10,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 10,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is factually accurate, complete, and semantically equivalent to the ground truth. (1) There are no numeric values (e.g., dollar amounts, percentages) in either the question or the original answer, so no quantitative inaccuracies exist; the years 2022 and 2023 are correctly referenced. (2) The LLM correctly identifies the evolution in GM's risk disclosures: in 2022, the focus was on financial and logistical challenges of global platform recalls (specifically the Chevrolet Bolt EV), and in 2023, the emphasis expanded to include reputational damage tied to EV/AV leadership ambitions. (3) The multi-hop reasoning is sound—synthesizing information across two years of filings, connecting the Bolt EV recall to broader strategic concerns, and linking safety risks to innovation positioning. (4) The LLM uses direct quotes from filings (e.g., 'materially adversely affect our business', 'concerns about the safety of our products') that align with the documented shift in tone and strategic framing. Wording differs slightly from the original answer but conveys the same core insight: a shift from cost-centric to reputation- and strategy-centric risk perception. All entities—GM, Chevrolet Bolt EV, EV/AV technologies, 2022 and 2023—are correctly identified and contextualized. No omissions or inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1493,
        "completion_tokens": 367,
        "total_tokens": 1860
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did the Guaranteed Senior Notes issued by Costco's Japanese subsidiary evolve between 2022 and 2024, and what does this indicate about the company's long-term financing strategy?",
      "original_answer": "In 2022, the Guaranteed Senior Notes issued by Costco's Japanese subsidiary were described in general terms, indicating only their existence and that they were valued using Level 3 inputs. By 2024, the company provided significantly more detailed information, disclosing that in November 2023, the subsidiary issued four new Guaranteed Senior Notes totaling approximately $500 at fixed interest rates ranging from 1.400% to 2.120%, with maturities extending from 2033 to 2043. Additionally, in July 2024, the subsidiary repaid $77 of these notes. This evolution indicates a more transparent and strategic approach to long-term financing, with a focus on fixed-rate debt and extended maturities to manage future liquidity needs.",
      "llm_answer": "The Guaranteed Senior Notes issued by Costco’s Japanese subsidiary were initially created in late 2023 with a total issuance of roughly $500 million of fixed‑rate notes (1.400%–2.120% interest, maturing 2033‑2043).  During 2024 the subsidiary repaid about $77 million of those notes, and the parent company fully retired the $1 billion 2.750% Senior Notes in May 2024.  This evolution shows that the company is gradually reducing reliance on the Japanese‑subsidiary debt and shifting financing toward its broader senior note program and cash‑based repayments, reflecting a long‑term strategy of consolidating and streamlining its capital structure while maintaining access to diversified, low‑cost long‑term funding.",
      "correctness_score": 5,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a mix of correct and incorrect information. It correctly identifies the $500 million issuance of Guaranteed Senior Notes by Costco's Japanese subsidiary in late 2023 at fixed rates between 1.400% and 2.120%, with maturities from 2033 to 2043, and the $77 million repayment in 2024, which aligns with the ground truth. However, it introduces a fact not present in the original answer: the retirement of a $1 billion 2.750% Senior Note by the parent company in May 2024. This detail is absent from the ground truth and shifts the interpretation of the financing strategy incorrectly. (2) Quantitative accuracy is partially correct: $500 million and $77 million are accurate (allowing for 'million' clarification), and interest rates and maturities match. However, the addition of the $1 billion note retirement introduces a significant false quantitative claim. (3) The multi-hop reasoning is flawed because the LLM infers a strategic shift away from Japanese subsidiary debt and toward centralization, which is not supported by the original answer. The ground truth emphasizes increased transparency and use of fixed-rate, long-term debt through the subsidiary—not a reduction in reliance on it. The conclusion about 'consolidating and streamlining' is speculative and contradicts the original indication of expanded, more detailed subsidiary-level financing. (4) Contextual relevance is high because the answer addresses the evolution of the notes and attempts to interpret long-term strategy. However, due to factual inaccuracies and incorrect inference, the qualitative and correctness scores are moderate. The core facts about the subsidiary's notes are right, but the strategic interpretation is misaligned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 476,
        "total_tokens": 1846
      },
      "error": null
    },
    {
      "question_id": 81,
      "question": "How did the value of Cisco's available-for-sale debt investments change between 2022 and 2023, and what does this indicate about the company's investment strategy?",
      "original_answer": "In 2022, Cisco reported gains from available-for-sale debt investments at $9 million, indicating a relatively minor role in their investment portfolio. By 2023, the total value of these investments dropped significantly from $15,592 million to $9,865 million, a decrease of $5,727 million. This indicates a strategic reduction in the company's holdings of available-for-sale debt instruments, suggesting a shift in investment focus or risk management approach.",
      "llm_answer": "The available‑for‑sale debt investment balance fell sharply from $15,592 million at the end of fiscal 2023 to $9,865 million at the end of fiscal 2024—a decline of $5,727 million (≈37%). This reduction reflects Cisco’s use of cash to fund large‑scale acquisitions (notably the $27.5 billion Splunk purchase), repay debt, and return capital to shareholders through dividends and share repurchases, indicating a strategic shift toward prioritizing cash for acquisitions and shareholder returns over holding a large portfolio of debt securities.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors in dates and direction of change. The original answer states that Cisco's available-for-sale debt investments decreased from $15,592 million in 2022 to $9,865 million in 2023. However, the LLM incorrectly claims the drop was from 2023 to 2024, reversing the timeline and misrepresenting the fiscal years. This is a critical error in entity accuracy (time periods). (2) While the dollar amounts ($15,592M, $9,865M) and the calculated difference ($5,727M) are numerically correct and the 37% decline is approximately accurate, the misalignment in years undermines the quantitative accuracy. The calculation itself is sound, but applied to the wrong time frame. (3) The reasoning introduces new information not in the ground truth—specifically, the Splunk acquisition and use of cash for acquisitions/shareholder returns. While plausible context, this represents an unsupported inference and fails the multi-hop reasoning test, as the original data does not link the investment drop to these specific actions. The original answer correctly infers a strategic reduction but does so without overreaching into unverified causal claims. (4) The answer is contextually relevant and addresses both parts of the question (change in value and strategic implication), but the incorrect years and speculative reasoning significantly reduce correctness. The core numerical data is accurate, but the temporal inversion and unsupported causal explanation make the overall answer partially correct at best.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1254,
        "completion_tokens": 427,
        "total_tokens": 1682
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How has JPMorgan Chase's exposure to system damage risks evolved from 2023 to 2024, particularly in relation to third-party vendor attacks and data recovery challenges?",
      "original_answer": "In 2023, JPMorgan Chase highlighted risks related to system damage primarily through unauthorized access, zero-day vulnerabilities, and disruptions from distributed denial-of-service attacks. The company emphasized the risk of undetected vulnerabilities due to incomplete system enhancements and the potential for data loss or manipulation. By 2024, the exposure evolved to include more specific emphasis on ransomware attacks targeting third-party vendors and the risk of losses exceeding cyber insurance coverage. Additionally, JPMorgan Chase noted increased complexity in recovering from data theft or destruction, with a new concern around the inability to prevent systems from processing fraudulent transactions. These changes indicate a growing awareness of external cyber threats and their financial implications.",
      "llm_answer": "JPMorgan Chase’s exposure to system‑damage risks has risen from 2023 to 2024, driven by a growing reliance on third‑party vendors and heightened cyber‑threat sophistication.  The 2024 filing emphasizes that cyber attacks—especially ransomware and supply‑chain breaches targeting vendors—pose a more severe threat to operational continuity, data integrity and regulatory compliance, while data‑recovery challenges are amplified by the expanding interconnectivity of cloud, mobile and fintech platforms.  Consequently, the bank anticipates greater operational costs, potential litigation and reputational damage if these risks are not effectively managed.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the evolution of JPMorgan Chase's system-damage risks from 2023 to 2024 with a focus on third-party vendor attacks and data recovery challenges. It accurately notes increased emphasis on third-party risks and operational impacts. However, it omits specific details present in the ground truth, such as the shift toward ransomware attacks exceeding cyber insurance coverage and the new concern about systems processing fraudulent transactions undetected. While it mentions supply-chain breaches and ransomware, it does not explicitly state the financial risk of losses surpassing insurance limits, which is a key 2024 development. (2) There are no numeric values, percentages, or dollar amounts in either the original or LLM answer, so quantitative accuracy is not compromised—scored as 10 by default. (3) The multi-hop reasoning is partially sound: the model correctly infers increased third-party and data recovery risks from 2023 to 2024 and synthesizes the growing threat landscape. However, it fails to incorporate the specific evolution in risk characterization—particularly the inability to prevent fraudulent transaction processing and insurance coverage shortfalls—indicating incomplete synthesis across years. (4) The answer is contextually relevant and well-articulated, capturing the broader trend of increasing cyber risk exposure. The omission of key specific risks mentioned in the ground truth prevents a higher score, but core elements (third-party vendor attacks, data recovery complexity) are addressed with reasonable accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1373,
        "completion_tokens": 438,
        "total_tokens": 1812
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "What operational investments has Costco made by 2024 to support the private-label growth strategy mentioned in its 2022 filing?",
      "original_answer": "In 2022, Costco emphasized increasing the penetration of its private-label items as a merchandising strategy to manage inflationary pressures and maintain competitive pricing. By 2024, Costco had made tangible operational investments to support this strategy, including the operation of various processing, packaging, and manufacturing facilities dedicated to the production of private-label items. These facilities, referenced in the 2024 filing, represent a significant evolution from the earlier strategic focus, demonstrating a shift from sourcing private-label products externally to building internal production capabilities to scale the initiative.",
      "llm_answer": "Costco has invested in expanding its warehouse footprint and private‑label capabilities through the opening of new warehouses and the development of private‑label merchandise, as highlighted in its 2022 filing and reinforced by the 2024 updates on new warehouse openings and ongoing sustainability initiatives. These operational investments support its strategy to grow private‑label sales and increase overall membership revenue.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer is partially correct but misses key operational investments described in the ground truth. (1) Correct elements: The answer correctly identifies that Costco is investing in private-label growth, referencing both the 2022 strategy and 2024 updates. There are no numeric inaccuracies, so quantitative accuracy is high. (2) However, the LLM incorrectly identifies 'expanding warehouse footprint' and 'sustainability initiatives' as the primary operational investments supporting private-label growth, which is not supported by the original answer. The ground truth specifies that by 2024, Costco invested in internal processing, packaging, and manufacturing facilities dedicated to private-label production—representing a shift toward vertical integration. This critical detail is missing. (3) Multi-hop reasoning is partially sound—linking 2022 strategy to 2024 actions—but fails to synthesize the correct operational evolution from external sourcing to internal production. Instead, it substitutes with general warehouse expansion, which may support overall growth but is not specifically tied to private-label manufacturing. (4) Contextual relevance is moderate because the answer addresses private-label strategy and timelines, but the core operational investment is mischaracterized. Thus, while the direction is plausible, the factual specificity and qualitative accuracy are significantly lacking, warranting a mid-range score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1266,
        "completion_tokens": 397,
        "total_tokens": 1664
      },
      "error": null
    },
    {
      "question_id": 82,
      "question": "How did UnitedHealth Group's approach to Medicaid managed care contract bidding evolve between 2022 and 2023, particularly in terms of assumptions and risks associated with bid accuracy?",
      "original_answer": "In 2022, UnitedHealth Group emphasized the risk of losing Medicaid members if it failed to renew state Medicaid managed care contracts, highlighting the importance of contract renewals to retain enrolled members. By 2023, the company placed greater emphasis on the assumptions behind its bids, noting that if these assumptions—such as enrollment, utilization, and medical costs—were materially incorrect due to unforeseen program changes or competitor pricing, it could materially affect results of operations and cash flows. This reflects an evolution from a focus on contract renewal risk to a more detailed discussion of the assumptions and competitive dynamics involved in the bidding process itself.",
      "llm_answer": "UnitedHealth Group’s approach to Medicaid managed‑care bidding remained focused on submitting bids based on assumptions about enrollment, utilization, medical costs and related factors, but the risk of bid inaccuracy persisted. In 2023, as in 2022, inaccurate assumptions—such as unexpected enrollment shifts, policy changes, or lower competitor bids—could materially and adversely affect the company’s results of operations, financial position and cash flows.",
      "correctness_score": 6,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is partially correct but misses a key evolution in UnitedHealth Group's risk disclosure between 2022 and 2023, which is central to the question. (1) What was correct: The LLM accurately describes the types of assumptions used in bidding (enrollment, utilization, medical costs) and correctly notes that inaccurate assumptions could materially affect financial results in both years. The entities (UnitedHealth Group, Medicaid managed care), time periods (2022, 2023), and financial impacts are correctly identified. (2) Quantitative accuracy: There are no numerical values in the ground truth or LLM response, so this criterion is satisfied by default—no inaccuracies. (3) Multi-hop reasoning assessment: The question requires a comparison across two years to identify a shift in emphasis. The ground truth shows a clear evolution—from 2022's focus on contract renewal risk and member retention to 2023's focus on bid assumptions and competitive dynamics. The LLM fails to capture this shift, instead stating that the approach 'remained focused,' implying continuity rather than evolution. This misrepresents the core reasoning required. (4) Justification for scores: Correctness is 6 because key facts about bid assumptions and risks are present, but the critical evolution in focus is omitted. Qualitative accuracy is low (5) due to flawed reasoning and failure to synthesize the change over time. Quantitative accuracy is 10 (no numbers, no errors). Contextual relevance is 8 because the answer addresses Medicaid bidding risks but not the specific evolution asked for.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 433,
        "total_tokens": 1734
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How did MET's investment in Municipals evolve from 2022 to 2023, particularly in terms of its valuation hierarchy classification?",
      "original_answer": "In 2022, MET's investment in Municipals was valued at $14,212 million and primarily categorized under 'Estimated Fair Value' without a detailed breakdown of valuation hierarchy levels. By 2023, the investment in Municipals decreased to $159 million and was explicitly classified under 'Level 2' of the fair value hierarchy. This indicates a significant reduction in the size of the Municipals investment and a more transparent categorization within the fair value hierarchy in 2023.",
      "llm_answer": "From 2022 to 2023, MetLife’s investment in Municipals remained classified as Level 2 in the fair‑value hierarchy. In the 2023 table (page 308), the “Municipals” line shows $147 million classified as Level 2 (with no Level 1 or Level 3 amounts), and the same $147 million appears in 2022 (page 308), indicating no change in its valuation level. Thus, the Municipal holdings stayed in Level 2 throughout the period.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect in both quantitative and qualitative aspects. (1) Quantitatively, it states that MetLife's investment in Municipals was $147 million in both 2022 and 2023, which contradicts the ground truth: in 2022, the investment was $14,212 million, and in 2023 it dropped to $159 million. The LLM underreports the 2022 value by over $14 trillion (likely a typo or misreading), and slightly misstates the 2023 value ($147M vs $159M). (2) The ground truth states that in 2022, the Municipals investment was categorized under 'Estimated Fair Value' without a detailed breakdown of hierarchy levels, whereas the LLM claims it was explicitly classified as Level 2 in 2022 — this is factually wrong. Only in 2023 was the investment explicitly classified as Level 2. (3) The reasoning is flawed: the LLM asserts no change occurred, but the ground truth shows a massive reduction in investment size and an improvement in valuation transparency. The model fails the multi-hop requirement by not recognizing the shift from undifferentiated fair value reporting in 2022 to explicit Level 2 classification in 2023. (4) Contextual relevance is moderate because it addresses the right topic (valuation hierarchy of Municipals) and time frame, but with incorrect data and conclusions. Overall, the answer misrepresents both the magnitude of change and the evolution in disclosure clarity.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1219,
        "completion_tokens": 385,
        "total_tokens": 1604
      },
      "error": null
    },
    {
      "question_id": 84,
      "question": "How has Microsoft's approach to Office 365 subscriptions evolved in terms of licensing flexibility and customer agreement models from fiscal year 2022 to 2024?",
      "original_answer": "In fiscal year 2022, Office 365 subscriptions were primarily managed under volume licensing programs and were recognized as part of unearned revenue, invoiced annually at the beginning of each contract period and recognized ratably over the coverage period. By fiscal year 2024, Microsoft introduced more structured and flexible customer agreement models, including the Microsoft Customer Agreement, Microsoft Online Subscription Agreement, and Microsoft Products and Services Agreement, which allowed customers to subscribe to cloud services seamlessly and directly, with options for monthly or annual subscriptions and no organization-wide commitment. This represents a shift toward enhanced customer-centric licensing flexibility.",
      "llm_answer": "From fiscal 2022 through 2024 Microsoft’s licensing model for Office 365 shifted from a primarily on‑premises perpetual‑license/Software Assurance (SA) approach toward a cloud‑first subscription framework.  The 2022 10‑K notes that Office 365 is delivered as a cloud service on a subscription basis, with revenue recognized ratably over the contract term, and that Office 365’s desktop apps and cloud services are treated as a single performance obligation.  Subsequent pages (2023‑2024) describe the evolution of volume‑licensing vehicles—Enterprise Agreements, Microsoft Customer Agreements, Microsoft Online Subscription Agreements, and the Microsoft Products and Services Agreement—that now bundle perpetual licenses with optional SA and provide flexible, non‑expiring subscription terms.  This reflects a broader move to offer customers greater flexibility in choosing subscription‑only, term‑based, or perpetual‑plus‑SA options, and to simplify licensing through unified, digital agreements.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in terms of factual content and context, with accurate descriptions of Microsoft's shift toward more flexible subscription models and the introduction of agreements like the Microsoft Customer Agreement, Microsoft Online Subscription Agreement, and Microsoft Products and Services Agreement. It correctly identifies the ratable revenue recognition model and references the bundling of desktop and cloud services as a single performance obligation, consistent with the ground truth. Quantitatively, there are no specific numbers (e.g., dollar amounts, percentages) in the original or LLM answer, so accuracy is not compromised in that regard—scored as 10. However, the LLM introduces a minor inaccuracy by suggesting that in fiscal 2022, Office 365 was part of a 'primarily on-premises perpetual-license/Software Assurance (SA)' model. This mischaracterizes the model: by 2022, Office 365 was already a cloud-first, subscription-based service, not an on-premises model transitioning away from perpetual licenses. The ground truth emphasizes volume licensing and unearned revenue recognition, not a hybrid perpetual+SA framework. Additionally, the LLM implies that perpetual licenses are still bundled with subscription options in the new agreements, which is not supported by the ground truth—by 2024, the shift was toward direct, flexible cloud subscriptions without organization-wide commitments, not hybrid models. This affects qualitative accuracy, as the reasoning slightly misrepresents the evolution. Nonetheless, the core of the answer—increased licensing flexibility, new agreement structures, and customer-centric models—is correct and relevant. Contextual relevance is high as it directly addresses the evolution in licensing and agreement models from 2022 to 2024.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1435,
        "completion_tokens": 488,
        "total_tokens": 1924
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did the composition of MET's Level 3 Fixed Maturity Securities AFS change between 2022 and 2023, and what does this indicate about the company's investment strategy?",
      "original_answer": "In 2022, MET's Level 3 Fixed Maturity Securities AFS included $1 million in Corporate bonds, $1 million in Foreign Bonds, and $11 million in Equity Securities. By 2023, the Level 3 composition shifted significantly, with $54 million in Corporate bonds, $2 million in Foreign Bonds, and $828 million in Other Investments. This indicates a strategic shift toward increasing exposure in Other Investments while maintaining a relatively small position in Level 3 fixed maturity securities overall. The significant increase in Other Investments within Level 3 suggests a more aggressive approach to portfolio diversification or risk management.",
      "llm_answer": "Between 2022 and 2023, the composition of MET's Level 3 Fixed Maturity Securities AFS shifted significantly: corporate bonds decreased from $55 million to $54 million, foreign bonds rose from $2 million to $8 million, and other investments (primarily Level 3) increased from $3 million to $8 million, while the total Level 3 balance grew from $58 million to $64 million. This indicates a modest reallocation toward foreign bonds and alternative assets, reflecting a strategy to diversify holdings and potentially enhance yield or manage duration within the fixed‑maturity portfolio.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, MET's Level 3 Fixed Maturity Securities AFS consisted of $1M in Corporate bonds, $1M in Foreign Bonds, and $11M in Equity Securities—not $55M, $2M, and $3M as stated. In 2023, the correct values are $54M in Corporate bonds, $2M in Foreign Bonds, and $828M in Other Investments, not $54M, $8M, and $8M. The LLM incorrectly reports a total Level 3 balance increase from $58M to $64M, which does not align with the ground truth composition (which would sum to $13M in 2022 and $884M in 2023). (2) The quantitative inaccuracies are severe: corporate bonds were $1M (not $55M) in 2022, foreign bonds did not rise to $8M (they decreased to $2M), and 'Other Investments' surged to $828M (not $8M). The LLM underreports this key shift by two orders of magnitude. (3) The multi-hop reasoning is flawed—the LLM fails to recognize the strategic pivot toward 'Other Investments' as a major risk or diversification move, instead characterizing changes as 'modest reallocation.' It misses the elimination of Equity Securities and the massive increase in Other Investments, which is central to the correct interpretation. (4) While the answer addresses the question's structure and attempts to infer strategy, the severe numerical errors and mischaracterization of the portfolio shift undermine both qualitative and quantitative accuracy. Contextual relevance is moderate because the response follows the right format and discusses strategy, but factual correctness is very low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1311,
        "completion_tokens": 432,
        "total_tokens": 1743
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How has Microsoft's strategic positioning of Office 365 evolved between 2022 and 2024, particularly in terms of its role within the broader cloud services portfolio and its response to competitive pressures from AI-driven offerings?",
      "original_answer": "In 2022, Office 365 was explicitly listed as a key component of Microsoft's service and other revenue, positioned alongside Azure, Dynamics 365, and Xbox as a core cloud-based solution. By 2024, Office 365 had evolved into a more integrated part of Microsoft’s broader AI-infused cloud services portfolio, reflecting the company's strategic shift to infuse generative AI capabilities into commercial offerings. The 2024 filing notes that Microsoft is devoting significant resources to develop and deploy AI models, platforms, and infrastructure to meet customer needs, indicating that Office 365 is now part of this AI-enhanced competitive strategy. This shift was driven by increasing competitive pressures from companies entering the AI market and offering alternative models such as free applications funded by advertising or open-source AI models, which Microsoft must counter with enhanced, integrated cloud experiences.",
      "llm_answer": "Microsoft's strategic positioning of Office 365 has evolved from a standalone on-premises productivity suite to a core component of its integrated cloud services portfolio, with revenue recognized ratably over time due to its interdependent desktop and cloud components. This evolution reflects a deliberate shift toward subscription-based, AI-enhanced offerings (e.g., Office 365 E3/E5 with Copilot) to counter competitive pressures from AI-driven platforms like Google Workspace and Amazon Web Services, while maintaining its role as a key revenue driver within Microsoft's broader cloud strategy (Azure + Office 365).",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of strategic evolution, competitive context, and integration into Microsoft's cloud and AI strategy. (1) There are no numeric values in the question or answers, so quantitative accuracy is not applicable—scored as 10 by default since no numbers were misstated. (2) The LLM correctly identifies the shift in Office 365’s positioning from a core cloud service in 2022 to an AI-integrated offering by 2024, noting its role within the broader cloud portfolio (e.g., alongside Azure), which matches the original answer. It also correctly references competitive pressures from AI-driven platforms like Google Workspace and AWS, consistent with the ground truth’s mention of competitive threats from advertising-funded or open-source AI models. (3) The multi-hop reasoning is sound: the answer synthesizes Office 365’s evolution, its integration with AI (e.g., Copilot in E3/E5 plans), and competitive dynamics. However, it slightly overreaches by specifying 'Office 365 E3/E5 with Copilot' and 'subscription-based' enhancements without explicit confirmation from the original answer, which does not name specific licensing tiers or Copilot. While factually plausible and contextually reasonable, this detail is not present in the ground truth, making it an inference beyond the provided data. Also, the LLM incorrectly frames Office 365 as having evolved 'from a standalone on-premises productivity suite', which misrepresents the timeline—the shift from on-premises to cloud occurred well before 2022. The original answer starts the analysis in 2022 with Office 365 already established as a cloud service. This minor historical inaccuracy affects qualitative precision. (4) Despite these nuances, the core facts—strategic integration into AI-enhanced cloud services, competitive response, and role in Microsoft’s cloud revenue—are accurately conveyed. Hence, correctness and qualitative accuracy are high but not perfect. Contextual relevance is excellent as all parts of the question are addressed directly and appropriately.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1407,
        "completion_tokens": 562,
        "total_tokens": 1969
      },
      "error": null
    },
    {
      "question_id": 85,
      "question": "How did UnitedHealth Group's recognition and handling of credit-related impairments evolve between 2022 and 2023, particularly in terms of their evaluation methodology and financial impact?",
      "original_answer": "In 2022, UnitedHealth Group evaluated available-for-sale debt securities for credit-related impairments by analyzing expected cash flows, underlying credit quality, and credit ratings of issuers, concluding that there was no significant credit deterioration since purchase and that unrealized losses were primarily due to interest rate increases. The allowance for credit losses was not material. By 2023, the company formalized its impairment recognition process by distinguishing between credit-related and non-credit-related impairments, recording credit-related impairments as an allowance against investment income and non-credit-related impairments through other comprehensive income. Additionally, the company emphasized a more structured evaluation framework that includes present value of expected cash flows, the extent of fair value decline relative to amortized cost, and issuer-specific financial conditions. This reflects a more detailed and segmented approach to impairment recognition and financial reporting.",
      "llm_answer": "UnitedHealth Group's handling of credit-related impairments for available-for-sale debt securities remained consistent in methodology between 2022 and 2023, relying on discounted cash flow analysis, issuer credit quality assessments, and fair value comparisons to amortized cost. While the 2023 document confirms no material credit-related impairments were recorded (stating \"the allowance for credit losses... was not material\" as of December 31, 2023), the evaluation criteria and processes for assessing impairment—particularly regarding issuer financial condition and expected cash flows—were unchanged from prior periods, with no significant credit deterioration observed in the portfolio.",
      "correctness_score": 3,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 3,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core claim that UnitedHealth Group's methodology remained 'unchanged' between 2022 and 2023. The ground truth states that in 2023, the company formalized a new, more structured approach by distinguishing between credit-related and non-credit-related impairments, recording them differently in financial statements (allowance against investment income vs. other comprehensive income), and enhancing its evaluation framework. The LLM incorrectly asserts no change occurred. (2) Quantitatively, the answer correctly notes that the allowance for credit losses was 'not material' in both years, which aligns with the ground truth and is accurately represented. There are no numerical discrepancies, though the focus on lack of materiality downplays the methodological evolution. (3) The multi-hop reasoning fails because the model does not synthesize the evolution in accounting treatment and evaluation criteria over time. Instead, it assumes consistency without acknowledging the shift in segmentation and reporting of impairments, which is central to the question. (4) While the answer is contextually relevant—discussing impairment evaluation, cash flows, and credit quality—it misses the key qualitative shift in methodology, leading to a low correctness and qualitative accuracy score despite acceptable quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1440,
        "completion_tokens": 385,
        "total_tokens": 1826
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did the allocation and valuation of Fixed Maturity Securities AFS in MET's pension and other postretirement benefit plans evolve from 2022 to 2023?",
      "original_answer": "In 2022, Fixed Maturity Securities AFS accounted for 84% of U.S. Pension Benefits and 95% of U.S. Other Postretirement Benefits. By 2023, the total estimated fair value of Fixed Maturity Securities AFS was $6,714 million for Pension Benefits and $1,274 million for Other Postretirement Benefits. This indicates a shift from a primarily percentage-based allocation in 2022 to a more detailed valuation breakdown in 2023, showing both the scale and composition of MET's holdings.",
      "llm_answer": "The allocation of Fixed Maturity Securities AFS in MET’s pension and other postretirement benefit plans shifted slightly from 2022 to 2023, with corporate holdings declining marginally from $2,946 million to $3,029 million and U.S. government bonds increasing from $1,462 million to $1,537 million; overall, total fixed‑maturity AFS rose from $6,802 million (2022) to $6,714 million (2023) while the proportion of Level 2 assets grew and Level 3 holdings remained minimal. Valuation-wise, the fair‑value hierarchy placed the majority of these securities in Level 2 (e.g., $4,924 million in 2023 versus $5,091 million in 2022), with only modest Level 3 amounts ($64 million in 2023 vs. $58 million in 2022), reflecting a stable but slightly re‑weighted composition of corporate, government, foreign, and municipal bonds across the two years.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, Fixed Maturity Securities AFS were reported as percentages of total allocations (84% for U.S. Pension Benefits and 95% for U.S. Other Postretirement Benefits), but the LLM incorrectly presents dollar amounts for 2022 ($6,802 million total) and breaks down corporate and government holdings that are not in the original answer. The 2023 fair values in the ground truth are $6,714 million (Pension) and $1,274 million (Other Postretirement), but the LLM combines these or misattributes them, claiming total fixed-maturity AFS declined to $6,714 million in 2023 without separating the two benefit types. The LLM introduces granular data (e.g., Level 2/Level 3 valuations, corporate vs. government bonds) that are not present or verifiable from the original answer. (2) Calculations and numbers are largely fabricated: the original answer does not provide a 2022 total dollar value, so the $6,802 million figure has no basis; the split between corporate and government securities is also absent in the ground truth. The LLM’s claim of a decline from $6,802M to $6,714M contradicts the ground truth, which only gives 2023 dollar values and 2022 percentages—no direct comparison can be made. (3) Multi-hop reasoning is flawed: the model fails to recognize that the 2022 data is percentage-based while 2023 is valuation-based, which is the key evolution highlighted in the original answer. Instead, it assumes comparable dollar figures exist for both years and invents a trend. It also introduces fair value hierarchy details (Level 2/3) not mentioned in the ground truth, indicating hallucination. (4) The contextual relevance is moderate because the answer addresses the general topic—evolution of allocation and valuation of Fixed Maturity Securities AFS—but the qualitative and quantitative inaccuracies severely undermine correctness. The core insight from the original answer (shift from percentage allocation to explicit valuation) is missed entirely. Thus, the correctness score is low due to major factual and reasoning errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1330,
        "completion_tokens": 573,
        "total_tokens": 1904
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did Lowe's strategic positioning of the Kitchens & Bath product category evolve between 2022 and 2023, and what does this suggest about its relative importance in the company's product portfolio?",
      "original_answer": "In 2022, Kitchens & Bath was grouped under the Home Décor division alongside categories like Appliances, Décor, Flooring, and Paint, suggesting a more design-focused positioning. By 2023, Kitchens & Bath was listed among core construction and renovation categories such as Lumber, Building Materials, and Rough Plumbing, indicating a strategic repositioning toward home improvement and remodeling. This shift suggests that Lowe's placed greater strategic emphasis on Kitchens & Bath as a key growth area tied to higher-value home projects, aligning with its broader 'Total Home' strategy.",
      "llm_answer": "Between 2022 and 2023, Lowe's strategic positioning of the Kitchens & Bath product category evolved from being part of the broader Home Décor segment (which includes Kitchens & Bath) to being explicitly highlighted as a key category within the Home Décor segment in the 2023 sales breakdown. The 2023 data shows Home Décor (including Kitchens & Bath) accounted for 35.3% of total sales ($34,025M), up from 35.2% in 2022 ($31,536M), indicating sustained and growing strategic emphasis on this category. This reflects its relative importance as a core growth driver within Lowe's product portfolio, particularly as part of the \"Elevate assortment\" pillar of its Total Home strategy, though it remains secondary to Building Products (32.4% in 2023) and Hardlines (29.7% in 2023) in overall revenue contribution.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. Most critically, it incorrectly states that Kitchens & Bath remained within the Home Décor segment in 2023, when the ground truth confirms it was repositioned into a construction and renovation grouping (with Lumber, Building Materials, etc.), indicating a strategic shift in categorization. This misrepresents the core evolution of strategic positioning. (2) The quantitative data is fabricated: the LLM provides specific sales figures ($34,025M in 2023, $31,536M in 2022) and percentages (35.3%, 35.2%) for Home Décor including Kitchens & Bath, but these numbers do not appear in the ground truth and cannot be verified. There is no mention of such figures in the original answer, nor are they consistent with public 10-K filings for those years. The claim that Building Products was 32.4% and Hardlines 29.7% in 2023 is also unsupported by the provided truth. (3) The multi-hop reasoning is flawed: while the LLM attempts to infer strategic importance from sales share, it fails to recognize the organizational reclassification as a signal of strategic repositioning toward remodeling and higher-value projects. Instead, it assumes continuity within Home Décor, contradicting the ground truth. (4) Despite these errors, the answer is contextually relevant—it addresses the question's intent about strategic importance and ties Kitchens & Bath to the 'Total Home' strategy, which aligns thematically with the ground truth. However, the incorrect entity grouping and invented metrics severely undermine factual correctness, warranting a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1362,
        "completion_tokens": 447,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How has Mondelez International's strategic focus on Cheese & Grocery evolved between 2022 and 2024, and what does this suggest about its prioritization of snack categories for long-term growth?",
      "original_answer": "In 2022, Mondelez directly produced Cheese & Grocery products, generating $1,990 million in total net revenues from this category. By 2024, the company no longer reported direct production in this category and instead indicated only a strategic stake in Cheese & Grocery, positioning it as an adjacent category within its broader snacking portfolio. This shift suggests a refocusing on core snack categories like biscuits and chocolate, while maintaining a presence in Cheese & Grocery through a lighter footprint. The change aligns with Mondelez's stated strategy of prioritizing long-term growth in core snacking segments and managing costs amid inflationary pressures.",
      "llm_answer": "Between 2022 and 2024, Mondelez International’s strategic focus on Cheese & Grocery evolved from a niche, opportunistic expansion into a more deliberate, growth‑oriented priority. In 2022 the company acquired Cheese & Grocery businesses (e.g., Clif Bar and Chipita) to broaden its snack portfolio, and by 2024 it was actively integrating these assets while emphasizing “snacking” as its core mission, signaling that Cheese & Grocery is now a key pillar for long‑term, sustainable growth rather than a peripheral add‑on. This shift reflects a prioritization of high‑margin, globally scalable snack categories—particularly cheese‑based and grocery‑adjacent products—to drive future revenue and earnings expansion.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer is largely incorrect and contradicts the ground truth in both direction and substance. (1) Quantitatively, the answer fabricates acquisitions (Clif Bar, Chipita) and omits the actual $1,990 million revenue figure from Cheese & Grocery in 2022, which is a key data point in the original answer. There are no correct numbers cited. (2) The qualitative reasoning is flawed: the ground truth states Mondelez exited direct production in Cheese & Grocery by 2024 and reduced its involvement to a strategic stake, whereas the LLM claims the opposite—that the company deepened its commitment and integrated these assets as a 'key pillar' for growth. This is a fundamental inversion of the actual strategic shift. (3) The multi-hop reasoning fails: instead of synthesizing the reduction in direct operations and repositioning as an adjacent category, the model incorrectly infers expansion and integration. (4) Contextually, the answer addresses the general theme of strategic focus on snack categories, but misrepresents the direction of change and the nature of Mondelez's actions, leading to an incorrect conclusion about prioritization. The model appears to confuse Mondelez with another company or misattribute acquisition activity. Overall, the answer is factually wrong on core elements, with significant errors in entities, strategy direction, and financial data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 380,
        "total_tokens": 1737
      },
      "error": null
    },
    {
      "question_id": 86,
      "question": "How did Abbott's presentation of its enteral feeding product lineup, specifically the positioning of Jevity relative to Freego™ products, change between the 2022 and 2023 10-K filings?",
      "original_answer": "In the 2022 10-K filing, Jevity was listed first among enteral feeding products, followed by Glucerna 1.2 Cal, Glucerna 1.5 Cal, Osmolite®, Oxepa®, Freego™ (Enteral Pump), and Freego™ sets. In the 2023 filing, Jevity remained listed first, but the Freego™ (Enteral Pump) and Freego™ sets were now mentioned immediately after Jevity, before the Glucerna and Osmolite® product lines. This change in listing order suggests a shift in product emphasis within the enteral feeding category, with Freego™ products receiving more prominent placement alongside Jevity in 2023 compared to 2022.",
      "llm_answer": "Abbott’s 10‑K presentation of its enteral‑feeding portfolio shows a shift in how it positions Jevity relative to the Freego™ line.  In the 2022 filing the Jevity products are highlighted as the core “enteral nutrition” offering and are placed alongside other legacy formulas (e.g., Glucerna 1.2 Cal, Osmolite), while Freego™ is mentioned only as a separate pump‑system brand.  By the 2023 filing the narrative reframes the lineup, positioning Freego™ (the enteral pump and its accessories) as a distinct, stand‑alone product family and moves Jevity to a secondary, “nutritional‑product” category, emphasizing its role as a “standard” formula rather than the flagship enteral solution.  This repositioning reflects a clearer separation of the pump hardware (Freego™) from the liquid formulas (Jevity).",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in its characterization of Abbott's product lineup presentation in the 2022 and 2023 10-K filings. While it correctly identifies Jevity and Freego™ as part of the enteral feeding product portfolio and references the correct years, it fabricates a narrative not supported by the ground truth. According to the original answer, the change was purely in the *order of listing*: in 2022, Jevity was listed first, followed by Glucerna, Osmolite®, Oxepa®, and then Freego™ products; in 2023, Jevity remained first, but Freego™ (Enteral Pump) and Freego™ sets were moved up immediately after Jevity, before Glucerna and Osmolite®. This indicates a shift in emphasis, not a reclassification. However, the LLM incorrectly claims that in 2023, Jevity was demoted to a 'secondary' role and reframed as a 'standard' formula, while Freego™ was elevated as a 'stand-alone product family' and Jevity was separated into a 'nutritional-product category'. There is no evidence in the ground truth that Jevity was demoted or that the company reframed it as secondary or non-flagship. The ground truth only reports a change in listing order, not a narrative or categorical repositioning. The LLM introduces interpretive claims about 'narrative reframing' and 'clearer separation' that are not present in the source data. Quantitatively, there are no numbers to verify, so accuracy is scored as 10 by default. Contextually, the answer addresses the right topic and companies, but the reasoning is flawed and the synthesis is incorrect—this is not a valid multi-hop inference from the data provided. The qualitative accuracy is low because the entities and years are correct, but the interpretation of the relationship and positioning is factually wrong.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 478,
        "total_tokens": 1833
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did MET's investment in municipals evolve from 2022 to 2023 in terms of fair value and classification, and what does this suggest about the company's credit risk management strategy?",
      "original_answer": "In 2022, MET held $14,212 million in municipals, classified under the 'fixed maturity securities AFS' category, with a fair value that included $2,464 million in gross unrealized gains and only $13 million in gross unrealized losses. By 2023, this investment had significantly declined to just $159 million, now categorized under the 'fixed maturity securities AFS' and classified entirely within Level 2 of the fair value hierarchy, indicating a shift in MET's positioning. This dramatic reduction suggests a strategic move to reduce credit exposure to municipals, likely as part of a broader risk management adjustment to limit potential losses in this asset class.",
      "llm_answer": "From 2022 to 2023, MetLife’s municipal holdings in its fixed‑maturity AFS portfolio declined modestly in fair‑value hierarchy classification—remaining Level 2 in both years—but the dollar amount fell from $159 million (2022) to $147 million (2023). This reduction reflects a deliberate shift toward higher‑quality, lower‑risk assets, indicating that the company is tightening its credit‑risk exposure within the municipal sector as part of its broader risk‑management strategy.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors. According to the ground truth, MET's municipal holdings were $14,212 million in 2022, not $159 million as stated by the LLM. The LLM incorrectly reports that holdings declined from $159M (2022) to $147M (2023), when in reality the decline was from $14,212M to $159M—a massive reduction, not a modest one. Additionally, the LLM fails to mention the $2,464 million in gross unrealized gains and $13 million in gross unrealized losses in 2022, which are key indicators of portfolio health and risk. (2) The quantitative inaccuracies are severe: the dollar amounts are off by over an order of magnitude, and the direction of the timeline is effectively reversed (the LLM implies a small decline from 159 to 147, but the truth is a drop from over 14,000 to 159). No correct calculations can be derived from these wrong inputs. (3) The reasoning is partially sound in interpreting the reduction as a credit risk management move, which aligns with the ground truth’s conclusion. However, because the multi-hop synthesis is based on incorrect data (wrong amounts, no mention of unrealized gains/losses), the reasoning is undermined. The LLM correctly identifies the classification as 'fixed maturity securities AFS' and Level 2 in 2023, but incorrectly implies it was also Level 2 in 2022 without specifying that the 2022 data included different hierarchy levels or that the 2023 classification is newly narrowed to Level 2. (4) The contextual relevance is moderate because the answer addresses the right topic—MET's municipal investments and credit risk strategy—but the severe numerical errors and missing key details (especially the scale of divestment and unrealized gains) drastically reduce its factual value. Correctness is scored very low due to fundamental data inaccuracies.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1296,
        "completion_tokens": 499,
        "total_tokens": 1795
      },
      "error": null
    },
    {
      "question_id": 87,
      "question": "How did Abbott's use of interest rate hedge contracts evolve between 2022 and 2023, particularly in terms of their notional value and the impact on fixed-rate debt management?",
      "original_answer": "In 2022, Abbott had interest rate hedge contracts totaling approximately $2.2 billion, which were used to manage exposure to changes in the fair value of fixed-rate debt by converting fixed-rate obligations into variable-rate obligations. By 2023, Abbott continued to use these contracts for the same purpose, and the notional value remained consistent at approximately $2.2 billion. However, in 2023, the company provided more detailed disclosures about the impact of these contracts on the carrying value of fixed-rate debt, indicating a more refined approach to interest rate risk management.",
      "llm_answer": "Abbott’s interest rate hedge contracts remained roughly stable in notional value, decreasing slightly from about $2.9 billion at the end of 2022 to approximately $2.2 billion by the end of 2023.  The reduction reflects the maturity of $700 million of hedges in 2023, but the hedges continue to convert a portion of its fixed‑rate debt to variable rates, thereby managing the fair‑value exposure of its fixed‑rate borrowings.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. According to the ground truth, Abbott's notional value of interest rate hedge contracts was approximately $2.2 billion in both 2022 and 2023, with no decrease. However, the LLM claims a drop from $2.9 billion in 2022 to $2.2 billion in 2023, which is incorrect. The mention of a $700 million maturity in 2023 is unsupported by the original answer and introduces a fabricated detail. (2) The quantitative accuracy is low because the starting notional value is wrong ($2.9B vs $2.2B), and the implied reduction of $700M is not present in the ground truth. The correct answer states the value remained consistent, so any suggestion of change is erroneous. (3) Qualitatively, the LLM correctly identifies the purpose of the hedges—converting fixed-rate debt to variable-rate to manage fair-value exposure—which aligns with the original answer. It also correctly frames the ongoing use of hedges for interest rate risk management. However, it fails to mention the key qualitative evolution noted in the ground truth: Abbott’s enhanced disclosure and more refined approach in 2023, which reflects a maturation in reporting and risk management transparency. This omission weakens the multi-hop synthesis, as the evolution aspect of the question is underaddressed. (4) Contextual relevance is high because the answer stays focused on Abbott, interest rate hedges, notional value, and debt management, addressing the core intent of the question. Despite incorrect numbers, the conceptual framework is appropriate. Overall, the answer is partially correct in intent and purpose but fails on key facts and completeness of the evolution narrative.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1262,
        "completion_tokens": 476,
        "total_tokens": 1738
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How did 3M's issuance and management of fixed rate registered notes evolve between 2022 and 2024, particularly in terms of repayment activity and interest rate strategies?",
      "original_answer": "In 2022, 3M had a significant amount of fixed rate registered notes, including $600 million of 10-year notes due 2030 with a coupon rate of 3.05%, and $650 million of 30-year notes due 2050 with a coupon rate of 3.70%. The company also issued $3.25 billion in fixed rate registered notes in August 2019, including $1.0 billion of 10-year notes due 2029 and $1.0 billion of 30-year notes due 2049. In 2024, 3M repaid $1.1 billion in medium-term notes that matured, and in 2023, it repaid $500 million in fixed-rate registered notes. Additionally, interest rate swaps initiated in 2021 converted portions of the fixed-rate notes due 2049 and 2050 into floating-rate debt through mid-2028, indicating a strategic shift toward managing interest rate exposure. This shows a decrease in the amount of fixed-rate debt outstanding and a shift toward floating-rate instruments through swaps.",
      "llm_answer": "Between 2022 and 2024 3M’s fixed‑rate registered notes were issued in 2022 ($1.75 bn of 5‑, 10‑ and 30‑year notes) and in 2023 ($2.25 bn of 3‑, 5‑, 10‑ and 29.5‑year notes) and 2024 ($3.25 bn of 3.5‑, 5.5‑, 10‑ and 30‑year notes).  Each issuance carried a fixed coupon (ranging from 1.75 % to 4.00 %) and was later swapped to floating‑rate exposure for portions maturing through mid‑2028.  Repayment activity shows that in 2024 3M retired $1.1 bn of medium‑term notes that matured, while in 2023 it repaid $500 million of fixed‑rate registered notes and $650 million of fixed‑rate medium‑term notes, and in 2022 it retired €600 million and $600 million of fixed‑rate medium‑term notes.  The company also used interest‑rate swaps (e.g., an $800 million swap in 2021) to convert portions of its long‑dated fixed‑rate debt into floating‑rate debt, thereby managing interest‑rate risk and shaping its overall interest‑rate strategy.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in both issuance amounts and years. The ground truth states that 3M issued $3.25 billion in fixed-rate notes in *August 2019*, not in 2022–2024 as the LLM claims. The LLM incorrectly states that 3M issued $1.75B in 2022, $2.25B in 2023, and $3.25B in 2024 — none of which are supported by the original answer. Additionally, the original answer does not mention any note issuances by 3M in 2022, 2023, or 2024, only repayments. The LLM fabricates issuance activity during this period. (2) Regarding repayment activity, the LLM correctly notes the $1.1B repayment in 2024 (medium-term notes) and the $500M repayment of fixed-rate registered notes in 2023, which aligns with the ground truth. However, it incorrectly adds a $650M repayment of medium-term notes in 2023 and claims 3M retired €600M and $600M of medium-term notes in 2022 — none of which are mentioned in the original answer. The original answer only specifies outstanding notes from prior years (e.g., 2019 issuance) and does not mention 2022 repayments. (3) On interest rate strategies, the LLM correctly identifies the use of interest rate swaps initiated in 2021 to convert long-dated fixed-rate debt (due 2049 and 2050) into floating-rate through mid-2028, which matches the original answer. It also correctly frames this as a strategy to manage interest rate risk. However, it invents a specific $800M swap not mentioned in the ground truth. (4) While the LLM captures the general strategic shift toward floating-rate via swaps, it completely misrepresents the issuance timeline and invents multiple transactions not present in the source. This undermines the multi-hop reasoning, as it fails to correctly synthesize the evolution of debt management — instead implying new issuances during 2022–2024 when the actual trend was repayment and conversion via swaps of older debt. The contextual relevance is moderate because it addresses the right themes (issuance, repayment, swaps), but the factual foundation is largely incorrect. Quantitative accuracy is very low due to fabricated dollar amounts, years, and instruments. Qualitative accuracy is partially correct on strategy but flawed in entity and temporal alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1458,
        "completion_tokens": 603,
        "total_tokens": 2062
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has the role of securities issuances in Schwab's capital structure evolved between 2023 and 2024, particularly in relation to its overall funding sources and capital management strategy?",
      "original_answer": "In 2023, securities issuances by CSC were identified as a primary source of capital, directly supporting the company's capital management strategy, which included balance sheet growth and financial support to subsidiaries. By 2024, while still listed as one of several funding sources, securities issuances were positioned among a broader set of liquidity tools, including FHLB borrowings, repurchase agreements, and CDs, indicating a more diversified funding approach. This shift suggests a strategic evolution where securities issuances remain important but are more integrated within a wider capital structure framework.",
      "llm_answer": "Based on the 2023 and 2024 SEC filings, Schwab's capital structure strategy evolved significantly through active debt issuance and regulatory capital management. In 2023, the company issued $7.35 billion in new senior unsecured debt (including $3.5B in May 2023 and $1.35B in August 2023 at higher rates), while redeeming all floating-rate notes in February 2024. This coincided with a strategic shift to include AOCI in regulatory capital calculations (as proposed by the Fed), leading to a higher Common Equity Tier 1 ratio (24.5% in 2023 vs. 21.9% in 2022) and a strengthened leverage ratio (8.5% in 2023 vs. 7.2% in 2022). Schwab maintained its capital management focus on returning excess capital to shareholders via dividends (targeting 20-30% of net income) while ensuring sufficient capital buffers to meet regulatory requirements and support subsidiary funding needs, particularly through brokered CDs and FHLB borrowings.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies and introduces unsupported quantitative details not present in the ground truth. (1) Quantitative Accuracy: The LLM claims Schwab issued $7.35 billion in senior unsecured debt in 2023, including specific tranches ($3.5B in May, $1.35B in August), and redeemed floating-rate notes in February 2024. These specific issuances and redemptions are not mentioned in the ground truth and cannot be verified from the provided information. Additionally, the reported capital ratios (24.5% CET1 in 2023, 21.9% in 2022, leverage ratio 8.5% in 2023) are not present in the original answer and appear fabricated. (2) Completeness: While the question asks about the evolution of securities issuances in capital structure and funding sources, the LLM focuses heavily on debt issuance details and regulatory capital changes not supported by the ground truth, missing the core narrative of diversification of funding sources. (3) Entity Accuracy: The company (Schwab/CSC) and general concepts (securities issuances, FHLB borrowings, CDs) are correctly identified, but specific financial instruments and dates are incorrectly attributed. (4) Reasoning: The LLM attempts multi-hop reasoning by linking debt activity to capital management and subsidiary support, but the logic is built on incorrect data. The ground truth emphasizes a strategic shift toward diversified funding (including FHLB, repos, CDs) with securities issuances becoming one of many tools, whereas the LLM overemphasizes debt issuance without clearly articulating the broader strategic evolution in funding mix. (5) Semantic Equivalence: The LLM answer is not semantically equivalent to the ground truth—it introduces a different narrative centered on specific debt transactions and regulatory capital changes rather than the evolution of securities issuances within a diversified funding framework. While it mentions some correct elements (e.g., subsidiary funding, use of FHLB and CDs), the emphasis and factual basis are misaligned. Thus, the answer is partially correct in context but fails on key factual and quantitative dimensions.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1399,
        "completion_tokens": 572,
        "total_tokens": 1972
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How did Coca-Cola's contingent payment obligations related to fairlife evolve from 2022 to 2024, and what does this indicate about fairlife's performance against its financial targets?",
      "original_answer": "In 2022, Coca-Cola disclosed that it had a $270 million liability for contingent milestone payments related to its acquisition of fairlife, based on fairlife achieving certain financial targets through 2024. The company also noted that the first milestone payment of $100 million was made in 2021 after fairlife met its 2020 targets. By 2024, the remaining contingent payment was described as a milestone payment contingent on fairlife achieving certain financial targets through 2024 and was payable in 2025. This indicates that fairlife had met at least one set of financial targets (2020), triggering the initial $100 million payment, and that the company remained on track to potentially meet the remaining targets through 2024, as the obligation was still active and had not been rescinded or adjusted downward.",
      "llm_answer": "Coca-Cola's contingent payment obligations related to fairlife decreased from $6,126 million at the end of 2023 to $6,148 million at the end of 2024, but this reflects the inclusion of the full liability amount in the fair‑value hierarchy disclosures rather than an actual increase in the obligation. The key indicator of fairlife’s performance is that the company has met the financial targets required for milestone payments through 2024, prompting the recognition of the remaining contingent consideration and the associated $275 million milestone payment in 2023, which demonstrates that fairlife is on track to achieve its agreed‑upon financial objectives.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains major factual inaccuracies. The contingent payment obligation is stated as decreasing from $6,126 million to $6,148 million, which is both numerically incorrect and nonsensical (a decrease to a higher number). The actual contingent liability was $270 million in 2022, with a $100 million payment already made in 2021. The LLM claims a $275 million milestone payment was made in 2023, which contradicts the ground truth stating the remaining obligation was still contingent and payable in 2025. (2) Quantitative accuracy is extremely low: the numbers cited ($6.1B range) are off by an order of magnitude compared to the correct $270M liability. The $275M payment in 2023 is fabricated; no such payment is mentioned in the ground truth. (3) The reasoning is flawed: the LLM incorrectly infers that the obligation was recognized due to targets being met, while the ground truth indicates the obligation remained active and no final determination was made by 2024. It fails to mention the $100M payment in 2021 for 2020 targets, a key data point showing past performance. (4) Contextual relevance is moderate because the answer addresses contingent payments and fairlife's performance, but the severe factual and numerical errors undermine the response. The conclusion about fairlife being 'on track' is speculative and not as nuanced as the original answer, which noted the obligation remained active but not yet paid. Overall, the answer misrepresents the financial data and timeline, leading to an incorrect assessment of fairlife's performance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 434,
        "total_tokens": 1813
      },
      "error": null
    },
    {
      "question_id": 89,
      "question": "How has Oracle's strategic emphasis on Oracle Cloud Infrastructure (OCI) evolved between 2022 and 2024, particularly in terms of its global market positioning and integration with enterprise IT solutions?",
      "original_answer": "In 2022, Oracle's financial disclosures emphasized revenue contributions from cloud and license businesses, which generated $36.052 billion, representing 85% of total revenues, with no explicit strategic language about Oracle Cloud Infrastructure's positioning. By 2024, Oracle significantly elevated OCI's role, describing it as a core component of Oracle Cloud Services alongside SaaS, and emphasizing its ability to provide 'comprehensive and integrated applications and infrastructure services' that enable customers to choose deployment models best suited to their needs. This reflects a clear strategic shift toward positioning OCI as a central pillar in Oracle’s enterprise IT offerings, not just a contributor to cloud revenue.",
      "llm_answer": "Oracle's strategic emphasis on Oracle Cloud Infrastructure (OCI) has evolved from a complementary offering to a central pillar of its cloud strategy, with increasing integration into enterprise IT solutions. By fiscal 2024, OCI is positioned as a key growth driver, supported by significant investments in infrastructure (e.g., $6.866B capital expenditures in 2024) and expanded adoption of cloud services, which grew 6-7% in constant currency during fiscal 2022–2023. This aligns with Oracle's broader shift toward cloud-based delivery models, as evidenced by its focus on cloud license and support revenues (now 85% of total revenue) and the integration of OCI into hybrid and multi-cloud customer deployments. The company actively promotes OCI as part of its \"Oracle Cloud Services\" portfolio, emphasizing its role in enabling enterprise IT modernization alongside traditional on-premise and hybrid solutions.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies Oracle's strategic shift in emphasizing OCI as a central pillar by 2024 and notes integration with enterprise IT solutions, which aligns with the ground truth. However, there are key quantitative inaccuracies: the LLM states cloud services grew 6-7% in constant currency during fiscal 2022–2023, but this figure is not present in the ground truth and cannot be verified from the provided data. Additionally, the $6.866B capital expenditure in 2024 is mentioned without confirmation in the original answer, making it potentially incorrect or unsupported. The 85% cloud and license revenue figure is correctly attributed but misdated — the ground truth specifies this was from 2022, while the LLM implies it is current (2024), which distorts the evolution. (2) The original answer emphasizes that in 2022, Oracle did not use strategic language about OCI positioning, but by 2024, it was described as a core component. The LLM captures this shift qualitatively but undermines accuracy by introducing unverified numbers and misplacing the 85% revenue context. (3) The multi-hop reasoning is sound in structure — connecting financial trends, strategic language, and enterprise integration — but relies on unsupported figures that weaken the factual foundation. (4) Despite these issues, the core narrative of strategic evolution is accurate and relevant, earning high marks for qualitative accuracy and contextual relevance. The correctness score is reduced due to significant but not central quantitative errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1426,
        "completion_tokens": 428,
        "total_tokens": 1854
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has the treatment and risk profile of PALs evolved between 2023 and 2024, particularly in terms of credit loss allowance and collateralization?",
      "original_answer": "In 2023, there was a slight decrease in PALs, and the allowance for credit losses was influenced by improved credit quality metrics and lower projected loss rates. By 2024, all PALs were fully collateralized by securities with fair values exceeding borrowings, and no allowance for credit losses for PALs was required as they were all subject to the collateral maintenance practical expedient under ASC 326. This indicates a strengthening in the risk profile and treatment of PALs over the period.",
      "llm_answer": "The allowance for credit losses on First Mortgages and HELOCs declined from $32 million (66 % of the portfolio) and $2 million (1 % of the portfolio) at year‑end 2023 to $14 million (51 % of First Mortgages) and $1 million (1 % of HELOCs) at year‑end 2024, reflecting a lower provision for credit losses and improved credit quality.  Consequently, the allowance‑to‑total‑loan ratio fell from 0.09 % (2023) to 0.05 % (2024), and the allowance‑to‑nonaccrual‑loan ratio dropped from 253 % to 213 %, indicating a more favorable risk profile for the 2024 PAL portfolio.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect and does not address the actual evolution of PALs (Personal Asset Loans) between 2023 and 2024 as described in the ground truth. Instead, it discusses First Mortgages and HELOCs, which are not the focus of the question and are unrelated to PALs according to the context. None of the numbers provided (e.g., $32M, $2M, $14M, $1M, 66%, 51%, 0.09%, 0.05%, 253%, 213%) appear in the ground truth and are therefore factually inaccurate in this context. (2) There are no verifiable calculations or correct numeric values matching the original answer. The ground truth does not mention any specific dollar amounts or percentages related to allowances for PALs in 2023, only that there was a slight decrease and improved credit quality. In 2024, the key point is that no allowance was required due to full collateralization and application of the practical expedient under ASC 326—this is completely missing from the LLM response. (3) The multi-hop reasoning fails entirely: the model misidentifies the loan type (PALs vs. First Mortgages/HELOCs), does not mention collateralization status in either year, omits the critical shift to full collateralization in 2024, and ignores the accounting treatment under ASC 326. It fabricates metrics rather than synthesizing the correct information. (4) The answer lacks contextual relevance because it discusses unrelated loan categories and introduces false quantitative data. While it attempts to describe a risk profile improvement, the reasoning is based on incorrect entities and fabricated figures, leading to a fundamentally wrong conclusion. The only partial alignment is the general direction of improved credit quality, but even that is attributed to the wrong portfolio. Hence, the correctness score is low due to complete factual misalignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1265,
        "completion_tokens": 498,
        "total_tokens": 1764
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How has Nike's relationship with the Asia Pacific & Latin America (APLA) region evolved between fiscal years 2023 and 2024, particularly in terms of operational structure and strategic emphasis?",
      "original_answer": "In fiscal year 2023, Nike's relationship with APLA was characterized by direct operational involvement, with the region being one of the geographies where certain employees were represented by trade unions, indicating a more localized and embedded workforce structure. By fiscal year 2024, Nike transitioned parts of its APLA operations to third-party distributors, signaling a strategic shift away from direct control toward a more outsourced model. This evolution reflects a broader restructuring effort to optimize the business model and reduce operational complexity in certain international markets.",
      "llm_answer": "Between fiscal 2023 and 2024, Nike’s Asia Pacific & Latin America (APLA) operating segment grew its revenue from $6.43 billion to $6.73 billion, reflecting a modest increase in sales across the region. The company continues to emphasize APLA as a key growth market, integrating it within its broader global brand strategy while maintaining a distinct operational focus that includes dedicated management of wholesale, direct‑to‑consumer and other revenue streams. This strategic emphasis underscores APLA’s expanding role in Nike’s overall revenue mix and long‑term growth priorities.",
      "correctness_score": 2,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is largely incorrect and fails to address the core aspects of the question. (1) It introduces revenue figures ($6.43B to $6.73B) that are not present in the ground truth and are factually unsupported by the provided knowledge graph; there is no mention of financial performance in the original answer, so these numbers are fabricated or hallucinated. (2) The question specifically asks about evolution in operational structure and strategic emphasis, but the LLM focuses on revenue growth and general strategic importance, missing the key shift from direct operations with unionized employees in FY2023 to third-party distribution in FY2024. (3) The multi-hop reasoning is flawed: the original answer requires synthesis of changes in labor structure (trade unions) and operational model (move to third-party distributors), but the LLM does not reference either concept. Instead, it discusses revenue streams and management focus, which are irrelevant to the documented structural shift. (4) While the mention of APLA as a growth market may seem contextually plausible, it misrepresents the actual strategic evolution—Nike reduced direct control, not expanded operational investment. The answer is semantically unrelated to the ground truth despite being framed around the same region and time period. Minor credit is given for correctly identifying APLA and the fiscal years in context, but no factual alignment exists on the key points.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 399,
        "total_tokens": 1708
      },
      "error": null
    },
    {
      "question_id": 90,
      "question": "How did Abbott's positioning and strategic emphasis on Pedialyte evolve between 2022 and 2023, particularly in relation to its U.S. Pediatric Nutritional business and product portfolio expansion?",
      "original_answer": "In 2022, Pedialyte was highlighted as a key growth driver within Abbott's U.S. Pediatric Nutritional business, with sales increasing 10.3% for the year, alongside Similac and PediaSure. By 2023, Pedialyte was formally included in Abbott's product portfolio under the Nutritional Products segment, listed among major brands such as Ensure, Glucerna, and PediaSure, signaling a more structured integration into Abbott's broader nutritional offerings. This reflects a strategic evolution from being a contributor to growth in 2022 to being a formally recognized and embedded part of the company's core U.S. Pediatric Nutritional product lineup in 2023.",
      "llm_answer": "Abbott’s strategic focus on Pedialyte and the broader U.S. pediatric nutritional portfolio intensified between 2022 and 2023, as reflected by double‑digit sales growth in the U.S. Pediatric Nutritionals line (up 10 % in 2021 and continuing to accelerate in 2022‑23) and a specific emphasis on Pedialyte as a growth driver within the segment.  The company expanded the Pedialyte portfolio with new formulations and packaging, reinforcing its positioning in pediatric hydration and reinforcing its competitive edge against private‑label and regional brands.  This product‑portfolio expansion was a key component of Abbott’s broader nutritional‑products growth strategy, which saw total nutritional sales rise 8.5 % (excluding FX) in 2021 and continued to outpace overall segment growth in 2022‑23.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several inaccuracies in numbers and timeframes. The ground truth states that Pedialyte sales increased by 10.3% in 2022, but the LLM incorrectly references 'double-digit sales growth' and cites a 10% increase in 2021 (not mentioned in the original answer), and claims acceleration in 2022–23 without specifying the correct 2022 figure. It also references 8.5% nutritional sales growth in 2021, which is not part of the ground truth and introduces data from outside the provided context. (2) The quantitative inaccuracies are significant: the correct figure is a 10.3% increase for Pedialyte in 2022, not generalized 'double-digit' growth or unspecified acceleration. No data is provided for 2023 sales performance in the ground truth, so claiming continued acceleration is unsupported. (3) The qualitative reasoning partially captures the strategic emphasis on Pedialyte, such as its role as a growth driver and portfolio expansion, but misses the key multi-hop insight that Pedialyte was formally integrated into the Nutritional Products segment in 2023 and listed alongside Ensure, Glucerna, and PediaSure—signaling structural recognition. This evolution from growth contributor in 2022 to formally embedded brand in 2023 is the core of the strategic shift and is not adequately conveyed. (4) Contextual relevance is high because the answer addresses Abbott’s strategic focus, pediatric nutrition, and product expansion. However, due to incorrect figures, misplaced years, and failure to capture the key 2023 structural integration, the overall correctness is only partial. The answer provides plausible narrative but lacks factual alignment with the ground truth, especially on the critical 2023 development.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1373,
        "completion_tokens": 476,
        "total_tokens": 1849
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How did RTX's financial position regarding its 7.100% notes due 2027 evolve from 2022 to 2023, and what does this indicate about its debt management strategy?",
      "original_answer": "In 2022, RTX disclosed an aggregate principal balance of $6 million for its 7.100% notes due 2027. By 2023, RTX had a stake in the same notes with an aggregate principal balance of $135 million. This indicates a significant increase in RTX's exposure to this particular debt instrument, suggesting a shift in its debt management strategy, possibly involving refinancing or restructuring.",
      "llm_answer": "RTX's total principal long-term debt increased from $31,249 million in 2022 to $43,697 million in 2023, reflecting new issuances of $7.5 billion in long‑term notes and term loans that were used to refinance the $10 billion bridge loan and repay maturing debt. This shift shows a strategic move to extend the average maturity of its borrowings and lock in financing at lower weighted‑average interest rates (4.0% in 2023 versus 4.6% in 2022), indicating a focus on strengthening the balance sheet and managing debt‑service costs.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 4,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in addressing the specific question about RTX's 7.100% notes due 2027. The ground truth states that the aggregate principal balance for these specific notes increased from $6 million in 2022 to $135 million in 2023. The LLM instead discusses RTX's total long-term debt and general refinancing activities, citing figures like $31,249 million and $43,697 million, which are unrelated to the 7.100% notes due 2027. These numbers do not appear in the ground truth and are therefore factually inaccurate in this context. (2) The quantitative inaccuracies are severe: the LLM invents large-scale debt figures and interest rate changes (e.g., 4.0% vs 4.6%) that pertain to overall debt, not the specific 7.100% notes. There is no mention in the ground truth of a $10 billion bridge loan or $7.5 billion in new issuances related to these notes. (3) The reasoning fails the multi-hop requirement: the question asks for an analysis of a specific debt instrument (7.100% notes due 2027) across two years, but the LLM generalizes to overall debt strategy without isolating or referencing the correct instrument. It does not mention the 7.100% rate or the 2027 maturity at all, indicating a failure to identify the correct entity. (4) While the answer discusses debt management strategy in broad terms—such as extending maturities and reducing interest rates—this is not relevant to the specific question about the 7.100% notes. The actual indication from the ground truth is a significant increase in exposure to a high-interest note, which may suggest a different strategy (e.g., buyback, restructuring, or internal reallocation), but this is missed entirely. Thus, despite some plausible qualitative themes, the answer is factually and contextually misaligned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1231,
        "completion_tokens": 489,
        "total_tokens": 1720
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has Nike's relationship with Converse evolved in terms of revenue performance and strategic positioning between fiscal 2023 and fiscal 2024?",
      "original_answer": "In fiscal 2023, Converse revenues decreased by 15% on a currency-neutral basis, driven by declines in North America and Western Europe, with both wholesale and direct-to-consumer channels experiencing drops in unit sales and average selling price. By fiscal 2024, Converse was described as a wholly-owned subsidiary that operates on a stand-alone basis, indicating a strategic shift toward maintaining it as a distinct brand within Nike’s portfolio. This evolution reflects a move from a financially struggling entity in 2023 to a more strategically positioned brand in 2024, despite the earlier revenue contraction.",
      "llm_answer": "Between fiscal 2023 and fiscal 2024, Converse revenue declined 15% on a currency-neutral basis, driven by double-digit drops in North America and Western Europe across both wholesale and direct-to-consumer channels, with wholesale revenue falling 16% and direct sales declining 14% due to reduced traffic and promotional pricing pressures. While Converse's earnings before interest and taxes fell 30% to $474 million, this reflected gross margin compression from foreign currency headwinds and lower ASPs, partially offset by reduced operating expenses. In contrast, Nike Brand revenues grew 4% overall (5% constant currency), with Greater China up 8% and footwear up 6% on higher ASPs and mix, though this growth was muted by currency headwinds impacting reported revenue. Strategically, Converse remains a distinct reportable segment under Nike's portfolio but continues to face significant headwinds in its core markets, while Nike Brand demonstrates modest recovery in key regions like Greater China.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer includes several details not present in the ground truth and contains inaccuracies in key quantitative figures. The ground truth states that Converse revenues decreased by 15% on a currency-neutral basis in fiscal 2023, which the LLM correctly reports. However, the LLM adds specific channel breakdowns (wholesale -16%, DTC -14%) and a figure for EBIT ($474 million, down 30%) that are not in the original answer and cannot be verified against the provided ground truth. These additions introduce unverified data, reducing quantitative accuracy. (2) The ground truth does not mention Converse's EBIT, gross margin compression, foreign currency impacts on margins, or operating expense reductions—these are extraneous details possibly drawn from external knowledge but not supported here. Additionally, the LLM discusses Nike Brand revenue growth (4% overall, 5% constant currency), Greater China up 8%, and footwear up 6%, none of which are part of the original answer focused solely on Converse’s performance and strategic positioning. (3) Regarding multi-hop reasoning, the LLM correctly identifies the revenue decline in Converse in fiscal 2023 but fails to address the key strategic evolution highlighted in the ground truth: that by fiscal 2024, Converse was positioned as a stand-alone, wholly-owned subsidiary operating independently—a strategic repositioning indicating structural change. Instead, the LLM states Converse 'remains a distinct reportable segment,' which is semantically close but lacks the emphasis on strategic shift toward stand-alone operations. (4) While the LLM captures the revenue decline correctly and maintains focus on Converse’s challenges, it introduces unsupported financial metrics and shifts attention to Nike Brand performance, which dilutes the response. The core fact of Converse’s 15% decline is accurate, and the qualitative direction of strategic distinctness is partially captured, but the inclusion of unverified numbers and tangential information reduces correctness. Hence, correctness is scored at 5 (partially correct with significant errors), quantitative accuracy at 4 (several unsupported numbers), qualitative accuracy at 6 (some correct reasoning but incomplete synthesis of strategic evolution), and contextual relevance at 8 (mostly on-topic with some digressions).",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1404,
        "completion_tokens": 626,
        "total_tokens": 2031
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has Coca-Cola's financial risk assessment regarding digital evolution changed from 2022 to 2024, particularly in terms of its impact on sales growth and margin improvement?",
      "original_answer": "In 2022, Coca-Cola viewed digital evolution as a risk factor that could negatively impact its business if it failed to implement digital transformation initiatives effectively, potentially leading to a loss in sales and brand relevance. By 2024, the company shifted its stance, identifying digital evolution as a strategic dependency, emphasizing that its future success would rely on expanding digital capabilities to increase sales and improve margins. The 2024 filing explicitly states that failure to digitalize operations could adversely impact financial performance, indicating a stronger financial linkage to digital initiatives than in 2022.",
      "llm_answer": "From 2022 to 2024, Coca-Cola’s risk assessment shifted from focusing mainly on traditional health‑related concerns (e.g., obesity, sugar‑sweetened beverage taxes) to explicitly linking digital evolution to its financial outlook. In 2022 the company warned that failing to meet evolving consumer product and shopping preferences—especially the rapid shift to mobile‑based and e‑commerce purchasing—could erode sales and growth. By 2024 the filing emphasizes that successful digitization of the Coca‑Cola system (through data, AI, automation and personalized digital experiences) is now a core priority; otherwise, the ability to grow sales and improve margins will be compromised, and the costs of digital initiatives could directly hurt profitability. Thus, the risk has moved from a generic consumer‑preference warning to a strategic, margin‑focused digital‑transformation risk.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly identifies the shift in Coca-Cola's risk assessment from 2022 to 2024 regarding digital evolution. In 2022, the company framed digital evolution as a risk tied to changing consumer preferences and e-commerce shifts that could erode sales—consistent with the original answer. By 2024, it reframed digital transformation as a core strategic dependency for sales growth and margin improvement, which is accurately reflected. (2) There are no numeric values (e.g., dollar amounts, percentages) in either the question or ground truth, so quantitative accuracy is not applicable—no errors present. (3) The multi-hop reasoning is sound: the model synthesizes changes in risk framing across two years, connects digital evolution to financial outcomes (sales and margins), and correctly infers an escalation in strategic importance. The only minor shortcoming is that the LLM adds context not in the original—mentioning 'costs of digital initiatives could directly hurt profitability'—which, while plausible, is not stated in the ground truth and slightly extends beyond the provided information. (4) Despite this small addition, the answer remains factually consistent, semantically equivalent, and fully relevant to the question, capturing the core evolution in risk perception and its financial implications.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1389,
        "completion_tokens": 384,
        "total_tokens": 1774
      },
      "error": null
    },
    {
      "question_id": 91,
      "question": "How has Oracle's strategic emphasis on Oracle Cloud Services evolved from fiscal year 2022 to 2024, particularly in terms of research and development investment and the positioning of cloud offerings relative to on-premise solutions?",
      "original_answer": "In fiscal year 2022, Oracle invested $7.2 billion in research and development, highlighting its commitment to enhancing Oracle Cloud Services, including Oracle SaaS and OCI, as part of a broader strategy to offer flexible and interoperable deployment models. Oracle positioned cloud services as a key differentiator against competitors by emphasizing rapid deployment, security, and integration. By fiscal year 2024, Oracle continued to emphasize cloud services but restructured its messaging to position Oracle Cloud Software-as-a-Service and Oracle Cloud Infrastructure as central to enabling customers to 'choose the best option that meets their specific business needs.' While the 2024 report does not specify the R&D investment amount, the increased focus on cloud-first positioning and integration with customer-specific needs indicates a strategic deepening of Oracle's commitment to cloud services over on-premise offerings.",
      "llm_answer": "Oracle has steadily increased its R&D investment to accelerate cloud innovation, with spending rising from $7.2 billion in fiscal 2022 to $7.9 billion in fiscal 2023 and $8.5 billion in fiscal 2024. This reflects a strategic shift toward cloud‑centric offerings, as the company emphasizes migrating customers from on‑premise solutions to Oracle Cloud Services—highlighted by its focus on SaaS, OCI, and hybrid deployment flexibility—while positioning cloud license and support revenues as a growing share of total sales.",
      "correctness_score": 4,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in quantitative data. While it correctly states Oracle's $7.2 billion R&D investment in fiscal 2022 (matching the ground truth), it fabricates figures for fiscal 2023 ($7.9 billion) and fiscal 2024 ($8.5 billion). The original answer explicitly states that the 2024 report does not specify R&D investment, making the LLM's precise figures unsupported and incorrect. These fabricated numbers undermine the core factual basis of the response. (2) The qualitative aspects partially align with the ground truth: the emphasis on cloud-centric offerings, migration from on-premise, focus on SaaS and OCI, and hybrid flexibility are consistent themes. However, the LLM overstates the strategic narrative by implying a continuous, quantifiable increase in R&D investment, which is not confirmed in the source. The original answer emphasizes a shift in messaging and positioning—'choose the best option that meets their specific business needs'—which the LLM does not capture accurately. (3) Multi-hop reasoning is partially sound: the model connects R&D spending to cloud strategy and recognizes the shift toward cloud-first positioning. However, it fails to acknowledge the absence of 2024 R&D data, indicating a failure in proper information synthesis across years. Instead of noting the lack of data and focusing on qualitative shifts in messaging (as in the original), it invents numbers, breaking the chain of valid reasoning. (4) Contextual relevance is high—the answer addresses the evolution of Oracle’s cloud strategy, R&D trends, and positioning relative to on-premise solutions. Despite incorrect numbers, the overall direction and intent of the answer are aligned with the question. However, due to major quantitative errors and flawed reasoning, the correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1384,
        "completion_tokens": 501,
        "total_tokens": 1886
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has the status and availability of shares under the Norwest Corporation Directors' Formula Stock Award Plan evolved between 2023 and 2024?",
      "original_answer": "In 2023, the Norwest Corporation Directors' Formula Stock Award Plan was described as a plan under which shares of common stock were awarded to non-employee directors, with the ability to defer receipt of awards until a future year. However, it was noted that no future stock awards or deferrals could be made under this plan. In 2024, the 10-K filing further clarified that no future awards or deferrals would be made under the plan and that column (a) of the equity compensation table reflected all shares issuable under the plan upon distribution of outstanding awards or deferred compensation benefits. This indicates that by 2024, the plan was fully closed to any new activity and only existing obligations remained. The number of shares issuable in 2024 related to this plan was minimal (only 391 shares), showing that the plan had effectively concluded its active phase.",
      "llm_answer": "The Norwest Corporation Directors' Formula Stock Award Plan, which previously issued shares to non-employee directors, was discontinued and no future awards or deferrals will be made under this plan. This is confirmed in the \"Material Features of Equity Compensation Plans Not Approved by Shareholders\" section on page 13, which states that \"No future stock awards or deferrals may be made under this plan.\" Consequently, the status and availability of shares under this specific plan have been permanently discontinued as of 2024.",
      "correctness_score": 7,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer correctly identifies that the Norwest Corporation Directors' Formula Stock Award Plan was discontinued and that no future awards or deferrals can be made, which aligns with the ground truth for both 2023 and 2024. It accurately reflects the plan's status as closed to new activity and cites a relevant section from the filing, enhancing credibility. However, the LLM omits key quantitative and qualitative details present in the original answer: specifically, the minimal number of shares still issuable in 2024 (391 shares) and the clarification that column (a) of the equity compensation table reflects all remaining obligations. This missing detail weakens completeness, especially regarding the 'availability of shares' aspect of the question. While the conclusion that the plan was discontinued is correct, the evolution between 2023 and 2024 is underdeveloped—the original answer notes that in 2023 the plan was already inactive but still had deferral mechanics, and by 2024 it was fully confirmed as closed with only residual distributions pending. The LLM does not capture this progression or the fact that the 2024 filing provided further clarification. Entity accuracy and contextual relevance are strong, with correct company and plan identification. Reasoning is sound but not fully multi-hop, as it fails to synthesize the change over time and the significance of the 391 shares. Quantitative accuracy is high but not perfect due to omission rather than error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1351,
        "completion_tokens": 408,
        "total_tokens": 1759
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has McDonald's disclosure around food safety concerns evolved between 2022 and 2023, particularly in relation to supply chain risks and cost volatility?",
      "original_answer": "In 2022, McDonald's characterized food safety concerns primarily as reputational risks that could impact brand perception and financial results due to incidents like food-borne illness or contamination. The focus was on the potential damage to consumer trust and the company's image. By 2023, the framing had evolved to emphasize food safety concerns as contributors to supply chain volatility, specifically in relation to commodity cost fluctuations. The 2023 filing noted that food safety issues, along with other macroeconomic and regulatory factors, could exacerbate volatility in the prices of key ingredients like beef, chicken, and pork, thereby affecting profitability. This indicates a shift in emphasis from reputational impact to financial exposure through supply chain disruption and cost pressures.",
      "llm_answer": "Between 2022 and 2023, McDonald’s disclosures show a continued focus on supply chain and cost volatility risks, but with less explicit linkage to food safety compared to prior years. In the 2022 filing (pages 29–33), supply chain disruptions were highlighted as a risk under \"Macroeconomic and Market Conditions,\" with emphasis on commodity price volatility, inflation, and external shocks (e.g., geopolitical events, pandemics) affecting input costs and operational continuity. By 2023 (pages 31–35), this language evolved to frame supply chain interruptions more broadly within \"Macroeconomic and Market Conditions,\" linking them to inflationary pressures, currency fluctuations, and commodity market volatility, while still underscoring their potential to increase costs and disrupt operations. However, the 2023 filing (page 33) shifts focus toward ESG-related pressures and regulatory complexity, with food safety concerns relegated to a standalone section (page 31) that emphasizes brand reputation risks rather than direct supply chain cost impacts. Notably, the 2023 disclosure reduces explicit discussion of supply chain cost volatility in favor of integrating it into broader macroeconomic risks, while food safety remains a consistent but non-evolving priority, framed around brand protection rather than financial quantification. (Sources: MCD_10k_2022.pdf pages 29–33; MCD_10k_2023.pdf pages 31, 33, 35)",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim about the evolution of McDonald's disclosures, directly contradicting the ground truth. The original answer states that in 2023, McDonald's explicitly reframed food safety concerns as contributors to supply chain volatility and commodity cost fluctuations—marking a shift from reputational to financial risk framing. However, the LLM answer incorrectly asserts that food safety was 'relegated to a standalone section' in 2023 and 'framed around brand reputation risks rather than direct supply chain cost impacts,' with 'less explicit linkage to food safety' and 'non-evolving priority.' This is the opposite of the ground truth: the 2023 filing increased the linkage between food safety and financial/supply chain risks, rather than reducing it. While the LLM correctly identifies sections and general risk categories (e.g., macroeconomic conditions, inflation, commodity volatility), and page numbers are plausible, the central reasoning and synthesis are flawed. There are no numerical values to verify, so quantitative accuracy is scored as 10 by default. Qualitative accuracy is low due to incorrect multi-hop reasoning and misrepresentation of the evolution across years. Contextual relevance is moderate because the answer discusses related topics (supply chain, cost volatility, ESG) but fails to capture the key shift in risk framing. The sources cited do not support the conclusion drawn, indicating a misinterpretation of the filings.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1559,
        "completion_tokens": 411,
        "total_tokens": 1970
      },
      "error": null
    },
    {
      "question_id": 92,
      "question": "How has the carrying value and interest rate of TMO's 1.750% 7-Year Senior Notes evolved between 2023 and 2024?",
      "original_answer": "In 2023, TMO's 1.750% 7-Year Senior Notes, due on October 15, 2028, had a carrying value of $700 million and an effective interest rate of 1.89%. In 2024, both the carrying value and effective interest rate remained unchanged at $700 million and 1.89% respectively. This indicates that there was no change in the financial structure or valuation of this particular debt instrument over the period.",
      "llm_answer": "Based on the provided 10-K filings, Thermo Fisher Scientific's 1.750% 7-Year Senior Notes (due April 15, 2027) had a carrying value of $662 million at December 31, 2023 (as reported on page 61 of the 2023 filing and page 46 of the 2024 filing), and $621 million at December 31, 2024 (as shown on page 48 of the 2024 filing and page 62 of the 2024 filing). The effective interest rate for this tranche was 1.97% at December 31, 2023 and decreased to 1.89% at December 31, 2024, reflecting the amortization of discounts and debt issuance costs over the life of the notes.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains multiple critical factual errors. First, the maturity date of the notes is incorrect: the ground truth states the notes are due on October 15, 2028, but the LLM claims they are due April 15, 2027. Second, the carrying values are wrong: the ground truth reports a stable $700 million in both 2023 and 2024, but the LLM reports $662 million in 2023 and $621 million in 2024—both incorrect and implying a decline not present in the data. Third, the effective interest rate is misstated: the ground truth shows a constant 1.89% in both years, but the LLM reports 1.97% in 2023 and a decrease to 1.89% in 2024, which contradicts the actual data. (2) Quantitative accuracy is very low: none of the dollar amounts or interest rates match the ground truth, and the implied trend (declining carrying value, changing interest rate) is factually incorrect. The cited page numbers suggest the model may have misread or hallucinated data from the filings. (3) Multi-hop reasoning is flawed: the model fails to correctly identify that the carrying value and interest rate remained unchanged between years, which is the key insight. It incorrectly infers amortization effects despite no such change in the ground truth. The synthesis across years and documents is invalid due to incorrect base data. (4) Contextual relevance is moderate—the response addresses the right type of information (carrying value, interest rate, evolution over time) and references specific filing pages, showing an attempt to ground the answer. However, the factual inaccuracies severely undermine correctness. Overall, the answer is mostly incorrect due to wrong entities, numbers, and reasoning.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1232,
        "completion_tokens": 463,
        "total_tokens": 1696
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How did RTX's exposure to its 7.000% notes due 2038 change between 2022 and 2023, and what does this suggest about its approach to managing long-term debt maturities?",
      "original_answer": "In 2022, RTX disclosed an aggregate principal balance of $11 million for its 7.000% notes due 2038. By 2023, this amount had increased significantly to $148 million. This suggests that RTX either issued additional tranches of this note or restructured its debt to extend maturities, indicating a strategic shift toward increasing exposure to this particular long-term debt instrument.",
      "llm_answer": "Between 2022 and 2023 the balance of RTX’s 7.000% notes due 2038 remained unchanged at $148 million in both years, indicating that the company did not increase or decrease its exposure to that specific tranche of long‑term debt. This stability suggests that RTX is maintaining a relatively steady long‑term debt maturity profile, focusing instead on issuing new debt across a range of maturities rather than adjusting the outstanding amount of the 2038 notes.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in stating that the balance of RTX’s 7.000% notes due 2038 remained unchanged at $148 million in both 2022 and 2023. According to the ground truth, the principal balance was $11 million in 2022 and increased to $148 million in 2023 — a significant change, not stability. This error completely inverts the factual situation. (2) The quantitative inaccuracies are severe: the 2022 figure is off by over 90%, and the claim of no change contradicts the actual 13.5x increase. Calculations or comparisons based on this would be invalid. (3) The multi-hop reasoning fails because the model did not correctly retrieve or synthesize the exposure change over time; instead, it assumed stability, leading to an incorrect conclusion about RTX’s debt strategy. The correct inference — that RTX likely issued additional notes or restructured debt to extend maturities — is missed entirely. (4) The contextual relevance is low but not zero, as the answer addresses the right topic (debt maturity management), but with entirely wrong data and reasoning. Scores reflect near-total factual inaccuracy despite relevant framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1215,
        "completion_tokens": 329,
        "total_tokens": 1545
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How did McDonald's financial relationship with its franchisees evolve between 2022 and 2023, particularly regarding the collection of rent and royalties?",
      "original_answer": "In 2022, McDonald's disclosed that it had deferred approximately $1 billion in rent and royalties from franchisees, primarily during the first half of 2020, due to the impact of government restrictions related to COVID-19. By the end of 2021, the company had collected substantially all of these deferred amounts. In contrast, the 2023 filing reflects a return to standard operations, with no mention of ongoing deferrals or pandemic-related financial accommodations. Instead, the 2023 report outlines the normalization of franchise operations, including a detailed breakdown of restaurant ownership types, which indicates that franchisees were operating under regular financial obligations without pandemic-era relief measures.",
      "llm_answer": "Between 2022 and 2023, McDonald's financial relationship with its franchisees regarding rent and royalties remained fundamentally consistent in structure but showed notable quantitative shifts. The company continued to collect rent based on a percentage of sales with minimum payments, along with royalties tied to sales, and initial fees—though the specific amounts evolved as reflected in the financial statements. While the provided text does not detail major structural changes, it highlights that the company recorded rental income from franchised restaurants (including minimum rent and variable percent-of-sales rent) and royalty revenues, both of which are key components of franchisee-related revenue. Additionally, the company deferred rent and royalty collections during the early stages of the pandemic (2020), but by 2021 had largely collected these amounts, indicating a return to normal collection patterns by 2023.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly notes that McDonald's deferred rent and royalties during the pandemic (specifically in 2020) and had largely collected these amounts by 2021, with normal operations resuming by 2023. However, it fails to include the key quantitative detail from the original answer—namely, that approximately $1 billion was deferred. This omission significantly impacts quantitative accuracy. The LLM mentions 'quantitative shifts' and 'evolved amounts' but provides no actual figures from 2022 or 2023, nor does it clarify that the deferrals were primarily in early 2020 and fully resolved by end of 2021, which is central to the timeline. (2) The original answer specifies a $1 billion deferral, which the LLM omits entirely—this is a major factual gap. While the LLM correctly references the return to normal operations by 2023, it does not explicitly state that the 2023 filing shows no ongoing deferrals or pandemic-related accommodations, which is a key contrast to the earlier period. (3) The reasoning is partially sound: the LLM correctly infers a return to standard operations and understands the structure of rent and royalty collection. It connects pandemic-era deferrals to later normalization, showing acceptable multi-hop synthesis between 2020 events and 2023 outcomes. However, it misframes the evolution as occurring 'between 2022 and 2023', when the actual evolution (deferral and collection) occurred earlier, with 2022–2023 being the period of normalized operations. This misalignment in timing weakens the reasoning. (4) The contextual relevance is high because the answer addresses franchisee financial relationships, rent, royalties, and pandemic impacts. Qualitative accuracy is moderate due to correct conceptual understanding but flawed temporal framing. Quantitative accuracy is low due to missing the $1 billion figure and lack of specific data. Correctness score is 6 due to accurate core concepts but significant omissions in key facts and timeline precision.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1416,
        "completion_tokens": 542,
        "total_tokens": 1958
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How has The Coca-Cola Company's financial stake in Embotelladora Andina S.A. evolved from 2022 to 2024, and what does this indicate about the company's strategic positioning with respect to this equity investment?",
      "original_answer": "In 2022, Coca-Cola recognized a gain of $39 million from the partial sale of its ownership interest in Embotelladora Andina S.A., indicating a strategic refranchising or divestiture move while retaining an equity stake. By 2024, Coca-Cola still held a financial stake in Andina, with a carrying value of $90 million and a fair value of $168 million, showing that the company maintained its involvement but with a relatively modest valuation compared to other equity investments. This indicates a partial exit strategy rather than a complete divestiture, with ongoing but reduced exposure.",
      "llm_answer": "From 2022 to 2024, The Coca-Cola Company’s equity stake in Embotelladora Andina S.A. declined from a 28% ownership interest (reflected in the 2022 consolidated balance sheet as part of the Bottling Investments segment) to a reduced carrying value of $90 million on its balance sheet by the end of 2024, with the equity‑method investment balance falling from $19,671 million in 2023 to $18,087 million in 2024. This reduction—driven by divestitures, impairment charges and the reclassification of the business as held for sale—signals that Coca‑Cola is strategically downsizing its equity exposure in Latin‑American bottlers and refocusing capital on higher‑margin, growth‑oriented assets such as its equity method investments in higher‑growth markets and its global bottling partnerships.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly states the $90 million carrying value in 2024 (matching ground truth), it fabricates a 28% ownership interest in 2022 and invents equity-method investment balances of $19,671 million in 2023 and $18,087 million in 2024, which are not present in the original answer and are implausibly large (over $19 billion in bottler investments). These numbers are orders of magnitude off and completely unsupported by the ground truth. The original answer mentions a $39 million gain from partial sale in 2022, which the LLM omits entirely. (2) The LLM incorrectly attributes the reduction to 'impairment charges' and 'reclassification as held for sale,' which are not mentioned in the ground truth. Instead, the original answer emphasizes a strategic refranchising move with ongoing stake retention. The LLM also introduces unverified details about Latin American bottlers and capital reallocation to 'higher-growth markets' not present in the original. (3) The multi-hop reasoning is partially sound in that it infers a strategic downsizing trend, which aligns with the 'partial exit strategy' in the original. However, it overreaches by adding unsupported specifics about ownership percentages, balance sheet figures, and strategic rationale. (4) The contextual relevance is fair because the answer addresses the evolution of the stake and strategic positioning, but the severe quantitative inaccuracies and invented data points drastically undermine correctness. The qualitative reasoning is somewhat aligned but based on false premises. Thus, the correctness score is low due to major factual and numerical errors, despite capturing a general directional trend.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1360,
        "completion_tokens": 475,
        "total_tokens": 1836
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How has Oracle's strategic investment in cloud infrastructure evolved from 2022 to 2024, particularly regarding internal development efforts and the positioning of Oracle Cloud Infrastructure in its product portfolio?",
      "original_answer": "In 2022, Oracle emphasized internal development as a core strategy, dedicating significant resources to research and development to maintain and improve its existing product suite, including cloud technologies. The company highlighted its global R&D workforce and the importance of innovation in response to evolving market demands. By 2024, this focus had evolved into a more product-specific strategy with the explicit introduction of Oracle Cloud Infrastructure (OCI) as a central offering within Oracle Cloud Services. OCI was positioned as a comprehensive and integrated infrastructure solution, indicating a shift from general cloud development to a structured, customer-facing product portfolio. This evolution demonstrates a strategic deepening of Oracle's cloud infrastructure commitment, aligning internal R&D with the delivery of a defined, market-ready suite of cloud services.",
      "llm_answer": "From 2022 to 2024, Oracle’s strategic investment in cloud infrastructure evolved from a focus on expanding its Oracle Cloud Infrastructure (OCI) offerings and internal development of cloud services to a more integrated positioning of OCI within its broader product portfolio. The company emphasized scaling its cloud data center capacity, extending the Oracle Cloud through new geographic regions, and enhancing automated delivery of cloud capabilities on a quarterly cadence. Internally, Oracle continued to invest heavily in research and development and cloud-related infrastructure, while also leveraging acquisitions and strategic partnerships to strengthen its cloud ecosystem. By 2024, Oracle Cloud Services were being delivered through a secure, scalable platform managed across global data centers, with cloud license and infrastructure revenues recognized ratably over contractual periods, reflecting a matured and expanded cloud strategy embedded across its applications, infrastructure, and services offerings.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is largely correct in its overall narrative and contextually relevant, accurately reflecting Oracle's increased investment in cloud infrastructure from 2022 to 2024. It correctly identifies ongoing internal development, R&D investment, expansion of data centers, geographic scaling, and the maturation of Oracle Cloud Infrastructure (OCI) as a strategic priority. There are no specific numeric values (e.g., dollar amounts, percentages, headcount) in either the original or LLM answer, so quantitative accuracy is not compromised—scored 10. However, the original answer emphasizes a key evolution: in 2022, Oracle focused on general internal R&D across its product suite, and by 2024, this had sharpened into a product-specific strategy with OCI positioned as a central, integrated offering. The LLM answer implies this shift but inaccurately suggests OCI was already a major focus in 2022, whereas the ground truth indicates that the explicit positioning of OCI as a central product occurred by 2024, not earlier. This misrepresents the timeline of strategic evolution, missing the nuance that OCI’s central role emerged over time rather than being a starting point. While the LLM mentions integration and maturity by 2024, it does not clearly capture the shift from broad R&D emphasis to a structured, customer-facing OCI product strategy. This affects qualitative accuracy, particularly in multi-hop reasoning and entity-year alignment, warranting a 7. Contextual relevance is high as the response stays focused on Oracle’s cloud strategy evolution and addresses both internal development and portfolio positioning, hence a 9.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1495,
        "completion_tokens": 447,
        "total_tokens": 1942
      },
      "error": null
    },
    {
      "question_id": 93,
      "question": "How did TMO's involvement with The Binding Site Group evolve between 2023 and 2024, and what does this indicate about the company's integration and strategic focus post-acquisition?",
      "original_answer": "In 2023, TMO acquired The Binding Site Group for $2.70 billion as part of its Specialty Diagnostics segment, expanding its portfolio in diagnostics for blood cancers and immune disorders. By 2024, the company had integrated the acquisition into its asset base, with The Binding Site Group contributing to the 19-year weighted-average amortization period for customer relationships among definite-lived intangible assets. This evolution indicates a strategic focus on long-term value creation through integration of acquired innovation into its core diagnostics offerings.",
      "llm_answer": "TMO's involvement with The Binding Site Group evolved from its 2023 acquisition (completed January 3, 2023) as a specialty‑diagnostics add‑on that expanded Thermo Fisher’s portfolio in blood‑cancer diagnostics, to a continued integration reflected in the 2024 financial disclosures where the company reports the acquisition within the Specialty Diagnostics segment and includes related goodwill, intangible assets and amortization schedules. This progression underscores Thermo Fisher’s strategy of building a more integrated, high‑growth diagnostics franchise by acquiring complementary businesses and then leveraging those assets for cross‑selling and synergistic value creation.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all key facts are correct: the 2023 acquisition (specifically dated January 3, 2023, which matches public filings), the $2.70 billion price is implied as part of the Specialty Diagnostics segment (though not explicitly stated in the LLM answer, it's contextually accurate), and the integration into intangible assets by 2024 is correctly noted. The mention of amortization schedules aligns with the ground truth’s reference to the 19-year weighted-average amortization period for customer relationships, though the exact figure (19 years) is omitted. (2) The entity identification is accurate: TMO (Thermo Fisher Scientific), The Binding Site Group, and the Specialty Diagnostics segment are all correctly named and contextualized. (3) The reasoning is sound: the answer traces the evolution from acquisition to integration and infers strategic intent—building a high-growth diagnostics franchise through complementary acquisitions and synergy realization—which is consistent with the ground truth’s emphasis on long-term value creation and integration of innovation. (4) The only minor gap is the omission of the specific 19-year amortization period, which is a factual detail present in the original answer and relevant to post-acquisition integration metrics. However, the LLM does reference amortization schedules generally, indicating awareness. Wording differs but semantic meaning is equivalent. The answer is contextually excellent, fully addressing both the evolution and strategic implications. Thus, correctness is docked slightly (9/10) for the missing amortization detail, but quantitative accuracy remains perfect as no stated numbers are incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1321,
        "completion_tokens": 475,
        "total_tokens": 1797
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How has the disclosure and accessibility of the Directors' Code of Conduct evolved between 2022 and 2024, particularly in terms of website links and scope of application?",
      "original_answer": "In 2022, the Directors' Code of Conduct was posted on BNY Mellon's website at a specific URL: https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-of-conduct.pdf, and it applied to all directors. By 2024, while the scope of application remained the same—applying to all directors—the URL for the Directors' Code of Conduct had changed to https://www.bny.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-ofconduct.pdf. This indicates a change in the website structure or domain branding, likely reflecting a broader rebranding from 'BNY Mellon' to 'BNY', while maintaining the same governance policy content and disclosure intent.",
      "llm_answer": "Between 2022 and 2024, BNY Mellon’s Directors’ Code of Conduct remained accessible via dedicated, permanent links on its corporate website—specifically at https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-of-conduct.pdf in 2022 and the same URL structure continued to be used in 2024 (e.g., https://www.bnymellon.com/content/dam/bnymellon/documents/pdf/investor-relations/directors-code-of-conduct.pdf). The scope of application stayed consistent, covering all directors of BNY Mellon and stating that any amendments or waivers would be disclosed on the website, with no expansion or contraction of the code’s applicability observed across the two filings.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is partially correct but contains a critical factual error regarding the URL in 2024. The original answer confirms that the URL changed from 'bnymellon.com' to 'bny.com' in 2024, reflecting a rebranding. However, the LLM incorrectly states that the same URL structure and domain (bnymellon.com) were used in 2024, which contradicts the ground truth. This undermines the quantitative and qualitative accuracy. (2) While the scope of application (all directors) is correctly identified and consistent across years, the key evolution in website accessibility—the domain change from 'bnymellon.com' to 'bny.com'—is entirely missed. The LLM asserts continuity in the URL where there was actually a meaningful change in domain branding. (3) The multi-hop reasoning is partially sound: the model correctly identifies that the scope did not change and that the code remained publicly accessible. However, it fails to synthesize the correct information about the URL evolution between 2022 and 2024, which is central to the question about 'disclosure and accessibility'. (4) The contextual relevance is high because the answer addresses both website links and scope of application as asked. However, due to the significant factual inaccuracy in the URL (a core piece of evidence), the correctness and accuracy scores are low. Minor note: the LLM repeats the same URL twice, suggesting unawareness of the change, further confirming the error.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1355,
        "completion_tokens": 404,
        "total_tokens": 1760
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How has McDonald's relationship with franchisees evolved in terms of financial reporting and strategic emphasis between 2022 and 2023?",
      "original_answer": "In 2022, McDonald's noted that the results of operations from restaurant businesses purchased and sold in transactions with franchisees were not material to the consolidated financial statements, indicating a limited financial impact from such transactions. By 2023, the company explicitly included franchisees and licensees as key stakeholders in its business model, emphasizing their role alongside company-operated restaurants in a detailed breakdown of restaurant ownership types. This shift reflects a more strategic and transparent focus on franchisees as integral to McDonald's global business structure.",
      "llm_answer": "Between 2022 and 2023, McDonald’s financial reporting and strategic emphasis regarding its relationship with franchisees remained consistent in structure but showed notable shifts in scale and focus. The company continued to recognize royalty and rental income from franchisees based on a percentage of sales, with minimum rent payments recognized straight-line over the lease term and variable rent tied to sales performance. There was an increased emphasis on technology and brand licensing revenues, particularly from third-party platforms like Dynamic Yield (prior to its sale in 2022) and brand licensing arrangements, which are recognized as revenue when underlying sales occur. Additionally, McDonald’s maintained its practice of allocating costs between property/equipment and accounts receivable when sharing capital improvement costs with franchisees, and it continued to consolidate revenue on a gross basis when acting as principal in technology platform arrangements. While the overall framework of franchise financial reporting did not undergo major structural changes, the 2023 filings reflect a strategic refinement in how these relationships contribute to overall revenue streams, particularly through enhanced disclosures on leasing practices, impairment reviews, and the growing contribution of non-restaurant operations.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains some accurate details about McDonald's financial reporting practices, such as the recognition of royalty and rental income, straight-line rent accounting, and cost allocation with franchisees. These elements are factually consistent with typical SEC disclosures and reflect correct understanding of accounting frameworks, earning a moderate score on quantitative accuracy. However, the core of the original answer focuses on a strategic shift in how McDonald’s positioned franchisees in its business model — from noting immateriality of transactions in 2022 to explicitly identifying franchisees and licensees as key stakeholders in 2023. This evolution in narrative and strategic emphasis is entirely missing from the LLM response. Instead, the LLM emphasizes continuity in accounting policies and introduces details about technology platforms like Dynamic Yield and brand licensing, which are not mentioned in the ground truth and appear tangential. The answer fails to capture the multi-hop insight: the change in tone and disclosure strategy reflecting deeper integration of franchisees into the company’s strategic narrative. While the financial mechanics described may be accurate, they do not address the specific evolution in reporting and strategic emphasis highlighted in the original answer. Thus, despite some correct background information, the LLM misses the central point, resulting in a low correctness score due to lack of alignment with the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1484,
        "completion_tokens": 410,
        "total_tokens": 1894
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How did the accounting treatment or status of the contingent consideration liabilities related to the Clif Bar acquisition evolve between 2023 and 2024, particularly in terms of fair value measurement and purchase price allocation adjustments?",
      "original_answer": "In 2023, the contingent consideration liabilities related to the Clif Bar acquisition were actively measured at fair value using a Monte Carlo simulation, with $548 million classified as long-term liabilities at December 31, 2023. These liabilities were tied to performance targets in 2025 and 2026 and were subject to fair value adjustments recorded in selling, general, and administrative expenses. By 2024, there is no direct mention of the contingent consideration liabilities; instead, the 2024 filing references purchase price allocation adjustments for Clif Bar during 2023. This indicates that the contingent consideration may have been finalized or reclassified as part of the purchase price allocation process, though the 2024 disclosure does not provide updated figures or valuation methods for these liabilities.",
      "llm_answer": "Based on the provided SEC 10-K pages, the contingent consideration liabilities related to the Clif Bar acquisition were measured at fair value using a Monte Carlo simulation with Level 3 inputs (including financial projections, discount rates, and volatility assumptions). As of December 31, 2023, the total liability was $680 million ($548 million classified as long-term), and as of December 31, 2022, it was $642 million ($452 million long-term). The liability was adjusted during 2023 through fair value changes recorded in selling, general, and administrative expenses, with the 2023 balance increasing from $642 million to $680 million due to accruals and fair value adjustments.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant quantitative inaccuracies. The ground truth states that the contingent consideration liability was $548 million (long-term) as of December 31, 2023, but the LLM claims the total liability was $680 million ($548 million long-term), which contradicts the source. There is no mention in the original answer of a $680 million total or a $642 million balance as of 2022; these figures are fabricated or misattributed. Additionally, the LLM asserts that the liability increased from $642M to $680M in 2023 due to accruals and fair value adjustments, but this calculation and narrative are not supported by the ground truth. (2) The original answer does not provide any 2022 figure or total liability amount—only the $548 million long-term portion for 2023. The LLM incorrectly introduces a total liability figure and a prior-year number not present in the ground truth, failing the quantitative accuracy check. (3) Qualitatively, the LLM correctly identifies the use of Monte Carlo simulation and Level 3 inputs, as well as the classification of fair value changes in SG&A expenses, which aligns with the original answer’s description of fair value measurement practices. It also correctly notes that the liability was actively measured in 2023. However, it completely omits the key evolution asked in the question: the absence of contingent consideration disclosures in 2024 and the shift toward purchase price allocation adjustments. This missing synthesis between 2023 and 2024 severely undermines the multi-hop reasoning required. (4) Contextually, the answer is relevant and uses appropriate financial terminology, but the inclusion of false numerical data and failure to address the 2024 status—which is central to the question—results in a low correctness score. While some methodological details are accurate, the core evolution of the liability’s accounting treatment is not properly conveyed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1401,
        "completion_tokens": 525,
        "total_tokens": 1927
      },
      "error": null
    },
    {
      "question_id": 94,
      "question": "How has AMD's strategic emphasis on Vulkan API support evolved between 2022 and 2024, and what does this reveal about its approach to maintaining competitiveness in the discrete GPU market?",
      "original_answer": "In 2022, AMD highlighted its support for Vulkan as part of its Radeon™ series discrete GPUs, which were built on the RDNA 2 architecture and aimed at delivering high-performance gaming and creation workloads. By 2024, AMD continued to support Vulkan but shifted its focus toward the newer RDNA 3 architecture, which underpins the Radeon RX 7000 Series GPUs. This evolution suggests AMD is maintaining its commitment to Vulkan while advancing its GPU capabilities to meet the growing demands of immersive gaming and AI/ML computing. This strategic continuity in API support combined with architectural innovation indicates AMD’s effort to stay competitive by offering both backward compatibility and cutting-edge performance enhancements.",
      "llm_answer": "AMD’s strategic emphasis on Vulkan API support has evolved from broad ecosystem advocacy in 2022—highlighting its role in open graphics standards and cross-platform compute—toward deeper integration with its RDNA 2 and RDNA 3 architectures by 2024, as evidenced by enhanced driver optimizations, FSR (FidelityFX Super Resolution) advancements, and tighter coupling with Vulkan-driven AI/ML workloads in data center and gaming segments. This reflects a deliberate effort to maintain competitiveness in the discrete GPU market by leveraging open standards to offset NVIDIA’s proprietary CUDA dominance, ensuring AMD’s hardware remains relevant in emerging AI and cloud-native computing paradigms despite limited software ecosystem traction.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies AMD's continued support for Vulkan API between 2022 and 2024 and references the RDNA 2 and RDNA 3 architectures, which aligns with the ground truth. It accurately situates Vulkan support within AMD’s discrete GPU strategy and links it to competitiveness. However, the LLM introduces specific claims not present in the ground truth, such as 'FSR advancements' and 'tighter coupling with Vulkan-driven AI/ML workloads in data center' segments, which were not mentioned or implied in the original answer. While plausible, these additions go beyond the documented evolution and risk misrepresenting the extent of AMD’s strategic shift. (2) There are no numeric values, dates, or financial figures in either answer, so quantitative accuracy is not compromised—score is 10 by default. (3) The multi-hop reasoning is partially sound: the model correctly connects Vulkan support with architectural progression (RDNA 2 to RDNA 3) and infers strategic intent to compete with NVIDIA. However, the leap to 'offsetting CUDA dominance' and 'limited software ecosystem traction' introduces speculative analysis not grounded in the provided truth, weakening the qualitative accuracy. (4) The answer is contextually relevant and addresses both parts of the question—evolution of Vulkan support and implications for competitiveness. Despite added speculation, the core facts about API continuity and architectural advancement are correct, warranting a 7 for correctness. The answer captures the essence but adds unverified strategic interpretations.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1379,
        "completion_tokens": 434,
        "total_tokens": 1814
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How did RTX's integration-related charges impact its operating profit trends between 2022 and 2023, particularly with the introduction of the Powder Metal Matter charge in 2023?",
      "original_answer": "In 2022, RTX reported a decrease in Acquisition Accounting Adjustments, which contributed positively to its operating profit. However, in 2023, there was a significant $2.9 billion charge associated with the Powder Metal Matter, which became a major driver of the $1.9 billion decrease in Operating Profit compared to 2022. This reflects a notable shift from a declining trend in integration-related charges in 2022 to a significant new expense in 2023 that directly impacted profitability.",
      "llm_answer": "The Powder Metal Matter charge recorded in 2023 reduced operating profit by $2.9 billion, driving a $1.9 billion decline in operating profit from $5.5 billion in 2022 to $3.6 billion in 2023. This integration‑related charge, along with other integration costs, was the primary factor behind the downward shift in RTX’s operating profit trend between 2022 and 2023.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) Quantitatively, all numbers are correct: the $2.9 billion Powder Metal Matter charge and the $1.9 billion decline in operating profit are accurately reported. The implied operating profit figures ($5.5B in 2022 and $3.6B in 2023) are consistent with a $1.9B decrease and are reasonably inferred, though not explicitly stated in the original answer. (2) The entity identification is correct—RTX, 2022–2023 timeframe, Powder Metal Matter charge, and integration-related costs are all properly referenced. (3) The reasoning is sound: the LLM correctly identifies the 2023 charge as a primary driver of the profit decline, capturing the shift in trend from 2022 to 2023. However, it omits the specific mention of declining Acquisition Accounting Adjustments in 2022, which was a key contrast point in the original answer (i.e., integration costs were decreasing in 2022 but surged in 2023). This minor omission slightly weakens the multi-hop synthesis, which is why qualitative accuracy is 9 rather than 10. (4) The answer is contextually relevant, directly addressing the impact of integration-related charges on operating profit trends. Overall, the LLM conveys the core factual and quantitative content with high fidelity, meriting a correctness score of 9.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1221,
        "completion_tokens": 369,
        "total_tokens": 1591
      },
      "error": null
    },
    {
      "question_id": 95,
      "question": "How has MDLZ's relationship with Clif Bar evolved between 2023 and 2024, particularly in terms of acquisition-related financial activities?",
      "original_answer": "In 2023, MDLZ acquired Clif Bar, as noted in the 2023 10-K filing, with specific reference to the August 1, 2022 acquisition and related financial impacts such as integration costs and contingent consideration adjustments. By 2024, the relationship had evolved to include purchase price allocation adjustments for Clif Bar during the prior year, as detailed in the 2024 10-K filing. This indicates that the company had moved beyond the initial acquisition phase into a period of financial recalibration and consolidation of the Clif Bar acquisition.",
      "llm_answer": "Based on the provided SEC 10-K filings, MDLZ's relationship with Clif Bar evolved significantly between 2023 and 2024 in terms of acquisition-related financial activities. In 2023, MDLZ acquired Clif Bar for $2.9 billion (as noted in the \"Organic Net Revenue\" discussion on page 39, referencing the August 1, 2022 acquisition), which added incremental net revenues of $507 million (constant currency) through the one-year anniversary. However, the 2024 filings (pages 85-89) do not indicate any additional acquisition, divestiture, or financial activity involving Clif Bar—MDLZ's focus shifted to exiting its JDEP investment (selling remaining shares for €2.2 billion in November 2024) and recording intangible asset impairments related to brands acquired through past acquisitions (including Clif Bar, as noted in Note 6 on page 87). No new acquisition-related financial events for Clif Bar are disclosed in 2024.",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer contains several factual inaccuracies that significantly undermine its correctness. First, it incorrectly states that MDLZ acquired Clif Bar in 2023 for $2.9 billion, referencing August 1, 2022 — this contradicts the ground truth, which clarifies that the acquisition occurred on August 1, 2022, not in 2023. While the $2.9 billion figure and August 1, 2022 date are accurate, attributing the acquisition to 2023 is a major error in timeline alignment. Second, the claim that Clif Bar contributed $507 million in incremental net revenue (constant currency) through its one-year anniversary is not present in the original answer and lacks corroboration from the ground truth, making it potentially fabricated or misattributed. Third, the LLM asserts that no new acquisition-related financial events for Clif Bar are disclosed in 2024, but this contradicts the ground truth, which explicitly states that the 2024 10-K includes purchase price allocation adjustments for Clif Bar — a key post-acquisition financial activity. The mention of intangible asset impairments related to Clif Bar in Note 6 is partially relevant but framed as part of broader impairments without confirming whether Clif Bar was specifically impaired, which introduces ambiguity. The focus on JDEP divestiture, while contextually accurate for MDLZ’s 2024 activities, distracts from the core question about Clif Bar’s evolving financial relationship. Multi-hop reasoning is partially sound — the model attempts to connect filings across years — but fails to accurately represent the nature of 2024 financial activities related to Clif Bar. Quantitative accuracy is moderate: some numbers are correct (acquisition date, price), but others (like $507M revenue) are unverified and potentially incorrect. Qualitative accuracy suffers due to misattribution of timing and omission of purchase price adjustments in 2024. Contextual relevance is high — the answer stays focused on acquisition-related financials and cites appropriate sections — but factual errors reduce overall correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1364,
        "completion_tokens": 552,
        "total_tokens": 1916
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has Gulfstream's approach to energy efficient engines evolved from 2023 to 2024, and what specific aircraft developments reflect this shift?",
      "original_answer": "In 2023, Gulfstream emphasized its leadership in the use of sustainable aviation fuel (SAF) and energy efficient engines, focusing on continuous R&D investment to develop technologically advanced business jets. However, no new aircraft model powered by energy efficient engines was introduced that year. By 2024, Gulfstream had transitioned from announcement and development phases to actual production of energy efficient engines, as evidenced by the introduction of the G700, which features 'all-new engines' designed for high-speed performance and efficiency. This marks a tangible evolution from strategic positioning in 2023 to operational realization in 2024.",
      "llm_answer": "Gulfstream’s energy‑efficient engine strategy continued its shift toward sustainability from 2023 to 2024, emphasizing broader use of sustainable aviation fuel (SAF) and carbon‑neutral travel options. The newest models—particularly the ultra‑long‑range G700 (certified in early 2024) and the long‑range G800/G400 introduced in 2021—reflect this shift through improved fuel efficiency, reduced emissions, and the ability to operate on 100 % SAF, exemplified by the world’s first transatlantic 100 % SAF flight in November 2023.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 6,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the general direction of Gulfstream's shift toward energy efficiency and sustainability, correctly noting the emphasis on sustainable aviation fuel (SAF) and the introduction of advanced aircraft. However, it contains significant factual inaccuracies. The G800/G400 were not introduced in 2021, and the G700 was not merely 'certified in early 2024'—the ground truth emphasizes that 2024 marked the transition to actual production of new, all-new engines with the G700 as the key model reflecting this shift. The original answer highlights that no new aircraft with energy-efficient engines was introduced in 2023, but the LLM implies operational progress (e.g., transatlantic 100% SAF flight in Nov 2023) as part of Gulfstream’s engine development, which is misleading—this flight was a demonstration, not a reflection of new engine deployment. (2) Quantitative inaccuracies include the claim about the G800/G400 introduction in 2021, which is incorrect per the ground truth (no mention of G800/G400 in this context), and the implication that the 100% SAF flight directly reflects engine development, which overreaches the evidence. The date of the SAF flight (Nov 2023) is accurate, but its relevance to engine evolution is misrepresented. (3) The multi-hop reasoning is partially sound—linking SAF use and aircraft models to energy efficiency—but fails to correctly synthesize the evolution from R&D focus in 2023 to production in 2024. Instead, it conflates fuel usage demonstrations with engine technology shifts. (4) The contextual relevance is high because the answer addresses Gulfstream’s strategy and aircraft developments, but correctness is reduced due to incorrect model timelines and overstatement of 2023 achievements. The core evolution—strategic positioning to operational realization—is not clearly conveyed, leading to a moderate score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 512,
        "total_tokens": 1809
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has AMD's relationship with semi-custom SoC products evolved from 2022 to 2024, particularly in terms of revenue structure and strategic positioning?",
      "original_answer": "In 2022, AMD's relationship with semi-custom SoC products was characterized by dependency, with revenue derived from both non-recurring engineering fees and sales of the products themselves, and success was directly tied to third-party product performance. By 2024, AMD's relationship evolved to one of active production and broader strategic integration, as semi-custom SoC products became part of a more diversified product portfolio that includes AI accelerators, GPUs, APUs, and DPUs. This shift indicates a more central and controlled role for AMD in the development and commercialization of these products, aligning them more closely with long-term industry trends and internal innovation strategies.",
      "llm_answer": "From 2022 through 2024 AMD’s semi‑custom SoC revenue remained a small, project‑driven component of its overall business, driven by design‑and‑development fees and sales of custom ASICs that are tightly linked to the success of the customer’s own products.  The company continues to report these revenues under “Custom products” in its Gaming segment, recognizing them over the production period using a cost‑plus‑margin input method, but the segment’s overall contribution has not expanded materially; instead, AMD has increasingly emphasized its higher‑margin CPUs, GPUs and data‑center offerings, positioning semi‑custom SoCs as a niche, opportunistic revenue stream rather than a core growth pillar.",
      "correctness_score": 4,
      "quantitative_accuracy": 8,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains some correct elements but diverges significantly from the ground truth in terms of strategic evolution. (1) Correctly identifies that semi-custom SoC revenue is tied to customer product success and includes non-recurring engineering (NRE) fees and product sales, and accurately notes reporting under 'Custom products' in the Gaming segment. The cost-plus-margin revenue recognition method is also factually consistent. (2) No explicit numeric values (e.g., revenue amounts, percentages) are present in either answer, so quantitative accuracy is not penalized—format and references are consistent where implied. (3) However, the multi-hop reasoning is flawed: the ground truth states that by 2024, AMD evolved to a more central, integrated role with semi-custom SoCs becoming part of a diversified portfolio including AI accelerators, GPUs, APUs, and DPUs—indicating strategic expansion. In contrast, the LLM claims semi-custom SoCs remain a 'niche, opportunistic revenue stream' and that AMD has de-emphasized them, which contradicts the upward strategic integration described in the original. This misrepresents the core evolution in strategic positioning. (4) While contextually relevant and using accurate terminology, the LLM answer fails to capture the key shift from dependency to active, strategic integration, resulting in a partially correct but ultimately misleading conclusion. Hence, correctness is scored low despite some factual accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1353,
        "completion_tokens": 405,
        "total_tokens": 1758
      },
      "error": null
    },
    {
      "question_id": 96,
      "question": "How has the company's structure of preferred share authorization evolved between fiscal years 2023 and 2024, and what does this indicate about its capital strategy?",
      "original_answer": "The company's preferred share authorization structure remained unchanged between fiscal years 2023 and 2024, with 127.5 million Preferred Shares at $0.20 par value and 500 thousand A Preferred Shares at $1.00 par value authorized in both years. Additionally, no Preferred Shares or A Preferred Shares were issued or outstanding in either year. This indicates that the company has not utilized or pursued any changes in its preferred share structure as part of its capital strategy during this period.",
      "llm_answer": "The company's preferred share authorization remains unchanged between fiscal 2023 and 2024, with no issued or outstanding preferred shares reported in either year. This indicates a stable capital structure with no new preferred equity being authorized or utilized, suggesting the company is prioritizing other capital allocation strategies like share repurchases and debt management over preferred share issuance.",
      "correctness_score": 8,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly states that the preferred share authorization remained unchanged between fiscal years 2023 and 2024 and that no preferred shares were issued or outstanding in either year, which aligns with the ground truth. However, it omits the specific breakdown of authorized shares — namely, 127.5 million Preferred Shares at $0.20 par value and 500 thousand A Preferred Shares at $1.00 par value — which are key quantitative details from the original answer. (2) While the absence of issued/outstanding shares is accurately reported, the specific authorized amounts are missing, reducing quantitative completeness. The numbers that are mentioned (i.e., no changes, no issuances) are factually correct, and no incorrect calculations are made. (3) The reasoning is sound: the lack of change and issuance supports the conclusion of a stable capital strategy. The inference that the company may be prioritizing other strategies like share repurchases and debt management is reasonable and adds contextual insight, though this specific emphasis is not in the ground truth. It does not contradict it, but represents a slight expansion. (4) The answer is contextually relevant and captures the core factual and inferential content of the original, but the omission of precise authorized share classes and par values prevents a top score. The missing specifics impact completeness in a multi-hop financial context where exact authorizations matter for capital structure analysis.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1232,
        "completion_tokens": 412,
        "total_tokens": 1645
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has the framing of reputational risk related to adverse publicity evolved between 2022 and 2024 in BK's risk disclosures, particularly in terms of associated impacts or linked concerns?",
      "original_answer": "In 2022, BK identified adverse publicity as a risk that could negatively affect its business, financial condition, and results of operations, and linked it with government scrutiny and other reputational harm. By 2024, the framing of this risk remained present but was expanded to include broader reputational impacts from sustainability concerns such as climate change and diversity, in addition to being tied to new operational models like the platforms operating model transition. This indicates a broadening of the contexts in which adverse publicity could negatively impact BK's reputation and business outcomes.",
      "llm_answer": "Between 2022 and 2024, BK’s risk disclosures show a clear evolution in how reputational risk tied to adverse publicity is framed—from a generic “reputation” concern to a more explicit linkage with operational failures, cybersecurity incidents, and broader stakeholder scrutiny. In the 2022 filing (pages 2‑6), reputational risk appears only as one of several bullet‑point threats, listed alongside operational errors, technology disruptions, and regulatory actions, without detailing any specific reputational impact. By the 2024 filing (pages 3‑7), the same theme is retained but is now embedded in richer language that connects reputational harm directly to “adverse events, publicity, government scrutiny or other reputational harm” and to “impacts from geopolitical events, acts of terrorism, war, natural disasters, the physical effects of climate change, pandemics and other similar events,” underscoring that reputational damage can arise not just from internal mishaps but from external shocks that attract public and regulatory attention. Moreover, the 2024 text explicitly ties reputational risk to “sustainability concerns, including a focus on climate change and diversity,” reflecting a newer, ESG‑driven dimension that was absent in the earlier version. Thus, the framing has shifted from a broad, undifferentiated warning to a nuanced, multi‑factor narrative that associates reputational risk with specific operational, technological, regulatory, and ESG‑related exposures and their potential fallout on the bank’s brand and stakeholder trust.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns closely with the ground truth. It correctly identifies the evolution of BK's risk disclosures from 2022 to 2024 regarding reputational risk and adverse publicity. The 2022 framing is accurately described as linking adverse publicity to government scrutiny and reputational harm, though in more general terms. The 2024 expansion is correctly noted, including the addition of sustainability concerns like climate change and diversity, which reflects an ESG-driven broadening—this matches the ground truth. The LLM adds contextual detail not in the original answer—such as connections to cybersecurity, geopolitical events, and operational models—but these are consistent with typical 10-K risk factor language and do not contradict the ground truth; they enrich it without introducing inaccuracies. The mention of 'platforms operating model transition' in the ground truth is slightly more specific than the LLM’s 'operational failures' and 'technology disruptions,' but the LLM’s phrasing is a reasonable interpretation. No numeric data is present in the question or answers, so quantitative accuracy is scored based on correct years (2022, 2024) and document references (pages), which are accurate. The reasoning is sound, multi-hop synthesis across years and themes is correct, and the answer fully addresses the question about evolution in framing and associated impacts. The only reason for not scoring a 10 is that the LLM slightly overgeneralizes the 2022 disclosure as 'generic' and omits explicit mention of the 'platforms operating model' linkage in 2024, which is a minor omission. Overall, the answer is factually correct, comprehensive, and contextually appropriate.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1554,
        "completion_tokens": 467,
        "total_tokens": 2021
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How did Amazon's financial investment and valuation approach toward Anthropic, PBC evolve from 2023 to 2024, particularly in terms of investment classification and the factors affecting its valuation?",
      "original_answer": "In 2023, Amazon disclosed a $1.25 billion convertible note investment in Anthropic, PBC, classified as available-for-sale and reported at fair value with unrealized gains and losses included in 'Accumulated other comprehensive income (loss).' The note was categorized as a Level 3 asset, and Amazon had an agreement to invest an additional $2.75 billion in a second convertible note by Q1 2024. By 2024, the investment was still classified as available-for-sale but was noted to be part of a broader portfolio of convertible debt investments in private companies, primarily referencing Anthropic, PBC. The 2024 filing emphasized increased complexity in valuing private company investments due to the lack of readily available market data and global economic uncertainty, indicating a shift toward acknowledging heightened valuation risk. While the classification remained consistent, the 2024 disclosure placed more emphasis on the challenges of valuation rather than the mechanics of the investment itself.",
      "llm_answer": "Amazon’s investment in Anthropic, PBC was initially classified as an available‑for‑sale convertible note (recorded at fair value with unrealized gains/losses in OCI) and later re‑classified to a Level 3 equity investment; its valuation is driven by the lack of market pricing for private‑company equity, complex valuation inputs, and evolving economic conditions, which together cause the carrying value to be highly sensitive to observable price changes and impairment indicators. Consequently, while the 2023 10‑K reflects a $754 million carrying value for Anthropic, the 2024 filing shows the investment still held at fair value but subject to more pronounced valuation adjustments due to these factors.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies. First, it incorrectly states that Amazon reclassified the investment from a convertible note to a Level 3 equity investment in 2024, while the ground truth confirms the investment remained classified as available-for-sale and continued to be a convertible note (Level 3 asset, but debt, not equity). This mischaracterization of the investment type and classification change is a major error. Second, the LLM claims a $754 million carrying value for Anthropic in 2023, which does not appear in the ground truth; the original answer specifies a $1.25 billion investment, with no mention of a $754 million carrying value. This number is unsupported and likely incorrect. (2) Quantitative accuracy is low: the $754 million figure is unverified and contradicts the disclosed $1.25 billion investment. The additional $2.75 billion commitment is entirely omitted. No correct calculations are presented, and key numbers are either wrong or missing. (3) The multi-hop reasoning is partially sound in that the model attempts to synthesize valuation challenges (lack of market pricing, complex inputs, economic conditions), which aligns with the 2024 emphasis on valuation difficulty. However, it fails to correctly track the continuity of classification (no reclassification occurred) and misrepresents the nature of the investment (debt vs. equity). The answer also omits the contractual agreement to invest an additional $2.75 billion by Q1 2024, a key element of the evolution. (4) Contextual relevance is high because the answer addresses the core themes of investment classification and valuation challenges over time. However, due to significant factual and quantitative errors—especially the false reclassification and incorrect carrying value—the overall correctness score is low. The qualitative accuracy is moderate because some reasoning about valuation complexity is valid, but the foundational facts are flawed.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1441,
        "completion_tokens": 534,
        "total_tokens": 1976
      },
      "error": null
    },
    {
      "question_id": 97,
      "question": "How has the nature of the risks related to the protection of MDLZ's intellectual property, including know-how, evolved between 2023 and 2024?",
      "original_answer": "In 2023, MDLZ emphasized the importance of protecting its intellectual property rights, particularly trademarks, patents, copyrights, and know-how, through a combination of legal mechanisms such as patent and trademark laws, licensing agreements, and third-party nondisclosure agreements. The company expressed concern that failure to protect these rights or any legal changes reducing intellectual property protections—especially in response to developments in artificial intelligence technologies—could significantly harm its competitiveness and financial condition. In 2024, while the company maintained its emphasis on the significance of intellectual property rights, it did not specifically mention artificial intelligence as a factor affecting protection. Instead, the 2024 disclosure focused on the broader risks of legal or regulatory non-compliance and the potential for civil or criminal penalties, reputational damage, and financial loss due to litigation or enforcement actions. This shift indicates a broadening of the risk context without the specific emphasis on AI-related threats present in 2023.",
      "llm_answer": "Between 2023 and 2024, the risks to MDLZ’s intellectual property protection shifted from a general focus on legal enforcement and third‑party infringement to heightened concern over emerging threats from artificial‑intelligence technologies and potential changes in law that could weaken existing protections. The 2024 filing emphasizes that failure to obtain or adequately safeguard IP rights—especially in light of AI developments—could diminish competitiveness and materially harm the business, whereas the 2023 discussion primarily highlighted the cost and reputational risks of infringement litigation without stressing AI‑related vulnerabilities. Consequently, the nature of the IP risk has become more forward‑looking and technology‑specific, adding a new dimension to the company’s exposure.",
      "correctness_score": 3,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer is largely incorrect in its characterization of the evolution of MDLZ's intellectual property risks between 2023 and 2024. According to the ground truth, in 2023 MDLZ specifically mentioned artificial intelligence as a concern in relation to intellectual property protection, while in 2024 this AI-specific reference was dropped and the focus broadened to include general legal and regulatory non-compliance risks, penalties, and reputational harm. However, the LLM answer incorrectly reverses this trend: it claims that AI concerns were absent in 2023 and then newly emphasized in 2024, stating that 'the 2024 filing emphasizes...AI developments'—which contradicts the original answer. This is a critical factual inversion. There are no numerical values in the question or answers, so quantitative accuracy is not applicable in a meaningful way, but since no numbers are present or misrepresented, a score of 10 is appropriate by default. The qualitative accuracy is low because the core reasoning is flawed—the multi-hop synthesis across years is incorrect, and the direction of change is misrepresented. Contextual relevance is moderate because the answer addresses the right topic (IP protection risks) and discusses relevant themes like legal enforcement and competitiveness), but the misrepresentation of the timeline and emphasis undermines the validity. The answer creates a narrative contrary to the ground truth, making it substantially misleading despite using plausible language.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1477,
        "completion_tokens": 412,
        "total_tokens": 1889
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has Goldman Sachs' treatment of Non-Employee Director Equity Award Agreements evolved between the 2023 and 2024 SEC filings, particularly in terms of referenced agreements and their timelines?",
      "original_answer": "In 2023, Goldman Sachs referenced Non-Employee Director Equity Award Agreements through Exhibit 10.17, which pointed to an amendment dated November 28, 2008. By 2024, the company continued to disclose these agreements under the same exhibit number (10.18), but the referenced source shifted to Exhibit 10.69 from the 2008 Annual Report, indicating a formalization or consolidation of prior amendments. This evolution shows a continuation of the policy with deeper historical documentation being emphasized in the later filing.",
      "llm_answer": "Based on the provided SEC filing excerpts, the treatment of Non-Employee Director Equity Award Agreements has evolved through updated forms referenced in the 2024 10-K. Specifically, the company has incorporated newer award agreement forms (e.g., \"Form of Non-Employee Director RSU Award Agreement\" dated 2023/2024, referenced in Exhibit 10.31-10.33 and further detailed in Items 10.31–10.33 of the 2024 filing) that supersede older pre-2015 agreements (e.g., those cited in 2014 filings as \"pre2015\" forms). The 2024 filing explicitly includes updated agreements for \"Year-End RSU Award Agreement (fully vested)\" and \"Year-End RSU Award Agreement (Base and/or Supplemental)\" under Item 10.35–10.36, indicating a formalized, current framework for director equity compensation that replaces prior iterations. This evolution reflects a shift from historical pre-2015 templates to newer, explicitly documented agreements effective in 2023–2024, as evidenced by the inclusion of these forms in the 2024 filing's Exhibit list and the \"Amendments to Certain Non-Employee Director Equity Award Agreements\" referenced in the 2008 filing (which are now superseded by the newer forms). The timeline shows a progression from early 2008–2014 disclosures of older agreements to the 2024 filing's updated, current forms, with no indication of further amendments beyond the 2023–2024 versions.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 2,
      "contextual_relevance": 4,
      "detailed_feedback": "The LLM answer is largely incorrect and fails to align with the ground truth. (1) It references Exhibit numbers 10.31–10.36 in the 2024 filing, which do not match the ground truth exhibit numbers (10.18 and 10.69). The original answer states that in 2023, the agreement was referenced under Exhibit 10.17 and in 2024 under Exhibit 10.18, with a shift to referencing Exhibit 10.69 from the 2008 Annual Report. The LLM instead invents new exhibit numbers and claims the 2024 filing includes 'Form of Non-Employee Director RSU Award Agreement' under Items 10.31–10.36, which is unsupported by the ground truth. (2) The dates mentioned (2023/2024 agreements, pre-2015 forms) are speculative and not corroborated; the ground truth only confirms a continued reference to a 2008 amendment and a shift in documentation source, not the creation of new agreement forms. (3) The multi-hop reasoning is flawed: the LLM incorrectly infers a formalized update in 2023–2024 based on non-existent exhibit references and mischaracterizes the evolution as a replacement of old templates, whereas the ground truth describes a continuity of policy with a shift in citation to emphasize historical documentation. (4) The answer introduces concepts like 'Year-End RSU Award Agreement (fully vested)' and 'Amendments...referenced in the 2008 filing' being superseded, which are not present or implied in the original answer. While the question is addressed in theme (evolution of director equity agreements), the factual inaccuracies in entities, exhibits, dates, and reasoning severely undermine correctness. Minor credit is given for attempting to trace a timeline and recognizing a shift in documentation, but the core facts are incorrect.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1488,
        "completion_tokens": 465,
        "total_tokens": 1954
      },
      "error": null
    },
    {
      "question_id": 98,
      "question": "How has BKNG's relationship with travel service providers evolved between 2022 and 2023 in terms of revenue recognition and contractual responsibilities?",
      "original_answer": "In 2022, BKNG described its relationship with travel service providers as one where it connects consumers to providers through its platforms, emphasizing its role as an intermediary without taking responsibility for delivering the travel services. The company highlighted that it earns revenues primarily from facilitating reservations and also mentioned the impact of cancellations during the pandemic recovery phase. By 2023, BKNG provided more detailed accounting treatment around its contracts with travel service providers, specifying that it recognizes revenue on a net basis due to its role as an agent, and further clarified its revenue recognition timing as occurring at the point when travelers begin using the arranged services. This reflects a shift from a general description of the relationship to a more structured and accounting-driven dependency on travel service providers, particularly in how it recognizes commissions and transaction revenues.",
      "llm_answer": "Based on the provided document pages, BKNG's relationship with travel service providers evolved between 2022 and 2023 in terms of revenue recognition and contractual responsibilities as follows:  \n\n1.  **Revenue Recognition Shift to Net Basis**: BKNG continues to present revenue on a net basis for its online travel reservation services, meaning it recognizes revenue as the commission or margin earned from travel service providers (e.g., commissions or transaction net revenue) rather than the gross amount charged to travelers. This is explicitly stated in the 2023 document (page 83), which confirms that contracts with travel providers give them the ability to market reservation availability without transferring responsibility for delivering services to BKNG, necessitating net revenue presentation.  \n\n2.  **Increased Merchant-Based Transactions**: BKNG has expanded its use of \"merchant\" transactions, where it facilitates payments from travelers *to* travel service providers (e.g., handling payments, refunds, and charging fees). This shift, highlighted in the 2023 document (page 84), increases BKNG's contractual responsibilities (e.g., managing payment processing, chargebacks, and refunds) and directly impacts revenue recognition, as merchant revenues (including transaction net revenue and credit card rebates) are now a larger component of its earnings. This evolution reflects a strategic move toward more integrated payment handling (\"Connected Trip\" strategy), though it introduces additional expenses that negatively affect operating margins despite revenue growth.  \n\nThese changes are consistent across both 2022 and 2023 filings, with the 2023 document further detailing the operational and financial implications of this expanded merchant model.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in its description of BKNG's revenue recognition practices and correctly identifies that revenue is recognized on a net basis due to BKNG's role as an agent, citing the appropriate 2023 document page (83). It accurately notes the increased emphasis on merchant-based transactions and expanded contractual responsibilities in payment processing, refunds, and chargebacks, which aligns with the 'Connected Trip' strategy mentioned in the 2023 filing. However, the LLM answer diverges from the original (ground truth) answer by emphasizing the expansion of 'merchant-based transactions' as a key evolution between 2022 and 2023, while the ground truth focuses on a shift from a general description of the provider relationship to a more detailed, accounting-driven clarification of revenue recognition timing—specifically that revenue is recognized when travelers begin using services. The LLM does not mention this timing change, which is a core element of the original answer. Additionally, while the LLM claims these changes are 'consistent across both 2022 and 2023 filings,' the ground truth indicates a clear evolution in disclosure depth and accounting specificity, implying progression rather than consistency. This misrepresents the nature of the evolution. There are no numerical inaccuracies (quantitative accuracy is perfect), and the entities (BKNG, travel service providers, years 2022–2023) are correct. The reasoning is sound but synthesizes different aspects of the filings than required, missing the central point about revenue recognition timing and overemphasizing merchant model expansion not highlighted in the ground truth. Contextual relevance is high as the answer addresses revenue recognition and contractual roles, but misses the precise evolution described in the original.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1685,
        "completion_tokens": 495,
        "total_tokens": 2180
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "What specific changes occurred in the structure of Goldman Sachs' executive life insurance policy disclosures between the 2023 and 2024 10-K filings?",
      "original_answer": "In the 2023 10-K filing, Goldman Sachs included the Goldman Sachs & Co. LLC Executive Life Insurance Policy and Certificate with Metropolitan Life Insurance Company (Exhibit 10.11) and a form of the policy with Pacific Life & Annuity Company (Exhibit 10.12). In the 2024 10-K filing, these exhibits were not only retained but renumbered to 10.12 and 10.13 respectively, indicating a reorganization of exhibit numbering. This renumbering and retention of the policies in the 2024 filing demonstrates a structural update in how the policies are presented within the filing, rather than a substantive change in the policies themselves.",
      "llm_answer": "The executive life insurance policy disclosures remained unchanged between the 2023 and 2024 10-K filings. Both years reference the same policy details in Item 10 (specifically Exhibit 10.12 and 10.13), which describe the Goldman Sachs & Co. LLC Executive Life Insurance Policy with Metropolitan Life Insurance Company and Pacific Life & Annuity Company for Participating Managing Directors, including the form of restriction on Policy Owner's Rights. No new or modified disclosures related to executive life insurance policies appear in the 2024 filing.",
      "correctness_score": 4,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer incorrectly states that the executive life insurance policy disclosures 'remained unchanged' between the 2023 and 2024 filings, which contradicts the ground truth. The key structural change was the renumbering of exhibits: in 2023, the policies were listed as Exhibits 10.11 and 10.12, but in 2024 they were renumbered to 10.12 and 10.13 respectively. The LLM incorrectly claims both policies were referenced as Exhibits 10.12 and 10.13 in both years, which is factually wrong. (2) Quantitatively, the LLM gets the exhibit numbers partially right for 2024 but misrepresents the 2023 numbering, leading to an inaccurate comparison. There are no calculations in this question, but the exhibit numbers are critical data points and must be accurate. (3) The multi-hop reasoning fails because the model does not recognize that the renumbering across years constitutes a structural change in disclosure format. Instead, it concludes there was no change, missing the core point of the question. The synthesis across years is flawed. (4) While the LLM correctly identifies the companies (Metropolitan Life Insurance Company, Pacific Life & Annuity Company) and the nature of the policies, it mischaracterizes the exhibit history and thus the structural evolution. The answer is contextually relevant and addresses the right topic, but the factual error on exhibit numbering undermines correctness. Hence, correctness and qualitative accuracy are low, quantitative accuracy is moderate due to partial number correctness, and relevance is high.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1297,
        "completion_tokens": 429,
        "total_tokens": 1727
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How has the strategic importance and manufacturing approach for FBAR filters evolved between 2022 and 2024, particularly in terms of internal fabrication and competitive positioning?",
      "original_answer": "In 2022, FBAR filters were highlighted as a key product utilizing Broadcom’s proprietary processes, fabricated internally to protect IP and accelerate time to market, alongside vertical-cavity surface emitting lasers and side emitting lasers. The internal fabrication was specifically emphasized as a means to maintain competitive advantage by safeguarding innovation. By 2024, FBAR filters remained part of the internal fabrication strategy, but the context expanded to include a more comprehensive list of competitors in the semiconductor space, such as Qorvo, Qualcomm, and Skyworks, indicating a more intense competitive environment. This suggests that while the internal manufacturing strategy for FBAR filters remained consistent, the competitive pressure in wireless communications increased significantly, requiring Broadcom to reinforce its IP protections and innovation cycle.",
      "llm_answer": "Between 2022 and 2024, Broadcom’s strategic focus on FBAR filters shifted from primarily outsourcing manufacturing to leveraging internal fabrication capabilities to maintain a competitive edge. In the 2022 filing, the company emphasized outsourcing most manufacturing but highlighted internal fabrication for proprietary processes like FBAR filters to protect IP and accelerate time-to-market. By 2024, this approach was reinforced as part of a broader strategy to optimize fabrication processes for internally produced devices, ensuring differentiation in high-value markets. This evolution underscores a deliberate move toward vertical integration for critical components, strengthening Broadcom’s position against competitors reliant on external suppliers.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual error in claiming that Broadcom shifted from 'outsourcing most manufacturing' to internal fabrication between 2022 and 2024. The original answer states that FBAR filters were already fabricated internally in 2022 as part of a strategy to protect IP and accelerate time to market, with no mention of prior outsourcing. This misrepresents the evolution as a shift toward vertical integration, whereas the ground truth indicates consistency in internal fabrication strategy. (2) There are no numeric values, dates, or calculations in either answer, so quantitative accuracy is not applicable—no errors in this regard, hence a score of 10. (3) The multi-hop reasoning is flawed: the LLM incorrectly infers a strategic shift over time that is not supported by the original data. While both years mention internal fabrication, the actual evolution noted in the ground truth is the expansion of competitive pressure (with mention of Qorvo, Qualcomm, Skyworks in 2024), not a change in manufacturing approach. The LLM fails to mention this key competitive context, which is central to the original answer. (4) Contextual relevance is high because the answer addresses FBAR filters, internal fabrication, IP protection, and competitive positioning—but the reasoning and factual basis are partially incorrect, leading to a moderate correctness score. The answer sounds plausible but mischaracterizes the strategic evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1420,
        "completion_tokens": 407,
        "total_tokens": 1828
      },
      "error": null
    },
    {
      "question_id": 99,
      "question": "How has BMY's strategic positioning of Krazati evolved between 2023 and 2024, particularly in terms of clinical development focus and financial valuation?",
      "original_answer": "In 2023, Krazati was positioned as part of BMY’s oncology portfolio with specific clinical trials listed: KRYSTAL-17 for 1L NSCLC TPS<50%, KRYSTAL-10 for 2L CRC, and KRYSTAL-12* for 2L+ Mutated NSCLC. By 2024, BMY had acquired Mirati for $4.8 billion, securing full rights to Krazati, which had already received FDA and EMA approvals for second-line NSCLC and FDA approval for advanced KRAS-mutated colorectal cancer. Additionally, Krazati was now being developed in combination with a PD-1 inhibitor for first-line NSCLC, indicating a significant expansion in its clinical and commercial strategy.",
      "llm_answer": "BMY's strategic positioning of Krazati has evolved significantly between 2023 and 2024 through two major acquisitions that expanded its clinical development focus and financial valuation. In 2023, BMS acquired Mirati Therapeutics for $4.8 billion (net $4.1 billion after cash acquired), gaining rights to Krazati (a KRAS inhibitor approved for second-line NSCLC and colorectal cancer) and the PRMT5 inhibitor asset, with the deal including $1.0 billion in contingent value rights. This was followed by the $4.1 billion acquisition of RayzeBio in February 2024, which added an actinium-based radiopharmaceutical platform and RYZ101 (Phase III for gastroenteropancreatic neuroendocrine tumors). The combined impact of these acquisitions, particularly the $4.9 billion total consideration allocated to Mirati (including $248 million for contingent value rights) and $3.8 billion for RayzeBio, drove a substantial increase in R&D investment, with $12.1 billion expensed on Acquired IPRD for Karuna and $12,122 million for RayzeBio's IPRD assets in 2024. Financially, the acquisitions contributed to a significant rise in intangible assets, with Krazati's definite-lived acquired product rights valued at $640 million and indefinite-lived IPRD assets at $3.5 billion, while the goodwill from Mirati ($152 million) and RayzeBio ($152 million) reflected the strategic premium paid for these pipeline assets.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The core error is the misrepresentation of BMY's (Bristol Myers Squibb) acquisition of Mirati: while the $4.8 billion figure is correct, the LLM incorrectly states that the acquisition occurred in 2023, whereas the ground truth indicates it was completed in 2024. Furthermore, the LLM fabricates a second acquisition of RayzeBio for $4.1 billion in February 2024 and ties it to Krazati's development, which is false—RayzeBio is unrelated to Krazati. The financial figures such as $12.1 billion expensed on Acquired IPRD for Karuna and $12,122 million for RayzeBio are not only irrelevant to Krazati but also factually incorrect in this context. The $640 million definite-lived product rights and $3.5 billion IPRD valuation for Krazati are not supported by the ground truth and appear invented. (2) Quantitative accuracy is severely lacking: while the $4.8 billion Mirati acquisition is correct, the net $4.1 billion after cash, $1.0 billion CVR, $248 million for CVRs, $3.8 billion RayzeBio, $152 million goodwill each, and R&D expensing figures are either incorrect or misattributed. The ground truth does not mention any of these specific valuations for Krazati. (3) Multi-hop reasoning fails: the question asks about the evolution of Krazati’s strategic positioning in clinical development and valuation. The LLM incorrectly links RayzeBio’s acquisition to Krazati, conflates multiple unrelated assets, and misses the actual clinical evolution—specifically, the shift to combination therapy with a PD-1 inhibitor in first-line NSCLC. It also fails to mention the specific trials (KRYSTAL-17, -10, -12*) from 2023. (4) Contextual relevance is moderate because the answer discusses BMY, oncology, acquisitions, and some correct elements like Krazati’s approvals, but the focus is derailed by irrelevant and false information. The core evolution of Krazati’s clinical strategy is overshadowed by fabricated financials and incorrect M&A details. Thus, despite touching on relevant themes, the answer is largely factually incorrect and misleading.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1501,
        "completion_tokens": 568,
        "total_tokens": 2070
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How has the relationship between BKNG and travel service providers evolved between 2022 and 2023, particularly in terms of how BKNG manages financial obligations and incentives related to these providers?",
      "original_answer": "In 2022, BKNG primarily competed with travel service providers, highlighting the intense and evolving nature of the competitive landscape in the online travel market. By 2023, BKNG's relationship with travel service providers shifted to a more dependent model, as evidenced by the increase in the 'Deferred merchant bookings' liability on its balance sheet, which reflects amounts estimated to be payable to travel service providers. Additionally, BKNG introduced more incentive programs, such as referral bonuses, rebates, and loyalty points, which are recognized as a reduction of revenue, indicating a strategic shift toward enhancing partnerships and incentivizing collaboration with travel service providers rather than solely competing with them.",
      "llm_answer": "Between 2022 and 2023, Booking Holdings (BKNG) refined its financial treatment of travel service providers by reclassifying certain indirect taxes (e.g., digital services taxes) from \"General and administrative\" to \"Sales and other expenses\" to better align expense presentation with revenue variability, as disclosed in the 2022 and 2023 10-K filings. Additionally, BKNG adopted new accounting standards for convertible debt instruments, which impacted how it records financial obligations related to debt issuances and interest expense, though this primarily affects its balance sheet and income statement presentation rather than direct incentives to travel providers. The core relationship with travel service providers remains centered on commission-based revenue (agency or merchant) and platform-driven growth, with no significant structural changes to incentive mechanisms reported in the provided documents.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 3,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in addressing the core of the question. While it mentions financial treatments and accounting changes, it completely misses the key shift in BKNG's relationship with travel service providers from competition in 2022 to dependence in 2023, as evidenced by the increase in 'Deferred merchant bookings' liability and the introduction of new incentive programs like referral bonuses, rebates, and loyalty points. These incentives are recognized as a reduction of revenue, indicating a strategic pivot toward partnership, which is central to the ground truth but absent in the LLM response. Instead, the LLM focuses on reclassification of indirect taxes and accounting for convertible debt—topics unrelated to the relationship dynamics with travel service providers. (2) There are no numeric values in either answer, so quantitative accuracy is not compromised; the LLM does not fabricate numbers. (3) The multi-hop reasoning is flawed: the question requires synthesizing changes in business model and financial obligations toward providers across 2022 and 2023, but the LLM fails to connect BKNG’s evolving dependency or incentive structures. It references correct document sources (10-K filings) but draws irrelevant conclusions. (4) The contextual relevance is low because the answer discusses peripheral accounting changes rather than the strategic evolution in provider relationships. The qualitative accuracy is poor due to incorrect entity focus (tax reclassification vs. deferred payments/incentives) and failure to identify the shift in business model. Correctness is very low because the answer does not reflect the actual evolution described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1431,
        "completion_tokens": 468,
        "total_tokens": 1900
      },
      "error": null
    },
    {
      "question_id": 100,
      "question": "How has Broadcom's involvement in the development of Custom Touch Controllers evolved from 2022 to 2024, particularly in terms of their role in the product lifecycle?",
      "original_answer": "In 2022, Broadcom was described as supplying Custom Touch Controllers as part of its semiconductor solutions for the wireless market. By 2024, the company's role had evolved to include producing these controllers as part of its broader custom silicon solutions, reflecting a deeper engagement in their development. This shift indicates a strategic move from being a component supplier to an active producer involved in the design and creation process.",
      "llm_answer": "From 2022 to 2024, Broadcom's involvement in Custom Touch Controllers shifted from a standalone mention in the 2022 document (where they were listed under \"Mobile Device Connectivity Solutions\" as \"Our touch controllers process signals from touch screens in mobile handsets and tablets\") to a more integrated role within broader semiconductor product families. By 2024, Custom Touch Controllers were explicitly grouped under \"Wireless\" in the product portfolio table, alongside RF front-end modules, Wi-Fi/Bluetooth, and GPS/GNSS solutions, indicating their continued focus on mobile device connectivity. The 2024 document also expanded their context within the \"Mobile Device Connectivity Solutions\" section, emphasizing their role in processing touch screen signals for mobile handsets and tablets, though no significant structural evolution in their lifecycle role is detailed beyond this categorization.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "The LLM answer is factually consistent with the provided documents in terms of content and categorization of Custom Touch Controllers within Broadcom's product portfolio across 2022 and 2024. It correctly identifies that in 2022, touch controllers were mentioned under 'Mobile Device Connectivity Solutions' and in 2024 were grouped under the 'Wireless' segment alongside other RF and connectivity products. There are no numeric inaccuracies (quantitative accuracy is high), and the entities (Broadcom, Custom Touch Controllers, years) are correctly identified. However, the LLM answer contradicts the ground truth by stating that 'no significant structural evolution in their lifecycle role is detailed,' which directly opposes the original answer's claim of a strategic shift from supplier to active producer involved in design and creation. The ground truth indicates a qualitative evolution in Broadcom’s role—from supplying to producing custom silicon—implying deeper engagement in the product lifecycle. The LLM fails to infer or report this strategic shift, likely due to over-reliance on explicit textual changes rather than interpreting strategic implications. While the LLM accurately reports what is stated in the filings, it misses the synthesized inference required for full correctness. Thus, while contextually relevant and factually precise on surface details, it lacks the deeper multi-hop reasoning needed to capture the evolution in Broadcom’s role, resulting in partial correctness.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1344,
        "completion_tokens": 411,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Union Pacific's approach to freight cars evolved from 2023 to 2024, particularly in terms of asset acquisition strategy?",
      "original_answer": "In 2023, Union Pacific primarily leased freight cars as part of its operational strategy, reflecting a reliance on leased assets for rail operations. By 2024, the company's strategy shifted toward acquiring freight cars, including lease buyouts of $143 million in 2024 compared to $57 million in 2023, indicating a more aggressive stance on asset ownership to support replacement and growth opportunities.",
      "llm_answer": "Union Pacific's freight‑car strategy shifted from a focus on acquiring new equipment in 2023 to a more balanced approach that emphasizes both replacement and growth in 2024.  The company plans to invest roughly $3.4 billion in capital projects next year, including the acquisition of new freight cars to modernize its fleet and support expanded capacity, while also maintaining a disciplined debt‑to‑EBITDA profile and leveraging its revolving credit facility for short‑term financing rather than relying on asset purchases.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both factual content and direction. The ground truth states that in 2023, Union Pacific primarily *leased* freight cars, but the LLM incorrectly claims the company was focused on *acquiring* new equipment in 2023—this inverts the actual strategy shift. The real evolution is from leasing (2023) to increased ownership via lease buyouts (2024), which the LLM fails to capture. (2) Quantitatively, the LLM introduces a $3.4 billion capital investment figure and mentions financing via credit facilities, none of which appear in the ground truth and are unverifiable here. Crucially, it omits the key quantitative comparison: lease buyouts increased from $57M in 2023 to $143M in 2024—a core data point showing the strategic shift. These numbers are entirely missing, and no correct calculations or figures from the original answer are included. (3) The multi-hop reasoning is flawed: the question requires synthesizing a strategic shift over time based on asset acquisition trends, but the LLM misrepresents the 2023 baseline and invents a narrative about 'modernizing the fleet' and 'balanced approach' not supported by the ground truth. It fails to identify the core shift from leasing to ownership via buyouts. (4) Contextual relevance is moderate—the response discusses freight car strategy and capital investment, so it stays on topic—but due to factual inaccuracies and invented details, it does not correctly reflect the documented evolution. The answer would mislead a user about Union Pacific's actual asset strategy trajectory.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1227,
        "completion_tokens": 436,
        "total_tokens": 1663
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "What were the financial and operational impacts of Nike's structural changes in APLA between FY2022 and FY2023, particularly regarding the transition of certain businesses to third-party distributors?",
      "original_answer": "In FY2022, Nike directly operated within APLA as part of its geographic operating segments, which included associated costs and foreign currency impacts such as non-recurring impairment charges due to the anticipated release of non-cash cumulative foreign currency translation losses from transitioning certain businesses to third-party distributors. By FY2023, Nike had shifted its relationship with APLA from direct operations to a strategic stake, where the company now oversees results through third-party distributors. This transition is reflected in the 2023 filing noting that APLA includes results for the NIKE and Jordan brands and referencing Note 18 on divestitures related to the transition. Operationally, this change represents a strategic shift to reduce direct operational overhead in APLA, likely aiming to improve financial efficiency and focus on brand management rather than local execution.",
      "llm_answer": "The transition of NIKE Brand businesses in certain Asia Pacific & Latin America (APLA) markets to third‑party distributors reduced the Company’s direct sales in those regions, leading to a modest decline in APLA revenue (from $5.955 bn in FY2022 to $5.955 bn in FY2022‑FY2023 with a slight dip in FY2023) and a corresponding increase in revenue recorded under Global Brand Divisions. This shift also generated foreign‑currency translation losses that were recognized in Corporate, contributing to a $4.7 bn EBIT loss for Global Brand Divisions in FY2023. Consequently, overall NIKE Brand revenue grew modestly, while the re‑allocation of sales to distributors helped offset some of the lost direct‑to‑consumer volume.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It claims APLA revenue was $5.955 billion in both FY2022 and FY2023 with a 'slight dip' in FY2023, but the original answer does not provide any specific revenue figures, so this quantification is fabricated. More critically, it states that the transition led to a $4.7 billion EBIT loss for Global Brand Divisions in FY2023 due to foreign currency translation losses — this number is entirely incorrect and not supported by the ground truth, which mentions non-recurring impairment charges and release of cumulative foreign currency translation losses but no such EBIT loss. (2) The quantitative inaccuracies are severe: the $5.955B revenue figure and $4.7B EBIT loss are not present in the original answer and contradict the qualitative description of impacts. There is no verification that these numbers come from actual filings, and they appear to be hallucinated. (3) The reasoning partially captures the multi-hop element — the transition from direct operations to third-party distributors in APLA and the associated foreign currency impact — but misrepresents the financial consequences. It incorrectly attributes the impact to EBIT of Global Brand Divisions rather than correctly framing it as a non-recurring charge related to cumulative translation losses. It also introduces 'revenue reallocation' and 'offset lost DTC volume' concepts not present in the original. (4) The contextual relevance is moderate because the answer addresses the structural change and its financial/operational implications, but the severe numerical errors and incorrect causal claims (e.g., massive EBIT loss) undermine factual correctness. The qualitative understanding of the strategic shift is partially accurate but overshadowed by fabrication of key metrics.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1420,
        "completion_tokens": 494,
        "total_tokens": 1915
      },
      "error": null
    },
    {
      "question_id": 101,
      "question": "How has Broadcom's involvement with InP lasers evolved from 2022 to 2024, particularly in terms of their internal fabrication strategy and competitive positioning?",
      "original_answer": "In 2022, Broadcom disclosed using internal fabrication facilities for products based on proprietary processes, including vertical-cavity surface emitting lasers and side emitting lasers using GaAs and InP lasers for fiber optic communications. By 2024, Broadcom continued this strategy but began emphasizing the competitive landscape more explicitly, listing companies like Coherent Corp., Lumentum Holdings Inc., and others as competitors in semiconductor solutions. This indicates a strategic shift toward highlighting InP laser capabilities as part of its competitive differentiation in the market.",
      "llm_answer": "From 2022 to 2024, Broadcom's involvement with InP lasers evolved from a focus on leveraging its internal III-V semiconductor fabrication capabilities—particularly for high-performance optical components like InP-based lasers used in fiber optics—to a more integrated strategy emphasizing proprietary manufacturing. In the 2022 10-K (pages 13–17), Broadcom highlighted its use of internal fabrication for advanced III-V processes, including InP lasers, to protect IP and accelerate time-to-market, while outsourcing commodity CMOS production. By 2024 (pages 12–15), this strategy remained central, with explicit emphasis on internal III-V wafer fabrication in the U.S. and Singapore to support mission-critical optical products, reinforcing its competitive positioning against peers like Cisco and Coherent. This vertical integration strengthened Broadcom’s control over critical optical component supply chains, enabling it to meet growing demand in AI-driven networking and telecommunications, thereby solidifying its leadership in high-value optical solutions.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth, but contains a minor inaccuracy in competitor identification that affects qualitative accuracy. (1) Correct elements: The LLM accurately captures Broadcom's continued use of internal fabrication for InP lasers from 2022 to 2024, citing proprietary III-V processes and strategic advantages like IP protection and supply chain control. It correctly notes the geographic locations (U.S. and Singapore) of fabrication facilities and ties the strategy to high-performance optical products for fiber optics and AI-driven networking. (2) Quantitative accuracy is perfect: no specific numbers (e.g., dollar amounts, percentages) are misstated; years (2022, 2024) and document references (10-K pages) are plausibly cited and consistent with the type of sourcing expected. (3) Multi-hop reasoning is strong—synthesizing Broadcom’s internal fabrication strategy across years and linking it to competitive positioning and market demand. However, the LLM incorrectly lists Cisco as a competitor in semiconductor solutions; the ground truth specifies Coherent Corp., Lumentum Holdings Inc., and others, but not Cisco. Cisco is more of a systems-level competitor, not a direct peer in III-V semiconductor components. This misidentification slightly undermines the competitive positioning analysis. (4) Despite this, the core evolution—increased emphasis on internal InP fabrication as a differentiator—is correctly inferred and well-articulated, and the answer remains highly relevant to the question. Hence, correctness and qualitative accuracy are slightly reduced, but not severely.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1420,
        "completion_tokens": 447,
        "total_tokens": 1867
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How has the ownership structure of Swoosh, LLC in relation to NIKE's Class A and Class B Common Stock evolved between 2022 and 2023, and what implications does this have for shareholder influence?",
      "original_answer": "In 2022, Swoosh, LLC beneficially owned approximately 77% of NIKE's Class A Common Stock, which would translate to approximately 16% ownership of Class B Common Stock if all shares were converted. In 2023, the ownership structure remained consistent with Swoosh, LLC still beneficially owning approximately 77% of Class A Common Stock, with a commensurate ownership percentage of approximately 16% in Class B Common Stock if all shares were converted. Despite the consistency in ownership percentages, the continued concentration of ownership in Swoosh, LLC implies sustained influence by Travis Knight, who has a significant role in managing the Class A Common Stock owned by Swoosh, LLC, potentially affecting shareholder decisions and market dynamics.",
      "llm_answer": "Between 2022 and 2023, the ownership structure of Swoosh, LLC relative to NIKE’s Class A and Class B Common Stock remained essentially unchanged: as of June 28 2024 (the latest date disclosed), Swoosh, LLC still beneficially owned about 77 % of the Class A Common Stock, which would translate to roughly 16 % of the Class B Common Stock if those shares were converted. This concentration means that a single entity controls the vast majority of voting power, giving it outsized influence over corporate decisions despite the smaller effective ownership in the Class B shares. Consequently, any sale of a large block of these shares could depress the market price of NIKE’s common stock and limit shareholder influence.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly reports that Swoosh, LLC beneficially owned approximately 77% of NIKE's Class A Common Stock in both 2022 and 2023, with a corresponding 16% ownership in Class B Common Stock if converted—this matches the ground truth exactly. The percentages are accurate and consistent across years, and the answer correctly reflects the stability of the ownership structure. (2) All numeric values (77%, 16%) are correct and match the original answer. The mention of 'as of June 28, 2024' is a minor extrapolation beyond the 2022–2023 scope but does not contradict the ground truth and likely reflects the date of the latest filing; this does not affect factual accuracy since the ownership remained unchanged. (3) The multi-hop reasoning is sound: the model correctly links Swoosh, LLC’s ownership of Class A shares to voting power concentration and infers implications for shareholder influence and market dynamics. It correctly identifies that Class A shares carry superior voting rights, hence 77% ownership translates to outsized control despite only 16% economic ownership in Class B terms. (4) The only minor shortcoming is the omission of Travis Knight’s specific role in managing the shares, which was mentioned in the original answer and adds context to *why* Swoosh, LLC maintains influence. However, the LLM captures the broader implication of concentrated control and market impact, making the answer largely complete and semantically equivalent. Thus, the answer is factually excellent with only slight room for added detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1380,
        "completion_tokens": 430,
        "total_tokens": 1811
      },
      "error": null
    },
    {
      "question_id": 102,
      "question": "How did PMI's strategic positioning of Reduced-Risk Products evolve from 2022 to 2023, particularly in terms of portfolio integration and market availability?",
      "original_answer": "In 2022, PMI classified Reduced-Risk Products (RRPs) as a distinct category, including heated tobacco units, heat-not-burn devices, e-vapor, and oral nicotine products, with separate net revenue reporting. By 2023, RRPs were integrated into a broader category called Smoke-Free Products (SFPs), which now also included wellness and healthcare offerings. Additionally, PMI reported that its smoke-free products were available in 84 markets by the end of 2023, a notable expansion from the unspecified market availability in 2022. This evolution reflects a strategic shift toward consolidating RRPs under a unified smoke-free vision and expanding their global footprint.",
      "llm_answer": "From 2022 to 2023, PMI shifted from a six‑segment geographic structure to a four‑segment model (Europe; South‑and‑Southeast Asia, Commonwealth of Independent States & Middle East & Africa; East Asia, Australia & PMI Duty‑Free; and Americas) while adding the Swedish Match and Wellness & Healthcare segments. The company continued to integrate its reduced‑risk product portfolio—especially heated‑tobacco (IQOS) and oral nicotine (ZYN from Swedish Match)—into these regional segments, expanding availability in 84 markets and reporting higher reduced‑risk net revenues ($9.1 bn in 2021, $6.8 bn in 2020, $5.6 bn in 2019). This integration reflects a strategic repositioning toward a smoke‑free future, with the new segment reporting reflecting the combined performance of combustible, reduced‑risk and newly acquired wellness/healthcare products.",
      "correctness_score": 5,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 6,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several correct elements but also significant inaccuracies. It correctly identifies PMI's strategic shift toward integrating reduced-risk products and mentions the expansion to 84 markets by 2023, which aligns with the ground truth. However, it incorrectly states that reduced-risk net revenues were $9.1bn in 2021, $6.8bn in 2020, and $5.6bn in 2019—these figures are not only outdated (the question focuses on 2022–2023) but also factually incorrect per the original answer, which does not provide those numbers. The LLM also fails to mention the key reclassification of Reduced-Risk Products (RRPs) into a new category called Smoke-Free Products (SFPs) in 2023, instead vaguely referring to 'new segment reporting' without naming SFPs or explaining the inclusion of wellness and healthcare under this umbrella. (2) Quantitative accuracy is low because the revenue figures cited are both irrelevant (from 2019–2021) and unsupported by the ground truth, which reports no specific RRP revenue numbers for those years. The only correct number is '84 markets' in 2023. (3) The reasoning partially captures the portfolio integration theme but misrepresents the nature of the reorganization—focusing on geographic segment changes rather than the core conceptual shift from RRPs to SFPs. The mention of Swedish Match and ZYN is contextually plausible but not present in the ground truth, introducing unverified details. (4) Despite these flaws, the answer remains contextually relevant by addressing strategic repositioning, portfolio integration, and market expansion. The qualitative accuracy is moderate due to correct directional insights but flawed execution on key facts and terminology. Correctness score is 5 due to partial factual alignment but major omissions and introduction of incorrect data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1381,
        "completion_tokens": 498,
        "total_tokens": 1879
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Caterpillar's strategic role in the reciprocating engines business evolved from 2022 to 2024, and what impact has this had on its revenue composition and gross margin potential?",
      "original_answer": "In 2022, Caterpillar primarily sold reciprocating engines through its global dealer network and through subsidiary Perkins Engines Company Limited, which operated 90 distributors across 171 countries. By 2024, Caterpillar expanded its involvement by including the remanufacturing of Caterpillar reciprocating engines and components, as well as offering remanufacturing services for other companies. This evolution from a seller to a full lifecycle service provider likely improved gross margin potential, as remanufacturing typically involves lower material costs compared to new engine production and leverages existing asset value. The shift also diversified revenue composition by incorporating service-based income streams alongside traditional product sales.",
      "llm_answer": "Caterpillar's strategic role in the reciprocating engines business has shifted from a primary revenue driver to a more integrated component within its broader Energy & Transportation segment, where engines are now sold alongside turbines, generator sets, and related services. This evolution has strengthened its revenue composition, as evidenced by a 3% increase in Energy & Transportation total sales to $28.854 billion in 2024, driven significantly by favorable price realization and growth in power generation applications (e.g., data center engines). Consequently, the segment's profit margin expanded to 19.9% of sales (from 17.6% in 2023), indicating improved gross margin potential through pricing power and product mix optimization rather than volume alone.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is largely incorrect in both factual content and reasoning. The original answer states that Caterpillar evolved from selling reciprocating engines through its dealer network and Perkins in 2022 to including remanufacturing services by 2024, which improved gross margins due to lower material costs and diversified revenue via service income. In contrast, the LLM answer claims a shift within the Energy & Transportation segment, citing a 3% increase in sales to $28.854 billion in 2024 and margin expansion from 17.6% in 2023 to 19.9%, none of which appears in the ground truth and cannot be verified from the provided context. These specific figures (e.g., $28.854B, 19.9%, 17.6%) are fabricated or hallucinated. (2) Quantitative accuracy is very low: no numbers from the LLM answer are supported by the original answer. The original contains no financial totals, percentages, or year-over-year margin data. The LLM invents precise metrics without basis. (3) The multi-hop reasoning is flawed. The question asks about evolution in the reciprocating engines business and its impact on revenue composition and gross margin. The correct reasoning involves identifying the shift from product sales to lifecycle services (remanufacturing), which improves margins through cost efficiency. The LLM instead attributes margin gains to pricing power and product mix in power generation (e.g., data centers), which is not mentioned in the ground truth. It fails to mention remanufacturing, a core strategic evolution. (4) Contextual relevance is moderate because the LLM addresses Caterpillar’s engine business and margin trends, but it misrepresents the strategic shift and introduces unrelated financial data. While it attempts to answer the question’s structure (strategy → revenue → margins), the substance is factually incorrect. Thus, correctness is low due to major factual and reasoning errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1392,
        "completion_tokens": 519,
        "total_tokens": 1911
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How did BNY Mellon's approach to disclosing amendments to the Directors' Code of Conduct evolve between 2022 and 2023, particularly in terms of the mechanisms and transparency commitments outlined for informing stakeholders of changes?",
      "original_answer": "BNY Mellon's approach to disclosing amendments to the Directors' Code of Conduct remained consistent between 2022 and 2023, with the company reaffirming its commitment to post any amendments or waivers on its website in both years. There was no change in the specific mechanism or transparency commitment described across the two years, indicating a stable governance communication strategy.",
      "llm_answer": "Between 2022 and 2023, BNY Mellon’s approach to disclosing amendments to the Directors’ Code of Conduct shifted from a general statement of intent to a more specific, proactive commitment. In the 2022 filing, the company merely noted that any amendments or waivers to the Code of Conduct (including those for executive officers) would be disclosed on its website, without detailing the mechanism or timeline. By 2023, the language explicitly pledged to “disclose on our website any amendments to or waivers of (i) the Code of Conduct relating to executive officers… and (ii) the Directors’ Code of Conduct relating to our directors,” underscoring a clearer, more transparent mechanism for informing stakeholders of changes. This evolution reflects a move from a passive promise to an active, publicly accessible disclosure policy.",
      "correctness_score": 2,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 2,
      "contextual_relevance": 5,
      "detailed_feedback": "The LLM answer is factually incorrect in its core claim. The ground truth states that BNY Mellon's approach to disclosing amendments to the Directors' Code of Conduct remained consistent between 2022 and 2023, with no change in mechanism or transparency commitment. The LLM incorrectly asserts that there was an evolution from a 'general statement of intent' in 2022 to a 'clearer, more transparent mechanism' in 2023, characterizing it as a shift from passive to active disclosure. This misrepresents the actual filings. There are no numeric values in the question or answers, so quantitative accuracy is not applicable—scored as 10 by default due to absence of numerical errors. However, the qualitative accuracy is very low because the model fabricated a change in disclosure policy that did not occur, failing the multi-hop reasoning test by drawing an unsupported conclusion from the data. Contextual relevance is moderate—the response addresses the right topic (disclosure of amendments to the Directors’ Code of Conduct) and the correct company and years—but the analysis is based on a false premise. The semantic meaning diverges significantly from the original answer, making the response misleading despite correct entity and year identification.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1327,
        "completion_tokens": 350,
        "total_tokens": 1677
      },
      "error": null
    },
    {
      "question_id": 103,
      "question": "How has Nike's strategic approach to the APLA market evolved between FY22 and FY23, particularly in terms of operational structure and market participation?",
      "original_answer": "In FY22, Nike operated directly in APLA, maintaining a significant presence through its NIKE Direct operations and wholesale distribution, with APLA contributing to the 14% growth in the NIKE Direct business. By FY23, Nike began transitioning certain businesses within APLA to third-party distributors, signaling a strategic shift away from direct market participation in some parts of the region. This change indicates a move toward a more distributed, partner-driven model in APLA, altering the way Nike engages with that market.",
      "llm_answer": "Between FY22 and FY23, Nike shifted from a wholesale‑centric operating model in APLA to a distributor‑driven model, reducing its direct presence in that region. This strategic change is reflected in the FY23 filing where APLA revenues are reported under “Asia Pacific & Latin America” and show a modest decline in Global Brand Divisions revenue (from $58 M in FY22 to $45 M in FY23), while the company notes that future APLA revenue growth will be reduced due to the transition to third‑party distributors. Consequently, Nike’s operational structure in APLA moved from managing its own sales and inventory to relying on independent distributors, altering its market participation and reducing its direct operational footprint in the region.",
      "correctness_score": 4,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. The ground truth does not mention specific revenue figures for APLA ($58M in FY22, $45M in FY23), nor does it state that APLA revenues are reported under 'Asia Pacific & Latin America' or that there was a decline in Global Brand Divisions revenue. These numbers and reporting structures are not supported by the original answer and appear to be fabricated or misattributed. (2) The calculation of a revenue decline from $58M to $45M is entirely absent from the ground truth, which focuses on qualitative strategic shifts rather than financial performance metrics for APLA. There is no mention of revenue amounts or changes in the original answer, so these figures severely undermine quantitative accuracy. (3) The qualitative reasoning about Nike transitioning to third-party distributors in FY23 is correct and aligns with the original answer’s description of a shift toward a partner-driven model. The identification of a strategic shift from direct operations to distributor reliance is a valid synthesis and addresses the core of the question regarding operational structure and market participation. However, the model incorrectly frames the starting point as 'wholesale-centric' in FY22, whereas the original answer emphasizes 'NIKE Direct operations and wholesale distribution' as key, indicating a direct presence, not a wholesale-centric model. (4) Despite the correct directional insight about the strategic shift, the inclusion of false financial data and mischaracterization of the FY22 model significantly reduce correctness and quantitative accuracy. The answer is contextually relevant and attempts multi-hop reasoning, but the invented numbers result in a low overall correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1320,
        "completion_tokens": 493,
        "total_tokens": 1813
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has the impact of Favorable Price Realization on Caterpillar's sales and profitability evolved from 2022 to 2024?",
      "original_answer": "In 2022, favorable price realization contributed to a $9.223 billion increase in total sales and revenues, driven by higher end-user demand and changes in dealer inventories. By 2024, favorable price realization continued to play a key role, partially offsetting a $2.251 billion decrease in sales volume and contributing to an increase in profit from $10.335 billion in 2023 to $10.792 billion in 2024. This indicates that while Caterpillar faced declining sales volume in 2024, the company leveraged pricing strategies more effectively to maintain profitability.",
      "llm_answer": "From 2022 to 2024, the impact of favorable price realization on Caterpillar's sales and profitability evolved significantly. In 2021, favorable price realization contributed to a 22% increase in consolidated sales and revenues, helping drive a 51% increase in operating profit and a rise in profit margin from 10.9% to 13.5%, as documented on pages 32-36 of the 2021 10-K. However, by 2024, as noted on pages 28-31 of the 2024 10-K, sales and revenues declined 3% year-over-year to $64.809 billion, with the overview explicitly stating that the profit impact of lower sales volume was \"more than offset by favorable price realization.\" This indicates that while favorable price realization remained a critical factor in mitigating volume declines and supporting profitability in 2024, its positive effect was now counterbalanced by reduced sales volume across key segments like Construction Industries and Resource Industries, particularly in North America. The 2024 outlook further notes expectations of \"unfavorable price realization\" in Construction and Resource Industries during the first quarter of 2025, suggesting that the favorable price realization trend observed in prior years was not sustained into 2025.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It incorrectly references 2021 data (e.g., '22% increase in sales', 'profit margin from 10.9% to 13.5%') when the question asks about 2022–2024, which undermines the entire analysis. The ground truth states that in 2022, favorable price realization contributed $9.223 billion to sales growth, but the LLM does not mention this figure or year correctly. Instead, it cites a 22% increase from the 2021 10-K, which is outside the requested timeframe. For 2024, the LLM correctly notes that favorable price realization offset lower sales volume and supports profitability, and it accurately references a decline in sales to $64.809 billion, which aligns with Caterpillar’s 2024 10-K. However, it fails to include the key ground truth figures: the $2.251 billion sales volume decrease and the profit increase from $10.335B (2023) to $10.792B (2024). (2) Quantitative accuracy is severely compromised: the $9.223B price realization impact in 2022 is omitted, the 2021 percentage-based metrics are misapplied, and the correct 2024 profit figures are not mentioned. The $64.809B revenue number is correct, but without linking it to the price-volume tradeoff quantitatively, the analysis lacks precision. (3) The reasoning shows partial multi-hop capability—linking price realization to profitability in 2024 and anticipating a shift in 2025—but it is based on incorrect time periods and missing core data. The synthesis across years is flawed due to the use of 2021 data instead of 2022. (4) Contextual relevance is fair because the answer addresses the role of price realization in sales and profitability over time and correctly identifies the trend of pricing offsetting volume declines in 2024. However, the use of incorrect years and missing key financial figures results in a low correctness score. The answer misrepresents the evolution by starting in 2021 and omitting 2022 entirely with correct data.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1438,
        "completion_tokens": 532,
        "total_tokens": 1970
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has General Motors' approach to EV manufacturing capacity evolved between 2023 and 2024, particularly in terms of strategic focus and supply chain development?",
      "original_answer": "In 2023, General Motors emphasized significant investments in EV manufacturing capacity based on expectations for future EV demand, acknowledging the risks and uncertainties associated with such investments, including high fixed costs and limitations on closing facilities. By 2024, GM's strategy had evolved to include a stronger emphasis on developing a resilient, scalable, and sustainable North American-focused EV supply chain. This included advancing strategic sourcing initiatives to secure supply through investments in raw materials suppliers and the execution of multi-year supply agreements. The shift indicates a more structured and regionally focused approach to EV manufacturing, aiming to mitigate supply chain risks and ensure long-term scalability.",
      "llm_answer": "Between 2023 and 2024, GM’s EV manufacturing capacity strategy shifted from broad, capital‑intensive expansion to a more focused, supply‑chain‑driven approach.  The company emphasized developing a resilient, North‑American‑centric EV supply chain through strategic sourcing, multi‑year raw‑material agreements, and investments in battery‑cell suppliers, while also scaling its EV production capacity to meet long‑term demand.  This evolution reflects a tighter integration of raw‑material procurement and production planning to mitigate inflationary pressures and material‑availability risks.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures the evolution in GM's strategy from 2023 to 2024: shifting from capital-intensive expansion to a more structured, supply-chain-focused approach. Key elements such as developing a resilient, North American-centric supply chain, strategic sourcing, multi-year agreements, and investments in raw materials and battery suppliers are all present and factually correct. (2) There are no numeric values, dates, or financial figures in the question or answers that require verification—both responses reference 2023 and 2024 appropriately, with no discrepancies in timeframes or amounts. (3) The multi-hop reasoning is sound: the model synthesizes changes in strategic focus and supply chain development across two years, correctly identifying the shift in emphasis from manufacturing capacity alone to integrated supply chain resilience and scalability. (4) The only minor shortcoming is that the LLM answer does not explicitly mention GM’s acknowledgment of risks like high fixed costs and facility closure limitations in 2023, which is included in the original answer. However, it does reference 'inflationary pressures and material-availability risks,' which are thematically consistent. Overall, the answer is semantically equivalent, contextually precise, and factually correct, warranting a high score with only a slight deduction for a minor omission in qualitative depth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1343,
        "completion_tokens": 404,
        "total_tokens": 1747
      },
      "error": null
    },
    {
      "question_id": 104,
      "question": "How has Pfizer's financial commitment to Paxlovid evolved from 2022 to 2024, based on remaining performance obligations disclosed in the 10-K filings?",
      "original_answer": "In 2022, Pfizer's 10-K filing did not disclose specific remaining performance obligations related to Paxlovid. However, by 2024, Pfizer reported that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, indicating a significant ongoing financial commitment tied to future delivery of the product. This shows a clear evolution from an undefined obligation in 2022 to a quantified $1 billion commitment in 2024.",
      "llm_answer": "Pfizer’s financial commitment to Paxlovid has declined significantly from 2022 to 2024. In 2022, Paxlovid generated $18.933 billion in revenue, but by 2024 revenue had fallen to $5.716 billion, reflecting the transition from government‑procured EUA sales to commercial market sales and the impact of inventory returns. Remaining performance obligations for Paxlovid total approximately $1 billion as of December 31, 2024, with expected deliveries extending through 2028.",
      "correctness_score": 3,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. While it correctly states that remaining performance obligations for Paxlovid were approximately $1 billion as of December 31, 2024, it incorrectly claims that Pfizer's financial commitment has 'declined significantly' from 2022 to 2024. The original answer clarifies that in 2022, no specific remaining performance obligations were disclosed for Paxlovid, meaning there is no basis for claiming a decline in commitment—rather, the obligation evolved from undefined to quantified. The LLM introduces revenue figures ($18.933 billion in 2022 and $5.716 billion in 2024) that were not part of the original answer and are irrelevant to the question about 'remaining performance obligations.' These numbers, while potentially accurate in another context, misrepresent the nature of the financial commitment being asked about. (2) The $1 billion figure for 2024 is correct and matches the ground truth, but the inclusion of unrelated revenue data and the erroneous conclusion about declining commitment undermine quantitative accuracy. There are no calculations in the original answer to verify, but the LLM fabricates a trend that isn't supported by the disclosed obligations. (3) The multi-hop reasoning is flawed: the question asks specifically about the evolution of 'remaining performance obligations,' not revenue trends. The LLM conflates revenue with contractual obligations, which are distinct financial concepts. It fails to recognize that the absence of disclosure in 2022 does not imply a higher obligation, and thus cannot support a 'decline' narrative. (4) Contextual relevance is moderate because the answer does address Paxlovid and mentions the correct $1 billion obligation in 2024, but it distracts with irrelevant revenue data and draws an incorrect conclusion, reducing its overall usefulness. The core of the question—how obligations evolved from undefined to $1 billion—is overshadowed by incorrect framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1233,
        "completion_tokens": 538,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Caterpillar's approach to monitoring supplier financial viability evolved between 2022 and 2023, particularly in terms of risk mitigation strategies and contractual agreements?",
      "original_answer": "In 2022, Caterpillar indicated that it uses 'a variety of agreements with suppliers to protect our intellectual property and processes to monitor and mitigate risks of the supply base causing a business disruption,' including monitoring supplier financial viability. By 2023, Caterpillar maintained the same monitoring approach but placed a more explicit emphasis on 'supplier financial viability' as a key risk factor, listing it as the first risk under its supply chain disclosures. Additionally, in 2023, Caterpillar reinforced its global strategic sourcing models to build long-term supplier relationships and leverage enterprise spend, suggesting a potentially more structured or prioritized focus on supplier financial health compared to 2022.",
      "llm_answer": "Caterpillar's approach to monitoring supplier financial viability has remained consistent in its core requirements—requiring suppliers to maintain industry-leading quality, timely delivery, and financial stability to prevent supply chain disruptions—while expanding risk mitigation through formalized agreements and contractual safeguards. In 2023, the company emphasized enhanced monitoring of supplier financial viability, including the use of contractual agreements to protect intellectual property and ensure financial accountability, though specific changes to contractual terms between 2022 and 2023 are not detailed in the provided documents. The foundational structure of supplier agreements, including the 90-day termination clause and obligations to report financial condition, remained unchanged, with no indication of new risk mitigation strategies or contractual modifications in the 2023 filings compared to 2022.",
      "correctness_score": 5,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains some correct elements but misses key aspects of the evolution in Caterpillar's approach between 2022 and 2023. While it correctly notes that Caterpillar monitors supplier financial viability and uses contractual agreements, it incorrectly claims there were 'no new risk mitigation strategies or contractual modifications' in 2023, which contradicts the ground truth. The original answer highlights that in 2023, Caterpillar explicitly prioritized 'supplier financial viability' as the first-listed supply chain risk and reinforced global strategic sourcing models to build long-term relationships and leverage enterprise spend—indicating a more structured focus. The LLM answer fails to capture this shift in emphasis and strategic framing. (2) There are no numeric values, dates, or calculations in either answer, so quantitative accuracy is not applicable; the LLM does not introduce any incorrect numbers, so it scores highly here by default. (3) The multi-hop reasoning is flawed: the model should have compared the 2022 and 2023 disclosures and identified the change in emphasis and strategic language, but instead concludes no changes occurred. This represents a failure in synthesizing the evolution across years despite having the correct entities (Caterpillar, supplier financial viability, risk mitigation). (4) Contextual relevance is strong—the response stays on topic and addresses supplier monitoring and contracts—but the qualitative inaccuracy in reasoning and omission of key strategic shifts limits correctness. The answer is partially correct but misses the core evolution described in the ground truth.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1428,
        "completion_tokens": 454,
        "total_tokens": 1882
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Visa's approach to Risk and Identity Solutions evolved between 2022 and 2024, particularly in terms of its strategic positioning and integration within its value-added services?",
      "original_answer": "In 2022, Visa positioned Risk and Identity Solutions as part of a broader set of value-added services aimed at supporting clients, but without detailed elaboration on specific capabilities or strategic direction. By 2024, Risk and Identity Solutions were embedded within a more structured value-added services framework, with a clear three-pillar strategy: (1) services for Visa transactions, (2) network-agnostic services for non-Visa transactions, and (3) services beyond payments. This evolution reflects a more strategic and comprehensive integration of Risk and Identity Solutions into Visa's broader service portfolio, with an emphasis on scalability and business outcomes.",
      "llm_answer": "Between 2022 and 2024, Visa has strategically positioned and integrated its Risk and Identity Solutions as a core component of its value-added services, emphasizing AI-driven fraud prevention and authentication within its broader \"Visa Protect\" suite. The company expanded this offering with new products like Visa Deep Authorization (AI-powered CNP risk scoring), Visa Protect for A2A Payments, and Visa Risk Manager (scheme-agnostic AI fraud management), while embedding these tools across its network of networks strategy to enhance security for both Visa and non-Visa transactions. This evolution reflects a shift from standalone risk tools to an integrated, AI-powered layer supporting its expanded focus on B2B payments, open banking, and global money movement.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent in terms of dates (2022–2024) and correctly identifies the strategic evolution of Visa's Risk and Identity Solutions within its value-added services. It accurately reflects the integration of these services into broader offerings and highlights advancements in AI-driven fraud prevention and authentication. However, while the original answer emphasizes a clear three-pillar strategic framework introduced by 2024—(1) services for Visa transactions, (2) network-agnostic services for non-Visa transactions, and (3) services beyond payments—the LLM answer does not explicitly mention this structured three-pillar strategy. Instead, it references specific products (e.g., Visa Deep Authorization, Visa Risk Manager) and initiatives like 'Visa Protect' and 'network of networks,' which are contextually relevant but not detailed in the ground truth. These product names and suite branding may be accurate but are not verifiable from the provided ground truth, introducing potential hallucination or over-specificity. The reasoning is sound and captures the directional shift from standalone tools to integrated, scalable solutions, aligning with the core evolution described. There are no numerical inaccuracies (quantitative accuracy is perfect), and the response is highly relevant to the question. However, the absence of the explicit three-pillar structure—a key element in the original answer—reduces completeness and fidelity in qualitative synthesis, warranting a score of 7 for both correctness and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1371,
        "completion_tokens": 427,
        "total_tokens": 1798
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has the company's exposure to shelf space limitations as a risk factor evolved between 2022 and 2023, particularly in relation to changes in retail customer policies and the expansion of alternative retail channels?",
      "original_answer": "In 2022, the company noted that it had been and could continue to be negatively affected by changes in retail customer policies such as limitations on access to shelf space and delisting of products. By 2023, the company was actively impacted by these limitations and described them as part of a broader set of evolving retail dynamics, including the growth of eCommerce and alternative retail channels such as subscription services and direct-to-consumer businesses. This evolution indicates a shift from potential risk to an actively experienced challenge, with the company planning to invest more in digital and analytics capabilities to adapt.",
      "llm_answer": "The company's exposure to shelf space limitations as a risk factor has intensified between 2022 and 2023 due to evolving retail dynamics. In 2023, the company highlighted increased dependence on key retailers, changes in retail customer policies (including inventory de-stocking, fulfillment requirements, and limitations on shelf space access), and the emergence of alternative retail channels like eCommerce and direct-to-consumer models, which have created pricing pressures and threatened relationships with traditional retailers. While Brexit was deemed non-material, the broader shift toward retail consolidation and digital channels has amplified shelf space risks, particularly as the company noted that \"the retail landscape continues to evolve\" with eCommerce growth accelerating during the pandemic, directly impacting its ability to secure and maintain shelf space in key markets.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of the evolution of shelf space limitations as a risk factor from 2022 to 2023. It correctly identifies that in 2023, the company was actively impacted by retail customer policies such as shelf space limitations and highlights the role of alternative retail channels like eCommerce and direct-to-consumer models. The mention of 'evolving retail dynamics' and the impact on traditional retail relationships matches the original answer's emphasis on a shift from potential risk to active challenge. However, the LLM adds details not present in the ground truth, such as 'inventory de-stocking', 'fulfillment requirements', and 'pricing pressures', which, while plausible, are not supported in the original answer. Additionally, the reference to Brexit being 'non-material' is extraneous and not part of the original response, suggesting some overreach in synthesis. Despite this, the core multi-hop reasoning—comparing the company's risk characterization across years and linking it to retail channel shifts—is sound. There are no numerical inaccuracies (quantitative accuracy is perfect by default, as no specific numbers are involved), and the answer is highly relevant to the question. The qualitative accuracy is slightly reduced due to the inclusion of unsupported specifics, but the overall meaning and key facts remain aligned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1403,
        "completion_tokens": 389,
        "total_tokens": 1792
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Oracle's approach to hybrid deployments evolved between fiscal years 2023 and 2024, particularly in terms of product offerings and strategic emphasis?",
      "original_answer": "In fiscal 2023, Oracle emphasized hybrid deployments as part of its broader deployment models, including on-premise, cloud-based, and hybrid options such as Oracle Exadata Cloud@Customer and Dedicated Region offerings. The company highlighted its commitment to providing customers with choice and flexibility in how they deploy Oracle technologies. By fiscal 2024, Oracle continued to support hybrid deployments but introduced more specific product integrations and services tailored for hybrid environments, indicating a strategic shift toward deeper integration and support for customer-managed cloud and on-premise IT environments. This evolution reflects Oracle's ongoing investment in making hybrid deployments more interoperable and extensible with other IT and cloud environments.",
      "llm_answer": "Oracle's hybrid deployment strategy has shifted decisively toward cloud-centric offerings between FY2023 and FY2024, with a clear strategic emphasis on expanding its Oracle Cloud SaaS portfolio and infrastructure services as the primary growth vector. The company explicitly states that cloud services revenues now represent 37% of total revenue (up from 32% in FY2023 and 25% in FY2022), and its applications cloud services and license support revenues account for 46%, 47%, and 42% of total cloud services and license support revenues respectively across the three years. This evolution is underscored by the company's focus on \"flexible deployment models\" that combine on-premise and cloud-based solutions, including hybrid options like Oracle Cloud@Customer and multicloud integrations, while simultaneously driving customers toward full migration to Oracle Cloud through its \"material migration\" of existing on-premise workloads. The company's product strategy now centers on its Fusion Cloud SaaS suite (ERP, EPM, SCM, HCM, Sales/Service/Marketing) built on OCI, positioning cloud as the preferred deployment model for new implementations and expansions.",
      "correctness_score": 4,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "The LLM answer contains significant factual inaccuracies, particularly in quantitative claims. The ground truth does not mention any revenue percentages (e.g., cloud services at 37% of total revenue, applications cloud at 46%, etc.), nor does it provide year-over-year revenue breakdowns for FY2022–FY2024. These numbers appear fabricated or hallucinated, severely undermining quantitative accuracy. There is also no mention in the original answer of a 'decisive shift toward cloud-centric offerings' or a strategic push for 'full migration to Oracle Cloud'—instead, the truth emphasizes continued support and deeper integration for hybrid deployments, not a move away from them. The LLM incorrectly frames Oracle's strategy as cloud migration-focused rather than hybrid integration-focused. However, the LLM does correctly identify relevant hybrid offerings like Oracle Cloud@Customer (similar to Exadata Cloud@Customer in the truth) and mentions flexible deployment models, indicating partial entity and contextual understanding. It also touches on product integrations and SaaS suites (Fusion Cloud), which aligns with Oracle’s broader strategy, though not specifically highlighted in the ground truth for this evolution. The reasoning is partially sound in connecting hybrid models with cloud services, but the multi-hop synthesis is flawed due to reliance on incorrect data. While the answer is relevant to Oracle's deployment strategy and addresses product offerings and strategic emphasis, it misrepresents the direction of evolution. Semantic equivalence fails on key points: the original emphasizes enhanced hybrid integration, while the LLM emphasizes cloud migration. Thus, correctness is partially achieved on context and some entities, but fails on core facts and numerical accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1489,
        "completion_tokens": 485,
        "total_tokens": 1974
      },
      "error": null
    },
    {
      "question_id": 105,
      "question": "How has Pfizer's financial commitment to Paxlovid evolved between 2022 and 2024, based on remaining performance obligations and contracted revenue expectations?",
      "original_answer": "In 2022, Pfizer indicated that Paxlovid had the potential to provide ongoing revenue streams, though it acknowledged that post-pandemic revenues might not match the levels seen during the pandemic. By 2024, Pfizer reported that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, with contracted revenue expected to be recognized from 2025 through 2028. This reflects a continued but reduced financial commitment compared to the pandemic period, as the company anticipates delivery and revenue recognition over a multi-year horizon rather than immediate high-volume sales.",
      "llm_answer": "Based on the provided 10-K disclosures, Pfizer's financial commitment to Paxlovid has significantly contracted between 2022 and 2024. In 2022, Paxlovid generated $18.9 billion in revenue (representing a major portion of total revenue), but by 2024, revenue from Paxlovid had plummeted to $5.7 billion. This decline reflects the transition from government procurement to commercial markets, with the U.S. government discontinuing distribution of EUA-labeled Paxlovid by the end of 2023 and shifting to commercial pricing. While $1 billion in contracted revenue from remaining performance obligations for Paxlovid is expected to be recognized through 2028 (as disclosed in the \"Remaining Performance Obligations\" section of page 109), the scale of Pfizer's financial commitment has clearly diminished from its pandemic peak, with revenues now proportionally focused on other products like Comirnaty and core biopharmaceutical offerings.",
      "correctness_score": 6,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains several factual inaccuracies, particularly in the revenue figures for Paxlovid. The ground truth does not specify exact revenue amounts for 2022 or 2024, but the LLM claims $18.9 billion in 2022 and $5.7 billion in 2024. While these numbers may reflect actual reported figures, they are not mentioned in the original answer (ground truth), which focuses on forward-looking remaining performance obligations and expectations, not historical revenue. Thus, introducing these specific past revenues goes beyond the scope of the provided truth and risks misalignment if those numbers were not in the source documents used for the knowledge graph. (2) The $1 billion in remaining performance obligations as of December 31, 2024, expected to be recognized from 2025 through 2028, is correctly reported and aligns with the ground truth. This is a key multi-hop element and is accurately reflected. (3) The reasoning about reduced financial commitment due to the shift from government to commercial markets and the end of EUA distribution by the U.S. government is plausible context but not present in the original answer. While it may be true, it introduces external inference not supported by the ground truth, weakening qualitative accuracy. (4) The core of the question—how the financial commitment evolved based on remaining obligations and contracted revenue—is partially addressed: the $1B figure and multi-year recognition are correct. However, the emphasis on past revenue decline, while contextually relevant, distracts from the forward-looking contractual obligations that are the focus of the original answer. The model synthesizes some correct elements but adds unsupported specifics and shifts emphasis, leading to a partially correct but not fully aligned response. Hence, correctness is scored at 6 due to partial factual match with significant extraneous and unverified numerical claims.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1393,
        "completion_tokens": 522,
        "total_tokens": 1915
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has Caterpillar's relationship with its independent dealers evolved between 2022 and 2023, particularly in terms of contractual obligations and strategic emphasis?",
      "original_answer": "In 2022, Caterpillar described its relationship with independent dealers in general terms as part of its global sales and marketing strategy. By 2023, the company formalized and detailed these relationships through standardized sales and service agreements, granting dealers the right to purchase, sell, and service Caterpillar products within specified territories. In exchange, dealers were obligated to develop and promote Caterpillar products, maintain adequate sales and support personnel, and keep detailed financial records accessible to Caterpillar. This represents a shift from a general partnership model to a more structured contractual framework, indicating a strategic emphasis on formalizing dealer relationships to enhance control and accountability.",
      "llm_answer": "Caterpillar's relationship with its independent dealers remained fundamentally unchanged in structure—dealers continue to operate under standard sales and service agreements that grant them rights to purchase, sell, and service products within defined territories, with obligations to promote the brand, maintain inventory, and provide support. However, in 2023, the company emphasized deeper strategic collaboration, particularly through enhanced financing programs (e.g., Cat Financial’s marketing initiatives that fund dealer incentives) and a renewed focus on leveraging dealer networks for aftermarket parts and service revenue, reinforcing the dealer’s role as a critical channel for both new product adoption and long-term customer relationships. The contractual framework itself did not undergo significant revision, but the strategic emphasis shifted toward maximizing dealer-enabled growth in emerging markets and optimizing the dealer network’s contribution to overall profitability.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies regarding the evolution of Caterpillar's dealer relationships between 2022 and 2023. The ground truth states that Caterpillar moved from a general partnership model in 2022 to a formalized, standardized contractual framework in 2023, emphasizing increased control and accountability. In contrast, the LLM claims the 'contractual framework itself did not undergo significant revision,' which directly contradicts the ground truth. This is a major error in qualitative accuracy. (2) There are no numeric values, dates, or financial figures in either the question or answers, so quantitative accuracy is not applicable—no errors in this regard, hence a score of 10. (3) The multi-hop reasoning is flawed: the model fails to recognize the key shift from informal/general descriptions in 2022 to explicit, standardized agreements in 2023. Instead, it invents a narrative about 'enhanced financing programs' and 'renewed focus on aftermarket parts' that are not supported by the ground truth. The strategic emphasis in the original answer is on formalization and control, not financing or profitability optimization through dealers. (4) While the LLM answer is contextually relevant—addressing dealer relationships, territories, and strategic roles—it misrepresents the core factual development. The answer sounds plausible and uses relevant terminology but misses the central factual shift documented in the knowledge graph, leading to a low correctness and qualitative accuracy score despite good structure and relevance.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1445,
        "completion_tokens": 436,
        "total_tokens": 1881
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How did the company's financial allocation or operational focus related to Africa/Eurasia evolve from 2022 to 2023, based on capital expenditures and restructuring charges?",
      "original_answer": "In 2022, the company reported capital expenditures for Africa/Eurasia at $33 million, showing a steady increase from $13 million in 2021 and $8 million in 2020. However, in 2023, the company indicated that approximately 10% of the cumulative pretax charges from the 2022 Global Productivity Initiative would relate to initiatives undertaken in Africa/Eurasia, signaling a shift in focus toward restructuring and cost optimization in the region rather than continued capital investment. This reflects a strategic evolution from growth-oriented capital allocation to operational restructuring within Africa/Eurasia.",
      "llm_answer": "From 2022 to 2023, the company’s operational focus in Africa/Eurasia shifted toward cost efficiency and productivity initiatives, as evidenced by a decline in its share of Global Productivity Initiative charges from 11% in 2022 to 5% in 2023, while cumulative pretax charges related to the initiative in Africa/Eurasia decreased from $110 million (2022) to $32 million (2023). This reduction aligns with broader restructuring efforts that prioritized high-impact regions like Europe (45% of charges) and Asia Pacific (5%), reflecting a strategic reallocation of resources away from Africa/Eurasia toward more profitable segments such as Europe and Asia Pacific.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, in 2022, capital expenditures for Africa/Eurasia were $33 million, with no mention of restructuring charges for that year being $110 million or 11%. Instead, the ground truth states that in 2023, approximately 10% of the cumulative pretax charges from the 2022 Global Productivity Initiative relate to Africa/Eurasia—no specific dollar amount is provided. The LLM incorrectly invents figures such as $110 million (2022) and $32 million (2023), and falsely claims a decline from 11% to 5%, which is not supported by the original answer. (2) All numeric values in the LLM response—percentages (11%, 5%), dollar amounts ($110M, $32M), and regional allocations (Europe 45%, Asia Pacific 5%)—are fabricated and do not appear in the ground truth. The original answer does not provide any breakdown of charges by region beyond the 10% for Africa/Eurasia in 2023, nor does it compare 2022 vs 2023 shares. (3) The multi-hop reasoning is flawed. While the LLM attempts to infer a strategic shift, it misrepresents the nature of the shift: the ground truth indicates a move from capital investment to restructuring, but the LLM incorrectly frames it as a reduction in restructuring activity and a reallocation away from Africa/Eurasia. In fact, the original answer suggests increased focus on restructuring *in* Africa/Eurasia in 2023, not decreased. (4) The contextual relevance is moderate because the answer addresses the general theme of strategic evolution in Africa/Eurasia, but the qualitative and quantitative inaccuracies severely undermine correctness. Due to completely incorrect numbers and reversed logic, the correctness score is low at 2, with similarly low scores for quantitative and qualitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1325,
        "completion_tokens": 492,
        "total_tokens": 1817
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has Qualcomm's strategic focus on 5G technologies evolved from 2022 to 2024, particularly in terms of investment emphasis and commercialization outcomes?",
      "original_answer": "In 2022, Qualcomm was heavily investing in 5G technologies as part of its broader strategy to expand beyond mobile handsets into areas like automotive and IoT, with an emphasis on developing leading and cost-effective 5G-based technologies and products. The company acknowledged significant risks around the success of these investments due to potential regulatory hurdles, competition, and the long design-in cycles typical of new industries like automotive. By 2024, Qualcomm had transitioned from a primarily investment phase to a more mature stage where it had developed a leading patent portfolio in 5G NR and was actively licensing these technologies. The company reported generating the majority of its QTL revenues from OFDMA-based products, including multimode 3G/4G/5G devices such as smartphones, indicating a successful commercialization phase. This shift shows that Qualcomm moved from strategic investment and development in 5G across multiple industries to a position of market leadership and monetization in 5G technologies.",
      "llm_answer": "From 2022 to 2024, Qualcomm’s 5G strategy shifted from foundational technology development and broad patent licensing toward aggressive commercialization and integration across diverse industries. While maintaining heavy investment in 5G NR patents and OFDMA-based standards, the company emphasized monetizing its extensive 5G patent portfolio (with over 200 5G license agreements) and expanding QCT’s 5G modem-RF and RFFE offerings—particularly in multimode 5G/4G/3G devices—while facing intensified competition from vertically integrated rivals like Apple and Samsung, as well as Chinese OEMs pursuing semiconductor self-sufficiency. This focus drove revenue growth in QCT’s 5G components and sustained high-margin QTL licensing, but also heightened risks from customer concentration and supply chain vulnerabilities in China.",
      "correctness_score": 7,
      "quantitative_accuracy": 6,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer captures the core evolution of Qualcomm's 5G strategy from development to commercialization, aligning with the ground truth’s narrative of shifting from investment to monetization. It correctly identifies continued investment in 5G NR and OFDMA-based technologies and highlights QTL licensing and QCT product expansion, which are contextually accurate. However, it introduces specific quantitative claims not present in the ground truth—such as 'over 200 5G license agreements'—which cannot be verified from the original answer and may be factually inaccurate or unsupported by the provided knowledge graph. (2) There are no explicit numbers in the ground truth to validate dollar amounts, percentages, or exact counts like the 200+ agreements; thus, this unverified figure reduces quantitative accuracy. The ground truth emphasizes revenue generation from OFDMA-based products and multimode devices, which the LLM correctly echoes, but does not specify agreement counts. (3) The multi-hop reasoning is sound: the model synthesizes investment emphasis (R&D, patent development) with commercialization outcomes (licensing, product integration) across time (2022 to 2024), correctly inferring a strategic maturation. It also appropriately notes risks (competition, supply chain), though these are more detailed than the original, which only broadly mentioned regulatory, competitive, and design-in cycle risks. (4) While the LLM adds plausible details (e.g., Apple/Samsung competition, Chinese OEM self-sufficiency), these are not in the ground truth and slightly extend beyond the provided facts, though they don’t contradict them. The core progression—investment to leadership/monetization—is preserved, warranting a high qualitative and contextual score. However, the unsupported '200 agreements' claim prevents full marks for correctness and quantitative accuracy.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1469,
        "completion_tokens": 512,
        "total_tokens": 1982
      },
      "error": null
    },
    {
      "question_id": 106,
      "question": "How has Pfizer's financial and strategic positioning of Paxlovid evolved between 2022 and 2024, particularly in terms of revenue contribution and contractual commitments?",
      "original_answer": "In 2022, Paxlovid generated $76 million in revenue, marking its initial contribution as a newly launched product targeting high-risk COVID-19 patients. By 2024, while direct revenue figures for Paxlovid are not explicitly stated, Pfizer disclosed approximately $1 billion in remaining performance obligations tied to future Paxlovid deliveries under existing contracts. This indicates a strategic shift from initial market entry to securing longer-term contractual commitments, despite potential market or regulatory challenges reflected in the context of government returns and adjustments in 2024.",
      "llm_answer": "Between 2022 and 2024, Pfizer's Paxlovid revenue declined sharply—from $18.9 billion in 2022 to $1.279 billion in 2023 and $5.716 billion in 2024—reflecting its transition from government‑procured EUA sales to commercial market pricing. The company recorded a $3.5 billion non‑cash revenue reversal in Q4 2023 for expected returns of EUA‑labeled courses, followed by a $771 million favorable adjustment in Q1 2024 after 5.1 million courses were returned, and recognized $442 million from a U.S. strategic national stockpile supply in Q3 2024. Remaining performance obligations for Paxlovid amount to roughly $1 billion of contracted revenue, to be recognized through 2028 as the company fulfills long‑term supply agreements.",
      "correctness_score": 2,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. According to the ground truth, Paxlovid generated $76 million in revenue in 2022, not $18.9 billion as claimed by the LLM. The LLM fabricates detailed revenue figures for 2023 ($1.279 billion) and 2024 ($5.716 billion), which are not supported by the original answer and contradict the stated $76M in 2022. The $3.5 billion non-cash revenue reversal, $771 million favorable adjustment, and $442 million from the U.S. stockpile are specific details not present in the ground truth and appear to be hallucinated or misattributed. Only the $1 billion in remaining performance obligations for Paxlovid through 2028 aligns with the ground truth, though the original answer does not specify a 2028 timeline. (2) Quantitative accuracy is extremely low: all major financial figures are incorrect. The original answer states $76M in 2022 revenue; the LLM claims $18.9B—a more than 200-fold overstatement. No revenue figures for 2024 are given in the ground truth, so the LLM’s $5.716B is unsupported. The calculation of trends or declines is therefore based on false premises. (3) The multi-hop reasoning is flawed. While the LLM attempts to show a strategic shift from government to commercial markets and cites contractual obligations, it does so using fabricated data. The original answer notes a strategic shift inferred from remaining performance obligations despite lack of direct revenue disclosure, but the LLM invents a detailed narrative with precise quarterly adjustments and returns not present in the source. (4) Contextual relevance is moderate—the answer addresses revenue trends and contractual commitments as asked, and correctly identifies Paxlovid as a key product in Pfizer’s portfolio with evolving financial positioning. However, due to severe factual and quantitative errors, the overall correctness score is very low. Semantic equivalence fails on core facts, though the general direction of strategic evolution (from launch to contracts) is loosely aligned.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1336,
        "completion_tokens": 550,
        "total_tokens": 1887
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has the company's exposure to credit market tightness as a supply chain risk evolved between 2022 and 2023, and what does this indicate about its changing vulnerability to external financial conditions?",
      "original_answer": "In 2022, tighter credit or capital markets were described as a risk that 'negatively impacts' suppliers, with a direct concern that this could disrupt the supply of raw and packaging materials. By 2023, the framing shifted to indicate that the company's operations are 'impacted by' these conditions, suggesting a broader recognition of ongoing vulnerability. This evolution reflects a continuation of concern over credit market conditions but with a more integrated perspective on how such financial constraints affect not just suppliers, but the company's overall supply chain resilience.",
      "llm_answer": "Between 2022 and 2023, the company’s exposure to credit market tightness as a supply chain risk shifted from a more acute, pandemic‑related shock to a persistent, macro‑economic constraint. In the 2022 filing, it highlighted “the impact on our suppliers of tighter credit or capital markets” as one of many supply‑chain disruption factors, but framed it as a contingent, short‑term concern tied to pandemic‑induced volatility. By 2023, the language broadened and deepened: the same risk was listed alongside geopolitical conflicts, climate events and labor shortages, and was presented as a structural vulnerability that could “adversely affect our business, results of operations, cash flows and financial condition” if not remedied. This evolution indicates that the company’s vulnerability to external financial conditions has grown—credit tightening is now treated as a core, ongoing supply‑chain stressor rather than a temporary pandemic effect, underscoring heightened sensitivity to broader monetary tightening and market liquidity pressures.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the evolution in risk language between 2022 and 2023 regarding credit market tightness as a supply chain risk. It accurately captures that in 2022, the risk was framed around impacts on suppliers, and in 2023, it was broadened to include direct impacts on the company. However, the LLM adds contextual details not present in the original answer, such as characterizing 2022 concerns as 'pandemic-related' and 'short-term', and describing the 2023 framing as part of a group including geopolitical and climate risks. These additions, while plausible, are not supported by the ground truth and introduce speculative interpretation. (2) There are no numerical values, dates, or calculations in either answer, so quantitative accuracy is not applicable—scored as 10 by default since no inaccuracies exist. (3) The multi-hop reasoning is partially sound: the model correctly synthesizes a shift in risk perception across years, but overreaches by inferring the pandemic as a causal context and categorizing the risk alongside other 2023 risks not mentioned in the ground truth. The core evolution—narrow supplier impact to broader operational impact—is correctly identified, supporting a moderate qualitative score. (4) The answer is contextually relevant and addresses both parts of the question: how exposure evolved and what it indicates about vulnerability. The conclusion about heightened sensitivity is consistent with the original answer’s implication of increased integration of financial risks into supply chain resilience planning. However, the added narrative reduces factual precision, justifying a 7 on correctness and qualitative accuracy despite strong overall alignment in direction and structure.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1424,
        "completion_tokens": 478,
        "total_tokens": 1903
      },
      "error": null
    },
    {
      "question_id": 107,
      "question": "How has Pfizer's financial commitment and contractual obligations related to Paxlovid evolved from 2022 to 2024, based on disclosed figures and agreements?",
      "original_answer": "In 2022, Paxlovid was under Emergency Use Authorization (EUA) in the U.S. and had received conditional marketing authorization (CMA) in the EU and full approval in Japan, indicating early-stage regulatory and commercial momentum. By 2024, Pfizer disclosed that remaining performance obligations for Paxlovid totaled approximately $1 billion as of December 31, 2024, reflecting firm orders from long-term contracts with customers. This shows a significant financial commitment to Paxlovid, with delivery expected from 2025 through 2028, subject to renegotiation. Additionally, 2024 included a $771 million favorable final adjustment related to a prior revenue reversal tied to Paxlovid EUA-labeled treatment courses returned by the U.S. government, indicating ongoing financial adjustments and evolving contractual dynamics.",
      "llm_answer": "From 2022 to 2024 Pfizer’s contractual and financial commitments tied to Paxlovid shifted dramatically. In 2022 the company recorded $18.9 billion in Paxlovid revenue and held a large reserve of EUA‑labeled courses, but by 2023 it reversed $3.5 billion of that revenue as the U.S. government wound down its pandemic stockpile and began transitioning Paxlovid to commercial sales. In 2024 the company recognized only $5.7 billion in Paxlovid revenue, recorded a $771 million favorable adjustment to the 2023 reversal, and recognized $442 million of revenue from a new U.S. strategic national stockpile agreement, while deferred revenue balances fell from $5.1 billion (2023) to $2.2 billion (2024). Consequently, remaining performance obligations for Paxlovid now amount to roughly $1 billion of contracted revenue expected to be recognized through 2028, reflecting a marked decline in government‑driven purchases and a shift toward commercial‑market sales.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies, particularly in the quantitative details. While the $771 million favorable adjustment and the $1 billion remaining performance obligations are correctly reported and align with the original answer, the LLM introduces several figures not present in the ground truth: $18.9 billion Paxlovid revenue in 2022, $5.7 billion in 2024, a $3.5 billion revenue reversal, $442 million from a new stockpile agreement, and deferred revenue dropping from $5.1B to $2.2B. These specific numbers are not supported by the original answer and contradict or add to disclosed data without basis. (2) The original answer does not mention revenue figures for 2022 or 2024, nor does it reference a $3.5 billion reversal or deferred revenue balances. The only numeric figures in the ground truth are the $1 billion in remaining performance obligations and the $771 million favorable adjustment—both of which the LLM correctly includes. However, the addition of unsupported financials severely undermines quantitative accuracy. (3) The reasoning framework—showing a shift from government to commercial sales and evolving contractual dynamics—is conceptually aligned with the original answer’s theme of evolving financial commitments. The multi-hop synthesis is partially sound in that it connects regulatory status (implied from 2022) to later contractual obligations (2024), but it fabricates intermediate financial data rather than relying solely on disclosed figures. (4) The contextual relevance is high because the answer addresses the evolution of financial and contractual commitments over time and correctly identifies key developments like the $771M adjustment and $1B forward obligations. However, the correctness score is low due to the inclusion of unverified revenue and reversal figures, which distort the factual picture. The answer appears plausible but is not factually accurate per the knowledge graph source.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1447,
        "completion_tokens": 532,
        "total_tokens": 1979
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How has the financial liability and risk exposure related to Aearo Technologies' respirator mask/asbestos litigation evolved from 2023 to 2024?",
      "original_answer": "In 2023, MMM had an accrual of $574 million for respirator mask/asbestos liabilities excluding Aearo, and Aearo was in bankruptcy proceedings, which resulted in a stay of litigation. By 2024, MMM, through Aearo, had accruals of $51 million specifically for Aearo-related asbestos, silica-related, and coal mine dust claims. Additionally, Aearo’s liability was limited by its agreement with Cabot, where Cabot assumed responsibility for claims involving exposure prior to January 1, 1997, as long as Aearo continued to pay a quarterly fee of $100,000. This represents a shift from a broader liability exposure under bankruptcy protection in 2023 to a more defined and limited liability framework in 2024, with Aearo actively managing its share of liability through contractual arrangements and cost-sharing with other co-defendants.",
      "llm_answer": "The financial liability and risk exposure related to Aearo Technologies' respirator mask/asbestos litigation decreased from 2023 to 2024, with the Company's accrual for respirator mask/asbestos liabilities (excluding Aearo accruals) declining from $574 million as of December 31, 2023 to $523 million as of December 31, 2024. This reduction reflects the $36 million increase in accruals recorded in 2024, offset by ongoing claim resolutions and the continued decline in the volume of new and pending matters. The Company still cannot estimate the upper bound of potential excess liability due to inherent uncertainties in claim volume, cost trends, and allocation among co‑defendants.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains significant factual and quantitative errors that undermine its correctness. (1) The key numbers are incorrect: the original answer states that in 2023, 3M (MMM) had a $574 million accrual for respirator mask/asbestos liabilities *excluding Aearo*, while Aearo itself had a separate $51 million accrual in 2024. However, the LLM incorrectly claims that the accrual declined from $574 million in 2023 to $523 million in 2024, which is not supported by the ground truth. The $523 million figure does not appear in the original answer, nor is there any mention of a $36 million increase in accruals in 2024. (2) The LLM misrepresents the evolution of Aearo’s liability: it fails to mention that Aearo was in bankruptcy in 2023 with a stay of litigation, and that by 2024, Aearo had $51 million in specific accruals for asbestos, silica, and coal mine dust claims. This contractual and structural shift—especially the cost-sharing agreement with Cabot, where Cabot assumed pre-1997 liability in exchange for a $100,000 quarterly fee—is entirely omitted. (3) The reasoning is flawed: the LLM implies a continuous decline in overall liability managed by MMM, but the original answer distinguishes between MMM’s broader liabilities and Aearo’s separate, newly defined liability framework post-bankruptcy. The LLM fails to perform the required multi-hop synthesis between MMM and Aearo’s distinct financial positions and legal statuses across years. (4) While the LLM correctly identifies that liabilities are hard to estimate due to uncertainties in claims and co-defendant allocation, this generic point does not compensate for the missing core facts. The answer is contextually relevant to litigation liability trends but fundamentally misrepresents the entities, numbers, and structural changes involved. Minor formatting flexibility is allowed, but the numerical discrepancies and omission of key contractual arrangements result in a low correctness score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1378,
        "completion_tokens": 530,
        "total_tokens": 1908
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How did the retail share of Skoal, a product of MO, change between 2023 and 2024, and how does this compare to its shipment volume trend between 2020 and 2021?",
      "original_answer": "The retail share of Skoal decreased from 9.3% in 2023 to 7.6% in 2024, indicating a decline in market presence. In contrast, Skoal's shipment volume was also declining between 2020 and 2021, dropping from 208.5 million packs/cans in 2020 to 197.4 million packs/cans in 2021. Both metrics show a consistent downward trend, suggesting a potential long-term challenge for the product's performance in the market.",
      "llm_answer": "The retail share of Skoal declined from 12.6% in 2023 to 7.6% in 2024, reflecting a drop in its market share within the oral tobacco segment. This share loss occurred alongside a 1.0% decrease in reported domestic shipment volume for the oral tobacco products segment in 2024 compared to 2023, driven by retail share declines and trade inventory movements, partially offset by industry growth in oral nicotine pouches.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual errors in key numbers. It states that Skoal's retail share was 12.6% in 2023, which is incorrect — the ground truth is 9.3%. The 2024 value (7.6%) is correct. This major discrepancy in the starting point of the trend undermines the accuracy of the response. Additionally, the question asks for a comparison with shipment volume trends between 2020 and 2021, but the LLM instead discusses shipment volume changes between 2023 and 2024, which is off-topic and irrelevant to the query. It references a '1.0% decrease in reported domestic shipment volume for 2024 vs 2023', which is not supported by the ground truth and does not address the required 2020–2021 period. (2) The ground truth reports shipment volume dropping from 208.5 million to 197.4 million packs/cans between 2020 and 2021 — a decline of 11.1 million or about 5.3%. The LLM fails to mention these figures or this time frame at all, missing a core part of the question. (3) The multi-hop reasoning is flawed: while the LLM correctly identifies a decline in retail share (albeit with wrong magnitude due to incorrect 2023 number), it fails to connect this with the historical shipment trend as required. Instead, it substitutes an unrelated recent shipment trend, breaking the logical synthesis across time periods and metrics. (4) The contextual relevance is moderate because it discusses Skoal, retail share, and shipment volumes — all relevant topics — but applies them to the wrong years and incorrect data. The qualitative reasoning appears structured but is based on incorrect inputs, leading to misleading conclusions. Due to major quantitative errors and failure to address the required time periods, the overall correctness score is low.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1210,
        "completion_tokens": 480,
        "total_tokens": 1690
      },
      "error": null
    },
    {
      "question_id": 108,
      "question": "How has Qualcomm's approach to multimedia technologies evolved from 2022 to 2024, particularly in terms of engineering focus areas and integration into product offerings?",
      "original_answer": "In 2022, Qualcomm emphasized engineering expertise in multimedia technologies such as camera, video, display, and computer vision as part of a broader set of capabilities including modem, RF, and sensor perception technologies. The focus was on enhancing existing products and developing new technologies for industries beyond mobile handsets, such as automotive and IoT. By 2024, the company's description of its multimedia technology efforts remained consistent, but there was a notable expansion in the integration of AI, particularly generative AI, into its research and development strategy. Additionally, in 2024, Qualcomm placed greater emphasis on enabling developers to design and deploy applications across multiple device categories and industries, signaling a more deliberate diversification strategy. This evolution reflects a shift from primarily hardware-centric multimedia innovation in 2022 to a more platform-oriented, AI-enhanced approach by 2024.",
      "llm_answer": "From 2022 to 2024, Qualcomm’s engineering focus shifted from primarily advancing OFDMA-based 4G/LTE technologies toward deeper integration of 5G NR capabilities and broader multimedia applications—including AI-driven camera, video, and XR processing—within its Snapdragon platforms. This evolution is reflected in its R&D investments, which now span AI (including generative AI), automotive, IoT, and multimode connectivity, while maintaining a strong emphasis on foundational wireless patents essential for 3G/4G/5G standards. The company’s patent licensing strategy continues to underpin its product portfolio, enabling widespread adoption of 5G multimode devices and supporting new markets like automotive and edge computing.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in describing Qualcomm's engineering focus. The original answer states that in 2022, Qualcomm focused on multimedia technologies like camera, video, display, and computer vision, with expansion into AI and generative AI by 2024, along with a platform-oriented developer strategy. The LLM incorrectly frames the evolution as a shift from 'OFDMA-based 4G/LTE technologies' to 5G NR and multimedia, which is not supported by the ground truth. There is no mention in the original answer of a shift away from 4G/LTE or OFDMA, nor is there evidence that multimedia evolution was framed as a departure from those technologies. Instead, the actual evolution was from hardware-centric multimedia to AI-enhanced, platform-oriented development. (2) There are no numeric values, dates, or calculations in either answer, so quantitative accuracy is not applicable—scored as 10 by default since no numbers are misstated. (3) The multi-hop reasoning is flawed: the LLM fails to correctly synthesize the evolution of multimedia focus (camera, video, display, CV in 2022 → AI/generative AI integration and developer enablement in 2024), instead inventing a narrative around wireless technology transition (4G to 5G) that is not the focus of the question. The mention of automotive and IoT is partially correct but framed incorrectly around connectivity rather than multimedia diversification. (4) Contextual relevance is moderate—the answer discusses R&D and technology evolution in Qualcomm and mentions AI and generative AI, which are relevant, but misdirects the core evolution from multimedia engineering to wireless modulation schemes. The focus on Snapdragon and patent licensing is plausible but not aligned with the specific multimedia technology evolution described in the ground truth. Thus, while some elements are contextually related, the central reasoning is misaligned, leading to a low correctness and qualitative accuracy score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1429,
        "completion_tokens": 539,
        "total_tokens": 1968
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How did 3M's financial relationship with the Aearo Entities evolve between 2023 and 2024, particularly in terms of equity investment and intercompany balances?",
      "original_answer": "In 2023, 3M reconsolidated the Aearo Entities, which resulted in the removal of a $0.7 billion asset balance in equity and other investments and a $0.6 billion net liability for former intercompany amounts from its consolidated balance sheet as of December 31, 2023. By 2024, the Aearo Entities were no longer consolidated, and instead, 3M now 'has a stake in' them, indicating a shift from full consolidation to a retained equity interest. This reflects a significant change in the financial structure and relationship between 3M and the Aearo Entities.",
      "llm_answer": "Between 2023 and 2024, 3M's financial relationship with the Aearo Entities evolved significantly through the CAE Settlement and subsequent restructuring of their bankruptcy proceedings. In 2023, 3M increased its accrual for Combat Arms Earplugs liabilities by $4.3 billion and paid $147 million in December 2023 to settle bellwether cases, while also reconsolidating the previously deconsolidated Aearo Entities in Q2 2023, which resulted in a $0.7 billion asset balance in equity investments and a $0.6 billion net liability for intercompany amounts. By January 2024, 3M amended the settlement to elect cash payments for the $1 billion portion (previously potentially payable in stock), and following the Aearo Entities' bankruptcy dismissal in June 2023, 3M resumed mediation efforts and finalized the CAE Settlement terms, leading to additional payments of $250 million in December 2023 and $253 million on January 31, 2024. This resulted in a total accrued liability of $5.0 billion for Combat Arms Earplugs as of December 31, 2023, reflected in other current liabilities ($1.5 billion) and other liabilities ($3.5 billion).",
      "correctness_score": 4,
      "quantitative_accuracy": 5,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains some correct facts but introduces significant inaccuracies and irrelevant details. It correctly notes the reconsolidation of the Aearo Entities in 2023 and mentions the $0.7 billion equity investment asset and $0.6 billion intercompany net liability, which aligns with the ground truth. However, it incorrectly frames these as increases or accruals tied to the CAE Settlement and Combat Arms Earplugs litigation, which is not supported by the original answer. The original answer does not mention a $4.3 billion accrual, $147M, $250M, or $253M payments, nor does it link the reconsolidation directly to litigation payments. These figures appear to be hallucinated or misattributed. (2) Quantitatively, the $0.7B and $0.6B figures are correct and match the ground truth, but all other numbers (e.g., $4.3B, $147M, $250M, $253M, $5.0B total liability) are not present in the original answer and are therefore factually incorrect. The calculation of a $5.0B total liability is unsupported. (3) The reasoning is flawed: the original answer describes a structural change in consolidation status — from reconsolidation in 2023 to deconsolidation with a retained equity stake in 2024. The LLM fails to mention the key point that by 2024, the Aearo Entities were no longer consolidated, instead overemphasizing litigation payments and settlement amendments unrelated to the core financial relationship evolution. The multi-hop synthesis is incorrect — it conflates liability accruals and settlement payments with changes in consolidation and intercompany balances. (4) The contextual relevance is moderate because it discusses 3M and Aearo Entities and touches on intercompany balances, but the focus on litigation payments and unverified accruals distracts from the actual evolution of the financial relationship. The core shift from consolidation to equity stake is missing in 2024, which is central to the question. Thus, while some data points are accurate, the overall narrative misrepresents the financial evolution.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1423,
        "completion_tokens": 552,
        "total_tokens": 1975
      },
      "error": null
    },
    {
      "question_id": 109,
      "question": "How has Visa's Risk and Identity Solutions evolved between 2022 and 2024, particularly in terms of their strategic positioning within the company's broader value-added services portfolio?",
      "original_answer": "In 2022, Visa's Risk and Identity Solutions were described as tools that 'transform data into insights for near real-time decisions' and included named products like Visa Advanced Authorization and Visa Secure. These solutions were positioned primarily around fraud prevention and payment security, with an emphasis on helping clients protect account holder data and prevent fraud in the context of omnichannel commerce. By 2024, Risk and Identity Solutions had been elevated as one of five core categories within a more expansive value-added services portfolio that now includes Open Banking Solutions and Advisory Services. The 2024 report highlights that Visa offered more than 200 products and services as of September 30, 2024, many designed to work together for 'high impact business outcomes,' indicating a broader strategic integration of Risk and Identity Solutions within a more diversified services ecosystem.",
      "llm_answer": "Visa’s Risk and Identity Solutions have evolved from a collection of fraud‑prevention tools into a broader, AI‑driven suite that is positioned as a core value‑added service within its “network‑of‑networks” strategy.  In the 2024 filing the company highlights new products such as Visa Deep Authorization, Visa Protect for A2A Payments and Visa Risk Manager with scheme‑agnostic Advanced Authorization, emphasizing real‑time risk scoring, token‑level protection and cross‑network fraud prevention.  These offerings are marketed alongside Open Banking and Advisory services, underscoring a strategic shift toward integrated, data‑rich identity and fraud management that supports both Visa Direct and Visa B2B Connect money‑movement initiatives.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is largely correct and aligns well with the ground truth in terms of strategic evolution and positioning of Visa's Risk and Identity Solutions between 2022 and 2024. It accurately captures the shift from a fraud-prevention focus to a more integrated, strategic role within Visa’s broader value-added services portfolio. The mention of new products like Visa Deep Authorization, Visa Protect for A2A Payments, and Visa Risk Manager with scheme-agnostic Advanced Authorization is consistent with the direction of innovation described in the 2024 context, even if these specific product names are not in the original answer; they plausibly extend the existing product line (e.g., evolution of Visa Advanced Authorization). The integration with Open Banking and Advisory Services is correctly noted, reflecting the 2024 strategic positioning. However, the LLM introduces the term 'AI-driven' and 'network-of-networks strategy' which are not present or verifiable in the original answer, adding interpretation beyond the source. It also omits the specific detail that Visa offered more than 200 products and services as of September 30, 2024—a key quantitative and strategic data point from the ground truth. While the LLM correctly identifies the broader strategic integration, it does not explicitly state the elevation of Risk and Identity Solutions as one of five core categories, slightly weakening the completeness of the multi-hop synthesis. All dates and numbers mentioned (none incorrect) are consistent or reasonably inferred. Wording differences are acceptable under semantic equivalence, but the omission of the 200+ products metric and the addition of unverified strategic terminology prevent a top score. Contextual relevance is excellent, directly addressing the evolution and strategic positioning as asked.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1425,
        "completion_tokens": 494,
        "total_tokens": 1920
      },
      "error": null
    },
    {
      "question_id": 110,
      "question": "How did RTX's disclosure and quantification of Acquisition Accounting Adjustments' impact on operating profit evolve between 2023 and 2024?",
      "original_answer": "In 2023, RTX provided specific quantified impacts of Acquisition Accounting Adjustments on operating profit, showing a negative impact of $1,998 million in 2023, compared to $1,893 million in 2022 and $2,203 million in 2021. By 2024, RTX shifted its disclosure approach by providing qualitative policy context about the components of these adjustments, but did not include updated quantitative figures for the current year's impact on operating profit. This represents a move from concrete numerical disclosure to a more conceptual explanation of acquisition accounting practices without continuing the year-over-year quantification.",
      "llm_answer": "Between 2023 and 2024, RTX's disclosure of Acquisition Accounting Adjustments shifted from being presented as a separate line item within operating profit (with a $1,998 million negative impact in 2023 and $1,893 million in 2022) to being reported as a distinct adjustment of $2,058 million in 2024, reflecting the amortization of acquired intangibles, property‑plant‑equipment fair‑value adjustments, and customer contractual obligations. This evolution shows a more explicit quantification of the adjustments, though the underlying components remain consistent across periods.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core claim. The ground truth states that RTX stopped providing quantitative figures for Acquisition Accounting Adjustments in 2024 and shifted to qualitative disclosure only. However, the LLM claims RTX provided a specific $2,058 million adjustment in 2024, which directly contradicts the original answer. This is a major factual error. The 2023 figure of $1,998 million is correct, as is the 2022 figure of $1,893 million, but the 2024 number is fabricated. (2) Quantitative accuracy is very low: while 2022 and 2023 numbers are correct, the introduction of a false $2,058 million figure for 2024 makes the quantitative response misleading. There is no calculation error per se, but the data itself is incorrect. (3) The multi-hop reasoning is flawed: the model incorrectly infers that RTX continued and even enhanced its quantitative disclosure in 2024, when in fact it did the opposite—discontinuing numerical disclosure. The synthesis across years is therefore invalid. (4) Contextual relevance is moderate because the answer addresses the right topic (evolution of acquisition accounting disclosures) and mentions relevant components (amortization, fair value adjustments), but the central claim about increased quantification is false. The qualitative accuracy is low because the reasoning and entity relationships (especially across time) are misrepresented. Correctness score is low due to the critical error in the 2024 disclosure approach.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1301,
        "completion_tokens": 416,
        "total_tokens": 1717
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How has Microsoft's Office 365 Commercial revenue contribution to the Microsoft Cloud evolved between fiscal years 2022 and 2023, and what does this indicate about its growth trajectory within the broader cloud ecosystem?",
      "original_answer": "In fiscal year 2022, Office 365 Commercial was explicitly cited as a key growth driver within the Productivity and Business Processes segment, contributing to an 18% overall revenue increase for the company. By fiscal year 2023, Office 365 Commercial was included in a newly disclosed consolidated Microsoft Cloud revenue figure, which reached $111.6 billion in FY2023, up from $91.4 billion in FY2022. This indicates that Office 365 Commercial continued to grow as part of a broader, increasingly transparent cloud revenue portfolio that now includes Azure, LinkedIn (commercial portion), Dynamics 365, and other cloud services.",
      "llm_answer": "Microsoft's Office 365 Commercial revenue grew from $44,970 million in fiscal 2022 to $48,848 million in fiscal 2023, reflecting a $3,878 million increase (≈ 8.6%). This rise contributed to the broader Microsoft Cloud revenue expanding from $91.4 billion in 2022 to $111.6 billion in 2023, underscoring Office 365 Commercial's strengthening role within the cloud ecosystem and its accelerating growth trajectory.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 8,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies in the quantitative details. While the Microsoft Cloud revenue figures are correct ($91.4 billion in FY2022 and $111.6 billion in FY2023), the LLM fabricates specific Office 365 Commercial revenue numbers: $44,970 million in FY2022 and $48,848 million in FY2023. These exact figures do not appear in the ground truth and are not disclosed in Microsoft's public filings as standalone line items for those years. The 8.6% growth rate is therefore also invented. The original answer does not provide specific Office 365 Commercial revenue amounts but correctly states its role as a growth driver and inclusion in the consolidated Microsoft Cloud figure. (2) The calculation of the Microsoft Cloud growth is correct (from $91.4B to $111.6B), but the Office 365-specific calculation is based on non-existent data. (3) The reasoning partially captures the multi-hop element by linking Office 365 Commercial to the broader Microsoft Cloud growth, but it fails the synthesis test by asserting unverified granular revenue data. The original answer correctly emphasizes the change in disclosure strategy (from segment-level to consolidated cloud reporting), which the LLM overlooks. (4) The contextual relevance is high because the answer addresses the evolution and growth trajectory within the cloud ecosystem, but correctness is severely undermined by hallucinated numbers. Thus, the correctness score is low despite relevant framing.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1279,
        "completion_tokens": 413,
        "total_tokens": 1692
      },
      "error": null
    },
    {
      "question_id": 111,
      "question": "How did Merck's alliance revenue related to Lynparza evolve between 2023 and 2024, and what factors contributed to the change?",
      "original_answer": "In 2023, alliance revenue for Lynparza was part of Merck's broader alliance revenue reporting, which included profits based on product sales net of cost of sales and commercialization costs. By 2024, alliance revenue related to Lynparza specifically grew by 9%, driven by higher demand in most international markets. This growth indicates a positive shift in Lynparza's market performance during the period.",
      "llm_answer": "Alliance revenue from Lynparza increased 9% in 2024, driven by higher demand in most international markets, while overall oncology sales grew 18% (22% excluding foreign exchange) due to Keytruda’s expansion across multiple indications and higher pricing. The growth in Lynparza’s alliance revenue was part of a broader oncology performance that included strong Keytruda sales ($29,482 million in 2024) and new approvals for Keytruda in combination therapies.",
      "correctness_score": 7,
      "quantitative_accuracy": 9,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM correctly states that Lynparza's alliance revenue grew by 9% in 2024, which matches the ground truth. It also accurately identifies higher international demand as the driver of growth. However, the LLM introduces information not present in the original answer—specifically, Keytruda's sales performance ($29,482 million), its 18% oncology growth, and new combination therapy approvals—which, while potentially true, are not part of the ground truth and distract from the specific focus on Lynparza's alliance revenue evolution. (2) The 9% growth figure is accurate and correctly attributed to 2024. No calculation errors are present. The dollar amount for Keytruda is plausible but irrelevant to the question and not verifiable from the ground truth. (3) The multi-hop reasoning is partially sound: the model correctly identifies the year-over-year change in Lynparza alliance revenue and its cause. However, it fails to mention that in 2023, Lynparza's revenue was reported only as part of broader alliance revenue, which is a key contextual detail from the original answer about how the reporting evolved. This omission reduces completeness and qualitative accuracy. (4) The correctness score is 7 because core facts (9% growth, international demand) are accurate, but the answer adds extraneous details and misses a key nuance about reporting changes from 2023 to 2024. Quantitative accuracy is high (9) due to correct percentages and figures. Qualitative accuracy is 7 due to missing context and some irrelevant expansion. Contextual relevance is 9 because the main point is addressed, even with some off-topic content.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1211,
        "completion_tokens": 450,
        "total_tokens": 1661
      },
      "error": null
    },
    {
      "question_id": 112,
      "question": "How has the treatment and disclosure of the Procter & Gamble 2014 Stock and Incentive Compensation Plan evolved between 2023 and 2024, particularly in terms of its regulatory context and inclusion in equity compensation reporting?",
      "original_answer": "In 2023, the 2014 Stock and Incentive Compensation Plan was disclosed in the context of regulatory documentation and was referenced alongside other compensation plans and agreements, such as the 2009 and 2019 plans, indicating its active role in executive compensation. By 2024, the plan was included in a broader list of equity compensation plans for reporting on stock issuances upon exercise of options, suggesting a shift from regulatory disclosure to a focus on ownership structure and equity compensation transparency. This evolution indicates a more integrated view of the 2014 plan within the company’s overall equity compensation framework.",
      "llm_answer": "The Procter & Gamble 2014 Stock and Incentive Compensation Plan (the 2014 Plan) remains part of the company’s equity compensation framework but is now administered alongside newer plans, particularly the 2019 Stock and Incentive Compensation Plan, which replaced it as the primary plan for future equity grants. The 2014 Plan’s terms and conditions continue to be referenced in regulatory filings, but its future use is limited, with no new grants anticipated under it. Disclosures related to the 2014 Plan are included in the company’s equity compensation reporting, primarily within the context of historical plan documentation and governance oversight by the Compensation and Leadership Development Committee.",
      "correctness_score": 8,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 8,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually accurate in stating that the 2014 Plan remains part of Procter & Gamble's equity compensation framework but is no longer used for new grants, with the 2019 Plan now serving as the primary vehicle. It correctly identifies the continued regulatory disclosure of the 2014 Plan and its inclusion in equity compensation reporting, particularly in historical and governance contexts. There are no numeric inaccuracies (quantitative accuracy is perfect), and all entities—such as the 2014 and 2019 plans, the Compensation and Leadership Development Committee—are correctly named and contextualized. The reasoning is sound, reflecting an understanding of plan succession and disclosure practices. However, the LLM answer does not fully capture the evolution highlighted in the ground truth: the shift from regulatory-focused disclosure in 2023 to a broader integration into equity compensation transparency and ownership structure reporting in 2024. While the LLM mentions ongoing disclosure and reporting, it does not explicitly note the change in emphasis or the plan’s inclusion in a 'broader list' of equity plans for stock issuance reporting in 2024, which is a key nuance in the evolution. This omission slightly weakens the qualitative accuracy and completeness, though the core facts remain correct. The answer is highly relevant and well-framed, hence a high contextual relevance score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1361,
        "completion_tokens": 390,
        "total_tokens": 1751
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How has the treatment of the 1992 Stock Plan evolved between the 2023 and 2024 10-K filings, particularly in terms of its role within the company's equity compensation structure?",
      "original_answer": "In the 2023 10-K filing, the 1992 Stock Plan was referenced as an adopted plan with specific terms and conditions incorporated by reference to prior filings. However, in the 2024 10-K filing, the 1992 Stock Plan is listed among other equity compensation plans in a consolidated table that outlines shares authorized for issuance upon the exercise of options, warrants, and rights. This indicates a shift from a standalone referenced plan to one being tracked alongside newer plans, suggesting its role has transitioned from active adoption to a more passive stake within the broader equity compensation framework.",
      "llm_answer": "The treatment of the 1992 Stock Plan has evolved from being a primary equity compensation vehicle in earlier periods to a legacy plan that now only allows for future grants under the newer 2019 Plan, which supersedes it. While the 1992 Plan remains referenced in historical disclosures, its role has diminished significantly, with the 2019 Plan now serving as the sole equity compensation plan for future awards, reflecting a strategic shift toward newer, more flexible equity structures.",
      "correctness_score": 4,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "The LLM answer contains no numeric data, so quantitative accuracy is not applicable; however, since there are no incorrect numbers, it is scored as 10 by default. The answer is contextually relevant as it addresses the evolution of the 1992 Stock Plan's role in equity compensation. However, it introduces significant factual inaccuracies: it claims the 1992 Plan has been superseded by the 2019 Plan and that no future grants are allowed under the 1992 Plan, which is not supported by the ground truth. The original answer states that the 1992 Plan is now included in a consolidated table of equity plans in the 2024 10-K, indicating a shift in disclosure format and administrative tracking—not a formal replacement or cessation of grants. The LLM incorrectly infers a strategic shift and supersedence by the 2019 Plan, which is not mentioned in the ground truth. This reflects a failure in multi-hop reasoning: instead of accurately synthesizing the change in disclosure treatment (from standalone reference to consolidated listing), the model fabricates a narrative about plan succession. While the general idea of diminished role has some alignment, the specific reasoning and factual basis are incorrect, leading to a low correctness and qualitative accuracy score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1283,
        "completion_tokens": 353,
        "total_tokens": 1637
      },
      "error": null
    },
    {
      "question_id": 113,
      "question": "How has the company's emphasis on large-scale transformations evolved between 2023 and 2024, particularly in terms of client spending patterns and revenue conversion timelines?",
      "original_answer": "In 2023, the filing noted that clients were reducing or deferring spending on smaller contracts with shorter durations and that there was a slowdown in client spending, especially for consulting services. However, clients were still prioritizing large-scale transformations, which convert to revenue over a longer period. In 2024, the filing reiterated that clients continued to prioritize large-scale transformations, emphasizing the ongoing shift toward longer-duration contracts. While there was no explicit quantitative metric provided in either year, the repeated emphasis in both filings on the extended revenue conversion timeline for large-scale transformations indicates a strategic reinforcement of this focus, especially amid ongoing economic volatility.",
      "llm_answer": "Between 2023 and 2024, Accenture’s focus on large‑scale transformations remained strong, but client spending patterns shifted toward longer‑duration, high‑value projects that convert to revenue over an extended period. This evolution is reflected in the company’s risk disclosures, which note that while overall economic volatility has slowed growth in some markets, clients continue to prioritize large‑scale transformations and are willing to commit resources to initiatives that deliver sustained revenue streams. Consequently, the firm’s revenue conversion timelines have lengthened, aligning with the extended implementation cycles typical of these transformational engagements.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and aligns well with the ground truth. (1) It correctly captures that client spending patterns in both 2023 and 2024 showed a continued prioritization of large-scale transformations despite economic volatility, with a shift toward longer-duration contracts. The answer accurately reflects that revenue conversion timelines have lengthened due to the nature of these projects. (2) There are no numeric values in the original or LLM answer, so quantitative accuracy is not compromised—both rely on qualitative disclosures. (3) The multi-hop reasoning is sound: the LLM synthesizes the evolution across two years, noting continuity in strategic emphasis and linking client behavior (deferring smaller projects, favoring large transformations) to revenue conversion timelines. The only minor shortcoming is that the LLM does not explicitly mention the 2023 detail about clients reducing spending on smaller, shorter-duration contracts, which slightly reduces completeness. However, the core evolution—continued prioritization and extended timelines—is correctly conveyed. (4) The answer is contextually relevant, directly addressing client spending patterns and revenue conversion timelines as asked. Wording differs but meaning is semantically equivalent. Thus, a score of 9 is justified—very close to perfect, with only a minor omission in detail.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1369,
        "completion_tokens": 381,
        "total_tokens": 1750
      },
      "error": null
    },
    {
      "question_id": 114,
      "question": "How did Accenture's issuance of Class A Ordinary Shares for employee compensation change from fiscal 2023 to 2024, and what was the impact on the company's equity structure?",
      "original_answer": "In fiscal 2023, Accenture acquired Class A Ordinary Shares primarily through share withholding for payroll tax obligations related to employee equity awards. In fiscal 2024, the company issued 7,970 Class A Ordinary Shares specifically for employee share programs, while also purchasing 12,181 treasury shares. This shift reflects a more active use of Class A Ordinary Shares for compensation purposes in 2024. The equity structure was impacted as Class A Ordinary Shares increased from 15,656,591 in 2023 to 15,664,561 in 2024, while treasury shares decreased in value from $(3,408,491) million to $(6,678,037) million, indicating a significant reallocation of shares for employee programs.",
      "llm_answer": "From fiscal 2023 to 2024, Accenture issued 7.97 million Class A ordinary shares for employee share programs, increasing the Class A share count from 15,664,561 to 15,672,485 and raising total shareholders’ equity from $22.1 billion to $28.3 billion. This issuance expanded Accenture’s equity base and diluted existing shareholders, reflecting a larger pool of shares reserved for employee compensation.",
      "correctness_score": 3,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 4,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. It states that Accenture issued 7.97 million shares in 2024, which aligns numerically with the ground truth (7,970 shares, assuming unit is thousands), but this is presented as a net issuance without acknowledging the concurrent purchase of 12,181 treasury shares, which is a critical part of the equity movement. More critically, the LLM claims the Class A share count increased from 15,664,561 to 15,672,485, which contradicts the ground truth: the correct 2023 Class A share count is 15,656,591, increasing to 15,664,561 in 2024 (an increase of 7,970). The LLM reversed the years and inflated the base number. Additionally, the total shareholders’ equity figures of $22.1B and $28.3B are entirely fabricated and not supported by the original answer or typical SEC filing data. (2) The quantitative inaccuracies are severe: the share count progression is wrong, equity values are incorrect, and the net impact on treasury shares (a key part of the equity structure change) is omitted. The $6.7B decrease in treasury stock value is not reflected. (3) The reasoning is partially sound in identifying that share issuance for employee programs affects equity structure and may dilute shareholders, but it fails the multi-hop synthesis: it does not contrast 2023 (acquisition via withholding) with 2024 (active issuance), nor does it incorporate the treasury share purchases. The conclusion about dilution is speculative without supporting data. (4) The contextual relevance is moderate because it addresses employee share programs and equity impact, but the factual foundation is flawed, leading to a misleading narrative. Due to major numerical and logical errors, the correctness score is low despite some topical alignment.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1280,
        "completion_tokens": 488,
        "total_tokens": 1768
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How did MDLZ's exposure to Canadian-denominated debt instruments change between 2022 and 2023, and how does this shift compare to the company's overall trend in managing foreign currency-denominated debt during this period?",
      "original_answer": "In 2022, MDLZ reported a decrease in Canadian notes of $3 million, continuing a trend of declining balances from $17 million in 2019 to $7 million in 2020 and $3 million in 2021. However, in 2023, the company experienced an increase in Canadian notes by $8 million, reversing the previous downward trajectory. This shift contrasts with the broader pattern of fluctuating foreign currency exposure, where Euro notes decreased significantly from $211 million in 2021 to $81 million in 2023, while Swiss franc notes also showed volatility. The reversal in Canadian notes indicates a notable deviation from the prior year's trend of reducing exposure to this currency denomination.",
      "llm_answer": "Based on the provided document pages, MDLZ's exposure to Canadian-denominated debt instruments increased significantly from $443 million (as of December 31, 2022) to $453 million (as of December 31, 2023), reflecting a modest rise in the notional amount of Canadian‑dollar notes designated for net‑investment hedging. This shift aligns with the company’s broader strategy of managing foreign‑currency‑denominated debt, as evidenced by a net increase in overall net‑investment‑hedge notional exposure—particularly in Canadian‑dollar debt—while the company continued to adjust its hedging program to mitigate currency risk across its international operations.",
      "correctness_score": 2,
      "quantitative_accuracy": 2,
      "qualitative_accuracy": 3,
      "contextual_relevance": 5,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is factually incorrect in its core quantitative claims. According to the ground truth, MDLZ's Canadian-denominated debt decreased to $3 million in 2022 and then increased by $8 million in 2023 (to $11 million), not from $443 million to $453 million. The LLM's figures are off by over two orders of magnitude, indicating a severe factual error. (2) The numbers cited ($443M and $453M) do not match the ground truth data at all—there is no mention of such large amounts in the original answer, and no indication that Canadian notes were even close to $400M in recent years. The calculation of a $10M increase is therefore also incorrect. (3) The reasoning is flawed: the LLM claims the increase 'aligns with the company’s broader strategy,' but the ground truth states that the 2023 increase reverses a multi-year trend of decline, making it a deviation, not an alignment. Additionally, the LLM fails to mention the key contrast with other currencies like the Euro (down from $211M to $81M) and Swiss franc volatility, which are central to the multi-hop comparison asked in the question. (4) While the LLM attempts to address both parts of the question (change in Canadian exposure and comparison to overall trend), it does so with entirely incorrect data and mischaracterized trends, leading to a low correctness score. The contextual relevance is moderate because it discusses hedging and foreign currency debt, but the qualitative and quantitative inaccuracies severely undermine the response.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1352,
        "completion_tokens": 419,
        "total_tokens": 1772
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How has Accenture's approach to engaging with growth-stage companies evolved from 2023 to 2024, particularly in terms of strategic involvement and investment activity?",
      "original_answer": "In 2023, Accenture Ventures was described as primarily partnering with growth-stage companies that create innovative enterprise technologies. By 2024, the relationship evolved from a partnership model to a more direct investment approach, indicating a deeper financial and strategic commitment. This shift from 'partners with' to 'invests in' growth-stage firms suggests Accenture is taking a more active role in shaping innovation ecosystems through capital allocation, aligning with its broader innovation strategy supported by $1.3 billion in R&D spending in fiscal 2023 and $1.2 billion in fiscal 2024.",
      "llm_answer": "From 2023 to 2024, Accenture’s engagement with growth-stage companies shifted from a general innovation focus to a more strategic, investment-driven approach. In 2024, Accenture Ventures explicitly partnered with and invested in growth-stage companies developing innovative enterprise technologies, particularly in areas like AI, blockchain, and quantum, while also expanding its innovation hubs and R&D efforts to scale these solutions globally. This evolution reflects a deeper integration of growth-stage company collaboration into Accenture’s core strategy to drive client innovation and market leadership.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer correctly identifies the evolution in Accenture's approach from 2023 to 2024, noting a shift toward deeper strategic involvement with growth-stage companies. However, it inaccurately states that in 2024 Accenture 'partnered with and invested in' these firms, while the ground truth emphasizes a shift *from* partnership (2023) *to* direct investment (2024), indicating a change in model rather than dual activity. The LLM blurs this distinction, implying both activities coexist in 2024 without clarifying the strategic evolution. (2) There are no numeric values in the LLM answer, so quantitative accuracy is not compromised—no incorrect figures were introduced. The ground truth includes R&D spending ($1.3B in FY23, $1.2B in FY24), which the LLM omits, but does not fabricate numbers. (3) The multi-hop reasoning is partially sound: the model connects Accenture Ventures, growth-stage companies, and innovation strategy, but fails to clearly articulate the transition from 'partners with' to 'invests in' as a strategic shift. It adds details like AI, blockchain, and quantum, which may be contextually plausible but are not in the original answer and introduce unsupported specificity. (4) Contextual relevance is high—the response stays focused on Accenture’s evolving engagement model and ties it to broader innovation goals. The core idea of increased strategic commitment is preserved, though precision on the nature of the shift is lacking. Thus, correctness is reduced to 7 due to misrepresentation of the partnership-to-investment evolution, despite strong relevance and no numerical errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1309,
        "completion_tokens": 447,
        "total_tokens": 1756
      },
      "error": null
    },
    {
      "question_id": 115,
      "question": "How has Merck's financial and strategic involvement in the Lynparza collaboration with AstraZeneca evolved from 2022 to 2024, particularly in terms of asset amortization and alliance revenue growth?",
      "original_answer": "In 2022, Merck was amortizing an intangible asset balance of $1.1 billion related to Lynparza, which included capitalized milestone payments, and was expected to be amortized through 2028. By 2024, the focus shifted from asset amortization to revenue growth, with alliance revenue from Lynparza increasing by 9% due to higher demand in international markets. Additionally, in early 2025, Lynparza received a new approval in China for adjuvant treatment in early breast cancer, indicating an expansion in its therapeutic footprint and strategic importance to Merck.",
      "llm_answer": "From 2022 to 2024, Merck’s Lynparza collaboration with AstraZeneca saw alliance revenue grow from $989 million (2021) to $1,311 million (2024), reflecting higher demand and pricing. The intangible asset balance for Lynparza, which includes capitalized milestone payments, is being amortized through 2028, and Merck recorded $153 million of cumulative amortization catch‑up expense in 2021 that is reflected in subsequent periods. While the provided pages do not detail specific changes in amortization expense after 2021, the growing alliance revenue indicates an expanding financial involvement, and the amortization schedule remains tied to projected cash flows through 2028.",
      "correctness_score": 4,
      "quantitative_accuracy": 3,
      "qualitative_accuracy": 5,
      "contextual_relevance": 7,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains significant factual inaccuracies. The ground truth states that in 2022, Merck was amortizing a $1.1 billion intangible asset related to Lynparza, but the LLM incorrectly references a $153 million cumulative amortization catch-up expense from 2021, which is not mentioned in the original answer and shifts focus away from the correct 2022–2024 amortization context. Additionally, the LLM claims alliance revenue grew from $989 million (2021) to $1,311 million (2024), but this data is not present in the ground truth, which only states a 9% revenue increase in 2024 due to international demand—no specific dollar figures or 2021–2024 revenue trajectory is provided in the original. (2) The quantitative inaccuracies are critical: the $1.1 billion asset balance in 2022 is omitted entirely, and the $153 million catch-up expense is fabricated or misattributed. The 9% growth cited in the original is replaced with unsupported absolute revenue figures. (3) The reasoning partially captures the shift toward revenue growth but fails to correctly synthesize the multi-hop elements: it does not link the 2022 amortization of $1.1 billion through 2028 to the 2024 shift in focus, nor does it mention the new 2025 China approval that underscores strategic expansion—this key strategic development is missing. (4) While the LLM attempts to address financial evolution and mentions amortization through 2028 (partially correct), it introduces unverified numbers and omits key strategic updates. The contextual relevance is moderate because it discusses revenue and amortization, but the factual foundation is flawed, reducing overall correctness to partially accurate with major omissions and errors.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1323,
        "completion_tokens": 471,
        "total_tokens": 1794
      },
      "error": null
    },
    {
      "question_id": 116,
      "question": "How has AVGO's strategic emphasis on ValueOps changed between 2023 and 2024, and what does this indicate about its evolving role in the Distributed Software portfolio?",
      "original_answer": "In 2023, ValueOps was listed as one of several key offerings under AVGO's Distributed Software portfolio, positioned alongside other solutions like DevOps and AIOps without specific elaboration on its strategic role. By 2024, ValueOps was elevated to be one of the three core domains—alongside DevOps and AIOps—that AVGO's distributed software solutions are 'organized in the domains of,' with an explicit emphasis on delivering 'end-to-end visibility across all stages of the digital lifecycle.' This indicates a strategic shift where ValueOps became more central to AVGO's value proposition, aligning it more deeply with business outcomes and customer experiences. The change reflects a broader evolution from being a feature in the portfolio to a foundational pillar supporting enterprise digital transformation.",
      "llm_answer": "AVGO’s strategic emphasis on ValueOps has intensified in 2024, with the portfolio now explicitly positioning ValueOps as a core pillar of its Distributed Software offerings alongside DevOps and AIOps, reflecting a deeper integration of value‑stream management into its broader cloud‑native strategy. This shift underscores AVGO’s evolving role as a provider of end‑to‑end digital‑lifecycle orchestration, moving beyond traditional DevOps tools to deliver comprehensive visibility and automation that align business, development, and operational teams for faster, higher‑value software delivery.",
      "correctness_score": 9,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 9,
      "contextual_relevance": 10,
      "detailed_feedback": "The LLM answer is highly accurate and captures the core strategic shift in AVGO's emphasis on ValueOps from 2023 to 2024. It correctly identifies that ValueOps became a core pillar alongside DevOps and AIOps in 2024, which aligns with the ground truth. The answer reflects the elevated role of ValueOps as foundational rather than just a feature, and correctly conveys the emphasis on end-to-end visibility and alignment across teams—consistent with 'end-to-end visibility across all stages of the digital lifecycle' in the original answer. While the LLM does not explicitly contrast the 2023 state (where ValueOps was listed among other offerings without elaboration), it still accurately represents the 2024 evolution and the broader strategic implication. There are no numeric values to verify, so quantitative accuracy is scored as 10. The reasoning is sound and synthesizes the multi-hop change in strategic positioning. The only minor omission is the lack of explicit mention of the 2023 baseline, which slightly affects completeness but does not undermine the overall correctness. Hence, a 9 is justified for correctness and qualitative accuracy. Contextual relevance is perfect—the response directly addresses the question’s focus on strategic change and evolving role.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1357,
        "completion_tokens": 355,
        "total_tokens": 1713
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How did FedEx's strategic approach to Network 2.0 within the DRIVE transformation evolve between 2023 and 2024, particularly in terms of expected cost savings and implementation risks?",
      "original_answer": "In 2023, FedEx emphasized the strategic importance of Network 2.0 as part of its DRIVE transformation, noting that significant investments were being made with the expectation of achieving operational efficiencies, network flexibility, and alignment of the cost base with demand. However, the filing acknowledged that the failure to successfully execute Network 2.0 within the expected time frame and cost could adversely affect future results. By 2024, FedEx shifted focus to the integration complexities of Network 2.0, including risks related to harmonizing operating practices, maintaining customer and service provider agreements, addressing labor and cultural differences, and managing unforeseen expenses. The 2024 filing also noted that the actual amount and timing of cost savings and permanent cost reductions might differ from expectations, and that asset impairment charges, tax impacts, and litigation risks could arise. This reflects a transition from strategic planning and investment justification in 2023 to operational integration and financial risk mitigation in 2024.",
      "llm_answer": "FedEx’s DRIVE transformation, anchored by Network 2.0, continued its multi‑year effort to boost efficiency and align costs with demand. In 2023‑2024 the company announced further steps—including the one FedEx consolidation, the Tricolor redesign of the international air network, and a European workforce‑reduction plan—while acknowledging that achieving the anticipated cost savings and operational flexibility is uncertain and may be delayed. The firm warns that integration risks, potential regulatory or legal challenges, and the need to adjust its air network after the USPS contract expires could erode expected savings and increase expenses. Consequently, while cost‑reduction targets are set, the actual magnitude and timing of those savings remain subject to execution risk and may differ materially from current expectations.",
      "correctness_score": 7,
      "quantitative_accuracy": 10,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "The LLM answer is factually consistent with the ground truth in terms of the evolution of FedEx's Network 2.0 strategy between 2023 and 2024, particularly regarding the shift from strategic investment to integration risks and uncertainty around cost savings. It correctly identifies that in 2023–2024, FedEx emphasized operational efficiency and cost alignment, and acknowledges execution risks and potential delays in realizing savings—matching the 2023 emphasis on expected benefits and risks of failure. The mention of integration risks, regulatory or legal challenges, and air network adjustments post-USPS contract aligns with the 2024 focus on operational complexities and financial risks such as litigation and unforeseen expenses. However, the LLM answer omits specific 2024 risks highlighted in the original answer, including harmonizing operating practices, maintaining customer and service provider agreements, labor and cultural differences, and asset impairment or tax impacts. While it captures the general theme of execution risk and uncertainty in timing and magnitude of savings, it does not fully reflect the depth of multi-hop synthesis across the two years—particularly the transition in tone and focus from strategic justification (2023) to integration and financial risk mitigation (2024). There are no numerical inaccuracies (quantitative accuracy is perfect as no incorrect numbers are presented), and the context is highly relevant. The answer paraphrases effectively but lacks completeness in qualitative details necessary for a top score.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1490,
        "completion_tokens": 427,
        "total_tokens": 1917
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How did the financial impact from equity method investment contracts evolve between 2022 and 2023, and what does this indicate about MDLZ's engagement with these investments?",
      "original_answer": "In 2022, MDLZ reported a net liability of $3 million related to equity method investment contracts. By 2023, this position had shifted to a gain of $7 million from equity method investment contracts, indicating a reversal in financial impact and potentially more active or favorable engagement with these investments. This evolution highlights a strategic or operational shift in how MDLZ managed these equity method investments over the two years.",
      "llm_answer": "The financial impact from MDLZ's equity method investment contracts shifted from a $168 million after‑tax gain in 2021 to a $148 million after‑tax loss in 2023, reflecting a reversal in fair‑value movements. This change indicates that MDLZ's exposure to these investments has become more volatile and less favorable, suggesting a reduced or more cautious engagement with the associated hedging strategies.",
      "correctness_score": 1,
      "quantitative_accuracy": 1,
      "qualitative_accuracy": 1,
      "contextual_relevance": 2,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer is almost entirely incorrect in both quantitative and qualitative aspects. The ground truth states that MDLZ had a net liability of $3 million in 2022 and a gain of $7 million in 2023, indicating a positive shift. However, the LLM claims a $168 million after-tax gain in 2021 and a $148 million after-tax loss in 2023—numbers and years that do not align with the question or the truth. The years referenced (2021 and 2023) skip 2022 and misrepresent the timeline. (2) The numerical values are completely inaccurate: $168M gain and $148M loss are not present in the ground truth, and no such after-tax figures were mentioned. There is no mention of fair-value movements or hedging strategies in the original answer, making those additions unfounded. (3) The multi-hop reasoning is flawed—the question asks for evolution between 2022 and 2023, but the model references 2021 and 2023, failing to address the correct time frame and drawing incorrect conclusions about volatility and reduced engagement. The actual answer indicates improved or more favorable engagement, opposite to the LLM’s conclusion. (4) The contextual relevance is low because the answer discusses unrelated years and financial impacts, though it does attempt to interpret strategic engagement, which is part of the question. However, due to massive factual errors, the overall correctness score is near zero.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1220,
        "completion_tokens": 390,
        "total_tokens": 1610
      },
      "error": null
    },
    {
      "question_id": 117,
      "question": "How did Broadcom's (AVGO) estimated cost to complete for the VMware Cloud Foundation July 2024 releases evolve from fiscal year 2023 to fiscal year 2024, and what does this indicate about the development progress relative to expectations?",
      "original_answer": "The estimated cost to complete for the VMware Cloud Foundation July 2024 releases remained unchanged at $38 million from fiscal year 2023 to fiscal year 2024. This consistency in the cost estimate indicates that the development progress for this product was proceeding largely as planned, with actual expenditures aligning with earlier projections. The lack of an increase or decrease in the estimated cost to complete suggests that Broadcom (AVGO) did not encounter significant unexpected expenses or delays in the development timeline for this specific release.",
      "llm_answer": "The estimated cost to complete the VMware Cloud Foundation July 2024 releases fell from $38 million in fiscal 2023 to $38 million in fiscal 2024 (the same absolute amount, though the percentage of completion rose from 67 % to 67 % and the remaining cost was unchanged), while the March 2025 release’s remaining cost increased to $185 million and the July 2025 release’s to $65 million. This modest rise in the unfinished work—particularly for the later‑stage releases—signals that development is progressing ahead of schedule for the July 2024 launch but that later releases still require more investment than initially anticipated, indicating a mixed outlook relative to expectations.",
      "correctness_score": 3,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 3,
      "contextual_relevance": 6,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a critical factual error: it states that the estimated cost to complete 'fell from $38 million in fiscal 2023 to $38 million in fiscal 2024', which incorrectly implies a change when the ground truth confirms the cost remained unchanged. While the dollar amount ($38 million) is correct for both years, the phrasing suggests a decrease and misrepresents the stability of the cost estimate. Additionally, the LLM introduces irrelevant and unsupported data—percentages of completion (67%) and cost figures for March 2025 and July 2025 releases—that are not present in the original answer and cannot be verified from the provided ground truth. (2) The quantitative accuracy is partially correct in that the $38 million figure is accurate, but the inclusion of unverified percentages and later-release costs undermines reliability. There are no calculations in the question, but the comparison is misrepresented by implying a change. (3) The multi-hop reasoning is flawed: the question focuses solely on the July 2024 release and its cost evolution; the LLM incorrectly expands the scope to later releases and infers a 'mixed outlook' and 'progressing ahead of schedule'—conclusions not supported by the ground truth. The correct reasoning should have emphasized that stable costs indicate development is on track, not ahead of schedule. (4) Contextual relevance is moderate because the answer addresses the July 2024 release and cost trend but distracts with extraneous details and draws incorrect implications. The core message about development progress is misrepresented, leading to a low correctness score despite some accurate elements.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1335,
        "completion_tokens": 457,
        "total_tokens": 1792
      },
      "error": null
    },
    {
      "question_id": 118,
      "question": "How has the strategic positioning of FedEx Office's Ship and Go kiosk evolved between 2023 and 2024, and what does this indicate about the company's approach to e-commerce logistics and returns management?",
      "original_answer": "In 2023, the Ship and Go kiosk was described primarily as a self-serve shipping solution available in approximately 1,300 locations, allowing customers to generate labels via mobile or QR code and drop off packages securely. While it mentioned facilitating e-commerce returns, the integration was not emphasized. By 2024, the description of Ship and Go remained consistent in terms of presence (still in approximately 1,300 locations) and core functionality, but there was a notable shift in emphasis: it was now more explicitly tied to FedEx Returns Technology and Consolidated Returns, highlighting its role in in-store printing of return labels and enabling customers to drop off returns without a box or label. This evolution indicates a strategic shift toward positioning Ship and Go not just as a shipping tool, but as a key node in FedEx's broader e-commerce returns infrastructure.",
      "llm_answer": "Between 2023 and 2024, FedEx Office’s Ship and Go kiosk expanded from roughly 1,300 locations to broader national coverage, emphasizing self-serve label generation and drop‑off for e‑commerce and returns, while integrating with FedEx Returns Technology to enable in‑store printing of return labels and Consolidated Returns drop‑offs. This evolution reflects FedEx’s strategy to strengthen its last‑mile e‑commerce logistics and returns management through convenient, technology‑driven self‑service options that leverage its extensive retail footprint.",
      "correctness_score": 6,
      "quantitative_accuracy": 4,
      "qualitative_accuracy": 7,
      "contextual_relevance": 9,
      "detailed_feedback": "Detailed explanation: (1) The LLM answer contains a significant factual inaccuracy regarding the number of Ship and Go kiosk locations. The original answer states that the presence remained at approximately 1,300 locations in both 2023 and 2024, with no expansion. However, the LLM claims the kiosk 'expanded from roughly 1,300 locations to broader national coverage,' which contradicts the ground truth and misrepresents the quantitative scale of the rollout. This is a critical error in quantitative accuracy. (2) While the LLM correctly identifies the integration with FedEx Returns Technology and Consolidated Returns, and accurately notes the functionality of in-store printing of return labels and drop-offs, it incorrectly implies growth in footprint, which was not part of the evolution. The core strategic shift — emphasizing returns infrastructure — is correctly interpreted, supporting qualitative accuracy. (3) The multi-hop reasoning is partially sound: the model correctly synthesizes the connection between Ship and Go, returns technology, and e-commerce logistics strategy. However, it fails to recognize that the physical footprint did not change, undermining the validity of the 'expansion' narrative. (4) Contextual relevance is high because the answer addresses both years, the evolution in function, and the strategic implications for e-commerce and returns. Despite incorrect expansion claims, the overall direction of analysis aligns with the question. Correctness score is reduced due to the major quantitative inaccuracy, even though the qualitative interpretation of strategic intent is reasonable.",
      "hop_count": 2,
      "document_relationship": "inter_document_same_company",
      "pattern": null,
      "token_usage": {
        "prompt_tokens": 1374,
        "completion_tokens": 442,
        "total_tokens": 1816
      },
      "error": null
    }
  ],
  "evaluation_summary": {
    "total_questions": 1000,
    "successful_evaluations": 1000,
    "failed_evaluations": 0,
    "average_correctness_score": 5.0,
    "average_quantitative_accuracy": 5.67,
    "average_qualitative_accuracy": 5.37,
    "average_contextual_relevance": 7.6,
    "score_distribution": {
      "excellent": 150,
      "good": 166,
      "fair": 326,
      "poor": 358
    }
  },
  "original_experiment_metadata": {
    "model": "nemotron-nano-30b",
    "experiment": "e4_page_window_relevance_desc",
    "pattern": "qualitative_2hop_cross_year",
    "total_questions": 1000
  }
}